PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Feng, Y; Johansson, J; Shao, RJ; Manneras, L; Fernandez-Rodriguez, J; Billig, H; Stener-Victorin, E				Feng, Yi; Johansson, Julia; Shao, Ruijin; Manneras, Louise; Fernandez-Rodriguez, Julia; Billig, Hakan; Stener-Victorin, Elisabet			Hypothalamic Neuroendocrine Functions in Rats with Dihydrotestosterone-Induced Polycystic Ovary Syndrome: Effects of Low-Frequency Electro-Acupuncture	PLOS ONE			English	Article							ESTROGEN-RECEPTOR-BETA; CORTICOTROPIN-RELEASING-FACTOR; BLOOD-FLOW RESPONSES; ANDROGEN REGULATION; GENE-EXPRESSION; ADIPOSE-TISSUE; HORMONE; ACUPUNCTURE; NEURONS; STIMULATION	Adult female rats continuously exposed to androgens from prepuberty have reproductive and metabolic features of polycystic ovary syndrome (PCOS). We investigated whether such exposure adversely affects estrous cyclicity and the expression and distribution of gonadotropin-releasing hormone (GnRH), GnRH receptors, and corticotrophin-releasing hormone (CRH) in the hypothalamus and whether the effects are mediated by the androgen receptor (AR). We also assessed the effect of low-frequency electro-acupuncture (EA) on those variables. At 21 days of age, rats were randomly divided into three groups (control, PCOS, and PCOS EA; n = 12/group) and implanted subcutaneously with 90-day continuous-release pellets containing vehicle or 5 alpha-dihydrostestosterone (DHT). From age 70 days, PCOS EA rats received 2-Hz EA (evoking muscle twitches) five times/week for 4-5 weeks. Hypothalamic protein expression was measured by immunohistochemistry and western blot. DHT-treated rats were acyclic, but controls had regular estrous cycles. In PCOS rats, hypothalamic medial preoptic AR protein expression and the number of AR- and GnRH-immunoreactive cells were increased, but CRH was not affected; however, GnRH receptor expression was decreased in both the pituitary and hypothalamus. Low-frequency EA restored estrous cyclicity within 1 week and reduced the elevated hypothalamic GnRH and AR expression levels. EA did not affect GnRH receptor or CRH expression. Interestingly, nuclear AR co-localized with GnRH in the hypothalamus. Thus, rats with DHT-induced PCOS have disrupted estrous cyclicity and an increased number of hypothalamic cells expressing GnRH, most likely mediated by AR activation. Repeated low-frequency EA normalized estrous cyclicity and restored GnRH and AR protein expression. These results may help explain the beneficial neuroendocrine effects of low-frequency EA in women with PCOS.	[Feng, Yi; Johansson, Julia; Shao, Ruijin; Manneras, Louise; Billig, Hakan; Stener-Victorin, Elisabet] Univ Gothenburg, Inst Neurosci & Physiol, Dept Physiol, Sahlgrenska Acad, Gothenburg, Sweden; [Feng, Yi] Fudan Univ, Dept Neurobiol & Integrat Med, Shanghai Med Coll, Shanghai 200433, Peoples R China; [Fernandez-Rodriguez, Julia] Univ Gothenburg, Ctr Cellular Imaging, Core Facil, Sahlgrenska Acad, Gothenburg, Sweden	University of Gothenburg; Fudan University; University of Gothenburg	Feng, Y (corresponding author), Univ Gothenburg, Inst Neurosci & Physiol, Dept Physiol, Sahlgrenska Acad, Gothenburg, Sweden.	elisabet.stener-victorin@neuro.gu.se	Shao, Linus R/M-3134-2019; Billig, Hakan/E-8891-2011; Stener-Victorin, Elisabet/W-6322-2018; Shao, Linus R/M-3059-2019	Shao, Linus R/0000-0002-1339-9570; Billig, Hakan/0000-0001-6140-9182; Stener-Victorin, Elisabet/0000-0002-3424-1502; Shao, Linus R/0000-0002-1339-9570; Fernandez-Rodriguez, Julia/0000-0003-4522-0966; Feng, Yi/0000-0002-7156-6023	Swedish Medical Research Council [2008-72VP-15445-01A]; Novo Nordisk Foundation; Wilhelm and Martina Lundgren's Science Fund; Hjalmar Svensson Foundation; Tore Nilson Foundation; Ake Wiberg Foundation; Adlerbert Research Foundation; Ekhaga Foundation; Swedish federal government [ALFFGBG-10984]; Regional Research and Development agreement [VGFOUREG-5171, VGFOUREG-11296, VGFOUREG-7861]; Chinese Special Fund for Postdoctorial studies [200801170]	Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Wilhelm and Martina Lundgren's Science Fund; Hjalmar Svensson Foundation; Tore Nilson Foundation; Ake Wiberg Foundation; Adlerbert Research Foundation; Ekhaga Foundation; Swedish federal government; Regional Research and Development agreement; Chinese Special Fund for Postdoctorial studies	The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was supported by grants from the Swedish Medical Research Council (Project No. 2008-72VP-15445-01A); Novo Nordisk Foundation; Wilhelm and Martina Lundgren's Science Fund; Hjalmar Svensson Foundation; Tore Nilson Foundation; Ake Wiberg Foundation; Adlerbert Research Foundation; Ekhaga Foundation; Swedish federal government under the letters of understanding agreement of Medical Education (ALFFGBG-10984) and Regional Research and Development agreement (VGFOUREG-5171, 11296 and 7861), and Chinese Special Fund for Postdoctorial studies (No. 200801170).	Ahmed MI, 2008, HUM REPROD, V23, P2564, DOI 10.1093/humrep/den273; Azziz R, 1998, J CLIN ENDOCR METAB, V83, P2317, DOI 10.1210/jc.83.7.2317; Barontini M, 2001, ARCH MED RES, V32, P544, DOI 10.1016/S0188-4409(01)00325-3; Blank SK, 2006, HUM REPROD UPDATE, V12, P351, DOI 10.1093/humupd/dml017; CHEN BY, 1992, ACUPUNCTURE ELECTRO, V17, P15, DOI 10.3727/036012992816357846; CUMMING DC, 1984, CLIN ENDOCRINOL, V20, P643, DOI 10.1111/j.1365-2265.1984.tb00114.x; Dronavalli S, 2007, CLIN OBSTET GYNECOL, V50, P244, DOI 10.1097/GRF.0b013e31802f35a0; Foecking EM, 2008, HORM BEHAV, V53, P673, DOI 10.1016/j.yhbeh.2007.12.013; Foecking EM, 2005, BIOL REPROD, V72, P1475, DOI 10.1095/biolreprod.105.039800; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; Hayes FJ, 1998, J CLIN ENDOCR METAB, V83, P2343, DOI 10.1210/jc.83.7.2343; HERBISON AE, 1992, NEUROSCIENCE, V50, P283, DOI 10.1016/0306-4522(92)90423-Y; HERBISON AE, 1995, NEUROENDOCRINOLOGY, V61, P1, DOI 10.1159/000126810; Hu YC, 2004, P NATL ACAD SCI USA, V101, P11209, DOI 10.1073/pnas.0404372101; Kagitani F, 2005, JPN J PHYSIOL, V55, P149, DOI 10.2170/jjphysiol.R2120; Kallo I, 2001, J NEUROENDOCRINOL, V13, P741, DOI 10.1046/j.1365-2826.2001.00708.x; LANZONE A, 1995, FERTIL STERIL, V63, P1195, DOI 10.1016/S0015-0282(16)57596-7; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; MANN JJ, 2005, INT J NEUROPSYCHOPH, V21, P1; Manneras L, 2008, ENDOCRINOLOGY, V149, P3559, DOI 10.1210/en.2008-0053; Manneras L, 2007, ENDOCRINOLOGY, V148, P3781, DOI 10.1210/en.2007-0168; Manneras L, 2009, AM J PHYSIOL-REG I, V296, pR1124, DOI 10.1152/ajpregu.90947.2008; MARCONDES F. K., 2002, Braz. J. Biol., V62, P609, DOI 10.1590/S1519-69842002000400008; Naftolin F, 2007, REPROD SCI, V14, P101, DOI 10.1177/1933719107301059; Norman RJ, 2007, LANCET, V370, P685, DOI 10.1016/S0140-6736(07)61345-2; Patisaul HB, 1999, MOL BRAIN RES, V67, P165, DOI 10.1016/S0169-328X(99)00058-3; Paxinos G., 2005, RAT BRAIN STEREOTAXI; RIVEST S, 1995, ENDOCR REV, V16, P177, DOI 10.1210/er.16.2.177; Shao RJ, 2004, FEBS LETT, V569, P293, DOI 10.1016/j.febslet.2004.05.079; Shao RJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE604, DOI 10.1152/ajpendo.00350.2006; Shao RJ, 2006, J ENDOCRINOL, V190, P857, DOI 10.1677/joe.1.06896; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIVERS BD, 1983, NATURE, V304, P345, DOI 10.1038/304345a0; Shughrue PJ, 1996, STEROIDS, V61, P678, DOI 10.1016/S0039-128X(96)00222-X; Silverman Ann-Judith, 1994, P1683; Skynner MJ, 1999, ENDOCRINOLOGY, V140, P5195, DOI 10.1210/en.140.11.5195; Steckler TL, 2009, ENDOCRINOLOGY, V150, P1456, DOI 10.1210/en.2008-1256; Stener-Victorin E, 2008, J NEUROENDOCRINOL, V20, P290, DOI 10.1111/j.1365-2826.2007.01634.x; Stener-Victorin E, 2000, BIOL REPROD, V63, P1497, DOI 10.1095/biolreprod63.5.1497; Stener-Victorin E, 2004, BIOL REPROD, V70, P329, DOI 10.1095/biolreprod.103.022368; Stener-Victorin E, 2003, AUTON NEUROSCI-BASIC, V108, P50, DOI 10.1016/j.autneu.2003.08.006; Stener-Victorin E, 2000, ACTA OBSTET GYN SCAN, V79, P180, DOI 10.1034/j.1600-0412.2000.079003180.x; Stener-Victorin E, 2001, NEUROPEPTIDES, V35, P227, DOI 10.1054/npep.2002.0878; Stener-Victorin E, 2006, J APPL PHYSIOL, V101, P84, DOI 10.1152/japplphysiol.01593.2005; Stener-Victorin Elisabet, 2003, Reprod Biol Endocrinol, V1, P33, DOI 10.1186/1477-7827-1-33; Stengl V, 2004, CENT EUR J CHEM, V2, P16, DOI 10.2478/BF02476182; Walters KA, 2008, BIOL REPROD, V78, P380, DOI 10.1095/biolreprod.107.064089; Witkin JW, 1999, MICROSC RES TECHNIQ, V44, P11, DOI 10.1002/(SICI)1097-0029(19990101)44:1<11::AID-JEMT3>3.0.CO;2-W; Wu TJ, 1997, J NEUROBIOL, V33, P983, DOI 10.1002/(SICI)1097-4695(199712)33:7<983::AID-NEU9>3.0.CO;2-4	50	43	50	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2009	4	8							e6638	10.1371/journal.pone.0006638	http://dx.doi.org/10.1371/journal.pone.0006638			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	483BG	19680559	gold, Green Published, Green Submitted			2023-01-03	WOS:000268936200005
J	Brook, I				Brook, Itzhak			Rediscovering My Voice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												ib6@georgetown.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	2009	302	3					236	236		10.1001/jama.2009.981	http://dx.doi.org/10.1001/jama.2009.981			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	470BR	19602676				2023-01-03	WOS:000267948100001
J	Iglehart, JK				Iglehart, John K.			A New Era of For-Profit Hospice Care - The Medicare Benefit	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Back AL, 2009, ARCH INTERN MED, V169, P474, DOI 10.1001/archinternmed.2008.583; Medicare Payment Advisory Commission, 2009, REP C MED PAYM POL; *NAT HOSP PALL CAR, NAT END OF LIF ORG R	3	23	23	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 25	2009	360	26					2701	2703		10.1056/NEJMp0902437	http://dx.doi.org/10.1056/NEJMp0902437			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	461RC	19553645				2023-01-03	WOS:000267286600004
J	Estep, PW; Warner, JB; Bulyk, ML				Estep, Preston Wayne, III; Warner, Jason B.; Bulyk, Martha L.			Short-Term Calorie Restriction in Male Mice Feminizes Gene Expression and Alters Key Regulators of Conserved Aging Regulatory Pathways	PLOS ONE			English	Article							LIFE-SPAN EXTENSION; DIETARY RESTRICTION; MAMMALIAN TARGET; BODY-WEIGHT; DWARF MICE; GROWTH; RAPAMYCIN; STRESS; LONGEVITY; TOR	Background: Calorie restriction (CR) is the only intervention known to extend lifespan in a wide range of organisms, including mammals. However, the mechanisms by which it regulates mammalian aging remain largely unknown, and the involvement of the TOR and sirtuin pathways (which regulate aging in simpler organisms) remain controversial. Additionally, females of most mammals appear to live longer than males within species; and, although it remains unclear whether this holds true for mice, the relationship between sex-biased and CR-induced gene expression remains largely unexplored. Methodology/Principal Findings: We generated microarray gene expression data from livers of male mice fed high calorie or CR diets, and we find that CR significantly changes the expression of over 3,000 genes, many between 10- and 50-fold. We compare our data to the GenAge database of known aging-related genes and to prior microarray expression data of genes expressed differently between male and female mice. CR generally feminizes gene expression and many of the most significantly changed individual genes are involved in aging, hormone signaling, and p53-associated regulation of the cell cycle and apoptosis. Among the genes showing the largest and most statistically significant CR-induced expression differences are Ddit4, a key regulator of the TOR pathway, and Nnmt, a regulator of lifespan linked to the sirtuin pathway. Using western analysis we confirmed post-translational inhibition of the TOR pathway. Conclusions: Our data show that CR induces widespread gene expression changes and acts through highly evolutionarily conserved pathways, from microorganisms to mammals, and that its life-extension effects might arise partly from a shift toward a gene expression profile more typical of females.			Estep, PW (corresponding author), Longenity Inc, Lincoln, MA USA.	pestep@post.harvard.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [F32AR051287] Funding Source: NIH RePORTER; NIAMS NIH HHS [F32 AR051287] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Amador-Noguez D, 2004, AGING CELL, V3, P423, DOI 10.1111/j.1474-9728.2004.00125.x; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Bauer M, 2004, PHYSIOL GENOMICS, V17, P230, DOI 10.1152/physiolgenomics.00203.2003; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Berriz GF, 2003, BIOINFORMATICS, V19, P2502, DOI 10.1093/bioinformatics/btg363; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; BURGER JM, 2004, SCI AGING KNOWLEDGE, pPE30, DOI DOI 10.1126/SAGEKE.2004.28.PE30; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; de Magalhaes JP, 2005, NUCLEIC ACIDS RES, V33, pD537, DOI 10.1093/nar/gki017; DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fu CX, 2006, MECH AGEING DEV, V127, P905, DOI 10.1016/j.mad.2006.09.006; Fu CX, 2004, J NUTR, V134, P2965, DOI 10.1093/jn/134.11.2965; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4; HOAG WG, 1963, ANN NY ACAD SCI, V108, P805, DOI 10.1111/j.1749-6632.1963.tb13421.x; *I LAB AN RES I, 1996, GUID CAR US LAB AN; INGRAM DK, 1982, MECH AGEING DEV, V20, P253, DOI 10.1016/0047-6374(82)90092-6; Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2007, AGING CELL, V6, P731, DOI 10.1111/j.1474-9726.2007.00341.x; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kawauchi K, 2005, J IMMUNOL, V174, P5261, DOI 10.4049/jimmunol.174.9.5261; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Lane MA, 2001, ANN NY ACAD SCI, V928, P287; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liang HY, 2003, EXP GERONTOL, V38, P1353, DOI 10.1016/j.exger.2003.10.019; Lin SJ, 2004, GENE DEV, V18, P12, DOI 10.1101/gad.1164804; Linford NJ, 2007, AGING CELL, V6, P673, DOI 10.1111/j.1474-9726.2007.00319.x; Liss B, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf088; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Miller RA, 2002, AGING CELL, V1, P22, DOI 10.1046/j.1474-9728.2002.00006.x; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; *NCBI, 2007, ENTR GEN; Novoradovskaya N, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-20; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; ORENTREICH N, 1993, J NUTR, V123, P269; PROMISLOW DEL, 1992, P ROY SOC B-BIOL SCI, V247, P203, DOI 10.1098/rspb.1992.0030; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2; Redman LM, 2009, MOL CELL ENDOCRINOL, V299, P129, DOI 10.1016/j.mce.2008.10.014; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; SEGALL PE, 1976, MECH AGEING DEV, V5, P109, DOI 10.1016/0047-6374(76)90012-9; Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006; Sharp ZD, 2005, J GERONTOL A-BIOL, V60, P293, DOI 10.1093/gerona/60.3.293; Shimokawa I, 2003, FASEB J, V17, P1108, DOI 10.1096/fj.02-0819fje; Sjogren K, 2002, Minerva Endocrinol, V27, P299; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Strand AD, 2002, HUM MOL GENET, V11, P2207, DOI 10.1093/hmg/11.19.2207; Suckow M. A., 2000, LAB MOUSE; Swindell WR, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-353; Tsuchiya M, 2006, AGING CELL, V5, P505, DOI 10.1111/j.1474-9726.2006.00240.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Walford RL, 2002, J GERONTOL A-BIOL, V57, pB211, DOI 10.1093/gerona/57.6.B211; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang X, 2006, GENOME RES, V16, P995, DOI 10.1101/gr.5217506; YUAN R, 2008, AGING STUDY LIFESPAN	73	62	68	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2009	4	4							e5242	10.1371/journal.pone.0005242	http://dx.doi.org/10.1371/journal.pone.0005242			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437TU	19370158	Green Published, gold			2023-01-03	WOS:000265510600006
J	Mascioni, A; Bentley, BE; Camarda, R; Dilts, DA; Fink, P; Gusarova, V; Hoiseth, SK; Jacob, J; Lin, SL; Malakian, K; McNeil, LK; Mininni, T; Moy, F; Murphy, E; Novikova, E; Sigethy, S; Wen, YX; Zlotnick, GW; Tsao, DHH				Mascioni, Alessandro; Bentley, Breagh E.; Camarda, Rosaria; Dilts, Deborah A.; Fink, Pamela; Gusarova, Viktoria; Hoiseth, Susan K.; Jacob, Jaison; Lin, Shuo L.; Malakian, Karl; McNeil, Lisa K.; Mininni, Terri; Moy, Franklin; Murphy, Ellen; Novikova, Elena; Sigethy, Scott; Wen, Yingxia; Zlotnick, Gary W.; Tsao, Desiree H. H.			Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; B NEISSERIA-MENINGITIDIS; ALTERNATIVE CONFORMATIONS; ANTIBODY COMPLEXES; NMR-SPECTROSCOPY; CHEMICAL-SHIFT; SEROGROUP-B; PROTEIN; LIPOPROTEIN; ANTIGEN	LP2086 is a family of outer membrane lipoproteins from Neisseria meningitidis, which elicits bactericidal antibodies and are currently undergoing human clinical trials in a bivalent formulation where each antigen represents one of the two known LP2086 subfamilies. Here we report the NMR structure of the recombinant LP2086 variant B01, a representative of the LP2086 subfamily B. The structure reveals a novel fold composed of two domains: a "taco-shaped" N-terminal beta-sheet and a C-terminal beta-barrel connected by a linker. The structure in micellar solution is consistent with a model of LP2086 anchored to the outer membrane bilayer through its lipidated N terminus. A long flexible chain connects the folded part of the protein to the lipid anchor and acts as spacer, making both domains accessible to the host immune system. Antibodies broadly reactive against members from both subfamilies have been mapped to the N terminus. A surface of subfamily-defining residues was identified on one face of the protein, offering an explanation for the induction of subfamily-specific bactericidal antibodies.	[Jacob, Jaison; Malakian, Karl; Moy, Franklin; Tsao, Desiree H. H.] Wyeth Res, Struct Biol & Computat Chem, Cambridge, MA 02140 USA; [Bentley, Breagh E.; Camarda, Rosaria; Dilts, Deborah A.; Fink, Pamela; Gusarova, Viktoria; Hoiseth, Susan K.; Lin, Shuo L.; McNeil, Lisa K.; Mininni, Terri; Murphy, Ellen; Novikova, Elena; Sigethy, Scott; Zlotnick, Gary W.] Wyeth Vaccines Res, Pearl River, NY 10965 USA	Pfizer; Pfizer	Tsao, DHH (corresponding author), Wyeth Res, Struct Biol & Computat Chem, 200 Cambridge Pk Dr, Cambridge, MA 02140 USA.	dtsao@wyeth.com						BENTLEY AT, 1988, J BACTERIOL, V170, P1063, DOI 10.1128/jb.170.3.1063-1068.1988; Buck-Koehntop BA, 2005, J MOL BIOL, V354, P652, DOI 10.1016/j.jmb.2005.09.038; Cantini F, 2006, J BIOL CHEM, V281, P7220, DOI 10.1074/jbc.M508595200; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CRESPI HL, 1968, SCIENCE, V161, P796, DOI 10.1126/science.161.3843.795; Decanniere K, 2001, J MOL BIOL, V313, P473, DOI 10.1006/jmbi.2001.5075; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W. L., 2000, PYMOL; Deschamps ML, 2005, J BIOMOL NMR, V31, P155, DOI 10.1007/s10858-004-7912-6; Fletcher LD, 2004, INFECT IMMUN, V72, P2088, DOI 10.1128/IAI.72.4.2088-2100.2004; Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103; Hilty C, 2004, CHEMBIOCHEM, V5, P467, DOI 10.1002/cbic.200300815; Hwang PM, 2002, P NATL ACAD SCI USA, V99, P13560, DOI 10.1073/pnas.212344499; Jodar L, 2002, LANCET, V359, P1499, DOI 10.1016/S0140-6736(02)08416-7; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LEX A, 1986, J IMMUNOL, V137, P2676; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Madico G, 2006, J IMMUNOL, V177, P501, DOI 10.4049/jimmunol.177.1.501; MARKLEY JL, 1968, SCIENCE, V161, P1249, DOI 10.1126/science.161.3847.1249; Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911; Matsuo H, 1999, J AM CHEM SOC, V121, P9903, DOI 10.1021/ja991881g; Metzler WJ, 1996, J AM CHEM SOC, V118, P6800, DOI 10.1021/ja9604875; Morley SL, 2001, VACCINE, V20, P666, DOI 10.1016/S0264-410X(01)00410-8; Nassif X, 2000, SCIENCE, V287, P1767, DOI 10.1126/science.287.5459.1767; Nietlispach D, 2005, J BIOMOL NMR, V31, P161, DOI 10.1007/s10858-004-8195-7; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Pillai S, 2005, VACCINE, V23, P2206, DOI 10.1016/j.vaccine.2005.01.056; POOLMAN JT, 1995, INFECT AGENT DIS, V4, P13; Rosen O, 2005, BIOCHEMISTRY-US, V44, P7250, DOI 10.1021/bi047387t; Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Sharon M, 2003, STRUCTURE, V11, P225, DOI 10.1016/S0969-2126(03)00011-X; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Walters KJ, 1999, P NATL ACAD SCI USA, V96, P7877, DOI 10.1073/pnas.96.14.7877; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580; Zhu DZ, 2006, VACCINE, V24, P5420, DOI 10.1016/j.vaccine.2006.03.051; Zhu DZ, 2005, INFECT IMMUN, V73, P6838, DOI 10.1128/IAI.73.10.6838-6845.2005	39	62	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	2009	284	13					8729	8737		10.1074/jbc.M808831200	http://dx.doi.org/10.1074/jbc.M808831200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421ZW	19103601	Green Published, hybrid			2023-01-03	WOS:000264397800057
J	Kearney, MK; Weininger, RB; Vachon, MLS; Harrison, RL; Mount, BM				Kearney, Michael K.; Weininger, Radhule B.; Vachon, Mary L. S.; Harrison, Richard L.; Mount, Balfour M.			Self-care of Physicians Caring for Patients at the End of Life "Being Connected ... A Key to My Survival"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WRITTEN EMOTIONAL EXPRESSION; STRESS REDUCTION; MENTAL-HEALTH; OF-LIFE; SURGICAL ONCOLOGISTS; HOSPITAL CONSULTANTS; PERSONAL WELLNESS; CONTROLLED-TRIAL; PALLIATIVE CARE; IMMUNE FUNCTION	Physicians providing end-of-life care are subject to a variety of stresses that may lead to burnout and compassion fatigue at both individual and team levels. Through the story of an oncologist, we discuss the prodromal symptoms and signs leading to burnout and compassion fatigue and present the evidence for prevention. We define and discuss factors that contribute to burnout and compassion fatigue and consider factors that may mitigate burnout. We explore the practice of empathy and discuss an approach for physicians to maximize wellness through self-awareness in the setting of caring for patients with end-stage illness. Finally, we discuss some practical applications of self-care in the workplace.	[Kearney, Michael K.] Santa Barbara Cottage Hosp, Palliat Care Serv, Santa Barbara, CA 93102 USA; [Kearney, Michael K.] Visiting Nurse & Hosp Care Santa Barbara, Santa Barbara, CA USA; [Weininger, Radhule B.] La Casa de Maria Retreat & Conf Ctr, Santa Barbara, CA USA; [Vachon, Mary L. S.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Vachon, Mary L. S.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Harrison, Richard L.] Univ British Columbia, Counseling Psychol Program, Vancouver, BC V5Z 1M9, Canada; [Mount, Balfour M.] McGill Univ, Dept Med, Montreal, PQ, Canada	Santa Barbara Cottage Hospital; University of Toronto; University of Toronto; University of British Columbia; McGill University	Kearney, MK (corresponding author), Santa Barbara Cottage Hosp, Palliat Care Serv, POB 689,Pueblo Bath St, Santa Barbara, CA 93102 USA.	mkearney@sbch.org						Allegra CJ, 2005, J ONCOL PRACT, V1, P140, DOI 10.1200/jop.2005.1.4.140; Armstrong J, 2004, J CLIN ONCOL, V22, P4425, DOI 10.1200/JCO.2004.07.138; Arnold D, 2005, J HUMANIST PSYCHOL, V45, P239, DOI 10.1177/0022167805274729; Asai M, 2007, PSYCHO-ONCOLOGY, V16, P421, DOI 10.1002/pon.1066; Balch CM, 2007, ANN SURG ONCOL, V14, P3029, DOI 10.1245/s10434-007-9588-0; BARNARD D, 2000, CROSSING OVER NARRAT; Beddoe AE, 2004, J NURS EDUC, V43, P305; Boston PH, 2006, J PAIN SYMPTOM MANAG, V32, P13, DOI 10.1016/j.jpainsymman.2006.01.009; Brady DW, 2002, ANN INTERN MED, V137, P220, DOI 10.7326/0003-4819-137-3-200208060-00025; Bressi C, 2008, BRIT J CANCER, V98, P1046, DOI 10.1038/sj.bjc.6604270; Calhoun L.G., 1999, FACILITATING POSTTRA; Calhoun LG, 1998, LEA SER PER CLIN PSY, P215; Cepeda MS, 2008, J PAIN SYMPTOM MANAG, V35, P623, DOI 10.1016/j.jpainsymman.2007.08.011; Charon R, 2001, JAMA-J AM MED ASSOC, V286, P1897, DOI 10.1001/jama.286.15.1897; CHARON R, 2008, NARRATIVE MED HONORI, P156; Cohen-Katz Joanne, 2004, Holist Nurs Pract, V18, P302; Coster JS, 1997, PROF PSYCHOL-RES PR, V28, P5, DOI 10.1037/0735-7028.28.1.5; Dahlin Marie E, 2007, BMC Med Educ, V7, P6, DOI 10.1186/1472-6920-7-6; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; Desalvo Louise, 1999, WRITING WAY HEALING; Elit L, 2004, GYNECOL ONCOL, V94, P134, DOI 10.1016/j.ygyno.2004.04.014; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; *EUR COMM, 2004, PROM DEV INT PALL CA; Fallowfield L, 2003, BRIT J CANCER, V89, P1445, DOI 10.1038/sj.bjc.6601309; Fallowfield L, 2002, LANCET, V359, P650, DOI 10.1016/S0140-6736(02)07810-8; Figley C.R., 2002, TREATING COMPASSION; Figley CR., 2013, COMPASSION FATIGUE C; Fillion L, 2009, PSYCHO-ONCOLOGY, V18, P1300, DOI 10.1002/pon.1513; Frisina PG, 2004, J NERV MENT DIS, V192, P629, DOI 10.1097/01.nmd.0000138317.30764.63; GARFIELD C, 1995, SOMETIMES MY HEART G; Gentry J., 2002, TREATING COMPASSION; Graham J, 1996, PALLIATIVE MED, V10, P185, DOI 10.1177/026921639601000302; Graham J, 2002, EUR J CANCER CARE, V11, P188, DOI 10.1046/j.1365-2354.2002.00338.x; Grossman P, 2004, J PSYCHOSOM RES, V57, P35, DOI 10.1016/S0022-3999(03)00573-7; Grunfeld E, 2000, CAN MED ASSOC J, V163, P166; Halbesleben JRB, 2008, HEALTH CARE MANAGE R, V33, P29, DOI 10.1097/01.HMR.0000304493.87898.72; Harris AHS, 2006, J CONSULT CLIN PSYCH, V74, P243, DOI 10.1037/0022-006X.74.2.243; HARRISON RL, PSYCHOTHERA IN PRESS; Haward R, 2003, BRIT J CANCER, V89, P15, DOI 10.1038/sj.bjc.6601073; Hojat M, 2002, AM J PSYCHIAT, V159, P1563, DOI 10.1176/appi.ajp.159.9.1563; HUGGARD PK, 2008, MANAGING COMPASSION; Jackson VA, 2008, J PALLIAT MED, V11, P893, DOI 10.1089/jpm.2007.2480; Johnson T.A., 2006, PROFESSIONALS WEEP E, P3; Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016; Kash KM, 2000, ONCOLOGY-NY, V14, P1621; Kearney M, 2009, PLACE HEALING WORKIN; Keeton K, 2007, OBSTET GYNECOL, V109, P949, DOI 10.1097/01.AOG.0000258299.45979.37; Kjeldmand D, 2004, PATIENT EDUC COUNS, V55, P230, DOI 10.1016/j.pec.2003.09.009; KOBASA SC, 1982, J PERS SOC PSYCHOL, V42, P168, DOI 10.1037/0022-3514.42.1.168; KOBASA SC, 1979, J PERS SOC PSYCHOL, V37, P1, DOI 10.1037/0022-3514.37.1.1; Kornfield Jack, 2008, WISE HEART GUIDE UNI; Kuerer HM, 2007, ANN SURG ONCOL, V14, P3043, DOI 10.1245/s10434-007-9579-1; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Le Blanc PM, 2007, J APPL PSYCHOL, V92, P213, DOI 10.1037/0021-9010.92.1.213; Leiter MP, 2005, NEW HORIZ MANAG, P544; Linley PA, 2005, PSYCHOTHER PSYCHOSOM, V74, P185, DOI 10.1159/000084004; Mackereth Peter A, 2005, Eur J Oncol Nurs, V9, P147, DOI 10.1016/j.ejon.2004.04.006; Maslach C, 2001, ANNU REV PSYCHOL, V52, P397, DOI 10.1146/annurev.psych.52.1.397; Maslach C, 2003, CURR DIR PSYCHOL SCI, V12, P189, DOI 10.1111/1467-8721.01258; Maslach C., 1996, MASLACH BURNOUT INVE, V3rd; Maslach C, 2008, J APPL PSYCHOL, V93, P498, DOI 10.1037/0021-9010.93.3.498; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Morgan Nancy P, 2008, Oncologist, V13, P196, DOI 10.1634/theoncologist.2007-0147; Mount BM, 2007, J PAIN SYMPTOM MANAG, V33, P372, DOI 10.1016/j.jpainsymman.2006.09.014; Muscatello MRA, 2006, PSYCHOL REP, V99, P641, DOI 10.2466/PR0.99.2.641-650; Neff KD, 2007, J RES PERS, V41, P139, DOI 10.1016/j.jrp.2006.03.004; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Novack DH, 1999, ACAD MED, V74, P516, DOI 10.1097/00001888-199905000-00017; O'Cleirigh C, 2008, BRIT J HEALTH PSYCH, V13, P81, DOI 10.1348/135910707X250884; Pearlman L.A., 1999, SECONDARY TRAUMATIC, P51; Pennebaker J.W., 1997, OPENING HEALING POWE; Perry Beth, 2008, Can Oncol Nurs J, V18, P87; Petrie KJ, 2004, PSYCHOSOM MED, V66, P272, DOI 10.1097/01.psy.0000116782.49850.d3; Pierce B, 2007, J PALLIAT CARE, V23, P32, DOI 10.1177/082585970702300105; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; Rabinowitz S, 1996, AAOHN J, V44, P28; RAMIREZ AJ, 1995, BRIT J CANCER, V71, P1263, DOI 10.1038/bjc.1995.244; Ramirez AJ, 1996, LANCET, V347, P724, DOI 10.1016/S0140-6736(96)90077-X; Robinson Katya, 2004, J Palliat Med, V7, P637, DOI 10.1089/jpm.2004.7.637; ROHAN EA, 2005, EXLPORATION VICARIOU; Saakvitne, 1995, TRAUMA THERAPIST COU, P31; Salston M, 2003, J TRAUMA STRESS, V16, P167, DOI 10.1023/A:1022899207206; Shanafelt T, 2006, J CLIN ONCOL, V24, P4020, DOI 10.1200/JCO.2006.05.8248; Shanafelt TD, 2005, J GEN INTERN MED, V20, P559, DOI 10.1007/s11606-005-0102-8; Shanafelt TD, 2005, ONCOLOGY-BASEL, V68, P23, DOI 10.1159/000084519; SHAPIRO S, 2008, MINDFULNESS THERAPEU; Shapiro S. L., 2005, INT J STRESS MANAGE, V12, P164, DOI [10.1037/1072-5245.12.2.164, DOI 10.1037/1072-5245.12.2.164]; Shapiro SL, 2007, TRAIN EDUC PROF PSYC, V1, P105, DOI 10.1037/1931-3918.1.2.105; Shapiro SL, 1998, J BEHAV MED, V21, P581, DOI 10.1023/A:1018700829825; SHAPIRO SL, CASS SEM JUN 27 2008; Siegal Dan, 2017, DR DAN SIEGALS HAND; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; SPANN C, 2004, POET HEALER CONT POE; Spickard A, 2002, JAMA-J AM MED ASSOC, V288, P1447, DOI 10.1001/jama.288.12.1447; Stamm B.H., 2002, PSYCHOSOCIAL STRESS, P107; Stanton AL, 2002, J CLIN ONCOL, V20, P4160, DOI 10.1200/JCO.2002.08.521; Taylor C, 2005, LANCET, V366, P742, DOI 10.1016/S0140-6736(05)67178-4; TEDESCHI RG, 1995, TRAUMA TRANSFORMATIO, P43; Travado L, 2005, PSYCHO-ONCOLOGY, V14, P661, DOI 10.1002/pon.890; Vachon M., 2007, PRINCIPLES PRACTICE, V3rd, P667; VACHON MLS, 1995, PALLIATIVE MED, V9, P91, DOI 10.1177/026921639500900202; Vachon MLS, 2009, HDB PSYCHIAT PALLIAT; Vachon MLS., 1987, OCCUPATIONAL STRESS; VACHON MLS, 2008, PALLIATIVE MED, P75; VACHON MLS, PSYCHOONCOL IN PRESS; Valent P., 2002, TREATING COMPASSION, P17; Wallace BA, 2006, AM PSYCHOL, V61, P690, DOI 10.1037/0003-066X.61.7.690; West CP, 2006, JAMA-J AM MED ASSOC, V296, P1071, DOI 10.1001/jama.296.9.1071; Whippen DA, 2004, J CLIN ONCOL, V22, p532S; WHIPPEN DA, 1991, J CLIN ONCOL, V9, P1916, DOI 10.1200/JCO.1991.9.10.1916; Wright B, 2004, PALLIATIVE MED, V18, P3, DOI 10.1191/0269216304pm866ed	111	258	263	0	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	2009	301	11					1155	1164		10.1001/jama.2009.352	http://dx.doi.org/10.1001/jama.2009.352			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	419UC	19293416				2023-01-03	WOS:000264244200021
J	Kuo, Y; Sharma, G; Freeman, JL; Goodwin, JS				Kuo, Yong-Fang; Sharma, Gulshan; Freeman, Jean L.; Goodwin, James S.			Growth in the Care of Older Patients by Hospitalists in the United States.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMBULATORY-CARE; MEDICINE; SERVICE; PHYSICIANS; OUTCOMES; QUALITY; CANCER; ASSOCIATION; IMPACT; BREAST	Background: National and population-based information on the increase in patient care by hospitalists in the United States is lacking. Methods: Using a 5% sample of Medicare beneficiaries in 1995, 1997, 1999, and the period from 2001 through 2006, we identified 120,226 physicians in general internal medicine who were providing care to older patients in 5800 U.S. hospitals. We defined hospitalists as general internists who derived 90% or more of their Medicare claims for evaluation-and-management services from the care of hospitalized patients. We then calculated the percentage of all inpatient Medicare services provided by hospitalists and identified patient and hospital characteristics associated with the receipt of hospitalist services. Results: The percentage of physicians in general internal medicine who were identified as hospitalists increased from 5.9% in 1995 to 19.0% in 2006, and the percentage of all claims for inpatient evaluation-and-management services by general internists that were attributed to hospitalists increased from 9.1% to 37.1% during this same period. Accompanying the increase in care by hospitalists was an increase in the percentage of all hospitalized Medicare patients who were treated by general internists (both hospitalists and traditional, non-hospital-based general internists), from 46.4% in 1995 to 61.0% in 2006. In a multilevel, multivariable analysis controlling for patient and hospital characteristics, the odds of receiving care from a hospitalist increased by 29.2% per year from 1997 through 2006. In 2006, there was marked geographic variation in the rates of care provided by hospitalists, with rates of more than 70% in some hospital-referral regions. Conclusions: These analyses of data from Medicare claims showed a substantial increase in the care of hospitalized patients by hospitalist physicians from 1995 to 2006. N Engl J Med 2009;360:1102-12.	[Kuo, Yong-Fang] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Kuo, Y (corresponding author), Univ Texas Med Branch, Dept Internal Med, 301 Univ Blvd, Galveston, TX 77555 USA.	yokuo@utmb.edu			Americans Independence Center [5P30AG024832]; Center for Population Health and Health Disparities [5P50CA105631]; University of Texas Medical Branch; NATIONAL CANCER INSTITUTE [P50CA105631, K05CA134923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG033134, P30AG024832] Funding Source: NIH RePORTER	Americans Independence Center; Center for Population Health and Health Disparities; University of Texas Medical Branch; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the Claude D. Pepper Older Americans Independence Center (5P30AG024832) and the Center for Population Health and Health Disparities (5P50CA105631) at the University of Texas Medical Branch.	Auerbach AD, 2002, ANN INTERN MED, V137, P859, DOI 10.7326/0003-4819-137-11-200212030-00006; Ayanian JZ, 2002, NEW ENGL J MED, V347, P1678, DOI 10.1056/NEJMsa020080; Baldwin LM, 2002, MED CARE, V40, P82; Coffman J, 2005, MED CARE RES REV, V62, P379, DOI 10.1177/1077558705277379; Freed David H, 2004, Health Care Manag (Frederick), V23, P238; Freed GL, 2007, PEDIATRICS, V120, P33, DOI 10.1542/peds.2007-0304; Glasheen JJ, 2007, ARCH INTERN MED, V167, P727, DOI 10.1001/archinte.167.7.727; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; Kearns PJ, 2001, ARCH INTERN MED, V161, P235, DOI 10.1001/archinte.161.2.235; Keating NL, 2005, J GEN INTERN MED, V20, P38, DOI 10.1111/j.1525-1497.2004.40079.x; Kralovec PD, 2006, J HOSP MED, V1, P75, DOI 10.1002/jhm.82; Lackan NA, 2004, MED CARE, V42, P116, DOI 10.1097/01.mlr.0000108765.86294.1b; Landrigan CP, 2006, PEDIATRICS, V117, P1736, DOI 10.1542/peds.2005-0609; Lindenauer PK, 2007, NEW ENGL J MED, V357, P2589, DOI 10.1056/NEJMsa067735; Lindenauer PK, 1999, ANN INTERN MED, V130, P343, DOI 10.7326/0003-4819-130-4-199902161-00003; Meltzer D, 2002, ANN INTERN MED, V137, P866, DOI 10.7326/0003-4819-137-11-200212030-00007; Palmer HC, 2001, AM J MED, V111, P627, DOI 10.1016/S0002-9343(01)00976-7; Saint S, 2000, Eff Clin Pract, V3, P35; *SHM, 2008, SOC HOSP MED REL RES; Snyder CF, 2008, J GEN INTERN MED, V23, P254, DOI 10.1007/s11606-007-0497-5; *SOC HOSP MED, 2007, HOSP MED SPEC SHOWS; The Dartmouth Atlas of Health Care, ZIP COD CROSSW FIL H; Vansaghi LM, 2008, AM J MED, V121, P349, DOI 10.1016/j.amjmed.2007.11.019; VASILEVSKIS EE, 2007, RISE HOSP CALIFORNIA; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; Wachter RM, 2008, MED CLIN N AM, V92, P265, DOI 10.1016/j.mcna.2007.10.008	27	180	180	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 12	2009	360	11					1102	1112		10.1056/NEJMsa0802381	http://dx.doi.org/10.1056/NEJMsa0802381			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	417BW	19279342	Bronze, Green Accepted			2023-01-03	WOS:000264051000008
J	Winkelmayer, WC; Liu, J; Brookhart, MA				Winkelmayer, Wolfgang C.; Liu, Jun; Brookhart, M. Alan			Altitude and All-Cause Mortality in Incident Dialysis Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-DISEASE; HIF-1	Context Patients undergoing dialysis at higher altitude receive lower erythropoietin doses, yet achieve higher hemoglobin concentrations. Increased iron availability caused by activation of hypoxia- induced factors at higher altitude may explain this finding. Hypoxia- induced factors are also involved in other pathways that may affect morbidity and mortality. Objective To study whether mortality differed by altitude in patients initiating dialysis. Design, Setting, and Participants Retrospective cohort of patients initiating dialysis in the United States between 1995 and 2004. Patients were stratified by the average elevation of their residential zip code. Covariates included age, sex, race, Medicaid coverage, dialysis modality, comorbidities, and reported laboratory measurements. We constructed proportional hazards models of all- cause mortality, stratifying by year, and censoring patients at 5 years from first dialysis, at the end of the database ( December 31, 2004), or loss to follow- up. We also compared age- and sex- adjusted standardized mortality rates of US patients receiving dialysis with the general population. Main Outcome Measure Mortality from any cause. Results A total of 804 812 patients initiated dialysis and were followed up for a median of 1.78 years. Crude mortality rates per 1000 person- years were 220.1 at an altitude lower than 76 m ( <250 ft), 221.2 from 76 through 609 m ( 250- 1999 ft), 214.6 from 610 through 1218 m ( 2000- 3999 ft), 184.9 from 1219 through 1828 m ( 4000 to 5999 ft), and 177.2 at an altitude higher than 1828 m ( > 6000 ft). After multivariable adjustment, compared with patients living at an altitude of lower than 76 m, the relative mortality rates were 0.97 ( 95% confidence interval [ CI], 0.96- 0.98) for those living from 76 through 609 m; 0.93 ( 95% CI, 0.91- 0.95), from 610 through 1218 m; 0.88 ( 95% CI, 0.84- 0.91), from 1219 through 1828 m, and 0.85 ( 95% CI, 0.79-0.92) higher than 1828 m. Age- and sex- standardized mortality decreased more with altitude in patients receiving dialysis than in the general population. Conclusions Altitude was inversely associated with all- cause mortality among US patients receiving dialysis.	[Winkelmayer, Wolfgang C.; Liu, Jun; Brookhart, M. Alan] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Boston, MA 02120 USA; [Winkelmayer, Wolfgang C.; Liu, Jun; Brookhart, M. Alan] Harvard Univ, Sch Med, Boston, MA 02120 USA; [Winkelmayer, Wolfgang C.] Brigham & Womens Hosp, Div Renal, Dept Med, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Winkelmayer, WC (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, 1620 Tremont St,Ste 3-030, Boston, MA 02120 USA.	wwinkelmayer@partners.org			American Heart Association [0535232N]; National Institute on Aging [AG-027400]; NATIONAL INSTITUTE ON AGING [K25AG027400] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Winkelmayer is supported by Scientist Development Grant 0535232N from the American Heart Association. Dr Brookhart is supported by career development award AG-027400 from the National Institute on Aging.	Baibas N, 2005, J EPIDEMIOL COMMUN H, V59, P274, DOI 10.1136/jech.2004.025510; Brookhart MA, 2008, J AM SOC NEPHROL, V19, P1389, DOI 10.1681/ASN.2007111181; BUECHLEY RW, 1979, AM J EPIDEMIOL, V109, P663, DOI 10.1093/oxfordjournals.aje.a112729; *CDC WONDER, COMPR MORT FIL 1999; Dawn B, 2005, AM J PHYSIOL-HEART C, V289, pH522, DOI 10.1152/ajpheart.00274.2005; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Maxwell P, 2003, J AM SOC NEPHROL, V14, P2712, DOI 10.1097/01.ASN.0000092792.97122.E0; MORTIMER EA, 1977, NEW ENGL J MED, V296, P581, DOI 10.1056/NEJM197703172961101; REGENSTEINER JG, 1985, JAMA-J AM MED ASSOC, V253, P3124, DOI 10.1001/jama.253.21.3124; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; WEINBERG CR, 1987, RADIAT RES, V112, P381, DOI 10.2307/3577265	11	47	49	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2009	301	5					508	512		10.1001/jama.2009.84	http://dx.doi.org/10.1001/jama.2009.84			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402CS	19190315	Bronze			2023-01-03	WOS:000262992400020
J	Vasan, A; Kim, JY				Vasan, Ashwin; Kim, Jim Yong			Essential medicines pricing-reform needed	LANCET			English	Editorial Material							MIDDLE-INCOME COUNTRIES; CHRONIC DISEASES; PRICES; DRUGS		[Vasan, Ashwin; Kim, Jim Yong] Partners Hlth, Boston, MA USA; [Vasan, Ashwin] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Infect Dis Epidemiol Unit, London WC1E 7HT, England; [Kim, Jim Yong] Harvard Univ, Sch Publ Hlth, FXB Ctr Hlth & Human Rights, Boston, MA 02115 USA; [Kim, Jim Yong] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA	Partners Healthcare System; University of London; London School of Hygiene & Tropical Medicine; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Vasan, A (corresponding author), Partners Hlth, Boston, MA USA.	ashwin.vasan@lshtm.ac.uk						Abegunde DO, 2007, LANCET, V370, P1929, DOI 10.1016/S0140-6736(07)61696-1; Beaglehole R, 2003, LANCET, V362, P903, DOI 10.1016/S0140-6736(03)14335-8; CAMERON A, 2008, LANCET          1201; Gupta R, 2002, TROP MED INT HEALTH, V7, P970, DOI 10.1046/j.1365-3156.2002.00960.x; Hagmann M, 2001, B WORLD HEALTH ORGAN, V79, P904; Laing RO, 2001, HEALTH POLICY PLANN, V16, P13, DOI 10.1093/heapol/16.1.13; Laing RO, 2000, INT J TUBERC LUNG D, V4, pS194; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Sharma DC, 2003, LANCET, V362, P1467, DOI 10.1016/S0140-6736(03)14735-6; *UNAIDS, 2008, 2008 REP GLOB AIDS E; Vasan A, 2006, B WORLD HEALTH ORGAN, V84, P393, DOI 10.2471/BLT.05.025684; *WHO, 2008, MED PRIC INF; *WHO, 2008, DRUG REG STAT DAT AI; *WHO UNICEF UNAIDS, 2005, SOURC PRIC SEL MED D; 2008, CLINTON FDN SIGNS PR; 2008, CAMPAIGN ACCESS ESSE	16	4	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 17	2009	373	9659					191	193		10.1016/S0140-6736(08)61763-8	http://dx.doi.org/10.1016/S0140-6736(08)61763-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	395QB	19042013				2023-01-03	WOS:000262537500007
J	Grossman, D				Grossman, Daniel			Should the contraceptive pill be available without prescription? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							ORAL-CONTRACEPTIVES; HORMONAL CONTRACEPTION; NATIONAL-SURVEY; UNITED-STATES; WOMENS; ACCESS; MEXICO; GUIDELINES; ATTITUDES; FAILURE		[Grossman, Daniel] Ibis Reprod Hlth, San Francisco, CA USA; [Grossman, Daniel] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Grossman, D (corresponding author), Ibis Reprod Hlth, San Francisco, CA USA.	DGrossman@ibisreproductivehealth.org	Potter, Joseph E/A-3122-2008					Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1; Editorial, 2008, LANCET, V371, P275; Foster DG, 2006, OBSTET GYNECOL, V108, P1107, DOI 10.1097/01.AOG.0000239122.98508.39; Gardner JS, 2008, J AM PHARM ASSOC, V48, P212, DOI 10.1331/JAPhA.2008.07138; Gianfrancesco F., 2002, DRUG BENEFIT TRENDS, V14, P13; Gianfrancesco F, 2002, DRUG BENEFIT TRENDS, V14, P44; Glasier A, 2008, J FAM PLAN REPROD H, V34, P213, DOI 10.1783/147118908786000497; Grossman D, 2006, AM J PUBLIC HEALTH, V96, P791, DOI 10.2105/AJPH.2004.040774; Grossman D, 2008, OBSTET GYNECOL, V112, P572, DOI 10.1097/AOG.0b013e31818345f0; Kost K, 2008, CONTRACEPTION, V77, P10, DOI 10.1016/j.contraception.2007.09.013; Landau SC, 2006, CONTRACEPTION, V74, P463, DOI 10.1016/j.contraception.2006.07.006; Moos MK, 2003, CONTRACEPTION, V67, P115, DOI 10.1016/S0010-7824(02)00472-9; *NAT I REPR HLTH, EXP MED COV EC STAT; *POP REF BUR, FAM PLANN WORLDW 200; Schwingl PJ, 1999, AM J OBSTET GYNECOL, V180, P241, DOI 10.1016/S0002-9378(99)70182-1; Shah MA, 2001, INT J GYNECOL OBSTET, V73, P243, DOI 10.1016/S0020-7292(01)00375-7; Shotorbani S, 2006, CONTRACEPTION, V73, P501, DOI 10.1016/j.contraception.2005.12.001; Smith JD, 2005, J MIDWIFERY WOM HEAL, V50, P380, DOI 10.1016/j.jmwh.2005.01.011; Stewart FH, 2001, JAMA-J AM MED ASSOC, V285, P2232, DOI 10.1001/jama.285.17.2232; Tatum C, 2005, CONTRACEPTION, V71, P208, DOI 10.1016/j.contraception.2004.08.018; Trussell J, 2004, CONTRACEPTION, V70, P89, DOI 10.1016/j.contraception.2004.03.009; WHO, 2004, MED EL CRIT CONTR US, V3; Yeatman SE, 2006, STUD FAMILY PLANN, V37, P197, DOI 10.1111/j.1728-4465.2006.00098.x; ZAVALA AS, 1987, STUD FAMILY PLANN, V18, P284, DOI 10.2307/1966857	24	7	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 23	2008	337								a3044	10.1136/bmj.a3044	http://dx.doi.org/10.1136/bmj.a3044			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	394EL	19106138				2023-01-03	WOS:000262428400003
J	Nickoloff, BJ				Nickoloff, Brian J.			Saving the skin from drug-induced detachment	NATURE MEDICINE			English	Editorial Material							TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON-SYNDROME; CYTOTOXIC T-CELLS; RISK		Loyola Univ, Chicago Med Ctr, Maywood, IL 60153 USA	Loyola University Chicago	Nickoloff, BJ (corresponding author), Loyola Univ, Chicago Med Ctr, Bldg 112,Room 301,2160 S 1st Ave, Maywood, IL 60153 USA.	bnickol@lumc.edu						Abe R, 2003, AM J PATHOL, V162, P1515, DOI 10.1016/S0002-9440(10)64284-8; Benyo Z, 2006, MOL PHARMACOL, V70, P1844, DOI 10.1124/mol.106.030833; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; CORREIA O, 1993, ARCH DERMATOL, V129, P466, DOI 10.1001/archderm.129.4.466; Ferrell PB, 2008, PHARMACOGENOMICS, V9, P1543, DOI 10.2217/14622416.9.10.1543; Le Cleach L, 2000, CLIN EXP IMMUNOL, V119, P225, DOI 10.1046/j.1365-2249.2000.01119.x; MIYAUCHI H, 1991, ARCH DERMATOL, V127, P851, DOI 10.1001/archderm.127.6.851; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Nassif A, 2002, J INVEST DERMATOL, V118, P728, DOI 10.1046/j.1523-1747.2002.01622.x; Quinn AM, 2005, ARCH DERMATOL, V141, P683, DOI 10.1001/archderm.141.6.683; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Watanabe H, 2008, J IMMUNOL, V180, P5826, DOI 10.4049/jimmunol.180.9.5826; WOLKENSTEIN P, 1995, ARCH DERMATOL, V131, P544, DOI 10.1001/archderm.131.5.544	14	12	12	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	DEC	2008	14	12					1311	1313		10.1038/nm1208-1311	http://dx.doi.org/10.1038/nm1208-1311			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	379JX	19057552				2023-01-03	WOS:000261393600011
J	Schuster, MG; Edwards, JE; Sobel, JD; Darouiche, RO; Karchmer, AW; Hadley, S; Slotman, G; Panzer, H; Biswas, P; Rex, JH				Schuster, Mindy G.; Edwards, John E., Jr.; Sobel, Jack D.; Darouiche, Rabih O.; Karchmer, Adolf W.; Hadley, Susan; Slotman, Gus; Panzer, Helene; Biswas, Pinaki; Rex, John H.			Empirical fluconazole versus placebo for intensive care unit patients - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; SURGICAL-PATIENTS; DOUBLE-BLIND; PROSPECTIVE MULTICENTER; NEUTROPENIC PATIENTS; CANDIDAL INFECTIONS; AMPHOTERICIN-B; RISK-FACTORS; EPIDEMIOLOGY; PROPHYLAXIS	Background: Invasive infection with Candida species is an important cause of morbidity and mortality in intensive care unit (ICU) patients. Optimal preventive strategies have not been clearly defined. Objective: To see whether empirical fluconazole improves clinical outcomes more than placebo in adult ICU patients at high risk for invasive candidiasis. Design: Double-blind, placebo-controlled, randomized trial conducted from 1995 to 2000. Setting: 26 ICUs in the United States. Patients: 270 adult ICU patients with fever despite administration of broad-spectrum antibiotics. All had central venous catheters and an Acute Physiology and Chronic Health Evaluation II score greater than 16. Intervention: Patients were randomly assigned to either intravenous fluconazole, 800 mg daily, or placebo for 2 weeks and were followed for 4 weeks thereafter. Two hundred forty-nine participants were available for outcome assessment. Measurements: A composite primary outcome that defined success as all 4 of the following: resolution of fever; absence of invasive fungal infection; no discontinuation because of toxicity; and no need for a nonstudy, systemic antifungal medication (as assessed by a blinded oversight committee). Results: Only 44 of 122 (36%) fluconazole recipients and 48 of 127 (38%) placebo recipients had a successful outcome (relative risk, 0.95 [95% CI, 0.69 to 1.32; P = 0.781). The main reason for failure was lack of resolution of fever (51 % for fluconazole and 57% for placebo). Documented invasive candidiasis occurred in 5% of fluconazole recipients and 9% of placebo recipients (relative risk, 0.57 [CI, 0.22 to 1.491). Seven (5%) fluconazole recipients and 10 (7%) placebo recipients had adverse events resulting in discontinuation of the study drug. Discontinuation because of abnormal liver test results occurred in 3 (2%) fluconazole recipients and 5 (4%) placebo recipients. Limitations: Twenty-one randomly assigned patients were not included in the analysis because they either did not meet entry criteria or did not have postbaseline assessments. Fewer fungal infections than anticipated occurred in the control group. Confidence bounds were wide and did not exclude potentially important differences in outcomes between groups. Conclusion: In critically ill adults with risk factors for invasive candidiasis, empirical fluconazole did not clearly improve a composite outcome more than placebo.	[Schuster, Mindy G.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Harbor Med Ctr, Torrance, CA 90509 USA; Wayne State Univ, Sch Med, Detroit Med Ctr, Detroit, MI USA; Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX 77030 USA; Univ Texas Houston, Sch Med, Houston, TX USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Tufts Univ New England Med Ctr, Boston, MA USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA; Pfizer, New York, NY USA	University of Pennsylvania; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Detroit Medical Center; Wayne State University; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; University of Texas System; University of Texas Health Science Center Houston; Harvard University; Beth Israel Deaconess Medical Center; Tufts Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Pfizer	Schuster, MG (corresponding author), Univ Penn, Sch Med, 3 Silverstein,Suite E,3400 Spruce St, Philadelphia, PA 19104 USA.	schustem@mail.med.upenn.edu		Rex, John/0000-0003-3265-5872				AbiSaid D, 1997, CLIN INFECT DIS, V24, P1122, DOI 10.1086/513663; Ables AZ, 2000, INFECT DIS CLIN PRAC, V9, P169, DOI 10.1097/00019048-200009040-00006; BERENGUER J, 1993, DIAGN MICR INFEC DIS, V17, P103, DOI 10.1016/0732-8893(93)90020-8; Blumberg HM, 2001, CLIN INFECT DIS, V33, P177, DOI 10.1086/321811; BROSS J, 1989, AM J MED, V87, P614, DOI 10.1016/S0002-9343(89)80392-4; Cruciani M, 2005, INTENS CARE MED, V31, P1479, DOI 10.1007/s00134-005-2794-y; Eggimann P, 1999, CRIT CARE MED, V27, P1066, DOI 10.1097/00003246-199906000-00019; Garbino J, 2002, INTENS CARE MED, V28, P1708, DOI 10.1007/s00134-002-1540-y; GARBINO J, 1998, CLIN INTENSIVE CARE, V9, P25; Golan Y, 2005, ANN INTERN MED, V143, P857, DOI 10.7326/0003-4819-143-12-200512200-00004; Hughes WT, 1997, CLIN INFECT DIS, V25, P551, DOI 10.1086/513764; Macphail GLP, 2002, MYCOSES, V45, P141, DOI 10.1046/j.1439-0507.2002.00741.x; NollaSalas J, 1997, INTENS CARE MED, V23, P23, DOI 10.1007/s001340050286; Pelz RK, 2001, ANN SURG, V233, P542, DOI 10.1097/00000658-200104000-00010; Petri MG, 1997, INTENS CARE MED, V23, P317, DOI 10.1007/s001340050334; PITTET D, 1994, ANN SURG, V220, P751, DOI 10.1097/00000658-199412000-00008; PIZZO PA, 1993, NEW ENGL J MED, V328, P1323; Rentz AM, 1998, CLIN INFECT DIS, V27, P781, DOI 10.1086/514955; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; Rex JH, 2003, CLIN INFECT DIS, V36, P1221, DOI 10.1086/374850; REX JH, 1995, ANTIMICROB AGENTS CH, V39, P1, DOI 10.1128/AAC.39.1.1; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WEY SB, 1988, ARCH INTERN MED, V148, P2642, DOI 10.1001/archinte.148.12.2642; White MH, 1997, CLIN INFECT DIS, V24, P1129, DOI 10.1086/513661; WINGARD JR, 1993, ANTIMICROB AGENTS CH, V37, P1847, DOI 10.1128/AAC.37.9.1847; WRIGARD JR, 1991, NEW ENGL J MED, V325, P1274; Zaoutis TE, 2005, CLIN INFECT DIS, V41, P1232, DOI 10.1086/496922	27	152	164	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	2008	149	2					83	90		10.7326/0003-4819-149-2-200807150-00004	http://dx.doi.org/10.7326/0003-4819-149-2-200807150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	329GA	18626047				2023-01-03	WOS:000257853700002
J	Hunder, NN; Wallen, H; Cao, JH; Hendricks, DW; Reilly, JZ; Rodmyre, R; Jungbluth, A; Gnjatic, S; Thompson, JA; Yee, C				Hunder, Naomi N.; Wallen, Herschel; Cao, Jianhong; Hendricks, Deborah W.; Reilly, John Z.; Rodmyre, Rebecca; Jungbluth, Achim; Gnjatic, Sacha; Thompson, John A.; Yee, Cassian			Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							T-CELLS; IMMUNE-RESPONSE; ADOPTIVE IMMUNOTHERAPY; CANCER-PATIENTS; TUMOR-ANTIGENS; PHASE-I; LYMPHOCYTES; THERAPY; PEPTIDE; SPECIFICITIES	We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1. We infused these cells into a patient with refractory metastatic melanoma who had not undergone any previous conditioning or cytokine treatment. We show that the transferred CD4+ T cells mediated a durable clinical remission and led to endogenous responses against melanoma antigens other than NY-ESO-1.	[Hunder, Naomi N.; Wallen, Herschel; Cao, Jianhong; Hendricks, Deborah W.; Reilly, John Z.; Rodmyre, Rebecca; Yee, Cassian] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; [Thompson, John A.; Yee, Cassian] Univ Washington, Seattle, WA 98195 USA; [Jungbluth, Achim; Gnjatic, Sacha] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res New York Branch, New York, NY 10021 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center	Yee, C (corresponding author), Fred Hutchinson Canc Res Ctr, Room D3-100,1100 Fairview Ave N, Seattle, WA 98109 USA.	cyee@fhcrc.org	Thompson, John A/T-7985-2019	Thompson, John A/0000-0002-0872-7306; Gnjatic, Sacha/0000-0001-5643-9520	NATIONAL CANCER INSTITUTE [R01CA104711, R21CA128283] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000037] Funding Source: NIH RePORTER; NCI NIH HHS [CA1047113, R21 CA128283-02, R01 CA104711-05, CA12823, R21 CA128283, R01 CA104711] Funding Source: Medline; NCRR NIH HHS [M01 RR000037-47, M01 RR000037] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Gattinoni L, 2006, NAT REV IMMUNOL, V6, P383, DOI 10.1038/nri1842; Gnjatic S, 2003, P NATL ACAD SCI USA, V100, P8862, DOI 10.1073/pnas.1133324100; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; GREENBERG PD, 1985, J EXP MED, V161, P1122, DOI 10.1084/jem.161.5.1122; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Khong HT, 2004, J IMMUNOTHER, V27, P472, DOI 10.1097/00002371-200411000-00007; Li YQ, 2005, J IMMUNOL, V175, P2261, DOI 10.4049/jimmunol.175.4.2261; Liao XS, 2004, MOL THER, V9, P757, DOI 10.1016/j.ymthe.2004.02.011; Mackensen A, 2006, J CLIN ONCOL, V24, P5060, DOI 10.1200/JCO.2006.07.1100; Mitchell MS, 2002, J CLIN ONCOL, V20, P1075, DOI 10.1200/JCO.20.4.1075; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; Odunsi K, 2007, P NATL ACAD SCI USA, V104, P12837, DOI 10.1073/pnas.0703342104; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; ROMERDAHL CA, 1988, CANCER RES, V48, P2325; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zeng G, 2002, CANCER RES, V62, P3630	20	683	734	0	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2008	358	25					2698	2703		10.1056/NEJMoa0800251	http://dx.doi.org/10.1056/NEJMoa0800251			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314NC	18565862	Green Accepted, Bronze			2023-01-03	WOS:000256815100006
J	Robinson, RG; Jorge, RE; Moser, DJ; Acion, L; Solodkin, A; Small, SL; Fonzetti, P; Hegel, M; Arndt, S				Robinson, Robert G.; Jorge, Ricardo E.; Moser, David J.; Acion, Laura; Solodkin, Ana; Small, Steven L.; Fonzetti, Pasquale; Hegel, Mark; Arndt, Stephan			Escitalopram and problem-solving therapy for prevention of poststroke depression - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; MOOD DISORDERS; ANXIETY DISORDER; MAJOR DEPRESSION; STROKE PATIENTS; HEART-DISEASE; PLACEBO; MORTALITY; SYMPTOMS; NORTRIPTYLINE	Context Depression occurs in more than half of patients who have experienced a stroke. Poststroke depression has been shown in numerous studies to be associated with both impaired recovery in activities of daily living and increased mortality. Prevention of depression thus represents a potentially important goal. Objective To determine whether treatment with escitalopram or problem- solving therapy over the first year following acute stroke will decrease the number of depression cases that develop compared with placebo medication. Design, Setting, and Participants A multisite randomized controlled trial for prevention of depression among 176 nondepressed patients was conducted within 3 months following acute stroke from July 9, 2003, to October 1, 2007. The 12- month trial included 3 groups: a double- blind placebo- controlled comparison of escitalopram ( n= 59) with placebo ( n= 58), and a nonblinded problem- solving therapy group ( n= 59). Main Outcome Measures The main outcome measure was the development of major or minor poststroke depression based on symptoms elicited by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders ( Fourth Edition) ( DSM- IV) and the diagnostic criteria from DSM- IV for depression due to stroke with major depressivelike episode or minor depression ( ie, research criteria). Results Patients who received placebo were significantly more likely to develop depression than individuals who received escitalopram ( 11 major and 2 minor cases of depression [ 22.4%] vs 3 major and 2 minor cases of depression [ 8.5%], adjusted hazard ratio [ HR], 4.5; 95% confidence interval [ CI], 2.4- 8.2; P <. 001) and also more likely than individuals who received problem- solving therapy ( 5 major and 2 minor cases of depression [ 11.9%], adjusted HR, 2.2; 95% CI, 1.4- 3.5; P <. 001). These results were adjusted for history of mood disorders and remained significant after considering possible confounders such as age, sex, treatment site, and severity of impairment in the model. Using an intention- to-treat conservative method of analyzing the data, which assumed that all 27 patients who did not start randomized treatment would have developed depression, and controlling for prior history of mood disorders, escitalopram was superior to placebo ( 23.1% vs 34.5%; adjusted HR, 2.2; 95% CI, 1.2- 3.9; P=. 007), while problem- solving therapy was not significantly better than placebo( 30.5% vs 34.5%; adjusted HR, 1.1; 95% CI, 0.8- 1.5; P=. 51). Adverse events, including all- cause hospitalizations, nausea, and adverse effects associated with escitalopram were not significantly different between the 3 groups. Conclusions In this study of nondepressed patients with recent stroke, the use of escitalopram or problem- solving therapy resulted in a significantly lower incidence of depression over 12 months of treatment compared with placebo, but problem- solving therapy did not achieve significant results over placebo using the intention- to- treat conservative method of analysis. Trial Registration clinicaltrials. gov Identifier: NCT00071643.	[Robinson, Robert G.; Jorge, Ricardo E.; Moser, David J.; Acion, Laura; Arndt, Stephan] Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA; [Acion, Laura; Arndt, Stephan] Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA 52242 USA; [Solodkin, Ana; Small, Steven L.] Univ Chicago, Dept Neurol, Chicago, IL 60637 USA; [Fonzetti, Pasquale] Cornell Univ, Burke Rehabil Ctr, Weill Med Coll, White Plains, NY USA; [Hegel, Mark] Dartmouth Med Sch, Dept Psychiat, Hanover, NH USA; [Hegel, Mark] Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH USA	University of Iowa; University of Iowa; University of Chicago; Cornell University; Dartmouth College; Dartmouth College	Robinson, RG (corresponding author), Univ Iowa, Dept Psychiat, Carver Coll Med, 200 Hawkins Dr, Iowa City, IA 52242 USA.	robert-robinson@uiowa.edu	Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; Small, Steven/0000-0002-5293-6172; Moser, David/0000-0003-4102-5266; Acion, Laura/0000-0001-5213-6012	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH065134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054942] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH-65134, R01 MH065134] Funding Source: Medline; NINDS NIH HHS [R01 NS054942-01A2, R01 NS054942] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Almeida OP, 2006, J CLIN PSYCHIAT, V67, P1104, DOI 10.4088/JCP.v67n0713; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSEN G, 1994, ACTA PSYCHIAT SCAND, V90, P190, DOI 10.1111/j.1600-0447.1994.tb01576.x; ASTROM M, 1993, STROKE, V24, P976, DOI 10.1161/01.STR.24.7.976; Bender R, 2001, CONTROL CLIN TRIALS, V22, P102, DOI 10.1016/S0197-2456(00)00134-3; Berg A, 2003, STROKE, V34, P138, DOI 10.1161/01.STR.0000048149.84268.07; BURVILL PW, 1995, BRIT J PSYCHIAT, V166, P320, DOI 10.1192/bjp.166.3.320; CAPLAN GA, 1964, CONCEPTUAL MODEL PRI; Chen Y, 2007, INT CLIN PSYCHOPHARM, V22, P159, DOI 10.1097/YIC.0b013e32807fb028; *COMM PREV MENT DI, 1997, RED RISKS MENT DIS F; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEIBEL JH, 1982, ARCH PHYS MED REHAB, V63, P276; Forer S, 1987, FUNCTIONAL INDEPENDE; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; Hegel MT, 2002, BEHAV THER, V33, P511, DOI 10.1016/S0005-7894(02)80014-4; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; House A, 2001, STROKE, V32, P696, DOI 10.1161/01.STR.32.3.696; HOUSE A, 1991, BRIT J PSYCHIAT, V158, P83, DOI 10.1192/bjp.158.1.83; Jorge RE, 2003, AM J PSYCHIAT, V160, P1823, DOI 10.1176/appi.ajp.160.10.1823; Kimura M, 2003, AM J GERIAT PSYCHIAT, V11, P320, DOI 10.1176/appi.ajgp.11.3.320; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; KUNITZ SC, 1984, STROKE, V15, P740, DOI 10.1161/01.STR.15.4.740; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Moore N, 2005, INT CLIN PSYCHOPHARM, V20, P131, DOI 10.1097/00004850-200505000-00002; MORRIS PLP, 1993, AM J PSYCHIAT, V150, P124; MORRIS PLP, 1990, INT J PSYCHIAT MED, V20, P349, DOI 10.2190/N8VU-6LWU-FLJN-XQKV; MORRIS PLP, 1993, AUST NZ J PSYCHIAT, V27, P443, DOI 10.3109/00048679309075801; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Narushima K, 2003, J NERV MENT DIS, V191, P645, DOI 10.1097/01.nmd.0000092197.97693.d2; Narushima K, 2007, BRIT J PSYCHIAT, V190, P260, DOI 10.1192/bjp.bp.106.025064; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Palomaki H, 1999, J NEUROL NEUROSUR PS, V66, P490, DOI 10.1136/jnnp.66.4.490; Paradiso S, 1997, INT J PSYCHIAT MED, V27, P137, DOI 10.2190/BWJA-KQP3-7VUY-D06T; Randolph C., 1998, REPEATABLE BATTERY A; Rasmussen A, 2003, PSYCHOSOMATICS, V44, P216, DOI 10.1176/appi.psy.44.3.216; Robinson R.G., 2006, CLIN NEUROPSYCHIATRY; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Robinson RG, 2000, AM J PSYCHIAT, V157, P351, DOI 10.1176/appi.ajp.157.3.351; Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; SCHUBERT DSP, 1992, PSYCHOSOMATICS, V33, P290, DOI 10.1016/S0033-3182(92)71967-7; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shimoda K, 1998, J NEUROPSYCH CLIN N, V10, P34, DOI 10.1176/jnp.10.1.34; Spitzer RL, 1995, STRUCTURED CLIN INTE; Starr L B, 1982, Soc Work Res Abstr, V18, P28; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Tamminga CA, 2002, BIOL PSYCHIAT, V52, P589, DOI 10.1016/S0006-3223(02)01470-1; Thom T, 2006, CIRCULATION, V113, pE85, DOI 10.1161/CIRCULATIONAHA.105.171600; Williams LS, 2004, AM J PSYCHIAT, V161, P1090, DOI 10.1176/appi.ajp.161.6.1090; Wong ML, 2001, NAT REV NEUROSCI, V2, P343, DOI 10.1038/35072566	53	247	269	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2391	2400		10.1001/jama.299.20.2391	http://dx.doi.org/10.1001/jama.299.20.2391			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505948	Green Accepted, Bronze			2023-01-03	WOS:000256151900023
J	Angulo-Barturen, I; Jimenez-Diaz, MB; Mulet, T; Rullas, J; Herreros, E; Ferrer, S; Jimenez, E; Mendoza, A; Regadera, J; Rosenthal, PJ; Bathurst, I; Pompliano, DL; de las Heras, FG; Gargallo-Viola, D				Angulo-Barturen, Inigo; Belen Jimenez-Diaz, Maria; Mulet, Teresa; Rullas, Joaquin; Herreros, Esperanza; Ferrer, Santiago; Jimenez, Elena; Mendoza, Alfonso; Regadera, Javier; Rosenthal, Philip J.; Bathurst, Ian; Pompliano, David L.; Gomez de las Heras, Federico; Gargallo-Viola, Domingo			A Murine Model of falciparum-Malaria by In Vivo Selection of Competent Strains in Non-Myelodepleted Mice Engrafted with Human Erythrocytes	PLOS ONE			English	Article								To counter the global threat caused by Plasmodium falciparum malaria, new drugs and vaccines are urgently needed. However, there are no practical animal models because P. falciparum infects human erythrocytes almost exclusively. Here we describe a reliable falciparum murine model of malaria by generating strains of P. falciparum in vivo that can infect immunodeficient mice engrafted with human erythrocytes. We infected NODscid/beta 2m-/- mice engrafted with human erythrocytes with P. falciparum obtained from in vitro cultures. After apparent clearance, we obtained isolates of P. falciparum able to grow in peripheral blood of engrafted NODscid/beta 2m-/- mice. Of the isolates obtained, we expanded in vivo and established the isolate Pf3D7(0087/N9) as a reference strain for model development. Pf3D7(0087/N9) caused productive persistent infections in 100% of engrafted mice infected intravenously. The infection caused a relative anemia due to selective elimination of human erythrocytes by a mechanism dependent on parasite density in peripheral blood. Using this model, we implemented and validated a reproducible assay of antimalarial activity useful for drug discovery. Thus, our results demonstrate that P. falciparum contains clones able to grow reproducibly in mice engrafted with human erythrocytes without the use of myeloablative methods.	[Angulo-Barturen, Inigo; Belen Jimenez-Diaz, Maria; Mulet, Teresa; Rullas, Joaquin; Herreros, Esperanza; Ferrer, Santiago; Jimenez, Elena; Mendoza, Alfonso; Gomez de las Heras, Federico; Gargallo-Viola, Domingo] GlaxoSmithKline Inc, ID CEDD, Dis Developing World, Madrid, Spain; [Regadera, Javier] Univ Autonoma Madrid, Fac Med, Dept Anat, Histol & Neurosci, Madrid, Spain; [Rosenthal, Philip J.] Univ Calif San Francisco, San Francisco General Hosp, Dept Med, San Francisco, CA USA; [Bathurst, Ian] MMV, Geneva, Switzerland; [Pompliano, David L.] GlaxoSmithKline Inc, ID CEDD, Collegeville, PA USA	GlaxoSmithKline; Autonomous University of Madrid; University of California System; University of California San Francisco; GlaxoSmithKline	Angulo-Barturen, I (corresponding author), GlaxoSmithKline Inc, ID CEDD, Dis Developing World, Madrid, Spain.	inigo.x.angulo@gsk.com	Herreros, Esperanza/GQH-7182-2022; Mendoza-Losana, Alfonso/AAF-4383-2021; Ferrer-Bazaga, Santiago/AAA-7749-2021	Mendoza-Losana, Alfonso/0000-0003-2493-4118; Ferrer-Bazaga, Santiago/0000-0002-6672-551X	GlaxoSmithKline-Diseases of the Developing World	GlaxoSmithKline-Diseases of the Developing World	Maria Belen Jimenez-Diaz, Teresa Mulet and Joaquin Rullas were funded by Medicines for Malaria Venture Miniportfolio Agreement with GlaxoSmithKline-Diseases of the Developing World	Angulo I, 2000, BLOOD, V95, P212; [Anonymous], 1999, HDB ANIMAL MODELS IN; BADELL E, 1995, PARASITOL TODAY, V11, P235, DOI 10.1016/0169-4758(95)80088-3; Badell E, 2000, J EXP MED, V192, P1653, DOI 10.1084/jem.192.11.1653; Barry AE, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030034; BELL CA, 1990, ANTIMICROB AGENTS CH, V34, P1381, DOI 10.1128/AAC.34.7.1381; Bogdanova A, 2007, BLOOD, V110, P762, DOI 10.1182/blood-2006-12-063602; Bouharoun-Tayoun H, 2004, EXP PARASITOL, V108, P47, DOI 10.1016/j.exppara.2004.07.004; Bray PG, 2003, TRENDS PARASITOL, V19, P232, DOI 10.1016/S1471-4922(03)00069-2; BURWELL EL, 1953, AM J PHYSIOL, V172, P718, DOI 10.1152/ajplegacy.1953.172.3.718; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Christianson SW, 1997, J IMMUNOL, V158, P3578; DAS BP, 1977, J MED CHEM, V20, P531, DOI 10.1021/jm00214a014; DEBRUIN D, 1994, P NATL ACAD SCI USA, V91, P619, DOI 10.1073/pnas.91.2.619; DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710; Dondorp AM, 2000, PARASITOL TODAY, V16, P228, DOI 10.1016/S0169-4758(00)01666-5; Druilhe P, 2005, PLOS MED, V2, P1135, DOI 10.1371/journal.pmed.0020344; Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002; Fidock DA, 2004, NAT REV DRUG DISCOV, V3, P509, DOI 10.1038/nrd1416; Foley M, 1997, INT J PARASITOL, V27, P231, DOI 10.1016/S0020-7519(96)00152-X; FREY T, 1995, CYTOMETRY, V21, P265, DOI 10.1002/cyto.990210307; FROIDEVAUX S, 1991, J IMMUNOL METHODS, V137, P275, DOI 10.1016/0022-1759(91)90034-D; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Gysin Jurg, 1998, P419; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P143; He HZ, 2002, TRANSPLANTATION, V73, P853, DOI 10.1097/00007890-200203270-00005; HEISCHKEIL R, 1971, Zeitschrift fuer Tropenmedizin und Parasitologie, V22, P243; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Jimenez-Diaz MB, 2005, CYTOM PART A, V67A, P27, DOI 10.1002/cyto.a.20169; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; KLOTZ FW, 1987, J EXP MED, V165, P1713, DOI 10.1084/jem.165.6.1713; Kollet O, 2000, BLOOD, V95, P3102, DOI 10.1182/blood.V95.10.3102.010k14_3102_3105; Landau Irene, 1998, P401; Lavazec C, 2006, NUCLEIC ACIDS RES, V34, P6696, DOI 10.1093/nar/gkl942; Layez C, 2005, BLOOD, V106, P3632, DOI 10.1182/blood-2005-04-1574; Levy JE, 2000, J CLIN INVEST, V105, P1209, DOI 10.1172/JCI9635; Melkus MW, 2006, NAT MED, V12, P1316, DOI 10.1038/nm1431; MOHAN K, 1998, MALARIA PARASITE BIO, P467; MOORE JM, 1995, J EXP MED, V181, P2265, DOI 10.1084/jem.181.6.2265; Moreno A, 2006, INT J PARASITOL, V36, P361, DOI 10.1016/j.ijpara.2005.10.012; Moreno A, 2001, ANTIMICROB AGENTS CH, V45, P1847, DOI 10.1128/AAC.45.6.1847-1853.2001; Moreno A, 2007, TRENDS PARASITOL, V23, P254, DOI 10.1016/j.pt.2007.04.004; Motulsky H. A., 2003, FITTING MODELS BIOLO; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Pichler J, 2002, CYTOMETRY, V50, P231, DOI 10.1002/cyto.10125; Price RN, 2001, AM J TROP MED HYG, V65, P614, DOI 10.4269/ajtmh.2001.65.614; Rajan TV, 1996, PARASITOL TODAY, V12, P479, DOI 10.1016/S0169-4758(96)10066-1; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; ROWE AW, 1968, CRYOBIOLOGY, V5, P119, DOI 10.1016/S0011-2240(68)80154-3; Sabater AM, 2005, PARASITOL RES, V95, P97, DOI 10.1007/s00436-004-1249-7; Sanni Latifu A, 2002, Methods Mol Med, V72, P57, DOI 10.1385/1-59259-271-6:57; SCHLICHTHERLE M, METHODS MALARIA RES, P5; SHULTZ LD, 1995, J IMMUNOL, V154, P180; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Su XZ, 1998, EXP PARASITOL, V89, P262, DOI 10.1006/expr.1998.4299; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TSUJI M, 1995, VACCINE, V13, P1389, DOI 10.1016/0264-410X(95)00081-B; WEATHERALL DJ, 1983, CIBA F SYMP, V94, P74; WILLIMANN K, 1995, J EXP MED, V182, P643, DOI 10.1084/jem.182.3.643; Yacoub-Youssef H, 2005, TRANSPL IMMUNOL, V15, P157, DOI 10.1016/j.trim.2005.07.002; Yeramian P, 2005, J INFECT DIS, V192, P319, DOI 10.1086/430928	62	110	120	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2008	3	5							e2252	10.1371/journal.pone.0002252	http://dx.doi.org/10.1371/journal.pone.0002252			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	391UK	18493601	Green Published, gold, Green Submitted			2023-01-03	WOS:000262258700056
J	Clement, EA; Richard, A; Thwaites, M; Ailon, J; Peters, S; Dickson, CT				Clement, Elizabeth A.; Richard, Alby; Thwaites, Megan; Ailon, Jonathan; Peters, Steven; Dickson, Clayton T.			Cyclic and Sleep-Like Spontaneous Alternations of Brain State Under Urethane Anaesthesia	PLOS ONE			English	Article								Background: Although the induction of behavioural unconsciousness during sleep and general anaesthesia has been shown to involve overlapping brain mechanisms, sleep involves cyclic fluctuations between different brain states known as active (paradoxical or rapid eye movement: REM) and quiet (slow-wave or non-REM: nREM) stages whereas commonly used general anaesthetics induce a unitary slow-wave brain state. Methodology/Principal Findings: Long-duration, multi-site forebrain field recordings were performed in urethane-anaesthetized rats. A spontaneous and rhythmic alternation of brain state between activated and deactivated electroencephalographic (EEG) patterns was observed. Individual states and their transitions resembled the REM/nREM cycle of natural sleep in their EEG components, evolution, and time frame (similar to 11 minute period). Other physiological variables such as muscular tone, respiration rate, and cardiac frequency also covaried with forebrain state in a manner identical to sleep. The brain mechanisms of state alternations under urethane also closely overlapped those of natural sleep in their sensitivity to cholinergic pharmacological agents and dependence upon activity in the basal forebrain nuclei that are the major source of forebrain acetylcholine. Lastly, stimulation of brainstem regions thought to pace state alternations in sleep transiently disrupted state alternations under urethane. Conclusions/Significance: Our results suggest that urethane promotes a condition of behavioural unconsciousness that closely mimics the full spectrum of natural sleep. The use of urethane anaesthesia as a model system will facilitate mechanistic studies into sleep-like brain states and their alternations. In addition, it could also be exploited as a tool for the discovery of new molecular targets that are designed to promote sleep without compromising state alternations.	[Clement, Elizabeth A.; Peters, Steven; Dickson, Clayton T.] Univ Alberta, Ctr Neurosci, Edmonton, AB, Canada; [Richard, Alby; Thwaites, Megan; Ailon, Jonathan; Dickson, Clayton T.] Univ Alberta, Dept Psychol, Edmonton, AB, Canada; [Dickson, Clayton T.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Alberta	Dickson, CT (corresponding author), Univ Alberta, Ctr Neurosci, Edmonton, AB, Canada.	cdickson@ualberta.ca	Sanguansri, Luz/B-6630-2011; Peters, Steven/AAT-5974-2021	Sanguansri, Luz/0000-0003-1908-7604; Peters, Steven/0000-0002-4799-1265; Dickson, Clayton/0000-0002-3849-8110; Clement, Elizabeth/0000-0001-8222-4048	Canadian Institutes of Health [MOP 77625]; Alberta Heritage Foundation for Medical Research (AHFMR) [summer studentships]; Natural Sciences and Engineering Research Council of Canada [summer studentships]	Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This study was supported by a Canadian Institutes of Health Research grant (MOP 77625 to CTD). CTD is a Scholar of the Alberta Heritage Foundation for Medical Research (AHFMR). SRP and JA were supported by Natural Sciences and Engineering Research Council of Canada summer studentships. SRP was additionally supported by an AHFMR summer studentship.	ASERINSK.E, 1965, SCIENCE, V150, P763, DOI 10.1126/science.150.3697.763-a; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BLAND BH, 1993, PROG NEUROBIOL, V41, P157, DOI 10.1016/0301-0082(93)90007-F; BORBELY AA, 1976, BRAIN RES, V114, P305, DOI 10.1016/0006-8993(76)90673-9; BUENO JR, 1968, PSYCHOPHARMACOLOGIA, V12, P400, DOI 10.1007/BF00401345; CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0; Carvalho RC, 2006, BRAIN RES, V1122, P179, DOI 10.1016/j.brainres.2006.09.008; CHAPUT M, 1980, J PHYSIOL-PARIS, V76, P551; Contreras D, 1997, J NEUROSCI, V17, P1179; Datta S, 2000, BEHAV NEUROSCI, V114, P1239, DOI 10.1037/0735-7044.114.6.1239; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; Detari L, 1997, BRAIN RES, V759, P112, DOI 10.1016/S0006-8993(97)00252-7; DICKSON C, 2007, CAN J NEUROL SCI S, V3; DICKSON C, 2007, SOC NEUROSCI; Dringenberg HC, 1998, NEUROSCI BIOBEHAV R, V22, P243, DOI 10.1016/S0149-7634(97)00012-2; Eschenko O, 2006, J NEUROSCI, V26, P12914, DOI 10.1523/JNEUROSCI.3175-06.2006; Ferrara M, 1999, Sleep Res Online, V2, P15; GRAHN DA, 1989, AM J PHYSIOL, V256, pR840, DOI 10.1152/ajpregu.1989.256.4.R840; Hara K, 2002, ANESTH ANALG, V94, P313, DOI 10.1097/00000539-200202000-00015; Hobson JA, 2002, NAT REV NEUROSCI, V3, P679, DOI 10.1038/nrn915; HOBSON JA, 1975, SCIENCE, V189, P55, DOI 10.1126/science.1094539; Horner RL, 1999, NEUROSCIENCE, V93, P215, DOI 10.1016/S0306-4522(99)00126-8; Hunter JD, 1998, RESP PHYSIOL, V112, P71, DOI 10.1016/S0034-5687(98)00018-8; JONES BE, 1993, PROG BRAIN RES, V98, P61; Jones BE, 2003, FRONT BIOSCI-LANDMRK, V8, pS438, DOI 10.2741/1074; Kinney GG, 1998, BRAIN RES, V809, P307, DOI 10.1016/S0006-8993(98)00878-6; Koblin DD, 2002, ANESTH ANALG, V94, P241, DOI 10.1097/00000539-200202000-00002; Lee J, 2004, P NATL ACAD SCI USA, V101, P18195, DOI 10.1073/pnas.0408089101; Lu J, 2006, NATURE, V441, P589, DOI 10.1038/nature04767; MCCARLEY RW, 1975, SCIENCE, V189, P58, DOI 10.1126/science.1135627; Molle M, 2006, J NEUROPHYSIOL, V96, P62, DOI 10.1152/jn.00014.2006; Murakami M, 2005, NEURON, V46, P285, DOI 10.1016/j.neuron.2005.02.025; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Nelson LE, 2004, ANESTHESIOLOGY, V100, P1341, DOI 10.1097/00000542-200406000-00003; NOMEIR AA, 1989, TOXICOL APPL PHARM, V97, P203, DOI 10.1016/0041-008X(89)90326-8; Ocampo-Garces A, 2000, J NEUROPHYSIOL, V84, P2699; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; Rechtschaffen A, 2002, SLEEP, V25, p68B, DOI 10.1093/sleep/25.1.68; Rechtschaffen A, 2002, SLEEP, V25, P18, DOI 10.1093/sleep/25.1.18; Rechtschaffen A, 1999, SLEEP, V22, P11, DOI 10.1093/sleep/22.1.11; ROBINSON TE, 1977, BRAIN RES, V124, P544, DOI 10.1016/0006-8993(77)90954-4; ROBINSON TE, 1978, EXP NEUROL, V61, P485, DOI 10.1016/0014-4886(78)90018-3; Sceniak MP, 2006, J NEUROPHYSIOL, V95, P3865, DOI 10.1152/jn.01196.2005; SHAFER A, 1995, ANESTHESIOLOGY, V83, P1331, DOI 10.1097/00000542-199512000-00024; SHOUSE MN, 1992, BRAIN RES, V571, P50, DOI 10.1016/0006-8993(92)90508-7; Siapas AG, 1998, NEURON, V21, P1123, DOI 10.1016/S0896-6273(00)80629-7; SIEGEL JM, 2005, PRINCIPLES PRACTICE; Sinton CM, 2004, SEMIN NEUROL, V24, P211, DOI 10.1055/s-2004-835067; SOTOMAYOR RE, 1990, TOXICOL IND HEALTH, V6, P71, DOI 10.1177/074823379000600106; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1993, J NEUROSCI, V13, P3266; Steriade M., 1999, ELECTROENCEPHALOGRAP, P28; Tung A, 2004, ANESTHESIOLOGY, V100, P1419, DOI 10.1097/00000542-200406000-00014; Tung A, 2004, SLEEP MED REV, V8, P213, DOI 10.1016/j.smrv.2004.01.003; Tung A, 2002, ANESTHESIOLOGY, V97, P906, DOI 10.1097/00000542-200210000-00024; Tung A, 2001, ANESTH ANALG, V92, P1232; Tung A, 2001, BRAIN RES, V908, P155, DOI 10.1016/S0006-8993(01)02629-4; Tung A, 2001, LIFE SCI, V69, P855, DOI 10.1016/S0024-3205(01)01179-1; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; VERTES RP, 1982, PROG NEUROBIOL, V19, P159, DOI 10.1016/0301-0082(82)90005-3; Whelan PJ, 2003, METHODS, V30, P127, DOI 10.1016/S1046-2023(03)00074-4; Wolansky T, 2006, J NEUROSCI, V26, P6213, DOI 10.1523/JNEUROSCI.5594-05.2006; YLINEN A, 1995, J NEUROSCI, V15, P30	65	243	243	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e2004	10.1371/journal.pone.0002004	http://dx.doi.org/10.1371/journal.pone.0002004			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414674	Green Submitted, Green Published, gold			2023-01-03	WOS:000260867300023
J	Palella, FJ; Armon, C; Buchacz, K; Cole, SR; Chmiel, JS; Novak, RM; Wood, K; Moorman, AC; Brooks, JT				Palella, Frank J., Jr.; Armon, Carl; Buchacz, Kate; Cole, Stephen R.; Chmiel, Joan S.; Novak, Richard M.; Wood, Kathleen; Moorman, Anne C.; Brooks, John T.		HOPS HIV Outpatient Study	The Association of HIV Susceptibility Testing With Survival Among HIV-Infected Patients Receiving Antiretroviral Therapy: A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PHENOTYPIC DRUG-RESISTANCE; MARGINAL STRUCTURAL MODELS; SOCIETY-USA PANEL; DISEASE PROGRESSION; RECOMMENDATIONS; PREVALENCE; MANAGEMENT; INHIBITORS; EVOLUTION	Background: HIV-1 genotypic and phenotypic susceptibility testing (GPT) optimizes antiretroviral selection, but its effect on survival is unknown. Objective: To evaluate the association between GPT and survival. Design: Cohort study. Setting: 10 U.S. HIV clinics. Patients: 2699 HIV-infected patients eligible for GPT (plasma HIV RNA level > 1000 copies/mL) seen from 1999 through 2005. Measurements: Demographic characteristics, clinical factors, GPT use, all-cause mortality, and crude and adjusted hazard ratios (HRs) for the association of GPT with survival. Results: Patients were followed for a median of 3.3 years; 915 (34%) had GPT. Patients who had GPT had lower mortality rates than those who did not (2.0 vs. 2.7 deaths per 100 person-years). In standard Cox models, GPT was associated with improved survival (adjusted HR, 0.69 [95% CI, 0.51 to 0.94]; P = 0.017) after controlling for demographic characteristics, CD4(+) cell count, HIV RNA level, and intensity of clinical follow-up. In subgroup analyses, GPT was associated with improved survival for the 2107 highly active antiretroviral therapy (HAART)-experienced patients (2.2 vs. 3.2 deaths per 100 person-years for patients who had GPT vs. those who did not have GPT; adjusted HR, 0.60 [CI, 0.43 to 0.82]; P = 0.002) and for the 921 triple antiretroviral class -experienced patients (2.1 vs. 3.1 deaths per 100 person-years; adjusted HR, 0.61 [CI 0.40 to 0.93]; P = 0.022). Marginal structural models supported associations between GPT and improved survival in the overall cohort (adjusted HR, 0.54; P = 0.001) and in the HAART-experienced group (adjusted HR, 0.56; P = 0.003). Limitations: Use of GPT was not randomized. Residual confounding may exist. Conclusion: Use of GPT was independently associated with improved survival among HAART-experienced patients.	[Palella, Frank J., Jr.; Chmiel, Joan S.] Northwestern Univ, Feinberg Sch Med, Div Infect Dis, Chicago, IL 60611 USA; [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA; [Armon, Carl; Wood, Kathleen] Cerner Corp, Vienna, VA USA; [Novak, Richard M.] Univ Illinois, Chicago, IL USA	Northwestern University; Feinberg School of Medicine; Centers for Disease Control & Prevention - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Palella, FJ (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Infect Dis, 645 N Michigan Ave,Suite 900, Chicago, IL 60611 USA.	f-palella@northwestern.edu		Moorman, Anne/0000-0003-2411-2798	Centers for Disease Control and Prevention [200-2006-18797]	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	By the Centers for Disease Control and Prevention ( contract no. 200-2006-18797).	*AIDS ED TRAIN CTR, 2006, CLIN MAN MAN HIV INF; Barbour JD, 2002, J VIROL, V76, P11104, DOI 10.1128/JVI.76.21.11104-11112.2002; Baxter JD, 2000, AIDS, V14, pF83, DOI 10.1097/00002030-200006160-00001; Beerenwinkel N, 2003, NUCLEIC ACIDS RES, V31, P3850, DOI 10.1093/nar/gkg575; Brown AJL, 2000, J VIROL, V74, P10269, DOI 10.1128/JVI.74.22.10269-10273.2000; Cole SR, 2003, AM J EPIDEMIOL, V158, P687, DOI 10.1093/aje/kwg206; Hales G, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010018; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Hogg RS, 2006, PLOS MED, V3, P1570, DOI 10.1371/journal.pmed.0030356; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Little SJ, 2001, BRIT MED J, V322, P1074, DOI 10.1136/bmj.322.7294.1074; Lucas GM, 2004, AIDS, V18, P1539, DOI 10.1097/01.aids.0000131339.68666.1a; Lucas GM, 2005, J ANTIMICROB CHEMOTH, V55, P413, DOI 10.1093/jac/dki042; Martinez-Picado J, 2005, J VIROL, V79, P5907, DOI 10.1128/JVI.79.10.5907-5913.2005; Miller V, 2001, AIDS, V15, P309, DOI 10.1097/00002030-200102160-00003; Moorman AC, 1999, ANN EPIDEMIOL, V9, P349, DOI 10.1016/S1047-2797(99)00005-8; *PAN ANT GUID AD A, 2008, PAN ANT GUID AD AD G; Patel K, 2008, CLIN INFECT DIS, V46, P1751, DOI 10.1086/587900; Richman DD, 2004, AIDS, V18, P1393, DOI 10.1097/01.aids.0000131310.52526.c7; Sarmati L, 2002, J CLIN MICROBIOL, V40, P335, DOI 10.1128/JCM.40.2.335-340.2002; Shafer RW, 2002, CLIN MICROBIOL REV, V15, P247, DOI 10.1128/CMR.15.2.247-277.2002; *SURV RISK ASS DIV, 2005, HIV 1 STRAIN PRIM DR; Weinstein MC, 2001, ANN INTERN MED, V134, P440, DOI 10.7326/0003-4819-134-6-200103200-00008; Weinstock HS, 2004, J INFECT DIS, V189, P2174, DOI 10.1086/420789; Wensing AMJ, 2005, J INFECT DIS, V192, P958, DOI 10.1086/432916	27	38	41	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2009	151	2					73	W21		10.7326/0003-4819-151-2-200907210-00003	http://dx.doi.org/10.7326/0003-4819-151-2-200907210-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478RH	19620160				2023-01-03	WOS:000268605300001
J	Dyer, C				Dyer, Clare			Assisted suicide: the fight goes on	BRITISH MEDICAL JOURNAL			English	Editorial Material												ClareDyer@aol.com							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 16	2009	339								b2868	10.1136/bmj.b2868	http://dx.doi.org/10.1136/bmj.b2868			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	472BX	19608622				2023-01-03	WOS:000268105200003
J	Dixon, BS; Beck, GJ; Vazquez, MA; Greenberg, A; Delmez, JA; Allon, M; Dember, LM; Himmelfarb, J; Gassman, JJ; Greene, T; Radeva, MK; Davidson, IJ; Ikizler, TA; Braden, GL; Fenves, AZ; Kaufman, JS; Cotton, JR; Martin, KJ; McNeil, JW; Rahman, A; Lawson, JH; Whiting, JF; Hu, B; Meyers, CM; Kusek, JW; Feldman, HI				Dixon, Bradley S.; Beck, Gerald J.; Vazquez, Miguel A.; Greenberg, Arthur; Delmez, James A.; Allon, Michael; Dember, Laura M.; Himmelfarb, Jonathan; Gassman, Jennifer J.; Greene, Tom; Radeva, Milena K.; Davidson, Ingemar J.; Ikizler, T. Alp; Braden, Gregory L.; Fenves, Andrew Z.; Kaufman, James S.; Cotton, James R., Jr.; Martin, Kevin J.; McNeil, James W.; Rahman, Asif; Lawson, Jeffery H.; Whiting, James F.; Hu, Bo; Meyers, Catherine M.; Kusek, John W.; Feldman, Harold I.		DAC Study Grp	Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE CELL-PROLIFERATION; VASCULAR ACCESS SURVIVAL; PRACTICE PATTERNS; PREVENTION; FISTULAS; OUTCOMES; FAILURE; ASSOCIATION; CLOPIDOGREL; INHIBITION	BACKGROUND Arteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity. METHODS We conducted a randomized, double-blind, placebo-controlled trial of extended-release dipyridamole, at a dose of 200 mg, and aspirin, at a dose of 25 mg, given twice daily after the placement of a new arteriovenous graft until the primary outcome, loss of primary unassisted patency (i.e., patency without thrombosis or requirement for intervention), was reached. Secondary outcomes were cumulative graft failure and death. Primary and secondary outcomes were analyzed with the use of a Cox proportional-hazards regression with adjustment for prespecified covariates. RESULTS At 13 centers in the United States, 649 patients were randomly assigned to receive dipyridamole plus aspirin (321 patients) or placebo (328 patients) over a period of 4.5 years, with 6 additional months of follow-up. The incidence of primary unassisted patency at 1 year was 23% (95% confidence interval [CI], 18 to 28) in the placebo group and 28% (95% CI, 23 to 34) in the dipyridamole-aspirin group, an absolute difference of 5 percentage points. Treatment with dipyridamole plus aspirin significantly prolonged the duration of primary unassisted patency (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P = 0.03) and inhibited stenosis. The incidences of cumulative graft failure, death, the composite of graft failure or death, and serious adverse events (including bleeding) did not differ significantly between study groups. CONCLUSIONS Treatment with dipyridamole plus aspirin had a significant but modest effect in reducing the risk of stenosis and improving the duration of primary unassisted patency of newly created grafts. (ClinicalTrials.gov number, NCT00067119.)	[Dixon, Bradley S.] Univ Iowa, Coll Med, Iowa City, IA 52242 USA; [Dixon, Bradley S.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA; [Beck, Gerald J.; Gassman, Jennifer J.; Radeva, Milena K.; Hu, Bo] Cleveland Clin Fdn, Cleveland, OH 44195 USA; [Vazquez, Miguel A.; Davidson, Ingemar J.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Fenves, Andrew Z.] Baylor Med Ctr, Dallas, TX USA; [Cotton, James R., Jr.] Tyler Nephrol Associates, Tyler, TX USA; [Greenberg, Arthur; Lawson, Jeffery H.] Duke Univ, Durham, NC USA; [Delmez, James A.] Washington Univ, St Louis, MO 63130 USA; [Martin, Kevin J.] St Louis Univ, St Louis, MO 63103 USA; [Allon, Michael] Univ Alabama Birmingham, Birmingham, AL USA; [Dember, Laura M.] Boston Univ, Boston, MA 02215 USA; [Himmelfarb, Jonathan; Whiting, James F.] Maine Med Ctr, Portland, ME USA; [Greene, Tom] Univ Utah, Salt Lake City, UT USA; [Ikizler, T. Alp] Vanderbilt Univ, Nashville, TN USA; [Braden, Gregory L.] Baystate Med Ctr, Springfield, MA USA; [McNeil, James W.] Vasc Surg Associates, Baton Rouge, LA USA; [Rahman, Asif] Charleston Area Med Ctr, Charleston, WV USA; [Meyers, Catherine M.; Kusek, John W.] NIDDK, NIH, Bethesda, MD USA; [Feldman, Harold I.] Univ Penn, Philadelphia, PA 19104 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Cleveland Clinic Foundation; University of Texas System; University of Texas Southwestern Medical Center Dallas; Duke University; Washington University (WUSTL); Saint Louis University; University of Alabama System; University of Alabama Birmingham; Boston University; Maine Medical Center; Utah System of Higher Education; University of Utah; Vanderbilt University; Baystate Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Pennsylvania	Dixon, BS (corresponding author), Univ Iowa, Coll Med, E-300D GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	bradley-dixon@uiowa.edu		Ikizler, Talat/0000-0002-5717-4218; Dixon, Bradley/0000-0002-2534-3259; Greenberg, Arthur/0000-0002-2838-8401	National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health [U01DK058981, U01DK058982, U01DK058973, U01DK058985, U01DK058978, U01DK058968, U01DK058986, U01DK058966]; Boehringer Ingelheim Pharmaceuticals; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK058978, U01DK058968, U01DK058986, U01DK058981, U01DK058973, U01DK058982, U01DK058966, U01DK058985] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (under cooperative agreements U01DK058981, U01DK058982, U01DK058973, U01DK058985, U01DK058978, U01DK058968, U01DK058986, and U01DK058966) and Boehringer Ingelheim Pharmaceuticals, which also provided the extended- release dipyridamole plus aspirin and matched placebo.	Allon M, 2007, CLIN J AM SOC NEPHRO, V2, P786, DOI 10.2215/CJN.00860207; CHESEBRO JH, 1984, NEW ENGL J MED, V310, P209, DOI 10.1056/NEJM198401263100401; Cinat ME, 1999, ANN VASC SURG, V13, P191, DOI 10.1007/s100169900241; Crowther MA, 2002, J AM SOC NEPHROL, V13, P2331, DOI 10.1097/01.ASN.0000027356.16598.99; Dember LM, 2008, JAMA-J AM MED ASSOC, V299, P2164, DOI 10.1001/jama.299.18.2164; DEPNER TA, 1995, ASAIO J, V41, pM745, DOI 10.1097/00002480-199507000-00112; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Dixon BS, 2005, CLIN TRIALS, V2, P400, DOI 10.1191/1740774505cn110oa; Dorffler-Melly J, 2005, COCHRANE DB SYST REV, V1; Dubey RK, 1998, HYPERTENSION, V31, P516, DOI 10.1161/01.HYP.31.1.516; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; FAXON DP, 1984, AM J CARDIOL, V53, pC72, DOI 10.1016/0002-9149(84)90751-3; Feldman HI, 1996, J AM SOC NEPHROL, V7, P523; Gibson KD, 2001, J VASC SURG, V34, P694, DOI 10.1067/mva.2001.117890; Gradzki R, 2001, AM J KIDNEY DIS, V38, P1240, DOI 10.1053/ajkd.2001.29220; Halkes PHA, 2006, LANCET, V367, P1665; HESS H, 1985, LANCET, V1, P415; Himmelfarb J, 2007, JAMA-J AM MED ASSOC, V297, P2630, DOI 10.1001/jama.297.23.2630; Hodges TC, 1997, J VASC SURG, V26, P1009, DOI 10.1016/S0741-5214(97)70014-4; INGERMANWOJENSKI CM, 1988, EXP MOL PATHOL, V48, P116, DOI 10.1016/0014-4800(88)90050-0; Kaufman JS, 2003, J AM SOC NEPHROL, V14, P2313, DOI 10.1097/01.ASN.0000081661.10246.33; Miller PE, 2000, AM J KIDNEY DIS, V36, P68, DOI 10.1053/ajkd.2000.8269; Reddan D, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022422.79790.A8; Roy-Chaudhury P, 2006, J AM SOC NEPHROL, V17, P1112, DOI 10.1681/ASN.2005050615; Saran R, 2002, AM J KIDNEY DIS, V40, P1255, DOI 10.1053/ajkd.2002.36895; SINGH JP, 1994, J AM COLL CARDIOL, V23, P665, DOI 10.1016/0735-1097(94)90752-8; Spergel LM, 2007, J NEPHROL, V20, P288; SREEDHARA R, 1994, KIDNEY INT, V45, P1477, DOI 10.1038/ki.1994.192; The ESPRIT Study Group, 2007, LANCET, V369, P274; U.S. Renal Data System, 2006, 2006 ANN DAT REP ATL; *US REN DAT SYST, 2007, 2007 ANN DAT REP ATL; WANG SK, 1987, BIOMETRICS, V43, P193, DOI 10.2307/2531959; Woods JD, 1997, AM J KIDNEY DIS, V30, P50, DOI 10.1016/S0272-6386(97)90564-3; Xue JL, 2003, AM J KIDNEY DIS, V42, P1013, DOI 10.1016/j.ajkd.2003.07.004; Yevzlin AS, 2006, SEMIN DIALYSIS, V19, P535, DOI 10.1111/j.1525-139X.2006.00218.x	35	193	201	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 21	2009	360	21					2191	2201		10.1056/NEJMoa0805840	http://dx.doi.org/10.1056/NEJMoa0805840			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447QI	19458364	Green Accepted			2023-01-03	WOS:000266206000006
J	Koek, MBG; Buskens, E; van Weelden, H; Steegmans, PHA; Bruijnzeel-Koomen, CAFM; Sigurdsson, V				Koek, Mayke B. G.; Buskens, Erik; van Weelden, Huib; Steegmans, Paul H. A.; Bruijnzeel-Koomen, Carla A. F. M.; Sigurdsson, Vigfus			Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC PLAQUE PSORIASIS; BRITISH-PHOTODERMATOLOGY-GROUP; NARROW-BAND UVB; EARLY MYCOSIS-FUNGOIDES; GROUP-WORKSHOP-REPORT; HEALTH SURVEY; 3 TIMES; THERAPY; GUIDELINES; SKIN	Objective To determine whether ultraviolet B phototherapy at home is equally safe and equally effective as ultraviolet B phototherapy in an outpatient setting for patients with psoriasis. Design Pragmatic multicentre single blind randomised clinical trial (PLUTO study). Setting Dermatology departments of 14 hospitals in the Netherlands. Participants 196 patients with psoriasis who were clinically eligible for narrowband (TL-01) ultraviolet B phototherapy. The first 105 consecutive patients were also followed for one year after therapy. Intervention Ultraviolet B phototherapy at home using a TL-01 home phototherapy unit compared with standard narrowband ultraviolet B phototherapy in an outpatient setting. Both therapies were done in a setting reflecting routine daily practice in the Netherlands. Main outcome measures The main outcome measure was effectiveness as measured by the proportion of patients with a 50% or more reduction of the baseline psoriasis area and severity index (PASI) or self administered psoriasis area and severity index (SAPASI), called the PASI 50 and SAPASI 50 (relevant treatment effect). Another outcome of effectiveness was the percentage reduction in median scores on the PASI as well as SAPASI. Also the proportions of patients reaching the PASI 75 and SAPASI 75 (successful treatment effect), and the PASI 90 and SAPASI 90 (almost complete clearance) were calculated. Other secondary outcomes were quality of life (SF-36, psoriasis disability index), burden of treatment (questionnaire), patients' preferences and satisfaction (questionnaire), and dosimetry and short term side effects (diary). Results 82% of the patients treated at home compared with 79% of the patients treated in an outpatient setting reached the SAPASI 50 (difference 2.8%, 95% confidence interval -8.6% to 14.2%), and 70% compared with 73% reached the PASI 50 (-2.3%, -15.7% to 11.1%). For patients treated at home the median SAPASI score decreased 82% (from 6.7 to 1.2) and the median PASI score decreased 74% (from 8.4 to 2.2), compared with 79% (from 7.0 to 1.4) and 70% (from 7.0 to 2.1) for patients treated in an outpatient setting. Treatment effect as defined by the mean decline in PASI and SAPASI scores was significant (P<0.001) and similar across groups (P>0.3). Total cumulative doses of ultraviolet B light were similar (51.5 v46.1 J/cm(2), difference 5.4, 95% confidence interval -5.2 to 16.0), and the occurrence of short term side effects did not differ. The burden of undergoing ultraviolet B phototherapy was significantly lower for patients treated at home (differences 1.23 to 3.01, all P <= 0.001). Quality of life increased equally regardless of treatment, but patients treated at home more often rated their experience with the therapy as "excellent" (42%, 38/90) compared with patients treated in the outpatient department (23%, 20/88; P=0.001). Conclusion Ultraviolet B phototherapy administered at home is equally safe and equally effective, both clinically and for quality of life, as ultraviolet B phototherapy administered in an outpatient setting. Furthermore, ultraviolet B phototherapy at home resulted in a lower burden of treatment and led to greater patients' satisfaction. Trial registration Current Controlled Trials ISRCTN83025173 and Clinicaltrials.gov NCT00150930.	[van Weelden, Huib; Bruijnzeel-Koomen, Carla A. F. M.; Sigurdsson, Vigfus] Univ Med Ctr Utrecht, Dept Dermatol Allergol, NL-3584 CX Utrecht, Netherlands; [Buskens, Erik] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Buskens, Erik] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3584 CX Utrecht, Netherlands; [Steegmans, Paul H. A.] St Antonius Hosp, Dept Dermatol, Nieuwegein, Netherlands	Utrecht University; Utrecht University Medical Center; University of Groningen; Utrecht University; Utrecht University Medical Center; St. Antonius Hospital Utrecht		author@koek.com		buskens, erik/0000-0002-6463-1106	Netherlands Organisation for Health Research and Development [945-02-017]	Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development)	This study was supported by grant 945-02-017 from the Netherlands Organisation for Health Research and Development. The funder had no role in the study design; in the collection, management, analysis, and interpretation of data; in the preparation, review, or approval of the manuscript, or in the decision to submit the article for publication. The researchers are independent from the funders. Competing interests: None declared.	Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; ABEL EA, 1985, CUTIS, V35, P127; Barbagallo J, 2001, CUTIS, V68, P345; Biella U, 1985, Z Arztl Fortbild (Jena), V79, P531; Bilsland D, 1997, BRIT J DERMATOL, V137, P327, DOI 10.1046/j.1365-2133.1997.18441939.x; Cameron H, 2002, BRIT J DERMATOL, V147, P973, DOI 10.1046/j.1365-2133.2002.04996.x; Cameron H, 2002, BRIT J DERMATOL, V147, P957, DOI 10.1046/j.1365-2133.2002.04860.x; Carrozza P, 2000, DERMATOLOGY, V200, P35, DOI 10.1159/000018312; DARCY C, 1984, JNCI, V73, P75; Dawe RS, 1998, BRIT J DERMATOL, V138, P833; de Gruijl FR, 2001, J PHOTOCH PHOTOBIO B, V63, P19, DOI 10.1016/S1011-1344(01)00199-3; DRAKE LA, 1993, J AM ACAD DERMATOL, V28, P632, DOI 10.1016/S0190-9622(08)81783-5; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P643; Feldman SR, 1996, J INVEST DERMATOL, V106, P183, DOI 10.1111/1523-1747.ep12329912; Feldman SR, 1996, CUTIS, V58, P71; FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; FINLAY AY, 1987, CLIN EXP DERMATOL, V12, P8, DOI 10.1111/j.1365-2230.1987.tb01844.x; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; FLEISCHER AB, 1994, J INVEST DERMATOL, V102, P967, DOI 10.1111/1523-1747.ep12384205; Fleischer Alan B. Jr., 1999, Journal of Dermatology (Tokyo), V26, P210; Flytstrom I, 2008, BRIT J DERMATOL, V158, P116, DOI 10.1111/j.1365-2133.2007.08284.x; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; *GERM DERM SOC DDG, 1999, CONS LETT HOM UV TRE; GERRITSEN MJP, 2000, NED TIJDSCHR DERMATO, V10, P101; Gottlieb AB, 2004, J AM ACAD DERMATOL, V51, P534, DOI 10.1016/j.jaad.2004.02.021; Gupta G, 1999, BRIT J DERMATOL, V140, P887, DOI 10.1046/j.1365-2133.1999.02820.x; Heydendael VMR, 2003, NEW ENGL J MED, V349, P658, DOI 10.1056/NEJMoa021359; Ibbotson SH, 2004, BRIT J DERMATOL, V151, P283, DOI 10.1111/j.1365-2133.2004.06128.x; JORDAN WP, 1981, J AM ACAD DERMATOL, V4, P584, DOI 10.1016/S0190-9622(81)70061-6; Kirke SM, 2007, J INVEST DERMATOL, V127, P1641, DOI 10.1038/sj.jid.5700767; Koek Mayke B G, 2006, BMC Med Res Methodol, V6, P39, DOI 10.1186/1471-2288-6-39; Koek MBG, 2006, BRIT J DERMATOL, V154, P701, DOI 10.1111/j.1365-2133.2006.07136.x; KRICKER A, 1995, INT J CANCER, V60, P489, DOI 10.1002/ijc.2910600411; LARKO O, 1979, BRIT J DERMATOL, V101, P13, DOI 10.1111/j.1365-2133.1979.tb15286.x; Leaute-Labreze C, 2001, ARCH DERMATOL, V137, P1035; Lebwohl M, 2003, NEW ENGL J MED, V349, P2004, DOI 10.1056/NEJMoa030002; Leonardi CL, 2003, NEW ENGL J MED, V349, P2014, DOI 10.1056/NEJMoa030409; LOWE NJ, 1992, SEMIN DERMATOL, V11, P284; MATTO DM, 2003, MED CONTACT, V58, P950; MILSTEIN HJ, 1982, J AM ACAD DERMATOL, V6, P355, DOI 10.1016/S0190-9622(82)70029-5; Murphy GM, 1997, IRISH J MED SCI, V166, P92, DOI 10.1007/BF02944196; Naldi L, 2005, BRIT J DERMATOL, V152, P597, DOI 10.1111/j.1365-2133.2005.06563.x; Papoutsaki M, 2007, J AM ACAD DERMATOL, V57, P269, DOI 10.1016/j.jaad.2006.12.003; PARRISH JA, 1982, PHOTOCHEM PHOTOBIOL, V36, P187, DOI 10.1111/j.1751-1097.1982.tb04362.x; PAUL BS, 1983, ARCH DERMATOL, V119, P122, DOI 10.1001/archderm.119.2.122; POCOCK SJ, 1993, CLIN TRIALS PRACTICA, P66; Pocock SJ., 1993, CLIN TRIALS PRACTICA, P123; Prince A, 1994, Ned Tijdschr Geneeskd, V138, P373; RESNIK KS, 1993, J AM ACAD DERMATOL, V29, P73, DOI 10.1016/0190-9622(93)70155-M; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Sarkany RPE, 1999, BRIT J DERMATOL, V140, P195, DOI 10.1111/j.1365-2133.1999.02649.x; Saurat JH, 2008, BRIT J DERMATOL, V158, P558, DOI 10.1111/j.1365-2133.2007.08315.x; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SLAPER H, 1986, PHOTODERMATOLOGY, V3, P271; SNELLMAN E, 1995, PHOTOCHEM PHOTOBIOL, V62, P769, DOI 10.1111/j.1751-1097.1995.tb08728.x; Soares Isabel, 2002, Rev Port Cardiol, V21, P1191; Spuls PI, 1997, BRIT J DERMATOL, V137, P943, DOI 10.1046/j.1365-2133.1997.19902071.x; Tanew A, 1999, ARCH DERMATOL, V135, P519, DOI 10.1001/archderm.135.5.519; *TASK FORC PSOR NE, 2008, GUID PHOT SYST THER; Trochim WM, 2016, RES METHODS ESSENTIA; van Vloten W A, 1993, Ned Tijdschr Geneeskd, V137, P2525; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Yelverton CB, 2008, ARCH DERMATOL, V144, P1224, DOI 10.1001/archderm.144.9.1224; 2008, PRAGMATIC VERSUS EXP; 1991, NATL PSORIASIS FDN B, V22, P15	66	78	81	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 7	2009	338								b1542	10.1136/bmj.b1542	http://dx.doi.org/10.1136/bmj.b1542			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444GW	19423623	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000265969700001
J	Weiner, LM; Dhodapkar, MV; Ferrone, S				Weiner, Louis M.; Dhodapkar, Madhov V.; Ferrone, Soldano			Monoclonal antibodies for cancer immunotherapy	LANCET			English	Review							NON-HODGKINS-LYMPHOMA; DENDRITIC CELL MATURATION; METASTATIC BREAST-CANCER; MHC CLASS-I; HUMAN ANTIIDIOTYPIC ANTIBODIES; MEDIATED ANTIGEN PRESENTATION; FC-GAMMA RECEPTORS; COATED TUMOR-CELLS; CROSS-PRESENTATION; IMMUNE-RESPONSE	Monoclonal antibodies are effective treatments for many malignant diseases. However, the ability of antibodies to initiate tumour-antigen-specific immune responses has received less attention than have other mechanisms of antibody action. We describe the rationale and evidence for the development of antibodies that can stimulate host tumour-antigen-specific immune responses. Such responses can be induced through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cross-presentation of tumour antigens, or by triggering of the idiotypic network. Future treatment modifications or combinations might be able to prolong, amplify, and shape these immune responses to increase the clinical benefits of antibody therapy for human cancer.	[Weiner, Louis M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20016 USA; [Dhodapkar, Madhov V.] Yale Univ, Sect Hematol, New Haven, CT USA; [Dhodapkar, Madhov V.] Rockefeller Univ, Lab Tumor Immunol & Immunotherapy, New York, NY 10021 USA; [Ferrone, Soldano] Univ Pittsburgh, Inst Canc, Dept Surg, Pittsburgh, PA USA; [Ferrone, Soldano] Univ Pittsburgh, Inst Canc, Dept Pathol, Pittsburgh, PA USA; [Ferrone, Soldano] Univ Pittsburgh, Inst Canc, Dept Immunol, Pittsburgh, PA USA	Georgetown University; Yale University; Rockefeller University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weiner, LM (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW,Suite E501, Washington, DC 20016 USA.	weinerl@georgetown.edu			Damon Runyon Cancer Research Fund; Dana Foundation [CA106802, CA109465];  [CA51008];  [CAS0633];  [CA121033];  [CA105500]; NATIONAL CANCER INSTITUTE [R01CA105500, R01CA050633, R01CA121033, R01CA109465, R01CA106802, P30CA051008] Funding Source: NIH RePORTER	Damon Runyon Cancer Research Fund; Dana Foundation; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	LMW is supported by grants CA51008, CAS0633, CA121033. MVD is supported by the Damon Runyon Cancer Research Fund, the Dana Foundation and grants CA106802 and CA109465. SF is sponsored by grant CA105500.	Akiyama K, 2003, J IMMUNOL, V170, P1641, DOI 10.4049/jimmunol.170.4.1641; Amigorena S, 1999, SEMIN IMMUNOL, V11, P385, DOI 10.1006/smim.1999.0196; Amigorena S, 2002, J EXP MED, V195, pF1, DOI 10.1084/jem.20011925; AUSTIN EB, 1989, IMMUNOLOGY, V67, P525; Baneijee D, 2008, J IMMUNOTHER, V31, P113, DOI 10.1097/CJI.0b013e31815a5892; Bave U, 2003, J IMMUNOL, V171, P3296, DOI 10.4049/jimmunol.171.6.3296; Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Bradt BM, 2003, CLIN CANCER RES, V9, p4007S; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Chamuleau MED, 2004, CANCER RES, V64, P5546, DOI 10.1158/0008-5472.CAN-04-1350; Chang CC, 2005, J BIOL CHEM, V280, P10164, DOI 10.1074/jbc.M409161200; Chatterjee SK, 1998, CANCER RES, V58, P1217; CHEUNG NKV, 1994, CANCER RES, V54, P2228; Cheung NKV, 2000, CLIN CANCER RES, V6, P2653; Clark JI, 1997, CANCER IMMUNOL IMMUN, V44, P265, DOI 10.1007/s002620050382; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Coiffier B, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.32749; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Davis TA, 1999, CLIN CANCER RES, V5, P611; de Bono JS, 2004, ANN ONCOL, V15, P1825, DOI 10.1093/annonc/mdh472; den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295; Dhodapkar KM, 2007, J EXP MED, V204, P1359, DOI 10.1084/jem.20062545; Dhodapkar KM, 2005, P NATL ACAD SCI USA, V102, P6243, DOI 10.1073/pnas.0502547102; Dhodapkar KM, 2005, P NATL ACAD SCI USA, V102, P2910, DOI 10.1073/pnas.0500014102; Dhodapkar KM, 2002, J EXP MED, V195, P125, DOI 10.1084/jem.20011097; Dhodapkar MV, 2008, CELL DEATH DIFFER, V15, P39, DOI 10.1038/sj.cdd.4402247; Durrant LG, 2001, INT J CANCER, V92, P414, DOI 10.1002/ijc.1194; FAGERBERG J, 1993, CANCER IMMUNOL IMMUN, V37, P264, DOI 10.1007/BF01518521; FAGERBERG J, 1995, CANCER RES, V55, P1824; FAGERBERG J, 1995, P NATL ACAD SCI USA, V92, P4773, DOI 10.1073/pnas.92.11.4773; Fischer N, 2007, PATHOBIOLOGY, V74, P3, DOI 10.1159/000101046; FOON KA, 1995, J CLIN INVEST, V96, P334, DOI 10.1172/JCI118039; Foon KA, 1998, CLIN CANCER RES, V4, P1117; Franki SN, 2008, BLOOD, V111, P1504, DOI 10.1182/blood-2007-03-080507; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Groh V, 2005, P NATL ACAD SCI USA, V102, P6461, DOI 10.1073/pnas.0501953102; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Heijnen I A, 1997, Int Rev Immunol, V16, P29, DOI 10.3109/08830189709045702; Herlyn Dorothee, 2003, Cancer Chemother Biol Response Modif, V21, P287; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Jinushi M, 2006, P NATL ACAD SCI USA, V103, P9190, DOI 10.1073/pnas.0603503103; Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; Kawano K, 2005, CANCER RES, V65, P6002; KOPROWSKI H, 1984, P NATL ACAD SCI-BIOL, V81, P216, DOI 10.1073/pnas.81.1.216; Kreitman RJ, 2001, NEW ENGL J MED, V345, P241, DOI 10.1056/NEJM200107263450402; Leonard JP, 2002, SEMIN ONCOL, V29, P81, DOI 10.1053/sonc.2002.30149; LOSMAN MJ, 1991, P NATL ACAD SCI USA, V88, P3421, DOI 10.1073/pnas.88.8.3421; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MITTELMAN A, 1992, P NATL ACAD SCI USA, V89, P466, DOI 10.1073/pnas.89.2.466; Murray JL, 2004, CANCER RES, V64, P5481, DOI 10.1158/0008-5472.CAN-04-0517; Nagata Y, 2002, P NATL ACAD SCI USA, V99, P10629, DOI 10.1073/pnas.112331099; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; OEGEN JG, 2002, NAT IMMUNOL, V3, P611; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Ravetch JV, 2001, ANNU REV IMMUNOL, V19, P275, DOI 10.1146/annurev.immunol.19.1.275; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; ROBINS RA, 1991, CANCER RES, V51, P5425; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; SALEH MN, 1993, J IMMUNOL, V151, P3390; Schultes BC, 1998, CANCER IMMUNOL IMMUN, V46, P201, DOI 10.1007/s002620050479; Schuurhuis DH, 2002, J IMMUNOL, V168, P2240, DOI 10.4049/jimmunol.168.5.2240; Sedlik C, 2003, J IMMUNOL, V170, P846, DOI 10.4049/jimmunol.170.2.846; Selenko N, 2002, J CLIN IMMUNOL, V22, P124, DOI 10.1023/A:1015463811683; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Shields RL, 2001, J BIOL CHEM, V276, P6591, DOI 10.1074/jbc.M009483200; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Spendlove I, 2000, EUR J IMMUNOL, V30, P2944, DOI 10.1002/1521-4141(200010)30:10<2944::AID-IMMU2944>3.0.CO;2-U; STEINITZ M, 1988, J IMMUNOL, V141, P3516; STEPLEWSKI Z, 1983, SCIENCE, V221, P865, DOI 10.1126/science.6879183; Sulica A, 2001, Int Rev Immunol, V20, P371, DOI 10.3109/08830180109054414; Taylor C, 2007, CLIN CANCER RES, V13, P5133, DOI 10.1158/1078-0432.CCR-07-0507; Umana P, 1999, NAT BIOTECHNOL, V17, P176, DOI 10.1038/6179; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wagner U, 2001, CLIN CANCER RES, V7, P1154; Weiner LM, 2008, CLIN CANCER RES, V14, P502, DOI 10.1158/1078-0432.CCR-07-1509; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; WENG WK, 2005, ASCO ANN M ED BOOK C, P200; WETTENDORFF M, 1989, P NATL ACAD SCI USA, V86, P3787, DOI 10.1073/pnas.86.10.3787; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Yao TJ, 1999, CLIN CANCER RES, V5, P77	93	204	218	2	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	2009	373	9668					1033	1040		10.1016/S0140-6736(09)60251-8	http://dx.doi.org/10.1016/S0140-6736(09)60251-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	422AA	19304016	Green Accepted			2023-01-03	WOS:000264398200031
J	Drazen, JM; Desai, NR; Green, P				Drazen, Jeffrey M.; Desai, Nihar R.; Green, Philip			Fighting On.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Desai, Nihar R.; Green, Philip] Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital			Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890					0	9	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2009	360	5					444	445		10.1056/NEJMp0809496	http://dx.doi.org/10.1056/NEJMp0809496			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399PS	19179313				2023-01-03	WOS:000262812400003
J	Fanello, CI; Karema, C; Avellino, P; Bancone, G; Uwimana, A; Lee, SJ; d'Alessandro, U; Modiano, D				Fanello, Caterina I.; Karema, Corine; Avellino, Pamela; Bancone, Germana; Uwimana, Aline; Lee, Sue J.; d'Alessandro, Umberto; Modiano, David			High Risk of Severe Anaemia after Chlorproguanil-Dapsone plus Artesunate Antimalarial Treatment in Patients with G6PD (A-) Deficiency	PLOS ONE			English	Article								Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common inherited human enzyme defect. This deficiency provides some protection from clinical malaria, but it can also cause haemolysis after administration of drugs with oxidant properties. Methods: The safety of chlorproguanil-dapsone+artesunate (CD+A) and amodiaquine+sulphadoxine-pyrimethamine (AQ+SP) for the treatment of uncomplicated P. falciparum malaria was evaluated according to G6PD deficiency in a secondary analysis of an open-label, randomized clinical trial [1]. 702 children, treated with CD+A or AQ+SP and followed for 28 days after treatment were genotyped for G6PD A-deficiency. Findings: In the first 4 days following CD+A treatment, mean haematocrit declined on average 1.94% (95% CI 1.54 to 2.33) and 1.05% per day (95% CI 0.95 to 1.15) respectively in patients with G6PD deficiency and normal patients; a mean reduction of 1.3% per day was observed among patients who received AQ+SP regardless of G6PD status (95% CI 1.25 to 1.45). Patients with G6PD deficiency recipients of CD+A had significantly lower haematocrit than the other groups until day 7 (p = 0.04). In total, 10 patients had severe post-treatment haemolysis requiring blood transfusion. Patients with G6PD deficiency showed a higher risk of severe anaemia following treatment with CD+A (RR = 10.2; 95% CI 1.8 to 59.3) or AQ+SP ( RR = 5.6; 95% CI 1.0 to 32.7). Conclusions: CD+A showed a poor safety profile in individuals with G6PD deficiency most likely as a result of dapsone induced haemolysis. Screening for G6PD deficiency before drug administration of potentially pro-oxidants drugs, like dapsone-containing combinations, although seldom available, is necessary.	[Lee, Sue J.] Univ Oxford, Nuffield Dept Med, Ctr Vaccinol & Trop Med, Oxford, England; [Karema, Corine; Uwimana, Aline] Natl Malaria Control Program, Kigali, Rwanda; [Avellino, Pamela; Bancone, Germana; Modiano, David] Univ Roma La Sapienza, Dept Publ Hlth Sci, Rome, Italy; [Fanello, Caterina I.; Lee, Sue J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Res Unit, Bangkok 10700, Thailand; [d'Alessandro, Umberto] Prince Leopold Inst Trop Med, Antwerp, Belgium	University of Oxford; Sapienza University Rome; Mahidol University; Institute of Tropical Medicine (ITM)	Fanello, CI (corresponding author), Univ Oxford, Nuffield Dept Med, Ctr Vaccinol & Trop Med, Oxford, England.	Caterina.Fanello@ndm.ox.ac.uk	Fanello, Caterina/AAT-9679-2021; D'Alessandro, Umberto/D-3457-2015	Fanello, Caterina/0000-0003-1932-9562; D'Alessandro, Umberto/0000-0001-6341-5009; Bancone, Germana/0000-0003-4550-0431	Sir Halley Stewart Trust; University of Rome La Sapienza; EU, Sixth Framework Programme, BIOMALPAR Network of Excellence [LSHP-CT-2004-503578]; Belgian Development Cooperation (DGIS); Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium	Sir Halley Stewart Trust; University of Rome La Sapienza; EU, Sixth Framework Programme, BIOMALPAR Network of Excellence; Belgian Development Cooperation (DGIS); Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium	CIF was funded by the Sir Halley Stewart Trust. The laboratory analyses were financed by the University of Rome La Sapienza and by the EU, Sixth Framework Programme, BIOMALPAR Network of Excellence, Contract Number LSHP-CT-2004-503578. The clinical study was financed by the Belgian Development Cooperation (DGIS) in collaboration with the Prince Leopold Institute of Tropical Medicine, Antwerp, Belgium. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; BATTISTUZZI G, 1977, AM J HUM GENET, V29, P31; Beutler E, 2002, BLOOD CELL MOL DIS, V28, P93, DOI 10.1006/bcmd.2002.0490; Beutler E, 2007, AM J TROP MED HYG, V77, P779, DOI 10.4269/ajtmh.2007.77.779; Brabin BJ, 2004, DRUG SAFETY, V27, P633, DOI 10.2165/00002018-200427090-00002; DEGOWIN RL, 1966, B WORLD HEALTH ORGAN, V35, P165; Fanello CI, 2008, T ROY SOC TROP MED H, V102, P412, DOI 10.1016/j.trstmh.2008.01.013; Munyanganizi R, 2006, J MED SCREEN, V13, P129, DOI 10.1258/096914106778440626; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; Sulo J, 2002, LANCET, V360, P1136, DOI 10.1016/S0140-6736(02)11198-6; Taylor WRJ, 2004, DRUG SAFETY, V27, P25, DOI 10.2165/00002018-200427010-00003; Tishkoff SA, 2001, SCIENCE, V293, P455, DOI 10.1126/science.1061573; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WHITE NJ, 1992, ADV PARASIT, P84; WHO, 2003, ASS MON ANT DRUG EFF; *WHO, 2008, QSMMCIEA117 WHO; *WHO, 2004, WHOHTMMAL20051106; Wolf Ronni, 2002, Dermatol Online J, V8, P2; Wootton DG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001779	19	44	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2008	3	12							e4031	10.1371/journal.pone.0004031	http://dx.doi.org/10.1371/journal.pone.0004031			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437DI	19112496	Green Accepted, Green Published, Green Submitted, gold			2023-01-03	WOS:000265466000004
J	Li, TS; Dai, Y; Kuang, JQ; Jiang, JM; Han, Y; Qiu, ZF; Xie, J; Zuo, LY; Li, YL				Li, Taisheng; Dai, Yi; Kuang, Jiqiu; Jiang, Jingmei; Han, Yang; Qiu, Zhifeng; Xie, Jing; Zuo, Lingyan; Li, Yanling			Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese HIV/AIDS Patients: Multicentric Observation Cohort	PLOS ONE			English	Article							DRUG-RESISTANCE; THERAPY; HEPATOTOXICITY	Background: The purpose of this study was to evaluate the efficacy and safety of three nevirapine-based antiretroviral treatments for adult antiretroviral-naive Chinese patients with HIV-1 infection. Methodology: This was a prospective, multicenter study. 198 antiretroviral-naive HIV-1 positive subjects with CD4 lymphocyte counts between 100/ul and 350/ul and plasma HIV-1 RNA levels more than 500 copies/ml were randomized to start three NVP-based antiretroviral treatments: group A, NVP+AZT+ddI; group B, NVP+3TC+d4T; group C, NVP+AZT+3TC. Viral responses, immunologic responses, adverse events and drug resistence were monitored at baseline and the end of week 4, 12, 24, 36, 52. Viralogical response and immunological response were also comparaed in different strata of baseline CD4 T lymphocyte counts and plasma HIV-1 RNA concentrations. At baseline, the plasma HIV-1 RNA was 4.44 +/- 0.68, 4.52 +/- 0.71 and 4.41 +/- 0.63 Ig copies/ml in group A, B and C respectively (p = 0.628). At the end of the study, the plasma viral load reached 2.54 +/- 1.11, 1.89 +/- 0.46 and 1.92 +/- 0.58 Ig copies/ml in group A, B and C respectively (p<0.001). At week 52, suppression of plasma HIV-1 RNA to less than 50 copies/ml was achieved in more patients in group B and C than in group A (68.2%, 69% vs. 39.7%; p<0.001). In planned subgroup analyses, the decrease of viral response rate was seen in group A when CD4 cell count.200/ul (subgroup H). But in subgroup L, viral response rate of three groups has no significant statistic difference. There were no statistically significant differences among three groups in immunological response wthin any of the CD4 or pVL strata. 3 out of 193 patients with available genotype at baseline showed primary drug resistant. Of 26 patients with virologic failure, 17 patients showed secondary drug resistant, 16 subjects in group A and 1 subject in group B. Logistic regression analysis indicated that presence of hepatotoxicity was associated with HCV-Ab positive (OR = 2.096, 95% CI: 1.106-3.973, P = 0.023) and higher CD4 baseline (CD4 count.250/ul)( OR = 2.096, 95% CI: 1.07-4.107, P = 0.031). Conclusion: Our findings strongly support the use of 3TC+d4T and 3TC+AZT as the nucleoside analogue combination in NVP-based antiretroviral therapy. The regimen of AZT+ddI+NVP produced poor virological response especially in the stratum of CD4 count more than 200/ul. More patients showed secondary drug resistant in this arm too. Patients with HCV-Ab+ and CD4 count.250/ul appear to have significantly high risk of hepatoxicity.	[Li, Taisheng; Dai, Yi; Kuang, Jiqiu; Han, Yang; Qiu, Zhifeng; Xie, Jing; Zuo, Lingyan; Li, Yanling] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing 100037, Peoples R China; [Jiang, Jingmei] Peking Union Med Coll, Sch Basic Med, Dept Epidemiol & Med Stat, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Li, TS (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing 100037, Peoples R China.	litsh@263.net	han, yang/GRS-2388-2022; li, yan/GTI-4638-2022		National Key Technologies R&D Programm for the 10th Five-year Plan [2004BA719A10]; Clinial Key Research Project of Affiliated Medical Institution of Ministry of Health, and National Sciences foundation of China [30571641]	National Key Technologies R&D Programm for the 10th Five-year Plan; Clinial Key Research Project of Affiliated Medical Institution of Ministry of Health, and National Sciences foundation of China	This study was Supported by the National Key Technologies R&D Programm for the 10th Five-year Plan (2004BA719A10). Clinial Key Research Project of Affiliated Medical Institution of Ministry of Health, and National Sciences foundation of China (30571641). The sponsors only provided the funds.	[Anonymous], 2004, DIVISION AIDS TABLE; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bartlett JA, 2006, AIDS, V20, P2051, DOI 10.1097/01.aids.0000247578.08449.ff; *CHIN GOV OFF WEB, 2006, HIV VICT CHIN ASS; Conway B, 2001, AIDS, V15, P1269, DOI 10.1097/00002030-200107060-00008; Dube MP, 2005, AIDS, V19, P1807, DOI 10.1097/01.aids.0000183629.20041.bb; French Martyn, 2002, HIV Clin Trials, V3, P177; Gandhi RT, 2006, JAIDS-J ACQ IMM DEF, V42, P426, DOI 10.1097/01.qai.0000226789.51992.3f; HOGG RS, 2001, JAMA-J AM MED ASSOC, V286, P2560; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Ma LY, 2007, JAIDS-J ACQ IMM DEF, V44, P14, DOI 10.1097/01.qai.0000243049.27580.cc; MONTANER JSG, 1998, JAMA-J AM MED ASSOC, V297, P930; Nunez M, 2006, J HEPATOL, V44, pS132, DOI 10.1016/j.jhep.2005.11.027; PHILLIPS AN, 2001, JAMA-J AM MED ASSOC, V286, P2568; Pujari SN, 2005, JAIDS-J ACQ IMM DEF, V39, P199; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; STERN J, 2002, 14 INT AIDS C JUL 7; Sulkowski MS, 2002, HEPATOLOGY, V35, P182, DOI 10.1053/jhep.2002.30319; *UK GROUP TRANSM H, 2005, BMJ-BRIT MED J, DOI DOI 10.1136/BMJ.38665.534595.55; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Weinstock HS, 2004, J INFECT DIS, V189, P2174, DOI 10.1086/420789; Weitzel T, 1999, AIDS, V13, P2309, DOI 10.1097/00002030-199911120-00018; *XINH, 2004, WHAT IS 4 FREE ON CA	23	34	47	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 12	2008	3	12							e3918	10.1371/journal.pone.0003918	http://dx.doi.org/10.1371/journal.pone.0003918			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	436ZW	19081791	Green Submitted, Green Published, gold			2023-01-03	WOS:000265456300002
J	Kenyon, S; Pike, K; Jones, DR; Brocklehurst, P; Marlow, N; Salt, A; Taylor, DJ				Kenyon, S.; Pike, K.; Jones, D. R.; Brocklehurst, P.; Marlow, N.; Salt, A.; Taylor, D. J.			Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE I trial	LANCET			English	Article							BEHAVIORAL OUTCOMES; PREMATURE RUPTURE; BRAIN-DAMAGE; AGE; INFECTION; CHILDREN; BIRTH; QUESTIONNAIRE; HEALTH	Background The ORACLE I trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for women with preterm rupture of the membranes without overt signs of clinical infection, by use of a factorial randomised design. The aim of the present study-the ORACLE Children Study I-was to determine the long-term effects on children of these interventions. Methods We assessed children at age 7 years born to the 4148 women who had completed the ORACLE I trial and who were eligible for follow-up with a structured parental questionnaire to assess the child's health status. Functional impairment was defined as the presence of any level of functional impairment (severe, moderate, or mild) derived from the mark III Multi-Attribute Health Status classification system. Educational outcomes were assessed with national curriculum test results for children resident in England. Findings Outcome was determined for 3298 (75%) eligible children. There was no difference in the proportion of children with any functional impairment after prescription of erythromycin, with or without co-amoxiclav, compared with those born to mothers who received no erythromycin (594 [38.3%] of 1551 children vs 655 [40.4%] of 1620; odds ratio 0.91, 95% CI 0.79-1.05) or after prescription of co-amoxiclav, with or without erythromycin, compared with those born to mothers who received no co-amoxiclav (645 [40.6%] of 1587 vs 604 [38.1%] of 1584; 1.11, 0.96-1.28). Neither antibiotic had a significant effect on the overall level of behavioural difficulties experienced, on specific medical conditions, or on the proportions of children achieving each level in reading, writing, or mathematics at key stage one. Interpretation The prescription of antibiotics for women with preterm rupture of the membranes seems to have little effect on the health of children at 7 years of age. Funding UK Medical Research Council.	[Kenyon, S.; Pike, K.; Taylor, D. J.] Univ Leicester, Reprod Sci Sect, Leicester LE1 6TP, Leics, England; [Jones, D. R.] Univ Leicester, Dept Hlth Sci, Leicester LE1 6TP, Leics, England; [Brocklehurst, P.] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; [Marlow, N.] Univ Nottingham, Acad Div Child Hlth, Nottingham NG7 2RD, England; [Salt, A.] UCL, Great Ormond St Hosp Children, London, England; [Salt, A.] UCL, Inst Child Hlth, London, England	University of Leicester; University of Leicester; University of Oxford; University of Nottingham; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Kenyon, S (corresponding author), Univ Leicester, Reprod Sci Sect, 22-28 Princess Rd W, Leicester LE1 6TP, Leics, England.	oracle@leicester.ac.uk	Brocklehurst, Peter/B-5804-2011; Marlow, Neil/D-2918-2009	Marlow, Neil/0000-0001-5890-2953; Kenyon, Sara/0000-0002-0756-9617	UK Medical Research Council; University Hospitals of Leicester; Medical Research Council [G9226450] Funding Source: researchfish; MRC [G9226450] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University Hospitals of Leicester; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by the UK Medical Research Council and sponsored by University Hospitals of Leicester and approved by their research and development directorate. We thank all the women and children who took part in the study and the obstetricians and midwives who recruited them to the original ORACLE trials. We thank the Office of National Statistics, the NHS National Strategic Tracing Service, and the Data Services Group within the Department of Children, Schools and Families. We also thank the key stage one group (Maggie McLean, John Crookes, Peter Tymms, and Tony Cline) for helpful comments on educational aspects. We thank Steve Gould, Barbara Farrell, Phil Edwards, and Martin Rosser for advice on questionnaire design. We convened a group of experts from within the field to help us understand and interpret these finding before publication. This group consisted of Martin Whittle, Alison Bedford Russell, Phil Bennett, Kate Costeloe, Francis Cowan, Olaf Dammann, Diana Elbourne, Catherine Elliott, Mike Millar, lane Norman, Micheal O'Shea, Max Parmar, Roberto Romero, and Dieter Wolke.	Altman DG, 2006, PRACTICAL STAT MED R; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Cuffe Steven P, 2005, J Atten Disord, V9, P392, DOI 10.1177/1087054705280413; Dammann O, 2005, BJOG-INT J OBSTET GY, V112, P4, DOI 10.1111/j.1471-0528.2005.00576.x; Dammann O, 2007, DEV NEUROSCI-BASEL, V29, P280, DOI 10.1159/000105469; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Feeny D, 2004, SOC SCI MED, V58, P799, DOI 10.1016/S0277-9536(03)00254-5; Gates S, 2004, BJOG-INT J OBSTET GY, V111, P213, DOI 10.1111/j.1471-0528.2004.00059.x; Gomez R, 1997, PRETERM LABOR, P85; Gomez R, 2007, J MATERN-FETAL NEO M, V20, P167, DOI 10.1080/14767050601135485; Goncalves LF, 2002, MENT RETARD DEV D R, V8, P3, DOI 10.1002/mrdd.10008; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Gotsch F, 2007, CLIN OBSTET GYNECOL, V50, P652, DOI 10.1097/GRF.0b013e31811ebef6; Jobe A H, 2001, Semin Neonatol, V6, P331, DOI 10.1053/siny.2001.0068; Johnson S, 2007, SEMIN FETAL NEONAT M, V12, P363, DOI 10.1016/j.siny.2007.05.004; Kenyon S, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-55; KENYON S, 2008, BMC PREGNANCY CHILDB, V8, P14; KENYON S, 2008, LANCET          0918, DOI DOI 10.1016/S0140-6736(08)61203-9; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Marlow N, 2004, ARCH DIS CHILD-FETAL, V89, pF224, DOI 10.1136/adc.2002.019752; Marlow N, 2007, PEDIATRICS, V120, P793, DOI 10.1542/peds.2007-0440; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Miralles R, 2005, PEDIATR RES, V57, P570, DOI 10.1203/01.PDR.0000155944.48195.97; Montgomery Alan A, 2003, BMC Med Res Methodol, V3, P26, DOI 10.1186/1471-2288-3-26; *QUAL CURR AUTH, 2007, KEY STAG 1 ASS REP A; ROMERO R, 1988, AM J OBSTET GYNECOL, V159, P661, DOI 10.1016/S0002-9378(88)80030-9; Royal College of Obstetricians and Gynaecologists, 2006, PRET PREL RUPT MEMBR; SAIGAL S, 1994, J PEDIATR-US, V125, P411, DOI 10.1016/S0022-3476(05)83288-3; Salt A, 2006, EARLY HUM DEV, V82, P185, DOI 10.1016/j.earlhumdev.2005.12.015; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83	33	94	99	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2008	372	9646					1310	1318		10.1016/S0140-6736(08)61202-7	http://dx.doi.org/10.1016/S0140-6736(08)61202-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18804274	Green Submitted			2023-01-03	WOS:000260060500029
J	Henkind, SJ; Sinnett, JC				Henkind, Steven J.; Sinnett, J. Christopher			Patient care, square-rigger sailing, and safety	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TEAMWORK		[Henkind, Steven J.] CCI Grp, Larchmont, NY 10538 USA; [Sinnett, J. Christopher] US Coast Guard, US Coast Guard Barque Eagle, New London, CT USA		Henkind, SJ (corresponding author), CCI Grp, 7 S Ridge Rd, Larchmont, NY 10538 USA.	sjh37@verizon.net						Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Baker DP, 2005, JT COMM J QUAL PATIE, V31, P185, DOI 10.1016/S1553-7250(05)31025-7; Gawande Atul, 2007, New Yorker, P86; Grogan EL, 2004, J AM COLL SURGEONS, V199, P843, DOI 10.1016/j.jamcollsurg.2004.08.021; *HLTH SAF EX, 1996, PUBL OTO; *JCAHO, 2006, JT PERSPECTIVES PATI, V6, P9; Kohn L.T., 2000, TO ERR IS HUMAN BUIL; Morey JC, 2002, HEALTH SERV RES, V37, P1553, DOI 10.1111/1475-6773.01104; National Institute for Occupational Safety and Health, 2004, NIOSH PUBL, V2004-146; Okie S, 2007, NEW ENGL J MED, V356, P2665, DOI 10.1056/NEJMp078085; Petersen L A, 1998, Jt Comm J Qual Improv, V24, P77; Pizzi L, 2001, AHRQ PUBLICATION; Salas E, 2001, HUM FACTORS, V43, P641, DOI 10.1518/001872001775870386; *US COAST GUARD, 1998, USCG PUBL; Winters BD, 2006, JAMA-J AM MED ASSOC, V296, P1645, DOI 10.1001/jama.296.13.1645	15	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2008	300	14					1691	1693		10.1001/jama.300.14.1691	http://dx.doi.org/10.1001/jama.300.14.1691			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	356YF	18840843				2023-01-03	WOS:000259812800031
J	Sprake, C; Cantillon, P; Metcalf, J; Spencer, J				Sprake, Caroline; Cantillon, Peter; Metcalf, Jane; Spencer, John			Teaching rounds - Teaching in an ambulatory care setting	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							12 TIPS; EDUCATION	Four third- year medical students are coming to the clinic for half a day a week. They have just finished their basic clinical skills training and the aim of their attendance is to further develop their history taking and examination skills in the maelstrom of clinical practice. What organisational issues do you need to consider?	[Sprake, Caroline; Metcalf, Jane; Spencer, John] Univ Newcastle, Sch Med Sci Educ Dev, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Cantillon, Peter] Natl Univ Ireland Univ Coll Galway, Dept Gen Practice, Galway, Ireland	Newcastle University - UK; Ollscoil na Gaillimhe-University of Galway	Spencer, J (corresponding author), Univ Newcastle, Sch Med Sci Educ Dev, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	j.a.spencer@ncl.ac.uk						*CAN I HLTH INF, 1998, NAT AMB CAR REP SYST; Dent JA, 2001, MED TEACH, V23, P345, DOI 10.1080/01421590120057012; Howe A, 2003, BRIT MED J, V327, P326, DOI 10.1136/bmj.327.7410.326; Irby DM, 2008, BRIT MED J, V336, P384, DOI 10.1136/bmj.39456.727199.AD; IRBY DM, 1995, ACAD MED, V70, P898, DOI 10.1097/00001888-199510000-00014; Ker JS, 2002, MED TEACH, V24, P437, DOI 10.1080/01421590220145842; Lipsky MS, 1999, MED TEACH, V21, P469; Sackett DL, 2000, EVIDENCE BASED MED P; Schuwirth LWT, 2006, BMJ-BRIT MED J, V333, P544, DOI 10.1136/bmj.38952.701875.94; Smail S, 2006, EDUC PRIM CARE, V17, P171, DOI 10.1080/14739879.2006.11864055; Spencer J, 2000, MED EDUC, V34, P851, DOI 10.1046/j.1365-2923.2000.00779.x; Spencer J, 2003, BMJ-BRIT MED J, V326, P591, DOI 10.1136/bmj.326.7389.591; WOOLLISCROFT JO, 1989, ACAD MED, V64, P644, DOI 10.1097/00001888-198911000-00002	13	7	7	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2008	337	7671							a1156	10.1136/bmj.a1156	http://dx.doi.org/10.1136/bmj.a1156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354EP	18768554				2023-01-03	WOS:000259622000036
J	Hammer, SM; Eron, JJ; Reiss, P; Schooley, RT; Thompson, MA; Walmsley, S; Cahn, P; Fischl, MA; Gatell, JM; Hirsch, MS; Jacobsen, DM; Montaner, JSG; Richman, DD; Yeni, PG; Volberding, PA				Hammer, Scott M.; Eron, Joseph J., Jr.; Reiss, Peter; Schooley, Robert T.; Thompson, Melanie A.; Walmsley, Sharon; Cahn, Pedro; Fischl, Margaret A.; Gatell, Jose M.; Hirsch, Martin S.; Jacobsen, Donna M.; Montaner, Julio S. G.; Richman, Douglas D.; Yeni, Patrick G.; Volberding, Paul A.			Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; TREATMENT-NAIVE PATIENTS; EXPERIENCED HIV-1-INFECTED PATIENTS; TENOFOVIR DISOPROXIL FUMARATE; REVERSE-TRANSCRIPTASE INHIBITORS; CHRONIC KIDNEY-DISEASE; CD4 CELL COUNTS; CLINICAL-TRIALS; DOUBLE-BLIND; OPEN-LABEL	Context The availability of new antiretroviral drugs and formulations, including drugs in new classes, and recent data on treatment choices for antiretroviral- naive and - experienced patients warrant an update of the International AIDS Society - USA guidelines for the use of antiretroviral therapy in adult human immunodeficiency virus ( HIV) infection. Objectives To summarize new data in the field and to provide current recommendations for the antiretroviral management and laboratory monitoring of HIV infection. This report provides guidelines in key areas of antiretroviral management: when to initiate therapy, choice of initial regimens, patient monitoring, when to change therapy, and how best to approach treatment options, including optimal use of recently approved drugs ( maraviroc, raltegravir, and etravirine) in treatment- experienced patients. Data Sources and Study Selection A 14- member panel with expertise in HIV research and clinical care was appointed. Data published or presented at selected scientific conferences since the last panel report ( August 2006) through June 2008 were identified. Data Extraction and Synthesis Data that changed the previous guidelines were reviewed by the panel ( according to section). Guidelines were drafted by section writing committees and were then reviewed and edited by the entire panel. Recommendations were made by panel consensus. Conclusions New data and considerations support initiating therapy before CD4 cell count declines to less than 350/mu L. In patients with 350 CD4 cells/mu L or more, the decision to begin therapy should be individualized based on the presence of comorbidities, risk factors for progression to AIDS and non- AIDS diseases, and patient readiness for treatment. In addition to the prior recommendation that a high plasma viral load ( eg, > 100 000 copies/ mL) and rapidly declining CD4 cell count ( > 100/mu L per year) should prompt treatment initiation, active hepatitis B or C virus coinfection, cardiovascular disease risk, and HIV- associated nephropathy increasingly prompt earlier therapy. The initial regimen must be individualized, particularly in the presence of comorbid conditions, but usually will include efavirenz or a ritonavir- boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors ( tenofovir/ emtricitabine or abacavir/ lamivudine). Treatment failure should be identified and managed promptly, with the goal of therapy, even in heavily pretreated patients, being an HIV- 1 RNA level below assay detection limits.	[Hammer, Scott M.] Columbia Univ Coll Phys & Surg, Div Infect Dis, New York, NY 10032 USA; [Eron, Joseph J., Jr.] Univ N Carolina, Chapel Hill, NC USA; [Reiss, Peter] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Schooley, Robert T.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Thompson, Melanie A.] AIDS Res Consortium Atlanta, Atlanta, GA USA; [Walmsley, Sharon] Univ Toronto, Toronto, ON, Canada; [Cahn, Pedro] Univ Buenos Aires, Sch Med, Hosp Juan Fernandez, Buenos Aires, DF, Argentina; [Cahn, Pedro] Fdn Huesped, Buenos Aires, DF, Argentina; [Fischl, Margaret A.] Univ Miami, Miami, FL USA; [Gatell, Jose M.] Univ Barcelona, Barcelona, Spain; [Hirsch, Martin S.] Harvard Univ, Sch Med, Boston, MA USA; [Jacobsen, Donna M.] Int AIDS Soc USA, San Francisco, CA USA; [Volberding, Paul A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Volberding, Paul A.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Montaner, Julio S. G.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Richman, Douglas D.] Univ Calif San Diego, San Diego, CA 92103 USA; [Richman, Douglas D.] Vet Affairs San Diego Healthcare Syst, San Diego, CA USA; [Yeni, Patrick G.] Hop Bichat Claude Bernard, F-75877 Paris 18, France; [Yeni, Patrick G.] Xavier Bichat Med Sch, Paris, France	Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of Amsterdam; Academic Medical Center Amsterdam; University of California System; University of California San Diego; University of Toronto; University of Buenos Aires; University of Miami; University of Barcelona; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of British Columbia; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Hammer, SM (corresponding author), Columbia Univ Coll Phys & Surg, Div Infect Dis, 630 W 168th St, New York, NY 10032 USA.	smh48@columbia.edu	Montaner, Julio/K-7621-2012; Gatell, Jose M/ABC-3607-2020	Walmsley, Sharon/0000-0002-3959-5692				Alvarez D, 2006, J VIRAL HEPATITIS, V13, P683, DOI 10.1111/j.1365-2893.2006.00749.x; Arribas JR, 2008, JAIDS-J ACQ IMM DEF, V47, P74, DOI 10.1097/QAI.0b013e31815acab8; Badiou S, 2006, J INFECTION, V52, P335, DOI 10.1016/j.jinf.2005.07.020; Bangalore S, 2007, AM J MED, V120, P713, DOI 10.1016/j.amjmed.2006.08.033; Barreiro P, 2007, J INFECT DIS, V195, P973, DOI 10.1086/512086; Braithwaite RS, 2008, ANN INTERN MED, V148, P178, DOI 10.7326/0003-4819-148-3-200802050-00004; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; *BRIST MYERS SQUIB, 2007, REYAT PACK INS; BRUYAND M, 2008, 15 C RETR OPP INF FE; Cameron DW, 2008, J INFECT DIS, V198, P234, DOI 10.1086/589622; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Choi AI, 2007, J AM SOC NEPHROL, V18, P2968, DOI 10.1681/ASN.2007040402; CLELJSEN RM, 2007, J ANTIMICROB CHEMOTH, V60, P897; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; CLUMECK N, 2007, 11 EUR AIDS C OCT 24; COOPER D, 2007, 14 C RETR OPP INF FE; COOPER D, 2008, 15 C RETR OPP INF FE; Danesh J, 2008, PLOS MED, V5, P600, DOI 10.1371/journal.pmed.0050078; De Lazzari E, 2008, HIV MED, V9, P221, DOI 10.1111/j.1468-1293.2008.00552.x; De Wit S, 2008, DIABETES CARE, V31, P1224, DOI 10.2337/dc07-2013; Delfraissy JFO, 2008, AIDS, V22, P385, DOI 10.1097/QAD.0b013e3282f3f16d; Dube MP, 2007, JAIDS-J ACQ IMM DEF, V45, P508, DOI 10.1097/QAI.0b013e3181142d26; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; ELSADR W, 2008, 15 C RETR OPP INF FE; Emery S, 2008, J INFECT DIS, V197, P1133, DOI 10.1086/586713; Joseph E, 2006, LANCET, V368, P476, DOI 10.1016/S0140-6736(06)69155-1; Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723, DOI 10.1056/NEJMoa062744; Gallant JE, 2006, NEW ENGL J MED, V354, P251, DOI 10.1056/NEJMoa051871; Gallant JE, 2004, JAMA-J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191; GATHE J, 2008, 15 C RETR OPP INF FE; Gras L, 2007, JAIDS-J ACQ IMM DEF, V45, P183, DOI 10.1097/QAI.0b013e31804d685b; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Gulick RM, 2006, JAMA-J AM MED ASSOC, V296, P769, DOI 10.1001/jama.296.7.769; Gupta SK, 2005, CLIN INFECT DIS, V40, P1559, DOI 10.1086/430257; Gupta SK, 2004, CLIN NEPHROL, V61, P1; Hammer SM, 2006, JAMA-J AM MED ASSOC, V296, P827, DOI 10.1001/jama.296.7.827; HARDY D, 2008, 15 C RETR OPP INF FE; HARRIS M, 2008, 15 C RETR OPP INF FE; HAUBRICH R, 2008, 15 C RETR OPP INF FE; HAUBRICH RH, 2007, 14 C RETR OPP INF FE; Hazuda DJ, 2007, ANTIVIR THER, V12, pS10; Hicks CB, 2006, LANCET, V368, P466, DOI 10.1016/S0140-6736(06)69154-X; Hill A, 2007, AIDS, V21, P1651, DOI 10.1097/QAD.0b013e3282703593; Hirsch MS, 2008, CLIN INFECT DIS, V47, P266, DOI 10.1086/589297; Holland DT, 2004, ANTIMICROB AGENTS CH, V48, P824, DOI 10.1128/AAC.48.3.824-831.2004; Jaen A, 2008, JAIDS-J ACQ IMM DEF, V47, P212, DOI 10.1097/QAI.0b013e31815ee282; JOHNSON M, 2008, 15 C RETR OPP INF FE; Kaplan JE, 2003, CLIN INFECT DIS, V37, P951, DOI 10.1086/377606; KAYITENKORE K, 2006, 16 INT AIDS C AUG 13; KEARNEY BP, 2002, 6 INT C DRUG THER HI; Kempf DJ, 2004, J INFECT DIS, V189, P51, DOI 10.1086/380509; Khoo SH, 2006, JAIDS-J ACQ IMM DEF, V41, P461, DOI 10.1097/01.qai.0000218345.65434.21; Kuller L., 2008, 15 C RETR OPP INF FE; Lau B, 2007, JAIDS-J ACQ IMM DEF, V44, P179, DOI 10.1097/01.qai.0000247229.68246.c5; Law MG, 2006, HIV MED, V7, P218, DOI 10.1111/j.1468-1293.2006.00362.x; Lazzarin A, 2007, LANCET, V370, P39, DOI 10.1016/S0140-6736(07)61048-4; Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72; Lichtenstein KA, 2008, JAIDS-J ACQ IMM DEF, V47, P27, DOI 10.1097/QAI.0b013e31815acacc; LODWICK R, 2008, 15 C RETR OPP INF FE; Lotsch J, 2007, ANTIMICROB AGENTS CH, V51, P3264, DOI 10.1128/AAC.00036-07; Long JL, 2008, AIDS, V22, P489, DOI 10.1097/QAD.0b013e3282f47082; Luber AD, 2007, HIV MED, V8, P457, DOI 10.1111/j.1468-1293.2007.00496.x; Lucas GM, 2004, AIDS, V18, P541, DOI 10.1097/00002030-200402200-00022; Lundgren JD, 2008, HIV MED, V9, P72, DOI 10.1111/j.1468-1293.2007.00534.x; Lundgren JD, 2008, J INFECT DIS, V197, P1145, DOI 10.1086/529523; Lyons F, 2007, AIDS, V21, P1053, DOI 10.1097/QAD.0b013e3281053a1e; Madruga JV, 2007, LANCET, V370, P29, DOI 10.1016/S0140-6736(07)61047-2; Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c; Markowitz M, 2006, JAIDS-J ACQ IMM DEF, V43, P509, DOI 10.1097/QAI.0b013e31802b4956; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Mauskopf J, 2005, JAIDS-J ACQ IMM DEF, V39, P562; May M, 2007, AIDS, V21, P1185, DOI 10.1097/QAD.0b013e328133f285; MAYER H, 2006, 16 INT AIDS C AUG 13; McMahon MA, 2007, NEW ENGL J MED, V356, P2614, DOI 10.1056/NEJMoa067710; Mocroft A, 2007, ANTIVIR THER, V12, P325; MOLINA JM, 2008, 15 C RETR OPP INF FE; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Moyle G, 2006, ANTIVIR THER, V11, P73; Moyle GJ, 2003, JAIDS-J ACQ IMM DEF, V33, P22, DOI 10.1097/00126334-200305010-00004; Neal B, 2008, PLOS MED, V5, P526, DOI 10.1371/journal.pmed.0050084; Neaton JD, 2008, CURR OPIN HIV AIDS, V3, P112, DOI 10.1097/COH.0b013e3282f3808b; Nelson MR, 2007, AIDS, V21, P1273, DOI 10.1097/QAD.0b013e3280b07b33; Malan DR, 2008, JAIDS-J ACQ IMM DEF, V47, P161, DOI 10.1097/QAI.0b013e31815ace6a; Opravil M, 2002, AIDS, V16, P1371, DOI 10.1097/00002030-200207050-00009; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Park-Wyllie LY, 2007, CLIN INFECT DIS, V45, P933, DOI 10.1086/521252; Parsonage MJ, 2005, HIV MED, V6, P341, DOI 10.1111/j.1468-1293.2005.00318.x; Patel P, 2008, ANN INTERN MED, V148, P728, DOI 10.7326/0003-4819-148-10-200805200-00005; *PER HIV GUID WORK, PUBL HLTH SERV TASK; PHILLIPS A, 2008, 15 C RETR OPP INF FE; Phillips AN, 2007, AIDS, V21, P1717; Phillips AN, 2007, BRIT MED J, V334, P76, DOI 10.1136/bmj.39064.406389.94; Podzamczer D, 2007, JAIDS-J ACQ IMM DEF, V44, P139, DOI 10.1097/QAI.0b013e31802bf122; Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Rauch A, 2006, CLIN INFECT DIS, V43, P99, DOI 10.1086/504874; Reisler RB, 2003, JAIDS-J ACQ IMM DEF, V34, P379, DOI 10.1097/00126334-200312010-00004; Reynes J, 2007, AIDS PATIENT CARE ST, V21, P533, DOI 10.1089/apc.2006.0174; Ribaudo HJ, 2008, J INFECT DIS, V197, P1006, DOI 10.1086/529208; Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609; Riedel DJ, 2008, AIDS PATIENT CARE ST, V22, P113, DOI 10.1089/apc.2007.0034; Ripamonti D, 2007, AIDS, V21, P2409, DOI 10.1097/QAD.0b013e32825a69d1; Rosso R, 2006, J ANTIMICROB CHEMOTH, V57, P1168, DOI 10.1093/jac/dkl136; SAAG M, 2007, 4 INT AIDS SOC C HIV; Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7; SCHOLLER M, 2006, 13 C RETR OPP INF FE; SEMINARI E, 2005, 6 INT WORKSH CLIN PH; SHERMAN K, 2008, 15 C RETR OPP INF FE; Skrabal K, 2007, J CLIN MICROBIOL, V45, P279, DOI 10.1128/JCM.01118-06; Smit C, 2006, AIDS, V20, P741, DOI 10.1097/01.aids.0000216375.99560.a2; SMITH K, 2007, 4 INT AIDS SOC C HIV; SMITH KY, 2008, 15 C RETR OPP INF FE; STEIGBIGEL R, 2008, 15 C RETR OPP INF FE; STEIGBIGEL R, 2007, 14 C RETR OPP INF FE; Stein JH, 2008, LANCET, V371, P1391, DOI 10.1016/S0140-6736(08)60491-2; Sterling TR, 2003, J INFECT DIS, V188, P1659, DOI 10.1086/379741; Szczech A, 2002, CLIN NEPHROL, V57, P336; Szczech LA, 2002, KIDNEY INT, V61, P195, DOI 10.1046/j.1523-1755.2002.00094.x; TROTTIER B, 2008, 17 ANN CAN C HIV AID; van Luin M, 2008, CURR OPIN HIV AIDS, V3, P266, DOI 10.1097/COH.0b013e3282f82c1b; Vingerhoets J, 2007, ANTIVIR THER, V12, pS34; von Hentig N, 2006, EUR J MED RES, V11, P377; WALMSLEY S, 2007, 11 C RETR OPP INF OC; Walmsley SL, 2008, JAIDS-J ACQ IMM DEF, V47, P429, DOI 10.1097/QAI.0b013e318160a529; Walmsley SL, 2007, AIDS, V21, P2245, DOI 10.1097/QAD.0b013e3282ef6db7; Ward DJ, 2006, AIDS PATIENT CARE ST, V20, P542, DOI 10.1089/apc.2006.20.542; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Wensing AMJ, 2008, AIDS, V22, P625, DOI 10.1097/QAD.0b013e3282f5e062; WHEELER W, 2007, 14 C RETR OPP INF FE; Winston JA, 2001, NEW ENGL J MED, V344, P1979, DOI 10.1056/NEJM200106283442604; Wood E, 2007, HIV MED, V8, P80, DOI 10.1111/j.1468-1293.2007.00430.x; ZOLOPA A, 2008, 15 C RETR OPP INF FE	137	777	826	3	132	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	2008	300	5					555	570		10.1001/jama.300.5.555	http://dx.doi.org/10.1001/jama.300.5.555			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	333YG	18677028				2023-01-03	WOS:000258188900017
J	Pasanen, K; Parkkari, J; Pasanen, M; Hiilloskorpi, H; Makinen, T; Jarvinen, M; Kannus, P				Pasanen, Kati; Parkkari, Jari; Pasanen, Matti; Hiilloskorpi, Hannele; Makinen, Tanja; Jarvinen, Markku; Kannus, Pekka			Neuromuscular training and the risk of leg injuries in female floorball players: cluster randomised controlled study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EUROPEAN TEAM HANDBALL; SOCCER INJURIES; ANKLE SPRAINS; CONTROLLED-TRIAL; SPORTS INJURIES; FOLLOW-UP; PREVENTION; PROGRAM; OSTEOARTHRITIS; INTERVENTION	Objective To investigate whether a neuromuscular training programme is effective in preventing non-contact leg injuries in female floorball players. Design Cluster randomised controlled study. Setting 28 top level female floorball teams in Finland. Participants 457 players (mean age 24 years)-256 (14 teams) in the intervention group and 201 (14 teams) in the control group-followed up for one league season (six months). Intervention A neuromuscular training programme to enhance players' motor skills and body control, as well as to activate and prepare their neuromuscular system for sports specific manoeuvres. Main outcome measure Acute non-contact injuries of the legs. Results During the season, 72 acute non-contact leg injuries occurred, 20 in the intervention group and 52 in the control group. The injury incidence per 1000 hours playing and practise in the intervention group was 0.65 (95% confidence interval 0.37 to 1.13) and in the control group was 2.08 (1.58 to 2.72). The risk of non-contact leg injury was 66% lower (adjusted incidence rate ratio 0.34, 95% confidence interval 0.20 to 0.57) in the intervention group. Conclusion A neuromuscular training programme was effective in preventing acute non-contact injuries of the legs in female floorball players. Neuromuscular training can be recommended in the weekly training of these athletes. Trial registration Current Controlled Trials ISRCTN26550281.	[Pasanen, Kati; Parkkari, Jari; Pasanen, Matti; Hiilloskorpi, Hannele; Makinen, Tanja] UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, FIN-33501 Tampere, Finland; [Kannus, Pekka] UKK Inst Hlth Promot Res, Injury & Osteoporosis Res Ctr, FIN-33501 Tampere, Finland; [Jarvinen, Markku] Univ Tampere, Tampere Univ Hosp & Med Sch, Dept Surg, FIN-33101 Tampere, Finland	UKK Institute; UKK Institute; Tampere University; Tampere University Hospital	Pasanen, K (corresponding author), UKK Inst Hlth Promot Res, Tampere Res Ctr Sports Med, FIN-33501 Tampere, Finland.	kati.pasanen@uta.fi	Pasanen, Kati/Z-2085-2018	Pasanen, Kati/0000-0002-0427-2877				Aaltonen S, 2007, ARCH INTERN MED, V167, P1585, DOI 10.1001/archinte.167.15.1585; Deacon A, 1997, MED J AUSTRALIA, V166, P187, DOI 10.5694/j.1326-5377.1997.tb140072.x; EKSTRAND J, 1983, AM J SPORT MED, V11, P116, DOI 10.1177/036354658301100302; EKSTRAND J, 1983, INT J SPORTS MED, V4, P124, DOI 10.1055/s-2008-1026025; EKSTRAND J, 1983, MED SCI SPORT EXER, V15, P267, DOI 10.1249/00005768-198315030-00014; Emery CA, 2005, CAN MED ASSOC J, V172, P749, DOI 10.1503/cmaj.1040805; Heidt RS, 2000, AM J SPORT MED, V28, P659, DOI 10.1177/03635465000280050601; Hewett TE, 1999, AM J SPORT MED, V27, P699, DOI 10.1177/03635465990270060301; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Kofotolis ND, 2007, AM J SPORT MED, V35, P458, DOI 10.1177/0363546506294857; Lofgren O., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P211; Lohmander LS, 2007, AM J SPORT MED, V35, P1756, DOI 10.1177/0363546507307396; McGuine TA, 2006, AM J SPORT MED, V34, P1103, DOI 10.1177/0363546505284191; McHugh MP, 2006, AM J SPORT MED, V34, P464, DOI 10.1177/0363546505280427; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; Olsen O, 2005, BMJ-BRIT MED J, V330, P1, DOI DOI 10.1136//BMJ.38330.632801.8F; Parkkari J, 2004, INT J SPORTS MED, V25, P209, DOI 10.1055/s-2004-819935; Pasanen K, 2008, SCAND J MED SCI SPOR, V18, P49, DOI 10.1111/j.1600-0838.2007.00640.x; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Snellman K, 2001, INT J SPORTS MED, V22, P531, DOI 10.1055/s-2001-17609; Soderman K, 2000, KNEE SURG SPORT TR A, V8, P356, DOI 10.1007/s001670000147; Verhagen E, 2004, AM J SPORT MED, V32, P1385, DOI 10.1177/0363546503262177; Wedderkopp N, 1999, SCAND J MED SCI SPOR, V9, P41; Wedderkopp N, 1997, SCAND J MED SCI SPOR, V7, P342; Wikstrom J, 1997, SCAND J MED SCI SPOR, V7, P38	25	70	71	2	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2008	337	7661							a295	10.1136/bmj.a295	http://dx.doi.org/10.1136/bmj.a295			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330SA	18595903	Green Published			2023-01-03	WOS:000257961900034
J	Morch, LS; Lokkegaard, E; Andreasen, AH; Kruger-Kjaer, S; Lidegaard, O				Morch, Lina Steinrud; Lokkegaard, Ellen; Andreasen, Anne Helms; Kruger-Kjaer, Susanne; Lidegaard, Ojvind			Hormone Therapy and Ovarian Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPLACEMENT THERAPY; SWEDISH WOMEN; RISK; DENMARK; REGISTRY; HEALTH	Context Studies have suggested an increased risk of ovarian cancer among women taking postmenopausal hormone therapy. Data are sparse on the differential effects of formulations, regimens, and routes of administration. Objective To assess risk of ovarian cancer in perimenopausal and postmenopausal women receiving different hormone therapies. Design and Setting Nationwide prospective cohort study including all Danish women aged 50 through 79 years from 1995 through 2005 through individual linkage to Danish national registers. Redeemed prescription data from the National Register of Medicinal Product Statistics provided individually updated exposure information. The National Cancer Register and Pathology Register provided ovarian cancer incidence data. Information on confounding factors and effect modifiers was from other national registers. Poisson regression analyses with 5-year age bands included hormone exposures as time-dependent covariates. Participants A total of 909 946 women without hormone-sensitive cancer or bilateral oophorectomy. Main Outcome Measure Ovarian cancer. Results In an average of 8.0 years of follow-up (7.3 million women-years), 3068 incident ovarian cancers, of which 2681 were epithelial cancers, were detected. Compared with women who never took hormone therapy, current users of hormones had incidence rate ratios for all ovarian cancers of 1.38 (95% confidence interval [CI], 1.26-1.51) and 1.44 ( 95% CI, 1.30-1.58) for epithelial ovarian cancer. The risk declined with years since last use: 0 to 2 years, 1.22 ( 95% CI, 1.02-1.46); more than 2 to 4 years, 0.98 ( 95% CI, 0.75-1.28); more than 4 to 6 years, 0.72 ( 95% CI, 0.50-1.05), and more than 6 years, 0.63 ( 95% CI, 0.41-0.96). For current users the risk of ovarian cancer did not differ significantly with different hormone therapies or duration of use. The incidence rates in current and never users of hormones were 0.52 and 0.40 per 1000 years, respectively, ie, an absolute risk increase of 0.12 ( 95% CI, 0.01-0.17) per 1000 years. This approximates 1 extra ovarian cancer for roughly 8300 women taking hormone therapy each year. Conclusion Regardless of the duration of use, the formulation, estrogen dose, regimen, progestin type, and route of administration, hormone therapy was associated with an increased risk of ovarian cancer. JAMA. 2009; 302(3):298-305 www.jama.com	[Morch, Lina Steinrud; Lidegaard, Ojvind] Univ Copenhagen, Gynaecol Clin, Rigshosp, DK-2100 Copenhagen, Denmark; [Lokkegaard, Ellen] Univ Copenhagen, Hillerod Hosp, Gynaecol Obstetr Dept, Copenhagen, Denmark; [Morch, Lina Steinrud; Andreasen, Anne Helms] Glostrup Univ Hosp, Res Ctr Prevent & Hlth, Glostrup, Denmark; [Kruger-Kjaer, Susanne] Danish Canc Soc, Dept Virus Hormones & Canc, Inst Canc Epidemiol, Osterbro, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; Danish Cancer Society	Morch, LS (corresponding author), Univ Copenhagen, Gynaecol Clin, Rigshosp, Sect 3341,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	linamorch@yahoo.dk		Kjaer, Susanne/0000-0002-8347-1398; Andreasen, Anne Helms/0000-0002-2350-9884; Lokkegaard, Ellen/0000-0003-4149-5663; Morch, Lina/0000-0001-6506-2569	Danish Cancer Society [DP05006]	Danish Cancer Society(Danish Cancer Society)	This study was supported by grant J No. DP05006 from the Danish Cancer Society.	Anderson GL, 2003, JAMA-J AM MED ASSOC, V290, P1739, DOI 10.1001/jama.290.13.1739; Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0; Danforth KN, 2007, BRIT J CANCER, V96, P151, DOI 10.1038/sj.bjc.6603527; Glud E, 2004, ARCH INTERN MED, V164, P2253, DOI 10.1001/archinte.164.20.2253; Greiser CM, 2007, HUM REPROD UPDATE, V13, P453, DOI 10.1093/humupd/dmm012; Hammar M, 1996, MATURITAS, V25, P193, DOI 10.1016/S0378-5122(96)01065-1; Hundrup YA, 2000, ACTA OBSTET GYN SCAN, V79, P194, DOI 10.1080/j.1600-0412.2000.079003194.x; Jensen AR, 2002, EUR J CANCER PREV, V11, P359, DOI 10.1097/00008469-200208000-00007; Kjaerbye-Thygesen Anette, 2007, Ugeskr Laeger, V169, P50; Lacey JV, 2006, JNCI-J NATL CANCER I, V98, P1397, DOI 10.1093/jnci/djj375; Lokkegaard E, 2007, ACTA OBSTET GYN SCAN, V86, P1342, DOI 10.1080/00016340701505523; Nielsen LH, 2008, PHARMACOEPIDEM DR S, V17, P384, DOI 10.1002/pds.1549; Riman T, 2002, JNCI-J NATL CANCER I, V94, P497, DOI 10.1093/jnci/94.7.497; Soegaard M, 2007, CANCER EPIDEM BIOMAR, V16, P1160, DOI 10.1158/1055-9965.EPI-07-0089; STORM HH, 1988, INT J EPIDEMIOL, V17, P44, DOI 10.1093/ije/17.1.44; Storm HH, 1997, DAN MED BULL, V44, P535	16	139	144	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	2009	302	3					298	305		10.1001/jama.2009.1052	http://dx.doi.org/10.1001/jama.2009.1052			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	470BR	19602689	Bronze			2023-01-03	WOS:000267948100023
J	Koehn, BH; Schoenberger, SP				Koehn, Brent H.; Schoenberger, Stephen P.			Tumor immunotherapy: making an immortal army	NATURE MEDICINE			English	Editorial Material							CELLS		[Koehn, Brent H.; Schoenberger, Stephen P.] La Jolla Inst Allergy & Immunol, Cellular Immunol Lab, La Jolla, CA USA	La Jolla Institute for Immunology	Koehn, BH (corresponding author), La Jolla Inst Allergy & Immunol, Cellular Immunol Lab, La Jolla, CA USA.	sps@liai.org			NATIONAL CANCER INSTITUTE [R01CA081261] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081261-10, R01 CA081261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.iy.12.040194.003511; Croce Jenifer C., 2008, V469, P3, DOI 10.1007/978-1-60327-469-2_1; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Herodotus, 1972, HISTORIES; Malhotra S, 2009, CELL STEM CELL, V4, P27, DOI 10.1016/j.stem.2008.12.004; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Stemberger C, 2009, SEMIN IMMUNOL, V21, P62, DOI 10.1016/j.smim.2009.02.004; Surh CD, 2008, IMMUNITY, V29, P848, DOI 10.1016/j.immuni.2008.11.002	8	11	12	0	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2009	15	7					731	732		10.1038/nm0709-731	http://dx.doi.org/10.1038/nm0709-731			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	468HE	19584859	Green Accepted, Bronze			2023-01-03	WOS:000267806900021
J	Blennow, M; Ewald, U; Fritz, T; Holmgren, PA; Jeppsson, A; Lindberg, E; Lundqvist, A; Lindeberg, SN; Olhager, E; Ostlund, I; Simic, M; Sjors, G; Stigson, L; Fellman, V; Hellstrom-Westas, L; Norman, M; Westgren, M; Holmstrom, G; Laurini, R; Stjernqvist, K; Kallen, K; Lagercrantz, H; Marsal, K; Serenius, F; Wennergren, M; Nilstun, T; Olausson, PO; Stromberg, B				Blennow, Mats; Ewald, Uwe; Fritz, Tomas; Holmgren, Per Ake; Jeppsson, Annika; Lindberg, Eva; Lundqvist, Anita; Lindeberg, Solveig Norden; Olhager, Elisabeth; Ostlund, Ingrid; Simic, Marija; Sjoers, Gunnar; Stigson, Lennart; Fellman, Vineta; Hellstrom-Westas, Lena; Norman, Mikael; Westgren, Magnus; Holmstrom, Gerd; Laurini, Ricardo; Stjernqvist, Karin; Kallen, Karin; Lagercrantz, Hugo; Marsal, Karel; Serenius, Fredrik; Wennergren, Margareta; Nilstun, Tore; Olausson, Petra Otterblad; Stromberg, Bo		EXPRESS Grp	One-Year Survival of Extremely Preterm Infants After Active Perinatal Care in Sweden	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WEEKS GESTATIONAL-AGE; INTENSIVE-CARE; BIRTH-WEIGHT; POPULATION; MORBIDITY; BORN; MORTALITY; LEVEL; MANAGEMENT; THRESHOLD	Context Up-to-date information on infant survival after extremely preterm birth is needed for assessing perinatal care services, clinical guidelines, and parental counseling. Objective To determine the 1-year survival in all infants born before 27 gestational weeks in Sweden during 2004-2007. Design, Setting, and Patients Population-based prospective observational study of extremely preterm infants (707 live-born and 304 stillbirths) born to 887 mothers in 904 deliveries (102 multiple births) in all obstetric and neonatal units in Sweden from April 1, 2004, to March 31, 2007. Main Outcome Measures Infant survival to 365 days and survival without major neonatal morbidity (intraventricular hemorrhage grade > 2, retinopathy of prematurity stage > 2, periventricular leukomalacia, necrotizing enterocolitis, severe bronchopulmonary dysplasia). Associations between perinatal interventions and survival. Results The incidence of extreme prematurity was 3.3 per 1000 infants. Overall perinatal mortality was 45% (from 93% at 22 weeks to 24% at 26 weeks), with 30% stillbirths, including 6.5% intrapartum deaths. Of live-born infants, 91% were admitted to neonatal intensive care and 70% survived to 1 year of age (95% confidence interval [CI], 67%-73%). The Kaplan-Meier survival estimates for 22, 23, 24, 25, and 26 weeks were 9.8% (95% CI, 4%-23%), 53% ( 95% CI, 44%-63%), 67% (95% CI, 59%-75%), 82% (95% CI, 76%-87%), and 85% ( 95% CI, 81%-90%), respectively. Lower risk of infant death was associated with tocolytic treatment (adjusted for gestational age odds ratio [ OR], 0.43; 95% CI, 0.36-0.52), antenatal corticosteroids (OR, 0.44; 95% CI, 0.24-0.81), surfactant treatment within 2 hours after birth ( OR, 0.47; 95% CI, 0.32-0.71), and birth at a level III hospital (OR, 0.49; 95% CI, 0.32-0.75). Among 1-year survivors, 45% had no major neonatal morbidity. Conclusion During 2004 to 2007, 1-year survival of infants born alive at 22 to 26 weeks of gestation in Sweden was 70% and ranged from 9.8% at 22 weeks to 85% at 26 weeks. JAMA. 2009;301(21):2225-2233 www.jama.com	[Blennow, Mats] Karolinska Univ Hosp, Dept Pediat, Huddinge, Sweden; [Blennow, Mats; Norman, Mikael] Karolinska Inst, Dept Clin Invest Intervent & Technol, Stockholm, Sweden; [Ewald, Uwe] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Fritz, Tomas] Sahlgrens Univ Hosp, Dept Obstet & Gynecol, S-41345 Gothenburg, Sweden; [Holmgren, Per Ake] Umea Univ, Dept Clin Sci Obstetr & Gynecol, Umea, Sweden; [Jeppsson, Annika] Linkoping Univ, Dept Obstet & Gynecol, Linkoping, Sweden; [Lindberg, Eva] Univ Orebro, Dept Pediat, Orebro, Sweden; [Lundqvist, Anita] Lund Univ, Dept Hlth Sci, Lund, Sweden; [Lindeberg, Solveig Norden] Uppsala Univ, Dept Obstet & Gynecol, Uppsala, Sweden; [Olhager, Elisabeth] Linkoping Univ, Dept Pediat, S-58183 Linkoping, Sweden; [Ostlund, Ingrid] Orebro Univ Hosp, Dept Obstet & Gynecol, Orebro, Sweden; [Simic, Marija] Karolinska Univ Hosp Solna, Dept Obstet & Gynecol, Stockholm, Sweden; [Sjoers, Gunnar; Stromberg, Bo] Uppsala Univ, Dept Pediat, Uppsala, Sweden; [Stigson, Lennart] Sahlgrens Univ Hosp, Dept Pediat, Gothenburg, Sweden; [Fellman, Vineta] Lund Univ, Dept Pediat, S-22100 Lund, Sweden; [Hellstrom-Westas, Lena] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; [Norman, Mikael] Karolinska Univ Hosp, Dept Pediat, Huddinge, Sweden; [Westgren, Magnus] Karolinska Univ Hosp Huddinge, Dept Obstet & Gynecol, Stockholm, Sweden; [Holmstrom, Gerd] Uppsala Univ, Dept Ophthalmol, Uppsala, Sweden; [Laurini, Ricardo] Nordland Hosp, Dept Pathol, Bodo, Norway; [Stjernqvist, Karin] Lund Univ, Dept Psychol, S-22100 Lund, Sweden; [Kallen, Karin] Lund Univ, Ctr Reprod Epidemiol, S-22100 Lund, Sweden; [Lagercrantz, Hugo] Karolinska Inst, Dept Women & Child Hlth, Stockholm, Sweden; [Lagercrantz, Hugo] Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Marsal, Karel] Lund Univ, Dept Obstet & Gynecol, S-22100 Lund, Sweden; [Serenius, Fredrik] Umea Univ, Dept Clin Sci, S-90187 Umea, Sweden; [Wennergren, Margareta] Sahlgrens Univ Hosp, Dept Obstet & Gynecol, Gothenburg, Sweden; [Nilstun, Tore] Lund Univ, Dept Med Eth, S-22100 Lund, Sweden; [Olausson, Petra Otterblad] Natl Board Hlth & Welf, Ctr Epidemiol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Uppsala University; Sahlgrenska University Hospital; Umea University; Linkoping University; Orebro University; Lund University; Uppsala University; Linkoping University; Orebro University; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Sahlgrenska University Hospital; Lund University; Uppsala University; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Uppsala University; Lund University; Lund University; Karolinska Institutet; Lund University; Umea University; Sahlgrenska University Hospital; Lund University; National Board of Health & Welfare	Marsal, K (corresponding author), Univ Lund Hosp, Dept Obstet & Gynecol, S-22185 Lund, Sweden.	karel.marsal@med.lu.se	Blennow, Mats/AAX-6202-2021	Simic, Marija/0000-0002-1804-4015; Hellstrom-Westas, Lena/0000-0003-3498-6069; Blennow, Mats/0000-0001-9517-0261; Norman, Mikael/0000-0003-4191-3781	Swedish Research Council [521-2006-3858]; Swedish National Board of Health and Welfare; Swedish government; Evy and Gunnar Sandberg Foundation; Lund University and Umea University	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish National Board of Health and Welfare; Swedish government; Evy and Gunnar Sandberg Foundation; Lund University and Umea University	This study was supported by Swedish Research Council grant 521-2006-3858; and by grants from the Swedish National Board of Health and Welfare and from Grants to Researchers in the Public Health Care from the Swedish government. The grants were administered by Lund University and Umea University and used to compensate the 2 research administrators working part time with conduct of the study and collection and management of the data. Karin Kallen, PhD, reported grant support from the Evy and Gunnar Sandberg Foundation.	BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; Chan K, 2001, AM J OBSTET GYNECOL, V185, P220, DOI 10.1067/mob.2001.115280; Costeloe K, 2000, PEDIATRICS, V106, P659, DOI 10.1542/peds.106.4.659; Cust A. E., 2003, Archives of Disease in Childhood, V88, pF15, DOI 10.1136/fn.88.1.F15; Cuttini M, 2000, LANCET, V355, P2112, DOI 10.1016/S0140-6736(00)02378-3; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; Doyle LW, 2001, PEDIATRICS, V108, P134, DOI 10.1542/peds.108.1.134; Draper ES, 2009, ARCH DIS CHILD-FETAL, V94, pF158, DOI 10.1136/adc.2008.141531; Effer SB, 2002, BJOG-INT J OBSTET GY, V109, P740; El-Metwally D, 2000, J PEDIATR-US, V137, P616, DOI 10.1067/mpd.2000.109143; Evans DJ, 2001, ARCH DIS CHILD-FETAL, V84, pF79, DOI 10.1136/fn.84.2.F79; Field DJ, 2008, BMJ-BRIT MED J, V336, P1221, DOI 10.1136/bmj.39555.670718.BE; Finnstrom O, 1997, ACTA PAEDIATR, V86, P503, DOI 10.1111/j.1651-2227.1997.tb08921.x; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Gole GA, 2005, ARCH OPHTHALMOL-CHIC, V123, P991, DOI 10.1001/archopht.123.7.991; Hakansson S, 2004, PEDIATRICS, V114, P58, DOI 10.1542/peds.114.1.58; Herber-Jonat S, 2006, AM J OBSTET GYNECOL, V195, P16, DOI 10.1016/j.ajog.2006.02.043; Hoekstra RE, 2004, PEDIATRICS, V113, pE1, DOI 10.1542/peds.113.1.e1; Holmgren PA, 2001, ACTA OBSTET GYN SCAN, V80, P525, DOI 10.1034/j.1600-0412.2001.080006525.x; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Johansson S, 2004, PEDIATRICS, V113, P1230, DOI 10.1542/peds.113.5.1230; Kamper J, 2004, ACTA PAEDIATR, V93, P225, DOI 10.1080/08035250310022298; Larroque B, 2004, ARCH DIS CHILD-FETAL, V89, P139, DOI 10.1136/adc.2002.020396; Lee SK, 2003, AM J OBSTET GYNECOL, V188, P617, DOI 10.1067/mob.2003.139; Levene M, 2004, ACTA PAEDIATR, V93, P149, DOI 10.1080/08035250310007745; Malloy MH, 2008, PEDIATRICS, V122, P285, DOI 10.1542/peds.2007-2620; Markestad T, 2005, PEDIATRICS, V115, P1289, DOI 10.1542/peds.2004-1482; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; Martin JA, 2008, PEDIATRICS, V121, P788, DOI 10.1542/peds.2007-3753; Morse SB, 2000, PEDIATRICS, V105, P1046, DOI 10.1542/peds.105.5.1046; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Pignotti MS, 2008, PEDIATRICS, V121, pE193, DOI 10.1542/peds.2007-0513; Rautava L, 2007, PEDIATRICS, V119, pE257, DOI 10.1542/peds.2006-1964; Schmidt B, 2003, JAMA-J AM MED ASSOC, V289, P1124, DOI 10.1001/jama.289.9.1124; Schmitt SK, 2006, PEDIATRICS, V117, P154, DOI 10.1542/peds.2005-0484; Serenius F, 2004, ACTA PAEDIATR, V93, P1081, DOI [10.1080/08035250410027751, 10.1111/j.1651-2227.2004.tb02721.x]; Stark AR, 2007, PEDIATRICS, V119, P401, DOI 10.1542/peds.2006-3180; Sutton L, 1999, PAEDIATR PERINAT EP, V13, P288; Tommiska V, 2007, PEDIATRICS, V119, P29, DOI 10.1542/peds.2006-1472; Tyson JE, 2008, NEW ENGL J MED, V358, P1672, DOI 10.1056/NEJMoa073059; Vanhaesebrouck P, 2004, PEDIATRICS, V114, P663, DOI 10.1542/peds.2003-0903-L; Vanpee M, 2007, ACTA PAEDIATR, V96, P10, DOI 10.1111/j.1651-2227.2007.00063.x; Vento M, 2008, PEDIATRICS, V122, P1113, DOI 10.1542/peds.2008-1422; World Health Organization, WORLD HLTH REP 2005	45	444	460	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 3	2009	301	21					2225	2233		10.1001/jama.2009.771	http://dx.doi.org/10.1001/jama.2009.771			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	452PQ	19491184	Bronze			2023-01-03	WOS:000266554100020
J	Longo, C; Patanarut, A; George, T; Bishop, B; Zhou, WD; Fredolini, C; Ross, MM; Espina, V; Pellacani, G; Petricoin, EF; Liotta, LA; Luchini, A				Longo, Caterina; Patanarut, Alexis; George, Tony; Bishop, Barney; Zhou, Weidong; Fredolini, Claudia; Ross, Mark M.; Espina, Virginia; Pellacani, Giovanni; Petricoin, Emanuel F., III; Liotta, Lance A.; Luchini, Alessandra			Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers	PLOS ONE			English	Article							GROWTH-FACTOR RECEPTOR; IMATINIB MESYLATE; SERUM; TEMPERATURE; TARGET; MARKER; LIGAND; FUTURE; URINE; TRIAL	Background: The blood proteome is thought to represent a rich source of biomarkers for early stage disease detection. Nevertheless, three major challenges have hindered biomarker discovery: a) candidate biomarkers exist at extremely low concentrations in blood; b) high abundance resident proteins such as albumin mask the rare biomarkers; c) biomarkers are rapidly degraded by endogenous and exogenous proteinases. Methodology and Principal Findings: Hydrogel nanoparticles created with a N-isopropylacrylamide based core (365 nm)-shell (167 nm) and functionalized with a charged based bait (acrylic acid) were studied as a technology for addressing all these biomarker discovery problems, in one step, in solution. These harvesting core-shell nanoparticles are designed to simultaneously conduct size exclusion and affinity chromatography in solution. Platelet derived growth factor (PDGF), a clinically relevant, highly labile, and very low abundance biomarker, was chosen as a model. PDGF, spiked in human serum, was completely sequestered from its carrier protein albumin, concentrated, and fully preserved, within minutes by the particles. Particle sequestered PDGF was fully protected from exogenously added tryptic degradation. When the nanoparticles were added to a 1 mL dilute solution of PDGF at non detectable levels (less than 20 picograms per mL) the concentration of the PDGF released from the polymeric matrix of the particles increased within the detection range of ELISA and mass spectrometry. Beyond PDGF, the sequestration and protection from degradation for a series of additional very low abundance and very labile cytokines were verified. Conclusions and Significance: We envision the application of harvesting core-shell nanoparticles to whole blood for concentration and immediate preservation of low abundance and labile analytes at the time of venipuncture.	[Longo, Caterina; Pellacani, Giovanni] Univ Modena, Dept Dermatol, I-41100 Modena, Italy; [Longo, Caterina; George, Tony; Zhou, Weidong; Fredolini, Claudia; Ross, Mark M.; Espina, Virginia; Petricoin, Emanuel F., III; Liotta, Lance A.; Luchini, Alessandra] George Mason Univ, Ctr Appl Proteom & Mol Med, Manassas, VA USA; [Patanarut, Alexis; Bishop, Barney] George Mason Univ, Dept Chem & Biochem, Manassas, VA USA	Universita di Modena e Reggio Emilia; George Mason University; George Mason University	Longo, C (corresponding author), Univ Modena, Dept Dermatol, I-41100 Modena, Italy.	aluchini@gmu.edu	pellacani, giovanni/E-8573-2011; Luchini, Alessandra/M-5340-2014; Longo, Caterina/A-8046-2012	pellacani, giovanni/0000-0002-7222-2951; Luchini, Alessandra/0000-0003-1599-0214; Longo, Caterina/0000-0002-8218-3896; Fredolini, Claudia/0000-0002-7674-2014; Espina, Virginia/0000-0001-5080-5972	George Mason University; Italian Istituto Superiore di Sanita; U.S. Department of Energy [DE-FC52-04NA25455]; NIH [1R21CA137706-01]; NATIONAL CANCER INSTITUTE [R21CA137706] Funding Source: NIH RePORTER	George Mason University; Italian Istituto Superiore di Sanita; U.S. Department of Energy(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was partially supported by 1) George Mason University, 2) the Italian Istituto Superiore di Sanita' in the framework of the Italy/USA cooperation agreement between the U.S. Department of Health and Human Services, George Mason University, and the Italian Ministry of Public Health, and 3) the U.S. Department of Energy (grant number DE-FC52-04NA25455). The data herein was incorporated in the NIH grant submission number 1R21CA137706-01. The funding organizations did not have any role in data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Ayache S, 2006, AM J CLIN PATHOL, V126, P174, DOI 10.1309/3WM7XJ7RD8BCLNKX; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Barratt J, 2007, CAN MED ASSOC J, V177, P361, DOI 10.1503/cmaj.061590; Baxter EJ, 2002, HUM MOL GENET, V11, P1391, DOI 10.1093/hmg/11.12.1391; Board R, 2005, DRUG RESIST UPDATE, V8, P75, DOI 10.1016/j.drup.2005.03.004; Borst C, 2008, J CHROMATOGR A, V1204, P191, DOI 10.1016/j.chroma.2008.05.052; BOWENPOPE DF, 1984, BLOOD, V64, P458; Braude E. A., 1955, DETERMINATION ORGANI; Cai WS, 2005, J INCL PHENOM MACRO, V51, P41, DOI 10.1007/s10847-004-5238-3; Cho EC, 2008, NANO LETT, V8, P168, DOI 10.1021/nl072346e; Couvreur P, 2008, SMALL, V4, P247, DOI 10.1002/smll.200700731; Denizli A, 2001, J BIOCHEM BIOPH METH, V49, P391, DOI 10.1016/S0165-022X(01)00209-3; Dodziuk H., 2006, CYCLODEXTRINS THEIR; Drury JL, 2003, BIOMATERIALS, V24, P4337, DOI 10.1016/S0142-9612(03)00340-5; Elmas B, 2002, COLLOID POLYM SCI, V280, P1137, DOI 10.1007/s00396-002-0740-x; Fortina P, 2005, TRENDS BIOTECHNOL, V23, P168, DOI 10.1016/j.tibtech.2005.02.007; Frederick M J, 2001, Expert Rev Mol Med, V3, P1, DOI 10.1017/S1462399401003301; Fredolini C, 2008, NANO RES, V1, P502, DOI 10.1007/s12274-008-8054-z; Fredriksson L, 2004, CYTOKINE GROWTH F R, V15, P197, DOI 10.1016/j.cytogfr.2004.03.007; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hennink WE, 2002, ADV DRUG DELIVER REV, V54, P13, DOI 10.1016/j.addr.2012.09.009; Hoffman AS, 2002, ADV DRUG DELIVER REV, V54, P3, DOI 10.1016/j.addr.2012.09.010; Jahnz-Rozyk K, 2003, ALLERGY, V58, P595, DOI 10.1034/j.1398-9995.2003.00083.x; JIN S, ARCH DERMATOL RES, V8, P451; Jones CD, 2000, MACROMOLECULES, V33, P8301, DOI 10.1021/ma001398m; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kagami S, 2005, J INVEST DERMATOL, V124, P1088, DOI 10.1111/j.0022-202X.2005.23700.x; KATAOKA K, 1994, MACROMOLECULES, V27, P1061, DOI 10.1021/ma00082a028; Kubo T, 2008, CANCER-AM CANCER SOC, V112, P2119, DOI 10.1002/cncr.23437; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Liotta LA, 2003, NATURE, V425, P905, DOI 10.1038/425905a; Lopez MF, 2005, CLIN CHEM, V51, P1946, DOI 10.1373/clinchem.2005.053090; LORAND JP, 1959, J ORG CHEM, V24, P769, DOI 10.1021/jo01088a011; Luchini A, 2008, NANO LETT, V8, P350, DOI 10.1021/nl072174l; Mader HS, 2008, MICROCHIM ACTA, V162, P1, DOI 10.1007/s00604-008-0947-8; Mathew P, 2004, J CLIN ONCOL, V22, P3323, DOI 10.1200/JCO.2004.10.116; McArthur GA, 2005, J CLIN ONCOL, V23, P866, DOI 10.1200/JCO.2005.07.088; Merrell Karen, 2004, J Biomol Tech, V15, P238; Moghimi SM, 2005, FASEB J, V19, P311, DOI 10.1096/fj.04-2747rev; Nayak S, 2005, SMALL, V1, P416, DOI 10.1002/smll.200400089; Pecora R, 1985, BER BUNSEN PHYS CHEM, DOI DOI 10.1002/BBPC.19870910455; Pelton R, 2000, ADV COLLOID INTERFAC, V85, P1, DOI 10.1016/S0001-8686(99)00023-8; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Petricoin EF, 2006, NAT REV CANCER, V6, P961, DOI 10.1038/nrc2011; Robak E, 2007, EUR CYTOKINE NETW, V18, P181, DOI 10.1684/ecn.2007.0103; Sakamoto JH, 2005, TECHNOL CANCER RES T, V4, P627, DOI 10.1177/153303460500400606; Sereikaite J, 2006, BIOMED CHROMATOGR, V20, P195, DOI 10.1002/bmc.552; Smith ER, 2008, CLIN CANCER RES, V14, P2378, DOI 10.1158/1078-0432.CCR-07-1253; Uekama K, 2006, J INCL PHENOM MACRO, V56, P3, DOI 10.1007/s10847-006-9052-y; Yamauchi A., 2006, GLUCOSE SENSING TOPI, P237; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49; Zhang YL, 2006, CHEM-EUR J, V12, P1377, DOI 10.1002/chem.200500982; Zhou M, 2004, ELECTROPHORESIS, V25, P1289, DOI 10.1002/elps.200405866	54	77	79	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2009	4	3							e4763	10.1371/journal.pone.0004763	http://dx.doi.org/10.1371/journal.pone.0004763			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437OE	19274087	Green Published, Green Submitted, gold			2023-01-03	WOS:000265496000004
J	Papeo, L; Vallesi, A; Isaja, A; Rumiati, RI				Papeo, Liuba; Vallesi, Antonino; Isaja, Alessio; Rumiati, Raffaella Ida			Effects of TMS on Different Stages of Motor and Non-Motor Verb Processing in the Primary Motor Cortex	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; WORD RECOGNITION; MENTAL ROTATION; LANGUAGE; BRAIN; ACTIVATION; MECHANISMS; SYSTEM; REPRESENTATION; COMPATIBILITY	The embodied cognition hypothesis suggests that motor and premotor areas are automatically and necessarily involved in understanding action language, as word conceptual representations are embodied. This transcranial magnetic stimulation (TMS) study explores the role of the left primary motor cortex in action-verb processing. TMS-induced motor-evoked potentials from right-hand muscles were recorded as a measure of M1 activity, while participants were asked either to judge explicitly whether a verb was action-related (semantic task) or to decide on the number of syllables in a verb (syllabic task). TMS was applied in three different experiments at 170, 350 and 500 ms post-stimulus during both tasks to identify when the enhancement of M1 activity occurred during word processing. The delays between stimulus onset and magnetic stimulation were consistent with electrophysiological studies, suggesting that word recognition can be differentiated into early (within 200 ms) and late (within 400 ms) lexical-semantic stages, and post-conceptual stages. Reaction times and accuracy were recorded to measure the extent to which the participants' linguistic performance was affected by the interference of TMS with M1 activity. No enhancement of M1 activity specific for action verbs was found at 170 and 350 ms post-stimulus, when lexical-semantic processes are presumed to occur (Experiments 1-2). When TMS was applied at 500 ms post-stimulus (Experiment 3), processing action verbs, compared with non-action verbs, increased the M1-activity in the semantic task and decreased it in the syllabic task. This effect was specific for hand-action verbs and was not observed for action-verbs related to other body parts. Neither accuracy nor RTs were affected by TMS. These findings suggest that the lexical-semantic processing of action verbs does not automatically activate the M1. This area seems to be rather involved in post-conceptual processing that follows the retrieval of motor representations, its activity being modulated (facilitated or inhibited), in a top-down manner, by the specific demand of the task.	[Papeo, Liuba; Isaja, Alessio; Rumiati, Raffaella Ida] Scuola Int Super Studi Avanzati, Sector Cognit Neurosci, Trieste, Italy; [Vallesi, Antonino] Rotman Res Inst Baycrest, Toronto, ON, Canada	International School for Advanced Studies (SISSA); University of Toronto; University Toronto Affiliates; Baycrest	Papeo, L (corresponding author), Scuola Int Super Studi Avanzati, Sector Cognit Neurosci, Trieste, Italy.	rumiati@sissa.it	Papeo, Liuba/O-4336-2017; Vallesi, Antonino/E-8987-2011	Vallesi, Antonino/0000-0002-4087-2845	PRIN	PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN))	This research was supported by a PRIN to RIR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barsalou LW, 1999, BEHAV BRAIN SCI, V22, P577, DOI 10.1017/S0140525X99532147; Ben Shalom D, 2008, NEUROSCIENTIST, V14, P119, DOI 10.1177/1073858407305726; Berndt RS, 2002, J NEUROLINGUIST, V15, P353, DOI 10.1016/S0911-6044(01)00030-6; Boulenger V, 2006, J COGNITIVE NEUROSCI, V18, P1607, DOI 10.1162/jocn.2006.18.10.1607; Buccino G, 2005, COGNITIVE BRAIN RES, V24, P355, DOI 10.1016/j.cogbrainres.2005.02.020; Carreiras M, 2005, J COGNITIVE NEUROSCI, V17, P1803, DOI 10.1162/089892905774589217; DeRenzi E, 1995, CORTEX, V31, P619, DOI 10.1016/S0010-9452(13)80016-0; Ehrsson HH, 2003, J NEUROPHYSIOL, V90, P3304, DOI 10.1152/jn.01113.2002; EIMER M, 1995, ACTA PSYCHOL, V90, P301, DOI 10.1016/0001-6918(95)00022-M; Fischer MH, 2008, Q J EXP PSYCHOL, V61, P825, DOI 10.1080/17470210701623605; Floel A, 2003, EUR J NEUROSCI, V18, P704, DOI 10.1046/j.1460-9568.2003.02774.x; Fodor J. A, 2001, MIND DOESNT WORK WAY; Gallese V, 2005, COGN NEUROPSYCHOL, V22, P455, DOI 10.1080/02643290442000310; Ganis G, 2000, CEREB CORTEX, V10, P175, DOI 10.1093/cercor/10.2.175; GERGELY G, 1995, COGNITION, V56, P165, DOI 10.1016/0010-0277(95)00661-H; Harris JA, 2008, J COGNITIVE NEUROSCI, V20, P734, DOI 10.1162/jocn.2008.20048; Hauk O, 2006, NEUROIMAGE, V30, P1383, DOI 10.1016/j.neuroimage.2005.11.048; Hauk O, 2004, NEURON, V41, P301, DOI 10.1016/S0896-6273(03)00838-9; Hebb D. O., 1949, ORG BEHAV NEUROPHYSI; Iwaki S, 1999, NEUROREPORT, V10, P1793, DOI 10.1097/00001756-199906030-00031; Jeannerod M, 1999, Q J EXP PSYCHOL-A, V52, P1, DOI 10.1080/027249899391205; Johnson SH, 2002, NEUROIMAGE, V17, P1693, DOI 10.1006/nimg.2002.1265; Kellenbach ML, 2002, J COGNITIVE NEUROSCI, V14, P561, DOI 10.1162/08989290260045819; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Koch G, 2006, J NEUROSCI, V26, P7452, DOI 10.1523/JNEUROSCI.1158-06.2006; KORNBLUM S, 1990, PSYCHOL REV, V97, P253, DOI 10.1037/0033-295X.97.2.253; KORNBLUM S, 1992, TUTORIALS MOTOR BEHA, P713; KOSSLYN SM, 1995, NEUROPSYCHOLOGIA, V33, P1335, DOI 10.1016/0028-3932(95)00067-D; Kosslyn SM, 2001, NEUROREPORT, V12, P2519, DOI 10.1097/00001756-200108080-00046; Kosslyn SM, 1998, PSYCHOPHYSIOLOGY, V35, P151, DOI 10.1111/1469-8986.3520151; Laurienti PJ, 2004, EXP BRAIN RES, V158, P405, DOI 10.1007/s00221-004-1913-2; LAWS KR, 1995, MEMORY, V3, P397, DOI 10.1080/09658219508253158; LU C, 2005, PSYCHON B RES, V2, P174; Luzzatti C, 2002, BRAIN LANG, V81, P432, DOI 10.1006/brln.2001.2536; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Marinkovic K, 2003, NEURON, V38, P487, DOI 10.1016/S0896-6273(03)00197-1; Meister IG, 2003, NEUROPSYCHOLOGIA, V41, P401, DOI 10.1016/S0028-3932(02)00179-3; NEELY JH, 1977, J EXP PSYCHOL GEN, V106, P226, DOI 10.1037/0096-3445.106.3.226; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Oliveri M, 2004, J COGNITIVE NEUROSCI, V16, P374, DOI 10.1162/089892904322926719; Paivio A., 1971, IMAGERY VERBAL PROCE; PAPAGNO C, 1993, J NEUROL NEUROSUR PS, V56, P286, DOI 10.1136/jnnp.56.3.286; Penolazzi B, 2007, BIOL PSYCHOL, V74, P374, DOI 10.1016/j.biopsycho.2006.09.008; Pulvermuller F, 2005, NAT REV NEUROSCI, V6, P576, DOI 10.1038/nrn1706; Pulvermuller F, 2005, J COGNITIVE NEUROSCI, V17, P884, DOI 10.1162/0898929054021111; Pulvermuller F, 2005, EUR J NEUROSCI, V21, P793, DOI 10.1111/j.1460-9568.2005.03900.x; Pulvermuller F, 2002, PROG NEUROBIOL, V67, P85, DOI 10.1016/S0301-0082(02)00014-X; PULVERMULLER F, 2004, BRAIN LANG, V78, P113; Pylyshyn Zenon, 1984, COMPUTATION COGNITIO; Reynolds C, 1999, NEUROLOGY, V53, P730, DOI 10.1212/WNL.53.4.730; Rizzolatti G, 2004, ANNU REV NEUROSCI, V27, P169, DOI 10.1146/annurev.neuro.27.070203.144230; Rizzolatti G, 1998, TRENDS NEUROSCI, V21, P188, DOI 10.1016/S0166-2236(98)01260-0; ROBERTSON EM, 2008, J COGNITIVE NEUROSCI, V15, P948; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Schieber MH, 2001, J NEUROPHYSIOL, V86, P2125, DOI 10.1152/jn.2001.86.5.2125; Sereno SC, 1998, NEUROREPORT, V9, P2195, DOI 10.1097/00001756-199807130-00009; Southgate V, 2008, COGNITION, V107, P1059, DOI 10.1016/j.cognition.2007.10.002; TALMY L, 1985, WEAVING LEXICON, P57; TAYLOR B., 1977, LINGUIST PHILOS, V1, P199, DOI DOI 10.1007/BF00351103; Tettamanti M, 2005, J COGNITIVE NEUROSCI, V17, P273, DOI 10.1162/0898929053124965; Tomasino B, 2005, COGN NEUROPSYCHOL, V22, P348, DOI 10.1080/02643290442000185; Tomasino B, 2007, NEUROIMAGE, V36, pT128, DOI 10.1016/j.neuroimage.2007.03.035; Tomasino B, 2008, NEUROPSYCHOLOGIA, V46, P1915, DOI 10.1016/j.neuropsychologia.2008.01.015; Walsh V, 1999, NEUROPSYCHOLOGIA, V37, P125; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; YENDLER Z, 1957, PHYLOSOPHICAL REV, V66, P143	66	137	138	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2009	4	2							e4508	10.1371/journal.pone.0004508	http://dx.doi.org/10.1371/journal.pone.0004508			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	601TH	19240793	Green Submitted, Green Published, gold			2023-01-03	WOS:000278086700001
J	MacArthur, C; Jolly, K; Ingram, L; Freemantle, N; Dennis, CL; Hamburger, R; Brown, J; Chambers, J; Khan, K				MacArthur, Christine; Jolly, Kate; Ingram, Lucy; Freemantle, Nick; Dennis, Cindy-Lee; Hamburger, Ros; Brown, Julia; Chambers, Jackie; Khan, Khalid			Antenatal peer support workers and initiation of breast feeding: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-INCOME; COUNSELORS; EFFICACY	Objective To assess the effectiveness of an antenatal service using community based breastfeeding peer support workers on initiation of breast feeding. Design Cluster randomised controlled trial. Setting Community antenatal clinics in one primary care trust in a multiethnic, deprived population. Participants 66 antenatal clinics with 2511 pregnant women: 33 clinics including 1140 women were randomised to receive the peer support worker service and 33 clinics including 1371 women were randomised to receive standard care. Intervention An antenatal peer support worker service planned to comprise a minimum of two contacts with women to provide advice, information, and support from approximately 24 weeks' gestation within the antenatal clinic or at home. The trained peer support workers were of similar ethnic and sociodemographic backgrounds to their clinic population. Main outcome measure Initiation of breast feeding obtained from computerised maternity records of the hospitals where women from the primary care trust delivered. Results The sample was multiethnic, with only 9.4% of women being white British, and 70% were in the lowest 10th for deprivation. Most of the contacts with peer support workers took place in the antenatal clinics. Data on initiation of breast feeding were obtained for 2398 of 2511 ( 95.5%) women ( 1083/ 1140 intervention and 1315/ 1371 controls). The groups did not differ for initiation of breast feeding: 69.0% ( 747/ 1083) in the intervention group and 68.1% ( 896/ 1315) in the control groups; cluster adjusted odds ratio 1.11 ( 95% confidence interval 0.87 to 1.43). Ethnicity, parity, and mode of delivery independently predicted initiation of breast feeding, but randomisation to the peer support worker service did not. Conclusion A universal service for initiation of breast feeding using peer support workers provided within antenatal clinics serving a multiethnic, deprived population was ineffective in increasing initiation rates. Trial registration Current Controlled Trials ISRCTN16126175.	[MacArthur, Christine; Jolly, Kate; Ingram, Lucy; Freemantle, Nick] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England; [Dennis, Cindy-Lee] Univ Toronto, Toronto, ON, Canada; [Hamburger, Ros; Brown, Julia; Chambers, Jackie] Heart Birmingham Teaching Primary Care Trust, Birmingham, W Midlands, England; [Khan, Khalid] Univ Birmingham, Sch Clin & Expt Med, Birmingham, W Midlands, England; [Khan, Khalid] Birmingham Womens Hosp, Birmingham, W Midlands, England	University of Birmingham; University of Toronto; University of Birmingham; Birmingham Women's Hospital	Jolly, K (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England.	c.b.jolly@bham.ac.uk	Jolly, Kate/AAA-1341-2019; Khan, Khalid S/AAT-8824-2020; MacArthur, Christine/ABA-8601-2021; Dennis, Cindy-Lee/ABA-2860-2020	Jolly, Kate/0000-0002-6224-2115; Khan, Khalid S/0000-0001-5084-7312; MacArthur, Christine/0000-0003-0434-2158; Dennis, Cindy-Lee/0000-0002-0135-7242; Freemantle, Nick/0000-0001-5807-5740	Heart of Birmingham Teaching Primary Care Trust	Heart of Birmingham Teaching Primary Care Trust	Heart of Birmingham Teaching Primary Care Trust.	Anderson AK, 2005, ARCH PEDIAT ADOL MED, V159, P836, DOI 10.1001/archpedi.159.9.836; [Anonymous], 2002, INFANT FEEDING 2000; Bolling K, 2007, INFANT FEEDING SURVE; Britton C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001141.pub3; Cattaneo A, 2005, PUBLIC HEALTH NUTR, V8, P39, DOI 10.1079/PHN2005660; Chapman DJ, 2004, ARCH PEDIAT ADOL MED, V158, P897, DOI 10.1001/archpedi.158.9.897; Collet D., 1991, MODELLING BINARY DAT, V2nd; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Dyson L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001688.pub2; Dyson L., 2006, PROMOTION BREASTFEED, P242; Fairbank L., 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/hta4250; Graffy J, 2004, BRIT MED J, V328, P26, DOI 10.1136/bmj.328.7430.26; Guise Jeanne-Marie, 2003, Ann Fam Med, V1, P70, DOI 10.1370/afm.56; Haider R, 2000, LANCET, V356, P1643, DOI 10.1016/S0140-6736(00)03159-7; MacArthur C, 2002, LANCET, V359, P378, DOI 10.1016/S0140-6736(02)07596-7; Morrow AL, 1999, LANCET, V353, P1226, DOI 10.1016/S0140-6736(98)08037-4; Muirhead PE, 2006, BRIT J GEN PRACT, V56, P191; TAYLOR B, MATERNITY MORTALITY	18	40	41	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 30	2009	338								b131	10.1136/bmj.b131	http://dx.doi.org/10.1136/bmj.b131			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405EQ	19181730	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000263206000002
J	Ganzini, L; Goy, ER; Dobscha, SK				Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.			Prevalence of depression and anxiety in patients requesting physicians' aid in dying: cross sectional survey	BRITISH MEDICAL JOURNAL			English	Article							MENTAL STATUS QUESTIONNAIRE; REDUCING SUICIDAL IDEATION; TERMINALLY-ILL PATIENTS; PRIMARY-CARE PATIENTS; ASSISTED SUICIDE; HASTENED DEATH; OLDER PATIENTS; CANCER; HOPELESSNESS; DESIRE	Objective To determine the prevalence of depression and anxiety in terminally ill patients pursuing aid in dying from physicians. Design Cross sectional survey. Setting State of Oregon, USA. Participants 58 Oregonians, most terminally ill with cancer or amyotrophic lateral sclerosis, who had either requested aid in dying from a physician or contacted an aid in dying advocacy organisation. Main outcome measures Diagnosis of depression or anxiety according to the hospital anxiety and depression scale and the structured clinical interview for the Diagnostic and Statistical Manual of Mental Disorders. Results 15 study participants met "caseness" criteria for depression, and 13 met criteria for anxiety. 42 patients died by the end of the study; 18 received a prescription fora lethal drug under the Death with Dignity Act, and nine died by lethal ingestion. 15 participants who received a prescription for a lethal drug did not meet criteria for depression; three did. All three depressed participants died by legal ingestion within two months of the research interview. Conclusion Although most terminally ill Oregonians who receive aid in dying do not have depressive disorders, the current practice of the Death with Dignity Act may fail to protect some patients whose choices are influenced by depression from receiving a prescription for a lethal drug.	[Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.] Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Hlth Serv Res & Dev, Portland, OR 97239 USA; [Ganzini, Linda; Goy, Elizabeth R.; Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University	Ganzini, L (corresponding author), Portland VA Med Ctr, Columbia Ctr Study Chron Comorbid Mental & Phys D, Hlth Serv Res & Dev, POB 1034, Portland, OR 97239 USA.	Linda.Ganzini@va.gov			Northwest Health Foundation	Northwest Health Foundation	Northwest Health Foundation. The funding source had no role in any aspect of the study or this paper.	Appelbaum P.S., 2001, MACARTHUR COMPETENCE; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; Blank K, 2001, J AM GERIATR SOC, V49, P153, DOI 10.1046/j.1532-5415.2001.49036.x; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Carlson B, 2005, J PALLIAT MED, V8, P1160, DOI 10.1089/jpm.2005.8.1160; CHOCHINOV HM, 1994, AM J PSYCHIAT, V151, P537; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Conwell Y, 2000, J AM GERIATR SOC, V48, P23, DOI 10.1111/j.1532-5415.2000.tb03024.x; Conwell Y, 2002, BIOL PSYCHIAT, V52, P193, DOI 10.1016/S0006-3223(02)01347-1; Emanuel EJ, 2005, J CLIN ONCOL, V23, P6456, DOI 10.1200/JCO.2005.06.001; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; First M.B., 1997, USERS GUIDE STRUCTUR; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ganzini L, 1999, NEUROLOGY, V52, P1434, DOI 10.1212/WNL.52.7.1434; Ganzini L, 2006, J CLIN ETHIC, V17, P27; Ganzini L, 1996, AM J PSYCHIAT, V153, P1469; Ganzini L, 2000, AM J PSYCHIAT, V157, P595, DOI 10.1176/appi.ajp.157.4.595; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Ganzini L, 2002, NEW ENGL J MED, V347, P582, DOI 10.1056/NEJMsa020562; Ganzini L, 2008, J GEN INTERN MED, V23, P154, DOI 10.1007/s11606-007-0476-x; Henriksson MM, 1995, J AFFECT DISORDERS, V36, P11, DOI 10.1016/0165-0327(95)00047-X; Hotopf M, 2002, PALLIATIVE MED, V16, P81, DOI 10.1191/02169216302pm507oa; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Passik SD, 1998, J CLIN ONCOL, V16, P1594, DOI 10.1200/JCO.1998.16.4.1594; PEREZSTABLE EJ, 1990, ARCH INTERN MED, V150, P1083, DOI 10.1001/archinte.150.5.1083; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Rosenfeld B, 2006, PSYCHOSOMATICS, V47, P504, DOI 10.1176/appi.psy.47.6.504; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; SMYER MA, 1979, J AM GERIATR SOC, V27, P263, DOI 10.1111/j.1532-5415.1979.tb06128.x; Tolle SW, 2004, J CLIN ETHIC, V15, P111; Unutzer J, 2006, J AM GERIATR SOC, V54, P1550, DOI 10.1111/j.1532-5415.2006.00882.x; Werth JL, 2004, BEHAV SCI LAW, V22, P627, DOI 10.1002/bsl.616; Wilson KG, 2007, HEALTH PSYCHOL, V26, P314, DOI 10.1037/0278-6133.26.3.314; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 2007, COMPASSION CHOICES O	37	87	88	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2008	337	7676							a1682	10.1136/bmj.a1682	http://dx.doi.org/10.1136/bmj.a1682			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	363WS	18842645	Green Published, hybrid			2023-01-03	WOS:000260298800034
J	Karkan, D; Pfeifer, C; Vitalis, TZ; Arthur, G; Ujiie, M; Chen, QQ; Tsai, S; Koliatis, G; Gabathuler, R; Jefferies, WA				Karkan, Delara; Pfeifer, Cheryl; Vitalis, Timothy Z.; Arthur, Gavin; Ujiie, Maki; Chen, Qingqi; Tsai, Sam; Koliatis, Gerrasimo; Gabathuler, Reinhard; Jefferies, Wilfred A.			A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier	PLOS ONE			English	Article							ANTITRANSFERRIN RECEPTOR ANTIBODY; MELANOMA-ASSOCIATED ANTIGEN-P97; GLYCOPROTEIN-MEDIATED EFFLUX; CENTRAL-NERVOUS-SYSTEM; 1ST TOTAL-SYNTHESIS; TRANSFERRIN RECEPTOR; ALZHEIMERS-DISEASE; DRUG-DELIVERY; IN-VITRO; P-GLYCOPROTEIN	Background: Therapeutic intervention in many neurological diseases is thwarted by the physical obstacle formed by the blood-brain barrier (BBB) that excludes most drugs from entering the brain from the blood. Thus, identifying efficacious modes of drug delivery to the brain remains a "holy grail'' in molecular medicine and nanobiotechnology. Brain capillaries, that comprise the BBB, possess an endogenous receptor that ferries an iron-transport protein, termed p97 (melanotransferrin), across the BBB. Here, we explored the hypothesis that therapeutic drugs "piggybacked'' as conjugates of p97 can be shuttled across the BBB for treatment of otherwise inoperable brain tumors. Approach: Human p97 was covalently linked with the chemotherapeutic agents paclitaxel (PTAX) or adriamycin (ADR) and following intravenous injection, measured their penetration into brain tissue and other organs using radiolabeled and fluorescent derivatives of the drugs. In order to establish efficacy of the conjugates, we used nude mouse models to assess p97-drug conjugate activity towards glioma and mammary tumors growing subcutaneously compared to those growing intracranially. Principal Findings: Bolus-injected p97-drug conjugates and unconjugated p97 traversed brain capillary endothelium within a few minutes and accumulated to 1-2% of the injected by 24 hours. Brain delivery with p97-drug conjugates was quantitatively 10 fold higher than with free drug controls. Furthermore, both free-ADR and p97-ADR conjugates equally inhibited the subcutaneous growth of gliomas growing outside the brain. Evocatively, only p97-ADR conjugates significantly prolonged the survival of animals bearing intracranial gliomas or mammary tumors when compared to similar cumulated doses of free-ADR. Significance: This study provides the initial proof of concept for p97 as a carrier capable of shuttling therapeutic levels of drugs from the blood to the brain for the treatment of neurological disorders, including classes of resident and metastatic brain tumors. It may be prudent, therefore, to consider implementation of this novel delivery platform in various clinical settings for therapeutic intervention in acute and chronic neurological diseases.	[Karkan, Delara; Vitalis, Timothy Z.; Arthur, Gavin; Chen, Qingqi; Tsai, Sam; Koliatis, Gerrasimo; Gabathuler, Reinhard] BioMarin Pharmaceut Inc, Vancouver, BC, Canada; [Pfeifer, Cheryl; Vitalis, Timothy Z.; Ujiie, Maki; Tsai, Sam; Koliatis, Gerrasimo; Gabathuler, Reinhard; Jefferies, Wilfred A.] Univ British Columbia, Biomed Res Ctr, Dept Med Genet, Michael Smith Lab, Vancouver, BC, Canada; [Pfeifer, Cheryl; Vitalis, Timothy Z.; Ujiie, Maki; Tsai, Sam; Koliatis, Gerrasimo; Gabathuler, Reinhard; Jefferies, Wilfred A.] Univ British Columbia, Biomed Res Ctr, Dept Microbiol & Immunol, Michael Smith Lab, Vancouver, BC, Canada; [Pfeifer, Cheryl; Vitalis, Timothy Z.; Ujiie, Maki; Tsai, Sam; Koliatis, Gerrasimo; Gabathuler, Reinhard; Jefferies, Wilfred A.] Univ British Columbia, Biomed Res Ctr, Dept Zool, Michael Smith Lab, Vancouver, BC, Canada	BioMarin Pharmaceutical Inc.; University of British Columbia; University of British Columbia; University of British Columbia	Karkan, D (corresponding author), BioMarin Pharmaceut Inc, Vancouver, BC, Canada.	wilf@brc.ubc.ca		Pfeifer, Cheryl/0000-0001-8584-228X	BioMarin Pharmaceutical (Canada) Inc.; Canadian Institute of Health Research	BioMarin Pharmaceutical (Canada) Inc.; Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	Financial support for this study was provided by BioMarin Pharmaceutical (Canada) Inc. (Formerly Synapse Technologies Inc.) and by grants to WAJ from the Canadian Institute of Health Research. These studies were performed at BioMarin Pharmaceutical (Canada) Inc. (Formerly Synapse Technologies Inc., Vancouver, Canada) and in the laboratory of WAJ at the University of British Columbia, Canada.	Abulrob A, 2005, J NEUROCHEM, V95, P1201, DOI 10.1111/j.1471-4159.2005.03463.x; Ambruosi A, 2006, J MICROENCAPSUL, V23, P582, DOI 10.1080/02652040600788080; ARCAMONE F, 1969, BIOTECHNOL BIOENG, V11, P1101, DOI 10.1002/bit.260110607; Ayrton A, 2001, XENOBIOTICA, V31, P469, DOI 10.1080/00498250110060969; BANKS WA, 1994, J NEUROCHEM, V62, P2404; Bartus R T, 1999, Curr Opin Drug Discov Devel, V2, P152; Bicamumpaka C, 1998, ONCOL REP, V5, P1381; BLASBERG RG, 1983, ANN NEUROL, V14, P202, DOI 10.1002/ana.410140207; BLASBERG RG, 1983, J CEREBR BLOOD F MET, V3, P215, DOI 10.1038/jcbfm.1983.29; Boado RJ, 2007, BIOCONJUGATE CHEM, V18, P447, DOI 10.1021/bc060349x; Brigger I, 2004, J CONTROL RELEASE, V100, P29, DOI 10.1016/j.jconrel.2004.07.019; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; *BRIST MYERSSQUIBB, 2004, GREEN SYNTH PATHW AW; BROWN JP, 1982, NATURE, V296, P171, DOI 10.1038/296171a0; Chen Y., 2004, Current Drug Delivery, V1, P361, DOI 10.2174/1567201043334542; Chertok B, 2008, BIOMATERIALS, V29, P487, DOI 10.1016/j.biomaterials.2007.08.050; Coloma MJ, 2000, PHARMACEUT RES, V17, P266, DOI 10.1023/A:1007592720793; Cressant A, 2004, J NEUROSCI, V24, P10229, DOI 10.1523/JNEUROSCI.3558-04.2004; Demeule M, 2003, BLOOD, V102, P1723, DOI 10.1182/blood-2003-01-0166; Demeule M, 2002, J NEUROCHEM, V83, P924, DOI 10.1046/j.1471-4159.2002.01201.x; Egleton Richard D, 2005, NeuroRx, V2, P44, DOI 10.1007/BF03206641; Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011; Fine RL, 2006, CLIN CANCER RES, V12, P5770, DOI 10.1158/1078-0432.CCR-05-2356; FOOD MR, 1994, J BIOL CHEM, V269, P3034; FORNARI FA, 1994, MOL PHARMACOL, V45, P649; FRIDEN PM, 1993, ADV EXP MED BIOL, V331, P129; Gao KP, 2006, INT J PHARMACEUT, V310, P213, DOI 10.1016/j.ijpharm.2005.11.040; Goodman J., 2001, STORY TAXOL NATURE P; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Habgood MD, 2000, CELL MOL NEUROBIOL, V20, P231, DOI 10.1023/A:1007001923498; HEIMANS JJ, 1994, ANN ONCOL, V5, P951, DOI 10.1093/oxfordjournals.annonc.a058736; HELLSTROM I, 1983, INT J CANCER, V31, P553, DOI 10.1002/ijc.2910310505; HOLTON RA, 1994, J AM CHEM SOC, V116, P1597, DOI 10.1021/ja00083a066; HOLTON RA, 1994, J AM CHEM SOC, V116, P1599, DOI 10.1021/ja00083a067; HOLTON RA, 1995, SCI APPL, P97; Hubensack M, 2008, J CANCER RES CLIN, V134, P597, DOI 10.1007/s00432-007-0323-9; JEFFERIES WA, 1985, IMMUNOLOGY, V54, P333; JEFFERIES WA, 1984, NATURE, V312, P162, DOI 10.1038/312162a0; Kas HS, 2004, ADV EXP MED BIOL, V553, P221; KAYE AH, 1986, CANCER RES, V46, P1367; KENNARD ML, 1993, BIOTECHNOL BIOENG, V42, P480, DOI 10.1002/bit.260420411; Kennard ML, 1996, NAT MED, V2, P1230, DOI 10.1038/nm1196-1230; Kim DK, 2001, NEUROPSYCHOPHARMACOL, V25, P84, DOI 10.1016/S0893-133X(00)00230-X; Kinoshita M, 2006, P NATL ACAD SCI USA, V103, P11719, DOI 10.1073/pnas.0604318103; KONDO A, 1987, BRAIN RES, V412, P73, DOI 10.1016/0006-8993(87)91441-7; Kratz F, 1998, J PHARM SCI-US, V87, P338, DOI 10.1021/js970246a; Kreuter J, 2004, J NANOSCI NANOTECHNO, V4, P484, DOI 10.1166/jnn.2003.077; Lee HJ, 2000, J PHARMACOL EXP THER, V292, P1048; Lee HJ, 2002, J CEREBR BLOOD F MET, V22, P223, DOI 10.1097/00004647-200202000-00010; *MAYOCLINIC MICR, 2007, DOX INTR ROUT; McAllister LD, 2000, NEUROSURGERY, V46, P51, DOI 10.1093/neurosurgery/46.1.51; Michaelis K, 2006, J PHARMACOL EXP THER, V317, P1246, DOI 10.1124/jpet.105.097139; MOMPARLER RL, 1976, CANCER RES, V36, P2891; Moos T, 2001, J NEUROCHEM, V79, P119, DOI 10.1046/j.1471-4159.2001.00541.x; Moroo I, 2003, MICROCIRCULATION, V10, P457, DOI 10.1038/sj.mn.7800213; NEUWELT EA, 1980, NEUROSURGERY, V6, P49, DOI 10.1227/00006123-198001000-00007; NEUWELT EA, 1979, J CLIN INVEST, V64, P684, DOI 10.1172/JCI109509; NEUWELT EA, 1980, NEUROSURGERY, V7, P44, DOI 10.1227/00006123-198007000-00007; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; OHKAWA K, 1993, CANCER RES, V53, P4238; OHNISHI T, 1995, BIOCHEM PHARMACOL, V49, P1541, DOI 10.1016/0006-2952(95)00082-B; Olivier Jean-Christophe, 2005, NeuroRx, V2, P108, DOI 10.1007/BF03206647; Pan WH, 1999, EXP NEUROL, V160, P454, DOI 10.1006/exnr.1999.7215; PAPOIAN T, 1990, AM J PATHOL, V136, P1201; Pardridge W M, 1991, Semin Cell Biol, V2, P419; PARDRIDGE WM, 1991, J PHARMACOL EXP THER, V259, P66; PARDRIDGE WM, 1987, METABOLISM, V36, P892, DOI 10.1016/0026-0495(87)90099-0; Pardridge WM, 1998, J NEUROCHEM, V70, P1781; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; Pardridge WM., 2007, J CONTROL RELEASE; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Rapoport SI, 2000, CELL MOL NEUROBIOL, V20, P217, DOI 10.1023/A:1007049806660; RAUB TJ, 1991, J CELL PHYSIOL, V149, P141, DOI 10.1002/jcp.1041490118; REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207; RISAU W, 1986, DEV BIOL, V117, P537, DOI 10.1016/0012-1606(86)90321-0; Roney C, 2005, J CONTROL RELEASE, V108, P193, DOI 10.1016/j.jconrel.2005.07.024; Rothenberger S, 1996, BRAIN RES, V712, P117, DOI 10.1016/0006-8993(96)88505-2; Rousselle C, 2000, MOL PHARMACOL, V57, P679, DOI 10.1124/mol.57.4.679; ROYER I, 1995, RAPID COMMUN MASS SP, V9, P495, DOI 10.1002/rcm.1290090605; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; Saleh M, 1997, INT J CANCER, V72, P664, DOI 10.1002/(SICI)1097-0215(19970807)72:4<664::AID-IJC19>3.3.CO;2-3; Saunders NR, 1999, CLIN EXP PHARMACOL P, V26, P11, DOI 10.1046/j.1440-1681.1999.02986.x; Saunders NR, 1999, CLIN EXP PHARMACOL P, V26, P85, DOI 10.1046/j.1440-1681.1999.02987.x; Saunders NR, 2000, CELL MOL NEUROBIOL, V20, P29, DOI 10.1023/A:1006991809927; SELCMAN M, 1995, GLIOBLASTOMA MALIGNA, P449; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; Sharma US, 1997, PHARM RES-DORDR, V14, P992, DOI 10.1023/A:1012136925030; SILBERGELD DL, 1995, ANTI-CANCER DRUG, V6, P270, DOI 10.1097/00001813-199504000-00011; Smith MW, 2006, J DRUG TARGET, V14, P191, DOI 10.1080/10611860600650086; SPARREBOOM A, 1995, J CHROMATOGR B, V664, P383, DOI 10.1016/0378-4347(94)00495-Q; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Stewart PA, 2000, CELL MOL NEUROBIOL, V20, P149, DOI 10.1023/A:1007026504843; Strandberg JJ, 2006, TOXICOL LETT, V166, P11, DOI 10.1016/j.toxlet.2006.05.007; Takamiya Y, 1997, BRIT J CANCER, V76, P445, DOI 10.1038/bjc.1997.408; Temsamani J, 2001, EXPERT OPIN BIOL TH, V1, P773, DOI 10.1517/14712598.1.5.773; Trail PA, 1997, CANCER RES, V57, P100; Tsuji A, 1998, THER DRUG MONIT, V20, P588, DOI 10.1097/00007691-199810000-00024; Tsuji Akira, 2005, NeuroRx, V2, P54, DOI 10.1007/BF03206642; UEDA F, 1993, J NEUROCHEM, V60, P106, DOI 10.1111/j.1471-4159.1993.tb05828.x; WALL ME, 1995, CANCER RES, V55, P753; Wolff JEA, 1999, J CANCER RES CLIN, V125, P481, DOI 10.1007/s004320050305; Yamada T, 1999, BRAIN RES, V845, P1, DOI 10.1016/S0006-8993(99)01767-9; Yang J, 2004, PROTEIN EXPRES PURIF, V34, P28, DOI 10.1016/j.pep.2003.09.007; Zhou QY, 2007, CLIN CANCER RES, V13, P4271, DOI 10.1158/1078-0432.CCR-07-0658; Zhou QY, 2007, J PHARMACOL EXP THER, V321, P265, DOI 10.1124/jpet.106.118265	106	71	94	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2008	3	6							e2469	10.1371/journal.pone.0002469	http://dx.doi.org/10.1371/journal.pone.0002469			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	406IK	18575595	Green Published, gold			2023-01-03	WOS:000263288000002
J	Trock, BJ; Han, M; Freedland, SJ; Humphreys, EB; DeWeese, TL; Partin, AW; Walsh, PC				Trock, Bruce J.; Han, Misop; Freedland, Stephen J.; Humphreys, Elizabeth B.; DeWeese, Theodore L.; Partin, Alan W.; Walsh, Patrick C.			Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIGEN DOUBLING TIME; RADIATION-THERAPY; BREAST-CANCER; POSTOPERATIVE RADIOTHERAPY; LOCAL RECURRENCE; FAILURE; SURGERY; PSA	Context Biochemical disease recurrence after radical prostatectomy often prompts salvage radiotherapy, but no studies to date have had sufficient numbers of patients or follow-up to determine whether radiotherapy improves survival, and if so, the sub-group of men most likely to benefit. Objectives To quantify the relative improvement in prostate cancer-specific survival of salvage radiotherapy vs no therapy after biochemical recurrence following prostatectomy, and to identify subgroups for whom salvage treatment is most beneficial. Design, Setting, and Patients Retrospective analysis of a cohort of 635 US men undergoing prostatectomy from 1982-2004, followed up through December 28, 2007, who experienced biochemical and/or local recurrence and received no salvage treatment (n = 397), salvage radiotherapy alone (n = 160), or salvage radiotherapy combined with hormonal therapy (n = 78). Main Outcome Measure Prostate cancer-specific survival defined from time of recurrence until death from disease. Results With a median follow-up of 6 years after recurrence and 9 years after prostatectomy, 116 men (18%) died from prostate cancer, including 89 (22%) who received no salvage treatment, 18 (11%) who received salvage radiotherapy alone, and 9 (12%) who received salvage radiotherapy and hormonal therapy. Salvage radiotherapy alone was associated with a significant 3-fold increase in prostate cancer-specific survival relative to those who received no salvage treatment (hazard ratio [HR], 0.32 [95% confidence interval {CI}, 0.19-0.54]; P <.001). Addition of hormonal therapy to salvage radiotherapy was not associated with any additional increase in prostate cancer-specific survival (HR, 0.34 [95% CI, 0.17-0.69]; P = .003). The increase in prostate cancer-specific survival associated with salvage radiotherapy was limited to men with a prostate-specific antigen doubling time of less than 6 months and remained after adjustment for pathological stage and other established prognostic factors. Salvage radiotherapy initiated more than 2 years after recurrence provided no significant increase in prostate cancer-specific survival. Men whose prostate-specific antigen level never became undetectable after salvage radiotherapy did not experience a significant increase in prostate cancer-specific survival. Salvage radiotherapy also was associated with a significant increase in overall survival. Conclusions Salvage radiotherapy administered within 2 years of biochemical recurrence was associated with a significant increase in prostate cancer-specific survival among men with a prostate-specific antigen doubling time of less than 6 months, independent of other prognostic features such as pathological stage or Gleason score. These preliminary findings should be validated in other settings, and ultimately, in a randomized controlled trial.	[Trock, Bruce J.; Han, Misop; Humphreys, Elizabeth B.; Partin, Alan W.; Walsh, Patrick C.] Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA; [DeWeese, Theodore L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21287 USA; [Freedland, Stephen J.] Durham Vet Affairs Med Ctr, Surg Sect, Durham, NC USA; [Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Dept Surg, Durham, NC USA; [Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Dept Pathol, Durham, NC USA	Johns Hopkins University; Johns Hopkins University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Duke University; Duke University	Trock, BJ (corresponding author), Johns Hopkins Univ, Sch Med, James Buchanan Brady Urol Inst, 600 N Wolfe St,546 Phipps Bldg, Baltimore, MD 21287 USA.	btrock@jhmi.edu			NATIONAL CANCER INSTITUTE [P50CA058236, P30CA006973] Funding Source: NIH RePORTER; NCI NIH HHS [CA58236, P30 CA006973, P50 CA058236, P50 CA058236-13] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V366, P2087; Anscher MS, 2000, INT J RADIAT ONCOL, V48, P369, DOI 10.1016/S0360-3016(00)00645-3; Boccon-Gibod L, 2007, EUR UROL SUPPL, V6, P521, DOI 10.1016/j.eursup.2007.01.026; Bolla M, 2005, LANCET, V366, P572, DOI 10.1016/S0140-6736(05)67101-2; Buskirk SJ, 2006, J UROLOGY, V176, P985, DOI 10.1016/j.juro.2006.04.083; Chawla AK, 2002, UROLOGY, V59, P726, DOI 10.1016/S0090-4295(02)01540-6; Choo R, 2006, BJU INT, V98, P773, DOI 10.1111/j.1464-410X.2006.06423.x; Han M, 2001, UROL CLIN N AM, V28, P555, DOI 10.1016/S0094-0143(05)70163-4; Harrell Frank E., 2001, REGRESSION MODELING; Katz MS, 2003, J CLIN ONCOL, V21, P483, DOI 10.1200/JCO.2003.12.043; Leventis AK, 2001, J CLIN ONCOL, V19, P1030, DOI 10.1200/JCO.2001.19.4.1030; Liauw SL, 2003, UROLOGY, V61, P1204, DOI 10.1016/S0090-4295(03)00044-X; Maffezzini M, 2007, EUR UROL, V51, P605, DOI 10.1016/j.eururo.2006.10.062; Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; PARTIN AW, 1994, UROLOGY, V43, P649, DOI 10.1016/0090-4295(94)90180-5; Penson DF, 2007, J UROLOGY, V177, P2020, DOI 10.1016/j.juro.2007.01.121; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Ragaz J, 2005, JNCI-J NATL CANCER I, V97, P116, DOI 10.1093/jnci/djh297; Song DY, 2002, UROLOGY, V60, P281, DOI 10.1016/S0090-4295(02)01709-0; Stephenson AJ, 2004, JAMA-J AM MED ASSOC, V291, P1325, DOI 10.1001/jama.291.11.1325; Stephenson AJ, 2007, J CLIN ONCOL, V25, P2035, DOI 10.1200/JCO.2006.08.9607; Thompson IM, 2006, JAMA-J AM MED ASSOC, V296, P2329, DOI 10.1001/jama.296.19.2329; Ward JF, 2005, NAT CLIN PRACT UROL, V2, P174, DOI 10.1038/ncpuro0145; Ward JF, 2004, J UROLOGY, V172, P2244, DOI 10.1097/01.ju.0000145262.34748.2b	25	514	524	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 18	2008	299	23					2760	2769		10.1001/jama.299.23.2760	http://dx.doi.org/10.1001/jama.299.23.2760			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314JH	18560003	Bronze, Green Accepted			2023-01-03	WOS:000256805200024
J	Yu, JKL; Tok, TS; Tsai, JJ; Chang, WS; Dzimadzi, RK; Yen, PH; Makombe, SD; Nkhata, A; Schouten, EJ; Kamoto, K; Harries, AD				Yu, Joseph Kwong-Leung; Tok, Teck-Siang; Tsai, Jih-Jin; Chang, Wu-Shou; Dzimadzi, Rose K.; Yen, Ping-Hsiang; Makombe, Simon D.; Nkhata, Amon; Schouten, Erik J.; Kamoto, Kelita; Harries, Anthony D.			What Happens to Patients on Antiretroviral Therapy Who Transfer Out to Another Facility?	PLOS ONE			English	Article								Background: Long term retention of patients on antiretroviral therapy ( ART) in Africa's rapidly expanding programmes is said to be 60% at 2 years. Many reports from African ART programmes make little mention of patients who are transferred out to another facility, yet Malawi's national figures show a transfer out of 9%. There is no published information about what happens to patients who transfer-out, but this is important because if they transfer-in and stay alive in these other facilities then national retention figures will be better than previously reported. Methodology/Principal Findings: Of all patients started on ART over a three year period in Mzuzu Central Hospital, North Region, Malawi, those who transferred out were identified from the ART register and master cards. Clinic staff attempted to trace these patients to determine whether they had transferred in to a new ART facility and their outcome status. There were 805 patients (19% of the total cohort) who transferred out, of whom 737 (92%) were traced as having transferred in to a new ART facility, with a median time of 1.3 months between transferring-out and transferring-in. Survival probability was superior and deaths were lower in the transfer-out patients compared with those who did not transfer. Conclusion/Significance: In Mzuzu Central Hospital, patients who transfer-out constitute a large proportion of patients not retained on ART at their original clinic of registration. Good documentation of transfer-outs and transfer-ins are needed to keep track of national outcomes. Furthermore, the current practice of regarding transfer-outs as being double counted in national cohorts and subtracting this number from the total national registrations to get the number of new patients started on ART is correct.	[Yu, Joseph Kwong-Leung] Mzuzu Cent Hosp, Taiwan Med Mission Malawi, Mzuzu, Malawi; [Yu, Joseph Kwong-Leung; Tok, Teck-Siang; Yen, Ping-Hsiang] Pingtung Christian Hosp, Int Med Cooperat & Development Ctr, Pingtung, Taiwan; [Yu, Joseph Kwong-Leung; Tsai, Jih-Jin] Kaohsiung Med Univ Hosp, Kaohsiung Med Univ Div Infect Dis, Coll Med, Kaohsiung, Taiwan; [Yu, Joseph Kwong-Leung; Chang, Wu-Shou] Dept Hlth, Bureau Int Cooperation, Taipei, Taiwan; [Dzimadzi, Rose K.] Minist Hlth, Mzuzu Central Hosp, Office Hosp Director, Mzuzu, Malawi; [Makombe, Simon D.; Nkhata, Amon; Schouten, Erik J.; Kamoto, Kelita; Harries, Anthony D.] Minist Hlth, HIV Unit, Lilongwe, Malawi; [Schouten, Erik J.] Management Sci Hlth, Lilongwe, Malawi; [Harries, Anthony D.] Family Hlth Int, Lilongwe, Malawi; [Harries, Anthony D.] London Sch Hyg & Trop Med, London, England	Kaohsiung Medical University; Kaohsiung Medical University Hospital; University of London; London School of Hygiene & Tropical Medicine	Yu, JKL (corresponding author), Mzuzu Cent Hosp, Taiwan Med Mission Malawi, Mzuzu, Malawi.	adharries@malawi.net	TSAI, JIH-JIN/GOP-2776-2022	TSAI, JIH-JIN/0000-0003-2226-8916				Boulle A, 2007, SEX TRANSM INFECT, V83, P503, DOI 10.1136/sti.2007.027748; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Calmy A, 2006, AIDS, V20, P1163, DOI 10.1097/01.aids.0000226957.79847.d6; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Libamba E, 2005, INT J TUBERC LUNG D, V9, P1062; Meijnen S, 2002, INT J TUBERC LUNG D, V6, P666; *MIN HLTH MAL HIV, 2006, ARV THER MAL 30 JUN; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Wester CW, 2005, JAIDS-J ACQ IMM DEF, V40, P336, DOI 10.1097/01.qai.0000159668.80207.5b; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; Yu JKL, 2007, B WORLD HEALTH ORGAN, V85, P550, DOI 10.2471/BLT.06.037739	12	21	21	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 30	2008	3	4							e2065	10.1371/journal.pone.0002065	http://dx.doi.org/10.1371/journal.pone.0002065			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381YR	18446230	Green Published, gold, Green Submitted			2023-01-03	WOS:000261572300034
J	Platt, MJ				Platt, Mary Jane			Long-term outcome for very preterm infants	LANCET			English	Editorial Material							BIRTH; CHILDREN; POPULATION; COHORT; MOTOR; AGE		Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England	University of Liverpool	Platt, MJ (corresponding author), Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England.	mjplatt@liverpool.ac.uk	Platt, MJ/K-4588-2012	Platt, MJ/0000-0002-9372-9575				Baird G, 2006, LANCET, V368, P210, DOI 10.1016/S0140-6736(06)69041-7; Bowen JR, 2002, J PAEDIATR CHILD H, V38, P438, DOI 10.1046/j.1440-1754.2002.00039.x; Cooke RWI, 2003, ARCH DIS CHILD, V88, P482, DOI 10.1136/adc.88.6.482; Dodge JA, 1997, ARCH DIS CHILD, V77, P493, DOI 10.1136/adc.77.6.493; Larroque B, 2008, LANCET, V371, P813, DOI 10.1016/S0140-6736(08)60380-3; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Marlow N, 2007, PEDIATRICS, V120, P793, DOI 10.1542/peds.2007-0440; Moser Kath, 2007, Health Stat Q, P13; PHAROAH POD, 1994, ARCH DIS CHILD, V70, P264, DOI 10.1136/adc.70.4.264; Platt MJ, 2007, LANCET, V369, P43, DOI 10.1016/S0140-6736(07)60030-0; Sutton PD., 2004, NATL VITAL STAT REP, V55, P1; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201	12	5	5	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 8	2008	371	9615					787	788		10.1016/S0140-6736(08)60354-2	http://dx.doi.org/10.1016/S0140-6736(08)60354-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272NQ	18328908				2023-01-03	WOS:000253866500004
J	Steinbrook, R				Steinbrook, Robert			A Higher Bar -- Vermont's New Law on Marketing Prescribed Products.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						*COMM MASS, 105CMR970000 COMM MA; SORRELL WH, 2009, PHARM MARKETING DISC; *STAT VERM, ACT REL MARK PRESCR; Steinbrook R, 2008, NEW ENGL J MED, V359, P559, DOI 10.1056/NEJMp0805309	4	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 2	2009	361	1					8	9		10.1056/NEJMp0904719	http://dx.doi.org/10.1056/NEJMp0904719			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	464UK	19516028				2023-01-03	WOS:000267533100004
J	Cubbon, RM; Witte, KKA				Cubbon, Richard M.; Witte, Klaus K. A.			Cardiac resynchronisation therapy for chronic heart failure and conduction delay	BMJ-BRITISH MEDICAL JOURNAL			English	Review							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; VENTRICULAR SYSTOLIC DYSFUNCTION; CARE-HF TRIAL; RESYNCHRONIZATION THERAPY; ATRIAL-FIBRILLATION; MORTALITY; DYSSYNCHRONY; METAANALYSIS; PREVALENCE; SYMPTOMS		[Cubbon, Richard M.; Witte, Klaus K. A.] Univ Leeds, Div Cardiovasc & Diabet Res, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Witte, KKA (corresponding author), Univ Leeds, Div Cardiovasc & Diabet Res, Leeds LS2 9JT, W Yorkshire, England.	klauswitte@hotmail.com		Witte, Klaus/0000-0002-7146-7105				Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Beshai JF, 2007, NEW ENGL J MED, V357, P2461, DOI 10.1056/NEJMoa0706695; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Chattopadhyay S, 2008, EUR J HEART FAIL, V10, P412, DOI 10.1016/j.ejheart.2008.02.004; Chung ES, 2008, CIRCULATION, V117, P2608, DOI 10.1161/CIRCULATIONAHA.107.743120; Clark AL, 2008, EUR J HEART FAIL, V10, P696, DOI 10.1016/j.ejheart.2008.05.001; Cleland JGF, 2008, HEART, V94, P278, DOI 10.1136/hrt.2007.128991; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Cleland J, 2008, J AM COLL CARDIOL, V52, P438, DOI 10.1016/j.jacc.2008.04.036; Cleland JGF, 2006, EUR HEART J, V27, P1928, DOI 10.1093/eurheartj/ehl099; Cowie MR, 1997, EUR HEART J, V18, P208; Daubert JP, 2008, J AM COLL CARDIOL, V51, P1357, DOI 10.1016/j.jacc.2007.09.073; Desai AS, 2004, JAMA-J AM MED ASSOC, V292, P2874, DOI 10.1001/jama.292.23.2874; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Foley PWX, 2008, EUROPACE, V10, P1302, DOI 10.1093/europace/eun263; Freemantle N, 2006, EUR J HEART FAIL, V8, P433, DOI 10.1016/j.ejheart.2005.11.014; Healey JS, 2007, EUR HEART J, V28, P1746, DOI 10.1093/eurheartj/ehl438; Khan NK, 2007, EUR J HEART FAIL, V9, P491, DOI 10.1016/j.ejheart.2006.11.003; Linde C, 2008, J AM COLL CARDIOL, V52, P1834, DOI 10.1016/j.jacc.2008.08.027; Sweeney MO, 2003, CIRCULATION, V107, P2932, DOI 10.1161/01.CIR.0000072769.17295.B1; Thackray SDR, 2003, EUR HEART J, V24, P1143, DOI 10.1016/S0195-668X(03)00199-4; Upadhyay GA, 2008, J AM COLL CARDIOL, V52, P1239, DOI 10.1016/j.jacc.2008.06.043; Uretsky BF, 2008, J CARD FAIL, V14, P670, DOI 10.1016/j.cardfail.2008.06.001; Witte KKA, 2006, J CARD FAIL, V12, P199, DOI 10.1016/j.cardfail.2005.12.003; Witte KK, 2008, CAN J CARDIOL, V24, P379, DOI 10.1016/S0828-282X(08)70601-9; Witte KKA, 2008, EUR J HEART FAIL, V10, P1224, DOI 10.1016/j.ejheart.2008.09.017; Yao GQ, 2007, EUR HEART J, V28, P42, DOI 10.1093/eurheartj/ehl382; Yap YG, 2007, HEART, V93, P832, DOI 10.1136/hrt.2006.102186; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	31	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 28	2009	338								b1265	10.1136/bmj.b1265	http://dx.doi.org/10.1136/bmj.b1265			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440JV	19401320				2023-01-03	WOS:000265697500003
J	Katikireddi, SV; Cloud, GC				Katikireddi, Srinivasa Vittal; Cloud, Geoffrey Christopher			Planning a patient's discharge from hospital	BRITISH MEDICAL JOURNAL			English	Editorial Material							PROSPECTIVE AUDIT; MEDICAL PATIENTS; READMISSION; CARE; RISK		[Katikireddi, Srinivasa Vittal] NHS Lothian, Edinburgh EH8 9RS, Midlothian, Scotland; [Cloud, Geoffrey Christopher] Univ London St Georges Hosp, Dept Clin Neurosci, London SW17 0QT, England	St Georges University London	Katikireddi, SV (corresponding author), NHS Lothian, Edinburgh EH8 9RS, Midlothian, Scotland.	vkatikireddi@yahoo.co.uk		Katikireddi, Srinivasa/0000-0001-6593-9092; Cloud, Geoffrey/0000-0002-8365-6907				Abramson J S, 1993, Health Soc Work, V18, P57; BOULT C, 1993, J AM GERIATR SOC, V41, P811, DOI 10.1111/j.1532-5415.1993.tb06175.x; Brown A, 1999, J SOC ADMIN PHARM, V16, P199; *CAR ENGL, 2002, HOSP DISCH PRACT BRI; Carers UK, 2007, REAL CHANG NOT SHORT; Chu LW, 1999, GERONTOLOGY, V45, P220, DOI 10.1159/000022091; Dawson R, 1998, ANN ROY COLL SURG, V80, P229; *DEP HLTH, 2007, NAT FRAM NHS CONT HE; *DEP HLTH, 2003, DISCH HOSP PATHW PRO; Kwok T, 1999, J ROY COLL PHYS LOND, V33, P153; Macaulay EM, 1996, BRIT J SURG, V83, P788, DOI 10.1002/bjs.1800830619; Melis RJF, 2004, BRIT MED J, V329, P360, DOI 10.1136/bmj.329.7462.360; Nazareth I, 2001, AGE AGEING, V30, P33, DOI 10.1093/ageing/30.1.33; SACHS SB, 2000, NURS PRACT FORUM, V11, P65; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; *SIGN, 2003, 65 SIGN; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	17	12	13	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 12	2008	337								a2694	10.1136/bmj.a2694	http://dx.doi.org/10.1136/bmj.a2694			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399CC	19074562				2023-01-03	WOS:000262777000002
J	Kutner, JS; Smith, MC; Corbin, L; Hemphill, L; Benton, K; Mellis, BK; Beaty, B; Felton, S; Yamashita, TE; Bryant, LL; Fairclough, DL				Kutner, Jean S.; Smith, Marlaine C.; Corbin, Lisa; Hemphill, Linnea; Benton, Kathryn; Mellis, B. Karen; Beaty, Brenda; Felton, Sue; Yamashita, Traci E.; Bryant, Lucinda L.; Fairclough, Diane L.			Massage therapy versus simple touch to improve pain and mood in patients with advanced cancer	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; SYMPTOM ASSESSMENT SCALE; AROMATHERAPY MASSAGE; END; CARE; MANAGEMENT; VALIDITY; TRIALS; COMPLEMENTARY; QUESTIONNAIRE	Background: Small studies of variable quality suggest that massage therapy may relieve pain and other symptoms. Objective: To evaluate the efficacy of massage for decreasing pain and symptom distress and improving quality of life among persons with advanced cancer. Design: Multisite, randomized clinical trial. Setting: Population-based Palliative Care Research Network. Patients: 380 adults with advanced cancer who were experiencing moderate-to-severe pain; 90% were enrolled in hospice. Intervention: Six 30-minute massage or simple-touch sessions over 2 weeks. Measurements: Primary outcomes were immediate ( Memorial Pain Assessment Card, 0- to 10-point scale) and sustained ( Brief Pain Inventory [BPI], 0- to 10-point scale) change in pain. Secondary outcomes were immediate change in mood (Memorial Pain Assessment Card) and 60-second heart and respiratory rates and sustained change in quality of life ( McGill Quality of Life Questionnaire, 0- to 10-point scale), symptom distress (Memorial Symptom Assessment Scale, 0- to 4-point scale), and analgesic medication use (parenteral morphine equivalents [mg/d]). Immediate outcomes were obtained just before and after each treatment session. Sustained outcomes were obtained at baseline and weekly for 3 weeks. Results: 298 persons were included in the immediate outcome analysis and 348 in the sustained outcome analysis. A total of 82 persons did not receive any allocated study treatments ( 37 massage patients, 45 control participants). Both groups demonstrated immediate improvement in pain (massage, -1.87 points [95% CI, -2.07 to -1.67 points]; control, -0.97 point [CI, -1.18 to -0.76 points]) and mood (massage, 1.58 points [CI, 1.40 to 1.76 points]; control, 0.97 point [CI, 0.78 to 1.16 points]). Massage was superior for both immediate pain and mood (mean difference, 0.90 and 0.61 points, respectively; P < 0.001). No between-group mean differences occurred over time in sustained pain (BPI mean pain, 0.07 point [CI, -0.23 to 0.37 points]; BPI worst pain, -0.14 point CI, -0.59 to 0.31 points]), quality of life (McGill Quality of Life Questionnaire overall, 0.08 point [CI, -0.37 to 0.53 points]), symptom distress (Memorial Symptom Assessment Scale global distress index, -0.002 point [CI, -0.12 to 0.12 points]), or analgesic medication use (parenteral morphine equivalents, -0.10 mg/d [CI, -0.25 to 0.05 mg/d]). Limitations: The immediate outcome measures were obtained by unblinded study therapists, possibly leading to reporting bias and the overestimation of a beneficial effect. The generalizability to all patients with advanced cancer is uncertain. The differential beneficial effect of massage therapy over simple touch is not conclusive without a usual care control group. Conclusion: Massage may have immediately beneficial effects on pain and mood among patients with advanced cancer. Given the lack of sustained effects and the observed improvements in both study groups, the potential benefits of attention and simple touch should also be considered in this patient population.	Univ Colorado, Sch Med, Coll Nursing, Denver, CO 80202 USA; Univ Colorado, Sch Publ Hlth, Denver, CO 80202 USA; [Kutner, Jean S.] Univ Colorado Denver, Div Gen Internal Med, Sch Med, Coll Nursing, Aurora, CO 80045 USA; Univ Colorado Denver, Sch Publ Hlth, Aurora, CO 80045 USA; Florida Atlantic Univ, Boca Raton, FL 33431 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Colorado School of Public Health; University of Colorado System; University of Colorado Denver; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; Colorado School of Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; State University System of Florida; Florida Atlantic University	Kutner, JS (corresponding author), Univ Colorado Denver, Div Gen Internal Med, Sch Med, Coll Nursing, B180,POB 6511,Acad Off 1, Aurora, CO 80045 USA.	jean.kutner@ucdenver.edu; diane.fairclough@ucdenver.edu			the National Institutes of Health; National Center for Complementary and Alternative Medicine [1R01AT0100601A2]; Mendel/Asarch Lung Cancer Family Foundation; Paul Beeson Physician Faculty Scholars; Robert Wood Johnson Generalist Physician Faculty Scholars Program; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001006] Funding Source: NIH RePORTER	the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Mendel/Asarch Lung Cancer Family Foundation; Paul Beeson Physician Faculty Scholars; Robert Wood Johnson Generalist Physician Faculty Scholars Program(Robert Wood Johnson Foundation (RWJF)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	By the National Institutes of Health and National Center for Complementary and Alternative Medicine (1R01AT0100601A2), Mendel/Asarch Lung Cancer Family Foundation Grants Program, Paul Beeson Physician Faculty Scholars in Aging Research Award, and Robert Wood Johnson Generalist Physician Faculty Scholars Program (Dr. Kutner).	Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *AM MESS THER ASS, 2008, GLOSS MESS TERMS; Billhult A, 2001, CANCER NURS, V24, P180, DOI 10.1097/00002820-200106000-00003; Billhult Annika, 2007, Clin Nurs Res, V16, P85, DOI 10.1177/1054773806298488; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; BRUERA E, 1998, OXFORD TXB PALLIATIV, P179; Buss Mary Kathleen, 2004, J Palliat Med, V7, P405, DOI 10.1089/1096621041349437; Casarett David J, 2002, J Palliat Med, V5, P397, DOI 10.1089/109662102320135289; Cassileth BR, 2004, J PAIN SYMPTOM MANAG, V28, P244, DOI 10.1016/j.jpainsymman.2003.12.016; Chang Victor T, 2004, Expert Rev Pharmacoecon Outcomes Res, V4, P171, DOI 10.1586/14737167.4.2.171; Chang VT, 1998, CANCER, V83, P173, DOI 10.1002/(SICI)1097-0142(19980701)83:1<173::AID-CNCR23>3.0.CO;2-T; Chang VT, 2004, CANCER INVEST, V22, P526, DOI 10.1081/CNV-200026487; Chang VT, 2000, CANCER, V89, P1162, DOI 10.1002/1097-0142(20000901)89:5<1162::AID-CNCR26>3.0.CO;2-Y; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cohen SR, 2001, PALLIATIVE MED, V15, P363, DOI 10.1191/026921601680419401; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Cohen SR, 2000, CANCER-AM CANCER SOC, V89, P1854, DOI 10.1002/1097-0142(20001015)89:8<1854::AID-CNCR28>3.0.CO;2-C; *COMM CAR END LIF, 1997, APPR DEATH IMPR CAR; Diehr P, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-51; Du Pen SL, 1999, J CLIN ONCOL, V17, P361, DOI 10.1200/JCO.1999.17.1.361; Elliott BA, 1996, J PAIN SYMPTOM MANAG, V12, P209, DOI 10.1016/0885-3924(96)00124-8; Ernst E, 2000, BRIT MED J, V320, P513, DOI 10.1136/bmj.320.7233.513; EVANS C, 1985, LANCET, V1, P1204; Fellowes, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002287, DOI 10.1002/14651858.CD002287.PUB2]; FERRELLTORRY AT, 1993, CANCER NURS, V16, P93; Field TM, 1998, AM PSYCHOL, V53, P1270, DOI 10.1037/0003-066X.53.12.1270; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; Fitzmaurice GM, 2001, STAT MED, V20, P1009, DOI 10.1002/sim.718; Galer BS, 1997, NEUROLOGY, V48, P332, DOI 10.1212/WNL.48.2.332; Goldstone L A, 2000, Complement Ther Nurs Midwifery, V6, P169, DOI 10.1054/ctnm.2000.0493; Hernandez-Reif M, 2004, J PSYCHOSOM RES, V57, P45, DOI 10.1016/S0022-3999(03)00500-2; Hwang SS, 2004, CANCER INVEST, V22, P678, DOI 10.1081/CNV-200032911; INGHAM J, 1998, OXFORD TXB PALLIATIV, P203; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Jensen TS, 2001, EUR J PHARMACOL, V429, P1, DOI 10.1016/S0014-2999(01)01302-4; KELLER E, 1986, NURS RES, V35, P101; Kelly AM, 2001, EMERG MED J, V18, P205, DOI 10.1136/emj.18.3.205; Kutner Jean S, 2003, Palliat Support Care, V1, P231; Kutner JS, 2007, J PAIN SYMPTOM MANAG, V34, P227, DOI 10.1016/j.jpainsymman.2006.11.016; Kutner Jean S, 2005, Cancer Control, V12, P186; Kutner JS, 2001, J PAIN SYMPTOM MANAG, V21, P473, DOI 10.1016/S0885-3924(01)00281-0; Longworth J C, 1982, ANS Adv Nurs Sci, V4, P44; McMillan SC, 2000, CANCER NURS, V23, P327, DOI 10.1097/00002820-200010000-00001; Miller MG, 1999, J PAIN SYMPTOM MANAG, V18, P9, DOI 10.1016/S0885-3924(99)00036-6; Myers Cynthia D, 2008, J Soc Integr Oncol, V6, P19; Nelson JP, 2006, J HOLIST NURS, V24, P152, DOI 10.1177/0898010105282524; *NIH, 2004, NAT I HLTH STAT OF T; Owens M K, 1991, Holist Nurs Pract, V6, P24; Pan CX, 2000, J PAIN SYMPTOM MANAG, V20, P374, DOI 10.1016/S0885-3924(00)00190-1; Philip J, 1998, SUPPORT CARE CANCER, V6, P539, DOI 10.1007/s005200050212; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Post-White Janice, 2003, Integr Cancer Ther, V2, P332, DOI 10.1177/1534735403259064; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Richards K C, 2000, AACN Clin Issues, V11, P77, DOI 10.1097/00044067-200002000-00010; Sagar SM, 2008, CURR ONCOL, V15, P42, DOI 10.3747/co.2008.197; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Smith Marlaine, 2007, J Soc Integr Oncol, V5, P139, DOI 10.2310/7200.2007.014; Soden K, 2004, PALLIATIVE MED, V18, P87, DOI 10.1191/0269216304pm874oa; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Twycross R, 1996, J PAIN SYMPTOM MANAG, V12, P273, DOI 10.1016/S0885-3924(96)00149-2; Westcombe AM, 2003, PALLIATIVE MED, V17, P300, DOI 10.1191/0269216303pm769rr; *WHO EXP COMM, 1990, CANC PAIN REL PALL C; Wilkie D J, 2000, Hosp J, V15, P31	66	143	148	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 16	2008	149	6					369	W72		10.7326/0003-4819-149-6-200809160-00003	http://dx.doi.org/10.7326/0003-4819-149-6-200809160-00003			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	348SM	18794556	Green Accepted			2023-01-03	WOS:000259230200001
J	Nunn, AJ; Mwaba, P; Chintu, C; Mwinga, A; Darbyshire, JH; Zumla, A				Nunn, Andrew J.; Mwaba, Peter; Chintu, Chifumbe; Mwinga, Alwyn; Darbyshire, Janet H.; Zumla, Alimuddin		UNZA UCLMS Project LUCOT Collabora	Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE; HIV-1-INFECTED ADULTS; COTE-DIVOIRE; RESISTANCE; MALAWI; PYRIMETHAMINE; MORBIDITY; MALARIA; ABIDJAN; AFRICA	Objective To assess the impact of prophylactic oral cotrimoxazole in reducing mortality in HIV positive Zambian adults being treated for pulmonary tuberculosis. Design Double blind placebo controlled randomised clinical trial. Participants Two groups of antiretroviral treatment naive adults with HIV infection: patients newly diagnosed as having tuberculosis and receiving tuberculosis treatment either for the first time or for retreatment after relapse; previously treated patients not receiving treatment. Intervention Oral co-trimoxazole or matching placebo daily. Primary outcome measures Time to death and occurrence of serious adverse events related to study drug. Results 1003 patients were randomised: 835 (416 co-trimoxazole, 419 placebo) were receiving treatment for tuberculosis, 762 (376 co-trimoxazole, 386 placebo) of them newly diagnosed previously untreated patients and 73 (40 co-trimoxazole, 33 placebo) receiving a retreatment regimen; 168 (84 co-trimoxazole, 84 placebo) were not on treatment but had received treatment in the past. Of 835 participants receiving tuberculosis treatment, follow-up information was available for 757, with a total of 1012.6 person years of follow-up. A total of 310 (147 cotrimoxazole, 163 placebo) participants died, corresponding to death rates of 27.3 and 34.4 per 100 person years. In the Cox regression analysis, the hazard ratio for death (co-trimoxazole:placebo) was 0.79 (95% confidence interval 0.63 to 0.99). The effect of co-trimoxazole waned with time, possibly owing to falling adherence levels; in a per protocol analysis based on patients who spent at least 90% of their time at risk supplied with study drug, the hazard ratio was 0.65 (0.45 to 0.93). Conclusions Prophylaxis with co-trimoxazole reduces mortality in HIV infected adults with pulmonary tuberculosis. Co-trimoxazole was generally safe and well tolerated.	[Nunn, Andrew J.; Darbyshire, Janet H.] MRC, Clin Trials Unit, London NW1 2DA, England; [Mwaba, Peter; Chintu, Chifumbe; Mwinga, Alwyn] UNZA, Sch Med, Univ Teaching Hosp, Lusaka, Zambia; [Zumla, Alimuddin] UCL, Ctr Infect Dis & Int Hlth, London W1T 4JF, England	Medical Research Council Clinical Trials Unit; University of Zambia; University of London; University College London	Nunn, AJ (corresponding author), MRC, Clin Trials Unit, London NW1 2DA, England.	ajn@ctu.mrc.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020; Mwaba, Peter/V-6017-2019	ZUMLA, Alimuddin/0000-0002-5111-5735; Nunn, Andrew/0000-0002-9158-4595	MRC [MC_U122888469] Funding Source: UKRI; Medical Research Council [MC_U122888469] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Bortolotti W, 2002, AIDS, V16, P1309, DOI 10.1097/00002030-200207050-00002; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Grimwade K, 2005, AIDS, V19, P163, DOI 10.1097/00002030-200501280-00008; Gwanzura L, 2003, INT J ANTIMICROB AG, V21, P557, DOI 10.1016/S0924-8579(03)00052-9; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; *JOINT UN PROGR HI, 2000, PROV WHO UNAIDS SECR; Kassa-Kelembho E, 2003, ACTA TROP, V89, P67, DOI 10.1016/j.actatropica.2003.09.004; Laufer MK, 2006, AM J TROP MED HYG, V75, P373, DOI 10.4269/ajtmh.2006.75.373; Malamba SS, 2006, AM J TROP MED HYG, V75, P375, DOI 10.4269/ajtmh.2006.75.375; Martinson NA, 2007, AIDS, V21, P2043, DOI 10.1097/QAD.0b013e3282eea47f; Maynart M, 2001, J ACQ IMMUN DEF SYND, V26, P130, DOI 10.1097/00126334-200102010-00004; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; MURRAY J, 2000, INT J TUBERC LUNG D, V6, P1035; Mwansa J, 2002, EMERG INFECT DIS, V8, P92, DOI 10.3201/eid0801.010018; Mwaungulu FBD, 2004, B WORLD HEALTH ORGAN, V82, P354; Mwinga A, 2002, LANCET, V360, P1050, DOI 10.1016/S0140-6736(02)11141-X; Nyamande K, 2007, INT J TUBERC LUNG D, V11, P1308; Royston P, 2005, STATA J, V5, P279, DOI 10.1177/1536867X0500500212; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; WHO, 2005, TB HIV RES PRIOR RES; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 2008, GLOB TUB CONTR SURV; World Health Organization, 2003, TREATM TUB GUID NAT, DOI DOI 10.1016/S0035-9203(99)90185-2; World Health Organization, 2006, WHO EXP CONS COTR PR; Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/00002030-200305020-00015; Zachariah R, 2002, T ROY SOC TROP MED H, V96, P202, DOI 10.1016/S0035-9203(02)90306-8	27	65	65	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 26	2008	337	7663							a257	10.1136/bmj.a257	http://dx.doi.org/10.1136/bmj.a257			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	335EG	18617486	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000258273000040
J	Cavanaugh, K; Huizinga, MM; Wallston, KA; Gebretsadik, T; Shintani, A; Davis, D; Gregory, RP; Fuchs, L; Malone, R; Cherrington, A; Pignone, M; DeWalt, DA; Elasy, TA; Rothman, RL				Cavanaugh, Kerri; Huizinga, Mary Margaret; Wallston, Kenneth A.; Gebretsadik, Tebeb; Shintani, Ayumi; Davis, Dianne; Gregory, Rebecca Pratt; Fuchs, Lynn; Malone, Robb; Cherrington, Andrea; Pignone, Michael; DeWalt, Darren A.; Elasy, Tom A.; Rothman, Russell L.			Association of numeracy and diabetes control	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH LITERACY; KNOWLEDGE; SCALE	Background: The influence of a patient's quantitative skills (numeracy) on the management of diabetes is only partially understood. Objective: To examine the association between diabetes-related numeracy and glycemic control and other diabetes measurements. Design: Cross-sectional survey. Setting: 2 primary care and 2 diabetes clinics at 3 medical centers. Participants: 398 adult patients with type 1 or type 2 diabetes mellitus enrolled between March 2004 and November 2005. Measurements: Health literacy, general numeracy, and diabetes-related numeracy assessed by using the Rapid Estimate of Adult Literacy in Medicine; the Wide Range Achievement Test, 3rd edition; and the Diabetes Numeracy Test (DNT), respectively. The primary outcome was most recent level of hemoglobin A(1c). Additional measurements were diabetes knowledge, perceived self-efficacy of diabetes self-management, and self-management behaviors. Results: The median DNT score was 65% (interquartile range, 42% to 81%). Common errors included misinterpreting glucose meter readings and miscalculating carbohydrate intake and medication dosages. Lower DNT scores were associated with older age, nonwhite race, fewer years of education, lower reported income, lower literacy and general numeracy skills, lower perceived self-efficacy, and selected self-management behaviors. Patients scoring in the lowest DNT quartile (score < 42%) had a median hemoglobin A(1c) level of 7.6% (interquartile range, 6.5% to 9.0%) compared with 7.1% (interquartile range, 6.3% to 8.1%) in those scoring in the highest quartile (P = 0.119 for trend). A regression analysis adjusted for age, sex, race, income, and other factors found a modest association between DNT score and hemoglobin A1c level. Limitation: Causality cannot be determined in this cross-sectional study, especially with its risk for unmeasured confounding variables. Conclusion: Poor numeracy skills were common in patients with diabetes. Low diabetes-related numeracy skills were associated with worse perceived self-efficacy, fewer self-management behaviors, and possibly poorer glycemic control.	[Rothman, Russell L.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Sch Med, Nashville, TN 37232 USA; Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA; Univ N Carolina, Chapel Hill, NC USA; Univ Alabama Birmingham, Birmingham, AL USA	Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham	Rothman, RL (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Sch Med, 6100 Med Ctr E,N Tower, Nashville, TN 37232 USA.	russell.rothman@vanderbilt.edu	Albertin, Paloma C/X-1093-2018; Fuchs, Lynn/AAV-3828-2021	Fuchs, Lynn/0000-0003-2099-5247; DeWalt, Darren/0000-0003-2270-751X; Rothman, Russsell/0000-0002-1506-3990; Pignone, Michael/0000-0002-6657-7342	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, K23DK065294] Funding Source: NIH RePORTER; NIDDK NIH HHS [5K23DK065294, 5P60DK020593] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Apter AJ, 2006, J ASTHMA, V43, P705, DOI 10.1080/02770900600925585; Ashcraft MH, 2001, J EXP PSYCHOL GEN, V130, P224, DOI 10.1037/0096-3445.130.2.224; Baker DW, 1999, PATIENT EDUC COUNS, V38, P33, DOI 10.1016/S0738-3991(98)00116-5; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Davis T C, 1993, Fam Med, V25, P391; Davis T C, 1991, Fam Med, V23, P433; DeVellis R. F.., 1991, SCALE DEV THEORY APP; DeWalt DA, 2005, ARCH INTERN MED, V165, P1943, DOI 10.1001/archinte.165.17.1943; DeWalt DA, 2007, AM J HEALTH BEHAV, V31, pS27; Estrada CA, 2004, AM J MED SCI, V328, P88, DOI 10.1097/00000441-200408000-00004; Fitzgerald JT, 1998, DIABETES CARE, V21, P706, DOI 10.2337/diacare.21.5.706; Gazmararian JA, 2003, PATIENT EDUC COUNS, V51, P267, DOI 10.1016/S0738-3991(02)00239-2; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Harrell Frank E., 2001, REGRESSION MODELING; Hodge M B, 1999, Nurse Educ, V24, P41, DOI 10.1097/00006223-199907000-00010; HUIZINGA MM, 2008, BMC HLTH SE IN PRESS; *I MED, 2004, HLTH LIT PRESCR END; KIRSCH IS, NCES PUBLICATION; Kutner M., 2005, NCES PUBLICATION; Lipkus IM, 2001, MED DECIS MAKING, V21, P37, DOI 10.1177/0272989X0102100105; Montori VM, 2005, J GEN INTERN MED, V20, P1071, DOI 10.1111/j.1525-1497.2005.051498.x; Morris Nancy S, 2006, BMC Fam Pract, V7, P49, DOI 10.1186/1471-2296-7-49; Parker RM, 1999, JAMA-J AM MED ASSOC, V281, P552; Rothman RL, 2005, DIABETES EDUCATOR, V31, P215, DOI 10.1177/0145721705275002; Rothman RL, 2006, AM J PREV MED, V31, P391, DOI 10.1016/j.amepre.2006.07.025; Schapira MM, 2006, J HEALTH COMMUN, V11, P569, DOI 10.1080/10810730600829916; Schapira MM, 2004, RISK ANAL, V24, P665, DOI 10.1111/j.0272-4332.2004.00466.x; Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; Sheridan SL, 2003, J GEN INTERN MED, V18, P884, DOI 10.1046/j.1525-1497.2003.21102.x; Toobert DJ, 2000, DIABETES CARE, V23, P943, DOI 10.2337/diacare.23.7.943; Wallston KA, 2007, J BEHAV MED, V30, P395, DOI 10.1007/s10865-007-9110-y; Wilkinson G, 1993, WRAT 3 WIDE RANGE AC; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166	34	236	238	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 20	2008	148	10					737	U40		10.7326/0003-4819-148-10-200805200-00006	http://dx.doi.org/10.7326/0003-4819-148-10-200805200-00006			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308EX	18490687				2023-01-03	WOS:000256372200003
J	Saura, D; Rodriguez, D; Marin, F; de la Morena, G; Solis, I; Valdes, M				Saura, Daniel; Rodriguez, Daniel; Marin, Francisco; de la Morena, Gonzalo; Solis, Ines; Valdes, Mariano			Unable to speak - because of a drip	LANCET			English	Editorial Material							CONTRAST ECHOCARDIOGRAPHY		[Saura, Daniel; Rodriguez, Daniel; Marin, Francisco; de la Morena, Gonzalo; Solis, Ines; Valdes, Mariano] Hosp Univ Virgen Arrixaca, Serv Cardiol, Murcia 30120, Spain	Hospital Clinico Universitario Virgen de la Arrixaca	Saura, D (corresponding author), Hosp Univ Virgen Arrixaca, Serv Cardiol, Ctra Murcia Cartagena S-N, Murcia 30120, Spain.	danielsaura@secardiologia.es	de la Morena, Gonzalo/B-4077-2017; Marin, Francisco/AAD-9429-2022	de la Morena, Gonzalo/0000-0001-8495-7085; Saura, Daniel/0000-0002-7824-2814				BOMMER WJ, 1984, J AM COLL CARDIOL, V3, P6, DOI 10.1016/S0735-1097(84)80423-4; Lucas RV, 1995, HEART DIS INFANTS CH, P874; SRIVASTAVA TN, 1995, ANN INTERN MED, V122, P396, DOI 10.7326/0003-4819-122-5-199503010-00025	3	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 10	2008	371	9624					1636	1636		10.1016/S0140-6736(08)60696-0	http://dx.doi.org/10.1016/S0140-6736(08)60696-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	298VO	18468547				2023-01-03	WOS:000255715400032
J	Cacchio, A; De Blasis, E; Necozione, S; di Orio, F; Santilli, V				Cacchio, Angelo; De Blasis, Elisabetta; Necozione, Stefano; di Orio, Ferdinando; Santilli, Valter			Mirror Therapy for Chronic Complex Regional Pain Syndrome Type 1 and Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Cacchio, Angelo; Santilli, Valter] Univ Roma La Sapienza, Rome, Italy; [De Blasis, Elisabetta] Santissimi Filippo & Nicola Hosp Avezzano, Avezzano, Italy; [Necozione, Stefano; di Orio, Ferdinando] Univ Aquila, I-67100 Laquila, Italy	Sapienza University Rome; University of L'Aquila	Cacchio, A (corresponding author), Univ Roma La Sapienza, Rome, Italy.	angelo.cacchio@tin.it	Longo, Umile Giuseppe/K-9147-2016; Cacchio, Angelo/AAT-4844-2021	Longo, Umile Giuseppe/0000-0003-4063-9821; Cacchio, Angelo/0000-0001-8850-7938; Santilli, Valter/0000-0002-2547-6801; NECOZIONE, Stefano/0000-0003-2501-1665				Bruehl S, 1999, PAIN, V81, P147, DOI 10.1016/S0304-3959(99)00011-1; Maihofner C, 2003, NEUROLOGY, V61, P1707, DOI 10.1212/01.WNL.0000098939.02752.8E; McCabe CS, 2003, RHEUMATOLOGY, V42, P97, DOI 10.1093/rheumatology/keg041; Moseley GL, 2004, NEUROLOGY, V62, P1644, DOI 10.1212/01.WNL.0000123019.13575.5E; Ramachandran VS, 1996, P ROY SOC B-BIOL SCI, V263, P377, DOI 10.1098/rspb.1996.0058	5	89	100	3	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 6	2009	361	6					634	636		10.1056/NEJMc0902799	http://dx.doi.org/10.1056/NEJMc0902799			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479NR	19657134				2023-01-03	WOS:000268667300027
J	Gostin, LO				Gostin, Lawrence O.			Regulating the Safety of Pharmaceuticals The FDA, Preemption, and the Public's Health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TORT LITIGATION; LIABILITY		Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC 20001 USA	Georgetown University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu		Gostin, Lawrence/0000-0001-5286-4044				DeAngelis CD, 2008, JAMA-J AM MED ASSOC, V300, P1939, DOI 10.1001/jama.2008.513; *FOOD DRUG ADM SCI, 2007, SCI MISS RISK REP SU; Gostin L., 2008, PUBLIC HLTH LAW POWE; Gostin LO, 2008, JAMA-J AM MED ASSOC, V299, P2313, DOI 10.1001/jama.299.19.2313; Institute of Medicine, 2006, FUT DRUG SAF PROM PR; Kesselheim AS, 2009, NEW ENGL J MED, V360, P559, DOI 10.1056/NEJMp0809403; Kessler DA, 2008, GEORGETOWN LAW J, V96, P461; MCGARITY THOMAS O., 2008, PREEMPTION WAR FEDER; *US HR, 2008, FDA CAR STAFF OBJ AG; 2006, FED REG, V71, P3922	10	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 20	2009	301	19					2036	2037		10.1001/jama.2009.680	http://dx.doi.org/10.1001/jama.2009.680			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446YU	19454642				2023-01-03	WOS:000266159600028
J	Pellegrini, M; Calzascia, T; Elford, AR; Shahinian, A; Lin, AE; Dissanayake, D; Dhanji, S; Nguyen, LT; Gronski, MA; Morre, M; Assouline, B; Lahl, K; Sparwasser, T; Ohashi, PS; Mak, TW				Pellegrini, Marc; Calzascia, Thomas; Elford, Alisha R.; Shahinian, Arda; Lin, Amy E.; Dissanayake, Dilan; Dhanji, Salim; Nguyen, Linh T.; Gronski, Matthew A.; Morre, Michel; Assouline, Brigitte; Lahl, Katharina; Sparwasser, Tim; Ohashi, Pamela S.; Mak, Tak W.			Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies	NATURE MEDICINE			English	Article							REGULATORY T-CELLS; E3 UBIQUITIN LIGASE; TGF-BETA; CBL-B; TRANSGENIC MICE; NEGATIVE REGULATION; IMMUNE-RESPONSE; CUTTING EDGE; IN-VITRO; INTERLEUKIN-7	Identifying key factors that enhance immune responses is crucial for manipulating immunity to tumors. We show that after a vaccine-induced immune response, adjuvant interleukin-7 (IL-7) improves antitumor responses and survival in an animal model. The improved immune response is associated with increased IL-6 production and augmented T helper type 17 cell differentiation. Furthermore, IL-7 modulates the expression of two ubiquitin ligases: Casitas B-lineage lymphoma b (Cbl-b), a negative regulator of T cell activation, is repressed, and SMAD-specific E3 ubiquitin protein ligase-2 (Smurf2) is enhanced, which antagonizes transforming growth factor-beta signaling. Notably, we show that although short term IL-7 therapy potently enhances vaccine-mediated immunity, in the absence of vaccination it is inefficient in promoting antitumor immune responses, despite inducing homeostatic proliferation of T cells. The ability of adjuvant IL-7 to antagonize inhibitory networks at the cellular and molecular level has major implications for immunotherapy in the treatment of tumors.	[Pellegrini, Marc; Calzascia, Thomas; Elford, Alisha R.; Shahinian, Arda; Lin, Amy E.; Dissanayake, Dilan; Dhanji, Salim; Nguyen, Linh T.; Ohashi, Pamela S.; Mak, Tak W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada; [Pellegrini, Marc; Calzascia, Thomas; Lin, Amy E.; Dissanayake, Dilan; Dhanji, Salim; Nguyen, Linh T.; Ohashi, Pamela S.; Mak, Tak W.] Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON, Canada; [Gronski, Matthew A.] Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA USA; [Morre, Michel; Assouline, Brigitte] Cytheris Inc, Issy Les Moulineaux, France; [Lahl, Katharina] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Munich, Germany; [Sparwasser, Tim] Ctr Expt & Clin Infect Res, Inst Infect Immunol, Hanover, NH USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Virginia; Technical University of Munich	Ohashi, PS (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON, Canada.	pohashi@uhnres.utoronto.ca	Sparwasser, Tim D/AAA-4306-2022; Lin, Amy Erica/ABG-4745-2020; Pellegrini, Marc/F-7670-2014; Lahl, Katharina/AAA-1909-2021; Sparwasser, Tim/AAF-7085-2019	Lin, Amy Erica/0000-0002-0554-2832; Lahl, Katharina/0000-0003-4919-331X; Sparwasser, Tim/0000-0001-5645-902X; Dissanayake, Dilan/0000-0003-4270-7015; Ohashi, Pamela S./0000-0003-2915-9317; Pellegrini, Marc/0000-0003-3627-3126; Gronski, Matthew/0000-0003-4779-5720; Calzascia, Thomas/0000-0001-8225-6744	Canadian Institute for Health; Ontario Institute for Cancer Research; Terry Fox Cancer Foundation National Cancer Institute of Canada; Boninchi Foundation (Geneva, Switzerland); National Cancer Institute of Canada; Cancer Research Institute (New York)	Canadian Institute for Health(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research; Terry Fox Cancer Foundation National Cancer Institute of Canada; Boninchi Foundation (Geneva, Switzerland); National Cancer Institute of Canada(Canadian Cancer Society (CCS)); Cancer Research Institute (New York)	E. Deenick and R. Kalaf assisted with the injection of mice. M. Nikpour assisted with statistical analyses. This work was supported by a Canadian Institute for Health Research grant and funding from the Ontario Institute for Cancer Research to P. S. O. and a Terry Fox Cancer Foundation National Cancer Institute of Canada grant to T. W. M. T. C. was supported by the Boninchi Foundation (Geneva, Switzerland) and is a Research Fellow of The Terry Fox Foundation through an award from the National Cancer Institute of Canada. M. P. holds an Irvington Institute Fellowship with the Cancer Research Institute (New York). P. S. O. holds a Canada Research Chair in autoimmunity and tumor immunity.	AOKI T, 1992, P NATL ACAD SCI USA, V89, P3850, DOI 10.1073/pnas.89.9.3850; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bai YL, 2004, MOL CELL, V15, P825, DOI 10.1016/j.molcel.2004.07.021; Bellone M, 2008, TRENDS IMMUNOL, V29, P235, DOI 10.1016/j.it.2008.02.003; Calzascia T, 2007, J CLIN INVEST, V117, P3833, DOI 10.1172/JCI32567; CAYEUX S, 1995, EUR J IMMUNOL, V25, P2325, DOI 10.1002/eji.1830250831; Chiang JY, 2007, J CLIN INVEST, V117, P1029, DOI 10.1172/JCI29472; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Dudley ME, 2008, J CLIN ONCOL, V26, P5233, DOI 10.1200/JCO.2008.16.5449; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763; Fry TJ, 2002, BLOOD, V99, P3892, DOI 10.1182/blood.V99.11.3892; Fry TJ, 2001, BLOOD, V97, P1525, DOI 10.1182/blood.V97.6.1525; Gajewski TF, 2006, IMMUNOL REV, V213, P131, DOI 10.1111/j.1600-065X.2006.00442.x; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Gronski MA, 2004, NAT MED, V10, P1234, DOI 10.1038/nm1114; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; King CG, 2006, NAT MED, V12, P1088, DOI 10.1038/nm1449; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Li LQ, 2006, NAT IMMUNOL, V7, P1157, DOI 10.1038/ni1398; Lin AE, 2007, CURR OPIN IMMUNOL, V19, P665, DOI 10.1016/j.coi.2007.10.002; Liu SJ, 2007, INT IMMUNOL, V19, P1213, DOI 10.1093/intimm/dxm093; Loeser S, 2007, J EXP MED, V204, P879, DOI 10.1084/jem.20061699; LYNCH DH, 1994, J EXP MED, V179, P31, DOI 10.1084/jem.179.1.31; Martin-Orozco N, 2006, J EXP MED, V203, P817, DOI 10.1084/jem.20060219; Melchionda F, 2005, J CLIN INVEST, V115, P1177, DOI 10.1172/JCI200523134; Mempel TR, 2006, IMMUNITY, V25, P129, DOI 10.1016/j.immuni.2006.04.015; Miller PW, 2000, HUM GENE THER, V11, P53, DOI 10.1089/10430340050016157; Mueller DL, 2004, NAT IMMUNOL, V5, P883, DOI 10.1038/ni1106; Muller AJ, 2006, NAT REV CANCER, V6, P613, DOI 10.1038/nrc1929; Muranski P, 2008, BLOOD, V112, P362, DOI 10.1182/blood-2007-11-120998; Nanjappa SG, 2008, J CLIN INVEST, V118, P1027, DOI 10.1172/JCI32020; Ogura H, 2008, IMMUNITY, V29, P628, DOI 10.1016/j.immuni.2008.07.018; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Pellegrini M, 2003, P NATL ACAD SCI USA, V100, P14175, DOI 10.1073/pnas.2336198100; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; Prendergast GC, 2007, CANCER RES, V67, P3500, DOI 10.1158/0008-5472.CAN-06-4626; Rosenberg SA, 2006, J IMMUNOTHER, V29, P313, DOI 10.1097/01.cji.0000210386.55951.c2; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Speiser DE, 1997, J EXP MED, V186, P645, DOI 10.1084/jem.186.5.645; Strasser A, 2004, TRENDS IMMUNOL, V25, P610, DOI 10.1016/j.it.2004.08.012; Tripathi P, 2007, J IMMUNOL, V178, P4027, DOI 10.4049/jimmunol.178.7.4027; Wohlfert EA, 2006, J IMMUNOL, V176, P1316, DOI 10.4049/jimmunol.176.3.1316; Wohlfert EA, 2004, J IMMUNOL, V173, P1059, DOI 10.4049/jimmunol.173.2.1059; Yang BL, 2008, NAT IMMUNOL, V9, P1356, DOI 10.1038/ni.1670; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878; Zou WP, 2005, NAT REV CANCER, V5, P263, DOI 10.1038/nrc1586	55	158	168	0	10	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	MAY	2009	15	5					528	536		10.1038/nm.1953	http://dx.doi.org/10.1038/nm.1953			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	443DB	19396174				2023-01-03	WOS:000265889300031
J	Kiser, AK; Pronovost, PJ				Kiser, Ava K.; Pronovost, Peter J.			Management of Diseases Without Current Treatment Options Something Can Be Done	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RESPIRATORY-DISTRESS-SYNDROME; RETINITIS-PIGMENTOSA; SURVIVORS		[Kiser, Ava K.] Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol, Baltimore, MD 21218 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Dept Anesthesiol & Crit Care, Baltimore, MD 21218 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Dept Surg, Baltimore, MD 21218 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kiser, AK (corresponding author), 550 N Broadway,6th Floor, Baltimore, MD 21205 USA.	abittne1@jhmi.edu	Bittner, Ava/AAK-8778-2021	Bittner, Ava/0000-0002-9498-2230	NEI NIH HHS [K23 EY018356-02, K23 EY018356] Funding Source: Medline; NINR NIH HHS [P30 NR008995-05, P30 NR008995] Funding Source: Medline; NATIONAL EYE INSTITUTE [K23EY018356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [P30NR008995] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Cohen S, 2007, JAMA-J AM MED ASSOC, V298, P1685, DOI 10.1001/jama.298.14.1685; Davydow DS, 2008, PSYCHOSOM MED, V70, P512, DOI 10.1097/PSY.0b013e31816aa0dd; HECKENLIVELY JR, 1988, AM J OPHTHALMOL, V105, P504, DOI 10.1016/0002-9394(88)90242-5; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Kiser AK, 2008, CLIN EXP OPTOM, V91, P166, DOI 10.1111/j.1444-0938.2007.00224.x; Ormel J, 1997, PSYCHOL MED, V27, P1065, DOI 10.1017/S0033291797005321; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Westfall JM, 2007, JAMA-J AM MED ASSOC, V297, P403, DOI 10.1001/jama.297.4.403; Woolf SH, 2008, JAMA-J AM MED ASSOC, V299, P211, DOI 10.1001/jama.2007.26; Zhao X, 2007, P NATL ACAD SCI USA, V104, P12831, DOI 10.1073/pnas.0705803104	10	4	5	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	2009	301	16					1708	1709		10.1001/jama.2009.506	http://dx.doi.org/10.1001/jama.2009.506			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435NN	19383962	Green Accepted			2023-01-03	WOS:000265350700027
J	Campbell, BH				Campbell, Bruce H.			The Code	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												bcampbel@mcw.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	2009	301	14					1415	1416		10.1001/jama.2009.459	http://dx.doi.org/10.1001/jama.2009.459			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	429MN	19351928				2023-01-03	WOS:000264924900001
J	Wood, E; Werb, D; Marshall, BDL; Montaner, JSG; Kerr, T				Wood, Evan; Werb, Daniel; Marshall, Brandon D. L.; Montaner, Julio S. G.; Kerr, Thomas			The war on drugs: a devastating public-policy disaster	LANCET			English	Editorial Material							HIV		[Wood, Evan; Werb, Daniel; Marshall, Brandon D. L.; Montaner, Julio S. G.; Kerr, Thomas] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Wood, Evan; Montaner, Julio S. G.; Kerr, Thomas] Univ British Columbia, Fac Med, Div Aids, Dept Med, Vancouver, BC, Canada; [Werb, Daniel; Marshall, Brandon D. L.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of British Columbia	Wood, E (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	uhri-ew@cfenet.ubc.ca	Marshall, Brandon/B-4895-2010; Montaner, Julio/K-7621-2012	Marshall, Brandon/0000-0002-0134-7052; 				[Anonymous], 2003, INT J DRUG POLICY, DOI DOI 10.1016/S0955-3959(03)00005-7; Bluthenthal R. N., 1999, International Journal of Drug Policy, V10, P25, DOI 10.1016/S0955-3959(98)00076-0; Degenhardt L, 2008, PLOS MED, V5, P1053, DOI 10.1371/journal.pmed.0050141; *EUR MON CTR DRUGS, 2008, STAT B 2008; FAZEY C, 2003, INT J DRUG POLICY, V14, P159; FELLNER J, 2008, TARGETING BLACKS DRU; HANSON S, 2008, WASHINGTON POST 1125; JELSMA M, 2003, INT J DRUG POLICY, V14, P195; Jurgens R, 2009, LANCET INFECT DIS, V9, P57, DOI 10.1016/S1473-3099(08)70305-0; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; MORRIS SK, 2003, INT J DRUG POLICY, V14, P209; *UN OFF DRUGS CRIM, 2002, 2005 WORLD DRUG REP; Werb D, 2008, J PUBLIC HEALTH POL, V29, P440, DOI 10.1057/jphp.2008.29	13	39	39	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	2009	373	9668					989	990		10.1016/S0140-6736(09)60455-4	http://dx.doi.org/10.1016/S0140-6736(09)60455-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	422AA	19282025				2023-01-03	WOS:000264398200009
J	Brown, CJ; Roth, DL; Allman, RM; Sawyer, P; Ritchie, CS; Roseman, JM				Brown, Cynthia J.; Roth, David L.; Allman, Richard M.; Sawyer, Patricia; Ritchie, Christine S.; Roseman, Jeffrey M.			Trajectories of Life-Space Mobility After Hospitalization	ANNALS OF INTERNAL MEDICINE			English	Article							FUNCTIONAL DECLINE; OLDER-ADULTS; MULTICOMPONENT INTERVENTION; RANDOMIZED-TRIAL; NATURAL-HISTORY; ACUTE-CARE; OUTCOMES; DELIRIUM; PREVALENCE; DISABILITY	Background: Life space is a measure of where a person goes, the frequency of going there, and the dependency in getting there. It may be a more accurate measure of mobility in older adults because it reflects participation in society as well as physical ability. Objective: To assess effects of hospitalization on life space in older adults, and to compare life-space trajectories associated with surgical and nonsurgical hospitalizations. Design: Prospective observational study. Setting: Central Alabama. Participants: 687 community-dwelling Medicare beneficiaries at least 65 years of age with surgical (n = 44), nonsurgical (n = 167), or no (n = 476) hospitalizations. Measurements: Life-Space Assessment (LSA) scores before and after hospitalization (range, 0 to 120; higher scores reflect greater mobility). Results: Mean age of participants was 74.6 years (SD, 6.3). Fifty percent were black, and 46% were male. Before hospitalization, adjusted LSA scores were similar in participants with surgical and nonsurgical admissions. Life-space assessment scores decreased in both groups immediately after hospitalization; however, participants with surgical hospitalizations had a greater decrease in scores (12.1 more points [95% CI, 3.6 to 20.7 points]; P = 0.005) than those with nonsurgical hospitalizations. However, participants with surgical hospitalizations recovered more rapidly over time (gain of 4.7 more points [CI, 2.0 to 7.4 points] per ln [week after discharge]; P < 0.001). Score recovery for participants with nonsurgical hospitalizations did not significantly differ from the null (average recovery, 0.7 points [CI,-0.6 to 1.9 points] per ln [week after discharge]). Limitation: Life space immediately before and after hospitalization was self-reported, often after hospital discharge. Conclusion: Hospitalization decreases life space in older adults. Surgical hospitalizations are associated with immediate marked life-space declines followed by rapid recovery, in contrast to nonsurgical hospitalizations, which are associated with more modest immediate declines and little evidence of recovery after several years of follow-up.	Birmingham & Atlanta Vet Affairs Geriatr Res, Birmingham, AL USA; Ctr Clin, Birmingham, AL USA; Univ Alabama Birmingham, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham	Brown, CJ (corresponding author), Birmingham Vet Affairs Med Ctr, 11G,700 S 19th St, Birmingham, AL 35233 USA.	cbrown@aging.uab.edu; droth@uab.edu	Allman, Richard M./O-1693-2019	Allman, Richard M./0000-0002-1850-6515; Brown, Cynthia J/0000-0002-1629-5507	National Institute on Aging [R01 AG015062]; Veterans Affairs Research Career Development Award [E4-3842VA]; John A. Hartford Foundation; NATIONAL INSTITUTE ON AGING [R01AG015062] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Veterans Affairs Research Career Development Award(US Department of Veterans Affairs); John A. Hartford Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Primary Funding Source: National Institute on Aging.; Grant Support: By a Veterans Affairs Research Career Development Award (E4-3842VA) (Dr. Brown) and a John A. Hartford Foundation-funded Southeast Center of Excellence in Geriatric Medicine Special Fellows grant (Dr. Brown). The UAB Study of Aging is funded through a grant from the National Institute on Aging (R01 AG015062).	Ahmed A, 2007, AM J CARDIOL, V99, P549, DOI 10.1016/j.amjcard.2006.08.065; *AL RUR HLTH ASS, 1998, HLTH STAT RUR AL; Baker PS, 2003, J AM GERIATR SOC, V51, P1610, DOI 10.1046/j.1532-5415.2003.51512.x; Brown CJ, 2004, J AM GERIATR SOC, V52, P1263, DOI 10.1111/j.1532-5415.2004.52354.x; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Counsell SR, 2000, J AM GERIATR SOC, V48, P1572, DOI 10.1111/j.1532-5415.2000.tb03866.x; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Dubois MF, 2007, J CLIN EPIDEMIOL, V60, P1040, DOI 10.1016/j.jclinepi.2006.12.011; HIRSCH CH, 1990, J AM GERIATR SOC, V38, P1296, DOI 10.1111/j.1532-5415.1990.tb03451.x; *I MED, 2006, FUT DIS AM; Incalzi RA, 1996, ARCH INTERN MED, V156, P425, DOI 10.1001/archinte.156.4.425; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; JETTE AM, 2006, PHYS THER, V86, P726, DOI DOI 10.1093/PTJ/86.5.726; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LAZARUS BA, 1991, ARCH INTERN MED, V151, P2452, DOI 10.1001/archinte.151.12.2452; Littell R.C., 1996, SAS SYSTEMS MIXED MO; Marcantonio ER, 2003, J AM GERIATR SOC, V51, P4, DOI 10.1034/j.1601-5215.2002.51002.x; MARGITIC SE, 1993, J AM GERIATR SOC, V41, P258, DOI 10.1111/j.1532-5415.1993.tb06703.x; McAvay GJ, 2006, J AM GERIATR SOC, V54, P1245, DOI 10.1111/j.1532-5415.2006.00815.x; McCusker J, 2002, ARCH INTERN MED, V162, P457, DOI 10.1001/archinte.162.4.457; MCVEY LJ, 1989, ANN INTERN MED, V110, P79, DOI 10.7326/0003-4819-110-1-79; MELIN AL, 1992, MED CARE, V30, P1004, DOI 10.1097/00005650-199211000-00004; Nikolaus T, 1999, AGE AGEING, V28, P543, DOI 10.1093/ageing/28.6.543; Parker M, 2001, J GERONTOL SOC WORK, V35, P35, DOI [DOI 10.1300/J083V35N04_04, 10.1300/J083v35n04_04]; Peak EL, 2005, J BONE JOINT SURG AM, V87A, P247, DOI 10.2106/JBJS.C.01513; Peel C, 2005, PHYS THER, V85, P1008, DOI 10.1093/ptj/85.10.1008; Roseman, 2006, AGING HLTH, V2, P417, DOI [10.2217/1745509x.2.3.417, DOI 10.2217/1745509X.2.3.417]; RUEL M, 2005, SABISTON SPENCER SUR, P1476; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; Sager MA, 1998, CLIN GERIATR MED, V14, P669; Shumway-Cook A, 2005, J AM GERIATR SOC, V53, P1217, DOI 10.1111/j.1532-5415.2005.53372.x; Singer J., 2003, APPL LONGITUDINAL DA; Smith GL, 2003, J AM COLL CARDIOL, V41, P1510, DOI 10.1016/S0735-1097(03)00185-2; Sullivan DH, 1999, JAMA-J AM MED ASSOC, V281, P2013, DOI 10.1001/jama.281.21.2013; VAITKEVICUS VP, 2003, PRINCIPLES GERIATRIC, P361; WARSHAW GA, 1982, JAMA-J AM MED ASSOC, V248, P847, DOI 10.1001/jama.248.7.847; World Health Organisation, 2001, ICF INT CLASFUNCT	40	131	131	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 17	2009	150	6					372	W67		10.7326/0003-4819-150-6-200903170-00005	http://dx.doi.org/10.7326/0003-4819-150-6-200903170-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	423AJ	19293070	Green Accepted			2023-01-03	WOS:000264468500002
J	Valentin, A; Capuzzo, M; Guidet, B; Moreno, R; Metnitz, B; Bauer, P; Metnitz, P				Valentin, Andreas; Capuzzo, Maurizia; Guidet, Bertrand; Moreno, Rui; Metnitz, Barbara; Bauer, Peter; Metnitz, Philipp		Res Grp Quality Improvement ESICM; SEE Study Investigators	Errors in administration of parenteral drugs in intensive care units: multinational prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICATION ERRORS; EVENTS; WORKLOAD; SAFETY; SCORE	Objective To assess on a multinational level the frequency, characteristics, contributing factors, and preventive measures of administration errors in parenteral medication in intensive care units. Design Observational, prospective, 24 hour cross sectional study with self reporting by staff. Setting 113 intensive care units in 27 countries. Participants 1328 adults in intensive care. Main outcome measures Number of errors; impact of errors; distribution of error characteristics; distribution of contributing and preventive factors. Results 861 errors affecting 441 patients were reported: 74.5 (95% confidence interval 69.5 to 79.4) events per 100 patient days. Three quarters of the errors were classified as errors of omission. Twelve patients (0.9% of the study population) experienced permanent harm or died because of medication errors at the administration stage. In a multiple logistic regression with patients as the unit of analysis, odds ratios for the occurrence of at least one parenteral medication error were raised for number of organ failures (odds ratio per increase of one organ failure: 1.19, 95% confidence interval 1.05 to 1.34); use of any intravenous medication (yes v no: 2.73, 1.39 to 5.36); number of parenteral administrations (per increase of one parenteral administration: 1.06, 1.04 to 1.08); typical interventions in patients in intensive care (yes v no: 1.50, 1.14 to 1.96); larger intensive care unit (per increase of one bed: 1.01, 1.00 to 1.02); number of patients per nurse (per increase of one patient: 1.30, 1.03 to 1.64); and occupancy rate (per 10% increase: 1.03, 1.00 to 1.05). Odds ratios for the occurrence of parenteral medication errors were decreased for presence of basic monitoring (yes v no: 0.19, 0.07 to 0.49); an existing critical incident reporting system (yes v no: 0.69, 0.53 to 0.90); an established routine of checks at nurses' shift change (yes v no: 0.68, 0.52 to 0.90); and an increased ratio of patient turnover to the size of the unit (per increase of one patient: 0.73, 0.57 to 0.93). Conclusions Parenteral medication errors at the administration stage are common and a serious safety problem in intensive care units. With the increasing complexity of care in critically ill patients, organisational factors such as error reporting systems and routine checks can reduce the risk for such errors.	[Valentin, Andreas] Med Univ Vienna, Dept Emergency Med, Vienna, Austria; [Valentin, Andreas] Rudolfstiftung Hosp, Dept Med 2, Intens Care Unit, A-1030 Vienna, Austria; [Capuzzo, Maurizia] Univ Hosp Ferrara, Dept Anaesthesia & Intens Care, Ferrara, Italy; [Guidet, Bertrand] INSERM, Unite Rech Epidemiol Syst Informat & Modelisat, Paris, France; [Guidet, Bertrand] Univ Paris 06, Fac Med, Paris, France; [Guidet, Bertrand] Hop St Antoine, AP HP, Serv Reanimat Med, F-75571 Paris, France; [Moreno, Rui] Hosp St Antonio dos Capuchos, Ctr Hosp Lisboa Cent EPE, Dept Intens Care, Lisbon, Portugal; [Metnitz, Barbara; Bauer, Peter] Med Univ Vienna, Sect Med Stat, Vienna, Austria; [Metnitz, Philipp] Med Univ Vienna, Dept Anaesthesiol & Gen Intens Care, Vienna, Austria	Medical University of Vienna; Rudolfstiftung Hospital; University of Ferrara; Arcispedale Sant'Anna; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centro Hospitalar de Lisboa Ocidental, EPE; Medical University of Vienna; Medical University of Vienna	Valentin, A (corresponding author), Med Univ Vienna, Dept Emergency Med, Vienna, Austria.	andreas.valentin@meduniwien.ac.at	Monedero, Pablo/A-1696-2008	Monedero, Pablo/0000-0002-1596-5644; Valentin, Andreas/0000-0001-7443-3595; Breen, Dorothy/0000-0001-5010-4017	Austrian Center for Documentation and Quality Assurance in Intensive Care Medicine (ASDI)	Austrian Center for Documentation and Quality Assurance in Intensive Care Medicine (ASDI)	Funding: The SEE study was supported and funded by the Austrian Center for Documentation and Quality Assurance in Intensive Care Medicine (ASDI) and endorsed by the European Society of Intensive Care Medicine (ESICM).	[Anonymous], 1993, AM J HOSP PHARM, V50, P305, DOI DOI 10.1093/AJHP/50.2.305; Beckmann U, 2003, CRIT CARE MED, V31, P1006, DOI 10.1097/01.CCM.0000060016.21525.3C; Bracco D, 2001, INTENS CARE MED, V27, P137, DOI 10.1007/s001340000751; Calabrese AD, 2001, INTENS CARE MED, V27, P1592, DOI 10.1007/s001340101065; Cullen DJ, 1997, CRIT CARE MED, V25, P1289, DOI 10.1097/00003246-199708000-00014; DONCHIN Y, 1995, CRIT CARE MED, V23, P294, DOI 10.1097/00003246-199502000-00015; Fahimi Fanak, 2008, Aust Crit Care, V21, P110, DOI 10.1016/j.aucc.2007.10.004; Herout PM, 2004, CRIT CARE MED, V32, P428, DOI 10.1097/01.CCM.0000108876.12846.B7; Hugonnet S, 2007, CRIT CARE MED, V35, P76, DOI 10.1097/01.CCM.0000251125.08629.3F; Kopp BJ, 2006, CRIT CARE MED, V34, P415, DOI 10.1097/01.CCM.0000198106.54306.D7; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; McCauley K, 2006, CHEST, V130, P1571, DOI 10.1378/chest.130.5.1571; Minvielle E, 2008, J CRIT CARE, V23, P236, DOI 10.1016/j.jcrc.2007.11.006; Miranda DR, 1997, INTENS CARE MED, V23, P760, DOI 10.1007/s001340050406; Parshuram CS, 2003, CRIT CARE MED, V31, P2483, DOI 10.1097/01.CCM.0000089638.83803.B2; Ream RS, 2007, PEDIATR CRIT CARE ME, V8, P366, DOI 10.1097/01.PCC.0000269379.40748.AF; Rothschild JM, 2005, CRIT CARE MED, V33, P1694, DOI 10.1097/01.CCM.0000171609.91035.BD; Sexton JB, 2000, BMJ-BRIT MED J, V320, P745, DOI 10.1136/bmj.320.7237.745; Sheldon Tony, 2007, BMJ, V334, P925, DOI 10.1136/bmj.39199.498137.DB; Stanhope N, 1999, J EVAL CLIN PRACT, V5, P5, DOI 10.1046/j.1365-2753.1999.00146.x; Tang FI, 2007, J CLIN NURS, V16, P447, DOI 10.1111/j.1365-2702.2005.01540.x; Tarnow-Mordi WO, 2000, LANCET, V356, P185, DOI 10.1016/S0140-6736(00)02478-8; Tissot E, 1999, INTENS CARE MED, V25, P353, DOI 10.1007/s001340050857; Valentin A, 2007, CURR OPIN CRIT CARE, V13, P697, DOI 10.1097/MCC.0b013e3282f12cc8; Valentin A, 2006, INTENS CARE MED, V32, P1591, DOI 10.1007/s00134-006-0290-7; van den Bemt PMLA, 2002, CRIT CARE MED, V30, P846, DOI 10.1097/00003246-200204000-00022; Vincent C, 1999, J EVAL CLIN PRACT, V5, P13, DOI 10.1046/j.1365-2753.1999.00147.x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wasserfallen JB, 2004, CRIT CARE MED, V32, P655, DOI 10.1097/01.CCM.0000114835.97789.AB; Webster CS, 2005, ANAESTHESIA, V60, P1115, DOI 10.1111/j.1365-2044.2005.04301.x; Zohar D, 2007, CRIT CARE MED, V35, P1312, DOI 10.1097/01.CCM.0000262404.10203.C9	31	178	189	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 12	2009	338								b814	10.1136/bmj.b814	http://dx.doi.org/10.1136/bmj.b814			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	419FV	19282436	Green Published, hybrid			2023-01-03	WOS:000264205400001
J	Stiglitz, JE				Stiglitz, Joseph E.			Trade agreements and health in developing countries	LANCET			English	Editorial Material									[Stiglitz, Joseph E.] Columbia Univ, New York, NY 10027 USA	Columbia University	Stiglitz, JE (corresponding author), Columbia Univ, New York, NY 10027 USA.	jes322@columbia.edu						*EUR COMM, BIL TRAD REL, P2; Matthijs G, 2004, BRIT MED J, V329, P1358, DOI 10.1136/bmj.329.7479.1358; *MED SANS FRONT, 2006, PEOPL NOT GETT TREAT, P2; *OFF US TRAD REPR, TRAD AGR, P2; Smith RD, 2009, LANCET, V373, P684, DOI 10.1016/S0140-6736(08)61779-1; Smith RD, 2009, LANCET, V373, P768, DOI 10.1016/S0140-6736(08)61780-8; SOEKIRMAN KD, 2008, ASIA PACIFIC J CLI S, V10, P557; STIGLITZ JE, 2006, MAKING GLOBALIZATION, P2; *UN DEV PROGR, 2003, MAK GLOB TRAD WORK P, P2; 2007, MED NEWS TODAY  0207, P2	10	28	28	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2009	373	9661					363	365		10.1016/S0140-6736(08)61772-9	http://dx.doi.org/10.1016/S0140-6736(08)61772-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	401BC	19167055	Green Published			2023-01-03	WOS:000262912100009
J	Byakika-Tusiime, J; Chinn, LW; Oyugi, JH; Obua, C; Bangsberg, DR; Kroetz, DL				Byakika-Tusiime, Jayne; Chinn, Leslie W.; Oyugi, Jessica H.; Obua, Celestino; Bangsberg, David R.; Kroetz, Deanna L.			Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults	PLOS ONE			English	Article								Background: Generic antiretroviral therapy is the mainstay of HIV treatment in resource-limited settings, yet there is little evidence confirming the bioequivalence of generic and brand name formulations. We compared the steady-state pharmacokinetics of lamivudine, stavudine and nevirapine in HIV-infected subjects who were receiving a generic formulation (Triomune (R)) or the corresponding brand formulations (Epivir (R), Zerit (R), and Viramune (R)). Methodology/Principal Findings: An open-label, randomized, crossover study was carried out in 18 HIV-infected Ugandan subjects stabilized on Triomune-40. Subjects received lamivudine (150 mg), stavudine (40 mg), and nevirapine (200 mg) in either the generic or brand formulation twice a day for 30 days, before switching to the other formulation. At the end of each treatment period, blood samples were collected over 12 h for pharmacokinetic analysis. The main outcome measures were the mean AUC(0-12h) and C(max). Bioequivalence was defined as a geometric mean ratio between the generic and brand name within the 90% confidence interval of 0.8-1.25. The geometric mean ratios and the 90% confidence intervals were: stavudine C(max), 1.3 (0.99-1.71) and AUC(0-12h), 1.1 (0.87-1.38); lamivudine C(max), 0.8 (0.63-0.98) and AUC(0-12h), 0.8 (0.65-0.99); and nevirapine C(max), 1.1 (0.95-1.23) and AUC(0-12h), 1.1 (0.95-1.31). The generic formulation was not statistically bioequivalent to the brand formulations during steady state, although exposures were comparable. A mixed random effects model identified about 50% intersubject variability in the pharmacokinetic parameters. Conclusions/Significant Findings: These findings provide support for the use of Triomune in resource-limited settings, identification of the sources of intersubject variability in these populations is critical.	Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA; [Chinn, Leslie W.; Kroetz, Deanna L.] Univ Calif San Francisco, Dept Biopharm Sci, San Francisco, CA 94143 USA; [Oyugi, Jessica H.] Makerere Univ, Fac Med, Infect Dis Inst, Kampala, Uganda; [Obua, Celestino] Makerere Univ, Dept Pharmacol & Therapeut, Kampala, Uganda; [Bangsberg, David R.] Harvard Univ, Sch Med, Mass Gen Hosp, Harvard Initiative Glob Hlth, Boston, MA USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Makerere University; Makerere University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Byakika-Tusiime, J (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Div Epidemiol, Berkeley, CA 94720 USA.	deanna.kroetz@ucsf.edu		Obua, Celestino/0000-0001-6949-3059; Chinn, Leslie/0000-0003-3127-6758	AIDS Care and Research in Africa (ACRiA); Doris Duke Charitable Foundation; NIH [GM61390, AA014784, MH54907, AA015287]; Amgen [Fellowship]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U19GM061390, U01GM061390] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [K24AA015287, R21AA014784] Funding Source: NIH RePORTER	AIDS Care and Research in Africa (ACRiA); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen(Amgen); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This research was funded by the AIDS Care and Research in Africa (ACRiA) grant, supported by the Doris Duke Charitable Foundation (JB-T) and by NIH grants GM61390 (DLK), AA014784 (DRB), MH54907 (DRB)and AA015287 (DRB). LWC was funded by an Amgen Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson PL, 2006, JAIDS-J ACQ IMM DEF, V42, P441, DOI 10.1097/01.qai.0000225013.53568.69; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; Hosseinipour MC, 2007, AIDS, V21, P59, DOI 10.1097/QAD.0b013e3280117ca0; Lang T, 2001, PHARMACOGENETICS, V11, P399, DOI 10.1097/00008571-200107000-00004; Mistri HN, 2007, J CHROMATOGR B, V853, P320, DOI 10.1016/j.jchromb.2007.03.047; Narang VS, 2005, J CLIN PHARMACOL, V45, P265, DOI 10.1177/0091270004273343; Oyugi JH, 2007, AIDS, V21, P965, DOI 10.1097/QAD.0b013e32802e6bfa; Oyugi JH, 2004, JAIDS-J ACQ IMM DEF, V36, P1100, DOI 10.1097/00126334-200408150-00014; Penzak SR, 2007, HIV MED, V8, P86, DOI 10.1111/j.1468-1293.2007.00432.x; Saitoh A, 2007, AIDS, V21, P2191, DOI 10.1097/QAD.0b013e3282ef9695; von Hentig N, 2006, BRIT J CLIN PHARMACO, V62, P552, DOI 10.1111/j.1365-2125.2006.02664.x; *WHO GUID DEV GROU, 2007, IMP ADD 2006 WHO GUI; Wyen C, 2008, J ANTIMICROB CHEMOTH, V61, P914, DOI 10.1093/jac/dkn029; Yuen GJ, 2001, J CLIN PHARMACOL, V41, P277, DOI 10.1177/00912700122010096; Zhang JF, 2003, J EVOL ECON, V13, P529, DOI 10.1007/s00191-003-0178-4	15	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2008	3	12							e3981	10.1371/journal.pone.0003981	http://dx.doi.org/10.1371/journal.pone.0003981			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437AV	19096711	Green Published, gold, Green Submitted			2023-01-03	WOS:000265458800004
J	Bell, CL; Watson, B; Waring, WS				Bell, Claire L.; Watson, Bruce; Waring, W. Stephen			Drug point - Acute psychosis caused by co-amoxiclav	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Bell, Claire L.; Waring, W. Stephen] Royal Infirm Edinburgh NHS Trust, Scottish Poisons Informat Bur, Edinburgh EH16 4SA, Midlothian, Scotland; [Watson, Bruce] Royal Infirm Edinburgh NHS Trust, Dept Pharm, Edinburgh EH16 4SA, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Waring, WS (corresponding author), Royal Infirm Edinburgh NHS Trust, Scottish Poisons Informat Bur, Edinburgh EH16 4SA, Midlothian, Scotland.	s.waring@ed.ac.uk		Waring, William Stephen/0000-0001-6442-4548				MACKNIN ML, 1987, PEDIATR INFECT DIS J, V6, P873, DOI 10.1097/00006454-198709000-00024; *MED HEALTHC PROD, DRUG AN PRINTS DAT S; Sweetman S. C., 2007, MARTINDALE COMPLETE	3	4	4	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2008	337	7676							a2117	10.1136/bmj.a2117	http://dx.doi.org/10.1136/bmj.a2117			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363WS	18945734				2023-01-03	WOS:000260298800041
J	Raleigh, VS; Cooper, J; Bremner, SA; Scobie, S				Raleigh, Veena S.; Cooper, Jeremy; Bremner, Stephen A.; Scobie, Sarah			Patient safety indicators for England from hospital administrative data: case-control analysis and comparison with US data	BRITISH MEDICAL JOURNAL			English	Article							ADVERSE EVENTS; HEALTH-CARE; REVIEWER; QUALITY	Objective To assess the feasibility of deriving patient safety indicators for England from routine hospital data and whether they can indicate adverse outcomes for patients. Design Nine patient safety indicators developed by the United States Agency for Healthcare Research and Quality ( AHRQ) were derived using hospital episode statistics for England for 2003- 4, 2004- 5, and 2005- 6. A case- control analysis was undertaken to compare length of stay and mortality between cases ( patients experiencing the particular safety event measured by an indicator) and controls matched for age, sex, health resource group ( standard groupings of clinically similar treatments that use similar levels of healthcare resource), main specialty, and trust. Comparisons were undertaken with US data. Setting All NHS trusts in England. Participants Inpatients in NHS trusts. Results There was fair consistency in national rates for the nine indicators across three years. For all but one indicator, hospital stays were longer in cases than in matched controls (range 0.2- 17.1 days, P< 0.001). Mortality in cases was also higher than in controls ( 5.7-27.1%, P< 0.001), except for the obstetric trauma indicators. Excess length of stay and mortality in cases was greatest for postoperative hip fracture and sepsis. England's rates were lower than US rates for these indicators. Increased length of stay in cases was generally greater in England than in the US. Excess mortality was also higher in England than in the US, except for the obstetric trauma indicators where there were few deaths in both countries. Differences between England and the US in excess length of stay and mortality were most marked for postoperative hip fracture. Conclusions Hospital administrative data provide a potentially useful low burden, low cost source of information on safety events. Indicators can be derived with English data and show that cases have poorer outcomes than matched controls. These data therefore have potential for monitoring safety events. Further validation, for example, of individual cases, is needed and levels of event recording need to improve. Differences between England and the US might reflect differences in the depth of event coding and in health systems and patterns of healthcare provision.	[Raleigh, Veena S.; Cooper, Jeremy; Bremner, Stephen A.] Healthcare Commiss, London EC1Y 8TG, England; [Raleigh, Veena S.] Univ Surrey, Surrey GU2 7WG, England; [Scobie, Sarah] Natl Patient Safety Agcy, London W1T 5HD, England	University of Surrey	Raleigh, VS (corresponding author), Healthcare Commiss, London EC1Y 8TG, England.	raleigh@healthcarecommission.org.uk	Bremner, Stephen/R-4038-2016	Bremner, Stephen/0000-0003-0790-7070	Health and Social Care Information Centre	Health and Social Care Information Centre	The Healthcare Commission received a small grant from the Health and Social Care Information Centre to support the initial recoding work.	BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; *BRIST ROYAL INF I, 2001, LEARN BRIST REP PUBL, pCH21; Darzi A., 2008, HIGH QUALITY CARE AL; *DEP HHS AG HEALTH, 2007, AHRQ QUAL IND GUID P; Department of Health, 2007, PAYM RES GUID 2008 0; Foster, 2004, BMJ-BRIT MED J, V329, P369, DOI 10.1136/bmj.329.7462.369; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; McDonald KM, 2002, AHRQ PUBLICATION, V02-0038; Millar J, 2004, OECD HLTH TECHNICAL; National Audit Office, 2005, SAF PLAC PAT LEARN I; Polancich S, 2006, AM J MED QUAL, V21, P262, DOI 10.1177/1062860606288244; Runciman WB, 2000, INT J QUAL HEALTH C, V12, P379, DOI 10.1093/intqhc/12.5.379; Sari A, 2006, BMJ-BRIT MED J, V334, P79; Serden L, 2003, HEALTH POLICY, V65, P101, DOI 10.1016/S0168-8510(02)00208-7; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Vincent C, 2005, PATIENT SAFETY; Wilson RM, 1995, MED J AUSTRALIA, V163, P458, DOI 10.5694/j.1326-5377.1995.tb124691.x; Zhan CL, 2003, JAMA-J AM MED ASSOC, V290, P1868, DOI 10.1001/jama.290.14.1868	18	44	44	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 17	2008	337								a1702	10.1136/bmj.a1702	http://dx.doi.org/10.1136/bmj.a1702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	374FI	18930971	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000261028200002
J	Ahmed, S; Rienstra, M; Crijns, HJGM; Links, TP; Wiesfeld, ACP; Hillege, HL; Bosker, HA; Lok, DJA; Van Veldhuisen, DJ; Van Gelder, IC				Ahmed, Sheba; Rienstra, Michiel; Crijns, Harry J. G. M.; Links, Thera P.; Wiesfeld, Ans C. P.; Hillege, Hans L.; Bosker, Hans A.; Lok, Dirk J. A.; Van Veldhuisen, Dirk J.; Van Gelder, Isabelle C.		CONVERT Investigators	Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Conference on Late Breaking Clinical Trials held at the Heart-Rhythm-Society	MAY 13, 2007	Denver, CO	Heart Rhythm Soc			ELECTRICAL CARDIOVERSION RACE; LOW-DOSE AMIODARONE; QUALITY-OF-LIFE; RHYTHM-CONTROL; MYOCARDIAL-INFARCTION; SERIAL CARDIOVERSION; EFFICACY; SAFETY; TOXICITY; ABLATION	Context Amiodarone effectively suppresses atrial fibrillation but causes many adverse events. Objective To compare major events in patients randomized to receive episodic amiodarone treatment with those who received continuous amiodarone treatment while still aiming to prevent atrial fibrillation. Design, Setting, and Participants A randomized trial of 209 ambulatory patients with recurrent symptomatic persistent atrial fibrillation, conducted from December 2002 through March 2007 at 7 Dutch medical centers. Intervention Patients were randomly assigned to receive either episodic or continuous amiodarone treatment after electrical cardioversion following amiodarone loading. Episodic amiodarone treatment was discontinued after a month of sinus rhythm and reinitiated if atrial fibrillation relapsed ( 1 month peri - electrical cardioversion). In the continuous treatment group amiodarone was maintained throughout. Main Outcome Measures The primary end point was a composite of amiodarone and underlying heart disease - related major events. The secondary end points were all- cause mortality and cardiovascular hospitalizations. Results After a median follow- up of 2.1 years ( range, 0.4- 2.5 years), 51 ( 48%) of those receiving episodic treatment vs 64( 62%) receiving continuous treatment had sinus rhythm ( P=. 05). There were 85 atrial fibrillation recurrences ( 80%) amongthe episodic treatment group vs 56 ( 54%) in the continuous treatment group ( P <. 001). No significant difference existed in the incidence of the primary composite end point between each group ( 37[35%] episodic vs 34 [ 33%] continuous; incidence rate difference, 0.2; 95% confidence interval [ CI], - 10.2 to 10.6). However, there were nonstatistically significant differences in the incidence of amiodarone- related major events ( 20 [ 19%] episodic vs 25 [ 24%] continuous; incidence rate difference, - 2.0; 95% CI, - 8.7 to 4.6) and underlying heart disease - related major events ( 17[ 16%] episodic vs9[ 9%] continuous; incidence rate difference, 3.6; 95% CI, - 1.6 to 8.7). All- cause mortality and cardiovascular hospitalizations were higheramong those receiving episodic treatment ( 56 [ 53%] vs 35 [ 34%], P=. 02). Conclusions In this study population, there was no difference in the composite of amiodarone and cardiac major adverse events between groups. However, patients receiving episodic treatment had a significantly increased rate of atrial fibrillation recurrence and a significantly higher rate of all- cause mortality and cardiovascular hospitalizations. Trial Registration clinicaltrials. gov Identifier: NCT00392431.	[Ahmed, Sheba; Rienstra, Michiel; Wiesfeld, Ans C. P.; Van Veldhuisen, Dirk J.; Van Gelder, Isabelle C.] Univ Groningen, Dept Cardiol, Thoraxctr, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Links, Thera P.] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9700 RB Groningen, Netherlands; [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Trial Coordinat Ctr, NL-9700 RB Groningen, Netherlands; [Van Gelder, Isabelle C.] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands; [Crijns, Harry J. G. M.] Maastricht Univ Med Ctr, Dept Cardiol, Maastricht, Netherlands; [Bosker, Hans A.] Rijnstate Hosp, Dept Cardiol, Arnhem, Netherlands; [Lok, Dirk J. A.] Deventer Hosp, Dept Cardiol, Deventer, Netherlands	University of Groningen; University of Groningen; University of Groningen; Interuniversity Cardiology Institute of the Netherlands; Utrecht University; Maastricht University; Maastricht University Medical Centre (MUMC); Rijnstate Hospital; Deventer Hospital	Van Gelder, IC (corresponding author), Univ Groningen, Dept Cardiol, Thoraxctr, Univ Med Ctr Groningen, POB 30-001, NL-9700 RB Groningen, Netherlands.	I.C.van.Gelder@thorax.umcg.nl	van Veldhuisen, Dirk Jan/E-8967-2014	Rienstra, Michiel/0000-0002-2581-070X; tuininga, ype/0000-0002-7861-8623				Cairns JA, 1997, LANCET, V349, P675, DOI 10.1016/S0140-6736(96)08171-8; Calkins H, 2007, HEART RHYTHM, V4, P816, DOI 10.1016/j.hrthm.2007.04.005; Cappato R, 2005, CIRCULATION, V111, P1100, DOI 10.1161/01.CIR.0000157153.30978.67; Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2; Connolly SJ, 1999, CIRCULATION, V100, P2025, DOI 10.1161/01.CIR.100.19.2025; Essebag V, 2004, PACE, V27, P1519, DOI 10.1111/j.1540-8159.2004.00670.x; Fuster V, 2006, EUR HEART J, V27, P1979, DOI 10.1093/eurheartj/ehl176; GREENBERG ML, 1987, J AM COLL CARDIOL, V9, P1148, DOI 10.1016/S0735-1097(87)80320-0; GREENE HL, 1989, PROG CARDIOVASC DIS, V31, P319, DOI 10.1016/0033-0620(89)90029-7; Haffajee C.I, 1987, CLIN CARDIOL, V10, P16; Hagens VE, 2005, AM HEART J, V149, P1106, DOI 10.1016/j.ahj.2004.11.030; Hagens VE, 2004, J AM COLL CARDIOL, V43, P241, DOI 10.1016/j.jacc.2003.08.037; Hemels MEW, 2006, J AM COLL CARDIOL, V48, P1001, DOI 10.1016/j.jacc.2006.05.043; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; HOLT DW, 1983, AM HEART J, V106, P840, DOI 10.1016/0002-8703(83)90006-6; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KERIN NZ, 1989, J CLIN PHARMACOL, V29, P418, DOI 10.1002/j.1552-4604.1989.tb03354.x; Lafuente-Lafuente C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005049.pub2; Levy S, 1999, CIRCULATION, V99, P3028, DOI 10.1161/01.CIR.99.23.3028; Roy D, 2000, NEW ENGL J MED, V342, P913, DOI 10.1056/NEJM200003303421302; Singh BN, 2005, NEW ENGL J MED, V352, P1861, DOI 10.1056/NEJMoa041705; Singh SN, 2006, J AM COLL CARDIOL, V48, P721, DOI 10.1016/j.jacc.2006.03.051; Tieleman RG, 1997, AM J CARDIOL, V79, P53, DOI 10.1016/S0002-9149(96)00675-3; TRIP MD, 1991, AM J MED, V91, P507, DOI 10.1016/0002-9343(91)90187-3; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; Vassallo P, 2007, JAMA-J AM MED ASSOC, V298, P1312, DOI 10.1001/jama.298.11.1312; Vorperian VR, 1997, J AM COLL CARDIOL, V30, P791, DOI 10.1016/S0735-1097(97)00220-9; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zimetbaum P, 2007, NEW ENGL J MED, V356, P935, DOI 10.1056/NEJMct065916	30	62	63	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 15	2008	300	15					1784	1792		10.1001/jama.300.15.1784	http://dx.doi.org/10.1001/jama.300.15.1784			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	359QA	18854540				2023-01-03	WOS:000260002000030
J	Wang, JH; Lozier, J; Johnson, G; Kirshner, S; Verthelyi, D; Pariser, A; Shores, E; Rosenberg, A				Wang, Jinhai; Lozier, Jay; Johnson, Gibbes; Kirshner, Susan; Verthelyi, Daniela; Pariser, Anne; Shores, Elizabeth; Rosenberg, Amy			Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment	NATURE BIOTECHNOLOGY			English	Article							ACID ALPHA-GLUCOSIDASE; T-CELL TOLERANCE; FACTOR-VIII INHIBITORS; LONG-TERM ACCEPTANCE; HUMAN GROWTH-HORMONE; SEVERE HEMOPHILIA-A; DISEASE TYPE-II; REPLACEMENT THERAPY; IMMUNE TOLERANCE; FABRY-DISEASE	Lysosomal storage diseases are characterized by deficiencies in lysosomal enzymes, allowing accumulation of target substrate in cells and eventually causing cell death. Enzyme replacement therapy is the principal treatment for most of these diseases. However, these therapies are often complicated by immune responses to the enzymes, blocking efficacy and causing severe adverse outcomes by neutralizing product activity. It is thus crucial to understand the relationships between genetic mutations, endogenous residual enzyme proteins (cross-reactive immunologic material), development of neutralizing antibodies and their impact on clinical outcomes of lysosomal storage diseases. For patients in whom neutralizing antibodies may cause severe adverse clinical outcomes, it is paramount to develop tolerance inducing protocols to preclude, where predictable, or treat such life-threatening responses.	[Wang, Jinhai; Johnson, Gibbes; Kirshner, Susan; Verthelyi, Daniela; Shores, Elizabeth; Rosenberg, Amy] US FDA, Ctr Drug Evaluat & Res, Div Therapeut Proteins, Off Biotechnol Prod, Bethesda, MD 20892 USA; [Lozier, Jay] NIH, Dept Lab Med, Ctr Clin, Bethesda, MD 20892 USA; [Pariser, Anne] US FDA, Ctr Drug Evaluat & Res, Div Gastroenterol Prod, Off New Drugs, Silver Spring, MD 20993 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); US Food & Drug Administration (FDA)	Rosenberg, A (corresponding author), US FDA, Ctr Drug Evaluat & Res, Div Therapeut Proteins, Off Biotechnol Prod, NIH Bldg 29B,8800 Rockville Pike, Bethesda, MD 20892 USA.	amy.rosenberg@fda.hhs.gov			Intramural NIH HHS [Z01 SC003811-33] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC003811] Funding Source: NIH RePORTER; CLINICAL CENTER [Z01CL080015] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CLINICAL CENTER		ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; Ahangari G, 2004, INT J IMMUNOPATH PH, V17, P33, DOI 10.1177/039463200401700105; Amalfitano A, 2001, GENET MED, V3, P132, DOI 10.1097/00125817-200103000-00008; Anandacoomarasamy A, 2006, INTERN MED J, V36, P474, DOI 10.1111/j.1445-5994.2006.01113.x; ANTONARAKIS SE, 1995, BLOOD, V86, P2206, DOI 10.1182/blood.V86.6.2206.bloodjournal8662206; Bearden CM, 2005, AM J TRANSPLANT, V5, P50, DOI 10.1111/j.1600-6143.2003.00646.x; Bennett CL, 2005, BLOOD, V106, P3343, DOI 10.1182/blood-2005-02-0508; Berntorp Erik, 2000, Haematologica, V85, P48; Brackmann HH, 1996, VOX SANG, V70, P30, DOI 10.1111/j.1423-0410.1996.tb01346.x; Brooks DA, 2003, TRENDS MOL MED, V9, P450, DOI 10.1016/j.molmed.2003.08.004; CARDOSO AI, 1993, ACTA ENDOCRINOL-COP, V129, P20, DOI 10.1530/acta.0.1290020; Casadevall N, 2005, J AM SOC NEPHROL, V16, pS67, DOI 10.1681/ASN.2004110959; Chemnitz J, 2002, AM J HEMATOL, V71, P105, DOI 10.1002/ajh.10204; Chentoufi AA, 2002, DIABETES, V51, P1383, DOI 10.2337/diabetes.51.5.1383; Cobbold SP, 2006, IMMUNOL REV, V213, P239, DOI 10.1111/j.1600-065X.2006.00428.x; Cornall RJ, 1998, CIBA F SYMP, V215, P21; Daley SR, 2007, J IMMUNOL, V179, P3648, DOI 10.4049/jimmunol.179.6.3648; Darabi K, 2006, AM J CLIN PATHOL, V125, P592, DOI 10.1309/RLNM-J01W-BJRN-LH03; Desai DD, 2007, J IMMUNOL, V178, P6217, DOI 10.4049/jimmunol.178.10.6217; Ewenstein BM, 1997, BLOOD, V89, P1115, DOI 10.1182/blood.V89.3.1115; FABBRO D, 1987, AM J HUM GENET, V40, P15; Gao W, 2007, AM J TRANSPLANT, V7, P1722, DOI 10.1111/j.1600-6143.2007.01842.x; Garman RD, 2004, CLIN EXP IMMUNOL, V137, P496, DOI 10.1111/j.1365-2249.2004.02567.x; Garman SC, 2002, MOL GENET METAB, V77, P3, DOI 10.1016/S1096-7192(02)00151-8; Germain DP, 2001, MUTAT RES-FUND MOL M, V483, P89, DOI 10.1016/S0027-5107(01)00232-9; Ghosh P, 2003, NAT REV MOL CELL BIO, V4, P202, DOI 10.1038/nrm1050; Goodeve A, 2003, BLOOD COAGUL FIBRIN, V14, pS17, DOI 10.1097/00001721-200306001-00005; Goodeve AC, 2000, THROMB HAEMOSTASIS, V83, P844; Goodnow CC, 2005, NATURE, V435, P590, DOI 10.1038/nature03724; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; HARADA H, 1993, BLOOD, V81, P2658; Haribhai D, 2003, J IMMUNOL, V170, P3007, DOI 10.4049/jimmunol.170.6.3007; Harmatz P, 2006, J PEDIATR-US, V148, P533, DOI 10.1016/j.jpeds.2005.12.014; Haznedaroglu IC, 2002, CLIN APPL THROMB-HEM, V8, P193, DOI 10.1177/107602960200800301; Hermans MMP, 2004, HUM MUTAT, V23, P47, DOI 10.1002/humu.10286; Herndon RM, 2005, MULT SCLER, V11, P409, DOI 10.1191/1352458505ms1209oa; Herve M, 2007, J EXP MED, V204, P1583, DOI 10.1084/jem.20062287; Herzog RW, 2002, HUM GENE THER, V13, P1281, DOI 10.1089/104303402760128513; Horn J, 2007, CLIN IMMUNOL, V122, P156, DOI 10.1016/j.clim.2006.10.002; Huang WH, 2003, TRANSPLANTATION, V75, P368, DOI 10.1097/01.TP.0000044360.20396.AB; Hunley TE, 2004, PEDIATRICS, V114, pE532, DOI 10.1542/peds.2003-0988-L; Joseph A, 2008, CLIN EXP IMMUNOL, V152, P138, DOI 10.1111/j.1365-2249.2008.03602.x; Kakavanos R, 2003, LANCET, V361, P1608, DOI 10.1016/S0140-6736(03)13311-9; Kakkis E, 2004, P NATL ACAD SCI USA, V101, P829, DOI 10.1073/pnas.0305480101; Kang HK, 2005, J IMMUNOL, V174, P3247, DOI 10.4049/jimmunol.174.6.3247; Keystone E, 2007, ARTHRITIS RHEUM-US, V56, P3896, DOI 10.1002/art.23059; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kishnani PS, 2007, NEUROLOGY, V68, P99, DOI 10.1212/01.wnl.0000251268.41188.04; Knobe KE, 2002, ACTA PAEDIATR, V91, P910, DOI 10.1080/080352502760148621; Koren E., 2002, Current Pharmaceutical Biotechnology, V3, P349, DOI 10.2174/1389201023378175; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201; Kuter DJ, 2002, BLOOD, V100, P3457, DOI 10.1182/blood.V100.10.3457; Kyewski B, 2006, ANNU REV IMMUNOL, V24, P571, DOI 10.1146/annurev.immunol.23.021704.115601; Lacroix-Desmazes S, 2002, NEW ENGL J MED, V346, P662, DOI 10.1056/NEJMoa011979; Li JZ, 2001, BLOOD, V98, P3241, DOI 10.1182/blood.V98.12.3241; Linthorst GE, 2004, KIDNEY INT, V66, P1589, DOI 10.1111/j.1523-1755.2004.00924.x; Lozier JN, 2002, P NATL ACAD SCI USA, V99, P12991, DOI 10.1073/pnas.192219599; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; Mire-Sluis AR, 2004, J IMMUNOL METHODS, V289, P1, DOI 10.1016/j.jim.2004.06.002; MONGINI PKA, 1984, J IMMUNOL, V132, P1647; Ohashi PS, 2002, CURR OPIN IMMUNOL, V14, P744, DOI 10.1016/S0952-7915(02)00406-5; Oldenburg J, 2006, HAEMOPHILIA, V12, P15, DOI 10.1111/j.1365-2516.2006.01361.x; PIRCHER H, 1993, EUR J IMMUNOL, V23, P669, DOI 10.1002/eji.1830230315; Reipert BM, 2007, BRIT J HAEMATOL, V136, P12, DOI 10.1111/j.1365-2141.2006.06359.x; Romball CG, 1999, J INTERF CYTOK RES, V19, P671, DOI 10.1089/107999099313820; Rosenberg M, 1999, BLOOD, V93, P2081, DOI 10.1182/blood.V93.6.2081.406k07_2081_2088; Salooja N, 2002, BRIT J HAEMATOL, V118, P839, DOI 10.1046/j.1365-2141.2002.03666.x; Shankar G, 2006, TRENDS BIOTECHNOL, V24, P274, DOI 10.1016/j.tibtech.2006.04.001; Shimada E, 2002, TRANSFUSION, V42, P766, DOI 10.1046/j.1537-2995.2002.00117.x; Siemionow M, 2002, J HAND SURG-AM, V27A, P1095, DOI 10.1053/jhsu.2002.36524; St Clair EW, 2007, ANNU REV MED, V58, P329, DOI 10.1146/annurev.med.58.061705.145449; Sun B, 2007, AM J HUM GENET, V81, P1042, DOI 10.1086/522236; Thorland EC, 1999, HAEMOPHILIA, V5, P101, DOI 10.1046/j.1365-2516.1999.00303.x; Tivol EA, 1997, J IMMUNOL, V158, P5091; Vedder AC, 2006, MOL GENET METAB, V89, P239, DOI 10.1016/j.ymgme.2006.04.013; Vedder AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000598; Waldmann H, 2006, IMMUNOL REV, V212, P301, DOI 10.1111/j.0105-2896.2006.00406.x; Warrier I, 1997, J PEDIAT HEMATOL ONC, V19, P23, DOI 10.1097/00043426-199701000-00003; WEIGLE WO, 1987, CRC CR REV IMMUNOL, V7, P285; Whitmer KJ, 1997, J IMMUNOL, V159, P644; Wilcox WR, 2004, AM J HUM GENET, V75, P65, DOI 10.1086/422366; Winsor-Hines D, 2004, J IMMUNOL, V173, P4715, DOI 10.4049/jimmunol.173.7.4715; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; Withers DR, 2007, BLOOD, V109, P4856, DOI 10.1182/blood-2006-08-043414; Zeiser R, 2006, BLOOD, V108, P390, DOI 10.1182/blood-2006-01-0329; Zhang MF, 2003, J IMMUNOL, V170, P3954, DOI 10.4049/jimmunol.170.8.3954; Zinkernagel RM, 2000, SEMIN IMMUNOL, V12, P163, DOI 10.1006/smim.2000.0253	88	124	140	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	AUG	2008	26	8					901	908		10.1038/nbt.1484	http://dx.doi.org/10.1038/nbt.1484			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	335WX	18688246	Green Accepted			2023-01-03	WOS:000258325500024
J	Konrad, R; Ferry, N; Gatehouse, AMR; Babendreier, D				Konrad, Roger; Ferry, Natalie; Gatehouse, Angharad M. R.; Babendreier, Dirk			Potential Effects of Oilseed Rape Expressing Oryzacystatin-1 (OC-1) and of Purified Insecticidal Proteins on Larvae of the Solitary Bee Osmia bicornis	PLOS ONE			English	Article							BT CORN POLLEN; APIS-MELLIFERA; HONEY-BEES; PROTEASE INHIBITORS; SNOWDROP LECTIN; TRANSGENE PRODUCTS; LIGNARIA HYMENOPTERA; LEARNING-ABILITIES; DIGESTIVE ENZYMES; RISK-ASSESSMENT	Despite their importance as pollinators in crops and wild plants, solitary bees have not previously been included in nontarget testing of insect-resistant transgenic crop plants. Larvae of many solitary bees feed almost exclusively on pollen and thus could be highly exposed to transgene products expressed in the pollen. The potential effects of pollen from oilseed rape expressing the cysteine protease inhibitor oryzacystatin-1 (OC-1) were investigated on larvae of the solitary bee Osmia bicornis (= O. rufa). Furthermore, recombinant OC-1 (rOC-1), the Bt toxin Cry1Ab and the snowdrop lectin Galanthus nivalis agglutinin (GNA) were evaluated for effects on the life history parameters of this important pollinator. Pollen provisions from transgenic OC-1 oilseed rape did not affect overall development. Similarly, high doses of rOC-1 and Cry1Ab as well as a low dose of GNA failed to cause any significant effects. However, a high dose of GNA (0.1%) in the larval diet resulted in significantly increased development time and reduced efficiency in conversion of pollen food into larval body weight. Our results suggest that OC-1 and Cry1Ab expressing transgenic crops would pose a negligible risk for O. bicornis larvae, whereas GNA expressing plants could cause detrimental effects, but only if bees were exposed to high levels of the protein. The described bioassay with bee brood is not only suitable for early tier non-target tests of transgenic plants, but also has broader applicability to other crop protection products.	[Konrad, Roger; Babendreier, Dirk] Agroscope Reckenholz Tanikon Res Stn ART, Zurich, Switzerland; [Ferry, Natalie; Gatehouse, Angharad M. R.] Newcastle Univ, Sch Biol, Inst Res Env & Sustainabil, Newcastle Upon Tyne, Tyne & Wear, England	Swiss Federal Research Station Agroscope; Swiss Federal Research Station for Agroecology & Agriculture; Newcastle University - UK	Konrad, R (corresponding author), Agroscope Reckenholz Tanikon Res Stn ART, Zurich, Switzerland.	roger.konrad@art.admin.ch		Ferry, Natalie/0000-0003-3728-4302; Gatehouse, Angharad/0000-0002-6406-2927	Swiss Office for the Environment (FOEN)	Swiss Office for the Environment (FOEN)	This research was financially supported by the Swiss Office for the Environment (FOEN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABE K, 1987, AGR BIOL CHEM TOKYO, V51, P2763; Abel CA, 2003, J ENTOMOL SCI, V38, P545, DOI 10.18474/0749-8004-38.4.545; Babendreier D, 2004, APIDOLOGIE, V35, P293, DOI 10.1051/apido:2004016; Babendreier D, 2008, ENTOMOL EXP APPL, V126, P148, DOI 10.1111/j.1570-7458.2007.00652.x; Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004; Bell HA, 2004, AGR FOREST ENTOMOL, V6, P215, DOI 10.1111/j.1461-9555.2004.00225.x; BELZUNCES LP, 1994, COMP BIOCHEM PHYS B, V109, P63, DOI 10.1016/0305-0491(94)90142-2; BONADEBOTTINO M, 1993, DEFENCE COLZA INSECT; Bosch J, 2006, J ECON ENTOMOL, V99, P408, DOI 10.1603/0022-0493-99.2.408; Bosch J, 2002, ECOL ENTOMOL, V27, P129, DOI 10.1046/j.1365-2311.2002.00406.x; Bosch J, 2004, APIDOLOGIE, V35, P469, DOI 10.1051/apido:2004035; BOSCH J, BEE POLLINA IN PRESS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodsgaard HF, 2003, APIDOLOGIE, V34, P139, DOI 10.1051/apido:2003003; Burgess EPJ, 1996, J INSECT PHYSIOL, V42, P823, DOI 10.1016/0022-1910(96)00045-5; Christou P, 2006, TRENDS PLANT SCI, V11, P302, DOI 10.1016/j.tplants.2006.04.001; CORBET SA, 1991, BEE WORLD, V72, P47, DOI 10.1080/0005772X.1991.11099079; Cox D.R., 1990, ANAL SURVIVAL DATA; Down RE, 1996, J INSECT PHYSIOL, V42, P1035, DOI 10.1016/S0022-1910(96)00065-0; Duan JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001415; Fearing PL, 1997, MOL BREEDING, V3, P169, DOI 10.1023/A:1009611613475; Ferry N, 2006, TRANSGENIC RES, V15, P13, DOI 10.1007/s11248-005-4803-x; Ferry N, 2003, MOL ECOL, V12, P493, DOI 10.1046/j.1365-294X.2003.01736.x; FREE J. B., 1955, INSECTES SOCIAUX, V2, P195, DOI 10.1007/BF02224381; Gatehouse AMR, 1997, MOL BREEDING, V3, P49, DOI 10.1023/A:1009600321838; Gathmann A, 2002, J ANIM ECOL, V71, P757, DOI 10.1046/j.1365-2656.2002.00641.x; Girard C, 1998, TRANSGENIC RES, V7, P239, DOI 10.1023/A:1008813910751; Greenleaf SS, 2006, P NATL ACAD SCI USA, V103, P13890, DOI 10.1073/pnas.0600929103; Hanley AV, 2003, J APICULT RES, V42, P77, DOI 10.1080/00218839.2003.11101097; HILDER VA, 1995, TRANSGENIC RES, V4, P18, DOI 10.1007/BF01976497; Hogervorst PAM, 2006, J INSECT PHYSIOL, V52, P614, DOI 10.1016/j.jinsphys.2006.02.011; HOGERVORST PAM, 2008, AGR ENTOMOL IN PRESS; HOLM S, 1979, SCAND J STAT, V6, P65; JAMES C, 2007, ISAAA BRIEF; JOUANIN L, 2000, RECOMBINANT PROTEASE, P179; Klein AM, 2007, P ROY SOC B-BIOL SCI, V274, P303, DOI 10.1098/rspb.2006.3721; LEACH ML, 1994, J ECON ENTOMOL, V87, P311, DOI 10.1093/jee/87.2.311; Lehrman Anna, 2007, Environmental Biosafety Research, V6, P271, DOI 10.1051/ebr:2007039; MALONE LA, 1995, J ECON ENTOMOL, V88, P46, DOI 10.1093/jee/88.1.46; Malone LA, 2002, APIDOLOGIE, V33, P447, DOI 10.1051/apido:2002030; Malone LA, 2001, APIDOLOGIE, V32, P287, DOI 10.1051/apido:2001130; Malone LA, 2000, APIDOLOGIE, V31, P25, DOI 10.1051/apido:2000104; Malone LA, 1998, J INSECT PHYSIOL, V44, P141, DOI 10.1016/S0022-1910(97)00096-6; McGregor S. E., 1976, Agriculture Handbook, United States Department of Agriculture; Morandin LA, 2003, ENVIRON ENTOMOL, V32, P555, DOI 10.1603/0046-225X-32.3.555; MORITZ B, 1987, J INSECT PHYSIOL, V33, P923, DOI 10.1016/0022-1910(87)90004-7; O'Toole Christopher, 1993, P169; Pham-Delegue MH, 2000, ENTOMOL EXP APPL, V95, P21, DOI 10.1023/A:1003923309473; RAW A, 1972, T ROY ENT SOC LONDON, V124, P213; RAW A, 1974, OIKOS, V25, P54, DOI 10.2307/3543545; Romeis J, 2003, OECOLOGIA, V134, P528, DOI 10.1007/s00442-002-1144-9; Rose R, 2007, APIDOLOGIE, V38, P368, DOI 10.1051/apido:2007022; Roshchina VV., 1993, EXCRETORY FUNCTION H, DOI [10.1007/978-3-642-78130-8, DOI 10.1007/978-3-642-78130-8]; Roulston TH, 2000, ECOL MONOGR, V70, P617, DOI 10.1890/0012-9615(2000)070[0617:WGPCOP]2.0.CO;2; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; Sick Martina, 2004, Mitteilungen der Deutschen Gesellschaft fuer Allgemeine und Angewandte Entomologie, V14, P423; TASEI JN, 1988, APIDOLOGIE, V19, P291, DOI 10.1051/apido:19880308; Tasei JN, 2002, HONEY BEES: ESTIMATING THE ENVIRONMENTAL IMPACT OF CHEMICALS, P101, DOI 10.1201/9780203218655.ch7; Tesoriero Donato, 2003, Bulletin of Insectology, V56, P169; Thompson HM, 1999, ECOTOXICOLOGY, V8, P147, DOI 10.1023/A:1026444029579; VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1; Wcislo WT, 1996, ANNU REV ENTOMOL, V41, P257, DOI 10.1146/annurev.en.41.010196.001353; Westcott L, 2001, BEE WORLD, V82, P115, DOI 10.1080/0005772X.2001.11099514; Westerkamp C, 2000, CROP SCI, V40, P1209, DOI 10.2135/cropsci2000.4051209x; Westrich P., 1989, WILDBIENEN BADEN WUR; Wilkaniec Z, 2003, J APICULT RES, V42, P29, DOI 10.1080/00218839.2003.11101084; Winfree R, 2007, ECOL LETT, V10, P1105, DOI 10.1111/j.1461-0248.2007.01110.x	67	33	33	2	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2008	3	7							e2664	10.1371/journal.pone.0002664	http://dx.doi.org/10.1371/journal.pone.0002664			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	417DX	18628826	Green Published, Green Accepted, gold			2023-01-03	WOS:000264057200010
J	Steinbrook, R				Steinbrook, Robert			The (slowly) vanishing prescription pad	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						Fischer MA, 2007, DRUG SAFETY, V30, P461, DOI 10.2165/00002018-200730060-00001; Grossman JM, 2007, HEALTH AFFAIR, V26, pW393, DOI 10.1377/hlthaff.26.3.w393; Institute of Medicine, 2007, PREV MED ERR; *SURESCRIPTS, 2007, NAT PROGR REP E PRES	4	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2008	359	2					115	117		10.1056/NEJMp0802864	http://dx.doi.org/10.1056/NEJMp0802864			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323PJ	18614780				2023-01-03	WOS:000257459000002
J	Gueugniaud, PY; David, JS; Chanzy, E; Hubert, H; Dubien, PY; Mauriaucourt, P; Braganca, C; Billeres, X; Clotteau-Lambert, MP; Fuster, P; Thiercelin, D; Debaty, G; Ricard-Hibon, A; Roux, P; Espesson, C; Querellou, E; Ducros, L; Ecollan, P; Halbout, L; Savary, D; Guillaumee, F; Maupoint, R; Capelle, P; Bracq, C; Dreyfus, P; Nouguier, P; Gache, A; Meurisse, C; Boulanger, B; Lae, C; Metzger, J; Raphael, V; Beruben, A; Wenzel, V; Guinhouya, C; Vilhelm, C; Marret, E				Gueugniaud, Pierre-Yves; David, Jean-Stephane; Chanzy, Eric; Hubert, Herve; Dubien, Pierre-Yves; Mauriaucourt, Patrick; Braganca, Coralie; Billeres, Xavier; Clotteau-Lambert, Marie-Paule; Fuster, Patrick; Thiercelin, Didier; Debaty, Guillaume; Ricard-Hibon, Agnes; Roux, Patrick; Espesson, Catherine; Querellou, Emgan; Ducros, Laurent; Ecollan, Patrick; Halbout, Laurent; Savary, Dominique; Guillaumee, Frederic; Maupoint, Regine; Capelle, Philippe; Bracq, Cecile; Dreyfus, Philippe; Nouguier, Philippe; Gache, Antoine; Meurisse, Claude; Boulanger, Bertrand; Lae, Claude; Metzger, Jacques; Raphael, Valerie; Beruben, Arielle; Wenzel, Volker; Guinhouya, Comlavi; Vilhelm, Christian; Marret, Emmanuel			Vasopressin and epinephrine vs. epinephrine alone in cardiopulmonary resuscitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; GUIDELINES; PRESSURE	Background: During the administration of advanced cardiac life support for resuscitation from cardiac arrest, a combination of vasopressin and epinephrine may be more effective than epinephrine or vasopressin alone, but evidence is insufficient to make clinical recommendations. Methods: In a multicenter study, we randomly assigned adults with out-of-hospital cardiac arrest to receive successive injections of either 1 mg of epinephrine and 40 IU of vasopressin or 1 mg of epinephrine and saline placebo, followed by administration of the same combination of study drugs if spontaneous circulation was not restored and subsequently by additional epinephrine if needed. The primary end point was survival to hospital admission; the secondary end points were return of spontaneous circulation, survival to hospital discharge, good neurologic recovery, and 1-year survival. Results: A total of 1442 patients were assigned to receive a combination of epinephrine and vasopressin, and 1452 to receive epinephrine alone. The treatment groups had similar baseline characteristics except that there were more men in the group receiving combination therapy than in the group receiving epinephrine alone (P=0.03). There were no significant differences between the combination-therapy and the epinephrine-only groups in survival to hospital admission (20.7% vs. 21.3%; relative risk of death, 1.01; 95% confidence interval [CI], 0.97 to 1.05), return of spontaneous circulation (28.6% vs. 29.5%; relative risk, 1.01; 95% CI, 0.97 to 1.06), survival to hospital discharge (1.7% vs. 2.3%; relative risk, 1.01; 95% CI, 1.00 to 1.02), 1-year survival (1.3% vs. 2.1%; relative risk, 1.01; 95% CI, 1.00 to 1.02), or good neurologic recovery at hospital discharge (37.5% vs. 51.5%; relative risk, 1.29; 95% CI, 0.81 to 2.06). Conclusions: As compared with epinephrine alone, the combination of vasopressin and epinephrine during advanced cardiac life support for out-of-hospital cardiac arrest does not improve outcome. (ClinicalTrials.gov number, NCT00127907.).	[Gueugniaud, Pierre-Yves; David, Jean-Stephane] Univ Lyon 1, Hospices Civils Lyon, SAMU 69, F-69365 Lyon, France; [Chanzy, Eric] SAMU 93, Bobigny, France; [Hubert, Herve; Guinhouya, Comlavi; Vilhelm, Christian] Univ Lille, Hlth Engn Inst, Lille, France; [Dubien, Pierre-Yves] Hop Edouard Herriot, SMUR, Lyon, France; [Mauriaucourt, Patrick] SAMU 59, Lille, France; [Braganca, Coralie] SAMU 33, Bordeaux, France; [Billeres, Xavier] Bataillon Marins Pompiers, Marseille, France; [Clotteau-Lambert, Marie-Paule] SAMU 44, Nantes, France; [Fuster, Patrick] CHU Lyon Sud, SMUR, Lyon, France; [Thiercelin, Didier] SAMU 06, Nice, France; [Debaty, Guillaume] SAMU 38, Grenoble, France; [Ricard-Hibon, Agnes] Hop Beaujon, SMUR, Beaujon, France; [Roux, Patrick] SAMU 31, Toulouse, France; [Espesson, Catherine] SAMU 42, St Etienne, France; [Querellou, Emgan] SAMU 29, Brest, France; [Ducros, Laurent] CHU Lariboisiere, SMUR, Paris, France; [Ecollan, Patrick] CHU Pitie Salpetriere, SMUR, Paris, France; [Halbout, Laurent] SAMU 14, Caen, France; [Savary, Dominique] SAMU 74, Annecy, France; [Guillaumee, Frederic] Hop Croix Rousse, SMUR, F-69317 Lyon, France; [Maupoint, Regine] SAMU 01, Bourg en Bresse, France; [Capelle, Philippe] Maubeuge Hosp, SMUR, Maubeuge, France; [Bracq, Cecile] Dunkerque Hosp, SMUR, Dunkerque, France; [Dreyfus, Philippe] SAMU 21, Dijon, France; [Nouguier, Philippe] SAMU 13, Marseille, France; [Gache, Antoine] SAMU 30, Nimes, France; [Meurisse, Claude] Valenciennes Hosp, SMUR, Valenciennes, France; [Boulanger, Bertrand] SAMU 56, Vannes, France; [Lae, Claude] Annemasse Hosp, SMUR, Annemasse, France; [Metzger, Jacques] St Denis Hosp, SMUR, St Denis, France; [Raphael, Valerie] Aulnay Hosp, SMUR, Aulnay Sous Bois, France; [Beruben, Arielle] Montfermeil Hosp, SMUR, Montfermeil, France; [Marret, Emmanuel] Hop Tenon, F-75970 Paris, France; [Wenzel, Volker] Innsbruck Med Univ, Innsbruck, Austria	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite de Lille - ISITE; Universite de Lille; CHU Lyon; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; CH de Valenciennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Medical University of Innsbruck	Gueugniaud, PY (corresponding author), CHU Lyon Sud, Pole Urgence, Dept Anesthesiol & Crit Care Med, F-69495 Lyon, France.	pierre-yves.gueugniaud@chu-lyon.fr	Hubert, Herve/A-8520-2012; David, Jean Stephane/H-9399-2019; Debaty, Guillaume/M-2810-2013	Hubert, Herve/0000-0003-2944-7597; David, Jean Stephane/0000-0001-6274-7044; Debaty, Guillaume/0000-0003-2879-0326				ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; Adnet F, 2004, RESUSCITATION, V63, P7, DOI 10.1016/j.resuscitation.2004.04.001; Aung K, 2005, ARCH INTERN MED, V165, P17, DOI 10.1001/archinte.165.1.17; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; Bunch TJ, 2003, NEW ENGL J MED, V348, P2626, DOI 10.1056/NEJMoa023053; Callaway CW, 2006, AM J CARDIOL, V98, P1316, DOI 10.1016/j.amjcard.2006.06.022; Cobb LA, 2002, JAMA-J AM MED ASSOC, V288, P3008, DOI 10.1001/jama.288.23.3008; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; European Resuscitation Council, 2000, RESUSCITATION, V46, P3; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Holzer M, 2002, NEW ENGL J MED, V346, P549; International Liaison Committee on R, 2005, RESUSCITATION, V67, P213; LINDNER KH, 1992, ANESTHESIOLOGY, V77, P662, DOI 10.1097/00000542-199210000-00008; LINDNER KH, 1995, CIRCULATION, V91, P215, DOI 10.1161/01.CIR.91.1.215; Mally S, 2007, CRIT CARE, V11, DOI 10.1186/cc5726; Mayr VD, 2001, CIRCULATION, V104, P1651, DOI 10.1161/hc3901.095896; Popp E, 2007, RESUSCITATION, V72, P137, DOI 10.1016/j.resuscitation.2006.05.015; Prengel AW, 1996, STROKE, V27, P1241, DOI 10.1161/01.STR.27.7.1241; Sanders AB, 2005, JAMA-J AM MED ASSOC, V293, P363, DOI 10.1001/jama.293.3.363; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Wenzel V, 2000, J AM COLL CARDIOL, V35, P527, DOI 10.1016/S0735-1097(99)00562-8; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Wenzel V, 1999, CIRCULATION, V99, P1379, DOI 10.1161/01.CIR.99.10.1379	26	198	209	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2008	359	1					21	30		10.1056/NEJMoa0706873	http://dx.doi.org/10.1056/NEJMoa0706873			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320PB	18596271				2023-01-03	WOS:000257246000004
J	Polderman, KH				Polderman, Kees H.			Induced hypothermia and fever control for prevention and treatment of neurological injuries	LANCET			English	Review							TRAUMATIC BRAIN-INJURY; HOSPITAL CARDIAC-ARREST; MILD SYSTEMIC HYPOTHERMIA; WHOLE-BODY HYPOTHERMIA; PROMISING TREATMENT MODALITY; FOCAL CEREBRAL-ISCHEMIA; INTENSIVE-CARE-UNIT; SPINAL-CORD-INJURY; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA	Increasing evidence suggests that induction of mild hypothermia (32-35 degrees C) in the first hours after an ischaemic event can prevent or mitigate permanent injuries. This effect has been shown most clearly for postanoxic brain injury; but could also apply to other organs such as the heart and kidneys. Hypothermia has also been used as a treatment for traumatic brain injury, stroke, hepatic encephalopathy, myocardial infarction, and other indications. Hypothermia is a highly promising treatment in neurocritical care; thus, physicians caring for patients with neurological injuries, both in and outside the intensive care unit, are likely to be confronted with questions about temperature management more frequently. This Review discusses the available evidence for use of controlled hypothermia, and also deals with fever control. Besides discussing the evidence, the aim is to provide information to help guide treatments more effectively with regard to timing, depth, duration, and effective management of side-effects. In particular, the rate of rewarming seems to be an important factor in establishing successful use of hypothermia in the treatment of neurological injuries.	[Polderman, Kees H.] Univ Med Ctr Utrecht, Dept Intens Care, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Polderman, KH (corresponding author), Univ Med Ctr Utrecht, Dept Intens Care, POB 85500, NL-3508 GA Utrecht, Netherlands.	k.polderman@tip.nl	Polderman, Kees H/K-3623-2012					Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Al-Senani FM, 2004, RESUSCITATION, V62, P143, DOI 10.1016/j.resuscitation.2004.02.016; Alam HB, 2006, J TRAUMA, V60, P134, DOI 10.1097/01.ta.0000198469.95292.ec; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; ALLEN BT, 1994, J VASC SURG, V19, P332, DOI 10.1016/S0741-5214(94)70108-3; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS21; ANDERSON S, 2006, STROKE, V37, P163; Anderson SW, 2006, ANN NEUROL, V60, P518, DOI 10.1002/ana.21018; Auer RN, 2001, ANN NY ACAD SCI, V939, P271; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; BASH SE, 1987, J AM COLL CARDIOL, V10, P1095, DOI 10.1016/S0735-1097(87)80351-0; Battin MR, 2003, PEDIATRICS, V111, P244, DOI 10.1542/peds.111.2.244; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Belliard G, 2007, RESUSCITATION, V75, P252, DOI 10.1016/j.resuscitation.2007.04.014; BENSON D W, 1959, Anesth Analg, V38, P423; BERGER R, 1994, CHEST, V106, P872, DOI 10.1378/chest.106.3.872; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard S., 1998, EMERG MED AUSTRALAS, V10, P25; Bernard SA, 1997, ANN EMERG MED, V30, P146, DOI 10.1016/S0196-0644(97)70133-1; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625; Bissonnette B, 2000, ANESTHESIOLOGY, V93, P611, DOI 10.1097/00000542-200009000-00008; Boodhwani M, 2007, J THORAC CARDIOV SUR, V134, P1443, DOI 10.1016/j.jtcvs.2007.08.016; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Busch M, 2006, ACTA ANAESTH SCAND, V50, P1277, DOI 10.1111/j.1399-6576.2006.01147.x; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Cambria RP, 1997, J VASC SURG, V25, P234, DOI 10.1016/S0741-5214(97)70365-3; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Conrad MF, 2007, ANN THORAC SURG, V83, pS856, DOI 10.1016/j.athoracsur.2006.10.096; *COOL MI 2, COOL ADJ THER PERC I; *COOL RCN, COOL PREV RAD NEPHR; Dae MW, 2002, AM J PHYSIOL-HEART C, V282, pH1584, DOI 10.1152/ajpheart.00980.2001; Dalrymple-Hay MJR, 1999, EUR J CARDIO-THORAC, V15, P515, DOI 10.1016/S1010-7940(99)00074-3; Deakin CD, 1998, ANAESTHESIA, V53, P848, DOI 10.1046/j.1365-2044.1998.00563.x; Debillon T, 2003, DEV MED CHILD NEUROL, V45, P17, DOI 10.1017/S0012162203000045; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Diringer MN, 2004, CRIT CARE MED, V32, P1611; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; EDGREN E, 1994, LANCET, V343, P1055, DOI 10.1016/S0140-6736(94)90179-1; Edwards P, 2005, LANCET, V365, P1957; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; FAY T, 1943, ASS RES NERV MENT DI, V24, P611; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Felberg RA, 2001, CIRCULATION, V104, P1799, DOI 10.1161/hc4001.097037; FLACHS J, 1977, LANCET, V1, P489; FRANK SM, 1994, J VASC SURG, V19, P687, DOI 10.1016/S0741-5214(94)70043-5; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Grigore AM, 2001, ANESTHESIOLOGY, V95, P1110, DOI 10.1097/00000542-200111000-00014; Grocott HP, 2002, STROKE, V33, P537, DOI 10.1161/hs0202.102600; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hale SL, 2003, J AM COLL CARDIOL, V41, p381A; Hale SL, 1997, AM J PHYSIOL-HEART C, V273, pH220, DOI 10.1152/ajpheart.1997.273.1.H220; Hale SL, 1997, BASIC RES CARDIOL, V92, P351, DOI 10.1007/BF00788947; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Hartemink KJ, 2004, CRIT CARE, V8, pR343, DOI 10.1186/cc2928; Hayashi N., 2004, BRAIN HYPOTHERMIA TR; Hayashi S, 2002, ACT NEUR S, V81, P83; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Hickey RW, 2003, CRIT CARE MED, V31, P531, DOI 10.1097/01.CCM.0000050323.84293.11; Hildebrand F, 2005, CYTOKINE, V31, P382, DOI 10.1016/j.cyto.2005.06.008; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2002, NEW ENGL J MED, V346, P549; HORVATH SM, 1953, SCIENCE, V118, P100, DOI 10.1126/science.118.3056.100; Isaka M, 2006, J VASC SURG, V43, P1257, DOI 10.1016/j.jvs.2006.02.017; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jalan R, 2003, TRANSPLANTATION, V75, P2034, DOI 10.1097/01.TP.0000066240.42113.FF; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Karkar KM, 2002, EPILEPSIA, V43, P932, DOI 10.1046/j.1528-1157.2002.03902.x; Kawahara F, 2003, ACTA ANAESTH SCAND, V47, P419, DOI 10.1034/j.1399-6576.2003.00063.x; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Liu YQ, 2004, STROKE, V35, P1460, DOI 10.1161/01.STR.0000128029.50221.fa; Maeda T, 1999, BRAIN RES, V818, P228, DOI 10.1016/S0006-8993(98)01269-4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARTIN TD, 1994, ANN THORAC SURG, V57, P298, DOI 10.1016/0003-4975(94)90987-3; Matsumoto M, 1997, ANESTHESIOLOGY, V86, P1120, DOI 10.1097/00000542-199705000-00016; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mayer S., 2005, THERAPEUTIC HYPOTHER; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MELLERGARD P, 1991, NEUROSURGERY, V28, P709, DOI 10.1227/00006123-199105000-00012; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MOAT NE, 1992, EUR J CARDIO-THORAC, V6, P579, DOI 10.1016/1010-7940(92)90130-P; Mora CT, 1996, J THORAC CARDIOV SUR, V112, P514, DOI 10.1016/S0022-5223(96)70280-5; Mori K, 2000, CRIT CARE MED, V28, pA168; Moriyama Y, 1996, ANGIOLOGY, V47, P595, DOI 10.1177/000331979604700608; Munakata M, 2000, BRAIN DEV-JPN, V22, P373, DOI 10.1016/S0387-7604(00)00169-8; Nagao K, 2000, J AM COLL CARDIOL, V36, P776, DOI 10.1016/S0735-1097(00)00779-8; Nagao S, 2003, J CLIN NEUROSCI, V10, P208, DOI 10.1016/S0967-5868(02)00322-3; Nagao S, 2000, ACT NEUR S, V76, P547; NASLUND TC, 1992, ANN SURG, V215, P409, DOI 10.1097/00000658-199205000-00002; Nathan HJ, 2001, CIRCULATION, V104, pI85; Nathan HJ, 2007, J THORAC CARDIOV SUR, V133, P1206, DOI 10.1016/j.jtcvs.2006.09.112; NAYLOR CD, 1994, LANCET, V343, P559; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Nybo L, 2002, J PHYSIOL-LONDON, V545, P697, DOI 10.1113/jphysiol.2002.030023; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; OKU K, 1994, RESUSCITATION, V27, P141, DOI 10.1016/0300-9572(94)90007-8; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Otake H, 2007, J AM COLL CARDIOL, V49, P250, DOI 10.1016/j.jacc.2006.06.080; Park CK, 1998, ACT NEUR S, V71, P225; PFAMMATTER JP, 1995, ANN THORAC SURG, V60, P556, DOI 10.1016/0003-4975(95)00425-K; Piepgras A, 2001, NEUROSURGERY, V48, P1128, DOI 10.1097/00006123-200105000-00033; Plourde G, 1997, J THORAC CARDIOV SUR, V114, P123, DOI 10.1016/S0022-5223(97)70125-9; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2003, CIRCULATION, V108, P581; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polderman KH, 2001, J NEUROSURG, V94, P853; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; POLDERMAN KH, 2007, CARDIAC ARREST SCI P, P859; POLDERMAN KH, 2003, INTENS CARE MED, V29, P1637; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Samra SK, 2007, STROKE, V38, P1864, DOI 10.1161/STROKEAHA.106.477448; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Simbruner G, 1999, INTENS CARE MED, V25, P1111, DOI 10.1007/s001340051020; Small DL, 1999, PROG CARDIOVASC DIS, V42, P185, DOI 10.1016/S0033-0620(99)70002-2; SMITH PLC, 1995, ANN THORAC SURG, V59, P1359, DOI 10.1016/0003-4975(95)00104-S; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Stone GW, 2006, CIRCULATION, V114, P811; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; Svensson LG, 1998, ANN THORAC SURG, V66, P132, DOI 10.1016/S0003-4975(98)00359-2; Takata T, 1999, J NEUROL SCI, V165, P94, DOI 10.1016/S0022-510X(99)00089-1; TAKINO M, 1991, INTENS CARE MED, V17, P419, DOI 10.1007/BF01720680; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Thoresen M, 2000, PEDIATRICS, V106, P92, DOI 10.1542/peds.106.1.92; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; VERLOOY J, 1995, ACTA NEUROCHIR, V134, P76, DOI 10.1007/BF01428508; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; WILLIAMS GR, 1958, ANN SURG, V148, P462, DOI 10.1097/00000658-195809000-00014; Yahagi N, 1998, J CLIN ANESTH, V10, P120, DOI 10.1016/S0952-8180(97)00255-9; Yan Y, 2001, Chin J Traumatol, V4, P8; Yanagawa Y, 1998, RESUSCITATION, V39, P61, DOI 10.1016/S0300-9572(98)00118-X; Zausinger S, 2003, STROKE, V34, P2246, DOI 10.1161/01.STR.0000083622.65684.21; Zeiner A, 2000, STROKE, V31, P86, DOI 10.1161/01.STR.31.1.86; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	180	421	464	1	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 7	2008	371	9628					1955	1969		10.1016/S0140-6736(08)60837-5	http://dx.doi.org/10.1016/S0140-6736(08)60837-5			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539227				2023-01-03	WOS:000256538500032
J	Stevenson, DG				Stevenson, David G.			Planning for the future - Long-term care and the 2008 election	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Stevenson, DG (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							[Anonymous], 2007, LONG TERM CARE FINAN; Grabowski DC, 2007, MILBANK Q, V85, P579, DOI 10.1111/j.1468-0009.2007.00502.x; National Commission for Quality Long-Term Care, 2007, IS INT REC IMPR QUAL; VLADECK BC, 1980, 20 CENTURY FUND UNLO; Wiener JM, 2001, MILBANK Q, V79, P207, DOI 10.1111/1468-0009.00204	5	9	9	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 8	2008	358	19					1985	1987		10.1056/NEJMp0802347	http://dx.doi.org/10.1056/NEJMp0802347			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296WY	18463373				2023-01-03	WOS:000255577700001
J	Markowitz, AJ; Rabow, MW				Markowitz, Amy J.; Rabow, Michael W.			Management of intractable nausea and vomiting in patients at the end of life - "I was feeling nauseous all of the time ... nothing was working"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Wood GJ, 2007, JAMA-J AM MED ASSOC, V298, P1196, DOI 10.1001/jama.298.10.1196	1	2	2	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1826	1826		10.1001/jama.299.15.1826	http://dx.doi.org/10.1001/jama.299.15.1826			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413877				2023-01-03	WOS:000254954800027
J	Raoof, M; Nawaz, H; Nusrat, R; Pabaney, AH; Randhawa, AR; Rehman, R; Rizvi, NB; Naqvi, H				Raoof, Mustafa; Nawaz, Haq; Nusrat, Rabeeya; Pabaney, Aqueel Hussain; Randhawa, Ali Raza; Rehman, Rabeea; Rizvi, Nida Butool; Naqvi, Haider			Awareness and Use of Benzodiazepines in Healthy Volunteers and Ambulatory Patients Visiting a Tertiary Care Hospital: A Cross Sectional Survey	PLOS ONE			English	Article							GENERAL-POPULATION; PREVALENCE; PRESCRIPTION; ISSUES; BRAZIL; TERM	Background: Indiscriminate prescription of Benzodiazepines in Pakistan and subsequent availability over-the-counter without prescription is a major public health problem, requiring systematic inquiry through research. Additionally, there is limited data on the awareness and use of Benzodiazepines from developing countries making it impossible to devise meaningful health policies. Methodology/Principal Findings: This was an Observational, Cross-Sectional study. conducted at Aga Khan University. A total of 475 (58.5% males, 41.5% females) people visiting a tertiary care hospital were interviewed by means of a structured questionnaire. The results showed that majority of population was aware of one or more Benzodiazepines (80.4%) and 30.4% had used them at some point in life. 42.4% of the users had been using it for more than a year. Commonest reason for use was sleep disturbance. Frequency of usage was higher for females, married individuals, educated (>Grade12), high socioeconomic status and housewives. More (59%) were prescribed than not and of them most by GP (58.5%). Only 36.5% of them were particularly told about the long-term addiction potential by the use of these drugs. Conclusion: Easy availability, access to re-fills without prescription and self prescription compounded with the lack of understanding of abuse potential of benzodiazepines constitutes a significant problem demanding serious consideration from health policy makers.	[Raoof, Mustafa; Nawaz, Haq; Nusrat, Rabeeya; Pabaney, Aqueel Hussain; Randhawa, Ali Raza; Rehman, Rabeea; Rizvi, Nida Butool] Aga Khan Univ, Coll Med, Karachi, Pakistan; [Naqvi, Haider] Aga Khan Univ, Med Coll, Dept Psychiat, Karachi, Pakistan	Aga Khan University; Aga Khan University	Raoof, M (corresponding author), Aga Khan Univ, Coll Med, Karachi, Pakistan.	mustafaraoof@yahoo.com	Raoof, Mustafa/D-1664-2012					Ahmad K, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-51; Ali B S, 2002, J Pak Med Assoc, V52, P513; de las Cuevas C, 2004, MED SCI MONITOR, V10, pCR288; FUENTEALBA R, 2000, REV PANAM SALUD PUBL, V7, P79; Galduroz JCF, 2005, ADDICT BEHAV, V30, P545, DOI 10.1016/j.addbeh.2004.08.004; Huang BJ, 2006, J CLIN PSYCHIAT, V67, P1062, DOI 10.4088/JCP.v67n0708; Kapczinski F, 2001, SUBST USE MISUSE, V36, P1053, DOI 10.1081/JA-100104489; Khan M M, 1998, J Pak Med Assoc, V48, P293; Khawaja Muhammad Rizwamillah, 2005, JPMA Journal of the Pakistan Medical Association, V55, P259; LADER M, 1984, CURR MED RES OPIN, V8, P120, DOI 10.1185/03007998409109550; LADER M, 1984, PROG NEURO-PSYCHOPH, V8, P85, DOI 10.1016/0278-5846(84)90139-8; LYNDON RW, 1988, AUST NZ J PSYCHIAT, V22, P293, DOI 10.3109/00048678809161210; Magrini N, 1996, EUR J CLIN PHARMACOL, V50, P19, DOI 10.1007/s002280050063; Neutel C Ineke, 2003, Can J Clin Pharmacol, V10, P202; Neutel CI, 2005, INT REV PSYCHIATR, V17, P189, DOI 10.1080/09540260500071863; Ohayon MM, 2002, J CLIN PSYCHIAT, V63, P817, DOI 10.4088/JCP.v63n0912; ROTH T, 1992, J CLIN PSYCHIAT, V53, P14; SWARTZ M, 1991, AM J PUBLIC HEALTH, V81, P592, DOI 10.2105/AJPH.81.5.592; Uchibayashi M, 2007, YAKUGAKU ZASSHI, V127, P217, DOI 10.1248/yakushi.127.217; VOGEL G, 1992, J CLIN PSYCHIAT, V53, P19	20	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 19	2008	3	3							e1804	10.1371/journal.pone.0001804	http://dx.doi.org/10.1371/journal.pone.0001804			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370KY	18350143	gold, Green Published, Green Submitted			2023-01-03	WOS:000260762300009
J	Calverley, PMA				Calverley, P. M. A.			Leaving invasive ventilation behind	LANCET			English	Editorial Material							POSITIVE-PRESSURE VENTILATION; OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; NONINVASIVE VENTILATION; RESPIRATORY-FAILURE; EXACERBATIONS; METAANALYSIS; EXTUBATION; EDEMA		Aintree Univ Hosp NHS Fdn Trust, Sch Clin Sci, Liverpool L9 7AL, Merseyside, England	Aintree University Hospitals NHS Foundation Trust; University of Liverpool	Calverley, PMA (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Sch Clin Sci, Liverpool L9 7AL, Merseyside, England.	pmacal@liverpool.ac.uk						Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Elliott MW, 2005, BRIT MED BULL, V72, P83, DOI 10.1093/bmb/ldh042; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Ferrer M, 2006, AM J RESP CRIT CARE, V173, P164, DOI 10.1164/rccm.200505-718OC; Ferrer M, 2009, LANCET, V374, P1082, DOI 10.1016/S0140-6736(09)61038-2; Gray A, 2008, NEW ENGL J MED, V359, P142, DOI 10.1056/NEJMoa0707992; Keenan SP, 2002, JAMA-J AM MED ASSOC, V287, P3238, DOI 10.1001/jama.287.24.3238; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; Peter JV, 2006, LANCET, V367, P1155, DOI 10.1016/S0140-6736(06)68506-1; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Vital FM, 2008, COCHRANE DB SYST REV, V3; Wildman MJ, 2007, BRIT MED J, V335, P1132, DOI 10.1136/bmj.39371.524271.55	13	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2009	374	9695					1044	1045		10.1016/S0140-6736(09)61462-8	http://dx.doi.org/10.1016/S0140-6736(09)61462-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501HA	19682736				2023-01-03	WOS:000270370900007
J	Planel, E; Bretteville, A; Liu, L; Virag, L; Du, AL; Yu, WH; Dickson, DW; Whittington, RA; Duff, KE				Planel, Emmanuel; Bretteville, Alexis; Liu, Li; Virag, Laszlo; Du, Angela L.; Yu, Wai Haung; Dickson, Dennis W.; Whittington, Robert A.; Duff, Karen E.			Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia	FASEB JOURNAL			English	Article						Alzheimer's disease; hypothermia; tau hyperphosphorylation; microtubules	GLYCOGEN-SYNTHASE KINASE-3-BETA; PAIRED HELICAL FILAMENTS; PROTEIN PHOSPHATASE 2A; ALZHEIMERS-DISEASE; TAU-PROTEIN; IN-VIVO; STABLE MICROTUBULES; P301L TAU; PHOSPHORYLATION; KINASE	Alzheimer's disease and other tauopathies are characterized by the presence of intracellular neurofibrillary tangles composed of hyperphosphorylated, insoluble tau. General anesthesia has been shown to be associated with increased risk of Alzheimer's disease, and we have previously demonstrated that anesthesia induces hypothermia, which leads to overt tau hyperphosphorylation in the brain of mice regardless of the anesthetic used. To investigate whether anesthesia enhances the long-term risk of developing pathological forms of tau, we exposed a mouse model with tauopathy to anesthesia and monitored the outcome at two time points-during anesthesia, or 1 wk after exposure. We found that exposure to isoflurane at clinically relevant doses led to increased levels of phospho-tau, increased insoluble, aggregated forms of tau, and detachment of tau from microtubules. Furthermore, levels of phospho-tau distributed in the neuropil, as well as in cell bodies increased. Interestingly, the level of insoluble tau was increased 1 wk following anesthesia, suggesting that anesthesia precipitates changes in the brain that provoke the later development of tauopathy. Overall, our results suggest that anesthesia-induced hypothermia could lead to an acceleration of tau pathology in vivo that could have significant clinical implications for patients with early stage, or overt neurofibrillary tangle pathology.-Planel, E., Bretteville, A., Liu, L., Virag, L., Du, A. L., Yu, W. Y., Dickson, D. W., Whittington, R. A., Duff, K. E. Acceleration and persistence of neurofibrillary pathology in a mouse model of tauopathy following anesthesia. FASEB J. 23, 2595-2604 ( 2009)	[Planel, Emmanuel; Bretteville, Alexis; Liu, Li; Du, Angela L.; Yu, Wai Haung; Duff, Karen E.] Columbia Univ, Med Ctr, Dept Pathol, Taub Inst Alzheimers Dis Res, New York, NY 10032 USA; [Planel, Emmanuel] Univ Laval, Ctr Hosp Univ Quebec, Ctr Hosp Univ Laval, Quebec City, PQ, Canada; [Virag, Laszlo; Whittington, Robert A.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY 10032 USA; [Planel, Emmanuel; Duff, Karen E.] New York State Psychiat Inst & Hosp, Dept Integrat Neurosci, New York, NY 10032 USA; [Dickson, Dennis W.] Mayo Clin Jacksonville, Dept Pathol & Neurosci, Jacksonville, FL 32224 USA	Columbia University; Laval University; Columbia University; New York State Psychiatry Institute; Mayo Clinic	Duff, KE (corresponding author), Columbia Univ, Med Ctr, Dept Pathol, Taub Inst Alzheimers Dis Res, P&S Bldg 12-461,630 W 168th St, New York, NY 10032 USA.	ked2115@columbia.edu	Duff, Karen EK/C-2510-2009	Planel, Emmanuel/0000-0001-5128-0565; Duff, Karen/0000-0002-6177-868X; Dickson, Dennis W/0000-0001-7189-7917; Yu, Wai Haung/0000-0001-7186-6731	Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation; National Institute of Neurological Disorders and Stroke [NS048447]; National Institute on Aging [AG017216]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS048447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG017216] Funding Source: NIH RePORTER	Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors are grateful to Dr. Jada Lewis ( Mayo Clinic, Jacksonville, FL, USA) for help with the motor function analysis. We thank Dr. Peter Davies (Albert Einstein College of Medicine, Bronx, NY, USA) for the generous gift of antibodies. We are also grateful to Helen Y. Figueroa and Mathieu Herman for technical help. This work was supported by an Institute for the Study of Aging/Alzheimer's Drug Discovery Foundation grant ( to E. P.), a National Institute of Neurological Disorders and Stroke grant (NS048447), and a National Institute on Aging grant (AG017216; to K. E. D.).	Ancelin ML, 2001, BRIT J PSYCHIAT, V178, P360, DOI 10.1192/bjp.178.4.360; Avila J, 2004, NAT MED, V10, P460, DOI 10.1038/nm0504-460; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bianchi SL, 2008, NEUROBIOL AGING, V29, P1002, DOI 10.1016/j.neurobiolaging.2007.02.009; BOHNEN N, 1994, INT J NEUROSCI, V77, P181, DOI 10.3109/00207459408986029; Bone I, 2000, ANAESTHESIA, V55, P592, DOI 10.1046/j.1365-2044.2000.01479-5.x; Bretteville A, 2008, J ALZHEIMERS DIS, V14, P431; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Eckenhoff RG, 2004, ANESTHESIOLOGY, V101, P703, DOI 10.1097/00000542-200409000-00019; ECKENHOFF RG, 2007, CELL SCI REV, V4, P78; Fujishiro H, 2008, ACTA NEUROPATHOL, V116, P17, DOI 10.1007/s00401-008-0383-1; Giannakopoulos P, 2003, NEUROLOGY, V60, P1495, DOI 10.1212/01.WNL.0000063311.58879.01; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; Gong CX, 2000, J BIOL CHEM, V275, P5535, DOI 10.1074/jbc.275.8.5535; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GURLAND G, 1993, P NATL ACAD SCI USA, V90, P8827, DOI 10.1073/pnas.90.19.8827; Holtzmam A, 2000, MED HYPOTHESES, V55, P440, DOI 10.1054/mehy.2000.1085; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Johansson C, 1996, AGING CLIN EXP RES, V8, P189, DOI 10.1007/BF03339676; Kim D, 1999, BRAIN RES, V839, P253, DOI 10.1016/S0006-8993(99)01724-2; Ksiezak-Reding H, 2003, BBA-MOL BASIS DIS, V1639, P159, DOI 10.1016/j.bbadis.2003.09.001; LAMY C, 1989, NEUROPATH APPL NEURO, V15, P563, DOI 10.1111/j.1365-2990.1989.tb01255.x; Levy SF, 2005, J BIOL CHEM, V280, P13520, DOI 10.1074/jbc.M413490200; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; Merrick SE, 1997, J NEUROSCI, V17, P5726; Noble W, 2005, P NATL ACAD SCI USA, V102, P6990, DOI 10.1073/pnas.0500466102; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; Planel E, 2002, DRUG DEVELOP RES, V56, P491, DOI 10.1002/ddr.10100; Planel E, 2001, J BIOL CHEM, V276, P34298, DOI 10.1074/jbc.M102780200; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Planel E, 2008, J NEUROSCI, V28, P12798, DOI 10.1523/JNEUROSCI.4101-08.2008; REES DI, 1985, TEX MED, V81, P45; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Ritchie K, 1997, Int Psychogeriatr, V9, P309, DOI 10.1017/S1041610297004468; Sahara N, 2002, J NEUROCHEM, V83, P1498, DOI 10.1046/j.1471-4159.2002.01241.x; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; Tolivia J, 2006, ANAL QUANT CYTOL, V28, P43; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; Weaver CL, 2000, NEUROBIOL AGING, V21, P719, DOI 10.1016/S0197-4580(00)00157-3; Xie ZC, 2006, ANESTHESIOLOGY, V104, P988, DOI 10.1097/00000542-200605000-00015; Xie ZC, 2006, EXP GERONTOL, V41, P346, DOI 10.1016/j.exger.2006.01.014; Zhu XW, 2002, NEUROSIGNALS, V11, P270, DOI 10.1159/000067426	52	99	104	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2595	2604		10.1096/fj.08-122424	http://dx.doi.org/10.1096/fj.08-122424			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19279139	Green Published			2023-01-03	WOS:000268836700028
J	McCartney, M				McCartney, Margaret			Hospital Hygiene Are superbug fears turning patients into hospital cleaners?	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				Coombes R, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b833	1	3	3	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 25	2009	338								b729	10.1136/bmj.b729	http://dx.doi.org/10.1136/bmj.b729			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	417DR	19244305				2023-01-03	WOS:000264056200002
J	Erb, RM; Son, HS; Samanta, B; Rotello, VM; Yellen, BB				Erb, Randall M.; Son, Hui S.; Samanta, Bappaditya; Rotello, Vincent M.; Yellen, Benjamin B.			Magnetic assembly of colloidal superstructures with multipole symmetry	NATURE			English	Article							PARTICLES; CRYSTALS; CRYSTALLIZATION; CLUSTERS	The assembly of complex structures out of simple colloidal building blocks is of practical interest for building materials with unique optical properties ( for example photonic crystals(1) and DNA biosensors(2)) and is of fundamental importance in improving our understanding of self- assembly processes occurring on molecular to macroscopic length scales(3-5). Here we demonstrate a self-assembly principle that is capable of organizing a diverse set of colloidal particles into highly reproducible, rotationally symmetric arrangements. The structures are assembled using the magneto-static interaction between effectively diamagnetic and paramagnetic particles within a magnetized ferrofluid. The resulting multipolar geometries resemble electrostatic charge configurations such as axial quadrupoles ('Saturn rings'), axial octupoles ('flowers'), linear quadrupoles (poles) and mixed multipole arrangements ('two tone'), which represent just a few examples of the type of structure that can be built using this technique.	[Erb, Randall M.; Son, Hui S.; Yellen, Benjamin B.] Duke Univ, Dept Mech Engn & Mat Sci, Ctr Biol Inspired Mat & Mat Syst, Durham, NC 27708 USA; [Samanta, Bappaditya; Rotello, Vincent M.] Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA	Duke University; University of Massachusetts System; University of Massachusetts Amherst	Yellen, BB (corresponding author), Duke Univ, Dept Mech Engn & Mat Sci, Ctr Biol Inspired Mat & Mat Syst, Box 90300,Hudson Hall, Durham, NC 27708 USA.	yellen@duke.edu	Erb, Randall M/E-6337-2014; Erb, Randall M/O-1984-2018; Erb, Randall M/B-1986-2012	Erb, Randall M/0000-0002-6351-395X; 	US National Science Foundation [NSEC DMI-0531171, MRSEC DMR-0213695, CMMI-0608819, CMMI-0625480]	US National Science Foundation(National Science Foundation (NSF))	The authors would like to thank the US National Science Foundation (grants NSEC DMI-0531171 and MRSEC DMR-0213695 to V. M. R. and grants CMMI-0608819 and CMMI-0625480 to B.B.Y.) for supporting this work.	Biswal SL, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.041406; Cho YS, 2005, J AM CHEM SOC, V127, P15968, DOI 10.1021/ja0550632; Dinsmore AD, 2002, SCIENCE, V298, P1006, DOI 10.1126/science.1074868; Dreyfus R, 2005, NATURE, V437, P862, DOI 10.1038/nature04090; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Erb RM, 2008, J APPL PHYS, V103, DOI 10.1063/1.2831789; HALSEY TC, 1992, SCIENCE, V258, P761, DOI 10.1126/science.258.5083.761; HELGESEN G, 1990, PHYS REV A, V42, P7271, DOI 10.1103/PhysRevA.42.7271; Kim SH, 2008, LANGMUIR, V24, P2365, DOI 10.1021/la703037g; Leunissen ME, 2005, NATURE, V437, P235, DOI 10.1038/nature03946; Manoharan VN, 2003, SCIENCE, V301, P483, DOI 10.1126/science.1086189; Musevic I, 2006, SCIENCE, V313, P954, DOI 10.1126/science.1129660; Ozin GA, 2001, ADV FUNCT MATER, V11, P95, DOI 10.1002/1616-3028(200104)11:2<95::AID-ADFM95>3.0.CO;2-O; PANOFSKY WKH, 1955, CLASSICAL ELECT MAGN, P84; Shevchenko EV, 2006, NATURE, V439, P55, DOI 10.1038/nature04414; SKJELTORP AT, 1983, PHYS REV LETT, V51, P2306, DOI 10.1103/PhysRevLett.51.2306; Velev OD, 2000, SCIENCE, V287, P2240, DOI 10.1126/science.287.5461.2240; Whitesides GM, 2002, SCIENCE, V295, P2418, DOI 10.1126/science.1070821; Xia YN, 2001, ADV MATER, V13, P409, DOI 10.1002/1521-4095(200103)13:6<409::AID-ADMA409>3.0.CO;2-C; Yellen BB, 2005, P NATL ACAD SCI USA, V102, P8860, DOI 10.1073/pnas.0500409102; Yin YD, 2001, J AM CHEM SOC, V123, P8718, DOI 10.1021/ja011048v; Zerrouki D, 2008, NATURE, V455, P380, DOI 10.1038/nature07237; Zhuang JQ, 2008, ANGEW CHEM INT EDIT, V47, P2208, DOI 10.1002/anie.200705049	23	358	371	7	341	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	2009	457	7232					999	1002		10.1038/nature07766	http://dx.doi.org/10.1038/nature07766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	408HF	19225522				2023-01-03	WOS:000263425400039
J	Heal, CF; Buettner, PG; Cruickshank, R; Graham, D; Browning, S; Pendergast, J; Drobetz, H; Gluer, R; Lisec, C				Heal, Clare F.; Buettner, Petra G.; Cruickshank, Robert; Graham, David; Browning, Sheldon; Pendergast, Jayne; Drobetz, Herwig; Gluer, Robert; Lisec, Carl			Does single application of topical chloramphenicol to high risk sutured wounds reduce incidence of wound infection after minor surgery? Prospective randomised placebo controlled double blind trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ANTIBIOTIC-PROPHYLAXIS; OCULAR CHLORAMPHENICOL; DERMATOLOGICAL SURGERY; MUPIROCIN RESISTANCE; CONTACT-DERMATITIS; GENERAL-PRACTICE; APLASTIC-ANEMIA; EPIDEMIOLOGY; OINTMENT	Objective To determine the effectiveness of a single application of topical chloramphenicol ointment in preventing wound infection after minor dermatological surgery. Design Prospective randomised placebo controlled double blind multicentre trial. Setting Primary care in a regional centre in Queensland, Australia. Participants 972 minor surgery patients. Interventions A single topical dose of chloramphenicol ( n= 488) or paraffin ointment ( n= 484; placebo). Main outcome measure Incidence of infection. Results The incidence of infection in the chloramphenicol group ( 6.6%; 95% confidence interval 4.9 to 8.8) was significantly lower than that in the control group ( 11.0%; 7.9 to 15.1) ( P= 0.010). The absolute reduction in infection rate was 4.4%, the relative reduction was 40%, and the relative risk of wound infection in the control group was 1.7 ( 95% confidence interval 1.1 to 2.5) times higher than in the intervention group. The number needed to treat was 22.8. Conclusion Application of a single dose of topical chloramphenicol to high risk sutured wounds after minor surgery produces a moderate absolute reduction in infection rate that is statistically but not clinically significant. Trial registration Current Controlled Trials	[Heal, Clare F.; Drobetz, Herwig; Gluer, Robert] James Cook Univ, Sch Med, Mackay Base Hosp, Mackay, Qld 4740, Australia; [Buettner, Petra G.] James Cook Univ, Townsville, Qld 4811, Australia; [Cruickshank, Robert; Graham, David; Pendergast, Jayne] Walkerston Med Ctr, Mackay, Qld 4740, Australia; [Browning, Sheldon] Molescan Mackay, Mackay, Qld 4740, Australia; [Lisec, Carl] Townsville Gen Hosp, Townsville, Qld 4740, Australia	James Cook University; James Cook University	Heal, CF (corresponding author), James Cook Univ, Sch Med, Mackay Base Hosp, Mackay, Qld 4740, Australia.	clare.heal@jcu.edu.au	Heal, Clare/D-3786-2015	Heal, Clare/0000-0002-5041-2666; Drobetz, Herwig/0000-0003-0837-2696	Chris Silagy scholarship; Royal Australian College of General Practice	Chris Silagy scholarship; Royal Australian College of General Practice	Research was funded by the Chris Silagy scholarship from the Royal Australian College of General Practice. The authors' work is independent of this funding.	ALLEN LV, 2007, SECUNDUM ARTEM, P4; Amici JM, 2005, BRIT J DERMATOL, V153, P967, DOI 10.1111/j.1365-2133.2005.06861.x; *AUSTR GOV BUR MET, 2008, CLIM DAT ONL; Australian Bureau of Statistics, 2006, CENS POP HOUS BAS CO; BLONDEEL A, 1978, CONTACT DERMATITIS, V4, P270, DOI 10.1111/j.1600-0536.1978.tb04557.x; BRADLEY SF, 1995, INFECT CONT HOSP EP, V16, P354; *BRIT MED ASS ROYA, 2006, BRIT NAT FORM, P605; Bruce J, 2001, J HOSP INFECT, V49, P99, DOI 10.1053/jhin.2001.1045; BUCKLEY S, 1999, BRIT MED J, V300, P1497; Cho CY, 1998, DERMATOL CLIN, V16, P25, DOI 10.1016/S0733-8635(05)70485-X; COLEBROOK L, 1948, LANCET, V252, P682, DOI 10.1016/S0140-6736(48)91114-3; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; Dixon AJ, 2006, DERMATOL SURG, V32, P819, DOI 10.1111/j.1524-4725.2006.32167.x; EDLICH RF, 1992, WOUND HEALING, P581; Edwards PS, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003949.PUB2; Erel E, 1999, BRIT J PLAST SURG, V52, P326; Fukuda M, 2002, CORNEA, V21, pS86, DOI 10.1097/01.ico.0000263125.99262.42; HAAS AF, 1995, J AM ACAD DERMATOL, V32, P155, DOI 10.1016/0190-9622(95)90119-1; Heal C, 2006, BMJ-BRIT MED J, V332, P1053, DOI 10.1136/bmj.38800.628704.AE; Heal Clare, 2006, Aust Fam Physician, V35, P825; Heal C, 2006, MED J AUSTRALIA, V185, P255, DOI 10.5694/j.1326-5377.2006.tb00555.x; Kamath S, 2005, INJURY, V36, P783, DOI 10.1016/j.injury.2005.01.001; Laporte JR, 1998, BRIT J CLIN PHARMACO, V46, P181, DOI 10.1046/j.1365-2125.1998.00773.x; Lathlean S, 1999, Aust Fam Physician, V28 Suppl 1, pS28; LEYDEN JJ, 1979, JAMA-J AM MED ASSOC, V242, P1276, DOI 10.1001/jama.242.12.1276; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; Messingham MJ, 2005, DERMATOL SURG, V31, P1068; Miller MA, 1996, INFECT CONT HOSP EP, V17, P811; Pasapula C, 2004, J HAND SURG-BRIT EUR, V29B, P634, DOI 10.1016/j.jhsb.2004.07.004; *PFIZ, 2005, PROD INF CHLOR EYE O; Platt R, 1998, NEW HORIZ-SCI PRACT, V6, pS53; Rayner SA, 1996, DRUG SAFETY, V14, P273, DOI 10.2165/00002018-199614050-00001; *THER GUID, 2006, THER GUID ANT VERS 1; THOMAS S, 1990, WOUND MANAGEMENT DRE, P9	36	52	52	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 15	2009	338								a2812	10.1136/bmj.a2812	http://dx.doi.org/10.1136/bmj.a2812			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405AD	19147639	Green Published, hybrid			2023-01-03	WOS:000263193400001
J	Bindman, AB; Chattopadhyay, A; Auerback, GM				Bindman, Andrew B.; Chattopadhyay, Arpita; Auerback, Glenna M.			Interruptions in Medicaid Coverage and Risk for Hospitalization for Ambulatory Care-Sensitive Conditions	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-INSURANCE; MANAGED CARE; ENROLLMENT; CANCER	Background: Many low-income U.S. citizens experience interruptions in health insurance coverage. Objective: To determine the rate of hospitalization for ambulatory care-sensitive conditions among Medicaid beneficiaries with interruptions in coverage. Design: Retrospective cohort study. Setting: California Medicaid population. Patients: 4 735 797 adults in California age 18 to 64 years who received a minimum of 1 month of Medicaid coverage between 1998 to 2002. Measurement: Time to hospitalization for an ambulatory care sensitive condition. Results: Sixty-two percent of Medicaid beneficiaries experienced at least 1 interruption in coverage during the study period. The 3 most common ambulatory care-sensitive conditions resulting in a hospitalization were heart failure, diabetes, and chronic obstructive pulmonary disease. Interruptions in coverage were associated with a higher risk for hospitalization for an ambulatory care-sensitive condition (adjusted hazard ratio, 3.66 [95% CI, 3.59 to 3.72]; P < 0.001). In subgroup analyses, the association between interrupted coverage and hospitalization was stronger for beneficiaries eligible through the Temporary Aid to Needy Families program (adjusted hazard ratio, 8.56 [CI, 8.06 to 9.08]) than for beneficiaries eligible through the Supplemental Security Income program (adjusted hazard ratio, 1.72 [CI, 1.67 to 1.76]), who typically retain Medicare coverage even when their Medicaid coverage is interrupted. Limitation: The study lacked information on why interruptions occurred and whether beneficiaries with interruptions transitioned to other insurance coverage. Conclusion: Interruptions in Medicaid coverage are associated with a higher rate of hospitalization for ambulatory care-sensitive conditions. Policies that reduce the frequency of interruptions in Medicaid coverage might prevent some of the health events that trigger hospitalization and high-cost health care spending.	[Bindman, Andrew B.] San Francisco Gen Hosp, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Bindman, AB (corresponding author), San Francisco Gen Hosp, Bldg 10,Ward 13,1001 Potrero Ave, San Francisco, CA 94110 USA.	abindman@medsfgh.ucsf.edu	Dalla Zuanna, Teresa/G-3133-2015		The Commonwealth Fund; national, private foundation	The Commonwealth Fund; national, private foundation	By The Commonwealth Fund, a national, private foundation that supports independent research on health and social issues.	Agency for Healthcare Research and Quality, 2002, AHRQ QUAL IND GUID P; ANDERSEN PK, 1982, ANN STAT, V10, P1100, DOI 10.1214/aos/1176345976; Bindman AB, 2005, HEALTH SERV RES, V40, P19, DOI 10.1111/j.1475-6773.2005.00340.x; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bradley CJ, 2005, CANCER-AM CANCER SOC, V103, P1712, DOI 10.1002/cncr.20954; Carrasquillo O, 1998, AM J PUBLIC HEALTH, V88, P464, DOI 10.2105/AJPH.88.3.464; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; *ER MARD ASS, 2002, US MARK RES IMPR ENR; FLEMING ST, 1995, MED CARE RES REV, V52, P88, DOI 10.1177/107755879505200106; Hadley J, 2003, MED CARE RES REV, V60, p3S, DOI 10.1177/1077558703254101; Harman JS, 2003, PSYCHIAT SERV, V54, P999, DOI 10.1176/appi.ps.54.7.999; *I MED, 2004, INS AM HLTH; *KAIS COMM, 2001, STAT NAT MED ENR SPE; *KAIS COMM MED UN, 2006, WHO NEEDS MED AID; KLEIN J, 2002, MED CARE STAT SECTIO; Klein K, 2005, ENTRANCES EXITS HLTH, V855, P1; Kruzikas DT, 2004, PREVENTABLE HOSPITAL; PAGE C, 1999, GUIDE MEDICAL PROGRA; Perkins CI, 2001, MED CARE, V39, P1224, DOI 10.1097/00005650-200111000-00009; RAINS J, 2001, OSHPD MEDICAL MATCH; Short PF, 2003, HEALTH AFFAIR, V22, P244, DOI 10.1377/hlthaff.22.6.244; SHORT PF, 2003, CHURN CHURN CHURN IN, V688, P1; *US GOV ACC OFF, 2007, MED STAT REP CIT DOC; YAMAGUCHI K, 1991, EVENT HIST ANAL, P182	24	73	74	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 16	2008	149	12					854	+		10.7326/0003-4819-149-12-200812160-00004	http://dx.doi.org/10.7326/0003-4819-149-12-200812160-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	384VI	19075204				2023-01-03	WOS:000261771900002
J	Touboul, C; Badiou, W; Saada, J; Pelage, JP; Payen, D; Vicaut, E; Jacob, D; Rafii, A				Touboul, Cyril; Badiou, Wassim; Saada, Julien; Pelage, Jean-Pierre; Payen, Didier; Vicaut, Eric; Jacob, Denis; Rafii, Arash			Efficacy of Selective Arterial Embolisation for the Treatment of Life-Threatening Post-Partum Haemorrhage in a Large Population	PLOS ONE			English	Article								Background: The objective of this study was to assess efficacy and determine the optimal indication of selective arterial embolisation (SAE) in patients with life-threatening post-partum haemorrhage (PPH). Methodology/Principal Findings: One hundred and two patients with PPH underwent SAE and were included from January 1998 to January 2002 in our university care center. Embolisation was considered effective when no other surgical procedure was required. Univariate and multivariate statistical analysis were performed. SAE was effective for 73 patients (71.5%), while 29 required surgical procedures. SAE was effective in 88.6% of women with uterine atony that was associated with positive outcome (OR 4.13, 1.35-12.60), whereas caesarean deliveries (OR 0.16, 0.04-0.5) and haemodynamic shock (OR 0.21, 0.07-0.60) were associated with high failure rates, 47.6% and 39.1%, respectively. Conclusions/Significance: Success rate for SAE observed in a large population is lower than previously reported. It is most likely to succeed for uterine atony but not recommended in case of haemodynamic shock or after caesarean section.	[Touboul, Cyril; Badiou, Wassim; Saada, Julien; Jacob, Denis] Hop Lariboisiere, AP HP, Dept Obstet & Gynaecol, F-75475 Paris, France; [Pelage, Jean-Pierre] Hop Lariboisiere, AP HP, Dept Vasc Imaging, Paris, France; [Payen, Didier] Hop Lariboisiere, AP HP, Dept Anaesthesiol & Critical Care, Paris, France; [Vicaut, Eric] Hop Lariboisiere, AP HP, Dept Nuclear Med, Paris, France; [Rafii, Arash] Weill Cornell Med Coll, Dept Genet Med & Obstet & Gynecol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Touboul, C (corresponding author), Hop Lariboisiere, AP HP, Dept Obstet & Gynaecol, F-75475 Paris, France.	jat2021@qatar-med.cornell.edu	Pelage, Jean-Pierre/L-2488-2015; Rafii, Arash/E-4106-2013					ABDRABBO SA, 1994, AM J OBSTET GYNECOL, V171, P694, DOI 10.1016/0002-9378(94)90084-1; Bouvier-Colle M H, 2001, J Gynecol Obstet Biol Reprod (Paris), V30, P768; Bouvier-Colle M H, 2001, J Gynecol Obstet Biol Reprod (Paris), V30, pS5; BURCHELL R C, 1968, Journal of Obstetrics and Gynaecology of the British Commonwealth, V75, P642; CHATTOPADHYAY SK, 1990, INT J GYNECOL OBSTET, V32, P345, DOI 10.1016/0020-7292(90)90112-X; CLARK SL, 1985, OBSTET GYNECOL, V66, P353; Corr P, 2001, BEST PRACT RES CL OB, V15, P557, DOI 10.1053/beog.2001.0200; den Hertog CEC, 2001, EUR J OBSTET GYN R B, V94, P8, DOI 10.1016/S0301-2115(00)00311-0; Descargues G, 2004, HUM REPROD, V19, P339, DOI 10.1093/humrep/deh082; EVANS S, 1985, SURG GYNECOL OBSTET, V160, P250; GILBERT L, 1987, BRIT J OBSTET GYNAEC, V94, P67, DOI 10.1111/j.1471-0528.1987.tb02255.x; Nizard J, 2003, HUM REPROD, V18, P844, DOI 10.1093/humrep/deg161; OLEARY JA, 1995, J REPROD MED, V40, P189; Ornan D, 2003, OBSTET GYNECOL, V102, P904, DOI 10.1016/S0029-7844(03)00769-5; Pelage JP, 1999, ACTA OBSTET GYN SCAN, V78, P698, DOI 10.1034/j.1600-0412.1999.780807.x; Pelage JP, 1998, RADIOLOGY, V208, P359, DOI 10.1148/radiology.208.2.9680559; POESCHMANN RP, 1991, BRIT J OBSTET GYNAEC, V98, P528, DOI 10.1111/j.1471-0528.1991.tb10364.x; Prendiville WJ, 1996, EUR J OBSTET GYN R B, V69, P19, DOI 10.1016/0301-2115(95)02529-4; PRENDIVILLE WJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000007, DOI 10.1002/14651858.CD000007]; Salomon LJ, 2003, HUM REPROD, V18, P849, DOI 10.1093/humrep/deg168; Tamizian O, 2002, BEST PRACT RES CL OB, V16, P81, DOI 10.1053/beog.2002.0257; Vedantham S, 1997, AM J OBSTET GYNECOL, V176, P938, DOI 10.1016/S0002-9378(97)70624-0	22	56	60	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2008	3	11							e3819	10.1371/journal.pone.0003819	http://dx.doi.org/10.1371/journal.pone.0003819			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	436YG	19043573	Green Published, Green Submitted, gold			2023-01-03	WOS:000265451400010
J	Talmor, D; Sarge, T; Malhotra, A; O'Donnell, CR; Ritz, R; Lisbon, A; Novack, V; Loring, SH				Talmor, Daniel; Sarge, Todd; Malhotra, Atul; O'Donnell, Carl R.; Ritz, Ray; Lisbon, Alan; Novack, Victor; Loring, Stephen H.			Mechanical Ventilation Guided by Esophageal Pressure in Acute Lung Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							END-EXPIRATORY PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; TRANSPULMONARY PRESSURES; VOLUME CURVE; RECRUITMENT; STRATEGY; DERECRUITMENT; CYTOKINES; OUTCOMES; MODEL	Background: Survival of patients with acute lung injury or the acute respiratory distress syndrome (ARDS) has been improved by ventilation with small tidal volumes and the use of positive end-expiratory pressure (PEEP); however, the optimal level of PEEP has been difficult to determine. In this pilot study, we estimated transpulmonary pressure with the use of esophageal balloon catheters. We reasoned that the use of pleural-pressure measurements, despite the technical limitations to the accuracy of such measurements, would enable us to find a PEEP value that could maintain oxygenation while preventing lung injury due to repeated alveolar collapse or overdistention. Methods: We randomly assigned patients with acute lung injury or ARDS to undergo mechanical ventilation with PEEP adjusted according to measurements of esophageal pressure (the esophageal-pressure-guided group) or according to the Acute Respiratory Distress Syndrome Network standard-of-care recommendations (the control group). The primary end point was improvement in oxygenation. The secondary end points included respiratory-system compliance and patient outcomes. Results: The study reached its stopping criterion and was terminated after 61 patients had been enrolled. The ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen at 72 hours was 88 mm Hg higher in the esophageal-pressure-guided group than in the control group (95% confidence interval, 78.1 to 98.3; P=0.002). This effect was persistent over the entire follow-up time (at 24, 48, and 72 hours; P=0.001 by repeated-measures analysis of variance). Respiratory-system compliance was also significantly better at 24, 48, and 72 hours in the esophageal-pressure-guided group (P=0.01 by repeated-measures analysis of variance). Conclusions: As compared with the current standard of care, a ventilator strategy using esophageal pressures to estimate the transpulmonary pressure significantly improves oxygenation and compliance. Multicenter clinical trials are needed to determine whether this approach should be widely adopted. (ClinicalTrials.gov number, NCT00127491.).	[Talmor, Daniel; Sarge, Todd; Ritz, Ray; Lisbon, Alan; Loring, Stephen H.] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [O'Donnell, Carl R.] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA; [Malhotra, Atul] Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; [Malhotra, Atul] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA; [Novack, Victor] Harvard Univ, Harvard Clin Res Inst, Boston, MA 02115 USA; [Talmor, Daniel; Sarge, Todd; Malhotra, Atul; O'Donnell, Carl R.; Lisbon, Alan; Loring, Stephen H.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Talmor, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 1 Deaconess Rd,CC-470, Boston, MA 02215 USA.	dtalmor@bidmc.harvard.edu		O'Donnell, Carl/0000-0003-1788-006X	National Heart, Lung, and Blood Institute [HL-52586]; Respironics; INO Therapeutics; Tri-anim; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052586, K24HL093218] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Respironics; INO Therapeutics; Tri-anim; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Supported in part by a grant from the National Heart, Lung, and Blood Institute (HL-52586). Dr. Malhotra reports receiving consulting fees from Respironics. Mr. Ritz reports receiving consulting fees from INO Therapeutics and lecture fees from Tri-anim and serving on the advisory boards of Cardinal Health and Respironics. No other potential conflict of interest relevant to this article was reported.	*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BEYER J, 1982, INTENS CARE MED, V8, P75, DOI 10.1007/BF01694870; Brower RG, 2004, NEW ENGL J MED, V351, P327; Chieveley-Williams S, 2002, CHEST, V121, P533, DOI 10.1378/chest.121.2.533; Chiumello D, 1999, AM J RESP CRIT CARE, V160, P109, DOI 10.1164/ajrccm.160.1.9803046; COLEBATCH HJH, 1979, J APPL PHYSIOL, V47, P683, DOI 10.1152/jappl.1979.47.4.683; de Chazal I, 2003, BRIT J ANAESTH, V91, P81, DOI 10.1093/bja/aeg146; FARIDY EE, 1966, J APPL PHYSIOL, V21, P1453, DOI 10.1152/jappl.1966.21.5.1453; Gattinoni L, 2003, EUR RESPIR J, V22, p15S, DOI 10.1183/09031936.03.00021303; Grasso S, 2005, AM J RESP CRIT CARE, V171, P1002, DOI 10.1164/rccm.200407-940OC; Harris RS, 2000, AM J RESP CRIT CARE, V161, P432; Imai Y, 2003, JAMA-J AM MED ASSOC, V289, P2104, DOI 10.1001/jama.289.16.2104; Jonson B, 1999, AM J RESP CRIT CARE, V159, P1172, DOI 10.1164/ajrccm.159.4.9801088; Maggiore SM, 2001, AM J RESP CRIT CARE, V164, P795, DOI 10.1164/ajrccm.164.5.2006071; Malbrain MLNG, 2005, CRIT CARE MED, V33, P315, DOI 10.1097/01.CCM.0000153408.09806.1B; Malbrain MLNG, 1999, INTENS CARE MED, V25, P1453, DOI 10.1007/s001340051098; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; MILICEMILI J, 1964, J APPL PHYSIOL, V19, P207, DOI 10.1152/jappl.1964.19.2.207; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Nishida T, 2004, CRIT CARE MED, V32, P1358, DOI 10.1097/01.CCM.0000128573.28173.2E; Pelosi P, 2001, AM J RESP CRIT CARE, V164, P122, DOI 10.1164/ajrccm.164.1.2007010; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Shapiro NI, 2006, CRIT CARE MED, V34, P1025, DOI 10.1097/01.CCM.0000206104.18647.A8; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; Talmor D, 2006, CRIT CARE MED, V34, P1389, DOI 10.1097/01.CCM.0000215515.49001.A2; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; Washko GR, 2006, J APPL PHYSIOL, V100, P753, DOI 10.1152/japplphysiol.00697.2005; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WYSZOGRODSKI I, 1975, J APPL PHYSIOL, V38, P461, DOI 10.1152/jappl.1975.38.3.461; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	36	656	724	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2008	359	20					2095	2104		10.1056/NEJMoa0708638	http://dx.doi.org/10.1056/NEJMoa0708638			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	371IB	19001507	Green Accepted			2023-01-03	WOS:000260823900008
J	Bray, GA				Bray, George A.			Is new hope on the horizon for obesity?	LANCET			English	Editorial Material							PHARMACOTHERAPY; METAANALYSIS; RIMONABANT; OVERWEIGHT; TRIALS		[Bray, George A.] Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Bray, GA (corresponding author), Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	george.Bray@PBRC.edu						Astrup A, 2008, LANCET, V372, P1906, DOI 10.1016/S0140-6736(08)61525-1; Bray GA, 1999, ENDOCR REV, V20, P805, DOI 10.1210/er.20.6.805; Bray GA., 2007, BATTLE BULGE; Bray GA, 2007, PHARMACOL REV, V59, P151, DOI 10.1124/pr.59.2.2; Christensen R, 2007, LANCET, V370, P1706, DOI 10.1016/S0140-6736(07)61721-8; European Medicines Agency, 2008, PUBL STAT BEXTR VALD; Galuska D. A., 2008, Morbidity and Mortality Weekly Report, V57, P765; Haddock CK, 2002, INT J OBESITY, V26, P262, DOI 10.1038/sj.ijo.0801889; Nissen SE, 2008, JAMA-J AM MED ASSOC, V299, P1547, DOI 10.1001/jama.299.13.1547; Rucker D, 2007, BMJ-BRIT MED J, V335, P1194, DOI 10.1136/bmj.39385.413113.25; Simons-Morton DG, 2006, JAMA-J AM MED ASSOC, V295, P826, DOI 10.1001/jama.295.7.826; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P586, DOI 10.1038/clpt.1992.69	12	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV-DEC	2008	372	9653					1859	1860		10.1016/S0140-6736(08)61792-4	http://dx.doi.org/10.1016/S0140-6736(08)61792-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	379IA	19041787				2023-01-03	WOS:000261388700005
J	Cantin, AM				Cantin, Andre M.			Childhood pneumonia and oxygen treatment	LANCET			English	Editorial Material							PAPUA-NEW-GUINEA; CHILDREN; HYPOXEMIA; MORTALITY; WORLD		[Cantin, Andre M.] Univ Sherbrooke, Dept Med, Div Pulm, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Cantin, AM (corresponding author), Univ Sherbrooke, Dept Med, Div Pulm, Sherbrooke, PQ J1H 5N4, Canada.	andre.cantin@usherbrooke.ca						Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904; Duke T, 2001, INT J TUBERC LUNG D, V5, P511; DUKE T, 2008, LANCET          0818; Enarson P, 2008, B WORLD HEALTH ORGAN, V86, P344, DOI 10.2471/BLT.07.048017; Fu LY, 2006, PEDIATRICS, V118, pE1822, DOI 10.1542/peds.2005-2673; Matai S, 2008, ANN TROP PAEDIATR, V28, P71, DOI 10.1179/146532808X270716; ONYANGO FE, 1993, BRIT MED J, V306, P612, DOI 10.1136/bmj.306.6878.612; Scott JAG, 2008, J CLIN INVEST, V118, P1291, DOI 10.1172/JCI33947; Smyth A, 1998, ANN TROP PAEDIATR, V18, P31, DOI 10.1080/02724936.1998.11747923; Steinhoff M, 2007, LANCET, V369, P1409, DOI 10.1016/S0140-6736(07)60644-8; Williams BG, 2002, LANCET INFECT DIS, V2, P25, DOI 10.1016/S1473-3099(01)00170-0	12	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	2008	372	9646					1278	1280		10.1016/S0140-6736(08)61165-4	http://dx.doi.org/10.1016/S0140-6736(08)61165-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18708249				2023-01-03	WOS:000260060500006
J	Whitelaw, A				Whitelaw, Andrew			Collapse of GMC hearing into research misconduct	LANCET			English	Editorial Material							NEGATIVE EXTRATHORACIC PRESSURE; FAILURE; TRIAL		[Whitelaw, Andrew] Univ Bristol, Dept Clin Sci, Bristol BS10 5NB, Avon, England	University of Bristol	Whitelaw, A (corresponding author), Univ Bristol, Dept Clin Sci, Bristol BS10 5NB, Avon, England.	andrew.whitelaw@bris.ac.uk						Azzopardi D, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-17; Chalmers I, 2001, BRIT MED J, V323, P280, DOI 10.1136/bmj.323.7307.280; Farthing M, 2000, BRIT MED J, V321, P1485, DOI 10.1136/bmj.321.7275.1485; *GEN MED COUNC, 2008, FITN PRACT PAN; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Hey E, 2006, PEDIATRICS, V117, P2244, DOI 10.1542/peds.2006-0819; Hey E, 2002, ARCH DIS CHILD, V86, P1, DOI 10.1136/adc.86.1.1; Jenny C, 2007, PEDIATRICS, V119, P797, DOI 10.1542/peds.2006-2472; Samuels MP, 1996, PEDIATRICS, V98, P1154; Stenson BJ, 2004, ARCH DIS CHILD-FETAL, V89, pF321, DOI 10.1136/adc.2002.021931; Telford K, 2006, LANCET, V367, P1080, DOI 10.1016/S0140-6736(06)68475-4	11	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	2008	372	9646					1283	1284		10.1016/S0140-6736(08)61532-9	http://dx.doi.org/10.1016/S0140-6736(08)61532-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18929890				2023-01-03	WOS:000260060500009
J	Lee, SW; Hong, YS				Lee, Sung-Woo; Hong, Yun-Sik			Extracorporeal life-support in patients requiring CPR	LANCET			English	Editorial Material							CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; BYPASS		[Lee, Sung-Woo; Hong, Yun-Sik] Korea Univ, Emergency Dept, Ansan Hosp, Seoul 425707, South Korea	Korea University; Korea University Medicine (KU Medicine)	Lee, SW (corresponding author), Korea Univ, Emergency Dept, Ansan Hosp, Seoul 425707, South Korea.	kuedlee@korea.ac.kr						*AM HEART ASS, 2005, CIRCULATION, V112, P47; CHEN YS, 2008, LANCET          0707; Dalton HJ, 2005, SEMIN PERINATOL, V29, P24, DOI 10.1053/j.semperi.2005.02.005; Eich C, 2005, RESUSCITATION, V67, P145, DOI 10.1016/j.resuscitation.2005.05.002; Martin GB, 1998, CHEST, V113, P743, DOI 10.1378/chest.113.3.743; MULLER XM, 2001, ASAIO J, V46, P426; Nagao K, 2000, J AM COLL CARDIOL, V36, P776, DOI 10.1016/S0735-1097(00)00779-8; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Schultz SC, 1996, RESUSCITATION, V33, P13, DOI 10.1016/S0300-9572(96)00986-0; Shin JS, 2007, RESUSCITATION, V73, P309, DOI 10.1016/j.resuscitation.2006.09.011	11	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 16	2008	372	9638					512	514		10.1016/S0140-6736(08)60959-9	http://dx.doi.org/10.1016/S0140-6736(08)60959-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18603292				2023-01-03	WOS:000258582300006
J	Iheanacho, I				Iheanacho, Ike			Not a silly story	BRITISH MEDICAL JOURNAL			English	Editorial Material												iiheanacho@bmjgroup.com						2008, BRIT MED J, V337, pA618	1	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 26	2008	337	7663							a919	10.1136/bmj.a919	http://dx.doi.org/10.1136/bmj.a919			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	335EG	18650231				2023-01-03	WOS:000258273000048
J	Carrano, AC; Liu, Z; Dillin, A; Hunter, T				Carrano, Andrea C.; Liu, Zheng; Dillin, Andrew; Hunter, Tony			A conserved ubiquitination pathway determines longevity in response to diet restriction	NATURE			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; LIFE-SPAN; PHARYNGEAL DEVELOPMENT; TRANSCRIPTION FACTOR; GENETICS; DAF-16; LIGASE; INSULIN/IGF-1; DEGRADATION	Dietary restriction extends longevity in diverse species, suggesting that there is a conserved mechanism for nutrient regulation and prosurvival responses(1). Here we show a role for the HECT (homologous to E6AP carboxy terminus) E3 ubiquitin ligase WWP-1 as a positive regulator of lifespan in Caenorhabditis elegans in response to dietary restriction. We find that overexpression of wwp-1 in worms extends lifespan by up to 20% under conditions of ad libitum feeding. This extension is dependent on the FOXA transcription factor pha-4, and independent of the FOXO transcription factor daf-16. Reduction of wwp-1 completely suppresses the extended longevity of diet-restricted animals. However, the loss of wwp-1 does not affect the long lifespan of animals with compromised mitochondrial function or reduced insulin/IGF-1 signalling. Overexpression of a mutant form of WWP-1 lacking catalytic activity suppresses the increased lifespan of diet-restricted animals, indicating that WWP-1 ubiquitin ligase activity is essential for longevity. Furthermore, we find that the E2 ubiquitin conjugating enzyme, UBC-18, is essential and specific for diet-restriction-induced longevity. UBC-18 interacts with WWP-1 and is required for the ubiquitin ligase activity of WWP-1 and the extended longevity of worms overexpressing wwp-1. Taken together, our results indicate that WWP-1 and UBC-18 function to ubiquitinate substrates that regulate diet-restriction-induced longevity.	[Carrano, Andrea C.; Liu, Zheng; Dillin, Andrew; Hunter, Tony] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Liu, Zheng; Dillin, Andrew] Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; [Liu, Zheng; Dillin, Andrew] Glenn Ctr Aging Res, La Jolla, CA 92037 USA	Salk Institute; Howard Hughes Medical Institute; Salk Institute	Dillin, A (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Dillin@salk.edu	Liu, Zheng/E-6302-2012	Liu, Zheng/0000-0002-7968-3849	National Institutes of Health (NIH) National Center for Research Resources (NCRR); National Cancer Institute [CA 14195, CA 54418, CA 82683]; National Institute of Diabetes and Digestive and Kidney Diseases [DK 070696]; National Institute on Aging [AG 027463, AG 032560]; Ellison Medical and Glenn Medical Foundations; American Cancer Society; NATIONAL CANCER INSTITUTE [P30CA014195, R01CA082683, P01CA054418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG027463, R21AG032560] Funding Source: NIH RePORTER	National Institutes of Health (NIH) National Center for Research Resources (NCRR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Ellison Medical and Glenn Medical Foundations; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank members of the Dillin laboratory for discussion, and P. Marks and H. Sun for their help. We thank A. Brunet for the solid-plate diet-restriction protocol. wwp-1(ok1102) was generated by the C. elegans Gene Knockout Consortium, and some strains were provided by the Caenorhabditis Genetics Center, which is funded by the National Institutes of Health (NIH) National Center for Research Resources (NCRR). This work was supported by grants from the National Cancer Institute (CA 14195, CA 54418 and CA 82683) to T. H., and grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK 070696) and the National Institute on Aging (AG 027463 and AG 032560), and the Ellison Medical and Glenn Medical Foundations to A. D. A. C. C. was supported by an American Cancer Society Postdoctoral Fellowship and The Rossi Endowment. T. H. is a Frank and Else Schilling American Cancer Society Professor.	Alcedo J, 2004, NEURON, V41, P45, DOI 10.1016/S0896-6273(03)00816-X; Apfeld J, 1999, NATURE, V402, P804, DOI 10.1038/45544; Astin JW, 2008, DNA REPAIR, V7, P267, DOI 10.1016/j.dnarep.2007.10.004; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; BRENNER S, 1974, GENETICS, V77, P71; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Dillin A, 2002, SCIENCE, V298, P2398, DOI 10.1126/science.1077780; Dillin A, 2002, SCIENCE, V298, P830, DOI 10.1126/science.1074240; Fay DS, 2003, DEVELOPMENT, V130, P3319, DOI 10.1242/dev.00561; Fay DS, 2004, DEV BIOL, V271, P11, DOI 10.1016/j.ydbio.2004.03.022; Feng JL, 2001, DEV CELL, V1, P633, DOI 10.1016/S1534-5807(01)00071-5; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; HOPE IA, 1999, C ELEGANS PRACTICAL, P62; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lee SS, 2003, NAT GENET, V33, P40, DOI 10.1038/ng1056; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 2001, NAT GENET, V28, P139, DOI 10.1038/88850; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Mair W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004535; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Qiu XH, 2006, DEV BIOL, V291, P239, DOI 10.1016/j.ydbio.2005.11.045; Rual JF, 2004, GENOME RES, V14, P2162, DOI 10.1101/gr.2505604; Sheaffer KL, 2008, CURR BIOL, V18, P1355, DOI 10.1016/j.cub.2008.07.097; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; Wolff S, 2006, CELL, V124, P1039, DOI 10.1016/j.cell.2005.12.042; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200	38	91	103	1	46	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 16	2009	460	7253					396	U113		10.1038/nature08130	http://dx.doi.org/10.1038/nature08130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	470MO	19553937	Green Accepted			2023-01-03	WOS:000267979000039
J	Doyal, L				Doyal, Len			Personal View Euthanasia and free speech in Ireland	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London, London WC1E 7HU, England	University of London	Doyal, L (corresponding author), Univ London, London WC1E 7HU, England.	l.doyal@qmul.ac.uk						Battin MP, 2007, J MED ETHICS, V33, P591, DOI 10.1136/jme.2007.022335; Doyal L, 2001, BMJ-BRIT MED J, V323, P1079, DOI 10.1136/bmj.323.7321.1079; DOYAL L, 2009, IRISH TIMES     0424; DOYAL L, 2006, 1 DO NO HARM, P461; Doyal Len., 2006, CLIN ETHICS, V1, P65, DOI DOI 10.1258/147775006777254579; Lewis P, 2007, J LAW MED ETHICS, V35, P197, DOI 10.1111/j.1748-720X.2007.00124.x; MINIHAN M, 2009, IRISH TIMES     0418; 2009, PRIME TIME      0428	8	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAY 27	2009	338								b2109	10.1136/bmj.b2109	http://dx.doi.org/10.1136/bmj.b2109			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	451WT	19474015				2023-01-03	WOS:000266502300015
J	Enoch, S; Roshan, A; Shah, M				Enoch, Stuart; Roshan, Amit; Shah, Mamta			Emergency and early management of burns and scalds	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PEDIATRIC BURNS; RESUSCITATION; GUIDELINES; MORTALITY; DEATH; CARE; ABC		[Shah, Mamta] Cent Manchester & Manchester Childrens Hosp NHS T, Manchester, Lancs, England; [Enoch, Stuart] Univ Hosp Manchester, Manchester M23 9LT, Lancs, England; [Roshan, Amit] Addenbrookes Hosp, Cambridge Univ Hosp, Cambridge CB2 8QE, England	Royal Manchester Children's Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Shah, M (corresponding author), Booth Hall Childrens Hosp, Reg Paediat Burns Unit, Manchester M9 7AA, Lancs, England.	mamta.shah@cmmc.nhs.uk	Roshan, Amit/AAV-5512-2020	Roshan, Amit/0000-0002-2034-2759				Allison K, 2004, EMERG MED J, V21, P112, DOI 10.1136/emj.2003.008789; Alsbjorn B, 2007, BURNS, V33, P155, DOI 10.1016/j.burns.2006.07.025; Barrow RE, 2000, RESUSCITATION, V45, P91, DOI 10.1016/S0300-9572(00)00175-1; Bloemsma GC, 2008, BURNS, V34, P1103, DOI 10.1016/j.burns.2008.02.010; *BRIT BURN ASS, 2008, EM MAN SEV BURSN COU; Cubison TCS, 2006, BURNS, V32, P992, DOI 10.1016/j.burns.2006.02.007; Hettiaratchy S, 2004, BMJ-BRIT MED J, V329, P101, DOI 10.1136/bmj.329.7457.101; Hudspith J, 2004, BRIT MED J, V328, P1487, DOI 10.1136/bmj.328.7454.1487; La Hei ER, 2006, BURNS, V32, P550, DOI 10.1016/j.burns.2005.11.014; McGill DJ, 2007, BURNS, V33, P833, DOI 10.1016/j.burns.2006.10.404; *NAT BURN CAR REV, 2001, STAND STRAT BURN CAR, P68; Peck MD, 2008, BURNS, V34, P303, DOI 10.1016/j.burns.2007.08.014; Pereira C, 2004, BURNS, V30, P761, DOI 10.1016/j.burns.2004.05.012; Perel P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub3; Pham TN, 2008, J BURN CARE RES, V29, P257, DOI 10.1097/BCR.0b013e31815f3876; Renkielska A, 2006, BURNS, V32, P867, DOI 10.1016/j.burns.2006.01.024; Ryan CM, 1998, NEW ENGL J MED, V338, P362, DOI 10.1056/NEJM199802053380604; Sawada Y, 1997, BURNS, V23, P55, DOI 10.1016/S0305-4179(96)00080-0; Wachtel TL, 2000, BURNS, V26, P156, DOI 10.1016/S0305-4179(99)00047-9; Wharton SM, 2001, BURNS, V27, P183, DOI 10.1016/S0305-4179(00)00097-8; Whitaker IS, 2008, ANN PLAS SURG, V60, P333, DOI 10.1097/SAP.0b013e31806bf446; *WHO, FACTS INJ BURNS; Wilkinson E, 1998, BURNS, V24, P139, DOI 10.1016/S0305-4179(98)80001-6; Yuan J, 2007, J BURN CARE RES, V28, P514, DOI 10.1097/BCR.0B013E318053DB13	24	31	34	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 8	2009	338								b1037	10.1136/bmj.b1037	http://dx.doi.org/10.1136/bmj.b1037			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	431ZI	19357185				2023-01-03	WOS:000265102900001
J	Fellstrom, BC; Jardine, AG; Schmieder, RE; Holdaas, H; Bannister, K; Beutler, J; Chae, DW; Chevaile, A; Cobbe, SM; Gronhagen-Riska, C; De Lima, JJ; Lins, R; Mayer, G; McMahon, AW; Parving, HH; Remuzzi, G; Samuelsson, O; Sonkodi, S; Suleymanlar, G; Tsakiris, D; Tesar, V; Todorov, V; Wiecek, A; Wuthrich, RP; Gottlow, M; Johnsson, E; Zannad, F				Fellstroem, Bengt C.; Jardine, Alan G.; Schmieder, Roland E.; Holdaas, Hallvard; Bannister, Kym; Beutler, Jaap; Chae, Dong-Wan; Chevaile, Alejandro; Cobbe, Stuart M.; Groenhagen-Riska, Carola; De Lima, Jose J.; Lins, Robert; Mayer, Gert; McMahon, Alan W.; Parving, Hans-Henrik; Remuzzi, Giuseppe; Samuelsson, Ola; Sonkodi, Sandor; Sueleymanlar, Gultekin; Tsakiris, Dimitrios; Tesar, Vladimir; Todorov, Vasil; Wiecek, Andrzej; Wuethrich, Rudolf P.; Gottlow, Mattis; Johnsson, Eva; Zannad, Faiez		AURORA Study Grp	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANT RECIPIENTS; TYPE-2 DIABETES-MELLITUS; CARDIAC OUTCOMES; DIALYSIS PATIENTS; DISEASE; ATORVASTATIN; CHOLESTEROL; CORONARY; INFLAMMATION; RISK	Background Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved. Methods We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events. Results After 3 months, the mean reduction in low-density lipoprotein (LDL) cholesterol levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg per deciliter (2.6 mmol per liter). During a median follow-up period of 3.8 years, 396 patients in the rosuvastatin group and 408 patients in the placebo group reached the primary end point (9.2 and 9.5 events per 100 patient-years, respectively; hazard ratio for the combined end point in the rosuvastatin group vs. the placebo group, 0.96; 95% confidence interval [CI], 0.84 to 1.11; P = 0.59). Rosuvastatin had no effect on individual components of the primary end point. There was also no significant effect on all-cause mortality (13.5 vs. 14.0 events per 100 patient-years; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P = 0.51). Conclusions In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)	[Fellstroem, Bengt C.] Univ Uppsala Hosp, Renal Unit, Dept Med Sci, SE-75185 Uppsala, Sweden; [Samuelsson, Ola] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Gottlow, Mattis; Johnsson, Eva] AstraZeneca, Molndal, Sweden; [Jardine, Alan G.; Cobbe, Stuart M.] British Heart Fdn, Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Schmieder, Roland E.] Univ Hosp, Erlangen, Germany; [Holdaas, Hallvard] Univ Oslo, Rikshosp, N-0027 Oslo, Norway; [Bannister, Kym] Royal Adelaide Hosp, Adelaide, SA 5000, Australia; [Beutler, Jaap] Jeroen Bosch Hosp, Shertogenbosch, Netherlands; [Chae, Dong-Wan] Seoul Natl Univ, Bundang Hosp, Kyonggi Do, South Korea; [Chevaile, Alejandro] Hosp Cent Dr Ignacio Morones Prieto, San Luis Potosi, Mexico; [Groenhagen-Riska, Carola] Helsinki Univ Hosp, Helsinki, Finland; [De Lima, Jose J.] Univ Sao Paulo, Fac Med, Hosp Clin, Heart Inst InCor, Sao Paulo, Brazil; [Lins, Robert] ZNA Stuivenberg, Antwerp, Belgium; [Mayer, Gert] Med Univ Innsbruck, Innsbruck, Austria; [McMahon, Alan W.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; [Parving, Hans-Henrik] Rigshosp, DK-2100 Copenhagen, Denmark; [Parving, Hans-Henrik] Aarhus Univ, Aarhus, Denmark; [Remuzzi, Giuseppe] Osped Riuniti Bergamo, Azienda Osped, I-24100 Bergamo, Italy; [Sonkodi, Sandor] Szeged Sci Univ, Szeged, Hungary; [Sueleymanlar, Gultekin] Akdeniz Univ, TR-07058 Antalya, Turkey; [Tsakiris, Dimitrios] Gen Hosp Veria, Veria, Greece; [Tesar, Vladimir] Charles Univ Prague, Prague, Czech Republic; [Todorov, Vasil] Univ Hosp, Pleven, Bulgaria; [Wiecek, Andrzej] Med Univ Silesia, Katowice, Poland; [Wuethrich, Rudolf P.] Univ Zurich Hosp, CH-8091 Zurich, Switzerland; [Zannad, Faiez] Ctr Hosp Univ, Ctr Invest Clin, Nancy, France; [Zannad, Faiez] Nancy Univ, Nancy, France	Uppsala University; Uppsala University Hospital; Sahlgrenska University Hospital; AstraZeneca; University of Glasgow; University of Erlangen Nuremberg; University of Oslo; National Hospital Norway; Royal Adelaide Hospital; Jeroen Bosch Ziekenhuis; Seoul National University (SNU); Hospital Central Dr. Ignacio Morones Prieto; University of Helsinki; Helsinki University Central Hospital; Universidade de Sao Paulo; ZNA Stuivenberg; Medical University of Innsbruck; University of Alberta; Rigshospitalet; University of Copenhagen; Aarhus University; Ospedali Riuniti di Bergamo; Szeged University; Akdeniz University; Charles University Prague; Medical University Pleven; Medical University Silesia; University of Zurich; University Zurich Hospital; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine	Fellstrom, BC (corresponding author), Univ Uppsala Hosp, Renal Unit, Dept Med Sci, SE-75185 Uppsala, Sweden.	bengt.fellstrom@medsci.uu.se	Johnson, David/F-2897-2011; Zoccali, Carmine/B-9445-2009; Zannad, Faiez/K-4649-2019; Gowdak, Luis Henrique Wolff/M-7153-2017; Healy, Helen/G-2686-2010; Švára, František/S-8133-2019; Tesar, Vladimir/O-2312-2017; Gowdak, Luis Henrique Wolff/C-4844-2012; Jardine, Alan/L-5770-2019; Švára, František/R-4544-2017; Suleymanlar, Gultekin/C-2106-2016; Remuzzi, Giuseppe/V-9766-2017	Johnson, David/0000-0001-5491-3460; Gowdak, Luis Henrique Wolff/0000-0002-6785-7506; Healy, Helen/0000-0003-4342-5300; Tesar, Vladimir/0000-0001-6982-0689; Gowdak, Luis Henrique Wolff/0000-0002-6785-7506; Švára, František/0000-0002-9189-7524; Suleymanlar, Gultekin/0000-0001-7935-6402; Bos, Willem Jan W/0000-0002-5062-2567; Mayer, Gert/0000-0002-5039-543X; Dehais, frederic/0000-0003-0854-7919; Maxwell, Alexander P./0000-0002-6110-7253; Mount, Peter/0000-0001-7637-3661; Jardine, Alan/0000-0001-5815-9370; Debska-Slizien, Maria Alicja/0000-0001-8210-8063; Remuzzi, Giuseppe/0000-0002-6194-3446; Van der Niepen, Patricia/0000-0002-6401-1580; van Buren, Marjolijn/0000-0002-1822-6863	Novartis; Roche; Merck-Schering-Plough; Wyeth; Amgen; AstraZeneca; Genzyme; Vifor	Novartis(Novartis); Roche(Roche Holding); Merck-Schering-Plough(Merck & CompanySchering Plough Corporation); Wyeth(Wyeth); Amgen(Amgen); AstraZeneca(AstraZeneca); Genzyme(Sanofi-AventisGenzyme Corporation); Vifor	Dr. Fellstrom reports receiving consulting fees from AstraZeneca, Novartis, Roche, and Wyeth, lecture fees from Astellas, Novartis, and Roche, and grant support from Novartis, Roche, Merck-Schering-Plough, and Wyeth and serving as national coordinator for the Study of Heart and Renal Protection (SHARP) study at Oxford University's Clinical Trial Service Unit; Dr. Jardine, receiving consulting fees from Novartis, AstraZeneca, and Wyeth and lecture fees from Novartis and Astellas; Dr. Schmie-der, receiving consulting and lecture fees from AstraZeneca, Novartis, Merck Sharp & Dohme, and Pfizer; Dr. Holdaas, receiving consulting fees from Novartis, AstraZeneca, and Schering-Plough and lecture fees from Novartis and AstraZeneca, and serving as national coordinator for the SHARP study; Dr. Bannister, receiving consulting fees from Baxter, Amgen, and Genzyme, lecture fees from Servier and Boehringer Ingelheim, and grant support from Amgen; Dr. Beutler, receiving lecture fees from Pfizer; Dr. Chevaile, receiving consulting fees from AstraZeneca; Dr. Cobbe, receiving consulting fees and grant support from AstraZeneca; Dr. Gronhagen-Riska, receiving grant support from AstraZeneca and serving as national coordinator for the SHARP study; Dr. De Lima, receiving consulting fees from AstraZeneca; Dr. Lins, receiving consulting fees from AstraZeneca and Novartis and lecture fees from Servier and Sanofi-Aventis; Dr. Mayer, receiving consulting fees from AstraZeneca and Genzyme, lecture fees from Genzyme and Amgen, and grant support from Amgen; Dr. McMahon, receiving consulting fees from AstraZeneca and Schering-Plough and lecture fees from AstraZeneca; Dr. Parving, receiving consulting and lecture fees from AstraZeneca, Merck, and Novartis and having equity ownership and stock options in Novo Nordisk; Dr. Remuzzi, serving on the Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients with Progressive Renal Disease (PLANET) and AURORA advisory committees for AstraZeneca; Dr. Samuelsson, receiving lecture fees from AstraZeneca; Dr. Sonkodi, receiving lecture fees from AstraZeneca, Richter Gedeon Nyrt, and Egis Nyrt; Dr. Tesar, receiving lecture fees from Amgen and Novartis; Dr. Wiecek, receiving consulting fees from AstraZeneca; Dr. Wuthrich, receiving consulting fees from Amgen, Genzyme, Novartis, and Vifor, lecture fees from Amgen, Vifor, and Wyeth, and grant support from Amgen, Genzyme, Novartis, Vifor, and Wyeth; Mr. Gottlow, being an employee of and owning stock or having other ownership interest in AstraZeneca; Dr. Johnsson, being an employee of and owning stock or having other ownership interest in AstraZeneca; and Dr. Zannad, receiving consulting fees from Servier, Novartis, ResMed, Daiichi Sankyo, Pfizer, AstraZeneca, and Merck and lecture fees from Pfizer, Daiichi Sankyo, Servier, and Medtronic. All authors except for employees of AstraZeneca received honoraria for serving on the steering committee of the AURORA study. No other potential conflict of interest relevant to this article was reported.; We thank all the participating patients, study nurses, investigators, and members of the AURORA data and safety monitoring board and clinical end-point committee for making the trial possible; Dr. A. H. Zwinderman (Amsterdam) for independent data analysis; and Karin Sabel (AstraZeneca, Molndal, Sweden), study team leader. AstraZeneca provided and funded editorial support for an earlier version of the article.	Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Baigent C, 2008, LANCET, V371, P2084; Baigent C, 2000, LANCET, V356, P147, DOI 10.1016/S0140-6736(00)02456-9; Baigent C, 2003, KIDNEY INT, V63, pS207, DOI 10.1046/j.1523-1755.63.s84.4.x; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Baigent C, 2007, SEMIN DIALYSIS, V20, P498, DOI 10.1111/j.1525-139X.2007.00340.x; Dale KM, 2006, JAMA-J AM MED ASSOC, V295, P74, DOI 10.1001/jama.295.1.74; Fellstrom B, 2005, CURR CONTR TRIALS C, V6, DOI 10.1186/1468-6708-6-9; Fellstrom B, 2007, KIDNEY BLOOD PRESS R, V30, P314, DOI 10.1159/000106803; Foley RN, 2005, J AM SOC NEPHROL, V16, P489, DOI 10.1681/ASN.2004030203; Ford I, 2007, NEW ENGL J MED, V357, P1477, DOI 10.1056/NEJMoa065994; Forrester JS, 2007, AM J CARDIOL, V99, P732, DOI 10.1016/j.amjcard.2006.09.125; Geluk CA, 2005, EUR HEART J, V26, P1314, DOI 10.1093/eurheartj/ehi253; Guerin AP, 2008, CURR HYPERTENS REP, V10, P107, DOI 10.1007/s11906-008-0021-2; Herzog CA, 2008, SEMIN DIALYSIS, V21, P300, DOI 10.1111/j.1525-139X.2008.00455.x; Holdaas H, 2005, AM J TRANSPLANT, V5, P2929, DOI 10.1111/j.1600-6143.2005.01105.x; Holdaas H, 2003, LANCET, V361, P2024, DOI 10.1016/S0140-6736(03)13638-0; Kidney Disease Outcomes Quality Initiative (K/DOQI) Group, 2003, AM J KIDNEY DIS S, V41, pI; Kjekshus J, 2007, NEW ENGL J MED, V357, P2248, DOI 10.1056/NEJMoa0706201; Krane V, 2008, KIDNEY INT, V74, P1461, DOI 10.1038/ki.2008.484; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Mason NA, 2005, AM J KIDNEY DIS, V45, P119, DOI 10.1053/j.ajkd.2004.09.025; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; *ROY COLL PHYS, 2006, CHRON KIDN DIS AD UK; Sarnak MJ, 2003, AM J KIDNEY DIS, V41, pS11, DOI 10.1016/S0272-6386(03)00372-X; Sever PS, 2003, LANCET, V361, P1149, DOI 10.1016/S0140-6736(03)12948-0; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Shepherd J, 2008, J AM COLL CARDIOL, V51, P1448, DOI 10.1016/j.jacc.2007.11.072; Tavazzi L, 2008, LANCET, V372, P1231, DOI 10.1016/S0140-6736(08)61240-4; Thavendiranathan P, 2006, ARCH INTERN MED, V166, P2307, DOI 10.1001/archinte.166.21.2307; Tonelli M, 2004, CIRCULATION, V110, P1557, DOI 10.1161/01.CIR.0000143892.84582.60; Tonelli M, 2006, BMJ-BRIT MED J, V332, P1426, DOI 10.1136/bmj.38814.566019.2F; Vaziri ND, 2006, AM J PHYSIOL-RENAL, V290, pF262, DOI 10.1152/ajprenal.00099.2005; Wanner C, 2005, NEW ENGL J MED, V353, P1640; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545	35	1407	1452	4	129	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	2009	360	14					1395	1407		10.1056/NEJMoa0810177	http://dx.doi.org/10.1056/NEJMoa0810177			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427AL	19332456	Green Published			2023-01-03	WOS:000264751800005
J	Hong, HS; Lee, J; Lee, E; Kwon, YS; Lee, E; Ahn, W; Jiang, MH; Kim, JC; Son, Y				Hong, Hyun Sook; Lee, Jungsun; Lee, EunAh; Kwon, Young Sam; Lee, Eunkyung; Ahn, Woosung; Jiang, Mei Hua; Kim, Jae Chan; Son, Youngsook			A new role of substance P as an injury-inducible messenger for mobilization of CD29(+) stromal-like cells	NATURE MEDICINE			English	Article							MESENCHYMAL STEM-CELLS; GROWTH-FACTOR RECEPTOR; BONE-MARROW STROMA; MYOCARDIAL-INFARCTION; PROTEIN-KINASE; WOUND REPAIR; DIFFERENTIATION; ACTIVATION; PROLIFERATION; EXPRESSION	Tissue injury may create a specific microenvironment for inducing the systemic participation of stromal-like cells in the repair process. Here we show that substance P is an injury-inducible factor that acts early in the wound healing process to induce CD29(+) stromal-like cell mobilization. Likewise, mobilization of such cells also occurs in uninjured mice, rats and rabbits if substance P is intravenously injected. Upon further characterization these substance P-mobilized CD29(+) cells were found to be similar to stromal cells from a number of connective tissues, including bone marrow (that is, bone marrow stromal cells, or BMSCs). Both substance P injection and transfusion of autologously derived substance P-mobilized CD29(+) cells from uninjured rabbits accelerated wound healing in an alkali burn model. Also, epithelial engraftment of the transfused cells into the injured tissue occurred during the wound healing. Finally, using human BMSCs as a test population, we show that substance P stimulates transmigration, cell proliferation, activation of the extracellular signal-related kinases (Erk) 1 and 2 and nuclear translocation of beta-catenin in vitro. This finding highlights a previously undescribed function of substance P as a systemically acting messenger of injury and a mobilizer of CD29(+) stromal-like cells to participate in wound healing.	[Kwon, Young Sam; Kim, Jae Chan] Chung Ang Univ, Coll Med, Dept Ophthalmol, Seoul 140757, South Korea; [Hong, Hyun Sook; Lee, EunAh; Lee, Eunkyung; Ahn, Woosung; Jiang, Mei Hua; Son, Youngsook] Kyung Hee Univ, Grad Sch Biotechnol, Yongin 441706, South Korea; [Hong, Hyun Sook; Lee, EunAh; Lee, Eunkyung; Ahn, Woosung; Jiang, Mei Hua; Son, Youngsook] Kyung Hee Univ, Coll Life Sci, Dept Genet Engn, Yongin 441706, South Korea; [Hong, Hyun Sook; Lee, Jungsun] Seoul Natl Univ Technol, MCTT, Inst Res & Dev, Seoul 139743, South Korea	Chung Ang University; Chung Ang University Hospital; Kyung Hee University; Kyung Hee University	Kim, JC (corresponding author), Chung Ang Univ, Coll Med, Dept Ophthalmol, Hangangro 3,65-207, Seoul 140757, South Korea.	jck50ey@kornet.net; ysson@khu.ac.kr	HONG, HYUN SOOK/AAI-3017-2020; Ahn, Woosung/GXG-2482-2022	HONG, HYUN SOOK/0000-0003-3659-1386; Ahn, Woosung/0000-0001-6933-4947				Al-Sarraj A, 2002, NEUROSCI LETT, V332, P111, DOI 10.1016/S0304-3940(02)00939-4; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Castagliuolo I, 2000, J BIOL CHEM, V275, P26545, DOI 10.1074/jbc.M003990200; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; De Boer J, 2004, TISSUE ENG, V10, P393, DOI 10.1089/107632704323061753; GALLAR J, 1990, INVEST OPHTH VIS SCI, V31, P1968; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Ho WZ, 1997, J IMMUNOL, V159, P5654; Kawada H, 2004, BLOOD, V104, P3581, DOI 10.1182/blood-2004-04-1488; Kidd BL, 2003, NEUROREPORT, V14, P2189, DOI 10.1097/00001756-200312020-00011; Kuznetsov SA, 2001, J CELL BIOL, V153, P1133, DOI 10.1083/jcb.153.5.1133; Kuznetsov SA, 2007, STEM CELLS, V25, P1830, DOI 10.1634/stemcells.2007-0140; Lai XN, 1998, PEPTIDES, V19, P1209, DOI 10.1016/S0196-9781(98)00068-0; Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301-472X(02)00883-4; Lim Mira, 2003, Ocul Surf, V1, P53; LOTZ M, 1987, SCIENCE, V235, P893, DOI 10.1126/science.2433770; MILLER A, 1981, NEUROSCI LETT, V23, P243, DOI 10.1016/0304-3940(81)90005-7; Nakamura M, 2003, DIABETOLOGIA, V46, P839, DOI 10.1007/s00125-003-1105-9; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Oh JY, 2008, STEM CELLS, V26, P1047, DOI 10.1634/stemcells.2007-0737; Opalenik SR, 2005, FASEB J, V19, P1561, DOI 10.1096/fj.04-2978fje; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ortiz LA, 2003, P NATL ACAD SCI USA, V100, P8407, DOI 10.1073/pnas.1432929100; PAYAN DG, 1983, J IMMUNOL, V131, P1613; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; RAMESHWAR P, 1993, BLOOD, V81, P391; Rameshwar P, 2001, J NEUROIMMUNOL, V121, P22, DOI 10.1016/S0165-5728(01)00443-X; RAMESHWAR P, 1995, BLOOD, V86, P482, DOI 10.1182/blood.V86.2.482.bloodjournal862482; Rameshwar P, 2001, BLOOD, V97, P3025, DOI 10.1182/blood.V97.10.3025; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Rochefort GY, 2006, STEM CELLS, V24, P2202, DOI 10.1634/stemcells.2006-0164; Rojas M, 2005, AM J RESP CELL MOL, V33, P145, DOI 10.1165/rcmb.2004-0330OC; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Sato Y, 2005, BLOOD, V106, P756, DOI 10.1182/blood-2005-02-0572; Singh D, 2000, P NATL ACAD SCI USA, V97, P388, DOI 10.1073/pnas.97.1.388; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; Watanabe M, 2002, JPN J OPHTHALMOL, V46, P616, DOI 10.1016/S0021-5155(02)00617-2; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood-2004-02-0526; Yamada N, 2004, INVEST OPHTH VIS SCI, V45, P1125, DOI 10.1167/iovs.03-0626; Yang CM, 2002, CELL SIGNAL, V14, P913, DOI 10.1016/S0898-6568(02)00039-6; Ye J, 2004, EYE, V18, P839, DOI 10.1038/sj.eye.6701346; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326; Zhong J, 2006, J CELL PHYSIOL, V207, P540, DOI 10.1002/jcp.20605	46	279	288	2	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					425	435		10.1038/nm.1909	http://dx.doi.org/10.1038/nm.1909			11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	19270709				2023-01-03	WOS:000264937200030
J	Mayers, JR; Iliff, BW; Swoap, SJ				Mayers, Jared R.; Iliff, Benjamin W.; Swoap, Steven J.			Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction	FASEB JOURNAL			English	Article						obesity; dieting; body temperature; heart rate	SMALL-MOLECULE ACTIVATORS; CEREVISIAE LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; HEART-RATE; DIETARY RESTRICTION; BODY-TEMPERATURE; SIRT1; DISEASE; LEPTIN; EXPRESSION	Dietary supplementation with resveratrol may produce calorie restriction-like effects on metabolic and longevity endpoints in mice. In this study, we sought to determine whether resveratrol treatment elicited other hallmark changes associated with calorie restriction, namely bradycardia and decreased body temperature. We found that during short-term treatment, wild-type mice on a calorie-restricted diet experienced significant decreases in both heart rate and body temperature after only 1 day whereas those receiving resveratrol exhibited no such change after 1 wk. We also used ob/ob mice to study the effects of long-term treatment because previous studies had indicated the therapeutic value of resveratrol against the linked morbidities of obesity and diabetes. After 12 wk, resveratrol treatment had produced no changes in either heart rate or body temperature. Strikingly, and in contrast to previous findings, we found that resveratrol-treated mice had significantly reduced endurance in a treadmill test. Quantitative reverse transcriptase-polymerase chain reaction suggested that a proposed target of resveratrol, Sirt1, was activated in resveratrol-treated ob/ob mice. Thus, we conclude that the bradycardia and hypothermia associated with calorie restriction occur through mechanisms unaffected by the actions of resveratrol and that further studies are needed to examine the differential effects of resveratrol in a leptin-deficient background.-Mayers, J. R., Iliff, B. W., Swoap, S. J. Resveratrol treatment in mice does not elicit the bradycardia and hypothermia associated with calorie restriction. FASEB J. 23, 1032-1040 (2009)	[Mayers, Jared R.; Iliff, Benjamin W.; Swoap, Steven J.] Williams Coll, Dept Biol, Williamstown, MA 01267 USA	Williams College	Swoap, SJ (corresponding author), Williams Coll, Dept Biol, Williamstown, MA 01267 USA.	sswoap@williams.edu		Mayers, Jared/0000-0002-8607-1787	U.S. National Institutes of Health [R15 HL081101-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R15HL081101] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by U.S. National Institutes of Health grant R15 HL081101-01 to S.J.S.	Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bass TM, 2007, MECH AGEING DEV, V128, P546, DOI 10.1016/j.mad.2007.07.007; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Bordone L, 2005, NAT REV MOL CELL BIO, V6, P298, DOI 10.1038/nrm1616; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Chen D, 2007, TRENDS MOL MED, V13, P64, DOI 10.1016/j.molmed.2006.12.004; Chen WP, 2007, EUR J PHARMACOL, V568, P269, DOI 10.1016/j.ejphar.2007.04.062; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kaeberlein M, 2006, NATURE, V444, P280, DOI 10.1038/nature05308; Kakuma T, 2000, ENDOCRINOLOGY, V141, P4576, DOI 10.1210/en.141.12.4576; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lane MA, 1999, TOXICOL SCI, V52, P41, DOI 10.1093/toxsci/52.suppl_1.41; Lane MA, 1996, P NATL ACAD SCI USA, V93, P4159, DOI 10.1073/pnas.93.9.4159; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896; Mager DE, 2006, FASEB J, V20, P631, DOI 10.1096/fj.05-5263com; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Ogden CL, 2008, JAMA-J AM MED ASSOC, V299, P2401, DOI 10.1001/jama.299.20.2401; Overton JM, 2004, PHYSIOL BEHAV, V81, P749, DOI 10.1016/j.physbeh.2004.04.025; Pagano C, 2008, NUTR METAB CARDIOVAS, V18, P189, DOI 10.1016/j.numecd.2006.05.009; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pervaiz S, 2003, FASEB J, V17, P1975, DOI 10.1096/fj.03-0168rev; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; Rikke BA, 2003, MECH AGEING DEV, V124, P663, DOI 10.1016/S0047-6374(03)00003-4; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sowden GL, 2007, AM J PHYSIOL-REG I, V292, pR962, DOI 10.1152/ajpregu.00405.2006; Stanley S, 2005, PHYSIOL REV, V85, P1131, DOI 10.1152/physrev.00015.2004; Sun C, 2007, CELL METAB, V6, P307, DOI 10.1016/j.cmet.2007.08.014; Swoap SJ, 2008, AM J PHYSIOL-HEART C, V294, pH1581, DOI 10.1152/ajpheart.01000.2007; Swoap SJ, 2004, AM J PHYSIOL-REG I, V286, pR108, DOI 10.1152/ajpregu.00405.2003; Varady KA, 2007, AM J CLIN NUTR, V86, P7, DOI 10.1093/ajcn/86.1.7; Viswanathan M, 2005, DEV CELL, V9, P605, DOI 10.1016/j.devcel.2005.09.017; Wolf G, 2006, NUTR REV, V64, P89, DOI [10.1111/j.1753-4887.2006.tb00192.x, 10.1301/nr.2006.feb.89-92]; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	53	31	33	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2009	23	4					1032	1040		10.1096/fj.08-115923	http://dx.doi.org/10.1096/fj.08-115923			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZO	19056839	Green Published			2023-01-03	WOS:000266651600007
J	Busse, JW; Kaur, J; Mollon, B; Bhandari, M; Tornetta, P; Schuenemann, HJ; Guyatt, GH				Busse, Jason W.; Kaur, Jagdeep; Mollon, Brent; Bhandari, Mohit; Tornetta, Paul, III; Schuenemann, Holger J.; Guyatt, Gordon H.			Low intensity pulsed ultrasonography for fractures: systematic review of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ELECTRICAL-STIMULATION; ULTRASOUND THERAPY; METAANALYSIS; RECOMMENDATIONS; STRENGTH; QUALITY	Objective To determine the efficacy of low intensity pulsed ultrasonography for healing of fractures. Design Systematic review of randomised controlled trials. Data sources Electronic literature search without language restrictions of CINAHL, Embase, Medline, HealthSTAR, and the Cochrane Central Registry of Controlled Trials, from inception of the database to 10 September 2008. Review methods Eligible studies were randomised controlled trials that enrolled patients with any kind of fracture and randomly assigned them to low intensity pulsed ultrasonography or to a control group. Two reviewers independently agreed on eligibility; three reviewers independently assessed methodological quality and extracted outcome data. All outcomes were included and meta-analyses done when possible. Results 13 randomised trials, of which five assessed outcomes of importance to patients, were included. Moderate quality evidence from one trial found no effect of low intensity pulsed ultrasonography on functional recovery from conservatively managed fresh clavicle fractures; whereas low quality evidence from three trials suggests benefit in non-operatively managed fresh fractures (faster radiographic healing time mean 36.9%, 95% confidence interval 25.6% to 46.0%). A single trial provided moderate quality evidence suggesting no effect of low intensity pulsed ultrasonography on return to function among non-operatively treated stress fractures. Three trials provided very low quality evidence for accelerated functional improvement after distraction osteogenesis. One trial provided low quality evidence for a benefit of low intensity pulsed ultrasonography in accelerating healing of established non-unions managed with bone graft. Four trials provided low quality evidence for acceleration of healing of operatively managed fresh fractures. Conclusion Evidence for the effect of low intensity pulsed ultrasonography on healing of fractures is moderate to very low in quality and provides conflicting results. Although overall results are promising, establishing the role of low intensity pulsed ultrasonography in the management of fractures requires large, blinded trials, directly addressing patient important outcomes such as return to function.	[Busse, Jason W.] Inst Work & Hlth, Toronto, ON M5G 2E9, Canada; [Busse, Jason W.; Kaur, Jagdeep; Bhandari, Mohit; Guyatt, Gordon H.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Mollon, Brent] Univ Western Ontario, Schulich Sch Med & Dent, London, ON, Canada; [Tornetta, Paul, III] Boston Univ, Sch Med, Boston, MA 02215 USA; [Schuenemann, Holger J.] Italian Natl Canc Inst Regina Elena, Unit Clin Res Dev & INFORMAt Translat, Dept Epidemiol, Rome, Italy; [Schuenemann, Holger J.] Italian Natl Canc Inst Regina Elena, Dept Epidemiol, CLAR Res Team, Rome, Italy	Institute for Work & Health; McMaster University; Western University (University of Western Ontario); Boston University	Busse, JW (corresponding author), Inst Work & Hlth, 481 Univ Ave, Toronto, ON M5G 2E9, Canada.	jbusse@iwh.on.ca	Bhandari, Mohit/AAQ-1675-2021; Busse, Jason/CAH-3696-2022	Busse, Jason/0000-0002-0178-8712; Schunemann, Holger/0000-0003-3211-8479; Tornetta, Paul/0000-0002-6448-8864				Akai M, 2002, BIOELECTROMAGNETICS, V23, P132, DOI 10.1002/bem.106; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Basso O, 1998, J HAND SURG-BRIT EUR, V23B, P136, DOI 10.1016/S0266-7681(98)80248-9; Boutron I, 2005, J CLIN EPIDEMIOL, V58, P1233, DOI 10.1016/j.jclinepi.2005.05.004; Busse JW, 2008, ACTA ORTHOP, V79, P689, DOI 10.1080/17453670810016722; Busse JW, 2004, ARCH PHYS MED REHAB, V85, P1653, DOI 10.1016/j.apmr.2003.12.040; Busse JW, 2002, CAN MED ASSOC J, V166, P437; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; *COCHR COLL, 2006, COCHR REV HDB; Cook SD, 1997, CLIN ORTHOP RELAT R, P198; Day SM, 2000, ORTHOPAEDIC BASIC SC, P371; EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623-199506000-00016; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gotzsche PC, 2000, BRIT MED J, V321, P585, DOI 10.1136/bmj.321.7261.585; Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174; Heckman J D, 1997, Bull Hosp Jt Dis, V56, P63; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Khan Y, 2008, J BONE JOINT SURG AM, V90A, P138, DOI 10.2106/JBJS.G.01218; Mollon B, 2008, J BONE JOINT SURG AM, V90A, P2322, DOI 10.2106/JBJS.H.00111; PILLA AA, 1991, ELECTROMAGNETICS IN MEDICINE AND BIOLOGY, P331; Pogue JM, 1997, CONTROL CLIN TRIALS, V18, P580, DOI 10.1016/S0197-2456(97)00051-2; PRAEMER A, 1999, MUSCULOSKELETAL COND, P83; Rubin C, 2001, J BONE JOINT SURG AM, V83A, P259, DOI 10.2106/00004623-200102000-00015; SONG F, 2000, HEALTH TECHNOL ASSES, V4, P111; Wachovia Capital Markets, 2007, EQ RES BON GROWTH ST	27	78	80	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 27	2009	338								b351	10.1136/bmj.b351	http://dx.doi.org/10.1136/bmj.b351			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	417DT	19251751	Green Published, hybrid			2023-01-03	WOS:000264056400003
J	Silvester, JA; Rashid, M				Silvester, Jocelyn Anne; Rashid, Mohsin			A Patient's Journey Coeliac disease and a gluten-free diet	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Rashid, Mohsin] Dalhousie Univ, Fac Med, Dept Paediat, Div Gastroenterol,IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada	Dalhousie University	Rashid, M (corresponding author), Dalhousie Univ, Fac Med, Dept Paediat, Div Gastroenterol,IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada.	mohsin.rashid@iwk.nshealth.ca	Silvester, Jocelyn/T-2680-2019	Silvester, Jocelyn/0000-0002-3615-1666				GODLEE F, 2009, BRIT MED J, V338, pB821; Harnden A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b491; Jones R, 2009, BRIT MED J, V338, DOI 10.1136/bmj.a3058; Willis HWM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3066	4	5	5	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 19	2009	338								b380	10.1136/bmj.b380	http://dx.doi.org/10.1136/bmj.b380			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	417CH	19228765				2023-01-03	WOS:000264052200003
J	Gervas, J; Starfield, B; Heath, I				Gervas, Juan; Starfield, Barbara; Heath, Iona			Is clinical prevention better than cure?	LANCET			English	Editorial Material							HEALTH; CARE		[Gervas, Juan] Equipo CESCA, Med Canencia Sierra Garganta Montes & El Cuadron, Madrid, Spain; [Starfield, Barbara] Johns Hopkins Univ, Baltimore, MD USA; [Heath, Iona] Royal Coll Gen Practitioners, London, England	Novartis; Johns Hopkins University	Gervas, J (corresponding author), Equipo CESCA, Med Canencia Sierra Garganta Montes & El Cuadron, Madrid, Spain.	jgervasc@meditex.es						BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; Bentzen N, 2003, WONCA DICT GEN FAMIL; Bodenheimer T, 2006, NEW ENGL J MED, V355, P861, DOI 10.1056/NEJMp068155; Canadian Health Services Research Foundation, 2004, J Health Serv Res Policy, V9, P191; COCHRANE A L, 1955, R Soc Health J, V75, P584; Fleetcroft Robert, 2006, J Health Serv Res Policy, V11, P27, DOI 10.1258/135581906775094316; Fugelli P, 2006, PATIENT EDUC COUNS, V60, P267, DOI 10.1016/j.pec.2005.11.002; GERVAS J, 2002, EUR J GEN PRACT, V8, P47; Gervas Juan, 2006, Gac Sanit, V20 Suppl 1, P127, DOI 10.1157/13086036; Gray JAM, 1999, LANCET, V354, P1550, DOI 10.1016/S0140-6736(98)08482-7; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Heath I, 2007, BRIT MED J, V334, P19, DOI 10.1136/bmj.39066.541678.B7; HOLTZMAN NA, 1979, INT J HEALTH SERV, V9, P25, DOI 10.2190/9PJP-8R5C-JKJP-LK7A; Ilich I., 1976, MED NEMESIS EXPROPRI; Maciosek MV, 2006, AM J PREV MED, V31, P52, DOI 10.1016/j.amepre.2006.03.012; Moynihan R, 2002, BMJ-BRIT MED J, V324, P859, DOI 10.1136/bmj.324.7342.859; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Richens J, 2000, LANCET, V355, P400, DOI 10.1016/S0140-6736(99)09109-6; Starfield B, 2001, BRIT J GEN PRACT, V51, P303; Steinberg EP, 2005, HEALTH AFFAIR, V24, P80, DOI 10.1377/hlthaff.24.1.80; StewartBrown S, 1997, BRIT MED J, V314, P533, DOI 10.1136/bmj.314.7080.533; van den Hoogen PCW, 2000, NEW ENGL J MED, V342, P1, DOI 10.1056/NEJM200001063420101	22	52	56	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 6	2008	372	9654					1997	1999		10.1016/S0140-6736(08)61843-7	http://dx.doi.org/10.1016/S0140-6736(08)61843-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	380NE	19059049				2023-01-03	WOS:000261471600026
J	Russell, RB; Aloy, P				Russell, Robert B.; Aloy, Patrick			Targeting and tinkering with interaction networks	NATURE CHEMICAL BIOLOGY			English	Review							PROTEIN-PROTEIN INTERACTIONS; YEAST SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR-BINDING; SMALL-MOLECULE INHIBITION; CELL-CELL COMMUNICATION; SYSTEMATIC DISCOVERY; DRUG DISCOVERY; 2-HYBRID ANALYSIS; C-ELEGANS; PEPTIDES	Biological interaction networks have been in the scientific limelight for nearly a decade. Increasingly, the concept of network biology and its various applications are becoming more commonplace in the community. Recent years have seen networks move from pretty pictures with limited application to solid concepts that are increasingly used to understand the fundamentals of biology. They are no longer merely results of postgenome analysis projects, but are now the starting point of many of the most exciting new scientific developments. We discuss here recent progress in identifying and understanding interaction networks, new tools that use them in predictive ways in exciting areas of biology, and how they have become the	[Russell, Robert B.] European Mol Biol Lab, D-69117 Heidelberg, Germany; [Aloy, Patrick] Inst Biomed Res, Barcelona 08028, Spain; [Aloy, Patrick] Barcelona Supercomp Ctr, Barcelona 08028, Spain; [Aloy, Patrick] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain	European Molecular Biology Laboratory (EMBL); Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; Universitat Politecnica de Catalunya; Barcelona Supercomputer Center (BSC-CNS); ICREA	Russell, RB (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	russell@embl.de; patrick.aloy@irbbarcelona.org	Russell, Rob/AAH-9145-2019; Aloy, Patrick/AAB-3538-2019; Russell, Robert/GWU-6389-2022	Russell, Rob/0000-0002-1905-4717; Russell, Robert/0000-0002-7213-1398; Aloy, Patrick/0000-0002-3557-0236	Spanish Ministerio de Educacion y Ciencia [PSE-010000-2007-1 and BIO2007-62426]; European Commission [LSHG-CT-2005-512028]; ICREA Funding Source: Custom	Spanish Ministerio de Educacion y Ciencia(Spanish Government); European Commission(European CommissionEuropean Commission Joint Research Centre); ICREA(ICREA)	We thank the Institute for Research in Biomedicine (IRB Barcelona) and the Banco Bilbao Vizcaya Argentaria Foundation (BBVA Foundation) for organizing the Barcelona Biomed Conference "Targeting and Tinkering with Interaction Networks.'' We also thank R. Weiss (Princeton University) for providing the images for Figure 3 and A. Zanzoni (IRB Barcelona) for help with Figure 1. P. A. acknowledges the financial support received from the Spanish Ministerio de Educacion y Ciencia through the grants PSE-010000-2007-1 and BIO2007-62426. We are both supported by the grant 3D-Repertoire from the European Commission under FP6 contract LSHG-CT-2005-512028.	Adrian FJ, 2006, NAT CHEM BIOL, V2, P95, DOI 10.1038/nchembio760; Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Aloy P, 2006, NAT REV MOL CELL BIO, V7, P188, DOI 10.1038/nrm1859; Aloy Patrick, 2007, Genome Biol, V8, P316, DOI 10.1186/gb-2007-8-10-316; ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Apic G, 2005, FEBS LETT, V579, P1872, DOI 10.1016/j.febslet.2005.02.023; Atsumi S, 2008, NATURE, V451, P86, DOI 10.1038/nature06450; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Bashor CJ, 2008, SCIENCE, V319, P1539, DOI 10.1126/science.1151153; Basu S, 2005, NATURE, V434, P1130, DOI 10.1038/nature03461; Berger Michael F., 2006, V338, P245; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Borneman AR, 2007, SCIENCE, V317, P815, DOI 10.1126/science.1140748; Borneman AR, 2006, GENE DEV, V20, P435, DOI 10.1101/gad.1389306; Braisted AC, 2003, J AM CHEM SOC, V125, P3714, DOI 10.1021/ja034247i; Bulter T, 2004, P NATL ACAD SCI USA, V101, P2299, DOI 10.1073/pnas.0306484101; Bushell KM, 2008, GENOME RES, V18, P622, DOI 10.1101/gr.7187808; Chen MT, 2005, NAT BIOTECHNOL, V23, P1551, DOI 10.1038/nbt1162; Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180; Collins SR, 2007, MOL CELL PROTEOMICS, V6, P439, DOI 10.1074/mcp.M600381-MCP200; de Lorenzo V, 2006, NAT BIOTECHNOL, V24, P952, DOI 10.1038/nbt0806-952; Edwards RJ, 2007, NAT CHEM BIOL, V3, P108, DOI 10.1038/nchembio854; Eyckerman S, 2005, NAT METHODS, V2, P427, DOI 10.1038/NMETH760; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flannick J, 2006, GENOME RES, V16, P1169, DOI 10.1101/gr.5235706; Gavin AC, 2006, NATURE, V440, P631, DOI 10.1038/nature04532; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Gisler SM, 2008, MOL CELL PROTEOMICS, V7, P1362, DOI 10.1074/mcp.M800079-MCP200; Gomez MJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100156; He MM, 2005, SCIENCE, V310, P1022, DOI 10.1126/science.1116304; Isalan M, 2005, PLOS BIOL, V3, P488, DOI 10.1371/journal.pbio.0030064; Isalan M, 2008, NATURE, V452, P840, DOI 10.1038/nature06847; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jansen R, 2003, SCIENCE, V302, P449, DOI 10.1126/science.1087361; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Jhoti H, 2007, CURR OPIN CHEM BIOL, V11, P485, DOI 10.1016/j.cbpa.2007.07.010; Johnson Z, 2004, BIOCHEM SOC T, V32, P366, DOI 10.1042/BST0320366; Juan D, 2008, P NATL ACAD SCI USA, V105, P934, DOI 10.1073/pnas.0709671105; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kashtan N, 2005, P NATL ACAD SCI USA, V102, P13773, DOI 10.1073/pnas.0503610102; Keasling JD, 2008, NAT BIOTECHNOL, V26, P298, DOI 10.1038/nbt0308-298; Kelley BP, 2003, P NATL ACAD SCI USA, V100, P11394, DOI 10.1073/pnas.1534710100; Kiemer Lars, 2007, Trends Biotechnol, V25, P448, DOI 10.1016/j.tibtech.2007.08.002; Koyuturk M, 2006, J COMPUT BIOL, V13, P182, DOI 10.1089/cmb.2006.13.182; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795; Lee MS, 2007, CANCER RES, V67, P11359, DOI 10.1158/0008-5472.CAN-07-2235; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Li QR, 2008, GENOME RES, V18, P1294, DOI 10.1101/gr.076661.108; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Linding R, 2007, CELL, V129, P1415, DOI 10.1016/j.cell.2007.05.052; Lindsay MA, 2005, DRUG DISCOV TODAY, V10, P1683, DOI 10.1016/S1359-6446(05)03670-6; Mahrus S, 2008, CELL, V134, P866, DOI 10.1016/j.cell.2008.08.012; Mani KM, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.2; Matilla-Duenas A, 2008, CEREBELLUM, V7, P97, DOI 10.1007/s12311-008-0020-5; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Mukhopadhyay A, 2008, NAT PROTOC, V3, P698, DOI 10.1038/nprot.2008.38; Neduva V, 2005, PLOS BIOL, V3, P2090, DOI 10.1371/journal.pbio.0030405; Neduva V, 2006, CURR OPIN BIOTECH, V17, P465, DOI 10.1016/j.copbio.2006.08.002; Neumann T, 2007, CURR TOP MED CHEM, V7, P1630, DOI 10.2174/156802607782341073; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orchard S, 2007, NAT BIOTECHNOL, V25, P894, DOI 10.1038/nbt1324; PACHE R, PLOS COMPUT IN PRESS; Papageorgiou AC, 2004, TRENDS PHARMACOL SCI, V25, P558, DOI 10.1016/j.tips.2004.09.008; Paumi CM, 2007, MOL CELL, V26, P15, DOI 10.1016/j.molcel.2007.03.011; Pawson T, 2005, FEBS LETT, V579, P1808, DOI 10.1016/j.febslet.2005.02.013; Pawson T, 2003, PHILOS T R SOC A, V361, P1251, DOI 10.1098/rsta.2003.1197; Pazos F, 2008, METHODS MOL BIOL, V484, P523, DOI 10.1007/978-1-59745-398-1_31; Pearson H, 2007, NATURE, V446, P8, DOI 10.1038/446008a; Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Saez-Rodriguez J, 2008, BIOINFORMATICS, V24, P840, DOI 10.1093/bioinformatics/btn018; Sharan R, 2006, NAT BIOTECHNOL, V24, P427, DOI 10.1038/nbt1196; Stein A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002524; Stein A, 2008, FEBS LETT, V582, P1245, DOI 10.1016/j.febslet.2008.02.020; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Suthram S, 2005, NATURE, V438, P108, DOI 10.1038/nature04135; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van der Greef J, 2005, NAT REV DRUG DISCOV, V4, P961, DOI 10.1038/nrd1904; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vazquez ME, 2003, J AM CHEM SOC, V125, P10150, DOI 10.1021/ja0351847; Vetter D, 2002, J CELL BIOCHEM, P79, DOI 10.1002/jcb.10408; Vidalain PO, 2004, METHODS, V32, P363, DOI 10.1016/j.ymeth.2003.10.001; Warner JB, 2008, NAT METHODS, V5, P347, DOI [10.1038/NMETH.1188, 10.1038/nmeth.1188]; Wei CC, 2005, GENOME RES, V15, P577, DOI 10.1101/gr.3329005; Wells JA, 2007, NATURE, V450, P1001, DOI 10.1038/nature06526; Wolf YI, 2002, BIOESSAYS, V24, P105, DOI 10.1002/bies.10059; Xu JHJ, 2008, TOXICOL SCI, V105, P97, DOI 10.1093/toxsci/kfn109; Yeh BJ, 2007, NAT CHEM BIOL, V3, P521, DOI 10.1038/nchembio0907-521; Yokobayashi Y, 2002, P NATL ACAD SCI USA, V99, P16587, DOI 10.1073/pnas.252535999; YU H, 2008, SCIENCE         0821, DOI DOI 10.1126/SCIENCE.1158684; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008	98	79	80	1	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1552-4450			NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2008	4	11					666	673		10.1038/nchembio.119	http://dx.doi.org/10.1038/nchembio.119			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	364CY	18936751				2023-01-03	WOS:000260315000011
J	Audrey, S; Abel, J; Blazeby, JM; Falk, S; Campbell, R				Audrey, Suzanne; Abel, Julian; Blazeby, Jane M.; Falk, Stephen; Campbell, Rona			What oncologists tell patients about survival benefits of palliative chemotherapy and implications for informed consent: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							DECISION-MAKING; CANCER-PATIENTS; CARE; COMMUNICATION; INFORMATION; PARTICIPATE; FAMILIES; LIFE; TOLD	Objective To examine how much oncologists tell patients about the survival benefit of palliative chemotherapy during consultations at which decisions about treatment are made. Design Qualitative study in which consultations were observed and digitally recorded. Setting Teaching hospital and district general hospital in south west England. Participants 37 patients with advanced non-small cell lung cancer (n=12), pancreatic cancer (n=13), and colorectal cancer (n=12); and nine oncologists, including four consultants and five registrars. Main outcome measures All recordings were transcribed completely, anonymised, and electronically coded with ATLAS.ti. Constant comparison was used to identify themes and patterns. The framework method of data management, in which data were charted, was used to aid transparency of interpretation. Results During the consultations, information given to patients about survival benefit included numerical data ("about fourweeks"), an idea of timescales ("a few months extra', vague references ("buy you some time"), or no mention at all. In most consultations (26/37) discussion of survival benefit was vague or non-existent. Conclusions Most patients were not given clear information about the survival gain of palliative chemotherapy. To aid decision making and informed consent, we recommend that oncologists sensitively describe the benefits and limitations of this treatment, including survival gain.	[Audrey, Suzanne; Campbell, Rona] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; [Abel, Julian] Weston Area Healthcare Trust, Weston Super Mare BS23 4TQ, England; [Blazeby, Jane M.] Univ Bristol, Clin Sci S Bristol, Bristol BS8 2PR, Avon, England; [Blazeby, Jane M.] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; [Blazeby, Jane M.] Univ Hosp Bristol NHS Fdn Trust, Div Head & Neck Surg, Bristol BS2 8HW, Avon, England; [Falk, Stephen] Univ Hosp Bristol NHS Fdn Trust, Bristol Haematol & Oncol Ctr, Bristol BS2 8ED, Avon, England	University of Bristol; University of Bristol; University of Bristol; University of Bristol; Bristol Haematology & Oncology Centre; University of Bristol	Audrey, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	Suzanne.Audrey@bristol.ac.uk	Blazeby, Jane/H-6703-2019	Blazeby, Jane/0000-0002-3354-3330	Cancer Research UK [C17713/A6132]	Cancer Research UK(Cancer Research UK)	Cancer Research UK. C17713/A6132.	Ajaj A, 2001, BRIT MED J, V323, P1160, DOI 10.1136/bmj.323.7322.1160; Archer V R, 1999, Oncologist, V4, P470; Baile WF, 2006, J CLIN ONCOL, V24, P3217, DOI 10.1200/JCO.2006.06.2935; Bowcock SJ, 2004, BRIT MED J, V328, P1430, DOI 10.1136/bmj.328.7453.1430; Charles C, 2000, BRIT MED J, V320, P1220, DOI 10.1136/bmj.320.7244.1220; De Amici D, 2000, CONTROL CLIN TRIALS, V21, P103, DOI 10.1016/S0197-2456(99)00054-9; de Haes H, 2003, PATIENT EDUC COUNS, V50, P43, DOI 10.1016/S0738-3991(03)00079-X; de Kort SJ, 2006, EUR J CANCER, V42, P835, DOI 10.1016/j.ejca.2005.10.026; Department of Health, 2001, CONS WHAT YOU HAV RI; Department of Health, 2000, NHS CANC PLAN PLAN I; Fallowfield L, 2001, BRIT MED J, V323, P1144, DOI 10.1136/bmj.323.7322.1144; Fallowfield LJ, 2002, PALLIATIVE MED, V16, P297, DOI 10.1191/0269216302pm575oa; Faulkner A, 1998, BRIT MED J, V316, P130; Gattellari M, 2001, SOC SCI MED, V52, P1865, DOI 10.1016/S0277-9536(00)00303-8; Glaser B. G., 1998, DOING GROUNDED THEOR; Hagerty RG, 2005, ANN ONCOL, V16, P1005, DOI 10.1093/annonc/mdi211; Jenkins V, 2001, BRIT J CANCER, V84, P48, DOI 10.1054/bjoc.2000.1573; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Koedoot CG, 2002, J CLIN ONCOL, V20, P3658, DOI 10.1200/JCO.2002.12.012; Leighl NB, 2004, J CLIN ONCOL, V22, P1759, DOI 10.1200/JCO.2004.02.166; Maguire P, 2002, BRIT MED J, V325, P697, DOI 10.1136/bmj.325.7366.697; Matsuyama R, 2006, J CLIN ONCOL, V24, P3490, DOI 10.1200/JCO.2005.03.6236; Mayo E., 1933, HUMAN PROBLEMS IND C; MUHR T, 1997, ATLAS TI WINDOWS; MUNDAY D, 2001, BRIT MED J, V322, P232; *NAT I HLTH CLIN E, 2001, TECHN APPR GUID, V26; *NAT I HLTH CLIN E, 2005, IR OX RALT TREATM AD; *NAT I HLTH CLIN E, 2007, NICE TECHN APPR GUID, V118; *NAT I HLTH CLIN E, 2001, TECHN APPR NICE, V25; *NAT I HLTH CLIN E, 2005, TECHN APPR GUID, V93; *NAT I HLTH CLIN E, 2007, TECHN APPR GUID, V118; National Institute for Health and Clinical Excellence, 2001, GUID US GEMC TREATM; National Institute for Health and Clinical Excellence, 2007, UND NICE GUID INF PE; National Institute for Health and Clinical Excellence, 2005, DIAGN TREATM LUNG CA; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Ritchie J., 2003, GUIDE SOCIAL SCI STU, V1, P77; Sanders T, 2003, EUR J CANCER CARE, V12, P166, DOI 10.1046/j.1365-2354.2003.00370.x; Thorne S, 2006, QUAL HEALTH RES, V16, P318, DOI 10.1177/1049732305285341	38	75	76	0	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 30	2008	337	7668							a752	10.1136/bmj.a752	http://dx.doi.org/10.1136/bmj.a752			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	350OM	18669570	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000259362100026
J	Coovadia, HM; Schaller, JG				Coovadia, H. M.; Schaller, Jane G.			HIV/AIDS in children: a disaster in the making	LANCET			English	Editorial Material							HIV TRANSMISSION; SURVIVAL; COUNTRIES		[Schaller, Jane G.] British Columbia Childrens Hosp, Dept Pediat, Int Pediat Assoc, Vancouver, BC V6H 3V4, Canada; [Coovadia, H. M.] Nelson Mandela Sch Med, ZA-4013 Congella, South Africa	BC Childrens Hospital; University of British Columbia; University of Kwazulu Natal	Schaller, JG (corresponding author), British Columbia Childrens Hosp, Dept Pediat, Int Pediat Assoc, Vancouver, BC V6H 3V4, Canada.	jschaller@cw.bc.ca						Bryce J, 2008, LANCET, V371, P1247, DOI 10.1016/S0140-6736(08)60559-0; Coovadia H, 2008, CURR OPIN INFECT DIS, V21, P11, DOI 10.1097/QCO.0b013e3282f40689; Jackson DJ, 2007, AIDS, V21, P509, DOI 10.1097/QAD.0b013e32801424d2; Kumwenda NI, 2008, NEW ENGL J MED, V359, P119, DOI 10.1056/NEJMoa0801941; Orne-Gliemann J, 2008, AIDS, V22, P797, DOI 10.1097/QAD.0b013e3282f4f45a; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Stringer EM, 2008, B WORLD HEALTH ORGAN, V86, P57, DOI 10.2471/BLT.07.043117; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; *UNAIDS WHO, 2007, AIDS EP UPD; UNICEF, 2007, STAT WORLDS CHILDR 2; *WHO UNAIDS UNICEF, 2007, UN ACC SCAL PRIOR HI; Wilfert CM, 2007, J INFECT DIS, V195, P165, DOI 10.1086/510255	12	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL-AUG	2008	372	9635					271	273		10.1016/S0140-6736(08)61090-9	http://dx.doi.org/10.1016/S0140-6736(08)61090-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	331WH	18657693				2023-01-03	WOS:000258042800009
J	Mehanna, HM; Moledina, J; Travis, J				Mehanna, Hisham M.; Moledina, Jamil; Travis, Jane			Refeeding syndrome: what it is, and how to prevent and treat it	BRITISH MEDICAL JOURNAL			English	Review							CRITICALLY ILL PATIENTS; SEVERE HYPOPHOSPHATEMIA		[Mehanna, Hisham M.; Moledina, Jamil] Univ Hosp Coventry, Inst Head & Neck Studies & Educ, Dept Otorhinolaryngol Head & Neck Surg, Coventry CV2 2DX, W Midlands, England; [Mehanna, Hisham M.] Heart England Fdn Trust, Birmingham, W Midlands, England; [Travis, Jane] Univ Hosp Coventry, Dept Dietet, Coventry, W Midlands, England	University of Warwick; Heart of England NHS Foundation Trust; University of Warwick	Mehanna, HM (corresponding author), Univ Hosp Coventry, Inst Head & Neck Studies & Educ, Dept Otorhinolaryngol Head & Neck Surg, Coventry CV2 2DX, W Midlands, England.	Hisham.Mehanna@uhcw.nhs.uk		Mehanna, Hisham/0000-0002-5544-6224				CAMP MA, 1990, MINER ELECTROL METAB, V16, P365; Crook MA, 2001, NUTRITION, V17, P632, DOI 10.1016/S0899-9007(01)00542-1; Dewar H, 2001, POCKET GUIDE CLIN NU, P131; *EV BAS ON CALL DA, 2007, LEV EV; HAYEK ME, 1989, ARCH SURG-CHICAGO, V124, P1325; Hearing SD, 2004, BRIT MED J, V328, P908, DOI 10.1136/bmj.328.7445.908; Klein CJ, 1998, J AM DIET ASSOC, V98, P795, DOI 10.1016/S0002-8223(98)00179-5; KNOCHEL JP, 1977, ARCH INTERN MED, V137, P203, DOI 10.1001/archinte.137.2.203; Marik PE, 1996, ARCH SURG-CHICAGO, V131, P1043, DOI 10.1001/archsurg.1996.01430220037007; Martinez MJ, 2006, NUTR HOSP, V21, P657; MCCRAY S, 2004, PRACTICAL GASTROENTE, V27, P26; National Institute for Health and Clinical Excellence, 2006, NUTR SUPP AD CLIN GU; Perreault MM, 1997, ANN PHARMACOTHER, V31, P683, DOI 10.1177/106002809703100603; REULER JB, 1985, NEW ENGL J MED, V312, P1035, DOI 10.1056/NEJM198504183121606; SILVIS SE, 1972, GASTROENTEROLOGY, V62, P513; SOLOMON SM, 1990, JPEN-PARENTER ENTER, V14, P90, DOI 10.1177/014860719001400190; Terlevich A, 2003, ALIMENT PHARM THER, V17, P1325, DOI 10.1046/j.1365-2036.2003.01567.x; VEVERBRANTS E, 1969, J CLIN ENDOCR METAB, V29, P55, DOI 10.1210/jcem-29-1-55; WACKER WEC, 1968, NEW ENGL J MED, V278, P658, DOI 10.1056/NEJM196803212781205; Weinster RL, 1980, AM J CLIN NUTR, V34, P393	20	297	314	0	43	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 28	2008	336	7659					1495	1498		10.1136/bmj.a301	http://dx.doi.org/10.1136/bmj.a301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	324GN	18583681	Green Published			2023-01-03	WOS:000257505900039
J	Bonevski, B; Wilson, A; Henry, DA				Bonevski, Billie; Wilson, Amanda; Henry, David A.			An Analysis of News Media Coverage of Complementary and Alternative Medicine	PLOS ONE			English	Article							NATIONAL-SURVEY; BREAST-CANCER; HEALTH; GENETICS; BENEFITS; THERAPY; STORIES; IMPACT; DRUGS	Background: To examine the accuracy and adequacy of lay media news stories about complementary and alternative medicines and therapies. Methodology/Principal Findings: A descriptive analysis of news stories about complementary and alternative medicine (CAM) in the Australian media using a national medical news monitoring website, mediadoctor.org.au. Each story was rated against 10 criteria by two individuals. Consensus scores of 222 news articles reporting therapeutic claims about complementary medicines posted on mediadoctor.org.au between 1 January 2004 and 1 September 2007 were calculated. The overall rating score for 222 CAM articles was 50% (95% CI 47% to 53%). There was a statistically significant (F = 3.68, p = 0.006) difference in cumulative mean scores according to type of therapy: biologically based practices (54%, 95% CI 50% to 58%); manipulative body based practices (46%, 95% CI 39% to 54%), whole medical systems (45%, 95% CI 32% to 58%), mind body medicine (41%, 95% CI 31% to 50%) and energy medicine (33%, 95% CI 11% to 55%). There was a statistically significant difference in cumulative mean scores (F = 3.72, p = 0.0001) according to the clinical outcome of interest with stories about cancer treatments (62%, 95% CI 54% to 70%) scoring highest and stories about treatments for children's behavioural and mental health concerns scoring lowest (31%, 95% CI 19% to 43%). Significant differences were also found in scores between media outlets. Conclusions/Significance: There is substantial variability in news reporting practices about CAM. Overall, although they may be improving, the scores remain generally low. It appears that much of the information the public receives about CAM is inaccurate or incomplete.	[Bonevski, Billie; Wilson, Amanda] Univ Newcastle, Discipline Clin Pharmacol, Newcastle, NSW 2308, Australia; [Henry, David A.] Inst Clin Evaluat Sci, Toronto, ON, Canada	University of Newcastle; University of Toronto	Bonevski, B (corresponding author), Univ Newcastle, Discipline Clin Pharmacol, Newcastle, NSW 2308, Australia.	billie.bonevski@newcastle.edu.au	Bonevski, Billie/G-7298-2013; Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020	Bonevski, Billie/0000-0001-8505-622X; Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242; Wilson, Amanda/0000-0001-5681-9611	Hunter Medical Research Institute; University of Newcastle	Hunter Medical Research Institute; University of Newcastle	This research was funded by a grant from the Hunter Medical Research Institute and a grant from the University of Newcastle.	[Anonymous], 1994, MEDIA INFORM AUSTR; *AUSTR MED ASS, 2002, COMPL MED POS STAT; Berman B M, 1997, J Altern Complement Med, V3, P191, DOI 10.1089/acm.1997.3.191; Bubela TM, 2004, CAN MED ASSOC J, V170, P1399, DOI 10.1503/cmaj.1030762; BUCHER HC, 1994, BRIT MED J, V309, P761, DOI 10.1136/bmj.309.6957.761; Caspi O, 2003, ALTERN THER HEALTH M, V9, P58; Cassels A, 2003, CAN MED ASSOC J, V168, P1133; Chapman S, 2005, MED J AUSTRALIA, V183, P247, DOI 10.5694/j.1326-5377.2005.tb07029.x; Chapman S, 2001, HEALTH PROMOT INT, V16, P137, DOI 10.1093/heapro/16.2.137; Cohen MM, 2005, J ALTERN COMPLEM MED, V11, P995, DOI 10.1089/acm.2005.11.995; *COMM AUSTR, 2003, COMPL MED AUSTR HLTH, P163; Condit CM, 1998, AM J HUM GENET, V62, P979, DOI 10.1086/301784; Dolan G, 2004, INT J CONSUM STUD, V28, P147, DOI DOI 10.1111/J.1470-6431.2003.00363.X; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2000, BRIT MED J, V321, P707; ERNST E, 2002, CLIN RES COMPLEMENTA, P171; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Haas JS, 2004, ANN INTERN MED, V140, P184, DOI 10.7326/0003-4819-140-3-200402030-00009; Hann D M, 2005, Integr Cancer Ther, V4, P294, DOI 10.1177/1534735405282109; Henderson L, 1999, SOCIOL HEALTH ILL, V21, P560, DOI 10.1111/1467-9566.00173; *HOUS LORDS SEL CO, 2000, SESS 1999 2000 REP C; HUX JE, 1995, MED DECIS MAKING, V15, P152, DOI 10.1177/0272989X9501500208; Johnson T, 1998, NEW ENGL J MED, V339, P87, DOI 10.1056/NEJM199807093390206; Lupton D, 1995, AUST J PUBLIC HEALTH, V19, P501; MacLennan AH, 2002, PREV MED, V35, P166, DOI 10.1006/pmed.2002.1057; McGinn T, 2004, CAN MED ASSOC J, V171, P1369, DOI 10.1503/cmaj.1031981; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; National Center for Complementary and Alternative Medicine, 2002, WHAT IS COMPL ALT ME; *R STARCH WORLDW I, 1997, AM TALK SCI MED NEWS; Ransohoff D F, 2001, Eff Clin Pract, V4, P185; Rutten LJF, 2005, PATIENT EDUC COUNS, V57, P250, DOI 10.1016/j.pec.2004.06.006; Schwartz LM, 2004, ANN INTERN MED, V140, P226, DOI 10.7326/0003-4819-140-3-200402030-00015; Shuchman M, 1997, ANN INTERN MED, V126, P976, DOI 10.7326/0003-4819-126-12-199706150-00008; Smith DE, 2005, MED J AUSTRALIA, V183, P190, DOI 10.5694/j.1326-5377.2005.tb06992.x; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; Vickers A, 2000, BRIT MED J, V321, P683, DOI 10.1136/bmj.321.7262.683; Voss M, 2002, AM J PUBLIC HEALTH, V92, P1158, DOI 10.2105/AJPH.92.7.1158; Wells J, 2001, ANN INTERN MED, V135, P1029, DOI 10.7326/0003-4819-135-12-200112180-00006; Wilkes MS, 1997, J HEALTH COMMUN, V2, P3, DOI 10.1080/108107397127888; WILKES MS, 1997, J HEALTH COMMUN, V2, P61; Woloshin S, 2002, JAMA-J AM MED ASSOC, V287, P2856, DOI 10.1001/jama.287.21.2856; Woloshin S, 2006, MED J AUSTRALIA, V184, P576, DOI 10.5694/j.1326-5377.2006.tb00384.x; Woodward KN, 2005, HUM EXP TOXICOL, V24, P219, DOI 10.1191/0960327105ht529oa; 2001, REP GUID	44	40	41	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2008	3	6							e2406	10.1371/journal.pone.0002406	http://dx.doi.org/10.1371/journal.pone.0002406			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	405UD	18545688	Green Published, gold			2023-01-03	WOS:000263248800044
J	Hutchison, JS; Ward, RE; Lacroix, J; Hebert, PC; Barnes, MA; Bohn, DJ; Dirks, PB; Doucette, S; Fergusson, D; Gottesman, R; Joffe, AR; Kirpalani, HM; Meyer, PG; Morris, KP; Moher, D; Singh, RN; Skippen, PW				Hutchison, James S.; Ward, Roxanne E.; Lacroix, Jacques; Hebert, Paul C.; Barnes, Marcia A.; Bohn, Desmond J.; Dirks, Peter B.; Doucette, Steve; Fergusson, Dean; Gottesman, Ronald; Joffe, Ari R.; Kirpalani, Haresh M.; Meyer, Philippe G.; Morris, Kevin P.; Moher, David; Singh, Ram N.; Skippen, Peter W.		Hypothermia Pediat Head Injury Tri; Canadian Crit Care Trials Grp	Hypothermia therapy after traumatic brain injury in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MODERATE HYPOTHERMIA; HEAD-INJURY; MANAGEMENT; SEVERITY; TRIAL	Background: Hypothermia therapy improves survival and the neurologic outcome in animal models of traumatic brain injury. However, the effect of hypothermia therapy on the neurologic outcome and mortality among children who have severe traumatic brain injury is unknown. Methods: In a multicenter, international trial, we randomly assigned children with severe traumatic brain injury to either hypothermia therapy (32.5 degreesC for 24 hours) initiated within 8 hours after injury or to normothermia (37.0 degreesC). The primary outcome was the proportion of children who had an unfavorable outcome (i.e., severe disability, persistent vegetative state, or death), as assessed on the basis of the Pediatric Cerebral Performance Category score at 6 months. Results: A total of 225 children were randomly assigned to the hypothermia group or the normothermia group; the mean temperatures achieved in the two groups were 33.1+/-1.2 degreesC and 36.9+/-0.5 degreesC, respectively. At 6 months, 31% of the patients in the hypothermia group, as compared with 22% of the patients in the normothermia group, had an unfavorable outcome (relative risk, 1.41; 95% confidence interval [CI], 0.89 to 2.22; P=0.14). There were 23 deaths (21%) in the hypothermia group and 14 deaths (12%) in the normothermia group (relative risk, 1.40; 95% CI, 0.90 to 2.27; P=0.06). There was more hypotension (P=0.047) and more vasoactive agents were administered (P<0.001) in the hypothermia group during the rewarming period than in the normothermia group. Lengths of stay in the intensive care unit and in the hospital and other adverse events were similar in the two groups. Conclusions: In children with severe traumatic brain injury, hypothermia therapy that is initiated within 8 hours after injury and continued for 24 hours does not improve the neurologic outcome and may increase mortality. (Current Controlled Trials number, ISRCTN77393684.).	[Hutchison, James S.; Bohn, Desmond J.] Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Bohn, Desmond J.] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Dirks, Peter B.] Hosp Sick Children, Dept Surg Neurosurg, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.; Bohn, Desmond J.] Univ Toronto, Interdept Div Crit Care, Fac Med, Toronto, ON, Canada; [Hutchison, James S.; Barnes, Marcia A.] Hosp Sick Children, Res Inst, Neurosci & Mental Hlth Res Program, Toronto, ON M5G 1X8, Canada; [Ward, Roxanne E.; Moher, David] Childrens Hosp Eastern Ontario, Res Inst, Chalmers Res Grp, Ottawa, ON K1H 8L1, Canada; [Hebert, Paul C.; Doucette, Steve; Fergusson, Dean] Ottawa Gen Hosp, Dept Crit Care Med, Clin Epidemiol Program, Ottawa Hlth Res Inst, Ottawa, ON K1H 8L6, Canada; [Moher, David] Univ Ottawa, Dept Pediat, Fac Med, Ottawa, ON K1N 6N5, Canada; [Moher, David] Univ Ottawa, Dept Epidemiol & Community Med, Fac Med, Ottawa, ON K1N 6N5, Canada; [Lacroix, Jacques] Hop St Justine, Div Intens Care, Dept Pediat, Montreal, PQ H3T 1C5, Canada; [Gottesman, Ronald] Montreal Childrens Hosp, Dept Pediat Intens Care, Montreal, PQ H3H 1P3, Canada; [Barnes, Marcia A.] Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada; [Joffe, Ari R.] Stollery Childrens Hosp, Dept Pediat Intens Care, Edmonton, AB, Canada; [Kirpalani, Haresh M.] McMaster Childrens Hosp, Intens Care Unit, Hamilton, ON, Canada; [Meyer, Philippe G.] Grp Hosp Necker Enfants Malad, Neurointens Care Unit, Paris, France; [Morris, Kevin P.] Birmingham Childrens Hosp, Intens Care Unit, Birmingham, W Midlands, England; [Singh, Ram N.] Childrens Hosp Western Ontario, Dept Pediat Intens Care, London, ON N6A 5A5, Canada; [Skippen, Peter W.] British Columbia Childrens Hosp, Dept Pediat Intens Care, Vancouver, BC V6H 3V4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Universite de Montreal; McGill University; University of Guelph; Stollery Children's Hospital; McMaster University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Birmingham; Western University (University of Western Ontario); BC Childrens Hospital; University of British Columbia	Hutchison, JS (corresponding author), Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jamie.hutchison@sickkids.ca	Adelson, David/W-2083-2019; Kirkham, Fenella/C-2442-2009; Meyer, Philippe/ABE-4242-2020; kasyan, george/ABB-4616-2021	Kirkham, Fenella/0000-0002-2443-7958; Meyer, Philippe/0000-0002-3829-6631; kasyan, george/0000-0001-7919-2217; Fergusson, Dean/0000-0002-3389-2485; skippen, peter/0000-0001-6716-0381; Moher, David/0000-0003-2434-4206				ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Atkins DL, 2006, PEDIATRICS, V117, pE955, DOI 10.1542/peds.2006-0206; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COHEN MJ, 1995, CHILDRENS MEMORY SCA; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Gioia G.A, 2000, BEHAV RATING INVENTO; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; HENDRICK EB, 1959, ARCH SURG-CHICAGO, V79, P362; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Wechsler D., 2014, WECHSLER PRESCHOOL P; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D.A., 1997, WECHSLER INTELLIGENC	34	409	435	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 5	2008	358	23					2447	2456		10.1056/NEJMoa0706930	http://dx.doi.org/10.1056/NEJMoa0706930			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308HY	18525042	Bronze			2023-01-03	WOS:000256380700004
J	Tyson, JE; Parikh, NA; Langer, J; Green, C; Higgins, RD				Tyson, Jon E.; Parikh, Nehal A.; Langer, John; Green, Charles; Higgins, Rosemary D.		Natl Inst Child Hlth & Human Dev N	Intensive care for extreme prematurity - Moving beyond gestational age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROSS MOTOR FUNCTION; BIRTH-WEIGHT; DATING FORMULAS; POPULATION; CHILDREN; DELIVERY; DETERMINANTS; THRESHOLD; DECISIONS; BIOMETRY	Background: Decisions regarding whether to administer intensive care to extremely premature infants are often based on gestational age alone. However, other factors also affect the prognosis for these patients. Methods: We prospectively studied a cohort of 4446 infants born at 22 to 25 weeks' gestation (determined on the basis of the best obstetrical estimate) in the Neonatal Research Network of the National Institute of Child Health and Human Development to relate risk factors assessable at or before birth to the likelihood of survival, survival without profound neurodevelopmental impairment, and survival without neurodevelopmental impairment at a corrected age of 18 to 22 months. Results: Among study infants, 3702 (83%) received intensive care in the form of mechanical ventilation. Among the 4192 study infants (94%) for whom outcomes were determined at 18 to 22 months, 49% died, 61% died or had profound impairment, and 73% died or had impairment. In multivariable analyses of infants who received intensive care, exposure to antenatal corticosteroids, female sex, singleton birth, and higher birth weight (per each 100-g increment) were each associated with reductions in the risk of death and the risk of death or profound or any neurodevelopmental impairment; these reductions were similar to those associated with a 1-week increase in gestational age. At the same estimated likelihood of a favorable outcome, girls were less likely than boys to receive intensive care. The outcomes for infants who underwent ventilation were better predicted with the use of the above factors than with use of gestational age alone. Conclusions: The likelihood of a favorable outcome with intensive care can be better estimated by consideration of four factors in addition to gestational age: sex, exposure or nonexposure to antenatal corticosteroids, whether single or multiple birth, and birth weight. (ClinicalTrials.gov numbers, NCT00063063 and NCT00009633.).	[Tyson, Jon E.; Parikh, Nehal A.; Green, Charles] Univ Texas Houston, Sch Med, Ctr Clin Res & Evidence Based Med, Houston, TX 77030 USA; [Langer, John] Res Triangle Inst, Res Triangle Pk, NC 27709 USA; [Higgins, Rosemary D.] NICHHD, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health Science Center Houston; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Tyson, JE (corresponding author), Univ Texas Houston, Sch Med, Ctr Clin Res & Evidence Based Med, MSB 2-106,6431 Fannin St, Houston, TX 77030 USA.	jon.e.tyson@uth.tmc.edu	Parikh, Nehal/AAB-9981-2022	Parikh, Nehal/0000-0002-1375-1247	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD027904, U10HD027851, U10HD034216, U10HD027880, U10HD027871, U10HD021364, U10HD021385, U10HD040461, U10HD027856, U10HD021373, U10HD040689, U10HD027853, U10HD040492] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD040521, U01HD036790, U10HD027881, U10HD034167, U10HD040498, U10HD021397, U10HD021415] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125, M01RR000997, UL1RR024148, M01RR000044, M01RR008084, M01RR000070, M01RR000750, M01RR006022, M01RR000039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS048152] Funding Source: NIH RePORTER; NCATS NIH HHS [UL1 TR000454] Funding Source: Medline; NCRR NIH HHS [M01 RR000070, M01 RR000039, M01 RR 00997, M01 RR 00750, UL1 RR024148, M01 RR 00039, M01 RR 00070, M01 RR000044, M01 RR000997, M01 RR 00044, M01 RR 06022, M01 RR008084, M01 RR 00125, M01 RR006022, M01 RR000750, M01 RR000125, UL1 RR24148, M01 RR 08084] Funding Source: Medline; NICHD NIH HHS [U10 HD27871, U10 HD40492, U10 HD021385, U10 HD40461, U10 HD27904, U01 HD36790, U01 HD036790, U10 HD21397, U10 HD040461, U10 HD027851, U10 HD21385, U10 HD027871, U10 HD27856, U10 HD021373, U10 HD034216, U10 HD27880, U10 HD40689, U10 HD40521, U10 HD027856, U10 HD27853, U10 HD27851, U10 HD040498, U10 HD034167, U10 HD27881, U10 HD40498, U10 HD040689, U10 HD040492, U10 HD021364, U10 HD21415, U10 HD021397, U10 HD21364, U10 HD040521, U10 HD027853, U10 HD21373, U10 HD027880, U10 HD34216, U10 HD027904] Funding Source: Medline; NINDS NIH HHS [K23 NS048152-04, 5K23NS048152-02, K23 NS048152] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCATS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ambalavanan N, 2005, PEDIATRICS, V116, P1367, DOI 10.1542/peds.2004-2099; American College of Obstetricians and Gynecologists, 2002, OBSTET GYNECOL, V100, P617; [Anonymous], 2006, Lancet, V368, P1844; [Anonymous], CONS PRIC IND INFL C; Atkins DL, 2006, PEDIATRICS, V117, pE955, DOI 10.1542/peds.2006-0206; BALLARD JL, 1979, J PEDIATR-US, V95, P769, DOI 10.1016/S0022-3476(79)80734-9; Blackmon LR, 2004, PEDIATRICS, V114, P1362, DOI 10.1542/peds.2004-1915; Bottoms SF, 1997, AM J OBSTET GYNECOL, V176, P960, DOI 10.1016/S0002-9378(97)70386-7; Callaghan WM, 2007, PAEDIATR PERINAT EP, V21, P79, DOI 10.1111/j.1365-3016.2007.00864.x; Chervenak FA, 1998, AM J OBSTET GYNECOL, V178, P678, DOI 10.1016/S0002-9378(98)70477-6; Donovan EF, 1999, J PEDIATR-US, V135, P147, DOI 10.1016/S0022-3476(99)70015-6; Doyle LW, 2001, PEDIATRICS, V108, P134, DOI 10.1542/peds.108.1.134; Finer NN, 2004, PEDIATRICS, V114, P651, DOI 10.1542/peds.2004-0394; Gjessing HK, 1999, AM J PUBLIC HEALTH, V89, P213, DOI 10.2105/AJPH.89.2.213; Higgins RD, 2005, PEDIATRICS, V115, P1392, DOI 10.1542/peds.2004-1989; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; KRAMER MS, 1988, JAMA-J AM MED ASSOC, V260, P3306, DOI 10.1001/jama.260.22.3306; Lorenz JM, 2000, J PEDIATR-US, V137, P593, DOI 10.1067/mpd.2000.110532; Lynch CD, 2007, PAEDIATR PERINAT EP, V21, P86, DOI 10.1111/j.1365-3016.2007.00865.x; MacDonald H, 2002, PEDIATRICS, V110, P1024, DOI 10.1542/peds.110.5.1024; Mongelli M, 1996, AM J OBSTET GYNECOL, V174, P278, DOI 10.1016/S0002-9378(96)70408-8; Morin I, 2005, BJOG-INT J OBSTET GY, V112, P145, DOI 10.1111/j.1471-0528.2004.00311.x; Mul T, 1996, ULTRASOUND OBST GYN, V8, P397; Nutting PA, 2005, ANN FAM MED, V3, P529, DOI 10.1370/afm.371; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Paris JJ, 2005, PEDIATRICS, V115, P1415, DOI 10.1542/peds.2004-1950; Partridge J C, 2001, J Perinatol, V21, P27; Peerzada JM, 2004, J PEDIATR-US, V145, P492, DOI 10.1016/j.jpeds.2004.06.018; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Saigal S, 2003, ARCH PEDIAT ADOL MED, V157, P261, DOI 10.1001/archpedi.157.3.261; Saltvedt S, 2004, ULTRASOUND OBST GYN, V24, P42, DOI 10.1002/uog.1047; Schmitt SK, 2006, PEDIATRICS, V117, P154, DOI 10.1542/peds.2005-0484; Sheldon T, 2001, BRIT MED J, V322, P1383, DOI 10.1136/bmj.322.7299.1383; SNIDJERS T, 2002, MULTILEVEL ANAL INTR; Stark AR, 2007, PEDIATRICS, V119, P401, DOI 10.1542/peds.2006-3180; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Tyson JE, 2003, CLIN PERINATOL, V30, P363, DOI 10.1016/S0095-5108(03)00028-9; Tyson JE, 1996, JAMA-J AM MED ASSOC, V276, P1645, DOI 10.1001/jama.276.20.1645; Vohr BR, 2005, PEDIATRICS, V116, P123, DOI 10.1542/peds.2004-1810; Wilcox AJ, 2000, BRIT MED J, V321, P1259, DOI 10.1136/bmj.321.7271.1259	40	632	653	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 17	2008	358	16					1672	1681		10.1056/NEJMoa073059	http://dx.doi.org/10.1056/NEJMoa073059			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	288DO	18420500	Green Submitted, Green Accepted			2023-01-03	WOS:000254966600005
J	Ferner, R; Beard, K				Ferner, Robin; Beard, Keith			Over the counter medicines: proceed with caution	BRITISH MEDICAL JOURNAL			English	Editorial Material							PARACETAMOL		[Ferner, Robin] City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England; [Beard, Keith] Victoria Infirm, Mansionhouse Unit, Glasgow G41 3DX, Lanark, Scotland	University of Birmingham	Ferner, R (corresponding author), City Hosp, W Midlands Ctr Adverse Drug React, Birmingham B18 7QH, W Midlands, England.	r.e.ferner@bham.ac.uk		Ferner, Robin/0000-0003-3769-1346				Bateman DN, 2003, QJM-INT J MED, V96, P125, DOI 10.1093/qjmed/hcg015; CAMPBELL D, 2008, OBSERVER        0217, P1; Choudhry NK, 2005, ANN INTERN MED, V142, P910, DOI 10.7326/0003-4819-142-11-200506070-00009; Cohen JP, 2005, BRIT MED J, V330, P39, DOI 10.1136/bmj.330.7481.39; Glasgow JFT, 2006, DRUG SAFETY, V29, P1111, DOI 10.2165/00002018-200629120-00003; Glasier A, 1998, NEW ENGL J MED, V339, P1, DOI 10.1056/NEJM199807023390101; Hawton K, 2001, BMJ-BRIT MED J, V322, P1203, DOI 10.1136/bmj.322.7296.1203; JENKINS R, 2007, TIMES           1215; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Mansfield PR, 2005, BMJ-BRIT MED J, V330, P5, DOI 10.1136/bmj.330.7481.5; *MED HEALTHC PROD, 2006, LIST A CONS LIST SUB; *MED HEALTHC PROD, 2007, LIST B CONS LIST SUB; *MED HEALTHC PROD, AV MED; *MHRA, 2008, YELL CARD HELP MAK M; Pichichero ME, 2007, JAMA-J AM MED ASSOC, V298, P1772, DOI 10.1001/jama.298.15.1772; Rajkumar SV, 2004, MAYO CLIN PROC, V79, P899, DOI 10.4065/79.7.899; Reeves D, 2007, J ANTIMICROB CHEMOTH, V59, P333, DOI 10.1093/jac/dkl502; *ROYAL PHARM SOC G, 2007, RPS E PIC REF PRESCR; SAUL S, 2007, NY TIMES        1024; WISE J, 1997, BRIT MED J, V314, P1297; 2008, GET BRACKNELL   0111; 2006, CURR PROB PHARMACOVI, V31, P11; 2002, MAIL MHRA UPDATING S, V130, P3	23	19	21	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					694	696		10.1136/bmj.39504.389676.AD	http://dx.doi.org/10.1136/bmj.39504.389676.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369225	Green Published			2023-01-03	WOS:000254675600022
J	Hawkes, N				Hawkes, Nigel			There's no biological alternative, says Parliament	BRITISH MEDICAL JOURNAL			English	Editorial Material												nigel.hawkes@thetimes.co.uk							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 15	2008	336	7644					588	588		10.1136/bmj.39512.653727.59	http://dx.doi.org/10.1136/bmj.39512.653727.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279OM	18340072	Green Published			2023-01-03	WOS:000254364500029
J	Frayne, J; Taylor, A; Cameron, G; Hadfield, AT				Frayne, Jan; Taylor, Abby; Cameron, Gus; Hadfield, Andrea T.			Structure of Insoluble Rat Sperm Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH) via Heterotetramer Formation with Escherichia coli GAPDH Reveals Target for Contraceptive Design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-CHLOROHYDRIN; ANTIFERTILITY COMPOUNDS; RESOLUTION STRUCTURE; GLYCOLYTIC ENZYME; MOTILITY; SPERMATOZOA; INHIBITION; (S)-ALPHA-CHLOROHYDRIN; METABOLISM; MOUSE	Sperm glyceraldehyde-3-phosphate dehydrogenase has been shown to be a successful target for a non-hormonal contraceptive approach, but the agents tested to date have had unacceptable side effects. Obtaining the structure of the sperm-specific isoform to allow rational inhibitor design has therefore been a goal for a number of years but has proved intractable because of the insoluble nature of both native and recombinant protein. We have obtained soluble recombinant sperm glyceraldehyde-3-phosphate dehydrogenase as a heterotetramer with the Escherichia coli glyceraldehyde-3- phosphate dehydrogenase in a ratio of 1:3 and have solved the structure of the heterotetramer which we believe represents a novel strategy for structure determination of an insoluble protein. A structure was also obtained where glyceraldehyde 3-phosphate binds in the P-s pocket in the active site of the sperm enzyme subunit in the presence of NAD. Modeling and comparison of the structures of human somatic and sperm-specific glyceraldehyde-3-phosphate dehydrogenase revealed few differences at the active site and hence rebut the long presumed structural specificity of 3-chlorolactaldehyde for the sperm isoform. Thecontraceptive activity of alpha-chlorohydrin and its apparent specificity for the sperm isoform in vivo are likely to be due to differences in metabolism to 3-chlorolactaldehyde in spermatozoa and somatic cells. However, further detailed analysis of the sperm glyceraldehyde-3-phosphate dehydrogenase structure revealed sites in the enzyme that do show significant difference compared with published somatic glyceraldehyde-3- phosphate dehydrogenase structures that could be exploited by structure-based drug design to identify leads for novel male contraceptives.	[Frayne, Jan; Taylor, Abby; Cameron, Gus; Hadfield, Andrea T.] Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol	Frayne, J (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Univ Walk, Bristol BS8 1TD, Avon, England.	jan.frayne@bristol.ac.uk; a.t.hadfield@bristol.ac.uk		Frayne, Jan/0000-0002-1113-7761	Biotechnology and Biological Sciences Research Council; Medical Research Council [G0500367] Funding Source: researchfish; MRC [G0500367] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported in part by the Biotechnology and Biological Sciences Research Council.	Aronov AM, 1999, P NATL ACAD SCI USA, V96, P4273, DOI 10.1073/pnas.96.8.4273; Aronov AM, 1998, J MED CHEM, V41, P4790, DOI 10.1021/jm9802620; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bakker BM, 2000, MOL BIOCHEM PARASIT, V106, P1, DOI 10.1016/S0166-6851(99)00197-8; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; Bone W, 2001, J ANDROL, V22, P464; Bone W, 2000, INT J ANDROL, V23, P284; Bressi JC, 2001, J MED CHEM, V44, P2080, DOI 10.1021/jm000472o; BROWNWOODMAN PDC, 1978, BIOCHEM J, V170, P23, DOI 10.1042/bj1700023; Bunch DO, 1998, BIOL REPROD, V58, P834, DOI 10.1095/biolreprod58.3.834; COPPOLA JA, 1969, LIFE SCI PT 1 PHYSI, V8, P43, DOI 10.1016/0024-3205(69)90291-4; Cowan-Jacob SW, 2003, ACTA CRYSTALLOGR D, V59, P2218, DOI 10.1107/S0907444903020493; Duee E, 1996, J MOL BIOL, V257, P814, DOI 10.1006/jmbi.1996.0204; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; ERICSSON RJ, 1970, J REPROD FERTIL, V22, P213; FORD WCL, 1981, J REPROD FERTIL, V63, P75; Ford WCL, 2006, HUM REPROD UPDATE, V12, P269, DOI 10.1093/humupd/dmi053; FORD WCL, 1982, J REPROD FERTIL, V65, P177; FORD WCL, 1981, CONTRACEPTION, V24, P577, DOI 10.1016/0010-7824(81)90061-5; FORD WCL, 1983, J REPROD FERTIL, V69, P147; Ismail SA, 2005, ACTA CRYSTALLOGR D, V61, P1508, DOI 10.1107/S0907444905026740; Jelks K, 2001, REPROD TOXICOL, V15, P11; Jenkins JL, 2006, ACTA CRYSTALLOGR D, V62, P290, DOI 10.1107/S0907444905042289; JONES AR, 1983, EXPERIENTIA, V39, P784, DOI 10.1007/BF01990326; KIRTON KT, 1970, J REPROD FERTIL, V21, P275; KOCHMAN M, 1974, FEBS LETT, V41, P104, DOI 10.1016/0014-5793(74)80964-6; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARKOVICH DS, 1975, FEBS LETT, V58, P138, DOI 10.1016/0014-5793(75)80243-2; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101; MORAS D, 1975, J BIOL CHEM, V250, P9137; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OBERLANDER G, 1994, J REPROD FERTIL, V100, P551; OSBORNE HH, 1975, BIOCHEM J, V151, P37, DOI 10.1042/bj1510037; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potterton L, 2004, ACTA CRYSTALLOGR D, V60, P2288, DOI 10.1107/S0907444904023716; Rossman M.G., 1975, ENZYMES, P62; SEGAL HL, 1953, J BIOL CHEM, V204, P265; SETTY BS, 1970, INDIAN J EXP BIOL, V8, P49; STEVENSON D, 1984, INT J ANDROL, V7, P79, DOI 10.1111/j.1365-2605.1984.tb00762.x; STEVENSON D, 1985, J REPROD FERTIL, V74, P157; Suresh S, 2001, J MOL BIOL, V309, P423, DOI 10.1006/jmbi.2001.4588; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANCALENBERGH S, 1995, J MED CHEM, V38, P3838, DOI 10.1021/jm00019a014; Verlinde CLM, 2001, DRUG RESIST UPDATE, V4, P50, DOI 10.1054/drup.2000.0177; VERLINDE CLMJ, 1994, J MED CHEM, V37, P3605, DOI 10.1021/jm00047a017; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; WATSON HC, 1972, NATURE-NEW BIOL, V240, P130, DOI 10.1038/newbio240130a0; WELCH JE, 1992, BIOL REPROD, V46, P869, DOI 10.1095/biolreprod46.5.869; Welch JE, 2006, MOL REPROD DEV, V73, P1052, DOI 10.1002/mrd.20235; Welch JE, 2000, J ANDROL, V21, P328; Westhoff D, 1997, J CELL SCI, V110, P1821; Williams AC, 2001, J ANDROL, V22, P680	53	27	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 21	2009	284	34					22703	22712		10.1074/jbc.M109.004648	http://dx.doi.org/10.1074/jbc.M109.004648			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	483KG	19542219	hybrid, Green Published			2023-01-03	WOS:000268963100025
J	Wang, ZY; Ma, W; Chabot, JG; Quirion, R				Wang, Zhiyong; Ma, Weiya; Chabot, Jean-Guy; Quirion, Remi			Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia	FASEB JOURNAL			English	Article						neuropeptide; astrocyte; microglia; cytokine; kinase	PRIMARY SENSORY NEURONS; SPINAL NERVE LIGATION; PROTEIN-KINASE; NEUROPATHIC PAIN; PROINFLAMMATORY CYTOKINES; CENTRAL SENSITIZATION; MECHANICAL ALLODYNIA; SIGNAL-TRANSDUCTION; SUBSTANCE-P; EXPRESSION	Tolerance to morphine-induced analgesia is a well-established phenomenon, often limiting its usefulness in the long-term treatment of pain. The mechanisms underlying tolerance are not well understood. We previously suggested a possible role for spinal calcitonin gene-related peptide ( CGRP) in the development of tolerance to morphine-induced analgesia. In the present study, we demonstrate that CGRP is involved in morphine tolerance by differentially regulating the ERK-dependent up-regulation of IL-1 beta, TNF-alpha, and microsomal prostaglandin E synthase-1 (mPGES-1) in astrocytes and p38-dependent up-regulation of IL-6 in microglia in the rat spinal cord. A 7-d treatment with morphine induced tolerance to the antinociceptive effect and increased phosphorylated ERK localized in astrocytes and phosphorylated p38 enriched in microglia, both effects being inhibited by blocking CGRP receptors. Interestingly, the inhibition of the ERK pathway suppressed the development of tolerance and morphine-induced up-regulation of IL1 beta, TNF-alpha, and mPGES-1. Blockade of p38 activity also inhibited the development of tolerance and morphine-induced IL-6 up-regulation. Taken together, these data suggest that chronic morphine induces the synthesis of CGRP, which in turn acts on CGRP receptors located on astrocytes and microglia to stimulate ERK and p38, respectively, leading to increased synthesis and release of proinflammatory mediators resulting in tolerance to morphine-induced analgesia.-Wang, Z., Ma, W., Chabot, J.-G., Quirion, R. Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. FASEB J. 23, 2576-2586 ( 2009)	[Wang, Zhiyong; Ma, Weiya; Chabot, Jean-Guy; Quirion, Remi] McGill Univ, Douglas Mental Hlth Univ Inst, Montreal, PQ H4H 1R3, Canada	McGill University	Quirion, R (corresponding author), McGill Univ, Douglas Mental Hlth Univ Inst, 6875 Blvd LaSalle, Montreal, PQ H4H 1R3, Canada.	remi.quirion@douglas.mcgill.ca			Canadian Institutes of Health	Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR))	This study was supported by a grant from the Canadian Institutes of Health Research to R. Q.	Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Bird GC, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-31; Chen Y, 2008, J NEUROSCI, V28, P5836, DOI 10.1523/JNEUROSCI.4170-07.2008; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; CRIDLAND RA, 1988, NEUROPEPTIDES, V11, P23, DOI 10.1016/0143-4179(88)90024-8; Cui Y, 2006, BRAIN RES, V1069, P235, DOI 10.1016/j.brainres.2005.11.066; Cui Y, 2008, BRAIN BEHAV IMMUN, V22, P114, DOI 10.1016/j.bbi.2007.07.014; De Oliveira ACP, 2008, GLIA, V56, P844, DOI 10.1002/glia.20658; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; Doods H, 2007, TRENDS PHARMACOL SCI, V28, P580, DOI 10.1016/j.tips.2007.10.005; Fan XL, 2003, NEUROSCIENCE, V122, P997, DOI 10.1016/j.neuroscience.2003.08.062; Gardell LR, 2002, J NEUROSCI, V22, P6747; HAAS CA, 1991, EUR J NEUROSCI, V3, P708, DOI 10.1111/j.1460-9568.1991.tb00856.x; Ho TW, 2008, LANCET, V372, P2115, DOI 10.1016/S0140-6736(08)61626-8; HOKFELT T, 1992, ANN NY ACAD SCI, V657, P119; Houghton AK, 1999, PAIN, V82, P73, DOI 10.1016/S0304-3959(99)00034-2; Hutchinson MR, 2008, BRAIN BEHAV IMMUN, V22, P1178, DOI 10.1016/j.bbi.2008.05.004; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; Johnston IN, 2004, J NEUROSCI, V24, P7353, DOI 10.1523/JNEUROSCI.1850-04.2004; KANGRGA I, 1990, NEUROSCI LETT, V108, P155, DOI 10.1016/0304-3940(90)90723-M; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; King T, 2005, NEUROSIGNALS, V14, P194, DOI 10.1159/000087658; LEGREVES P, 1985, EUR J PHARMACOL, V115, P309, DOI 10.1016/0014-2999(85)90706-X; Lofgren O, 1997, NEUROPEPTIDES, V31, P601, DOI 10.1016/S0143-4179(97)90006-8; Ma WY, 2001, EUR J NEUROSCI, V14, P1091, DOI 10.1046/j.0953-816x.2001.01731.x; MAO J, 1994, J NEUROSCI, V14, P2301; Mayer DJ, 1999, P NATL ACAD SCI USA, V96, P7731, DOI 10.1073/pnas.96.14.7731; MENARD DP, 1995, J PHARMACOL EXP THER, V273, P887; Menard DP, 1996, J NEUROSCI, V16, P2342; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Parameswaran N, 2000, EUR J PHARMACOL, V389, P125, DOI 10.1016/S0014-2999(99)00874-2; Powell KJ, 1999, BRIT J PHARMACOL, V127, P631, DOI 10.1038/sj.bjp.0702587; Powell KJ, 2000, BRIT J PHARMACOL, V131, P875, DOI 10.1038/sj.bjp.0703655; Powell KJ, 2003, EUR J NEUROSCI, V18, P1572, DOI 10.1046/j.1460-9568.2003.02887.x; Poyner D, 1995, TRENDS PHARMACOL SCI, V16, P424, DOI 10.1016/S0165-6147(00)89093-8; Priller J, 1995, GLIA, V15, P447, DOI 10.1002/glia.440150408; Raghavendra V, 2004, NEUROPSYCHOPHARMACOL, V29, P327, DOI 10.1038/sj.npp.1300315; Raghavendra V, 2002, J NEUROSCI, V22, P9980, DOI 10.1523/jneurosci.22-22-09980.2002; REDDINGTON M, 1995, CAN J PHYSIOL PHARM, V73, P1047, DOI 10.1139/y95-148; ROSENFELD MG, 1984, SCIENCE, V225, P1315, DOI 10.1126/science.6089345; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Russo SJ, 2007, NAT NEUROSCI, V10, P93, DOI 10.1038/nn1812; Schaible HG, 1996, PROG BRAIN RES, V113, P423, DOI 10.1016/S0079-6123(08)61102-4; Tepper SJ, 2008, HEADACHE, V48, P1259, DOI 10.1111/j.1526-4610.2008.01214.x; Trang T, 2002, BRIT J PHARMACOL, V136, P37, DOI 10.1038/sj.bjp.0704681; Tsuda M, 2004, GLIA, V45, P89, DOI 10.1002/glia.10308; VAN RD, 1997, NEUROSCI BIOBEHAV R, V21, P649; Wang ZY, 2006, NEUROPHARMACOLOGY, V51, P764, DOI 10.1016/j.neuropharm.2006.05.024; Watkins LR, 2007, BRAIN BEHAV IMMUN, V21, P131, DOI 10.1016/j.bbi.2006.10.011; Watkins LR, 2005, TRENDS NEUROSCI, V28, P661, DOI 10.1016/j.tins.2005.10.001; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; Wimalawansa SJ, 1996, ENDOCR REV, V17, P533, DOI 10.1210/er.17.5.533; Ye Z, 1999, NEUROSCIENCE, V92, P1389, DOI 10.1016/S0306-4522(99)00088-3; Yue X, 2008, EUR J PHARMACOL, V584, P272, DOI 10.1016/j.ejphar.2008.02.013; Zhuang ZY, 2005, PAIN, V114, P149, DOI 10.1016/j.pain.2004.12.022; Zhuang ZY, 2006, J NEUROSCI, V26, P3551, DOI 10.1523/JNEUROSCI.5290-05.2006	59	81	95	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2009	23	8					2576	2586		10.1096/fj.08-128348	http://dx.doi.org/10.1096/fj.08-128348			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	481UE	19299480				2023-01-03	WOS:000268836700026
J	van der Meer, V; Bakker, MJ; van den Hout, WB; Rabe, KF; Sterk, PJ; Kievit, J; Assendelft, WJJ; Sont, JK				van der Meer, Victor; Bakker, Moira J.; van den Hout, Wilbert B.; Rabe, Klaus F.; Sterk, Peter J.; Kievit, Job; Assendelft, Willem J. J.; Sont, Jacob K.		SMASHING Self-Management Asthma	Internet-Based Self-management Plus Education Compared With Usual Care in Asthma A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; CHILDREN; ADULTS; VALIDITY; OUTCOMES; PROGRAM	Background: The Internet may support patient self-management of chronic conditions, such as asthma. Objective: To evaluate the effectiveness of Internet-based asthma self-management. Design: Randomized, controlled trial. Setting: 37 general practices and 1 academic outpatient department in the Netherlands. Patients: 200 adults with asthma who were treated with inhaled corticosteroids for 3 months or more during the previous year and had access to the Internet. Measurements: Asthma-related quality of life at 12 months (minimal clinically significant difference of 0.5 on the 7-point scale), asthma control, symptom-free days, lung function, and exacerbations. Intervention: Participants were randomly assigned by using a computer-generated permuted block scheme to Internet-based self-management (n = 101) or usual care (n = 99). The Internet-based self-management program included weekly asthma control monitoring and treatment advice, online and group education, and remote Web communications. Results: Asthma-related quality of life improved by 0.56 and 0.18 points in the Internet and usual care groups, respectively (adjusted between-group difference, 0.38 [95% CI, 0.20 to 0.56]). An improvement of 0.5 point or more occurred in 54% and 27% of Internet and usual care patients, respectively (adjusted relative risk, 2.00 [CI, 1.38 to 3.04]). Asthma control improved more in the Internet group than in the usual care group (adjusted difference, -0.47 [CI, -0.64 to -0.30]). At 12 months, 63% of Internet patients and 52% of usual care patients reported symptom-free days in the previous 2 weeks (adjusted absolute difference, 10.9% [CI, 0.05% to 21.3%]). Prebronchodilator FEV1 changed with 0.24 L and -0.01 L for Internet and usual care patients, respectively (adjusted difference, 0.25 L [CI, 0.03 to 0.46 L]). Exacerbations did not differ between groups. Limitation: The study was unblinded and lasted only 12 months. Conclusion: Internet-based self-management resulted in improvements in asthma control and lung function but did not reduce exacerbations, and improvement in asthma-related quality of life was slightly less than clinically significant.	[van der Meer, Victor] Leiden Univ, Med Ctr, NL-2300 RC Leiden, Netherlands; Univ Amsterdam, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam	van der Meer, V (corresponding author), Leiden Univ, Med Ctr, Postzone J-10-S,Room J-10-87,Albinusdreef 2,POB 9, NL-2300 RC Leiden, Netherlands.	v.van_der_meer@lumc.nl	Toussaint, Pieter/O-9523-2016; assendelft, willem/AAW-1854-2021; Sont, Jacob K/J-8071-2015; Sterk, P.J./AAK-8175-2020; Rabe, Klaus F./AAW-6296-2021; Assendelft, W.J.J./H-8008-2014	Toussaint, Pieter/0000-0001-7340-7213; assendelft, willem/0000-0002-2966-3778; Sont, Jacob K/0000-0002-5840-0651; Rabe, Klaus F./0000-0002-7020-1401; Assendelft, W.J.J./0000-0002-2966-3778; van den Hout, Wilbert B./0000-0002-6425-0135	Netherlands Organization for Health Research and Development [945-04-061, 920-03-354]; Netherlands Asthma Foundation [3.4.03.45]	Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and Development); Netherlands Asthma Foundation	By the Netherlands Organization for Health Research and Development (ZonMw grants 945-04-061 and 920-03-354) and Netherlands Asthma Foundation ( grant 3.4.03.45).	Armour C, 2007, THORAX, V62, P496, DOI 10.1136/thx.2006.064709; ASTHMA I, 2007, AM J RESP CRIT CARE, V175, P888; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Dennis SM, 2000, LANCET, V355, P1675, DOI 10.1016/S0140-6736(00)02238-8; Fonseca JA, 2005, CHEST, V128, P1258, DOI 10.1378/chest.128.3.1258; Geijer R M M, 2008, Ned Tijdschr Geneeskd, V152, P1146; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; *GLOB IN ASTHM, 1995, NIH PUBL; Green BB, 2008, JAMA-J AM MED ASSOC, V299, P2857, DOI 10.1001/jama.299.24.2857; Guyatt GH, 1998, BRIT MED J, V316, P690, DOI 10.1136/bmj.316.7132.690; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; Jones A, 2000, BMJ-BRIT MED J, V321, P1507, DOI 10.1136/bmj.321.7275.1507; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832, DOI 10.1164/ajrccm/147.4.832; Kamps AWA, 2000, PEDIATR PULM, V29, P39, DOI 10.1002/(SICI)1099-0496(200001)29:1<39::AID-PPUL7>3.3.CO;2-7; Kritikos V, 2005, J ASTHMA, V42, P795, DOI 10.1080/02770900500308627; Lamberts H., 1987, ICPC INT CLASSIFICAT; Lemaigre V, 2005, CHEST, V128, P3133, DOI 10.1378/chest.128.5.3133; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; National Asthma Education and Prevention Program, 2007, 3 NIH NAT ASTHM ED P; Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2; O'Byrne PM, 2006, LANCET, V368, P794, DOI 10.1016/S0140-6736(06)69289-1; Pinnock H, 2003, BMJ-BRIT MED J, V326, P477, DOI 10.1136/bmj.326.7387.477; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Solberg KE, 2008, LANCET, V371, P17, DOI 10.1016/S0140-6736(08)60052-5; Thoonen BPA, 2003, THORAX, V58, P30, DOI 10.1136/thorax.58.1.30; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Twisk JWR, 2003, APPL LONGITUDINAL DA; van der Meer V, 2007, CHEST, V132, P112, DOI 10.1378/chest.06-2787; van der Palen J, 2001, PATIENT EDUC COUNS, V43, P161, DOI 10.1016/S0738-3991(00)00155-5; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195, DOI 10.1164/ajrccm.165.2.2102127	35	137	139	0	25	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 21	2009	151	2					110	W31		10.7326/0003-4819-151-2-200907210-00008	http://dx.doi.org/10.7326/0003-4819-151-2-200907210-00008			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	478RH	19620163				2023-01-03	WOS:000268605300005
J	Lehar, J; Krueger, AS; Avery, W; Heilbut, AM; Johansen, LM; Price, ER; Rickles, RJ; Short, GF; Staunton, JE; Jin, XW; Lee, MS; Zimmermann, GR; Borisy, AA				Lehar, Joseph; Krueger, Andrew S.; Avery, William; Heilbut, Adrian M.; Johansen, Lisa M.; Price, E. Roydon; Rickles, Richard J.; Short, Glenn F., III; Staunton, Jane E.; Jin, Xiaowei; Lee, Margaret S.; Zimmermann, Grant R.; Borisy, Alexis A.			Synergistic drug combinations tend to improve therapeutically relevant selectivity	NATURE BIOTECHNOLOGY			English	Article							MULTICOMPONENT THERAPEUTICS; NETWORK; SYSTEMS; ROBUSTNESS; DISCOVERY; THERAPY; CELLS; MODEL; YEAST; CATECHOLAMINES	Drug combinations are a promising strategy to overcome the compensatory mechanisms and unwanted off-target effects that limit the utility of many potential drugs. However, enthusiasm for this approach is tempered by concerns that the therapeutic synergy of a combination will be accompanied by synergistic side effects. Using large scale simulations of bacterial metabolism and 94,110 multi-dose experiments relevant to diverse diseases, we provide evidence that synergistic drug combinations are generally more specific to particular cellular contexts than are single agent activities. We highlight six combinations whose selective synergy depends on multitarget drug activity. For one anti-inflammatory example, we show how such selectivity is achieved through differential expression of the drugs' targets in cell types associated with therapeutic, but not toxic, effects and validate its therapeutic relevance in a rat model of asthma. The context specificity of synergistic combinations creates many opportunities for therapeutically relevant selectivity and enables improved control of complex biological systems.	[Lehar, Joseph; Avery, William; Heilbut, Adrian M.; Johansen, Lisa M.; Price, E. Roydon; Rickles, Richard J.; Short, Glenn F., III; Staunton, Jane E.; Jin, Xiaowei; Lee, Margaret S.; Zimmermann, Grant R.; Borisy, Alexis A.] CombinatoRx Inc, Cambridge, MA USA; [Lehar, Joseph; Krueger, Andrew S.] Boston Univ Bioinformat Bioengn, Boston, MA USA	Zalicus Inc; Boston University	Lehar, J (corresponding author), CombinatoRx Inc, Cambridge, MA USA.	jlehar@combinatorx.com; aborisy@combinatorx.com	Heilbut, Adrian M/J-9427-2012	Heilbut, Adrian M/0000-0002-8169-7967	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI061345] Funding Source: NIH RePORTER; NIAID NIH HHS [U01 AI061345-01, U01 AI61345, U01 AI061345] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Apsel B, 2008, NAT CHEM BIOL, V4, P691, DOI 10.1038/nchembio.117; Araujo RP, 2005, BIOSYSTEMS, V80, P57, DOI 10.1016/j.biosystems.2004.10.002; BERENBAUM MC, 1985, J THEOR BIOL, V114, P413, DOI 10.1016/S0022-5193(85)80176-4; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; Bliss CI, 1939, ANN APPL BIOL, V26, P585, DOI 10.1111/j.1744-7348.1939.tb06990.x; Boone C, 2007, NAT REV GENET, V8, P437, DOI 10.1038/nrg2085; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Duarte NC, 2004, GENOME RES, V14, P1298, DOI 10.1101/gr.2250904; Edwards JS, 2000, BMC BIOINFORMATICS, V1, DOI 10.1186/1471-2105-1-1; Edwards JS, 2001, NAT BIOTECHNOL, V19, P125, DOI 10.1038/84379; Farr M, 1995, BRIT J RHEUMATOL, V34, P100; FILLIBEN JJ, 2005, ENG STAT HDB, V2007; GRECO WR, 1995, PHARMACOL REV, V47, P331; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; HOLM S, 1979, SCAND J STAT, V6, P65; Hoon S, 2008, NAT CHEM BIOL, V4, P498, DOI 10.1038/nchembio.100; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Hughes B, 2008, NAT REV DRUG DISCOV, V7; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kassouf W, 2005, CANCER RES, V65, P10524, DOI 10.1158/0008-5472.CAN-05-1536; Keasling JD, 2008, ACS CHEM BIOL, V3, P64, DOI 10.1021/cb7002434; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Kitano H, 2007, NAT REV DRUG DISCOV, V6, P202, DOI 10.1038/nrd2195; KLEYMAN TR, 1988, J MEMBRANE BIOL, V105, P1, DOI 10.1007/BF01871102; Kvien TK, 2008, ANN RHEUM DIS, V67, P942, DOI 10.1136/ard.2007.074401; Lehar J, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.51; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Loewe S., 1928, ERGEBN PHYSL, V27, P47, DOI [10.1007/BF02322290, DOI 10.1007/BF02322290]; Okamoto M, 1998, AIDS RES HUM RETROV, V14, P1239, DOI 10.1089/aid.1998.14.1239; Press W.H., 1997, NUMER RECIPES C; Qiu YH, 2005, J NEUROIMMUNOL, V167, P45, DOI 10.1016/j.jneuroim.2005.06.007; Radhakrishnan ML, 2008, J CHEM INF MODEL, V48, P1055, DOI 10.1021/ci700452r; Salicru AN, 2007, BRAIN BEHAV IMMUN, V21, P913, DOI 10.1016/j.bbi.2007.02.006; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schacke Heike, 2005, Curr Opin Investig Drugs, V6, P503; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Sharom JR, 2004, CURR OPIN CHEM BIOL, V8, P81, DOI 10.1016/j.cbpa.2003.12.007; St Onge RP, 2007, NAT GENET, V39, P199, DOI 10.1038/ng1948; Stelling J, 2004, CELL, V118, P675, DOI 10.1016/j.cell.2004.09.008; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Tischler J, 2008, NAT GENET, V40, P390, DOI 10.1038/ng.114; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Virmani R, 2004, CORONARY ARTERY DIS, V15, P313, DOI 10.1097/00019501-200409000-00003; Yang K, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.60; Yeh P, 2006, NAT GENET, V38, P489, DOI 10.1038/ng1755; Zarraga IGE, 2007, J AM COLL CARDIOL, V49, P1, DOI 10.1016/j.jacc.2006.10.003; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008; Zimmermann GR, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2602	49	637	705	10	135	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2009	27	7					659	U116		10.1038/nbt.1549	http://dx.doi.org/10.1038/nbt.1549			11	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	469OF	19581876	Green Accepted			2023-01-03	WOS:000267908500023
J	Ndekha, MJ; Oosterhout, JJG; Zijlstra, EE; Manary, M; Saloojee, H; Manary, MJ				Ndekha, MacDonald J.; Oosterhout, Joep J. Gvan; Zijlstra, Eduard E.; Manary, Micah; Saloojee, Haroon; Manary, Mark J.			Supplementary feeding with either ready-to-use fortified spread or corn-soy blend in wasted adults starting antiretroviral therapy in Malawi: randomised, investigator blinded, controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME-BASED THERAPY; EARLY MORTALITY; RURAL DISTRICT; SOUTH-AFRICA; FOOD; DETERMINANTS; PREVALENCE; ADHERENCE; CHILDREN; RWANDA	Objective To investigate the effect of two different food supplements on body mass index (BMI) in wasted Malawian adults with HIV who were starting antiretroviral therapy. Design Randomised, investigator blinded, controlled trial. Setting Large, public clinic associated with a referral hospital in Blantyre, Malawi. Participants 491 adults with BMI < 18.5. Interventions Ready-to-use fortified spread (n = 245) or corn-soy blend (n = 246). Main outcome measures Primary outcomes: changes in BMI and fat-free body mass after 3.5 months. Secondary outcomes: survival, CD4 count, HIV viral load, quality of life, and adherence to antiretroviral therapy. Results The mean BMI at enrolment was 16.5. After 14 weeks, patients receiving fortified spread had a greater increase in BMI and fat-free body mass than those receiving corn-soy blend: 2.2 (SD 1.9) v 1.7 (SD 1.6) (difference 0.5, 95% confidence interval 0.2 to 0.8), and 2.9 (SD 3.2) v 2.2 (SD 3.0) kg (difference 0.7 kg, 0.2 to 1.2 kg), respectively. The mortality rate was 27% for those receiving fortified spread and 26% for those receiving corn-soy blend. No significant differences in the CD4 count, HIV viral load, assessment of quality of life, or adherence to antiretroviral therapy were noted between the two groups. Conclusion Supplementary feeding with fortified spread resulted in a greater increase in BMI and lean body mass than feeding with corn-soy blend. Trial registration Current Controlled Trials ISRCTN67515515.	[Ndekha, MacDonald J.; Manary, Mark J.] Univ Malawi, Coll Med, Dept Community Hlth, Blantyre, Malawi; [Oosterhout, Joep J. Gvan; Zijlstra, Eduard E.] Univ Malawi, Coll Med, Dept Med, Blantyre, Malawi; [Manary, Micah; Saloojee, Haroon] Univ Witwatersrand, Dept Paediat, Johannesburg, South Africa; [Manary, Mark J.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Manary, Mark J.] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA	University of Malawi; University of Malawi; University of Witwatersrand; Washington University (WUSTL); Baylor College of Medicine	Manary, MJ (corresponding author), St Louis Childrens Hosp, Dept Pediat, 1 Childrens Pl, St Louis, MO 63110 USA.	manary@kids.wustl.edu	Saloojee, Haroon/J-5642-2019	Saloojee, Haroon/0000-0002-8298-7210; Manary, Mark/0000-0003-2733-9568	Academy for Educational Development (AED); AIDS Care Research in Africa (ACRiA)	Academy for Educational Development (AED); AIDS Care Research in Africa (ACRiA)	This study was supported by the USAID funded Food and Nutrition Technical Assistance (FANTA) Project of the Academy for Educational Development (AED) and AIDS Care Research in Africa (ACRiA). The AED provided expert review before making a funding decision, and the comments of those reviewers were considered in formulation of the final design. After agreeing to fund the study, neither sponsor played a role in the implementation, data collection, data analyses, or writing of this report.	[Anonymous], 2000, MEAS HLTH DAYS; Au JT, 2006, AIDS, V20, P2116, DOI 10.1097/01.aids.0000247580.16073.1b; Bowie C, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-12; Bukusuba J, 2007, BRIT J NUTR, V98, P211, DOI 10.1017/S0007114507691806; Caulfield Laura E., 1999, Food and Nutrition Bulletin, V20, P183; Ciliberto MA, 2005, AM J CLIN NUTR, V81, P864, DOI 10.1093/ajcn/81.4.864; Dannhauser A, 1999, EUR J CLIN NUTR, V53, P165, DOI 10.1038/sj.ejcn.1600691; Etard JF, 2006, AIDS, V20, P1181, DOI 10.1097/01.aids.0000226959.87471.01; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Hoddinott J., 2002, 136 FCND INT FOOD PO; Kotler DP, 1996, AM J CLIN NUTR, V64, P489; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; Leyna G H, 2007, East Afr Med J, V84, P163; Liechty CA, 2007, TROP MED INT HEALTH, V12, P929, DOI 10.1111/j.1365-3156.2007.01874.x; Lowrance D, 2007, JAIDS-J ACQ IMM DEF, V46, P56; Mahlungulu S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004536.pub2; Manary MJ, 2006, FOOD NUTR BULL, V27, pS83, DOI 10.1177/15648265060273S305; Moh R, 2007, AIDS, V21, P2483, DOI 10.1097/QAD.0b013e3282f09876; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Mwaniki Angela, ACHIEVING FOOD SECUR; Ndekha MJ, 2005, ACTA PAEDIATR, V94, P222, DOI 10.1080/08035250410022503; *ORC MACR, 2005, MAL DEM HLTH SURV 20; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; TJON A, 1990, ANN TROP PAEDIATR, V10, P411; van der Sande MAB, 2004, JAIDS-J ACQ IMM DEF, V37, P1288, DOI 10.1097/01.qai.0000122708.59121.03; van Griensven J, 2007, T ROY SOC TROP MED H, V101, P793, DOI 10.1016/j.trstmh.2007.02.020; van Oosterhout JJ, 2005, TROP MED INT HEALTH, V10, P464, DOI 10.1111/j.1365-3156.2005.01409.x; Waterlow JC, 1992, PROTEIN ENERGY MALNU; World Health Organisation, 2003, NUTR REQ PEOPL LIV H; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0	31	72	73	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	2009	338								b1867	10.1136/bmj.b1867	http://dx.doi.org/10.1136/bmj.b1867			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	448NU	19465470	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000266270100004
J	Senthivinayagam, S; Mishra, P; Paramasivam, SK; Yallapragada, S; Chatterjee, M; Wong, L; Rana, A; Rana, B				Senthivinayagam, Subramanian; Mishra, Prajna; Paramasivam, Suresh Kanna; Yallapragada, Srinivas; Chatterjee, Malay; Wong, Lucas; Rana, Ajay; Rana, Basabi			Caspase-mediated Cleavage of beta-Catenin Precedes Drug-induced Apoptosis in Resistant Cancer Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAIL-INDUCED APOPTOSIS; RECEPTOR-GAMMA ACTIVATION; SENSITIZES TUMOR-CELLS; HUMAN COLON-CANCER; COLORECTAL-CANCER; IN-VITRO; HEPATOCELLULAR CARCINOMAS; DEATH RECEPTORS; GENE-EXPRESSION; TARGETING DEATH	A delicate balance between cell death and survival pathways maintains normal physiology, which is altered in many cancers, shifting the balance toward increased survival. Several studies have established a close connection between the Wnt/beta-catenin pathway and tumorigenesis, aberrant activation of which might contribute toward increased cancer cell growth and survival. Extensive research is underway to identify therapeutic agents that can induce apoptosis specifically in cancer cells with minimal collateral damage to normal cells. Although tumor necrosis factor-related apoptosis-inducing ligand( TRAIL) can induce apoptosis specifically in tumor cells, many cancer cells develop resistance, which can be overcome by combinatorial treatment with other agents: for example, peroxisome proliferator-activated receptor gamma (PPAR gamma) ligands. To identify the molecular target mediating combinatorial drug-induced apoptosis, we focused on beta-catenin, a protein implicated in oncogenesis. Our results show that co-treatment of TRAIL-resistant cancer cells with TRAIL and the PPAR gamma ligand troglitazone leads to a reduction of beta-catenin expression, coinciding with maximal apoptosis. Modulation of beta-catenin levels via ectopic overexpression or small interference RNA-mediated gene silencing modulates drug-induced apoptosis, indicating involvement of beta-catenin in regulating this pathway. More in-depth studies indicated a post-translational mechanism, independent of glycogen synthase kinase-3 beta activity regulating beta-catenin expression following combinatorial drug treatment. Furthermore, TRAIL- and troglitazone-induced apoptosis was preceded by a cleavage of beta-catenin, which was complete in a fully apoptotic population, and was mediated by caspases-3 and -8. These results demonstrate beta-catenin as a promising new target of drug-induced apoptosis, which can be targeted to sensitize apoptosis-resistant cancer cells.	[Senthivinayagam, Subramanian; Mishra, Prajna; Paramasivam, Suresh Kanna; Rana, Basabi] Loyola Univ, Dept Med, Div Gastroenterol Hepatol & Nutr, Maywood, IL 60153 USA; [Rana, Ajay; Rana, Basabi] Loyola Univ, Dept Pharmacol & Expt Therapeut, Maywood, IL 60153 USA; [Yallapragada, Srinivas] Texas A&M Univ, Hlth Sci Ctr, Dept Internal Med, Coll Med, Temple, TX 76504 USA; [Rana, Ajay; Rana, Basabi] Hines Vet Affairs Med Ctr, Hines, IL 60141 USA; [Chatterjee, Malay] Jadavpur Univ, Dept Pharmaceut Technol, Div Biochem, Kolkata 700032, India; [Wong, Lucas] Scott & White Hosp, Div Hematol Oncol, Temple, TX 76504 USA	Loyola University Chicago; Loyola University Chicago; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Jadavpur University	Rana, B (corresponding author), Loyola Univ Chicago, Bldg 101,Rm 2729,2160 S 1st Ave, Maywood, IL 60153 USA.	brana@lumc.edu	Senthivinayagam, Subramanian/E-3141-2012; Rana, Ajay/ABE-3739-2020	Senthivinayagam, Subramanian/0000-0001-8796-3640; Rana, Ajay/0000-0003-0951-2566; Mishra, Prajna/0000-0002-1906-0244	National Institutes of Health [CA121221, GM55835]; Veterans Affairs Merit and VISN 17; Susan Komen Breast Cancer Foundation; Veterans Affairs Merit award; NATIONAL CANCER INSTITUTE [R21CA121221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055835] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Merit and VISN 17(US Department of Veterans Affairs); Susan Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Veterans Affairs Merit award(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA121221 (to B. R.) and GM55835 (to A. R.). This work was also supported by Veterans Affairs Merit and VISN 17 awards (to B. R.), the Susan Komen Breast Cancer Foundation, and a Veterans Affairs Merit award (to A. R.).	Abe K, 2007, NEURON, V53, P387, DOI 10.1016/j.neuron.2007.01.016; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bonavida B, 1999, INT J ONCOL, V15, P793; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Fukuda K, 1999, INT J BIOCHEM CELL B, V31, P519, DOI 10.1016/S1357-2725(98)00119-8; Fulda S, 2004, CANCER RES, V64, P337, DOI 10.1158/0008-5472.CAN-03-1656; Gao JJ, 2005, P NATL ACAD SCI USA, V102, P17207, DOI 10.1073/pnas.0506893102; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Keane MM, 1999, CANCER RES, V59, P734; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Ling YH, 2001, MOL PHARMACOL, V59, P593, DOI 10.1124/mol.59.3.593; Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Miyoshi Y, 1998, CANCER RES, V58, P2524; Nayak TK, 2007, NUCL MED BIOL, V34, P185, DOI 10.1016/j.nucmedbio.2006.11.006; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Schultze K, 2006, APOPTOSIS, V11, P1503, DOI 10.1007/s10495-006-8896-3; Sharma C, 2004, J BIOL CHEM, V279, P35583, DOI 10.1074/jbc.M403143200; Sharma C, 2004, J BIOL CHEM, V279, P16927, DOI 10.1074/jbc.M309045200; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; SUREAU C, 1992, J VIROL, V66, P1241, DOI 10.1128/JVI.66.2.1241-1245.1992; Tan XP, 2008, HEPATOLOGY, V47, P1667, DOI 10.1002/hep.22225; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang HY, 2005, CANCER RES, V65, P8604, DOI 10.1158/0008-5472.CAN-05-1169; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Xiao JH, 2003, J BIOL CHEM, V278, P29954, DOI 10.1074/jbc.M304761200; Xie HM, 2005, J IMMUNOL, V175, P7981, DOI 10.4049/jimmunol.175.12.7981; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Yu J, 2006, HEPATOLOGY, V43, P134, DOI 10.1002/hep.20994; Zeng G, 2007, NEOPLASIA, V9, P951, DOI 10.1593/neo.07469; Zou W, 2007, CANCER BIOL THER, V6, P99, DOI 10.4161/cbt.6.1.3555	53	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	2009	284	20					13577	13588		10.1074/jbc.M900248200	http://dx.doi.org/10.1074/jbc.M900248200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	442YL	19289465	hybrid, Green Published			2023-01-03	WOS:000265877300035
J	Kalaany, NY; Sabatini, DM				Kalaany, Nada Y.; Sabatini, David M.			Tumours with PI3K activation are resistant to dietary restriction	NATURE			English	Article							GROWTH-FACTOR-I; CALORIC RESTRICTION; LIFE-SPAN; PHOSPHATIDYLINOSITOL 3-KINASES; ENERGY RESTRICTION; HUMAN CANCER; CELL-GROWTH; MUTATIONS; INSULIN; GENE	Dietary restriction delays the incidence and decreases the growth of various types of tumours, but the mechanisms underlying the sensitivity of tumours to food restriction remain unknown. Here we show that certain human cancer cell lines, when grown as tumour xenografts in mice, are highly sensitive to the anti-growth effects of dietary restriction, whereas others are resistant. Cancer cells that form dietary-restriction-resistant tumours carry mutations that cause constitutive activation of the phosphatidylinositol-3-kinase (PI3K) pathway and in culture proliferate in the absence of insulin or insulin-like growth factor 1. Substitution of an activated mutant allele of PI3K with wild-type PI3K in otherwise isogenic cancer cells, or the restoration of PTEN expression in a PTEN-null cancer cell line, is sufficient to convert a dietary-restriction-resistant tumour into one that is dietary-restriction-sensitive. Dietary restriction does not affect a PTEN-null mouse model of prostate cancer, but it significantly decreases tumour burden in a mouse model of lung cancer lacking constitutive PI3K signalling. Thus, the PI3K pathway is an important determinant of the sensitivity of tumours to dietary restriction, and activating mutations in the pathway may influence the response of cancers to dietary restriction-mimetic therapies.	[Kalaany, Nada Y.; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; [Kalaany, Nada Y.; Sabatini, David M.] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA; [Kalaany, Nada Y.; Sabatini, David M.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Sabatini, David M.] Broad Inst, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Sabatini, DM (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu		/0000-0002-1446-7256; Kalaany, Nada/0000-0001-7489-1035	Alexander and Margaret Stewart Trust Award; David H. Koch Cancer Research Award; National Institutes of Health [R01 AI04389, R01 CA129105]; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R01CA129105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047389] Funding Source: NIH RePORTER	Alexander and Margaret Stewart Trust Award; David H. Koch Cancer Research Award; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank B. Vogelstein for providing the isogenic DLD-1 cell lines and M. M. Georgescu for the doxycycline-inducible U87-MG cell line; T. Jacks for the KRAS<SUP>LA2</SUP>; p53<SUP>LSL/WT</SUP> mice and H. Wu for the Pb-Cre; PTEN<SUP>L/L</SUP> mice; F. Reinhardt for assistance with animal experiments; R. Bronson for histological analysis; the Histology Facility at the Koch Institute for Integrative Cancer Research and the Histology Core Laboratory at MIT for assistance with sectioning and immunohistochemistry; the Imaging Platform at the Broad Institute for assistance with image analysis; R. Weinberg, D. Guertin, Y. Chudnovsky and Y. Sancak for critical reading of the manuscript; and members of the Sabatini and Weinberg laboratories for support and discussions. This research is supported by the Alexander and Margaret Stewart Trust Award, the David H. Koch Cancer Research Award and National Institutes of Health grants R01 AI04389 and R01 CA129105. D. M. S. is an investigator of the Howard Hughes Medical Institute.	BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; CHENEY KE, 1983, J GERONTOL, V38, P420, DOI 10.1093/geronj/38.4.420; CHENEY KE, 1980, EXP GERONTOL, V15, P237, DOI 10.1016/0531-5565(80)90029-7; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kalaany NY, 2005, CELL METAB, V1, P231, DOI 10.1016/j.cmet.2005.03.001; Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; KLURFELD DM, 1989, J NUTR, V119, P286, DOI 10.1093/jn/119.2.286; Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13; Lamprecht MR, 2007, BIOTECHNIQUES, V42, P71, DOI 10.2144/000112257; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Moreschi C., 1909, ZIMMUNITATSFORSCH, V2, P651; Pugh TD, 1999, CANCER RES, V59, P1642; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rous P, 1914, J EXP MED, V20, P413, DOI 10.1084/jem.20.4.413; RUGGERI BA, 1989, CANCER RES, V49, P4130; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sell C, 2003, HORM METAB RES, V35, P705, DOI 10.1055/s-2004-814156; TANNENBAUM A, 1949, CANCER RES, V9, P724; TANNENBAUM A, 1953, CANCER RES, V13, P532; Thompson HJ, 2003, J MAMMARY GLAND BIOL, V8, P133, DOI 10.1023/A:1025743607445; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wapnir IL, 1996, BREAST CANCER RES TR, V41, P15, DOI 10.1007/BF01807032; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102; Zhu ZJ, 1997, CARCINOGENESIS, V18, P1007, DOI 10.1093/carcin/18.5.1007	38	333	345	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 9	2009	458	7239					725	U61		10.1038/nature07782	http://dx.doi.org/10.1038/nature07782			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	433GZ	19279572	Green Accepted			2023-01-03	WOS:000265193600032
J	Baker, BK; Ombaka, E				Baker, Brook K.; Ombaka, Eva			The danger of in-kind drug donations to the Global Fund	LANCET			English	Editorial Material							PHARMACEUTICAL-INDUSTRY; GENERIC ENTRY		[Baker, Brook K.] Hlth GAP NE Univ, Program Human Rights & Global Econ, Sch Law, Boston, MA 02115 USA	Northeastern University	Baker, BK (corresponding author), Hlth GAP NE Univ, Program Human Rights & Global Econ, Sch Law, 400 Huntington Ave, Boston, MA 02115 USA.	B.Baker@neu.edu						[Anonymous], PROTECTION DATA SUBM; [Anonymous], 2001, WHO GLOB STRAT CONT; [Anonymous], 2006, USE FLEXIBILITIES TR; Autier P., 2002, DRUG DONATIONS POSTE, P1; Bae JP, 1997, HEALTH SERV RES, V32, P87; BAKER B, 2004, DFID             AUG; Caines K., 2004, IMPACT PUBLIC PRIVAT; Caines K., 2004, GLOBAL HLTH PARTNERS; CHIEN C, 2007, PLOS ONE         MAR; Competition Bureau of Canada, 2007, CAN GEN DRUG SECT ST; Congressional Budgetary Office, 1998, INCR COMP GEN DRUGS; DALEN DM, 2006, HLTH EC RES PROG; Frank RG, 1997, J ECON MANAGE STRAT, V6, P75, DOI 10.1162/105864097567039; Frank RG, 2007, NEW ENGL J MED, V357, P1993, DOI 10.1056/NEJMp078193; *GLOB FUND FIGHT A, 2007, TUB MAL SUMM GLOB FU; Guilloux Allain, 2001, HIDDEN PRICE TAGS DI; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; HECHMANN R, 2007, J HUMANITARIAN ASST; Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; Hudson J., 2000, INT REV LAW ECON, V24, P103; KAHN T, 2006, BUS DAY         0207; KIMANI D, 2006, NATIONMEDIA     0123; LEWISLETTINGTON R, 2004, DFID             SEP; MANGWIRO C, 2007, REUTERS ALERT N 0529; Medicens Sans Frontieres, 2007, UNT WEB PRIC RED PRI; MORENOTORRES I, 2007, GENERIC ENTRY REGULA; Morton FMS, 1999, RAND J ECON, V30, P421, DOI 10.2307/2556056; Oyediran ABOO, 2002, B WORLD HEALTH ORGAN, V80, P817; Perez-Casas C, 2001, TROP MED INT HEALTH, V6, P960, DOI 10.1046/j.1365-3156.2001.00801.x; RATANAWIFITRASI.S, 2002, EFFECTIVE DRUG REGIS; Reiffen D, 2005, REV ECON STAT, V87, P37, DOI 10.1162/0034653053327694; Reiffen David, 2005, BRANDED GENERICS STR; Rudholm N, 2001, REV IND ORGAN, V19, P351, DOI 10.1023/A:1011868404205; Saha A, 2006, INT J ECON BUS, V13, P15, DOI 10.1080/13571510500519905; Shretta R, 2001, HEALTH POLICY PLANN, V16, P161, DOI 10.1093/heapol/16.2.161; Thomas M.J.W., 2003, HUMAN FACTORS AEROSP, V3, P25; THORPE P, 2001, STUDY IMPLEMENTATION; *WHO, 2007, ANT THER HIV INF AD; *WHO, 2007, SUMM REP GLOB PRIC R; *WHO, 2000, 1 YEAR EXP INT GUID; *WORLD COMM ADV BO, 2005, M IND GEN DRUGS IND; World Health Organisation, 2007, PRIOR 2 LIN ANT DRUG; World Health Organization, 2006, MEAS TRANSP MED REG; World Health Organization, 1999, GUID DRUG DON; 2007, PLUS NEWS       1010	45	11	11	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 4	2009	373	9670					1218	1221		10.1016/S0140-6736(08)61487-7	http://dx.doi.org/10.1016/S0140-6736(08)61487-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	429SO	18848353				2023-01-03	WOS:000264940600036
J	Watson, M; McPherson, A; Murray, SA				Watson, Max; McPherson, Alan; Murray, Scott A.			Should hospices be exempt from following national cardiopulmonary resuscitation guidelines? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Watson, Max] No Ireland Hosp, Belfast BT15 3LH, Antrim, North Ireland; [Watson, Max] Univ Ulster, Coleraine, Ireland; [Murray, Scott A.] Univ Edinburgh, Primary Palliat Care Res Grp, Div Community Hlth Sci, Gen Practice Sect, Edinburgh EH8 9YL, Midlothian, Scotland	Ulster University; University of Edinburgh	Watson, M (corresponding author), No Ireland Hosp, Belfast BT15 3LH, Antrim, North Ireland.	max.watson@nihospicec.org						[Anonymous], NAT SURV PAT ACT DAT; *ROYAL COLL NURS B, 2007, DEC REL CARD RES JOI; Twycross R, 2003, INTRO PALLIATIVE CAR	3	4	4	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 26	2009	338								b965	10.1136/bmj.b965	http://dx.doi.org/10.1136/bmj.b965			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425LR	19325181				2023-01-03	WOS:000264639700005
J	Bederman, IR; Foy, S; Chandramouli, V; Alexander, JC; Previs, SF				Bederman, Ilya R.; Foy, Steven; Chandramouli, Visvanathan; Alexander, James C.; Previs, Stephen F.			Triglyceride Synthesis in Epididymal Adipose Tissue CONTRIBUTION OF GLUCOSE AND NON-GLUCOSE CARBON SOURCES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS ISOTOPOMER ANALYSIS; CARBOHYDRATE-FREE DIET; IN-VIVO; FATTY-ACIDS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; CHOLESTEROL-SYNTHESIS; GLYCERIDE-GLYCEROL; PLASMA-GLUCOSE; HIGH-PROTEIN; GLYCERONEOGENESIS	The obesity epidemic has generated interest in determining the contribution of various pathways to triglyceride synthesis, including an elucidation of the origin of triglyceride fatty acids and triglyceride glycerol. We hypothesized that a dietary intervention would demonstrate the importance of using glucose versus non-glucose carbon sources to synthesize triglycerides in white adipose tissue. C57BL/6J mice were fed either a low fat, high carbohydrate (HC) diet or a high fat, carbohydrate-free (CF) diet and maintained on (H2O)-H-2 (to determine total triglyceride dynamics) or infused with [6,6-H-2] glucose (to quantify the contribution of glucose to triglyceride glycerol). The (H2O)-H-2 labeling data demonstrate that although de novo lipogenesis contributed similar to 80% versus similar to 5% to the pool of triglyceride palmitate in HC-versus CF-fed mice, the epididymal adipose tissue synthesized similar to 1.5-fold more triglyceride in CF-versus HC-fed mice, i.e. 37 +/- 5 versus 25 +/- 3 mu mol x day(-1). The [6,6-H-2] glucose labeling data demonstrate that similar to 69 and similar to 28% of triglyceride glycerol is synthesized from glucose in HC-versus CF-fed mice, respectively. Although these data are consistent with the notion that non-glucose carbon sources (e. g. glyceroneogenesis) can make substantial contributions to the synthesis of triglyceride glycerol (i.e. the absolute synthesis of triglyceride glycerol from non-glucose substrates increased from similar to 8 to similar to 26 mu mol x day(-1) in HC-versus CF-fed mice), these observations suggest (i) the importance of nutritional status in affecting flux rates and (ii) the operation of a glycerol-glucose cycle.	[Previs, Stephen F.] Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; [Chandramouli, Visvanathan; Previs, Stephen F.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; [Alexander, James C.] Case Western Reserve Univ, Dept Math, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Previs, SF (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, Rm WG 48,10900 Euclid Ave, Cleveland, OH 44106 USA.	stephen.previs@case.edu			National Institutes of Health Metabolomics Roadmap Initiative [R33DK070291]; American Diabetes Association [1-04-JF-40]; Mt. Sinai Health Care Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R33DK070291] Funding Source: NIH RePORTER	National Institutes of Health Metabolomics Roadmap Initiative(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Mt. Sinai Health Care Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Metabolomics Roadmap Initiative Grant R33DK070291. This work was also supported by grants from the American Diabetes Association (Grant 1-04-JF-40) and the Mt. Sinai Health Care Foundation (Cleveland, OH).	BAKER N, 1972, J LIPID RES, V13, P716; BALLARD FJ, 1967, J BIOL CHEM, V242, P2746; BEALE EG, 2003, BIOCHEM SOC T, V31, P1125; Bederman IR, 2006, AM J PHYSIOL-ENDOC M, V290, pE1048, DOI 10.1152/ajpendo.00340.2005; Behn A, 2006, CURR OPIN CARDIOL, V21, P353, DOI 10.1097/01.hco.0000231406.84554.96; Bessesen DH, 2000, AM J PHYSIOL-ENDOC M, V278, pE1124, DOI 10.1152/ajpendo.2000.278.6.E1124; Botion LM, 1998, METABOLISM, V47, P1217, DOI 10.1016/S0026-0495(98)90326-2; Bray GA, 2006, ENDOCRINE, V29, P109, DOI 10.1385/ENDO:29:1:109; Brito SC, 2006, METABOLISM, V55, P84, DOI 10.1016/j.metabol.2005.07.010; Brunengraber DZ, 2003, AM J PHYSIOL-ENDOC M, V285, pE917, DOI 10.1152/ajpendo.00128.2003; Burgess SC, 2003, ANAL BIOCHEM, V318, P321, DOI 10.1016/S0003-2697(03)00158-1; Burgess SC, 2008, J APPL PHYSIOL, V104, P1852, DOI 10.1152/japplphysiol.90406.2008; Cadoudal T, 2008, DIABETES, V57, P2272, DOI 10.2337/db08-0477; Chacko SK, 2008, J APPL PHYSIOL, V104, P944, DOI 10.1152/japplphysiol.00752.2007; Chen JL, 2005, J BIOL CHEM, V280, P25396, DOI 10.1074/jbc.M413948200; Daniels SR, 2006, FUTURE CHILD, V16, P47, DOI 10.1353/foc.2006.0004; Dietz WH, 2004, NEW ENGL J MED, V350, P855, DOI 10.1056/NEJMp048008; Diraison F, 1997, J MASS SPECTROM, V32, P81, DOI 10.1002/(SICI)1096-9888(199701)32:1<81::AID-JMS454>3.0.CO;2-2; Forest C, 2003, BIOCHEM SOC T, V31, P1125; Hanson RW, 2003, BIOCHIMIE, V85, P1199, DOI 10.1016/j.biochi.2003.10.022; Jones JG, 2002, MAGNET RESON MED, V48, P535, DOI 10.1002/mrm.10234; KNEER P, 1968, J BIOL CHEM, V243, P2863; LEE WNP, 1994, AM J PHYSIOL, V266, pE699, DOI 10.1152/ajpendo.1994.266.5.E699; LEE WNP, 1994, AM J PHYSIOL, V266, pE372, DOI 10.1152/ajpendo.1994.266.3.E372; Leroyer SN, 2006, J BIOL CHEM, V281, P13141, DOI 10.1074/jbc.M512943200; NURJHAN N, 1986, DIABETES, V35, P1326, DOI 10.2337/diabetes.35.12.1326; Nye CK, 2008, J BIOL CHEM, V283, P27565, DOI 10.1074/jbc.M804393200; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; ROGNSTAD R, 1974, EUR J BIOCHEM, V47, P383, DOI 10.1111/j.1432-1033.1974.tb03703.x; Schoenheimer R, 1936, J BIOL CHEM, V114, P381; Siler SQ, 1998, AM J PHYSIOL-ENDOC M, V275, pE897, DOI 10.1152/ajpendo.1998.275.5.E897; Summers LKM, 2000, AM J CLIN NUTR, V71, P1470; Tordjman J, 2003, J BIOL CHEM, V278, P18785, DOI 10.1074/jbc.M206999200; Turner SM, 2003, AM J PHYSIOL-ENDOC M, V285, pE790, DOI 10.1152/ajpendo.00402.2002; WHITE LW, 1968, ARCH BIOCHEM BIOPHYS, V126, P552, DOI 10.1016/0003-9861(68)90441-4; Wolfe R.R., 2004, ISOTOPE TRACERS META; Xu J, 2002, J BIOL CHEM, V277, P50237, DOI 10.1074/jbc.M201208200; Yang DW, 1998, ANAL BIOCHEM, V258, P315, DOI 10.1006/abio.1998.2632	38	67	67	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 6	2009	284	10					6101	6108		10.1074/jbc.M808668200	http://dx.doi.org/10.1074/jbc.M808668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	412RU	19114707	Green Published, hybrid			2023-01-03	WOS:000263742700012
J	Jarvis, S				Jarvis, Sarah			Should the contraceptive pill be available without prescription? No	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ORAL-CONTRACEPTIVES; PREGNANCY		[Jarvis, Sarah] Royal Coll Gen Practitioners, London SW7 1PU, England		Jarvis, S (corresponding author), Royal Coll Gen Practitioners, London SW7 1PU, England.	Sarah.jarvis@gp-e85016.nhs.uk	Potter, Joseph E/A-3122-2008					BOTTING B, TRENDS FERTILITY CON; Churchill Dick, 2002, Int J Adolesc Med Health, V14, P153; Darroch JE, 2001, FAM PLANN PERSPECT, V33, P244, DOI 10.2307/3030191; *DEP HLTH, NAT SURV LOC HLTH SE; Free C, 2004, J FAM PLAN REPROD H, V30, P91, DOI 10.1783/147118904322995447; Mc Millan H M, 2004, Ir Med J, V97, P276; *NAT I CLIN EXC, 2005, 30 NAT I CLIN EXC; ROSENBERG MJ, 1995, CONTRACEPTION, V51, P283, DOI 10.1016/0010-7824(95)00074-K; Rosenberg MJ, 1998, FAM PLANN PERSPECT, V30, P89, DOI 10.2307/2991665; *SOC EXCL UN, 1999, TEEN PREGN REP; Thurman AR, 2007, J PEDIATR ADOL GYNEC, V20, P61, DOI 10.1016/j.jpag.2006.11.006; Wilkinson P, 2006, LANCET, V368, P1879, DOI 10.1016/S0140-6736(06)69777-8	12	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 23	2008	337								a3056	10.1136/bmj.a3056	http://dx.doi.org/10.1136/bmj.a3056			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	394EL	19106139				2023-01-03	WOS:000262428400004
J	Kagaayi, J; Gray, RH; Brahmbhatt, H; Kigozi, G; Nalugoda, F; Wabwire-Mangen, F; Serwadda, D; Sewankambo, N; Ddungu, V; Ssebagala, D; Sekasanvu, J; Kigozi, G; Makumbi, F; Kiwanuka, N; Lutalo, T; Reynolds, SJ; Wawer, MJ				Kagaayi, Joseph; Gray, Ronald H.; Brahmbhatt, Heena; Kigozi, Godfrey; Nalugoda, Fred; Wabwire-Mangen, Fred; Serwadda, David; Sewankambo, Nelson; Ddungu, Veronica; Ssebagala, Darix; Sekasanvu, Joseph; Kigozi, Grace; Makumbi, Fredrick; Kiwanuka, Noah; Lutalo, Tom; Reynolds, Steven J.; Wawer, Maria J.			Survival of Infants Born to HIV-Positive Mothers, by Feeding Modality, in Rakai, Uganda	PLOS ONE			English	Article								Background: Data comparing survival of formula-fed to breast-fed infants in programmatic settings are limited. We compared mortality and HIV-free of breast and formula-fed infants born to HIV-positive mothers in a program in rural, Rakai District Uganda. Methodology/Principal Findings: One hundred eighty two infants born to HIV-positive mothers were followed at one, six and twelve months postpartum. Mothers were given infant-feeding counseling and allowed to make informed choices as to whether to formula-feed or breast-feed. Eligible mothers and infants received antiretroviral therapy (ART) if indicated. Mothers and their newborns received prophylaxis for prevention of mother-to-child HIV transmission (pMTCT) if they were not receiving ART. Infant HIV infection was detected by PCR (Roche Amplicor 1.5) during the follow-up visits. Kaplan Meier time-to-event methods were used to compare mortality and HIV-free survival. The adjusted hazard ratio (Adjusted HR) of infant HIV-free survival was estimated by Cox regression. Seventy-five infants (41%) were formula-fed while 107 (59%) were breast-fed. Exclusive breast-feeding was practiced by only 25% of breast-feeding women at one month postpartum. The cumulative 12-month probability of infant mortality was 18% (95% CI = 11%-29%) among the formula-fed compared to 3% (95% CI = 1%-9%) among the breast-fed infants (unadjusted hazard ratio (HR) = 6.1(95% CI = 1.7-21.4, P-value<0.01). There were no statistically significant differentials in HIV-free survival by feeding choice (86% in the formula-fed compared to 96% in breast-fed group (Adjusted RH = 2.8[ 95% CI = 0.67-11.7, P-value = 0.16] Conclusions/Significance: Formula-feeding was associated with a higher risk of infant mortality than breastfeeding in this rural population. Our findings suggest that formula-feeding should be discouraged in similar African settings.	[Kigozi, Godfrey; Nalugoda, Fred; Ddungu, Veronica] Rakai Hlth Sci Program, Dept Clin Res Studies, Entebbe, Uganda; [Gray, Ronald H.; Brahmbhatt, Heena; Wawer, Maria J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Populat, Family & Reproduct Hlth, Baltimore, MD 21218 USA; [Wabwire-Mangen, Fred; Makumbi, Fredrick; Kiwanuka, Noah] Makerere Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Kampala, Uganda; [Serwadda, David] Makerere Univ, Sch Publ Hlth, Dept Dis Control, Kampala, Uganda; [Sewankambo, Nelson] Makerere Univ, Sch Med, Dept Med, Clin Epidemiol Unit, Kampala, Uganda; [Ssebagala, Darix; Sekasanvu, Joseph; Lutalo, Tom] Rakai Hlth Sci Program, Dept Biostat & Data Management, Entebbe, Uganda; [Kigozi, Grace] Rakai Hlth Sci Program, Dept Quality Control & Quality Assurance, Entebbe, Uganda; [Reynolds, Steven J.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21218 USA; [Reynolds, Steven J.] NIAID, NIH, Div Intramural Res, Lab Immunoregulat, Bethesda, MD USA	Rakai Health Sciences Program; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Makerere University; Makerere University; Makerere University; Rakai Health Sciences Program; Rakai Health Sciences Program; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kagaayi, J (corresponding author), Rakai Hlth Sci Program, Dept Clin Res Studies, Entebbe, Uganda.	jkagayi@rhsp.org		Sewankambo, Nelson/0000-0001-9362-053X; Kagaayi, Joseph/0000-0003-4101-3038; Reynolds, Steven/0000-0002-5403-2759	National Institute of Child Health and Human Development(NICHD); Presidential Emergency Plan for AIDS Relief(PEPFAR)	National Institute of Child Health and Human Development(NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Presidential Emergency Plan for AIDS Relief(PEPFAR)	National Institute of Child Health and Human Development(NICHD). Presidential Emergency Plan for AIDS Relief(PEPFAR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Becquet R, 2007, PLOS MED, V4, P139, DOI 10.1371/journal.pmed.0040017; Bedri A, 2008, LANCET, V372, P300, DOI 10.1016/S0140-6736(08)61114-9; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; Coovadia HM, 2007, AIDS, V21, P1837, DOI 10.1097/QAD.0b013e32826fb731; Coutsoudis A, 2003, ACTA PAEDIATR, V92, P890, DOI 10.1080/08035250310004261; Coutsoudis A, 2008, B WORLD HEALTH ORGAN, V86, P210, DOI 10.2471/BLT.07.041673; COX DR, 1968, J ROY STAT SOC B, V30, P248, DOI 10.1111/j.2517-6161.1968.tb00724.x; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; Kagaayi J, 2005, JAIDS-J ACQ IMM DEF, V39, P121, DOI 10.1097/01.qai.0000148530.66587.7c; Kuhn L, 2008, NEW ENGL J MED, V359, P130, DOI 10.1056/NEJMoa073788; Kumwenda NI, 2008, NEW ENGL J MED, V359, P119, DOI 10.1056/NEJMoa0801941; Mbori-Ngacha D, 2001, JAMA-J AM MED ASSOC, V286, P2413, DOI 10.1001/jama.286.19.2413; Palombi L, 2007, AIDS, V21, pS65, DOI 10.1097/01.aids.0000279708.09180.f5; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; WHO, 2006, ANT DRUGS TREAT PREG; *WHO, 2007, HIV INF FEED NEW EV; *WHO, 2006, WHO HIV INF FEED TEC	18	58	58	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2008	3	12							e3877	10.1371/journal.pone.0003877	http://dx.doi.org/10.1371/journal.pone.0003877			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	436ZP	19065270	Green Submitted, gold, Green Published			2023-01-03	WOS:000265455200003
J	Kesselheim, AS; Misono, AS; Lee, JL; Stedman, MR; Brookhart, MA; Choudhry, NK; Shrank, WH				Kesselheim, Aaron S.; Misono, Alexander S.; Lee, Joy L.; Stedman, Margaret R.; Brookhart, M. Alan; Choudhry, Niteesh K.; Shrank, William H.			Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							COMPARATIVE BIOEQUIVALENCE; FORMULATION SUBSTITUTION; MEDICATION ADHERENCE; AMLODIPINE BESYLATE; BETA-BLOCKER; DOUBLE-BLIND; OF-INTEREST; OPEN-LABEL; WARFARIN; CROSSOVER	Context Use of generic drugs, which are bioequivalent to brand- name drugs, can help contain prescription drug spending. However, there is concern among patients and physicians that brand- name drugs may be clinically superior to generic drugs. Objectives To summarize clinical evidence comparing generic and brand- name drugs used in cardiovascular disease and to assess the perspectives of editorialists on this issue. Data Sources Systematic searches of peer- reviewed publications in MEDLINE, EMBASE, and International Pharmaceutical Abstracts from January 1984 to August 2008. Study Selection Studies compared generic and brand- name cardiovascular drugs using clinical efficacy and safety end points. We separately identified editorials addressing generic substitution. Data Extraction We extracted variables related to the study design, setting, participants, clinical end points, and funding. Methodological quality of the trials was assessed by Jadad and Newcastle- Ottawa scores, and a meta- analysis was performed to determine an aggregate effect size. For editorials, we categorized authors' positions on generic substitution as negative, positive, or neutral. Results We identified 47 articles covering 9 subclasses of cardiovascular medications, of which 38 ( 81%) were randomized controlled trials ( RCTs). Clinical equivalence was noted in 7 of 7 RCTs ( 100%) of beta - blockers, 10 of 11 RCTs ( 91%) of diuretics, 5 of 7 RCTs ( 71%) of calcium channel blockers, 3 of 3 RCTs ( 100%) of antiplatelet agents, 2 of 2 RCTs ( 100%) of statins, 1 of 1 RCT ( 100%) of angiotensin- converting enzyme inhibitors, and 1 of 1 RCT ( 100%) of alpha - blockers. Among narrow therapeutic index drugs, clinical equivalence was reported in 1 of 1 RCT ( 100%) of class 1 antiarrhythmic agents and 5 of 5 RCTs ( 100%) of warfarin. Aggregate effect size ( n= 837) was - 0.03 ( 95% confidence interval, - 0.15 to 0.08), indicating no evidence of superiority of brand- name to generic drugs. Among 43 editorials, 23 ( 53%) expressed a negative view of generic drug substitution. Conclusions Whereas evidence does not support the notion that brand- name drugs used in cardiovascular disease are superior to generic drugs, a substantial number of editorials counsel against the interchangeability of generic drugs.	[Kesselheim, Aaron S.; Misono, Alexander S.; Lee, Joy L.; Stedman, Margaret R.; Brookhart, M. Alan; Choudhry, Niteesh K.; Shrank, William H.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Kesselheim, AS (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	akesselheim@partners.org	Kesselheim, Aaron/R-6793-2017	Kesselheim, Aaron/0000-0002-8867-2666; Lee, Joy/0000-0003-2589-8200	Attorney General Prescriber and Consumer Education Grant Program; Agency for Healthcare Research and Quality Post-Doctoral Fellowship in Health Services Research at the Harvard School of Public Health; National Institute on Aging [AG027400)]; National Heart, Lung, and Blood Institute [K23HL090505-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL090505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K25AG027400] Funding Source: NIH RePORTER	Attorney General Prescriber and Consumer Education Grant Program; Agency for Healthcare Research and Quality Post-Doctoral Fellowship in Health Services Research at the Harvard School of Public Health(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The study was supported in part by a grant from the Attorney General Prescriber and Consumer Education Grant Program. Dr Kesselheim's work was supported by an Agency for Healthcare Research and Quality Post- Doctoral Fellowship in Health Services Research at the Harvard School of Public Health. Dr Brookhart is supported by a career development award from the National Institute on Aging (AG027400). Dr Shrank is supported by a career development award from the National Heart, Lung, and Blood Institute (K23HL090505-01).	ABELLI C, 2001, STP PHARMA PRATIQUES, V11, P102; Ahrens W, 2007, PHARMACOEPIDEM DR S, V16, P1298, DOI 10.1002/pds.1494; AI-Jazairi AS, 2008, ANN SAUDI MED, V28, P33; Amit G, 2004, AM J CARDIOL, V93, P1558, DOI 10.1016/j.amjcard.2004.02.071; Ashraf Tariq, 2005, JPMA Journal of the Pakistan Medical Association, V55, P443; Assawawitoontip Surin, 2002, Journal of the Medical Association of Thailand, V85, pS118; AWAD R, 1992, INT J CLIN PHARM TH, V30, P18; BALLIN J, 1988, NEW YORK STATE J MED, V88, P121; Banahan BF, 1998, FORMULARY, V33, P1082; BECK M, 2008, WALL STREET J   0422, pD1; Benditt DG, 1999, J INTERV CARD ELECTR, V3, P145, DOI 10.1023/A:1009817413845; Benet LZ, 1999, TRANSPLANT P, V31, P1642, DOI 10.1016/S0041-1345(99)00083-4; Benson SR, 1998, AM J HEALTH-SYST PH, V55, P727, DOI 10.1093/ajhp/55.7.727; Bongers V, 1999, CLIN DRUG INVEST, V17, P103, DOI 10.2165/00044011-199917020-00004; Burns M, 1999, J THROMB THROMBOLYS, V7, P137, DOI 10.1023/A:1008829403320; Calvert RT, 1996, J PHARM PHARMACOL, V48, P9, DOI 10.1111/j.2042-7158.1996.tb05867.x; Canan B, 2007, J ENVIRON ENG GEOPH, V12, P255, DOI 10.2113/JEEG12.3.255; CARTER BL, 1993, PHARMACOTHERAPY, V13, P359; CARTER BL, 1989, PHARMACOTHERAPY, V9, P17; Chiang H T, 1995, Zhonghua Yi Xue Za Zhi (Taipei), V55, P366; Cohen J., 2013, STAT POWER ANAL BEHA; COLAIZZI JL, 1986, CLIN THER, V8, P370; *CONS ASS, 1997, DRUG THER B, V35, P9; DeCara JM, 1998, CHEST, V113, P261, DOI 10.1378/chest.113.2.261; Deeks J J, 2003, Health Technol Assess, V7, piii; Dunlap WP, 1996, PSYCHOL METHODS, V1, P170, DOI 10.1037/1082-989X.1.2.170; ELSAYED MS, 1989, MED SCI SPORT EXER, V21, P369; Fischer MA, 2004, PHARMACOEPIDEM DR S, V13, P207, DOI 10.1002/pds.872; Fischer MA, 2004, JAMA-J AM MED ASSOC, V291, P1850, DOI 10.1001/jama.291.15.1850; Gaither CA, 2001, J AM PHARM ASS, V41, P729, DOI [10.1016/S1086-5802(16)31308-0, DOI 10.1016/S1086-5802(16)31308-0]; GARG SK, 1984, INT J CLIN PHARM TH, V22, P618; Goldman DP, 2007, JAMA-J AM MED ASSOC, V298, P61, DOI 10.1001/jama.298.1.61; GRAHNEN A, 1984, EUR J CLIN PHARMACOL, V27, P595, DOI 10.1007/BF00556898; Haines ST, 1998, AM J HEALTH-SYST PH, V55, P729, DOI 10.1093/ajhp/55.7.729; Halkin H, 2003, CLIN PHARMACOL THER, V74, P215, DOI 10.1016/S0009-9236(03)00166-8; HANDLER J, 1998, PREV CARDIOL, V4, P13; Hedges L.V., 2014, STAT METHODS META AN; HENDELES L, 1993, AM J HOSP PHARM, V50, P323, DOI 10.1093/ajhp/50.2.323; Henderson JD, 2001, SOUTHERN MED J, V94, P16; Hope KA, 2001, ANN PHARMACOTHER, V35, P183, DOI 10.1345/aph.10207; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KAOJARERN S, 1990, Journal of the Medical Association of Thailand, V73, P191; KASMER RJ, 1987, DRUG INTEL CLIN PHAR, V21, P183; Keith LG, 1998, INT J FERTIL WOMEN M, V43, P139; Kesselheim AS, 2006, HEALTH AFFAIR, V25, P1637, DOI 10.1377/hlthaff.25.6.1637; Kim SH, 2007, CLIN THER, V29, P1924, DOI 10.1016/j.clinthera.2007.09.018; KOWEY PR, 1990, INTERN MED SPECIALIS, V11, P151; KOWEY PR, 1990, INTERN MED SPECIALIS, V11, P146; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Lee HL, 2005, CLIN THER, V27, P309, DOI 10.1016/j.clinthera.2005.03.004; LOFHOLM PW, 1991, US PHARM, V16, P44; LOFHOLM PW, 1991, US PHARM, V16, P46; LOFHOLM PW, 1991, US PHARM, V16, P51; MAITAI CK, 1984, E AFR MED J, V61, P6; MARTIN BK, 1984, J PHARM SCI, V73, P437, DOI 10.1002/jps.2600730404; MARZO A, 1995, ARZNEIMITTEL-FORSCH, V45-1, P109; MCCUE JD, 1991, P T, V16, P770; McGavock H, 2001, PHARMACOEPIDEM DR S, V10, P555, DOI 10.1002/pds.626; McLachlan AJ, 2007, AUST PRESCR, V30, P41, DOI 10.18773/austprescr.2007.021; MERALI RM, 1996, CAN J CLIN PHARM, V3, P29; Meredith P, 2003, CLIN THER, V25, P2875, DOI 10.1016/S0149-2918(03)80340-5; Meredith PA, 1996, DRUG SAFETY, V15, P233, DOI 10.2165/00002018-199615040-00001; MEYER BH, 1985, S AFR MED J, V68, P645; Meyer GF, 1999, TRANSPLANT P, V31, p10S, DOI 10.1016/S0041-1345(99)00105-0; Meyer M, 1998, PHARMACOTHERAPY, V18, P884; Meyer MC, 1998, AM J MANAG CARE, V4, P1183; Mignini F, 2007, CLIN EXP HYPERTENS, V29, P539, DOI 10.1080/10641960701744046; Milligan PE, 2002, ANN PHARMACOTHER, V36, P764, DOI 10.1345/aph.1A327; Mirfazaelian Ahmad, 2003, Daru, V11, P95; Murphy JE, 1999, ARCH INTERN MED, V159, P429, DOI 10.1001/archinte.159.5.429; Murray MD, 1997, PHARMACOTHERAPY, V17, P98; NEUTEL JM, 1998, CARDIOVASC REV REP, V19, P49; NOLANPE, 1989, AM J CARDIOL, V64, P1371; PAN HYM, 1984, MED J AUSTRALIA, V140, P221, DOI 10.5694/j.1326-5377.1984.tb104001.x; Park JY, 2004, CLIN THER, V26, P715, DOI 10.1016/S0149-2918(04)90071-9; Paterson JM, 2006, JAMA-J AM MED ASSOC, V296, P1969, DOI 10.1001/jama.296.16.1969-b; Pereira JA, 2005, ANN PHARMACOTHER, V39, P1188, DOI 10.1345/aph.1G003; Portoles A, 2005, ARZNEIMITTELFORSCH, V55, P212; Portoles Antonio, 2004, Current Therapeutic Research, V65, P34, DOI 10.1016/S0011-393X(04)90003-3; Rao TRK, 2003, CURR THER RES CLIN E, V64, P685, DOI 10.1016/j.curtheres.2003.09.014; Reiffel JA, 2004, PROG CARDIOVASC DIS, V47, P3, DOI 10.1016/j.pcad.2004.04.002; Reiffel JA, 2001, CURR OPIN CARDIOL, V16, P23, DOI 10.1097/00001573-200101000-00004; Reiffel JA, 2000, AM J CARDIOL, V85, p46D; RENN E, 2000, P T, V25, P487; RHEINSTEIN PH, 1990, DRUG SAFETY, V5, P114, DOI 10.2165/00002018-199000051-00018; RICHTONHEWETT S, 1988, ARCH INTERN MED, V148, P806, DOI 10.1001/archinte.148.4.806; Riechelmann RP, 2007, J CLIN ONCOL, V25, P4642, DOI 10.1200/JCO.2007.11.2482; ROCKOFF J, 2008, BALTIMORE SUN, pA1; ROSENTHAL R, 1982, PSYCHOL BULL, V92, P500, DOI 10.1037/0033-2909.92.2.500; ROSS MB, 1989, HOSP FORMUL, V24, P441; SANDERSON JH, 1986, LANCET, V1, P967; Sarkar Mohamadi A., 1995, Clinical Research and Regulatory Affairs, V12, P47, DOI 10.3109/10601339509079576; Saseen JJ, 1997, J CLIN PHARMACOL, V37, P526, DOI 10.1002/j.1552-4604.1997.tb04331.x; SAUL S, 2007, NY TIMES        1103, pA1; SAWONIAK AE, 2002, CAN J HOSP PHARM, V55, P215; SCHEIDT S, 1998, CARDIOVASC REV REP, V19, P46; SCHWARTZ LL, 1985, AM J MED, V79, P38, DOI 10.1016/0002-9343(85)90584-4; SHAROKY M, 1989, CLIN PHARMACY, V8, P496; SHRANK W, IN PRESS HLTH AFF; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; SINGH A, 1987, INT J CLIN PHARM TH, V25, P136; SOMBERG J, 1985, CARDIOVASC REV REP, V6, P1010; STAGNITTI M, 2004, TOP 5 THERAPEUTIC CL; Stelfox HT, 1998, NEW ENGL J MED, V338, P101, DOI 10.1056/NEJM199801083380206; STROM BL, 1987, NEW ENGL J MED, V316, P1456, DOI 10.1056/NEJM198706043162306; Swenson CN, 2000, AM J HEALTH-SYST PH, V57, P452, DOI 10.1093/ajhp/57.5.452; Tsai YS, 2007, CLIN THER, V29, P670, DOI 10.1016/j.clinthera.2007.04.013; Usha PR, 1997, CLIN DRUG INVEST, V14, P482, DOI 10.2165/00044011-199714060-00006; Verbeeck RK, 2006, EUR J PHARM SCI, V28, P1, DOI 10.1016/j.ejps.2005.12.001; WALDMAN SA, 1995, J CLIN PHARMACOL, V35, P163, DOI 10.1002/j.1552-4604.1995.tb05006.x; Weibert RT, 2000, ANN PHARMACOTHER, V34, P981, DOI 10.1345/aph.10068; Witt DM, 2003, PHARMACOTHERAPY, V23, P360, DOI 10.1592/phco.23.3.360.32103; Wittkowsky AK, 1997, PHARMACOTHERAPY, V17, P640; Wiwanitkit Viroj, 2002, BMC Clin Pharmacol, V2, P1, DOI 10.1186/1472-6904-2-1; 1995, GUIDANCE IND IMMEDIA	115	325	336	1	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 3	2008	300	21					2514	2526		10.1001/jama.2008.758	http://dx.doi.org/10.1001/jama.2008.758			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	377XR	19050195	Green Accepted			2023-01-03	WOS:000261286200020
J	Fromme, EK; Farber, NJ; Babbott, SF; Pickett, ME; Beasley, BW				Fromme, Erik K.; Farber, Neil J.; Babbott, Stewart F.; Pickett, Mary E.; Beasley, Brent W.			What Do You Do When Your Loved One Is Ill? The Line between Physician and Family Member	ANNALS OF INTERNAL MEDICINE			English	Article							DOCTOR; CARE	Conventional wisdom and professional ethics generally dictate that physicians should avoid doctoring family members because of potential conflicts of interest. Nevertheless, cross-sectional surveys find that the practice is commonplace. Physicians have unique opportunities to influence their family member's care because they possess knowledge and status within the health care system; however, when physicians participate in the care of family members, they must not lose objectivity and confuse their personal and professional roles. Because health care systems are complicated, medical information is difficult to understand, and medical errors are common, it can be a great relief for families to have someone "on the inside" who is accessible and trustworthy. Yet, the benefits of becoming involved in a loved one's care are accompanied by risks, especially when a physician takes action that a nonphysician would be incapable of performing. Except for convenience, most if not all of the benefits of getting involved can be realized by physician-family members acting as a family member or an advocate rather than as a physician. Rules about what is or what is not appropriate for physician family members are important but insufficient to guide physicians in every circumstance. Physician-family members can ask themselves, "What could I do in this situation if I did not have a medical degree?" and consider avoiding acts that require a medical license.	[Fromme, Erik K.] Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, Portland, OR 97239 USA	Oregon Health & Science University	Fromme, EK (corresponding author), Oregon Hlth & Sci Univ, Div Hematol & Med Oncol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	frommee@ohsu.edu	Beasley, Brent/AAE-9466-2021	Beasley, Brent/0000-0002-0997-9636	National Cancer Institute [K07CA109511-01A1]; NATIONAL CANCER INSTITUTE [K07CA109511] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr. Fromme is supported by a Career Development Award from the National Cancer Institute (K07CA109511-01A1).	*AM MED ASS, 2006, COD MED ETH CURR OP; DUSDIEKER LB, 1993, AM J DIS CHILD, V147, P146, DOI 10.1001/archpedi.1993.02160260036018; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Fromme E, 2003, JAMA-J AM MED ASSOC, V290, P2048, DOI 10.1001/jama.290.15.2048; Fromme EK, 2004, J FAM PRACTICE, V53, P299; GOLDMAN L, 2000, HDB PHYS HLTH ESSENT; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; LAPUMA J, 1991, NEW ENGL J MED, V325, P1290, DOI 10.1056/NEJM199110313251806; LAPUMA J, 1992, JAMA-J AM MED ASSOC, V267, P1810, DOI 10.1001/jama.267.13.1810; MARZUK PM, 1987, NEW ENGL J MED, V317, P1409, DOI 10.1056/NEJM198711263172209; SCHMALL V, 2000, CAREGIVER HELPBOOK P; Schneck SA, 1998, JAMA-J AM MED ASSOC, V280, P2039, DOI 10.1001/jama.280.23.2039; Spiro HM, 1998, ANN INTERN MED, V128, P152, DOI 10.7326/0003-4819-128-2-199801150-00014; STOUDEMIRE A, 1983, ANN INTERN MED, V98, P654, DOI 10.7326/0003-4819-98-5-654; WASSERMAN RC, 1989, PEDIATRICS, V83, P319; Wolff JL, 2008, ARCH INTERN MED, V168, P1409, DOI 10.1001/archinte.168.13.1409	16	18	18	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 2	2008	149	11					825	W170		10.7326/0003-4819-149-11-200812020-00011	http://dx.doi.org/10.7326/0003-4819-149-11-200812020-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	383AA	19047031				2023-01-03	WOS:000261645300008
J	DeKosky, ST; Williamson, JD; Fitzpatrick, AL; Kronmal, RA; Ives, DG; Saxton, JA; Lopez, OL; Burke, G; Carlson, MC; Fried, LP; Kuller, LH; Robbins, JA; Tracy, RP; Woolard, NF; Dunn, L; Snitz, BE; Nahin, RL; Furberg, CD				DeKosky, Steven T.; Williamson, Jeff D.; Fitzpatrick, Annette L.; Kronmal, Richard A.; Ives, Diane G.; Saxton, Judith A.; Lopez, Oscar L.; Burke, Gregory; Carlson, Michelle C.; Fried, Linda P.; Kuller, Lewis H.; Robbins, John A.; Tracy, Russell P.; Woolard, Nancy F.; Dunn, Leslie; Snitz, Beth E.; Nahin, Richard L.; Furberg, Curt D.		GEM Study Investigators	Ginkgo biloba for Prevention of Dementia A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTRACT EGB 761; MILD COGNITIVE IMPAIRMENT; VASCULAR DEMENTIA; ALZHEIMERS-DISEASE; CLINICAL-CRITERIA; DOUBLE-BLIND; EFFICACY; DIAGNOSIS; MEMORY; CONSENSUS	Context Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G biloba on dementia incidence are lacking. Objective To determine effectiveness of G biloba vs placebo in reducing the incidence of all- cause dementia and Alzheimer disease ( AD) in elderly individuals with normal cognition and those with mild cognitive impairment ( MCI). Design, Setting, and Participants Randomized, double- blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and 2008 with a median follow- up of 6.1 years. Three thousand sixty- nine community volunteers aged 75 years or older with normal cognition ( n= 2587) or MCI ( n= 482) at study entry were assessed every 6 months for incident dementia. Intervention Twice- daily dose of 120- mg extract of G biloba ( n= 1545) or placebo ( n= 1524). Main Outcome Measures Incident dementia and AD determined by expert panel consensus. Results Five hundred twenty- three individuals developed dementia ( 246 receiving placebo and 277 receiving G biloba) with 92% of the dementia cases classified as possible or probable AD, or AD with evidence of vascular disease of the brain. Rates of dropout and loss to follow- up were low ( 6.3%), and the adverse effect profiles were similar for both groups. The overall dementia rate was 3.3 per 100 person-years in participants assigned to G biloba and 2.9 per 100 person- years in the placebo group. The hazard ratio ( HR) for G biloba compared with placebo for all cause dementia was 1.12 ( 95% confidence interval [ CI], 0.94- 1.33; P=. 21) and for AD, 1.16 ( 95% CI, 0.97- 1.39; P=. 11). G biloba also had no effect on the rate of progression to dementia in participants with MCI ( HR, 1.13; 95% CI, 0.85- 1.50; P=. 39). Conclusions In this study, G biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI. Trial Registration clinicaltrials. gov Identifier: NCT00010803.	[DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [DeKosky, Steven T.; Ives, Diane G.; Saxton, Judith A.; Lopez, Oscar L.; Kuller, Lewis H.; Dunn, Leslie; Snitz, Beth E.] Univ Pittsburgh, Pittsburgh, PA USA; [Williamson, Jeff D.; Burke, Gregory; Woolard, Nancy F.; Furberg, Curt D.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Fitzpatrick, Annette L.; Kronmal, Richard A.] Univ Washington, Seattle, WA 98195 USA; [Carlson, Michelle C.; Fried, Linda P.] Johns Hopkins Univ, Baltimore, MD USA; [Robbins, John A.] Univ Calif Davis, Sacramento, CA 95817 USA; [Tracy, Russell P.] Univ Vermont, Burlington, VT USA; [Nahin, Richard L.] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA	University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; University of Washington; University of Washington Seattle; Johns Hopkins University; University of California System; University of California Davis; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	DeKosky, ST (corresponding author), Univ Virginia, Sch Med, POB 800793, Charlottesville, VA 22908 USA.	dekosky@virginia.edu		Nahin, Richard/0000-0002-3682-4816; DeKosky, Steven/0000-0003-3743-2758	National Center for Complementary and Alternative Medicine [U01 AT000162]; Office of Dietary Supplements; National Institute on Aging; National Heart, Lung, and Blood Institute; University of Pittsburgh Alzheimer's Disease Research Center [P50AG05133]; Roena Kulynych Center for Memory and Cognition Research; Wake Forest University School of Medicine; National Institute of Neurological Disorders and Stroke; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT000162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005133] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Office of Dietary Supplements(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of Pittsburgh Alzheimer's Disease Research Center(University of Pittsburgh); Roena Kulynych Center for Memory and Cognition Research; Wake Forest University School of Medicine; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grant U01 AT000162 from the National Center for Complementary and Alternative Medicine (NCCAM) and the Office of Dietary Supplements and National Institute on Aging; National Heart, Lung, and Blood Institute; University of Pittsburgh Alzheimer's Disease Research Center (P50AG05133); Roena Kulynych Center for Memory and Cognition Research; Wake Forest University School of Medicine; and National Institute of Neurological Disorders and Stroke. Schwabe Pharmaceuticals, Karlsruhe, Germany, donated the G biloba tablets and identical placebos in blister packs for the study.	Aguero-Torres H, 1998, AM J PUBLIC HEALTH, V88, P1452, DOI 10.2105/AJPH.88.10.1452; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1991, JAMA, V265, P3255; AUGUET M, 1982, GEN PHARMACOL-VASC S, V13, P169, DOI 10.1016/0306-3623(82)90075-1; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; BECKER JT, 1987, CORTEX, V23, P59, DOI 10.1016/S0010-9452(87)80019-9; BIRKS J, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003120; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Brunetti L, 2006, PLANTA MED, V72, P1296, DOI 10.1055/s-2006-951688; Chen X, 1997, CLIN EXP PHARMACOL P, V24, P958, DOI 10.1111/j.1440-1681.1997.tb02727.x; Chui HC, 2000, ARCH NEUROL-CHICAGO, V57, P191, DOI 10.1001/archneur.57.2.191; DeKosky ST, 2006, CONTEMP CLIN TRIALS, V27, P238, DOI 10.1016/j.cct.2006.02.007; Delis D.C., 1987, CALIFORNIA VERBAL LE; Dodge HH, 2008, NEUROLOGY, V70, P1809, DOI 10.1212/01.wnl.0000303814.13509.db; ERKINJUNTTI T, 1994, DEMENTIA, V5, P189, DOI 10.1159/000106721; Fitzpatrick AL, 2006, CONTEMP CLIN TRIALS, V27, P541, DOI 10.1016/j.cct.2006.06.007; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; Guralnik J M, 1997, J Am Med Womens Assoc (1972), V52, P113; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; Kawas CH, 2001, NEW ENGL J MED, V344, P1160, DOI 10.1056/NEJM200104123441509; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Lopez OL, 2003, NEUROEPIDEMIOLOGY, V22, P1, DOI 10.1159/000067110; Lopez OL, 2006, J NEUROL NEUROSUR PS, V77, P159, DOI 10.1136/jnnp.2004.045567; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Magsi H, 2005, J AM GERIATR SOC, V53, P295, DOI 10.1111/j.1532-5415.2005.53117.x; Mahady Gail B, 2002, J Cardiovasc Nurs, V16, P21; MARCOCCI L, 1994, BIOCHEM BIOPH RES CO, V201, P748, DOI 10.1006/bbrc.1994.1764; Maurer K, 1997, J PSYCHIATR RES, V31, P645, DOI 10.1016/S0022-3956(97)00022-8; McCarney R, 2008, INT J GERIATR PSYCH, V23, P1222, DOI 10.1002/gps.2055; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mohs R C, 1996, Int Psychogeriatr, V8, P195, DOI 10.1017/S1041610296002578; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; *PENT MED INC, 2006, NUTR BUS J S; Pietri S, 1997, J MOL CELL CARDIOL, V29, P733, DOI 10.1006/jmcc.1996.0316; Raven J. C., 1956, GUIDE USING COLOURED; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; ROCKWOOD K, 1994, CAN J NEUROL SCI, V21, P358, DOI 10.1017/S0317167100040968; Saxton J, 2000, CLIN NEUROPSYCHOL, V14, P526, DOI 10.1076/clin.14.4.526.7204; Schneider Lon S., 2005, Current Alzheimer Research, V2, P541, DOI 10.2174/156720505774932287; SNITZ BE, 2009, AGING MENT IN PRESS, V13; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Vellas B, 2006, NEUROLOGY, V67, pS6, DOI 10.1212/WNL.67.9_suppl_3.S6; Wechsler D, 1988, WECHSLER ADULT INTEL; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	49	432	457	2	75	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2008	300	19					2253	2262		10.1001/jama.2008.683	http://dx.doi.org/10.1001/jama.2008.683			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373IO	19017911	Green Accepted			2023-01-03	WOS:000260965500025
J	Mallet, L; Polosan, M; Jaafari, N; Baup, N; Welter, ML; Fontaine, D; du Montcel, ST; Yelnik, J; Chereau, I; Arbus, C; Raoul, S; Aouizerate, B; Damier, P; Chabardes, S; Czernecki, V; Ardouin, C; Krebs, MO; Bardinet, E; Chaynes, P; Burbaud, P; Cornu, P; Derost, P; Bougerol, T; Bataille, B; Mattei, V; Dormont, D; Devaux, B; Verin, M; Houeto, JL; Pollak, P; Benabid, AL; Agid, Y; Krack, P; Millet, B; Pelissolo, A				Mallet, Luc; Polosan, Mircea; Jaafari, Nematollah; Baup, Nicolas; Welter, Marie-Laure; Fontaine, Denys; du Montcel, Sophie Tezenas; Yelnik, Jerome; Chereau, Isabelle; Arbus, Christophe; Raoul, Sylvie; Aouizerate, Bruno; Damier, Philippe; Chabardes, Stephan; Czernecki, Virginie; Ardouin, Claire; Krebs, Marie-Odile; Bardinet, Eric; Chaynes, Patrick; Burbaud, Pierre; Cornu, Philippe; Derost, Philippe; Bougerol, Thierry; Bataille, Benoit; Mattei, Vianney; Dormont, Didier; Devaux, Bertrand; Verin, Marc; Houeto, Jean-Luc; Pollak, Pierre; Benabid, Alim-Louis; Agid, Yves; Krack, Paul; Millet, Bruno; Pelissolo, Antoine		STOC Study Grp	Subthalamic Nucleus Stimulation in Severe Obsessive-Compulsive Disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP BRAIN-STIMULATION; PARKINSONS-DISEASE; ELECTRICAL-STIMULATION; CAPSULAR STIMULATION; FOLLOW-UP; DSM-IV; RELIABILITY; INTERVIEW; SCALE; INTERRATER	Background: Severe, refractory obsessive-compulsive disorder (OCD) is a disabling condition. Stimulation of the subthalamic nucleus, a procedure that is already validated for the treatment of movement disorders, has been proposed as a therapeutic option. Methods: In this 10-month, crossover, double-blind, multicenter study assessing the efficacy and safety of stimulation of the subthalamic nucleus, we randomly assigned eight patients with highly refractory OCD to undergo active stimulation of the subthalamic nucleus followed by sham stimulation and eight to undergo sham stimulation followed by active stimulation. The primary outcome measure was the severity of OCD, as assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), at the end of two 3-month periods. General psychopathologic findings, functioning, and tolerance were assessed with the use of standardized psychiatric scales, the Global Assessment of Functioning (GAF) scale, and neuropsychological tests. Results: After active stimulation of the subthalamic nucleus, the Y-BOCS score (on a scale from 0 to 40, with lower scores indicating less severe symptoms) was significantly lower than the score after sham stimulation (mean [+/-SD], 19+/-8 vs. 28+/-7; P=0.01), and the GAF score (on a scale from 1 to 90, with higher scores indicating higher levels of functioning) was significantly higher (56+/-14 vs. 43+/-8, P=0.005). The ratings of neuropsychological measures, depression, and anxiety were not modified by stimulation. There were 15 serious adverse events overall, including 1 intracerebral hemorrhage and 2 infections; there were also 23 nonserious adverse events. Conclusions: These preliminary findings suggest that stimulation of the subthalamic nucleus may reduce the symptoms of severe forms of OCD but is associated with a substantial risk of serious adverse events. (ClinicalTrials.gov number, NCT00169377.).	[Mallet, Luc; Welter, Marie-Laure; Yelnik, Jerome; Czernecki, Virginie; Bardinet, Eric; Agid, Yves] CHU Pitie Salpetriere, INSERM, Avenir Team Behav Emot & Basal Ganglia IFR 70, Ctr Invest Clin,Assistance Publ Hop Paris, F-75013 Paris, France; [Polosan, Mircea; Bougerol, Thierry] Grenoble Univ Hosp, Dept Psychiat, Grenoble, France; [Chabardes, Stephan; Benabid, Alim-Louis] Grenoble Univ Hosp, Dept Neurosurg, Grenoble, France; [Ardouin, Claire; Pollak, Pierre; Krack, Paul] Grenoble Univ Hosp, Dept Neurol, Grenoble, France; [Jaafari, Nematollah] Univ Hosp Poitiers, Dept Psychiat, Poitiers, France; [Bataille, Benoit] Univ Hosp Poitiers, Dept Neurosurg, Poitiers, France; [Baup, Nicolas; Krebs, Marie-Odile] Univ Paris 05, INSERM, U796, Univ Dept Psychiat, Paris, France; [Devaux, Bertrand] Hop St Anne, Dept Neurosurg, F-75674 Paris, France; [Fontaine, Denys] Univ Hosp, Dept Neurosurg, Nice, France; [Mattei, Vianney] Univ Hosp, Dept Psychiat, Nice, France; [du Montcel, Sophie Tezenas] Univ Paris 06, Pitie Salpetriere Univ Hosp, Biostat & Med Informat Unit, Modeling Clin Res EA 3974, Paris, France; [du Montcel, Sophie Tezenas] Univ Paris 06, Pitie Salpetriere Univ Hosp, Clin Res Unit, Modeling Clin Res EA 3974, Paris, France; [Yelnik, Jerome; Agid, Yves] Univ Paris 06, INSERM, Inst Fed Rech Neurosci Unite Mixte Rech S679, U679, Paris, France; [Chereau, Isabelle] Univ Hosp Clermont Ferrand, Dept Psychiat, Clermont Ferrand, France; [Damier, Philippe] Univ Hosp Clermont Ferrand, Dept Neurol, Clermont Ferrand, France; [Arbus, Christophe] Univ Hosp Toulouse, Dept Psychiat, Toulouse, France; [Chaynes, Patrick] Univ Hosp Toulouse, Dept Neurosurg, Toulouse, France; [Raoul, Sylvie] Univ Hosp Nantes, Dept Neurosurg, Nantes, France; [Damier, Philippe] Univ Hosp Nantes, Dept Neurol, Nantes, France; [Aouizerate, Bruno] Univ Bordeaux 2, Charles Perrens Hosp, Dept Psychiat, F-33076 Bordeaux, France; [Aouizerate, Bruno; Burbaud, Pierre] Univ Bordeaux 2, CNRS, UMR5543, F-33076 Bordeaux, France; [Czernecki, Virginie] Pitie Salpetriere Univ Hosp, INSERM, U610, Paris, France; [Chaynes, Patrick] Pitie Salpetriere Univ Hosp, Dept Neurosurg, Paris, France; [Dormont, Didier] Pitie Salpetriere Univ Hosp, Dept Radiol, Paris, France; [Welter, Marie-Laure; Agid, Yves] Pitie Salpetriere Univ Hosp, Federat Malad Syst Nerveux, Paris, France; [Pelissolo, Antoine] Pitie Salpetriere Univ Hosp, Dept Psychiat, Paris, France; [Bardinet, Eric] CNRS, Unite Propre Rech, Lab Neurosci Cognit & Imagerie Cerebrale, LENA 640, Paris, France; [Verin, Marc] Univ Hosp, Dept Neurol, Rennes, France; [Millet, Bruno] Univ Hosp, Dept Psychiat, Rennes, France; [Houeto, Jean-Luc] Univ Poitiers, CHU Poitiers, Dept Neurol, EA 3808, Poitiers, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CHU Poitiers; Universite de Poitiers; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; CHU Nice; CHU Nice; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU Clermont Ferrand; CHU Clermont Ferrand; CHU de Toulouse; CHU de Toulouse; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CHU Rennes; CHU Rennes; CHU Poitiers; Universite de Poitiers	Mallet, L (corresponding author), CHU Pitie Salpetriere, INSERM, Avenir Team Behav Emot & Basal Ganglia IFR 70, Ctr Invest Clin,Assistance Publ Hop Paris, 47 Blvd Hop, F-75013 Paris, France.	luc.mallet@psl.aphp.fr	Verin, Marc/ABC-6924-2020; Benabid, Alim L/Q-3506-2017; Krebs, Marie-Odile/O-2104-2017; Coste, Jérôme/D-2070-2013; Yelnik, Jérôme/F-7153-2013; Tezenas du Montcel, Sophie/A-6207-2012; dormont, didier/B-2175-2012; Damier, Philippe/T-7829-2019; Mallet, Luc/F-7156-2013; Dormont, Didier/F-5492-2012; Sauleau, Paul/ABC-4459-2020	Krebs, Marie-Odile/0000-0002-4715-9890; Coste, Jérôme/0000-0002-3262-0867; Tezenas du Montcel, Sophie/0000-0002-2866-4330; Mallet, Luc/0000-0001-8061-1167; Fontaine, Denys/0000-0001-5012-6769; Worbe, Yulia/0000-0001-5903-9370; Krack, Paul/0000-0002-3508-7295; /0000-0002-7092-7747; PELISSOLO, Antoine/0000-0003-0465-5648; YELNIK, Jerome/0000-0003-4814-708X	Programme Hospitalier de la Recherche Clinique Assistance Publique-Hopitaux de Paris [AOM 03141]; Agence Nationale de la Recherche Program for Young Researchers [R05121DS]; Medtronic	Programme Hospitalier de la Recherche Clinique Assistance Publique-Hopitaux de Paris; Agence Nationale de la Recherche Program for Young Researchers(French National Research Agency (ANR)); Medtronic(Medtronic)	Supported by grants from the Programme Hospitalier de la Recherche Clinique Assistance Publique-Hopitaux de Paris (AOM 03141) and the Agence Nationale de la Recherche Program for Young Researchers (R05121DS). The stimulators were purchased from Medtronic, which had no role in the study. Medtronic provided funds for the meetings of the investigators of the study. Dr. Cornu reports receiving consulting fees from Medtronic; Dr. Houeto, lecture fees from Medtronic; Dr. Benadid, lecture fees and grant support from Medtronic; Dr. Agid, consulting fees from Medtronic; Dr. Krack, consulting and lecture fees from Medtronic; and Dr. Millet, grant support from Medtronic. No other potential conflict of interest relevant to this article was reported.	Abelson JL, 2005, BIOL PSYCHIAT, V57, P510, DOI 10.1016/j.biopsych.2004.11.042; Alegret M, 2001, ARCH NEUROL-CHICAGO, V58, P1223, DOI 10.1001/archneur.58.8.1223; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson D, 2003, J NEUROSURG, V98, P1104, DOI 10.3171/jns.2003.98.5.1104; Aouizerate B, 2004, J NEUROSURG, V101, P682, DOI 10.3171/jns.2004.101.4.0682; Aouizerate B, 2004, PROG NEUROBIOL, V72, P195, DOI 10.1016/j.pneurobio.2004.02.004; Ardouin C, 2006, MOVEMENT DISORD, V21, P1941, DOI 10.1002/mds.21098; Bejjani BP, 2000, J NEUROSURG, V92, P615, DOI 10.3171/jns.2000.92.4.0615; Benabid AL, 2005, CR BIOL, V328, P177, DOI 10.1016/j.crvi.2004.10.011; Benabid AL, 2002, MOVEMENT DISORD, V17, pS123, DOI 10.1002/mds.10153; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; COOPER JA, 1991, BRAIN, V114, P2095, DOI 10.1093/brain/114.5.2095; Dougherty DD, 2002, AM J PSYCHIAT, V159, P269, DOI 10.1176/appi.ajp.159.2.269; Fontaine D, 2004, J NEUROSURG, V100, P1084, DOI 10.3171/jns.2004.100.6.1084; Frank MJ, 2007, SCIENCE, V318, P1309, DOI 10.1126/science.1146157; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165; Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2394, DOI 10.1038/sj.npp.1301201; Guy W., 1976, ECDEU ASSESSMENT MAN, P218; Houeto JL, 2006, ARCH NEUROL-CHICAGO, V63, P1090, DOI 10.1001/archneur.63.8.1090; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; Jones B., 1989, DESIGN ANAL CROSS OV, P16; Karachi C, 2005, MOVEMENT DISORD, V20, P172, DOI 10.1002/mds.20302; Karachi C, 2002, J COMP NEUROL, V450, P122, DOI 10.1002/cne.10312; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; Lipsman N, 2007, NEUROSURGERY, V61, P1, DOI 10.1227/01.neu.0000279719.75403.f7; Maffei C, 1997, J PERS DISORD, V11, P279, DOI 10.1521/pedi.1997.11.3.279; Mallet L, 2002, LANCET, V360, P1302, DOI 10.1016/S0140-6736(02)11339-0; Mallet L, 2007, P NATL ACAD SCI USA, V104, P10661, DOI 10.1073/pnas.0610849104; Mattis S, 1988, DEMENTIA RATING SCAL; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Nuttin B, 1999, LANCET, V354, P1526, DOI 10.1016/S0140-6736(99)02376-4; Nuttin BJ, 2003, NEUROSURGERY, V52, P1263, DOI 10.1227/01.NEU.0000064565.49299.9A; Pallanti S, 2006, PROG NEURO-PSYCHOPH, V30, P400, DOI 10.1016/j.pnpbp.2005.11.028; PILLON B, 2001, HDB NEUROPSYCHOLOGY, V6, P311; Pollak P, 2002, MOVEMENT DISORD, V17, pS155, DOI 10.1002/mds.10158; Preisig M, 1999, EUR ARCH PSY CLIN N, V249, P174, DOI 10.1007/s004060050084; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Rezai AR, 2006, MOVEMENT DISORD, V21, pS197, DOI 10.1002/mds.20956; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Stein DJ, 2002, LANCET, V360, P397, DOI 10.1016/S0140-6736(02)09620-4; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sturm V, 2003, J CHEM NEUROANAT, V26, P293, DOI 10.1016/j.jchemneu.2003.09.003; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; WESCHLER D, 1997, WECHSLER MEMORY SCAL; Yelnik J, 2003, J NEUROSURG, V99, P89, DOI 10.3171/jns.2003.99.1.0089; Yelnik J, 2007, NEUROIMAGE, V34, P618, DOI 10.1016/j.neuroimage.2006.09.026	48	582	589	0	80	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 13	2008	359	20					2121	2134		10.1056/NEJMoa0708514	http://dx.doi.org/10.1056/NEJMoa0708514			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	371IB	19005196				2023-01-03	WOS:000260823900010
J	Kerse, N; Peri, K; Robinson, E; Wilkinson, T; von Randow, M; Kiata, L; Parsons, J; Latham, N; Parsons, M; Willingale, J; Brown, P; Arroll, B				Kerse, Ngaire; Peri, Kathy; Robinson, Elizabeth; Wilkinson, Tim; von Randow, Martin; Kiata, Liz; Parsons, John; Latham, Nancy; Parsons, Matthew; Willingale, Jane; Brown, Paul; Arroll, Bruce			Does a functional activity programme improve function, quality of life, and falls for residents in long term care? Cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FRAIL OLDER-PEOPLE; NURSING-HOME; NUTRITIONAL SUPPLEMENTATION; PHYSICAL-ACTIVITY; ELDERLY PERSONS; HEALTH-STATUS; PREVENTION; EXERCISE; MOBILITY; INTERVENTIONS	Objective To assess the effectiveness of an activity programme in improving function, quality of life, and falls in older people in residential care. Design Cluster randomised controlled trial with one year follow-up. Setting 41 low level dependency residential care homes in New Zealand. Participants 682 people aged 65 years or over. Interventions 330 residents were offered a goal setting and individualised activities of daily living activity programme by a gerontology nurse, reinforced by usual healthcare assistants; 352 residents received social visits. Main outcome measures Function (late life function and disability instruments, elderly mobility scale, FICSIT-4 balance test, timed up and go test), quality of life (life satisfaction index, EuroQol), and falls (time to fall over 12 months). Secondary outcomes were depressive symptoms and hospital admissions. Results 473 (70%) participants completed the trial. The programme had no impact overall. However, in contrast to residents with impaired cognition (no differences between intervention and control group), those with normal cognition in the intervention group may have maintained overall function (late life function and disability instrument total function, P=0.024) and lower limb function (late life function and disability instrument basic lower extremity, P=0.015). In residents with cognitive impairment, the likelihood of depression increased in the intervention group. No other outcomes differed between groups. Conclusion A programme of functional rehabilitation had minimal impact for elderly people in residential care with normal cognition but was not beneficial for those with poor cognition. Trial registration Australian Clinical Trials Register ACTRN12605000667617.	[Kerse, Ngaire; Kiata, Liz; Willingale, Jane; Brown, Paul; Arroll, Bruce] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Sch Populat Hlth, Auckland 1001, New Zealand; [Peri, Kathy; Parsons, John; Parsons, Matthew] Univ Auckland, Sch Nursing, Auckland 1001, New Zealand; [Robinson, Elizabeth] Univ Auckland, Dept Epidemiol & Biostat, Sch Populat Hlth, Auckland 1001, New Zealand; [Wilkinson, Tim] Univ Otago, Christchurch, New Zealand; [von Randow, Martin] Univ Auckland, Dept Sociol, Auckland 1001, New Zealand; [Latham, Nancy] Boston Univ, Sch Publ Hlth, Hlth & Disabil Res Unit, Boston, MA USA; Univ Auckland, Auckland 1001, New Zealand	University of Auckland; University of Auckland; University of Auckland; University of Otago; University of Auckland; Boston University; University of Auckland	Kerse, N (corresponding author), Univ Auckland, Dept Gen Practice & Primary Hlth Care, Sch Populat Hlth, Private Bag 92019, Auckland 1001, New Zealand.	n.kerse@auckland.ac.nz	Parsons, John/AAA-3842-2020; Latham, Nancy/K-3405-2012; Kerse, Ngaire/AFF-8119-2022; Wilkinson, Tim J/C-5515-2008	Parsons, John/0000-0003-0867-8564; Wilkinson, Tim J/0000-0002-4080-4164; Latham, Nancy/0000-0002-8516-0016; Parsons, Matthew/0000-0003-2004-1347	New Zealand Health Research Council; Accident Compensation Corporation	New Zealand Health Research Council(Health Research Council of New Zealand); Accident Compensation Corporation	New Zealand Health Research Council and Accident Compensation Corporation. The funders had no involvement in the research design or conduct or in interpretation of results.	Altman DG, 1996, BRIT MED J, V313, P570; Becker C, 2003, J AM GERIATR SOC, V51, P306, DOI 10.1046/j.1532-5415.2003.51103.x; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; BROWN AB, 1990, J APPL PHYSIOL, V69, P1725, DOI 10.1152/jappl.1990.69.5.1725; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; BUCHNER DM, 1992, ANNU REV PUBL HEALTH, V13, P469, DOI 10.1146/annurev.publhealth.13.1.469; DiPietro L, 2001, J GERONTOL A-BIOL, V56, P13, DOI 10.1093/gerona/56.suppl_2.13; Ebrahim S, 1997, AGE AGEING, V26, P253, DOI 10.1093/ageing/26.4.253; Elley CR, 2005, AUST NZ J PUBL HEAL, V29, P461, DOI 10.1111/j.1467-842X.2005.tb00227.x; FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; FOLMAN Y, 1994, ARCH PHYS MED REHAB, V75, P454, DOI 10.1016/0003-9993(94)90171-6; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; Hill KD, 1996, ARCH PHYS MED REHAB, V77, P1025, DOI 10.1016/S0003-9993(96)90063-5; HODGKINSON HM, 1972, AGE AGEING, V1, P233; Kerse N, 2004, J AM GERIATR SOC, V52, P524, DOI 10.1111/j.1532-5415.2004.52157.x; KING AH, 2001, PRIMARY HLTH CARE ST, P23; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Latham NK, 2003, J AM GERIATR SOC, V51, P291, DOI 10.1046/j.1532-5415.2003.51101.x; Manson JE, 1999, NEW ENGL J MED, V341, P650, DOI 10.1056/NEJM199908263410904; MCMURDO MET, 1994, ARCH PHYS MED REHAB, V75, P600; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM494, DOI 10.1093/gerona/54.10.M494; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; Norton R, 1999, AGE AGEING, V28, P135, DOI 10.1093/ageing/28.2.135; Peri K, 2008, J AM MED DIR ASSOC, V9, P253, DOI 10.1016/j.jamda.2007.11.008; Peri K, 2008, AGE AGEING, V37, P57, DOI 10.1093/ageing/afm135; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Rejeski WJ, 2001, J GERONTOL A-BIOL, V56, P23, DOI 10.1093/gerona/56.suppl_2.23; Reuben DB, 2002, MED CARE, V40, P416, DOI 10.1097/00005650-200205000-00007; Rubenstein LZ, 1996, CLIN GERIATR MED, V12, P881; Sayers SP, 2004, J AM GERIATR SOC, V52, P1554, DOI 10.1111/j.1532-5415.2004.52422.x; Simons LA, 1996, AUST NZ J MED, V26, P40, DOI 10.1111/j.1445-5994.1996.tb02905.x; Singh MAF, 2002, J GERONTOL A-BIOL, V57, pM262, DOI 10.1093/gerona/57.5.M262; SMITH R, 1994, PHYSIOTHERAPY, V80, P745; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; Westhoff MH, 2000, J AGING PHYS ACTIV, V8, P325, DOI 10.1123/japa.8.4.325; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	38	94	95	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2008	337	7675							a1445	10.1136/bmj.a1445	http://dx.doi.org/10.1136/bmj.a1445			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	360YE	18845605	hybrid, Green Published			2023-01-03	WOS:000260093900035
J	Kenyon, S; Pike, K; Jones, DR; Brocklehurst, P; Marlow, N; Salt, A; Taylor, DJ				Kenyon, S.; Pike, K.; Jones, D. R.; Brocklehurst, P.; Marlow, N.; Salt, A.; Taylor, D. J.			Childhood outcomes after prescription of antibiotics to pregnant women with spontaneous preterm labour: 7-year follow-up of the ORACLE II trial	LANCET			English	Article							BEHAVIORAL OUTCOMES; CHILDREN; BIRTH; AGE	Background The ORACLE II trial compared the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for women in spontaneous preterm labour and intact membranes, without overt signs of clinical infection, by use of a factorial randomised design. The aim of the present study-the ORACLE Children Study II-was to determine the long-term effects on children after exposure to antibiotics in this clinical situation. Methods We assessed children at age 7 years born to the 4221 women who had completed the ORACLE 11 study and who were eligible for follow-up with a structured parental questionnaire to assess the child's health status. Functional impairment was defined as the presence of any level of functional impairment (severe, moderate, or mild) derived from the mark III Multi-Attribute Health Status classification system. Educational outcomes were assessed with national curriculum test results for children resident in England. Findings Outcome was determined for 3196 (71%) eligible children. Overall, a greater proportion of children whose mothers had been prescribed erythromycin, with or without co-amoxiclav, had any functional impairment than did those whose mothers had received no erythromycin (658 [42.3%] of 1554 children vs 574 [38.3%] of 1498; odds ratio 1.18, 95% CI 1.02-1.37). Co-amoxiclav (with or without erythromycin) had no effect on the proportion of children with any functional impairment, compared with receipt of no co-amoxiclav (624 [40.7%] of 1523 vs 608 [40.0%] of 1520; 1.03, 0.89-1.19). No effects were seen with either antibiotic on the number of deaths, other medical conditions, behavioural patterns, or educational attainment. However, more children whose mothers had received erythromycin or co-amoxiclav developed cerebral palsy than did those born to mothers who received no erythromycin or no co-amoxiclav, respectively (erythromycin: 53 [3.3%] of 1611 vs 27 [1.7%] of 1562, 1.93, 1.21-3.09; co-amoxiclav: 50 [3.2%] of 1587 vs 30 [1.9%] of 1586, 1.69, 1.07-2.67). The number needed to harm with erythromycin was 64 (95% CI 37-209) and with co-amoxiclav 79 (42-591). Interpretation The prescription of erythromycin for women in spontaneous preterm labour with intact membranes was associated with an increase in functional impairment among their children at 7 years of age. The risk of cerebral palsy was increased by either antibiotic, although the overall risk of this condition was low. Funding UK Medical Research Council.	[Kenyon, S.; Pike, K.; Taylor, D. J.] Univ Leicester, Reprod Sci Sect, Leicester LE1 6TP, Leics, England; [Jones, D. R.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Brocklehurst, P.] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; [Marlow, N.] Univ Nottingham, Acad Div Child Hlth, Nottingham NG7 2RD, England; [Salt, A.] UCL, Great Ormond St Hosp Children, London, England; [Salt, A.] UCL, Inst Child Hlth, London, England	University of Leicester; University of Leicester; University of Oxford; University of Nottingham; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Kenyon, S (corresponding author), Univ Leicester, Reprod Sci Sect, 22-28 Princess Rd W, Leicester LE1 6TP, Leics, England.	oracle@leicester.ac.uk	Brocklehurst, Peter/B-5804-2011; Marlow, Neil/D-2918-2009	Marlow, Neil/0000-0001-5890-2953; Kenyon, Sara/0000-0002-0756-9617	UK Medical Research Council; University Hospitals of Leicester; Medical Research Council [G9226450] Funding Source: researchfish; MRC [G9226450] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University Hospitals of Leicester; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was funded by the UK Medical Research Council and sponsored by University Hospitals of Leicester and approved by their research and development directorate. We thank all the women and children who took part in the study and the obstetricians and midwives who recruited them to the original ORACLE trials. We thank the Office of National Statistics, the NHS National Strategic Tracing Service, and the Data Services Group within the Department of Children, Schools and Families. We also thank the key stage one group (Maggie McLean, John Crookes, Peter Tymms, and Tony Cline) for helpful comments on educational aspects. We thank Steve Gould, Barbara Farrell, Phil Edwards, and Martin Rosser for advice on questionnaire design. We convened a group of experts from within the field to help us understand and interpret these finding before publication. This group consisted of Martin Whittle, Alison Bedford Russell, Phil Bennett, Kate Costeloe, Francis Cowan, Olaf Dammann, Diana Elbourne, Catherine Elliott, Mike Millar, Jane Norman. Micheal O'Shea, Max Parmar, Roberto Romero, and Dieter Wolke.	Altman DG, 2006, PRACTICAL STAT MED R; American College of Obstetricians and Gynecologists Committee on Practice Bulletins, 2003, OBSTET GYNECOL, V101, P1039; [Anonymous], LANCET; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Cuffe Steven P, 2005, J Atten Disord, V9, P392, DOI 10.1177/1087054705280413; Dammann O, 2006, SEMIN FETAL NEONAT M, V11, P363, DOI 10.1016/j.siny.2006.02.003; Feeny D, 2004, SOC SCI MED, V58, P799, DOI 10.1016/S0277-9536(03)00254-5; Gates S, 2004, BJOG-INT J OBSTET GY, V111, P213, DOI 10.1111/j.1471-0528.2004.00059.x; Goncalves LF, 2002, MENT RETARD DEV D R, V8, P3, DOI 10.1002/mrdd.10008; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Jobe A H, 2001, Semin Neonatol, V6, P331, DOI 10.1053/siny.2001.0068; Johnson S, 2007, SEMIN FETAL NEONAT M, V12, P363, DOI 10.1016/j.siny.2007.05.004; Kallen BAJ, 2005, REPROD TOXICOL, V20, P209, DOI 10.1016/j.reprotox.2005.01.010; KENYON S, 2008, LANCET          0918, DOI DOI 10.1016/S0140-6736(08)61202-7; King J, 2002, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000246; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Montgomery Alan A, 2003, BMC Med Res Methodol, V3, P26, DOI 10.1186/1471-2288-3-26; *QUAL CURR AUTH, 2007, KEY STAG 1 ASS REP A; Romero R, 2006, BJOG-INT J OBSTET GY, V113, P118, DOI 10.1111/j.1471-0528.2006.01150.x; Russell ARB, 2006, BJOG-INT J OBSTET GY, V113, P758, DOI 10.1111/j.1471-0528.2006.00952.x; SAIGAL S, 1994, J PEDIATR-US, V125, P411, DOI 10.1016/S0022-3476(05)83288-3; Salt A, 2006, EARLY HUM DEV, V82, P185, DOI 10.1016/j.earlhumdev.2005.12.015; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83	26	223	230	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 11	2008	372	9646					1319	1327		10.1016/S0140-6736(08)61203-9	http://dx.doi.org/10.1016/S0140-6736(08)61203-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18804276	Bronze, Green Submitted			2023-01-03	WOS:000260060500030
J	San Miguel, JF; Schlag, R; Khuageva, NK; Dimopoulos, MA; Shpilberg, O; Kropff, M; Spicka, I; Petrucci, MT; Palumbo, A; Samoilova, OS; Dmoszynska, A; Abdulkadyrov, KM; Schots, R; Jiang, B; Mateos, M; Anderson, KC; Esseltine, DL; Liu, K; Cakana, A; van de Velde, H; Richardson, PG				San Miguel, Jesus F.; Schlag, Rudolf; Khuageva, Nuriet K.; Dimopoulos, Meletios A.; Shpilberg, Ofer; Kropff, Martin; Spicka, Ivan; Petrucci, Maria T.; Palumbo, Antonio; Samoilova, Olga S.; Dmoszynska, Anna; Abdulkadyrov, Kudrat M.; Schots, Rik; Jiang, Bin; Mateos, Maria-Victoria; Anderson, Kenneth C.; Esseltine, Dixie L.; Liu, Kevin; Cakana, Andrew; van de Velde, Helgi; Richardson, Paul G.		VISTA Trial Investigators	Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	49th Annual Meeting of the American-Society-of-Hematology	DEC 08-11, 2007	Atlanta, GA	Amer Soc Hematol			ELDERLY UNTREATED PATIENTS; COMBINATION CHEMOTHERAPY; PERIPHERAL NEUROPATHY; ASSESSMENT SCHEDULE; PROGNOSTIC-FACTORS; TRANSPLANTATION; DEXAMETHASONE; REVERSIBILITY; SENSITIVITY; THALIDOMIDE	Background: The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy. Methods: We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22, and 29 during cycles 5 to 9. The primary end point was the time to disease progression. Results: The time to progression among patients receiving bortezomib plus melphalan-prednisone (bortezomib group) was 24.0 months, as compared with 16.6 months among those receiving melphalan-prednisone alone (control group) (hazard ratio for the bortezomib group, 0.48; P<0.001). The proportions of patients with a partial response or better were 71% in the bortezomib group and 35% in the control group; complete-response rates were 30% and 4%, respectively (P<0.001). The median duration of the response was 19.9 months in the bortezomib group and 13.1 months in the control group. The hazard ratio for overall survival was 0.61 for the bortezomib group (P=0.008). Adverse events were consistent with established profiles of toxic events associated with bortezomib and melphalan-prednisone. Grade 3 events occurred in a higher proportion of patients in the bortezomib group than in the control group (53% vs. 44%, P=0.02), but there were no significant differences in grade 4 events (28% and 27%, respectively) or treatment-related deaths (1% and 2%). Conclusions: Bortezomib plus melphalan-prednisone was superior to melphalan-prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy. (ClinicalTrials.gov number, NCT00111319.).	[San Miguel, Jesus F.; Mateos, Maria-Victoria] Hosp Univ Salamanca, CIC, IBMCC USAL CSIC, Salamanca, Spain; [Schlag, Rudolf] Praxisklin Dr Schlag, Wurzburg, Germany; [Khuageva, Nuriet K.] SP Botkin Moscow City Clin Hosp, Moscow, Russia; [Dimopoulos, Meletios A.] Univ Athens, Sch Med, GR-11527 Athens, Greece; [Shpilberg, Ofer] Rabin Med Ctr, Petah Tiqwa, Israel; [Kropff, Martin] Univ Munster, Munster, Germany; [Spicka, Ivan] Univ Hosp Prague, Prague, Czech Republic; [Petrucci, Maria T.] Univ Roma La Sapienza, Rome, Italy; [Palumbo, Antonio] Univ Turin, Turin, Italy; [Samoilova, Olga S.] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia; [Dmoszynska, Anna] Med Univ Lublin, Lublin, Poland; [Abdulkadyrov, Kudrat M.] St Petersburg Clin Res Inst Hematol & Transfus, St Petersburg, Russia; [Schots, Rik] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium; [Jiang, Bin] Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China; [Anderson, Kenneth C.; Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Esseltine, Dixie L.] Millennium Pharmaceut Inc, Cambridge, MA USA; [Liu, Kevin] Johnson & Johnson, Raritan, NJ USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Athens Medical School; National & Kapodistrian University of Athens; Rabin Medical Center; University of Munster; General University Hospital Prague; Sapienza University Rome; University of Turin; Medical University of Lublin; Russian Research Institute of Hematology & Transfusiology; Peking University; Harvard University; Dana-Farber Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Johnson & Johnson; Johnson & Johnson USA	San Miguel, JF (corresponding author), Hosp Univ Salamanca, CIC, IBMCC USAL CSIC, Paseo San Vicente 58-182, Salamanca, Spain.	sanmigiz@usal.es	Zachee, Pierre/B-5391-2018; San-Miguel, Jesús F./V-8977-2018; Dimopoulos, Meletios Athanasios/AAD-4130-2019; Hajek, Roman/I-6639-2017; Greil, Richard F/C-7673-2017; ALEGRE, ADRIAN/AAE-4268-2021	Zachee, Pierre/0000-0002-2275-5143; San-Miguel, Jesús F./0000-0002-9183-4857; Hajek, Roman/0000-0001-6955-6267; Greil, Richard F/0000-0002-4462-3694; ALEGRE, ADRIAN/0000-0002-2423-822X; Dimopoulos, Meletios/0000-0001-8990-3254; Kuliczkowski, Kazimierz/0000-0001-6812-1421; Masszi, Tamas/0000-0002-9038-302X; CAVO, MICHELE/0000-0003-4514-3227; Spicka, Ivan/0000-0002-5451-5283; o'dwyer, michael/0000-0002-6173-7140; gunsilius, eberhard/0000-0003-1327-2921; abdulkadyrov, kudrat/0000-0002-3771-909X				ALEXANIAN R, 1969, J AMER MED ASSOC, V208, P1680, DOI 10.1001/jama.208.9.1680; Anagnostopoulos A, 2005, EUR J HAEMATOL, V75, P370, DOI 10.1111/j.1600-0609.2005.00532.x; Anderson KC, 2008, LEUKEMIA, V22, P231, DOI 10.1038/sj.leu.2405016; [Anonymous], 1998, J Clin Oncol, V16, P3832; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Augustson BM, 2005, J CLIN ONCOL, V23, P9219, DOI 10.1200/JCO.2005.03.2086; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Berenson JR, 2006, J CLIN ONCOL, V24, P937, DOI 10.1200/JCO.2005.03.2383; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; BOCCADORO M, 1991, J CLIN ONCOL, V9, P444, DOI 10.1200/JCO.1991.9.3.444; Child JA, 2003, NEW ENGL J MED, V348, P1875, DOI 10.1056/NEJMoa022340; Durie BGM, 2007, LEUKEMIA, V21, P1134, DOI 10.1038/sj.leu.2404582; Durie BGM, 2006, LEUKEMIA, V20, P2220, DOI 10.1038/sj.leu.2404428; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Facon T, 2006, BLOOD, V107, P1292, DOI 10.1182/blood-2005-04-1588; Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140-6736(07)61537-2; Greipp PR, 2005, J CLIN ONCOL, V23, P6281, DOI 10.1200/JCO.2005.07.904; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Hernandez JM, 2004, BRIT J HAEMATOL, V127, P159, DOI 10.1111/j.1365-2141.2004.05186.x; Jagannath S, 2004, BRIT J HAEMATOL, V127, P165, DOI 10.1111/j.1365-2141.2004.05188.x; Kyle RA, 2005, NEW ENGL J MED, V352, P841; Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269; Ma MH, 2003, CLIN CANCER RES, V9, P1136; Mateos MV, 2008, HAEMATOLOGICA, V93, P560, DOI 10.3324/haematol.12106; Mateos MV, 2006, BLOOD, V108, P2165, DOI 10.1182/blood-2006-04-019778; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Moreau P, 2007, BLOOD, V110, p353A; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Palumbo A, 2006, LANCET, V367, P825, DOI 10.1016/S0140-6736(06)68338-4; Palumbo A, 2007, J CLIN ONCOL, V25, P4459, DOI 10.1200/JCO.2007.12.3463; Panageas KS, 2007, J NATL CANCER I, V99, P428, DOI 10.1093/jnci/djk091; Richardson PG, 2008, J NATL CANCER I, V100, P373, DOI 10.1093/jnci/djn012; Richardson PG, 2007, BLOOD, V110, P3557, DOI 10.1182/blood-2006-08-036947; Richardson PG, 2006, J CLIN ONCOL, V24, P3113, DOI 10.1200/JCO.2005.04.7779; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Ries L., 2005, SEER CANC STAT REV 1; San Miguel JF, 2005, BLOOD, V106, p111A	38	1468	1501	0	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 28	2008	359	9					906	917		10.1056/NEJMoa0801479	http://dx.doi.org/10.1056/NEJMoa0801479			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	341IU	18753647	Green Published, Bronze			2023-01-03	WOS:000258708300005
J	Laopaiboon, M; Lumbiganon, P; McDonald, SJ; Henderson-Smart, DJ; Green, S; Crowther, CA; Laopaiboon, M; McDonald, SJ; Lumbiganon, P; Festin, MR; Ho, JJ; Hakimi, M; Henderson-Smart, DJ; Green, S; Crowther, CA; McDonald, SJ; Thomas, M; Narash, N; Ewens, M; Hakimi, M; Supriyah; Amanah, L; Lukitasari, D; Astuti, D; Amanah, L; Amanah, L; Lukitasari, D; Astuti, D; Ho, JJ; Cham, SS; Cham, SS; Aw, ET; Cham, SS; Lumbiganon, P; Khianman, B; Pharprapa, A; Nachaipet, J; Narash, N; Poombankor, R; Saenrien, B; Srisutthikamol, N; Panikom, S; Khunudom, C; Thipawat, S; Choonhapran, S; Nuanbuddee, S; Jarudphan, P; Hempira, A; Narash, N; Poombankor, R; Tharnprisan, P; Sarapon, P; Ponpun, O; Narash, N; Poombankor, R; Festin, MR; Ubaldo-Anzures, C; Canete, LN; Festin, JL; Torralba, E; Canete, LN; Magsipoc; Festin, JL; Henderson-Smart, D; Green, S; Crowther, CA; McDonald, SJ				Laopaiboon, M.; Lumbiganon, P.; McDonald, S. J.; Henderson-Smart, D. J.; Green, S.; Crowther, C. A.; Laopaiboon, M.; McDonald, S. J.; Lumbiganon, P.; Festin, M. R.; Ho, J. J.; Hakimi, M.; Henderson-Smart, D. J.; Green, S.; Crowther, C. A.; McDonald, S. J.; Thomas, M.; Narash, N.; Ewens, M.; Hakimi, M.; Supriyah; Amanah, L.; Lukitasari, D.; Astuti, D.; Amanah, L.; Amanah, L.; Lukitasari, D.; Astuti, D.; Ho, J. J.; Cham, S. S.; Cham, S. S.; Aw, E. T.; Cham, S. S.; Lumbiganon, P.; Khianman, B.; Pharprapa, A.; Nachaipet, J.; Narash, N.; Poombankor, R.; Saenrien, B.; Srisutthikamol, N.; Panikom, S.; Khunudom, C.; Thipawat, S.; Choonhapran, S.; Nuanbuddee, S.; Jarudphan, P.; Hempira, A.; Narash, N.; Poombankor, R.; Tharnprisan, P.; Sarapon, P.; Ponpun, O.; Narash, N.; Poombankor, R.; Festin, M. R.; Ubaldo-Anzures, C.; Canete, L. N.; Festin, J. L.; Torralba, E.; Canete, L. N.; Magsipoc; Festin, J. L.; Henderson-Smart, D.; Green, S.; Crowther, C. A.; McDonald, S. J.			Use of Evidence-Based Practices in Pregnancy and Childbirth: South East Asia Optimising Reproductive and Child Health in Developing Countries Project	PLOS ONE			English	Article								Background: The burden of mortality and morbidity related to pregnancy and childbirth remains concentrated in developing countries. SEA-ORCHID ( South East Asia Optimising Reproductive and Child Health In Developing countries) is evaluating whether a multifaceted intervention to strengthen capacity for research synthesis, evidence-based care and knowledge implementation improves adoption of best clinical practice recommendations leading to better health for mothers and babies. In this study we assessed current practices in perinatal health care in four South East Asian countries and determined whether they were aligned with best practice recommendations. Methodology/Principal Findings: We completed an audit of 9550 medical records of women and their 9665 infants at nine hospitals; two in each of Indonesia, Malaysia and The Philippines, and three in Thailand between January-December 2005. We compared actual clinical practices with best practice recommendations selected from the Cochrane Library and the World Health Organization Reproductive Health Library. Evidence-based components of the active management of the third stage of labour and appropriately treating eclampsia with magnesium sulphate were universally practiced in all hospitals. Appropriate antibiotic prophylaxis for caesarean section, a beneficial form of care, was practiced in less than 5% of cases in most hospitals. Use of the unnecessary practices of enema in labour ranged from 1% to 61% and rates of episiotomy for vaginal birth ranged from 31% to 95%. Other appropriate practices were commonly performed to varying degrees between countries and also between hospitals within the same country. Conclusions/Significance: Whilst some perinatal health care practices audited were consistent with best available evidence, several were not. We conclude that recording of clinical practices should be an essential step to improve quality of care. Based on these findings, the SEA-ORCHID project team has been developing and implementing interventions aimed at increasing compliance with evidence-based clinical practice recommendations to improve perinatal practice in South East Asia.					Ho, Jacqueline/E-5690-2015; Ho, Jacqueline J/AAN-4341-2020; Lumbiganon, Pisake/E-8634-2010; Hakimi, Mohammad/GOV-6587-2022; Withinunthakit, Siriporn/E-6131-2010; McDonald, Steve/AAE-1613-2020	Ho, Jacqueline/0000-0001-9939-7551; Ho, Jacqueline J/0000-0001-9939-7551; Lumbiganon, Pisake/0000-0001-9372-0071; McDonald, Steve/0000-0003-2832-5205	National Health and Medical Research Council of Australia [307703]; Wellcome Trust, United Kingdom [071672/Z/03/Z]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Wellcome Trust, United Kingdom(Wellcome Trust)	This study is jointly funded by an International Collaborative Research Grant from the National Health and Medical Research Council of Australia (No. 307703) and Wellcome Trust, United Kingdom (071672/Z/03/Z). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Basevi V, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001236; Brown H, 2007, BMC MED, V5, DOI 10.1186/1741-7015-5-7; Carroli G., 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000081, DOI 10.1002/14651858.CD000081]; *CHOIC CHALL CHANG, 2005, INT J OBSTET GYNECOL, V112, P1270; *COCHR LIB, 2004, CHICH; Cuervo L, 1999, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000330; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; C-L D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006116.pub2; Duley L, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000127; Duley L, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000128; Duley L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002960.pub2; *GLOB HLTH COUNC, 2002, MAK CHILDB SAF PROM; Henderson-Smart DJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-43; Kenyon S, 2013, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001058; Khalil K, 2005, BIRTH-ISS PERINAT C, V32, P283, DOI 10.1111/j.0730-7659.2005.00385.x; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lee C, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004790.pub2; PRENDIVILLE WJ, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000007, DOI 10.1002/14651858.CD000007]; Qian Xu, 2001, BMC Pregnancy Childbirth, V1, P1, DOI 10.1186/1471-2393-1-1; *RES WHO DEP REPR, MAT MORT 2000 EST DE; Roberts D, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004454.pub2; Smaill Fiona M, 2019, Cochrane Database Syst Rev, V2019, DOI 10.1002/14651858.CD000490.pub4; *STATACORP, 2003, STAT STAT SOFTW REL; *WHO REPR HLTH LIB, 2004, UPD SOFTW, V7; S AFRICAN MED J, V94, P117	25	29	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2008	3	7							e2646	10.1371/journal.pone.0002646	http://dx.doi.org/10.1371/journal.pone.0002646			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	417GZ	18612381	Green Published, Green Submitted, gold			2023-01-03	WOS:000264065800048
J	Roy, D; Talajic, M; Nattel, S; Wyse, DG; Dorian, P; Lee, KL; Bourassa, MG; Arnold, JMO; Buxton, AE; Camm, AJ; Connolly, SJ; Dubuc, M; Ducharme, A; Guerra, PG; Hohnloser, SH; Lambert, J; Le Heuzey, JY; O'Hara, G; Pedersen, OD; Rouleau, JL; Singh, BN; Stevenson, LW; Stevenson, WG; Thibault, B; Waldo, AL				Roy, Denis; Talajic, Mario; Nattel, Stanley; Wyse, D. George; Dorian, Paul; Lee, Kerry L.; Bourassa, Martial G.; Arnold, J. Malcolm O.; Buxton, Alfred E.; Camm, A. John; Connolly, Stuart J.; Dubuc, Marc; Ducharme, Anique; Guerra, Peter G.; Hohnloser, Stefan H.; Lambert, Jean; Le Heuzey, Jean-Yves; O'Hara, Gilles; Pedersen, Ole Dyg; Rouleau, Jean-Lucien; Singh, Bramah N.; Stevenson, Lynne Warner; Stevenson, William G.; Thibault, Bernard; Waldo, Albert L.		Atrial Fibrillation & Congestive H	Rhythm control versus rate control for atrial fibrillation and heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; VENTRICULAR SYSTOLIC DYSFUNCTION; ANTIARRHYTHMIC DRUG-THERAPY; SINUS RHYTHM; PROGNOSTIC-SIGNIFICANCE; RANDOMIZED-TRIAL; RISK; MORTALITY; MAINTENANCE; AMIODARONE	Background It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied. Methods We conducted a multicenter, randomized trial comparing the maintenance of sinus rhythm (rhythm control) with control of the ventricular rate (rate control) in patients with a left ventricular ejection fraction of 35% or less, symptoms of congestive heart failure, and a history of atrial fibrillation. The primary outcome was the time to death from cardiovascular causes. Results A total of 1376 patients were enrolled (682 in the rhythm-control group and 694 in the rate-control group) and were followed for a mean of 37 months. Of these patients, 182 (27%) in the rhythm-control group died from cardiovascular causes, as compared with 175 (25%) in the rate-control group (hazard ratio in the rhythm-control group, 1.06; 95% confidence interval, 0.86 to 1.30; P=0.59 by the log-rank test). Secondary outcomes were similar in the two groups, including death from any cause (32% in the rhythm-control group and 33% in the rate-control group), stroke (3% and 4%, respectively), worsening heart failure (28% and 31%), and the composite of death from cardiovascular causes, stroke, or worsening heart failure (43% and 46%). There were also no significant differences favoring either strategy in any predefined subgroup. Conclusions In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy.	[Roy, Denis; Talajic, Mario; Nattel, Stanley; Bourassa, Martial G.; Dubuc, Marc; Ducharme, Anique; Guerra, Peter G.; Lambert, Jean; Rouleau, Jean-Lucien; Thibault, Bernard] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; [Roy, Denis; Talajic, Mario; Nattel, Stanley; Bourassa, Martial G.; Dubuc, Marc; Ducharme, Anique; Guerra, Peter G.; Lambert, Jean; Rouleau, Jean-Lucien; Thibault, Bernard] Univ Montreal, Montreal, PQ, Canada; [Wyse, D. George] Libin Cardiovasc Inst, Calgary, AB, Canada; [Dorian, Paul] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Lee, Kerry L.] Duke Univ, Med Ctr, Durham, NC USA; [Arnold, J. Malcolm O.] London Hlth Sci Ctr, London, ON, Canada; [Buxton, Alfred E.] Rhode Isl Hosp, Lifespan Acad Ctr, Providence, RI USA; [Camm, A. John] Univ London St Georges Hosp, Med Ctr, London, England; [Connolly, Stuart J.] Populat Hlth Res Inst, Hamilton, ON, Canada; [Hohnloser, Stefan H.] Goethe Univ Frankfurt, Frankfurt, Germany; [Le Heuzey, Jean-Yves] Hop Europeen Georges Pompidou, Paris, France; [O'Hara, Gilles] Inst Cardiol Quebec, Quebec City, PQ, Canada; [Pedersen, Ole Dyg] Bispebjerg Hosp, Copenhagen, Denmark; [Singh, Bramah N.] W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA; [Stevenson, Lynne Warner; Stevenson, William G.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Waldo, Albert L.] Case Western Reserve Univ Hosp, Med Ctr, Cleveland, OH 44106 USA	Universite de Montreal; Universite de Montreal; Libin Cardiovascular Institute Of Alberta; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Duke University; London Health Sciences Centre; Lifespan Health Rhode Island; Rhode Island Hospital; St Georges University London; Population Health Research Institute; Goethe University Frankfurt; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Laval University; University of Copenhagen; Bispebjerg Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; Harvard University; Brigham & Women's Hospital; Case Western Reserve University; Case Western Reserve University Hospital	Roy, D (corresponding author), Montreal Heart Inst, 5000 Belanger St, Montreal, PQ H1T 1C8, Canada.	d_roy@icm-mhi.com	Arnold, Malcolm/G-2869-2011; Ducharme, Anique/AAC-5946-2020	Ducharme, Anique/0000-0003-1681-9187; Talajic, Mario/0000-0001-8469-4748; Bourassa, Martial G./0000-0002-4439-8650; jourdain, patrick/0000-0002-5202-6902; Raitt, Merritt/0000-0001-5638-7732; Nattel, Stanley/0000-0002-5565-3311				Agner E, 2002, AM HEART J, V144, P597, DOI 10.1067/mhj.2002.125326; *AM HEART ASS, 2002, 2002 HEART STROK STA; Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bardy GH, 2005, NEW ENGL J MED, V352, P225, DOI 10.1056/NEJMoa043399; Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; BOURASSA MG, 1993, J AM COLL CARDIOL, V22, pA14, DOI 10.1016/0735-1097(93)90456-B; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Brignole M, 2002, EUR HEART J, V23, P892, DOI 10.1053/euhj.2001.2971; Carlsson J, 2003, J AM COLL CARDIOL, V41, P1690, DOI 10.1016/S0735-1097(03)00332-2; CARSON PE, 1993, CIRCULATION, V87, P102; COPLEN SE, 1991, CIRCULATION, V83, P714; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; Deedwania PC, 1998, CIRCULATION, V98, P2574, DOI 10.1161/01.CIR.98.23.2574; DOVAL HC, 1994, LANCET, V344, P493, DOI 10.1016/S0140-6736(94)91895-3; Dries DL, 1998, J AM COLL CARDIOL, V32, P695, DOI 10.1016/S0735-1097(98)00297-6; Ehrlich JR, 2002, J CARDIOVASC ELECTR, V13, P399, DOI 10.1046/j.1540-8167.2002.00399.x; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; FLAKER GC, 1992, J AM COLL CARDIOL, V20, P527, DOI 10.1016/0735-1097(92)90003-6; Fuster V, 2006, CIRCULATION, V114, pE257, DOI 10.1161/CIRCULATIONAHA.106.177292; Gronefeld Gerian C, 2003, J Cardiovasc Pharmacol Ther, V8, P107, DOI 10.1177/107424840300800203; Hogg K, 2004, J AM COLL CARDIOL, V43, P317, DOI 10.1016/j.jacc.2003.07.046; Hohnloser SH, 2000, LANCET, V356, P1789, DOI 10.1016/S0140-6736(00)03230-X; Hsu LF, 2004, NEW ENGL J MED, V351, P2373, DOI 10.1056/NEJMoa041018; Hynes BJ, 2003, CURR OPIN CARDIOL, V18, P32, DOI 10.1097/00001573-200301000-00005; Lehto M, 2005, EUR HEART J, V26, P350, DOI 10.1093/eurheartj/ehi064; Maisel WH, 2003, AM J CARDIOL, V91, p2D, DOI 10.1016/S0002-9149(02)03373-8; Mathew J, 2000, CHEST, V118, P914, DOI 10.1378/chest.118.4.914; MIDDLEKAUFF HR, 1991, CIRCULATION, V84, P40, DOI 10.1161/01.CIR.84.1.40; Moser DK, 2002, CIRCULATION, V105, P2810, DOI 10.1161/01.CIR.0000021745.45349.BB; Naccarelli GV, 2003, J CARDIOVASC ELECTR, V14, pS281, DOI 10.1046/j.1540-8167.2003.90404.x; Nohria A, 2002, JAMA-J AM MED ASSOC, V287, P628, DOI 10.1001/jama.287.5.628; Olsson LG, 2006, J AM COLL CARDIOL, V47, P1997, DOI 10.1016/j.jacc.2006.01.060; Opolski G, 2004, CHEST, V126, P476, DOI 10.1378/chest.126.2.476; Stevenson WG, 1997, J AM COLL CARDIOL, V30, P1902; Stevenson WG, 1996, J AM COLL CARDIOL, V28, P1458, DOI 10.1016/S0735-1097(96)00358-0; Stulak JM, 2006, ANN THORAC SURG, V82, P494, DOI 10.1016/j.athoracsur.2006.03.075; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Van Gelder IC, 2002, NEW ENGL J MED, V347, P1834, DOI 10.1056/NEJMoa021375; Wang TJ, 2003, CIRCULATION, V107, P2920, DOI 10.1161/01.CIR.0000072767.89944.6E; Wyse DG, 2003, J CARDIOVASC ELECTR, V14, pS35, DOI 10.1046/j.1540-8167.14.s9.17.x; Wyse DG, 2002, NEW ENGL J MED, V347, P1825, DOI 10.1056/nejmoa021328; Zareba W, 2006, HEART RHYTHM, V3, P631, DOI 10.1016/j.hrthm.2006.02.012; Zipes DP, 2006, J AM COLL CARDIOL, V48, P1064, DOI DOI 10.1016/J.JACC.2006.07.008	43	1057	1114	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2008	358	25					2667	2677		10.1056/NEJMoa0708789	http://dx.doi.org/10.1056/NEJMoa0708789			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314NC	18565859				2023-01-03	WOS:000256815100003
J	Lee, BJ; Forbes, K				Lee, Brian J.; Forbes, Ken			Practice Quality Improvement Report The role of specialists in managing the health of populations with chronic illness: the example of chronic kidney disease	BRITISH MEDICAL JOURNAL			English	Article							STAGE RENAL-DISEASE; IMPACT; CARE; MORTALITY; OUTCOMES; RISK; NEPHROLOGIST; NEPHROPATHY; MORBIDITY; REFERRALS	Problem Specialty care has been used to manage individual patients at the discretion of generalists but not to drive improvements at the population level. Design Observational longitudinal study. Setting Kaiser Permanente Hawaii, with more than 10 000 members with documented chronic kidney disease. Key measures for improvement Rate of late referrals to nephrology care, defined as occurring within four months of end stage renal disease and the proportions of patients starting haemodialysis with a mature arteriovenous fistula and starting dialysis in the outpatient setting. Strategies for change Risk stratification of the entire population and unsolicited consultations provided by nephrologists to generalists, based on patients' risk level, enabled by an electronic population management database. Effects of change Between 2004 and 2008, the proportion of referrals occurring within four months of onset of end stage renal disease dropped from 37 of 116 (32%) to 10 of 84 (12%), P=0.001. The proportion of patients starting haemodialysis with a mature arteriovenous fistula increased from 19 of 108 (18%) to 27 of 76 (36%), P=0.006. The proportion of patients who started haemodialysis as outpatients increased from 39 of 113 (35%) to 47 of 84 (56%), P=0.003. Lessons learnt Turning the traditional referral system on its head by providing unsolicited, risk driven nephrology consultations is an effective strategy for increasing the quality of medical management of patients with chronic kidney disease in the primary care setting and improving the cost effective use of nephrology services. This approach may be broadly applicable to other specialty areas.	[Lee, Brian J.] Kaiser Permanente, Moanalua Med Ctr, Hawaii Reg, Honolulu, HI 96819 USA; [Forbes, Ken] Kaiser Permanente, Care Management Inst, Hawaii Reg, Honolulu, HI 96819 USA	Kaiser Permanente; Kaiser Permanente	Lee, BJ (corresponding author), Kaiser Permanente, Moanalua Med Ctr, Hawaii Reg, 3288 Moanalua Rd, Honolulu, HI 96819 USA.	brian.j.lee@kp.org			Nephrology Division and Care Management Institute of Kaiser Permanente, Hawaii Region	Nephrology Division and Care Management Institute of Kaiser Permanente, Hawaii Region	This work was jointly supported by the Nephrology Division and Care Management Institute of Kaiser Permanente, Hawaii Region.	Arora P, 1999, J AM SOC NEPHROL, V10, P1281; Caskey FJ, 2003, NEPHROL DIAL TRANSPL, V18, P1330, DOI 10.1093/ndt/gfg156; Chan MR, 2007, AM J MED, V120, P1063, DOI 10.1016/j.amjmed.2007.04.024; Chen SC, 2008, NEPHROLOGY, V13, P730, DOI 10.1111/j.1440-1797.2008.01023.x; Cheng ZQ, 2009, HYBRIDOMA, V28, P33, DOI 10.1089/hyb.2008.0069; *DELF GROUP LLC, 2007, DELF PROJ SHOWC NEPH; Ellis PA, 1998, QJM-MON J ASSOC PHYS, V91, P727, DOI 10.1093/qjmed/91.11.727; Ifudu O, 1996, AM J KIDNEY DIS, V28, P841, DOI 10.1016/S0272-6386(96)90383-2; Innes A, 2008, NEPHROL DIAL TRANSPL, V23, P2571, DOI 10.1093/ndt/gfn069; Jones C, 2006, NEPHROL DIAL TRANSPL, V21, P2133, DOI 10.1093/ndt/gfl198; Kazmi WH, 2004, NEPHROL DIAL TRANSPL, V19, P1808, DOI 10.1093/ndt/gfg573; Keane WF, 2006, CLIN J AM SOC NEPHRO, V1, P761, DOI 10.2215/CJN.01381005; Kessler M, 2003, AM J KIDNEY DIS, V42, P474, DOI 10.1016/S0272-6386(03)00805-9; Kinchen KS, 2002, ANN INTERN MED, V137, P479, DOI 10.7326/0003-4819-137-6-200209170-00007; Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x; Livaudais Gerard, 2006, Perm J, V10, P72; Martinez-Ramirez HR, 2006, AM J KIDNEY DIS, V47, P78, DOI 10.1053/j.ajkd.2005.09.015; Navaneethan SD, 2008, AM J MED, V121, pE17, DOI 10.1016/j.amjmed.2008.01.008; Noble E, 2008, NEPHROL DIAL TRANSPL, V23, P3845, DOI 10.1093/ndt/gfn385; Ravani P, 2005, J NEPHROL, V18, P188; Richards N, 2008, NEPHROL DIAL TRANSPL, V23, P556, DOI 10.1093/ndt/gfm839; Roderick P, 2002, NEPHROL DIAL TRANSPL, V17, P1252, DOI 10.1093/ndt/17.7.1252; Roubicek C, 2000, AM J KIDNEY DIS, V36, P35, DOI 10.1053/ajkd.2000.8241; Stack AG, 2003, AM J KIDNEY DIS, V41, P310, DOI 10.1053/ajkd.2003.50038; Thorp ML, 2004, AM J MANAG CARE, V10, P417; Yang XL, 2006, DIABETOLOGIA, V49, P2299, DOI 10.1007/s00125-006-0376-3; 2002, AM J KIDNEY DIS S, V39, pS1	27	34	34	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUL 8	2009	339								b2395	10.1136/bmj.b2395	http://dx.doi.org/10.1136/bmj.b2395			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	469KY	19586983				2023-01-03	WOS:000267898300002
J	Abdi, Z				Abdi, Zeinab			The paediatric analgesia wheel: are you ready to roll?	LANCET			English	Editorial Material							MEDICATION ERRORS; RESIDENTS		Leicester Royal Infirm, Leicester LE1 5WW, Leics, England	University of Leicester	Abdi, Z (corresponding author), Leicester Royal Infirm, Infirm Sq, Leicester LE1 5WW, Leics, England.	zeinababdi@hotmail.com						*GEN MED COUNC, 2007, RES PREV CAUS PRESCR; Glover ML, 2002, ACAD MED, V77, P1007, DOI 10.1097/00001888-200210000-00013; Hart AR, 2008, ARCH DIS CHILD, V93, P636, DOI 10.1136/adc.2008.139410; Heaton A, 2008, BRIT J CLIN PHARMACO, V66, P128, DOI 10.1111/j.1365-2125.2008.03197.x; Hixson R, 2009, ARCH DIS CHILD, V94, P268, DOI 10.1136/adc.2008.142380; Kaushal R, 2001, JAMA-J AM MED ASSOC, V285, P2114, DOI 10.1001/jama.285.16.2114; MENON L, 2006, PAEDIAT PERINAT DRUG, V7, P118; National Patient Safety Agency, 2007, SAF DOS IMPR US MED; Rowe C, 1998, ARCH DIS CHILD, V79, P56, DOI 10.1136/adc.79.1.56; Western Australia Commissioner for Children and Young People, 2020, NAT SERV FRAM CHILDR; Wong ICK, 2009, ARCH DIS CHILD, V94, P161, DOI 10.1136/adc.2007.116442; Wong IC, 2004, DRUG SAFETY, V27, P661, DOI 10.2165/00002018-200427090-00004	12	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2009	373	9678					1831	1832		10.1016/S0140-6736(09)61005-9	http://dx.doi.org/10.1016/S0140-6736(09)61005-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	453ND	19482202				2023-01-03	WOS:000266616400010
J	Di Pasquale, E; Chahinian, H; Sanchez, P; Fantini, J				Di Pasquale, Eric; Chahinian, Henri; Sanchez, Patrick; Fantini, Jacques			The Insertion and Transport of Anandamide in Synthetic Lipid Membranes Are Both Cholesterol-Dependent	PLOS ONE			English	Article							MOLECULAR CHARACTERIZATION; CANNABINOID RECEPTORS; RAFTS; ACID; SPHINGOSINE; HYDROLYSIS; MONOLAYERS; CELLS	Background: Anandamide is a lipid neurotransmitter which belongs to a class of molecules termed the endocannabinoids involved in multiple physiological functions. Anandamide is readily taken up into cells, but there is considerable controversy as to the nature of this transport process (passive diffusion through the lipid bilayer vs. involvement of putative proteic transporters). This issue is of major importance since anandamide transport through the plasma membrane is crucial for its biological activity and intracellular degradation. The aim of the present study was to evaluate the involvement of cholesterol in membrane uptake and transport of anandamide. Methodology/Principal Findings: Molecular modeling simulations suggested that anandamide can adopt a shape that is remarkably complementary to cholesterol. Physicochemical studies showed that in the nanomolar concentration range, anandamide strongly interacted with cholesterol monolayers at the air-water interface. The specificity of this interaction was assessed by: i) the lack of activity of structurally related unsaturated fatty acids (oleic acid and arachidonic acid at 50 nM) on cholesterol monolayers, and ii) the weak insertion of anandamide into phosphatidylcholine or sphingomyelin monolayers. In agreement with these data, the presence of cholesterol in reconstituted planar lipid bilayers triggered the stable insertion of anandamide detected as an increase in bilayer capacitance. Kinetics transport studies showed that pure phosphatidylcholine bilayers were weakly permeable to anandamide. The incorporation of cholesterol in phosphatidylcholine bilayers dose-dependently stimulated the translocation of anandamide. Conclusions/Significance: Our results demonstrate that cholesterol stimulates both the insertion of anandamide into synthetic lipid monolayers and bilayers, and its transport across bilayer membranes. In this respect, we suggest that besides putative anandamide protein-transporters, cholesterol could be an important component of the anandamide transport machinery. Finally, this study provides a mechanistic explanation for the key regulatory activity played by membrane cholesterol in the responsiveness of cells to anandamide.	[Di Pasquale, Eric; Chahinian, Henri; Sanchez, Patrick; Fantini, Jacques] Univ Aix Marseille 2, Ctr Rech Neurobiol & Neurophysiol Marseille,CNRS, Fac Sci St Jerome, Univ Aix Marseille 3,UMR 6231,INRA,USC 2027, F-13284 Marseille 07, France	Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Aix-Marseille Universite	Di Pasquale, E (corresponding author), Univ Aix Marseille 2, Ctr Rech Neurobiol & Neurophysiol Marseille,CNRS, Fac Sci St Jerome, Univ Aix Marseille 3,UMR 6231,INRA,USC 2027, F-13284 Marseille 07, France.	jacques.fantini@univ-cezanne.fr		Fantini, Jacques/0000-0001-8653-5521	University Paul Cezanne; Centre National de la Recherche Scientifique (CNRS); Institut National du Cancer (INCA)	University Paul Cezanne; Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France)	This work has been supported by academic funds from University Paul Cezanne, the Centre National de la Recherche Scientifique (CNRS) and a grant (FAN-BCL) from the Institut National du Cancer (INCA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam G., 1968, STRUCT CHEM MOL BIOL, P198; Ambrosi S, 2005, J LIPID RES, V46, P1953, DOI 10.1194/jlr.M500121-JLR200; Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Bari M, 2006, J IMMUNOL, V177, P4971, DOI 10.4049/jimmunol.177.8.4971; Biswas KK, 2003, HEPATOLOGY, V38, P1167, DOI 10.1053/jhep.2003.50459; Bojesen IN, 2003, J LIPID RES, V44, P1790, DOI 10.1194/jlr.M300170-JLR200; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; Cravatt BF, 1996, NATURE, V384, P83, DOI 10.1038/384083a0; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Fantini Jacques, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402005392; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; Fowler CJ, 2004, EUR J PHARMACOL, V492, P1, DOI 10.1016/j.ejphar.2004.03.048; Garmy N, 2005, ARCH BIOCHEM BIOPHYS, V440, P91, DOI 10.1016/j.abb.2005.06.001; Garmy N, 2005, J LIPID RES, V46, P36, DOI 10.1194/jlr.M400199-JLR200; Glaser ST, 2003, P NATL ACAD SCI USA, V100, P4269, DOI 10.1073/pnas.0730816100; Glaser ST, 2005, LIFE SCI, V77, P1584, DOI 10.1016/j.lfs.2005.05.007; HARRIS JS, 1995, BIOCHEMISTRY-US, V34, P3851, DOI 10.1021/bi00011a043; Jarho P, 1996, LIFE SCI, V58, pPL181; MAKRIYANNIS A, 1995, CANNABINOID RECEPTOR, P87; McFarland MJ, 2004, J BIOL CHEM, V279, P41991, DOI 10.1074/jbc.M407250200; Mechoulam R, 2005, P NATL ACAD SCI USA, V102, P17541, DOI 10.1073/pnas.0508644102; NAKANISHI K, 1989, CHEM PHARM BULL, V37, P211; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Okamoto Y, 2004, J BIOL CHEM, V279, P5298, DOI 10.1074/jbc.M306642200; Risselada HJ, 2008, P NATL ACAD SCI USA, V105, P17367, DOI 10.1073/pnas.0807527105; ROSE IA, 1980, P NATL ACAD SCI-BIOL, V77, P2439, DOI 10.1073/pnas.77.5.2439; Sarker KP, 2003, CELL MOL LIFE SCI, V60, P1200, DOI 10.1007/s00018-003-3055-2; Siegmund SV, 2005, HEPATOLOGY, V41, P1085, DOI 10.1002/hep.20667; Song ZH, 1996, MOL PHARMACOL, V49, P891; Tian X., 2000, J BIOL CHEM, V280, P29788; Tien H.T., 1974, BILAYER LIPID MEMBRA; van Zadelhoff G, 1998, BIOCHEM BIOPH RES CO, V248, P33, DOI 10.1006/bbrc.1998.8910; Vargas J, 2000, BIOPHYS J, V79, P934, DOI 10.1016/S0006-3495(00)76348-X	34	41	41	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2009	4	3							e4989	10.1371/journal.pone.0004989	http://dx.doi.org/10.1371/journal.pone.0004989			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437PP	19330032	Green Published, gold, Green Submitted			2023-01-03	WOS:000265499700002
J	Heerspink, HL; Ninomiya, T; Zoungas, S; de Zeeuw, D; Grobbee, DE; Jardine, MJ; Gallagher, M; Roberts, MA; Cass, A; Neal, B; Perkovic, V				Heerspink, HiddoJ Lambers; Ninomiya, Toshiharu; Zoungas, Sophia; de Zeeuw, Dick; Grobbee, Diederick E.; Jardine, Meg J.; Gallagher, Martin; Roberts, Matthew A.; Cass, Alan; Neal, Bruce; Perkovic, Vlado			Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials	LANCET			English	Article							CHRONIC KIDNEY-DISEASE; ENZYME-INHIBITOR; CLINICAL-TRIALS; FOLIC-ACID; HEMODIALYSIS; PREVENTION; RAMIPRIL; QUALITY	Background Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have shown the cardiovascular benefits of lowering blood pressure in the general population, there is uncertainty about the efficacy and tolerability of reducing blood pressure in patients on dialysis. We did a systematic review and meta-analysis to assess the effect of blood pressure lowering in patients on dialysis. Methods We systematically searched Medline, Embase, and the Cochrane Library database for trials reported between 1950 and November, 2008, without language restriction. We extracted a standardised dataset from randomised controlled trials of blood pressure lowering in patients on dialysis that reported cardiovascular outcomes. Meta-analysis was done with a random effects model. Findings We identified eight relevant trials, which provided data for 1679 patients and 495 cardiovascular events. Weighted mean systolic blood pressure was 4.5 mm Hg lower and diastolic blood pressure 2.3 mm Hg lower in actively treated patients than in controls. Blood pressure lowering treatment was associated with lower risks of cardiovascular events (RR 0.71, 95% CI 0.55-0.92; p=0.009), all-cause mortality (RR 0.80, 0.66-0.96; p=0.014), and cardiovascular mortality (RR 0.71, 0.50-0.99; p=0.044) than control regimens. The effects seem to be consistent across a range of patient groups included in the studies. Interpretation Treatment with agents that lower blood pressure should routinely be considered for individuals undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population. Funding National Health and Medical Research Council of Australia Program.	[Heerspink, HiddoJ Lambers; Ninomiya, Toshiharu; Zoungas, Sophia; Grobbee, Diederick E.; Jardine, Meg J.; Gallagher, Martin; Cass, Alan; Neal, Bruce; Perkovic, Vlado] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2050, Australia; [Heerspink, HiddoJ Lambers; de Zeeuw, Dick] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands; [Grobbee, Diederick E.] Univ Med Ctr Utrecht, Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Zoungas, Sophia] Monash Univ, Melbourne, Vic 3004, Australia; [Roberts, Matthew A.] Univ Melbourne, Dept Med, Melbourne, Vic 3010, Australia	University of Sydney; University of Groningen; Utrecht University; Utrecht University Medical Center; Monash University; University of Melbourne	Perkovic, V (corresponding author), Univ Sydney, George Inst Int Hlth, POB M201,Missenden Rd, Sydney, NSW 2050, Australia.	vperkovic@george.org.au	Jardine, Meg/AFR-1699-2022; Grobbee, Diederick/C-7651-2014; Heerspink, Hiddo J Lambers/K-3358-2014; Jardine, Meg/AAS-1864-2020; de Zeeuw, Dick/E-9080-2014; Perkovic, Vlado/AAY-1933-2021	Jardine, Meg/0000-0002-0160-2375; Grobbee, Diederick/0000-0003-4472-4468; Heerspink, Hiddo J Lambers/0000-0002-3126-3730; Jardine, Meg/0000-0002-0160-2375; de Zeeuw, Dick/0000-0003-3434-7777; Zoungas, Sophia/0000-0003-2672-0949; Gallagher, Martin/0000-0001-9187-6187; Neal, Bruce/0000-0002-0490-7465; Perkovic, Vlado/0000-0002-4257-7620	National Health and Medical Research Council of Australia Program [571281]; the Saal van Zwanenburg Stichting; Dutch Kidney Foundation; International Society of Hypertension Visiting Postdoctoral Fellowship; Foundation for High Blood Pressure Research Council of Australia; National Health and Medical Research Council of Australia Health Professional Research Fellowship; National Heart Foundation of Australia AstraZeneca research fellowship; National Health and Medical Research Council of Australia Senior Research Fellowship	National Health and Medical Research Council of Australia Program(National Health and Medical Research Council (NHMRC) of Australia); the Saal van Zwanenburg Stichting; Dutch Kidney Foundation; International Society of Hypertension Visiting Postdoctoral Fellowship; Foundation for High Blood Pressure Research Council of Australia; National Health and Medical Research Council of Australia Health Professional Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); National Heart Foundation of Australia AstraZeneca research fellowship(National Heart Foundation of Australia); National Health and Medical Research Council of Australia Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	HJLH was supported by a Fellowship from the Saal van Zwanenburg Stichting, Dutch Kidney Foundation, and International Society of Hypertension Visiting Postdoctoral Fellowship awarded by the Foundation for High Blood Pressure Research Council of Australia. SZ was supported by a National Health and Medical Research Council of Australia Health Professional Research Fellowship. VP was supported by a National Heart Foundation of Australia AstraZeneca research fellowship. AC was supported by a National Health and Medical Research Council of Australia Senior Research Fellowship. This work was supported in part by a National Health and Medical Research Council of Australia Program grant (ID number 571281).	Agarwal R, 2009, HYPERTENSION, V53, P500, DOI 10.1161/HYPERTENSIONAHA.108.125674; Bakris G, 2008, AM J KIDNEY DIS, V51, pS1, DOI 10.1053/j.ajkd.2008.01.015; Bolton K, 2005, AM J KIDNEY DIS, V45, pS7, DOI 10.1053/j.ajkd.2005.01.016; Cice G, 2003, J AM COLL CARDIOL, V41, P1438, DOI 10.1016/S0735-1097(03)00241-9; CICE G, 2006, J HYPERTENS        S, V24, pS56; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Li PKT, 2003, ANN INTERN MED, V139, P105, DOI 10.7326/0003-4819-139-2-200307150-00010; Mann JFE, 2001, ANN INTERN MED, V134, P629, DOI 10.7326/0003-4819-134-8-200104170-00007; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; NAKAO N, 2007, J AM SOC NEPHROL, V18, pA709; Neal B, 2000, LANCET, V356, P1955; Perkovic V, 2007, J AM SOC NEPHROL, V18, P2766, DOI 10.1681/ASN.2007020256; Phrommintikul A, 2007, LANCET, V369, P381, DOI 10.1016/S0140-6736(07)60194-9; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Stidley CA, 2006, J AM SOC NEPHROL, V17, P513, DOI 10.1681/ASN.2004110921; Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466; Suzuki H, 2008, AM J KIDNEY DIS, V52, P501, DOI 10.1053/j.ajkd.2008.04.031; Takahashi A, 2006, NEPHROL DIAL TRANSPL, V21, P2507, DOI 10.1093/ndt/gfl293; Tepel M, 2008, NEPHROL DIAL TRANSPL, V23, P3605, DOI 10.1093/ndt/gfn304; Turnbull F, 2003, LANCET, V362, P1527; Turnbull F., 2007, J HYPERTENS, V25, P951, DOI [DOI 10.1097/HJH.0B013E3280BAD9B4, 10.1097/HJH.0b013-3280bad9b4]; Udayaraj UP, 2009, AM J KIDNEY DIS, V53, P70, DOI 10.1053/j.ajkd.2008.08.030; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Vianna Areuza C A, 2007, Hemodial Int, V11, P210, DOI 10.1111/j.1542-4758.2007.00171.x; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Woodward M., 2005, EPIDEMIOLOGY DESIGN; Wrone EM, 2004, J AM SOC NEPHROL, V15, P420, DOI 10.1097/01.ASN.0000110181.64655.6C; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zannad F, 2006, KIDNEY INT, V70, P1318, DOI 10.1038/sj.ki.5001657; Zoungas S, 2006, J AM COLL CARDIOL, V47, P1108, DOI 10.1016/j.jacc.2005.10.064	33	228	249	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	2009	373	9668					1009	1015		10.1016/S0140-6736(09)60212-9	http://dx.doi.org/10.1016/S0140-6736(09)60212-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	422AA	19249092	Green Published			2023-01-03	WOS:000264398200028
J	Fuentes, R; Petersson, P; Siesser, WB; Caron, MG; Nicolelis, MAL				Fuentes, Romulo; Petersson, Per; Siesser, William B.; Caron, Marc G.; Nicolelis, Miguel A. L.			Spinal Cord Stimulation Restores Locomotion in Animal Models of Parkinson's Disease	SCIENCE			English	Article							TRIGEMINAL NERVE-STIMULATION; DEEP BRAIN-STIMULATION; L-DOPA; SUBTHALAMIC NUCLEUS; MOTOR; RAT; MOVEMENT; NEURONS; CORTEX	Dopamine replacement therapy is useful for treating motor symptoms in the early phase of Parkinson's disease, but it is less effective in the long term. Electrical deep-brain stimulation is a valuable complement to pharmacological treatment but involves a highly invasive surgical procedure. We found that epidural electrical stimulation of the dorsal columns in the spinal cord restores locomotion in both acute pharmacologically induced dopamine-depleted mice and in chronic 6-hydroxydopamine-lesioned rats. The functional recovery was paralleled by a disruption of aberrant low-frequency synchronous corticostriatal oscillations, leading to the emergence of neuronal activity patterns that resemble the state normally preceding spontaneous initiation of locomotion. We propose that dorsal column stimulation might become an efficient and less invasive alternative for treatment of Parkinson's disease in the future.	[Fuentes, Romulo; Petersson, Per; Caron, Marc G.; Nicolelis, Miguel A. L.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Petersson, Per] Lund Univ, Dept Expt Med Sci, Neuronano Res Ctr, BMC F10, S-22184 Lund, Sweden; [Siesser, William B.; Caron, Marc G.] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA; [Nicolelis, Miguel A. L.] Duke Univ, Ctr Neuroengn, Durham, NC 27710 USA; [Nicolelis, Miguel A. L.] Duke Univ, Dept Biomed Engn, Durham, NC 27710 USA; [Nicolelis, Miguel A. L.] Duke Univ, Dept Psychol & Neurosci, Durham, NC 27710 USA; [Nicolelis, Miguel A. L.] ELS IINN, BR-59066060 Natal, RN, Brazil; [Nicolelis, Miguel A. L.] Ecole Polytech Fed Lausanne, CH-1015 Lausanne, Switzerland	Duke University; Lund University; Duke University; Duke University; Duke University; Duke University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne	Fuentes, R (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.	fuentes@neuro.duke.edu	Petersson, Per/A-5740-2010; Fuentes, Romulo/N-4258-2019; Fuentes, Romulo/AFR-1296-2022; Petersson, Per/P-1878-2019	Petersson, Per/0000-0001-6697-0171; Fuentes, Romulo/0000-0002-6282-7287; Fuentes, Romulo/0000-0002-6282-7287; Petersson, Per/0000-0001-6697-0171	National Institute of Neurological Disorders and Stroke (NINDS) [R33NS049534]; International Neuroscience Network Foundation; Ruth K. Broad Postdoctoral Award; NRC; Knut and Alice Wallenberg Foundation;  [R01NS019576];  [R01MH073853]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH073853] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS049534, R33NS049534, R01NS019576] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); International Neuroscience Network Foundation; Ruth K. Broad Postdoctoral Award; NRC(National Research Centre (NRC)); Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); ; ; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank W. M. Chan, G. Lehew, and J. Meloy for outstanding technical assistance; R. Gainetdinov, S.-C. Lin, H. Zhang, and K. Dzirasa for valuable comments; and S. Halkiotis for proofreading the manuscript. This work was supported by the National Institute of Neurological Disorders and Stroke (NINDS) R33NS049534 and the International Neuroscience Network Foundation to M.A.L.N., R01NS019576 and R01MH073853 to M.G.C., Ruth K. Broad Postdoctoral Award to R.F., and NRC and Knut and Alice Wallenberg Foundation to P.P. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NINDS or the National Institutes of Health. M.A.L.N. dedicates this paper to Lily Safra for her continuing support and to the memory of his grandfather, Angelo Nicolelis, who suffered from Parkinson's disease. M.A.L.N. acknowledges a visiting professorship, Chaire Blaise Pascal, from the Region Ile de France at the Ecole Superieure de Physique et de Chimie Industrielles, Paris.	Benabid AL, 2003, CURR OPIN NEUROBIOL, V13, P696, DOI 10.1016/j.conb.2003.11.001; Berke JD, 2004, NEURON, V43, P883, DOI 10.1016/j.neuron.2004.08.035; Brooks DJ, 2006, BIOL PSYCHIAT, V59, P908, DOI 10.1016/j.biopsych.2005.12.017; Brown P, 2001, J NEUROSCI, V21, P1033, DOI 10.1523/JNEUROSCI.21-03-01033.2001; BRUDZYNSKI SM, 1993, CAN J PHYSIOL PHARM, V71, P394, DOI 10.1139/y93-060; CARLSSON A, 1972, ACTA NEUROL SCAND, V48, P11; Cenci MA, 2002, NAT REV NEUROSCI, V3, P574, DOI 10.1038/nrn877; Costa RM, 2006, NEURON, V52, P359, DOI 10.1016/j.neuron.2006.07.030; DeGiorgio CM, 2006, EPILEPSIA, V47, P1213, DOI 10.1111/j.1528-1167.2006.00594.x; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Drouot' X, 2004, NEURON, V44, P769, DOI 10.1016/j.neuron.2004.11.023; Fahn S, 2003, ANN NY ACAD SCI, V991, P1, DOI 10.1111/j.1749-6632.2003.tb07458.x; Fanselow EE, 2000, J NEUROSCI, V20, P8160; GLICKSTEIN M, 1991, TRENDS NEUROSCI, V14, P480, DOI 10.1016/0166-2236(91)90055-Y; Grillner S, 2008, BRAIN RES REV, V57, P2, DOI 10.1016/j.brainresrev.2007.06.027; Hammond C, 2007, TRENDS NEUROSCI, V30, P357, DOI 10.1016/j.tins.2007.05.004; Hornykiewicz O, 2002, AMINO ACIDS, V23, P65, DOI 10.1007/s00726-001-0111-9; LLOYD KG, 1975, J PHARMACOL EXP THER, V195, P453; Perlmutter JS, 2006, ANNU REV NEUROSCI, V29, P229, DOI 10.1146/annurev.neuro.29.051605.112824; Plaha P, 2006, BRAIN, V129, P1732, DOI 10.1093/brain/awl127; SAKAI K, 1994, BRAIN RES, V633, P144, DOI 10.1016/0006-8993(94)91533-4; Schlesinger I, 2007, MOVEMENT DISORD, V22, P2394, DOI 10.1002/mds.21739; SHAW KM, 1980, Q J MED, V49, P283; Smith Y, 2004, TRENDS NEUROSCI, V27, P520, DOI 10.1016/j.tins.2004.07.004; Sotnikova TD, 2005, PLOS BIOL, V3, P1488, DOI 10.1371/journal.pbio.0030271; WALL PD, 1970, BRAIN, V93, P505, DOI 10.1093/brain/93.3.505; Wilson CJ, 2005, NEURON, V45, P575, DOI 10.1016/j.neuron.2004.12.053; Winkler C, 2002, NEUROBIOL DIS, V10, P165, DOI 10.1006/nbdi.2002.0499	28	189	223	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	2009	323	5921					1578	1582		10.1126/science.1164901	http://dx.doi.org/10.1126/science.1164901			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	421EN	19299613	Green Accepted			2023-01-03	WOS:000264342300031
J	Brooks, JP; Roehr, B				Brooks, Jay P.; Roehr, Bob			Should men who have ever had sex with men be allowed to give blood? No	BRITISH MEDICAL JOURNAL			English	Editorial Material							DONORS; TRANSFUSION; RIGHTS; IMPACT		Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Brooks, JP (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.	brooksj@uthscsa.edu						Brooks JP, 2004, VOX SANG, V87, P280, DOI 10.1111/j.1423-0410.2004.00567.x; *CDCP, 2007, HIV AIDS SURV REP, V17, P1; FISHMAN L, 2007, BLOODY TRUTH BLOOD D; *FOOD DRUG ADM CTR, 2007, FDA POL BLOOD DON ME; Franklin IM, 2007, TRANSFUSION MED, V17, P161, DOI 10.1111/j.1365-3148.2007.00754.x; Germain M, 2003, TRANSFUSION, V43, P25, DOI 10.1046/j.1537-2995.2003.00281.x; Hurley R, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b779; KASSING DW, OFFICE PRESIDENT PRE; KLEINMAN S, 2006, BEHAV BASED BLOOD DO; KRUPNICK M, 2008, OAKLAND TRIBUNE 1124; Leiss W, 2007, MSM DONOR DEFERRAL R; McCarthy LJ, 2007, TRANSFUSION, V47, P760, DOI 10.1111/j.1537-2995.2007.01187.x; Roehr B, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b311; Sanchez AM, 2005, TRANSFUSION, V45, P404, DOI 10.1111/j.1537-2995.2005.03421.x; Shilts R., 1987, BAND PLAYED; Soldan K, 2003, VOX SANG, V84, P265, DOI 10.1046/j.1423-0410.2003.00295.x; Spencer B, 2006, TRANSFUSION, V46, P869, DOI 10.1111/j.1537-2995.2006.00814.x; Sullivan MT, 2007, TRANSFUSION, V47, P385, DOI 10.1111/j.1537-2995.2007.01128.x; Titmuss, 1971, GIFT RELATIONSHIP; WRIGHT T, 2008, SPARTAN DAILY   0313	20	12	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 26	2009	338								b318	10.1136/bmj.b318	http://dx.doi.org/10.1136/bmj.b318			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	417DS	19246549				2023-01-03	WOS:000264056300005
J	Schiff, GD; Galanter, WL				Schiff, Gordon D.; Galanter, William L.			Promoting More Conservative Prescribing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DRUG; TRIAL; CARE		[Schiff, Gordon D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Med,Ctr Patient Safety Res & Practice, Boston, MA 02120 USA; [Galanter, William L.] Univ Illinois, Dept Med, Chicago, IL USA; [Galanter, William L.] Univ Illinois, Dept Pharm Practice, Chicago, IL USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schiff, GD (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gen Med,Ctr Patient Safety Res & Practice, 1620 Tremont,3rd Floor, Boston, MA 02120 USA.	gschiff@partners.org	Callahan, Charles D/L-1641-2013	Galanter, William/0000-0001-7811-5391	AHRQ [5U18HS016973-03, 5U18HS016973-04] Funding Source: Federal RePORTER; AHRQ HHS [U18HS016973] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016973] Funding Source: NIH RePORTER	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Association of American Medical Colleges, 2008, IND FUND MED ED REP; Association of American Medical Colleges, 2008, CONT ISS MED ED SAF; DeAngelis CD, 2004, JAMA-J AM MED ASSOC, V292, P1363, DOI 10.1001/jama.292.11.1363; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Jones OAH, 2004, CRIT REV TOXICOL, V34, P335, DOI 10.1080/10408440490464697; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; Lasser KE, 2002, JAMA-J AM MED ASSOC, V287, P2215, DOI 10.1001/jama.287.17.2215; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Macht D I, 1994, Osler Libr Newsl, P1; Padwal RS, 2007, LANCET, V369, P71, DOI 10.1016/S0140-6736(07)60033-6; Schiff GD, 2003, ARCH INTERN MED, V163, P893, DOI 10.1001/archinte.163.8.893; Sigurgceirsson B, 2002, ARCH DERMATOL, V138, P353, DOI 10.1001/archderm.138.3.353; Waxman HA, 2005, NEW ENGL J MED, V352, P2576, DOI 10.1056/NEJMp058136; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823	14	35	36	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2009	301	8					865	867		10.1001/jama.2009.195	http://dx.doi.org/10.1001/jama.2009.195			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410WV	19244196				2023-01-03	WOS:000263609900030
J	Bonetta, L				Bonetta, Laura			RNA-Based Therapeutics: Ready for Delivery?	CELL			English	Editorial Material								Delivery of RNA-based therapeutics to specific tissues for treating a variety of diseases faces many hurdles. But with several clinical trials and a slew of studies in animal models underway, the future of RNA-based therapeutics seems bright.											0	46	50	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 20	2009	136	4					581	584		10.1016/j.cell.2009.02.010	http://dx.doi.org/10.1016/j.cell.2009.02.010			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	411XX	19239878	Bronze			2023-01-03	WOS:000263688200008
J	Redman, LM; Heilbronn, LK; Martin, CK; de Jonge, L; Williamson, DA; Delany, JP; Ravussin, E				Redman, Leanne M.; Heilbronn, Leonie K.; Martin, Corby K.; de Jonge, Lilian; Williamson, Donald A.; Delany, James P.; Ravussin, Eric		Pennington CALERIE Team	Metabolic and Behavioral Compensations in Response to Caloric Restriction: Implications for the Maintenance of Weight Loss	PLOS ONE			English	Article							ENERGY-EXPENDITURE; PHYSICAL-ACTIVITY; INDIVIDUALS; ADAPTATION; REQUIREMENTS; CHAMBER; HUMANS; WOMEN; GAIN	Background: Metabolic and behavioral adaptations to caloric restriction (CR) in free-living conditions have not yet been objectively measured. Methodology and Principal Findings: Forty-eight (36.8 +/- 61.0 y), overweight (BMI 27.8 +/- 60.7 kg/m(2)) participants were randomized to four groups for 6-months; Control: energy intake at 100% of energy requirements; CR: 25% calorie restriction; CR+EX: 12.5% CR plus 12.5% increase in energy expenditure by structured exercise; LCD: low calorie diet (890 kcal/d) until 15% weight reduction followed by weight maintenance. Body composition (DXA) and total daily energy expenditure (TDEE) over 14-days by doubly labeled water (DLW) and activity related energy activity (AREE) were measured after 3 (M3) and 6 (M6) months of intervention. Weight changes at M6 were -1.0 +/- 1.1% (Control), -10.4 +/- 0.9% (CR), -10.0 +/- 0.8% (CR+EX) and -13.9 +/- 0.8% (LCD). At M3, absolute TDEE was significantly reduced in CR (-454 +/- 76 kcal/d) and LCD (-633 +/- 66 kcal/d) but not in CR+EX or controls. At M6 the reduction in TDEE remained lower than baseline in CR (-316 +/- 118 kcal/d) and LCD (-389 +/- 124 kcal/d) but reached significance only when CR and LCD were combined (-351 +/- 83 kcal/d). In response to caloric restriction (CR/LCD combined), TDEE adjusted for body composition, was significantly lower by 2431651 and -240 +/- 83 kcal/d at M3 and M6, respectively, indicating a metabolic adaptation. Likewise, physical activity (TDEE adjusted for sleeping metabolic rate) was significantly reduced from baseline at both time points. For control and CR+EX, adjusted TDEE (body composition or sleeping metabolic rate) was not changed at either M3 or M6. Conclusions: For the first time we show that in free-living conditions, CR results in a metabolic adaptation and a behavioral adaptation with decreased physical activity levels. These data also suggest potential mechanisms by which CR causes large inter-individual variability in the rates of weight loss and how exercise may influence weight loss and weight loss maintenance.	[Redman, Leanne M.; Heilbronn, Leonie K.; Martin, Corby K.; de Jonge, Lilian; Williamson, Donald A.; Delany, James P.; Ravussin, Eric] Pennington Biomed Res Ctr, Baton Rouge, LA USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Redman, LM (corresponding author), Pennington Biomed Res Ctr, Baton Rouge, LA USA.	ravusse@pbrc.edu	Biguzzi, Felipe A/E-4724-2015; Ravussin, Eric/N-1985-2017; Redman, Leanne M/N-1986-2017; Heilbronn, Leonie K/H-1874-2013; Martin, Corby K./N-1976-2017	Ravussin, Eric/0000-0003-2129-547X; Heilbronn, Leonie K/0000-0003-2106-7303; Martin, Corby K./0000-0002-8125-4015; DeLany, James/0000-0003-0366-3849; de Jonge, Lilian/0000-0001-5900-0695	CALERIE [U01 AG20478, NCT00099151]; National Health and Medical Research Council of Australia; Neil Hamilton-Fairley Training Fellowship [ID 349553]; NIH [K23 DK068052-01A2]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476, K23DK068052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG020478] Funding Source: NIH RePORTER	CALERIE; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Neil Hamilton-Fairley Training Fellowship; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	CALERIE (U01 AG20478), NCT00099151 (clinicaltrials.gov). This work was supported by U01 AG20478 (ER); National Health and Medical Research Council of Australia, Neil Hamilton-Fairley Training Fellowship (ID 349553) to LMR and NIH grant K23 DK068052-01A2 to CKM. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLISON DB, 1995, INT J OBESITY, V19, P644; DEGROOT LCPGM, 1989, AM J CLIN NUTR, V50, P1314, DOI 10.1093/ajcn/50.6.1314; DELANY JP, 1989, J APPL PHYSIOL, V67, P1922, DOI 10.1152/jappl.1989.67.5.1922; FRICKER J, 1991, AM J CLIN NUTR, V53, P826, DOI 10.1093/ajcn/53.4.826; Frisard MI, 2007, J GERONTOL A-BIOL, V62, P783, DOI 10.1093/gerona/62.7.783; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539; HEYMAN MB, 1992, AM J PHYSIOL, V263, pR250, DOI 10.1152/ajpregu.1992.263.2.R250; JAMES WPT, 1982, HUM NUTR-CLIN NUTR, V36, P331; KEESEY RE, 1989, MED CLIN N AM, V73, P15, DOI 10.1016/S0025-7125(16)30689-7; KEMNITZ JW, 1993, J GERONTOL, V48, pB17, DOI 10.1093/geronj/48.1.B17; Keys A., 1950, BIOL HUMAN STARVATIO, V2; LEIBEL RL, 1995, NEW ENGL J MED, V332, P621, DOI 10.1056/NEJM199503093321001; LEIBEL RL, 1984, METABOLISM, V33, P164, DOI 10.1016/0026-0495(84)90130-6; Levine JA, 2005, SCIENCE, V307, P584, DOI 10.1126/science.1106561; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; Martin CK, 2007, OBESITY, V15, P2964, DOI 10.1038/oby.2007.354; Nguyen T, 2003, MED BIOL ENG COMPUT, V41, P572, DOI 10.1007/BF02345320; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; RACETTE SB, 1994, AM J PHYSIOL-ENDOC M, V267, pE585, DOI 10.1152/ajpendo.1994.267.4.E585; RAVUSSIN E, 1985, AM J CLIN NUTR, V41, P753, DOI 10.1093/ajcn/41.4.753; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; Rosenbaum M, 2003, AM J PHYSIOL-REG I, V285, pR183, DOI 10.1152/ajpregu.00474.2002; Rosenbaum M, 1996, AM J PHYSIOL-REG I, V270, pR496, DOI 10.1152/ajpregu.1996.270.3.R496; ROSENBAUM M, 2008, AM J CLIN N IN PRESS; SACHER GA, 1977, HDB BIOL AGING, P582; Schoeller DA, 1997, AM J CLIN NUTR, V66, P551, DOI 10.1093/ajcn/66.3.551; SCHOELLER DA, 1988, J NUTR, V118, P1278, DOI 10.1093/jn/118.11.1278; SCHULZ LO, 1992, J APPL PHYSIOL, V72, P23, DOI 10.1152/jappl.1992.72.1.23; SOHAL RS, 1996, OXIDATIVE STRESS CAL, P59; TATARANNI PA, 1995, AM J CLIN NUTR, V61, P1013; VANSANT G, 1989, INT J OBESITY, V13, P87; VELTHUISTEWIERIK EJM, 1995, INT J OBESITY, V19, P318; Ware J. E., 2002, SF 36 HLTH SURVEY MA; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinsier RL, 2002, AM J CLIN NUTR, V75, P499, DOI 10.1093/ajcn/75.3.499; Weinsier RL, 2000, AM J CLIN NUTR, V72, P1088; ZURLO F, 1992, AM J PHYSIOL, V263, pE296, DOI 10.1152/ajpendo.1992.263.2.E296	38	231	233	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 9	2009	4	2							e4377	10.1371/journal.pone.0004377	http://dx.doi.org/10.1371/journal.pone.0004377			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437JN	19198647	Green Published, gold, Green Submitted			2023-01-03	WOS:000265483900002
J	Taieb, A; Picardo, M				Taieb, Alain; Picardo, Mauro			Vitiligo	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							308-NM EXCIMER-LASER; DOUBLE-BLIND TRIAL; TACROLIMUS OINTMENT; UV-B; GENERALIZED VITILIGO; SEGMENTAL VITILIGO; REPIGMENTATION; THERAPY; PLACEBO; EPIDEMIOLOGY		[Taieb, Alain] Ctr Hosp Univ Bordeaux, Natl Reference Ctr Rare Skin Dis, Dept Dermatol & Pediat Dermatol, Bordeaux, France; [Picardo, Mauro] San Gallicano Dermatol Inst, Rome, Italy	CHU Bordeaux; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG)	Taieb, A (corresponding author), Hop St Andre, Dept Dermatol, 1 Rue Jean Burguet, F-33075 Bordeaux, France.	alain.taieb@chu-bordeaux.fr	TAIEB, ALAIN/AAB-1085-2021; Picardo, Mauro/A-6978-2011	Picardo, Mauro/0000-0003-4899-6639	Pierre Fabre Laboratories; Galderma Laboratories	Pierre Fabre Laboratories; Galderma Laboratories	Drs. Taieb and Picardo are coordinators of the VETF, whose meetings in Paris have been supported by Pierre Fabre Laboratories. Dr. Picardo serves as the president of the European Society for Pigment Cell Research, which received a donation from Galderma Laboratories to organize a workshop on vitiligo at the 2008 International Pigment Cell Conference. No other potential conflict of interest relevant to this article was reported. We thank Dr. Yvon Gauthier for providing an earlier version of Figure 3 and for discussing an earlier draft of the manuscript and Alida de Pase for offering advice on camouflage techniques.	Alkhateeb A, 2003, PIGM CELL RES, V16, P208, DOI 10.1034/j.1600-0749.2003.00032.x; Anbar TS, 2006, PHOTODERMATOL PHOTO, V22, P157, DOI 10.1111/j.1600-0781.2006.00222.x; Attili VR, 2008, INT J DERMATOL, V47, P663, DOI 10.1111/j.1365-4632.2008.03672.x; BARONA MI, 1995, J AM ACAD DERMATOL, V33, P621, DOI 10.1016/0190-9622(95)91282-7; BETTERLE C, 1985, DERMATOLOGICA, V171, P419, DOI 10.1159/000249466; Boisseau-Garsaud AM, 2000, INT J DERMATOL, V39, P18, DOI 10.1046/j.1365-4362.2000.00880.x; Boissy RE, 2004, PIGM CELL RES, V17, P208, DOI 10.1111/j.1600-0749.2004.00130.x; Caron-Schreinemachers ALDB, 2005, ACTA DERM-VENEREOL, V85, P24, DOI 10.1080/00015550410022203; Casacci M, 2007, J EUR ACAD DERMATOL, V21, P956, DOI 10.1111/j.1468-3083.2007.02151.x; Chiaverini C, 2002, J EUR ACAD DERMATOL, V16, P137, DOI 10.1046/j.1468-3083.2002.00407.x; Dell'Anna ML, 2006, PIGM CELL RES, V19, P406, DOI 10.1111/j.1600-0749.2006.00333.x; FALABELLA R, 1988, ARCH DERMATOL, V124, P1649, DOI 10.1001/archderm.124.11.1649; Forschner Tobias, 2007, J Dtsch Dermatol Ges, V5, P467, DOI 10.1111/j.1610-0387.2007.06280.x; Gauthier Y, 2003, PIGM CELL RES, V16, P322, DOI 10.1034/j.1600-0749.2003.00070.x; GAUTHIER Y, 1992, J AM ACAD DERMATOL, V26, P191, DOI 10.1016/0190-9622(92)70024-A; Gauthier Y, 1995, EUR J DERMATOL, V5, P704; Gawkrodger DJ, 2008, BRIT J DERMATOL, V159, P1051, DOI 10.1111/j.1365-2133.2008.08881.x; Hamzavi I, 2004, ARCH DERMATOL, V140, P677, DOI 10.1001/archderm.140.6.677; Hann SK, 1996, J AM ACAD DERMATOL, V35, P671, DOI 10.1016/S0190-9622(96)90718-5; Hartmann A, 2008, ACTA DERM-VENEREOL, V88, P474, DOI 10.2340/00015555-0464; HOWITZ J, 1977, ARCH DERMATOL, V113, P47, DOI 10.1001/archderm.113.1.47; Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592; Kakourou T, 2005, J AM ACAD DERMATOL, V53, P220, DOI 10.1016/j.jaad.2005.03.032; LAN C, 2008, J EUR ACAD DERM 0623; Lan CCE, 2005, BRIT J DERMATOL, V153, P498, DOI 10.1111/j.1365-2133.2005.06739.x; Lee HS, 1999, J AM ACAD DERMATOL, V40, P21, DOI 10.1016/S0190-9622(99)70524-4; Liu JB, 2005, CLIN EXP DERMATOL, V30, P327, DOI 10.1111/j.1365-2230.2005.01813.x; Mason CP, 2005, CLIN EXP DERMATOL, V30, P344, DOI 10.1111/j.1365-2230.2005.01779.x; Mehrabi D, 2006, ARCH DERMATOL, V142, P927, DOI 10.1001/archderm.142.7.927; Njoo MD, 1998, ARCH DERMATOL, V134, P1532, DOI 10.1001/archderm.134.12.1532; Njoo MD, 2000, J AM ACAD DERMATOL, V42, P760, DOI 10.1067/mjd.2000.103813; Njoo MD, 2000, J AM ACAD DERMATOL, V42, P245, DOI 10.1016/S0190-9622(00)90133-6; Olsson MJ, 1997, ACTA DERM-VENEREOL, V77, P463; Ongenae K, 2005, DERMATOLOGY, V210, P279, DOI 10.1159/000084751; Parsad D, 2004, J AM ACAD DERMATOL, V50, P63, DOI 10.1016/S0190-9622(03)00786-2; Parsad D, 2008, INDIAN J DERMATOL VE, V74, pS37; Passeron T, 2004, ARCH DERMATOL, V140, P1065, DOI 10.1001/archderm.140.9.1065; Radakovic-Fijan S, 2001, J AM ACAD DERMATOL, V44, P814, DOI 10.1067/mjd.2001.113475; Rajatanavin N, 2008, INT J DERMATOL, V47, P402, DOI 10.1111/j.1365-4632.2008.03356.x; Rustin MHA, 2007, BRIT J DERMATOL, V157, P861, DOI 10.1111/j.1365-2133.2007.08177.x; Seiter S, 2000, INT J DERMATOL, V39, P624, DOI 10.1046/j.1365-4362.2000.00006.x; Taieb A, 2007, PIGM CELL RES, V20, P27, DOI 10.1111/j.1600-0749.2006.00355.x; van Geel N, 2004, ARCH DERMATOL, V140, P1203, DOI 10.1001/archderm.140.10.1203; Westerhof W, 1997, ARCH DERMATOL, V133, P1525; WHITTON ME, 2006, COCHRANE DB SYST REV, V1; Yones SS, 2007, ARCH DERMATOL, V143, P578, DOI 10.1001/archderm.143.5.578; Yu HS, 2003, J INVEST DERMATOL, V120, P56, DOI 10.1046/j.1523-1747.2003.12011.x	48	242	255	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	2009	360	2					160	U100		10.1056/NEJMcp0804388	http://dx.doi.org/10.1056/NEJMcp0804388			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	391UG	19129529				2023-01-03	WOS:000262258300009
J	Gargioli, C; Coletta, M; De Grandis, F; Cannata, SM; Cossu, G				Gargioli, Cesare; Coletta, Marcello; De Grandis, Fabrizio; Cannata, Stefano M.; Cossu, Giulio			PlGF-MMP-9-expressing cells restore microcirculation and efficacy of cell therapy in aged dystrophic muscle	NATURE MEDICINE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GENE-EXPRESSION; SKELETAL-MUSCLE; MDX MICE; MOUSE; MATRIX-METALLOPROTEINASE-9; MESOANGIOBLASTS; ANGIOGENESIS; COLLAGEN	Sclerosis and reduced microvessel density characterize advanced stages of muscular dystrophy and hamper cell or gene delivery, precluding treatment of most individuals with Duchenne muscular dystrophy. Modified tendon fibroblasts expressing an angiogenic factor (placenta growth factor, PlGF) and a metalloproteinase (matrix metalloproteinase-9, MMP-9) are able to restore a vascular network and reduce collagen deposition, allowing efficient cell therapy in aged dystrophic mice. These data open the possibility of extending new therapies to currently untreatable individuals.	[Gargioli, Cesare; Coletta, Marcello; De Grandis, Fabrizio; Cossu, Giulio] San Raffaele Biomed Pk Fdn Rome, I-10028 Rome, Italy; [Gargioli, Cesare; De Grandis, Fabrizio; Cannata, Stefano M.] Univ Roma Tor Vergata, Dept Biol, I-00173 Rome, Italy; [Cossu, Giulio] Ist Sci San Raffaele, Stem Cell Res Inst, I-20132 Milan, Italy; [Cossu, Giulio] Univ Milan, Dept Biol, I-20129 Milan, Italy	University of Rome Tor Vergata; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan	Cossu, G (corresponding author), San Raffaele Biomed Pk Fdn Rome, 100 Via Castel Romano, I-10028 Rome, Italy.	cossu.giulio@hsr.it		Gargioli, Cesare/0000-0003-1742-3969	Italian Ministry of Health and of Research [RBINO63EWP]; European Community	Italian Ministry of Health and of Research; European Community(European Commission)	We would like to thank E. Dejana (University of Milan) for the gift of HUVECs, BV13 antibody to vascular endothelial cadherin and for helpful discussion; S. Bernardini for advice on histology; and S. Iacovelli for technical help. This work was supported by grants from Duchenne Parent Project Onlus, BMW, Association Francaise contre les Myopathies, the Italian Ministry of Health and of Research (grant RBINO63EWP) and the European Community (MyoAmp).	Allen DL, 2001, AM J PHYSIOL-CELL PH, V280, pC637, DOI 10.1152/ajpcell.2001.280.3.C637; Azeh I, 1998, NEUROSCI LETT, V256, P127, DOI 10.1016/S0304-3940(98)00776-9; Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630; Brunelli S, 2007, P NATL ACAD SCI USA, V104, P264, DOI 10.1073/pnas.0608277104; Cossu G, 2007, TRENDS MOL MED, V13, P520, DOI 10.1016/j.molmed.2007.10.003; De Falco S, 2002, TRENDS CARDIOVAS MED, V12, P241, DOI 10.1016/S1050-1738(02)00168-8; FERRARI G, 1995, HUM GENE THER, V6, P733, DOI 10.1089/hum.1995.6.6-733; Forst J, 1999, NEUROMUSCULAR DISORD, V9, P176, DOI 10.1016/S0960-8966(98)00113-8; Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085; GOLDSPINK G, 1994, NEUROMUSCULAR DISORD, V4, P183, DOI 10.1016/0960-8966(94)90019-1; Goodwin AM, 2007, MICROVASC RES, V74, P172, DOI 10.1016/j.mvr.2007.05.006; KIRKEBY S, 1988, BRIT J EXP PATHOL, V69, P597; Kobayashi K, 2006, ARTERIOSCL THROM VAS, V26, P1465, DOI 10.1161/01.ATV.0000223865.64812.26; MARSHALL PA, 1989, MUSCLE NERVE, V12, P528, DOI 10.1002/mus.880120703; Minasi MG, 2002, DEVELOPMENT, V129, P2773; Muntoni Francesco, 2005, Neuromuscul Disord, V15, P450, DOI 10.1016/j.nmd.2005.02.007; PASTORET C, 1995, J NEUROL SCI, V129, P97, DOI 10.1016/0022-510X(94)00276-T; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; ROWLAND LP, 1976, ARCH NEUROL-CHICAGO, V33, P315, DOI 10.1001/archneur.1976.00500050001001; Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254; Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WEBSTER DF, 1982, BRIT J EXP PATHOL, V63, P50; WOESSNER JF, 1961, ARCH BIOCHEM BIOPHYS, V93, P440, DOI 10.1016/0003-9861(61)90291-0	26	100	102	0	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2008	14	9					973	978		10.1038/nm.1852	http://dx.doi.org/10.1038/nm.1852			6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	345IB	18660817				2023-01-03	WOS:000258988600031
J	Liu, B; Beral, V; Balkwill, A; Green, J; Sweetland, S; Reeves, G				Liu, Bette; Beral, Valerie; Balkwill, Angela; Green, Jane; Sweetland, Sian; Reeves, Gillian		Million Women Study Collaborators	Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SYMPTOMATIC GALLSTONE DISEASE; RISK; CHOLECYSTECTOMY; CONSUMPTION; STAY	Objective To determine whether transdermal compared with oral use of hormone replacement therapy reduces the risk of gallbladder disease in postmenopausal women. Design Prospective cohort study (Million Women Study). Setting Women registered with the National Health Service (NHS) in England and Scotland. Participants 1001391 postmenopausal women (mean age 56) recruited between 1996 and 2001 from NHS breast screening centres and followed by record linkage to routinely collected NHS hospital admission data for gallbladder disease. Main outcome measures Adjusted relative risk and standardised incidence rates of hospital admission for gallbladder disease or cholecystectomy according to use of hormone replacement therapy. Results During follow-up 19 889 women were admitted for gallbladder disease; 17 190 (86%) had a cholecystectomy. Compared with never users of hormone replacement therapy, current users were more likely to be admitted for gallbladder disease (relative risk 1.64, 95% confidence interval 1.58 to 1.69) but risks were substantially lower with transdermal therapy than with oral therapy (relative risk 1.17, 1.10 to 1.24 v 1.74, 1.68 to 1.80; heterogeneity P < 0.001). Among women using oral therapy, equine oestrogens were associated with a slightly greater risk of gallbladder disease than estradiol (relative risk 1.79, 1.72 to 1.87 v 1.62, 1.54 to 1.70; heterogeneity P<0.001) and higher doses of oestrogen increased the risk more than lower doses: equine oestrogens > 0.625 mg, 1.91 (1.78 to 2.04) v <= 0.625 mg, 1.76 (1.68 to 1.84); heterogeneity P=0.02; estradiol. > 1 mg, 1.68 (1.59 to 1.77) v <= l mg, 1.44 (1.31 to 1.59); heterogeneity P=0.003. The risk of gallbladder disease decreased with time since stopping therapy (trend P=0.004). Results were similar taking cholecystectomy as the outcome. Standardised hospital admission rates per 100 women over five years for cholecystectomy were 1.1 in never users, 1.3 with transdermal therapy, and 2.0 with oral therapy. Conclusion Gallbladder disease is common in postmenopausal women and use of hormone replacement therapy increases the risk. Use of transdermal therapy rather than oral therapy over a five year period could avoid one cholecystectomy in every 140 users.	[Liu, Bette; Beral, Valerie; Balkwill, Angela; Green, Jane; Sweetland, Sian; Reeves, Gillian] Univ Oxford, Epidemiol Unit, Oxford OX3 7LF, England	University of Oxford	Liu, B (corresponding author), Univ Oxford, Epidemiol Unit, Oxford OX3 7LF, England.	Bette.Liu@ceu.ox.ac.uk		Liu, Bette/0000-0002-0787-5825; Balkwill, Angela/0000-0002-6327-6245	Cancer Research UK [C570/A5028]; NHS; UK Medical Research Council [G0700474]; MRC [G9900923, G0700474] Funding Source: UKRI; Medical Research Council [G0700474, G9900923] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); NHS; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by Cancer Research UK [grant No C570/A5028], the NHS breast screening programme, and the UK Medical Research Council [grant No G0700474]. The funders had no involvement in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of this manuscript.	Banks E, 2004, JAMA-J AM MED ASSOC, V291, P2212, DOI 10.1001/jama.291.18.2212; Banks E, 2001, J Epidemiol Biostat, V6, P357; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Beral V, 2007, LANCET, V369, P1703, DOI 10.1016/S0140-6736(07)60534-0; Cirillo DJ, 2005, JAMA-J AM MED ASSOC, V293, P330, DOI 10.1001/jama.293.3.330; COULTER A, 1986, CONTRACEPTION, V33, P127, DOI 10.1016/0010-7824(86)90079-X; GANGAR K, 1989, BRIT MED J, V299, P601, DOI 10.1136/bmj.299.6699.601-a; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; *INF CTR, 2007, HOSP EP STAT; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Leitzmann MF, 1998, ANN INTERN MED, V128, P417, DOI 10.7326/0003-4819-128-6-199803150-00001; Leitzmann MF, 2003, AM J CLIN NUTR, V78, P339, DOI 10.1093/ajcn/78.2.339; Leitzmann MF, 2002, GASTROENTEROLOGY, V123, P1823, DOI 10.1053/gast.2002.37054; Liu B, 2008, J PUBLIC HEALTH-UK, V30, P161, DOI 10.1093/pubmed/fdn011; Liu B, 2007, J CLIN EPIDEMIOL, V60, P1190, DOI 10.1016/j.jclinepi.2007.02.007; LUMSDEN M, 2004, MENOPAUSE HORMONE RE, P187; Mamdani MM, 2000, CAN MED ASSOC J, V162, P1421; MEHTA D, 1999, BRIT NATL FORMULARY; MURRAY FE, 1994, GUT, V35, P107, DOI 10.1136/gut.35.1.107; Office of Population Censuses and Surveys, 2000, CLASS SURG OP PROC; PETITTI DB, 1988, GASTROENTEROLOGY, V94, P91, DOI 10.1016/0016-5085(88)90614-2; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Sweetman S. C., 2007, MARTINDALE COMPLETE; The Million Women Study Collaborative Group, 1999, BREAST CANCER RES, V1, P73, DOI DOI 10.1186/BCR16; THIJS C, 1993, AM J PUBLIC HEALTH, V83, P1113, DOI 10.2105/AJPH.83.8.1113; Tsai CJ, 2006, AM J MED, V119, P760, DOI 10.1016/j.amjmed.2006.02.040; Watson J, 2007, EUR J CLIN PHARMACOL, V63, P843, DOI 10.1007/s00228-007-0320-6; Williams B, 2000, J PUBLIC HEALTH MED, V22, P68, DOI 10.1093/pubmed/22.1.68; World Health Organization, 2004, ICD 10 INT STAT CLAS	32	51	57	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 2	2008	337	7664							a386	10.1136/bmj.a386	http://dx.doi.org/10.1136/bmj.a386			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339EN	18617493	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000258561000030
J	Finn, OJ				Finn, Olivera J.			Molecular origins of cancer - Cancer immunology	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							REGULATORY T-CELLS; TUMOR-ASSOCIATED ANTIGEN; DENDRITIC CELLS; METASTATIC MELANOMA; MONOCLONAL-ANTIBODY; IN-VIVO; INDOLEAMINE 2,3-DIOXYGENASE; INFILTRATING LYMPHOCYTES; MEDIATED REGRESSION; INFECTIOUS-DISEASES		Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Finn, OJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Immunol, E1044,Biomed Sci Tower, Pittsburgh, PA 15261 USA.	ojfinn@pitt.edu	Yousry, Tarek A/B-3417-2009		NATIONAL CANCER INSTITUTE [P50CA090440, P01CA073743, R01CA056103, R01CA168392] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA168392, P01 CA073743, P50 CA090440, R01 CA056103] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnoudse CA, 2006, CURR OPIN IMMUNOL, V18, P105, DOI 10.1016/j.coi.2005.11.001; Albonico HU, 1998, MED HYPOTHESES, V51, P315, DOI 10.1016/S0306-9877(98)90055-X; Anderson MJ, 2007, J IMMUNOL, V179, P7184, DOI 10.4049/jimmunol.179.10.7184; Anderson MJ, 2007, J IMMUNOL, V178, P1268, DOI 10.4049/jimmunol.178.3.1268; Antonia SJ, 2006, CLIN CANCER RES, V12, P878, DOI 10.1158/1078-0432.CCR-05-2013; Appella E, 1995, Biomed Pept Proteins Nucleic Acids, V1, P177; AWWAD M, 1989, CANCER RES, V49, P1649; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Baxevanis CN, 2006, CANCER IMMUNOL IMMUN, V55, P85, DOI 10.1007/s00262-005-0692-3; Bergmann C, 2007, CANCER IMMUNOL IMMUN, V56, P1429, DOI 10.1007/s00262-007-0280-9; Bernhardt SL, 2006, BRIT J CANCER, V95, P1474, DOI 10.1038/sj.bjc.6603437; Butts C, 2005, J CLIN ONCOL, V23, P6674, DOI 10.1200/JCO.2005.13.011; Carlos CA, 2005, J IMMUNOL, V175, P1628, DOI 10.4049/jimmunol.175.3.1628; Cavallo F, 2006, ADV IMMUNOL, V90, P175, DOI 10.1016/S0065-2776(06)90005-4; CHEEVER MA, 1981, CANCER RES, V41, P2658; CHEEVER MA, 1981, J IMMUNOL, V126, P1318; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chesnut R W, 1995, Pharm Biotechnol, V6, P847; Chikamatsu K, 2007, HEAD NECK-J SCI SPEC, V29, P120, DOI 10.1002/hed.20490; Cramer DW, 2005, CANCER EPIDEM BIOMAR, V14, P1125, DOI 10.1158/1055-9965.EPI-05-0035; Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Disis ML, 2004, J CLIN ONCOL, V22, P1916, DOI 10.1200/JCO.2004.09.005; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Dunn GP, 2005, NAT IMMUNOL, V6, P852, DOI 10.1038/ni0805-852b; Dunn GP, 2005, NAT IMMUNOL, V6, P722, DOI 10.1038/ni1213; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Emens LA, 2005, CANCER RES, V65, P8059, DOI 10.1158/0008-5472.CAN-05-1797; Fay JW, 2006, CANCER IMMUNOL IMMUN, V55, P1209, DOI 10.1007/s00262-005-0106-6; Fecci PE, 2006, CANCER RES, V66, P3294, DOI 10.1158/0008-5472.CAN-05-3773; Finke LH, 2007, VACCINE, V25, pB97, DOI 10.1016/j.vaccine.2007.06.067; Gallo P, 2007, INT J CANCER, V120, P574, DOI 10.1002/ijc.22274; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garcia-Hernandez MD, 2008, CANCER RES, V68, P861, DOI 10.1158/0008-5472.CAN-07-0445; Giaccone G, 2005, J CLIN ONCOL, V23, P3235, DOI 10.1200/JCO.2005.08.409; GILLIS S, 1978, J EXP MED, V148, P1093, DOI 10.1084/jem.148.4.1093; Gould P, 2006, LANCET ONCOL, V7, P710, DOI 10.1016/S1470-2045(06)70846-4; Graziano DF, 2005, CANC TREAT, V123, P89; HELLSTROM KE, 1982, SPRINGER SEMIN IMMUN, V5, P127; Hislop AD, 2007, ANNU REV IMMUNOL, V25, P587, DOI 10.1146/annurev.immunol.25.022106.141553; Hodge JW, 2003, CLIN CANCER RES, V9, P1837; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925; Houston A, 2003, BRIT J CANCER, V89, P1345, DOI 10.1038/sj.bjc.6601240; Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140-6736(00)03231-1; Inoges S, 2006, J NATL CANCER I, V98, P1292, DOI 10.1093/jnci/djj358; Jager E, 2002, CURR OPIN IMMUNOL, V14, P178, DOI 10.1016/S0952-7915(02)00318-7; Ji H, 2006, ONCOGENE, V25, P2105, DOI 10.1038/sj.onc.1209237; June CH, 2007, J CLIN INVEST, V117, P1466, DOI 10.1172/JCI32446; Kao H, 2001, CLIN CANCER RES, V7, p773S; Kao H, 2001, J EXP MED, V194, P1313, DOI 10.1084/jem.194.9.1313; Kim ES, 2004, SEMIN ONCOL, V31, P61, DOI 10.1053/j.seminoncol.2003.12.016; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kohrt HE, 2005, PLOS MED, V2, P904, DOI 10.1371/journal.pmed.0020284; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Krone B, 2003, EUR J CANCER, V39, P2372, DOI 10.1016/S0959-8049(03)00625-7; Kusmartsev S, 2005, J IMMUNOL, V175, P4583, DOI 10.4049/jimmunol.175.7.4583; Lien S., 2008, V181, P131; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Lollini PL, 2006, NAT REV CANCER, V6, P204, DOI 10.1038/nrc1815; Lowy DR, 2006, J CLIN INVEST, V116, P1167, DOI 10.1172/JCI28607; Ludewig B, 2004, J EXP MED, V200, P637, DOI 10.1084/jem.20040358; Mackensen A, 2006, J CLIN ONCOL, V24, P5060, DOI 10.1200/JCO.2006.07.1100; Mahnke K, 2007, INT J CANCER, V120, P2723, DOI 10.1002/ijc.22617; Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051; MELIEF CJM, 1989, COLD SH Q B, V54, P597; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Muller AJ, 2007, CURR CANCER DRUG TAR, V7, P31, DOI 10.2174/156800907780006896; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Nagaraj S, 2007, ADV EXP MED BIOL, V601, P213; NORTH RJ, 1986, J EXP MED, V164, P1652, DOI 10.1084/jem.164.5.1652; Palucka AK, 2006, J IMMUNOTHER, V29, P545, DOI 10.1097/01.cji.0000211309.90621.8b; Patel PH, 2008, ANN PHARMACOTHER, V42, P91, DOI 10.1345/aph.1K429; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388; Powell DJ, 2007, J IMMUNOL, V179, P4919, DOI 10.4049/jimmunol.179.7.4919; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Redfern CH, 2006, J CLIN ONCOL, V24, P3107, DOI 10.1200/JCO.2005.04.4289; Renkvist N, 2001, CANCER IMMUNOL IMMUN, V50, P3, DOI 10.1007/s002620000169; Ribas A, 2007, ONCOLOGIST, V12, P873, DOI 10.1634/theoncologist.12-7-873; Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x; Rock KL, 2005, SPRINGER SEMIN IMMUN, V26, P231, DOI 10.1007/s00281-004-0173-3; Roithmaier S, 2007, J HEART LUNG TRANSPL, V26, P845, DOI 10.1016/j.healun.2007.05.019; Russell JP, 2004, J IMMUNOL, V172, P4059, DOI 10.4049/jimmunol.172.7.4059; Saeland E, 2007, CANCER IMMUNOL IMMUN, V56, P1225, DOI 10.1007/s00262-006-0274-z; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; Schmielau J, 2001, CANCER RES, V61, P4756; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma P, 2007, P NATL ACAD SCI USA, V104, P3967, DOI 10.1073/pnas.0611618104; Simson L, 2007, J IMMUNOL, V178, P4222, DOI 10.4049/jimmunol.178.7.4222; Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977; SLINGLUFF CL, 1994, CURR OPIN IMMUNOL, V6, P733, DOI 10.1016/0952-7915(94)90077-9; Small EJ, 2007, CLIN CANCER RES, V13, P1810, DOI 10.1158/1078-0432.CCR-06-2318; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Soares MM, 2001, J IMMUNOL, V166, P6555, DOI 10.4049/jimmunol.166.11.6555; SRIVASTAVA PK, 1988, IMMUNOL TODAY, V9, P78, DOI 10.1016/0167-5699(88)91269-8; SUN ZT, 1991, CANCER DETECT PREV, V15, P313; Suzuki H, 2005, CLIN CANCER RES, V11, P1521, DOI 10.1158/1078-0432.CCR-04-0538; Teicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654; Uyttenhove C, 2003, NAT MED, V9, P1269, DOI 10.1038/nm934; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Vlad AM, 2004, ADV IMMUNOL, V82, P249, DOI 10.1016/S0065-2776(04)82006-6; Wahlin BE, 2007, CLIN CANCER RES, V13, P388, DOI 10.1158/1078-0432.CCR-06-1734; Weiner GJ, 2004, EXPERT OPIN BIOL TH, V4, P375, DOI 10.1517/14712598.4.3.375; Woo EY, 2001, CANCER RES, V61, P4766; Wu CJ, 2006, ADV IMMUNOL, V90, P133, DOI 10.1016/S0065-2776(06)90004-2; Wu CJ, 2005, CLIN CANCER RES, V11, P4504, DOI 10.1158/1078-0432.CCR-05-0036; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zeng G, 2006, J IMMUNOL, V177, P3582, DOI 10.4049/jimmunol.177.6.3582; Zheng XF, 2006, J IMMUNOL, V177, P5639, DOI 10.4049/jimmunol.177.8.5639; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	116	668	706	7	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2008	358	25					2704	2715		10.1056/NEJMra072739	http://dx.doi.org/10.1056/NEJMra072739			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314NC	18565863				2023-01-03	WOS:000256815100007
J	Richards, T				Richards, Tessa			Purely medicinal?	BRITISH MEDICAL JOURNAL			English	Editorial Material												trichards@bmj.com						Brown H, 2007, BRIT MED J, V334, P664, DOI 10.1136/bmj.39153.511701.BE; 2008, BMJ, V336, P694	2	9	9	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 29	2008	336	7646					693	693		10.1136/bmj.39527.454560.59	http://dx.doi.org/10.1136/bmj.39527.454560.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	283ZS	18369224	Green Published			2023-01-03	WOS:000254675600021
J	Olson, P; Hanahan, D				Olson, Peter; Hanahan, Douglas			Breaching the Cancer Fortress	SCIENCE			English	Editorial Material							PANCREATIC-CANCER; COMBINATION THERAPY; STEM-CELLS; FIBROBLASTS; PARADIGM		[Olson, Peter] Univ Calif San Francisco, Ctr Comprehens Canc, Ctr Diabet, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco	Olson, P (corresponding author), Univ Calif San Francisco, Ctr Comprehens Canc, Ctr Diabet, San Francisco, CA 94143 USA.	polson@diabetes.ucsf.edu; dh@ucsf.edu						Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Chu GC, 2007, J CELL BIOCHEM, V101, P887, DOI 10.1002/jcb.21209; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Jain RK, 1999, ANNU REV BIOMED ENG, V1, P241, DOI 10.1146/annurev.bioeng.1.1.241; Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987; Jaster R, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-26; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275	16	52	52	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	2009	324	5933					1400	1401		10.1126/science.1175940	http://dx.doi.org/10.1126/science.1175940			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	456VD	19520948				2023-01-03	WOS:000266878700031
J	Madoff, RD				Madoff, Robert D.			Rectal cancer: optimum treatment leads to optimum results	LANCET			English	Editorial Material							TOTAL MESORECTAL EXCISION; SHORT-TERM RADIOTHERAPY; PREOPERATIVE RADIOTHERAPY; RANDOMIZED-TRIAL; LOCAL RECURRENCE; POSTOPERATIVE CHEMORADIOTHERAPY; IRRADIATED PATIENTS; FOLLOW-UP; MRC CR07; MULTICENTER		Univ Minnesota, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Madoff, RD (corresponding author), Univ Minnesota, Minneapolis, MN 55455 USA.	madoff@umn.edu						ADAM IJ, 1994, LANCET, V344, P707, DOI 10.1016/S0140-6736(94)92206-3; Birgisson H, 2005, J CLIN ONCOL, V23, P8697, DOI 10.1200/JCO.2005.02.9017; Bujko K, 2004, RADIOTHER ONCOL, V72, P15, DOI 10.1016/j.radonc.2003.12.006; CEDERMARK B, 1995, CANCER-AM CANCER SOC, V75, P2269, DOI 10.1002/1097-0142(19950501)75:9<2269::AID-CNCR2820750913>3.0.CO;2-I; Folkesson J, 2005, J CLIN ONCOL, V23, P5644, DOI 10.1200/JCO.2005.08.144; Fowler JM, 2007, RADIOLOGY, V243, P132, DOI 10.1148/radiol.2431051825; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; MACFARLANE JK, 1993, LANCET, V341, P457, DOI 10.1016/0140-6736(93)90207-W; Marijnen CAM, 2005, J CLIN ONCOL, V23, P1847, DOI 10.1200/JCO.2005.05.256; Martling A, 2005, BRIT J SURG, V92, P225, DOI 10.1002/bjs.4834; Peeters KCMJ, 2005, J CLIN ONCOL, V23, P6199, DOI 10.1200/JCO.2005.14.779; Peeters KCMJ, 2007, ANN SURG, V246, P693, DOI 10.1097/01.sla.0000257358.56863.ce; Quirke P, 2009, LANCET, V373, P821, DOI 10.1016/S0140-6736(09)60485-2; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0; Wibe A, 2002, DIS COLON RECTUM, V45, P857, DOI 10.1007/s10350-004-6317-7	16	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 7	2009	373	9666					790	792		10.1016/S0140-6736(09)60459-1	http://dx.doi.org/10.1016/S0140-6736(09)60459-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	416BT	19269501				2023-01-03	WOS:000263980900007
J	Sakkas, GK; Mulligan, K; DaSilva, M; Doyle, JW; Khatami, H; Schleich, T; Kent-Braun, JA; Schambelan, M				Sakkas, Giorgos K.; Mulligan, Kathleen; DaSilva, Makani; Doyle, Julie W.; Khatami, Hootan; Schleich, Thomas; Kent-Braun, Jane A.; Schambelan, Morris			Creatine Fails to Augment the Benefits from Resistance Training in Patients with HIV Infection: A Randomized, Double-Blind, Placebo-Controlled Study	PLOS ONE			English	Article								Background: Progressive resistance exercise training (PRT) improves physical functioning in patients with HIV infection. Creatine supplementation can augment the benefits derived from training in athletes and improve muscle function in patients with muscle wasting. The objective of this study was to determine whether creatine supplementation augments the effects of PRT on muscle strength, energetics, and body composition in HIV-infected patients. Methodology/Principal Findings: This is a randomized, double blind, placebo-controlled, clinical research center-based, outpatient study in San Francisco. 40 HIV-positive men (20 creatine, 20 placebo) enrolled in a 14-week study. Subjects were randomly assigned to receive creatine monohydrate or placebo for 14 weeks. Treatment began with a loading dose of 20 g/day or an equivalent number of placebo capsules for 5 days, followed by maintenance dosing of 4.8 g/day or placebo. Beginning at week 2 and continuing to week 14, all subjects underwent thrice-weekly supervised resistance exercise while continuing on the assigned study medication (with repeated 6-week cycles of loading and maintenance). The main outcome measurements included muscle strength (one repetition maximum), energetics (P-31 magnetic resonance spectroscopy), composition and size (magnetic resonance imaging), as well as total body composition (dual-energy X-ray absorptiometry). Thirty-three subjects completed the study (17 creatine, 16 placebo). Strength increased in all 8 muscle groups studied following PRT, but this increase was not augmented by creatine supplementation (average increase 44 vs. 42%, difference 2%, 95% CI 29.5% to 13.9%) in creatine and placebo, respectively). There were no differences between groups in changes in muscle energetics. Thigh muscle cross-sectional area increased following resistance exercise, with no additive effect of creatine. Lean body mass (LBM) increased to a significantly greater extent with creatine. Conclusions/Significance: Resistance exercise improved muscle size, strength and function in HIV-infected men. While creatine supplementation produced a greater increase in LBM, it did not augment the robust increase in strength derived from PRT.	[Sakkas, Giorgos K.; Mulligan, Kathleen; Schambelan, Morris] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Sakkas, Giorgos K.; Mulligan, Kathleen; DaSilva, Makani; Khatami, Hootan; Schambelan, Morris] San Francisco Gen Hosp, Div Endocrinol, San Francisco, CA USA; [Sakkas, Giorgos K.] Univ Thessaly, Dept Med, Thessaly, Greece; [Doyle, Julie W.] No Calif Inst Res & Ed, San Francisco, CA USA; [Schleich, Thomas] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; [Kent-Braun, Jane A.] Univ Massachusetts, Dept Exercise Sci, Amherst, MA 01003 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of Thessaly; Northern California Institute for Research & Education; University of California System; University of California Santa Cruz; University of Massachusetts System; University of Massachusetts Amherst	Sakkas, GK (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.	morrie@sfghgcrc.ucsf.edu	Sakkas, Giorgos K./AAJ-4745-2021	Sakkas, Giorgos K./0000-0002-2462-995X	National Center for Complementary and Alternative Medicine of the National Institutes of Health [AT00491, DK45833, DK54615, RR-00083]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000491] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833, R01DK054615] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The study was performed under a grant from the National Center for Complementary and Alternative Medicine of the National Institutes of Health (AT00491, DK45833, DK54615, RR-00083). Creatine monohydrate and placebo were donated by Jarrow Universal Herbs, Inc., but they provided neither funds for this study nor any input on data analysis.	BALSOM PD, 1994, SPORTS MED, V18, P268, DOI 10.2165/00007256-199418040-00005; Culpepper RM, 1998, SOUTHERN MED J, V91, P890, DOI 10.1097/00007611-199809000-00032; Derave W, 2004, J APPL PHYSIOL, V97, P852, DOI 10.1152/japplphysiol.00206.2004; Dolan SE, 2006, ARCH INTERN MED, V166, P1225, DOI 10.1001/archinte.166.11.1225; EARNEST CP, 1995, ACTA PHYSIOL SCAND, V153, P207, DOI 10.1111/j.1748-1716.1995.tb09854.x; Gilliam JD, 2000, MED SCI SPORT EXER, V32, P993; GORDON A, 1995, CARDIOVASC RES, V30, P413, DOI 10.1016/0008-6363(95)00062-3; Green AL, 1996, AM J PHYSIOL-ENDOC M, V271, pE821, DOI 10.1152/ajpendo.1996.271.5.E821; GREENHAFF PL, 1994, AM J PHYSIOL, V266, pE725, DOI 10.1152/ajpendo.1994.266.5.E725; Grinspoon S, 2000, ANN INTERN MED, V133, P348, DOI 10.7326/0003-4819-133-5-200009050-00010; Grinspoon S, 2005, NEW ENGL J MED, V352, P48, DOI 10.1056/NEJMra041811; Grinspoon S, 2003, CLIN INFECT DIS, V36, pS69, DOI 10.1086/367561; Hespel P, 2001, J PHYSIOL-LONDON, V536, P625, DOI 10.1111/j.1469-7793.2001.0625c.xd; Hubal MJ, 2005, MED SCI SPORT EXER, V37, P964, DOI 10.1249/01.mss.0000170469.90461.5f; Izquierdo M, 2002, MED SCI SPORT EXER, V34, P332, DOI 10.1097/00005768-200202000-00023; Karatzaferi C, 1999, EUR J APPL PHYSIOL O, V80, P508, DOI 10.1007/s004210050626; Kent-Braun JA, 2000, J APPL PHYSIOL, V89, P1072, DOI 10.1152/jappl.2000.89.3.1072; Kent-Braun JA, 2002, J APPL PHYSIOL, V93, P1813, DOI 10.1152/japplphysiol.00091.2002; Kilduff LP, 2002, MED SCI SPORT EXER, V34, P1176, DOI 10.1097/00005768-200207000-00019; Kinugasa R, 2004, EUR J APPL PHYSIOL, V91, P230, DOI 10.1007/s00421-003-0970-8; Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1; Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x; Kreider RB, 1998, MED SCI SPORT EXER, V30, P73, DOI 10.1097/00005768-199801000-00011; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; Lox CL, 1996, INT J BEHAV MED, V3, P55, DOI 10.1207/s15327558ijbm0301_5; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Mujika I, 1997, INT J SPORTS MED, V18, P491, DOI 10.1055/s-2007-972670; Murata H, 2000, J BIOL CHEM, V275, P20251, DOI 10.1074/jbc.C000228200; Nissen SL, 2003, J APPL PHYSIOL, V94, P651, DOI 10.1152/japplphysiol.00755.2002; Nolte LA, 2001, DIABETES, V50, P1397, DOI 10.2337/diabetes.50.6.1397; Rawson ES, 2002, ACTA PHYSIOL SCAND, V174, P57, DOI 10.1046/j.1365-201x.2002.00924.x; RIGSBY LW, 1992, MED SCI SPORT EXER, V24, P6; Robinson FP, 2007, BIOL RES NURS, V8, P177, DOI 10.1177/1099800406295520; Roubenoff R, 2001, MED SCI SPORT EXER, V33, P1811, DOI 10.1097/00005768-200111000-00003; Shevitz AH, 2005, JAIDS-J ACQ IMM DEF, V38, P399, DOI 10.1097/01.qai.0000152647.89008.2b; SINNWELL TM, 1995, J CLIN INVEST, V96, P126, DOI 10.1172/JCI118012; SMITH DA, 1992, ANN PHARMACOTHER, V26, P653, DOI 10.1177/106002809202600510; SMITH DA, 1992, ANN PHARMACOTHER, V26, P520, DOI 10.1177/106002809202600414; Smith SA, 1999, J APPL PHYSIOL, V87, P116, DOI 10.1152/jappl.1999.87.1.116; Snow RJ, 1998, J APPL PHYSIOL, V84, P1667, DOI 10.1152/jappl.1998.84.5.1667; Syrotuik DG, 2004, J STRENGTH COND RES, V18, P610; Szczech LA, 2004, KIDNEY INT, V66, P1145, DOI 10.1111/j.1523-1755.2004.00865.x; Tarnopolsky M, 2004, MUSCLE NERVE, V29, P51, DOI 10.1002/mus.10527; Tarnopolsky MA, 2004, NEUROLOGY, V62, P1771, DOI 10.1212/01.WNL.0000125178.18862.9D; Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C; Tarnopolsky M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000991; Volek JS, 2004, EUR J APPL PHYSIOL, V91, P628, DOI 10.1007/s00421-003-1031-z; Volek JS, 1997, J AM DIET ASSOC, V97, P765, DOI 10.1016/S0002-8223(97)00189-2; Walter MC, 2002, J NEUROL, V249, P1717, DOI 10.1007/s00415-002-0923-x; Walter MC, 2000, NEUROLOGY, V54, P1848, DOI 10.1212/WNL.54.9.1848; Winett RA, 2000, JAMA-J AM MED ASSOC, V284, P175, DOI 10.1001/jama.284.2.175; Yarasheski KE, 2001, J APPL PHYSIOL, V90, P133, DOI 10.1152/jappl.2001.90.1.133; Zange J, 2002, ANN NEUROL, V52, P126, DOI 10.1002/ana.10197	54	27	28	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 26	2009	4	2							e4605	10.1371/journal.pone.0004605	http://dx.doi.org/10.1371/journal.pone.0004605			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437KX	19242554	Green Published, gold, Green Submitted			2023-01-03	WOS:000265487500010
J	Disis, ML; Bernhard, H; Jaffee, EM				Disis, Mary L.; Bernhard, Helga; Jaffee, Elizabeth M.			Use of tumour-responsive T cells as cancer treatment	LANCET			English	Review							COLONY-STIMULATING FACTOR; DONOR LYMPHOCYTE INFUSIONS; ANTIGEN-PRESENTING CELLS; NODE-NEGATIVE MELANOMA; IN-VIVO PERSISTENCE; ANTITUMOR IMMUNITY; DENDRITIC CELLS; BREAST-CANCER; ADJUVANT IMMUNOTHERAPY; ADOPTIVE IMMUNOTHERAPY	The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.	[Disis, Mary L.] Univ Washington, Ctr Translat Med Womens Hlth, Tumor Vaccine Grp, Seattle, WA 98109 USA; [Bernhard, Helga] Tech Univ Munich, Dept Haematol Oncol, Klinikum Rechts Isar, Munich, Germany; [Bernhard, Helga] GSF Munich, Inst Hlth & Environm, Clin Cooperat Grp Antigen Specif Immunotherapy, Munich, Germany; [Jaffee, Elizabeth M.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA	University of Washington; University of Washington Seattle; Technical University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Johns Hopkins University	Disis, ML (corresponding author), Univ Washington, Ctr Translat Med Womens Hlth, Tumor Vaccine Grp, Seattle, WA 98109 USA.	ndisis@u.washington.edu		Jaffee, Elizabeth/0000-0003-3841-6549	US National Institutes of Health [CA85374, CA101190, U19CA72108, P50CA88843, CA62924]; Athena Water; Research Council of Germany [SFB 456]; Wilhelm Sander Foundation; CSF National Research Center for Environment and Health-Clinical Cooperation Group Vaccinology; Sol Goldman Pancreatic Cancer Research Center; NATIONAL CANCER INSTITUTE [P50CA062924, R01CA101190, U19CA072108, R01CA085374, P50CA088843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR002319, UL1TR000423] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Athena Water; Research Council of Germany; Wilhelm Sander Foundation; CSF National Research Center for Environment and Health-Clinical Cooperation Group Vaccinology; Sol Goldman Pancreatic Cancer Research Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	MLD is supported by US National Institutes of Health (NIH) grants CA85374 and CA101190, and Athena Water. HB is supported by grants from the Research Council of Germany SFB 456, the Wilhelm Sander Foundation and the CSF National Research Center for Environment and Health-Clinical Cooperation Group Vaccinology. EMJ is supported by the Dana and Albert "Cubby" Broccoli Professorship; NIH grants U19CA72108, P50CA88843, and CA62924; and the Sol Goldman Pancreatic Cancer Research Center. We thank Sally Zebrick, Molly Boettcher, and Julia Muller for assistance in manuscript preparation.	Ackerman AL, 2004, NAT IMMUNOL, V5, P678, DOI 10.1038/ni1082; Alferink J, 1998, SCIENCE, V282, P1338, DOI 10.1126/science.282.5392.1338; Antony PA, 2005, J IMMUNOL, V174, P2591, DOI 10.4049/jimmunol.174.5.2591; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Banerjea A, 2005, DIS COLON RECTUM, V48, P2322, DOI 10.1007/s10350-005-0203-9; Bates GJ, 2006, J CLIN ONCOL, V24, P5373, DOI 10.1200/JCO.2006.05.9584; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Behn U, 2007, IMMUNOL REV, V216, P142; Bendandi M, 1999, NAT MED, V5, P1171, DOI 10.1038/13928; BERD D, 1984, CANCER RES, V44, P5439; Bishop MR, 2004, J CLIN ONCOL, V22, P3886, DOI 10.1200/JCO.2004.01.127; Bocchia M, 2005, LANCET, V365, P657; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Bonnett D, 1999, P NATL ACAD SCI USA, V96, P8639, DOI 10.1073/pnas.96.15.8639; Butterfield LH, 2003, CLIN CANCER RES, V9, P998; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Cesana GC, 2006, J CLIN ONCOL, V24, P1169, DOI 10.1200/JCO.2005.03.6830; Chakraborty NG, 2004, HUM IMMUNOL, V65, P794, DOI 10.1016/j.humimm.2004.05.012; CIBOTTI R, 1992, P NATL ACAD SCI USA, V89, P416, DOI 10.1073/pnas.89.1.416; Coccoris M, 2005, CURR GENE THER, V5, P583, DOI 10.2174/156652305774964730; Cohen PA, 2000, CRIT REV IMMUNOL, V20, P17; Coulie PG, 1999, ADV CANCER RES, V76, P213, DOI 10.1016/S0065-230X(08)60778-2; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; Czerniecki BJ, 2007, CANCER RES, V67, P1842, DOI 10.1158/0008-5472.CAN-06-4038; Dang YS, 2007, CLIN CANCER RES, V13, P1883, DOI 10.1158/1078-0432.CCR-06-2083; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Dazzi F, 2000, BLOOD, V96, P2712; Disis ML, 2004, J CLIN IMMUNOL, V24, P571, DOI 10.1023/B:JOCI.0000040928.67495.52; Disis ML, 2002, J CLIN ONCOL, V20, P2624, DOI 10.1200/JCO.2002.06.171; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Dong HD, 2003, J MOL MED, V81, P281, DOI 10.1007/s00109-003-0430-2; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dudley ME, 2005, J CLIN ONCOL, V23, P2346, DOI 10.1200/JCO.2005.00.240; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Duval L, 2006, CLIN CANCER RES, V12, P1229, DOI 10.1158/1078-0432.CCR-05-1485; EHRKE MJ, 1989, SEMIN ONCOL, V16, P230; Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869.x; Engels B, 2007, MOL ASPECTS MED, V28, P115, DOI 10.1016/j.mam.2006.12.006; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Fiore F, 2007, BLOOD, V110, P921, DOI 10.1182/blood-2006-09-044321; Foss FM, 2002, SEMIN ONCOL, V29, P5, DOI 10.1053/sonc.2002.33076; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Gao Q, 2007, J CLIN ONCOL, V25, P2586, DOI 10.1200/JCO.2006.09.4565; Gattinoni L, 2005, J CLIN INVEST, V115, P1616, DOI 10.1172/JCI24480; Gattinoni L, 2005, J EXP MED, V202, P907, DOI 10.1084/jem.20050732; Germeau C, 2005, J EXP MED, V201, P241, DOI 10.1084/jem.20041379; Goodell V, 2008, MOL CANCER THER, V7, P449, DOI 10.1158/1535-7163.MCT-07-0386; Greten TF, 1999, J CLIN ONCOL, V17, P1047, DOI 10.1200/JCO.1999.17.3.1047; Harris JE, 2000, J CLIN ONCOL, V18, P148, DOI 10.1200/JCO.2000.18.1.148; Heemskerk MHM, 2004, J EXP MED, V199, P885, DOI 10.1084/jem.20031110; Hersey P, 2002, J CLIN ONCOL, V20, P4181, DOI 10.1200/JCO.2002.12.094; Hollatz G, 2008, J IMMUNOL METHODS, V331, P69, DOI 10.1016/j.jim.2007.11.007; Inoges S, 2006, J NATL CANCER I, V98, P1292, DOI 10.1093/jnci/djj358; Inokuma M, 2007, J IMMUNOL, V179, P2627, DOI 10.4049/jimmunol.179.4.2627; Jaffee EM, 2001, J CLIN ONCOL, V19, P145, DOI 10.1200/JCO.2001.19.1.145; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jocham D, 2004, LANCET, V363, P594, DOI 10.1016/S0140-6736(04)15590-6; Kaufman HL, 2005, J CLIN INVEST, V115, P1903, DOI 10.1172/JCI24624; Kaufman HL, 2004, J CLIN INVEST, V113, P664, DOI 10.1172/JCI200421148; Klebanoff CA, 2005, P NATL ACAD SCI USA, V102, P9571, DOI 10.1073/pnas.0503726102; Knutson KL, 2001, J CLIN INVEST, V107, P477, DOI 10.1172/JCI11752; Knutson KL, 2002, CLIN CANCER RES, V8, P1014; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; Kolenko V, 1997, J IMMUNOL, V159, P3057; Kroczek RA, 2004, CURR OPIN IMMUNOL, V16, P321, DOI 10.1016/j.coi.2004.03.002; Lehner PJ, 1996, CURR OPIN IMMUNOL, V8, P59, DOI 10.1016/S0952-7915(96)80106-3; Lesimple T, 2006, CLIN CANCER RES, V12, P7380, DOI 10.1158/1078-0432.CCR-06-1879; Loftus DJ, 1996, J EXP MED, V184, P647, DOI 10.1084/jem.184.2.647; Lokhorst HM, 2000, J CLIN ONCOL, V18, P3031, DOI 10.1200/JCO.2000.18.16.3031; Lurquin C, 2005, J EXP MED, V201, P249, DOI 10.1084/jem.20041378; Marijt WAE, 2003, P NATL ACAD SCI USA, V100, P2742, DOI 10.1073/pnas.0530192100; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Matar P, 2000, EUR J CANCER, V36, P1060, DOI 10.1016/S0959-8049(00)00044-7; Maus MV, 2002, NAT BIOTECHNOL, V20, P143, DOI 10.1038/nbt0202-143; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Mullins DW, 1999, J IMMUNOL, V162, P6811; Munz C, 1999, J IMMUNOL, V162, P25; NORTH RJ, 1982, J EXP MED, V155, P1063, DOI 10.1084/jem.155.4.1063; Oelke M, 2003, NAT MED, V9, P619, DOI 10.1038/nm869; Ohlen C, 2001, J IMMUNOL, V166, P2863, DOI 10.4049/jimmunol.166.4.2863; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Palena C, 2005, BLOOD, V106, P3515, DOI 10.1182/blood-2005-03-1214; Parkhurst MR, 1996, J IMMUNOL, V157, P2539; POLAK L, 1975, IMMUNOLOGY, V28, P939; Quintarelli C, 2007, BLOOD, V110, P2793, DOI 10.1182/blood-2007-02-072843; Radoja S, 2001, J IMMUNOL, V167, P5042, DOI 10.4049/jimmunol.167.9.5042; Redfern CH, 2006, J CLIN ONCOL, V24, P3107, DOI 10.1200/JCO.2005.04.4289; RIDDELL SR, 1990, J IMMUNOL METHODS, V128, P189, DOI 10.1016/0022-1759(90)90210-M; Romero P, 2002, IMMUNOL REV, V188, P81, DOI 10.1034/j.1600-065X.2002.18808.x; Roszkowski JJ, 2005, CANCER RES, V65, P1570, DOI 10.1158/0008-5472.CAN-04-2076; Sadovnikova E, 1998, EUR J IMMUNOL, V28, P193, DOI 10.1002/(SICI)1521-4141(199801)28:01<193::AID-IMMU193>3.3.CO;2-B; Salazar LG, 2003, CLIN CANCER RES, V9, P5559; Schiavoni G, 2000, BLOOD, V95, P2024, DOI 10.1182/blood.V95.6.2024; SCHWARTZ RH, 1993, SCI AM, V269, P62, DOI 10.1038/scientificamerican0893-62; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; Shedlock DJ, 2003, SCIENCE, V300, P337, DOI 10.1126/science.1082305; Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3; Simons JW, 1997, CANCER RES, V57, P1537; Slingluff CL, 2004, J CLIN ONCOL, V22, P4474, DOI 10.1200/JCO.2004.10.212; Smith JW, 2003, J CLIN ONCOL, V21, P1562, DOI 10.1200/JCO.2003.09.020; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Sondak VK, 2006, CLIN CANCER RES, V12, p2337S, DOI 10.1158/1078-0432.CCR-05-2555; Sondak VK, 2002, J CLIN ONCOL, V20, P2058, DOI 10.1200/JCO.2002.08.071; Sosman JA, 2002, J CLIN ONCOL, V20, P2067, DOI 10.1200/JCO.2002.08.072; Speiser DE, 2005, J CLIN INVEST, V115, P739, DOI 10.1172/JCI200523373; Sprangers B, 2007, NAT CLIN PRACT ONCOL, V4, P404, DOI 10.1038/ncponc0848; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; Teague RM, 2006, NAT MED, V12, P335, DOI 10.1038/nm1359; Thomas AM, 2004, J EXP MED, V200, P297, DOI 10.1084/jem.20031435; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; Toes REM, 1996, CANCER RES, V56, P3782; van der Bruggen P, 2006, CURR OPIN IMMUNOL, V18, P98, DOI 10.1016/j.coi.2005.11.013; Van Parijs L, 1998, IMMUNITY, V8, P265, DOI 10.1016/S1074-7613(00)80478-1; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Weinschenk T, 2002, CANCER RES, V62, P5818; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; Yamshchikov GV, 2005, J IMMUNOL, V174, P6863, DOI 10.4049/jimmunol.174.11.6863; Yang SX, 2005, J IMMUNOL, V175, P3715, DOI 10.4049/jimmunol.175.6.3715; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Yu P, 2006, CURR OPIN IMMUNOL, V18, P226, DOI 10.1016/j.coi.2006.01.004; Zhang H, 2005, NAT MED, V11, P1238, DOI 10.1038/nm1312; Zhao YB, 2005, J IMMUNOL, V174, P4415, DOI 10.4049/jimmunol.174.7.4415; Zhou JH, 2005, J IMMUNOL, V175, P7046, DOI 10.4049/jimmunol.175.10.7046; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216; Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806	129	127	137	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	2009	373	9664					673	683		10.1016/S0140-6736(09)60404-9	http://dx.doi.org/10.1016/S0140-6736(09)60404-9			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410FS	19231634	Green Accepted			2023-01-03	WOS:000263563500032
J	Yang, JJ; Cheng, C; Yang, WJ; Pei, DQ; Cao, XY; Fan, YP; Pounds, SB; Neale, G; Trevino, LR; French, D; Campana, D; Downing, JR; Evans, WE; Pui, CH; Devidas, M; Bowman, WP; Camitta, BM; Willman, CL; Davies, SM; Borowitz, MJ; Carroll, WL; Hunger, SP; Relling, MV				Yang, Jun J.; Cheng, Cheng; Yang, Wenjian; Pei, Deqing; Cao, Xueyuan; Fan, Yiping; Pounds, Stanley B.; Neale, Geoffrey; Trevino, Lisa R.; French, Deborah; Campana, Dario; Downing, James R.; Evans, William E.; Pui, Ching-Hon; Devidas, Meenakshi; Bowman, W. P.; Camitta, Bruce M.; Willman, Cheryl L.; Davies, Stella M.; Borowitz, Michael J.; Carroll, William L.; Hunger, Stephen P.; Relling, Mary V.			Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMAL RESIDUAL DISEASE; CHILDRENS ONCOLOGY GROUP; CORONARY-ARTERY-DISEASE; P-GLYCOPROTEIN; RISK; METHOTREXATE; EXPRESSION; INTERLEUKIN-15; POLYMORPHISMS; IDENTIFICATION	Context Pediatric acute lymphoblastic leukemia ( ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response. Objectives To assess the contribution of inherited genetic variation to therapy response and to identify germline single- nucleotide polymorphisms ( SNPs) associated with risk of minimal residual disease ( MRD) after remission induction chemotherapy. Design, Setting, and Patients Genome- wide interrogation of 476 796 germline SNPs to identify genotypes that were associated with MRD in 2 independent cohorts of children with newly diagnosed ALL: 318 patients in St Jude Total Therapy protocols XIIIB and XV and 169 patients in Children's Oncology Group trial P9906. Patients were enrolled between 1994 and 2006 and last follow- up was in 2006. Main Outcome Measures Minimal residual disease at the end of induction therapy, measured by flow cytometry. Results There were 102 SNPs associated with MRD in both cohorts ( median odds ratio, 2.18; P <=. 0125), including 5 SNPs in the interleukin 15 ( IL15) gene. Of these 102 SNPs, 21 were also associated with hematologic relapse ( P <. 05). Of 102 SNPs, 21 were also associated with antileukemic drug disposition, generally linking MRD eradication with greater drug exposure. In total, 63 of 102 SNPs were associated with early response, relapse, or drug disposition. Conclusion Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.	[Yang, Jun J.; Cheng, Cheng; Yang, Wenjian; Pei, Deqing; Cao, Xueyuan; Fan, Yiping; Pounds, Stanley B.; Neale, Geoffrey; Trevino, Lisa R.; French, Deborah; Campana, Dario; Downing, James R.; Evans, William E.; Pui, Ching-Hon; Relling, Mary V.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; [Devidas, Meenakshi] Univ Florida, Gainesville, FL USA; [Bowman, W. P.] Cook Childrens Med Ctr, Ft Worth, TX USA; [Camitta, Bruce M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Willman, Cheryl L.] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA; [Davies, Stella M.] Cincinnati Childrens Hosp & Med Ctr, Cincinnati, OH USA; [Borowitz, Michael J.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA; [Carroll, William L.] NYU Med Ctr, New York, NY 10016 USA; [Hunger, Stephen P.] Childrens Hosp, Aurora, CO USA; [Hunger, Stephen P.] Univ Colorado, Ctr Canc, Aurora, CO USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; State University System of Florida; University of Florida; Cook Children's Medical Center; Medical College of Wisconsin; University of New Mexico; Cincinnati Children's Hospital Medical Center; Johns Hopkins University; Johns Hopkins Medicine; New York University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Relling, MV (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 262 Danny Thomas Pl,MS313, Memphis, TN 38105 USA.	mary.relling@stjude.org	Yang, Jun/B-6976-2008; Cheng, Cheng/N-8075-2018; Downing, James R./N-8102-2018; Relling, Mary/N-5032-2018; Devidas, Meenakshi/H-1170-2019; Pounds, Stanley B/N-2480-2018; Pui, Ching-Hon/N-8076-2018; Yang, Jun J./ABG-5646-2020; Evans, William E./C-2069-2012	Yang, Jun/0000-0002-0770-9659; Devidas, Meenakshi/0000-0002-1099-3478; Pounds, Stanley B/0000-0002-9167-2114; Pui, Ching-Hon/0000-0003-0303-5658; Yang, Jun J./0000-0002-0770-9659; Evans, William E./0000-0002-9333-5322	National Institutes of Health [CA 093552-02, CA 51001, CA 78224, CA 21765, CA R3736401, CA 60419, CA 086011, CA 98543, CA 29139]; National Institute of General Medical Sciences; Pharmacogenetics Research Network and Database [U01 GM61393, U01 GM61374]; NATIONAL CANCER INSTITUTE [R01CA093552, R29CA051001, R01CA086011, R01CA051001, R37CA036401, U10CA098413, U10CA029139, R01CA060419, U10CA098543, R01CA078224, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061374, U01GM061393] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Pharmacogenetics Research Network and Database(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants CA 093552-02, CA 51001, CA 78224, CA 21765, CA R3736401, CA 60419, CA 086011, CA 98543, CA 29139, and National Institutes of Health (NIH)/National Institute of General Medical Sciences (NIGMS) Pharmacogenetics Research Network and Database grants U01 GM61393 and U01 GM61374 (http://www.pharmgkb.org) from the National Cancer Institute and NIGMS; by the American Lebanese Syrian Associated Charities; and by CureSearch.	Aithal GP, 1999, LANCET, V353, P717, DOI 10.1016/S0140-6736(98)04474-2; Bleyer WA, 1997, J PEDIAT HEMATOL ONC, V19, P530, DOI 10.1097/00043426-199711000-00008; Borowitz MJ, 2003, LEUKEMIA, V17, P1566, DOI 10.1038/sj.leu.2403001; Bostrom BC, 2003, J PEDIAT HEMATOL ONC, V25, P114, DOI 10.1097/00043426-200302000-00006; Budagian V, 2006, CYTOKINE GROWTH F R, V17, P259, DOI 10.1016/j.cytogfr.2006.05.001; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Cario G, 2007, J CLIN ONCOL, V25, P4813, DOI 10.1200/JCO.2007.11.8166; Carroll WL, 2006, PEDIATR BLOOD CANCER, V46, P570, DOI 10.1002/pbc.20722; Carroll WL, 2003, JAMA-J AM MED ASSOC, V290, P2061, DOI 10.1001/jama.290.15.2061; Cave H, 1998, NEW ENGL J MED, V339, P591, DOI 10.1056/NEJM199808273390904; Cheng C, 2004, STAT APPL GENET MOL, V3, P36; CONTER V, 1995, J CLIN ONCOL, V13, P2497, DOI 10.1200/JCO.1995.13.10.2497; Coustan-Smith E, 2000, BLOOD, V96, P2691, DOI 10.1182/blood.V96.8.2691; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; Davies SM, 2008, BLOOD, V111, P2984, DOI 10.1182/blood-2007-09-114082; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; Fehniger TA, 2001, BLOOD, V97, P14, DOI 10.1182/blood.V97.1.14; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fleury Isabelle, 2004, Am J Pharmacogenomics, V4, P331, DOI 10.2165/00129785-200404050-00006; Flohr T, 2008, LEUKEMIA, V22, P771, DOI 10.1038/leu.2008.5; Holleman A, 2006, BLOOD, V107, P769, DOI 10.1182/blood-2005-07-2930; Hunter DJ, 2007, NEW ENGL J MED, V357, P436, DOI 10.1056/NEJMp078120; Kadan-Lottick NS, 2003, JAMA-J AM MED ASSOC, V290, P2008, DOI 10.1001/jama.290.15.2008; Kager L, 2005, J CLIN INVEST, V115, P110, DOI 10.1172/JCI200522477; Kishi S, 2004, BLOOD, V103, P67, DOI 10.1182/blood-2003-06-2105; Kishi S, 2007, BLOOD, V109, P4151, DOI 10.1182/blood-2006-10-054528; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEU BL, 1995, CANCER CHEMOTH PHARM, V35, P432, DOI 10.1007/s002800050258; LEWIS AD, 1992, CANCER RES, V52, P4379; Lugthart S, 2005, CANCER CELL, V7, P375, DOI 10.1016/j.ccr.2005.03.002; Malo N, 2008, AM J HUM GENET, V82, P375, DOI 10.1016/j.ajhg.2007.10.012; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; Plasschaert SLA, 2004, CLIN PHARMACOL THER, V76, P220, DOI 10.1016/j.clpt.2004.05.007; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Pui C.-H., 2004, Annals of Hematology, V83, pS124; Pui CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Pui CH, 2007, NAT REV DRUG DISCOV, V6, P149, DOI 10.1038/nrd2240; Rabbee N, 2006, BIOINFORMATICS, V22, P7, DOI 10.1093/bioinformatics/bti741; Relling MV, 1999, BLOOD, V93, P2817; RELLING MV, 1994, MOL PHARMACOL, V45, P352; Richards JB, 2008, LANCET, V371, P1505, DOI 10.1016/S0140-6736(08)60599-1; Rocha JCC, 2005, BLOOD, V105, P4752, DOI 10.1182/blood-2004-11-4544; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802; Schmidt S, 2006, BLOOD, V107, P2061, DOI 10.1182/blood-2005-07-2853; Schultz KR, 2007, BLOOD, V109, P926, DOI 10.1182/blood-2006-01-024729; Schwarz UI, 2008, NEW ENGL J MED, V358, P999, DOI 10.1056/NEJMoa0708078; Sorich MJ, 2008, PLOS MED, V5, P646, DOI 10.1371/journal.pmed.0050083; Stanulla M, 2005, JAMA-J AM MED ASSOC, V293, P1485, DOI 10.1001/jama.293.12.1485; Szczepanski T, 2001, LANCET ONCOL, V2, P409, DOI 10.1016/S1470-2045(00)00418-6; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Tissing WJE, 2007, BLOOD, V109, P3929, DOI 10.1182/blood-2006-11-056366; Valdes AM, 2008, AM J HUM GENET, V82, P1231, DOI 10.1016/j.ajhg.2008.04.006; van Asperen J, 2000, DRUG METAB DISPOS, V28, P264; van Dongen JJM, 1998, LANCET, V352, P1731, DOI 10.1016/S0140-6736(98)04058-6; Villikka K, 1999, CLIN PHARMACOL THER, V66, P589, DOI 10.1016/S0009-9236(99)90067-X; Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075; Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76; Yates CR, 2003, PHARM RES-DORDR, V20, P1794, DOI 10.1023/B:PHAM.0000003377.39548.f6; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; Zhang XJ, 2007, J INVEST DERMATOL, V127, P2544, DOI 10.1038/sj.jid.5700896; Zhou JB, 2007, BLOOD, V110, P1607, DOI 10.1182/blood-2006-09-045369	65	171	177	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	2009	301	4					393	403		10.1001/jama.2009.7	http://dx.doi.org/10.1001/jama.2009.7			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399CE	19176441	Green Accepted			2023-01-03	WOS:000262777200019
J	Pitchford, SC; Furze, RC; Jones, CP; Wengner, AM; Rankin, SM				Pitchford, Simon C.; Furze, Rebecca C.; Jones, Carla P.; Wengner, Antje M.; Rankin, Sara M.			Differential Mobilization of Subsets of Progenitor Cells from the Bone Marrow	CELL STEM CELL			English	Article							COLONY-STIMULATING FACTOR; ENDOTHELIAL GROWTH-FACTOR; HEMATOPOIETIC STEM-CELLS; ACUTE MYOCARDIAL-INFARCTION; G-CSF; IN-VIVO; AMD3100; BLOOD; NEOVASCULARIZATION; EXPRESSION	G-CSF stimulates mobilization of hematopoietic progenitor cells (HPCs) from bone marrow by disrupting the CXCR4/SDF-1 alpha retention axis. We show here that distinct factors and mechanisms regulate the mobilization of endothelial (EPCs) and stromal progenitor cells (SPCs). Pretreatment of mice with VEGF did not disrupt the CXCR4/SDF-1 alpha chemokine axis but stimulated entry of HPCs into the cell cycle via VEGFR1, reducing their migratory capacity in vitro and suppressing their mobilization in vivo. In contrast, VEGF pretreatment enhanced EPC mobilization via VEGFIR2 in response to CXCR4 antagonism. Furthermore, SPC mobilization was detected when the CXCR4 antagonist was administered to mice pretreated with VEGF, but not G-CSF. Thus, differential mobilization of progenitor cell subsets is dependent upon the cytokine milieu that regulates cell retention and proliferation. These findings may inform studies investigating mechanisms that regulate progenitor cell recruitment in disease and can be exploited to provide efficacious stem cell therapy for tissue regeneration.	[Pitchford, Simon C.; Furze, Rebecca C.; Jones, Carla P.; Wengner, Antje M.; Rankin, Sara M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England	Imperial College London	Rankin, SM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, London SW7 2AZ, England.	s.rankin@imperial.ac.uk		Jones, Carla P/0000-0002-4329-3267; Pitchford, Simon/0000-0003-3961-0407	British Heart Foundation [PGO5092]; European Community INNOCHEM [LSHB-CT-2005-518167]; Wellcome Trust [073677/Z/03/Z]; CNPq (Brazil)	British Heart Foundation(British Heart Foundation); European Community INNOCHEM(European Commission); Wellcome Trust(Wellcome TrustEuropean Commission); CNPq (Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was funded by the British Heart Foundation (project grant no. PGO5092), The European Community INNOCHEM (LSHB-CT-2005-518167), The Wellcome Trust (project grant no. 073677/Z/03/Z), and CNPq (Brazil). The authors wish to thank Ms. Anne Dewar for processing the bone marrow samples for histology and Ms. Gill Martin for assistance with the FACS Aria.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007; Bowie MB, 2006, J CLIN INVEST, V116, P2808, DOI 10.1172/JCI28310; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Calandra G, 2008, BONE MARROW TRANSPL, V41, P331, DOI 10.1038/sj.bmt.1705908; Capoccia BJ, 2006, BLOOD, V108, P2438, DOI 10.1182/blood-2006-04-013755; Cashen Amanda F, 2004, Curr Hematol Rep, V3, P406; Colvin GA, 2007, EXP HEMATOL, V35, P96, DOI 10.1016/j.exphem.2006.09.005; Ellis SG, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.09.003; Forster R, 1998, J IMMUNOL, V160, P1522; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x; Hill JM, 2005, J AM COLL CARDIOL, V46, P1643, DOI 10.1016/j.jacc.2005.01.067; Ince H, 2005, CIRCULATION, V112, P3097, DOI 10.1161/CIRCULATIONAHA.105.541433; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365-2796.2007.01844.x; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; LORD BI, 1989, P NATL ACAD SCI USA, V86, P9499, DOI 10.1073/pnas.86.23.9499; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Martin C, 2006, BRIT J HAEMATOL, V134, P326, DOI 10.1111/j.1365-2141.2006.06181.x; McKinstry WJ, 1997, BLOOD, V89, P65, DOI 10.1182/blood.V89.1.65.65_65_71; Meirelles LD, 2003, BRIT J HAEMATOL, V123, P702, DOI 10.1046/j.1365-2141.2003.04669.x; Moore MAS, 2001, ANN NY ACAD SCI, V938, P36; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; RANKIN SM, 2008, CURR OPIN PHARMACOL, V8, P1; Ripa RS, 2006, CIRCULATION, V113, P1983, DOI 10.1161/CIRCULATIONAHA.105.610469; ROBERTS AW, 1995, BLOOD, V86, P1600, DOI 10.1182/blood.V86.4.1600.bloodjournal8641600; Shepherd RM, 2006, BLOOD, V108, P3662, DOI 10.1182/blood-2006-06-030577; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Uchida N, 1997, BLOOD, V89, P465, DOI 10.1182/blood.V89.2.465; Wengner AM, 2008, BLOOD, V111, P42, DOI 10.1182/blood-2007-07-099648; Wilson A, 2007, ANN NY ACAD SCI, V1106, P64, DOI 10.1196/annals.1392.021; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoon CH, 2005, CIRCULATION, V112, P1618, DOI 10.1161/CIRCULATIONAHA.104.503433; ZOHINHOFER D, 2006, JAMA-J AM MED ASSOC, V295, P1003	43	231	250	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JAN 9	2009	4	1					62	72		10.1016/j.stem.2008.10.017	http://dx.doi.org/10.1016/j.stem.2008.10.017			11	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	395YN	19128793	Green Submitted, Bronze			2023-01-03	WOS:000262559500012
J	Ischenko, I; Camaj, P; Seeliger, H; Kleespies, A; Guba, M; De Toni, EN; Schwarz, B; Graeb, C; Eichhorn, ME; Jauch, KW; Bruns, CJ				Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; De Toni, E. N.; Schwarz, B.; Graeb, C.; Eichhorn, M. E.; Jauch, K-W; Bruns, C. J.			Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling	ONCOGENE			English	Article						5-fluorouracil; acquired resistance; thymidylate synthase; Src kinase inhibition; mouse xenograft pancreatic tumor model; epidermal growth factor receptor	THYMIDYLATE SYNTHASE INHIBITORS; COLORECTAL-CANCER CELLS; DIHYDROPYRIMIDINE DEHYDROGENASE; FAMILY KINASES; TUMOR-CELLS; STEM-CELLS; EXPRESSION; RESISTANCE; PROTEIN; DNA	Resistance to chemotherapy is believed to be a major cause of treatment failure in pancreatic cancer. Thus, it is necessary to explore alternative therapeutic modalities to overcome drug resistance in pancreatic cancer treatment. We tested the hypothesis that Src tyrosine kinase inhibition could augment the chemosensitivity of 5-fluorouracil (5-FU)-resistant human pancreatic cancer cells to 5-FU. As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU_Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells. Furthermore, when small-interfering RNA approach to silence Src gene expression was applied, the degree of 5-FU-induced apoptosis was increased in all cell lines independently of the chemoresistance status. Western blotting and RT-PCR analysis revealed that the expression of thymidylate synthase (TS) was higher in 5-FU-resistant cells, however, decreased significantly after pretreatment with PP2. Furthermore, the combination of 5-FU_PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway. Finally, PP2 in combination with 5-FU substantially decreased the in vivo tumor growth and inhibited distant metastases. Taken together, 5-FU chemoresistance can be reversed through indirect TS regulation by inhibiting Src tyrosine kinase. A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation.	[Ischenko, I.; Camaj, P.; Seeliger, H.; Kleespies, A.; Guba, M.; Schwarz, B.; Graeb, C.; Eichhorn, M. E.; Jauch, K-W; Bruns, C. J.] Univ Munich, Dept Surg, D-81377 Munich, Germany; [De Toni, E. N.] Univ Munich, Dept Gastroenterol, D-81377 Munich, Germany	University of Munich; University of Munich	Ischenko, I (corresponding author), Univ Munich, Dept Surg, Grosshadern Campus,Marchioninistr 15, D-81377 Munich, Germany.	Ivan.Ischenko@med.uni-muenchen.de	Eichhorn, Martin/AAU-7204-2020; Guba, Markus/M-4309-2019; Ischenko, Ivan/A-4591-2011; Eichhorn, Martin/GRE-9126-2022; De Toni, Enrico N/C-6496-2008	Eichhorn, Martin/0000-0002-0362-0374; 	Deutsche Forschungsgemeinschaft (DFG) [KFO 128/1-3]; Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm [GU 489/3-1]	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm(German Research Foundation (DFG))	We thank AstraZeneca for providing with AZM475271. This research was supported by the grant of the clinical research group KFO 128/1-3 of the Deutsche Forschungsgemeinschaft (DFG) and the research grant GU 489/3-1 of the Deutsche Forschungsgemeinschaft (DFG) of the Schwerpunktprogramm 'The tumor-vessel interface'. This report includes data that were generated during the doctoral thesis of Bettina Schwarz at the Medical School of the Ludwig-Maximilians-University, Munich.	BECK A, 1994, EUR J CANCER, V30A, P1517, DOI 10.1016/0959-8049(94)00216-R; Blaszkowsky Lawrence, 1998, Frontiers in Bioscience, V3, pE214; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Chu E, 1996, BIOESSAYS, V18, P191, DOI 10.1002/bies.950180306; Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Crnogorac-Jurcevic T, 2001, ONCOGENE, V20, P7437, DOI 10.1038/sj.onc.1204935; DECAPRIO JA, 1991, J CLIN ONCOL, V9, P2128, DOI 10.1200/JCO.1991.9.12.2128; Duxbury MS, 2004, CLIN CANCER RES, V10, P2307, DOI 10.1158/1078-0432.CCR-1183-3; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Ghoshal K, 1997, BIOCHEM PHARMACOL, V53, P1569, DOI 10.1016/S0006-2952(97)00040-3; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Hamaji Masayasu, 2002, Gan To Kagaku Ryoho, V29, P889; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; JOHNSTON PG, 1995, CANCER RES, V55, P1407; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kleespies A, 2006, DRUG RESIST UPDATE, V9, P1, DOI 10.1016/j.drup.2006.02.002; Koizumi F, 2004, INT J CANCER, V108, P464, DOI 10.1002/ijc.11539; KOLLMANNSBERGER C, 1996, CANCER, V78, P654; LONN U, 1984, CANCER RES, V44, P3414; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MAJOR PP, 1982, CANCER RES, V42, P3005; Masumoto N, 1997, Gan To Kagaku Ryoho, V24, P424; Miyazaki Y, 2001, GASTROENTEROLOGY, V120, P108, DOI 10.1053/gast.2001.20950; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; Nam JS, 2002, CLIN CANCER RES, V8, P2430; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Paul Manash K, 2004, Int J Med Sci, V1, P101; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064; Salonga D, 2000, CLIN CANCER RES, V6, P1322; Shi X, 2002, ONCOLOGY-BASEL, V62, P354, DOI 10.1159/000065068; Summy JM, 2005, PANCREAS, V31, P263, DOI 10.1097/01.mpa.0000178280.50534.0c; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Van Schaeybroeck S, 2005, CLIN CANCER RES, V11, P7480, DOI 10.1158/1078-0432.CCR-05-0328; Voboril R, 2004, J SURG RES, V120, P178, DOI 10.1016/j.jss.2003.11.023; Wang W, 2003, BRIT J CANCER, V88, P624, DOI 10.1038/sj.bjc.6600753; Wang WG, 2003, INT J CANCER, V104, P504, DOI 10.1002/ijc.10972; Wang WG, 2001, CANCER RES, V61, P5505; Wu YP, 1998, INT J ONCOL, V13, P1241; Yezhelyev MV, 2004, CLIN CANCER RES, V10, P8028, DOI 10.1158/1078-0432.CCR-04-0621; Zhao YP, 2006, J SURG RES, V136, P325, DOI 10.1016/j.jss.2006.06.031	47	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7212	7222		10.1038/onc.2008.326	http://dx.doi.org/10.1038/onc.2008.326			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794807				2023-01-03	WOS:000261384100008
J	Morris, BH; Oh, W; Tyson, JE; Stevenson, DK; Phelps, DL; O'Shea, TM; McDavid, GE; Perritt, RL; Van Meurs, KP; Vohr, BR; Grisby, C; Yao, Q; Pedroza, C; Das, A; Poole, WK; Carlo, WA; Duara, S; Laptook, AR; Salhab, WA; Shankaran, S; Poindexter, BB; Fanaroff, AA; Walsh, MC; Rasmussen, MR; Stoll, BJ; Cotten, CM; Donovan, EF; Ehrenkranz, RA; Guillet, R; Higgins, RD				Morris, Brenda H.; Oh, William; Tyson, Jon E.; Stevenson, David K.; Phelps, Dale L.; O'Shea, T. Michael; McDavid, Georgia E.; Perritt, Rebecca L.; Van Meurs, Krisa P.; Vohr, Betty R.; Grisby, Cathy; Yao, Qing; Pedroza, Claudia; Das, Abhik; Poole, W. Kenneth; Carlo, Waldemar A.; Duara, Shahnaz; Laptook, Abbot R.; Salhab, Walid A.; Shankaran, Seetha; Poindexter, Brenda B.; Fanaroff, Avroy A.; Walsh, Michele C.; Rasmussen, Maynard R.; Stoll, Barbara J.; Cotten, C. Michael; Donovan, Edward F.; Ehrenkranz, Richard A.; Guillet, Ronnie; Higgins, Rosemary D.		NICHD Neonatal Res Network	Aggressive vs. conservative phototherapy for infants with extremely low birth weight	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BAYESIAN SUBSET ANALYSIS; PEAK SERUM BILIRUBIN; CLINICAL-TRIALS; NEONATAL HYPERBILIRUBINEMIA; NEURODEVELOPMENTAL OUTCOMES; INTRACRANIAL HEMORRHAGE; PRETERM INFANTS; AGE; KERNICTERUS; CHILDREN	Background: It is unclear whether aggressive phototherapy to prevent neurotoxic effects of bilirubin benefits or harms infants with extremely low birth weight (1000 g or less). Methods: We randomly assigned 1974 infants with extremely low birth weight at 12 to 36 hours of age to undergo either aggressive or conservative phototherapy. The primary outcome was a composite of death or neurodevelopmental impairment determined for 91% of the infants by investigators who were unaware of the treatment assignments. Results: Aggressive phototherapy, as compared with conservative phototherapy, significantly reduced the mean peak serum bilirubin level (7.0 vs. 9.8 mg per deciliter [120 vs. 168 micromol per liter], P<0.01) but not the rate of the primary outcome (52% vs. 55%; relative risk, 0.94; 95% confidence interval [CI], 0.87 to 1.02; P=0.15). Aggressive phototherapy did reduce rates of neurodevelopmental impairment (26%, vs. 30% for conservative phototherapy; relative risk, 0.86; 95% CI, 0.74 to 0.99). Rates of death in the aggressive-phototherapy and conservative-phototherapy groups were 24% and 23%, respectively (relative risk, 1.05; 95% CI, 0.90 to 1.22). In preplanned subgroup analyses, the rates of death were 13% with aggressive phototherapy and 14% with conservative phototherapy for infants with a birth weight of 751 to 1000 g and 39% and 34%, respectively (relative risk, 1.13; 95% CI, 0.96 to 1.34), for infants with a birth weight of 501 to 750 g. Conclusions: Aggressive phototherapy did not significantly reduce the rate of death or neurodevelopmental impairment. The rate of neurodevelopmental impairment alone was significantly reduced with aggressive phototherapy. This reduction may be offset by an increase in mortality among infants weighing 501 to 750 g at birth. (ClinicalTrials.gov number, NCT00114543.).	[Morris, Brenda H.; Tyson, Jon E.; McDavid, Georgia E.] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX 77030 USA; [Oh, William; Vohr, Betty R.; Laptook, Abbot R.] Brown Univ, Women & Infants Hosp, Providence, RI 02912 USA; [Stevenson, David K.; Van Meurs, Krisa P.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Phelps, Dale L.; Guillet, Ronnie] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [O'Shea, T. Michael] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA; [Perritt, Rebecca L.; Yao, Qing; Poole, W. Kenneth] RTI Int, Res Triangle Pk, NC USA; [Grisby, Cathy; Donovan, Edward F.] Univ Cincinnati, Cincinnati, OH USA; [Pedroza, Claudia] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA; [Carlo, Waldemar A.] Univ Alabama, Birmingham, AL USA; [Duara, Shahnaz] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Salhab, Walid A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Shankaran, Seetha] Wayne State Univ, Detroit, MI USA; [Poindexter, Brenda B.] Indiana Univ, James Whitcomb Riley Hosp Children, Indianapolis, IN 46204 USA; [Fanaroff, Avroy A.; Walsh, Michele C.] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Rasmussen, Maynard R.] Univ Calif San Diego, Sharp Mary Birch Hosp Women, San Diego, CA 92103 USA; [Stoll, Barbara J.] Emory Univ, Atlanta, GA 30322 USA; [Cotten, C. Michael] Duke Univ, Durham, NC USA; [Ehrenkranz, Richard A.] Yale Univ, Sch Med, New Haven, CT USA; [Higgins, Rosemary D.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA	University of Texas System; University of Texas Health Science Center Houston; Brown University; Women & Infants Hospital Rhode Island; Stanford University; University of Rochester; Wake Forest University; Research Triangle Institute	Tyson, JE (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat, 6431 Fannin,MSB 3-226, Houston, TX 77030 USA.	jon.e.tyson@uth.tmc.edu	Das, Abhik/AAF-1883-2020	Das, Abhik/0000-0003-2722-0479; Pedroza, Claudia/0000-0003-4235-1282; Hintz, Susan/0000-0001-7023-4433	National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Natus; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021364, U10HD027880, U10HD027853, U10HD021373, U10HD027871, U10HD034216, U10HD021385, U10HD027904, U10HD040492, U10HD027856, U10HD027851, U10HD040461, U10HD040689] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD040521, U10HD040498, U10HD021397, U01HD036790] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024148, UL1RR024128, M01RR008084, KL2RR024149, M01RR006022, M01RR016587, M01RR007122] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Natus(National University of Singapore); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by grants from the National Institutes of Health and from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, which provided overall oversight for study conduct. All data analyses and interpretation were done independently of the funding agency. Natus Medical loaned light-emitting diode phototherapy lights to each center. These lights were used at the discretion of the attending neonatologist in treating infants in either treatment group. The lights were returned to Natus Medical or purchased at a prorated price after the study. Natus Medical played no role in the study design, data collection, data analysis, or manuscript preparation or revision.; Dr. Fanaroff reports receiving consulting fees, and Dr. Guillet grant support, from Natus. No other potential conflict of interest relevant to this article was reported.; We thank our medical and nursing colleagues and the infants and their parents.	Ahlfors CE, 2000, J PEDIATR-US, V137, P540, DOI 10.1067/mpd.2000.108566; BAYLEY N, 1993, BAYLEY SCALES INFANT, V2; Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927; BOGGS TR, 1967, J PEDIATR-US, V71, P553, DOI 10.1016/S0022-3476(67)80107-0; BRATLID D, 1990, CLIN PERINATOL, V17, P449, DOI 10.1016/S0095-5108(18)30578-5; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; BROWN AK, 1985, PEDIATRICS, V75, P393; CASHORE WJ, 1990, CLIN PERINATOL, V17, P437, DOI 10.1016/S0095-5108(18)30577-3; DeMets DL, 1999, LANCET, V354, P1983, DOI 10.1016/S0140-6736(99)03464-9; DIXON DO, 1994, BIOMETRICS, V50, P322; DIXON DO, 1991, BIOMETRICS, V47, P871, DOI 10.2307/2532645; GOPINATHAN V, 1994, FEBS LETT, V349, P197, DOI 10.1016/0014-5793(94)00666-0; GRAZIANI LJ, 1992, PEDIATRICS, V89, P229; Hack M, 2000, ARCH PEDIAT ADOL MED, V154, P725, DOI 10.1001/archpedi.154.7.725; Hintz SR, 1999, PEDIATR RES, V45, P54, DOI 10.1203/00006450-199901000-00009; JADAD AR, 2007, RANDOMIZED CONTROLLE, P13; Lilford RJ, 1995, BMJ-BRIT MED J, V311, P1621, DOI 10.1136/bmj.311.7020.1621; LIPSITZ PJ, 1985, PEDIATRICS, V75, P422; LUCEY JF, 1982, PEDIATRICS, V69, P381; Maisels MJ, 2001, CARE HIGH RISK NEONA, P324; Oh W, 2003, PEDIATRICS, V112, P773, DOI 10.1542/peds.112.4.773; OSHEA TM, 1992, PEDIATRICS, V90, P888; Oxman A, 2002, USERS GUIDES INTERAC; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; R Development Core Team, 2007, R LANG ENV STAT COMP; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SCHEIDT PC, 1990, PEDIATRICS, V85, P455; SCHEIDT PC, 1977, J PEDIATR-US, V91, P292, DOI 10.1016/S0022-3476(77)80835-4; Simon R, 2002, STAT MED, V21, P2909, DOI 10.1002/sim.1295; SIMON RM, 1995, RECENT ADV CLIN TRIA, P155; SINCLAIR JC, 1992, EFFECTIVE CARE NEWBO, P532; SISSON TRC, 1987, FASEB J, V46, P1883; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; TOZZI E, 1989, BIOL NEONATE, V56, P204; Tyson JE, 2008, NEW ENGL J MED, V358, P1672, DOI 10.1056/NEJMoa073059; VANDEBOR M, 1989, PEDIATRICS, V83, P915; Vohr BR, 2005, PEDIATRICS, V116, P635, DOI 10.1542/peds.2004-2247; Vreman HJ, 2004, SEMIN PERINATOL, V28, P326, DOI 10.1053/j.semperi.2004.09.003; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; WATCHKO JF, 1992, PEDIATRICS, V90, P707; Wong RJ, 2007, NEOREVIEWS, V8, pe77, DOI DOI 10.1542/NEO.8-2-E77; Yeo KL, 1998, PEDIATRICS, V102, P1426, DOI 10.1542/peds.102.6.1426	42	147	152	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 30	2008	359	18					1885	1896		10.1056/NEJMoa0803024	http://dx.doi.org/10.1056/NEJMoa0803024			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	366BL	18971491	Green Accepted			2023-01-03	WOS:000260454500005
J	Wiener, RS; Wiener, DC; Larson, RJ				Soylemez Wiener, Renda; Wiener, Daniel C.; Larson, Robin J.			Benefits and risks of tight glucose control in critically ill adults - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE INSULIN THERAPY; RANDOMIZED CONTROLLED-TRIAL; SURVIVING SEPSIS CAMPAIGN; GLYCEMIC CONTROL; BLOOD-GLUCOSE; MYOCARDIAL-INFARCTION; ISCHEMIC-STROKE; CARE PRACTICE; MANAGEMENT; HYPERGLYCEMIA	Context The American Diabetes Association and Surviving Sepsis Campaign recommend tight glucose control in critically ill patients based largely on 1 trial that shows decreased mortality in a surgical intensive care unit. Because similar studies report conflicting results and tight glucose control can cause dangerous hypoglycemia, the data underlying this recommendation should be critically evaluated. Objective To evaluate benefits and risks of tight glucose control vs usual care in critically ill adult patients. Data Sources MEDLINE ( 1950- 2008), the Cochrane Library, clinical trial registries, reference lists, and abstracts from conferences from both the American Thoracic Society ( 2001- 2008) and the Society of Critical Care Medicine ( 2004- 2008). Study Selection We searched for studies in any language in which adult intensive care patients were randomly assigned to tight vs usual glucose control. Of 1358 identified studies, 34 randomized trials ( 23 full publications, 9 abstracts, 2 unpublished studies) met inclusion criteria. Data Extraction and Analysis Two reviewers independently extracted information using a prespecified protocol and evaluated methodological quality with a standardized scale. Study investigators were contacted for missing details. We used both random- and fixed- effects models to estimate relative risks ( RRs). Results Twenty- nine randomized controlled trials totaling 8432 patients contributed data for this meta- analysis. Hospital mortality did not differ between tight glucose control and usual care overall ( 21.6% vs 23.3%; RR, 0.93; 95% confidence interval [ CI], 0.85- 1.03). There was also no significant difference in mortality when stratified by glucose goal ([ 1] very tight: <= 110 mg/ dL; 23% vs 25.2%; RR, 0.90; 95% CI, 0.77- 1.04; or [ 2] moderately tight: < 150 mg/ dL; 17.3% vs 18.0%; RR, 0.99; 95% CI, 0.83- 1.18) or intensive care unit setting ([ 1] surgical: 8.8% vs 10.8%; RR, 0.88; 95% CI, 0.63- 1.22; [ 2] medical: 26.9% vs 29.7%; RR, 0.92; 95% CI, 0.82- 1.04; or [ 3] medical- surgical: 26.1% vs 27.0%; RR, 0.95; 95% CI, 0.80- 1.13). Tight glucose control was not associated with significantly decreased risk for new need for dialysis ( 11.2% vs 12.1%; RR, 0.96; 95% CI, 0.76- 1.20), but was associated with significantly decreased risk of septicemia ( 10.9% vs 13.4%; RR, 0.76; 95% CI, 0.59- 0.97), and significantly increased risk of hypoglycemia ( glucose <= 40 mg/ dL; 13.7% vs 2.5%; RR, 5.13; 95% CI, 4.09- 6.43). Conclusion In critically ill adult patients, tight glucose control is not associated with significantly reduced hospital mortality but is associated with an increased risk of hypoglycemia.	[Soylemez Wiener, Renda; Larson, Robin J.] Dept Vet Affairs Med Ctr, VA Outcomes Grp, White River Jct, VT 05009 USA; [Soylemez Wiener, Renda; Larson, Robin J.] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA; [Wiener, Daniel C.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	VA Outcomes Group; Dartmouth College; Dartmouth College	Wiener, RS (corresponding author), Dept Vet Affairs Med Ctr, VA Outcomes Grp, 111 B, White River Jct, VT 05009 USA.	renda.s.wiener@dartmouth.edu	Wiener, Renda/AAO-1557-2020	Wiener, Renda/0000-0001-7712-2135				*AACE DIAB MELL CL, 2007, ENDOCR PRACT S1, V13, P1; Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08-S012; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; Arabi Y, 2006, CRIT CARE MED, V34, pA65, DOI 10.1097/00003246-200612002-00227; Aragon D, 2006, AM J CRIT CARE, V15, P370, DOI 10.4037/ajcc2006.15.4.370; Bellomo R, 2005, MAYO CLIN PROC, V80, P1546, DOI 10.4065/80.12.1546; Benito B, 2008, MED CLIN-BARCELONA, V130, P601, DOI 10.1157/13120338; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bilotta Federico, 2007, J Neurosurg Anesthesiol, V19, P156, DOI 10.1097/ANA.0b013e3180338e69; Bland DK, 2005, AM J CRIT CARE, V14, P370; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bruno A, 2008, STROKE, V39, P384, DOI 10.1161/STROKEAHA.107.493544; DAVIES RR, 1991, SCOT MED J, V36, P74, DOI 10.1177/003693309103600303; DELAROSA GD, 2006, INTENS CARE MED, pS237; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Dellinger RP, 2004, INTENS CARE MED, V30, P536, DOI 10.1007/s00134-004-2210-z; Farah R, 2007, ISRAEL MED ASSOC J, V9, P140; FERNANDEZ R, 2005, P AM THORAC SOC, V2, pA37; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Grey Neil J, 2004, Endocr Pract, V10 Suppl 2, P46; He Wei, 2007, Zhonghua Wai Ke Za Zhi, V45, P1052; HENDERSON WR, 2005, P AM THORAC SOC, V2, pA37; Hirshberg E, 2008, CHEST, V133, P1328, DOI 10.1378/chest.07-2702; Hoedemaekers CW, 2005, CRIT CARE, V9, pR790, DOI 10.1186/cc3911; *I HEALTHC IMPR, IMPL EFF GLUC CONTR; Iapichino G, 2008, INTENS CARE MED, V34, P1843, DOI 10.1007/s00134-008-1158-9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KIA M, 2005, 91 ANN CLIN C AM COL; Mackenzie I, 2005, INTENS CARE MED, V31, P1136, DOI 10.1007/s00134-005-2677-2; MACKENZIE IM, 2005, P AM THORAC SOC, V2, pA295; Malesker MA, 2007, AM J CRIT CARE, V16, P589; Malhotra A, 2006, NEW ENGL J MED, V354, P516, DOI 10.1056/NEJMe058304; McMullin J, 2004, INTENS CARE MED, V30, P798, DOI 10.1007/s00134-004-2242-4; McMullin J, 2007, J CRIT CARE, V22, P112, DOI 10.1016/j.jcrc.2006.08.002; Mechanick JI, 2007, CURR OPIN CLIN NUTR, V10, P193, DOI 10.1097/MCO.0b013e32802b7016; *MICH HLTH SAF COA, TOOLK INT CAR UN IMP; Mitchell Imogen, 2006, Crit Care Resusc, V8, P289; Mitchell I, 2006, INTENS CARE MED, V32, P867, DOI 10.1007/s00134-006-0135-4; Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8; Preiser JC, 2007, INTENS CARE MED, V33, P570, DOI 10.1007/s00134-006-0485-y; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; SABERI AA, 2004, P AM THORAC SOC, V1, pA38; Schultz MJ, 2006, PLOS MED, V3, P2177, DOI 10.1371/journal.pmed.0030456; Schultz MJ, 2006, INTENS CARE MED, V32, P618, DOI 10.1007/s00134-006-0099-4; STECHER A, 2006, EUR TRAUM C MAY 24 2; Stefanidis A, 2002, ACTA CARDIOL, V57, P357, DOI 10.2143/AC.57.5.2005453; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; van Wezel HB, 2006, J CLIN ENDOCR METAB, V91, P4144, DOI 10.1210/jc.2006-1199; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Walters MR, 2006, CEREBROVASC DIS, V22, P116, DOI 10.1159/000093239; Wang Ling-cong, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P748; Yu Wen-kui, 2005, Zhonghua Wai Ke Za Zhi, V43, P29	55	705	743	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					933	944		10.1001/jama.300.8.933	http://dx.doi.org/10.1001/jama.300.8.933			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728267	Bronze			2023-01-03	WOS:000258687100028
J	Cumming, RG; Sherrington, C; Lord, SR; Simpson, JM; Vogler, C; Cameron, ID; Naganathan, V				Cumming, Robert G.; Sherrington, Catherine; Lord, Stephen R.; Simpson, Judy M.; Vogler, Constance; Cameron, Ian D.; Naganathan, Vasi		Prevention Older Peoples Injury Fa	Cluster randomised trial of a targeted multifactorial intervention to prevent falls among older people in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESOURCE UTILIZATION; INPATIENTS; REDUCTION; INJURIES; WARDS	Objective To determine the efficacy of a targeted multifactorial falls prevention programme in elderly care wards with relatively short lengths of stay. Design Cluster randomised trial. Setting 24 elderly care wards in 12 hospitals in Sydney, Australia. Participants 3999 patients, mean age 79 years, with a median hospital stay of seven days. Interventions A nurse and physiotherapist each worked for 25 hours a week for three months in all intervention wards. They provided a targeted multifactorial intervention that included a risk assessment of falls, staff and patient education, drug review, modification of bedside and ward environments, an exercise programme, and alarms for selected patients. Main outcome measure Falls during hospital stay. Results Intervention and control wards were similar at baseline for previous rates of fails and individual patient characteristics. Overall, 381 falls occurred during the study. No difference was found in fall rates during follow-up between intervention and control wards: respectively, 9.26 falls per 1000 bed days and 9.20 falls per 1000 bed days (P=0.96). The incidence rate ratio adjusted for individual lengths of stay and previous fall rates in the ward was 0.96 (95% confidence interval 0.72 to 1.28). Conclusion A targeted multifactorial falls prevention programme was not effective among older people in hospital wards with relatively short lengths of stay. Trial registration Australian New Zealand Clinical Trials Registry ACTRNO 12605000467639.	[Cumming, Robert G.; Naganathan, Vasi] Concord Hosp, Ctr Educ & Res Ageing, Concord, NSW 2139, Australia; [Cumming, Robert G.; Sherrington, Catherine; Simpson, Judy M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; [Sherrington, Catherine] Univ Sydney, Fac Hlth Sci, Lidcombe, Australia; [Sherrington, Catherine; Lord, Stephen R.] Univ New S Wales, Prince Wales Med Res Inst, Kensington, NSW 2033, Australia; [Vogler, Constance] Royal N Shore Hosp, Dept Aged Care & Rehabil, St Leonards, NSW 2065, Australia; [Cameron, Ian D.] Univ Sydney, Rehabil Studies Unit, Ryde, Australia	Concord Repatriation General Hospital; University of Sydney; University of Sydney; Prince Wales Medical Research Institute; University of New South Wales Sydney; Royal North Shore Hospital; University of Sydney	Cumming, RG (corresponding author), Concord Hosp, Ctr Educ & Res Ageing, Concord, NSW 2139, Australia.	bobc@health.usyd.edu.au	Cumming, Robert G/R-1548-2016; Lord, Stephen R/C-9612-2011; Lindley, Richard/B-8148-2013; Sherrington, Catherine/S-9196-2019	Cumming, Robert G/0000-0002-0261-6103; Lindley, Richard/0000-0002-0104-5679; Sherrington, Catherine/0000-0001-8934-4368; Simpson, Judy M/0000-0001-5172-3004; Lord, Stephen R/0000-0002-7111-8802; Naganathan, Vasikaran/0000-0001-7243-0796				*AUSTR COUNC SAF Q, 2005, PREV FALLS HARM FALL; BATES DW, 1995, AM J MED, V99, P137, DOI 10.1016/S0002-9343(99)80133-8; Fonda D, 2006, MED J AUSTRALIA, V184, P379, DOI 10.5694/j.1326-5377.2006.tb00286.x; GILLESPIE LD, 2006, COCHRANE DB SYST REV; Haines TP, 2004, BMJ-BRIT MED J, V328, P676, DOI 10.1136/bmj.328.7441.676; Healey F, 2004, AGE AGEING, V33, P390, DOI 10.1093/ageing/afh130; Hill KD, 2007, AUST HEALTH REV, V31, P471, DOI 10.1071/AH070471; Hitcho EB, 2004, J GEN INTERN MED, V19, P732, DOI 10.1111/j.1525-1497.2004.30387.x; Lord S, 2001, FALLS OLDER PEOPLE R; MAYO NE, 1994, ARCH PHYS MED REHAB, V75, P1302; Nadkarni JB, 2005, GERONTOLOGY, V51, P329, DOI 10.1159/000086370; Oliver D, 2004, AGE AGEING, V33, P122, DOI 10.1093/ageing/afh017; Oliver D, 2007, BRIT MED J, V334, P82, DOI 10.1136/bmj.39049.706493.55; REUBEN DB, 1995, NEW ENGL J MED, V332, P1345, DOI 10.1056/NEJM199505183322007; SHANLEY C, 1998, PUTTING YOUR BEST FO; Thomas EJ, 2000, BRIT MED J, V320, P741, DOI 10.1136/bmj.320.7237.741; Vassallo M, 1998, INT J CLIN PRACT, V52, P233; Vassallo M, 2000, INT J CLIN PRACT, V54, P654; Vassallo M, 2004, J AM GERIATR SOC, V52, P335, DOI 10.1111/j.1532-5415.2004.52102.x; Vassallo M, 2003, AGE AGEING, V32, P338, DOI 10.1093/ageing/32.3.338	20	144	152	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 5	2008	336	7647					758	760B		10.1136/bmj.39499.546030.BE	http://dx.doi.org/10.1136/bmj.39499.546030.BE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	284JW	18332052	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000254703700032
J	Apps, JR; Beattie, RM				Apps, John R.; Beattie, R. Mark			Easily missed? Cow's milk allergy in children	BRITISH MEDICAL JOURNAL			English	Editorial Material							FOOD ALLERGY; CHILDHOOD; INFANTS; PREVENTION; FORMULAS; DISEASES		[Beattie, R. Mark] Southampton Gen Hosp, Paediat Med Unit, Southampton SO16 6YD, Hants, England; [Apps, John R.] N Cent Thames Fdn Sch Barnet & Chase Farm NHS Tru, Acad Fdn Programme, London EN2 8JL, England	University of Southampton; University of London; University College London	Beattie, RM (corresponding author), Southampton Gen Hosp, Paediat Med Unit, Southampton SO16 6YD, Hants, England.	Mark.beattie@suht.swest.nhs.uk		Beattie, Robert Mark/0000-0003-4721-0577				Eggesbo M, 2001, J PEDIATR-US, V139, P583, DOI 10.1067/mpd.2001.117067; Garrison MM, 2000, PEDIATRICS, V106, P184; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Heine RG, 2002, CURR OPIN ALLERGY CL, V2, P217, DOI 10.1097/00130832-200206000-00011; Host A, 1999, ARCH DIS CHILD, V81, P80, DOI 10.1136/adc.81.1.80; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; Host A, 2002, ANN ALLERG ASTHMA IM, V89, P33, DOI 10.1016/S1081-1206(10)62120-5; LUCCASSEN PLB, 1998, BRIT MED J, V316, P1563; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; McLean-Tooke APC, 2003, BMJ-BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Medeiros Lilian C. S., 2004, J. Pediatr. (Rio J.), V80, P363, DOI 10.1590/S0021-75572004000600006; Muraro A, 2004, PEDIAT ALLERG IMM-UK, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; National Institute for Health and Clinical Excellence, 2007, AT ECZ CHILD MAN AT; Salvatore S, 2002, PEDIATRICS, V110, P972, DOI 10.1542/peds.110.5.972; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2003, PEDIATRICS, V111, P1609; Vandenplas Y, 2007, ARCH DIS CHILD, V92, P902, DOI 10.1136/adc.2006.110999	18	13	13	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2009	339								b2275	10.1136/bmj.b2275	http://dx.doi.org/10.1136/bmj.b2275			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	466RB	19578085				2023-01-03	WOS:000267679000001
J	Raizada, N; Chauhan, LS; Babu, BS; Thakur, R; Khera, A; Wares, DF; Sahu, S; Bachani, D; Rewari, BB; Dewan, PK				Raizada, Neeraj; Chauhan, Lakbir Singh; Babu, B. Sai; Thakur, Rahul; Khera, Ajay; Wares, D. Fraser; Sahu, Suvanand; Bachani, D.; Rewari, B. B.; Dewan, Puneet K.			Linking HIV-Infected TB Patients to Cotrimoxazole Prophylaxis and Antiretroviral Treatment in India	PLOS ONE			English	Article								Background: HIV-infected persons suffering from tuberculosis experience high mortality. No programmatic studies from India have documented the delivery of mortality-reducing interventions, such as cotrimoxazole prophylactic treatment (CPT) and antiretroviral treatment (ART). To guide TB-HIV policy in India we studied the effectiveness of delivering CPT and ART to HIV-infected persons treated for tuberculosis in three districts in Andhra Pradesh, India, and evaluated factors associated with death. Methods and Findings: We retrospectively abstracted data for all HIV-infected tuberculosis patients diagnosed from March 2007 through August 2007 using standard treatment outcome definitions. 734 HIV-infected tuberculosis patients were identified; 493 (67%) were males and 569 (80%) were between the ages of 24-44 years. 710 (97%) initiated CPT, and 351 (50%) collected >60% of their monthly cotrimoxazole pouches provided throughout TB treatment. Access to ART was documented in 380 (51%) patients. Overall 130 (17%) patients died during TB treatment. Patients receiving ART were less likely to die (adjusted hazard ratio [HR] 0.4, 95% confidence interval [CI] 0.3-0.6), while males and those with pulmonary TB were more likely to die (HR 1.7, 95% CI 1.1-2.7, and HR 1.9, 95% CI 1.1-3.2 respectively). Conclusions: Among HIV-infected TB patients in India death was common despite the availability of free cotrimoxazole locally and ART from referral centres. Death was strongly associated with the absence of ART during TB treatment. To minimize death, programmes should promote high levels of ART uptake and closely monitor progress in implementation.				dewanp@searo.who.int		Raizada, Neeraj/0000-0003-2116-332X				Akksilp S, 2007, EMERG INFECT DIS, V13, P1001, DOI 10.3201/eid1307.061506; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Boeree MJ, 2005, TROP MED INT HEALTH, V10, P723, DOI 10.1111/j.1365-3156.2005.01433.x; Dheda K, 2004, J INFECT DIS, V190, P1670, DOI 10.1086/424676; El-Sadr WM, 2008, SEMIN RESP CRIT CARE, V29, P525, DOI 10.1055/s-0028-1085703; *GOV IND MIN HLTH, 2008, NACO NEWS NEWSL NAT; *GOV IND MIN HLTH, 2008, NAT FRAM JOINT TB HI; *GOV IND MIN HLTH, 2005, TECHN OP GUID TUB CO; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; Grimwade K, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003508.pub2; Jha P, 2008, NEW ENGL J MED, V358, P1137, DOI 10.1056/NEJMsa0707719; Kolappan C, 2006, B WORLD HEALTH ORGAN, V84, P555, DOI 10.2471/BLT.05.022087; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Ministry of Health and Family Welfare Government of India 2008, 2006, HIV SENT SURV HIV ES; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; NACO, 2007, GUIDELINES PREVENTIO; Narain JP, 2004, INDIAN J MED RES, V120, P277; *NAT AIDS CONTR OR, 2007, ANT TREATM GUID AD A; Pednekar MS, 2007, PREV MED, V44, P496, DOI 10.1016/j.ypmed.2007.02.017; Raizada N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002970; Sanguanwongse N, 2008, JAIDS-J ACQ IMM DEF, V48, P181, DOI 10.1097/QAI.0b013e318177594e; Swaminathan S, 2008, NATL MED J INDIA, V21, P3; Swaminathan S, 2006, TROP DOCT, V36, P73, DOI 10.1258/004947506776593387; TRINH TT, 2007, PLOS ONE, V2, pE507; *WHO, 2006, GUID COTR PROP HIV R; *WHO, 2004, INT POL COLL TB HIV; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 2008, GLOB TUB CONTR SURV; Zachariah R, 2003, AIDS, V17, P1053, DOI 10.1097/00002030-200305020-00015	30	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2009	4	6							e5999	10.1371/journal.pone.0005999	http://dx.doi.org/10.1371/journal.pone.0005999			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	461BB	19543396	gold, Green Published, Green Submitted			2023-01-03	WOS:000267237600012
J	Huggett, B; Scott, C				Huggett, Brady; Scott, Christopher			Gilead's deal of a lifetime	NATURE BIOTECHNOLOGY			English	Article																		Danzon PM, 2007, MANAG DECIS ECON, V28, P307, DOI 10.1002/mde.1343; LIM TM, 2006, THESIS CRANFIELD U	2	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	MAY	2009	27	5					423	423		10.1038/nbt0509-423	http://dx.doi.org/10.1038/nbt0509-423			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	444KS	19430443				2023-01-03	WOS:000265980500016
J	You, YN; Short, KR; Jourdan, M; Klaus, KA; Walrand, S; Nair, KS				You, Y. Nancy; Short, Kevin R.; Jourdan, Marion; Klaus, Katherine A.; Walrand, Stephane; Nair, K. Sreekumaran			The Effect of High Glucocorticoid Administration and Food Restriction on Rodent Skeletal Muscle Mitochondrial Function and Protein Metabolism	PLOS ONE			English	Article							MYOSIN HEAVY-CHAIN; SYNTHESIS RATES; OLD RATS; LEUCINE OXIDATION; ATP PRODUCTION; AMINO-ACIDS; STARVATION; TURNOVER; EXERCISE; HUMANS	Background: Glucocorticoids levels are high in catabolic conditions but it is unclear how much of the catabolic effects are due to negative energy balance versus glucocorticoids and whether there are distinct effects on metabolism and functions of specific muscle proteins. Methodology/Principal Findings: We determined whether 14 days of high dose methylprednisolone (MPred, 4 mg/kg/d) Vs food restriction (FR, food intake matched to MPred) in rats had different effects on muscle mitochondrial function and protein fractional synthesis rates (FSR). Lower weight loss (15%) occurred in FR than in MPred (30%) rats, while a 15% increase occurred saline-treated Controls. The per cent muscle loss was significantly greater for MPred than FR. Mitochondrial protein FSR in MPred rats was lower in soleus (51 and 43%, respectively) and plantaris (25 and 55%) than in FR, while similar decline in protein FSR of the mixed, sarcoplasmic, and myosin heavy chain occurred. Mitochondrial enzymatic activity and ATP production were unchanged in soleus while in plantaris cytochrome c oxidase activity was lower in FR than Control, and ATP production rate with pyruvate + malate in MPred plantaris was 28% lower in MPred. Branched-chain amino acid catabolic enzyme activities were higher in both FR and MPred rats indicating enhanced amino acid oxidation capacity. Conclusion/Significance: MPred and FR had little impact on mitochondrial function but reduction in muscle protein synthesis occurred in MPred that could be explained on the basis of reduced food intake. A greater decline in proteolysis may explain lesser muscle loss in FR than in MPred rats.			You, YN (corresponding author), Mayo Clin, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA.	nair.sree@mayo.edu	Short, Kevin R/AAC-2553-2020	Short, Kevin R/0000-0001-6704-9587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041973, T32DK007352] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK41973, R01 DK041973, T32 DK007352, T32-DK07352] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFTRING RP, 1988, AM J PHYSIOL, V254, pE292, DOI 10.1152/ajpendo.1988.254.3.E292; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V273, pE790, DOI 10.1152/ajpendo.1997.273.4.E790; BALAGOPAL P, 1994, ANAL BIOCHEM, V221, P72, DOI 10.1006/abio.1994.1381; Barazzoni R, 2005, ENDOCRINOLOGY, V146, P2098, DOI 10.1210/en.2004-1396; BEAUFRERE B, 1989, AM J PHYSIOL, V257, pE712, DOI 10.1152/ajpendo.1989.257.5.E712; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Boirie Y, 2001, DIABETES, V50, P2652, DOI 10.2337/diabetes.50.12.2652; Cooper AJL, 2002, ANAL BIOCHEM, V308, P100, DOI 10.1016/S0003-2697(02)00243-9; CZERWINSKI SM, 1989, J APPL PHYSIOL, V67, P2311, DOI 10.1152/jappl.1989.67.6.2311; CZERWINSKI SM, 1987, J APPL PHYSIOL, V63, P1504, DOI 10.1152/jappl.1987.63.4.1504; Dardevet D, 1998, J ENDOCRINOL, V156, P83, DOI 10.1677/joe.0.1560083; DARDEVET D, 1995, J CLIN INVEST, V96, P2113, DOI 10.1172/JCI118264; Duclos M, 2004, AM J PHYSIOL-ENDOC M, V286, pE159, DOI 10.1152/ajpendo.00281.2003; EMERY PW, 1995, CLIN SCI, V89, P383, DOI 10.1042/cs0890383; ESSEN P, 1992, CLIN PHYSIOL, V12, P287, DOI 10.1111/j.1475-097X.1992.tb00834.x; Fu AZ, 1998, AM J PHYSIOL-ENDOC M, V275, pE1023, DOI 10.1152/ajpendo.1998.275.6.E1023; HICKSON RC, 1995, AM J PHYSIOL-ENDOC M, V268, pE730, DOI 10.1152/ajpendo.1995.268.4.E730; KELLY FJ, 1986, MUSCLE NERVE, V9, P1, DOI 10.1002/mus.880090102; Koves TR, 2005, J BIOL CHEM, V280, P33588, DOI 10.1074/jbc.M507621200; LIEU FK, 1993, J APPL PHYSIOL, V75, P763, DOI 10.1152/jappl.1993.75.2.763; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Liu ZQ, 2001, J CLIN ENDOCR METAB, V86, P2136, DOI 10.1210/jc.86.5.2136; Ljungqvist OH, 1997, AM J PHYSIOL-ENDOC M, V273, pE564, DOI 10.1152/ajpendo.1997.273.3.E564; Lofberg E, 2002, EUR J CLIN INVEST, V32, P345, DOI 10.1046/j.1365-2362.2002.00993.x; LOUARD RJ, 1994, J CLIN ENDOCR METAB, V79, P278, DOI 10.1210/jc.79.1.278; MAGNUSSON K, 1990, METABOLISM, V39, P1113, DOI 10.1016/0026-0495(90)90080-V; MARONE JR, 1994, J APPL PHYSIOL, V77, P1685; Minet-Quinard R, 2000, JPEN-PARENTER ENTER, V24, P30, DOI 10.1177/014860710002400130; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Mittendorfer B, 2005, J PHYSIOL-LONDON, V563, P203, DOI 10.1113/jphysiol.2004.077180; PAULSON JC, 1954, J AM CHEM SOC, V76, P6198, DOI 10.1021/ja01652a104; POLLA B, 1994, ACTA PHYSIOL SCAND, V151, P353, DOI 10.1111/j.1748-1716.1994.tb09754.x; QUAN ZY, 1991, METABOLISM, V40, P1263, DOI 10.1016/0026-0495(91)90026-S; Rieu I, 2004, EXP GERONTOL, V39, P1315, DOI 10.1016/j.exger.2004.06.005; Robinson JB., 1987, MITOCHONDRIA PRACTIC, P153, DOI DOI 10.1016/J.BBRC.2005.02.135; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; Rooyackers OE, 1997, MUSCLE NERVE, pS93; Savary I, 1998, BRIT J NUTR, V79, P297, DOI 10.1079/BJN19980047; SHERWIN RS, 1978, J CLIN INVEST, V61, P1471, DOI 10.1172/JCI109067; Shimomura Y, 2001, CURR OPIN CLIN NUTR, V4, P419, DOI 10.1097/00075197-200109000-00013; Short KR, 2007, AM J PHYSIOL-ENDOC M, V292, pE642, DOI 10.1152/ajpendo.00397.2006; Short KR, 2004, J CLIN ENDOCR METAB, V89, P6198, DOI 10.1210/jc.2004-0908; Short KR, 2001, AM J PHYSIOL-ENDOC M, V280, pE761, DOI 10.1152/ajpendo.2001.280.5.E761; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Weber K, 2002, ENDOCRINOLOGY, V143, P177, DOI 10.1210/en.143.1.177; WIBOM R, 1990, SCAND J CLIN LAB INV, V50, P143, DOI 10.3109/00365519009089146; Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668	48	15	16	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2009	4	4							e5283	10.1371/journal.pone.0005283	http://dx.doi.org/10.1371/journal.pone.0005283			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437UZ	19381333	Green Submitted, Green Published, gold			2023-01-03	WOS:000265513700003
J	Busan, P; Barbera, C; Semenic, M; Monti, F; Pizzolato, G; Pelamatti, G; Battaglini, PP				Busan, Pierpaolo; Barbera, Claudia; Semenic, Mauro; Monti, Fabrizio; Pizzolato, Gilberto; Pelamatti, Giovanna; Battaglini, Piero Paolo			Effect of Transcranial Magnetic Stimulation (TMS) on Parietal and Premotor Cortex during Planning of Reaching Movements	PLOS ONE			English	Article							MEDIAL PARIETOOCCIPITAL CORTEX; MACAQUE MONKEY; AREA V6A; CORTICAL MECHANISMS; DORSAL PREMOTOR; EYE; SYSTEM; BRAIN; SELECTION; PATHWAYS	Background: Cerebral activation during planning of reaching movements occurs both in the superior parietal lobule (SPL) and premotor cortex (PM), and their activation seems to take place in parallel. Methodology: The activation of the SPL and PM has been investigated using transcranial magnetic stimulation (TMS) during planning of reaching movements under visual guidance. Principal Findings: A facilitory effect was found when TMS was delivered on the parietal cortex at about half of the time from sight of the target to hand movement, independently of target location in space. Furthermore, at the same stimulation time, a similar facilitory effect was found in PM, which is probably related to movement preparation. Conclusions: This data contributes to the understanding of cortical dynamics in the parieto-frontal network, and suggests that it is possible to interfere with the planning of reaching movements at different cortical points within a particular time window. Since similar effects may be produced at similar times on both the SPL and PM, parallel processing of visuomotor information is likely to take place in these regions.	[Busan, Pierpaolo; Battaglini, Piero Paolo] Univ Trieste, Dept Life Sci, BRAIN Ctr Neurosci, Trieste, Italy; [Barbera, Claudia; Pelamatti, Giovanna] Univ Trieste, Dept Psychol, I-34127 Trieste, Italy; [Semenic, Mauro; Monti, Fabrizio; Pizzolato, Gilberto] Univ Trieste, Dept Clin & Expt Med & Clin & Expt Neurosci, I-34127 Trieste, Italy	University of Trieste; University of Trieste; University of Trieste	Busan, P (corresponding author), Univ Trieste, Dept Life Sci, BRAIN Ctr Neurosci, Trieste, Italy.	busan@dfp.units.it		Battaglini, Piero Paolo/0000-0003-4697-8648	Ministero dell'Universita, Italy	Ministero dell'Universita, Italy	This work was supported by grants from the Ministero dell'Universita, Italy.	Anand S, 2002, BRAIN COGNITION, V50, P366, DOI 10.1016/S0278-2626(02)00512-2; Battaglia-Mayer A, 2007, CEREB CORTEX, V17, P1350, DOI 10.1093/cercor/bhl046; Buneo CA, 2008, EXP BRAIN RES, V188, P77, DOI 10.1007/s00221-008-1340-x; Caminiti R, 1998, CURR OPIN NEUROBIOL, V8, P753, DOI 10.1016/S0959-4388(98)80118-9; Connolly JD, 2000, J NEUROPHYSIOL, V84, P1645, DOI 10.1152/jn.2000.84.3.1645; Cui H, 2007, NEURON, V56, P552, DOI 10.1016/j.neuron.2007.09.031; Davare M, 2006, J NEUROSCI, V26, P2260, DOI 10.1523/JNEUROSCI.3386-05.2006; Duvernoy H.M., 1999, HUMAN BRAIN SURFACE; Fattori P, 2005, EUR J NEUROSCI, V22, P956, DOI 10.1111/j.1460-9568.2005.04288.x; Fattori P, 2001, EUR J NEUROSCI, V13, P2309, DOI 10.1046/j.0953-816x.2001.01618.x; Favilla M, 1996, NEUROPSYCHOLOGIA, V34, P609, DOI 10.1016/0028-3932(95)00135-2; Galletti C, 2003, EXP BRAIN RES, V153, P158, DOI 10.1007/s00221-003-1589-z; Galletti C, 1997, EUR J NEUROSCI, V9, P410, DOI 10.1111/j.1460-9568.1997.tb01410.x; Galletti C, 1999, EUR J NEUROSCI, V11, P575, DOI 10.1046/j.1460-9568.1999.00467.x; Grosbras MH, 2003, EUR J NEUROSCI, V18, P3121, DOI 10.1111/j.1460-9568.2003.03055.x; Herwig U, 2003, BRAIN TOPOGR, V16, P95, DOI 10.1023/B:BRAT.0000006333.93597.9d; Himmelbach M, 2006, NEUROPSYCHOLOGIA, V44, P2749, DOI 10.1016/j.neuropsychologia.2006.04.030; Johnson SH, 2003, PROG BRAIN RES, V142, P127; Kalaska JF, 1998, NOVART FDN SYMP, V218, P176; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; Kalaska JF, 1997, CURR OPIN NEUROBIOL, V7, P849, DOI 10.1016/S0959-4388(97)80146-8; Koch G, 2006, J NEUROSCI, V26, P7452, DOI 10.1523/JNEUROSCI.1158-06.2006; Marconi B, 2001, CEREB CORTEX, V11, P513, DOI 10.1093/cercor/11.6.513; Mars RB, 2007, CEREB CORTEX, V17, P2972, DOI 10.1093/cercor/bhm022; Matelli M, 2001, NEUROIMAGE, V14, pS27, DOI 10.1006/nimg.2001.0835; Mayer AB, 1998, EXP BRAIN RES, V123, P172, DOI 10.1007/s002210050559; Milner A.D., 2006, VISUAL BRAIN ACTION, Vsecond; Mottaghy FM, 2006, BEHAV NEUROL, V17, P177, DOI 10.1155/2006/768413; Naranjo JR, 2007, NEUROIMAGE, V34, P1673, DOI 10.1016/j.neuroimage.2006.07.049; Okamoto M, 2004, NEUROIMAGE, V21, P99, DOI 10.1016/j.neuroimage.2003.08.026; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Prado J, 2005, NEURON, V48, P849, DOI 10.1016/j.neuron.2005.10.010; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; Rizzolatti G, 1997, CURR OPIN NEUROBIOL, V7, P562, DOI 10.1016/S0959-4388(97)80037-2; Roth Y, 2007, J CLIN NEUROPHYSIOL, V24, P31, DOI 10.1097/WNP.0b013e31802fa393; Ryan S, 2006, EXP BRAIN RES, V173, P389, DOI 10.1007/s00221-006-0379-9; Sawaki L, 1999, EXP BRAIN RES, V127, P402, DOI 10.1007/s002210050808; Schluter ND, 1998, BRAIN, V121, P785, DOI 10.1093/brain/121.5.785; Silvanto J, 2008, NEUROIMAGE, V39, P549, DOI 10.1016/j.neuroimage.2007.09.008; Silvanto J, 2008, J NEUROPHYSIOL, V99, P2725, DOI 10.1152/jn.01392.2007; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Tanne J, 1995, NEUROREPORT, V7, P267, DOI 10.1097/00001756-199512000-00064; Tanne-Gariepy J, 2002, EXP BRAIN RES, V145, P91, DOI 10.1007/s00221-002-1078-9; Thielscher A, 2004, CLIN NEUROPHYSIOL, V115, P1697, DOI 10.1016/j.clinph.2004.02.019; Topper R, 1998, EXP BRAIN RES, V121, P371, DOI 10.1007/s002210050471; Walsh V, 2003, BRADFORD BOOKS, P1	46	35	35	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2009	4	2							e4621	10.1371/journal.pone.0004621	http://dx.doi.org/10.1371/journal.pone.0004621			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437LA	19247490	Green Published, gold, Green Submitted			2023-01-03	WOS:000265487800004
J	Sacks, FM; Bray, GA; Carey, VJ; Smith, SR; Ryan, DH; Anton, SD; McManus, K; Champagne, CM; Bishop, LM; Laranjo, N; Leboff, MS; Rood, JC; de Jonge, L; Greenway, FL; Loria, CM; Obarzanek, E; Williamson, DA				Sacks, Frank M.; Bray, George A.; Carey, Vincent J.; Smith, Steven R.; Ryan, Donna H.; Anton, Stephen D.; McManus, Katherine; Champagne, Catherine M.; Bishop, Louise M.; Laranjo, Nancy; Leboff, Meryl S.; Rood, Jennifer C.; de Jonge, Lilian; Greenway, Frank L.; Loria, Catherine M.; Obarzanek, Eva; Williamson, Donald A.			Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; RANDOMIZED-TRIAL; MONOUNSATURATED FAT; BODY-COMPOSITION; GLYCEMIC LOAD; OBESE ADULTS; DISEASE RISK; VEGAN DIET; MAINTENANCE; OVERWEIGHT	Background: The possible advantage for weight loss of a diet that emphasizes protein, fat, or carbohydrates has not been established, and there are few studies that extend beyond 1 year. Methods: We randomly assigned 811 overweight adults to one of four diets; the targeted percentages of energy derived from fat, protein, and carbohydrates in the four diets were 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%. The diets consisted of similar foods and met guidelines for cardiovascular health. The participants were offered group and individual instructional sessions for 2 years. The primary outcome was the change in body weight after 2 years in two-by-two factorial comparisons of low fat versus high fat and average protein versus high protein and in the comparison of highest and lowest carbohydrate content. Results: At 6 months, participants assigned to each diet had lost an average of 6 kg, which represented 7% of their initial weight; they began to regain weight after 12 months. By 2 years, weight loss remained similar in those who were assigned to a diet with 15% protein and those assigned to a diet with 25% protein (3.0 and 3.6 kg, respectively); in those assigned to a diet with 20% fat and those assigned to a diet with 40% fat (3.3 kg for both groups); and in those assigned to a diet with 65% carbohydrates and those assigned to a diet with 35% carbohydrates (2.9 and 3.4 kg, respectively) (P>0.20 for all comparisons). Among the 80% of participants who completed the trial, the average weight loss was 4 kg; 14 to 15% of the participants had a reduction of at least 10% of their initial body weight. Satiety, hunger, satisfaction with the diet, and attendance at group sessions were similar for all diets; attendance was strongly associated with weight loss (0.2 kg per session attended). The diets improved lipid-related risk factors and fasting insulin levels. Conclusions: Reduced-calorie diets result in clinically meaningful weight loss regardless of which macronutrients they emphasize. (ClinicalTrials.gov number, NCT00072995.) N Engl J Med 2009;360:859-73.	[Sacks, Frank M.; Bishop, Louise M.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Sacks, Frank M.; Carey, Vincent J.; Laranjo, Nancy] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Leboff, Meryl S.] Brigham & Womens Hosp, Dept Med, Div Endocrine, Boston, MA USA; [McManus, Katherine] Harvard Univ, Sch Med, Boston, MA USA; [McManus, Katherine] Brigham & Womens Hosp, Dept Nutr, Boston, MA 02115 USA; [Bray, George A.; Smith, Steven R.; Ryan, Donna H.; Anton, Stephen D.; Champagne, Catherine M.; Rood, Jennifer C.; de Jonge, Lilian; Greenway, Frank L.; Williamson, Donald A.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA USA; [Loria, Catherine M.; Obarzanek, Eva] NHLBI, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sacks, FM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.		Rood, Jennifer/N-1989-2017; Champagne, Catherine/N-1956-2017; Smith, Steven/HDM-9496-2022; Biguzzi, Felipe A/E-4724-2015; Greenway, Frank/N-1966-2017	Rood, Jennifer/0000-0001-5848-2987; Champagne, Catherine/0000-0001-6127-1072; Greenway, Frank/0000-0002-1766-6111; Ryan, Donna/0000-0001-8374-2277; Smith, Steven/0000-0002-5098-8147; de Jonge, Lilian/0000-0001-5900-0695	National Heart, Lung, and Blood Institute [HL073286]; General Clinical Research Center, National Institutes of Health [RR-02635]; Anian; Bristol-Myers Squibb; Clarus Health; Encore Pharmaceutical; Leptos Biomedical; MDRNA; Nuovo Nordisk; General Nutrition Corporation; Catalyst; Jenny Craig; Orexigen; Lithera; Basic Research; BAROnova; Lazard; Biologene; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL073286] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476, P30DK040561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); General Clinical Research Center, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Anian; Bristol-Myers Squibb(Bristol-Myers Squibb); Clarus Health; Encore Pharmaceutical; Leptos Biomedical; MDRNA; Nuovo Nordisk; General Nutrition Corporation; Catalyst; Jenny Craig; Orexigen; Lithera; Basic Research; BAROnova; Lazard; Biologene; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the National Heart, Lung, and Blood Institute (HL073286) and the General Clinical Research Center, National Institutes of Health (RR-02635). Dr. Greenway reports receiving consulting fees from or serving on a paid advisory board for Anian, Bristol-Myers Squibb, Clarus Health, Encore Pharmaceutical, Leptos Biomedical, MDRNA, Nuovo Nordisk, General Nutrition Corporation, Catalyst, Jenny Craig, Orexigen, Lithera, and Basic Research, receiving lecture fees from BAROnova, Lazard, and Biologene, and owning equity in Lithera. No other potential conflict of interest relevant to this article was reported.	BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Barnard ND, 2006, DIABETES CARE, V29, P1777, DOI 10.2337/dc06-0606; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; Champagne CM, 2004, J AM DIET ASSOC, V104, P199, DOI 10.1016/j.jada.2003.11.011; Dansinger ML, 2007, ANN INTERN MED, V147, P41, DOI 10.7326/0003-4819-147-1-200707030-00007; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Das SK, 2007, AM J CLIN NUTR, V85, P1023, DOI 10.1093/ajcn/85.4.1023; de Souza RJ, 2008, AM J CLIN NUTR, V88, P1; Due A, 2004, INT J OBESITY, V28, P1283, DOI 10.1038/sj.ijo.0802767; Flint A, 2000, INT J OBESITY, V24, P38, DOI 10.1038/sj.ijo.0801083; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FREEDMAN M, 2001, OBESITY REV S1, V9, P1, DOI DOI 10.1038/0BY.2001.113; GARDNER CD, 2007, JAMA-J AM MED ASSOC, V298, P178; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Jequier E, 2002, AM J MED, V113, P41, DOI 10.1016/S0002-9343(01)00991-3; Keogh JB, 2007, BRIT J NUTR, V97, P405, DOI 10.1017/S0007114507252687; KINSELL LW, 1964, METABOLISM, V13, P195, DOI 10.1016/0026-0495(64)90098-8; LeCheminant JD, 2007, NUTR J, V6, DOI 10.1186/1475-2891-6-36; Lichtenstein A, 2006, CIRCULATION, V114, pE629, DOI 10.1161/CIRCULATIONAHA.106.180281; Luscombe-Marsh ND, 2005, AM J CLIN NUTR, V81, P762, DOI 10.1093/ajcn/81.4.762; McLaughlin T, 2006, AM J CLIN NUTR, V84, P813, DOI 10.1093/ajcn/84.4.813; McManus K, 2001, INT J OBESITY, V25, P1503, DOI 10.1038/sj.ijo.0801796; McMillan-Price J, 2006, ARCH INTERN MED, V166, P1466, DOI 10.1001/archinte.166.14.1466; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; *NCEP EXP PAN DET, 2002, NIH PUBL; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Ornish D, 1998, JAMA-J AM MED ASSOC, V280, P2001, DOI 10.1001/jama.280.23.2001; Ornish D, 1999, JAMA-J AM MED ASSOC, V281, P1380; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Shai I, 2008, NEW ENGL J MED, V359, P229, DOI 10.1056/NEJMoa0708681; Simons-Morton DG, 2006, JAMA-J AM MED ASSOC, V295, P826, DOI 10.1001/jama.295.7.826; Skov AR, 1999, INT J OBESITY, V23, P528, DOI 10.1038/sj.ijo.0800867; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Svetkey LP, 2008, JAMA-J AM MED ASSOC, V299, P1139, DOI 10.1001/jama.299.10.1139; Toubro S, 1997, BRIT MED J, V314, P29, DOI 10.1136/bmj.314.7073.29; Turner-McGrievy GM, 2007, OBESITY, V15, P2276, DOI 10.1038/oby.2007.270; URBAN N, 1992, PREV MED, V21, P279, DOI 10.1016/0091-7435(92)90027-F; Volek Js, 2004, Nutr Metab (Lond), V1, P13, DOI 10.1186/1743-7075-1-13; Wadden TA, 2001, ARCH INTERN MED, V161, P218, DOI 10.1001/archinte.161.2.218; Willett WC, 2002, AM J MED, V113, P47, DOI 10.1016/S0002-9343(01)00992-5; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	42	1191	1207	6	332	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	2009	360	9					859	873		10.1056/NEJMoa0804748	http://dx.doi.org/10.1056/NEJMoa0804748			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	411CD	19246357	Green Published, Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000263624700004
J	Bonkowski, MS; Dominici, FP; Arum, O; Rocha, JS; Al Regaiey, KA; Westbrook, R; Spong, A; Panici, J; Masternak, MM; Kopchick, JJ; Bartke, A				Bonkowski, Michael S.; Dominici, Fernando P.; Arum, Oge; Rocha, Juliana S.; Al Regaiey, Khalid A.; Westbrook, Reyhan; Spong, Adam; Panici, Jacob; Masternak, Michal M.; Kopchick, John J.; Bartke, Andrzej			Disruption of Growth Hormone Receptor Prevents Calorie Restriction from Improving Insulin Action and Longevity	PLOS ONE			English	Article							LIFE-SPAN; TARGETED DISRUPTION; DIETARY RESTRICTION; GENE; MICE; EXPRESSION; RESISTANCE; MOUSE; YEAST	Most mutations that delay aging and prolong lifespan in the mouse are related to somatotropic and/or insulin signaling. Calorie restriction (CR) is the only intervention that reliably increases mouse longevity. There is considerable phenotypic overlap between long-lived mutant mice and normal mice on chronic CR. Therefore, we investigated the interactive effects of CR and targeted disruption or knock out of the growth hormone receptor (GHRKO) in mice on longevity and the insulin signaling cascade. Every other day feeding corresponds to a mild (i.e. 15%) CR which increased median lifespan in normal mice but not in GHRKO mice corroborating our previous findings on the effects of moderate (30%) CR on the longevity of these animals. To determine why insulin sensitivity improves in normal but not GHRKO mice in response to 30% CR, we conducted insulin stimulation experiments after one year of CR. In normal mice, CR increased the insulin stimulated activation of the insulin signaling cascade (IR/IRS/PI3K/AKT) in liver and muscle. Livers of GHRKO mice responded to insulin by increased activation of the early steps of insulin signaling, which was dissipated by altered PI3K subunit abundance which putatively inhibited AKT activation. In the muscle of GHRKO mice, there was elevated downstream activation of the insulin signaling cascade (IRS/PI3K/AKT) in the absence of elevated IR activation. Further, we found a major reduction of inhibitory Ser phosphorylation of IRS-1 seen exclusively in GHRKO muscle which may underpin their elevated insulin sensitivity. Chronic CR failed to further modify the alterations in insulin signaling in GHRKO mice as compared to normal mice, likely explaining or contributing to the absence of CR effects on insulin sensitivity and longevity in these long-lived mice.	[Bonkowski, Michael S.; Arum, Oge; Rocha, Juliana S.; Al Regaiey, Khalid A.; Westbrook, Reyhan; Spong, Adam; Panici, Jacob; Masternak, Michal M.; Bartke, Andrzej] So Illinois Univ, Sch Med, Dept Internal Med Geriatr Res, Springfield, IL USA; [Bonkowski, Michael S.; Bartke, Andrzej] So Illinois Univ, Sch Med, Dept Pharmacol & Physiol, Springfield, IL USA; [Dominici, Fernando P.] Univ Buenos Aires, Fac Farm & Bioquim, IQUIFIB, RA-1053 Buenos Aires, DF, Argentina; [Rocha, Juliana S.] Univ Fed Minas Gerais, Inst Biol Sci, Dept Morphol, Lab Cellular Biol, Belo Horizonte, MG, Brazil; [Al Regaiey, Khalid A.] King Saud Univ, Coll Med, Dept Physiol, Riyadh, Saudi Arabia; [Kopchick, John J.] Ohio Univ, Edison Biotechnol Inst, Dept Biomed Sci, Athens, OH 45701 USA	Southern Illinois University System; Southern Illinois University; Southern Illinois University System; Southern Illinois University; University of Buenos Aires; Universidade Federal de Minas Gerais; King Saud University; University System of Ohio; Ohio University	Bonkowski, MS (corresponding author), So Illinois Univ, Sch Med, Dept Internal Med Geriatr Res, Springfield, IL USA.	abartke@siumed.edu	Bartke, Andzej/D-6640-2017; Al-Regaiey, Khalid/AAG-4217-2019	Bartke, Andzej/0000-0002-2569-557X; Al-Regaiey, Khalid/0000-0001-9770-5637; Bonkowski, Michael/0000-0003-3416-4612; Dominici, Fernando Pablo/0000-0002-4351-0057	NIA [AG 19899, u19 AG023122]; Ellison Medical Foundation; SIU Geriatrics Medicine Initiative; Ohio's Eminent Scholars Program;  [AG19899-05]; NATIONAL INSTITUTE ON AGING [U19AG023122, R01AG019899] Funding Source: NIH RePORTER	NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Ellison Medical Foundation(Lawrence Ellison Foundation); SIU Geriatrics Medicine Initiative; Ohio's Eminent Scholars Program; ; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This project was supported by NIA, AG 19899 and u19 AG023122, by the Ellison Medical Foundation, and by the SIU Geriatrics Medicine Initiative. JJK is supported in part by the state of Ohio's Eminent Scholars Program that includes a gift from Milton and Lawrence Goll and by AG19899-05. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adochio R, 2009, ENDOCRINOLOGY, V150, P1165, DOI 10.1210/en.2008-0437; Al-Regaiey KA, 2005, ENDOCRINOLOGY, V146, P851, DOI 10.1210/en.2004-1120; Al-Regaiey KA, 2007, J GERONTOL A-BIOL, V62, P18, DOI 10.1093/gerona/62.1.18; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bartke A, 2008, HORM-INT J ENDOCRINO, V7, P17, DOI 10.14310/horm.2002.1111033; Bartke Andrzej, 2007, V35, P69; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Bonkowski MS, 2006, P NATL ACAD SCI USA, V103, P7901, DOI 10.1073/pnas.0600161103; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Coschigano KT, 2003, ENDOCRINOLOGY, V144, P3799, DOI 10.1210/en.2003-0374; de Magalhaes JP, 2005, GENETICS, V169, P265, DOI 10.1534/genetics.104.032292; Dominici FP, 2005, GROWTH HORM IGF RES, V15, P324, DOI 10.1016/j.ghir.2005.07.001; Dominici FP, 2000, J ENDOCRINOL, V166, P579, DOI 10.1677/joe.0.1660579; Gems D, 2002, AGING CELL, V1, P1, DOI 10.1046/j.1474-9728.2002.00003.x; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; Ishizuka T, 2004, ENDOCR RES, V30, P287, DOI 10.1081/ERC-120039580; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; KAHN CR, 2002, MOL CELL BIOL, V22, P965; Kenyon C, 2005, CELL, V120, P449, DOI 10.1016/j.cell.2005.02.002; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Liu H, 2007, ANN INTERN MED, V146, P104, DOI 10.7326/0003-4819-146-2-200701160-00005; Martin B, 2007, ENDOCRINOLOGY, V148, P4318, DOI 10.1210/en.2007-0161; McCurdy CE, 2005, DIABETES, V54, P1349, DOI 10.2337/diabetes.54.5.1349; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Robertson K, 2006, AM J PHYSIOL-ENDOC M, V291, pE491, DOI 10.1152/ajpendo.00378.2005; Sharp ZD, 2005, J GERONTOL A-BIOL, V60, P293, DOI 10.1093/gerona/60.3.293; STROBL JS, 1994, PHARMACOL REV, V46, P1; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Vance ML, 1999, NEW ENGL J MED, V341, P1206, DOI 10.1056/NEJM199910143411607; WEINDRUCH R, 2007, METABOLIC SHIFTS IND, V21; Zhou YH, 1997, P NATL ACAD SCI USA, V94, P13215, DOI 10.1073/pnas.94.24.13215	34	102	103	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2009	4	2							e4567	10.1371/journal.pone.0004567	http://dx.doi.org/10.1371/journal.pone.0004567			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437KU	19234595	Green Submitted, Green Published, gold			2023-01-03	WOS:000265487200018
J	Smith, RD; Correa, C; Oh, C				Smith, Richard D.; Correa, Carlos; Oh, Cecilia			Trade and Health 5 Trade, TRIPS, and pharmaceuticals	LANCET			English	Article							AFFORDABILITY; ACCESS; DRUGS	The World Trade Organization's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) set global minimum standards for the protection of intellectual property, substantially increasing and expanding intellectual-property rights, and generated clear gains for the pharmaceutical industry and the developed world. The question of whether TRIPS generates gains for developing countries, in the form of increased exports, is addressed in this paper through consideration of the importance of pharmaceuticals in health-care trade, outlining the essential requirements, implications, and issues related to TRIPS, and TRIPS-plus, in which increased restrictions are imposed as part of bilateral free-trade agreements. TRIPS has not generated substantial gains for developing countries, but has further increased pharmaceutical trade in developed countries. The unequal trade between developed and developing countries (ie, exporting and importing high-value patented drugs, respectively) raises the issue of access to medicines, which is exacerbated by TRIPS-plus provisions, although many countries have not even enacted provision for TRIPS flexibilities. Therefore this paper focuses on options that are available to the health community for negotiation to their advantage under TRIPS, and within the presence of TRIPS-plus.	[Smith, Richard D.] Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England; [Correa, Carlos] Univ Buenos Aires, Ctr Interdisciplinary Studies Ind Property & Econ, Buenos Aires, DF, Argentina; [Oh, Cecilia] UNDP Reg Ctr, Colombo, Sri Lanka	University of London; London School of Hygiene & Tropical Medicine; University of Buenos Aires	Smith, RD (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, Keppel St, London WC1E 7HT, England.	Richard.Smith@lshtm.ac.uk		Smith, Richard/0000-0003-3837-6559				ABBOTT F, 2007, WORLD TRADE ORG ACCE; *AGCM, 2007, DEC A364 MERCK PRINC; ANDO G, 2006, PHARM MARKET MALAYSI; *ASEAN SECR, 2005, REG REP ASEAN ROCK F; Azmi IM, 2001, J WORLD INTELLECTUAL, V4, P947; Babar ZUD, 2007, PLOS MED, V4, P466, DOI 10.1371/journal.pmed.0040082; BASU S, 2003, ZNET GLOBAL EC  0529; BLOUIN C, 2007, WHO SEARO M TRAD HLT; *BURR LIF SCI MED, 2007, BURR Q IND LIF SCI; Commission on Intellectual Property Rights, INT INT PROP RIGHTS; Correa CM, 2006, B WORLD HEALTH ORGAN, V84, P399, DOI 10.2471/BLT.05.023432; DEEPTI R, 2007, CHEM WEEK, P169; Dzung N.N, 2007, CHICAGO KENT J INTEL, V6, P138; Endeshaw A, 2005, J WORLD INTELLECT PR, V8, P211, DOI 10.1111/j.1747-1796.2005.tb00247.x; *FED TRAD COMM, 2002, GEN DRUG ENTR PRIOR; *GLOB TRAD INF SER, UK CUST EXC; Haakonsson SJ, 2007, DEV POLICY REV, V25, P71, DOI 10.1111/j.1467-7679.2007.00360.x; *KEI, 2007, KEI RES NOT 2007 REC; Kerry VB, 2007, GLOBALIZATION HEALTH, V3, DOI 10.1186/1744-8603-3-3; Kinnon CM, 1998, WORLD HEALTH FORUM, V19, P397; KRAUS L, 2004, VANDERBILT J TRANSNA, V37, pL527; MILSTIEN J, B WHO, V84, P360; *MIN INT TRAD IND, 3 IND MAST 1996 2020; *MITI, 2007, IND PROF CHEM MAL TR; MUSUNGU SF, 2004, S PERSPECTIVES R APR; *MYLPO, 2008, CALC PAT STAT INT PR; Oh C., 2006, International Journal of Intellectual Property Management, V1, P22, DOI 10.1504/IJIPM.2006.011020; Oxfam International, 2007, 102 OXF INT; *PIR1BO, 2007, 200711 PIR1BO; Priapantja Priapantja, 2000, ASEAN WORKSH TRIPS A; Schaffer Gregory C., 2003, DEFENDING INTERESTS; Smith R., 2003, GLOBAL PUBLIC GOODS; Smith RD, 2004, B WORLD HEALTH ORGAN, V82, P385; SMITH RD, 2009, LANCET          0122; Steinbrook R, 2007, NEW ENGL J MED, V357, P1996, DOI 10.1056/NEJMp0706918; *UNCTAD, 2005, W MACK PROD VIEW PHA; USTR (Office of the United States Trade Representative), 2007, SPEC 301 REP; *WHO, 2006, COMM INT PROP INN PU; WILBULPROPRASER.S, 2001, WORKSH DIFF PRIC FIN	39	94	94	2	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 21	2009	373	9664					684	691		10.1016/S0140-6736(08)61779-1	http://dx.doi.org/10.1016/S0140-6736(08)61779-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410FS	19167054	Green Submitted			2023-01-03	WOS:000263563500033
J	Riker, RR; Shehabi, Y; Bokesch, PM; Ceraso, D; Wisemandle, W; Koura, F; Whitten, P; Margolis, BD; Byrne, DW; Ely, EW; Rocha, MG				Riker, Richard R.; Shehabi, Yahya; Bokesch, Paula M.; Ceraso, Daniel; Wisemandle, Wayne; Koura, Firas; Whitten, Patrick; Margolis, Benjamin D.; Byrne, Daniel W.; Ely, E. Wesley; Rocha, Marcelo G.		SEDCOM Study Grp	Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; ACTIVATED PROTEIN-C; PROLONGED SEDATION; DAILY INTERRUPTION; BRAIN-DYSFUNCTION; DELIRIUM; EFFICACY; SAFETY; MULTICENTER	Context gamma- Aminobutyric acid receptor agonist medications are the most commonly used sedatives for intensive care unit ( ICU) patients, yet preliminary evidence indicates that the alpha(2) agonist dexmedetomidine may have distinct advantages. Objective To compare the efficacy and safety of prolonged sedation with dexmedetomidine vs midazolam for mechanically ventilated patients. Design, Setting, and Patients Prospective, double- blind, randomized trial conducted in 68 centers in 5 countries between March 2005 and August 2007 among 375 medical/ surgical ICU patients with expected mechanical ventilation for more than 24 hours. Sedation level and delirium were assessed using the Richmond Agitation-Sedation Scale ( RASS) and the Confusion Assessment Method for the ICU. Interventions Dexmedetomidine ( 0.2- 1.4 mu g/ kg per hour [ n= 244]) or midazolam ( 0.02- 0.1 mg/ kg per hour [ n= 122]) titrated to achieve light sedation ( RASS scores between - 2 and + 1) from enrollment until extubation or 30 days. Main Outcome Measures Percentage of time within target RASS range. Secondary end points included prevalence and duration of delirium, use of fentanyl and open-label midazolam, and nursing assessments. Additional outcomes included duration of mechanical ventilation, ICU length of stay, and adverse events. Results There was no difference in percentage of time within the target RASS range ( 77.3% for dexmedetomidine group vs 75.1% for midazolam group; difference, 2.2% [ 95% confidence interval {CI}, - 3.2% to 7.5%]; P=. 18). The prevalence of delirium during treatment was 54% ( n= 132/ 244) in dexmedetomidine-treated patients vs 76.6% ( n= 93/ 122) in midazolam- treated patients ( difference, 22.6% [ 95% CI, 14% to 33%]; P <. 001). Median time to extubation was 1.9 days shorter in dexmedetomidine- treated patients ( 3.7 days [ 95% CI, 3.1 to 4.0] vs 5.6 days [ 95% CI, 4.6 to 5.9]; P=. 01), and ICU length of stay was similar ( 5.9 days [ 95% CI, 5.7 to 7.0] vs 7.6 days [ 95% CI, 6.7 to 8.6]; P=. 24). Dexmedetomidine-treated patients were more likely to develop bradycardia ( 42.2% [ 103/ 244] vs 18.9% [ 23/ 122]; P <. 001), with a nonsignificant increase in the proportion requiring treatment ( 4.9% [ 12/ 244] vs 0.8% [ 1/ 122]; P=. 07), but had a lower likelihood of tachycardia ( 25.4% [ 62/ 244] vs 44.3% [ 54/ 122]; P <. 001) or hypertension requiring treatment ( 18.9% [ 46/ 244] vs 29.5% [ 36/ 122]; P=. 02). Conclusions There was no difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients. At comparable sedation levels, dexmedetomidine- treated patients spent less time on the ventilator, experienced less delirium, and developed less tachycardia and hypertension. The most notable adverse effect of dexmedetomidine was bradycardia. Trial Registration clinicaltrials.gov Identifier: NCT00216190.	[Riker, Richard R.] Maine Med Ctr, Inst Neurosci, Portland, ME 04102 USA; [Riker, Richard R.] Univ Vermont, Coll Med, Portland, ME USA; [Shehabi, Yahya] Univ New S Wales, Sch Clin, Randwick, NSW, Australia; [Bokesch, Paula M.; Wisemandle, Wayne] Hospira Inc, Lake Forest, IL USA; [Ceraso, Daniel] Univ Buenos Aires, Hosp Gen Agudos Juan A Fernandez, Buenos Aires, DF, Argentina; [Koura, Firas] Univ Kentucky, Coll Med, Hazard, KY USA; [Koura, Firas] Kentucky Lung Clin, Hazard, KY USA; [Whitten, Patrick] Univ Illinois, Coll Med, OSF St Francis Med Ctr, Peoria, IL 61656 USA; [Margolis, Benjamin D.] Resurrect W Suburban Hosp Med Ctr, Oak Pk, IL USA; [Byrne, Daniel W.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Ely, E. Wesley] Tennessee Valley Healthcare Syst VA VA GRECC, Vet Affairs Geriatr Res Educ Clin Ctr, Nashville, TN USA; [Rocha, Marcelo G.] Irmandade Santa Casa Misericordia, Porto Alegre, RS, Brazil	Maine Medical Center; University of Vermont; University of New South Wales Sydney; University of Buenos Aires; University of Kentucky; University of Illinois System; University of Illinois Peoria; Vanderbilt University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Riker, RR (corresponding author), Maine Med Ctr, Inst Neurosci, 22 Bramhall St, Portland, ME 04102 USA.	rikerr@mmc.org	Ely, E. Wesley/Z-2018-2019; Conrad, Steven/F-3257-2015; Byrne, Daniel/GRE-6302-2022; Riker, Richard/AAP-1760-2020	Ely, E. Wesley/0000-0003-3957-2172; Conrad, Steven/0000-0002-4014-969X; Riker, Richard/0000-0002-0682-6204; /0000-0002-4157-5148; SHEHABI, Yahya/0000-0003-4707-7462	Hospira Inc, Lake Forest, Illinois	Hospira Inc, Lake Forest, Illinois	This study was funded by Hospira Inc, Lake Forest, Illinois, which manufactures dexmedetomidine.	BAUER TM, 1995, LANCET, V346, P145, DOI 10.1016/S0140-6736(95)91209-6; Bernard GR, 2004, CHEST, V125, P2206, DOI 10.1378/chest.125.6.2206; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Bucknall TK, 2008, CRIT CARE MED, V36, P1444, DOI 10.1097/CCM.0b013e318168f82d; *CTR MED MED SERV, CMS PROP EXP QUAL PR; Dasta JF, 2004, ANN PHARMACOTHER, V38, P1130, DOI 10.1345/aph.1D615; de Wit M, 2008, CRIT CARE, V12, DOI 10.1186/cc6908; De Wolf AM, 2001, ANESTH ANALG, V93, P1205, DOI 10.1097/00000539-200111000-00031; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Guldbrand P, 2004, ACTA ANAESTH SCAND, V48, P944, DOI 10.1111/j.1399-6576.2004.00445.x; *HOSP INC, 2006, PROP PACK INS; Huupponen E, 2008, ACTA ANAESTH SCAND, V52, P289, DOI 10.1111/j.1399-6576.2007.01537.x; Jackson J.C., 2007, AM J RESP CRIT CARE, V175, pA22; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; MALDONADO J, PSYCHOSOMAT IN PRESS; Martin Eike, 2003, J Intensive Care Med, V18, P29, DOI 10.1177/0885066602239122; Martin J, 2006, INTENS CARE MED, V32, P1137, DOI 10.1007/s00134-006-0214-6; MAZE M, 2004, ANESTHETIC PHARM PHY, P473; Mikawa K, 1998, ANESTH ANALG, V87, P695, DOI 10.1097/00000539-199809000-00039; Nelson JE, 2006, ARCH INTERN MED, V166, P1993, DOI 10.1001/archinte.166.18.1993; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nishina K, 1999, ANESTH ANALG, V88, P452, DOI 10.1097/00000539-199902000-00042; Nishina K, 1998, ANESTH ANALG, V86, P159, DOI 10.1097/00000539-199801000-00032; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; PATEL RP, CRIT CARE M IN PRESS; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Pronovost PJ, 2008, JAMA-J AM MED ASSOC, V299, P2197, DOI 10.1001/jama.299.18.2197; Rhoney Denise H, 2003, J Intensive Care Med, V18, P139, DOI 10.1177/0885066603018003003; Riker RR, 2005, PHARMACOTHERAPY, V25, p8S, DOI 10.1592/phco.2005.25.5_Part_2.8S; RIKER RR, 2001, ANESTHESIOLOGY, V95, pA383; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Shehabi Y, 2008, ANAESTH INTENS CARE, V36, P570, DOI 10.1177/0310057X0803600423; Shehabi Y, 2004, INTENS CARE MED, V30, P2188, DOI 10.1007/s00134-004-2417-z; SPENCER EM, 1992, INTENS CARE MED, V18, P415, DOI 10.1007/BF01694344; Venn RM, 2003, INTENS CARE MED, V29, P201, DOI 10.1007/s00134-002-1579-9	48	1006	1135	3	95	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	2009	301	5					489	499		10.1001/jama.2009.56	http://dx.doi.org/10.1001/jama.2009.56			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402CS	19188334	Bronze			2023-01-03	WOS:000262992400018
J	Madsen, MV; Gotzsche, PC; Hrobjartsson, A				Madsen, Matias Vested; Gotzsche, Peter C.; Hrobjartsson, Asbjorn			Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMPARING PLACEBO; MULTICENTER; POWERLESS; OUTCOMES; NEEDLE	Objectives To study the analgesic effect of acupuncture and placebo acupuncture and to explore whether the type of the placebo acupuncture is associated with the estimated effect of acupuncture. Design Systematic review and meta- analysis of three armed randomised clinical trials. Data sources Cochrane Library, Medline, Embase, Biological Abstracts, and PsycLIT. Data extraction and analysis Standardised mean differences from each trial were used to estimate the effect of acupuncture and placebo acupuncture. The different types of placebo acupuncture were ranked from 1 to 5 according to assessment of the possibility of a physiological effect, and this ranking was meta- regressed with the effect of acupuncture. Data synthesis Thirteen trials ( 3025 patients) involving a variety of pain conditions were eligible. The allocation of patients was adequately concealed in eight trials. The clinicians managing the acupuncture and placebo acupuncture treatmentswere not blinded in any of the trials. One clearly outlying trial ( 70 patients) was excluded. A small difference was found between acupuncture and placebo acupuncture: standardised mean difference - 0.17 ( 95% confidence interval - 0.26 to - 0.08), corresponding to 4 mm ( 2 mm to 6 mm) on a 100 mm visual analogue scale. No statistically significant heterogeneity was present ( P= 0.10, I-2= 36%). A moderate difference was found between placebo acupuncture and no acupuncture: standardised mean difference - 0.42 (- 0.60 to - 0.23). However, considerable heterogeneity ( P< 0.001, I-2= 66%) was also found, as large trials reported both small and large effects of placebo. No association was detected between the type of placebo acupuncture and the effect of acupuncture ( P= 0.60). Conclusions A small analgesic effect of acupuncture was found, which seems to lack clinical relevance and cannot be clearly distinguished from bias. Whether needling at acupuncture points, or at any site, reduces pain independently of the psychological impact of the treatment ritual is unclear.	[Madsen, Matias Vested; Gotzsche, Peter C.; Hrobjartsson, Asbjorn] Rigshosp, Nord Cochrane Ctr, Dept 3343, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen	Hrobjartsson, A (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 3343, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	ah@cochrane.dk	Vested, Matias/HDN-3135-2022	Vested, Matias/0000-0002-5165-2725				Assefi NP, 2005, ANN INTERN MED, V143, P10, DOI 10.7326/0003-4819-143-1-200507050-00005; Berman BM, 2004, ANN INTERN MED, V141, P901, DOI 10.7326/0003-4819-141-12-200412210-00006; Casimiro L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003788.pub2; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Diener HC, 2006, LANCET NEUROL, V5, P310, DOI 10.1016/S1474-4422(06)70382-9; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; GHIA JN, 1976, PAIN, V2, P285, DOI 10.1016/0304-3959(76)90006-3; Gotzsche PC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000193.pub2; Green S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005319; Green S, 2002, Cochrane Database Syst Rev, pCD003527; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hrobjartsson A, 2002, J CLIN EPIDEMIOL, V55, P430, DOI 10.1016/S0895-4356(01)00496-6; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x; Irnich D, 2002, SCHMERZ, V16, P93, DOI 10.1007/s004820100094; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; KAPTCHUK TJ, 2000, WEB THAT HAS NO WEAV; LEWIT K, 1979, PAIN, V6, P83, DOI 10.1016/0304-3959(79)90142-8; MELCHART D, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001218; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MELZACK R, 1976, ANAESTHESIST, V25, P204; Proctor ML., 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002123; Streitberger K, 1998, LANCET, V352, P364, DOI 10.1016/S0140-6736(97)10471-8; ten Klooster PM, 2006, PAIN, V121, P151, DOI 10.1016/j.pain.2005.12.021; Trinh KV, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004870.pub3; Vickers A, 1999, BRIT MED J, V319, P973, DOI 10.1136/bmj.319.7215.973	30	219	230	2	38	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2009	338								a3115	10.1136/bmj.a3115	http://dx.doi.org/10.1136/bmj.a3115			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405EL	19174438	hybrid, Green Published			2023-01-03	WOS:000263205400001
J	Tilburt, JC; Emanuel, EJ; Kaptchuk, TJ; Curlin, FA; Miller, FG				Tilburt, Jon C.; Emanuel, Ezekiel J.; Kaptchuk, Ted J.; Curlin, Farr A.; Miller, Franklin G.			Prescribing "placebo treatments": results of national survey of US internists and rheumatologists	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE SURVEY; POWERFUL PLACEBO; PHYSICIANS; ATTITUDES; ETHICS	Objective To describe the attitudes and behaviours regarding placebo treatments, defined as a treatment whose benefits derive from positive patient expectations and not from the physiological mechanism of the treatment itself. Design Cross sectional mailed survey. Setting Physicians' clinical practices. Participants 1200 practising internists and rheumatologists in the United States. Main outcome measures Investigators measured physicians' self reported behaviours and attitudes concerning the use of placebo treatments, including measures of whether they would use or had recommended a "placebo treatment," their ethical judgments about the practice, what they recommended as placebo treatments, and how they typically communicate with patients about the practice. Results 679 physicians ( 57%) responded to the survey. About half of the surveyed internists and rheumatologists reported prescribing placebo treatments on a regular basis ( 46- 58%, depending on how the question was phrased). Most physicians ( 399, 62%) believed the practice to be ethically permissible. Few reported using saline ( 18, 3%) or sugar pills ( 12, 2%) as placebo treatments, while large proportions reported using over the counter analgesics ( 267, 41%) and vitamins ( 243, 38%) as placebo treatments within the past year. A small but notable proportion of physicians reported using antibiotics ( 86, 13%) and sedatives ( 86, 13%) as placebo treatments during the same period. Furthermore, physicians who use placebo treatments most commonly describe them to patients as a potentially beneficial medicine or treatment not typically used for their condition ( 241, 68%); only rarely do they explicitly describe them as placebos ( 18, 5%). Conclusions Prescribing placebo treatments seems to be common and is viewed as ethically permissible among the surveyed US internists and rheumatologists. Vitamins and over the counter analgesics are the most commonly used treatments. Physicians might not be fully transparent with their patients about the use of placebos and might have mixed motivations for recommending such treatments.	[Tilburt, Jon C.; Emanuel, Ezekiel J.; Miller, Franklin G.] NIH, Dept Bioeth, Bethesda, MD 20892 USA; [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Osher Inst, Boston, MA 02215 USA; [Curlin, Farr A.] Univ Chicago, Sect Internal Med, Chicago, IL 60637 USA; [Curlin, Farr A.] Univ Chicago, McClean Ctr Clin Med Eth, Chicago, IL 60637 USA	National Institutes of Health (NIH) - USA; Harvard University; Harvard Medical School; University of Chicago; University of Chicago	Tilburt, JC (corresponding author), NIH, Dept Bioeth, Bldg 10, Bethesda, MD 20892 USA.	tilburt.jon@mayo.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT002749] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095] Funding Source: NIH RePORTER; NCCIH NIH HHS [K23 AT002749, K24 AT004095] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		ABRAMOWITZ EW, 1948, NEW YORK STATE J MED, V48, P1927; *AM MED ASS, 2I06 CEJA AM MED ASS; American Association for Public Opinion Research, 2006, STAND DEF FIN DISP C, V4th; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Berger JT, 1999, WESTERN J MED, V170, P93; BOK S, 1974, SCI AM, V231, P17, DOI 10.1038/scientificamerican1174-17; BRODY H, 1982, ANN INTERN MED, V97, P112, DOI 10.7326/0003-4819-97-1-112; Brody H., 1977, PLACEBOS PHILOS MED; BROWN WA, 1994, NEUROPSYCHOPHARMACOL, V10, P265, DOI 10.1038/npp.1994.53; Cabot R.C., 1903, AM MED, V5, P344; FINDLEY F, 1953, MED CLIN N AM, V37, P1821; GOODWIN JS, 1979, ANN INTERN MED, V91, P106, DOI 10.7326/0003-4819-91-1-106; GRAY G, 1981, GEN HOSP PSYCHIAT, V3, P199, DOI 10.1016/0163-8343(81)90002-5; Hrobjartsson A, 2003, EVAL HEALTH PROF, V26, P153, DOI 10.1177/0163278703026002002; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Jefferson T., 1898, WRITINGS T JEFFERSON, V9; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; LESLIE A, 1954, AM J MED, V16, P854, DOI 10.1016/0002-9343(54)90450-7; LYNOE N, 1993, SOC SCI MED, V36, P767, DOI 10.1016/0277-9536(93)90037-5; Miller FG, 2006, J CLIN EPIDEMIOL, V59, P331, DOI 10.1016/j.jclinepi.2005.12.001; Nitzan U, 2004, BMJ-BRIT MED J, V329, P944, DOI 10.1136/bmj.38236.646678.55; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Shermon R, 2008, J GEN INTERN MED, V23, P7, DOI 10.1007/s11606-007-0332-z; SIMMONS B, 1978, J MED ETHICS, V4, P172, DOI 10.1136/jme.4.4.172; THOMSON RJ, 1982, NEW ZEAL MED J, V95, P492; Tuke DH., 1873, ILLUSTRATIONS INFLUE; 1946, NY J MED, V17, P722; 1954, LANCET, V2, P321; 1885, MED RECORD, V27, P576	29	166	170	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 23	2008	337								a1938	10.1136/bmj.a1938	http://dx.doi.org/10.1136/bmj.a1938			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	374FP	18948346	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000261028900001
J	Sofi, F; Cesari, F; Abbate, R; Gensini, GF; Casini, A				Sofi, Francesco; Cesari, Francesca; Abbate, Rosanna; Gensini, Gian Franco; Casini, Alessandro			Adherence to Mediterranean diet and health status: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To systematically review all the prospective cohort studies that have analysed the relation between adherence to a Mediterranean diet, mortality, and incidence of chronic diseases in a primary prevention setting. Design Meta- analysis of prospective cohort studies. Data sources English and non- English publications in PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials from 1966 to 30 June 2008. Studies reviewed Studies that analysed prospectively the association between adherence to a Mediterranean diet, mortality, and incidence of diseases; 12 studies, with a total of 1 574 299 subjects followed for a time ranging from three to 18 years were included. Results The cumulative analysis among eight cohorts ( 514 816 subjects and 33 576 deaths) evaluating overall mortality in relation to adherence to a Mediterranean diet showed that a two point increase in the adherence score was significantly associated with a reduced risk of mortality ( pooled relative risk 0.91, 95% confidence interval 0.89 to 0.94). Likewise, the analyses showed a beneficial role for greater adherence to a Mediterranean diet on cardiovascular mortality ( pooled relative risk 0.91, 0.87 to 0.95), incidence of or mortality from cancer ( 0.94, 0.92 to 0.96), and incidence of Parkinson's disease and Alzheimer's disease ( 0.87, 0.80 to 0.96). Conclusions Greater adherence to a Mediterranean diet is associated with a significant improvement in health status, as seen by a significant reduction in overall mortality ( 9%), mortality from cardiovascular diseases ( 9%), incidence of or mortality from cancer ( 6%), and incidence of Parkinson's disease and Alzheimer's disease ( 13%). These results seem to be clinically relevant for public health, in particular for encouraging a Mediterranean- like dietary pattern for primary prevention of major chronic diseases.	[Sofi, Francesco; Cesari, Francesca; Abbate, Rosanna] Univ Florence, Dept Med & Surg Crit Care, Thrombosis Ctr, I-50134 Florence, Italy; [Sofi, Francesco; Casini, Alessandro] Univ Careggi, Azienda Osped, Reg Agcy Nutr, Florence, Italy; [Gensini, Gian Franco] Onlus IRCCS, Don Carlo Gnocchi Fdn, Florence, Italy; [Casini, Alessandro] Univ Florence, Dept Clin Pathophysiol, Unit Clin Nutr, Florence, Italy; [Sofi, Francesco; Abbate, Rosanna; Casini, Alessandro] Univ Florence, Ctr Interdipartimentale Ric & Valorizzazione Alim, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; IRCCS Fondazione Don Carlo Gnocchi Onlus; University of Florence; University of Florence	Sofi, F (corresponding author), Univ Florence, Dept Med & Surg Crit Care, Thrombosis Ctr, Viale Morgagni 85, I-50134 Florence, Italy.	francescosofi@gmail.com	Nicolescu, Alina/M-8562-2017; Deleanu, Calin/G-7446-2011; Sofi, Francesco/W-4610-2019; Sofi, Francesco/J-3941-2016; Birzan, Liviu/H-3653-2013; Cesari, Francesca/K-7974-2016	Nicolescu, Alina/0000-0001-7022-8893; Deleanu, Calin/0000-0001-8206-5227; Sofi, Francesco/0000-0001-7113-7424; Sofi, Francesco/0000-0001-7113-7424; Birzan, Liviu/0000-0002-3479-6567; Cesari, Francesca/0000-0002-3616-6219				Bach A, 2006, PUBLIC HEALTH NUTR, V9, P132, DOI 10.1079/PHN2005936; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Genkinger JM, 2007, PLOS MED, V4, P1883, DOI 10.1371/journal.pmed.0040345; Hu FB, 2002, CURR OPIN LIPIDOL, V13, P3, DOI 10.1097/00041433-200202000-00002; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; Lichtenstein AH, 2006, CIRCULATION, V114, P82, DOI 10.1161/CIRCULATIONAHA.106.176158; Serra-Majem L, 2006, NUTR REV, V64, pS27, DOI 10.1301/nr.2006.feb.S27-S47; Sofi F, 2005, EUR J CLIN NUTR, V59, P584, DOI 10.1038/sj.ejcn.1602112; US Department of Health and Human Services and USDA, 2005, DIET GUID AM 2005; WHO/ FAO, 2003, DIET NUTR PREV CHRON, P916; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S; Willett WC, 2006, PUBLIC HEALTH NUTR, V9, P105, DOI 10.1079/PHN2005931	13	945	966	3	135	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 20	2008	337	7671							a1344	10.1136/bmj.a1344	http://dx.doi.org/10.1136/bmj.a1344			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354EP	18786971	hybrid, Green Published			2023-01-03	WOS:000259622000031
J	Saper, RB; Phillips, RS; Sehgal, A; Khouri, N; Davis, RB; Paquin, J; Thuppil, V; Kales, SN				Saper, Robert B.; Phillips, Russell S.; Sehgal, Anusha; Khouri, Nadia; Davis, Roger B.; Paquin, Janet; Thuppil, Venkatesh; Kales, Stefanos N.			Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPPLEMENTS; METAL; PRODUCTS; REMEDIES	Context Lead, mercury, and arsenic have been detected in a substantial proportion of Indian- manufactured traditional Ayurvedic medicines. Metals may be present due to the practice of rasa shastra ( combining herbs with metals, minerals, and gems). Whether toxic metals are present in both US- and Indian- manufactured Ayurvedic medicines is unknown. Objectives To determine the prevalence of Ayurvedic medicines available via the Internet containing detectable lead, mercury, or arsenic and to compare the prevalence of toxic metals in US- vs Indian- manufactured medicines and between rasa shastra and non - rasa shastra medicines. Design A search using 5 Internet search engines and the search terms Ayurveda and Ayurvedic medicine identified 25 Web sites offering traditional Ayurvedic herbs, formulas, or ingredients commonly used in Ayurveda, indicated for oral use, and available for sale. From 673 identified products, 230 Ayurvedic medicines were randomly selected for purchase in August- October 2005. Country of manufacturer/ Web site supplier, rasa shastra status, and claims of Good Manufacturing Practices were recorded. Metal concentrations were measured using x- ray fluorescence spectroscopy. Main Outcome Measures Prevalence of medicines with detectable toxic metals in the entire sample and stratified by country of manufacture and rasa shastra status. Results One hundred ninety- three of the 230 requested medicines were received and analyzed. The prevalence of metal- containing products was 20.7% ( 95% confidence interval [ CI], 15.2%- 27.1%). The prevalence of metals in US- manufactured products was 21.7% ( 95% CI, 14.6%- 30.4%) compared with 19.5% ( 95% CI, 11.3%-30.1%) in Indian products ( P=. 86). Rasa shastra compared with non - rasa shastra medicines had a greater prevalence of metals ( 40.6% vs 17.1%; P=. 007) and higher median concentrations of lead ( 11.5 mu g/g vs 7.0 mu g/ g; P=. 03) and mercury ( 20 800 mu g/ g vs 34.5 mu g/ g; P=. 04). Among the metal- containing products, 95% were sold by US Web sites and 75% claimed Good Manufacturing Practices. All metal-containing products exceeded 1 or more standards for acceptable daily intake of toxic metals. Conclusion One- fifth of both US- manufactured and Indian- manufactured Ayurvedic medicines purchased via the Internet contain detectable lead, mercury, or arsenic.	[Saper, Robert B.; Sehgal, Anusha; Khouri, Nadia] Boston Med Ctr, Dept Family Med, Boston, MA 02118 USA; [Saper, Robert B.; Sehgal, Anusha; Khouri, Nadia] Boston Univ, Sch Med, Dept Family Med, Boston, MA 02118 USA; [Phillips, Russell S.; Davis, Roger B.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Phillips, Russell S.; Davis, Roger B.] Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Osher Res Ctr, Boston, MA USA; [Kales, Stefanos N.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Paquin, Janet] US EPA, New England Reg Lab, N Chelmsford, MA USA; [Thuppil, Venkatesh] St Johns Med Coll, Natl Referral Ctr Lead Poisoning India, Bangalore, Karnataka, India; [Thuppil, Venkatesh] St Johns Med Coll, Dept Biochem & Biophys, Bangalore, Karnataka, India; [Kales, Stefanos N.] Harvard Univ, Sch Med, Cambridge Hlth Alliance, Cambridge, MA 02138 USA	Boston Medical Center; Boston University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; United States Environmental Protection Agency; St. John's National Academy of Health Sciences; St. John's Medical College; St. John's National Academy of Health Sciences; St. John's Medical College; Harvard University; Cambridge Health Alliance	Saper, RB (corresponding author), Boston Med Ctr, Dept Family Med, 1 Boston Med Ctr Pl,Dowling 5 S, Boston, MA 02118 USA.	robert.saper@bmc.org	Saper, Robert B/Y-4598-2018	Saper, Robert B/0000-0002-0992-6198	Career Development Award [K07 AT002915-03]; National Center for Complementary and Alternative Medicine (NCCAM); National Institutes of Health; Mid-Career Investigator Award [5K24AT000589-07]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K24AT000589, K07AT002915] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT000051] Funding Source: NIH RePORTER	Career Development Award; National Center for Complementary and Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mid-Career Investigator Award; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr Saper is supported by a Career Development Award (K07 AT002915-03) from the National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health. Dr Phillips is supported by a Mid-Career Investigator Award (5K24AT000589-07) from NCCAM.	*AM HERB PROD ASS, AHPA COD ETH BUS CON; BAER RD, 1988, J ETHNOPHARMACOL, V24, P31, DOI 10.1016/0378-8741(88)90137-7; *CAL ENV PROT AG, 2008, PROP 65 SAF HARB LEV; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P582; Dolan SP, 2003, J AGR FOOD CHEM, V51, P1307, DOI 10.1021/jf026055x; Dwivedi SK, 2002, ARCH ENVIRON HEALTH, V57, P229, DOI 10.1080/00039890209602941; Ernst E, 2002, EUR J CLIN PHARMACOL, V57, P891, DOI 10.1007/s00228-001-0400-y; Gogtay NJ, 2002, DRUG SAFETY, V25, P1005, DOI 10.2165/00002018-200225140-00003; Institute of Medicine and National Research Council, 2005, DIET SUPPL FRAM EV S; Kales SN, 2007, MED SCI MONITOR, V13, pCR295; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; McGinnis JM, 2006, ANN INTERN MED, V145, P364, DOI 10.7326/0003-4819-145-5-200609050-00136; Morris CA, 2003, JAMA-J AM MED ASSOC, V290, P1505, DOI 10.1001/jama.290.11.1505; Ramachandran R., 2006, FRONTLINE, V23; Raman P, 2004, J AGR FOOD CHEM, V52, P7822, DOI 10.1021/jf049150+; RIOUX J, 2005, LIGHT AYURVEDA J HLT, V3, P24; Saper RB, 2004, JAMA-J AM MED ASSOC, V292, P2868, DOI 10.1001/jama.292.23.2868; Satpute AD, 2003, RASA RATNA SAMUCHAYA; SHASTRI K, 1979, RASA TARANGINI SADAN; *US EPA, INT RISK INF SYST IR; 2007, FED REG         0625, P34838	21	292	301	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 27	2008	300	8					915	923		10.1001/jama.300.8.915	http://dx.doi.org/10.1001/jama.300.8.915			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	341AR	18728265	Bronze, Green Accepted			2023-01-03	WOS:000258687100026
J	Wood, E; Hogg, RS; Lima, VD; Kerr, T; Yip, B; Marshall, BDL; Montaner, JSG				Wood, Evan; Hogg, Robert S.; Lima, Viviane Dias; Kerr, Thomas; Yip, Benita; Marshall, Brandon D. L.; Montaner, Julio S. G.			Highly active antiretroviral therapy and survival in HIV-Infected injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE PROGRESSION; CELL COUNT; ADHERENCE; HAART; CARE; ACCESS; ADULTS; ERA	Context Highly active antiretroviral therapy ( HAART) is often withheld from injection drug users ( IDUs) infected with the human immunodeficiency virus ( HIV) based on the belief that their unstable lifestyles may predetermine a markedly inferior outcome with HAART. However, long- term evaluations of HIV treatment outcomes among IDUs in comparison with other risk groups are not available. Objective To compare survival rates among HIV- infected patients initiating HAART with and without a history of injection drug use. Design, Setting, and Patients Population- based, prospective cohort study ( HAART Observational Medical Evaluation and Research [ HOMER]) of 3116 antiretroviral-naive HIV- infected patients in a province- wide HIV/ AIDS treatment program in British Columbia, Canada. Of the 3116 patients, 915 were IDUs ( 29.4%), 579 were female ( 18.6%), and the median age was 39.4 years ( interquartile range, 33.3- 46.4 years). Treatment with HAART was initiated between August 1, 1996, and June 30, 2006. The median duration of follow- up was 5.3 years ( interquartile range, 2.8- 8.3 years) for IDUs and 4.3 years ( interquartile range, 2.0- 7.6 years) for non- IDUs. Patients were followed up until June 30, 2007. Data were analyzed between November 1, 2007, and May 26, 2008. Main Outcome Measure All- cause mortality. Results Overall, 622 individuals died ( 20.0%) during the study period ( 232 IDUs and 390 non- IDUs), for a crude mortality rate of 20.0% ( 95% confidence interval [ CI], 18.4%- 21.5%). At 84 months after the initiation of HAART, the product limit estimate of the cumulative all- cause mortality rate was similar between the 915 IDUs ( 26.5%; 95% CI, 23.2%- 29.8%) and 2201 non- IDUs ( 21.6%; 95% CI, 16.9%- 26.2%) ( Wilcoxon P=. 47). In multivariate time- updated Cox regression, the hazard ratio of mortality was similar between IDUs and non- IDUs ( 1.09; 95% CI, 0.92- 1.29). Conclusion In this study population, injection drug use was not associated with decreased survival among HIV- infected patients initiating HAART.	[Wood, Evan; Lima, Viviane Dias; Kerr, Thomas; Montaner, Julio S. G.] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Wood, Evan; Lima, Viviane Dias; Kerr, Thomas; Montaner, Julio S. G.] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Hogg, Robert S.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Simon Fraser University	Montaner, JSG (corresponding author), Univ British Columbia, AIDS Res Program, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	jmontaner@cfenet.ubc.ca	Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012; Marshall, Brandon/B-4895-2010	Hogg, Robert S/0000-0003-3463-5488; Marshall, Brandon/0000-0002-0134-7052				Aceijas C, 2006, ADDICTION, V101, P1246, DOI 10.1111/j.1360-0443.2006.01509.x; ALLISON PD, 2004, SURVIVAL ANAL USING; Ball AL, 2007, INT J DRUG POLICY, V18, P241, DOI 10.1016/j.drugpo.2007.07.001; Bruce RD, 2007, INFECT DIS CLIN N AM, V21, P149, DOI 10.1016/j.idc.2007.03.009; Chander G, 2006, DRUGS, V66, P769, DOI 10.2165/00003495-200666060-00004; Collett D., 1994, MODELLING SURVIVAL D; Ding L, 2005, ARCH INTERN MED, V165, P618, DOI 10.1001/archinte.165.6.618; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Lert F, 2007, INT J DRUG POLICY, V18, P255, DOI 10.1016/j.drugpo.2007.05.002; Lima VD, 2007, AIDS, V21, P1175, DOI 10.1097/QAD.0b013e32811ebf57; Loughlin A, 2004, AIDS CARE, V16, P485, DOI 10.1080/09540120410001683411; Maisels L, 2001, AIDS PATIENT CARE ST, V15, P185, DOI 10.1089/10872910151133701; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; Mocroft A, 2004, AIDS, V18, P2333, DOI 10.1097/00002030-200411190-00018; PARMAR M, 1995, SURVIVAL ANAL PRACTI; Poundstone KE, 2001, AIDS, V15, P1115, DOI 10.1097/00002030-200106150-00006; *PUBL HLTH AG CAN, EST HIV PREV INC CAN; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Tyndall MW, 2007, INT J DRUG POLICY, V18, P281, DOI 10.1016/j.drugpo.2006.11.009; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; Wood E, 2003, J INFECT DIS, V188, P1164, DOI 10.1086/378703; Wood E, 2007, LANCET, V370, P8, DOI 10.1016/S0140-6736(07)61025-3; World Health Organization, INT STAT CLASS DIS R	27	181	183	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 6	2008	300	5					550	554		10.1001/jama.300.5.550	http://dx.doi.org/10.1001/jama.300.5.550			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	333YG	18677027	Bronze			2023-01-03	WOS:000258188900016
J	Satyanand, T				Satyanand, Tara			Aftermath of the Bhopal accident	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Satyanand, T (corresponding author), The Lancet, London NW1 7BY, England.							MOORIS C, 2008, BBC NEWS        0529; 2008, TIMES INDIA     0529	2	3	4	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 7	2008	371	9628					1900	1900		10.1016/S0140-6736(08)60814-4	http://dx.doi.org/10.1016/S0140-6736(08)60814-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	310OI	18539211				2023-01-03	WOS:000256538500011
J	Canonico, M; Plu-Bureau, G; Lowe, GDO; Scarabin, PY				Canonico, Marianne; Plu-Bureau, Genevieve; Lowe, Gordon D. O.; Scarabin, Pierre-Yves			Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; ACTIVATED PROTEIN-C; TRANSDERMAL ESTROGEN/PROGESTERONE REGIMENS; CONJUGATED EQUINE ESTROGEN; FACTOR-V-LEIDEN; ORAL-CONTRACEPTIVES; CARDIOVASCULAR-DISEASE; ACQUIRED-RESISTANCE; PULMONARY-EMBOLISM; RANDOMIZED-TRIALS	Objective To assess the risk of venous thromboembolism in women using hormone replacement therapy by study design, characteristics of the therapy and venous thromboembolism, and clinical background. Design Systematic review and meta-analysis. Data sources Medline. Studies reviewed Eight observational studies and nine randomised controlled trials. Inclusion criteria Studies on hormone replacement therapy that reported venous thromboembolism. Review measures Homogeneity between studies was analysed using X-2 and I-2 statistics. Overall risk of venous thromboembolism was assessed from a fixed effects or random effects model. Results Meta-analysis of observational studies showed that oral oestrogen but not transdermal oestrogen increased the risk of venous thromboembolism. Compared with non-users of oestrogen, the odds ratio of first time venous thromboembolism in current users of oral oestrogen was 2.5 (95% confidence interval 1.9 to 3.4) and in current users of transdermal oestrogen was 1.2 (0.9 to 1.7). Past users of oral oestrogen had a similar risk of venous thromboembolism to never users. The risk of venous thromboembolism in women using oral oestrogen was higher in the first year of treatment (4.0, 2.9 to5.7) compared with treatment for more than one year(2.1, 1.3 to 3.8; P<0.05). No noticeable difference in the risk of venous thromboembolism was observed between unopposed oral oestrogen (2.2, 1.6 to 3.0) and opposed oral oestrogen (2.6, 2.0 to 3.2). Results from nine randomised controlled trials confirmed the increased risk of venous thromboembolism among women using oral oestrogen (2.1, 1.4 to 3.1). The combination of oral oestrogen and thrombogenic mutations or obesity further enhanced the risk of venous thromboembolism, whereas transdermal oestrogen did not seem to confer additional risk in women at high risk of venous thromboembolism. Conclusion Oral oestrogen increases the risk of venous thromboembolism, especially during the first year of treatment. Transdermal oestrogen may be safer with respect to thrombotic risk. More data are required to investigate differences in risk across the wide variety of hormone regimens, especially the different types of progestogens.	[Canonico, Marianne; Plu-Bureau, Genevieve; Scarabin, Pierre-Yves] Univ Paris Sud, INSERM, Cardiovasc Epidemiol Sect, Unit 780, Villejuif, France; [Canonico, Marianne] Univ Paris Sud, IFR69, Villejuif, France; [Plu-Bureau, Genevieve; Scarabin, Pierre-Yves] Univ Paris 05, Paris, France; [Lowe, Gordon D. O.] Univ Glasgow, Glasgow Royal Infirm, Div Cardiovasc & Med Sci, Glasgow G31 2ER, Lanark, Scotland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Cite; University of Glasgow	Canonico, M (corresponding author), Univ Paris Sud, INSERM, Cardiovasc Epidemiol Sect, Unit 780, Villejuif, France.	canonico@vjf.inserm.fr	Beau Yon de Jonage - Canonico, Marianne/ABE-4279-2021; Canonico, Marianne/F-9138-2013	Beau Yon de Jonage - Canonico, Marianne/0000-0002-2843-8640; Canonico, Marianne/0000-0002-2843-8640				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; [Anonymous], 1974, NEW ENGL J MED, V290, P15; Beral V, 2002, LANCET, V360, P942, DOI 10.1016/S0140-6736(02)11032-4; Bertina RM, 2001, EUR J OBSTET GYN R B, V95, P189, DOI 10.1016/S0301-2115(00)00488-7; CAINE YG, 1992, THROMB HAEMOSTASIS, V68, P392; Canonico M, 2006, J THROMB HAEMOST, V4, P1259, DOI 10.1111/j.1538-7836.2006.01933.x; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Canonico M, 2006, MATURITAS, V54, P372, DOI 10.1016/j.maturitas.2006.04.019; Cherry N, 2002, LANCET, V360, P2001; CONARD J, 1983, THROMB HAEMOSTASIS, V49, P252; Curb JD, 2006, ARCH INTERN MED, V166, P772, DOI 10.1001/archinte.166.7.772; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Daly E, 1996, LANCET, V348, P1027, DOI 10.1016/S0140-6736(96)24041-3; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; Douketis JD, 2005, J THROMB HAEMOST, V3, P943, DOI 10.1111/j.1538-7836.2005.01268.x; Emmerich J, 2001, THROMB HAEMOSTASIS, V86, P809; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; HAMMOND CB, 1979, AM J OBSTET GYNECOL, V133, P525, DOI 10.1016/0002-9378(79)90288-6; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 2002, ARTERIOSCL THROM VAS, V22, P1012, DOI 10.1161/01.ATV.0000018301.91721.94; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hoibraaten E, 2000, THROMB HAEMOSTASIS, V84, P961; Hoibraaten E, 2001, BRIT J HAEMATOL, V115, P415, DOI 10.1046/j.1365-2141.2001.03111.x; Holbraaten E, 1999, THROMB HAEMOSTASIS, V82, P1218; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Jick H, 1996, LANCET, V348, P981, DOI 10.1016/S0140-6736(96)07114-0; Lowe GDO, 2004, J INTERN MED, V256, P361, DOI 10.1111/j.1365-2796.2004.01400.x; Lowe GDO, 2001, THROMB HAEMOSTASIS, V86, P550; Lowe GDO, 2007, WOMENS HEALTH, V3, P87, DOI 10.2217/17455057.3.1.87; Miller J, 2002, ANN INTERN MED, V136, P680, DOI 10.7326/0003-4819-136-9-200205070-00011; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nelson HD, 2002, JAMA-J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872; Oger E, 2003, ARTERIOSCL THROM VAS, V23, P1671, DOI 10.1161/01.ATV.0000087141.05044.1F; Oger E, 1999, DRUG AGING, V14, P55, DOI 10.2165/00002512-199914010-00004; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Oger E, 2007, WOMENS VASCULAR HLTH, P436; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; Post MS, 2003, ARTERIOSCL THROM VAS, V23, P1116, DOI 10.1161/01.ATV.0000074146.36646.C8; QUINN DA, 1992, JAMA-J AM MED ASSOC, V268, P1689, DOI 10.1001/jama.268.13.1689; Rexrode KM, 2007, CIRCULATION, V115, P820, DOI 10.1161/CIRCULATIONAHA.106.675405; Rosendaal FR, 2003, J THROMB HAEMOST, V1, P1371, DOI 10.1046/j.1538-7836.2003.00264.x; Rosendaal FR, 2002, BRIT J HAEMATOL, V116, P851, DOI 10.1046/j.0007-1048.2002.03356.x; Rosing J, 1999, LANCET, V354, P2036, DOI 10.1016/S0140-6736(99)06092-4; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rymer J, 2003, BRIT MED J, V326, P322, DOI 10.1136/bmj.326.7384.322; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Scarabin PY, 1997, ARTERIOSCL THROM VAS, V17, P3071, DOI 10.1161/01.ATV.17.11.3071; Smith NL, 2006, ARTERIOSCL THROM VAS, V26, P2807, DOI 10.1161/01.ATV.0000245792.62517.3b; Smith NL, 2004, JAMA-J AM MED ASSOC, V292, P1581, DOI 10.1001/jama.292.13.1581; Straczek C, 2005, CIRCULATION, V112, P3495, DOI 10.1161/CIRCULATIONAHA.105.565556; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Utian WH, 2007, MENOPAUSE, V14, P168, DOI 10.1097/gme.0b013e31803167ab; Varas-Lorenzo C, 1998, AM J EPIDEMIOL, V147, P387; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; White H, 2004, J THROMB HAEMOST, V2, P2262, DOI 10.1111/j.1538-7836.2004.01075.x; Wu O, 2005, THROMB HAEMOSTASIS, V94, P17, DOI 10.1160/TH04-11-0759; Wu Olivia, 2005, Gend Med, V2 Suppl A, pS18, DOI 10.1016/S1550-8579(05)80061-0	66	352	366	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1227	+		10.1136/bmj.39555.441944.BE	http://dx.doi.org/10.1136/bmj.39555.441944.BE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18495631	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000256612700030
J	Milstein, JM				Milstein, Jay M.			Introducing spirituality in medical care - Transition from hopelessness to wholeness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							DEATH; HEALTH		Univ Calif Davis, Div Neonatol, Dept Pediat, Sacramento, CA 95817 USA	University of California System; University of California Davis	Milstein, JM (corresponding author), Univ Calif Davis, Div Neonatol, Dept Pediat, 2516 Stockton Blvd, Sacramento, CA 95817 USA.	jmmilstein@ucdavis.edu						Croog SH, 2001, ALZ DIS ASSOC DIS, V15, P201, DOI 10.1097/00002093-200110000-00006; Enyert G, 1999, Am J Hosp Palliat Care, V16, P455, DOI 10.1177/104990919901600207; Frank Arthur W, 1995, WOUNDED STORYTELLER, P53; Handzo G, 2004, SOUTH MED J, V97, P1242, DOI 10.1097/01.SMJ.0000146490.49723.AE; Lang A, 2004, INT J NURS STUD, V41, P869, DOI 10.1016/j.ijnurstu.2004.03.013; Lang A, 2003, DEATH STUD, V27, P851, DOI 10.1080/716100345; Milstein Jay, 2005, J Perinatol, V25, P563, DOI 10.1038/sj.jp.7211358; Milstein Jay M, 2007, Am J Hosp Palliat Care, V24, P343, DOI 10.1177/1049909107305645; Milstein Jay M, 2003, J Perinatol, V23, P333, DOI 10.1038/sj.jp.7210903; Park CL, 2007, J BEHAV MED, V30, P319, DOI 10.1007/s10865-007-9111-x; Puchalski CM, 2004, CLIN GERIATR MED, V20, P689, DOI 10.1016/j.cger.2004.07.004; Raingruber B, 2007, J HOLIST NURS, V25, P39, DOI 10.1177/0898010106289859; Rajajee S, 2007, INDIAN J PEDIATR, V74, P837, DOI 10.1007/s12098-007-0149-0; RAO N, 1986, ARCH PHYS MED REHAB, V67, P759, DOI 10.1016/0003-9993(86)90011-0; Schaap AHP, 1997, EUR J OBSTET GYN R B, V75, P161, DOI 10.1016/S0301-2115(97)00127-9	15	26	26	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 28	2008	299	20					2440	2441		10.1001/jama.299.20.2440	http://dx.doi.org/10.1001/jama.299.20.2440			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	305BD	18505954				2023-01-03	WOS:000256151900029
J	Argiris, A; Karamouzis, MV; Raben, D; Ferris, RL				Argiris, Athanassios; Karamouzis, Michalis V.; Raben, David; Ferris, Robert L.			Head and neck cancer	LANCET			English	Review							SQUAMOUS-CELL CARCINOMA; LOCALLY ADVANCED HEAD; LOCOREGIONALLY ADVANCED HEAD; CISPLATIN PLUS FLUOROURACIL; QUALITY-OF-LIFE; PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; 2ND PRIMARY TUMORS; RADIATION-THERAPY; HUMAN-PAPILLOMAVIRUS	Most head and neck cancers are squamous cell carcinomas that develop in the upper aerodigestive epithelium after exposure to carcinogens such as tobacco and alcohol. Human papillomavirus has also been strongly implicated as a causative agent in a subset of these cancers. The complex anatomy and vital physiological role of the tumour-involved structures dictate that the goals of treatment are not only to improve survival outcomes but also to preserve organ function. Major improvements have been accomplished in surgical techniques and radiotherapy delivery. Moreover, systemic therapy including chemotherapy and molecularly targeted agents-namely, the epidermal growth factor receptor inhibitors-has been successfully integrated into potentially curative treatment of locally advanced squamous-cell carcinoma of the head and neck. In deciding which treatment strategy would be suitable for an individual patient, important considerations include expected functional outcomes, ability to tolerate treatment, and comorbid illnesses. The collaboration of many specialties is the key for optimum assessment and decision making. We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck.	[Argiris, Athanassios; Karamouzis, Michalis V.] Univ Pittsburgh, Div Hematol Oncol, Dept Med, Pittsburgh, PA 15232 USA; [Argiris, Athanassios; Karamouzis, Michalis V.; Ferris, Robert L.] Univ Pittsburgh, Pittsburgh Canc Inst, Head & Neck Canc Program, Pittsburgh, PA USA; [Raben, David] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA; [Ferris, Robert L.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Ferris, Robert L.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA; [Ferris, Robert L.] Univ Pittsburgh, Pittsburgh Canc Inst, Canc Immunol Immunotherapy & Immunoprevent Progra, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; University of Colorado System; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Argiris, A (corresponding author), Univ Pittsburgh, Div Hematol Oncol, Dept Med, UPMC Canc Pavil,5th Floor, Pittsburgh, PA 15232 USA.	argirisae@upmc.edu	Karamouzis, Michalis/AAD-2860-2020	Argiris, Athanassios/0000-0003-4075-8812	NATIONAL CANCER INSTITUTE [P50CA097190] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA097190, P50CA097190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abendstein H, 2005, LARYNGOSCOPE, V115, P2183, DOI 10.1097/01.MLG.0000181507.69620.14; Adelstein DJ, 2003, J CLIN ONCOL, V21, P92, DOI 10.1200/JCO.2003.01.008; Allal AS, 2003, HEAD NECK-J SCI SPEC, V25, P833, DOI 10.1002/hed.10302; Ambrosch Petra, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P82, DOI 10.1097/MOO.0b013e3280147336; Annertz K, 2002, INT J CANCER, V101, P95, DOI 10.1002/ijc.10577; [Anonymous], 2006, SEER CANC STAT REV 1; Argiris A, 2003, CANC TREAT, V114, P15; Argiris A, 2004, HEAD NECK-J SCI SPEC, V26, P447, DOI 10.1002/hed.10394; Argiris A, 2004, CLIN CANCER RES, V10, P1956, DOI 10.1158/1078-0432.CCR-03-1077; Argiris A, 2003, ANN ONCOL, V14, P1306, DOI 10.1093/annonc/mdg330; Argiris Athanassios, 2005, J Natl Compr Canc Netw, V3, P393; Bachaud JM, 1996, INT J RADIAT ONCOL, V36, P999, DOI 10.1016/S0360-3016(96)00430-0; Balz V, 2003, CANCER RES, V63, P1188; Bentzen SM, 2003, INT J RADIAT BIOL, V79, P581, DOI 10.1080/09553000310001597002; Bernier J, 2005, HEAD NECK-J SCI SPEC, V27, P843, DOI 10.1002/hed.20279; Bernier J, 2005, NAT CLIN PRACT ONCOL, V2, P305, DOI 10.1038/ncponc0201; Bernier J, 2004, NEW ENGL J MED, V350, P1945, DOI 10.1056/NEJMoa032641; Bese NS, 2007, INT J RADIAT ONCOL, V68, P654, DOI 10.1016/j.ijrobp.2007.03.010; BLOT WJ, 1988, CANCER RES, V48, P3282; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Bourhis J, 2004, J CLIN ONCOL, V22, p489S; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Branstetter BF, 2005, RADIOLOGY, V235, P580, DOI 10.1148/radiol.2352040134; Brennan M, 2007, ORAL SURG ORAL MED O, V103, pS19, DOI 10.1016/j.tripleo.2006.10.015; Brizel DM, 1998, NEW ENGL J MED, V338, P1798, DOI 10.1056/NEJM199806183382503; Brockstein B, 2004, ANN ONCOL, V15, P1179, DOI 10.1093/annonc/mdh308; Budach V, 2005, J CLIN ONCOL, V23, P1125, DOI 10.1200/JCO.2005.07.010; Burtness B, 2005, J CLIN ONCOL, V23, P8646, DOI 10.1200/JCO.2005.02.4646; Calais G, 2006, J CLIN ONCOL, V24, p281S; Calais G, 1999, J NATL CANCER I, V91, P2081, DOI 10.1093/jnci/91.24.2081; Califano J, 1996, CANCER RES, V56, P2488; Capaccio P, 2000, HEAD NECK-J SCI SPEC, V22, P234, DOI 10.1002/(SICI)1097-0347(200005)22:3<234::AID-HED5>3.0.CO;2-3; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; Cohen EEW, 2004, J CLIN ONCOL, V22, P1743, DOI 10.1200/JCO.2004.06.147; Colevas AD, 2006, J CLIN ONCOL, V24, P2644, DOI 10.1200/JCO.2005.05.3348; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; COOPER JS, 2006, ANN M AM SOC THER RA; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; DEANDRES L, 1995, J CLIN ONCOL, V13, P1493, DOI 10.1200/JCO.1995.13.6.1493; Denis F, 2004, J CLIN ONCOL, V22, P69, DOI 10.1200/JCO.2004.08.021; Dey P, 2002, COCHRANE DB SYST REV, V2; Ding MS, 2005, OTOLARYNG CLIN N AM, V38, P371, DOI 10.1016/j.otc.2004.10.009; Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302; Do KA, 2003, CANCER CAUSE CONTROL, V14, P131, DOI 10.1023/A:1023060315781; Domenge C, 2000, BRIT J CANCER, V83, P1594, DOI 10.1054/bjoc.2000.1512; Duvvuri U, 2004, LARYNGOSCOPE, V114, P2228, DOI 10.1097/01.mlg.0000149464.73080.20; Eisbruch A, 2004, INT J RADIAT ONCOL, V59, P28, DOI 10.1016/j.ijrobp.2003.10.032; Ferlito A, 2006, ORAL ONCOL, V42, P14, DOI 10.1016/j.oraloncology.2005.03.009; FERRARA N, 2005, ONCOLOGY S3, V69, pS11; Ferris RL, 2005, IMMUNOL RES, V33, P113, DOI 10.1385/IR:33:2:113; Ferris RL, 2005, CANCER RES, V65, P2147, DOI 10.1158/0008-5472.CAN-04-3717; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; FORASTIERE AA, 1992, J CLIN ONCOL, V10, P1245, DOI 10.1200/JCO.1992.10.8.1245; Forastiere AA, 2006, J CLIN ONCOL, V24, P5517; Foulkes WD, 1996, BMJ-BRIT MED J, V313, P716, DOI 10.1136/bmj.313.7059.716; Fu KK, 2000, INT J RADIAT ONCOL, V48, P7, DOI 10.1016/S0360-3016(00)00663-5; Garavello W, 2006, ANN ONCOL, V17, P1459, DOI 10.1093/annonc/mdl166; Garden Adam S, 2006, Curr Oncol Rep, V8, P140, DOI 10.1007/s11912-006-0049-x; Garden AS, 2004, J CLIN ONCOL, V22, P2856, DOI 10.1200/JCO.2004.12.012; Gibson MK, 2005, J CLIN ONCOL, V23, P3562, DOI 10.1200/JCO.2005.01.057; Gillison ML, 2007, HEAD NECK-J SCI SPEC, V29, P779, DOI 10.1002/hed.20573; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Greenberg JS, 2003, CANCER, V98, P508, DOI 10.1002/cncr.11526; Ha PK, 2006, LANCET ONCOL, V7, P77, DOI 10.1016/S1470-2045(05)70540-4; Hashibe M, 2006, CANCER EPIDEM BIOMAR, V15, P696, DOI 10.1158/1055-9965.EPI-05-0710; Henke M, 2006, J CLIN ONCOL, V24, P4708, DOI 10.1200/JCO.2006.06.2737; Hitt R, 2005, J CLIN ONCOL, V23, P8636, DOI 10.1200/JCO.2004.00.1990; Hobbs CGL, 2006, CLIN OTOLARYNGOL, V31, P259, DOI 10.1111/j.1749-4486.2006.01246.x; Huguenin P, 2004, J CLIN ONCOL, V22, P4665, DOI 10.1200/JCO.2004.12.193; JANOT F, 2006, J CLIN ONCOL S18, V24, P5508; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jeremic B, 1997, RADIOTHER ONCOL, V43, P29, DOI 10.1016/S0167-8140(97)00048-0; Jeremic B, 2000, J CLIN ONCOL, V18, P1458, DOI 10.1200/JCO.2000.18.7.1458; Jones AS, 2004, HEAD NECK-J SCI SPEC, V26, P127, DOI 10.1002/hed.10361; Karamouzis MV, 2007, JAMA-J AM MED ASSOC, V298, P70, DOI 10.1001/jama.298.1.70; Kendal WS, 2007, ANN ONCOL, V18, P381, DOI 10.1093/annonc/mdl385; Khuri FR, 2006, JNCI-J NATL CANCER I, V98, P441, DOI 10.1093/jnci/djj091; Konski A, 2006, INT J RADIAT ONCOL, V66, P408, DOI 10.1016/j.ijrobp.2006.04.049; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Kuss I, 2004, CLIN CANCER RES, V10, P3755, DOI 10.1158/1078-0432.CCR-04-0054; LARAMORE GE, 1992, INT J RADIAT ONCOL, V23, P705, DOI 10.1016/0360-3016(92)90642-U; Le QTX, 1997, INT J RADIAT ONCOL, V39, P115, DOI 10.1016/S0360-3016(97)00284-8; Lee JJ, 2000, CLIN CANCER RES, V6, P1702; Lefebvre JL, 2006, LANCET ONCOL, V7, P747, DOI 10.1016/S1470-2045(06)70860-9; Lefebvre JL, 1996, J NATL CANCER I, V88, P890, DOI 10.1093/jnci/88.13.890; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Lippman SM, 2006, CLIN CANCER RES, V12, P3109, DOI 10.1158/1078-0432.CCR-05-2636; List MA, 1999, J CLIN ONCOL, V17, P1020, DOI 10.1200/JCO.1999.17.3.1020; List MA, 2000, J CLIN ONCOL, V18, P877, DOI 10.1200/JCO.2000.18.4.877; Lodi G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001829.pub3; Lopez-Albaitero A, 2006, J IMMUNOL, V176, P3402, DOI 10.4049/jimmunol.176.6.3402; Mao L, 1996, NAT MED, V2, P682, DOI 10.1038/nm0696-682; McCaul JA, 2002, LANCET ONCOL, V3, P280, DOI 10.1016/S1470-2045(02)00729-5; Mendenhall WM, 2006, AM J CLIN ONCOL-CANC, V29, P290, DOI 10.1097/01.coc.0000209510.19360.f9; Mendenhall WM, 2004, CANCER-AM CANCER SOC, V100, P1786, DOI 10.1002/cncr.20181; MORTON RP, 1985, CANCER CHEMOTH PHARM, V15, P283; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; MYERS EN, 1994, ANN OTO RHINOL LARYN, V103, P28, DOI 10.1177/000348949410300104; Nakamura K, 2006, INT J RADIAT ONCOL, V65, P1045, DOI 10.1016/j.ijrobp.2006.02.001; Ng SH, 2006, J CLIN ONCOL, V24, P4371, DOI 10.1200/JCO.2006.05.7349; Nguyen LN, 2002, LANCET ONCOL, V3, P693, DOI 10.1016/S1470-2045(02)00906-3; Olmi P, 2003, INT J RADIAT ONCOL, V55, P78, DOI 10.1016/S0360-3016(02)03792-6; PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel SG, 2005, CA-CANCER J CLIN, V55, P242, DOI 10.3322/canjclin.55.4.242; Pavia M, 2006, AM J CLIN NUTR, V83, P1126, DOI 10.1093/ajcn/83.5.1126; Perez-Ordonez B, 2006, J CLIN PATHOL, V59, P445, DOI 10.1136/jcp.2003.007641; PETERS LJ, 1993, INT J RADIAT ONCOL, V26, P3, DOI 10.1016/0360-3016(93)90167-T; Pfister DG, 2006, J CLIN ONCOL, V24, P3693, DOI 10.1200/JCO.2006.07.4559; Pfister DG, 2006, J CLIN ONCOL, V24, P1072, DOI 10.1200/JCO.2004.00.1792; Pignataro L, 1998, J CLIN ONCOL, V16, P3069, DOI 10.1200/JCO.1998.16.9.3069; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Posner MR, 2007, NEW ENGL J MED, V357, P1705, DOI 10.1056/NEJMoa070956; Proia NK, 2006, CANCER EPIDEM BIOMAR, V15, P1061, DOI 10.1158/1055-9965.EPI-05-0983; Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149; Roepman P, 2006, CANCER RES, V66, P2361, DOI 10.1158/0008-5472.CAN-05-3960; Rosenthal DI, 2006, J CLIN ONCOL, V24, P2636, DOI 10.1200/JCO.2006.06.0079; Ryu JK, 2007, INT J RADIAT ONCOL, V67, P643, DOI 10.1016/j.ijrobp.2006.09.043; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Saraiya M, 2007, J CLIN ONCOL, V25; Schmalbach Cecelia E, 2007, Curr Oncol Rep, V9, P139, DOI 10.1007/s11912-007-0012-5; Schwartz SM, 1998, JNCI-J NATL CANCER I, V90, P1626, DOI 10.1093/jnci/90.21.1626; Semrau R, 2006, INT J RADIAT ONCOL, V64, P1308, DOI 10.1016/j.ijrobp.2005.10.039; Shangina O, 2006, AM J EPIDEMIOL, V164, P367, DOI 10.1093/aje/kwj208; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Simental AA, 2006, ANN OTO RHINOL LARYN, V115, P846, DOI 10.1177/000348940611501109; Slebos RJC, 2006, CLIN CANCER RES, V12, P701, DOI 10.1158/1078-0432.CCR-05-2017; Smith BD, 2000, J CLIN ONCOL, V18, P2046, DOI 10.1200/JCO.2000.18.10.2046; Staar S, 2001, INT J RADIAT ONCOL, V50, P1161, DOI 10.1016/S0360-3016(01)01544-9; STEWART S, 2007, ANN M AM ASS CANC RE; Sturgis EM, 2002, CURR OPIN ONCOL, V14, P310, DOI 10.1097/00001622-200205000-00010; Suarez C, 2006, ORAL ONCOL, V42, P965, DOI 10.1016/j.oraloncology.2006.03.002; Suwinski R, 2003, INT J RADIAT ONCOL, V56, P399, DOI 10.1016/S0360-3016(02)04469-3; Suzuki M, 2006, RADIOTHER ONCOL, V78, P283, DOI 10.1016/j.radonc.2006.03.006; TRIZNA Z, 1992, OTOLARYNG CLIN N AM, V25, P1089; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8; TUYNS AJ, 1988, INT J CANCER, V41, P483, DOI 10.1002/ijc.2910410403; Vermorken J, 2007, J CLIN ONCOL S, V25, P6091; Vermorken JB, 2007, NEW ENGL J MED, V357, P1695, DOI 10.1056/NEJMoa071028; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014; VOKES EE, 1990, J CLIN ONCOL, V8, P911, DOI 10.1200/JCO.1990.8.5.911; Voynov G, 2006, TECHNOL CANCER RES T, V5, P529, DOI 10.1177/153303460600500510; Warnakulasuriya S, 2002, ADDICT BIOL, V7, P127, DOI 10.1080/13556210120091491; Weber RS, 2003, ARCH OTOLARYNGOL, V129, P44, DOI 10.1001/archotol.129.1.44; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wendt TG, 1998, J CLIN ONCOL, V16, P1318, DOI 10.1200/JCO.1998.16.4.1318; Witcher TP, 2007, BRIT J ORAL MAX SURG, V45, P19, DOI 10.1016/j.bjoms.2006.03.018; WOLF GT, 1991, NEW ENGL J MED, V324, P1685, DOI 10.1056/nejm199106133242402; Zorat PL, 2004, JNCI-J NATL CANCER I, V96, P1714, DOI 10.1093/jnci/djh306; [No title captured]	153	1373	1407	0	167	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2008	371	9625					1695	1709		10.1016/S0140-6736(08)60728-X	http://dx.doi.org/10.1016/S0140-6736(08)60728-X			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302XB	18486742	Green Accepted			2023-01-03	WOS:000256002200028
J	Kamath, AT; Rochat, AF; Christensen, D; Agger, EM; Andersen, P; Lambert, PH; Siegrist, CA				Kamath, Arun T.; Rochat, Anne-Francoise; Christensen, Dennis; Agger, Else Marie; Andersen, Peter; Lambert, Paul-Henri; Siegrist, Claire-Anne			A Liposome-Based Mycobacterial Vaccine Induces Potent Adult and Neonatal Multifunctional T Cells through the Exquisite Targeting of Dendritic Cells	PLOS ONE			English	Article								Background: In the search for more potent and safer tuberculosis vaccines, CAF01 was identified as a remarkable formulation. Based on cationic liposomes and including a synthetic mycobacterial glycolipid as TLR-independent immunomodulator, it induces strong and protective T helper-1 and T helper-17 adult murine responses to Ag85B-ESAT-6, a major mycobacterial fusion protein. Here, we assessed whether these properties extend to early life and how CAF01 mediates its adjuvant properties in vivo. Methods/Findings: Following adult or neonatal murine immunization, Ag85B-ESAT-6/CAF01 similarly reduced the post-challenge bacterial growth of M. bovis BCG, whereas no protection was observed using Alum as control. This protection was mediated by the induction of similarly strong Th1 and Th17 responses in both age groups. Multifunctional Th1 cells were already elicited after a single vaccine dose and persisted at high levels for at least 6 months even after neonatal priming. Unexpectedly, this potent adjuvanticity was not mediated by a massive targeting/activation of dendritic cells: in contrast, very few DCs in the draining lymph nodes were bearing the labeled antigen/adjuvant. The increased expression of the CD40 and CD86 activation markers was restricted to the minute portion of adjuvant-bearing DCs. However, vaccine-associated activated DCs were recovered several days after immunization. Conclusion: The potent adult and neonatal adjuvanticity of CAF01 is associated in vivo with an exquisite but prolonged DC uptake and activation, fulfilling the preclinical requirements for novel tuberculosis vaccines to be used in early life.			Kamath, AT (corresponding author), Univ Geneva, Fac Med, Collaborating Ctr Vaccinol & Neonatal Immunol, WHO,Dept Pathol Immunol, Geneva, Switzerland.	Claire-Anne.Siegrist@unige.ch	Christensen, Dennis/C-6378-2008	Christensen, Dennis/0000-0003-2382-8639; Andersen, Peter/0000-0002-5869-2551				Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Agger EM, 2006, VACCINE, V24, P5452, DOI 10.1016/j.vaccine.2006.03.072; Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116; Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118; Baumann S, 2006, CURR OPIN IMMUNOL, V18, P438, DOI 10.1016/j.coi.2006.05.016; Cendron D, 2007, EUR J IMMUNOL, V37, P549, DOI 10.1002/eji.200636343; Cooper AM, 2008, IMMUNOL REV, V226, P191, DOI 10.1111/j.1600-065X.2008.00702.x; Dadaglio G, 2002, J IMMUNOL, V168, P2219, DOI 10.4049/jimmunol.168.5.2219; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; de Jong R, 1998, SCIENCE, V280, P1435; GILLIS S, 1978, J IMMUNOL, V120, P2027; Giri PK, 2008, EXPERT OPIN BIOL TH, V8, P1759, DOI [10.1517/14712598.8.11.1759, 10.1517/14712598.8.11.1759 ]; Henri S, 2001, J IMMUNOL, V167, P741, DOI 10.4049/jimmunol.167.2.741; Hoft DF, 2008, LANCET, V372, P164, DOI 10.1016/S0140-6736(08)61036-3; Holten-Andersen L, 2004, INFECT IMMUN, V72, P1608, DOI 10.1128/IAI.72.3.1608-1617.2004; Hou WS, 2004, NAT IMMUNOL, V5, P583, DOI 10.1038/ni1071; Kamath AT, 2008, EUR J IMMUNOL, V38, P1247, DOI 10.1002/eji.200737889; Kamath AT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003683; Kamath AT, 2002, BLOOD, V100, P1734, DOI 10.1182/blood.V100.5.1734.h81702001734_1734_1741; Kaufmann SHE, 2008, SCAND J INFECT DIS, V40, P595, DOI 10.1080/00365540802032759; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Knuf M, 2008, J PEDIATR-US, V152, P655, DOI 10.1016/j.jpeds.2007.09.034; KORSHOLM KS, 2007, IMMUNOLOGY; Kovarik J, 2000, VIROLOGY, V268, P122, DOI 10.1006/viro.1999.0159; Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Mandalakas Anna M, 2005, Semin Pediatr Infect Dis, V16, P93, DOI 10.1053/j.spid.2005.01.001; Martin GH, 2003, LIBRARY, V4, P428, DOI 10.1093/library/4.4.428; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Miles DJC, 2008, CLIN VACCINE IMMUNOL, V15, P995, DOI 10.1128/CVI.00037-08; Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001; Olsen AW, 2004, INFECT IMMUN, V72, P6148, DOI 10.1128/IAI.72.10.6148-6150.2004; Randolph GJ, 2008, ANNU REV IMMUNOL, V26, P293, DOI 10.1146/annurev.immunol.26.021607.090254; Regner M, 2004, J IMMUNOL, V173, P2669, DOI 10.4049/jimmunol.173.4.2669; Reichenbach J, 2001, CURR OPIN ALLERGY CL, V1, P503, DOI 10.1097/00130832-200112000-00003; Riedl K, 2008, VACCINE, V26, P3461, DOI 10.1016/j.vaccine.2008.04.029; Roduit C, 2002, INFECT IMMUN, V70, P3521, DOI 10.1128/IAI.70.7.3521-3528.2002; Ruedl C, 2000, J IMMUNOL, V165, P4910, DOI 10.4049/jimmunol.165.9.4910; Schellack C, 2006, VACCINE, V24, P5461, DOI 10.1016/j.vaccine.2006.03.071; Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962; Siegrist CA, 2007, J COMP PATHOL, V137, pS4, DOI 10.1016/j.jcpa.2007.04.004; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Soares AP, 2008, J IMMUNOL, V180, P3569, DOI 10.4049/jimmunol.180.5.3569; Tacken PJ, 2007, NAT REV IMMUNOL, V7, P790, DOI 10.1038/nri2173; Teoh D, 2009, J IMMUNOL, V182, P2425, DOI 10.4049/jimmunol.0803661; Trunz BB, 2006, LANCET, V367, P1173, DOI 10.1016/S0140-6736(06)68507-3; Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1; Weeratna RD, 2001, FEMS IMMUNOL MED MIC, V32, P65, DOI 10.1016/S0928-8244(01)00267-X; Werninghaus K, 2009, J EXP MED, V206, P89, DOI 10.1084/jem.20081445; WHO, 2007, WKLY EPIDEMIOL REC, V82, P18; Willems F, 2009, EUR J IMMUNOL, V39, P26, DOI 10.1002/eji.200838391; Winthrop KL, 2006, NAT CLIN PRACT RHEUM, V2, P602, DOI 10.1038/ncprheum0336	52	72	75	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2009	4	6							e5771	10.1371/journal.pone.0005771	http://dx.doi.org/10.1371/journal.pone.0005771			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	453PV	19492047	Green Published, gold, Green Submitted			2023-01-03	WOS:000266624300008
J	Sokol, DK				Sokol, Daniel K.			Observations Ethics Man The death of DNR	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ALLOW NATURAL DEATH; CARDIOPULMONARY-RESUSCITATION		Univ London, London WC1E 7HU, England	University of London	Sokol, DK (corresponding author), Univ London, London WC1E 7HU, England.	daniel.sokol@talk21.com						Adams DH, 2006, J AM OSTEOPATH ASSOC, V106, P402; Chen YY, 2008, J MED ETHICS, V34, P887, DOI 10.1136/jme.2008.024570; Chessa F, 2004, HASTINGS CENT REP, V34, P4, DOI 10.2307/3527579; Cohen RW, 2004, HASTINGS CENT REP, V34, P4; Conroy SP, 2006, BRIT MED J, V332, P479, DOI 10.1136/bmj.332.7539.479; Jones GK, 2000, ACAD EMERG MED, V7, P48, DOI 10.1111/j.1553-2712.2000.tb01891.x; Jonsen AR, 2006, CLIN ETHICS; Venneman SS, 2008, J MED ETHICS, V34, P2, DOI 10.1136/jme.2006.018317	8	9	9	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	APR 30	2009	338								b1723	10.1136/bmj.b1723	http://dx.doi.org/10.1136/bmj.b1723			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	440JY	19406889				2023-01-03	WOS:000265697800010
J	Ferguson, MWJ; Duncan, J; Bond, J; Bush, J; Durani, P; So, K; Taylor, L; Chantrey, J; Mason, T; James, G; Laverty, H; Occleston, NL; Sattar, A; Ludlow, A; O'Kane, S				Ferguson, Mark W. J.; Duncan, Jonathan; Bond, Jeremy; Bush, James; Durani, Piyush; So, Karen; Taylor, Lisa; Chantrey, Jonquille; Mason, Tracey; James, Gaynor; Laverty, Hugh; Occleston, Nick L.; Sattar, Abdul; Ludlow, Anna; O'Kane, Sharon			Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies	LANCET			English	Article							GROWTH-FACTOR-BETA; NEUTRALIZING ANTIBODY; MECHANISMS; DISEASE; WOUNDS	Background Research into mechanisms of skin scarring identified transforming growth factor beta 3 (TGF beta 3) as a potential antiscarring therapy. We assessed scar improvement with avotermin (recombinant, active, human TGF beta 3). Methods In three double-blind, placebo-controlled studies, intradermal avotermin (concentrations ranging from 0.25 to 500 ng/100 mu L per linear cm wound margin) was administered to both margins of 1 cm, full-thickness skin incisions, before wounding and 24 h later, in healthy men and women. Treatments (avotermin and placebo or standard wound care) were randomly allocated to wound sites by a computer generated randomisation scheme, and within-participant controls compared avotermin versus placebo or standard wound care alone. Primary endpoints were visual assessment of scar formation at 6 months and 12 months after wounding in two studies, and from week 6 to month 7 after wounding in the third. investigators, participants, and scar assessors were blinded to treatment. Efficacy analyses were intention to treat. These studies are registered with ClinicalTrials.gov, numbers NCT00847925, NCT00847795, and NCT00629811. Results In two studies, avotermin 50 ng/100 mu L per linear cm significantly improved median score on a 100 mm visual analogue scale (VAS) by 5 mm (range -2 to 14; p=0.001) at month 6 and 8 mm (-29 to 18; p=0.0230) at month 12. In the third, avotermin significantly improved total scar scores at all concentrations versus placebo (mean improvement: from 14.84 mm [95 % Cl 5.5-24.2] at 5 ng/100 mu L per linear cm to 64.25 mm [49.4-79.1] at 500 ng/100 mu L per linear cm). Nine [60%] scars treated with avotermin 50 ng/100 mu L per linear cm showed 25% or less abnormal orientation of collagen fibres in the reticular dermis versus five [33%] placebo scars. After only 6 weeks from wounding, avotermin 500 ng/100 mu L per linear cm improved VAS score by 16.12 mm (95% CI 10.61-21.63). Adverse events at wound sites were similar for avotermin and controls. Erythema and oedema were more frequent with avotermin than with placebo, but were transient and deemed to be consistent with normal wound healing. Interpretation Avotermin has potential to provide an accelerated and permanent improvement in scarring.	[Ferguson, Mark W. J.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Duncan, Jonathan; Durani, Piyush; Chantrey, Jonquille] Univ Manchester, Dept Plast & Reconstruct Surg, Fac Med & Human Sci, Manchester, Lancs, England; [Bond, Jeremy; Taylor, Lisa] Ulster Hosp, No Ireland Plast & Maxillofacial Serv, Belfast, Antrim, North Ireland; [Ferguson, Mark W. J.; Duncan, Jonathan; Bond, Jeremy; Bush, James; Durani, Piyush; So, Karen; Taylor, Lisa; Chantrey, Jonquille; Mason, Tracey; James, Gaynor; Laverty, Hugh; Occleston, Nick L.; Sattar, Abdul; Ludlow, Anna; O'Kane, Sharon] Renovo, Manchester M13 9XX, Lancs, England	University of Manchester; University of Manchester	Ferguson, MWJ (corresponding author), Renovo, Manchester Incubator Bldg,48 Grafton St, Manchester M13 9XX, Lancs, England.	mark.ferguson@renovo.com		Durani, Piyush/0000-0002-4388-9570	Renovo	Renovo	This research was funded by Renovo. We thank all the volunteers who participated in the studies; Kathryn Quinn for assistance in the preparation of the manuscript; Andrew Kay, John Hutchison, and David Fairlamb for critically reviewing the report; and Adam Boanas for assistance with histological analyses.	Ashcroft GS, 1997, J INVEST DERMATOL, V108, P430, DOI 10.1111/1523-1747.ep12289705; ASHCROFT GS, 1995, J ANAT, V187, P1; Ashcroft GS, 1998, LAB INVEST, V78, P47; Bayat A, 2004, EXP DERMATOL, V13, P120, DOI 10.1111/j.0906-6705.2004.00165.x; Bayat A, 2003, BRIT MED J, V326, P88, DOI 10.1136/bmj.326.7380.88; Bond JS, 2008, PLAST RECONSTR SURG, V121, P487, DOI 10.1097/01.prs.0000299183.88334.37; Duncan JAL, 2006, PLAST RECONSTR SURG, V118, P909, DOI 10.1097/01.prs.0000232378.88776.b0; Ferguson MWJ, 2004, PHILOS T R SOC B, V359, P839, DOI 10.1098/rstb.2004.1475; Meier Karen, 2006, Expert Opin Emerg Drugs, V11, P39, DOI 10.1517/14728214.11.1.39; Mustoe TA, 2002, PLAST RECONSTR SURG, V110, P560, DOI 10.1097/00006534-200208000-00031; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; SHAH M, 1995, J CELL SCI, V108, P985; SHAH M, 1994, J CELL SCI, V107, P1137; SHAH M, 1992, LANCET, V339, P213, DOI 10.1016/0140-6736(92)90009-R; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; SOMMERLAD BC, 1978, BRIT J PLAST SURG, V31, P34, DOI 10.1016/0007-1226(78)90012-7; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1	17	190	208	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 11	2009	373	9671					1264	1274		10.1016/S0140-6736(09)60322-6	http://dx.doi.org/10.1016/S0140-6736(09)60322-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	432PN	19362676				2023-01-03	WOS:000265146300029
J	Mahoney, CM; Morgan, MR; Harrison, A; Humphries, MJ; Bass, MD				Mahoney, Claire M.; Morgan, Mark R.; Harrison, Andrew; Humphries, Martin J.; Bass, Mark D.			Therapeutic Ultrasound Bypasses Canonical Syndecan-4 Signaling to Activate Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTENSITY PULSED ULTRASOUND; CUTANEOUS WOUND REPAIR; NF-KAPPA-B; CELL-ADHESION; CYCLOOXYGENASE-2 EXPRESSION; ALPHA(5)BETA(1) INTEGRIN; DIRECTIONAL MIGRATION; HUMAN OSTEOBLASTS; IN-VITRO; FIBRONECTIN	The application of pulsed, low intensity ultrasound is emerging as a potent therapy for the treatment of complex bone fractures and tissue damage. Ultrasonic stimuli accelerate fracture healing by up to 40% and enhance tendon and ligament healing by promoting cell proliferation, migration, and matrix synthesis through an unresolved mechanism. Ultrasound treatment also induces closure of nonunion fractures, at a success rate (85% of cases) similar to that of surgical intervention (68-96%) while avoiding the complications associated with surgery. The regulation of cell adhesion necessary for wound healing depends on cooperative engagement of the extracellular matrix receptors, integrin and syndecan, as exemplified by the wound healing defects observed in syndecan-and integrin-knock-out mice. This report distinguishes the influence of ultrasound on signals downstream of the prototypic fibronectin receptors, alpha(5)beta(1) integrin and syndecan-4, which cooperate to regulate Rac1 and RhoA. Ultrasonic stimulation fails to activate integrins or induce cell spreading on poor, electrostatic ligands. By contrast, ultrasound treatment overcomes the necessity of engagement or expression of syndecan-4 during the process of focal adhesion formation, which normally requires simultaneous engagement of both receptors. Ultrasound exerts an influence downstream of syndecan-4 and PKC alpha to specifically activate Rac1, itself a critical regulator of tissue repair, and to a lesser extent RhoA. The ability of ultrasound to bypass syndecan-4 signaling, which is known to facilitate efficient tissue repair, explains the reduction in healing times observed in ultrasound-treated patients. By substituting for one of the key axes of adhesion-dependent signaling, ultrasound therapy has considerable potential as a clinical technique.	[Humphries, Martin J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; [Harrison, Andrew] Smith & Nephew, York YO10 5DF, N Yorkshire, England	University of Manchester; Smith & Nephew	Humphries, MJ (corresponding author), Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	martin.humphries@manchester.ac.uk		Humphries, Martin/0000-0002-4331-6967; Morgan, Mark/0000-0001-7728-9883	Wellcome Trust [045225, 074941]; Biotechnology and Biological Sciences Research Council; University of Manchester Strategic Fund	Wellcome Trust(Wellcome TrustEuropean Commission); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); University of Manchester Strategic Fund	This work was supported by Wellcome Trust Grants 045225 and 074941 (to M.J.H.). The Bioimaging Facility microscopes used in this study were purchased with grants from the Biotechnology and Biological Sciences Research Council, Wellcome Trust, and the University of Manchester Strategic Fund. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	ALKURDI D, 2008, COCHRANE DB SYST REV, V1; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671; Bass MD, 2008, J CELL BIOL, V181, P1013, DOI 10.1083/jcb.200711129; Bass MD, 2007, J CELL BIOL, V177, P527, DOI 10.1083/jcb.200610076; BASS MD, 2007, EUR PHYS J E, V3, P372; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhadriraju K, 2007, EXP CELL RES, V313, P3616, DOI 10.1016/j.yexcr.2007.07.002; Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; CAVANI A, 1993, J INVEST DERMATOL, V101, P600, DOI 10.1111/1523-1747.ep12366057; Chakravarti R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-83; Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014-5793(03)01157-8; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; COUCHMAN JR, 1983, J CELL BIOL, V96, P177, DOI 10.1083/jcb.96.1.177; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Doan N, 1999, J ORAL MAXIL SURG, V57, P409, DOI 10.1016/S0278-2391(99)90281-1; Echtermeyer F, 2001, J CLIN INVEST, V107, pR9, DOI 10.1172/JCI10559; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Gebauer D, 2005, ULTRASOUND MED BIOL, V31, P1391, DOI 10.1016/j.ultrasmedbio.2005.06.002; Grenache DG, 2007, J INVEST DERMATOL, V127, P455, DOI 10.1038/sj.jid.5700611; Grose R, 2002, DEVELOPMENT, V129, P2303; Hassanain HH, 2005, SURGERY, V137, P92, DOI 10.1016/j.surg.2004.06.012; HECKMAN JD, 1994, J BONE JOINT SURG AM, V76A, P26, DOI 10.2106/00004623-199401000-00004; Hsu HC, 2007, CELL SIGNAL, V19, P2317, DOI 10.1016/j.cellsig.2007.07.006; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; Katsumi A, 2002, J CELL BIOL, V158, P153, DOI 10.1083/jcb.200201105; Koo BK, 2006, J MOL BIOL, V355, P651, DOI 10.1016/j.jmb.2005.09.087; Kristiansen TK, 1997, J BONE JOINT SURG AM, V79A, P961, DOI 10.2106/00004623-199707000-00002; MAKAREM R, 1994, J BIOL CHEM, V269, P4005; Matthews HK, 2008, DEVELOPMENT, V135, P1771, DOI 10.1242/dev.017350; Morgan MR, 2007, NAT REV MOL CELL BIO, V8, P957, DOI 10.1038/nrm2289; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Ng COY, 2003, ULTRASOUND MED BIOL, V29, P1501, DOI 10.1016/S0301-5629(03)01018-4; Orr AW, 2008, CIRC RES, V103, P671, DOI 10.1161/CIRCRESAHA.108.182097; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Parvizi J, 2002, J ORTHOPAED RES, V20, P51, DOI 10.1016/S0736-0266(01)00069-9; Praemer A., 1992, MUSCULOSKELETAL COND, P85; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Saoncella S, 2004, J BIOL CHEM, V279, P47172, DOI 10.1074/jbc.C400299200; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Sun D, 2006, DRUG RESIST UPDATE, V9, P274, DOI 10.1016/j.drup.2006.12.001; Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200; Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160; Tscharntke M, 2007, J CELL SCI, V120, P1480, DOI 10.1242/jcs.03426; Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012; Warden SJ, 2006, AM J SPORT MED, V34, P1094, DOI 10.1177/0363546505286139; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518; Zhou SX, 2008, CELL SIGNAL, V20, P695, DOI 10.1016/j.cellsig.2007.12.005; Zhou SX, 2004, J BIOL CHEM, V279, P54463, DOI 10.1074/jbc.M404786200; Zweers MC, 2007, J INVEST DERMATOL, V127, P467, DOI 10.1038/sj.jid.5700546	55	27	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 27	2009	284	13					8889	8900		10.1074/jbc.M804281200	http://dx.doi.org/10.1074/jbc.M804281200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421ZW	19147498	hybrid, Green Published			2023-01-03	WOS:000264397800072
J	Qato, DM; Alexander, GC; Conti, RM; Johnson, M; Schumm, P; Lindau, ST				Qato, Dima M.; Alexander, G. Caleb; Conti, Rena M.; Johnson, Michael; Schumm, Phil; Lindau, Stacy Tessler			Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; NATIONAL-HEALTH	Context Despite concerns about drug safety, current information on older adults' use of prescription and over- the- counter medications and dietary supplements is limited. Objective To estimate the prevalence and patterns of medication use among older adults ( including concurrent use), and potential major drug- drug interactions. Design, Setting, and Participants Three thousand five community- residing individuals, aged 57 through 85 years, were drawn from a cross- sectional, nationally representative probability sample of the United States. In- home interviews, including medication logs, were administered between June 2005 and March 2006. Medication use was defined as prescription, over- the- counter, and dietary supplements used "on a regular schedule, like every day or every week." Concurrent use was defined as the regular use of at least 2 medications. Main Outcome Measure Population estimates of the prevalence of medication use, concurrent use, and potential major drug- drug interactions, stratified by age group and gender. Results The unweighted survey response rate was 74.8% ( weighted response rate, 75.5%). Eighty- one percent ( 95% confidence interval [ CI], 79.4%- 83.5%) used at least 1 prescription medication, 42% ( 95% CI, 39.7%- 44.8%) used at least 1 over- the-counter medication, and 49%( 95% CI, 46.2%- 52.7%) used a dietary supplement. Twenty-nine percent ( 95% CI, 26.6%- 30.6%) used at least 5 prescription medications concurrently; this was highest among men ( 37.1%; 95% CI, 31.7%- 42.4%) and women( 36.0%; 95% CI, 30.2%- 41.9%) aged 75 to 85 years. Among prescription medication users, concurrent use of over- the- counter medications was 46%( 95% CI, 43.4%- 49.1%) and concurrent use of dietary supplements was 52% ( 95% CI, 48.8%- 55.5%). Overall, 4% of individuals were potentially at risk of having a major drug- drug interaction; half of these involved the use of nonprescription medications. These regimens were most prevalent among men in the oldest age group ( 10%; 95% CI, 6.4%- 13.7%) and nearly half involved anticoagulants. No contraindicated concurrent drug use was identified. Conclusions In this sample of community- dwelling older adults, prescription and nonprescription medications were commonly used together, with nearly 1 in 25 individuals potentially at risk for a major drug- drug interaction.	[Qato, Dima M.; Lindau, Stacy Tessler] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; [Alexander, G. Caleb; Conti, Rena M.] Univ Chicago, Gen Internal Med Sect, Dept Med, Chicago, IL 60637 USA; [Alexander, G. Caleb; Lindau, Stacy Tessler] Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA; [Alexander, G. Caleb; Conti, Rena M.] Univ Chicago, Ctr Hlth & Social Sci, Chicago, IL 60637 USA; [Conti, Rena M.] Univ Chicago, Sect Pediat Hematol Oncol, Chicago, IL 60637 USA; [Johnson, Michael; Schumm, Phil] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; [Lindau, Stacy Tessler] Univ Chicago, Sect Geriatr, Dept Med, Chicago, IL 60637 USA; [Qato, Dima M.; Lindau, Stacy Tessler] Univ Chicago, Ctr Demog & Econ Aging, Chicago, IL 60637 USA; [Qato, Dima M.; Lindau, Stacy Tessler] Univ Chicago, NORC, Chicago Core Biomarkers Populat Based Res, Chicago, IL 60637 USA; [Qato, Dima M.] Univ Illinois, Dept Hlth Policy & Adm, Sch Publ Hlth, Chicago, IL USA; [Alexander, G. Caleb] Univ Illinois, Dept Pharm Practice, Sch Pharm, Chicago, IL USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Qato, DM (corresponding author), Univ Chicago, Dept Obstet & Gynecol, 5841 S Maryland Ave,MC 2050, Chicago, IL 60637 USA.	dqato@babies.bsd.uchicago.edu		Schumm, Phil/0000-0002-3050-2429; Qato, Dima/0000-0001-5411-6998; Conti, Rena/0000-0002-4190-1839	National Institutes of Health; National Institute on Aging; Office of Research on Women's Health; Office of AIDS Research; Office of Behavioral and Social Sciences Research [5R01AG021487]; NORC; Merck Foundation; Agency for Healthcare Research and Quality [K08 HS1569901A1]; Robert Wood Johnson Physician Faculty Scholars Program; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS015699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG032870, R01AG021487, P30AG012857] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Office of Research on Women's Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Office of Research on Women's Health (ORWH)); Office of AIDS Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of Behavioral and Social Sciences Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NORC; Merck Foundation(Merck & Company); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Robert Wood Johnson Physician Faculty Scholars Program(Robert Wood Johnson Foundation (RWJF)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The National Social Life, Health and Aging Project ( NSHAP) is supported by the National Institutes of Health, including the National Institute on Aging, the Office of Research on Women's Health, the Office of AIDS Research, and the Office of Behavioral and Social Sciences Research (5R01AG021487). NSHAP is also supported by NORC, whose staff was responsible for the data collection. The National Institutes of Health, National Institute on Aging University of Chicago - NORC Center on Demography and Economics of Aging Core on Biomarkers in Population-Based Health and Aging Research ( 5 P30 AG 012857) and the University of Chicago Program in Pharmaceutical Policy ( David Meltzer, principal investigator) also supported the effort of Dr Qato and Mssrs Schumm and Johnson on this article with a pilot grant ( Dr Lindau, principal investigator). The University of Chicago Program in Pharmaceutical Policy is supported by the Merck Foundation. Dr Alexander has career development awards from the Agency for Healthcare Research and Quality (K08 HS1569901A1) and the Robert Wood Johnson Physician Faculty Scholars Program. Supplies were donated to the NSHAP study by OraSure, Sunbeam, A&D Medical/LifeSource, Wilmer Eye Institute at the Johns Hopkins Bloomberg School of Public Health, Schleicher & Schuell Bioscience, BioMerieux, Roche Diagnostics, Digene, and Richard Williams.	Briesacher BA, 2007, J GEN INTERN MED, V22, P864, DOI 10.1007/s11606-007-0180-x; Budnitz DS, 2007, ANN INTERN MED, V147, P755, DOI 10.7326/0003-4819-147-11-200712040-00006; Catlin A, 2008, HEALTH AFFAIR, V27, P14, DOI 10.1377/hlthaff.27.1.14; *CERN MULT INC, LEX PLUS DAT; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; Curtis LH, 2007, JAMA-J AM MED ASSOC, V298, P1517, DOI 10.1001/jama.298.13.1517; Elmer GW, 2007, ANN PHARMACOTHER, V41, P1617, DOI 10.1345/aph.1K221; FILLENBAUM GG, 1993, AM J PUBLIC HEALTH, V83, P1577, DOI 10.2105/AJPH.83.11.1577; Gardiner P, 2006, ARCH INTERN MED, V166, P1968, DOI 10.1001/archinte.166.18.1968; Gaskin Darrell J, 2006, Am J Geriatr Pharmacother, V4, P96, DOI 10.1016/j.amjopharm.2006.06.008; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hanlon JT, 2001, DRUG AGING, V18, P123, DOI 10.2165/00002512-200118020-00005; Hensrud DD, 1999, MAYO CLIN PROC, V74, P443; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; *IMS, COMM REQ THER CLASS; *IMS, GEN MARK EXP SOAR 80; *IOM, 2006, FUT DRUG SAF PROM PR; Katz JN, 1996, MED CARE, V34, P73, DOI 10.1097/00005650-199601000-00006; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; Kris-Etherton, 2003, CIRCULATION, V107, P512, DOI 10.1161/01.CIR.0000054601.17182.B0; Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94; Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; *NACDA, NAT SOC LIF HLTH AG; QATO D, NATL SOCIAL LIFE HLT; Radimer K, 2004, AM J EPIDEMIOL, V160, P339, DOI 10.1093/aje/kwh207; Saaddine JB, 2006, ANN INTERN MED, V144, P465, DOI 10.7326/0003-4819-144-7-200604040-00005; STAGNITTI MN, 2004, STAT BRIEF 180 TOP 5; *STATACORP, 2007, STAT COMP PROGR VERS; *THOMS REUT HEALTH, MICR HEALTHC SER; *US BUR CENS, POV THRESH 2006; *US FDA, CDER DRUG BIOL APPR; *US FDA, SENT IN NAT STRAT MO	33	630	665	4	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2008	300	24					2867	2878						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386ZG	19109115	Green Accepted, Bronze			2023-01-03	WOS:000261920900020
J	Sharkey, N				Sharkey, Noel			COMPUTER SCIENCE The Ethical Frontiers of Robotics	SCIENCE			English	Editorial Material									[Sharkey, Noel] Univ Sheffield, Dept Comp Sci, Sheffield S1 4DP, S Yorkshire, England	University of Sheffield	Sharkey, N (corresponding author), Univ Sheffield, Dept Comp Sci, Sheffield S1 4DP, S Yorkshire, England.	noel@dcs.shef.ac.uk						Blum D, 2003, LOVE GOON PARK H HAR; BROOKS RA, 1986, IEEE T ROBOTIC AUTOM, V2, P14, DOI 10.1109/JRA.1986.1087032; Fong T, 2003, ROBOT AUTON SYST, V42, P143, DOI 10.1016/S0921-8890(02)00372-X; Forlizzi J, 2004, HUM-COMPUT INTERACT, V19, P25, DOI 10.1207/s15327051hci1901&2_3; *IFR STAT DEP, WORLD ROB REP 2008; *NAT RES COUNC COM, 2005, AUT VEH SUPP NAV OP; Sharkey N, 2008, IEEE INTELL SYST, V23, P14, DOI 10.1109/MIS.2008.60; Sharkey N, 2006, ARTIF INTELL REV, V25, P9, DOI 10.1007/s10462-007-9048-z; Sparrow R., 2002, Ethics and Information Technology, V4, P305, DOI 10.1023/A:1021386708994; SPARROW R, 2004, MIND MACH, V16, P141; TANAKA F, 2007, P NATL ACAD SCI USA, V194, P46; *UN PRESS INT, 2008, BAE SYST TECH BOOSTS; *US DEP DEF, 2005, LSD AT L DEF SYST WA; US Department of Defense, 2007, UNM SYST ROADM 2007	15	82	84	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	2008	322	5909					1800	1801		10.1126/science.1164582	http://dx.doi.org/10.1126/science.1164582			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	385FF	19095930				2023-01-03	WOS:000261799400041
J	Kojic, LD; Wiseman, SM; Ghaidi, F; Joshi, B; Nedev, H; Saragovi, HU; Nabi, IR				Kojic, Liliana D.; Wiseman, Sam M.; Ghaidi, Fariba; Joshi, Bharat; Nedev, Hinyu; Saragovi, H. Uri; Nabi, Ivan R.			Raft-Dependent Endocytosis of Autocrine Motility Factor/Phosphoglucose Isomerase: A Potential Drug Delivery Route for Tumor Cells	PLOS ONE			English	Article								Background: Autocrine motility factor/phosphoglucose isomerase (AMF/PGI) is the extracellular ligand for the gp78/AMFR receptor overexpressed in a variety of human cancers. We showed previously that raft-dependent internalization of AMF/PGI is elevated in metastatic MDA-435 cells, but not metastatic, caveolin-1-expressing MDA-231 cells, relative to non-metastatic MCF7 and dysplastic MCF10A cells suggesting that it might represent a tumor cell-specific endocytic pathway. Methodology/Principal Findings: Similarly, using flow cytometry, we demonstrate that raft-dependent endocytosis of AMF/PGI is increased in metastatic HT29 cancer cells expressing low levels of caveolin-1 relative to metastatic, caveolin-1expressing, HCT116 colon cells and non-metastatic Caco-2 cells. Therefore, we exploited the raft-dependent internalization of AMF/PGI as a potential tumor-cell specific targeting mechanism. We synthesized an AMF/PGI-paclitaxel conjugate and found it to be as efficient as free paclitaxel in inducing cytotoxicity and apoptosis in tumor cells that readily internalize AMF/PGI compared to tumor cells that poorly internalize AMF/PGI. Murine K1735-M1 and B16-F1 melanoma cells internalize FITC-conjugated AMF/PGI and are acutely sensitive to AMF/PGI-paclitaxel mediated cytotoxicity in vitro. Moreover, following in vivo intratumoral injection, FITC-conjugated AMF/PGI is internalized in K1735-M1 tumors. Intratumoral injection of AMF/PGI-paclitaxel induced significantly higher tumor regression compared to free paclitaxel, even in B16-F1 cells, known to be resistant to taxol treatment. Treatment with AMF/PGI-paclitaxel significantly prolonged the median survival time of tumor bearing mice. Free AMF/PGI exhibited a pro-survival role, reducing the cytotoxic effect of both AMF/PGI-paclitaxel and free paclitaxel suggesting that AMF/PGI-paclitaxel targets a pathway associated with resistance to chemotherapeutic agents. AMF/PGI-FITC uptake by normal murine spleen and thymus cells was negligible both in vitro and following intravenous injection in vivo where AMF/PGI-FITC was selectively internalized by subcutaneous B16-F1 tumor cells. Conclusions/Significance: The raft-dependent endocytosis of AMF/PGI may therefore represent a tumor cell specific endocytic pathway of potential value for drug delivery to tumor cells.	[Kojic, Liliana D.; Ghaidi, Fariba; Joshi, Bharat; Nabi, Ivan R.] Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, Vancouver, BC V5Z 1M9, Canada; [Wiseman, Sam M.; Ghaidi, Fariba] Univ British Columbia, St Pauls Hosp, Dept Surg, Vancouver, BC V5Z 1M9, Canada; [Nedev, Hinyu; Saragovi, H. Uri] McGill Univ, Lady Davis Res Inst, Montreal, PQ H3A 2T5, Canada	University of British Columbia; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; McGill University	Kojic, LD (corresponding author), Univ British Columbia, Dept Cellular & Physiol Sci, Inst Life Sci, Vancouver, BC V5Z 1M9, Canada.	irnabi@interchange.ubc.ca	Nabi, Ivan/GWZ-5144-2022	Nabi, Ivan/0000-0002-0670-0513	Canadian Institutes for Health Research [MOP-64333]; Michael Smith Scholar	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Scholar	Supported by grant MOP-64333 to IRN and SMW from the Canadian Institutes for Health Research. SMW is a Michael Smith Scholar. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bareford LA, 2007, ADV DRUG DELIVER REV, V59, P748, DOI 10.1016/j.addr.2007.06.008; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; BENLIMAME N, 1995, J CELL BIOL, V129, P459, DOI 10.1083/jcb.129.2.459; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; BODANSKY O, 1954, CANCER, V7, P1200, DOI 10.1002/1097-0142(195411)7:6<1200::AID-CNCR2820070612>3.0.CO;2-9; CHAPUT M, 1988, NATURE, V332, P454, DOI 10.1038/332454a0; Chiu CG, 2008, EXPERT REV ANTICANC, V8, P207, DOI 10.1586/14737140.8.2.207; FAIK P, 1988, NATURE, V332, P455, DOI 10.1038/332455a0; FILELLA X, 1991, TUMOR BIOL, V12, P360, DOI 10.1159/000217737; Funasaka T, 2005, FASEB J, V19, P1422, DOI 10.1096/fj.05-3699com; Funasaka T, 2002, INT J CANCER, V101, P217, DOI 10.1002/ijc.10617; Funasaka T, 2001, BIOCHEM BIOPH RES CO, V285, P118, DOI 10.1006/bbrc.2001.5135; Funasaka T, 2007, J BIOL CHEM, V282, P36362, DOI 10.1074/jbc.M706301200; Goetz JG, 2006, BIOCHEM SOC T, V34, P370, DOI 10.1042/BST0340370; Goetz JG, 2007, J CELL SCI, V120, P3553, DOI 10.1242/jcs.03486; Guillemard V, 2004, CURR CANCER DRUG TAR, V4, P313, DOI 10.2174/1568009043332989; Guillemard V, 2001, CANCER RES, V61, P694; GUIRGUIS R, 1990, J OCCUP ENVIRON MED, V32, P846, DOI 10.1097/00043764-199009000-00017; GURNEY ME, 1986, SCIENCE, V234, P574, DOI 10.1126/science.3020690; GURNEY ME, 1986, J CELL BIOL, V102, P2264, DOI 10.1083/jcb.102.6.2264; Haga A, 2003, INT J CANCER, V107, P707, DOI 10.1002/ijc.11449; JOSHI B, 2008, CANC RES IN PRESS; KANBE K, 1994, BBA-MOL CELL RES, V1222, P395, DOI 10.1016/0167-4889(94)90046-9; Kirkham M, 2005, BBA-MOL CELL RES, V1745, P273, DOI 10.1016/j.bbamcr.2005.06.002; Kojic LD, 2007, J BIOL CHEM, V282, P29305, DOI 10.1074/jbc.M704069200; KUMAR N, 1981, J BIOL CHEM, V256, P435; Lajoie P, 2007, J CELL MOL MED, V11, P644, DOI 10.1111/j.1582-4934.2007.00083.x; LAJOIE P, 2007, J CELL MOL MED UNPUB; Le PU, 2003, J CELL SCI, V116, P1059, DOI 10.1242/jcs.00327; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Leclerc N, 2000, J NEUROSCI RES, V60, P602, DOI 10.1002/(SICI)1097-4547(20000601)60:5<602::AID-JNR5>3.0.CO;2-F; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Marsh M, 2006, CELL, V124, P729, DOI 10.1016/j.cell.2006.02.007; NABI IR, 1990, CANCER RES, V50, P409; NABI IR, 1988, CANCER RES, V48, P1258; NABI IR, 1987, INT J CANCER, V40, P396, DOI 10.1002/ijc.2910400319; Niinaka Y, 1998, CANCER RES, V58, P2667; PATEL PS, 1995, NEOPLASMA, V42, P271; Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006; SCHWARTZ MK, 1973, CLIN CHEM, V19, P10; Silletti S, 1998, INT J CANCER, V76, P129, DOI 10.1002/(SICI)1097-0215(19980330)76:1<129::AID-IJC20>3.0.CO;2-6; Silletti S, 1998, INT J CANCER, V76, P120, DOI 10.1002/(SICI)1097-0215(19980330)76:1<120::AID-IJC19>3.3.CO;2-G; Silletti S, 1996, AM J PATHOL, V148, P1649; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Tsai YC, 2007, NAT MED, V13, P1504, DOI 10.1038/nm1686; Tsutsumi S, 2004, CLIN CANCER RES, V10, P7775, DOI 10.1158/1078-0432.CCR-04-1015; Tsutsumi S, 2003, CANCER RES, V63, P242; Tsutsumi S, 2002, CANCER RES, V62, P4484; Wang HJ, 2000, J CELL BIOL, V150, P1489, DOI 10.1083/jcb.150.6.1489; Watanabe H, 1996, CANCER RES, V56, P2960; Xu W, 1996, BLOOD, V87, P4502, DOI 10.1182/blood.V87.11.4502.bloodjournal87114502; Yanagawa T, 2004, LAB INVEST, V84, P513, DOI 10.1038/labinvest.3700057; Yang JL, 2005, ONCOLOGY-BASEL, V69, P224, DOI 10.1159/000088070	53	17	17	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2008	3	10							e3597	10.1371/journal.pone.0003597	http://dx.doi.org/10.1371/journal.pone.0003597			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	432KK	18974847	gold, Green Submitted, Green Published			2023-01-03	WOS:000265131700018
J	Snow, SJ				Snow, Stephanie J.			The art of medicine - John Snow: the making of a hero?	LANCET			English	Biographical-Item									Univ Manchester, Ctr Hist Sci Technol & Med, Manchester M13 9PL, Lancs, England	University of Manchester	Snow, SJ (corresponding author), Univ Manchester, Ctr Hist Sci Technol & Med, Manchester M13 9PL, Lancs, England.			Snow, Stephanie/0000-0001-9957-7835					0	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 5	2008	372	9632					22	23		10.1016/S0140-6736(08)60978-2	http://dx.doi.org/10.1016/S0140-6736(08)60978-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	321XN	18613323				2023-01-03	WOS:000257339900015
J	Ajani, JA; Winter, KA; Gunderson, LL; Pedersen, J; Benson, AB; Thomas, CR; Mayer, RJ; Haddock, MG; Rich, TA; Willett, C				Ajani, Jaffer A.; Winter, Kathryn A.; Gunderson, Leonard L.; Pedersen, John; Benson, Al B., III; Thomas, Charles R., Jr.; Mayer, Robert J.; Haddock, Michael G.; Rich, Tyvin A.; Willett, Christopher			Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SQUAMOUS-CELL CARCINOMA; DOSE RADIATION-THERAPY; EPIDERMOID CARCINOMA; CHEMORADIATION THERAPY; EUROPEAN-ORGANIZATION; CLINICAL-TRIALS; ONCOLOGY-GROUP; PHASE-II; CANCER; 5-FLUOROURACIL	Context Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5- year disease- free survival rate from concurrent fluorouracil/ mitomycin and radiation is only approximately 65%. Objective To compare the efficacy of cisplatin- based ( experimental) therapy vs mitomycin-based ( standard) therapy in treatment of anal canal carcinoma. Design, Setting, and Participants US Gastrointestinal Intergroup trial RTOG 9811, a multicenter, phase 3, randomized controlled trial comparing treatment with fluorouracil plus mitomycin and radiotherapy vs treatment with fluorouracil plus cisplatin and radiotherapy in 682 patients with anal canal carcinoma enrolled between October 31, 1998, and June 27, 2005. Stratifications included sex, clinical nodal status, and tumor diameter. Intervention Participants were randomly assigned to 1 of 2 intervention groups: ( 1) the mitomycin- based group ( n= 341), who received fluorouracil ( 1000 mg/ m(2) on days 1- 4 and 29- 32) plus mitomycin ( 10 mg/ m2 on days 1 and 29) and radiotherapy ( 45- 59 Gy) or ( 2) the cisplatin- based group ( n= 341), who received fluorouracil ( 1000 mg/ m2 on days 1- 4, 29- 32, 57- 60, and 85- 88) plus cisplatin ( 75 mg/ m2 on days 1, 29, 57, and 85) and radiotherapy ( 45- 59 Gy; start day= day 57). Main Outcome Measures The primary end point was 5- year disease- free survival; secondary end points were overall survival and time to relapse. Results A total of 644 patients were assessable. The median follow- up for all patients was 2.51 years. Median age was 55 years, 69% were women, 27% had a tumor diameter greater than 5 cm, and 26% had clinically positive nodes. The 5- year disease- free survival rate was 60% ( 95% confidence interval [ CI], 53%- 67%) in the mitomycin- based group and 54% ( 95% CI, 46%- 60%) in the cisplatin- based group ( P=. 17). The 5- year overall survival rate was75%( 95% CI, 67%- 81%) in the mitomycin-based group and 70% ( 95% CI, 63%- 76%) in the cisplatin- based group ( P=. 10). The 5- year local- regional recurrence and distant metastasis rates were 25% ( 95% CI, 20%-30%) and 15% ( 95% CI, 10%- 20%), respectively, for mitomycin- based treatment and 33%( 95% CI, 27%- 40%) and 19%( 95% CI, 14%- 24%), respectively, for cisplatin-based treatment. The cumulative rate of colostomy was significantly better for mitomycin-based than cisplatin- based treatment ( 10% vs 19%; P=. 02). Severe hematologic toxicity was worse with mitomycin- based treatment ( P <. 001). Conclusions In this population of patients with anal canal carcinoma, cisplatin-based therapy failed to improve disease- free- survival compared with mitomycinbased therapy, but cisplatin- based therapy resulted in a significantly worse colostomy rate. These findings do not support the use of cisplatin in place of mitomycin in combination with fluorouracil and radiotherapy in the treatment of anal canal carcinoma. Trial Registration clinicaltrials. gov Identifier: NCT00003596.	[Ajani, Jaffer A.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Winter, Kathryn A.] Radiat Therapy Oncol Grp, Philadelphia, PA USA; [Gunderson, Leonard L.] Mayo Clin, Scottsdale, AZ USA; [Pedersen, John] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Benson, Al B., III] Northwestern Univ, Chicago, IL 60611 USA; [Thomas, Charles R., Jr.] Univ Oregon, Portland, OR USA; [Mayer, Robert J.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Haddock, Michael G.] Mayo Clin, Rochester, MN USA; [Rich, Tyvin A.] Univ Virginia, Charlottesville, VA USA; [Willett, Christopher] Duke Univ, Durham, NC USA	University of Texas System; UTMD Anderson Cancer Center; Radiation Therapy Oncology Group (RTOG); Mayo Clinic; Mayo Clinic Phoenix; University of Alberta; Northwestern University; University of Oregon; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; University of Virginia; Duke University	Ajani, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Mail Stop 426, Houston, TX 77030 USA.	jajani@mdanderson.org			NCI NIH HHS [U10 CA37422, U10 CA21661, U10 CA32115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA037422, U10CA032115, U10CA021661] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allal AS, 1999, CANCER, V86, P405, DOI 10.1002/(SICI)1097-0142(19990801)86:3<405::AID-CNCR7>3.0.CO;2-Q; Arnott SJ, 1996, LANCET, V348, P1049; Bartelink H, 1997, J CLIN ONCOL, V15, P2040, DOI 10.1200/JCO.1997.15.5.2040; BOMAN BM, 1984, CANCER-AM CANCER SOC, V54, P114, DOI 10.1002/1097-0142(19840701)54:1<114::AID-CNCR2820540124>3.0.CO;2-P; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Cytel Software Corporation, 1992, E SOFTW PACK DES INT; DOCI R, 1992, ANN SURG, V215, P150, DOI 10.1097/00000658-199202000-00010; Flam M, 1996, J CLIN ONCOL, V14, P2527, DOI 10.1200/JCO.1996.14.9.2527; FROST DB, 1984, CANCER, V53, P1285, DOI 10.1002/1097-0142(19840315)53:6<1285::AID-CNCR2820530611>3.0.CO;2-N; Fuchshuber PR, 1997, J AM COLL SURGEONS, V185, P494, DOI 10.1016/S1072-7515(01)00967-X; Gerard JP, 1998, RADIOTHER ONCOL, V46, P249, DOI 10.1016/S0167-8140(97)00192-8; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GREENALL MJ, 1985, SURG GYNECOL OBSTET, V161, P509; Greene FL, 2002, AJCC CANC STAGING HD; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; JOHN M, 1998, P AM SOC CLIN ONC 5; Kalbfleisch J.D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLOTZ RG, 1967, CANCER-AM CANCER SOC, V20, P1727, DOI 10.1002/1097-0142(196710)20:10<1727::AID-CNCR2820201024>3.0.CO;2-1; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Martenson JA, 1996, INT J RADIAT ONCOL, V35, P745, DOI 10.1016/0360-3016(96)00146-0; MEROPOL NJ, 2005, P ASCO GASTR S COMB; National Cancer Institute, 1999, COMM TOX CRIT VERS 2; NIGRO ND, 1983, CANCER, V51, P1826, DOI 10.1002/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PAPILLON J, 1987, DIS COLON RECTUM, V30, P324, DOI 10.1007/BF02555448; Peiffert D, 2001, ANN ONCOL, V12, P397, DOI 10.1023/A:1011107105538; PINTOR MP, 1989, BRIT J SURG, V76, P806, DOI 10.1002/bjs.1800760814; RICH TA, 1993, RADIOTHER ONCOL, V27, P209, DOI 10.1016/0167-8140(93)90076-K; Sato H, 2005, DIS COLON RECTUM, V48, P1301, DOI 10.1007/s10350-004-0934-z; SCHNEIDER TC, 1981, SURGERY, V90, P729; SINGH R, 1981, CANCER, V48, P411, DOI 10.1002/1097-0142(19810715)48:2<411::AID-CNCR2820480232>3.0.CO;2-Z; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	34	618	624	1	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 23	2008	299	16					1914	1921		10.1001/jama.299.16.1914	http://dx.doi.org/10.1001/jama.299.16.1914			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	291AD	18430910	Bronze			2023-01-03	WOS:000255163800025
J	Maxwell, SA; Li, ZG; Jaya, D; Ballard, S; Ferrell, J; Fu, HA				Maxwell, Steve A.; Li, Zenggang; Jaya, David; Ballard, Scott; Ferrell, Jay; Fu, Haian			14-3-3 zeta Mediates Resistance of Diffuse Large B Cell Lymphoma to an Anthracycline-based Chemotherapeutic Regimen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG-CANCER CELLS; P53-MEDIATED APOPTOSIS; MITOTIC CATASTROPHE; GENE-EXPRESSION; PROTEINS; SURVIVAL; BAD; 14-3-3-PROTEINS; IDENTIFICATION; CARCINOMA	Patients presenting with diffuse large B cell lymphoma (DLBCL) are treated with a standard anthracycline-based chemotherapeutic mixture consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Half of DLBCL patients will develop chemo-refractory tumors due to the emergence of CHOP-resistant DLBCL cells. We isolated DLBCL cells that were resistant to CHOP as a model system to investigate the molecular basis of CHOP resistance. Resistant cells emerged from CHOP-sensitive DLBCL populations after repeated cycles of on-off exposure to stepwise increased dosages of CHOP. A proteomic analysis of CHOP-sensitive and -resistant DLBCL cells identified the zeta isoform of the 14-3-3 family as a differentially expressed protein. CHOP-sensitive cells showed reduced expression of 14-3-3 zeta protein in the presence of high-dose CHOP relative to control cells. In contrast, CHOP-resistant cells expressed markedly higher levels of 14-3-3 zeta regardless the presence of high-dose CHOP. Because 14-3-3 zeta is known to exert anti-apoptotic influences and chemoresistance in lung, colon, and prostate carcinoma, we hypothesized that 14-3-3 zeta promotes survival of DLBCL cells in CHOP. In support of our hypothesis, knockdown of 14-3-3 zeta by small interfering RNA restored the sensitivity of resistant DLBCL to CHOP-induce apoptosis. In addition, 14-3-3 zeta expression was highly up-regulated in a resected DLBCL lymph node relative to a normal lymph node by Western blot analysis. Furthermore, more than half of 35 DLBCL tissues showed elevated 14-3-3 zeta expression relative to normal lymph tissue by immunohistochemical analysis. Our study implicates 14-3-3 zeta in the pathogenesis of DLBCL and suggests a promising combination strategy with a 14-3-3 inhibitor for the treatment of refractory DLBCL.	[Maxwell, Steve A.; Ballard, Scott; Ferrell, Jay] Texas A&M Syst Hlth Sci Ctr, Dept Mol & Cellular Med, College Stn, TX 77840 USA; [Li, Zenggang; Jaya, David; Fu, Haian] Emory Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Emory University	Maxwell, SA (corresponding author), Texas A&M Syst Hlth Sci Ctr, Dept Mol & Cellular Med, Rm 440,Reynolds Med Bldg, College Stn, TX 77840 USA.	smaxwell@medicine.tamhsc.edu		jaye, david/0000-0001-7977-6909				Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Chatterjee D, 2004, INT J ONCOL, V25, P503; Chiang CW, 2003, MOL CELL BIOL, V23, P6350, DOI 10.1128/MCB.23.18.6350-6362.2003; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chumsri S, 2008, CURR OPIN MOL THER, V10, P323; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Coiffier B, 2002, ANTI-CANCER DRUG, V13, pS43, DOI 10.1097/00001813-200211002-00007; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dong S, 2008, LEUKEMIA, V22, P572, DOI 10.1038/sj.leu.2405064; Fan T, 2007, CANCER RES, V67, P7901, DOI 10.1158/0008-5472.CAN-07-0090; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Hill RP, 2007, JNCI-J NATL CANCER I, V99, P1435, DOI 10.1093/jnci/djm136; Huber E, 2004, J VIROL, V78, P7478, DOI 10.1128/JVI.78.14.7478-7489.2004; Jang JS, 2004, ONCOL RES, V14, P491, DOI 10.3727/0965040042380441; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kumar AP, 2003, CARCINOGENESIS, V24, P209, DOI 10.1093/carcin/24.2.209; Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5; Li ZG, 2008, P NATL ACAD SCI USA, V105, P162, DOI 10.1073/pnas.0710905105; Liou JY, 2007, CANCER RES, V67, P3185, DOI 10.1158/0008-5472.CAN-06-3431; Lossos IS, 2004, CLIN LYMPHOMA, V5, P128, DOI 10.1016/S1526-9655(11)70069-0; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Matta A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-169; Maxwell SA, 2000, APOPTOSIS, V5, P277, DOI 10.1023/A:1009660714216; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; Muslin AJ, 2005, CURR TOP DEV BIOL, V65, P211; Ng AK, 2007, SEMIN RADIAT ONCOL, V17, P169, DOI 10.1016/j.semradonc.2007.02.002; Ngan CY, 2008, CANCER SCI, V99, P129, DOI 10.1111/j.1349-7006.2007.00637.x; Niemantsverdriet M, 2008, ONCOGENE, V27, P1315, DOI 10.1038/sj.onc.1210742; Porter GW, 2006, SEMIN CANCER BIOL, V16, P193, DOI 10.1016/j.semcancer.2006.03.003; Qi WQ, 2007, MOL CARCINOGEN, V46, P847, DOI 10.1002/mc.20314; Qi WQ, 2005, INT J CANCER, V113, P359, DOI 10.1002/ijc.20492; Qi WQ, 2003, RADIAT RES, V160, P217, DOI 10.1667/RR3038; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; REFF ME, 1994, BLOOD, V83, P435; Rivera A, 2006, CELL MOL LIFE SCI, V63, P1425, DOI 10.1007/s00018-006-5521-5; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shoji Masahiro, 1994, Human Antibodies and Hybridomas, V5, P123; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Takihara Y, 2000, CARCINOGENESIS, V21, P2073, DOI 10.1093/carcin/21.11.2073; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wilker E, 2004, J MOL CELL CARDIOL, V37, P633, DOI 10.1016/j.yjmcc.2004.04.015; Zang L, 2004, J PROTEOME RES, V3, P604, DOI 10.1021/pr034131l; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	49	48	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 14	2009	284	33					22379	22389		10.1074/jbc.M109.022418	http://dx.doi.org/10.1074/jbc.M109.022418			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	481CE	19525224	hybrid, Green Published			2023-01-03	WOS:000268783700060
J	Goldenson, D				Goldenson, Dianna			A day late and a few million dollars short	NATURE BIOTECHNOLOGY			English	Editorial Material								The pitfalls of seeking and obtaining a patent term extension.	Darby & Darby, New York, NY USA		Goldenson, D (corresponding author), Darby & Darby, New York, NY USA.	dgoldenson@darbylaw.com						[Anonymous], 2008, US Patent, Patent No. [5,674,860, 5674860]; *ASTRAZENECA PLC, 2009, 4 QUART FULL YEAR RE; 2009, PFIZER REPOTS 4 QUAT	3	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	JUN	2009	27	6					538	542		10.1038/nbt0609-538	http://dx.doi.org/10.1038/nbt0609-538			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	458AC	19513055				2023-01-03	WOS:000266980500020
J	Zochowska, M; Paca, A; Schoehn, G; Andrieu, JP; Chroboczek, J; Dublet, B; Szolajska, E				Zochowska, Monika; Paca, Agnieszka; Schoehn, Guy; Andrieu, Jean-Pierre; Chroboczek, Jadwiga; Dublet, Bernard; Szolajska, Ewa			Adenovirus Dodecahedron, as a Drug Delivery Vector	PLOS ONE			English	Article								Background: Bleomycin (BLM) is an anticancer antibiotic used in many cancer regimens. Its utility is limited by systemic toxicity and dose-dependent pneumonitis able to progress to lung fibrosis. The latter can affect up to nearly 50% of the total patient population, out of which 3% will die. We propose to improve BLM delivery by tethering it to an efficient delivery vector. Adenovirus (Ad) dodecahedron base (DB) is a particulate vector composed of 12 copies of a pentameric viral protein responsible for virus penetration. The vector efficiently penetrates the plasma membrane, is liberated in the cytoplasmand has a propensity to concentrate around the nucleus; up to 300000 particles can be observed in one cell in vitro. Principal Findings: Dodecahedron (Dd) structure is preserved at up to about 50 degrees C at pH 7-8 and during dialysis, freezing and drying in the speed-vac in the presence of 150 mM ammonium sulfate, as well as during lyophilization in the presence of cryoprotectants. The vector is also stable in human serum for 2 h at 37 degrees C. We prepared a Dd-BLM conjugate which upon penetration induced death of transformed cells. Similarly to free bleomycin, Dd-BLM caused dsDNA breaks. Significantly, effective cytotoxic concentration of BLM delivered with Dd was 100 times lower than that of free bleomycin. Conclusions/Significance: Stability studies show that Dds can be conveniently stored and transported, and can potentially be used for therapeutic purposes under various climates. Successful BLM delivery by Ad Dds demonstrates that the use of virus like particle (VLP) results in significantly improved drug bioavailability. These experiments open new vistas for delivery of non-permeant labile drugs.			Zochowska, M (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland.	wisia@ibs.fr; ewasz@ibb.waw.pl	Chroboczek, Jadwiga/M-6554-2014	Szolajska, Ewa/0000-0002-7400-4333; Schoehn, Guy/0000-0002-1459-3201; Zochowska, Monika/0000-0002-3824-4962	PHS HHS [2P04B02329] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arndt D, 2001, DRUG DELIV, V8, P1; Balakireva L, 2003, J VIROL, V77, P4858, DOI 10.1128/JVI.77.8.4858-4866.2003; Berg K, 2005, CLIN CANCER RES, V11, P8476, DOI 10.1158/1078-0432.CCR-05-1245; BRADY JN, 1977, J VIROL, V23, P717, DOI 10.1128/JVI.23.3.717-724.1977; Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547; Chen PL, 2001, FEBS LETT, V500, P109, DOI 10.1016/S0014-5793(01)02598-4; Cobbold SP, 2006, IMMUNOL REV, V213, P239, DOI 10.1111/j.1600-065X.2006.00428.x; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; Fabry CMS, 2005, EMBO J, V24, P1645, DOI 10.1038/sj.emboj.7600653; Fender P, 1997, NAT BIOTECHNOL, V15, P52, DOI 10.1038/nbt0197-52; Fender P, 2005, VIROLOGY, V340, P167, DOI 10.1016/j.virol.2005.06.030; Fender P, 2008, VIROLOGY, V371, P155, DOI 10.1016/j.virol.2007.09.026; GABIZON A, 1990, CANCER RES, V50, P6371; GALLEGOS CO, 1989, VIROLOGY, V172, P616, DOI 10.1016/0042-6822(89)90204-3; Garcel A, 2006, J GENE MED, V8, P524, DOI 10.1002/jgm.862; Hecht SM, 2000, J NAT PROD, V63, P158, DOI 10.1021/np990549f; HECHT SM, 1994, BIOCONJUGATE CHEM, V5, P513, DOI 10.1021/bc00030a006; Horiuchi A, 2000, INT J CANCER, V88, P640, DOI 10.1002/1097-0215(20001115)88:4<640::AID-IJC19>3.0.CO;2-K; Ishizu KI, 2001, J VIROL, V75, P61, DOI 10.1128/JVI.75.1.61-72.2001; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Larkin JO, 2008, ULTRASOUND MED BIOL, V34, P406, DOI 10.1016/j.ultrasmedbio.2007.09.005; LEHANE DE, 1975, CANCER RES, V35, P2724; Lenz P, 2001, J IMMUNOL, V166, P5346, DOI 10.4049/jimmunol.166.9.5346; Li TC, 2003, VIROLOGY, V311, P115, DOI 10.1016/S0042-6822(03)00141-7; LOCK RB, 1994, CANCER RES, V54, P4933; Lock RB, 1996, CANCER RES, V56, P4006; McCarthy MP, 1998, J VIROL, V72, P32, DOI 10.1128/JVI.72.1.32-41.1998; Mir LM, 1996, GEN PHARMACOL-VASC S, V27, P745, DOI 10.1016/0306-3623(95)02101-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Noad R, 2003, TRENDS MICROBIOL, V11, P438, DOI 10.1016/S0966-842X(03)00208-7; NORRBY E, 1968, J GEN VIROL, V2, P135, DOI 10.1099/0022-1317-2-1-135; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; PODDEVIN B, 1991, BIOCHEM PHARMACOL, V42, pS67, DOI 10.1016/0006-2952(91)90394-K; Pron G, 1999, BIOCHEM PHARMACOL, V57, P45, DOI 10.1016/S0006-2952(98)00282-2; Puig PE, 2008, CELL BIOL INT, V32, P1031, DOI 10.1016/j.cellbi.2008.04.021; Rexroad J, 2006, J PHARM SCI-US, V95, P237, DOI 10.1002/jps.20496; SEBTI SM, 1991, CANCER RES, V51, P227; SEBTI SM, 1988, PHARMACOL THERAPEUT, V38, P321, DOI 10.1016/0163-7258(88)90009-5; Sersa G, 2008, EJSO-EUR J SURG ONC, V34, P232, DOI 10.1016/j.ejso.2007.05.016; Shi L, 2005, J PHARM SCI-US, V94, P1538, DOI 10.1002/jps.20377; Sleijfer S, 2001, CHEST, V120, P617, DOI 10.1378/chest.120.2.617; SLIWINSKA MA, 2008, MECH AGEING DEV; Song LZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002257; Sonoda S, 2007, CANCER BIOL THER, V6, P1276; TAKESHITA M, 1978, P NATL ACAD SCI USA, V75, P5983, DOI 10.1073/pnas.75.12.5983; Vives RR, 2004, VIROLOGY, V321, P332, DOI 10.1016/j.virol.2004.01.015; Wang CG, 2008, INT J PHARMACEUT, V351, P219, DOI 10.1016/j.ijpharm.2007.09.045; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; XI JA, 1992, J VIROL, V66, P6527, DOI 10.1128/JVI.66.11.6527-6532.1992; Yanai H, 2002, BJU INT, V89, P438, DOI 10.1046/j.1464-4096.2001.01836.x; Zubieta C, 2005, MOL CELL, V17, P121, DOI 10.1016/j.molcel.2004.11.041	52	47	49	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 15	2009	4	5							e5569	10.1371/journal.pone.0005569	http://dx.doi.org/10.1371/journal.pone.0005569			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446FY	19440379	Green Submitted, Green Published, gold			2023-01-03	WOS:000266107400013
J	Schweickert, WD; Pohlman, MC; Pohlman, AS; Nigos, C; Pawlik, AJ; Esbrook, CL; Spears, L; Miller, M; Franczyk, M; Deprizio, D; Schmidt, GA; Bowman, A; Barr, R; McCallister, KE; Hall, JB; Kress, JP				Schweickert, William D.; Pohlman, Mark C.; Pohlman, Anne S.; Nigos, Celerina; Pawlik, Amy J.; Esbrook, Cheryl L.; Spears, Linda; Miller, Megan; Franczyk, Mietka; Deprizio, Deanna; Schmidt, Gregory A.; Bowman, Amy; Barr, Rhonda; McCallister, Kathryn E.; Hall, Jesse B.; Kress, John P.			Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial	LANCET			English	Article							INTENSIVE-CARE-UNIT; RESPIRATORY-DISTRESS-SYNDROME; CONFUSION ASSESSMENT METHOD; AGITATION-SEDATION SCALE; GUILLAIN-BARRE-SYNDROME; ACUTE LUNG INJURY; CRITICAL ILLNESS; OLDER-ADULTS; DAILY INTERRUPTION; ACQUIRED WEAKNESS	Background Long-term complications of critical illness include intensive care unit (ICU)-acquired weakness and neuropsychiatric disease. Immobilisation secondary to sedation might potentiate these problems. We assessed the efficacy of combining daily interruption of sedation with physical and occupational therapy on functional outcomes in patients receiving mechanical ventilation in intensive care. Methods Sedated adults (a:18 years of age) in the ICU who had been on mechanical ventilation for less than 72 h, were expected to continue for at least 24 h, and who met criteria for baseline functional independence were eligible for enrolment in this randomised controlled trial at two university hospitals. We randomly assigned 104 patients by computer-generated, permuted block randomisation to early exercise and mobilisation (physical and occupational therapy) during periods of daily interruption of sedation (intervention; n=49) or to daily interruption of sedation with therapy as ordered by the primary care team (control; n=55). The primary endpoint-the number of patients returning to independent functional status at hospital discharge-was defined as the ability to perform six activities of daily living and the ability to walk independently. Therapists who undertook patient assessments were blinded to treatment assignment. Secondary endpoints included duration of delirium and ventilator-free days during the first 28 days of hospital stay. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00322010. Findings All 104 patients were included in the analysis. Return to independent functional status at hospital discharge occurred in 29 (59%) patients in the intervention group compared with 19 (35%) patients in the control group (p=0.02; odds ratio 2.7 [95% CI 1.2-6.1]). Patients in the intervention group had shorter duration of delirium (median 2.0 days, IQR 0.0-6.0 vs 4.0 days, 2.0-8.0; p=0.02), and more ventilator-free days (23.5 days, 7.4-25.6 vs 21.1 days, 0.0-23.8; p=0.05) during the 28-day follow-up period than did controls. There was one serious adverse event in 498 therapy sessions (desaturation less than 80%). Discontinuation of therapy as a result of patient instability occurred in 19 (4%) of all sessions, most commonly for perceived patient-ventilator asynchrony. Interpretation A strategy for whole-body rehabilitation-consisting of interruption of sedation and physical and occupational therapy in the earliest days of critical illness-was safe and well tolerated, and resulted in better functional outcomes at hospital discharge, a shorter duration of delirium, and more ventilator-free days compared with standard care. Funding None.	[Schweickert, William D.] Univ Penn, Dept Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Pohlman, Mark C.; Pohlman, Anne S.; Nigos, Celerina; McCallister, Kathryn E.; Hall, Jesse B.; Kress, John P.] Univ Chicago, Dept Med, Sect Pulm & Crit Care, Chicago, IL 60637 USA; [Pawlik, Amy J.; Esbrook, Cheryl L.; Spears, Linda; Miller, Megan; Franczyk, Mietka; Deprizio, Deanna] Univ Chicago, Therapy Serv Dept, Chicago, IL 60637 USA; [Schmidt, Gregory A.; Bowman, Amy] Univ Iowa, Dept Internal Med, Div Pulm Dis Crit Care & Occupat Med, Iowa City, IA 52242 USA; [Barr, Rhonda] Univ Iowa, Dept Rehabil Therapies, Iowa City, IA 52242 USA	University of Pennsylvania; University of Chicago; University of Chicago; University of Iowa; University of Iowa	Kress, JP (corresponding author), Univ Chicago, Dept Med, Sect Pulm & Crit Care, 5841 S Maryland,MC 6026, Chicago, IL 60637 USA.	jkress@medicine.bsd.uchicago.edu		Schmidt, Gregory/0000-0002-5013-6323				Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Bigatello LM, 2007, CRIT CARE MED, V35, P2491, DOI 10.1097/01.CCM.0000287589.16724.B2; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Collin C, 1988, Int Disabil Stud, V10, P61; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; De Jonghe B, 2005, CRIT CARE MED, V33, P120, DOI 10.1097/01.CCM.0000150268.04228.68; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; De Jonghe B, 2007, CRIT CARE CLIN, V23, P55, DOI 10.1016/j.ccc.2006.11.001; De Jonghe Bernard, 2004, Curr Opin Crit Care, V10, P47, DOI 10.1097/00075198-200402000-00008; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Griffiths RD, 1995, NUTRITION, V11, P428; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hodgin KE, 2009, CRIT CARE MED, V37, P561, DOI 10.1097/CCM.0b013e3181957449; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Ip SPS, 1999, CRIT CARE MED, V27, P2351, DOI 10.1097/00003246-199911000-00005; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, MED CARE, V14, P116, DOI 10.1097/00005650-197605001-00018; Keith R A, 1987, Adv Clin Rehabil, V1, P6; KLEYWEG RP, 1988, NEUROLOGY, V38, P1639, DOI 10.1212/WNL.38.10.1639; KLEYWEG RP, 1991, MUSCLE NERVE, V14, P1103, DOI 10.1002/mus.880141111; Kortebein P, 2007, JAMA-J AM MED ASSOC, V297, P1772, DOI 10.1001/jama.297.16.1772-b; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; Lin SM, 2004, CRIT CARE MED, V32, P2254, DOI 10.1097/01.CCM.0000145587.16421.BB; MAHONEY F I, 1965, Md State Med J, V14, P61; Marcantonio ER, 2003, J AM GERIATR SOC, V51, P4, DOI 10.1034/j.1601-5215.2002.51002.x; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Mudge AM, 2008, J AM GERIATR SOC, V56, P630, DOI 10.1111/j.1532-5415.2007.01607.x; NARAIN P, 1988, J AM GERIATR SOC, V36, P775, DOI 10.1111/j.1532-5415.1988.tb04259.x; Needham DM, 2007, J CRIT CARE, V22, P275, DOI 10.1016/j.jcrc.2007.02.001; Poon WS, 2005, ACT NEUR S, V93, P207; Pun BT, 2007, CHEST, V132, P624, DOI 10.1378/chest.06-1795; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Sager MA, 1996, ARCH INTERN MED, V156, P645, DOI 10.1001/archinte.156.6.645; Schweickert WD, 2004, CRIT CARE MED, V32, P1272, DOI 10.1097/01.CCM.0000127263.54807.79; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Schweickert WD, 2008, CRIT CARE, V12, DOI 10.1186/cc6151; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Tesch PA, 2008, J APPL PHYSIOL, V105, P902, DOI 10.1152/japplphysiol.90558.2008; Thomsen GE, 2008, CRIT CARE MED, V36, P1119, DOI 10.1097/CCM.0b013e318168f986; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D; Yohannes AM, 2005, AGE AGEING, V34, P491, DOI 10.1093/ageing/afi163	53	1830	1968	5	264	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2009	373	9678					1874	1882		10.1016/S0140-6736(09)60658-9	http://dx.doi.org/10.1016/S0140-6736(09)60658-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	453ND	19446324				2023-01-03	WOS:000266616400030
J	Keown, P; Mercer, G; Scott, J				Keown, Patrick; Mercer, Gavin; Scott, Jan			Retrospective analysis of hospital episode statistics, involuntary admissions under the Mental Health Act 1983, and number of psychiatric beds in England 1996-2006	BRITISH MEDICAL JOURNAL			English	Article							CARE; REINSTITUTIONALISATION	Objective To analyse the number of voluntary and involuntary (detentions under the Mental Health Act 1983) admissions for mental disorders between 1996 and 2006 in England. Design Retrospective analysis. Setting England. Main outcome measures Number of voluntary and involuntary admissions for mental disorders in England's health service, number of involuntary admissions to private beds, and number of NHS beds for patients with mental disorders or learning disabilities. Results Admissions for mental disorders in the NHS in England peaked in 1998 and then started to fall. Reductions in admissions were confined to patients with depression, learning disabilities, or dementia. Admissions for schizophrenic and manic disorders did not change whereas those for drug and alcohol problems increased. The number of NHS psychiatric beds decreased by 29%. The total number of involuntary admissions per annum increased by 20%, with a threefold increase in the likelihood of admission to a private facility. Patients admitted involuntarily occupied 23% of NHS psychiatric beds in 1996 but 36% in 2006. Conclusions Psychiatric inpatient care changed considerably in the decade from 1996 to 2006, with more involuntary admissions to fewer NHS beds. The case mix has shifted further towards psychotic and substance misuse disorders, which has changed the milieu of inpatient wards. Increasing proportions of involuntary patients were admitted to private facilities.	[Keown, Patrick; Mercer, Gavin] NHS Ctr, E Community Mental Hlth Team, Newcastle Upon Tyne NE6 1SG, Tyne & Wear, England; [Scott, Jan] Royal Victoria Infirm, Univ Dept Psychiat, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Keown, P (corresponding author), NHS Ctr, E Community Mental Hlth Team, Molineux St, Newcastle Upon Tyne NE6 1SG, Tyne & Wear, England.	p.j.keown@newcastle.ac.uk	Scott, Jan/F-2966-2010	Scott, Jan/0000-0002-7203-8601				Craig TK, 2004, BMJ-BRIT MED J, V329, P1067, DOI 10.1136/bmj.38246.594873.7C; Davidge M., 1993, SURVEY ENGLISH MENTA; *DEP HLTH, 2006, BED AV OCC; Glover G, 2006, BRIT J PSYCHIAT, V189, P441, DOI 10.1192/bjp.bp.105.020362; *INF CTR, 2007, INP FORM DET HOSP ME; JOHNSON S, 2005, BRIT MED J, V331, P4; Priebe S, 2005, BMJ-BRIT MED J, V330, P123, DOI 10.1136/bmj.38296.611215.AE; Priebe S, 2003, BRIT MED J, V326, P175, DOI 10.1136/bmj.326.7382.175; Wall S, 1999, BRIT MED J, V318, P1520, DOI 10.1136/bmj.318.7197.1520	9	48	48	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 25	2008	337	7676							a1837	10.1136/bmj.a1837	http://dx.doi.org/10.1136/bmj.a1837			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	363WS	18845592	Green Published, hybrid			2023-01-03	WOS:000260298800035
J	Tang, JW; Settles, GS				Tang, J. W.; Settles, G. S.			Coughing and aerosols	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Settles, Gary S/D-5260-2009						0	52	52	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2008	359	15					E19	E19		10.1056/NEJMicm072576	http://dx.doi.org/10.1056/NEJMicm072576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FS	18843121				2023-01-03	WOS:000259903100010
J	Hodnett, ED; Stremler, R; Willan, AR; Weston, JA; Lowe, NK; Simpson, KR; Fraser, WD; Gafni, A				Hodnett, Ellen D.; Stremler, Robyn; Willan, Andrew R.; Weston, Julie A.; Lowe, Nancy K.; Simpson, Kathleen R.; Fraser, William D.; Gafni, Amiram		SELAN Trial Grp	Effect on birth outcomes of a formalised approach to care in hospital labour assessment units: international, randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							OCCIPUT POSTERIOR POSITION; COMPLEX INTERVENTIONS; PAIN; PREGNANCY; ANXIETY; COMPLICATIONS; SATISFACTION; MANAGEMENT; DELIVERY; SUPPORT	Objective To determine if a complex nursing and midwifery intervention in hospital labour assessment units would increase the likelihood of spontaneous vaginal birth and improve other maternal and neonatal outcomes. Design Multicentre, randomised controlled trial with prognostic stratification by hospital. Setting 20 North American and UK hospitals. Participants 5002 nulliparous women experiencing contractions but not in active labour; 2501 were allocated to structured care and 2501 to usual care. Interventions Usual nursing or midwifery care or a minimum of one hour of care by a nurse or midwife trained in structured care, consisting of a formalised approach to assessment of and interventions for maternal emotional state, pain, and fetal position. Main outcome measures Primary outcome was spontaneous vaginal birth. Other outcomes included intrapartum interventions, women's views of their care, and indicators of maternal and fetal health during hospital stay and 6- 8 weeks after discharge. Results Outcome data were obtained for 4996 women. The rate of spontaneous vaginal birth was 64.0% ( n= 1597) in the structured care group and 61.3% ( n= 1533) in the usual care group ( odds ratio 1.12, 95% confidence interval 0.96 to 1.27). Fewer women allocated to structured care ( n= 403, 19.5%) rated staff helpfulness as less than very helpful than those allocated to usual care ( n= 544, 26.4%); odds ratio 0.67, 98.75% confidence interval 0.50 to 0.85. Fewer women allocated to structured care ( n= 233, 11.3%) were disappointed with the amount of attention received from staff than those allocated to usual care ( n= 407, 19.7%); odds ratio 0.51, 98.75% confidence interval 0.32 to 0.70. None of the other results met prespecified levels of statistical significance. Conclusion A structured approach to care in hospital labour assessment units increased satisfaction with care and was suggestive of a modest increase in the likelihood of spontaneous vaginal birth. Further study to strengthen the intervention is warranted. Trial registration Current Controlled Trials ISRCTN16315180.	[Hodnett, Ellen D.; Stremler, Robyn; Weston, Julie A.] Univ Toronto, Lawrence S Bloomberg Fac Nursing, Toronto, ON M5T 1P8, Canada; [Stremler, Robyn; Willan, Andrew R.] Hosp Sick Children, Program Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada; [Stremler, Robyn; Willan, Andrew R.] Univ Toronto, Res Inst, Toronto, ON M5T 1P8, Canada; [Willan, Andrew R.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON M5T 3M7, Canada; [Lowe, Nancy K.] Univ Colorado, Hlth Sci Ctr, Sch Nursing, Denver, CO 80262 USA; [Simpson, Kathleen R.] St Johns Mercy Med Ctr, St Louis, MO 63141 USA; [Fraser, William D.] Univ Montreal, Dept Obstet Gynecol, Montreal, PQ, Canada; [Gafni, Amiram] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Gafni, Amiram] McMaster Univ, Ctr Hlth Econ & Policy Evaluat, Hamilton, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Saint Johns Mercy Medical Center; Universite de Montreal; McMaster University; McMaster University	Hodnett, ED (corresponding author), Univ Toronto, Lawrence S Bloomberg Fac Nursing, 155 Coll St, Toronto, ON M5T 1P8, Canada.	ellen.hodnett@utoronto.ca	Lee, Shoo K/P-3016-2015	Soltani, Hora/0000-0001-9611-6777	Canadian Institutes of Health Research [MCT59614]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Canadian Institutes of Health Research (grant No MCT59614).	Astin JA, 2004, CLIN J PAIN, V20, P27, DOI 10.1097/00002508-200401000-00006; BECK NC, 1980, J PSYCHOSOM RES, V24, P343, DOI 10.1016/0022-3999(80)90026-4; BROWN S, 1994, BIRTH-ISS PERINAT C, V21, P4, DOI 10.1111/j.1523-536X.1994.tb00909.x; Campbell NC, 2007, BMJ-BRIT MED J, V334, P455, DOI 10.1136/bmj.39108.379965.BE; CHELMOW D, 1993, OBSTET GYNECOL, V81, P486; Cox J. L., 1994, PERINATAL PSYCHIAT U; CRAMOND W, 1962, LANCET, V2, P1241; CRANDON AJ, 1979, J PSYCHOSOM RES, V23, P109, DOI 10.1016/0022-3999(79)90014-X; ERICKSON MT, 1976, J PSYCHOSOM RES, V20, P207, DOI 10.1016/0022-3999(76)90022-2; Friedman EA, 1987, LABOR DELIVERY IMPAC; Gardberg M, 1998, OBSTET GYNECOL, V91, P746, DOI 10.1016/S0029-7844(98)00074-X; GARDBERG M, 1994, ACTA OBSTET GYN SCAN, V73, P45, DOI 10.3109/00016349409013392; Hawe P, 2004, BMJ-BRIT MED J, V328, P1561, DOI 10.1136/bmj.328.7455.1561; Hodnett ED, 2002, AM J OBSTET GYNECOL, V186, pS160, DOI 10.1067/mob.2002.121141; Hodnett ED, 2002, JAMA-J AM MED ASSOC, V288, P1373, DOI 10.1001/jama.288.11.1373; *I CLIN SYST IMPR, 2007, MAN LAB; Janssen PA, 2006, OBSTET GYNECOL, V108, P1463, DOI 10.1097/01.AOG.0000247644.64154.bb; KAPP TT, 1963, COMPR PSYCHIAT, V4, P9; LEDERMAN RP, 1979, NURS RES, V28, P94; McNiven PS, 1998, BIRTH-ISS PERINAT C, V25, P5, DOI 10.1046/j.1523-536x.1998.00005.x; *MEDSCINET, 2008, INT DAT SOL; Menacker Fay, 2005, Natl Vital Stat Rep, V54, P1; ODRISCOLL K, 1993, ACTIVE MANAGEMENT LA; OXOM H, 1986, OXOM FOOTE HUMAN LAB; PEARL ML, 1993, J REPROD MED, V38, P955; PORTER M, 1984, SOC SCI MED, V19, P1197, DOI 10.1016/0277-9536(84)90370-8; RUTHERFORD AM, 1981, NEW ZEAL MED J, V94, P419; SAUNDERS NJS, 1989, BRIT MED J, V299, P1423, DOI 10.1136/bmj.299.6713.1423; SIMKIN P, 1999, LABOR PROGR HDB EARL; Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611; Stremler R, 2005, BIRTH-ISS PERINAT C, V32, P243, DOI 10.1111/j.0730-7659.2005.00382.x; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; Watt Margo C., 2006, Cognitive Behaviour Therapy, V35, P248, DOI 10.1080/16506070600898553; WUITCHIK M, 1989, OBSTET GYNECOL, V73, P35	34	34	34	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 13	2008	337	7670							a1021	10.1136/bmj.a1021	http://dx.doi.org/10.1136/bmj.a1021			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354DT	18755762	hybrid, Green Published			2023-01-03	WOS:000259619800039
J	Makidon, PE; Bielinska, AU; Nigavekar, SS; Janczak, KW; Knowlton, J; Scott, AJ; Mank, N; Cao, ZY; Rathinavelu, S; Beer, MR; Wilkinson, JE; Blanco, LP; Landers, JJ; Baker, JR				Makidon, Paul E.; Bielinska, Anna U.; Nigavekar, Shraddha S.; Janczak, Katarzyna W.; Knowlton, Jessica; Scott, Alison J.; Mank, Nicholas; Cao, Zhengyi; Rathinavelu, Sivaprakash; Beer, Michael R.; Wilkinson, J. Erby; Blanco, Luz P.; Landers, Jeffrey J.; Baker, James R., Jr.			Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine	PLOS ONE			English	Article							T-LYMPHOCYTE RESPONSES; LONG-TERM PERSISTENCE; SURFACE-ANTIGEN; IMMUNE-RESPONSES; INTRANASAL IMMUNIZATION; ALUMINUM-HYDROXIDE; ANTIBODY AVIDITY; POTENT ENHANCER; DNA VACCINES; VIRUS	Background: Hepatitis B virus infection remains an important global health concern despite the availability of safe and effective prophylactic vaccines. Limitations to these vaccines include requirement for refrigeration and three immunizations thereby restricting use in the developing world. A new nasal hepatitis B vaccine composed of recombinant hepatitis B surface antigen (HBsAg) in a novel nanoemulsion (NE) adjuvant (HBsAg-NE) could be effective with fewer administrations. Methodology and Principal Findings: Physical characterization indicated that HBsAg-NE consists of uniform lipid droplets (349+/-17 nm) associated with HBsAg through electrostatic and hydrophobic interactions. Immunogenicity of HBsAg-NE vaccine was evaluated in mice, rats and guinea pigs. Animals immunized intranasally developed robust and sustained systemic IgG, mucosal IgA and strong antigen-specific cellular immune responses. Serum IgG reached >= 10(6) titers and was comparable to intramuscular vaccination with alum-adjuvanted vaccine (HBsAg-Alu). Normalization showed that HBsAg-NE vaccination correlates with a protective immunity equivalent or greater than 1000 IU/ml. Th1 polarized immune response was indicated by IFN-gamma and TNF-alpha cytokine production and elevated levels of IgG(2) subclass of HBsAg-specific antibodies. The vaccine retains full immunogenicity for a year at 4 degrees C, 6 months at 25 degrees C and 6 weeks at 40 degrees C. Comprehensive pre-clinical toxicology evaluation demonstrated that HBsAg-NE vaccine is safe and well tolerated in multiple animal models. Conclusions: Our results suggest that needle-free nasal immunization with HBsAg-NE could be a safe and effective hepatitis B vaccine, or provide an alternative booster administration for the parenteral hepatitis B vaccines. This vaccine induces a Th1 associated cellular immunity and also may provide therapeutic benefit to patients with chronic hepatitis B infection who lack cellular immune responses to adequately control viral replication. Long-term stability of this vaccine formulation at elevated temperatures suggests a direct advantage in the field, since potential excursions from cold chain maintenance could be tolerated without a loss in therapeutic efficacy.	[Makidon, Paul E.; Bielinska, Anna U.; Nigavekar, Shraddha S.; Janczak, Katarzyna W.; Knowlton, Jessica; Scott, Alison J.; Mank, Nicholas; Cao, Zhengyi; Rathinavelu, Sivaprakash; Beer, Michael R.; Blanco, Luz P.; Landers, Jeffrey J.; Baker, James R., Jr.] Univ Michigan, M NIMBS, Ann Arbor, MI 48109 USA; [Makidon, Paul E.; Wilkinson, J. Erby] Univ Michigan, Unit Lab Anim Med ULAM, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Makidon, PE (corresponding author), Univ Michigan, M NIMBS, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu	Rathinavelu, Sivaprakash/AAT-2526-2021	/0000-0002-8468-6518; Scott, Alison/0000-0001-6969-4707	Bill & Melinda Gates Foundation [Grand Challenges in Global Health Initiative 37868]; Natl Ctr Research Resourses of NIH [T32 RR07008]; NATIONAL CENTER FOR RESEARCH RESOURCES [T32RR007008] Funding Source: NIH RePORTER	Bill & Melinda Gates Foundation(Bill & Melinda Gates Foundation); Natl Ctr Research Resourses of NIH; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Funded by Bill & Melinda Gates Foundation through Grand Challenges in Global Health Initiative 37868. P. Makidon is supported by T32 RR07008 from Natl Ctr Research Resourses of NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguilar JC, 2004, IMMUNOL CELL BIOL, V82, P539, DOI 10.1111/j.0818-9641.2004.01278.x; Aguilar JC, 2003, BIOCHEM BIOPH RES CO, V310, P59, DOI 10.1016/j.bbrc.2003.08.120; Anttila M, 1999, CLIN EXP IMMUNOL, V118, P402; Assad S, 1999, VACCINE, V18, P57, DOI 10.1016/S0264-410X(99)00179-6; BETANCOURT AA, 2007, INT J INFEC IN PRESS; Bielinska AU, 2008, CLIN VACCINE IMMUNOL, V15, P348, DOI 10.1128/CVI.00440-07; Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148; Bielinska AU, 2007, INFECT IMMUN, V75, P4020, DOI 10.1128/IAI.00070-07; Brewer JM, 2006, IMMUNOL LETT, V102, P10, DOI 10.1016/j.imlet.2005.08.002; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P868; Chen HM, 2000, J CONTROL RELEASE, V67, P117, DOI 10.1016/S0168-3659(00)00199-1; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; CLASSEN DC, 1987, J CLIN MICROBIOL, V25, P600, DOI 10.1128/JCM.25.4.600-604.1987; Conti L, 2008, EUR J IMMUNOL, V38, P750, DOI 10.1002/eji.200737395; Davis SS, 2001, ADV DRUG DELIVER REV, V51, P21, DOI 10.1016/S0169-409X(01)00162-4; Debin A, 2002, VACCINE, V20, P2752, DOI 10.1016/S0264-410X(02)00191-3; Egan MA, 2004, VACCINE, V22, P3774, DOI 10.1016/j.vaccine.2004.03.011; Floreani A, 2004, VACCINE, V22, P607, DOI 10.1016/j.vaccine.2003.09.001; Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7; Geissler M, 1997, GASTROENTEROLOGY, V112, P1307, DOI 10.1016/S0016-5085(97)70145-8; GESEMANN M, 1995, VACCINE, V13, P443, DOI 10.1016/0264-410X(94)00010-K; Gherardi RK, 2001, BRAIN, V124, P1821, DOI 10.1093/brain/124.9.1821; Gilbert RJC, 2005, P NATL ACAD SCI USA, V102, P14783, DOI 10.1073/pnas.0505062102; Giudice EL, 2006, ADV DRUG DELIVER REV, V58, P68, DOI 10.1016/j.addr.2005.12.003; Graham BS, 2006, PLOS MED, V3, P18, DOI 10.1371/journal.pmed.0030057; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; Hamouda T, 2000, J APPL MICROBIOL, V89, P397, DOI 10.1046/j.1365-2672.2000.01127.x; Hamouda T, 2001, MICROBIOL RES, V156, P1, DOI 10.1078/0944-5013-00069; Hamouda T, 1999, J INFECT DIS, V180, P1939, DOI 10.1086/315124; Harandi Ali M, 2003, Curr Opin Investig Drugs, V4, P156; *HEP B FDN, 2007, HEP B CLIN TRIALS; HERBERT RA, 1999, PATHOLOGY MOUSE; Hilleman MR, 2001, VACCINE, V19, P1837, DOI 10.1016/S0264-410X(00)00364-9; HogenEsch H, 2002, VACCINE, V20, pS34, DOI 10.1016/S0264-410X(02)00169-X; Illum L, 2001, ADV DRUG DELIVER REV, V51, P1; Isaka M, 2001, VACCINE, V19, P1460, DOI 10.1016/S0264-410X(00)00348-0; Iyer S, 2004, VACCINE, V22, P1475, DOI 10.1016/j.vaccine.2003.10.023; Jaganathan KS, 2006, VACCINE, V24, P4201, DOI 10.1016/j.vaccine.2006.01.011; Katare YK, 2006, VACCINE, V24, P3599, DOI 10.1016/j.vaccine.2006.01.066; Khajuria A, 2007, VACCINE, V25, P4586, DOI 10.1016/j.vaccine.2007.03.051; Lambert PH, 2005, NAT MED, V11, pS54, DOI 10.1038/nm1216; Lemon SM, 1997, NEW ENGL J MED, V336, P196, DOI 10.1056/NEJM199701163360307; LEROUXROELS G, 1994, VACCINE, V12, P812, DOI 10.1016/0264-410X(94)90290-9; Little SF, 2004, BIOLOGICALS, V32, P62, DOI 10.1016/j.biologicals.2004.02.001; Lobaina Y, 2003, BIOCHEM BIOPH RES CO, V300, P745, DOI 10.1016/S0006-291X(02)02897-8; MAKHATADZE GI, 1990, J MOL BIOL, V213, P375, DOI 10.1016/S0022-2836(05)80197-4; McClary H, 2000, J VIROL, V74, P2255, DOI 10.1128/JVI.74.5.2255-2264.2000; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; Michel ML, 2005, J CLIN VIROL, V34, pS108, DOI 10.1016/S1386-6532(05)80019-8; *MICROCAL LLC, 2007, VP ITC MICR US MAN; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Myc A, 2003, VACCINE, V21, P3801, DOI 10.1016/S0264-410X(03)00381-5; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Niu MT, 1998, J CLIN EPIDEMIOL, V51, P503, DOI 10.1016/S0895-4356(98)00014-6; Park MH, 2003, TISSUE ANTIGENS, V62, P505, DOI 10.1046/j.1399-0039.2003.00141.x; Payette PJ, 2006, INTERVIROLOGY, V49, P144, DOI 10.1159/000089375; PETERSON DL, 1987, BIOESSAYS, V6, P258, DOI 10.1002/bies.950060604; Pittman PR, 2002, VACCINE, V20, pS48, DOI 10.1016/S0264-410X(02)00172-X; Poland GA, 2004, NEW ENGL J MED, V351, P2832, DOI 10.1056/NEJMcp041507; Saraf S, 2006, VACCINE, V24, P45, DOI 10.1016/j.vaccine.2005.07.053; Sato A, 2003, J IMMUNOL, V171, P3684, DOI 10.4049/jimmunol.171.7.3684; Schirmbeck R, 2001, J IMMUNOL, V166, P1405, DOI 10.4049/jimmunol.166.2.1405; SCHIRMBECK R, 1994, J IMMUNOL, V152, P1110; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; TALARO K, 1993, FDN MICROBIOLOGY, P806; van Ginkel FW, 2005, INFECT IMMUN, V73, P6892, DOI 10.1128/IAI.73.10.6892-6902.2005; Van Herck K, 1998, VACCINE, V16, P1933, DOI 10.1016/S0264-410X(98)00126-1; Vanlandschoot P, 2003, TRENDS IMMUNOL, V24, P144, DOI 10.1016/S1471-4906(03)00026-7; Vermont CL, 2002, INFECT IMMUN, V70, P584, DOI 10.1128/IAI.70.2.584-590.2002; *WHO, 2000, 204 WHO; Wieland SF, 2000, J VIROL, V74, P4165, DOI 10.1128/JVI.74.9.4165-4173.2000; Woo WP, 2006, J VIROL, V80, P3975, DOI 10.1128/JVI.80.8.3975-3984.2006; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398; Zuckerman JN, 2006, J MED VIROL, V78, P169, DOI 10.1002/jmv.20524; 2005, GATES FDN GRAND CHAL	75	112	129	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2008	3	8							e2954	10.1371/journal.pone.0002954	http://dx.doi.org/10.1371/journal.pone.0002954			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	422FK	18698426	Green Published, gold, Green Submitted			2023-01-03	WOS:000264412600040
J	Dusek, JA; Otu, HH; Wohlhueter, AL; Bhasin, M; Zerbini, LF; Joseph, MG; Benson, H; Libermann, TA				Dusek, Jeffery A.; Otu, Hasan H.; Wohlhueter, Ann L.; Bhasin, Manoj; Zerbini, Luiz F.; Joseph, Marie G.; Benson, Herbert; Libermann, Towia A.			Genomic Counter-Stress Changes Induced by the Relaxation Response	PLOS ONE			English	Article							PERIPHERAL-BLOOD; GENE-EXPRESSION; DISEASE; MODULATION; MEDICINE	Background: Mind-body practices that elicit the relaxation response (RR) have been used worldwide for millennia to prevent and treat disease. The RR is characterized by decreased oxygen consumption, increased exhaled nitric oxide, and reduced psychological distress. It is believed to be the counterpart of the stress response that exhibits a distinct pattern of physiology and transcriptional profile. We hypothesized that RR elicitation results in characteristic gene expression changes that can be used to measure physiological responses elicited by the RR in an unbiased fashion. Methods/Principal Findings: We assessed whole blood transcriptional profiles in 19 healthy, long-term practitioners of daily RR practice (group M), 19 healthy controls (group N-1), and 20 N-1 individuals who completed 8 weeks of RR training (group N-2). 2209 genes were differentially expressed in group M relative to group N-1 (p < 0.05) and 1561 genes in group N-2 compared to group N-1 (p, 0.05). Importantly, 433 (p, 10210) of 2209 and 1561 differentially expressed genes were shared among long-term (M) and short-term practitioners (N-2). Gene ontology and gene set enrichment analyses revealed significant alterations in cellular metabolism, oxidative phosphorylation, generation of reactive oxygen species and response to oxidative stress in long-term and short-term practitioners of daily RR practice that may counteract cellular damage related to chronic psychological stress. A significant number of genes and pathways were confirmed in an independent validation set containing 5 N-1 controls, 5 N-2 short-term and 6 M long-term practitioners. Conclusions/Significance: This study provides the first compelling evidence that the RR elicits specific gene expression changes in short-term and long-term practitioners. Our results suggest consistent and constitutive changes in gene expression resulting from RR may relate to long term physiological effects. Our study may stimulate new investigations into applying transcriptional profiling for accurately measuring RR and stress related responses in multiple disease settings.	[Dusek, Jeffery A.; Wohlhueter, Ann L.; Benson, Herbert] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Chestnut Hill, MA USA; [Dusek, Jeffery A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA; [Dusek, Jeffery A.; Otu, Hasan H.; Bhasin, Manoj; Zerbini, Luiz F.; Benson, Herbert; Libermann, Towia A.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Division of Interdisciplinary Med & Biotechnol, Boston, MA USA; [Otu, Hasan H.; Bhasin, Manoj; Zerbini, Luiz F.; Joseph, Marie G.; Libermann, Towia A.] Beth Israel Deaconess Med Ctr, BIDMC Genom Ctr, Boston, MA USA; [Benson, Herbert] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA USA; [Dusek, Jeffery A.] Abbott NW Hosp, Inst Hlth & Healing, Minneapolis, MN USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts General Hospital	Dusek, JA (corresponding author), Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Chestnut Hill, MA USA.	hbenson@partners.org; tliberma@bidmc.harvard.edu	Zerbini, Luiz/B-7720-2015	Zerbini, Luiz/0000-0003-0736-9508; Libermann, Towia/0000-0002-4006-8179; Bhasin, Manoj/0000-0001-5172-420X; Dusek, Jeffery/0000-0001-9581-0564; Otu, Hasan/0000-0002-9253-8152	Centers for Disease Control and Prevention (CDC) [H75/CCH 19124, H75/CCH 123424, R01 DP000339]; National Institutes of Health [M01 RR01032]; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [R01DP000339] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The study was funded by grants H75/CCH 19124, H75/CCH 123424 and R01 DP000339 (HB) from the Centers for Disease Control and Prevention (CDC) and M01 RR01032 (HB) from the National Institutes of Health (to Harvard-Thorndike BIDMC GCRC).	Astin JA, 2003, J AM BOARD FAM PRACT, V16, P131, DOI 10.3122/jabfm.16.2.131; BEARY JF, 1974, PSYCHOSOM MED, V36, P115, DOI 10.1097/00006842-197403000-00003; BENSON H, 1975, Journal of Human Stress, V1, P37; BENSON H, 1974, PSYCHIATRY, V37, P37, DOI 10.1080/00332747.1974.11023785; BENSON H, 1981, J FLA MED ASSOC, V68, P265; BENSON H, 1983, TRENDS NEUROSCI, V6, P281, DOI 10.1016/0166-2236(83)90120-0; Benson H, 1978, Cardiovasc Clin, V9, P113; Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Dusek JA, 2006, MED SCI MONITOR, V12, pCR1; Epel ES, 2006, PSYCHONEUROENDOCRINO, V31, P277, DOI 10.1016/j.psyneuen.2005.08.011; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; Escher JC, 2003, INFLAMM BOWEL DIS, V9, P34, DOI 10.1097/00054725-200301000-00006; GLASER R, 1990, ARCH GEN PSYCHIAT, V47, P707; GLASER R, 1993, BEHAV NEUROSCI, V107, P525, DOI 10.1037/0735-7044.107.3.525; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Irie M, 2002, PSYCHOTHER PSYCHOSOM, V71, P90, DOI 10.1159/000049351; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Jacobs GD, 1996, BIOFEEDBACK SELF-REG, V21, P121, DOI 10.1007/BF02284691; KESTERSON J, 1989, AM J PHYSIOL, V256, pR632, DOI 10.1152/ajpregu.1989.256.3.R632; Lazar SW, 2000, NEUROREPORT, V11, P1581, DOI 10.1097/00001756-200005150-00041; Lee Norman H, 2007, Methods Mol Biol, V353, P265; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li QZ, 2005, J ALTERN COMPLEM MED, V11, P29, DOI 10.1089/acm.2005.11.29; Morita K, 2005, NEUROSCI LETT, V381, P57, DOI 10.1016/j.neulet.2005.01.081; Nakao M, 2001, BEHAV MED, V26, P169, DOI 10.1080/08964280109595764; Peng CK, 2004, INT J CARDIOL, V95, P19, DOI 10.1016/j.ijcard.2003.02.006; PLATT JE, 1995, PROG NEURO-PSYCHOPH, V19, P65, DOI 10.1016/0278-5846(94)00105-Q; Segman RH, 2005, MOL PSYCHIATR, V10, P500, DOI 10.1038/sj.mp.4001636; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Sneath P.H., 1973, NUMERICAL TAXONOMY P; Sternberg EM, 1997, NAT MED, V3, P264, DOI 10.1038/nm0397-264; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; WALLACE RK, 1971, AM J PHYSIOL, V221, P795, DOI 10.1152/ajplegacy.1971.221.3.795; WARRENBURG S, 1980, Journal of Behavioral Medicine, V3, P73, DOI 10.1007/BF00844915; Yamaguchi T, 2002, BIOCHEM BIOPH RES CO, V293, P517, DOI 10.1016/S0006-291X(02)00233-4; Zheng KC, 2007, J OCCUP HEALTH, V49, P32, DOI 10.1539/joh.49.32; Zieker J, 2007, MOL PSYCHIATR, V12, P116, DOI 10.1038/sj.mp.4001905	38	150	151	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2008	3	7							e2576	10.1371/journal.pone.0002576	http://dx.doi.org/10.1371/journal.pone.0002576			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	406IM	18596974	Green Published, gold			2023-01-03	WOS:000263288200041
J	Muers, MF; Stephens, RJ; Fisher, P; Darlison, L; Higgs, CMB; Lowry, E; Nicholson, AG; O'Brien, M; Peake, M; Rudd, R; Snee, M; Steele, J; Girling, DJ; Nankivell, M; Pugh, C; Parmar, MKB				Muers, Martin F.; Stephens, Richard J.; Fisher, Patricia; Darlison, Liz; Higgs, Christopher M. B.; Lowry, Erica; Nicholson, Andrew G.; O'Brien, Mary; Peake, Michael; Rudd, Robin; Snee, Michael; Steele, Jeremy; Girling, David J.; Nankivell, Matthew; Pugh, Cheryl; Parmar, Mahesh K. B.		MS01 Trial Management Grp	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial	LANCET			English	Article							MVP MITOMYCIN-C; LUNG-CANCER; CISPLATIN CHEMOTHERAPY; CLINICAL-TRIALS; PHASE-III; VINORELBINE; VINBLASTINE; QLQ-C30	Background Malignant pleural mesothelioma is almost always fatal, and few treatment options are available. Although active symptom control (ASC) has been recommended for the management of this disease, no consensus exists for the role of chemotherapy. We investigated whether the addition of chemotherapy to ASC improved survival and quality of life. Methods 409 patients with malignant pleural mesothelioma, from 76 centres in the UK and two in Australia, were randomly assigned to ASC alone (treatment could include steroids, analgesic drugs, bronchodilators, palliative radiotherapy [n=136]); to ASC plus MVP (four cycles of mitomycin 6 mg/m(2), vinblastine 6 mg/m(2) and cisplatin 50 mg/m(2) every 3 weeks [n=137]); or to ASC plus vinorelbine (one injection of vinorelbine 30 mg/m(2) every week for 12 weeks [n=136]). Randomisation was done by minimisation, with stratification for WHO performance status, histology, and Centre. Follow-up was every 3 weeks to 21 weeks after randomisation, and every 8 weeks thereafter. Because of slow accrual, the two chemotherapy groups were combined and compared with ASC alone for the primary outcome of overall survival. Analysis was by intention to treat. This study is registered, number ISRCTN54469112. Findings At the time of analysis, 393 (96%) patients had died (ASC 132 [97%], ASC plus, MVP 132 [96%], ASC plus vinorelbine 129 [95%]). Compared with ASC alone, we noted a small, non-significant survival benefit for ASC plus chemotherapy (hazard ratio [HR] 0.89 [95% CI 0.72-1.10]; p=0.29). Median survival was 7.6 months in the ASC alone group and 8.5 months in the ASC plus chemotherapy group. Exploratory analyses suggested a survival advantage for ASC plus vinorelbine compared with ASC alone (HR 0.80 [0.63-1.02]; p=0.08), with a median survival of 9.5 months. There was no evidence of a survival benefit with ASC plus MVP (HR 0.99 [0.78-1.27]; p=0.95). We observed no between-group differences in four predefined quality-of-life subscales (physical functioning, pain, dyspnoea, and global health status) at any of the assessments in the first 6 months. Interpretation The addition of chemotherapy to ASC offers no significant benefits in terms of overall survival or quality of life. However, exploratory analyses suggested that vinorelbine merits further investigation.	[Stephens, Richard J.; Girling, David J.; Nankivell, Matthew; Pugh, Cheryl; Parmar, Mahesh K. B.] MRC, Clin Trials Unit, London NW1 2DA, England; [Muers, Martin F.] Leeds Gen Infirm, Leeds, W Yorkshire, England; [Fisher, Patricia] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Darlison, Liz; Peake, Michael] Univ Hosp Leicester, Leicester, Leics, England; [Higgs, Christopher M. B.] Dorothy House Hospice, Bath, Avon, England; [Lowry, Erica] Papworth Hosp, Papworth Everard, England; [Nicholson, Andrew G.] Royal Brompton Hosp, London SW3 6LY, England; [O'Brien, Mary] Royal Marsden Hosp, London SW3 6JJ, England; [Rudd, Robin; Steele, Jeremy] St Bartholomews Hosp, London, England; [Snee, Michael] Cookridge Hosp, Leeds LS16 6QB, W Yorkshire, England	Medical Research Council Clinical Trials Unit; Leeds General Infirmary; University of Leeds; Weston Park Hospital; University Hospitals of Leicester NHS Trust; University of Leicester; Papworth Hospital; Royal Brompton Hospital; Royal Marsden NHS Foundation Trust; University of London; Queen Mary University London; Cookridge Hospital	Stephens, RJ (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	rs@ctu.mrc.ac.uk	Ottensmeier, Christian H/E-8131-2012	Ottensmeier, Christian H/0000-0003-3619-1657; Lee, Siow Ming/0000-0002-1741-6235; Braybrooke, Jeremy/0000-0003-1943-7360; Sebag-Montefiore, David/0000-0002-5978-9259	MRC [MC_U122861375] Funding Source: UKRI; Cancer Research UK Funding Source: Medline; Medical Research Council [MC_U122861375] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Andreopoulou E, 2004, ANN ONCOL, V15, P1406, DOI 10.1093/annonc/mdh356; BERGMAN B, 1994, EUR J CANCER, V30A, P635, DOI 10.1016/0959-8049(94)90535-5; Byrne MJ, 1999, J CLIN ONCOL, V17, P25, DOI 10.1200/JCO.1999.17.1.25; Chapman A, 2008, THORAX, V63, P435, DOI 10.1136/thx.2007.081430; DEHAES JCJM, 1990, BRIT J CANCER, V62, P1034, DOI 10.1038/bjc.1990.434; Ellis P, 2006, J THORAC ONCOL, V1, P591, DOI 10.1097/01243894-200607000-00017; Gralla RJ, 2007, DRUGS, V67, P1403, DOI 10.2165/00003495-200767100-00003; Hodgson JT, 2005, BRIT J CANCER, V92, P587, DOI 10.1038/sj.bjc.6602307; LANGENDIJK H, 2004, MED RADIOL, P395; Middleton GW, 1998, ANN ONCOL, V9, P269, DOI 10.1023/A:1008236010868; Muers MF, 2004, THORAX, V59, P144, DOI 10.1136/thorax.2003.009290; Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105; RUSCH VW, 1995, CHEST, V107, pS322, DOI 10.1378/chest.107.6_Supplement.322S; Ryan CW, 1998, CHEST, V113, p66S, DOI 10.1378/chest.113.1_Supplement.66S; Steele JPC, 2000, J CLIN ONCOL, V18, P3912, DOI 10.1200/JCO.2000.18.23.3912; Stephens RJ, 1999, BRIT J CANCER, V79, P538, DOI 10.1038/sj.bjc.6690085; Tanvetyanon T, 2007, J THORAC ONCOL, V2, P1091, DOI 10.1097/JTO.0b013e31815cff64; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tossavainen A, 2004, INT J OCCUP ENV HEAL, V10, P22, DOI 10.1179/oeh.2004.10.1.22; van Meerbeeck JP, 2006, J THORAC ONCOL, V1, P279, DOI 10.1097/01243894-200605000-00001; van Meerbeeck JP, 2005, J CLIN ONCOL, V23, P6881, DOI 10.1200/JCO.20005.14.589; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; VOGELZANG NJ, 2002, P AM SOC CLIN ONCOL, V21; Wiggins J, 2001, THORAX, V56, P250	25	197	200	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 17	2008	371	9625					1685	1694		10.1016/S0140-6736(08)60727-8	http://dx.doi.org/10.1016/S0140-6736(08)60727-8			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302XB	18486741	Green Published			2023-01-03	WOS:000256002200027
J	Kaptchuk, TJ; Kelley, JM; Conboy, LA; Davis, RB; Kerr, CE; Jacobson, EE; Kirsch, I; Schyner, RN; Nam, BH; Nguyen, LT; Park, M; Rivers, AL; McManus, C; Kokkotou, E; Drossman, DA; Goldman, P; Lembo, AJ				Kaptchuk, Ted J.; Kelley, John M.; Conboy, Lisa A.; Davis, Roger B.; Kerr, Catherine E.; Jacobson, Eric E.; Kirsch, Irving; Schyner, Rosa N.; Nam, Bong Hyun; Nguyen, Long T.; Park, Min; Rivers, Andrea L.; McManus, Claire; Kokkotou, Efi; Drossman, Douglas A.; Goldman, Peter; Lembo, Anthony J.			Components of placebo effect: randomised controlled trial inpatients with irritable bowel syndrome	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROTEIN-CREATININE RATIO; RANDOM URINE PROTEIN; PROTEIN/CREATININE RATIO; ALBUMIN/CREATININE RATIO; END-POINT; HYPERTENSIVE DISORDERS; ADEQUATE RELIEF; KIDNEY-DISEASE; PREGNANCY; EXCRETION	Objective To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components. Design A six week single blind three arm randomised controlled trial. Setting Academic medical centre. Participants 262 adults (76% women), mean (SID) age 39 (14), diagnosed by Rome II criteria for and with a score of >= 150 on the symptom severity scale. Interventions For three weeks either waiting list (observation), placebo acupuncture alone ("limited"), or placebo acupuncture with a patient-practitioner relationship augmented by warmth, attention, and confidence ("augmented"). At three weeks, half of the patients were randomly assigned to continue in their originally assigned group for an additional three weeks. Main outcome measures Global improvement kale (range 1-7), adequate relief of symptoms, symptom severity score, and quality of life. Results At three weeks, scores on the global improvement scale were 3.8 (SID 1.0) v 4.3 (SD 1.4) v 5.0 (SID 1.3) for waiting list versus "limited" versus "augmented," respectively (P<0.001 for trend). The proportion of patients reporting adequate relief showed a similar pattern: 28% on waiting list, 44% in limited group, and 62% in augmented group (P<0.001 for trend). The same trend in response existed in symptom severity score (30 (63) v 42 (67) v 82 (89), P<0.001) and quality of life (3.6 (8.1) v 4.1 (9.4) v 9.3 (14.0), P<0.001). All pairwise comparisons between augmented and limited patient-practitioner relationship were significant: global improvement scale (P<0.001), adequate relief of symptoms (P<.001), symptom severity score (P=0.007), quality of life (P=0.01). Results were similar at six week follow-up. Conclusion Factors contributing to the placebo effect can be progressively combined in a manner resembling a graded dose escalation of component parts. Non-specific effects can produce statistically and clinically significant outcomes and the patient-practitioner relationship is the most robust component. Trial registration Clinical Trials NCTC0065403.	[Kaptchuk, Ted J.; Conboy, Lisa A.; Kerr, Catherine E.; Schyner, Rosa N.; Nam, Bong Hyun; Nguyen, Long T.; Park, Min; Rivers, Andrea L.; McManus, Claire] Harvard Univ, Sch Med, Osher Res Ctr, Boston, MA 02215 USA; [Kelley, John M.] Endicott Coll, Beverly, MA 01915 USA; [Davis, Roger B.; Kokkotou, Efi; Lembo, Anthony J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Jacobson, Eric E.] Harvard Univ, Sch Med, Dept Social Med, Boston, MA 02215 USA; [Kirsch, Irving] Univ Hull, Dept Psychol, Kingston Upon Hull HU6 7RX, N Humberside, England; [Drossman, Douglas A.] Univ N Carolina, Sch Med, Ctr Funct GI & Motil Disorders, Chapel Hill, NC 27699 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Hull; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Kaptchuk, TJ (corresponding author), Harvard Univ, Sch Med, Osher Res Ctr, 401 Park Dr, Boston, MA 02215 USA.	ted_kaptchuk@hms.harvard.edu	Kerr, Catherine E/D-3299-2009; Conboy, Lisa/ABC-5173-2021; Kirsch, Irving/P-9316-2019	Conboy, Lisa/0000-0003-2218-7841; Casas Gallegos, Isabel/0000-0002-2805-4604	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT004662] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001414, R21AT002564, R21AT002860] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NCCIH NIH HHS [1R01 AT001414-01, R01 AT004662, 1 R21 AT002564, 1R21 AT002860-01, 1K24 AT004095] Funding Source: Medline; NCRR NIH HHS [RR 01032] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Adelberg AM, 2001, AM J OBSTET GYNECOL, V185, P804, DOI 10.1067/mob.2001.117302; Al RA, 2004, OBSTET GYNECOL, V104, P367, DOI 10.1097/01.AOG.0000134788.01016.2a; Allan LG, 2002, EVAL HEALTH PROF, V25, P410, DOI 10.1177/0163278702238054; Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; BOLER L, 1987, OBSTET GYNECOL, V70, P99; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; BROWN MA, 1995, AUST NZ J OBSTET GYN, V35, P366, DOI 10.1111/j.1479-828X.1995.tb02143.x; Brown MA, 2000, AUST NZ J OBSTET GYN, V40, P133, DOI 10.1111/j.1479-828X.2000.tb01136.x; Brown MA, 2001, HYPERTENS PREGNANCY, V20, pIX, DOI 10.1081/PRG-100104165; Camilleri M, 2000, LANCET, V355, P1035, DOI 10.1016/S0140-6736(00)02033-X; Camilleri M, 2007, CLIN GASTROENTEROL H, V5, P534, DOI 10.1016/j.cgh.2007.03.004; Chan P, 2005, BJOG-INT J OBSTET GY, V112, P280, DOI 10.1111/j.1471-0528.2004.00395.x; CHUA S, 1992, EUR J OBSTET GYN R B, V43, P9, DOI 10.1016/0028-2243(92)90236-R; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Deeks JJ., 2001, SYSTEMATIC REV HLTH, P248, DOI DOI 10.1002/9780470693926.CH14; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Drossman DA, 2000, AM J GASTROENTEROL, V95, P999; Durnwald C, 2003, AM J OBSTET GYNECOL, V189, P848, DOI 10.1067/S0002-9378(03)00849-4; Egger M., 2008, SYSTEMATIC REV HLTH; Evans W, 2000, J Matern Fetal Med, V9, P233; FERRAZZANI S, 1990, AM J OBSTET GYNECOL, V162, P366, DOI 10.1016/0002-9378(90)90387-M; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; GINSBERG JM, 1983, NEW ENGL J MED, V309, P1543, DOI 10.1056/NEJM198312223092503; Gordon S, 2003, DIGEST DIS SCI, V48, P1317, DOI 10.1023/A:1024159226274; Haas D M, 2003, J Matern Fetal Neonatal Med, V14, P233, DOI 10.1080/jmf.14.4.233.236; Hall DR, 2002, INT J GYNECOL OBSTET, V77, P1, DOI 10.1016/S0020-7292(02)00008-5; Helewa ME, 1997, CAN MED ASSOC J, V157, P715; Hrobjartsson A, 2002, J CLIN EPIDEMIOL, V55, P430, DOI 10.1016/S0895-4356(01)00496-6; JASCHEVATZKY OE, 1990, OBSTET GYNECOL, V75, P604; Kaptchuk TJ, 2006, BMJ-BRIT MED J, V332, P391, DOI 10.1136/bmj.38726.603310.55; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 2002, ANN INTERN MED, V136, P817, DOI 10.7326/0003-4819-136-11-200206040-00011; Kieler H, 2003, BJOG-INT J OBSTET GY, V110, P12, DOI 10.1046/j.1471-0528.2003.01440.x; KUO VS, 1992, AM J OBSTET GYNECOL, V167, P723, DOI 10.1016/S0002-9378(11)91578-6; Lane C, 2006, NEPHROLOGY, V11, P245, DOI 10.1111/j.1440-1797.2006.00564.x; LAO TT, 1988, EUR J OBSTET GYN R B, V29, P121, DOI 10.1016/0028-2243(88)90138-4; Lembo T, 2001, AM J GASTROENTEROL, V96, P2662; LINDHEIMER MD, 1977, KIDNEY FUNCTION DIS, P1; LINDOW SW, 1992, BRIT J OBSTET GYNAEC, V99, P869, DOI 10.1111/j.1471-0528.1992.tb14431.x; Mangel AW, 2006, ALIMENT PHARM THERAP, V23, P879, DOI 10.1111/j.1365-2036.2006.02839.x; Mangel AW, 1998, J INT MED RES, V26, P76, DOI 10.1177/030006059802600203; Menzies J, 2007, HYPERTENS PREGNANCY, V26, P447, DOI 10.1080/10641950701521742; MILLER FG, 2008, IN PRESS J ROY SOC M; Myers GL, 2006, CLIN CHEM, V52, P5, DOI 10.1373/clinchem.2005.0525144; Neithardt AB, 2002, AM J OBSTET GYNECOL, V186, P883, DOI 10.1067/mob.2002.123055; Newman MG, 2003, AM J OBSTET GYNECOL, V188, P264, DOI 10.1067/mob.2003.84; Nisell H, 2006, ACTA OBSTET GYN SCAN, V85, P1327, DOI 10.1080/00016340600808747; Novick J, 2002, ALIMENT PHARM THER, V16, P1877, DOI 10.1046/j.1365-2036.2002.01372.x; PACHECOLOPEZ G, 2006, BRAIN BEHAV IMMUNOL, P403; Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x; Phelan LK, 2004, HYPERTENS PREGNANCY, V23, P135, DOI 10.1081/PRG-120028289; Price CP, 2005, CLIN CHEM, V51, P1577, DOI 10.1373/clinchem.2005.049742; QUADRI KHM, 1994, AM J KIDNEY DIS, V24, P416, DOI 10.1016/S0272-6386(12)80897-3; Ramos JGL, 1999, HYPERTENS PREGNANCY, V18, P209, DOI 10.3109/10641959909016194; Rinehart B K, 1999, J Perinatol, V19, P556, DOI 10.1038/sj.jp.7200271; Risberg A, 2004, SCAND J CLIN LAB INV, V64, P17, DOI 10.1080/00365510410003714; Robert M, 1997, OBSTET GYNECOL, V90, P893, DOI 10.1016/S0029-7844(97)00536-X; Rochiguez-Thompson D, 2001, AM J OBSTET GYNECOL, V185, P808; Saudan PJ, 1997, BRIT J OBSTET GYNAEC, V104, P1159, DOI 10.1111/j.1471-0528.1997.tb10940.x; Schiff E, 1996, AM J OBSTET GYNECOL, V175, P1313, DOI 10.1016/S0002-9378(96)70047-9; Skweres Tomasz, 2006, Ginekol Pol, V77, P415; Somanathan N, 2003, J Obstet Gynaecol, V23, P378; Taherian A.A., 2006, J RES MED SCI, V11, P6; Thompson WG, 1999, GUT, V45, P43; UTTENDORFSKY OT, 1988, EUR J OBSTET GYN R B, V27, P221, DOI 10.1016/0028-2243(88)90126-8; Valerio EG, 2005, HYPERTENS PREGNANCY, V24, P213, DOI 10.1080/10641950500281167; Vassalotti JA, 2007, AM J KIDNEY DIS, V50, P169, DOI 10.1053/j.ajkd.2007.06.013; Waugh J, 2005, HYPERTENS PREGNANCY, V24, P291, DOI 10.1080/10641950500281019; Waugh J, 2003, HYPERTENS PREGNANCY, V22, P77, DOI 10.1081/PRG-120017006; Wheeler TL, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2006.10.892; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Wikstrom AK, 2006, BJOG-INT J OBSTET GY, V113, P930, DOI 10.1111/j.1471-0528.2006.01007.x; Wongkitisophon Kitti, 2003, Journal of the Medical Association of Thailand, V86, P529; Yamasmit Waralak, 2003, J Med Assoc Thai, V86, P69; Young RA, 1996, J FAM PRACTICE, V42, P385; Zadehmodarres S, 2006, AUST NZ J OBSTET GYN, V46, P501, DOI 10.1111/j.1479-828X.2006.00649.x	77	792	803	4	97	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 3	2008	336	7651					999	1003		10.1136/bmj.39524.439618.25	http://dx.doi.org/10.1136/bmj.39524.439618.25			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	300EZ	18390493	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000255808400042
J	Yang, ZJ; Price, CD; Bosco, G; Tucci, M; El-Badri, NS; Mangar, D; Camporesi, EM				Yang, Zhong-Jin; Price, Chrystal D.; Bosco, Gerardo; Tucci, Micheal; El-Badri, Nagwa S.; Mangar, Devanand; Camporesi, Enrico M.			The Effect of Isovolemic Hemodilution with Oxycyte (R), a Perfluorocarbon Emulsion, on Cerebral Blood Flow in Rats	PLOS ONE			English	Article								Background: Cerebral blood flow (CBF) is auto-regulated to meet the brain's metabolic requirements. Oxycyte (R) is a perfluorocarbon emulsion that acts as a highly effective oxygen carrier compared to blood. The aim of this study is to determine the effects of Oxycyte (R) on regional CBF (rCBF), by evaluating the effects of stepwise isovolemic hemodilution with Oxycyte (R) on CBF. Methodology: Male rats were intubated and ventilated with 100% O-2 under isoflurane anesthesia. The regional (striatum) CBF (rCBF) was measured with a laser doppler flowmeter (LDF). Stepwise isovolemic hemodilution was performed by withdrawing 4ml of blood and substituting the same volume of 5% albumin or 2 ml Oxycyte (R) plus 2 ml albumin at 20-minute intervals until the hematocrit (Hct) values reached 5%. Principal Findings: In the albumin-treated group, rCBF progressively increased to approximately twice its baseline level (208 +/- 30%) when Hct levels were less than 10%. In the Oxycyte (R)-treated group on the other hand, rCBF increased by significantly smaller increments, and this group's mean rCBF was only slightly higher than baseline (118 +/- 18%) when Hct levels were less than 10%. Similarly, in the albumin-treated group, rCBF started to increase when hemodilution with albumin caused the CaO2 to decrease below 17.5 ml/dl. Thereafter, the increase in rCBF was accompanied by a nearly proportional decrease in the CaO2 level. In the Oxycyte (R)-treated group, the increase in rCBF was significantly smaller than in the albumin-treated group when the CaO2 level dropped below 10 ml/dl (142 +/- 20% vs. 186 +/- 26%), and rCBF returned to almost baseline levels (106 +/- 15) when the CaO2 level was below 7 ml/dl. Conclusions/Significance: Hemodilution with Oxycyte (R) was accompanied with higher CaO2 and PO2 than control group treated with albumin alone. This effect may be partially responsible for maintaining relatively constant CBF and not allowing the elevated blood flow that was observed with albumin.	[Price, Chrystal D.; El-Badri, Nagwa S.; Mangar, Devanand; Camporesi, Enrico M.] Univ S Florida, Dept Anesthesiol, Tampa, FL USA; [Yang, Zhong-Jin; Tucci, Micheal] SUNY Upstate Med Univ, Dept Anesthesiol, Syracuse, NY USA; [Bosco, Gerardo] Univ G dAnnunzio, Dept Physiol, Chieti, Italy	State University System of Florida; University of South Florida; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; G d'Annunzio University of Chieti-Pescara	Camporesi, EM (corresponding author), Univ S Florida, Dept Anesthesiol, Tampa, FL USA.	ecampore@health.usf.edu		BOSCO, GERARDO/0000-0001-6595-7944	Synthetic Blood International Inc. Costa Mesa, CA	Synthetic Blood International Inc. Costa Mesa, CA	The authors thank Synthetic Blood International Inc (Synthetic Blood International Inc. Costa Mesa, CA) for providing Oxycyte and an education grant that partially supported this work.	Briceno JC, 1997, ASAIO J, V43, P13; Briceno JC, 1999, ASAIO J, V45, P322, DOI 10.1097/00002480-199907000-00013; Cabrales P, 2004, AM J PHYSIOL-HEART C, V287, pH320, DOI 10.1152/ajpheart.01166.2003; Daugherty WP, 2004, NEUROSURGERY, V54, P1223, DOI 10.1227/01.NEU.0000119238.68938.5D; ECKSTEIN EC, 1989, T AM SOC ART INT ORG, V35, P188; FAITHFULL NS, 1992, BIOMAT ARTIF CELL IM, V20, P797, DOI 10.3109/10731199209119721; Faithfull NS, 2003, ADV EXP MED BIOL, V530, P271; Harada H, 2005, BRAIN RES PROTOC, V14, P165, DOI 10.1016/j.brainresprot.2004.12.007; Hill SE, 2005, ANN THORAC SURG, V80, P1401, DOI 10.1016/j.athoracsur.2005.03.107; HIRAGA S, 1987, CANCER RES, V47, P3296; HOLMAN WL, 1995, J THORAC CARDIOV SUR, V110, P774, DOI 10.1016/S0022-5223(95)70111-7; Jouan-Hureaux V, 2006, TRANSFUSION, V46, P1892, DOI 10.1111/j.1537-2995.2006.01000.x; KEIPERT PE, 1994, ADV EXP MED BIOL, V345, P197; KLINE RA, 1991, AM J SURG, V162, P103, DOI 10.1016/0002-9610(91)90168-D; LEE PA, 1988, AM J PHYSIOL, V254, pH719, DOI 10.1152/ajpheart.1988.254.4.H719; LEE PA, 1986, EXP MED BIOL, V200, P59; Lowe KC, 2001, J FLUORINE CHEM, V109, P59, DOI 10.1016/S0022-1139(01)00374-8; Lowe KC, 1999, BLOOD REV, V13, P171, DOI 10.1054/blre.1999.0113; Nolte D, 2000, ANESTHESIOLOGY, V93, P1261, DOI 10.1097/00000542-200011000-00020; Paxinos G, 1988, RAT BRAIN STEREOTAXI; PEERLESS SJ, 1981, STROKE, V12, P558, DOI 10.1161/01.STR.12.5.558; TODD MM, 1994, AM J PHYSIOL-HEART C, V267, pH2025, DOI 10.1152/ajpheart.1994.267.5.H2025; Todd MM, 1997, J CEREBR BLOOD F MET, V17, P1319, DOI 10.1097/00004647-199712000-00007; Tomiyama Y, 1999, AM J PHYSIOL-HEART C, V276, pH1190, DOI 10.1152/ajpheart.1999.276.4.H1190; Tomiyama Y, 2000, AM J PHYSIOL-HEART C, V279, pH1949, DOI 10.1152/ajpheart.2000.279.4.H1949; Tonnesen J, 2005, EXP PHYSIOL, V90, P349, DOI 10.1113/expphysiol.2004.029512; Vocelka C, 1995, J Extra Corpor Technol, V27, P6; WASCHKE KF, 1994, ANESTH ANALG, V79, P874; Woitzik J, 2005, NEUROL RES, V27, P509, DOI 10.1179/016164105X15677; Woitzik J, 2007, J NEUROSURG, V106, P872, DOI 10.3171/jns.2007.106.5.872	30	9	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2008	3	4							e2010	10.1371/journal.pone.0002010	http://dx.doi.org/10.1371/journal.pone.0002010			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	381TL	18431491	Green Published, Green Submitted, gold			2023-01-03	WOS:000261558700026
J	Charlier, C; Dromer, F; Leveque, C; Chartier, L; Cordoliani, YS; Fontanet, A; Launay, O; Lortholary, O				Charlier, Caroline; Dromer, Francoise; Leveque, Christophe; Chartier, Loic; Cordoliani, Yves-Sebastien; Fontanet, Arnaud; Launay, Odile; Lortholary, Olivier		French Cryptococcosis Study Grp	Cryptococcal Neuroradiological Lesions Correlate with Severity during Cryptococcal Meningoencephalitis in HIV-Positive Patients in the HAART Era	PLOS ONE			English	Article							INTRACEREBRAL MASS LESIONS; UNCONTROLLABLE INTRACRANIAL HYPERTENSION; RECONSTITUTION INFLAMMATORY SYNDROME; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CNS CRYPTOCOCCOSIS; VENTRICULOPERITONEAL SHUNTS; NEOFORMANS INFECTION; CEREBROSPINAL-FLUID; AIDS PATIENTS; MENINGITIS	Cryptococcal meningoencephalitis has an overall global mortality rate of 20% in AIDS patients despite antifungals. There is a need for additional means of precise assessment of disease severity. We thus studied the radiological brain images available from 62 HIV-positive patients with cryptococcocal meningoencephalitis to analyse the brain lesions associated with cryptococcosis in relationship with disease severity, and the respective diagnostic contribution of magnetic resonance (MR) versus computed tomography (CT). In this retrospective multicenter analysis, two neuroradiologists blindly reviewed the brain imaging. Prospectively acquired clinical and mycological data were available at baseline and during follow-up. Baseline images were abnormal on 92% of the MR scans contrasting with 53% of the CT scans. MR/CT cryptococcosis-related lesions included mass(es) (21%/9%), dilated perivascular spaces (46%/5%) and pseudocysts (8%/4%). The presence compared to absence of cryptococcosis-related lesions was significantly associated with high serum (78% vs. 42%, p = 0.008) and CSF (81% vs. 50%, p = 0.024) antigen titers, independently of neurological abnormalities. MR detected significantly more cryptococcosis-related lesions than CT for 17 patients who had had both investigations (76% vs. 24%, p = 0.005). In conclusion, MR appears more effective than CT for the evaluation of AIDS-associated cerebral cryptococcosis. Furthermore, brain imaging is an effective tool to assess the initial disease severity in this setting. Given this, we suggest that investigation for cryptococcosis-related lesions is merited, even in the absence of neurological abnormality, if a high fungal burden is suspected on the basis of high serum and/or CSF antigen titers.	[Charlier, Caroline; Dromer, Francoise; Lortholary, Olivier] Inst Pasteur, CNRS, Ctr Natl Reference Mycol & Antifong,URA 3012, Unite Mycol Mol, Paris, France; [Charlier, Caroline; Lortholary, Olivier] Ctr Infectiol Necker Pasteur, Serv Maladies Infect Trop, Hop Necker Enfants Malades, Fac Med Paris 5 Rene Descartes, Paris, France; [Leveque, Christophe; Cordoliani, Yves-Sebastien] Hop Val De Grace, Serv Radiodiagnost, Paris, France; [Chartier, Loic; Fontanet, Arnaud] Inst Pasteur, Unite Rech Expertise Epidemiol Malad Emergent, Paris, France; [Launay, Odile] CIC Vaccinol Cochin Pasteur, Pole Med Interne, Hop Cochin, Fac Med, Univ Paris Descartes, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Val-de-Grace Hospital; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Charlier, C (corresponding author), Inst Pasteur, CNRS, Ctr Natl Reference Mycol & Antifong,URA 3012, Unite Mycol Mol, Paris, France.	olortho@pasteur.fr	Charlier, Caroline/AAH-8547-2020; BRETAGNE, Stephane/H-6655-2019	Charlier, Caroline/0000-0002-9375-3620; BRETAGNE, Stephane/0000-0001-6870-3800; Baril, Laurence/0000-0003-2346-883X; Lozeron, Pierre/0000-0003-0816-6526; , arnaud/0000-0002-5239-6110	fellowship from the Assistance Publique-Hopitaux de Paris; CNRS; CANAM; Ensemble contre le SIDA - SIDACTION; Institut Pasteur	fellowship from the Assistance Publique-Hopitaux de Paris; CNRS(Centre National de la Recherche Scientifique (CNRS)); CANAM; Ensemble contre le SIDA - SIDACTION; Institut Pasteur(European Commission)	C. Charlier had a fellowship from the Assistance Publique-Hopitaux de Paris: medaille de l'Internat 2006 and from the Assistance Publique-Hopitaux de Paris, CNRS and CANAM: poste assistant hospitalier de recherche 2006 2007. The CryptoA/D study was financially supported by grants from Ensemble contre le SIDA - SIDACTION and from Institut Pasteur (Programme de recherches cliniques).	ANDREULA CF, 1993, J COMPUT ASSIST TOMO, V17, P438, DOI 10.1097/00004728-199305000-00019; Angstwurm K, 2004, EUR J NEUROL, V11, P353, DOI 10.1111/j.1468-1331.2004.00803.x; Arayawichanont Arkhom, 1999, Journal of the Medical Association of Thailand, V82, P991; Berkefeld J, 1999, NEURORADIOLOGY, V41, P129, DOI 10.1007/s002340050717; Bouffard JP, 2003, MOVEMENT DISORD, V18, P1354, DOI 10.1002/mds.10546; BOUREKAS EC, 1995, J COMPUT ASSIST TOMO, V19, P299, DOI 10.1097/00004728-199503000-00024; CENCI E, 2007, J INFECT; Charlier C, 2005, AM J PATHOL, V166, P421, DOI 10.1016/S0002-9440(10)62265-1; Chen S, 2000, CLIN INFECT DIS, V31, P499, DOI 10.1086/313992; Cheng Yu-Chen, 2003, J Chin Med Assoc, V66, P19; Chretien F, 2002, J INFECT DIS, V186, P522, DOI 10.1086/341564; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; CORDOLIANI YS, 1997, ENCY MEDICOCHIRURGIC; CORNELL SH, 1982, RADIOLOGY, V143, P703, DOI 10.1148/radiology.143.3.7079496; DarrasJoly C, 1996, CLIN INFECT DIS, V23, P369, DOI 10.1093/clinids/23.2.369; DENNING DW, 1991, AM J MED, V91, P267, DOI 10.1016/0002-9343(91)90126-I; Dromer F, 2004, AIDS, V18, P555, DOI 10.1097/00002030-200402200-00024; Dromer F, 2007, PLOS MED, V4, P297, DOI 10.1371/journal.pmed.0040021; Einsiedel L, 2004, CLIN INFECT DIS, V39, pE78, DOI 10.1086/424746; FUJITA NK, 1981, ANN INTERN MED, V94, P382, DOI 10.7326/0003-4819-94-3-382; GARCIA CA, 1985, NEUROLOGY, V35, P731, DOI 10.1212/WNL.35.5.731; Gray F, 2003, J NEUROPATH EXP NEUR, V62, P429, DOI 10.1093/jnen/62.5.429; Graybill JR, 2000, CLIN INFECT DIS, V30, P47, DOI 10.1086/313603; Hospenthal DR, 2000, CLIN INFECT DIS, V31, P1303, DOI 10.1086/317434; Kumwenda JJ, 2005, STROKE, V36, P960, DOI 10.1161/01.STR.0000162585.97216.ef; Lee SC, 1996, HUM PATHOL, V27, P839, DOI 10.1016/S0046-8177(96)90459-1; Lee VW, 1999, RADIOLOGY, V211, P507, DOI 10.1148/radiology.211.2.r99ma37507; Leveque C, 2002, ANN MED INTERNE, V153, P338; Liliang PC, 2002, CLIN INFECT DIS, V34, pE64, DOI 10.1086/340525; Lortholary O, 2005, AIDS, V19, P1043, DOI 10.1097/01.aids.0000174450.70874.30; Lortholary O, 1999, INFECT IMMUN, V67, P6314; Lortholary O, 2001, J INFECT DIS, V183, P294, DOI 10.1086/317937; MALESSA R, 1994, CLIN INVESTIGATOR, V72, P1020, DOI 10.1007/BF00577748; MATHEWS VP, 1992, AM J NEURORADIOL, V13, P1477; Mirza SA, 2003, CLIN INFECT DIS, V36, P789, DOI 10.1086/368091; Miszkiel KA, 1996, CLIN RADIOL, V51, P842, DOI 10.1016/S0009-9260(96)80080-8; Monari C, 2005, J INFECT DIS, V191, P307, DOI 10.1086/426828; Moosa MYS, 1997, CLIN INFECT DIS, V24, P131, DOI 10.1093/clinids/24.2.131; Park MK, 1999, CLIN INFECT DIS, V28, P629, DOI 10.1086/515161; POPOVICH MJ, 1990, AM J ROENTGENOL, V154, P603, DOI 10.2214/ajr.154.3.2106227; POST MJD, 1985, AM J ROENTGENOL, V145, P929, DOI 10.2214/ajr.145.5.929; Rambeloarisoa J, 2002, J INFECTION, V44, P185, DOI 10.1053/jinf.2001.0955; Ruiz A, 1997, J COMPUT ASSIST TOMO, V21, P175, DOI 10.1097/00004728-199703000-00003; Saag MS, 2000, CLIN INFECT DIS, V30, P710, DOI 10.1086/313757; SanchezPortocarrero J, 1997, DIAGN MICR INFEC DIS, V29, P193, DOI 10.1016/S0732-8893(97)81809-3; SCHMIDT S, 1995, CLIN NEUROL NEUROSUR, V97, P23, DOI 10.1016/0303-8467(94)00063-C; Schroeder PC, 2006, NEURORADIOLOGY, V48, P715, DOI 10.1007/s00234-006-0123-y; Skiest Daniel J, 2005, J Infect, V51, pe289, DOI 10.1016/j.jinf.2005.02.031; Skiest DJ, 2000, J INFECTION, V40, P274, DOI 10.1053/jinf.2000.0664; TIEN RD, 1991, AM J NEURORADIOL, V12, P283; Torres OH, 2000, ACTA NEUROL SCAND, V102, P340, DOI 10.1034/j.1600-0404.2000.102005340.x; Troncoso Alcides, 2002, J Int Assoc Physicians AIDS Care (Chic), V1, P131, DOI 10.1177/154510970200100404; van Toorn R, 2005, EUR J PAEDIATR NEURO, V9, P355, DOI 10.1016/j.ejpn.2005.02.002; van Toorn R, 2005, EUR J PAEDIATR NEURO, V9, P81, DOI 10.1016/j.ejpn.2005.01.001; Venkataramana A, 2006, NEUROLOGY, V67, P383, DOI 10.1212/01.wnl.0000227922.22293.93; WEHN SM, 1989, J COMPUT ASSIST TOMO, V13, P756, DOI 10.1097/00004728-198909000-00002; Woodworth GF, 2005, SURG NEUROL, V63, P529, DOI 10.1016/j.surneu.2004.08.069; ZUGER A, 1986, ANN INTERN MED, V104, P234, DOI 10.7326/0003-4819-104-2-234	58	78	82	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1950	10.1371/journal.pone.0001950	http://dx.doi.org/10.1371/journal.pone.0001950			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414656	Green Submitted, gold, Green Published			2023-01-03	WOS:000260867300005
J	Odd, DE; Lewis, G; Whitelaw, A; Gunnell, D				Odd, David E.; Lewis, Glyn; Whitelaw, Andrew; Gunnell, David			Resuscitation at birth and cognition at 8 years of age: a cohort study	LANCET			English	Article							RISK-FACTORS; NEWBORN ENCEPHALOPATHY; APGAR-SCORE; CHILDREN; INFANTS; TERM	Background Mild cerebral injury might cause subtle defects in cognitive function that are only detectable as the child grows older. Our aim was to determine whether infants receiving resuscitation after birth, but with no symptoms of encephalopathy, have reduced intelligence quotient (IQ) scores in childhood. Methods Three groups of infants were selected from the Avon Longitudinal Study of Parents and Children: infants who were resuscitated at birth but were asymptomatic for encephalopathy and had no further neonatal care (n=815), those who were resuscitated and had neonatal care for symptoms of encephalopathy (n=58), and the reference group who were not resuscitated, were asymptomatic for encephalopathy, and had no further neonatal care (n=10609). Cognitive function was assessed at a mean age of 8.6 years (SD 0.33); a low IQ score was defined as less than 80. IQ scores were obtained for 5953 children with a shortened version of the Weschler intelligence scale for children (WISC-III), the remaining 5529 were non-responders. All children did not complete all parts of the test, and therefore multiplied IQ values comparable to the full-scale test were only available for 5887 children. Results were adjusted for clinical and social covariates. Chained equations were used to impute missing values of covariates. Findings In the main analysis at 8 years of age (n=5887), increased risk of a low IQ score was recorded in both resuscitated infants asymptomatic for encephalopathy (odds ratio 1.65 [95% Cl 1.13-2.43]) and those with symptoms of encephalopathy (6.22 [1.57-24.65]). However, the population of asymptomatic infants was larger than that of infants with encephalopathy, and therefore the population attributable risk fraction for an IQ score that might be attributable to the need for resuscitation at birth was 3.4% (95% CI 0.5-6.3) for asymptomatic infants and 1.2% (0.2-2.2) for those who developed encephalopathy. Interpretation Infants who were resuscitated had increased risk of a low IQ score, even if they remained healthy during the neonatal period. Resuscitated infants asymptomatic for encephalopathy might result in a larger proportion of adults with low IQs than do those who develop neurological symptoms consistent with encephalopathy.	[Lewis, Glyn] Univ Bristol, Dept Community Based Med, Bristol, Avon, England; [Gunnell, David] Univ Bristol, Dept Social Med, Bristol, Avon, England	University of Bristol; University of Bristol	Odd, DE (corresponding author), Southmead Hosp, Neonatal Intens Care Unit, Bristol BS10 5NB, Avon, England.	david.odd@nbt.nhs.uk	Lewis, Glyn/E-9944-2012; Gunnell, David/ABE-6653-2020; Odd, David/G-8418-2016	Lewis, Glyn/0000-0001-5205-8245; Gunnell, David/0000-0002-0829-6470; Odd, David/0000-0002-6416-4966	Wellcome Trust [077036]; ESRC [ES/G007543/1] Funding Source: UKRI; Economic and Social Research Council [ES/G007543/1] Funding Source: researchfish; Medical Research Council [G9815508] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. This research was funded by a fellowship award (077036) to DO from the Wellcome Trust. The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for ALSPAC.	*AM AC PED COMM OB, 1996, OBSTET GYNECOL, V107, P1209; Badawi N, 1998, BMJ-BRIT MED J, V317, P1549, DOI 10.1136/bmj.317.7172.1549; Badawi N, 1998, BMJ-BRIT MED J, V317, P1554, DOI 10.1136/bmj.317.7172.1554; Baskett TF, 2006, BJOG-INT J OBSTET GY, V113, P769, DOI 10.1111/j.1471-0528.2006.00987.x; Blackman J A, 1988, J Perinatol, V8, P206; Draycott T, 2006, BJOG-INT J OBSTET GY, V113, P177, DOI 10.1111/j.1471-0528.2006.00800.x; Dutton G N, 2001, Semin Neonatol, V6, P477, DOI 10.1053/siny.2001.0078; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Kaufman A.S., 1994, INTELLIGENT TESTING; KROLL L, 1994, EUR J OBSTET GYN R B, V55, P175, DOI 10.1016/0028-2243(94)90034-5; MacLennan A, 1999, BMJ-BRIT MED J, V319, P1054, DOI 10.1136/bmj.319.7216.1054; MYERS RE, 1972, AM J OBSTET GYNECOL, V112, P246, DOI 10.1016/0002-9378(72)90124-X; O'Donnell CPF, 2006, J PEDIATR-US, V149, P486, DOI 10.1016/j.jpeds.2006.05.040; Odd DE, 2008, ARCH DIS CHILD-FETAL, V93, pF115, DOI 10.1136/adc.2007.123745; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS, V3; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS, V1-3; Office of Population Censuses and Surveys, 1991, STAND OCC CLASS, V2; PALMEKILANDER C, 1992, ACTA PAEDIATR, V81, P739, DOI 10.1111/j.1651-2227.1992.tb12094.x; PASAMANICK B, 1956, AM J PSYCHIAT, V112, P613, DOI 10.1176/ajp.112.8.613; PASQUIER F, 1995, J NEUROL NEUROSUR PS, V58, P81, DOI 10.1136/jnnp.58.1.81; PETERS TJ, 1984, EARLY HUM DEV, V9, P225, DOI 10.1016/0378-3782(84)90033-1; *RES COUNC UK, 2001, RES BIRTH NEWB LIF S; ROYSTON P, 2005, STATA J, V5, P681; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Saugstad OD, 2007, ACTA PAEDIATR, V96, P798, DOI 10.1111/j.1651-2227.2006.00348.x; Tan A, 2005, COCHRANE DB SYST REV, V2; Veltman DJ, 2005, PSYCHOL MED, V35, P175, DOI 10.1017/S0033291704002971; Viggedal G, 2002, ACTA PAEDIATR, V91, P1218, DOI 10.1080/080352502320777469; VILLAR J, 1990, AM J OBSTET GYNECOL, V163, P151, DOI 10.1016/S0002-9378(11)90690-5; Wechsler D., 1991, MANUAL WECHSLER INTE; WECHSLER D, 2004, WECHSLER INTELIGENCE	32	91	94	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 9	2009	373	9675					1615	1622		10.1016/S0140-6736(09)60244-0	http://dx.doi.org/10.1016/S0140-6736(09)60244-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	445QJ	19386357	Green Published, Bronze			2023-01-03	WOS:000266066300032
J	Jakob, SM; Takala, J				Jakob, Stephan M.; Takala, Jukka			Physical and occupational therapy during sedation stops	LANCET			English	Editorial Material							CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; RESPIRATORY-FAILURE; SKELETAL-MUSCLE; BED REST		[Jakob, Stephan M.; Takala, Jukka] Univ Bern, Dept Intens Care, CH-3010 Bern, Switzerland; [Jakob, Stephan M.; Takala, Jukka] Univ Hosp Bern, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern	Jakob, SM (corresponding author), Univ Bern, Dept Intens Care, CH-3010 Bern, Switzerland.	stephan.jakob@insel.ch						Ali NA, 2008, AM J RESP CRIT CARE, V178, P261, DOI 10.1164/rccm.200712-1829OC; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Ferrando AA, 1997, J APPL PHYSIOL, V82, P807, DOI 10.1152/jappl.1997.82.3.807; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Griffiths RD, 1995, NUTRITION, V11, P428; Hodgin KE, 2009, CRIT CARE MED, V37, P561, DOI 10.1097/CCM.0b013e3181957449; Kortebein P, 2007, JAMA-J AM MED ASSOC, V297, P1772, DOI 10.1001/jama.297.16.1772-b; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Nava S, 1998, ARCH PHYS MED REHAB, V79, P849, DOI 10.1016/S0003-9993(98)90369-0; Ruokonen E, 2009, INTENS CARE MED, V35, P282, DOI 10.1007/s00134-008-1296-0; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D	15	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2009	373	9678					1824	1826		10.1016/S0140-6736(09)60866-7	http://dx.doi.org/10.1016/S0140-6736(09)60866-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	453ND	19446327				2023-01-03	WOS:000266616400006
J	Finfer, S; Blair, D; Bellomo, R; McArthur, C; Mitchell, I; Myburgh, J; Norton, R; Potter, J; Chittock, D; Dhingra, V; Foster, D; Cook, D; Dodek, P; Hebert, P; Henderson, W; Heyland, D; McDonald, E; Ronco, J; Schweitzer, L; Peto, R; Sandercock, P; Sprung, C; Young, JD; Su, S; Heritier, S; Li, Q; Bompoint, S; Billot, L; Crampton, L; Darcy, F; Jayne, K; Kumarasinghe, V; Little, L; McEvoy, S; MacMahon, S; Pandey, S; Ryan, S; Shukla, R; Vijayan, B; Atherton, S; Bell, J; Hadfield, L; Hourigan, C; McArthur, C; Newby, L; Simmonds, C; Buhr, H; Eccleston, M; McGuinness, S; Parke, R; Bellomo, R; Bates, S; Goldsmith, D; Mercer, I; O'Sullivan, K; Gazzard, R; Hill, D; Tauschke, C; Ghelani, D; Nand, K; Reece, G; Sara, T; Elliott, S; Ernest, D; Hamilton, A; Ashley, R; Bailey, A; Crowfoot, E; Gissane, J; Mitchell, I; Ranse, J; Whiting, J; Douglas, K; Milliss, D; Tan, J; Wong, H; Blythe, D; Palermo, A; Hardie, M; Harrigan, P; McFadyen, B; Micallef, S; Parr, M; Boase, A; Tai, J; Williams, A; Cole, L; Seppelt, I; Weisbrodt, L; Whereat, S; Flanagan, A; Liang, J; Bass, F; Campbell, M; Hammond, N; Nicholson, L; Shehabi, Y; Foote, J; Peake, S; Williams, P; Deans, R; Fourie, C; Lassig-Smith, M; Lipman, J; Stuart, J; Bell, A; Field, T; McAllister, R; Marsden, K; Turner, A; Ankers, S; Bird, S; Finfer, S; Lee, R; O'Connor, A; Potter, J; Ramakrishnan, N; Raper, R; Dhiacou, V; Girling, K; Jovanovska, A; Myburgh, J; Groves, N; Holmes, J; Santamaria, J; Smith, R; Baker, S; Roberts, B; Andrews, L; Dinsdale, R; Fenton, R; Mackle, D; Mortimer, S; French, C; Little, L; Raunow, H; Gales, M; Hill, F; Rachakonda, S; Rogan, D; Allsop, C; Higgins, L; Robinson, B; Champagne, K; Doig, C; Knox, L; Taylor, P; Wilson, C; Drover, J; Hammond, S; Mann, E; Myers, M; Robinson, A; Harvey, J; Skrobik, Y; Baumgartner, A; Meade, L; Vlahakis, N; Ethier, C; Kramer-Kile, M; Mehta, S; Gaudert, C; Kanji, S; McArdle, T; Watpool, I; Clarke, F; Cook, D; McDonald, E; Tkaczyk, A; Marshall, J; Morrissey, J; Porretta, K; Smith, O; Wen, V; Ashley, BJ; Dodek, P; Mans, S; Bojilov, B; Code, K; Fowler, R; Marinoff, N; Chu, L; Granton, J; McGrath-Chong, M; Steinberg, M; Ferguson, N; Go, S; Matte, A; Rosenberg, J; Stevenson, J; Jacka, M; Sonnema, L; Autio, R; Chittock, D; Davies, D; Ganz, P; Gardner, M; Logie, S; Smith, L; Atkins, L; Auld, F; Stewart, M; Wood, G				Finfer, S.; Blair, D.; Bellomo, R.; McArthur, C.; Mitchell, I.; Myburgh, J.; Norton, R.; Potter, J.; Chittock, D.; Dhingra, V.; Foster, D.; Cook, D.; Dodek, P.; Hebert, P.; Henderson, W.; Heyland, D.; McDonald, E.; Ronco, J.; Schweitzer, L.; Peto, R.; Sandercock, P.; Sprung, C.; Young, J. D.; Su, S.; Heritier, S.; Li, Q.; Bompoint, S.; Billot, L.; Crampton, L.; Darcy, F.; Jayne, K.; Kumarasinghe, V.; Little, L.; McEvoy, S.; MacMahon, S.; Pandey, S.; Ryan, S.; Shukla, R.; Vijayan, B.; Atherton, S.; Bell, J.; Hadfield, L.; Hourigan, C.; McArthur, C.; Newby, L.; Simmonds, C.; Buhr, H.; Eccleston, M.; McGuinness, S.; Parke, R.; Bellomo, R.; Bates, S.; Goldsmith, D.; Mercer, I.; O'Sullivan, K.; Gazzard, R.; Hill, D.; Tauschke, C.; Ghelani, D.; Nand, K.; Reece, G.; Sara, T.; Elliott, S.; Ernest, D.; Hamilton, A.; Ashley, R.; Bailey, A.; Crowfoot, E.; Gissane, J.; Mitchell, I.; Ranse, J.; Whiting, J.; Douglas, K.; Milliss, D.; Tan, J.; Wong, H.; Blythe, D.; Palermo, A.; Hardie, M.; Harrigan, P.; McFadyen, B.; Micallef, S.; Parr, M.; Boase, A.; Tai, J.; Williams, A.; Cole, L.; Seppelt, I.; Weisbrodt, L.; Whereat, S.; Flanagan, A.; Liang, J.; Bass, F.; Campbell, M.; Hammond, N.; Nicholson, L.; Shehabi, Y.; Foote, J.; Peake, S.; Williams, P.; Deans, R.; Fourie, C.; Lassig-Smith, M.; Lipman, J.; Stuart, J.; Bell, A.; Field, T.; McAllister, R.; Marsden, K.; Turner, A.; Ankers, S.; Bird, S.; Finfer, S.; Lee, R.; O'Connor, A.; Potter, J.; Ramakrishnan, N.; Raper, R.; Dhiacou, V.; Girling, K.; Jovanovska, A.; Myburgh, J.; Groves, N.; Holmes, J.; Santamaria, J.; Smith, R.; Baker, S.; Roberts, B.; Andrews, L.; Dinsdale, R.; Fenton, R.; Mackle, D.; Mortimer, S.; French, C.; Little, L.; Raunow, H.; Gales, M.; Hill, F.; Rachakonda, S.; Rogan, D.; Allsop, C.; Higgins, L.; Robinson, B.; Champagne, K.; Doig, C.; Knox, L.; Taylor, P.; Wilson, C.; Drover, J.; Hammond, S.; Mann, E.; Myers, M.; Robinson, A.; Harvey, J.; Skrobik, Y.; Baumgartner, A.; Meade, L.; Vlahakis, N.; Ethier, C.; Kramer-Kile, M.; Mehta, S.; Gaudert, C.; Kanji, S.; McArdle, T.; Watpool, I.; Clarke, F.; Cook, D.; McDonald, E.; Tkaczyk, A.; Marshall, J.; Morrissey, J.; Porretta, K.; Smith, O.; Wen, V.; Ashley, B. J.; Dodek, P.; Mans, S.; Bojilov, B.; Code, K.; Fowler, R.; Marinoff, N.; Chu, L.; Granton, J.; McGrath-Chong, M.; Steinberg, M.; Ferguson, N.; Go, S.; Matte, A.; Rosenberg, J.; Stevenson, J.; Jacka, M.; Sonnema, L.; Autio, R.; Chittock, D.; Davies, D.; Ganz, P.; Gardner, M.; Logie, S.; Smith, L.; Atkins, L.; Auld, F.; Stewart, M.; Wood, G.		NICE-SUGAR Study Investigators; NICE Australia-New Zealand; SUGAR North Amer Management Comm; Inde-pendent Data Safety; Study Stat Ctr; Study Coordinating Ctr; Australia-New Zealand Site	Intensive versus Conventional Glucose Control in Critically Ill Patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TIGHT GLYCEMIC CONTROL; INSULIN THERAPY; MYOCARDIAL-INFARCTION; STRESS HYPERGLYCEMIA; DIABETIC-PATIENTS; BLOOD-GLUCOSE; CARE UNITS; MORTALITY; MANAGEMENT	Background The optimal target range for blood glucose in critically ill patients remains unclear. Methods Within 24 hours after admission to an intensive care unit (ICU), adults who were expected to require treatment in the ICU on 3 or more consecutive days were randomly assigned to undergo either intensive glucose control, with a target blood glucose range of 81 to 108 mg per deciliter (4.5 to 6.0 mmol per liter), or conventional glucose control, with a target of 180 mg or less per deciliter (10.0 mmol or less per liter). We defined the primary end point as death from any cause within 90 days after randomization. Results Of the 6104 patients who underwent randomization, 3054 were assigned to undergo intensive control and 3050 to undergo conventional control; data with regard to the primary outcome at day 90 were available for 3010 and 3012 patients, respectively. The two groups had similar characteristics at baseline. A total of 829 patients (27.5%) in the intensive-control group and 751 (24.9%) in the conventional-control group died (odds ratio for intensive control, 1.14; 95% confidence interval, 1.02 to 1.28; P = 0.02). The treatment effect did not differ significantly between operative (surgical) patients and nonoperative (medical) patients (odds ratio for death in the intensive-control group, 1.31 and 1.07, respectively; P = 0.10). Severe hypoglycemia (blood glucose level, = 40 mg per deciliter [2.2 mmol per liter]) was reported in 206 of 3016 patients (6.8%) in the intensive-control group and 15 of 3014 (0.5%) in the conventional-control group (P<0.001). There was no significant difference between the two treatment groups in the median number of days in the ICU (P = 0.84) or hospital (P = 0.86) or the median number of days of mechanical ventilation (P = 0.56) or renal-replacement therapy (P = 0.39). Conclusions In this large, international, randomized trial, we found that intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per deciliter. (ClinicalTrials.gov number, NCT00220987.)	[Su, S.; Heritier, S.; Li, Q.; Bompoint, S.; Billot, L.; Crampton, L.; Darcy, F.; Jayne, K.; Kumarasinghe, V.; Little, L.; McEvoy, S.; MacMahon, S.; Pandey, S.; Ryan, S.; Shukla, R.; Vijayan, B.; Study Stat Ctr; Study Coordinating Ctr] Univ Sydney, George Inst Int Hlth, Sydney, NSW 2006, Australia; [McArthur, C.; Atherton, S.; Bell, J.; Hadfield, L.; Hourigan, C.; Newby, L.; Simmonds, C.; Australia-New Zealand Site] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Buhr, H.; Eccleston, M.; McGuinness, S.; Parke, R.] Auckland City Hosp, Cardiovasc Intens Care Unit, Auckland, New Zealand; [Bellomo, R.; Bates, S.; Goldsmith, D.; Mercer, I.; O'Sullivan, K.] Austin Hosp, Melbourne, Vic 3084, Australia; [Gazzard, R.; Hill, D.; Tauschke, C.] Ballarat Base Hosp, Ballarat, Vic, Australia; [Ghelani, D.; Nand, K.; Reece, G.; Sara, T.] Blacktown Hosp, Blacktown, NSW, Australia; [Elliott, S.; Ernest, D.; Hamilton, A.] Box Hill Hosp, Box Hill, Vic, Australia; [Mitchell, I.; Ashley, R.; Bailey, A.; Crowfoot, E.; Gissane, J.; Ranse, J.; Whiting, J.] Canberra Hosp, Canberra, ACT, Australia; [Douglas, K.; Milliss, D.; Tan, J.; Wong, H.] Concord Repatriat Gen Hosp, Concord, NSW, Australia; [Blythe, D.; Palermo, A.] Fremantle Hosp, Fremantle, WA, Australia; [Hardie, M.; Harrigan, P.; McFadyen, B.] John Hunter Hosp, Newcastle, NSW, Australia; [Micallef, S.; Parr, M.] Liverpool Hosp, Liverpool, NSW, Australia; [Boase, A.; Tai, J.; Williams, A.] Middlemore Hosp, Auckland 6, New Zealand; [Cole, L.; Seppelt, I.; Weisbrodt, L.; Whereat, S.] Nepean Hosp, Nepean, NSW, Australia; [Flanagan, A.; Liang, J.] N Shore Hosp, Auckland, New Zealand; [Bass, F.; Campbell, M.; Hammond, N.; Nicholson, L.; Shehabi, Y.] Prince Wales Hosp, Sydney, NSW, Australia; [Foote, J.; Peake, S.; Williams, P.] Queen Elizabeth Hosp, Adelaide, SA, Australia; [Douglas, K.; Deans, R.; Fourie, C.; Lipman, J.; Stuart, J.] Royal Brisbane Hosp, Brisbane, Qld 4029, Australia; [Bell, A.; Field, T.; McAllister, R.; Marsden, K.; Turner, A.] Royal Hobart Hosp, Hobart, Tas, Australia; [Finfer, S.; Potter, J.; Ankers, S.; Bird, S.; Lee, R.; O'Connor, A.; Ramakrishnan, N.; Raper, R.] Royal N Shore Hosp, Sydney, NSW, Australia; [Myburgh, J.; Dhiacou, V.; Girling, K.; Jovanovska, A.] St George Hosp, Sydney, NSW, Australia; [Groves, N.; Holmes, J.; Santamaria, J.; Smith, R.] St Vincents Hosp, Melbourne, Vic, Australia; [Baker, S.; Roberts, B.] Sir Charles Gairdner Hosp, Perth, WA, Australia; [Andrews, L.; Dinsdale, R.; Fenton, R.; Mackle, D.; Mortimer, S.] Wellington Hosp, Wellington, New Zealand; [Little, L.; French, C.; Raunow, H.] Western Hosp, Melbourne, Vic, Australia; [Gales, M.; Hill, F.; Rachakonda, S.; Rogan, D.] Wollongong Hosp, Wollongong, NSW, Australia; [Allsop, C.] NSW Inst Trauma & Injury Management, Sydney, NSW, Australia; [Higgins, L.] Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia; [Robinson, B.] Univ Sydney, Fac Med, Kolling Inst, Sydney, NSW 2006, Australia; [Robinson, B.] Royal N Shore Hosp, Dept Endocrinol, Sydney, NSW, Australia; [Champagne, K.; Doig, C.; Knox, L.; Taylor, P.; Wilson, C.] Calgary Hlth Reg, Calgary, AB, Canada; [Drover, J.; Hammond, S.; Mann, E.; Myers, M.; Robinson, A.] Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada; [Harvey, J.; Skrobik, Y.] Maisonneuve Rosemont Hosp, Montreal, PQ, Canada; [Baumgartner, A.; Meade, L.; Vlahakis, N.] Mayo Clin, Rochester, MN USA; [Ethier, C.; Kramer-Kile, M.; Mehta, S.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Gaudert, C.; Kanji, S.; McArdle, T.; Watpool, I.] Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada; [Cook, D.; McDonald, E.; Clarke, F.; Tkaczyk, A.] St Josephs Healthcare, Hamilton, ON, Canada; [Marshall, J.; Morrissey, J.; Porretta, K.; Smith, O.; Wen, V.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Dodek, P.; Ashley, B. J.; Mans, S.] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; [Bojilov, B.; Code, K.; Fowler, R.; Marinoff, N.] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Chu, L.; Granton, J.; McGrath-Chong, M.; Steinberg, M.] Toronto Gen Hosp, Toronto, ON, Canada; [Ferguson, N.; Go, S.; Matte, A.; Rosenberg, J.; Stevenson, J.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Jacka, M.; Sonnema, L.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; [Chittock, D.; Autio, R.; Davies, D.; Ganz, P.; Gardner, M.; Logie, S.; Smith, L.] Vancouver Gen Hosp, Vancouver, BC, Canada; [Atkins, L.; Auld, F.; Stewart, M.; Wood, G.] Vancouver Isl Hlth Author, Victoria, BC, Canada	University of Sydney; Auckland City Hospital; Auckland City Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Blacktown & Mount Druitt Hospital; Box Hill Hospital; Australian National University; Canberra Hospital; Concord Repatriation General Hospital; University of Western Australia; John Hunter Hospital; Liverpool Hospital; Nepean Hospital; Royal Brisbane & Women's Hospital; Royal Hobart Hospital; Royal North Shore Hospital; University of Sydney; St George Hospital; St Vincent's Hospital Melbourne; University of Western Australia; Western Hospital; Wollongong Hospital; University of Sydney; Kolling Institute of Medical Research; Royal North Shore Hospital; University of Sydney; University of Calgary; Queens University - Canada; Universite de Montreal; Mayo Clinic; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; St. Paul's Hospital; University of Saskatchewan; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alberta; University of British Columbia; Vancouver Island Health Authority			schuetz, philipp/C-8475-2013; Ferguson, Niall/D-7619-2019; Morrissey, James H./GLR-5645-2022; FRENCH, CRAIG/HGA-5299-2022; Santamaria, John/M-9581-2019; Ernest, David/I-1699-2013; Morrissey, James H/H-4933-2011; Skrobik, Yoanna/K-8165-2014; Mehta, Sangeeta/C-4623-2015; Williams, Patricia/AAH-6571-2019; Billot, Laurent/Y-1241-2019; Parke, Rachael/AAX-4004-2021; French, Craig/ABF-5087-2020	schuetz, philipp/0000-0001-6400-4949; Ferguson, Niall/0000-0002-6213-5264; Morrissey, James H/0000-0002-1570-1569; Skrobik, Yoanna/0000-0002-5315-6020; Billot, Laurent/0000-0002-4975-9793; Parke, Rachael/0000-0003-4209-0334; French, Craig/0000-0003-1363-9711; Micallef, Sharon/0000-0002-8496-2324; Bellomo, Rinaldo/0000-0002-1650-8939; Hammond, Naomi/0000-0002-6559-7747; SHEHABI, Yahya/0000-0003-4707-7462; Mitchell, Imogen/0000-0001-6013-4922; Myburgh, John/0000-0003-4088-7016; Bompoint, Severine/0000-0001-5226-4321; Finfer, Simon/0000-0002-2785-5864	Australian National Health and Medical Research Council; Health Research Council of New Zealand; Canadian Institutes for Health Research	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Health Research Council of New Zealand(Health Research Council of New Zealand); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR))	Supported by grants from the Australian National Health and Medical Research Council, the Health Research Council of New Zealand, and the Canadian Institutes for Health Research.	Amer Diabet Assoc, 2008, DIABETES CARE, V31, pS12, DOI 10.2337/dc08-S012; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; Aragon D, 2006, AM J CRIT CARE, V15, P370, DOI 10.4037/ajcc2006.15.4.370; Bellomo R, 2005, MAYO CLIN PROC, V80, P1546, DOI 10.4065/80.12.1546; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Chase JG, 2007, CRIT CARE, V11, DOI 10.1186/cc6099; *CRIT CAR NUTR, 2007, US ENT NUTR VS PAR N; Duckworth W, 2009, NEW ENGL J MED, V360, P129, DOI 10.1056/NEJMoa0808431; Dunbar JC, 1996, ACTA DIABETOL, V33, P263; Finfer S, 2009, CRIT CARE RESUSC, V11, P46; Gale SC, 2007, AM SURGEON, V73, P454; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Herlein JA, 2006, ENDOCRINOLOGY, V147, P2781, DOI 10.1210/en.2005-1247; Inzucchi SE, 2006, NEW ENGL J MED, V355, P1903, DOI 10.1056/NEJMcp060094; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; Krumholz HM, 2008, NEW ENGL J MED, V358, P2537, DOI 10.1056/NEJMp0803740; Langley J, 2007, DIABETES-METAB RES, V23, P184, DOI 10.1002/dmrr.696; Mackenzie I, 2005, INTENS CARE MED, V31, P1136, DOI 10.1007/s00134-005-2677-2; Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Mitchell I, 2006, INTENS CARE MED, V32, P867, DOI 10.1007/s00134-006-0135-4; *NICE SUGAR STUD I, AM J RESP CRIT CARE; Patel A, 2008, NEW ENGL J MED, V358, P2560, DOI 10.1056/NEJMoa0802987; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rodbard Helena W, 2007, Endocr Pract, V13 Suppl 1, P1; Shulman R, 2007, CRIT CARE, V11, DOI 10.1186/cc5964; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Su S, 2007, COMPUT STAT DATA AN, V51, P3983, DOI 10.1016/j.csda.2006.06.008; Su S, 2007, J STAT SOFTW, V21, P1; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016	37	3057	3202	4	167	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	2009	360	13					1283	1297		10.1056/NEJMoa0810625	http://dx.doi.org/10.1056/NEJMoa0810625			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	423VP	19318384	Green Published			2023-01-03	WOS:000264524100004
J	Baillargeon, J; Giordano, TP; Rich, JD; Wu, ZH; Wells, K; Pollock, BH; Paar, DP				Baillargeon, Jacques; Giordano, Thomas P.; Rich, Josiah D.; Wu, Z. Helen; Wells, Katherine; Pollock, Brad H.; Paar, David P.			Accessing Antiretroviral Therapy Following Release From Prison	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE; ADHERENCE; INFECTION; STIGMA; COHORT; INCARCERATION; INTERRUPTION; COMMUNITY; OUTCOMES; INMATES	from prison may increase risk for adverse clinical outcomes, transmission of human immunodeficiency virus ( HIV), and drug- resistant HIV reservoirs in the community. The extent to which HIV- infected inmates experience ART interruption following release from prison is unknown. Objectives To determine the proportion of inmates who filled an ART prescription within 60 days after release from prison and to examine predictors of this outcome. Design, Setting, and Participants Retrospective cohort study of all 2115 HIV-infected inmates released from the Texas Department of Criminal Justice prison system between January 2004 and December 2007 and who were receiving ART before release. Main Outcome Measure Proportion of inmates who filled an ART prescription within 10, 30, and 60 days of release from prison. Results Among the entire study cohort ( N= 2115), an initial prescription for ART was filled by 115 ( 5.4%) inmates within 10 days of release ( 95% confidence interval [ CI], 4.5%- 6.5%), by 375 ( 17.7%) within 30 days ( 95% CI, 16.2%- 19.4%), and by 634 ( 30.0%) within 60 days ( 95% CI, 28.1%- 32.0%). In a multivariate analysis of predictors ( including sex, age, race/ ethnicity, viral load, duration of ART, year of discharge, duration of incarceration, parole, and AIDS Drug Assistance Program application assistance), Hispanic and African American inmates were less likely to fill a prescription within 10 days ( adjusted estimated risk ratio [ RR], 0.4 [ 95% CI, 0.2- 0.8] and 0.4 [ 95% CI, 0.3- 0.7], respectively) and 30 days ( adjusted estimated RR, 0.7 [ 95% CI, 0.5- 0.9] and 0.7 [ 95% CI, 0.5- 0.9]). Inmates with an undetectable viral load were more likely to fill a prescription within 10 days ( adjusted estimated RR, 1.8 [ 95% CI, 1.2- 2.7]), 30 days ( 1.5 [ 95% CI, 1.2- 1.8]), and 60 days ( 1.3 [ 95% CI, 1.1- 1.5]). Inmates released on parole were more likely to fill a prescription within 30 days ( adjusted estimated RR, 1.3 [ 95% CI, 1.1- 1.6]) and 60 days ( 1.5 [ 95% CI, 1.4- 1.7]). Inmates who received assistance completing a Texas AIDS Drug Assistance Program application were more likely to fill a prescription within 10 days ( adjusted estimated RR, 3.1 [ 95% CI, 2.0- 4.9]), 30 days ( 1.8 [ 95% CI, 1.4- 2.2]), and 60 days ( 1.3 [ 95% CI, 1.1- 1.4]). Conclusion Only a small percentage of Texas prison inmates receiving ART while incarcerated filled an initial ART prescription within 60 days of their release.	[Baillargeon, Jacques] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Baillargeon, Jacques; Paar, David P.] Univ Texas Med Branch, Correct Managed Care Div, Galveston, TX 77555 USA; [Wu, Z. Helen] Univ Texas Med Branch, Dept Obstet & Gynecol, Galveston, TX 77555 USA; [Paar, David P.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Houston Ctr Qual Care & Utilizat Studies, Houston, TX USA; [Rich, Josiah D.] Brown Med Sch, Dept Med, Providence, RI USA; [Wells, Katherine] Dept State Hlth Serv, Texas HIV Medicat Program, Austin, TX USA; [Pollock, Brad H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine; Baylor College of Medicine; Brown University; University of Texas System; University of Texas Health San Antonio	Baillargeon, J (corresponding author), Univ Texas Med Branch, Dept Prevent Med & Community Hlth, 301 Univ Blvd,Mail Route 1007, Galveston, TX 77555 USA.	jbaillar@utmb.edu		Giordano, Thomas/0000-0002-9346-5530	National Institute on Drug Abuse [R03DA023870-02, K24DA022112]; NATIONAL INSTITUTE ON DRUG ABUSE [K24DA022112, R03DA023870] Funding Source: NIH RePORTER	National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported by grant R03DA023870-02 from the National Institute on Drug Abuse. Dr Rich was supported by National Institute on Drug Abuse grant K24DA022112.	Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008; Baillargeon J, 2000, CLIN INFECT DIS, V31, P1476, DOI 10.1086/317478; Baillargeon J, 2009, AM J PSYCHIAT, V166, P103, DOI 10.1176/appi.ajp.2008.08030416; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Boutwell A, 2004, CLIN INFECT DIS, V38, P1761, DOI 10.1086/421410; *COUNC STAT GOV JU, EXPL FED MED DIS PRO; Derlega VJ, 2008, INT J STD AIDS, V19, P259, DOI 10.1258/ijsa.2007.007141; DIXON PS, 1993, AM J MED, V95, P629, DOI 10.1016/0002-9343(93)90359-W; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Gardner LI, 2005, AIDS, V19, P423, DOI 10.1097/01.aids.0000161772.51900.eb; Giordano TP, 2005, AIDS CARE, V17, P773, DOI 10.1080/09540120412331336652; Glass TR, 2006, JAIDS-J ACQ IMM DEF, V41, P385, DOI 10.1097/01.qai.0000186371.95301.52; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; *HJ KAIS FAM FDN N, 2008, NAT ADAP MON PROJ AN; Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S; Kahn JG, 2002, PUBLIC HEALTH REP, V117, P252, DOI 10.1016/S0033-3549(04)50159-0; Li XH, 2005, JAIDS-J ACQ IMM DEF, V38, P320; MacGowan RJ, 2003, INT J STD AIDS, V14, P519, DOI 10.1258/095646203767869110; Mallik-Kane K., 2008, HLTH PRISONER REENTR; MARUSCHAK L, 2007, HIV PRISONS 2005; Menke TJ, 2003, J NATL MED ASSOC, V95, P853; Morrow K. M., 2007, Journal of Correctional Health Care, V13, P27, DOI 10.1177/1078345807299457; Mumola C. J., 1999, SUBSTANCE ABUSE TREA; Palacio H, 2002, PUBLIC HEALTH REP, V117, P233, DOI 10.1016/S0033-3549(04)50158-9; Palepu A, 2004, ANTIVIR THER, V9, P713; *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1; Pence BW, 2007, JAIDS-J ACQ IMM DEF, V44, P159, DOI 10.1097/QAI.0b013e31802c2f51; *PEW CTR STAT, ONE 100 BARS AM 2008; Raimer BG, 2004, JAMA-J AM MED ASSOC, V292, P485, DOI 10.1001/jama.292.4.485; Rao D, 2008, AIDS BEHAV, V12, P265, DOI 10.1007/s10461-007-9268-x; Rich JD, 2001, J URBAN HEALTH, V78, P279, DOI 10.1093/jurban/78.2.279; Rintamaki LS, 2006, AIDS PATIENT CARE ST, V20, P359, DOI 10.1089/apc.2006.20.359; Shannon Kate, 2005, J Int Assoc Physicians AIDS Care (Chic), V4, P66, DOI 10.1177/1545109705284353; Springer SA, 2004, CLIN INFECT DIS, V38, P1754, DOI 10.1086/421392; Stephenson BL, 2005, PUBLIC HEALTH REP, V120, P84, DOI 10.1177/003335490512000114; Stokes ME, 2000, CATEGORICAL DATA ANA; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; WOHL DA, 2003, 10 C RETR OPP INF FE; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	39	202	205	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2009	301	8					848	857		10.1001/jama.2009.202	http://dx.doi.org/10.1001/jama.2009.202			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410WV	19244192	Green Accepted			2023-01-03	WOS:000263609900026
J	Moodie, EEM; Pai, NP; Klein, MB				Moodie, Erica E. M.; Pai, Nitika Pant; Klein, Marina B.			Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of HIV-Mono-Infected and HIV/Hepatitis C Co-Infected Cohorts	PLOS ONE			English	Article								The effects of highly active antiretroviral therapy (HAART) on progression of hepatic fibrosis in HIV-hepatitis C virus (HCV) co-infection are not well understood. Deaths from liver diseases have risen in the post-HAART era, yet some cross-sectional studies have suggested that HAART use is associated with improved fibrosis rates. In a retrospective cohort of 533 HIV mono-infected and 127 HIV/HCV co-infected patients, followed between January 1991 and July 2005 at a university-based HIV clinic, we investigated the relationship between cumulative HAART exposure and hepatic fibrosis, as measured by the aspartate aminotransferase-to-platelet ratio index (APRI). We used a novel methodological approach to estimate the dose-response relationship of the effect of HAART exposure on APRI. HAART was associated with increasing APRI over time in HIV/ HCV co-infected patients suggesting that they may be experiencing cumulative hepatotoxicity from antiretrovirals. The estimated median change (95% confidence interval) in APRI per one year of HAART intake was of -0.46% (-1.61% to 0.71%) in HIV mono-infected compared to 2.54% (-1.77% to 7.03%) in HIV/ HCV co-infected patients. Similar results were found when the direct effect of HAART intake since the last visit was estimated on the change in APRI. HAART use associated is with increased APRI in patients with HIV/ HCV co-infection. Therefore treatment for HCV infection may be required to slow the growing epidemic of end-stage liver disease in this population.	McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Pai, Nitika Pant; Klein, Marina B.] McGill Univ Hlth Ctr, Royal Victoria Hosp, Dept Med, Div Infect Dis Immunodeficiency, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; Royal Victoria Hospital	Moodie, EEM (corresponding author), McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada.	marina.klein@muhc.mcgill.ca		Pant Pai, Nitika/0000-0002-4672-0500; Klein, Marina/0000-0002-3063-8430	Fonds de la recherche en sante du Quebec (FRSQ) [Chercheur-Boursier salary award]; Reseau SIDA et Maladies Infectieuses; Natural Sciences and Engineering Research Council of Canada [University Faculty Award, Discovery Grant]; Canadian HIV Clinical Trials Network [Post-doctoral fellowship]	Fonds de la recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Reseau SIDA et Maladies Infectieuses; Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Canadian HIV Clinical Trials Network	This work was supported by an infrastructure grant from le Fonds de la recherche en sante du Quebec (FRSQ) Reseau SIDA et Maladies Infectieuses. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Moodie is the recipient of a University Faculty Award and a Discovery Grant from the Natural Sciences and Engineering Research Council of Canada. Dr. Pant Pai is supported by a Post-doctoral fellowship from the Canadian HIV Clinical Trials Network. Dr. Marina Klein is supported by a Chercheur-Boursier salary award from the FRSQ.	Al-Mohri H, 2005, HIV MED, V6, P375, DOI 10.1111/j.1468-1293.2005.00330.x; Al-Mohri H, 2007, JAIDS-J ACQ IMM DEF, V44, P463, DOI 10.1097/QAI.0b013e318030ff8e; Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022; Benhamou Y, 2001, HEPATOLOGY, V34, P283, DOI 10.1053/jhep.2001.26517; Bica I, 2001, CLIN INFECT DIS, V32, P492, DOI 10.1086/318501; BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x; *CTR INF DIS PREV, 2005, HIV AIDS EPI UPD; Forns X, 2002, HEPATOLOGY, V36, P986, DOI 10.1053/jhep.2002.36128; Fuster D, 2004, AIDS RES HUM RETROV, V20, P1293, DOI 10.1089/aid.2004.20.1293; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Hirano K., 2004, APPL BAYESIAN MODELI; Hogg RS, 1999, CAN MED ASSOC J, V160, P659; Imbens GW, 2000, BIOMETRIKA, V87, P706, DOI 10.1093/biomet/87.3.706; Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6; Kelleher TB, 2005, J HEPATOL, V43, P78, DOI 10.1016/j.jhep.2005.02.025; Macias J, 2004, AIDS, V18, P767, DOI [10.1097/01.aids.0000111417.91384.fd, 10.1097/00002030-200403260-00007]; Macias J, 2002, EUR J CLIN MICROBIOL, V21, P775, DOI 10.1007/s10096-002-0823-0; MAHARAJ B, 1986, LANCET, V1, P523; Marine-Barjoan E, 2004, AIDS, V18, P2163, DOI 10.1097/00002030-200411050-00008; Mehta SH, 2005, HEPATOLOGY, V41, P123, DOI 10.1002/hep.20541; Murphy DG, 2000, J CLIN MICROBIOL, V38, P4034, DOI 10.1128/JCM.38.11.4034-4041.2000; Nunes D, 2005, JAIDS-J ACQ IMM DEF, V40, P538, DOI 10.1097/01.qai.0000184856.31695.bf; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Robins J. M, 1997, CAUSAL INFERENCE COM; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; ROSENTHAL E, 2004, LIVER RELATED MORTAL; Salmon-Ceron D, 2005, J HEPATOL, V42, P799, DOI 10.1016/j.jhep.2005.01.022; SanchezQuijano A, 1995, EUR J CLIN MICROBIOL, V14, P949, DOI 10.1007/BF01691375; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; STERLING R, 2005, CAN ROUTINE NONINVAS; Sulkowski MS, 2005, AIDS, V19, P585, DOI 10.1097/01.aids.0000163935.99401.25; Tatsunami S, 2004, ACTA HAEMATOL-BASEL, V111, P181, DOI 10.1159/000077549; THOMAS D, 2007, STAGING LIVER DIS HI; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Yasui H, 2003, ANN NY ACAD SCI, V1010, P273, DOI 10.1196/annals.1299.047; Zylberberg H, 1998, CLIN INFECT DIS, V27, P1255, DOI 10.1086/514987	37	45	45	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2009	4	2							e4517	10.1371/journal.pone.0004517	http://dx.doi.org/10.1371/journal.pone.0004517			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437KG	19223976	gold, Green Published, Green Submitted			2023-01-03	WOS:000265485800017
J	Kitagaki, J; Yang, Y; Saavedra, JE; Colburn, NH; Keefer, LK; Perantoni, AO				Kitagaki, J.; Yang, Y.; Saavedra, J. E.; Colburn, N. H.; Keefer, L. K.; Perantoni, A. O.			Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53	ONCOGENE			English	Article						JS-K; nitric oxide (NO); ubiquitin; tumor; apoptosis; p53	IN-VITRO; BETA-CATENIN; APOPTOSIS; CANCER; DESTRUCTION; TRANSLATION; GLUTATHIONE; PATHWAYS; SYSTEM; GROWTH	Nitric oxide (NO) is a major effector molecule in cancer prevention. A number of studies have shown that NO prodrug JS-K (O-2-(2,4-dinitrophenyl) 1-[(4-ethoxy-carbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate) induces apoptotic cell death in vitro and in vivo, indicating that it is a promising new therapeutic for cancer. However, the mechanism of its tumor-killing activity remains unclear. Ubiquitin plays an important role in the regulation of tumorigenesis and cell apoptosis. Our earlier report has shown that inactivation of the ubiquitin system through blocking E1(ubiquitin-activating enzyme) activity preferentially induces apoptosis in p53-expressing transformed cells. As E1 has an active cysteine residue that could potentially interact with NO, we hypothesized that JS-K could inactivate E1 activity. E1 activity was evaluated by detecting ubiquitin-E1 conjugates through immunoblotting. JS-K strikingly inhibits the ubiquitin-E1 thioester formation in cells in a dose-dependent manner with an IC50 of approximately 2 mu M, whereas a JS-K analog that cannot release NO did not affect these levels in cells. Moreover, JS-K decreases total ubiquitylated proteins and increases p53 levels, which is mainly regulated by ubiquitin and proteasomal degradation. Furthermore, JS-K preferentially induces cell apoptosis in p53-expressing transformed cells. These findings indicate that JS-K inhibits E1 activity and kills transformed cells harboring wild-type p53.	[Kitagaki, J.; Yang, Y.; Perantoni, A. O.] Natl Canc Inst Frederick, Canc & Dev Biol Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21702 USA; [Saavedra, J. E.] Natl Canc Inst Frederick, Basic Res Program, SAIC Frederick, Ctr Canc Res,Natl Inst Hlth, Frederick, MD 21702 USA; [Colburn, N. H.] Natl Canc Inst Frederick, Lab Canc Prevent, Ctr Canc Res, NIH, Frederick, MD 21702 USA; [Keefer, L. K.] Natl Canc Inst Frederick, Comparat Carcinogenesis Lab, Ctr Canc Res, Natl Inst Hlth, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Perantoni, AO (corresponding author), Natl Canc Inst Frederick, Canc & Dev Biol Lab, Ctr Canc Res, Natl Inst Hlth, Bldg 538,Rm 221,1050 Boyles St, Frederick, MD 21702 USA.	yangyili@ncifcrf.gov; peranton@ncifcrf.gov	Keefer, Larry K/N-3247-2014	Keefer, Larry K/0000-0001-7489-9555	NIH; National Cancer Institute; Center for Cancer Research; National Cancer Institute [NOI-CO-12400]; NATIONAL CANCER INSTITUTE [ZIABC010025, ZIABC011188] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Center for Cancer Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the NIH Fellows Editorial Board for revisions of this paper. This work was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research and by National Cancer Institute Contract No. NOI-CO-12400 to SAIC Inc. JK was a fellow of the Japanese Society for the Promotion of Science.	Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Kiziltepe T, 2007, BLOOD, V110, P709, DOI 10.1182/blood-2006-10-052845; Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580; Liu J, 2004, MOL CANCER THER, V3, P709; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ren ZG, 2003, J CELL PHYSIOL, V197, P426, DOI 10.1002/jcp.10380; Saavedra JE, 2006, J MED CHEM, V49, P1157, DOI 10.1021/jm050700k; Shami PJ, 2006, J MED CHEM, V49, P4356, DOI 10.1021/jm060022h; Shami PJ, 2003, MOL CANCER THER, V2, P409; Simeone AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2095; Turchi JJ, 2006, P NATL ACAD SCI USA, V103, P4337, DOI 10.1073/pnas.0601001103; Yang YL, 2007, CANCER RES, V67, P9472, DOI 10.1158/0008-5472.CAN-07-0568; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Ying L, 2007, CANCER RES, V67, P1407, DOI 10.1158/0008-5472.CAN-06-2149	26	47	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					619	624		10.1038/onc.2008.401	http://dx.doi.org/10.1038/onc.2008.401			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18978812	Green Accepted			2023-01-03	WOS:000262866500015
J	Park, MP; Park, RHR				Park, M. P.; Park, R. H. R.			Fantastic feeding funnels	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Park, M. P.] Univ Glasgow, Dept Adult & Continuing Educ, Glasgow G3 6NH, Lanark, Scotland; [Park, R. H. R.] So Gen Hosp, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow; University of Glasgow	Park, MP (corresponding author), Univ Glasgow, Dept Adult & Continuing Educ, Glasgow G3 6NH, Lanark, Scotland.	mpark@educ.gla.ac.uk						ANKORI G, 1993, JEWISH ART, V19, P224; AWEKOTUKU NT, 2006, SENSIBLE OBJECTS COL, P121; Budrys V, 2006, EUR NEUROL, V55, P4, DOI 10.1159/000091136; CAWTHORNE T, 1962, P ROY SOC MED, V55, P213, DOI 10.1177/003591576205500308; De Tolnay Charles, 1966, HIERONYMUS BOSCH; Herrera H., 1983, FRIDA BIOGRAPHY F KA; KLINGENDER FD, 1966, GOYA DEMOCRATIC TRAD; LINFERT C, 1972, HIERONYMUS BOSCH; MUNDOR H, 1965, DOCTORS MED WORKS DA; PRICE R, 1981, MED HIST, V25, P269, DOI 10.1017/S002572730003458X; ZAMUDIOTAYLOR V, 2007, F KAHLO, P14	11	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 16	2008	337								a2888	10.1136/bmj.a2888	http://dx.doi.org/10.1136/bmj.a2888			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390SV	19088143				2023-01-03	WOS:000262184900006
J	Di Gallo, A; Kuehne, T				Di Gallo, Alain; Kuehne, Thomas			Ghost in the tree	LANCET			English	Editorial Material									[Di Gallo, Alain] Univ Psychiat Hosp, Dept Child & Adolescent Psychiat, Basel, Switzerland; [Kuehne, Thomas] Univ Childrens Hosp, Dept Oncol & Haematol, Basel, Switzerland		Di Gallo, A (corresponding author), Kinder & Jugendpsychiat Klin, Schaffhauserrheinweg 55, CH-4058 Basel, Switzerland.	alain.digallo@unibas.ch	Kuehne, Thomas/I-6143-2019	Kuehne, Thomas/0000-0002-7387-7028					0	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 1	2008	372	9649					1570	1570						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	367ZG	18984190	Bronze			2023-01-03	WOS:000260590500029
J	Little, P; Lewith, G; Webley, F; Evans, M; Beattie, A; Middleton, K; Barnett, J; Ballard, K; Oxford, F; Smith, P; Yardley, L; Hollinghurst, S; Sharp, D				Little, Paul; Lewith, George; Webley, Fran; Evans, Maggie; Beattie, Angela; Middleton, Karen; Barnett, Jane; Ballard, Kathleen; Oxford, Frances; Smith, Peter; Yardley, Lucy; Hollinghurst, Sandra; Sharp, Debbie			Randomised controlled trial of Alexander technique lessons, exercise, and massage (ATEAM) for chronic and recurrent back pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article							THERAPY; CARE; SEVERITY; QUALITY	Objective To determine the effectiveness of lessons in the Alexander technique, massage therapy, and advice from a doctor to take exercise (exercise prescription) along with nurse delivered behavioural counselling for patients with chronic or recurrent back pain. Design Factorial randomised trial. Setting 64 general practices in England. Participants 579 patients with chronic or recurrent low back pain; 144 were randomised to normal care, 147 to massage, 144 to six Alexander technique lessons, and 144 to 24 Alexander technique lessons; half of each of these groups were randomised to exercise prescription. Interventions Normal care (control), six sessions of massage, six or 24, lessons on the Alexander technique, and prescription for exercise from a doctor with nurse delivered behavioural counselling. Main outcome measures Roland Morris disability score (number of activities impaired by pain) and number of days in pain. Results Exercise and lessons in the Alexander technique, but not massage, remained effective atone year (compared with control Roland disability score 8.1: massage -0.58, 95% confidence interval -1.94 to 0.77, six lessons -1.40, -2.77 to -0.03, 24 lessons -3.4, -4.76 to -2.03, and exercise -1.29, -2.25 to -0.34). Exercise after six lessons achieved 72% of the effect of 24 lessons alone (Roland disability score -2.98 and -4.14, respectively). Number of days with back pain in the past four weeks were lower after lessons (compared with control median 21 days: 24 lessons -18, six lessons -10, massage -7) and quality of life improved significantly. No significant harms were reported. Conclusions One to one lessons in the Alexander technique from registered teachers have long term benefits for patients with chronic back pain. Six lessons followed by exercise prescription were nearly as effective as 24 lessons. Trial registration National Research Register N0028108728.	[Little, Paul; Lewith, George; Webley, Fran; Middleton, Karen; Barnett, Jane] Univ Southampton, Primary Care Grp, Community Clin Sci Div, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England; [Yardley, Lucy] Univ Southampton, Sch Psychol, Southampton SO16 5ST, Hants, England; [Smith, Peter] Univ Southampton, Dept Social Stat, Southampton SO9 5NH, Hants, England; [Evans, Maggie; Beattie, Angela; Hollinghurst, Sandra] Univ Bristol, Acad Unit Primary Hlth Care, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Ballard, Kathleen; Oxford, Frances] Soc Teachers Alexander Tech, London, England	University of Southampton; University of Southampton; University of Southampton; University of Bristol	Little, P (corresponding author), Univ Southampton, Primary Care Grp, Community Clin Sci Div, Aldermoor Hlth Ctr, Southampton SO16 5ST, Hants, England.	psl3@soton.ac.uk		Lewith, George/0000-0002-2364-3960; Yardley, Lucy/0000-0002-3853-883X; Little, Paul/0000-0003-3664-1873; sharp, deborah/0000-0003-3071-9860	Medical Research Council [G0001104] Funding Source: Medline; MRC [G0001104] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Assendelft W, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000447.PUB2; Beurskens AJHM, 1996, PAIN, V65, P71, DOI 10.1016/0304-3959(95)00149-2; BRERLEY S, 2003, BMC HLTH SERV R 0801, P3; BRERLEY S, 2003, BMC HLTH SERV R 0801, P16; CACCIATORE T, 2007, P INT SOC POST GAIT, P18; Cacciatore TW, 2005, PHYS THER, V85, P565; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; *CLIN STAND ADV GR, 1994, MAN GUID BACK PAIN; DAY SJ, 1989, BMJ-BRIT MED J, V299, P663, DOI 10.1136/bmj.299.6700.663; DEYO R, 1997, P 2 INT FOR PRIM CAR; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; Ernst E, 2003, FORSCH KOMP KLAS NAT, V10, P325, DOI 10.1159/000075886; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; Furlan AD, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001351.pub2; FURLAN AD, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001929; Godin G, 1996, AM J HEALTH PROMOT, V11, P87, DOI 10.4278/0890-1171-11.2.87; Goldby LJ, 2006, SPINE, V31, P1083, DOI 10.1097/01.brs.0000216464.37504.64; Gurfinkel V, 2006, J NEUROPHYSIOL, V96, P2678, DOI 10.1152/jn.00406.2006; Hayden JA, 2005, ANN INTERN MED, V142, P765, DOI 10.7326/0003-4819-142-9-200505030-00013; Heymans MW., 2004, COCHRANE DATABASE SY, DOI [10.1002/14651858.CD000261.pub2, DOI 10.1002/14651858.CD000261.PUB2]; HILLSDON M, 1995, J EPIDEMIOL COMMUN H, V49, P448, DOI 10.1136/jech.49.5.448; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; Hsieh LLC, 2006, BMJ-BRIT MED J, V332, P696, DOI 10.1136/bmj.38744.672616.AE; KLABERMOFFATT J, 1994, UNPUB EXERCISE BASED; KLABERMOFFETT J, 1999, BRIT MED J, V319, P279; Little P, 2001, SPINE, V26, P2065, DOI 10.1097/00007632-200110010-00003; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; MEADE TW, 1992, BRIT MED J, V304, P1310, DOI 10.1136/bmj.304.6837.1310; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Salovey P, 1992, VITAL HLTH STAT, V6; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Stewart WF, 1999, PAIN, V79, P291, DOI 10.1016/S0304-3959(98)00181-X; THOMAS K, 2008, BMJ-BRIT MED J, V333, P611; Underwood M, 2004, BMJ-BRIT MED J, V329, P1377, DOI 10.1136/bmj.38282.669225AE; van Tulder MW, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000335; VANTULDER MW, 2005, COCHRANE DB SYST REV, P335; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Waddell G, 2002, BACK PAIN INCAPACITY; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	43	96	98	2	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 23	2008	337	7667							a884	10.1136/bmj.a884	http://dx.doi.org/10.1136/bmj.a884			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346FD	18713809	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000259053100025
J	Barrington, MJ; Scott, DA				Barrington, Michael J.; Scott, David A.			Do we need to justify epidural analgesia beyond pain relief?	LANCET			English	Editorial Material							ANESTHESIA; METAANALYSIS; MORBIDITY; TRIALS		[Barrington, Michael J.; Scott, David A.] St Vincents Hosp, Dept Anaesthesia, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne	Barrington, MJ (corresponding author), St Vincents Hosp, Dept Anaesthesia, Fitzroy, Vic 3065, Australia.	michael.barrington@svhm.org.au						*AUSTR REG AN COLL, PROSP AUD PER NERV P; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Beattie WS, 2001, ANESTH ANALG, V93, P853, DOI 10.1097/00000539-200110000-00010; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Cameron CM, 2007, ANESTHESIOLOGY, V106, P997, DOI 10.1097/01.anes.0000265160.32309.10; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 2006, REGION ANESTH PAIN M, V31, P291, DOI 10.1016/j.rapm.2006.05.006; Park WY, 2001, ANN SURG, V234, P560; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; WIJEYSUNDERA DN, 2008, LANCET          0811	13	16	16	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					514	516		10.1016/S0140-6736(08)61122-8	http://dx.doi.org/10.1016/S0140-6736(08)61122-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18692892				2023-01-03	WOS:000258582300007
J	Weiner, LM				Weiner, Louis M.			Focus on research - Cancer immunotherapy - The endgame begins	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Weiner, Louis M.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA	Georgetown University	Weiner, LM (corresponding author), Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.				NCI NIH HHS [R01 CA121033, R01 CA050633-18, R01 CA050633, R01 CA121033-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA121033, R01CA050633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DURANT JR, 1987, NEW ENGL J MED, V316, P939, DOI 10.1056/NEJM198704093161509; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Taylor C, 2007, CLIN CANCER RES, V13, P5133, DOI 10.1158/1078-0432.CCR-07-0507	5	30	32	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 19	2008	358	25					2664	2665		10.1056/NEJMp0803663	http://dx.doi.org/10.1056/NEJMp0803663			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	314NC	18565858	Green Accepted			2023-01-03	WOS:000256815100002
J	Harrington, SE; Smith, TJ				Harrington, Sarah Elizabeth; Smith, Thomas J.			The role of chemotherapy at the end of life: "When is enough, enough?"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CELL LUNG-CANCER; PALLIATIVE CARE; BREAST-CANCER; SUPPORTIVE CARE; DECISION AID; PATIENTS PERCEPTIONS; COST-EFFECTIVENESS; TREATMENT OPTIONS; RANDOMIZED-TRIAL; IMMINENT DEATH	Patients face difficult decisions about chemotherapy near the end of life. Such treatment might prolong survival or reduce symptoms but cause adverse effects, prevent the patient from engaging in meaningful life review and preparing for death, and preclude entry into hospice. Palliative care and oncology clinicians should be logical partners in caring for patients with serious cancers for which symptom control, medically appropriate goal setting, and communication are paramount, but some studies have shown limited cooperation. We illustrate how clinicians involved in palliative care and oncology can more effectively work together with the story of Mr L, a previously healthy 56- year- old man, who wanted to survive his lung cancer at all costs. He lived 14 months with 3 types of chemotherapy, received chemotherapy just 6 days before his death, and resisted entering hospice until his prognosis and options were explicitly communicated. Approaches to communication about prognosis and treatment options and questions that patients may want to ask are discussed.	Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Thomas Palliat Care Program, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Smith, TJ (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, MCV Box 980230, Richmond, VA 23298 USA.	tsmith@hsc.vcu.edu	Harrington, Sarah Beth/AAR-4802-2020	Smith, Thomas/0000-0003-3040-6434	NATIONAL CANCER INSTITUTE [R01CA116227] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [G08LM009525] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA116227-01, R01 CA116227] Funding Source: Medline; NLM NIH HHS [G08 LM009525-01, G08 LM009525, 1G08LM009525-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Agrawal M, 2006, J CLIN ONCOL, V24, P4479, DOI 10.1200/JCO.2006.06.0269; [Anonymous], 1996, J Clin Oncol, V14, P671; Back A, 2006, ONCOLOGY-NY, V20, P67; Bakitas Marie, 2004, J Palliat Med, V7, P363, DOI 10.1089/109662104773709530; Balmer CE, 2001, PSYCHO-ONCOL, V10, P410, DOI 10.1002/pon.538; BENNER SE, 1994, CANCER INVEST, V12, P451, DOI 10.3109/07357909409021402; Bodenheimer T, 2007, ANN INTERN MED, V146, P301, DOI 10.7326/0003-4819-146-4-200702200-00011; Bremnes RM, 1995, EUR J CANCER, V31A, P1955, DOI 10.1016/0959-8049(95)00513-7; Brickner Leslea, 2004, J Palliat Med, V7, P411, DOI 10.1089/1096621041349518; Brown RF, 2001, BRIT J CANCER, V85, P1273, DOI 10.1054/bjoc.2001.2073; Bruera E, 2003, J PAIN SYMPTOM MANAG, V25, P412, DOI 10.1016/S0885-3924(02)00686-3; Brundage MD, 2001, PATIENT EDUC COUNS, V45, P149, DOI 10.1016/S0738-3991(01)00155-0; Campbell DE, 2004, ANN INTERN MED, V140, P269, DOI 10.7326/0003-4819-140-4-200402170-00009; Casarett D, 2005, J AM GERIATR SOC, V53, P249, DOI 10.1111/j.1532-5415.2005.53110.x; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; Casarett DJ, 2007, ANN INTERN MED, V146, P443, DOI 10.7326/0003-4819-146-6-200703200-00011; Casarett DJ, 2004, J AM GERIATR SOC, V52, P1923, DOI 10.1111/j.1532-5415.2004.52520.x; Chow E, 2001, CLIN ONCOL-UK, V13, P204, DOI 10.1053/clon.2001.9255; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Collins R, 2007, HEALTH TECHNOL ASSES, V11, P1; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; Creagan Edward T, 2004, Cancer Control, V11, P266; Dancey J, 2004, LUNG CANCER-J IASLC, V43, P183, DOI 10.1016/j.lungcan.2003.09.001; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; EISENBERG PD, 2002, ANN INTERN MED, V136; El Demery M, 2006, PROG UROL, V16, P320; Elsayem A, 2004, J CLIN ONCOL, V22, P2008, DOI 10.1200/JCO.2004.11.003; EMANUEL LL, 2007, NIH PUBLICATION; Fallowfield L, 2001, BRIT MED J, V323, P1144, DOI 10.1136/bmj.323.7322.1144; Finn JW, 2002, P AN M AM SOC CLIN, V21, P1452; Foley KM, 2001, IMPROVING PALLIATIVE; Gade G, 2008, J PALLIAT MED, V11, P180, DOI 10.1089/jpm.2007.0055; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Glynne-Jones R, 2006, CLIN ONCOL-UK, V18, P395, DOI 10.1016/j.clon.2006.01.005; Goldberg RM, 2007, ONCOLOGIST, V12, P38, DOI 10.1634/theoncologist.12-1-38; Grunfeld EA, 2006, J CLIN ONCOL, V24, P1090, DOI 10.1200/JCO.2005.01.9208; Hagerty RG, 2005, J CLIN ONCOL, V23, P1278, DOI 10.1200/JCO.2005.11.138; HAYES DF, 2008, UPTODATE; Helft PR, 2005, J CLIN ONCOL, V23, P3146, DOI 10.1200/JCO.2005.07.003; Hillner BE, 2005, CANCER-AM CANCER SOC, V104, P1871, DOI 10.1002/cncr.21411; Hirose T, 2005, INTERNAL MED, V44, P107, DOI 10.2169/internalmedicine.44.107; Jacobson M, 2006, HEALTH AFFAIR, V25, P437, DOI 10.1377/hlthaff.25.2.437; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Koedoot CG, 2004, EUR J CANCER, V40, P225, DOI 10.1016/j.ejca.2003.10.008; Koedoot CG, 2003, BRIT J CANCER, V89, P2219, DOI 10.1038/sj.bjc.6601445; Lamont E B, 2000, J Palliat Med, V3, P27, DOI 10.1089/jpm.2000.3.27; Lamont EB, 2001, ANN INTERN MED, V134, P1096, DOI 10.7326/0003-4819-134-12-200106190-00009; Lee SJ, 2003, BIOL BLOOD MARROW TR, V9, P389, DOI 10.1016/S1083-8791(03)00103-4; Lee SJ, 2001, JAMA-J AM MED ASSOC, V285, P1034, DOI 10.1001/jama.285.8.1034; Leighl NB, 2007, J CLIN ONCOL, V25; Mack JW, 2007, J CLIN ONCOL, V25, P5636, DOI 10.1200/JCO.2007.12.6110; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; Mallinger JB, 2006, PSYCHO-ONCOLOGY, V15, P297, DOI 10.1002/pon.954; Martoni AA, 2007, TUMORI J, V93, P417; Matsuyama R, 2006, J CLIN ONCOL, V24, P3490, DOI 10.1200/JCO.2005.03.6236; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Meropol NJ, 2007, J CLIN ONCOL, V25, P180, DOI 10.1200/JCO.2006.09.6081; Meropol NJ, 2003, J CLIN ONCOL, V21, P2589, DOI 10.1200/JCO.2003.10.072; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Murillo JR, 2006, ONCOLOGIST, V11, P1095, DOI 10.1634/theoncologist.11-10-1095; Neff P, 2002, J CLIN ONCOL, V20, P3035, DOI 10.1200/JCO.2002.20.13.3035; Passik Steven D, 2004, Palliat Support Care, V2, P419; Peele PB, 2005, MED DECIS MAKING, V25, P301, DOI 10.1177/0272989X05276851; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; PITORAK EF, 2002, PROJECT SAFE CONDUCT; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; Rabinowitz T, 2006, CANCER INVEST, V24, P68, DOI 10.1080/07357900500449678; Rabow MW, 2003, J PAIN SYMPTOM MANAG, V26, P1010, DOI 10.1016/j.jpainsymman.2003.03.002; Santoso JT, 2006, CANCER J, V12, P73, DOI 10.1097/00130404-200601000-00013; Schockett ER, 2005, J PAIN SYMPTOM MANAG, V30, P400, DOI 10.1016/j.jpainsymman.2005.04.013; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Shanafelt TD, 2004, J CLIN ONCOL, V22, P1966, DOI 10.1200/JCO.2004.08.176; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; Siminoff LA, 2006, PSYCHO-ONCOLOGY, V15, P1001, DOI 10.1002/pon.1040; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SMITH RC, 1988, PSYCHOSOMATICS, V29, P392, DOI 10.1016/S0033-3182(88)72339-7; Smith T J, 1998, J Palliat Med, V1, P221, DOI 10.1089/jpm.1998.1.221; Smith TJ, 2006, J CLIN ONCOL, V24, P3187, DOI 10.1200/JCO.2006.06.4451; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; SMITH TJ, 1995, J CLIN ONCOL, V13, P2464, DOI 10.1200/JCO.1995.13.9.2464; Smith TJ, 2000, J CLIN ONCOL, V18, P3441, DOI 10.1200/JCO.2000.18.19.3441; Smith TJ, 2001, J CLIN ONCOL, V19, P260, DOI 10.1200/JCO.2001.19.1.260; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Sullivan AM, 2007, J PALLIAT MED, V10, P882, DOI 10.1089/jpm.2007.0189; Tamburini M, 2000, SUPPORT CARE CANCER, V8, P223, DOI 10.1007/s005200050289; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Teno JM, 2004, ANN INTERN MED, V141, P159, DOI 10.7326/0003-4819-141-2-200407200-00017; Teno JM, 2007, J PAIN SYMPTOM MANAG, V34, P120, DOI 10.1016/j.jpainsymman.2007.04.014; The AM, 2001, WESTERN J MED, V174, P247, DOI 10.1136/ewjm.174.4.247; TOBIAS JS, 1993, BRIT MED J, V307, P1199, DOI 10.1136/bmj.307.6913.1199; WHELAN TJ, 2002, AHRQ PUBLICATION; Wright AA, 2007, NEW ENGL J MED, V357, P324, DOI 10.1056/NEJMp078074	96	198	199	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2667	E1		10.1001/jama.299.22.2667	http://dx.doi.org/10.1001/jama.299.22.2667			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544726	Green Accepted			2023-01-03	WOS:000256586200023
J	Markowitz, AJ; Rabow, MW				Markowitz, Amy J.; Rabow, Michael W.			Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Markowitz, Amy/0000-0001-9314-2814				Goldstein NE, 2008, JAMA-J AM MED ASSOC, V299, P1818, DOI 10.1001/jama.299.15.1818	1	2	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2679	2679		10.1001/jama.299.22.2679	http://dx.doi.org/10.1001/jama.299.22.2679			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544727				2023-01-03	WOS:000256586200024
J	Lynn, J				Lynn, Joanne			Making a difference - Palliative care beyond cancer - Reliable comfort and meaningfulness	BRITISH MEDICAL JOURNAL			English	Editorial Material							QUALITY IMPROVEMENT		Ctr Medicare & Medicaid Serv, Off Clin Stand & Qual, Baltimore, MD 21244 USA	Centers for Medicare & Medicaid Services	Lynn, J (corresponding author), Ctr Medicare & Medicaid Serv, Off Clin Stand & Qual, 7500 Secur Blvd, Baltimore, MD 21244 USA.	Joanne.Lynn@cms.hhs.gov						Arnold R, 2005, J PALLIAT MED, V8, P1086, DOI 10.1089/jpm.2005.8.1086; DAVIS K, 2007, MED HOMES COULD IMPR; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Lynn J, 2002, ANN INTERN MED, V137, P117, DOI 10.7326/0003-4819-137-2-200207160-00010; LYNN J, 2007, COMMON SENSE GUIDE I; LYNN J, 2007, IMPROVING CARE END L; LYNN J, 2004, SICK DEATH NOT GOING; Lynn J, 2007, J AM GERIATR SOC, V55, P1663, DOI 10.1111/j.1532-5415.2007.01380.x; Lynn J, 2007, MILBANK Q, V85, P185, DOI 10.1111/j.1468-0009.2007.00483.x	9	11	12	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					958	+		10.1136/bmj.39535.656319.94	http://dx.doi.org/10.1136/bmj.39535.656319.94			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296KC	18397941	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000255540900046
J	Chu, SY; Bachman, DJ; Callaghan, WM; Whitlock, EP; Dietz, PM; Berg, CJ; O'Keeffe-Rosetti, M; Bruce, FC; Hornbrook, MC				Chu, Susan Y.; Bachman, Donald J.; Callaghan, William M.; Whitlock, Evelyn P.; Dietz, Patricia M.; Berg, Cynthia J.; O'Keeffe-Rosetti, Maureen; Bruce, F. Carol; Hornbrook, Mark C.			Association between obesity during pregnancy and increased use of health care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL OBESITY; WEIGHT; TRENDS; RISK; IMPACT	Background: In the United States, obesity during pregnancy is common and increases obstetrical risks. An estimate of the increase in use of health care services associated with obesity during pregnancy is needed. Methods: We used electronic data systems of a large U.S. group-practice health maintenance organization to identify 13,442 pregnancies among women 18 years of age or older at the time of conception that resulted in live births or stillbirths. The study period was between January 1, 2000, and December 31, 2004. We assessed associations between measures of use of health care services and body-mass index (BMI, defined as the weight in kilograms divided by the square of the height in meters) before pregnancy or in early pregnancy. The women were categorized as underweight (BMI <18.5), normal (BMI 18.5 to 24.9), overweight (BMI 25.0 to 29.9), obese (BMI 30.0 to 34.9), very obese (BMI 35.0 to 39.9), or extremely obese (BMI greater/equal 40.0). The primary outcome was the mean length of hospital stay for delivery. Results: After adjustment for age, race or ethnic group, level of education, and parity, the mean (+/-SE) length of hospital stay for delivery was significantly (P<0.05) greater among women who were overweight (3.7+/-0.1 days), obese (4.0+/-0.1 days), very obese (4.1+/-0.1 days), and extremely obese (4.4+/-0.1 days) than among women with normal BMI (3.6+/-0.1 days). A higher-than-normal BMI was associated with significantly more prenatal fetal tests, obstetrical ultrasonographic examinations, medications dispensed from the outpatient pharmacy, telephone calls to the department of obstetrics and gynecology, and prenatal visits with physicians. A higher-than-normal BMI was also associated with significantly fewer prenatal visits with nurse practitioners and physician assistants. Most of the increase in length of stay associated with higher BMI was related to increased rates of cesarean delivery and obesity-related high-risk conditions. Conclusions: Obesity during pregnancy is associated with increased use of health care services.	[Chu, Susan Y.; Callaghan, William M.; Dietz, Patricia M.; Berg, Cynthia J.; Bruce, F. Carol] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; [Bachman, Donald J.; Whitlock, Evelyn P.; O'Keeffe-Rosetti, Maureen; Hornbrook, Mark C.] Kaiser Permanente NW, Ctr Hlth Res NW Hawaii SE, Portland, OR USA	Centers for Disease Control & Prevention - USA; Kaiser Permanente	Chu, SY (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K-23, Atlanta, GA 30341 USA.	syc1@cdc.gov						American College of Obstetricians and Gynecologists (ACOG), 2005, OBSTET GYNECOL, V106, P671, DOI [10.1097/00006250-200509000-00054, DOI 10.1097/00006250-200509000-00054]; Catalano PM, 2006, BJOG-INT J OBSTET GY, V113, P1126, DOI 10.1111/j.1471-0528.2006.00989.x; Cnattingius S, 1998, NEW ENGL J MED, V338, P147, DOI 10.1056/NEJM199801153380302; Cogswell M E., 2001, Prim Care Update Ob Gyns, V8, P89, DOI 10.1016/S1068-607X(00)00087-1; Ehrenberg HM, 2004, AM J OBSTET GYNECOL, V191, P969, DOI 10.1016/j.ajog.2004.06.057; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Galtier-Dereure F, 2000, AM J CLIN NUTR, V71, p1242S, DOI 10.1093/ajcn/71.5.1242s; GALTIERDEREURE F, 1995, INT J OBESITY, V19, P443; GARBACIAK JA, 1985, AM J OBSTET GYNECOL, V152, P238, DOI 10.1016/S0002-9378(85)80029-6; Hendler I, 2004, INT J OBESITY, V28, P1607, DOI 10.1038/sj.ijo.0802759; Heslehurst N, 2007, BJOG-INT J OBSTET GY, V114, P334, DOI 10.1111/j.1471-0528.2006.01230.x; Hornbrook MC, 2007, HEALTH SERV RES, V42, P908, DOI 10.1111/j.1475-6773.2006.00635.x; Kim SY, 2007, OBESITY, V15, P986, DOI 10.1038/oby.2007.621; Villamor E, 2006, LANCET, V368, P1164, DOI 10.1016/S0140-6736(06)69473-7; Yeh J, 2005, AM J OBSTET GYNECOL, V193, P1994, DOI 10.1016/j.ajog.2005.05.001	15	168	172	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 3	2008	358	14					1444	1453		10.1056/NEJMoa0706786	http://dx.doi.org/10.1056/NEJMoa0706786			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	282CY	18385496				2023-01-03	WOS:000254546400005
J	Amy, JJ; Tripathi, V				Amy, Jean-Jacques; Tripathi, Vrijesh			Contraception for women: an evidence based overview	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VENOUS THROMBOEMBOLISM; INTRAUTERINE-DEVICES; RISK; LEVONORGESTREL		[Amy, Jean-Jacques] European Journal Contracept & Reprod Hlth Care, B-1740 Ternat, Belgium; [Tripathi, Vrijesh] Univ W Indies, Fac Sci & Agr, St Augustine, Trinidad Tobago	University West Indies Mona Jamaica; University West Indies Saint Augustine	Amy, JJ (corresponding author), Florencestr 62, B-1050 Brussels, Belgium.	jeanjacques.amy@skynet.be						[Anonymous], 2003, ADDING IT BENEFITS I; Beral V, 2008, LANCET, V371, P303, DOI 10.1016/S0140-6736(08)60167-1; CHENG L, 2007, COCHRANE DB SYST REV; Cole JA, 2007, OBSTET GYNECOL, V109, P339, DOI 10.1097/01.AOG.0000250968.82370.04; El-Ibiary SY, 2008, EUR J CONTRACEP REPR, V13, P123, DOI 10.1080/13625180701829952; Grimes DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006034.pub2; GRIMES DA, 2007, COCHRANE DB SYST REV; Grimes DA, 2007, CONTRACEPTION, V75, pS55, DOI 10.1016/j.contraception.2006.12.004; Hillis SD, 1999, OBSTET GYNECOL, V93, P889, DOI 10.1016/S0029-7844(98)00539-0; Hubacher D, 2002, OBSTET GYNECOL SURV, V57, P120, DOI 10.1097/00006254-200202000-00024; Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438; Lopez LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006260.pub2; Lopez LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006964.pub2; Lopez LM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003552.pub2; Martinez F, 2007, EUR J CONTRACEP REPR, V12, P97, DOI 10.1080/13625180701300194; Piaggio G, 1999, LANCET, V353, P697; Polis CB, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005497.pub2; Raymond EG, 2007, OBSTET GYNECOL, V109, P181, DOI 10.1097/01.AOG.0000250904.06923.4a; Rosenberg MJ, 1998, AM J OBSTET GYNECOL, V179, P577, DOI 10.1016/S0002-9378(98)70047-X; TRUSSELL J, 2004, CONTRACEPTIVE TECHNO, P355; United Nations Department of Economic and Social Affairs, 2007, WORLD CONTR US; VANDERWIJDEN C, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001329; Varma R, 2006, EUR J OBSTET GYN R B, V125, P9, DOI 10.1016/j.ejogrb.2005.10.029; von Hertzen H, 2002, LANCET, V360, P1803, DOI 10.1016/S0140-6736(02)11767-3; WHO, 2004, MED EL CRIT CONTR US, V3; World Health Organization, 2008, SEL PRACT REC CONTR; Wu O, 2005, THROMB HAEMOSTASIS, V94, P17, DOI 10.1160/TH04-11-0759; XIONG X, 1995, CONTRACEPTION, V52, P23, DOI 10.1016/0010-7824(95)00120-Y	28	34	33	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2009	339								b2895	10.1136/bmj.b2895	http://dx.doi.org/10.1136/bmj.b2895			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481KF	19666684				2023-01-03	WOS:000268808200004
J	Olive, KP; Jacobetz, MA; Davidson, CJ; Gopinathan, A; McIntyre, D; Honess, D; Madhu, B; Goldgraben, MA; Caldwell, ME; Allard, D; Frese, KK; DeNicola, G; Feig, C; Combs, C; Winter, SP; Ireland-Zecchini, H; Reichelt, S; Howat, WJ; Chang, A; Dhara, M; Wang, LF; Ruckert, F; Grutzmann, R; Pilarsky, C; Izeradjene, K; Hingorani, SR; Huang, P; Davies, SE; Plunkett, W; Egorin, M; Hruban, RH; Whitebread, N; McGovern, K; Adams, J; Iacobuzio-Donahue, C; Griffiths, J; Tuveson, DA				Olive, Kenneth P.; Jacobetz, Michael A.; Davidson, Christian J.; Gopinathan, Aarthi; McIntyre, Dominick; Honess, Davina; Madhu, Basetti; Goldgraben, Mae A.; Caldwell, Meredith E.; Allard, David; Frese, Kristopher K.; DeNicola, Gina; Feig, Christine; Combs, Chelsea; Winter, Stephen P.; Ireland-Zecchini, Heather; Reichelt, Stefanie; Howat, William J.; Chang, Alex; Dhara, Mousumi; Wang, Lifu; Rueckert, Felix; Gruetzmann, Robert; Pilarsky, Christian; Izeradjene, Kamel; Hingorani, Sunil R.; Huang, Pearl; Davies, Susan E.; Plunkett, William; Egorin, Merrill; Hruban, Ralph H.; Whitebread, Nigel; McGovern, Karen; Adams, Julian; Iacobuzio-Donahue, Christine; Griffiths, John; Tuveson, David A.			Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer	SCIENCE			English	Article							DUCTAL ADENOCARCINOMA; SONIC HEDGEHOG; GEMCITABINE; GROWTH; METASTASIS; DIAGNOSIS; SURVIVAL; THERAPY; TUMORS; TRIAL	Pancreatic ductal adenocarcinoma (PDA) is among the most lethal human cancers in part because it is insensitive to many chemotherapeutic drugs. Studying a mouse model of PDA that is refractory to the clinically used drug gemcitabine, we found that the tumors in this model were poorly perfused and poorly vascularized, properties that are shared with human PDA. We tested whether the delivery and efficacy of gemcitabine in the mice could be improved by coadministration of IPI-926, a drug that depletes tumor-associated stromal tissue by inhibition of the Hedgehog cellular signaling pathway. The combination therapy produced a transient increase in intratumoral vascular density and intratumoral concentration of gemcitabine, leading to transient stabilization of disease. Thus, inefficient drug delivery may be an important contributor to chemoresistance in pancreatic cancer.	[Olive, Kenneth P.; Jacobetz, Michael A.; Gopinathan, Aarthi; McIntyre, Dominick; Honess, Davina; Madhu, Basetti; Goldgraben, Mae A.; Caldwell, Meredith E.; Allard, David; Frese, Kristopher K.; DeNicola, Gina; Feig, Christine; Winter, Stephen P.; Ireland-Zecchini, Heather; Reichelt, Stefanie; Howat, William J.; Griffiths, John; Tuveson, David A.] Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Cambridge CB2 ORE, England; [Davidson, Christian J.; Gopinathan, Aarthi; DeNicola, Gina; Combs, Chelsea; Wang, Lifu] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Chang, Alex; Dhara, Mousumi; Hruban, Ralph H.; Iacobuzio-Donahue, Christine] Sidney Canc Ctr, Sol Goldman Pancreat Canc Res Ctr, Dept Oncol, Baltimore, MD 21287 USA; [Chang, Alex; Dhara, Mousumi; Hruban, Ralph H.; Iacobuzio-Donahue, Christine] Sidney Canc Ctr, Sol Goldman Pancreat Canc Res Ctr, Dept Pathol, Baltimore, MD 21287 USA; [Chang, Alex; Dhara, Mousumi; Hruban, Ralph H.; Iacobuzio-Donahue, Christine] Johns Hopkins Univ, Baltimore, MD 21287 USA; [Wang, Lifu] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Gastroenterol, Sch Med, Shanghai 200025, Peoples R China; [Rueckert, Felix; Gruetzmann, Robert; Pilarsky, Christian] Univ Hosp Dresden, Dept Surg, D-01307 Dresden, Germany; [Izeradjene, Kamel; Hingorani, Sunil R.] Fred Hutchinson Canc Res Ctr, Clin Res & Publ Hlth Sci Div, Seattle, WA 98109 USA; [Izeradjene, Kamel; Hingorani, Sunil R.] Univ Washington, Seattle, WA 98109 USA; [Huang, Pearl] Merck & Co Inc, Oncol Franchise, N Wales, PA 19454 USA; [Davies, Susan E.] Cambridge Univ Hosp Natl Hlth Serv Fdn Trust, Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; [Plunkett, William] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Egorin, Merrill] Univ Pittsburgh, Med Ctr, Div Hematol & Oncol, Pittsburgh, PA 15213 USA; [Whitebread, Nigel; McGovern, Karen; Adams, Julian] Infin Pharmaceut, Cambridge, MA 01239 USA	Cancer Research UK; CRUK Cambridge Institute; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Shanghai Jiao Tong University; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Merck & Company; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tuveson, DA (corresponding author), Canc Res UK, Cambridge Res Inst, Li Ka Shing Ctr, Robinson Way, Cambridge CB2 ORE, England.	david.tuveson@cancer.org.uk	Griffiths, John R/F-2853-2010; McIntyre, Dominick/F-2998-2010; Iacobuzio-Donahue, Christine/ABF-1295-2020; Madhu, Basetti/AAW-9665-2020	McIntyre, Dominick/0000-0002-0269-6545; Iacobuzio-Donahue, Christine/0000-0002-4672-3023; Madhu, Basetti/0000-0001-5844-856X; Feig, Christine/0000-0003-1385-7049; Reichelt, Stefanie/0000-0003-4151-0712; Goldgraben, Mae/0000-0002-1111-2804; Pilarsky, Christian/0000-0002-7968-3283; DeNicola, Gina/0000-0001-6611-6696; Hingorani, Sunil/0000-0002-3869-8729; Olive, Kenneth/0000-0002-3392-8994	Lustgarten Foundation; University of Cambridge; Cancer Research UK; The Li Ka Shing Foundation; Hutchison Whampoa Limited; National Institute for Health Research Cambridge Biomedical Research Centre; NIH [CA101973, CA111292, CA084291, CA105490, K08 CA106610, CA15704, CA114028, F32CA123939-02, F32CA123887-01]; Mead Foundation; University of Pennsylvania GlaxoSmithKline Alternative Drug Discovery Initiative; NATIONAL CANCER INSTITUTE [K08CA114028, F32CA123939, U01CA084291, U01CA105490, F32CA123887, K08CA106610, P30CA015704, R01CA101973] Funding Source: NIH RePORTER	Lustgarten Foundation; University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); The Li Ka Shing Foundation; Hutchison Whampoa Limited; National Institute for Health Research Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mead Foundation; University of Pennsylvania GlaxoSmithKline Alternative Drug Discovery Initiative; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the animal care staffs of the Cambridge Research Institute (CRI), University of Pennsylvania Translational Research Labs, FHCRC, and University Hospital Dresden as well as the histology and genomics cores at CRI, and P. Calses for technical assistance. We also thank B. Bean of Transnetyx Inc. for developing high-throughput genotyping assays for the KPC mice. This research was supported by the Lustgarten Foundation, the University of Cambridge and Cancer Research UK, The Li Ka Shing Foundation and Hutchison Whampoa Limited, the National Institute for Health Research Cambridge Biomedical Research Centre, and NIH (grants CA101973, CA111292, CA084291, and CA105490 to D.A.T.; K08 CA106610 to C.I.-D.; and CA15704 and CA114028 to S.R.H.). S.R.H. was supported by a grant from the Mead Foundation. Preliminary studies were supported by a grant from the University of Pennsylvania GlaxoSmithKline Alternative Drug Discovery Initiative. K.P.O. and K.K.F. were supported by NIH under Ruth L. Kirschstein National Research Service Awards F32CA123939-02 (K.P.O.) and F32CA123887-01 (K.K.F.). In addition to being an officer of Infinity Pharmaceuticals, J.A. is a member of the Senior Advisory Boards of Constellation Pharma and Auspex Pharma. Cancer Research Technology, which is associated with Cancer Research UK, has filed a U.S. provisional patent application related to this work.	ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Bailey JM, 2008, CLIN CANCER RES, V14, P5995, DOI 10.1158/1078-0432.CCR-08-0291; Bruns CJ, 2002, INT J CANCER, V102, P101, DOI 10.1002/ijc.10681; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cook N, 2008, METHOD ENZYMOL, V439, P73, DOI 10.1016/S0076-6879(07)00406-5; Duan JX, 2008, J MED CHEM, V51, P2412, DOI 10.1021/jm701028q; EGORIN MJ, 1974, CANCER RES, V34, P2243; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2006, CANCER RES, V66, P95, DOI 10.1158/0008-5472.CAN-05-2168; Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796; Langer SJ, 2002, NUCLEIC ACIDS RES, V30, P3067, DOI 10.1093/nar/gkf421; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Melisi D, 2008, MOL CANCER THER, V7, P829, DOI 10.1158/1535-7163.MCT-07-0337; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Pola R, 2001, NAT MED, V7, P706, DOI 10.1038/89083; Sakamoto H, 2008, ULTRASOUND MED BIOL, V34, P525, DOI 10.1016/j.ultrasmedbio.2007.09.018; SCHULTZ RM, 1993, ONCOL RES, V5, P223; Shimamura T, 2007, CANCER RES, V67, P9903, DOI 10.1158/0008-5472.CAN-06-4558; Sofuni A, 2005, J GASTROENTEROL, V40, P518, DOI 10.1007/s00535-005-1578-z; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Tian H, 2009, P NATL ACAD SCI USA, V106, P4254, DOI 10.1073/pnas.0813203106; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Van Cutsem E, 2009, J CLIN ONCOL, V27, P2231, DOI 10.1200/JCO.2008.20.0238; Verma A, 2008, CLIN CANCER RES, V14, P2476, DOI 10.1158/1078-0432.CCR-07-4529; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275	27	2287	2354	15	410	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	2009	324	5933					1457	1461		10.1126/science.1171362	http://dx.doi.org/10.1126/science.1171362			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	456VD	19460966	Green Accepted			2023-01-03	WOS:000266878700050
J	Kritek, PA; Slutsky, AS; Hudson, LD				Kritek, Patricia A.; Slutsky, Arthur S.; Hudson, Leonard D.			Care of an Unresponsive Patient with a Poor Prognosis - Polling Results	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material													Slutsky, Arthur/M-3325-2019					Slutsky AS, 2009, NEW ENGL J MED, V360, P527, DOI 10.1056/NEJMclde0808330	1	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	2009	360	10					E15	U99		10.1056/NEJMclde0900810	http://dx.doi.org/10.1056/NEJMclde0900810			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	413WX	19264684				2023-01-03	WOS:000263824500016
J	McDermott, MM; Ades, P; Guralnik, JM; Dyer, A; Ferrucci, L; Liu, K; Nelson, M; Lloyd-Jones, D; Van Horn, L; Garside, D; Kibbe, M; Domanchuk, K; Stein, JH; Liao, YH; Tao, HM; Green, D; Pearce, WH; Schneider, JR; McPherson, D; Laing, ST; McCarthy, WJ; Shroff, A; Criqui, MH				McDermott, Mary M.; Ades, Philip; Guralnik, Jack M.; Dyer, Alan; Ferrucci, Luigi; Liu, Kiang; Nelson, Miriam; Lloyd-Jones, Donald; Van Horn, Linda; Garside, Daniel; Kibbe, Melina; Domanchuk, Kathryn; Stein, James H.; Liao, Yihua; Tao, Huimin; Green, David; Pearce, William H.; Schneider, Joseph R.; McPherson, David; Laing, Susan T.; McCarthy, Walter J.; Shroff, Adhir; Criqui, Michael H.			Treadmill Exercise and Resistance Training in Patients With Peripheral Arterial Disease With and Without Intermittent Claudication A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANKLE BRACHIAL INDEX; LOWER-EXTREMITY ISCHEMIA; PHYSICAL-ACTIVITY; LEG SYMPTOMS; CLINICAL CHARACTERISTICS; SUBSEQUENT DISABILITY; FUNCTIONAL IMPAIRMENT; CARDIOVASCULAR EVENTS; PERFORMANCE-MEASURES; SKELETAL-MUSCLE	Context Neither supervised treadmill exercise nor strength training for patients with peripheral arterial disease ( PAD) without intermittent claudication have been established as beneficial. Objective To determine whether supervised treadmill exercise or lower extremity resistance training improve functional performance of patients with PAD with or without claudication. Design, Setting, and Participants Randomized controlled clinical trial performed at an urban academic medical center between April 1, 2004, and August 8, 2008, involving 156 patients with PAD who were randomly assigned to supervised treadmill exercise, to lower extremity resistance training, or to a control group. Main Outcome Measures Six- minute walk performance and the short physical performance battery. Secondary outcomes were brachial artery flow- mediated dilation, treadmill walking performance, the Walking Impairment Questionnaire, and the 36- Item Short Form Health Survey physical functioning ( SF- 36 PF) score. Results For the 6- minute walk, those in the supervised treadmill exercise group increased their distance walked by 35.9 m ( 95% confidence interval [ CI], 15.3- 56.5 m; P <. 001) compared with the control group, whereas those in the resistance training group increased their distance walked by 12.4 m ( 95% CI, - 8.42 to 33.3 m; P=. 24) compared with the control group. Neither exercise group improved its short physical performance battery scores. For brachial artery flow- mediated dilation, those in the treadmill group had a mean improvement of 1.53% ( 95% CI, 0.35%- 2.70%; P=. 02) compared with the control group. The treadmill group had greater increases in maximal treadmill walking time ( 3.44 minutes; 95% CI, 2.05- 4.84 minutes; P <. 001); walking impairment distance score ( 10.7; 95% CI, 1.56- 19.9; P=. 02); and SF- 36 PF score ( 7.5; 95% CI, 0.00- 15.0; P=. 02) than the control group. The resistance training group had greater increases in maximal treadmill walking time ( 1.90 minutes; 95% CI, 0.49-3.31 minutes; P=. 009); walking impairment scores for distance ( 6.92; 95% CI, 1.07-12.8; P=. 02) and stair climbing ( 10.4; 95% CI, 0.00- 20.8; P=. 03); and SF- 36 PF score ( 7.5; 95% CI, 0.0- 15.0; P=. 04) than the control group. Conclusions Supervised treadmill training improved 6- minute walk performance, treadmill walking performance, brachial artery flow- mediated dilation, and quality of life but did not improve the short physical performance battery scores of PAD participants with and without intermittent claudication. Lower extremity resistance training improved functional performance measured by treadmill walking, quality of life, and stair climbing ability. Trial Registration clinicaltrials. gov Identifier: NCT00106327.	[McDermott, Mary M.; Lloyd-Jones, Donald; Domanchuk, Kathryn; Green, David] Northwestern Univ, Dept Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Dyer, Alan; Liu, Kiang; Lloyd-Jones, Donald; Van Horn, Linda; Garside, Daniel; Liao, Yihua; Tao, Huimin] Northwestern Univ, Dept Prevent Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Kibbe, Melina; Pearce, William H.] Northwestern Univ, Dept Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Ades, Philip] Univ Vermont, Dept Med, Burlington, VT USA; [Guralnik, Jack M.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA; [Ferrucci, Luigi] NIA, Lab Clin Epidemiol, Baltimore, MD 21224 USA; [Nelson, Miriam] Tufts Univ, Medford, MA 02155 USA; [Stein, James H.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; [Schneider, Joseph R.] Cent DuPage Hosp, Dept Surg, Winfield, IL USA; [McPherson, David; Laing, Susan T.] Univ Texas Houston, Hlth Sci Ctr, Dept Med, Houston, TX USA; [McCarthy, Walter J.] Rush Univ, Sch Med, Dept Surg, Chicago, IL 60612 USA; [Shroff, Adhir] Univ Illinois, Dept Med, Chicago, IL USA; [Criqui, Michael H.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Tufts University; University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Health Science Center Houston; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California San Diego	McDermott, MM (corresponding author), 750 Lake Shore Dr,10th Floor, Chicago, IL 60611 USA.	mdm608@northwestern.edu	Lloyd-Jones, Donald M/C-5899-2009	Laing, Susan/0000-0002-6504-6646; Lloyd-Jones, Donald/0000-0003-0847-6110; Stein, James/0000-0002-2770-8223	National Heart, Lung, and Blood Institute [R01-HL073551]; National Center for Research Resources [RR-00048]; National Institutes of Health; Intramural Research Program; National Institutes on Aging; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000048] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL073551, R44HL073551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG001050] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program; National Institutes on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants R01-HL073551 from the National Heart, Lung, and Blood Institute and by RR-00048 from the National Center for Research Resources, National Institutes of Health. This was also supported in part by the Intramural Research Program, National Institutes on Aging.	Allison MA, 2007, AM J PREV MED, V32, P328, DOI 10.1016/j.amepre.2006.12.010; Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; BASSEY EJ, 1990, EUR J APPL PHYSIOL, V60, P385, DOI 10.1007/BF00713504; Corretti MC, 2002, J AM COLL CARDIOL, V39, P257, DOI 10.1016/S0735-1097(01)01746-6; Criqui M H, 1996, Vasc Med, V1, P65; Curb JD, 2006, J AM GERIATR SOC, V54, P737, DOI 10.1111/j.1532-5415.2006.00700.x; Fowkes FGR, 2008, JAMA-J AM MED ASSOC, V300, P197, DOI 10.1001/jama.300.2.197; GARDNER AW, 1995, JAMA-J AM MED ASSOC, V274, P975, DOI 10.1001/jama.274.12.975; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; Garg PK, 2006, CIRCULATION, V114, P242, DOI 10.1161/CIRCULATIONAHA.105.605246; Gokce N, 2002, CIRCULATION, V105, P1567, DOI 10.1161/01.CIR.0000012543.55874.47; Gottdiener JS, 2004, J AM SOC ECHOCARDIOG, V17, P1086, DOI 10.1016/j.echo.2004.07.013; GREIG C, 1993, J AM GERIATR SOC, V41, P15, DOI 10.1111/j.1532-5415.1993.tb05941.x; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; Harel O, 2007, STAT MED, V26, P3057, DOI 10.1002/sim.2787; HARRIS LM, 1995, AM J CARDIOL, V76, P207, DOI 10.1016/S0002-9149(99)80066-6; HIATT WR, 1994, CIRCULATION, V90, P1866, DOI 10.1161/01.CIR.90.4.1866; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; Hirsch AT, 2001, JAMA-J AM MED ASSOC, V286, P1317, DOI 10.1001/jama.286.11.1317; Hollander M., 1973, NONPARAMETRIC STAT M; McDermott MM, 2008, J VASC SURG, V48, P1231, DOI 10.1016/j.jvs.2008.06.050; McDermott MM, 2008, J AM GERIATR SOC, V56, P724, DOI 10.1111/j.1532-5415.2008.01633.x; McDermott MM, 2007, J AM COLL CARDIOL, V50, P974, DOI 10.1016/j.jacc.2007.05.030; McDermott MM, 2007, J AM GERIATR SOC, V55, P400, DOI 10.1111/j.1532-5415.2007.01092.x; McDermott MM, 2000, J VASC SURG, V32, P1164, DOI 10.1067/mva.2000.108640; McDermott MM, 2000, CIRCULATION, V101, P1007, DOI 10.1161/01.CIR.101.9.1007; McDermott MM, 2002, ANN INTERN MED, V136, P873, DOI 10.7326/0003-4819-136-12-200206180-00008; McDermott MM, 2001, JAMA-J AM MED ASSOC, V286, P1599; McDermott MM, 2001, J AM GERIATR SOC, V49, P747, DOI 10.1046/j.1532-5415.2001.49151.x; McDermott MM, 2000, ANGIOLOGY, V51, P91, DOI 10.1177/000331970005100201; McDermott MM, 2004, JAMA-J AM MED ASSOC, V292, P453, DOI 10.1001/jama.292.4.453; MCDERMOTT MM, J VASC SURG IN PRESS; McGuigan MRM, 2001, J GERONTOL A-BIOL, V56, pB302, DOI 10.1093/gerona/56.7.B302; Montgomery PS, 1998, J AM GERIATR SOC, V46, P706, DOI 10.1111/j.1532-5415.1998.tb03804.x; NOBLE BJ, 1982, MED SCI SPORT EXER, V14, P406; OURIEL K, 1982, ARCH SURG-CHICAGO, V117, P1297; Peeters P, 1996, J GERONTOL A-BIOL, V51, pM147, DOI 10.1093/gerona/51A.4.M147; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Philpott A, 2007, ARTERIOSCL THROM VAS, V27, P2065, DOI 10.1161/ATVBAHA.107.149740; Raghunathan TE, 2004, ANNU REV PUBL HEALTH, V25, P99, DOI 10.1146/annurev.publhealth.25.102802.124410; Rantanen T, 1999, J GERONTOL A-BIOL, V54, pM172, DOI 10.1093/gerona/54.4.M172; Regensteiner JG, 1990, J VASC MED BIOL, V2, P142; Rucker-Whitaker C, 2004, J AM GERIATR SOC, V52, P922, DOI 10.1111/j.1532-5415.2004.52259.x; Shadman R, 2004, J AM COLL CARDIOL, V44, P618, DOI 10.1016/j.jacc.2004.04.044; SWERTS PMJ, 1990, PHYS THER, V70, P439, DOI 10.1093/ptj/70.7.439; Wang JC, 2005, CIRCULATION, V112, P3501, DOI 10.1161/CIRCULATIONAHA.105.548099; Ware J.E., 1993, SF 36 HLTH SURVEY MA; YAO ST, 1969, BRIT J SURG, V56, P676, DOI 10.1002/bjs.1800560910	49	284	292	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	2009	301	2					165	174		10.1001/jama.2008.962	http://dx.doi.org/10.1001/jama.2008.962			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	393VV	19141764	Green Accepted, Bronze			2023-01-03	WOS:000262405500018
J	Agopian, A; Gros, E; Aldrian-Herrada, G; Bosquet, N; Clayette, P; Divita, G				Agopian, Audrey; Gros, Edwige; Aldrian-Herrada, Gudrun; Bosquet, Nathalie; Clayette, Pascal; Divita, Gilles			A New Generation of Peptide-based Inhibitors Targeting HIV-1 Reverse Transcriptase Conformational Flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANGSTROM RESOLUTION; SYNTHETIC PEPTIDES; CRYSTAL-STRUCTURE; DNA-SYNTHESIS; PRIMER GRIP; DIMERIZATION; SUBUNIT; P66; TEMPLATE	The biologically active form of human immunodeficiency virus (HIV) type 1 reverse transcriptase (RT) is a heterodimer. The formation of RT is a two-step mechanism, including a rapid protein-protein interaction "the dimerization step,"followed by conformational changes "the maturation step,"yielding the biologically active form of the enzyme. We have previously proposed that the heterodimeric organization of RT constitutes an interesting target for the design of new inhibitors. Here, we propose a new class of RT inhibitors that targets protein-protein interactions and conformational changes involved in the maturation of heterodimeric reverse transcriptase. Based on a screen of peptides derived from the thumb domain of this enzyme, we have identified a short peptide PAW that inhibits the maturation step and blocks viral replication at subnano-molar concentrations. PAW only binds dimeric RT and stabilizes it in an inactive/non-processive conformation. From a mechanistic point of view, PAW prevents proper binding of primer/template by affecting the structural dynamics of the thumb/fingers of p66 subunit. Taken together, these results demonstrate that HIV-1 RT maturation constitutes an attractive target for AIDS chemotherapeutics.	[Agopian, Audrey; Gros, Edwige; Aldrian-Herrada, Gudrun; Divita, Gilles] UM1, UM2, CNRS,UMR 5237, Dept Mol Biophys & Therapeut,Ctr Rech Biochim Mac, F-34293 Montpellier, France; [Bosquet, Nathalie; Clayette, Pascal] SPI BIO Commissariat Energie Atom, F-9226 Fontenay Aux Roses, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; CEA; UDICE-French Research Universities; Universite Paris Saclay	Divita, G (corresponding author), UM1, UM2, CNRS,UMR 5237, Dept Mol Biophys & Therapeut,Ctr Rech Biochim Mac, 1919 Route Mende, F-34293 Montpellier, France.	gilles.divita@crbm.cnrs.fr	DIVITA, GILLES/AAV-9214-2021	Aldrian, Gudrun/0000-0002-7899-0572	CNRS; Agence Nationale de Recherche sur le SIDA and SIDACTION; Targeting Replication and Integration of HIV HIV; European Community [LSHB-CT-2003-503480]	CNRS(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de Recherche sur le SIDA and SIDACTION(ANRS); Targeting Replication and Integration of HIV HIV; European Community(European Commission)	This work was supported in part by the CNRS and by a grant from the Agence Nationale de Recherche sur le SIDA and SIDACTION. This work is part of the program "Targeting Replication and Integration of HIV HIV" supported by the European Community (EC, Grant LSHB-CT-2003-503480).	Agopian A, 2007, J MOL BIOL, V373, P127, DOI 10.1016/j.jmb.2007.07.044; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BECERRA SP, 1991, BIOCHEMISTRY-US, V30, P11707, DOI 10.1021/bi00114a015; Cabodevilla JF, 2001, EUR J BIOCHEM, V268, P1163, DOI 10.1046/j.1432-1327.2001.01939.x; Camarasa MJ, 2006, ANTIVIR RES, V71, P260, DOI 10.1016/j.antiviral.2006.05.021; De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424; Depollier J, 2005, BIOCHEMISTRY-US, V44, P1909, DOI 10.1021/bi0484264; DIVITA G, 1993, BIOCHEMISTRY-US, V32, P7966, DOI 10.1021/bi00082a018; DIVITA G, 1994, J BIOL CHEM, V269, P13080; Divita G, 1995, BIOCHEMISTRY-US, V34, P16337, DOI 10.1021/bi00050a014; DIVITA G, 1995, J MOL BIOL, V245, P508, DOI 10.1006/jmbi.1994.0042; DIVITA G, 1995, J BIOL CHEM, V270, P28642, DOI 10.1074/jbc.270.48.28642; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Figueiredo A, 2006, PLOS PATHOG, V2, P1051, DOI 10.1371/journal.ppat.0020119; Fisher TS, 2003, J MOL BIOL, V325, P443, DOI 10.1016/S0022-2836(02)01225-1; Fisher TS, 2002, J BIOL CHEM, V277, P22345, DOI 10.1074/jbc.M200282200; Ghosh M, 1996, BIOCHEMISTRY-US, V35, P8553, DOI 10.1021/bi952773j; Gros E, 2006, BBA-BIOMEMBRANES, V1758, P384, DOI 10.1016/j.bbamem.2006.02.006; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUANG SC, 1992, BIOCHEM BIOPH RES CO, V184, P986, DOI 10.1016/0006-291X(92)90688-H; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; Karber G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI DOI 10.1007/BF01863914; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; Morris MC, 2001, NAT BIOTECHNOL, V19, P1173, DOI 10.1038/nbt1201-1173; Morris MC, 1999, J BIOL CHEM, V274, P24941, DOI 10.1074/jbc.274.35.24941; Morris MC, 1999, BIOCHEMISTRY-US, V38, P15097, DOI 10.1021/bi9914558; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mulky A, 2004, J VIROL, V78, P7089, DOI 10.1128/JVI.78.13.7089-7096.2004; MULLER B, 1989, J BIOL CHEM, V264, P13975; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; RESTLE T, 1990, J BIOL CHEM, V265, P8986; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; RODGERS DW, 1995, P NATL ACAD SCI USA, V92, P1222, DOI 10.1073/pnas.92.4.1222; Roisin A, 2004, J BIOL CHEM, V279, P9208, DOI 10.1074/jbc.M311594200; Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5; Sluis-Cremer N, 2002, MOL PHARMACOL, V62, P398, DOI 10.1124/mol.62.2.398; Sluis-Cremer N, 2002, EUR J BIOCHEM, V269, P5103, DOI 10.1046/j.1432-1033.2002.03216.x; Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964; Tachedjian G, 2005, FEBS LETT, V579, P379, DOI 10.1016/j.febslet.2004.11.099; Tachedjian G, 2001, P NATL ACAD SCI USA, V98, P7188, DOI 10.1073/pnas.121055998; Tachedjian Gilda, 2003, Curr Opin Investig Drugs, V4, P966; Venezia CF, 2006, BIOCHEMISTRY-US, V45, P2779, DOI 10.1021/bi051915z; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; WANG J, 1994, P NATL ACAD SCI USA, V91, P7242, DOI 10.1073/pnas.91.15.7242; Wohrl BM, 1997, J BIOL CHEM, V272, P17581, DOI 10.1074/jbc.272.28.17581	48	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	2009	284	1					254	264		10.1074/jbc.M802199200	http://dx.doi.org/10.1074/jbc.M802199200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387TP	18952602	Green Submitted, hybrid			2023-01-03	WOS:000261974800029
J	Gross, E; Busse, B; Riemenschneider, M; Neubauer, S; Seck, K; Klein, HG; Kiechle, M; Lordick, F; Meindl, A				Gross, Eva; Busse, Birgit; Riemenschneider, Matthias; Neubauer, Steffi; Seck, Katharina; Klein, Hanns-Georg; Kiechle, Marion; Lordick, Florian; Meindl, Alfons			Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients	PLOS ONE			English	Article							DPD DEFICIENCY; IVS14+1G-GREATER-THAN-A MUTATION; 5-FLUOROURACIL TOXICITY; BREAST-CANCER; PHARMACOGENETICS; IDENTIFICATION; CHEMOTHERAPY; CAPECITABINE; PHARMACOKINETICS; FLUOROURACIL	Background: Cancer patients carrying mutations in the dihydropyrimidine dehydrogenase gene (DPYD) have a high risk to experience severe drug-adverse effects following chemotherapy with fluoropyrimidine drugs such as 5-fluorouracil (5-FU) or capecitabine. The pretreatment detection of this impairment of pyrimidine catabolism could prevent serious, potentially lethal side effects. As known deleterious mutations explain only a limited proportion of the drug-adverse events, we systematically searched for additional DPYD variations associated with enhanced drug toxicity. Methodology/Principal Findings: We performed a whole gene approach covering the entire coding region and compared DPYD genotype frequencies between cancer patients with good (n = 89) and with poor ( n = 39) tolerance of a fluoropyrimidine-based chemotherapy regimen. Applying logistic regression analysis and sliding window approaches we identified the strongest association with fluoropyrimidine-related grade III and IV toxicity for the non-synonymous polymorphism c.496A>G (p.Met166Val). We then confirmed our initial results using an independent sample of 53 individuals suffering from drug-adverse-effects. The combined odds ratio calculated for 92 toxicity cases was 4.42 [95% CI 2.12-9.23]; p (trend)<0.001; p (corrected) = 0.001; the attributable risk was 56.9%. Comparing tumor-type matched sets of samples, correlation of c.496A>G with toxicity was particularly present in patients with gastroesophageal and breast cancer, but did not reach significance in patients with colorectal malignancies. Conclusion: Our results show compelling evidence that, at least in distinct tumor types, a common DPYD polymorphism strongly contributes to the occurrence of fluoropyrimidine-related drug adverse effects. Carriers of this variant could benefit from individual dose adjustment of the fluoropyrimidine drug or alternate therapies.	[Gross, Eva; Neubauer, Steffi; Seck, Katharina; Kiechle, Marion; Meindl, Alfons] Tech Univ Munich, Klinikum Rechts Isar, Dept Gynecol, D-8000 Munich, Germany; [Busse, Birgit; Klein, Hanns-Georg] Ctr Human Genet & Lab Med, Martinsried, Germany; [Riemenschneider, Matthias] Tech Univ Munich, Klinikum Rechts Isar, Dept Psych & Psychotherapy, Munich, Germany; [Lordick, Florian] Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany	Technical University of Munich; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg	Gross, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Gynecol, D-8000 Munich, Germany.	eva.gross@lrz.tum.de			Kommission fur klinische Forschung (KKF); Technischen Universitat Munchen [18-02]; Deutsche Krebshilfe e.V. [107352]; German National Genome Research Network (NGFN) [01GS0465]	Kommission fur klinische Forschung (KKF); Technischen Universitat Munchen; Deutsche Krebshilfe e.V.(Deutsche Krebshilfe); German National Genome Research Network (NGFN)	This work was supported by the Kommission fur klinische Forschung (KKF) der Technischen Universitat Munchen (No. 18-02), by the Deutsche Krebshilfe e.V. (DKH No. 107352) and by the German National Genome Research Network (NGFN) (No. 01GS0465). The funding organizations had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ajani J, 2006, CANCER-AM CANCER SOC, V107, P221, DOI 10.1002/cncr.21986; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENFREDJ R, 2008, PATHOL BIOL PAR 0710; Bosch Tessa M., 2008, V448, P63, DOI 10.1007/978-1-59745-205-2_5; Ciccolini J, 2006, THER DRUG MONIT, V28, P678, DOI 10.1097/01.ftd.0000245771.82720.c7; Cinieri S, 2007, ANN ONCOL, V18, P63, DOI 10.1093/annonc/mdm227; Collie-Duguid ESR, 2000, PHARMACOGENETICS, V10, P217, DOI 10.1097/00008571-200004000-00002; Di Paolo A, 2001, ANN ONCOL, V12, P1301, DOI 10.1023/A:1012294617392; Diasio R B, 2001, Oncology (Williston Park), V15, P21; Diasio RB, 2000, PHARMACOLOGY, V61, P199, DOI 10.1159/000028401; Dobritzsch D, 2001, EMBO J, V20, P650, DOI 10.1093/emboj/20.4.650; Goldberg RM, 2006, ONCOLOGIST, V11, P981, DOI 10.1634/theoncologist.11-9-981; Gross E, 2003, INT J ONCOL, V22, P325; Gross E, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9201; HEGGIE GD, 1987, CANCER RES, V47, P2203; Hormozian F, 2007, CANCER LETT, V246, P82, DOI 10.1016/j.canlet.2006.02.004; Johnson MR, 2002, CLIN CANCER RES, V8, P768; Largillier R, 2006, CLIN CANCER RES, V12, P5496, DOI 10.1158/1078-0432.CCR-06-0320; Lazar A, 2008, DEUT MED WOCHENSCHR, V133, P1501, DOI 10.1055/s-2008-1081098; Maekawa K, 2007, J HUM GENET, V52, P804, DOI 10.1007/s10038-007-0186-6; Magne N, 2007, BRIT J CLIN PHARMACO, V64, P237, DOI 10.1111/j.1365-2125.2007.02869.x; Mattison LK, 2004, CLIN CANCER RES, V10, P2652, DOI 10.1158/1078-0432.CCR-03-0374; Mattison LK, 2002, PHARMACOGENETICS, V12, P133, DOI 10.1097/00008571-200203000-00007; Mercier C, 2008, J CLIN ONCOL, V26; Morel A, 2006, MOL CANCER THER, V5, P2895, DOI 10.1158/1535-7163.MCT-06-0327; Ogura K, 2005, CLIN CANCER RES, V11, P5104, DOI 10.1158/1078-0432.CCR-05-0217; Reerink O, 2004, ANTICANCER RES, V24, P1969; Ridge SA, 1998, BRIT J CLIN PHARMACO, V46, P151, DOI 10.1046/j.1365-2125.1998.00751.x; Rivera F, 2007, CANCER TREAT REV, V33, P315, DOI 10.1016/j.ctrv.2007.01.004; Saif AW, 2006, CLIN COLORECTAL CANC, V5, P359, DOI 10.3816/CCC.2006.n.007; Salgueiro N, 2004, GENET MED, V6, P102, DOI 10.1097/01.GIM.0000118061.66602.A5; Scheithauer W, 2003, ANN ONCOL, V14, P1735, DOI 10.1093/annonc/mdg500; Schwab M, 2008, J CLIN ONCOL, V26, P2131, DOI 10.1200/JCO.2006.10.4182; Seck K, 2005, CLIN CANCER RES, V11, P5886, DOI 10.1158/1078-0432.CCR-04-1784; Sun Weijing, 2005, Curr Oncol Rep, V7, P181, DOI 10.1007/s11912-005-0071-4; van Kuilenburg ABP, 2004, EUR J CANCER, V40, P939, DOI 10.1016/j.ejca.2003.12.004; van Kuilenburg ABP, 2002, BIOCHEM J, V364, P157, DOI 10.1042/bj3640157; van Kuilenburg ABP, 2002, PHARMACOGENETICS, V12, P555, DOI 10.1097/00008571-200210000-00007; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P251; van Kuilenburg ABP, 2000, CLIN CANCER RES, V6, P4705; van Kuilenburg ABP, 2007, EUR J CANCER, V43, P459, DOI 10.1016/j.ejca.2006.09.017; Vreken P, 1997, HUM GENET, V101, P333, DOI 10.1007/s004390050637; YOKOTA H, 1994, J BIOL CHEM, V269, P23192; Zhang H, 2007, MED ONCOL, V24, P251, DOI 10.1007/BF02698048; Zhou ZW, 2007, CHEMOTHERAPY, V53, P127, DOI 10.1159/000099984	45	84	88	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2008	3	12							e4003	10.1371/journal.pone.0004003	http://dx.doi.org/10.1371/journal.pone.0004003			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437CB	19104657	gold, Green Published, Green Submitted			2023-01-03	WOS:000265462400004
J	Bernstein, AS; Ludwig, DS				Bernstein, Aaron S.; Ludwig, David S.			The Importance of Biodiversity to Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NATURAL-PRODUCTS; DISEASE; EMERGENCE; RISK		[Bernstein, Aaron S.; Ludwig, David S.] Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Bernstein, Aaron S.] Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Bernstein, AS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	aaron.bernstein@childrens.harvard.edu	Bernstein, Aaron/AAF-3522-2021	Bernstein, Aaron/0000-0003-1703-1041; Ludwig, David/0000-0003-3307-8544				Becker S, 2008, APPL MICROBIOL BIOT, V79, P1, DOI 10.1007/s00253-008-1385-6; Brashares JS, 2004, SCIENCE, V306, P1180, DOI 10.1126/science.1102425; Chivian E, 2008, SUSTAINING LIFE HUMA; Dancey JE, 2006, CANCER BIOL THER, V5, P1065, DOI 10.4161/cbt.5.9.3175; Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536; Klotz U, 2006, INT J CLIN PHARM TH, V44, P478; LoGiudice K, 2003, P NATL ACAD SCI USA, V100, P567, DOI 10.1073/pnas.0233733100; Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v; Oberlies NH, 2004, J NAT PROD, V67, P129, DOI 10.1021/np030498t; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; *PRACT GREENH, WAST RED; Shankar P, 2005, JAMA-J AM MED ASSOC, V293, P1367, DOI 10.1001/jama.293.11.1367; Taylor LH, 2001, PHILOS T R SOC B, V356, P983, DOI 10.1098/rstb.2001.0888; Wolfe ND, 2005, P NATL ACAD SCI USA, V102, P7994, DOI 10.1073/pnas.0501734102	14	11	11	4	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 19	2008	300	19					2297	2299		10.1001/jama.2008.655	http://dx.doi.org/10.1001/jama.2008.655			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	373IO	19017916				2023-01-03	WOS:000260965500030
J	Masip, J; Mebazaa, A; Filippatos, GS				Masip, Josep; Mebazaa, Alexandre; Filippatos, Gerasimos S.			Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							METAANALYSIS; PRESSURE		[Masip, Josep] Consorci Sanit Integral, Barcelona 08025, Spain; [Mebazaa, Alexandre] Univ Paris 07, F-75010 Paris, France; [Filippatos, Gerasimos S.] Univ Athens, Athens 12461, Greece	UDICE-French Research Universities; Universite Paris Cite; National & Kapodistrian University of Athens	Masip, J (corresponding author), Consorci Sanit Integral, Barcelona 08025, Spain.		Nicholl, Jon/B-8257-2008; Filippatos, Gerasimos/ABA-4656-2021					Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Nieminen MS, 2005, EUR HEART J, V26, P384; Peter JV, 2006, LANCET, V367, P1155, DOI 10.1016/S0140-6736(06)68506-1; Plaisance P, 2007, EUR HEART J, V28, P2895, DOI 10.1093/eurheartj/ehm502; Winck JC, 2006, CRIT CARE, V10, DOI 10.1186/cc4905	5	16	16	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2008	359	19					2068	2069						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	368OW	18990784				2023-01-03	WOS:000260632700022
J	Hochman, M; Hochman, S; Bor, D; McCormick, D				Hochman, Michael; Hochman, Steven; Bor, David; McCormick, Danny			News media coverage of medication research - Reporting pharmaceutical company funding and use of generic medication names	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	New England Regional Meeting of the Society-General-Internal-Medicine	APR   14, 2008	Worcester, MA	Soc Gen Internal Med, New England Reg			CONFLICTS-OF-INTEREST; BIOMEDICAL-RESEARCH; DRUG NAMES; TRIALS; BRAND; SUBSTITUTION; ASSOCIATION; CONCLUSIONS; DISCLOSURE; JOURNALS	Context The news media are an important source of information about medical research for patients and even some physicians. Little is known about how frequently news articles report when medication research has received funding from pharmaceutical companies or how frequently news articles use generic vs brand medication names. Objectives To assess the reporting of pharmaceutical company funding and generic medication name use in news articles about medication studies and to determine the views of newspaper editors about these issues. Design, Setting, and Participants We reviewed US news articles from newspaper and online sources about all pharmaceutical company - funded medication studies published in the 5 most prominent general medical journals between April 1, 2004, and April 30, 2008. We also surveyed editors at the 100 most widely circulated newspapers in the United States. Main Outcome Measures The percentage of news articles indicating when studies have been pharmaceutical company - funded and the percentage that refer to medications by their generic vs brand names. Also the percentage of newspaper editors who indicate that their articles report pharmaceutical company funding; the percentage of editors who indicate that their articles refer to medications by generic names; and the percentage of newspapers with policies about these issues. Results Of the 306 news articles about medication research identified, 130 ( 42%; 95% confidence interval [ CI], 37%- 48%) did not report that the research had received company funding. Of the 277 of these articles reporting on medications with both generic and brand names, 186 ( 67%; 95% CI, 61%- 73%) referred to the study medications by their brand names in at least half of the medication references. Eighty-two of the 93 ( 88%) newspaper editors who responded to our survey reported that articles from their publications always or often indicated when studies had received company funding ( 95% CI, 80%- 94%), and 71 of 92 ( 77%) responding editors also reported that articles from their publications always or often referred to medications by the generic names ( 95% CI, 67%- 85%). However, only 3 of 92 newspapers ( 3%) had written policies stating that company funding sources of medical studies be reported ( 95% CI 1%- 9%), and 2 of 93 ( 2%) newspapers had written policies stating that medications should be referred to by their generic names ( 95% CI 1%- 8%). Conclusion News articles reporting on medication studies often fail to report pharmaceutical company funding and frequently refer to medications by their brand names despite newspaper editors' contention that this is not the case.	[Hochman, Michael; Bor, David; McCormick, Danny] Cambridge Hlth Alliance, Dept Med, Cambridge, MA USA; [Hochman, Michael; Bor, David; McCormick, Danny] Harvard Univ, Sch Med, Cambridge, MA 02138 USA; [Hochman, Steven] Pomona Coll, Claremont, CA 91711 USA	Harvard University; Cambridge Health Alliance; Harvard University; Claremont Colleges; Pomona College	Hochman, M (corresponding author), Cambridge Hosp, Dept Med, 1493 Cambridge St, Cambridge, MA 02139 USA.	miehochman@challiance.org						Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; American Society of Hospital Pharmacists, 1993, AM J HOSP PHARM, V50, P305; Ancker JS, 2007, SCI ENG ETHICS, V13, P147, DOI 10.1007/s11948-007-9011-z; *ASS HLTH CAR JOUR, STAT PRINC; *AUD BUR CIRC, 2006, FAS FAX REP MAJ US N; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bromley J, 2006, MED J AUSTRALIA, V185, P687, DOI 10.5694/j.1326-5377.2006.tb00767.x; Cassels A, 2003, CAN MED ASSOC J, V168, P1133; Caulfield T, 2004, PLOS MED, V1, P178, DOI 10.1371/journal.pmed.0010038; Cooper RJ, 2006, J GEN INTERN MED, V21, P1248, DOI 10.1111/j.1525-1497.2006.00598.x; DeAngelis CD, 2008, JAMA-J AM MED ASSOC, V299, P1833, DOI 10.1001/jama.299.15.1833; DeAngelis CD, 2001, JAMA-J AM MED ASSOC, V286, P89, DOI 10.1001/jama.286.1.89; Gundersen L, 1998, ANN INTERN MED, V129, P677, DOI 10.7326/0003-4819-129-8-199810150-00042; Haas JS, 2005, ANN INTERN MED, V142, P891, DOI 10.7326/0003-4819-142-11-200506070-00006; HENRY J, 2001, PRESCRIPTION DRUG TR; Hesse BW, 2005, ARCH INTERN MED, V165, P2618, DOI 10.1001/archinte.165.22.2618; *I SAF MED PRACT, 2003, DRAFT GUID SAF EL CO, V8; *INT COMM MED J ED, 2007, UN REQ MAN SUBM BIOM; Kjaergard LL, 2002, BMJ-BRIT MED J, V325, P249, DOI 10.1136/bmj.325.7358.249; *LEAD DIR INC, 2007, NEWS MED YELL BOOK; Li M, 2008, HEALTH EDUC RES, V23, P543, DOI 10.1093/her/cym028; LIEBERMAN T, 2005, COLUMBIA JOURNAL JUL; Mott DA, 2002, MED CARE, V40, P662, DOI 10.1097/00005650-200208000-00006; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; *NAT I HLTH CAR MA, 2002, PRIM GEN DRUGS PAT P; PARKER WA, 1983, AM J HOSP PHARM, V40, P38, DOI 10.1093/ajhp/40.1.38; Ridker PM, 2006, JAMA-J AM MED ASSOC, V295, P2270, DOI 10.1001/jama.295.19.2270; Schwab M, 2002, ARCH INTERN MED, V162, P1065, DOI 10.1001/archinte.162.9.1065; Schwartz RS, 2008, NEW ENGL J MED, V358, P1850, DOI 10.1056/NEJMe0802618; Schwitzer G, 2008, PLOS MED, V5, P700, DOI 10.1371/journal.pmed.0050095; Sharma V, 2003, ARCH PEDIAT ADOL MED, V157, P257, DOI 10.1001/archpedi.157.3.257; Steinman MA, 2007, J GEN INTERN MED, V22, P645, DOI 10.1007/s11606-006-0074-3; Woloshin S, 2002, JAMA-J AM MED ASSOC, V287, P2856, DOI 10.1001/jama.287.21.2856; 2006, NATL J CITATION REPO	34	36	36	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 1	2008	300	13					1544	1550		10.1001/jama.300.13.1544	http://dx.doi.org/10.1001/jama.300.13.1544			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	354CY	18827211				2023-01-03	WOS:000259617700018
J	Blanco, YC; Farias, AS; Goelnitz, U; Lopes, SCP; Arrais-Silva, WW; Carvalho, BO; Amino, R; Wunderlich, G; Santos, LMB; Giorgio, S; Costa, FTM				Blanco, Yara C.; Farias, Alessandro S.; Goelnitz, Uta; Lopes, Stefanie C. P.; Arrais-Silva, Wagner W.; Carvalho, Bruna O.; Amino, Rogerio; Wunderlich, Gerhard; Santos, Leonilda M. B.; Giorgio, Selma; Costa, Fabio T. M.			Hyperbaric Oxygen Prevents Early Death Caused by Experimental Cerebral Malaria	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; SEVERE FALCIPARUM-MALARIA; T-CELLS; INTERFERON-GAMMA; BRAIN TRAUMA; ISCHEMIA; CYTOKINES; EXPRESSION; PRESSURE; THERAPY	Background: Cerebral malaria (CM) is a syndrome characterized by neurological signs, seizures and coma. Despite the fact that CM presents similarities with cerebral stroke, few studies have focused on new supportive therapies for the disease. Hyperbaric oxygen (HBO) therapy has been successfully used in patients with numerous brain disorders such as stroke, migraine and atherosclerosis. Methodology/Principal Findings: C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) were exposed to daily doses of HBO (100% O-2, 3.0 ATA, 1-2 h per day) in conditions well-tolerated by humans and animals, before or after parasite establishment. Cumulative survival analyses demonstrated that HBO therapy protected 50% of PbA-infected mice and delayed CM-specific neurological signs when administrated after patent parasitemia. Pressurized oxygen therapy reduced peripheral parasitemia, expression of TNF-alpha, IFN-gamma and IL-10 mRNA levels and percentage of gamma delta and alpha beta CD4(+) and CD8(+) T lymphocytes sequestered in mice brains, thus resulting in a reduction of blood-brain barrier (BBB)dysfunction and hypothermia. Conclusions/Significance: The data presented here is the first indication that HBO treatment could be used as supportive therapy, perhaps in association with neuroprotective drugs, to prevent CM clinical outcomes, including death.	[Blanco, Yara C.; Farias, Alessandro S.; Lopes, Stefanie C. P.; Carvalho, Bruna O.; Santos, Leonilda M. B.; Costa, Fabio T. M.] State Univ Campinas UNICAMP, Dept Microbiol & Immunol, Campinas, SP, Brazil; [Blanco, Yara C.; Lopes, Stefanie C. P.; Arrais-Silva, Wagner W.; Carvalho, Bruna O.; Giorgio, Selma; Costa, Fabio T. M.] State Univ Campinas UNICAMP, Dept Parasitol, Sao Paulo, Brazil; [Goelnitz, Uta; Wunderlich, Gerhard] Univ Sao Paulo, Dept Parasitol ICB, Sao Paulo, Brazil; [Amino, Rogerio] Fed Univ Sao Paulo UNIFESP, Dept Biochem, Sao Paulo, Brazil	Universidade Estadual de Campinas; Universidade Estadual de Campinas; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Blanco, YC (corresponding author), State Univ Campinas UNICAMP, Dept Microbiol & Immunol, Campinas, SP, Brazil.	costaftm@unicamp.br	Costa, Fabio/E-1181-2012; Wunderlich, Gerhard/G-8245-2012; Farias, Alessandro/AAH-2228-2020; Giorgio, Selma/A-6701-2013; Farias, Alessandro/C-6879-2012; Lopes, Stefanie/A-8314-2012	Costa, Fabio/0000-0001-9969-7300; Wunderlich, Gerhard/0000-0003-1724-0337; Farias, Alessandro/0000-0001-6759-1819; Farias, Alessandro/0000-0001-6759-1819; Lopes, Stefanie/0000-0002-6981-2192	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2004/00638-6]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant n 2004/00638-6, and from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). YCB, WWA, ASF and SCPL were supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and UG was sponsored by a FAPESP fellowship. GW, SG and FTMC are CNPq fellows.	Al-Waili NS, 2006, THESCIENTIFICWORLDJO, V6, P425, DOI 10.1100/tsw.2006.78; Al-Waili NS, 2005, ADV THER, V22, P659, DOI 10.1007/BF02849960; Arrais-Silva WW, 2006, ACTA TROP, V98, P130, DOI 10.1016/j.actatropica.2006.03.001; Arrais-Silva WW, 2005, PARASITOL INT, V54, P1, DOI 10.1016/j.parint.2004.07.002; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x; Buras JA, 2000, AM J PHYSIOL-CELL PH, V278, pC292, DOI 10.1152/ajpcell.2000.278.2.C292; Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9; Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x; Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016; DEKOSSODO S, 1993, J IMMUNOL, V151, P4811; Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103; GADD MA, 1990, CRIT CARE MED, V18, P974, DOI 10.1097/00003246-199009000-00014; Gillman BM, 2004, INFECT IMMUN, V72, P6359, DOI 10.1128/IAI.72.11.6359-6366.2004; Gramaglia I, 2006, NAT MED, V12, P1417, DOI 10.1038/nm1499; Granowitz EV, 2002, UNDERSEA HYPERBAR M, V29, P216; GUDEWICZ TM, 1987, AVIAT SPACE ENVIR MD, V58, P673; Hermsen CC, 1997, PARASITE IMMUNOL, V19, P571, DOI 10.1046/j.1365-3024.1997.d01-175.x; Hink J, 2001, MED HYPOTHESES, V57, P764, DOI 10.1054/mehy.2001.1488; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7; IRANI DN, 1991, J IMMUNOL METHODS, V139, P223, DOI 10.1016/0022-1759(91)90192-I; Jennings VM, 1997, INFECT IMMUN, V65, P4883, DOI 10.1128/IAI.65.11.4883-4887.1997; Jennings VM, 1998, INFECT IMMUN, V66, P5972, DOI 10.1128/IAI.66.12.5972-5979.1998; Kaide CG, 2008, EMERG MED CLIN N AM, V26, P571, DOI 10.1016/j.emc.2008.01.005; Kaiser K, 2006, J INFECT DIS, V193, P987, DOI 10.1086/500844; KAPP JP, 1981, SURG NEUROL, V15, P43, DOI 10.1016/S0090-3019(81)80089-4; Lahat N, 1995, CLIN EXP IMMUNOL, V102, P655; Lee CC, 2006, J BIOMED SCI, V13, P143, DOI 10.1007/s11373-005-9037-7; Li Y, 2005, EXP NEUROL, V191, P198, DOI 10.1016/j.expneurol.2004.08.036; Lou M, 2004, STROKE, V35, P578, DOI 10.1161/01.STR.0000111599.77426.A0; Medana IM, 1997, AM J PATHOL, V150, P1473; Medana IM, 2006, INT J PARASITOL, V36, P555, DOI 10.1016/j.ijpara.2006.02.004; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; NEWTON CRJC, 1994, ARCH DIS CHILD, V70, P281, DOI 10.1136/adc.70.4.281; Newton CRJC, 1996, PEDIATR NEUROL, V15, P41, DOI 10.1016/0887-8994(96)00115-4; Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013; Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221; Ohganli Y, 2008, BRAIN RES BULL, V75, P668, DOI 10.1016/j.brainresbull.2007.11.002; Ostrowski RP, 2005, J CEREBR BLOOD F MET, V25, P554, DOI 10.1038/sj.jcbfm.9600048; Overbergh L, 2003, J Biomol Tech, V14, P33; PARK MK, 1992, CLIN INFECT DIS, V14, P720, DOI 10.1093/clinids/14.3.720; Patankar TF, 2002, RADIOLOGY, V224, P811, DOI 10.1148/radiol.2243010588; Piguet PF, 2001, AM J PATHOL, V159, P733, DOI 10.1016/S0002-9440(10)61744-0; PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168; Prakash D, 2006, J INFECT DIS, V194, P198, DOI 10.1086/504720; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; RENCRICCA NJ, 1981, AVIAT SPACE ENVIR MD, V52, P85; Renia L, 2006, INT J PARASITOL, V36, P547, DOI 10.1016/j.ijpara.2006.02.007; Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403; Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403; Schabitz WR, 2004, STROKE, V35, P1175, DOI 10.1161/01.STR.0000125868.86298.8e; Sobolewski P, 2005, INFECT IMMUN, V73, P6704, DOI 10.1128/IAI.73.10.6704-6710.2005; Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986; Thackham JA, 2008, WOUND REPAIR REGEN, V16, P321, DOI 10.1111/j.1524-475X.2008.00372.x; Veltkamp R, 2005, BRAIN RES, V1037, P134, DOI 10.1016/j.brainres.2005.01.006; Veltkamp R, 2005, STROKE, V36, P1679, DOI 10.1161/01.STR.0000173408.94728.79; WARRELL DA, 1988, LANCET, V2, P534; Wassmer SC, 2005, PLOS MED, V2, P885, DOI 10.1371/journal.pmed.0020245; WHITE NJ, 1985, LANCET, V1, P776; Yang ZJ, 2001, EUR J APPL PHYSIOL, V85, P96, DOI 10.1007/s004210100391; Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55; Yin W, 2002, BRAIN RES, V926, P165, DOI 10.1016/S0006-8993(01)03304-2; Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53	64	24	25	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2008	3	9							e3126	10.1371/journal.pone.0003126	http://dx.doi.org/10.1371/journal.pone.0003126			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	422HU	18769544	Green Submitted, Green Published, gold			2023-01-03	WOS:000264419100001
J	Pagnoni, G; Cekic, M; Guo, Y				Pagnoni, Giuseppe; Cekic, Milos; Guo, Ying			"Thinking about Not-Thinking": Neural Correlates of Conceptual Processing during Zen Meditation	PLOS ONE			English	Article							EVENT-RELATED FMRI; DEFAULT MODE; PREFRONTAL CORTEX; RESTING-STATE; HUMAN BRAIN; BASE-LINE; WORD; SELF; INFORMATION; ATTENTION	Recent neuroimaging studies have identified a set of brain regions that are metabolically active during wakeful rest and consistently deactivate in a variety the performance of demanding tasks. This "default network'' has been functionally linked to the stream of thoughts occurring automatically in the absence of goal-directed activity and which constitutes an aspect of mental behavior specifically addressed by many meditative practices. Zen meditation, in particular, is traditionally associated with a mental state of full awareness but reduced conceptual content, to be attained via a disciplined regulation of attention and bodily posture. Using fMRI and a simplified meditative condition interspersed with a lexical decision task, we investigated the neural correlates of conceptual processing during meditation in regular Zen practitioners and matched control subjects. While behavioral performance did not differ between groups, Zen practitioners displayed a reduced duration of the neural response linked to conceptual processing in regions of the default network, suggesting that meditative training may foster the ability to control the automatic cascade of semantic associations triggered by a stimulus and, by extension, to voluntarily regulate the flow of spontaneous mentation.	[Pagnoni, Giuseppe] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA; [Cekic, Milos] Emory Univ, Sch Med, Atlanta, GA USA; [Guo, Ying] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA USA	Emory University; Emory University; Emory University; Rollins School Public Health	Pagnoni, G (corresponding author), Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.	gpagnon@emory.edu	Pagnoni, Giuseppe/F-3398-2015; Cekic, Milos/AAR-8250-2020	Pagnoni, Giuseppe/0000-0002-8272-8091; 	Emory Center for Research on Complementary and Alternative Medicine in Neurodegenerative Diseases, National Institute of Health [P30-AT00609]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P30AT000609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH079251] Funding Source: NIH RePORTER	Emory Center for Research on Complementary and Alternative Medicine in Neurodegenerative Diseases, National Institute of Health; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by the Emory Center for Research on Complementary and Alternative Medicine in Neurodegenerative Diseases (National Institute of Health Grant P30-AT00609).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aboitiz F, 1997, BRAIN RES REV, V25, P381, DOI 10.1016/S0165-0173(97)00053-2; ANTROBUS JS, 1968, BRIT J PSYCHOL, V59, P423, DOI 10.1111/j.2044-8295.1968.tb01157.x; Austin JamesH, 1998, ZEN BRAIN UNDERSTAND; Barinaga M, 2003, SCIENCE, V302, P44, DOI 10.1126/science.302.5642.44; Binder JR, 1999, J COGNITIVE NEUROSCI, V11, P80, DOI 10.1162/089892999563265; Binder JR, 2005, NEUROIMAGE, V27, P677, DOI 10.1016/j.neuroimage.2005.04.029; Binder JR, 2005, J COGNITIVE NEUROSCI, V17, P905, DOI 10.1162/0898929054021102; Binder JR, 2003, J COGNITIVE NEUROSCI, V15, P372, DOI 10.1162/089892903321593108; Binder JR, 2001, HDB FUNCTIONAL NEURO, P187; BINDER JR, 2008, EPILEPSIA; BREFCZYNSKILEWI.JA, 2007, P NATL ACAD SCI US; Brosschot JF, 2006, J PSYCHOSOM RES, V60, P113, DOI 10.1016/j.jpsychores.2005.06.074; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Buckner RL, 2007, TRENDS COGN SCI, V11, P49, DOI 10.1016/j.tics.2006.11.004; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Carter OL, 2005, CURR BIOL, V15, pR412, DOI 10.1016/j.cub.2005.05.043; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Chan D, 2007, J ALTERN COMPLEM MED, V13, P651, DOI 10.1089/acm.2007.7022; Clark D, 2003, NEUROPSYCHOLOGIA, V41, P304, DOI 10.1016/S0028-3932(02)00163-X; Clayton IC, 1999, J ABNORM PSYCHOL, V108, P171, DOI 10.1037/0021-843X.108.1.171; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Damasio H, 2004, COGNITION, V92, P179, DOI 10.1016/j.cognition.2002.07.001; Daselaar SM, 2004, NEUROIMAGE, V23, P921, DOI 10.1016/j.neuroimage.2004.07.031; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Fuster J., 2015, PREFRONTAL CORTEX, V5th; Fuster JM, 2001, NEURON, V30, P319, DOI 10.1016/S0896-6273(01)00285-9; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hasson U, 2007, CEREB CORTEX, V17, P2899, DOI 10.1093/cercor/bhm016; Hofmann Stefan G., 2007, Cognitive Behaviour Therapy, V36, P193, DOI 10.1080/16506070701421313; Humphries C, 2006, J COGNITIVE NEUROSCI, V18, P665, DOI 10.1162/jocn.2006.18.4.665; Humphries C, 2007, NEUROIMAGE, V36, P924, DOI 10.1016/j.neuroimage.2007.03.059; Kane MJ, 2007, PSYCHOL SCI, V18, P614, DOI 10.1111/j.1467-9280.2007.01948.x; Kim, 2004, EIHEI DOGEN MYSTICAL; Knight J, 2004, NATURE, V432, P670, DOI 10.1038/432670a; Lou HC, 2004, P NATL ACAD SCI USA, V101, P6827, DOI 10.1073/pnas.0400049101; Lutz A, 2008, TRENDS COGN SCI, V12, P163, DOI 10.1016/j.tics.2008.01.005; Ma SH, 2004, J CONSULT CLIN PSYCH, V72, P31, DOI 10.1037/0022-006X.72.1.31; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; McGuire PK, 1996, NEUROREPORT, V7, P2095; McKiernan KA, 2006, NEUROIMAGE, V29, P1185, DOI 10.1016/j.neuroimage.2005.09.030; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Nishitani, 1982, RELIG NOTHINGNESS; Pagnoni G, 2007, NEUROBIOL AGING, V28, P1623, DOI 10.1016/j.neurobiolaging.2007.06.008; Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Shulman GL, 1997, J COGNITIVE NEUROSCI, V9, P648, DOI 10.1162/jocn.1997.9.5.648; Siegle GJ, 2002, BIOL PSYCHIAT, V51, P693, DOI 10.1016/S0006-3223(02)01314-8; Slagter HA, 2007, PLOS BIOL, V5, P1228, DOI 10.1371/journal.pbio.0050138; Smallwood J, 2008, J COGNITIVE NEUROSCI, V20, P458, DOI 10.1162/jocn.2008.20.3.458; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Stark CEL, 2001, P NATL ACAD SCI USA, V98, P12760, DOI 10.1073/pnas.221462998; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037//0022-006X.68.4.615; TEASDALE JD, 1995, MEM COGNITION, V23, P551, DOI 10.3758/BF03197257; Vincent JL, 2006, J NEUROPHYSIOL, V96, P3517, DOI 10.1152/jn.00048.2006; Wicker B, 2003, BRAIN RES REV, V43, P224, DOI 10.1016/j.brainresrev.2003.08.003; Xiao ZW, 2005, HUM BRAIN MAPP, V25, P212, DOI 10.1002/hbm.20105	62	108	110	0	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2008	3	9							e3083	10.1371/journal.pone.0003083	http://dx.doi.org/10.1371/journal.pone.0003083			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	422HM	18769538	Green Published, Green Submitted, gold			2023-01-03	WOS:000264418300001
J	Gray, A; Goodacre, S; Newby, DE; Masson, M; Sampson, F; Nicholl, J				Gray, Alasdair; Goodacre, Steve; Newby, David E.; Masson, Moyra; Sampson, Fiona; Nicholl, Jon		3CPO Trialists	Noninvasive ventilation in acute cardiogenic pulmonary edema	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; ACUTE HEART-FAILURE; EMERGENCY-DEPARTMENT PATIENTS; ACUTE RESPIRATORY-FAILURE; MYOCARDIAL-INFARCTION; SUPPORT VENTILATION; RANDOMIZED-TRIAL; OXYGEN-THERAPY; METAANALYSIS; MORTALITY	Background: Noninvasive ventilation (continuous positive airway pressure [CPAP] or noninvasive intermittent positive-pressure ventilation [NIPPV]) appears to be of benefit in the immediate treatment of patients with acute cardiogenic pulmonary edema and may reduce mortality. We conducted a study to determine whether noninvasive ventilation reduces mortality and whether there are important differences in outcome associated with the method of treatment (CPAP or NIPPV). Methods: In a multicenter, open, prospective, randomized, controlled trial, patients were assigned to standard oxygen therapy, CPAP (5 to 15 cm of water), or NIPPV (inspiratory pressure, 8 to 20 cm of water; expiratory pressure, 4 to 10 cm of water). The primary end point for the comparison between noninvasive ventilation and standard oxygen therapy was death within 7 days after the initiation of treatment, and the primary end point for the comparison between NIPPV and CPAP was death or intubation within 7 days. Results: A total of 1069 patients (mean [+/-SD] age, 77.7+/-9.7 years; female sex, 56.9%) were assigned to standard oxygen therapy (367 patients), CPAP (346 patients), or NIPPV (356 patients). There was no significant difference in 7-day mortality between patients receiving standard oxygen therapy (9.8%) and those undergoing noninvasive ventilation (9.5%, P=0.87). There was no significant difference in the combined end point of death or intubation within 7 days between the two groups of patients undergoing noninvasive ventilation (11.7% for CPAP and 11.1% for NIPPV, P=0.81). As compared with standard oxygen therapy, noninvasive ventilation was associated with greater mean improvements at 1 hour after the beginning of treatment in patient-reported dyspnea (treatment difference, 0.7 on a visual-analogue scale ranging from 1 to 10; 95% confidence interval [CI], 0.2 to 1.3; P=0.008), heart rate (treatment difference, 4 beats per minute; 95% CI, 1 to 6; P=0.004), acidosis (treatment difference, pH 0.03; 95% CI, 0.02 to 0.04; P<0.001), and hypercapnia (treatment difference, 0.7 kPa [5.2 mm Hg]; 95% CI, 0.4 to 0.9; P<0.001). There were no treatment-related adverse events. Conclusions: In patients with acute cardiogenic pulmonary edema, noninvasive ventilation induces a more rapid improvement in respiratory distress and metabolic disturbance than does standard oxygen therapy but has no effect on short-term mortality. (Current Controlled Trials number, ISRCTN07448447.).	[Gray, Alasdair; Masson, Moyra] Royal Infirm Edinburgh NHS Trust, Dept Emergency Med, Edinburgh EH16 4SA, Midlothian, Scotland; [Goodacre, Steve; Sampson, Fiona; Nicholl, Jon] Univ Sheffield, Sheffield, S Yorkshire, England; [Newby, David E.] Univ Edinburgh, Edinburgh, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh; University of Sheffield; University of Edinburgh	Gray, A (corresponding author), Royal Infirm Edinburgh NHS Trust, Dept Emergency Med, Little France, Edinburgh EH16 4SA, Midlothian, Scotland.	alasdair.gray@luht.scot.nhs.uk	Newby, David Ernest/AAB-1364-2019; Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784; Goodacre, Steve/0000-0003-0803-8444; Sampson, Fiona/0000-0003-2321-0302; Walter, Darren/0000-0002-0819-3287				Adams KF, 2005, AM HEART J, V149, P209, DOI 10.1016/j.ahj.2004.08.005; Agarwal R, 2005, POSTGRAD MED J, V81, P637, DOI 10.1136/pgmj.2004.031229; American Heart Association, 2005, HEART DIS STROKE STA; BARATZ DM, 1992, CHEST, V102, P1397, DOI 10.1378/chest.102.5.1397; Baudouin S, 2002, THORAX, V57, P192; Bellone A, 2004, CRIT CARE MED, V32, P1860, DOI 10.1097/01.CCM.0000139694.47326.B6; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; Chadda K, 2002, CRIT CARE MED, V30, P2457, DOI 10.1097/00003246-200211000-00009; Collins SP, 2006, ANN EMERG MED, V48, P260, DOI 10.1016/j.annemergmed.2006.01.038; Crane SD, 2004, EMERG MED J, V21, P155, DOI 10.1136/emj.2003.005413; Felker GM, 2003, AM HEART J, V145, pS18, DOI 10.1067/mhj.2003.150; Flather MD, 1997, CONTROL CLIN TRIALS, V18, P568, DOI 10.1016/S0197-2456(97)00024-X; Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217; Girou E, 2003, JAMA-J AM MED ASSOC, V290, P2985, DOI 10.1001/jama.290.22.2985; Karras DJ, 2000, ACAD EMERG MED, V7, P327, DOI 10.1111/j.1553-2712.2000.tb02231.x; KATZ JA, 1985, ANESTHESIOLOGY, V63, P598, DOI 10.1097/00000542-198512000-00008; Kelly CA, 2002, EUR HEART J, V23, P1379, DOI 10.1053/euhj.2001.3156; L'Her E, 2004, INTENS CARE MED, V30, P882, DOI 10.1007/s00134-004-2183-y; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Lenique F, 1997, AM J RESP CRIT CARE, V155, P500, DOI 10.1164/ajrccm.155.2.9032185; Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; NAUGHTON MT, 1995, CIRCULATION, V91, P1725, DOI 10.1161/01.CIR.91.6.1725; Nava S, 2003, AM J RESP CRIT CARE, V168, P1432, DOI 10.1164/rccm.200211-1270OC; Nieminen MS, 2006, EUR HEART J, V27, P2725, DOI 10.1093/eurheartj/ehl193; Peter JV, 2006, LANCET, V367, P1155, DOI 10.1016/S0140-6736(06)68506-1; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; STEVENSON R, 1993, BRIT MED J, V307, P909; Tavazzi L, 2006, EUR HEART J, V27, P1207, DOI 10.1093/eurheartj/ehi845; Thygesen K, 2007, EUR HEART J, V28, P2525	31	388	424	3	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 10	2008	359	2					142	151		10.1056/NEJMoa0707992	http://dx.doi.org/10.1056/NEJMoa0707992			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	323PJ	18614781				2023-01-03	WOS:000257459000005
J	Hackbarth, G; Reischauer, R; Mutti, A				Hackbarth, Glenn; Reischauer, Robert; Mutti, Anne			Collective accountability for medical care - Toward bundled medicare payments	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hackbarth, Glenn; Reischauer, Robert; Mutti, Anne] Med PAC, Washington, DC USA; [Reischauer, Robert] Urban Inst, Washington, DC 20037 USA	Urban Institute	Hackbarth, G (corresponding author), Med PAC, Washington, DC USA.							Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; *PENNS HLTH CAR CO, 2006, PENNS GUID COR ART B; Stason W., 1998, MED PARTICIPATING HE	5	126	126	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 3	2008	359	1					3	5		10.1056/NEJMp0803749	http://dx.doi.org/10.1056/NEJMp0803749			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	320PB	18596270				2023-01-03	WOS:000257246000002
J	Peters, JH; Hilbrands, LB; Koenen, HJPM; Joosten, I				Peters, Jorieke H.; Hilbrands, Luuk B.; Koenen, Hans J. P. M.; Joosten, Irma			Ex Vivo Generation of Human Alloantigen-Specific Regulatory T Cells from CD4(pos)CD25(high) T Cells for Immunotherapy	PLOS ONE			English	Article								Background: Regulatory T cell (Treg) based immunotherapy is a potential treatment for several immune disorders. By now, this approach proved successful in preclinical animal transplantation and auto-immunity models. In these models the success of Treg based immunotherapy crucially depends on the antigen-specificity of the infused Treg population. For the human setting, information is lacking on how to generate Treg with direct antigen-specificity ex vivo to be used for immunotherapy. Methodology/Principal Findings: Here, we demonstrate that in as little as two stimulation cycles with HLA mismatched allogeneic stimulator cells and T cell growth factors a very high degree of alloantigen-specificity was reached in magnetic bead isolated human CD4(pos)CD25(high) Treg. Efficient increases in cell numbers were obtained. Primary allogeneic stimulation appeared a prerequisite in the generation of alloantigen-specific Treg, while secondary allogeneic or polyclonal stimulation with anti-CD3 plus anti-CD28 monoclonal antibodies enriched alloantigen-specificity and cell yield to a similar extent. Conclusions/Significance: The ex vivo expansion protocol that we describe will very likely increase the success of clinical Treg-based immunotherapy, and will help to induce tolerance to selected antigens, while minimizing general immune suppression. This approach is of particular interest for recipients of HLA mismatched transplants.	[Peters, Jorieke H.; Koenen, Hans J. P. M.; Joosten, Irma] Radboud Univ Nijmegen, Med Ctr, Dept Bloodtransfus & Transplantat Immunol, NL-6525 ED Nijmegen, Netherlands; [Hilbrands, Luuk B.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Nephrol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Peters, JH (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Bloodtransfus & Transplantat Immunol, NL-6525 ED Nijmegen, Netherlands.	I.Joosten@abti.umcn.nl	Koenen, Hans J.P.M./A-2852-2014; Hilbrands, Luuk/B-4921-2011; Joosten, Irma/N-4418-2013	Hilbrands, Luuk/0000-0002-4935-9765; Joosten, Irma/0000-0003-2950-4977	Dutch Kidney Foundation [C05-2106]	Dutch Kidney Foundation	This study was supported by a grant of the Dutch Kidney Foundation (C05-2106). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afzali B, 2007, TISSUE ANTIGENS, V69, P545, DOI 10.1111/j.1399-0039.2007.00834.x; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Bushell A, 2005, J IMMUNOL, V174, P3290, DOI 10.4049/jimmunol.174.6.3290; Coenen JJA, 2007, TRANSPL IMMUNOL, V17, P237, DOI 10.1016/j.trim.2007.01.004; Cohen JL, 2002, J EXP MED, V196, P401, DOI 10.1084/jem.20020090; Earle KE, 2005, CLIN IMMUNOL, V115, P3, DOI 10.1016/j.clim.2005.02.017; Edinger M, 2003, NAT MED, V9, P1144, DOI 10.1038/nm915; Fu S, 2004, AM J TRANSPLANT, V4, P65, DOI 10.1046/j.1600-6143.2003.00293.x; Godfrey WR, 2004, BLOOD, V104, P453, DOI 10.1182/blood-2004-01-0151; GOLSHAYAN D, 2006, BLOOD; Hoffmann P, 2002, J EXP MED, V196, P389, DOI 10.1084/jem.20020399; Hoffmann P, 2006, BIOL BLOOD MARROW TR, V12, P267, DOI 10.1016/j.bbmt.2006.01.005; Hoffmann P, 2004, BLOOD, V104, P895, DOI 10.1182/blood-2004-01-0086; Jiang SP, 2003, BLOOD, V102, P2180, DOI 10.1182/blood-2003-04-1164; Jin LP, 2004, J IMMUNOL, V173, P3612, DOI 10.4049/jimmunol.173.6.3612; Joffre O, 2004, BLOOD, V103, P4216, DOI 10.1182/blood-2004-01-0005; Jones SC, 2003, BIOL BLOOD MARROW TR, V9, P243, DOI 10.1053/bbmt.2003.50027; Karakhanova S, 2006, J IMMUNOTHER, V29, P336, DOI 10.1097/01.cji.0000203080.43235.9e; Koenen HJPM, 2005, J IMMUNOL, V174, P7573, DOI 10.4049/jimmunol.174.12.7573; Koenen HJPM, 2003, J IMMUNOL, V171, P6431, DOI 10.4049/jimmunol.171.12.6431; Koh LP, 2007, BIOL BLOOD MARROW TR, V13, P1249, DOI 10.1016/j.bbmt.2007.08.003; Kohm AP, 2002, J IMMUNOL, V169, P4712, DOI 10.4049/jimmunol.169.9.4712; KREIJVELD E, 2006, J IMMUNOL METHODS; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Masteller EL, 2005, J IMMUNOL, V175, P3053, DOI 10.4049/jimmunol.175.5.3053; Mottet C, 2003, J IMMUNOL, V170, P3939, DOI 10.4049/jimmunol.170.8.3939; Nishimura E, 2004, INT IMMUNOL, V16, P1189, DOI 10.1093/intimm/dxh122; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Taams LS, 2002, EUR J IMMUNOL, V32, P1621, DOI 10.1002/1521-4141(200206)32:6<1621::AID-IMMU1621>3.0.CO;2-Q; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Trenado A, 2003, J CLIN INVEST, V112, P1688, DOI 10.1172/JCI17702; WICHLAN DG, 2006, J IMMUNOL METHODS; Yamazaki S, 2006, P NATL ACAD SCI USA, V103, P2758, DOI 10.1073/pnas.0510606103	37	71	78	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2008	3	5							e2233	10.1371/journal.pone.0002233	http://dx.doi.org/10.1371/journal.pone.0002233			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	391UK	18493605	gold, Green Published, Green Submitted			2023-01-03	WOS:000262258700041
J	McQuay, H				McQuay, Henry			Making a difference - Management of chronic pain - Help and hope at the bottom of the pile	BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE; IMPACT		[McQuay, Henry] The Churchill, Pain Relief Unit, Oxford OX3 7LJ, England; [McQuay, Henry] Univ Oxford, Nuffield Dept Anaesthet, Oxford OX1 2JD, England	University of Oxford; University of Oxford	McQuay, H (corresponding author), The Churchill, Pain Relief Unit, Oxford OX3 7LJ, England.	henry.mcquay@pru.ox.ac.uk						Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Katz WA, 2002, CLIN RHEUMATOL, V21, pS2, DOI 10.1007/s100670200028; Kemler MA, 2002, J PAIN SYMPTOM MANAG, V23, P433, DOI 10.1016/S0885-3924(02)00386-X; Lachaine J, 2007, PAIN RES MANAG, V12, P31, DOI 10.1155/2007/713835; Maniadakis N, 2000, PAIN, V84, P95, DOI 10.1016/S0304-3959(99)00187-6; McQuay HJ, 2007, HLTH CARE NEEDS ASSE, P519; Sprangers MAG, 2000, J CLIN EPIDEMIOL, V53, P895, DOI 10.1016/S0895-4356(00)00204-3	7	9	9	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					954	+		10.1136/bmj.39520.699190.94	http://dx.doi.org/10.1136/bmj.39520.699190.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397945	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000255540900041
J	Hoeft, F; Wu, DA; Hernandez, A; Glover, GH; Shimojo, S				Hoeft, Fumiko; Wu, Daw-An; Hernandez, Arvel; Glover, Gary H.; Shimojo, Shinsuke			Electronically Switchable Sham Transcranial Magnetic Stimulation (TMS) System	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; CURRENT DIRECTIONS; COIL ORIENTATION; WAVE-FORM; BRAIN; THRESHOLDS; ACTIVATION; DISEASE; FIBER; PULSE	Transcranial magnetic stimulation (TMS) is increasingly being used to demonstrate the causal links between brain and behavior in humans. Further, extensive clinical trials are being conducted to investigate the therapeutic role of TMS in disorders such as depression. Because TMS causes strong peripheral effects such as auditory clicks and muscle twitches, experimental artifacts such as subject bias and placebo effect are clear concerns. Several sham TMS methods have been developed, but none of the techniques allows one to intermix real and sham TMS on a trial-by-trial basis in a double-blind manner. We have developed an attachment that allows fast, automated switching between Standard TMS and two types of control TMS (Sham and Reverse) without movement of the coil or reconfiguration of the setup. We validate the setup by performing mathematical modeling, search-coil and physiological measurements. To see if the stimulus conditions can be blinded, we conduct perceptual discrimination and sensory perception studies. We verify that the physical properties of the stimulus are appropriate, and that successive stimuli do not contaminate each other. We find that the threshold for motor activation is significantly higher for Reversed than for Standard stimulation, and that Sham stimulation entirely fails to activate muscle potentials. Subjects and experimenters perform poorly at discriminating between Sham and Standard TMS with a figure-of-eight coil, and between Reverse and Standard TMS with a circular coil. Our results raise the possibility of utilizing this technique for a wide range of applications.	[Hoeft, Fumiko; Hernandez, Arvel] Stanford Univ, Sch Med, Ctr Interdisciplinary Brain Sci Res, Palo Alto, CA 94304 USA; [Hoeft, Fumiko; Wu, Daw-An; Shimojo, Shinsuke] CALTECH, Computat & Neural Syst & Div Biol, Pasadena, CA USA; [Wu, Daw-An] Harvard Univ, Dept Psychol, Cambridge, MA USA; [Glover, Gary H.] Stanford Univ, Sch Med, Dept Radiol, Palo Alto, CA USA	Stanford University; California Institute of Technology; Harvard University; Stanford University	Hoeft, F (corresponding author), Stanford Univ, Sch Med, Ctr Interdisciplinary Brain Sci Res, Palo Alto, CA 94304 USA.			Wu, Daw-An/0000-0003-4296-3369; Hernandez, Arvel/0000-0001-7653-9318	National Science Foundation [BCS-0305276, BCS-0305866]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This study was funded by the National Science Foundation under BCS-0305276 and BCS-0305866. The sponsors did not play any role in the study besides providing funding.	AMASSIAN VE, 1992, ELECTROEN CLIN NEURO, V85, P291, DOI 10.1016/0168-5597(92)90105-K; BARKER AT, 1991, ELECTROEN CLIN NEURO, P227; BARKER AT, 1985, LANCET, V1, P1106; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Chen R, 2000, MUSCLE NERVE, pS26; Corthout E, 2001, EXP BRAIN RES, V141, P128, DOI 10.1007/s002210100860; George MS, 2006, TRANSCRANIAL MAGNETI; Green D. M., 1966, SIGNAL DETECTION THE; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hallett M., 2005, MAGNETIC STIMULATION, V2nd; HARRINGTON A, 2002, SCI PLACEBO; Hill AC, 2000, NEUROREPORT, V11, P3257, DOI 10.1097/00001756-200009280-00041; Ilmoniemi RJ, 1999, CRIT REV BIOMED ENG, V27, P241; Jackson J.D., 1998, CLASSICAL ELECTRODYN, VThird; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P2015, DOI 10.1016/S1388-2457(01)00673-3; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Kaptchuk TJ, 2000, ALTERN THER HEALTH M, V6, P18; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Lisanby Sarah H, 2004, BRAIN STIMULATION PS; Maeda F, 2003, PSYCHOPHARMACOLOGY, V168, P359, DOI 10.1007/s00213-002-1216-x; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Mulleners WM, 2002, EUR J NEUROL, V9, P35, DOI 10.1046/j.1468-1331.2002.00334.x; Okabe S, 2003, MOVEMENT DISORD, V18, P382, DOI 10.1002/mds.10370; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; PASCUALLEONE A, 1994, ELECTROEN CLIN NEURO, V93, P42, DOI 10.1016/0168-5597(94)90090-6; Paus T, 2005, PHILOS T R SOC B, V360, P1109, DOI 10.1098/rstb.2005.1652; Robertson EM, 2003, J COGNITIVE NEUROSCI, V15, P948, DOI 10.1162/089892903770007344; ROTH BJ, 1990, IEEE T BIO-MED ENG, V37, P588, DOI 10.1109/10.55662; Ruohonen J, 2000, IEEE T BIO-MED ENG, V47, P145, DOI 10.1109/10.821731; Sakai K, 1997, EXP BRAIN RES, V113, P24, DOI 10.1007/BF02454139; Schatzberg AF, 2000, BIOL PSYCHIAT, V47, P736, DOI 10.1016/S0006-3223(00)00846-5; Vucic S, 2006, BRAIN, V129, P2436, DOI 10.1093/brain/awl172; Walsh V, 2005, TRANSCRANIAL MAGNETI; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8	35	19	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1923	10.1371/journal.pone.0001923	http://dx.doi.org/10.1371/journal.pone.0001923			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398456	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000260795500007
J	Scott, RC; Rosano, JM; Ivanov, Z; Wang, B; Chong, PLG; Issekutz, AC; Crabbe, DL; Kiani, MF				Scott, Robert C.; Rosano, Jenna M.; Ivanov, Zhanna; Wang, Bin; Chong, Parkson Lee-Gau; Issekutz, Andrew C.; Crabbe, Deborah L.; Kiani, Mohammad F.			Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function	FASEB JOURNAL			English	Article						adhesion molecules; liposomes; microenvironment; targeted drug delivery	ENDOTHELIAL GROWTH-FACTOR; STEM-CELL TRANSPLANTATION; P-SELECTIN; THERAPEUTIC ANGIOGENESIS; MYOCARDIAL-INFARCTION; DRUG CARRIERS; DELIVERY; ISCHEMIA; REPAIR; GENE	Recent attempts at rebuilding the myocardium using stem cells have yielded disappointing results. The lack of a supporting vasculature may, in part, explain these disappointing findings. However, concerns over possible side effects have hampered attempts at revascularizing the infarcted myocardium using systemic delivery of proangiogenic compounds. In this study, we develop the technology to enhance the morphology and function of postinfarct neovasculature. Previously, we have shown that the up-regulated expression of endothelial cell adhesion molecules in the myocardial infarction (MI) region provides a potential avenue for selectively targeting drugs to infarcted tissue. After treatment with anti-P-selectin-conjugated liposomes containing vascular endothelial growth factor ( VEGF), changes in cardiac function and vasculature post-MI were quantified in a rat MI model. Targeted delivery of VEGF to post-MI tissue resulted in significant increase in fractional shortening and improved systolic function. These functional improvements were accompanied by a 21% increase in the number of anatomical vessels and a 74% increase in the number of perfused vessels in the MI region of treated animals. No significant improvements in cardiac function were observed in untreated, systemic VEGF-treated, nontargeted liposome-treated, or blank immunoliposome-treated animals. Targeted delivery of low doses of proangiogenic compounds to post-MI tissue results in significant improvements in cardiac function and vascular structure.-Scott, R. C., Rosano, J. M., Ivanov, Z., Wang, B., Lee-Gau Chong, P., Issekutz, I. C., Crabbe, D. L., Kiani, M. F. Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J. 23, 3361-3367 ( 2009). www.fasebj.org	[Scott, Robert C.; Rosano, Jenna M.; Ivanov, Zhanna; Kiani, Mohammad F.] Temple Univ, Dept Mech Engn, Philadelphia, PA 19122 USA; [Kiani, Mohammad F.] Temple Univ, Dept Radiat Oncol, Philadelphia, PA 19122 USA; [Wang, Bin] Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; [Chong, Parkson Lee-Gau] Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA; [Crabbe, Deborah L.] Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19122 USA; [Issekutz, Andrew C.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University System of Georgia; Augusta University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Dalhousie University	Kiani, MF (corresponding author), Temple Univ, Dept Mech Engn, 1947 N 12th St, Philadelphia, PA 19122 USA.	mkiani@temple.edu	Chong, Parkson Lee-Gau/I-3297-2019	Crabbe, Deborah/0000-0003-0061-3985	The American Heart Association; Pennsylvania Department of Health; Nanotechnology Institiute	The American Heart Association(American Heart Association); Pennsylvania Department of Health; Nanotechnology Institiute	This work was supported by grants from The American Heart Association, the Pennsylvania Department of Health, and the Nanotechnology Institiute. The human VEGF<INF>165A</INF> was generously provided by Genentech, Inc. ( San Francisco, CA, USA).	Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chien K, 2006, SCIENTIST, V20, P34; Chukwuemeka AO, 2005, ANN THORAC SURG, V79, P204, DOI 10.1016/j.athoracsur.2004.06.105; Ehrhardt C, 2004, ADV DRUG DELIVER REV, V56, P527, DOI 10.1016/j.addr.2003.10.029; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; Fenton BM, 1999, BRIT J CANCER, V79, P464, DOI 10.1038/sj.bjc.6690072; Freedman SB, 2002, ANN INTERN MED, V136, P54, DOI 10.7326/0003-4819-136-1-200201010-00011; Freedman SB, 2001, J MOL CELL CARDIOL, V33, P379, DOI 10.1006/jmcc.2000.1329; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hiasa K, 2004, BASIC RES CARDIOL, V99, P165, DOI 10.1007/s00395-004-0456-9; Hughes GC, 2004, ANN THORAC SURG, V77, P812, DOI 10.1016/j.athoracsur.2003.09.060; Inoue M, 1998, CIRCULATION, V98, P2108, DOI 10.1161/01.CIR.98.20.2108; Jaakkola K, 2000, J AM COLL CARDIOL, V36, P122, DOI 10.1016/S0735-1097(00)00706-3; KIRBY C, 1984, BIO-TECHNOL, V2, P979, DOI 10.1038/nbt1184-979; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Lee RJ, 2000, CIRCULATION, V102, P898; LITWIN SE, 1994, CIRCULATION, V89, P345, DOI 10.1161/01.CIR.89.1.345; Lopez JJ, 1998, CARDIOVASC RES, V40, P272, DOI 10.1016/S0008-6363(98)00136-9; Matsumoto R, 2005, ARTERIOSCL THROM VAS, V25, P1168, DOI 10.1161/01.ATV.0000165696.25680.ce; Misao Y, 2006, CARDIOVASC RES, V71, P455, DOI 10.1016/j.cardiores.2006.05.002; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Palazzo AJ, 1998, AM J PHYSIOL-HEART C, V275, pH1865, DOI 10.1152/ajpheart.1998.275.5.H1865; PATILLO CB, 2007, THESIS TEMPLE U PHIL; Payne TR, 2007, J AM COLL CARDIOL, V50, P1677, DOI 10.1016/j.jacc.2007.04.100; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104; Saxena A, 2008, CIRCULATION, V117, P2224, DOI 10.1161/CIRCULATIONAHA.107.694992; Schwarz ER, 2000, J AM COLL CARDIOL, V35, P1323, DOI 10.1016/S0735-1097(00)00522-2; Scott RC, 2008, EXPERT OPIN DRUG DEL, V5, P459, DOI 10.1517/17425247.5.4.459 ; Scott RC, 2007, BIOTECHNOL BIOENG, V96, P795, DOI 10.1002/bit.21233; Ulbrich H, 2003, TRENDS PHARMACOL SCI, V24, P640, DOI 10.1016/j.tips.2003.10.004; Vertesaljai M, 2008, HEART FAIL REV, V13, P227, DOI 10.1007/s10741-007-9047-9; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; Walter UM, 1997, HYBRIDOMA, V16, P249, DOI 10.1089/hyb.1997.16.249; Wang B, 2005, AM J PHYSIOL-HEART C, V289, pH108, DOI 10.1152/ajpheart.00001.2005; WANG B, 2007, THESIS TEMPLE U PHIL; Wang B, 2008, ADV EXP MED BIOL, V614, P333, DOI 10.1007/978-0-387-74911-2_37; Wang B, 2007, AM J PHYSIOL-HEART C, V293, pH3732, DOI 10.1152/ajpheart.00735.2007; Wollert KC, 2008, CURR OPIN PHARMACOL, V8, P202, DOI 10.1016/j.coph.2007.12.011; Yoshioka T, 2005, STEM CELLS, V23, P355, DOI 10.1634/stemcells.2004-0200	41	99	109	2	28	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2009	23	10					3361	3367		10.1096/fj.08-127373	http://dx.doi.org/10.1096/fj.08-127373			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	501BQ	19535683				2023-01-03	WOS:000270354300013
J	Scarmeas, N; Luchsinger, JA; Schupf, N; Brickman, AM; Cosentino, S; Tang, MX; Stern, Y				Scarmeas, Nikolaos; Luchsinger, Jose A.; Schupf, Nicole; Brickman, Adam M.; Cosentino, Stephanie; Tang, Ming X.; Stern, Yaakov			Physical Activity, Diet, and Risk of Alzheimer Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDITERRANEAN DIET; GROWTH-FACTOR; COGNITIVE IMPAIRMENT; LEISURE ACTIVITIES; OLDER-ADULTS; LATE-LIFE; DEMENTIA; EXERCISE; BRAIN; POPULATION	Context Both higher adherence to a Mediterranean-type diet and more physical activity have been independently associated with lower Alzheimer disease ( AD) risk but their combined association has not been investigated. Objective To investigate the combined association of diet and physical activity with AD risk. Design, Setting, and Patients Prospective cohort study of 2 cohorts comprising 1880 community-dwelling elders without dementia living in New York, New York, with both diet and physical activity information available. Standardized neurological and neuropsychological measures were administered approximately every 1.5 years from 1992 through 2006. Adherence to a Mediterranean-type diet (scale of 0-9; trichotomized into low, middle, or high; and dichotomized into low or high) and physical activity (sum of weekly participation in various physical activities, weighted by the type of physical activity [light, moderate, vigorous]; trichotomized into no physical activity, some, or much; and dichotomized into low or high), separately and combined, were the main predictors in Cox models. Models were adjusted for cohort, age, sex, ethnicity, education, apolipoprotein E genotype, caloric intake, body mass index, smoking status, depression, leisure activities, a comorbidity index, and baseline Clinical Dementia Rating score. Main Outcome Measure Time to incident AD. Results A total of 282 incident AD cases occurred during a mean (SD) of 5.4 (3.3) years of follow-up. When considered simultaneously, both Mediterranean-type diet adherence (compared with low diet score, hazard ratio [HR] for middle diet score was 0.98 [95% confidence interval {CI}, 0.72-1.33]; the HR for high diet score was 0.60 [95% CI, 0.42-0.87]; P=.008 for trend) and physical activity (compared with no physical activity, the HR for some physical activity was 0.75 [95% CI, 0.54-1.04]; the HR for much physical activity was 0.67 [95% CI, 0.47-0.95]; P=.03 for trend) were associated with lower AD risk. Compared with individuals neither adhering to the diet nor participating in physical activity (low diet score and no physical activity; absolute AD risk of 19%), those both adhering to the diet and participating in physical activity (high diet score and high physical activity) had a lower risk of AD (absolute risk, 12%; HR, 0.65 [95% CI, 0.44-0.96]; P=.03 for trend). Conclusion In this study, both higher Mediterranean-type diet adherence and higher physical activity were independently associated with reduced risk for AD. JAMA. 2009; 302(6):627-637 www.jama.com	[Scarmeas, Nikolaos; Luchsinger, Jose A.; Schupf, Nicole; Brickman, Adam M.; Cosentino, Stephanie; Stern, Yaakov] Columbia Univ, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Scarmeas, Nikolaos; Schupf, Nicole; Brickman, Adam M.; Cosentino, Stephanie; Tang, Ming X.; Stern, Yaakov] Columbia Univ, Med Ctr, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Scarmeas, Nikolaos; Brickman, Adam M.; Cosentino, Stephanie; Stern, Yaakov] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA; [Luchsinger, Jose A.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Scarmeas, N (corresponding author), Columbia Univ, Med Ctr, Taub Inst Res Alzheimers Dis & Aging Brain, 622 W 168th St,19th Floor, New York, NY 10032 USA.	ns257@columbia.edu	Scarmeas, Nikolaos/AAD-2512-2020; Scarmeas, Nikolaos/AAD-2517-2020	Scarmeas, Nikolaos/0000-0001-6453-8908; Scarmeas, Nikolaos/0000-0001-6453-8908; Stern, Yaakov/0000-0001-7542-3241; Luchsinger, Jose/0000-0002-5886-3648	National Institute on Aging [AG028506, P01AG07232]; NATIONAL INSTITUTE ON AGING [P50AG008702, R01AG037212, R01AG028506, P01AG007232] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The study was supported by National Institute on Aging grants AG028506 and P01AG07232.	Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BLOMSTRAND E, 1989, ACTA PHYSIOL SCAND, V136, P473, DOI 10.1111/j.1748-1716.1989.tb08689.x; Borst SE, 2002, J AM GERIATR SOC, V50, P884, DOI 10.1046/j.1532-5415.2002.50215.x; Botto LD, 2001, AM J EPIDEMIOL, V153, P1016, DOI 10.1093/aje/153.10.1016; Carro E, 2001, J NEUROSCI, V21, P5678, DOI 10.1523/JNEUROSCI.21-15-05678.2001; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Colcombe SJ, 2003, J GERONTOL A-BIOL, V58, P176; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; D'Agostino RB, 2007, JAMA-J AM MED ASSOC, V297, P314, DOI 10.1001/jama.297.3.314; Forbes D, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006489.pub2; FORDYCE DE, 1991, BEHAV BRAIN RES, V43, P115, DOI 10.1016/S0166-4328(05)80061-0; GODIN G, 1985, Canadian Journal of Applied Sport Sciences, V10, P141; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; JACOBS DR, 1993, MED SCI SPORT EXER, V25, P81, DOI 10.1249/00005768-199301000-00012; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Luchsinger JA, 2002, ARCH NEUROL-CHICAGO, V59, P1258, DOI 10.1001/archneur.59.8.1258; Luchsinger JA, 2004, J AM GERIATR SOC, V52, P540, DOI 10.1111/j.1532-5415.2004.52159.x; Luchsinger JA, 2003, ARCH NEUROL-CHICAGO, V60, P203, DOI 10.1001/archneur.60.2.203; Luchsinger JA, 2007, CURR NEUROL NEUROSCI, V7, P366, DOI 10.1007/s11910-007-0057-8; Middleton LE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003124; MILLER DJ, 1994, MED SCI SPORT EXER, V26, P376; Neeper SA, 1996, BRAIN RES, V726, P49, DOI 10.1016/S0006-8993(96)00273-9; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Podewils LJ, 2005, AM J EPIDEMIOL, V161, P639, DOI 10.1093/aje/kwi092; Reuben DB, 2003, J AM GERIATR SOC, V51, P1125, DOI 10.1046/j.1532-5415.2003.51380.x; ROGERS RL, 1990, J AM GERIATR SOC, V38, P123, DOI 10.1111/j.1532-5415.1990.tb03472.x; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; SALLIS JF, 1993, MED SCI SPORT EXER, V25, P99, DOI 10.1249/00005768-199301000-00014; Scarmeas N, 2006, J NEUROL NEUROSUR PS, V77, P308, DOI 10.1136/jnnp.2005.072306; Scarmeas N, 2005, NEUROLOGY, V64, P1696, DOI 10.1212/01.WNL.0000162054.15428.E9; Scarmeas N, 2001, NEUROLOGY, V57, P2236, DOI 10.1212/WNL.57.12.2236; Scarmeas N, 2005, ARCH NEUROL-CHICAGO, V62, P1601, DOI 10.1001/archneur.62.10.1601; Scarmeas N, 2007, NEUROLOGY, V69, P1084, DOI 10.1212/01.wnl.0000277320.50685.7c; Scarmeas N, 2009, ARCH NEUROL-CHICAGO, V66, P216, DOI 10.1001/archneurol.2008.536; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; Scarmeas N, 2006, ARCH NEUROL-CHICAGO, V63, P1709, DOI 10.1001/archneur.63.12.noc60109; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Verghese J, 2003, NEW ENGL J MED, V348, P2508, DOI 10.1056/NEJMoa022252; Wang HX, 2002, AM J EPIDEMIOL, V155, P1081, DOI 10.1093/aje/155.12.1081; Wang L, 2006, ARCH INTERN MED, V166, P1115, DOI 10.1001/archinte.166.10.1115; Weuve J, 2004, JAMA-J AM MED ASSOC, V292, P1454, DOI 10.1001/jama.292.12.1454; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wilson RS, 2002, JAMA-J AM MED ASSOC, V287, P742, DOI 10.1001/jama.287.6.742	50	587	609	2	118	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	2009	302	6					627	637		10.1001/jama.2009.1144	http://dx.doi.org/10.1001/jama.2009.1144			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481ZI	19671904	Bronze, Green Accepted, Green Published			2023-01-03	WOS:000268852300021
J	Gilman, EB				Gilman, Ernest B.			The art of medicine Plague, arsenic, and a dried toad	LANCET			English	Editorial Material									NYU, Dept English, New York, NY 10003 USA	New York University	Gilman, EB (corresponding author), NYU, Dept English, New York, NY 10003 USA.	ernest.gilman@nyu.edu						Gilman Ernest B., 2009, PLAGUE WRITING EARLY; Healy M., 2001, FICTIONS DIS EARLY M; Karlen A., 1995, MAN MICROBES DIS PLA; Slack, 1985, IMPACT PLAGUE TUDOR, P201; Totaro Rebecca, 2005, SUFFERING PARADISE B	5	0	0	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 13	2009	373	9680					2018	2019		10.1016/S0140-6736(09)61100-4	http://dx.doi.org/10.1016/S0140-6736(09)61100-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	459DJ	19533834				2023-01-03	WOS:000267080100014
J	Pirker, R; Pereira, JR; Szczesna, A; von Pawel, J; Krzakowski, M; Ramlau, R; Vynnychenko, I; Park, K; Yu, CT; Ganul, V; Roh, JK; Bajetta, E; O'Byrne, K; de Marinis, F; Eberhardt, W; Goddemeier, T; Emig, M; Gatzemeier, U; Pirker, R; Thatcher, N; Armand, JP; Camus, P; Victor, N; Emig, M; Mueser, M; Pilz, K; Goddemeier, T; Montaner, I; Lachs, M; Hoang-Sayag, L; Alvarez, A; Coppola, F; Recondo, G; Richardet, E; Kirsten, F; Karapetis, C; Parente, P; Michael, M; White, S; Boyce, A; Lewis, C; Slancar, M; Pavlakis, N; Abdi, E; Underhill, C; Pittman, K; Burghuber, O; Pirker, R; Ruckser, R; Ulsperger, E; Kolb, R; Humblet, Y; Canon, JL; Bustin, F; Barrios, C; Gorini, C; Ferreira, CM; Pereira, J; Ivanova, N; Tomova, A; Tzekova, V; Chilingirov, P; Racheva, M; Gill, M; Orlandi, FJ; Reyes, J; Salman, P; Tomiskova, M; Roubec, J; Pesek, M; Musil, J; Zatloukal, P; Robinet, G; Riviere, A; Moro-Sibilot, D; Barlesi, F; Chouaid, C; Tourani, JM; Lena, H; Thiberville, L; Quoix, E; Schott, R; Lemarie, E; Schlimok, G; Loddenkemper, R; Eberhardt, W; Wilke, H; Martens, U; Waller, C; von Pawel, J; Griesinger, F; Gatzemeier, U; Schuette, W; Eschbach, C; Bischoff, H; Chemaissani, A; Wolf, J; Fischer, J; Bohnet, S; Klein, H; Kortsik, C; Peschel, C; Ittel, TH; Fett, W; Chua, D; Magyar, P; Ostoros, G; Somfay, A; Vinkler, I; Papai, Z; Szima, B; Mark, Z; Tehenes, S; O'Byrne, K; Brandes, A; Martoni, A; Marini, G; Artioli, F; Bajetta, E; Siena, S; de Marinis, F; Santoro, A; Barni, S; Berchem, G; Arrieta, O; Figueroa, J; Martinez, L; Llerena, E; Burgers, JA; Giaccone, G; Schramel, FMNH; Goey, SH; Stigt, JA; Jagiello, G; Jagiello-Gruszfeld, A; Szczesna, A; Ramlau, R; Krzakowski, M; Tomeczko, J; Teixeira, E; Parente, B; Kononova, G; Biakhov, M; Borisov, V; Gorbunova, V; Konev, A; Manzuk, L; Lukyanov, Y; Manikhas, G; Orlov, S; Heo, DS; Kim, SW; Park, K; Roh, JK; Choi, JH; Soo, R; Mazal, J; Kasan, P; Berzinec, P; Prochazka, M; Carrato, A; Pivlots, RB; Lianes, P; Villar, J; Paz-Ares, L; Cobo, M; Trigo, JM; Ayarra, AG; Constenla, M; Lario, AP; Brea, ML; Insa, A; Vivanco, GL; Brodin, O; Wagenius, G; Ochsenbein, A; Rauch, D; Knuth, A; Chang, GC; Perng, RP; Yang, CH; Yu, CT; Demirkazik, A; Demirelli, F; Nicolson, M; Falk, S; Price, A; Mulatero, C; Lee, SM; O'Brien, M; Gardiner, J; Laurence, V; Ferry, D; Paramonov, V; Bondarenko, I; Pylypenko, M; Ganul, V; Oliynichenko, P; Simonov, S; Shparyk, Y; Bashtan, V; Vynnychenko, I; Galaychuk, I; Hotko, Y				Pirker, Robert; Pereira, Jose R.; Szczesna, Aleksandra; von Pawel, Joachim; Krzakowski, Maciej; Ramlau, Rodryg; Vynnychenko, Ihor; Park, Keunchil; Yu, Chih-Teng; Ganul, Valentyn; Roh, Jae-Kyung; Bajetta, Emilio; O'Byrne, Kenneth; de Marinis, Filippo; Eberhardt, Wilfried; Goddemeier, Thomas; Emig, Michael; Gatzemeier, Ulrich; Pirker, R.; Thatcher, N.; Armand, J. P.; Camus, P.; Victor, N.; Emig, M.; Mueser, M.; Pilz, K.; Goddemeier, T.; Montaner, I.; Lachs, Martin; Hoang-Sayag, Loan; Alvarez, A.; Coppola, F.; Recondo, G.; Richardet, E.; Kirsten, F.; Karapetis, C.; Parente, P.; Michael, M.; White, S.; Boyce, A.; Lewis, C.; Slancar, M.; Pavlakis, N.; Abdi, E.; Underhill, C.; Pittman, K.; Burghuber, O.; Pirker, R.; Ruckser, R.; Ulsperger, E.; Kolb, R.; Humblet, Y.; Canon, J-L.; Bustin, F.; Barrios, C.; Gorini, C.; Ferreira, C. Moreira; Pereira, J.; Ivanova, N.; Tomova, A.; Tzekova, V.; Chilingirov, P.; Racheva, M.; Gill, M.; Orlandi, F. Javier; Reyes, J.; Salman, P.; Tomiskova, M.; Roubec, J.; Pesek, M.; Musil, J.; Zatloukal, P.; Robinet, G.; Riviere, A.; Moro-Sibilot, D.; Barlesi, F.; Chouaid, C.; Tourani, J-M.; Lena, H.; Thiberville, L.; Quoix, E.; Schott, R.; Lemarie, E.; Schlimok, G.; Loddenkemper, R.; Eberhardt, W.; Wilke, H.; Martens, U.; Waller, C.; von Pawel, J.; Griesinger, F.; Gatzemeier, U.; Schuette, W.; Eschbach, C.; Bischoff, H.; Chemaissani, A.; Wolf, J.; Fischer, J.; Bohnet, S.; Klein, H.; Kortsik, C.; Peschel, C.; Ittel, T. H.; Fett, W.; Chua, D.; Magyar, P.; Ostoros, G.; Somfay, A.; Vinkler, I.; Papai, Z.; Szima, B.; Mark, Z.; Tehenes, S.; O'Byrne, K.; Brandes, A.; Martoni, A.; Marini, G.; Artioli, F.; Bajetta, E.; Siena, S.; de Marinis, F.; Santoro, A.; Barni, S.; Berchem, G.; Arrieta, O.; Figueroa, J.; Martinez, L.; Llerena, E.; Burgers, J. A.; Giaccone, G.; Schramel, F. M. N. H.; Goey, S. H.; Stigt, J. A.; Jagiello, G.; Jagiello-Gruszfeld, A.; Szczesna, A.; Ramlau, R.; Krzakowski, M.; Tomeczko, J.; Teixeira, E.; Parente, B.; Kononova, G.; Biakhov, M.; Borisov, V.; Gorbunova, V.; Konev, A.; Manzuk, L.; Lukyanov, Y.; Manikhas, G.; Orlov, S.; Heo, D-S.; Kim, S-W.; Park, K.; Roh, J-K.; Choi, J-H.; Soo, R.; Mazal, J.; Kasan, P.; Berzinec, P.; Prochazka, M.; Carrato, A.; Pivlots, R. Bastus; Lianes, P.; Villar, J.; Paz-Ares, L.; Cobo, M.; Trigo, J. M.; Ayarra, A. Gurpide; Constenla, M.; Lario, A. Paredes; Brea, M. Lopez; Insa, A.; Vivanco, G. Lopez; Brodin, O.; Wagenius, G.; Ochsenbein, A.; Rauch, D.; Knuth, A.; Chang, G-C.; Perng, R. P.; Yang, C-H.; Yu, C-T.; Demirkazik, A.; Demirelli, F.; Nicolson, M.; Falk, S.; Price, A.; Mulatero, C.; Lee, S. M.; O'Brien, M.; Gardiner, J.; Laurence, V.; Ferry, D.; Paramonov, V.; Bondarenko, I.; Pylypenko, M.; Ganul, V.; Oliynichenko, P.; Simonov, S.; Shparyk, Y.; Bashtan, V.; Vynnychenko, I.; Galaychuk, I.; Hotko, Y.		FLEX Study Team	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; 1ST-LINE TREATMENT; CARBOPLATIN; COMBINATION; CISPLATIN; GEMCITABINE; PACLITAXEL; GEFITINIB; ERLOTINIB; THERAPY	Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in patients with advanced non-small-cell lung cancer. We therefore compared chemotherapy plus cetuximab with chemotherapy alone in patients with advanced EGFR-positive non-small-cell lung cancer. Methods In a multinational, multicentre, open-label, phase III trial, chemotherapy-naive patients (>= 18 years) with advanced EGFR-expressing histologically or cytologically proven stage wet IIIB or stage IV non-small-cell lung cancer were randomly assigned in a 1:1 ratio to chemotherapy plus cetuximab or just chemotherapy. Chemotherapy was cisplatin 80 mg/m(2) intravenous infusion on day 1, and vinorelbine 25 mg/m(2) intravenous infusion on days 1 and 8 of every 3-week cycle) for up to six cycles. Cetuximab-at a starting dose of 400 mg/m(2) intravenous infusion over 2 h on day 1, and from day 8 onwards at 250 mg/m(2) over 1 h per week-was continued after the end of chemotherapy until disease progression or unacceptable toxicity had occurred. The primary endpoint was overall survival. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00148798. Findings Between October, 2004, and January, 2006, 1125 patients were randomly assigned to chemotherapy plus cetuximab (n=557) or chemotherapy alone (n=568). Patients given chemotherapy plus cetuximab survived longer than those in the chemotherapy-alone group (median 11.3 months vs 10.1 months; hazard ratio for death 0.871 [95% CI 0.762-0.996]; p=0.044). The main cetuximab-related adverse event was acne-like rash (57 [10%] of 548, grade 3). Interpretation Addition of cetuximab to platinum-based chemotherapy represents a new treatment option for patients with advanced non-small-cell lung cancer.	[Pirker, Robert] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria; [Pereira, Jose R.] Inst Canc Amaldo Vieira Carvalho, Sao Paulo, Brazil; [Szczesna, Aleksandra] Mazowieckie Ctr Leczenia Chorob Pluc & Gruzlicy, Otwock, Poland; [von Pawel, Joachim] Asklepios Fachkliniken Muenchen Gauting, Gauting, Germany; [Krzakowski, Maciej] Maria Sklodowska Curie Mem Inst Oncol, Warsaw, Poland; [Ramlau, Rodryg] Wielkopolskie Ctr Chorob Pluc & Gruzlicy, Poznan, Poland; [Vynnychenko, Ihor] Sumy Reg Oncol Ctr, Sumy, Ukraine; [Park, Keunchil] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Yu, Chih-Teng] Chang Gung Mem Hosp, Tao Yuan, Taiwan; [Ganul, Valentyn] Ukraine Acad Med Sci, Inst Oncol, Kiev, Ukraine; [Roh, Jae-Kyung] Yonsei Univ, Coll Med, Seoul, South Korea; [Bajetta, Emilio] Natl Canc Inst, I-20133 Milan, Italy; [O'Byrne, Kenneth] St James Hosp, Dublin 8, Ireland; [de Marinis, Filippo] C Forlanini Hosp, Rome, Italy; [Eberhardt, Wilfried] Univ Duisburg Essen, Univ Hosp Essen, Essen, Germany; [Goddemeier, Thomas; Emig, Michael] Merck KGaA, Darmstadt, Germany; [Gatzemeier, Ulrich] Hosp Grosshansdorf, Grosshansdorf, Germany	Medical University of Vienna; Maria Sklodowska-Curie National Research Institute of Oncology; Ministry of Education & Science of Ukraine; Sumy State University; Sungkyunkwan University (SKKU); Samsung Medical Center; Chang Gung Memorial Hospital; Ministry of Health of Ukraine; National Cancer Institute; National Academy of Medical Sciences of Ukraine; Yonsei University; Yonsei University Health System; Fondazione IRCCS Istituto Nazionale Tumori Milan; Trinity College Dublin; Azienda Ospedaliera San Camillo-Forlanini; University of Duisburg Essen; Merck KGaA; Grosshansdorf Hospital	Pirker, R (corresponding author), Med Univ Vienna, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	robert.pirker@meduniwien.ac.at	de Marinis, Filippo/AAR-2826-2020; Martoni, Andrea/AAC-1707-2021; Bondarenko, Igor/W-9412-2019; Underhill, Craig/ABB-8092-2020; Barrios, Carlos/HJG-7197-2022; Arrieta, Oscar/ABH-6022-2020; Paz-Ares, Luis/AAH-2750-2019; christos, chouaid/R-4477-2018; Bondarenko, Igor N/GQP-1497-2022; Recondo, Gonzalo/GNP-1009-2022; Demirelli, Fuat/AAD-2151-2021; Berzinec, Peter/ABG-6237-2021; Jagiello-Gruszfeld, Agnieszka i/S-6924-2018; Hotko, Yevhen/F-9068-2019; Park, Keunchil/ABD-5852-2021; Vynnychenko, Ihor O/E-1684-2012; SIENA, SALVATORE/AAC-5806-2019; Demirkazık, Ahmet/AAG-7699-2020; Berchem, Guy/C-9364-2014; Lopez, Guillermo/F-3435-2012; Park, Keunchil/ABD-7072-2021	Bondarenko, Igor/0000-0002-7071-2471; Underhill, Craig/0000-0001-9335-2678; Barrios, Carlos/0000-0001-6021-667X; christos, chouaid/0000-0002-4290-5524; Bondarenko, Igor N/0000-0002-7071-2471; Recondo, Gonzalo/0000-0002-4755-9325; Jagiello-Gruszfeld, Agnieszka i/0000-0002-2698-5499; Hotko, Yevhen/0000-0002-4533-4210; Park, Keunchil/0000-0002-4846-7449; Vynnychenko, Ihor O/0000-0002-2339-6509; SIENA, SALVATORE/0000-0002-2681-2846; Berchem, Guy/0000-0003-0157-2257; Krzakowski, Maciej/0000-0003-3324-0900; Waller, Cornelius/0000-0002-5777-0212; Eberhardt, Wilfried Ernst Erich/0000-0003-4284-3586; Schuette, Wolfgang/0000-0002-7516-5649; Karapetis, Christos/0000-0003-1741-996X; Ostoros, Gyula/0000-0001-5339-7257; Trigo, Jose/0000-0002-4489-2683; Ramlau, Rodryg/0000-0002-3199-2298; burghuber, otto/0000-0002-8419-621X; O'Byrne, Kenneth/0000-0002-6754-5633; MORO-SIBILOT, Denis/0000-0001-6776-8610; Arrieta, Oscar/0000-0002-1164-3779; Ochsenbein, Adrian/0000-0003-1773-5436; INSA, AMELIA/0000-0002-3438-6170	Merck KGaA	Merck KGaA(Merck & Company)	Merck KGaA sponsored this study. We thank the participating patients and their families; Isil Montaner, Korinna Pilz, and Matthias Mueser for their contributions to the design and doing the trial; the study nurses, monitors, data managers, and support staff, Isabella Schmele for her support in the preparation of the report; and David Gandara for his critical review of the report.	Ardizzoni A, 2007, J NATL CANCER I, V99, P847, DOI 10.1093/jnci/djk196; Belani CP, 2008, CANCER-AM CANCER SOC, V113, P2512, DOI 10.1002/cncr.23902; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Butts CA, 2007, J CLIN ONCOL, V25, P5777, DOI 10.1200/JCO.2007.13.0856; Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915; Eberhard DA, 2008, J CLIN ONCOL, V26, P983, DOI 10.1200/JCO.2007.12.9858; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; GATZEMEIER U, 2008, J THORAC ONCOL, V3, pS265; Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; KELLY K, 2006, J CLIN ONCOL S, V24; KHAMBATAFORD S, 2008, J THORAC ONCOL, V3, pS304; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Lynch TJ, 2007, J THORAC ONCOL, V2, pS340, DOI 10.1097/01.JTO.0000283155.03863.e7; Lynch TJ, 2008, J THORAC ONCOL, V3, pS107, DOI 10.1097/JTO.0b013e318174e9d3; Mendelsohn J, 2002, J CLIN ONCOL, V20, p1S, DOI 10.1200/JCO.2002.07.121; NARAMURA M, 1993, CANCER IMMUNOL IMMUN, V37, P343, DOI 10.1007/BF01518458; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; Robert F, 2005, J CLIN ONCOL, V23, P9089, DOI 10.1200/JCO.2004.00.1438; Rosell R, 2008, ANN ONCOL, V19, P362, DOI 10.1093/annonc/mdm474; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Thienelt CD, 2005, J CLIN ONCOL, V23, P8786, DOI 10.1200/jco.2005.03.1997; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019; Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656	28	1087	1142	1	89	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 2	2009	373	9674					1525	1531		10.1016/S0140-6736(09)60569-9	http://dx.doi.org/10.1016/S0140-6736(09)60569-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440OT	19410716				2023-01-03	WOS:000265710300031
J	Chang, DK; Lin, CT; Wu, CH; Wu, HC				Chang, De-Kuan; Lin, Chin-Tarng; Wu, Chien-Hsun; Wu, Han-Chung			A Novel Peptide Enhances Therapeutic Efficacy of Liposomal Anti-Cancer Drugs in Mice Models of Human Lung Cancer	PLOS ONE			English	Article							STERICALLY STABILIZED LIPOSOMES; SOLID TUMORS; CHEMOTHERAPEUTIC-AGENTS; DOXORUBICIN DOXIL; SMALL-CELL; DELIVERY; PHARMACOKINETICS; EPITOPE; PHAGE; ACCUMULATION	Lung cancer is the leading cause of cancer-related mortality worldwide. The lack of tumor specificity remains a major drawback for effective chemotherapies and results in dose-limiting toxicities. However, a ligand-mediated drug delivery system should be able to render chemotherapy more specific to tumor cells and less toxic to normal tissues. In this study, we isolated a novel peptide ligand from a phage-displayed peptide library that bound to non-small cell lung cancer (NSCLC) cell lines. The targeting phage bound to several NSCLC cell lines but not to normal cells. Both the targeting phage and the synthetic peptide recognized the surgical specimens of NSCLC with a positive rate of 75% ( 27 of 36 specimens). In severe combined immunodeficiency (SCID) mice bearing NSCLC xenografts, the targeting phage specifically bound to tumor masses. The tumor homing ability of the targeting phage was inhibited by the cognate synthetic peptide, but not by a control or a WTY-mutated peptide. When the targeting peptide was coupled to liposomes carrying doxorubicin or vinorelbine, the therapeutic index of the chemotherapeutic agents and the survival rates of mice with human lung cancer xenografts markedly increased. Furthermore, the targeting liposomes increased drug accumulation in tumor tissues by 5.7-fold compared with free drugs and enhanced cancer cell apoptosis resulting from a higher concentration of bioavailable doxorubicin. The current study suggests that this tumor-specific peptide may be used to create chemotherapies specifically targeting tumor cells in the treatment of NSCLC and to design targeted gene transfer vectors or it may be used one in the diagnosis of this malignancy.	[Chang, De-Kuan; Wu, Chien-Hsun; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan; [Chang, De-Kuan; Lin, Chin-Tarng; Wu, Han-Chung] Natl Taiwan Univ, Coll Med, Inst Pathol, Taipei, Taiwan	Academia Sinica - Taiwan; National Taiwan University	Chang, DK (corresponding author), Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.	hcw0928@gate.sinica.edu.tw	Wu, Han-Chung/B-1209-2011	Wu, Han-Chung/0000-0002-5185-1169	Academia Sinica [5202402020-0]; National Science Council [NSC-96-2323-B-002-015, NSC96-3114-P-001-006-Y02]	Academia Sinica(Academia Sinica - Taiwan); National Science Council(Ministry of Science and Technology, Taiwan)	This work was supported by Research Grants from Academia Sinica (#5202402020-0 to HCW) and National Science Council (NSC-96-2323-B-002-015 and NSC96-3114-P-001-006-Y02 to HCW).	Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Bosslet K, 1998, CANCER RES, V58, P1195; BOUCHER Y, 1990, CANCER RES, V50, P4478; BOYLE P, 2000, EPIDEMIOLOGY LUNG CA, P13; Chen YC, 2007, CLIN VACCINE IMMUNOL, V14, P404, DOI 10.1128/CVI.00249-06; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Colbern GT, 1999, J LIPOSOME RES, V9, P523, DOI 10.3109/08982109909035551; Dharap SS, 2005, P NATL ACAD SCI USA, V102, P12962, DOI 10.1073/pnas.0504274102; DMello F, 1997, VIROLOGY, V237, P319, DOI 10.1006/viro.1997.8774; Drummond DC, 1999, PHARMACOL REV, V51, P691; Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958; GABIZON A, 1994, CANCER RES, V54, P987; Gabizon A, 1997, DRUGS, V54, P15, DOI 10.2165/00003495-199700544-00005; Harrington KJ, 2001, CLIN CANCER RES, V7, P243; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Hu W, 2003, LANCET ONCOL, V4, P721, DOI 10.1016/S1470-2045(03)01277-4; HUANG SK, 1992, CANCER RES, V52, P6774; Jain RK, 1996, ANN BIOMED ENG, V24, P457, DOI 10.1007/BF02648108; Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9; Kirpotin D, 1997, BIOCHEMISTRY-US, V36, P66, DOI 10.1021/bi962148u; Laginha KM, 2005, CLIN CANCER RES, V11, P6944, DOI 10.1158/1078-0432.CCR-05-0343; Lee TY, 2007, CANCER RES, V67, P10958, DOI 10.1158/0008-5472.CAN-07-2233; Lee TY, 2004, CANCER RES, V64, P8002, DOI 10.1158/0008-5472.CAN-04-1948; LI B, 1995, SCIENCE, V270, P1657, DOI 10.1126/science.270.5242.1657; Liu IJ, 2004, J INFECT DIS, V190, P797, DOI 10.1086/422753; Lo A, 2008, MOL CANCER THER, V7, P579, DOI 10.1158/1535-7163.MCT-07-2359; Marina NM, 2002, CLIN CANCER RES, V8, P413; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Mayer LD, 1997, J PHARMACOL EXP THER, V280, P1406; MINNA JD, 1982, CANCER PRINCIPLES PR, P396; Muggia F, 2001, EUR J CANCER, V37, pS15; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; Park JW, 2002, BREAST CANCER RES, V4, P93; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Pastorino F, 2006, CANCER RES, V66, P10073, DOI 10.1158/0008-5472.CAN-06-2117; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; Safra T, 2000, ANN ONCOL, V11, P1029, DOI 10.1023/A:1008365716693; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schiller JH, 2001, ONCOLOGY-BASEL, V61, P3, DOI 10.1159/000055386; SIEGAL T, 1995, J NEUROSURG, V83, P1029, DOI 10.3171/jns.1995.83.6.1029; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SPETH PAJ, 1988, CLIN PHARMACOKINET, V15, P15, DOI 10.2165/00003088-198815010-00002; Vaage J, 1997, BRIT J CANCER, V75, P482, DOI 10.1038/bjc.1997.84; Vasey PA, 1999, CLIN CANCER RES, V5, P83; Wu D.-K.C. Han-Chung, 2006, J CANC MOL, V2, P57; Wu HC, 2003, J GEN VIROL, V84, P2771, DOI 10.1099/vir.0.19228-0; YUAN F, 1995, CANCER RES, V55, P3752	49	112	122	0	34	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2009	4	1							e4171	10.1371/journal.pone.0004171	http://dx.doi.org/10.1371/journal.pone.0004171			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437ID	19137069	Green Published, gold			2023-01-03	WOS:000265479500002
J	David, R				David, Rosalie			The art of healing in ancient Egypt: a scientific reappraisal	LANCET			English	Editorial Material									[David, Rosalie] Univ Manchester, KNH Ctr Biomed Egyptol, Manchester M13 9PL, Lancs, England	University of Manchester	David, R (corresponding author), Univ Manchester, KNH Ctr Biomed Egyptol, Manchester M13 9PL, Lancs, England.							Campbell J, 2007, PHARM J, P735; Daumas F., 1957, B I FRANCAIS ARCHEOL, V56, P35; David AR, 2008, EGYPTIAN MUMMIES AND MODERN SCIENCE, P1, DOI 10.1017/CBO9780511499654; David R., 2004, MAGIC RATIONALITY AN; GHALIOUNGUI P, 1963, MED SCI ANCIENT EGYP; Nunn JF, 1996, ANCIENT EGYPTIAN MED	6	6	6	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	2008	372	9652					1802	1803		10.1016/S0140-6736(08)61749-3	http://dx.doi.org/10.1016/S0140-6736(08)61749-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	375KG	19048654				2023-01-03	WOS:000261112000014
J	Dillon, R; Hirschfield, GM; Allison, MED; Rege, KP				Dillon, Richard; Hirschfield, Gideon M.; Allison, Michael E. D.; Rege, Kanchan P.			Lesson of the week - Fatal reactivation of hepatitis B after chemotherapy for lymphoma	BRITISH MEDICAL JOURNAL			English	Article							VIRUS HBV REACTIVATION; IMMUNOSUPPRESSIVE THERAPY; CYTOTOXIC CHEMOTHERAPY; LAMIVUDINE PROPHYLAXIS; PREEMPTIVE LAMIVUDINE; INFECTION; RISK; PREVENTION; CARRIERS; CHOP		[Hirschfield, Gideon M.; Allison, Michael E. D.] Addenbrookes Hosp, Dept Hepatol, Cambridge CB2 2QQ, England; [Dillon, Richard; Rege, Kanchan P.] Hinchingbrooke Hosp, Dept Haematol, Huntingdon, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Hirschfield, GM (corresponding author), Addenbrookes Hosp, Dept Hepatol, Hills Rd, Cambridge CB2 2QQ, England.	gideon.hirschfield@uhn.on.ca	Hirschfield, Gideon M/M-2143-2015	Hirschfield, Gideon M/0000-0002-6736-2255; Allison, Michael/0000-0003-3677-3294; Dillon, Richard/0000-0001-9333-5296				Calabrese LH, 2006, ANN RHEUM DIS, V65, P983, DOI 10.1136/ard.2005.043257; Cheng AL, 2003, HEPATOLOGY, V37, P1320, DOI 10.1053/jhep.2003.50220; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Dai MS, 2004, ANN HEMATOL, V83, P769, DOI 10.1007/s00277-004-0899-y; Hui CK, 2006, GASTROENTEROLOGY, V131, P59, DOI 10.1053/j.gastro.2006.04.015; Kohrt HE, 2006, ALIMENT PHARM THERAP, V24, P1003, DOI 10.1111/j.1365-2036.2006.03081.x; Lalazar G, 2007, BRIT J HAEMATOL, V136, P699, DOI 10.1111/j.1365-2141.2006.06465.x; Lau GKK, 2003, GASTROENTEROLOGY, V125, P1742, DOI 10.1053/j.gastro.2003.09.026; Law JK, 2005, LEUKEMIA LYMPHOMA, V46, P1085, DOI 10.1080/10428190500062932; Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406; Li YH, 2006, CANCER-AM CANCER SOC, V106, P1320, DOI 10.1002/cncr.21701; Lok ASF, 2007, HEPATOLOGY, V45, P507, DOI 10.1002/hep.21513; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; Markovic S, 1999, HEPATO-GASTROENTEROL, V46, P2925; Sherman Morris, 2007, Can J Gastroenterol, V21 Suppl C, p5C; Yeo W, 2006, HEPATOLOGY, V43, P209, DOI 10.1002/hep.21051; Yeo W, 2004, BRIT J CANCER, V90, P1306, DOI 10.1038/sj.bjc.6601699	17	13	13	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 27	2008	337	7672							a423	10.1136/bmj.39490.680498.BE	http://dx.doi.org/10.1136/bmj.39490.680498.BE			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356SJ	18595895				2023-01-03	WOS:000259797600045
J	Weber, W; Vander Stoep, A; McCarty, RL; Weiss, NS; Biederman, J; McClellan, J				Weber, Wendy; Vander Stoep, Ann; McCarty, Rachelle L.; Weiss, Noel S.; Biederman, Joseph; McClellan, Jon			Hypericum perforatum (St John's Wort) for attention-deficit/hyperactivity disorder in children and adolescents - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; DAILY ATOMOXETINE TREATMENT; DOUBLE-BLIND; OPEN-LABEL; ALTERNATIVE THERAPIES; CHILDHOOD ATTENTION; METHYLPHENIDATE; COMPLEMENTARY; DEPRESSION; SYMPTOMS	Context Stimulant medication can effectively treat 60% to 70% of youth with attention-deficit/ hyperactivity disorder ( ADHD). Yet many parents seek alternative therapies, and Hypericum perforatum ( St John's wort) is 1 of the top 3 botanicals used. Objective To determine the efficacy and safety of H perforatum for the treatment of ADHD in children. Design, Setting, and Participants Randomized, double- blind, placebo-controlled trial conducted between March 2005 and August 2006 at Bastyr University, Kenmore, Washington, among a volunteer sample of 54 children aged 6 to 17 years who met Diagnostic and Statistical Manual of Mental Disorders ( Fourth Edition) criteria for ADHD by structured interview. Intervention After a placebo run- in phase of 1 week, participants were randomly assigned to receive 300 mg of H perforatum standardized to 0.3% hypericin ( n= 27) or a matched placebo ( n= 27) 3 times daily for 8 weeks. Other medications for ADHD were not allowed during the trial. Main Outcome Measures Performance on the ADHD Rating Scale - IV ( range, 0- 54) and Clinical Global Impression Improvement Scale ( range, 0- 7), and adverse events. Results One patient in the placebo group withdrew because of an adverse event. No significant difference was found in the change in ADHD Rating Scale - IV scores from baseline to week 8 between the treatment and placebo groups: inattentiveness improved 2.6 points ( 95% confidence interval [ CI], - 4.6 to - 0.6 points) with H perforatum vs 3.2 points ( 95% CI, - 5.7 to - 0.8 points) with placebo ( P=. 68) and hyperactivity improved 1.8 points ( 95% CI, - 3.7 to 0.1 points) with H perforatum vs 2.0 points ( 95% CI, - 4.1 to 0.1 points) with placebo ( P=. 89). There was also no significant difference between the 2 groups in the percentage of participants who met criteria for improvement ( score <= 2) on the Clinical Global Impression Improvement Scale ( H perforatum, 44.4%; 95% CI, 25.5%- 64.7% vs placebo, 51.9%; 95% CI, 31.9%- 71.3%; P=. 59). No difference between groups was found in the number of participants who experienced adverse effects during the study period ( H perforatum, 40.7%; 95% CI, 22.4%- 61.2% vs placebo, 44.4%; 95% CI, 25.5%- 64.7%; P=. 78). Conclusion In this study, use of H perforatum for treatment of ADHD over the course of 8 weeks did not improve symptoms. Trial Registration clinicaltrials. gov Identifier: NCT00100295.	[Weber, Wendy; McCarty, Rachelle L.] Bastyr Univ, Sch Naturopath Med, Kenmore, WA USA; [Vander Stoep, Ann] Univ Washington, Dept Psychiat & Behav Sci, Childrens Hosp & Reg Med Ctr, Seattle, WA 98195 USA; [Vander Stoep, Ann; Weiss, Noel S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [McClellan, Jon] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Biederman, Joseph] Massachusetts Gen Hosp, Dept Pediat Psychopharmacol, Boston, MA 02114 USA; [Biederman, Joseph] Harvard Univ, Dept Psychiat, Boston, MA 02115 USA	Seattle Children's Hospital; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Massachusetts General Hospital; Harvard University	Weber, W (corresponding author), 14500 Juanita Dr NE, Kenmore, WA USA.	wendyw@bastyr.edu			NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT000929, T32AT000815] Funding Source: NIH RePORTER; NCCIH NIH HHS [K23AT000929, T32AT00815, T32 AT000815-05, K23 AT000929-05, K23 AT000929, T32 AT000815] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Achenbach T.M., 2001, MULTICULTURAL SUPPLE; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baumgaertel A, 1999, PEDIATR CLIN N AM, V46, P977, DOI 10.1016/S0031-3955(05)70167-X; Biederman J, 2004, INT J NEUROPSYCHOPH, V7, P77, DOI 10.1017/S1461145703003973; Bussing R, 2002, PSYCHIAT SERV, V53, P1096, DOI 10.1176/appi.ps.53.9.1096; Cala S, 2003, PHARMACOTHERAPY, V23, P222, DOI 10.1592/phco.23.2.222.32092; Chan E, 2002, J DEV BEHAV PEDIATR, V23, pS37, DOI 10.1097/00004703-200202001-00007; Chan E, 2003, J DEV BEHAV PEDIATR, V24, P4, DOI 10.1097/00004703-200302000-00003; Conners C.K., 1997, CONNERSRATING SCALES; Davidson JRT, 2002, JAMA-J AM MED ASSOC, V287, P1807, DOI 10.1001/jama.287.14.1807; DUPAUL GJ, 1998, ADHD RATING SCALE, V4; Faraone Stephen V, 2003, World Psychiatry, V2, P104; Findling RL, 2003, J AM ACAD CHILD PSY, V42, P908, DOI 10.1097/01.CHI.0000046900.27264.2A; Froehlich TE, 2007, ARCH PEDIAT ADOL MED, V161, P857, DOI 10.1001/archpedi.161.9.857; Greenhill LL, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.3.e39; Homer CJ, 2000, PEDIATRICS, V105, P1158; Hubner WD, 2001, PHYTOTHER RES, V15, P367, DOI 10.1002/ptr.829; Kalachnik J., 1986, DRUG THERAPY BEHAV D, P153; Kasper S, 2007, EUR ARCH PSY CLIN N, V258, P59, DOI 10.1007/s00406-007-0779-2; Kelsey DK, 2004, PEDIATRICS, V114, pE1, DOI 10.1542/peds.114.1.e1; Kratochvil CJ, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200207000-00008; Linde K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000448.pub3; Markowitz JS, 2003, JAMA-J AM MED ASSOC, V290, P1500, DOI 10.1001/jama.290.11.1500; Michelson D, 2002, AM J PSYCHIAT, V159, P1896, DOI 10.1176/appi.ajp.159.11.1896; Michelson D, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.5.e83; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; National Institute of Mental Health, 1985, PSYCHOPHARMACOL BULL, V21, P839; Orth HCJ, 1999, J PHARM PHARMACOL, V51, P193, DOI 10.1211/0022357991772132; Orvaschel H, 1987, SCHEDULE AFFECTIVE D; Prasad S, 2007, CURR MED RES OPIN, V23, P379, DOI 10.1185/030079906X167309; Robison LM, 2004, INT CLIN PSYCHOPHARM, V19, P17, DOI 10.1097/00004850-200401000-00003; Schachter HA, 2001, CAN MED ASSOC J, V165, P1475; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; Spencer T, 2002, J CLIN PSYCHIAT, V63, P1140, DOI 10.4088/JCP.v63n1209; *STATACORP, 2007, STAT SE COMP PROGR V; Stubberfield TG, 1999, J PAEDIATR CHILD H, V35, P450, DOI 10.1046/j.1440-1754.1999.355401.x; Szegedi A, 2005, BMJ-BRIT MED J, V330, P759; Szegedi A, 2005, BMJ-BRIT MED J, V330, P503, DOI 10.1136/bmj.38356.655266.82; U.S. Census Bureau; American Community Survey (ACS), AM FACT FIND; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Visser SN, 2007, PEDIATRICS, V119, pS99, DOI 10.1542/peds.2006-2089O	41	44	45	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2633	2641		10.1001/jama.299.22.2633	http://dx.doi.org/10.1001/jama.299.22.2633			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544723	Green Accepted			2023-01-03	WOS:000256586200020
J	Barger, JL; Kayo, T; Vann, JM; Arias, EB; Wang, JL; Hacker, TA; Wang, Y; Raederstorff, D; Morrow, JD; Leeuwenburgh, C; Allison, DB; Saupe, KW; Cartee, GD; Weindruch, R; Prolla, TA				Barger, Jamie L.; Kayo, Tsuyoshi; Vann, James M.; Arias, Edward B.; Wang, Jelai; Hacker, Timothy A.; Wang, Ying; Raederstorff, Daniel; Morrow, Jason D.; Leeuwenburgh, Christiaan; Allison, David B.; Saupe, Kurt W.; Cartee, Gregory D.; Weindruch, Richard; Prolla, Tomas A.			A Low Dose of Dietary Resveratrol Partially Mimics Caloric Restriction and Retards Aging Parameters in Mice	PLOS ONE			English	Article								Resveratrol in high doses has been shown to extend lifespan in some studies in invertebrates and to prevent early mortality in mice fed a high-fat diet. We fed mice from middle age (14-months) to old age (30-months) either a control diet, a low dose of resveratrol (4.9 mg kg(-1) day(-1)), or a calorie restricted (CR) diet and examined genome-wide transcriptional profiles. We report a striking transcriptional overlap of CR and resveratrol in heart, skeletal muscle and brain. Both dietary interventions inhibit gene expression profiles associated with cardiac and skeletal muscle aging, and prevent age-related cardiac dysfunction. Dietary resveratrol also mimics the effects of CR in insulin mediated glucose uptake in muscle. Gene expression profiling suggests that both CR and resveratrol may retard some aspects of aging through alterations in chromatin structure and transcription. Resveratrol, at doses that can be readily achieved in humans, fulfills the definition of a dietary compound that mimics some aspects of CR.	[Barger, Jamie L.; Kayo, Tsuyoshi] LifeGen Technol LLC, Madison, WI USA; [Vann, James M.; Prolla, Tomas A.] Univ Wisconsin, Dept Med Genet, Madison, WI USA; [Vann, James M.; Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI USA; [Arias, Edward B.; Cartee, Gregory D.] Univ Michigan, Div Kinesiol, Ann Arbor, MI USA; [Wang, Jelai] Univ Alabama, Dept Biostat, Sect Stat Genet, Birmingham, AL USA; [Hacker, Timothy A.; Saupe, Kurt W.] Univ Wisconsin Madison, Dept Med, Madison, WI USA; [Wang, Ying; Raederstorff, Daniel] DSM Nutr Products Ltd, R&D Human Nutr & Hlth, Basel, Switzerland; [Morrow, Jason D.] Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN USA; [Morrow, Jason D.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN USA; [Leeuwenburgh, Christiaan] Univ Florida, Coll Med, Dept Aging & Geriat, Gainesville, FL USA; [Allison, David B.] Univ Alabama, Clin Nutr Res Ctr, Dept Biostat, Sect Stat Genet, Birmingham, AL USA; [Weindruch, Richard] Univ Wisconsin Madison, Vet Adm Hosp, Dept Med, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; DSM NV; Vanderbilt University; Vanderbilt University; State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison	Barger, JL (corresponding author), LifeGen Technol LLC, Madison, WI USA.	rhweindr@wisc.edu; taprolla@wisc.edu		Leeuwenburgh, Christiaan/0000-0003-0826-4257; Allison, David/0000-0003-3566-9399; Cartee, Gregory/0000-0001-5311-1722; Barger, Jamie/0000-0001-8694-0068	NIH [AG17994, AG21042, AG-000908, GM15431, DK48831, ES13125, AG020681]; NSF [EPSCoR 05026]; DSM Nutritional Products, Ltd.; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES013125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000908, R01AG021042, P30AG028740, R01AG020681, R01AG017994, K01AG000908] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); DSM Nutritional Products, Ltd.; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	CL: NIH AG17994 and AG21042, DBA: NSF EPSCoR 05026, KAS: NIH AG-000908, JDM: NIH GM15431, DK48831 and ES13125, TAP: NIH AG020681 Portions of this research were funded by DSM Nutritional Products, Ltd.; however, DSM had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barry WT, 2005, BIOINFORMATICS, V21, P1943, DOI 10.1093/bioinformatics/bti260; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bass TM, 2007, MECH AGEING DEV, V128, P546, DOI 10.1016/j.mad.2007.07.007; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Broberg CS, 2003, J AM SOC ECHOCARDIOG, V16, P814, DOI 10.1067/S0894-7317(03)00399-7; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Das DK, 2006, MOL INTERV, V6, P36, DOI 10.1124/mi.6.1.7; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Dhahbi JM, 2005, PHYSIOL GENOMICS, V23, P343, DOI 10.1152/physiolgenomics.00069.2005; Dunn SE, 1997, CANCER RES, V57, P4667; Flurkey K, 2002, MECH AGEING DEV, V123, P121, DOI 10.1016/S0047-6374(01)00339-6; Gazdag AC, 1999, DIABETES, V48, P1930, DOI 10.2337/diabetes.48.10.1930; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; HURSTING SD, 1993, CANCER RES, V53, P2750; Kaeberlein M, 2005, J BIOL CHEM, V280, P17038, DOI 10.1074/jbc.M500655200; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; KLINGE CM, 2008, FASEB J; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Lakatta EG, 2002, COMP BIOCHEM PHYS A, V132, P699, DOI 10.1016/S1095-6433(02)00124-1; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2004, FREE RADICAL BIO MED, V36, P1043, DOI 10.1016/j.freeradbiomed.2004.01.015; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; McCurdy CE, 2005, DIABETES, V54, P1349, DOI 10.2337/diabetes.54.5.1349; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Osley MA, 2007, MUTAT RES-FUND MOL M, V618, P65, DOI 10.1016/j.mrfmmm.2006.07.011; PENUMATHSA SV, 2008, J CELL MOL MED; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; SELMAN C, 2007, FASEB J; Sengupta S, 2006, BMC GENET, V7, DOI 10.1186/1471-2156-7-34; Thirunavukkarasu M, 2007, FREE RADICAL BIO MED, V43, P720, DOI 10.1016/j.freeradbiomed.2007.05.004; Weindruch R., 1988, RETARDATION AGING DI; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789	42	478	488	3	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2008	3	6							e2264	10.1371/journal.pone.0002264	http://dx.doi.org/10.1371/journal.pone.0002264			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	396TO	18523577	Green Published, Green Submitted, gold			2023-01-03	WOS:000262614300003
J	Peng, RD; Chang, HH; Bell, ML; McDermott, A; Zeger, SL; Samet, JM; Dominici, F				Peng, Roger D.; Chang, Howard H.; Bell, Michelle L.; McDermott, Aidan; Zeger, Scott L.; Samet, Jonathan M.; Dominici, Francesca			Coarse particulate matter air pollution and hospital admissions for cardiovascular and respiratory diseases among medicare patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEART-RATE-VARIABILITY; DAILY MORTALITY; FINE PARTICLES; COACHELLA VALLEY; US CITIES; ADULTS; SIZE; LUNG	Context Health risks of fine particulate matter of 2.5 mu m or less in aerodynamic diameter ( PM2.5) have been studied extensively over the last decade. Evidence concerning the health risks of the coarse fraction of greater than 2.5 mu m and 10 mu m or less in aerodynamic diameter ( PM10-2.5) is limited. Objective To estimate risk of hospital admissions for cardiovascular and respiratory diseases associated with PM10-2.5 exposure, controlling for PM2.5. Design, Setting, and Participants Using a database assembled for 108 US counties with daily cardiovascular and respiratory disease admission rates, temperature and dew- point temperature, and PM10-2.5 and PM2.5 concentrations were calculated with monitoring data as an exposure surrogate from January 1, 1999, through December 31, 2005. Admission rates were constructed from the Medicare National Claims History Files, for a study population of approximately 12 million Medicare enrollees living on average 9 miles ( 14.4 km) from collocated pairs of PM10 and PM2.5 monitors. Main Outcome Measures Daily counts of county- wide emergency hospital admissions for primary diagnoses of cardiovascular or respiratory disease. Results There were 3.7 million cardiovascular disease and 1.4 million respiratory disease admissions. A 10-mu g/m(3) increase in PM10-2.5 was associated with a 0.36% ( 95% posterior interval [ PI], 0.05% to 0.68%) increase in cardiovascular disease admissions on the same day. However, when adjusted for PM2.5, the association was no longer statistically significant ( 0.25%; 95% PI, - 0.11% to 0.60%). A 10-mu g/m(3) increase in PM10-2.5 was associated with a nonstatistically significant unadjusted 0.33% ( 95% PI, - 0.21% to 0.86%) increase in respiratory disease admissions and with a 0.26% ( 95% PI, - 0.32% to 0.84%) increase in respiratory disease admissions when adjusted for PM2.5. The unadjusted associations of PM2.5 with cardiovascular and respiratory disease admissions were 0.71% ( 95% PI, 0.45%- 0.96%) for same- day exposure and 0.44% ( 95% PI, 0.06% to 0.82%) for exposure 2 days before hospital admission. Conclusion After adjustment for PM2.5, there were no statistically significant associations between coarse particulates and hospital admissions for cardiovascular and respiratory diseases.	[Peng, Roger D.; Chang, Howard H.; McDermott, Aidan; Zeger, Scott L.; Dominici, Francesca] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; [Samet, Jonathan M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; [Bell, Michelle L.] Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Yale University	Dominici, F (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA.	fdominic@jhsph.edu	Bell, Michelle/Y-4608-2018	Bell, Michelle/0000-0002-3965-1359; Zeger, Scott/0000-0001-8907-1603	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES012054, P30ES003819] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES003819, P30 ES 03819, P30 ES003819-22, R01 ES012054-03, ES012054-03, R01 ES012054] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bell ML, 2007, ENVIRON HEALTH PERSP, V115, P989, DOI 10.1289/ehp.9621; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; *BOARD TRUST FED H, 2007, ANN REP BOARDS TRUST; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.2307/3433607; Carroll R.J., 2006, MEASUREMENT ERROR NO, VSecond, DOI DOI 10.1201/9781420010138; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Dominici F, 2005, J TOXICOL ENV HEAL A, V68, P1071, DOI 10.1080/15287390590935932; DUMOUCHEL WH, 1983, J AM STAT ASSOC, V78, P293, DOI 10.2307/2288631; Everson PJ, 2000, J ROY STAT SOC B, V62, P399, DOI 10.1111/1467-9868.00239; Gelman A., 2003, BAYESIAN DATA ANAL; Happo MS, 2007, INHAL TOXICOL, V19, P227, DOI 10.1080/08958370601067897; Health Effects Institute, 2003, REV AN NAT MORB MORT; Host S, 2008, OCCUP ENVIRON MED, V65, P544, DOI 10.1136/oem.2007.036194; Kan HD, 2007, ENVIRON INT, V33, P376, DOI 10.1016/j.envint.2006.12.001; LINDLEY DV, 1972, J ROY STAT SOC B, V34, P1; Lipsett MJ, 2006, ENVIRON HEALTH PERSP, V114, P1215, DOI 10.1289/ehp.8856; *NAT RES COUNC, 2004, RES PRIOR AIRB PART, V4; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Ostro BD, 2000, J EXPO ANAL ENV EPID, V10, P412, DOI 10.1038/sj.jea.7500094; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709, DOI 10.1080/10473289.2006.10464545; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SAMET JM, 2000, NATL MORBIDITY MO 1; SAMET JM, 2000, NATL MORBIDITY MO 2; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; *US EPA, 2005, REV NAT AMB AIR QUAL; US-EPA, 2004, AIR QUAL CRIT PART M; VANDERPOOL R, 2004, MULTISITE EVALUATION; Venkataraman C, 1999, INHAL TOXICOL, V11, P151, DOI 10.1080/089583799197221; WHITBY KT, 1978, ATMOS ENVIRON, V12, P135, DOI 10.1016/0004-6981(78)90196-8; WILLEKE K, 1975, JAPCA J AIR WASTE MA, V25, P529, DOI 10.1080/00022470.1975.10470110; Wilson WE, 1997, J AIR WASTE MANAGE, V47, P1238, DOI 10.1080/10473289.1997.10464074; Yeatts K, 2007, ENVIRON HEALTH PERSP, V115, P709, DOI 10.1289/ehp.9499; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279; 2006, FED REG, V17, P2620	40	290	297	1	49	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2008	299	18					2172	2179		10.1001/jama.299.18.2172	http://dx.doi.org/10.1001/jama.299.18.2172			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299XX	18477784	Green Accepted, Bronze			2023-01-03	WOS:000255790000024
J	Ferrer, M; Sellares, J; Valencia, M; Carrillo, A; Gonzalez, G; Badia, JR; Nicolas, JM; Torres, A				Ferrer, Miquel; Sellares, Jacobo; Valencia, Mauricio; Carrillo, Andres; Gonzalez, Gumersindo; Ramon Badia, Joan; Maria Nicolas, Josep; Torres, Antoni			Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; POSITIVE-PRESSURE VENTILATION; MECHANICAL VENTILATION; ACUTE EXACERBATIONS; COPD PATIENTS; FAILURE; RISK; PNEUMONIA; ETIOLOGY; SUPPORT	Background Non-invasive ventilation can prevent respiratory failure after extubation in individuals at increased risk of this complication, and enhanced survival in patients with hypercapnia has been recorded. We aimed to assess prospectively the effectiveness of non-invasive ventilation after extubation in patients with hypercapnia and as rescue therapy when respiratory failure develops. Methods We undertook a randomised controlled trial in three intensive-care units in Spain. We enrolled 106 mechanically ventilated patients with chronic respiratory disorders and hypercapnia after a successful spontaneous breathing trial. We randomly allocated participants by computer to receive after extubation either non-invasive ventilation for 24 h (n=54) or conventional oxygen treatment (n=52). The primary endpoint was avoidance of respiratory failure within 72 h after extubation. Analysis was by intention to treat. This trial is registered with clinicaltrials.gov, identifier NCT00539708. Findings Respiratory failure after extubation was less frequent in patients assigned non-invasive ventilation than in those allocated conventional oxygen therapy (8 [15%] vs 25 [48%]; odds ratio 5.32 [95% CI 2.11-13.46]; p<0.0001). In patients with respiratory failure, non-invasive ventilation as rescue therapy avoided reintubation in 17 of 27 patients. Non-invasive ventilation was independently associated with a lower risk of respiratory failure after extubation (adjusted odds ratio 0.17 [95% CI 0.06-0.44]; p<0.0001). 90-day mortality was lower in patients assigned non-invasive ventilation than in those allocated conventional oxygen (p=0.0146). Interpretation Early non-invasive ventilation after extubation diminished risk of respiratory failure and lowered 90-day mortality in patients with hypercapnia during a spontaneous breathing trial. Routine implementation of this strategy for management of mechanically ventilated patients with chronic respiratory disorders is advisable. Funding IDIBAPS, CibeRes, Fondo de Investigaciones Sanitarias, European Respiratory Society.	[Ferrer, Miquel; Sellares, Jacobo; Valencia, Mauricio; Ramon Badia, Joan; Torres, Antoni] Univ Barcelona, IDIBAPS, Hosp Clin, Serv Pneumol,Inst Clin Torax, E-08036 Barcelona, Spain; [Maria Nicolas, Josep] Univ Barcelona, IDIBAPS, Hosp Clin, Med Interna Serv, E-08036 Barcelona, Spain; [Carrillo, Andres; Gonzalez, Gumersindo] Hosp Morales Meseguer, Serv Cuidados Intens, Murcia, Spain; [Ferrer, Miquel; Sellares, Jacobo; Ramon Badia, Joan; Torres, Antoni] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp, Madrid, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III	Ferrer, M (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, Serv Pneumol,Inst Clin Torax, Villarroel 170, E-08036 Barcelona, Spain.	miferrer@clinic.ub.es	Torres, Antoni/H-6128-2017; Sellares, Jacobo/AAN-3250-2020	Torres, Antoni/0000-0002-8643-2167; Sellares, Jacobo/0000-0001-6047-1670; Ferrer, Miguel/0000-0001-8171-6673	FIS [04/1130]; CibeRes [CB06/06/0028]; IDIBAPS; European Respiratory Society; Fondo de Investigaciones Sanitarias;  [2009 SGR 911]	FIS(Instituto de Salud Carlos III); CibeRes; IDIBAPS; European Respiratory Society; Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); 	We thank the nursing staff of the three intensive-care units for their cooperation in this trial. This study was funded by grant FIS 04/1130, CibeRes (CB06/06/0028), 2009 SGR 911, and IDIBAPS (Institut d'Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain). MV is supported by fellowships from the European Respiratory Society and Fondo de Investigaciones Sanitarias.	*AM THOR SOC, 2001, AM J RESP CRIT CARE, V163, P283; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; APPENDINI L, 1994, AM J RESP CRIT CARE, V149, P1069, DOI 10.1164/ajrccm.149.5.8173743; BROCHARD L, 1995, NEW ENGL J MED, V333, P817, DOI 10.1056/NEJM199509283331301; Carlucci A, 2003, INTENS CARE MED, V29, P419, DOI 10.1007/s00134-002-1574-1; Confalonieri M, 1999, AM J RESP CRIT CARE, V160, P1585, DOI 10.1164/ajrccm.160.5.9903015; Confalonieri M, 1996, EUR RESPIR J, V9, P422, DOI 10.1183/09031936.96.09030422; Epstein SK, 2002, INTENS CARE MED, V28, P535, DOI 10.1007/s00134-002-1268-8; Epstein SK, 1998, AM J RESP CRIT CARE, V158, P489, DOI 10.1164/ajrccm.158.2.9711045; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Ferrer M, 2006, AM J RESP CRIT CARE, V173, P164, DOI 10.1164/rccm.200505-718OC; Ferrer M, 2003, AM J RESP CRIT CARE, V168, P1438, DOI 10.1164/rccm.200301-072OC; Ferrer M, 2003, AM J RESP CRIT CARE, V168, P70, DOI 10.1164/rccm.200209-1074OC; Girault C, 1999, AM J RESP CRIT CARE, V160, P86, DOI 10.1164/ajrccm.160.1.9802120; Hilbert G, 1998, EUR RESPIR J, V11, P1349, DOI 10.1183/09031936.98.11061349; Keenan SP, 2002, JAMA-J AM MED ASSOC, V287, P3238, DOI 10.1001/jama.287.24.3238; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; Lightowler JV, 2003, BMJ-BRIT MED J, V326, P185, DOI 10.1136/bmj.326.7382.185; Nava S, 2005, CRIT CARE MED, V33, P2465, DOI 10.1097/01.CCM.0000186416.44752.72; Nava S, 2003, AM J RESP CRIT CARE, V168, P1432, DOI 10.1164/rccm.200211-1270OC; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; Nseir S, 2002, EUR RESPIR J, V20, P1483, DOI 10.1183/09031936.02.00012902; Plant PK, 2001, THORAX, V56, P708, DOI 10.1136/thorax.56.9.708; Plant PK, 2000, LANCET, V355, P1931, DOI 10.1016/S0140-6736(00)02323-0; Schettino G, 2008, CRIT CARE MED, V36, P441, DOI 10.1097/01.CCM.0000300084.67277.90; Stell IM, 2001, AM J RESP CRIT CARE, V164, P2092, DOI 10.1164/ajrccm.164.11.2011147; TORRES A, 1995, AM J RESP CRIT CARE, V152, P137, DOI 10.1164/ajrccm.152.1.7599812; Woodhead MA, 1997, PNEUMONIA, P1	30	217	232	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP-OCT	2009	374	9695					1082	1088		10.1016/S0140-6736(09)61038-2	http://dx.doi.org/10.1016/S0140-6736(09)61038-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501HA	19682735				2023-01-03	WOS:000270370900030
J	Headdon, WG; Wilson, PM; Dalton, HR				Headdon, W. G.; Wilson, P. M.; Dalton, Harry R.			Case report The management of accidental hypothermia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RESUSCITATION; ARREST		[Headdon, W. G.; Wilson, P. M.; Dalton, Harry R.] Peninsula Coll Med & Dent, Plymouth, Devon, England; [Headdon, W. G.; Wilson, P. M.; Dalton, Harry R.] Royal Cornwall Hosp, Truro, Cornwall, England	University of Plymouth; Royal Cornwall Hospital	Dalton, HR (corresponding author), Peninsula Coll Med & Dent, Plymouth, Devon, England.	harry.dalton@rcht.cornwall.nhs.uk		Dalton, Harry/0000-0001-7786-5457				American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, 2005, CIRCULATION, V112, P136; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; Davis PR, 2006, J ROY ARMY MED CORPS, V152, P223; Epstein E, 2006, BMJ-BRIT MED J, V332, P706, DOI 10.1136/bmj.332.7543.706; Farstad M, 2001, EUR J CARDIO-THORAC, V20, P58, DOI 10.1016/S1010-7940(01)00713-8; Gilbert M, 2000, LANCET, V355, P375, DOI 10.1016/S0140-6736(00)01021-7; Graham CA, 2001, WILD ENVIRON MED, V12, P232, DOI 10.1580/1080-6032(2001)012[0232:TEIH]2.0.CO;2; HEARSE DJ, 1977, J MOL CELL CARDIOL, V9, P605, DOI 10.1016/S0022-2828(77)80357-X; HISLOP LJ, 1995, BMJ-BRIT MED J, V311, P725, DOI 10.1136/bmj.311.7007.725; Hughes A, 2007, EMERG MED J, V24, P511, DOI 10.1136/emj.2006.040261; Ireland AJ, 1997, J ACCID EMERG MED, V14, P255; Kibayashi K, 2003, MED SCI LAW, V43, P127, DOI 10.1258/rsmmsl.43.2.127; Kornberger E, 1999, RESUSCITATION, V41, P105, DOI 10.1016/S0300-9572(99)00069-6; Lefrant JY, 2003, INTENS CARE MED, V29, P414, DOI 10.1007/s00134-002-1619-5; Mattu A, 2002, AM J EMERG MED, V20, P314, DOI 10.1053/ajem.2002.32633; McInerney JJ, 2002, EMERG MED J, V19, P219, DOI 10.1136/emj.19.3.219; MOSS J, 1986, SURG GYNECOL OBSTET, V162, P501; Roggla M, 2002, WIEN KLIN WOCHENSCHR, V114, P315; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; SCHNEIDER SM, 1992, EMERG MED REP, V13, P1; SHIELDS CP, 1990, ANN EMERG MED, V19, P1093, DOI 10.1016/S0196-0644(05)81510-0; Silfvast T, 2003, RESUSCITATION, V59, P285, DOI 10.1016/S0300-9572(03)00237-5; Soar J, 2005, RESUSCITATION, V67, pS135, DOI 10.1016/j.resuscitation.2005.10.004; Steedman DJ, 1997, J ACCID EMERG MED, V14, P170; Steele MT, 1996, ANN EMERG MED, V27, P479, DOI 10.1016/S0196-0644(96)70237-8; Torossian A, 2008, BEST PRACT RES-CLIN, V22, P659, DOI 10.1016/j.bpa.2008.07.006; Walpoth BH, 1997, NEW ENGL J MED, V337, P1500, DOI 10.1056/NEJM199711203372103; Wilson E, 2007, EMERG MED J, V24, DOI 10.1136/emj.2006.041590; Wyatt JP, 2006, OXFORD HDB EMERGENCY	30	6	7	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 10	2009	338								b2085	10.1136/bmj.b2085	http://dx.doi.org/10.1136/bmj.b2085			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	458LI	19515708				2023-01-03	WOS:000267022000012
J	Biehl, J; Petryna, A; Gertner, A; Amon, JJ; Picon, PD				Biehl, Joao; Petryna, Adriana; Gertner, Alex; Amon, Joseph J.; Picon, Paulo D.			Judicialisation of the right to health in Brazil	LANCET			English	Editorial Material									[Biehl, Joao; Gertner, Alex] Princeton Univ, Dept Anthropol, Princeton, NJ 08544 USA; [Petryna, Adriana] Univ Penn, Dept Anthropol, Philadelphia, PA 19104 USA; [Amon, Joseph J.] Human RightsWatch, New York, NY USA; [Picon, Paulo D.] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Picon, Paulo D.] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil	Princeton University; University of Pennsylvania; Universidade Federal do Rio Grande do Sul	Biehl, J (corresponding author), Princeton Univ, Dept Anthropol, Princeton, NJ 08544 USA.	jbiehl@princeton.edu	Picon, Paulo/J-2448-2015; Gertner, Alex/S-8417-2019	Gertner, Alex/0000-0001-7781-3681; Amon, Joseph/0000-0002-2455-6703	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD047879] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AZEVEDO S, 2007, EPACA           1212; Biehl Joao, 2007, WILL LIVE AIDS THERA; DASILVA VA, 2008, CLAIMING RIGHT HLTH; FARIAS I, 2008, PRESA QUADRILHA ACUS; Hunt Paul, 2006, 61 SESS GEN ASS DAT; Messeder Ana Márcia, 2005, Cad. Saúde Pública, V21, P525, DOI 10.1590/S0102-311X2005000200019; Petryna A., 2009, EXPT TRAVEL CLIN TRI; PICON PD, 2007, EXEMPLOS PADROES PRE; SARLET I. W., 2008, DIREITOS FUNDAMENTAI, P11; *UN HIGH COMM HUM, 2008, 31 WHO UN HIGH COMM; 2008, ZERO HORA       0822	11	52	56	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN-JUL	2009	373	9682					2182	2184		10.1016/S0140-6736(09)61172-7	http://dx.doi.org/10.1016/S0140-6736(09)61172-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	463PQ	19560587	Green Submitted			2023-01-03	WOS:000267444500010
J	Katsuyama, Y; Kita, T; Funa, N; Horinouchi, S				Katsuyama, Yohei; Kita, Tomoko; Funa, Nobutaka; Horinouchi, Sueharu			Curcuminoid Biosynthesis by Two Type III Polyketide Synthases in the Herb Curcuma longa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GINGER ZINGIBER-OFFICINALE; CHALCONE SYNTHASE; ANIGOZANTHOS-PREISSII; ACID; DECARBOXYLATION; PATHWAY; COA; (S)-3,5-DIHYDROXYPHENYLGLYCINE; PHENYLPHENALENONES; INTERMEDIATE	Curcuminoids found in the rhizome of turmeric, Curcuma longa, possess various biological activities. Despite much attention regarding the biosynthesis of curcuminoids because of their pharmaceutically important properties and biosynthetically intriguing structures, no enzyme systems have been elucidated. Here we propose a pathway for curcuminoid biosynthesis in the herb C. longa, which includes two novel type III polyketide synthases. One of the type III polyketide synthases, named diketide-CoA synthase (DCS), catalyzed the formation of feruloyldiketide-CoA by condensing feruloyl-CoA and malonyl-CoA. The other, named curcumin synthase (CURS), catalyzed the in vitro formation of curcuminoids from cinnamoyldiketide-N-acetylcysteamine (a mimic of the CoA ester) and feruloyl-CoA. Co-incubation of DCS and CURS in the presence of feruloyl-CoA and malonyl-CoA yielded curcumin at high efficiency, although CURS itself possessed low activity for the synthesis of curcumin from feruloyl-CoA and malonyl-CoA. These findings thus revealed the curcumin biosynthetic route in turmeric, in which DCS synthesizes feruloyldiketide-CoA, and CURS then converts the diketide-CoA esters into a curcuminoid scaffold.	[Katsuyama, Yohei; Funa, Nobutaka; Horinouchi, Sueharu] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan; [Kita, Tomoko] House Foods Corp, Somatech Ctr, Chiba 2840033, Japan	University of Tokyo; House Foods Corporation	Horinouchi, S (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp		Katsuyama, Yohei/0000-0003-4905-5320	Research Grant Program 2005 of the New Energy and Industrial Technology Development Organization of Japan; Scientific Research on Priority Area "Applied Genomics" from Monkasho	Research Grant Program 2005 of the New Energy and Industrial Technology Development Organization of Japan; Scientific Research on Priority Area "Applied Genomics" from Monkasho(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported in part by the Research Grant Program 2005 of the New Energy and Industrial Technology Development Organization of Japan and a Grant-in-Aid for Scientific Research on Priority Area "Applied Genomics" from Monkasho.	Abe I, 2001, EUR J BIOCHEM, V268, P3354, DOI 10.1046/j.1432-1327.2001.02255.x; Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; Blecher M, 1981, Methods Enzymol, V72, P404; Brand S, 2006, PLANTA, V224, P413, DOI 10.1007/s00425-006-0228-x; Cao H, 2001, BIOL PHARM BULL, V24, P1389, DOI 10.1248/bpb.24.1389; Chen HW, 2001, P NATL ACAD SCI USA, V98, P14901, DOI 10.1073/pnas.221582098; DENNIFF P, 1980, J CHEM SOC PERK T 1, P2637, DOI 10.1039/p19800002637; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; GILBERT IH, 1995, BIOORG MED CHEM LETT, V5, P1587, DOI 10.1016/0960-894X(95)00276-Y; Guthrie JP, 2002, BIOORG CHEM, V30, P32, DOI 10.1006/bioo.2001.1231; HAMMES GG, 1974, ANNU REV BIOPHYS BIO, V3, P1, DOI 10.1146/annurev.bb.03.060174.000245; Hiserodt R, 1996, J CHROMATOGR A, V740, P51, DOI 10.1016/0021-9673(96)00103-3; HOLSCHER D, 1995, J CHEM SOC CHEM COMM, P525, DOI 10.1039/c39950000525; Holtz E, 2007, TETRAHEDRON, V63, P3293, DOI 10.1016/j.tet.2007.02.062; Houston JB, 2005, ARCH BIOCHEM BIOPHYS, V433, P351, DOI 10.1016/j.abb.2004.09.010; Jez JM, 2000, BIOCHEMISTRY-US, V39, P890, DOI 10.1021/bi991489f; Kamo T, 2000, BIOSCI BIOTECH BIOCH, V64, P2089, DOI 10.1271/bbb.64.2089; Katsuyama Y, 2007, J BIOL CHEM, V282, P37702, DOI 10.1074/jbc.M707569200; Katsuyama Y, 2008, MICROBIOL-SGM, V154, P2620, DOI 10.1099/mic.0.2008/018721-0; Kita T, 2008, BIOSCI BIOTECH BIOCH, V72, P1789, DOI 10.1271/bbb.80075; Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007; MARCUS JP, 1993, BIOCHEM BIOPH RES CO, V190, P1066, DOI 10.1006/bbrc.1993.1157; MATSUMURA S, 1985, B CHEM SOC JPN, V3, P310; Pfeifer V, 2001, J BIOL CHEM, V276, P38370, DOI 10.1074/jbc.M106580200; Ramirez-Ahumada MD, 2006, PHYTOCHEMISTRY, V67, P2017, DOI 10.1016/j.phytochem.2006.06.028; Ringman John M., 2005, Current Alzheimer Research, V2, P131, DOI 10.2174/1567205053585882; ROUGHLEY PJ, 1973, J CHEM SOC PERK T 1, P2379, DOI 10.1039/p19730002379; Schmitt B, 2000, PHYTOCHEMISTRY, V53, P331, DOI 10.1016/S0031-9422(99)00544-0; Schroder J, 1998, BIOCHEMISTRY-US, V37, P8417, DOI 10.1021/bi980204g; Schroder J, 1997, TRENDS PLANT SCI, V2, P373, DOI 10.1016/S1360-1385(97)01104-7; Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009; Song LJ, 2006, J AM CHEM SOC, V128, P14754, DOI 10.1021/ja065247w; Tayyem RR, 2006, NUTR CANCER, V55, P126, DOI 10.1207/s15327914nc5502_2; Weber WM, 2005, BIOORGAN MED CHEM, V13, P3811, DOI 10.1016/j.bmc.2005.03.035	34	110	121	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 24	2009	284	17					11160	11170		10.1074/jbc.M900070200	http://dx.doi.org/10.1074/jbc.M900070200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	437NP	19258320	Green Published, hybrid			2023-01-03	WOS:000265494500020
J	O'Connor, CM; Whellan, DJ; Lee, KL; Keteyian, SJ; Cooper, LS; Ellis, SJ; Leifer, ES; Kraus, WE; Kitzman, DW; Blumenthal, JA; Rendall, DS; Miller, NH; Fleg, JL; Schulman, KA; McKelvie, RS; Zannad, F; Pina, IL				O'Connor, Christopher M.; Whellan, David J.; Lee, Kerry L.; Keteyian, Steven J.; Cooper, Lawton S.; Ellis, Stephen J.; Leifer, Eric S.; Kraus, William E.; Kitzman, Dalane W.; Blumenthal, James A.; Rendall, David S.; Miller, Nancy Houston; Fleg, Jerome L.; Schulman, Kevin A.; McKelvie, Robert S.; Zannad, Faiez; Pina, Ileana L.		HF-ACTION Investigators	Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure HF-ACTION Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	81st Annual Scientific Session of the American-Heart-Association	NOV 08-12, 2008	New Orleans, LA	Amer Heart Assoc			CARDIAC-RESYNCHRONIZATION; INVESTIGATING OUTCOMES; DIAGNOSIS; MORTALITY; MORBIDITY; DESIGN; LIFE	Context Guidelines recommend that exercise training be considered for medically stable outpatients with heart failure. Previous studies have not had adequate statistical power to measure the effects of exercise training on clinical outcomes. Objective To test the efficacy and safety of exercise training among patients with heart failure. Design, Setting, and Patients Multicenter, randomized controlled trial of 2331 medically stable outpatients with heart failure and reduced ejection fraction. Participants in Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) were randomized from April 2003 through February 2007 at 82 centers within the United States, Canada, and France; median follow-up was 30 months. Interventions Usual care plus aerobic exercise training, consisting of 36 supervised sessions followed by home-based training, or usual care alone. Main Outcome Measures Composite primary end point of all-cause mortality or hospitalization and prespecified secondary end points of all-cause mortality, cardiovascular mortality or cardiovascular hospitalization, and cardiovascular mortality or heart failure hospitalization. Results The median age was 59 years, 28% were women, and 37% had New York Heart Association class III or IV symptoms. Heart failure etiology was ischemic in 51%, and median left ventricular ejection fraction was 25%. Exercise adherence decreased from a median of 95 minutes per week during months 4 through 6 of follow-up to 74 minutes per week during months 10 through 12. A total of 759 patients (65%) in the exercise training group died or were hospitalized compared with 796 patients (68%) in the usual care group (hazard ratio [HR], 0.93 [95% confidence interval {CI}, 0.84-1.02]; P=.13). There were nonsignificant reductions in the exercise training group for mortality (189 patients [16%] in the exercise training group vs 198 patients [17%] in the usual care group; HR, 0.96 [95% CI, 0.79-1.17]; P=.70), cardiovascular mortality or cardiovascular hospitalization (632 [55%] in the exercise training group vs 677 [58%] in the usual care group; HR, 0.92 [95% CI, 0.83-1.03]; P=.14), and cardiovascular mortality or heart failure hospitalization (344 [30%] in the exercise training group vs 393 [34%] in the usual care group; HR, 0.87 [95% CI, 0.75-1.00]; P=.06). In prespecified supplementary analyses adjusting for highly prognostic baseline characteristics, the HRs were 0.89 (95% CI, 0.81-0.99; P=.03) for all-cause mortality or hospitalization, 0.91 (95% CI, 0.82-1.01; P=.09) for cardiovascular mortality or cardiovascular hospitalization, and 0.85 (95% CI, 0.74-0.99; P=.03) for cardiovascular mortality or heart failure hospitalization. Other adverse events were similar between the groups. Conclusions In the protocol-specified primary analysis, exercise training resulted in nonsignificant reductions in the primary end point of all-cause mortality or hospitalization and in key secondary clinical end points. After adjustment for highly prognostic predictors of the primary end point, exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization. Trial Registration clinicaltrials.gov Identifier: NCT00047437	[O'Connor, Christopher M.; Whellan, David J.; Lee, Kerry L.; Ellis, Stephen J.; Rendall, David S.; Schulman, Kevin A.] Duke Clin Res Inst, Durham, NC USA; [O'Connor, Christopher M.; Kraus, William E.; Schulman, Kevin A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA; [Lee, Kerry L.] Duke Univ, Sch Med, Dept Biostat & Bioinformat, Durham, NC 27706 USA; [Blumenthal, James A.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA; [Whellan, David J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; [Keteyian, Steven J.] Henry Ford Hosp, Div Cardiovasc Med, Detroit, MI 48202 USA; [Cooper, Lawton S.; Leifer, Eric S.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA; [Fleg, Jerome L.] NHLBI, Div Cardiovasc Dis, Bethesda, MD 20892 USA; [Kitzman, Dalane W.] Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27109 USA; [Miller, Nancy Houston] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [McKelvie, Robert S.] Hamilton Hlth Sci, Hamilton, ON, Canada; [Zannad, Faiez] Univ Henri Poincare, Ctr Hosp Univ, INSERM, Ctr Invest Clin, Nancy, France; [Pina, Ileana L.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	Duke University; Duke University; Duke University; Duke University; Jefferson University; Henry Ford Health System; Henry Ford Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Wake Forest University; Stanford University; McMaster University; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Case Western Reserve University	O'Connor, CM (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC USA.	oconn002@mc.duke.edu	Zannad, Faiez/K-4649-2019	Zile, Michael/0000-0001-7076-221X; Kraus, William E/0000-0003-1930-9684; Hittinger, Luc/0000-0003-1933-5815; Goldberg, Lee/0000-0002-7906-9638; Handberg, Eileen/0000-0002-7805-9577; Hershberger, Ray/0000-0001-5683-6526	NHLBI NIH HHS [U01 HL064264, U01 HL066491-06, U01 HL066501, U01 HL064264-05, U01 HL063747, 5U01HL066494, 5U01HL066497, 5U01HL064250, 5U01HL064265, U01 HL066491, U01 HL068973-06, 5U01HL066501, U01 HL064257-01A2, U01 HL066494, U01 HL066501-06, U01 HL063747-06S1, 5U01HL068973, 5U01HL066491, 5U01HL063747, U01 HL068980, U01 HL068980-05, 5U01HL066482, U01 HL066482, 5U01HL064257, U01 HL064250-06, U01 HL066461, U01 HL068973, 5U01HL068980, U01 HL064257, 5U01HL066461, 5U01HL064264, U01 HL064250, U01 HL066461-06S1, U01 HL064265, U01 HL064265-04, U01 HL066497-04, U01 HL066497, U01 HL066482-04, U01 HL066494-04] Funding Source: Medline; NIA NIH HHS [R37 AG018915] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1988, JAMA, V259, P539; Arnold JMO, 2006, CAN J CARDIOL, V22, P23, DOI 10.1016/S0828-282X(06)70237-9; Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; Bensimhon DR, 2008, AM J CARDIOL, V102, P712, DOI 10.1016/j.amjcard.2008.04.047; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; COATS AJS, 1992, CIRCULATION, V85, P2119, DOI 10.1161/01.CIR.85.6.2119; Cohn JN, 2001, NEW ENGL J MED, V345, P1667, DOI 10.1056/NEJMoa010713; COHN JN, 1983, J AM COLL CARDIOL, V2, P755; COX DR, 1972, J R STAT SOC B, V34, P187; Curtis LH, 2008, ARCH INTERN MED, V168, P418, DOI 10.1001/archinternmed.2007.80; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Flynn KE, 2009, JAMA-J AM MED ASSOC, V301, P1451, DOI 10.1001/jama.2009.457; HAMBRECHT R, 1995, J AM COLL CARDIOL, V25, P1239, DOI 10.1016/0735-1097(94)00568-B; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Konstam MA, 2007, JAMA-J AM MED ASSOC, V297, P1319, DOI 10.1001/jama.297.12.1319; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; McKelvie RS, 2008, HEART FAIL REV, V13, P3, DOI 10.1007/s10741-007-9052-z; Narang R, 1996, EUR HEART J, V17, P120; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pfeffer MA, 2003, LANCET, V362, P759, DOI 10.1016/S0140-6736(03)14282-1; Piepoli MF, 2004, BMJ-BRIT MED J, V328, P189, DOI 10.1136/bmj.37938.645220.EE; Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; Smart N, 2004, AM J MED, V116, P693, DOI 10.1016/j.amjmed.2003.11.033; Whellan DJ, 2007, AM HEART J, V153, P201, DOI 10.1016/j.ahj.2006.11.007	28	1294	1355	1	86	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	2009	301	14					1439	1450		10.1001/jama.2009.454	http://dx.doi.org/10.1001/jama.2009.454			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	429MN	19351941	Bronze, Green Accepted			2023-01-03	WOS:000264924900024
J	Heffelfinger, JD; Voetsch, AC; Nakamura, GV; Sullivan, PS; McNaghten, AD; Huang, L				Heffelfinger, James D.; Voetsch, Andrew C.; Nakamura, Glenn V.; Sullivan, Patrick S.; McNaghten, A. D.; Huang, Laurence			Nonadherence to Primary Prophylaxis against Pneumocystis jirovecii Pneumonia	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; CARINII PNEUMONIA; UNITED-STATES; DRUG-USE; ADHERENCE; PATIENT; EPIDEMIOLOGY; BIAS; AIDS	Background: Despite the effectiveness of prophylaxis, Pneumocystis jirovecii pneumonia (PCP) continues to be the most common serious opportunistic infection among HIV-infected persons. We describe factors associated with nonadherence to primary PCP prophylaxis. Methodology/Principal Findings: We used 2000-2004 data from the Supplement to HIV/AIDS Surveillance (SHAS) project, a cross-sectional interview project of HIV-infected persons >= 18 years conducted in 18 states. We limited the analysis to persons who denied having prior PCP, reported having a current prescription to prevent PCP, and answered the question "In the past 30 days, how often were you able to take the PCP medication(s) exactly the way your doctor told you to take them?'' We used multivariable logistic regression to describe factors associated with nonadherence. Of 1,666 subjects prescribed PCP prophylaxis, 305 (18.3%) were nonadherent. Persons were more likely to be nonadherent if they reported using marijuana (adjusted odds ratio [aOR] = 1.6, 95% confidence interval [CI] = 1.1-2.4), non-injection drugs other than marijuana (aOR = 1.5, 95% CI = 1.0-2.1), or injection drugs (aOR = 2.3, 95% CI = 1.3-4.1) in the past year; their mental health was "not good'' for >= 1 day during the past month (aOR = 1.6, 95% CI = 1.2-2.2); their most recent CD4 count was,200 cells/mu L (aOR = 1.6, 95% CI = 1.1-2.2); or taking ART usually (aOR = 9.6, 95% CI = 6.7-13.7) or sometimes/rarely/never (aOR = 18.4, 95% CI = 11.1-30.4), compared with always, as prescribed. Conclusion/Significance: Providers should inquire about and promote strategies to improve adherence to PCP prophylaxis, particularly among persons who use illicit drugs, have mental health issues, and who are not compliant with ART to reduce the occurrence of PCP.	[Heffelfinger, James D.; Voetsch, Andrew C.; Nakamura, Glenn V.; McNaghten, A. D.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA; [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; [Huang, Laurence] Univ Calif San Francisco, HIV AIDS Div, San Francisco, CA 94143 USA; [Huang, Laurence] Univ Calif San Francisco, Div Pulmonary & Critical Care Med, San Francisco, CA 94143 USA	Centers for Disease Control & Prevention - USA; Emory University; Rollins School Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Heffelfinger, JD (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA.	izh7@cdc.gov	Voetsch, Andrew/CAF-1978-2022; Huang, Laurence/AAE-1590-2019; Huang, Laurence/AAZ-7120-2021	Huang, Laurence/0000-0003-3888-2195; Voetsch, Andrew/0000-0002-0783-1312; Sullivan, Patrick Sean/0000-0002-7728-0587	National Institutes of Health (NIH) [K24 087713]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL087713] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	LH was partly funded by the National Institutes of Health (NIH) K24 087713. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agresti A., 2012, CATEGORICAL DATA ANA; Altice FL, 2001, J ACQ IMMUN DEF SYND, V28, P47, DOI 10.1097/00042560-200109010-00008; Ammassari A, 2004, PSYCHOSOMATICS, V45, P394, DOI 10.1176/appi.psy.45.5.394; Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1007/s11606-002-0044-3; Berg KM, 2004, J GEN INTERN MED, V19, P1111, DOI 10.1111/j.1525-1497.2004.30445.x; Buehler JW, 1996, PUBLIC HEALTH REP, V111, P133; Carrieri MP, 2006, JAIDS-J ACQ IMM DEF, V41, P477, DOI 10.1097/01.qai.0000186364.27587.0e; *CDC, 1990, HIV AIDS SURV REP 19; *CDC, 1993, HIV AIDS SURV REP 19; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; Gordillo V, 1999, AIDS, V13, P1763, DOI 10.1097/00002030-199909100-00021; HAY JW, 1988, J ACQ IMMUN DEF SYND, V1, P466; HAYNES RB, 1980, HYPERTENSION, V2, P757, DOI 10.1161/01.HYP.2.6.757; Holmes WC, 2002, J GEN INTERN MED, V17, P677, DOI 10.1046/j.1525-1497.2002.00746.x; Howard AA, 2002, AIDS, V16, P2175, DOI 10.1097/00002030-200211080-00010; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Kaplan JE, 1999, J ACQ IMMUN DEF SYND, V21, P228, DOI 10.1097/00126334-199907010-00008; Kaplan Jonathan E, 2002, MMWR Recomm Rep, V51, P1; Lafeuillade A, 2001, INT J STD AIDS, V12, P18, DOI 10.1258/0956462011924290; Lundberg BE, 2000, AIDS, V14, P2559, DOI 10.1097/00002030-200011100-00019; Maisto SA, 2003, AM J ADDICTION, V12, pS12, DOI 10.1111/j.1521-0391.2003.tb00493.x; Martini M, 2004, EUR J EPIDEMIOL, V19, P585, DOI 10.1023/B:EJEP.0000032353.03967.ef; Morris A, 2004, EMERG INFECT DIS, V10, P1713, DOI 10.3201/eid1010.030985; Moss AR, 2004, CLIN INFECT DIS, V39, P1190, DOI 10.1086/424008; Murri R, 2004, J GEN INTERN MED, V19, P1104, DOI 10.1111/j.1525-1497.2004.30248.x; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SAMET JH, 1992, AM J MED, V92, P495, DOI 10.1016/0002-9343(92)90746-X; Starace F, 2002, JAIDS, V31, pS136, DOI 10.1097/00126334-200212153-00010; Sullivan PS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000552; SUMARTOJO E, 1993, AM REV RESPIR DIS, V147, P1311, DOI 10.1164/ajrccm/147.5.1311; Teshale EH, 2007, CLIN INFECT DIS, V44, P879, DOI 10.1086/511862; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND	33	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2009	4	3							e5002	10.1371/journal.pone.0005002	http://dx.doi.org/10.1371/journal.pone.0005002			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437PK	19319199	Green Published, Green Submitted, gold			2023-01-03	WOS:000265499200019
J	Janssen, DJA; Alsemgeest, TPG; Widdershoven, GAM; Wouters, EFM; Schols, JMGA; Spruit, MA				Janssen, Daisy J. A.; Alsemgeest, Ton P. G.; Widdershoven, Guy A. M.; Wouters, Emiel F. M.; Schols, Jos M. G. A.; Spruit, Martijn A.			The last wish of a patient with end stage chronic obstructive pulmonary disease	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Janssen, Daisy J. A.; Alsemgeest, Ton P. G.] Proteion Thuis, Cent Dept Treatment & Care, NL-6085 NM Horn, Netherlands; [Widdershoven, Guy A. M.] Univ Maastricht, Sch Publ Hlth & Primary Care, CAPHRI, Fac Hlth Med & Life Sci, NL-6229 ER Maastricht, Netherlands; [Wouters, Emiel F. M.] MUMC, Dept Resp Med, NL-6229 HX Maastricht, Netherlands; [Wouters, Emiel F. M.] Ctr Integrated Rehabil Organ Failure CIRO, NL-6085 NM Horn, Netherlands; [Schols, Jos M. G. A.] Univ Maastricht, Fac Hlth Med & Life Sci, Dept Gen Practice, NL-6229 HA Maastricht, Netherlands; [Spruit, Martijn A.] Ctr Integrated Rehabil Organ Failure CIRO, Dept Res Dev & Educ, NL-6085 NM Horn, Netherlands	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University	Janssen, DJA (corresponding author), Proteion Thuis, Cent Dept Treatment & Care, NL-6085 NM Horn, Netherlands.	daisyjanssen@proteion.nl	Janssen, Daisy J.A./AAW-2248-2021; Wouters, Emiel/ABD-6200-2021	Janssen, Daisy J.A./0000-0002-1827-9869; 					0	5	6	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 8	2008	337								a2701	10.1136/bmj.a2701	http://dx.doi.org/10.1136/bmj.a2701			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	399BY	19064602				2023-01-03	WOS:000262776600003
J	Agger, EM; Rosenkrands, I; Hansen, J; Brahimi, K; Vandahl, BS; Aagaard, C; Werninghaus, K; Kirschning, C; Lang, R; Christensen, D; Theisen, M; Follmann, F; Andersen, P				Agger, Else Marie; Rosenkrands, Ida; Hansen, Jon; Brahimi, Karima; Vandahl, Brian S.; Aagaard, Claus; Werninghaus, Kerstin; Kirschning, Carsten; Lang, Roland; Christensen, Dennis; Theisen, Michael; Follmann, Frank; Andersen, Peter			Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements	PLOS ONE			English	Article							OUTER-MEMBRANE PROTEIN; MEROZOITE SURFACE PROTEIN-1; TUBERCULOSIS SUBUNIT VACCINE; BACILLUS-CALMETTE-GUERIN; T-CELL EPITOPES; PROTECTIVE IMMUNITY; CORD FACTOR; IMMUNIZATION; RESPONSES; IMMUNOGENICITY	Background: It is now emerging that for vaccines against a range of diseases including influenza, malaria and HIV, the induction of a humoral response is insufficient and a substantial complementary cell-mediated immune response is necessary for adequate protection. Furthermore, for some diseases such as tuberculosis, a cellular response seems to be the sole effector mechanism required for protection. The development of new adjuvants capable of inducing highly complex immune responses with strong antigen-specific T-cell responses in addition to antibodies is therefore urgently needed. Methods and Findings: Herein, we describe a cationic adjuvant formulation (CAF01) consisting of DDA as a delivery vehicle and synthetic mycobacterial cordfactor as immunomodulator. CAF01 primes strong and complex immune responses and using ovalbumin as a model vaccine antigen in mice, antigen specific cell-mediated-and humoral responses were obtained at a level clearly above a range of currently used adjuvants (Aluminium, monophosphoryl lipid A, CFA/IFA, Montanide). This response occurs through Toll-like receptor 2, 3, 4 and 7-independent pathways whereas the response is partly reduced in MyD88-deficient mice. In three animal models of diseases with markedly different immunological requirement; Mycobacterium tuberculosis (cell-mediated), Chlamydia trachomatis (cell-mediated/humoral) and malaria (humoral) immunization with CAF01-based vaccines elicited significant protective immunity against challenge. Conclusion: CAF01 is potentially a suitable adjuvant for a wide range of diseases including targets requiring both CMI and humoral immune responses for protection.	[Agger, Else Marie; Rosenkrands, Ida; Hansen, Jon; Brahimi, Karima; Vandahl, Brian S.; Aagaard, Claus; Christensen, Dennis; Theisen, Michael; Follmann, Frank; Andersen, Peter] Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark; [Werninghaus, Kerstin; Kirschning, Carsten; Lang, Roland] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany	Statens Serum Institut; Technical University of Munich	Agger, EM (corresponding author), Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark.	eag@ssi.dk	Lang, Roland/C-3287-2011; Christensen, Dennis/C-6378-2008	Christensen, Dennis/0000-0003-2382-8639; Lang, Roland/0000-0003-0502-3677; Hansen, Jon Ulf/0000-0002-6410-5755; Follmann, Frank/0000-0002-8373-7774; Andersen, Peter/0000-0002-5869-2551	European Commission [LSHP-CT-2003-503367]	European Commission(European CommissionEuropean Commission Joint Research Centre)	This work was in part funded by the European Commission contract no. LSHP-CT-2003-503367.	Agger EM, 2006, VACCINE, V24, P5452, DOI 10.1016/j.vaccine.2006.03.072; Ahlborg N, 2000, INFECT IMMUN, V68, P2102, DOI 10.1128/IAI.68.4.2102-2109.2000; Bennekov T, 2006, EUR J IMMUNOL, V36, P3346, DOI 10.1002/eji.200636128; Brandt L, 2000, INFECT IMMUN, V68, P791, DOI 10.1128/IAI.68.2.791-795.2000; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; da Fonseca DM, 2007, IMMUNOLOGY, V121, P508, DOI 10.1111/j.1365-2567.2007.02597.x; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; Dietrich J, 2005, J IMMUNOL, V174, P6332, DOI 10.4049/jimmunol.174.10.6332; Dietrich J, 2007, J IMMUNOL, V178, P3721, DOI 10.4049/jimmunol.178.6.3721; Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV-100103136; Garcon N, 2007, EXPERT REV VACCINES, V6, P723, DOI 10.1586/14760584.6.5.723; Gavin AL, 2006, SCIENCE, V314, P1936, DOI 10.1126/science.1135299; Geisel RE, 2005, J IMMUNOL, V174, P5007, DOI 10.4049/jimmunol.174.8.5007; Gluck R, 2004, EXPERT OPIN BIOL TH, V4, P1139, DOI 10.1517/14712598.4.7.1139; Gramzinski RA, 2001, INFECT IMMUN, V69, P1643, DOI 10.1128/IAI.69.3.1643-1649.2001; Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681; Hansen J, 2008, J INFECT DIS, V198, P758, DOI 10.1086/590670; Heit A, 2007, EUR J IMMUNOL, V37, P2063, DOI 10.1002/eji.200737169; Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400; Hu JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001952; JOUVINMARCHE E, 1989, IMMUNOGENETICS, V29, P92, DOI 10.1007/BF00395856; Kamath AT, 2008, EUR J IMMUNOL, V38, P1247, DOI 10.1002/eji.200737889; Kazzaz J, 2006, J CONTROL RELEASE, V110, P566, DOI 10.1016/j.jconrel.2005.10.010; Kim SK, 2000, J IMMUNOL, V165, P7285, DOI 10.4049/jimmunol.165.12.7285; Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329; Korsholm KS, 2007, IMMUNOLOGY, V121, P216, DOI 10.1111/j.1365-2567.2007.02560.x; Lee EAM, 2002, INFECT IMMUN, V70, P1417, DOI 10.1128/IAI.70.3.1417-1421.2002; Lipford GB, 1997, EUR J IMMUNOL, V27, P3420, DOI 10.1002/eji.1830271242; MCMICHAEL AJ, 1981, CLIN EXP IMMUNOL, V43, P276; Moore T, 2003, J INFECT DIS, V188, P617, DOI 10.1086/377134; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; O'Hagan DT, 2007, EXPERT REV VACCINES, V6, P699, DOI 10.1586/14760584.6.5.699; Olsen AW, 2006, J INFECT DIS, V194, P1258, DOI 10.1086/508203; Olsen AW, 2001, INFECT IMMUN, V69, P2773, DOI 10.1128/IAI.69.5.2773-2778.2001; Ortiz L, 2000, INFECT IMMUN, V68, P1719, DOI 10.1128/IAI.68.3.1719-1723.2000; Pal S, 1997, INFECT IMMUN, V65, P3361, DOI 10.1128/IAI.65.8.3361-3369.1997; Pal S, 2005, INFECT IMMUN, V73, P8153, DOI 10.1128/IAI.73.12.8153-8160.2005; PIMM MV, 1979, INT J CANCER, V24, P780, DOI 10.1002/ijc.2910240614; Rafati S, 2005, VACCINE, V23, P3716, DOI 10.1016/j.vaccine.2005.02.009; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Rosenkrands I, 2005, INFECT IMMUN, V73, P5817, DOI 10.1128/IAI.73.9.5817-5826.2005; Schellack C, 2006, VACCINE, V24, P5461, DOI 10.1016/j.vaccine.2006.03.071; Skeiky YAW, 2004, J IMMUNOL, V172, P7618, DOI 10.4049/jimmunol.172.12.7618; SU H, 1995, VACCINE, V13, P1023, DOI 10.1016/0264-410X(95)00017-U; Su SB, 2005, J IMMUNOL, V175, P6303, DOI 10.4049/jimmunol.175.10.6303; Suzuki Y, 2004, CANCER RES, V64, P8754, DOI 10.1158/0008-5472.CAN-04-1691; Taylor RR, 1998, AM J TROP MED HYG, V58, P406, DOI 10.4269/ajtmh.1998.58.406; THEISEN M, 1994, INFECT IMMUN, V62, P3270, DOI 10.1128/IAI.62.8.3270-3275.1994; Tian JH, 1997, INFECT IMMUN, V65, P3032, DOI 10.1128/IAI.65.8.3032-3036.1997; Valmori D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI 10.1073/pnas.0703395104; VANDISSEL JT, LANCET UNPUB; Vangala A, 2006, J PHARM PHARMACOL, V58, P787, DOI 10.1211/jpp.58.6.0009; Zaks K, 2006, J IMMUNOL, V176, P7335, DOI 10.4049/jimmunol.176.12.7335	53	222	230	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2008	3	9							e3116	10.1371/journal.pone.0003116	http://dx.doi.org/10.1371/journal.pone.0003116			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	422JQ	18776936	Green Published, gold, Green Submitted			2023-01-03	WOS:000264424300001
J	Kumle, M				Kumle, Merethe			Declining breast cancer incidence and decreased HRT use	LANCET			English	Editorial Material							THERAPY		Univ Tromso, Inst Community Med, Fac Med, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Kumle, M (corresponding author), Univ Tromso, Inst Community Med, Fac Med, N-9037 Tromso, Norway.	Merethe.Kumle@ism.uit.no						Allemand H, 2008, B CANCER, V95, P11, DOI 10.1684/bdc.2008.0556; Beral V, 2006, J MED SCREEN, V13, P59, DOI 10.1258/096914106777589678; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Canfell K, 2008, MED J AUSTRALIA, V188, P1; Eggen AE, 2005, J CLIN ONCOL, V23, P3636, DOI 10.1200/JCO.2005.05.378; Hofvind S, 2008, ACTA ONCOL, V47, P225, DOI 10.1080/02841860701518041; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOHNSTON M, 2006, NZ HERALD       1220; Katalinic A, 2008, BREAST CANCER RES TR, V107, P427, DOI 10.1007/s10549-007-9566-z; Kerlikowske K, 2007, JNCI-J NATL CANCER I, V99, P1335, DOI 10.1093/jnci/djm111; Kliewer EV, 2007, NEW ENGL J MED, V357, P509; *NORW I PUBL HLTH, DRUG CONS NORW; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Soerjomataram I, 2007, J CLIN ONCOL, V25, P5038, DOI 10.1200/JCO.2007.13.7281; The Norwegian Cancer Registry, 2008, INC DAT BREAST CANC; Zahl PH, 2007, NEW ENGL J MED, V357, P510	18	95	97	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 23	2008	372	9639					608	610		10.1016/S0140-6736(08)61255-6	http://dx.doi.org/10.1016/S0140-6736(08)61255-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	340BX	18722851				2023-01-03	WOS:000258622200007
J	Fosarelli, P				Fosarelli, Pat			Medicine, spirituality, and patient care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Ecumen Inst Theol, Baltimore, MD 21210 USA		Fosarelli, P (corresponding author), Ecumen Inst Theol, 5400 Roland Ave, Baltimore, MD 21210 USA.	pfosarelli@stmarys.edu						Curlin FA, 2007, ARCH INTERN MED, V167, P649, DOI 10.1001/archinte.167.7.649; *JOINT COMM, 2004, SPIR ASS; KOENIG H, 2007, SPIRITUALITY PATIENT, pCH1; Koenig HG, 2002, JAMA-J AM MED ASSOC, V288, P487, DOI 10.1001/jama.288.4.487; Mueller PS, 2001, MAYO CLIN PROC, V76, P1225, DOI 10.4065/76.12.1225; Puchalski C, 2000, J Palliat Med, V3, P129, DOI 10.1089/jpm.2000.3.129; Silverman M. E., 2003, THE QUOTABLE OSLER	7	16	18	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 20	2008	300	7					836	838		10.1001/jama.300.7.836	http://dx.doi.org/10.1001/jama.300.7.836			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	338VM	18714065				2023-01-03	WOS:000258537500025
J	Gutierrez, OM; Mannstadt, M; Isakova, T; Rauh-Hain, JA; Tamez, H; Shah, A; Smith, K; Lee, H; Thadhani, R; Juppner, H; Wolf, M				Gutierrez, Orlando M.; Mannstadt, Michael; Isakova, Tamara; Rauh-Hain, Jose Alejandro; Tamez, Hector; Shah, Anand; Smith, Kelsey; Lee, Hang; Thadhani, Ravi; Juppner, Harald; Wolf, Myles			Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; VITAMIN-D; VASCULAR CALCIFICATION; ONCOGENIC OSTEOMALACIA; MINERAL METABOLISM; PHOSPHATE; SURVIVAL; FGF23; RACE	Background: Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown. Methods: We examined mortality according to serum phosphate levels in a prospective cohort of 10,044 patients who were beginning hemodialysis treatment and then analyzed FGF-23 levels and mortality in a nested case-control sample of 200 subjects who died and 200 who survived during the first year of hemodialysis treatment. We hypothesized that increased FGF-23 levels at the initiation of hemodialysis would be associated with increased mortality. Results: Serum phosphate levels in the highest quartile (>5.5 mg per deciliter [1.8 mmol per liter]) were associated with a 20% increase in the multivariable adjusted risk of death, as compared with normal levels (3.5 to 4.5 mg per deciliter [1.1 to 1.4 mmol per liter]) (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4). Median C-terminal FGF-23 (cFGF-23) levels were significantly higher in case subjects than in controls (2260 vs. 1406 reference units per milliliter, P<0.001). Multivariable adjusted analyses showed that increasing FGF-23 levels were associated with a monotonically increasing risk of death when examined either on a continuous scale (odds ratio per unit increase in log-transformed cFGF-23 values, 1.8; 95% CI, 1.4 to 2.4) or in quartiles, with quartile 1 as the reference category (odds ratio for quartile 2, 1.6 [95% CI, 0.8 to 3.3]; for quartile 3, 4.5 [95% CI, 2.2 to 9.4]; and for quartile 4, 5.7 [95% CI, 2.6 to 12.6]). Conclusions: Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment. Future studies might investigate whether FGF-23 is a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease.	[Gutierrez, Orlando M.; Isakova, Tamara; Rauh-Hain, Jose Alejandro; Tamez, Hector; Shah, Anand; Smith, Kelsey; Thadhani, Ravi; Wolf, Myles] Massachusetts Gen Hosp, Renal Unit, Boston, MA 02114 USA; [Mannstadt, Michael; Juppner, Harald] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Lee, Hang] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; [Juppner, Harald] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Juppner, Harald] Massachusetts Gen Hosp, Pediat Nephrol Unit, Dept Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Wolf, M (corresponding author), Univ Miami, Div Nephrol & Hypertens, Miller Sch Med, 1120 NW 14th St, Miami, FL 33136 USA.	mwolf2@med.miami.edu	Mannstadt, Michael/AAO-1124-2020	Mannstadt, Michael/0000-0003-0867-9778	NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR017376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK046718, K08DK081669, R21DK071674, R01DK076116] Funding Source: NIH RePORTER; NCRR NIH HHS [K30RR02229207, K23RR017376, K23 RR017376] Funding Source: Medline; NIDDK NIH HHS [R01DK076116, R37 DK046718-17, R37 DK046718, R21DK071674, R01 DK076116, R21 DK071674, K08 DK081669] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antoniucci DM, 2006, J CLIN ENDOCR METAB, V91, P3144, DOI 10.1210/jc.2006-0021; BELL NH, 1985, J CLIN INVEST, V76, P470, DOI 10.1172/JCI111995; Ben-Dov IZ, 2007, J CLIN INVEST, V117, P4003, DOI 10.1172/JCI32409; Benet-Pages A, 2005, HUM MOL GENET, V14, P385, DOI 10.1093/hmg/ddi034; Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2; Burnett SAM, 2006, J BONE MINER RES, V21, P1187, DOI 10.1359/JBMR.060507; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; Cozzolino M, 2005, KIDNEY INT, V68, P429, DOI 10.1111/j.1523-1755.2005.00421.x; De Beur SMJ, 2002, J BONE MINER RES, V17, P1102, DOI 10.1359/jbmr.2002.17.6.1102; Foley RN, 2007, J AM SOC NEPHROL, V18, P2575, DOI 10.1681/ASN.2006121411; Frankenfield DL, 2003, J AM SOC NEPHROL, V14, P180, DOI 10.1097/01.ASN.0000037400.83593.E6; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052; Gutierrez OM, 2008, KIDNEY INT, V73, P956, DOI 10.1038/ki.2008.4; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Kalantar-Zadeh K, 2006, KIDNEY INT, V70, P771, DOI 10.1038/sj.ki.5001514; Kestenbaum B, 2005, J AM SOC NEPHROL, V16, P520, DOI 10.1681/ASN.2004070602; Koiwa F, 2005, THER APHER DIAL, V9, P336, DOI 10.1111/j.1744-9987.2005.00293.x; Larsson T, 2003, KIDNEY INT, V64, P2272, DOI 10.1046/j.1523-1755.2003.00328.x; Melamed ML, 2006, KIDNEY INT, V70, P351, DOI 10.1038/sj.ki.5001542; Nagano N, 2006, KIDNEY INT, V69, P531, DOI 10.1038/sj.ki.5000020; RITZ E, 1973, KIDNEY INT, V4, P116, DOI 10.1038/ki.1973.90; Robinson BM, 2006, J AM SOC NEPHROL, V17, P2910, DOI 10.1681/ASN.2005101078; Saito H, 2005, J BIOL CHEM, V280, P2543, DOI 10.1074/jbc.M408903200; Shigematsu T, 2004, AM J KIDNEY DIS, V44, P250, DOI 10.1053/j.ajkd.2004.04.029; Shimada T, 2004, J CLIN INVEST, V113, P561, DOI 10.1172/JCI200419081; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Sitara D, 2006, AM J PATHOL, V169, P2161, DOI 10.2353/ajpath.2006.060329; Stubbs JR, 2007, J AM SOC NEPHROL, V18, P2116, DOI 10.1681/ASN.2006121385; Teng M, 2005, J AM SOC NEPHROL, V16, P1115, DOI 10.1681/ASN.2004070573; Teng M, 2003, NEW ENGL J MED, V349, P446, DOI 10.1056/NEJMoa022536; Tonelli, 2007, CIRCULATION, V116, pE556, DOI 10.1161/CIRCULATIONAHA.107.187927; Tonelli M, 2005, CIRCULATION, V112, P2627, DOI 10.1161/CIRCULATIONAHA.105.553198; *US REN DAT SYST, 2004, USRDS 2003 ANN DAT R; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Wolf M, 2007, KIDNEY INT, V72, P1004, DOI 10.1038/sj.ki.5002451; Wolf M, 2008, J AM SOC NEPHROL, V19, P1379, DOI 10.1681/ASN.2007091002; Yu XJ, 2005, ENDOCRINOLOGY, V146, P4647, DOI 10.1210/en.2005-0670	39	1304	1365	2	49	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2008	359	6					584	592		10.1056/NEJMoa0706130	http://dx.doi.org/10.1056/NEJMoa0706130			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334IY	18687639	Green Accepted			2023-01-03	WOS:000258216700006
J	Doody, RS; Gavrilova, SI; Sano, M; Thomas, RG; Aisen, PS; Bachurin, SO; Seely, L; Hung, D				Doody, Rachelle S.; Gavrilova, Svetlana I.; Sano, Mary; Thomas, Ronald G.; Aisen, Paul S.; Bachurin, Sergey O.; Seely, Lynn; Hung, David		Dimebon Investigators	Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study	LANCET			English	Article							MINI-MENTAL STATE; CONTROLLED TRIAL; DONEPEZIL; AD; GALANTAMINE; PREVALENCE; INVENTORY; DEMENTIA; EFFICACY; 1-YEAR	Background Although treatments for Alzheimer's disease sometimes improve cognition, functional ability, or behaviour compared with baseline levels, such improvements are inconsistent across studies and measures, and effects diminish over time. More effective treatments are needed. We assessed the safety, tolerability and efficacy of dimebon in the treatment of patients with mild-to-moderate Alzheimer's disease. Methods We enrolled 183 patients with mild-to-moderate Alzheimer's disease (mini-mental state examination [MMSE] scores 10-24) at 11 sites in Russia. Patients were randomly assigned by a computer-generated randomisation scheme to receive oral dimebon, 20 mg three times a day (60 mg/day [n=89]), or matched placebo (n=94). Other antidementia drugs were not allowed. The primary outcome measure assessed cognition, the difference in mean change from baseline to week 26, or last completed observation on the cognitive subscale of the Alzheimer's disease assessment scale (ADAS-cog). All patients and study personnel were blinded throughout the study. We compared dimebon with placebo with an intention-to-treat analysis, with last observation carried forward (ITT-LOCF) imputation. Analyses were repeated on the fully evaluable population, defined as all patients in the intention-to-treat population who had an ADAS-cog at week 26 and at least 80% compliance. 134 patients (68 in dimebon group, 66 in placebo group) enrolled in the 6-month blinded extension phase of the study. This trial is registered with Clinicaltrials.gov, number NCT00377715. Findings 155 (85%) patients completed the trial (78 [88%] in dimebon group, 77 [82%] in placebo group). Treatment with dimebon resulted in significant benefits in ADAS-cog compared with placebo (ITT-LOCF) at week 26 (mean drug-placebo difference -4.0 [95% CI -5.73 to -2.28]; p<0.0001). Results of the ITT-LOCF and the evaluable population analyses were much the same for all measures. Patients given dimebon were significantly improved over baseline for ADAS-cog (mean difference -1.9 [-2.92 to -0.85]; p=0.0005). Dimebon was well tolerated: dry mouth and depressed mood or depression were the most common adverse events associated with dimebon (12 [14%] patients for each symptom by week 26). The percentage of patients who had adverse events in the two groups did not differ. Interpretation Dimebon was safe, well tolerated, and significantly improved the clinical course of patients with mild-to-moderate Alzheimer's disease.	[Doody, Rachelle S.] Baylor Coll Med, Alzheimers Dis & Memory Disorders Ctr, Dept Neurol, Houston, TX 77030 USA; [Gavrilova, Svetlana I.] Russian Acad Med Sci, Alzheimers Dis & Related Disorders Res Ctr, Moscow, Russia; [Sano, Mary] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY USA; [Thomas, Ronald G.] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA; [Aisen, Paul S.] Georgetown Univ, Sch Med, Memory Disorders Program, Washington, DC USA; [Bachurin, Sergey O.] Russian Acad Sci, Inst Physiol Act Cpds, Chernogolovka 142432, Russia; [Seely, Lynn; Hung, David] Medivat Inc, San Francisco, CA USA	Baylor College of Medicine; Russian Academy of Medical Sciences; Icahn School of Medicine at Mount Sinai; University of California System; University of California San Diego; Georgetown University; Russian Academy of Sciences; Institute of Physiologically Active Compounds of the Russian Academy of Sciences	Doody, RS (corresponding author), Baylor Coll Med, Alzheimers Dis & Memory Disorders Ctr, Dept Neurol, 6550 Fannin St,Suite 1801, Houston, TX 77030 USA.	rdoody@bcm.tmc.edu	Sergey, Bachurin/I-1708-2018; Gavrilova, Svetlana/B-4548-2016	Gavrilova, Svetlana/0000-0001-6683-0240				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bachurin S, 2001, ANN NY ACAD SCI, V939, P425; Bachurin SO, 2003, ANN NY ACAD SCI, V993, P334, DOI 10.1111/j.1749-6632.2003.tb07541.x; Birks J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005593; COCKRELL JR, 1988, PSYCHOPHARMACOL BULL, V24, P689; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; ESTELLE F, 1994, NEW ENGL J MED, V330, P1663; Farlow M, 2000, EUR NEUROL, V44, P236, DOI 10.1159/000008243; Ferri CP, 2005, LANCET, V366, P2112, DOI 10.1016/S0140-6736(05)67889-0; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Grigor'ev VV, 2003, B EXP BIOL MED+, V136, P474, DOI 10.1023/B:BEBM.0000017097.75818.14; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Karlawish JHT, 1998, ARCH NEUROL-CHICAGO, V55, P1420, DOI 10.1001/archneur.55.11.1420; Lermontova NN, 2001, B EXP BIOL MED+, V132, P1079; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5; Mohs RC, 2001, NEUROLOGY, V57, P481, DOI 10.1212/WNL.57.3.481; Raskind MA, 2000, NEUROLOGY, V54, P2261, DOI 10.1212/WNL.54.12.2261; REISINGER TJG, 1997, DIELECTR NEWSLETT, V11, P3; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; ROSEN WG, 1980, ANN NEUROL, V7, P486, DOI 10.1002/ana.410070516; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489	27	372	414	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 19	2008	372	9634					207	215		10.1016/S0140-6736(08)61074-0	http://dx.doi.org/10.1016/S0140-6736(08)61074-0			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	327YH	18640457				2023-01-03	WOS:000257763900030
J	Murray, SA; Sheikh, A				Murray, Scott A.; Sheikh, Aziz			Making a difference - Palliative care beyond cancer - Care for all at the end of life	BRITISH MEDICAL JOURNAL			English	Editorial Material							ILLNESS		[Murray, Scott A.; Sheikh, Aziz] Univ Edinburgh, Div Community Hlth Sci, Gen Practice Sect, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Murray, SA (corresponding author), Univ Edinburgh, Div Community Hlth Sci, Gen Practice Sect, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland.	Scott.Murray@ed.ac.uk	Sheikh, Aziz/D-2818-2009; Ram, Prem/K-4511-2012	Sheikh, Aziz/0000-0001-7022-3056; Harris, Fiona/0000-0003-3258-5624; Grant, Liz/0000-0001-7248-7792				Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; MATHERS CD, 2006, UPDATED PROJECTIONS; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Reisfeld GM, 2007, J PALLIAT MED, V10, P247, DOI 10.1089/jpm.2007.10.247; World Health Organization, 2004, PALL CAR OLD PEOPL; World Health Organization, 2004, PALL CAR SOL FACTS; World Health Organization, 2005, PREVENTING CHRONIC D	10	122	125	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					958	+		10.1136/bmj.39535.491238.94	http://dx.doi.org/10.1136/bmj.39535.491238.94			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	296KC	18397942	Green Published, Green Submitted, Bronze			2023-01-03	WOS:000255540900045
J	Moryl, N; Coyle, N; Foley, KM				Moryl, Natalie; Coyle, Nessa; Foley, Kathleen M.			Managing an acute pain crisis in a patient with advanced cancer - "This is as much of a crisis as a code"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PALLIATIVE CARE; QT-INTERVAL; INTRAVENOUS METHADONE; PARENTERAL METHADONE; TRANSDERMAL FENTANYL; POSTOPERATIVE PAIN; BOWEL OBSTRUCTION; ASSISTED SUICIDE; OPIOID ROTATION; DOUBLE-BLIND	The assessment and management of an acute pain crisis in the setting of advanced illness is challenging. Using the case of Mr X, a 33- year- old man with advanced metastatic mucinous adenocarcinoma of the appendix and "15 out of 10" pain, we explore the issues of acute pain and its management. We define a pain crisis as an event in which the patient reports pain that is severe, uncontrolled, and causing distress for the patient, family members, or both. Our management strategy focuses on making a pain diagnosis, differentiating reversible from intractable causes of pain, and making decisions about further workup; selecting the opioid and monitoring and treating opioid adverse effects; titrating and rotating opioid and coanalgesics; consulting experts to treat a pain crisis as quickly as possible to prevent unnecessary suffering; and co- opting the available institutional resources. The timely intervention of a palliative care team and its expertise can provide the staff, patients, and their families the benefit of an interdisciplinary approach and help the patients address goals of care; understand the benefits and risks of treatment decisions; and meet the psychological, social, and existential needs of the patient and the family commonly seen in this setting.	[Moryl, Natalie; Coyle, Nessa; Foley, Kathleen M.] Mem Sloan Kettering Canc Ctr, Dept Neurol, Pain & Palliat Care Serv, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Foley, KM (corresponding author), Cornell Univ, Weill Med Coll, 1275 York Ave, New York, NY 10021 USA.	foleyk@mskcc.org						Al-Khatib SM, 2003, JAMA-J AM MED ASSOC, V289, P2120, DOI 10.1001/jama.289.16.2120; *AM PAIN SOC, 2007, PRINC AN US TREAT AC; [Anonymous], 2007, NCCN CLIN PRACTICE G; Anthony T, 2007, J PAIN SYMPTOM MANAG, V34, pS49, DOI 10.1016/j.jpainsymman.2007.04.011; Fernandes MDBD, 2007, REV LAT-AM ENFERM, V15, P318, DOI 10.1590/S0104-11692007000200019; Bell RF, 2005, ACTA ANAESTH SCAND, V49, P1405, DOI 10.1111/j.1399-6576.2005.00814.x; Ben-Ari Alon, 2007, J Pain Palliat Care Pharmacother, V21, P7, DOI 10.1300/J354v21n01_04; BERZOFF J, 2004, LIVING DYING; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Boettger Soenke, 2005, Palliat Support Care, V3, P227; Bookbinder M, 2005, J PAIN SYMPTOM MANAG, V29, P529, DOI 10.1016/j.jpainsymman.2004.05.011; Braiteh F, 2007, J PALLIAT MED, V10, P948, DOI 10.1089/jpm.2006.0257; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Bruera E, 2000, J PAIN SYMPTOM MANAG, V19, P427, DOI 10.1016/S0885-3924(00)00138-X; Bruera E, 1991, J Palliat Care, V7, P6; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Carver AC, 1999, NEUROLOGY, V53, P284, DOI 10.1212/WNL.53.2.284; CHALLONER K R, 1990, Journal of Emergency Medicine, V8, P67, DOI 10.1016/0736-4679(90)90391-8; Cherny N I, 1994, J Palliat Care, V10, P57; Cherny NI, 2006, NAT CLIN PRACT ONCOL, V3, P492, DOI 10.1038/ncponc0583; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; CODD EE, 1995, J PHARMACOL EXP THER, V274, P1263; Cohen MZ, 2003, J PAIN SYMPTOM MANAG, V25, P519, DOI 10.1016/S0885-3924(03)00068-X; Colucci R D, 2001, Am J Ther, V8, P231, DOI 10.1097/00045391-200107000-00004; Coyle N, 2006, J PAIN SYMPTOM MANAG, V32, P266, DOI 10.1016/j.jpainsymman.2006.04.003; Cranford Ronald E, 2002, HEC Forum, V14, P259, DOI 10.1023/A:1020533215676; CREWS JC, 1993, CANCER-AM CANCER SOC, V72, P2266, DOI 10.1002/1097-0142(19931001)72:7<2266::AID-CNCR2820720734>3.0.CO;2-P; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Davis MP, 2001, SUPPORT CARE CANCER, V9, P73, DOI 10.1007/s005200000180; EDWARDS ND, 1993, ANAESTHESIA, V48, P124; Ehret GB, 2007, EXPERT OPIN DRUG SAF, V6, P289, DOI 10.1517/14740338.6.3.289; Ellershaw JE, 2005, INT J PALLIAT NURS, V11, P132, DOI 10.12968/ijpn.2005.11.3.18032; FEUER DJ, 2004, CORTICOSTEROIDS RESO; Fine PG, 1999, J PAIN SYMPTOM MANAG, V17, P296, DOI 10.1016/S0885-3924(98)00144-4; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; FOLEY KM, 1993, SYMP PAIN R, P331; FOLEY KM, 2005, CANC PRINCIPLES PRAC, P2615; Foley KM, 2001, IMPROVING PALLIATIVE; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; Gorman AL, 1997, NEUROSCI LETT, V223, P5; GUTSTEIN BH, 2001, GOODMAN GILLMAN PHAR, P598; HOUDE RW, 1966, INT ENCY PHARM THERA, P59; Kaldjian Lauris C, 2004, Am J Hosp Palliat Care, V21, P381, DOI 10.1177/104990910402100514; Katcher J, 1999, J PAIN SYMPTOM MANAG, V17, P70, DOI 10.1016/S0885-3924(98)00115-8; Katchman AN, 2006, J PHARMACOL EXP THER, V316, P1098, DOI 10.1124/jpet.105.093393; Klepstad P, 2000, ACTA ANAESTH SCAND, V44, P656, DOI 10.1034/j.1399-6576.2000.440605.x; Klepstad P, 2000, EUR J CLIN PHARMACOL, V55, P713, DOI 10.1007/s002280050003; Kloke M, 2000, SUPPORT CARE CANCER, V8, P479, DOI 10.1007/s005200000153; Kornick CA, 2003, PAIN, V105, P499, DOI 10.1016/S0304-3959(03)00205-7; Krantz MJ, 2005, PHARMACOTHERAPY, V25, P1523, DOI 10.1592/phco.2005.25.11.1523; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Lussier D, 2004, ONCOLOGIST, V9, P571, DOI 10.1634/theoncologist.9-5-571; Manfredi PL, 2003, J PAIN SYMPTOM MANAG, V26, P687, DOI 10.1016/S0885-3924(03)00259-8; Marinella MA, 1997, SOUTHERN MED J, V90, P556, DOI 10.1097/00007611-199705000-00022; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; MELZAK R, 1993, PAIN MEASUREMENT ASS; Mercadante S, 1998, PAIN, V74, P5, DOI 10.1016/S0304-3959(97)00090-0; Mercadante S, 1996, PALLIATIVE MED, V10, P225; Mercadante S, 2007, J PALLIAT MED, V10, P338, DOI 10.1089/jpm.2006.0140; Mercadante Sebastiano L, 2007, Am J Hosp Palliat Care, V24, P13, DOI 10.1177/1049909106295431; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Moryl N, 2006, CANC MED, P1113; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Murillo Mauricio, 2004, Palliat Support Care, V2, P65; Nicholson AB, 2004, COCHRANE DB SYST REV, V2; OWEN JA, 1983, CLIN PHARMACOL THER, V34, P364, DOI 10.1038/clpt.1983.180; Pasternak GW, 2005, J PAIN SYMPTOM MANAG, V29, pS2, DOI 10.1016/j.jpainsymman.2005.01.011; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1991, PAIN, V47, P13, DOI 10.1016/0304-3959(91)90005-I; Portenoy RK, 2006, J PAIN SYMPTOM MANAG, V32, P532, DOI 10.1016/j.jpainsymman.2006.08.003; Prommer Eric, 2006, J Opioid Manag, V2, P130; Redinbaugh EM, 2003, BMJ-BRIT MED J, V327, P185, DOI 10.1136/bmj.327.7408.185; Reissig JE, 2005, ANN PHARMACOTHER, V39, P727, DOI 10.1345/aph.1E309; Ripamonti C, 1997, PAIN, V70, P109, DOI 10.1016/S0304-3959(96)03286-1; Ripamonti C, 2001, SUPPORT CARE CANCER, V9, P223, DOI 10.1007/s005200000198; Sandner-Kiesling A, 2003, CURR OPIN ANESTHESIO, V16, P535, DOI 10.1097/00001503-200310000-00015; Santiago-Palma J, 2001, CANCER, V92, P1919, DOI 10.1002/1097-0142(20011001)92:7<1919::AID-CNCR1710>3.0.CO;2-G; Sarhill N, 2001, SUPPORT CARE CANCER, V9, P84, DOI 10.1007/s005200000183; Sekine R, 2007, J PAIN SYMPTOM MANAG, V34, P566, DOI 10.1016/j.jpainsymman.2007.05.001; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; SOPALSKI MA, 2007, J HOSP PALLIAT NURS, V9, P13; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; Sulmasy Daniel P, 2002, Gerontologist, V42 Spec No 3, P24; Sulmasy DP, 2000, ANN INTERN MED, V133, P564, DOI 10.7326/0003-4819-133-7-200010030-00027; Tarcatu Dana, 2007, J Opioid Manag, V3, P167; Tomalik-Scharte D, 2008, PHARMACOGENOMICS J, V8, P4, DOI 10.1038/sj.tpj.6500462; Ventafridda V, 1990, J Palliat Care, V6, P7; Visser E, 2006, BIOMED PHARMACOTHER, V60, P341, DOI 10.1016/j.biopha.2006.06.021; Wedam EF, 2007, ARCH INTERN MED, V167, P2469, DOI 10.1001/archinte.167.22.2469; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; Wiffen P., 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001133; Wilson KG, 2007, J PAIN SYMPTOM MANAG, V33, P118, DOI 10.1016/j.jpainsymman.2006.07.016; Wilson Robin K, 2004, J Palliat Med, V7, P579, DOI 10.1089/1096621041838425; WILSON WC, 1992, JAMA-J AM MED ASSOC, V267, P949	99	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 26	2008	299	12					1457	1467		10.1001/jama.299.12.1457	http://dx.doi.org/10.1001/jama.299.12.1457			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278MY	18364488				2023-01-03	WOS:000254292200020
J	Haeberle, H; Bryan, LA; Vadakkan, TJ; Dickinson, ME; Lumpkin, EA				Haeberle, Henry; Bryan, Leigh A.; Vadakkan, Tegy J.; Dickinson, Mary E.; Lumpkin, Ellen A.			Swelling-Activated Ca2+ Channels Trigger Ca2+ Signals in Merkel Cells	PLOS ONE			English	Article								Merkel cell-neurite complexes are highly sensitive touch receptors comprising epidermal Merkel cells and sensory afferents. Based on morphological and molecular studies, Merkel cells are proposed to be mechanosensory cells that signal afferents via neurotransmission; however, functional studies testing this hypothesis in intact skin have produced conflicting results. To test this model in a simplified system, we asked whether purified Merkel cells are directly activated by mechanical stimulation. Cell shape was manipulated with anisotonic solution changes and responses were monitored by Ca2+ imaging with fura-2. We found that hypotonic-induced cell swelling, but not hypertonic solutions, triggered cytoplasmic Ca2+ transients. Several lines of evidence indicate that these signals arise from swelling-activated Ca2+-permeable ion channels. First, transients were reversibly abolished by chelating extracellular Ca2+, demonstrating a requirement for Ca2+ influx across the plasma membrane. Second, Ca2+ transients were initially observed near the plasma membrane in cytoplasmic processes. Third, voltage-activated Ca2+ channel (VACC) antagonists reduced transients by half, suggesting that swelling-activated channels depolarize plasma membranes to activate VACCs. Finally, emptying internal Ca2+ stores attenuated transients by 80%, suggesting Ca2+ release from stores augments swelling-activated Ca2+ signals. To identify candidate mechanotransduction channels, we used RT-PCR to amplify ion-channel transcripts whose pharmacological profiles matched those of hypotonic-evoked Ca2+ signals in Merkel cells. We found 11 amplicons, including PKD1, PKD2, and TRPC1, channels previously implicated in mechanotransduction in other cells. Collectively, these results directly demonstrate that Merkel cells are activated by hypotonic-evoked swelling, identify cellular signaling mechanisms that mediate these responses, and support the hypothesis that Merkel cells contribute to touch reception in the Merkel cell-neurite complex.	[Haeberle, Henry] Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA; [Haeberle, Henry; Bryan, Leigh A.; Lumpkin, Ellen A.] Baylor Coll Med, Dept Neurosci, Houston, TX USA; [Vadakkan, Tegy J.; Dickinson, Mary E.; Lumpkin, Ellen A.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX USA; [Lumpkin, Ellen A.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX USA	University of California System; University of California San Francisco; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Haeberle, H (corresponding author), Univ Calif San Francisco, Grad Program Neurosci, San Francisco, CA 94143 USA.	lumpkin@bcm.edu		Lumpkin, Ellen/0000-0002-1166-3374	Gillson Longenbaugh Foundation; Sandler Program in Basic Sciences; NIH [R01AR051219, R01HL077187, P20EB007076]; NSF graduate research fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P20EB007076] Funding Source: NIH RePORTER	Gillson Longenbaugh Foundation; Sandler Program in Basic Sciences; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF graduate research fellowship(National Science Foundation (NSF)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This work was supported by the Gillson Longenbaugh Foundation (E. A. L.), the Sandler Program in Basic Sciences (E. A. L.), the NIH (NIAMS R01AR051219 to E. A. L., NHLBI R01HL077187 and NIBIB P20EB007076 to M. E. D.) and the NSF (graduate research fellowship to H. H.). The funding agencies had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Altamirano J, 1998, J GEN PHYSIOL, V112, P145, DOI 10.1085/jgp.112.2.145; Arnaout MA, 2001, ANNU REV MED, V52, P93, DOI 10.1146/annurev.med.52.1.93; Baumann KI, 1996, NEUROSCI LETT, V213, P1, DOI 10.1016/0304-3940(96)12813-5; Blount P, 1996, BIOL CELL, V87, P1, DOI 10.1016/S0248-4900(97)89832-2; Chen Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1790, DOI 10.1152/ajpcell.1996.270.6.C1790; Cibulsky SM, 1999, J PHARMACOL EXP THER, V289, P1447; Colbert HA, 1997, J NEUROSCI, V17, P8259; CRIST JR, 1993, HEARING RES, V69, P194, DOI 10.1016/0378-5955(93)90107-C; DIETRICH A, 2007, PRESSURE INDUCED STO; Du HP, 1996, NEURON, V16, P183, DOI 10.1016/S0896-6273(00)80035-5; Dumont RA, 2002, JARO-J ASSOC RES OTO, V3, P375, DOI 10.1007/s101620020049; Fettiplace R, 2006, NAT REV NEUROSCI, V7, P19, DOI 10.1038/nrn1828; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Gong ZF, 2004, J NEUROSCI, V24, P9059, DOI 10.1523/JNEUROSCI.1645-04.2004; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; GOTTSCHALDT KM, 1981, SCIENCE, V214, P183, DOI 10.1126/science.7280690; Haeberle H, 2004, P NATL ACAD SCI USA, V101, P14503, DOI 10.1073/pnas.0406308101; Halata Z, 2003, ANAT REC PART A, V271A, P225, DOI 10.1002/ar.a.10029; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Hayashi Y, 1996, BIOPHYS J, V71, P1057, DOI 10.1016/S0006-3495(96)79306-2; Hitchcock IS, 2004, NEUROSCI LETT, V362, P196, DOI 10.1016/j.neulet.2004.02.071; Hudspeth AJ, 2000, CURR OPIN NEUROBIOL, V10, P631, DOI 10.1016/S0959-4388(00)00133-1; IGGO A, 1969, J PHYSIOL-LONDON, V200, P763, DOI 10.1113/jphysiol.1969.sp008721; IGGO A, 1984, SENSORY RECEPTOR MEC, P117; IKEDA I, 1994, J PHYSIOL-LONDON, V479, P247, DOI 10.1113/jphysiol.1994.sp020292; IKEDA K, 1991, ORL J OTO-RHINO-LARY, V53, P78, DOI 10.1159/000276192; Johnson KO, 2001, CURR OPIN NEUROBIOL, V11, P455, DOI 10.1016/S0959-4388(00)00234-8; Kellenberger S, 2002, PHYSIOL REV, V82, P735, DOI 10.1152/physrev.00007.2002; Kim J, 2003, NATURE, V424, P81, DOI 10.1038/nature01733; Kinkelin I, 1999, EUR J NEUROSCI, V11, P3963, DOI 10.1046/j.1460-9568.1999.00822.x; Kung C, 2004, MOL MICROBIOL, V53, P373, DOI 10.1111/j.1365-2958.2004.04180.x; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Liedtke W, 2003, P NATL ACAD SCI USA, V100, P14531, DOI 10.1073/pnas.2235619100; LUMPKIN EA, 1995, P NATL ACAD SCI USA, V92, P10297, DOI 10.1073/pnas.92.22.10297; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Lumpkin EA, 2007, NATURE, V445, P858, DOI 10.1038/nature05662; Maroto R, 2005, NAT CELL BIOL, V7, P179, DOI 10.1038/ncb1218; MILLS LR, 1995, J NEUROCYTOL, V24, P117, DOI 10.1007/BF01181555; NAGASAKI K, 1989, CELL CALCIUM, V10, P63, DOI 10.1016/0143-4160(89)90045-6; Nakafusa J, 2006, BRIT J DERMATOL, V155, P883, DOI 10.1111/j.1365-2133.2006.07441.x; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Nunzi MG, 2004, J NEUROCYTOL, V33, P359, DOI 10.1023/B:NEUR.0000044196.45602.92; Ogawa H, 1996, PROG NEUROBIOL, V49, P317, DOI 10.1016/0301-0082(96)00018-4; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; Pacitti E G, 1988, Prog Brain Res, V74, P37; Piontek KB, 2004, J AM SOC NEPHROL, V15, P3035, DOI 10.1097/01.ASN.0000144204.01352.86; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Tachibana T, 1997, ARCH HISTOL CYTOL, V60, P379, DOI 10.1679/aohc.60.379; Tazaki M, 1998, NEUROSCI LETT, V243, P69, DOI 10.1016/S0304-3940(98)00066-4; Toyoshima K, 1998, J HISTOCHEM CYTOCHEM, V46, P1329, DOI 10.1177/002215549804601113; Viana F, 2001, EUR J NEUROSCI, V13, P722, DOI 10.1046/j.0953-816x.2000.01441.x; Woodbury CJ, 2007, J COMP NEUROL, V505, P547, DOI 10.1002/cne.21517; YAMASHITA Y, 1992, J PHYSIOL-LONDON, V450, P143, DOI 10.1113/jphysiol.1992.sp019120; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	56	34	38	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2008	3	3							e1750	10.1371/journal.pone.0001750	http://dx.doi.org/10.1371/journal.pone.0001750			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369VW	18454189	gold, Green Published, Green Submitted			2023-01-03	WOS:000260723000004
J	Colman, RJ; Anderson, RM; Johnson, SC; Kastman, EK; Kosmatka, KJ; Beasley, TM; Allison, DB; Cruzen, C; Simmons, HA; Kemnitz, JW; Weindruch, R				Colman, Ricki J.; Anderson, Rozalyn M.; Johnson, Sterling C.; Kastman, Erik K.; Kosmatka, Kristopher J.; Beasley, T. Mark; Allison, David B.; Cruzen, Christina; Simmons, Heather A.; Kemnitz, Joseph W.; Weindruch, Richard			Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys	SCIENCE			English	Article							DIETARY RESTRICTION; ADULT MALE; LIFE-SPAN; MACAQUES	Caloric restriction (CR), without malnutrition, delays aging and extends life span in diverse species; however, its effect on resistance to illness and mortality in primates has not been clearly established. We report findings of a 20-year longitudinal adult-onset CR study in rhesus monkeys aimed at filling this critical gap in aging research. In a population of rhesus macaques maintained at the Wisconsin National Primate Research Center, moderate CR lowered the incidence of aging-related deaths. At the time point reported, 50% of control fed animals survived as compared with 80% of the CR animals. Furthermore, CR delayed the onset of age-associated pathologies. Specifically, CR reduced the incidence of diabetes, cancer, cardiovascular disease, and brain atrophy. These data demonstrate that CR slows aging in a primate species.	[Colman, Ricki J.; Anderson, Rozalyn M.; Johnson, Sterling C.; Cruzen, Christina; Simmons, Heather A.; Kemnitz, Joseph W.; Weindruch, Richard] Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA; [Johnson, Sterling C.; Kastman, Erik K.; Kosmatka, Kristopher J.; Kemnitz, Joseph W.; Weindruch, Richard] Univ Wisconsin, Dept Med, Madison, WI 53706 USA; [Johnson, Sterling C.; Kastman, Erik K.; Kosmatka, Kristopher J.; Weindruch, Richard] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA; [Beasley, T. Mark; Allison, David B.] Univ Alabama, Dept Biostat, Birmingham, AL 35294 USA; [Kemnitz, Joseph W.] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); William S Middleton Memorial Veterans Hospital; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison	Colman, RJ (corresponding author), Univ Wisconsin, Wisconsin Natl Primate Res Ctr, Madison, WI 53715 USA.	rcolman@primate.wisc.edu; rhweindr@wisc.edu	Kastman, Erik/N-6645-2016; Simmons, Heather/U-6081-2019; Kemnitz, Joseph/HGC-4406-2022; Kemnitz, Joseph/ABA-4668-2020	Kastman, Erik/0000-0001-7221-9042; Kemnitz, Joseph W/0000-0001-6511-404X; Allison, David/0000-0003-3566-9399; Colman, Ricki/0000-0001-9706-0525	NIH [P01 AG-11915, P51 RR000167]; Research Facilities Improvement Program [RR15459-01, RR020141-01]; William S. Middleton Memorial Veterans Hospital; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR015459, C06RR020141, P51RR000167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG011915] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Facilities Improvement Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); William S. Middleton Memorial Veterans Hospital; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We acknowledge the excellent technical assistance provided by S. Baum, J. Christensen, J. A. Adriansjach, C. E. Armstrong, D. G. McLaren, C. Dizack, D. Shanmuganayagam, J. Root, and the Animal Care, Veterinary and Pathology Staff of the WNPRC. R.W. is a cofounder and member of the board of LifeGen Technologies, a company focused on nutritional genomics, including the impact of dietary interventions on the aging process. This work was supported by NIH grants P01 AG-11915 and P51 RR000167. This research was conducted in part at the WNPRC, which received support from Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01. This research was supported in part by facilities and resources at the William S. Middleton Memorial Veterans Hospital.	Alexander GE, 2008, J NEUROSCI, V28, P2710, DOI 10.1523/JNEUROSCI.1852-07.2008; Anderson Rozalyn M., 2007, V35, P18; Bodkin NL, 2003, J GERONTOL A-BIOL, V58, P212; Colman RJ, 2008, J GERONTOL A-BIOL, V63, P556, DOI 10.1093/gerona/63.6.556; Colman RJ, 1998, AGING CLIN EXP RES, V10, P83, DOI 10.1007/BF03339642; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Gresl TA, 2001, AM J PHYSIOL-ENDOC M, V281, pE757, DOI 10.1152/ajpendo.2001.281.4.E757; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; KEMNITZ JW, 1993, J GERONTOL, V48, pB17, DOI 10.1093/geronj/48.1.B17; Kennedy BK, 2007, CELL MOL LIFE SCI, V64, P1323, DOI 10.1007/s00018-007-6470-y; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; MCCAY CM, 1989, NUTRITION, V5, P155; Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2; Rodriguez NA, 2002, J MED PRIMATOL, V31, P74, DOI 10.1034/j.1600-0684.2002.01001.x; Uno H, 1997, AGE, V20, P1, DOI 10.1007/s11357-997-0001-5; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; Weindruch R., 1988, RETARDATION AGING DI; Yankner BA, 2008, ANNU REV PATHOL-MECH, V3, P41, DOI 10.1146/annurev.pathmechdis.2.010506.092044	19	1544	1594	8	340	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 10	2009	325	5937					201	204		10.1126/science.1173635	http://dx.doi.org/10.1126/science.1173635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	468FK	19590001	Green Accepted			2023-01-03	WOS:000267802000047
J	Comi, RJ				Comi, Richard J.			Glucose Control in the Intensive Care Unit: A Roller Coaster Ride or a Swinging Pendulum?	ANNALS OF INTERNAL MEDICINE			English	Article							DIABETIC-PATIENTS; MYOCARDIAL-INFARCTION; STRESS HYPERGLYCEMIA; INSULIN THERAPY; INFECTION; MORTALITY; TIGHT	Many studies of tight control of blood glucose in critically ill patients are associated with poor outcomes. However, randomized studies of tight glucose control in patients admitted to coronary care or surgical intensive care units showed a reduction in mortality rates; supported by recommendations from professional organizations, many intensive care units implemented protocols for tight glucose control. More recent studies in medical intensive care units did not confirm the benefits of tight control, however, and the most recent study suggests that tight control increases mortality rates. Furthermore, tight control significantly increases episodes of hypoglycemia. The sum of the recent literature suggests that a degree of glucose control lies between the extremes of the adverse outcomes related to poor glucose control and those related to overly aggressive glucose control.	Dartmouth Hitchcock Med Ctr, Hitchcock Clin, Lebanon, NH 03756 USA	Dartmouth College	Comi, RJ (corresponding author), Dartmouth Hitchcock Med Ctr, Hitchcock Clin, 1 Med Ctr Dr, Lebanon, NH 03756 USA.							Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; CERRA FB, 1987, SURGERY, V101, P1; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Inzucchi SE, 2009, NEW ENGL J MED, V360, P1346, DOI 10.1056/NEJMe0901507; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Pomposelli JJ, 1998, JPEN-PARENTER ENTER, V22, P77, DOI 10.1177/014860719802200277; Shojania KG, 2007, ANN INTERN MED, V147, P224, DOI 10.7326/0003-4819-147-4-200708210-00179; Solomon CG, 2003, NEW ENGL J MED, V348, P579, DOI 10.1056/NEJMp030006; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300	17	6	6	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 2	2009	150	11					809	811		10.7326/0003-4819-150-11-200906020-00009	http://dx.doi.org/10.7326/0003-4819-150-11-200906020-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	452HC	19487715				2023-01-03	WOS:000266530000008
J	Finlay, I				Finlay, Ilora			The art of medicine Dying and choosing	LANCET			English	Editorial Material									House Lords, London SW1A 0PW, England		Finlay, I (corresponding author), House Lords, London SW1A 0PW, England.	FINLAYI@parliament.uk							0	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2009	373	9678					1840	1841		10.1016/S0140-6736(09)61012-6	http://dx.doi.org/10.1016/S0140-6736(09)61012-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	453ND	19504667	Green Submitted, Bronze			2023-01-03	WOS:000266616400015
J	Jencks, SF; Williams, MV; Coleman, EA				Jencks, Stephen F.; Williams, Mark V.; Coleman, Eric A.			Rehospitalizations among Patients in the Medicare Fee-for-Service Program	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Meeting on Reducing Hospital Readmissions	JAN 25, 2008	Washington, DC	Commwlth Fund, Acad Hlth			HEART-FAILURE; HOSPITAL READMISSIONS; RANDOMIZED-TRIAL; CARE	Background Reducing rates of rehospitalization has attracted attention from policymakers as a way to improve quality of care and reduce costs. However, we have limited information on the frequency and patterns of rehospitalization in the United States to aid in planning the necessary changes. Methods We analyzed Medicare claims data from 2003-2004 to describe the patterns of rehospitalization and the relation of rehospitalization to demographic characteristics of the patients and to characteristics of the hospitals. Results Almost one fifth (19.6%) of the 11,855,702 Medicare beneficiaries who had been discharged from a hospital were rehospitalized within 30 days, and 34.0% were rehospitalized within 90 days; 67.1% of patients who had been discharged with medical conditions and 51.5% of those who had been discharged after surgical procedures were rehospitalized or died within the first year after discharge. In the case of 50.2% of the patients who were rehospitalized within 30 days after a medical discharge to the community, there was no bill for a visit to a physician's office between the time of discharge and rehospitalization. Among patients who were rehospitalized within 30 days after a surgical discharge, 70.5% were rehospitalized for a medical condition. We estimate that about 10% of rehospitalizations were likely to have been planned. The average stay of rehospitalized patients was 0.6 day longer than that of patients in the same diagnosis-related group whose most recent hospitalization had been at least 6 months previously. We estimate that the cost to Medicare of unplanned rehospitalizations in 2004 was $17.4 billion. Conclusions Rehospitalizations among Medicare beneficiaries are prevalent and costly.	[Williams, Mark V.] Northwestern Univ, Feinberg Sch Med, Div Hosp Med, Chicago, IL 60611 USA; [Coleman, Eric A.] Univ Colorado, Div Hlth Care Policy & Res, Care Transit Program, Denver, CO 80202 USA	Northwestern University; Feinberg School of Medicine; University of Colorado System; University of Colorado Denver			Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Williams, Mark V/0000-0001-6107-0457				Adeyemo D, 2007, ANN ROY COLL SURG, V89, P363, DOI 10.1308/003588407X183409; ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; [Anonymous], 2007, MED MED STAT SUPPL; [Anonymous], 2008, FED REGISTER, V73, P23673; BARR M, 2006, ADV MED HOME PATIENT; BLUSTEIN J, 1994, AM J PUBLIC HEALTH, V84, P1018, DOI 10.2105/AJPH.84.6.1018; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Connolly Ceci, 2009, WASHINGTON POST 0130, pA1; Eicheldinger C, 2008, HEALTH CARE FINANC R, V29, P27; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Gohler A, 2006, J CARD FAIL, V12, P554, DOI 10.1016/j.cardfail.2006.03.003; *IOW FDN MED CAR, 2008, CHRON COND DAT WAR C; Jack BW, 2009, ANN INTERN MED, V150, P178, DOI 10.7326/0003-4819-150-3-200902030-00007; Medicare Payment Advisory Commission, 2005, REP C REF DEL SYST, P83; National Quality Forum, 2007, CAND HOSP CAR ADD PR; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Rollow W, 2006, ANN INTERN MED, V145, P342, DOI 10.7326/0003-4819-145-5-200609050-00134; Ross JS, 2008, ARCH INTERN MED, V168, P1371, DOI 10.1001/archinte.168.13.1371; *SAS I, SAS WIND VERS 8 2	22	3604	3655	3	106	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	2009	360	14					1418	1428		10.1056/NEJMsa0803563	http://dx.doi.org/10.1056/NEJMsa0803563			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	427AL	19339721				2023-01-03	WOS:000264751800007
J	Peikes, D; Chen, A; Schore, J; Brown, R				Peikes, Deborah; Chen, Arnold; Schore, Jennifer; Brown, Randall			Effects of Care Coordination on Hospitalization, Quality of Care, and Health Care Expenditures Among Medicare Beneficiaries 15 Randomized Trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Research Meeting of the Academy-Health	JUN 09-10, 2008	Washington, DC	Acad Hlth			CONGESTIVE-HEART-FAILURE; SELF-MANAGEMENT PROGRAM; DISEASE MANAGEMENT; SENSITIVE CONDITIONS; CLINICAL-OUTCOMES; ELDERLY-PATIENTS; DISCHARGE; RISK; COMMUNICATION; OPPORTUNITIES	Context Medicare expenditures of patients with chronic illnesses might be reduced through improvements in care, patient adherence, and communication. Objective To determine whether care coordination programs reduced hospitalizations and Medicare expenditures and improved quality of care for chronically ill Medicare beneficiaries. Design, Setting, and Patients Eligible fee- for- service Medicare patients ( primarily with congestive heart failure, coronary artery disease, and diabetes) who volunteered to participate between April 2002 and June 2005 in 15 care coordination programs ( each received a negotiated monthly fee per patient from Medicare) were randomly assigned to treatment or control ( usual care) status. Hospitalizations, costs, and some quality- of- care outcomes were measured with claims data for 18 309 patients ( n= 178 to 2657 per program) from patients' enrollment through June 2006. A patient survey 7 to 12 months after enrollment provided additional quality- of- care measures. Interventions Nurses provided patient education and monitoring ( mostly via telephone) to improve adherence and ability to communicate with physicians. Patients were contacted twice per month on average; frequency varied widely. Main Outcome Measures Hospitalizations, monthly Medicare expenditures, patient-reported and care process indicators. Results Thirteen of the 15 programs showed no significant ( P <. 05) differences in hospitalizations; however, Mercy had 0.168 fewer hospitalizations per person per year ( 90% confidence interval [ CI], - 0.283 to - 0.054; 17% less than the control group mean, P=. 02) and Charlestown had 0.118 more hospitalizations per person per year ( 90% CI, 0.025- 0.210; 19% more than the control group mean, P=. 04). None of the 15 programs generated net savings. Treatment group members in 3 programs ( Health Quality Partners [ HQP], Georgetown, Mercy) had monthly Medicare expenditures less than the control group by 9% to 14% (-$ 84; 90% CI, -$ 171 to $ 4; P=. 12; -$ 358; 90% CI, -$ 934 to $ 218; P=. 31; and -$ 112; 90% CI, -$ 231 to $ 8; P=. 12; respectively). Savings offset fees for HQP and Georgetown but not for Mercy; Georgetown was too small to be sustainable. These programs had favorable effects on none of the adherence measures and only a few of many quality of care indicators examined. Conclusions Viable care coordination programs without a strong transitional care component are unlikely to yield net Medicare savings. Programs with substantial in-person contact that target moderate to severe patients can be cost- neutral and improve some aspects of care. Trial Registration clinicaltrials.gov Identifier: NCT00627029.	[Peikes, Deborah; Chen, Arnold; Schore, Jennifer; Brown, Randall] Mathematica Policy Res Inc, Princeton, NJ 08550 USA	Mathematica	Brown, R (corresponding author), Mathematica Policy Res Inc, 600 Alexander Pk, Princeton, NJ 08550 USA.	rbrown@mathematica-mpr.com						Alexander GC, 2003, JAMA-J AM MED ASSOC, V290, P953, DOI 10.1001/jama.290.7.953; American Academy of Family Physicians; American Academy of Pediatrics; American College of Physicians; American Osteopathic Association, 2007, JOINT PRINC PAT CTR; Asch SM, 2006, NEW ENGL J MED, V354, P1147, DOI 10.1056/NEJMsa044464; Bell RA, 2001, ARCH INTERN MED, V161, P1977, DOI 10.1001/archinte.161.16.1977; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Brown AD, 2001, CAN J PUBLIC HEALTH, V92, P155, DOI 10.1007/BF03404951; BROWN R, 2007, EVALUATION MED COORD; Brown RS, 2001, RES DESIGN EVALUATIO; BROWN RS, 2000, DEMONSTRATION DESIGN; Burr J, 2003, SOUTH MED J, V96, P172, DOI 10.1097/01.SMJ.0000050680.55019.32; Castro CM, 2007, AM J HEALTH BEHAV, V31, pS85; CHEN A, 2007, FINAL REPORT C EVALU; Chen A., 2000, IDENTIFYING BEST PRA; Clark AM, 2005, ANN INTERN MED, V143, P659, DOI 10.7326/0003-4819-143-9-200511010-00010; Coleman E A, 2001, Eff Clin Pract, V4, P49; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Congressional Budget Office, 2004, AN LIT DIS MAN PROGR; *CTR MED MED SERV, DAT 2003 MED CURR BE, pCH1; *CTR MED MED SERV, FACT SHEET COMPL PHA; DeBusk RF, 2004, ANN INTERN MED, V141, P606, DOI 10.7326/0003-4819-141-8-200410190-00008; *DEP HHS, 2000, FED REGISTER, V65, P46466; Emmons KM, 2001, AM J PREV MED, V20, P68, DOI 10.1016/S0749-3797(00)00254-3; Galbreath AD, 2004, CIRCULATION, V110, P3518, DOI 10.1161/01.CIR.0000148957.62328.89; Goetzel RZ, 2005, HEALTH CARE FINANC R, V26, P1; Gravelle H, 2007, BMJ-BRIT MED J, V334, P31, DOI 10.1136/bmj.39020.413310.55; Ho PM, 2008, AM HEART J, V155, P772, DOI 10.1016/j.ahj.2007.12.011; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Jencks SF, 2003, JAMA-J AM MED ASSOC, V289, P305, DOI 10.1001/jama.289.3.305; Koelling TM, 2005, CIRCULATION, V111, P179, DOI 10.1161/01.CIR.0000151811.53450.B8; Kripalani S, 2008, MAYO CLIN PROC, V83, P529, DOI 10.4065/83.5.529; Leatherman S., 2005, QUALITY HLTH CARE ME; *LIFEMASTERS, OUTC DEL RES; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Makaryus AN, 2005, MAYO CLIN PROC, V80, P991, DOI 10.4065/80.8.991; Maniaci MJ, 2008, MAYO CLIN PROC, V83, P554, DOI 10.4065/83.5.554; *MATR HEALTHC HLTH, DIS MAN OUTC; Mattke S, 2007, AM J MANAG CARE, V13, P670; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; Medicare Payment Advisory Commission, 2008, DAT HEALTHC SPEND ME; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Payment policy for inpatient readmissions, 2007, REP C PROM GREAT EFF, P103; Pham HH, 2007, NEW ENGL J MED, V356, P1130, DOI 10.1056/NEJMsa063979; Powell CK, 2007, DIABETES EDUCATOR, V33, P144, DOI 10.1177/0145721706297452; Powell LH, 2008, AM HEART J, V156, P452, DOI 10.1016/j.ahj.2008.05.011; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Sanderson C, 2000, J Health Serv Res Policy, V5, P222; SHOJANIA KG, 2004, CLOS QUAL GAP CRIT A, V1; Sidorov J, 2002, DIABETES CARE, V25, P684, DOI 10.2337/diacare.25.4.684; Smith B, 2005, AM J MANAG CARE, V11, P701; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; Stewart S, 1999, AUST NZ J MED, V29, P220, DOI 10.1111/j.1445-5994.1999.tb00687.x; Stille CJ, 2005, ANN INTERN MED, V142, P700, DOI 10.7326/0003-4819-142-8-200504190-00038; Subramanian Usha, 2008, Congest Heart Fail, V14, P6, DOI 10.1111/j.1751-7133.2008.07174.x; Sylvia ML, 2008, DIS MANAGE, V11, P29, DOI 10.1089/dis.2008.111723; Thorpe KE, 2006, HEALTH AFFAIR, V25, pW378, DOI 10.1377/hlthaff.25.w378; Tsuyuki RT, 2001, ARCH INTERN MED, V161, P2337, DOI 10.1001/archinte.161.19.2337; Villagra VG, 2004, HEALTH AFFAIR, V23, P255, DOI 10.1377/hlthaff.23.4.255; Wheeler JRC, 2003, MED CARE, V41, P706; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028	63	560	563	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2009	301	6					603	618		10.1001/jama.2009.126	http://dx.doi.org/10.1001/jama.2009.126			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	405MN	19211468	Bronze			2023-01-03	WOS:000263229000025
J	Baztan, JJ; Suarez-Garcia, FM; Lopez-Arrieta, J; Rodriguez-Manas, L; Rodriguez-Artalejo, F				Baztan, Juan J.; Suarez-Garcia, Francisco M.; Lopez-Arrieta, Jesus; Rodriguez-Manas, Leocadio; Rodriguez-Artalejo, Fernando			Effectiveness of acute geriatric units on functional decline, living at home, and case fatality among older patients admitted to hospital for acute medical disorders: meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; ELDERS; ADULTS	Objective To assess the effectiveness of acute geriatric units compared with conventional care units in adults aged 65 or more admitted to hospital for acute medical disorders. Design Systematic review and meta- analysis. Data sources Medline, Embase, and the Cochrane Library up to 31 August 2008, and references from published literature. Review methods Randomised trials, non- randomised trials, and case- control studies were included. Exclusions were studies based on administrative databases, those that assessed care for a single disorder, those that evaluated acute and subacute care units, and those in which patients were admitted to the acute geriatric unit after three or more days of being admitted to hospital. Two investigators independently selected the studies and extracted the data. Results 11 studies were included of which five were randomised trials, four non- randomised trials, and two case- control studies. The randomised trials showed that compared with older people admitted to conventional care units those admitted to acute geriatric units had a lower risk of functional decline at discharge ( combined odds ratio 0.82, 95% confidence interval 0.68 to 0.99) and were more likely to live at home after discharge ( 1.30, 1.11 to 1.52), with no differences in case fatality ( 0.83, 0.60 to 1.14). The global analysis of all studies, including non-randomised trials, showed similar results. Conclusions Care of people aged 65 or more with acute medical disorders in acute geriatric units produces a functional benefit compared with conventional hospital care, and increases the likelihood of living at home after discharge.	[Baztan, Juan J.] Hosp Cent Cruz Roja, Dept Geriatr, Madrid, Spain; [Suarez-Garcia, Francisco M.] Dept Hlth, Oviedo, Spain; [Lopez-Arrieta, Jesus] La Paz Cantoblanco Univ Hosp, Dept Geriatr, Madrid, Spain; [Rodriguez-Manas, Leocadio] Univ Hosp, Dept Geriatr, Madrid, Spain; [Rodriguez-Artalejo, Fernando] Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Sch Med, Madrid, Spain	Autonomous University of Madrid	Baztan, JJ (corresponding author), Hosp Cent Cruz Roja, Dept Geriatr, Madrid, Spain.	jbaztan.hccruzr@salud.madrid.org		Rodriguez-Manas, Leocadio/0000-0002-6551-1333	RETICEF [RD06/0013]; Instituto de Salud Carlos III; Ministry of Health and Consumer Affairs;  [FIS PI05/90212]	RETICEF; Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Ministry of Health and Consumer Affairs; 	This study was partially funded by grant No FIS PI05/90212 and research on fragility and the elderly (RETICEF) grant No RD06/0013, Instituto de Salud Carlos III, Ministry of Health and Consumer Affairs.	ALTMAN DG, 2000, EVIDENCE BASED MED, P211; Asplund K, 1997, BMJ-BRIT MED J, V314, P1151; Bernabei R, 2002, AGING CLIN EXP RES, V14, P247; Calkins E, 1999, NEW WAYS TO CARE FOR OLDER PEOPLE, P99; Cameron I., 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [10.3310/hta4020, DOI 10.3310/HTA4020]; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Covinsky KE, 1997, J GEN INTERN MED, V12, P203, DOI 10.1007/s11606-006-5041-5; DAY P, 2004, NZHTA REPORT, V7; De MNA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005955; Ellis G, 2004, BRIT MED BULL, V71, P45, DOI 10.1093/bmb/ldh033; EVANS JG, 1997, BMJ-BRIT MED J, V315, P556; GOMEZPAVON J, 2006, REV ESP GERIATR GERO, V41, P77; GONZALEZMONTALV.JI, 2007, REV ESP GERIATR GERO, V42, P240; Gray L, 2007, AGE AGEING, V36, P1, DOI 10.1093/ageing/afl125; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jayadevappa R, 2003, INT J TECHNOL ASSESS, V19, P220, DOI 10.1017/S0266462303000205; Marin PP, 2007, REV MED CHILE, V135, P392; Norris SL, 2008, J AM GERIATR SOC, V56, P149, DOI 10.1111/j.1532-5415.2007.01530.x; Palmer RM, 2003, DIS MANAG HEALTH OUT, V11, P507, DOI 10.2165/00115677-200311080-00004; Parker G, 2000, J Health Serv Res Policy, V5, P176; Parker SG, 2006, AGE AGEING, V35, P551, DOI 10.1093/ageing/afl070; Reuben DB, 2000, J AM GERIATR SOC, V48, P1728, DOI 10.1111/j.1532-5415.2000.tb03890.x; ROCKWOOD K, 2006, CAN J GERIATR, V9, P102; Sager MA, 1996, ARCH INTERN MED, V156, P645, DOI 10.1001/archinte.156.6.645; Salkeld G, 2000, BMJ-BRIT MED J, V320, P341, DOI 10.1136/bmj.320.7231.341; Shepperd S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000356.pub2; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; van Haastregt JCM, 2000, BMJ-BRIT MED J, V320, P754, DOI 10.1136/bmj.320.7237.754	30	218	220	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 22	2009	338								b50	10.1136/bmj.b50	http://dx.doi.org/10.1136/bmj.b50			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405BS	19164393	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000263197700002
J	Dhalla, IA; Detsky, AS				Dhalla, Irfan A.; Detsky, Allan S.			Risks and benefits of importing prescription medications from lower-income countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Dhalla, Irfan A.; Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 427-600 Univ Ave, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						AUSTIN I, 2007, NY TIMES        1213; Choudhry NK, 2005, JAMA-J AM MED ASSOC, V293, P358, DOI 10.1001/jama.293.3.358; DECKER S, 2008, RANBAXY DELAY GENERI; *GREENE W, 2007, 200705A US INT TRAD; Hopkins-Tanne J, 2008, BRIT MED J, V336, P1266, DOI 10.1136/bmj.39601.618241.DB; Ricardo David, 1821, PRINCIPLES POLITICAL, V3rd; STAGNITTI MN, STAT BRIEF 205 TREND; Treanor J, 2004, NEW ENGL J MED, V351, P2037, DOI 10.1056/NEJMp048290; Yusuf S, 2004, AM HEART J, V148, P1, DOI 10.1016/j.ahj.2004.03.045; ZAMISKA N, 2007, WALL STREET J   1009; ZHANG D, 2007, SOFTWOOD LUMBAR WAR; 2007, MED AD NEWS      SEP	12	0	0	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2008	300	12					1453	1455		10.1001/jama.300.12.1453	http://dx.doi.org/10.1001/jama.300.12.1453			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351FR	18812537				2023-01-03	WOS:000259410400024
J	Allard, JS; Heilbronn, LK; Smith, C; Hunt, ND; Ingram, DK; Ravussin, E; de Cabo, R				Allard, Joanne S.; Heilbronn, Leonie K.; Smith, Carolina; Hunt, Nicole D.; Ingram, Donald K.; Ravussin, Eric; de Cabo, Rafael		Pennington CALERIE Team	In Vitro Cellular Adaptations of Indicators of Longevity in Response to Treatment with Serum Collected from Humans on Calorie Restricted Diets	PLOS ONE			English	Article								Calorie restriction (CR) produces several health benefits and increases lifespan in many species. Studies suggest that alternate-day fasting (ADF) and exercise can also provide these benefits. Whether CR results in lifespan extension in humans is not known and a direct investigation is not feasible. However, phenotypes observed in CR animals when compared to ad libitum fed (AL) animals, including increased stress resistance and changes in protein expression, can be simulated in cells cultured with media supplemented with blood serum from CR and AL animals. Two pilot studies were undertaken to examine the effects of ADF and CR on indicators of health and longevity in humans. In this study, we used sera collected from those studies to culture human hepatoma cells and assessed the effects on growth, stress resistance and gene expression. Cells cultured in serum collected at the end of the dieting period were compared to cells cultured in serum collected at baseline (before the dieting period). Cells cultured in serum from ADF participants, showed a 20% increase in Sirt1 protein which correlated with reduced triglyceride levels. ADF serum also induced a 9% decrease in proliferation and a 25% increase in heat resistance. Cells cultured in serum from CR participants induced an increase in Sirt1 protein levels by 17% and a 30% increase in PGC-1a mRNA levels. This first in vitro study utilizing human serum to examine effects on markers of health and longevity in cultured cells resulted in increased stress resistance and an up-regulation of genes proposed to be indicators of increased longevity. The use of this in vitro technique may be helpful for predicting the potential of CR, ADF and other dietary manipulations to affect markers of longevity in humans.	[Allard, Joanne S.; Smith, Carolina; Hunt, Nicole D.; Ingram, Donald K.; de Cabo, Rafael] NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA; [Heilbronn, Leonie K.; Ingram, Donald K.; Ravussin, Eric] Pennington Biomed Res Ctr, Baton Rouge, LA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Allard, JS (corresponding author), NIA, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA.	decabora@grc.nia.nih.gov	de Cabo, Rafael/E-7996-2010; Heilbronn, Leonie K/H-1874-2013; Ravussin, Eric/N-1985-2017; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/J-5230-2016	de Cabo, Rafael/0000-0003-2830-5693; Heilbronn, Leonie K/0000-0003-2106-7303; Ravussin, Eric/0000-0003-2129-547X; de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0002-3354-2442	Research Program of the NIH, National Institute on Aging [U01 AG20478]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000368, U01AG020478] Funding Source: NIH RePORTER	Research Program of the NIH, National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)NIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging, and also in part by research grant U01 AG20478 from the National Institutes of Health.	ALBANES D, 1988, JNCI-J NATL CANCER I, V80, P772, DOI 10.1093/jnci/80.10.772; Anson RM, 2003, P NATL ACAD SCI USA, V100, P6216, DOI 10.1073/pnas.1035720100; AUSTAD SN, 1989, EXP GERONTOL, V24, P83, DOI 10.1016/0531-5565(89)90037-5; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Colom B, 2007, CARDIOVASC RES, V74, P456, DOI 10.1016/j.cardiores.2007.02.001; Corton JC, 2005, J GERONTOL A-BIOL, V60, P1494, DOI 10.1093/gerona/60.12.1494; de Cabo R, 2003, EXP GERONTOL, V38, P631, DOI 10.1016/S0531-5565(03)00055-X; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gomez CR, 2006, MECH AGEING DEV, V127, P257, DOI 10.1016/j.mad.2005.10.002; GOODRICK CL, 1980, GERONTOLOGY, V26, P22, DOI 10.1159/000212390; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; Hall DM, 2000, J APPL PHYSIOL, V89, P749, DOI 10.1152/jappl.2000.89.2.749; Heilbronn LK, 2006, JAMA-J AM MED ASSOC, V295, P1539, DOI 10.1001/jama.295.13.1539; Heilbronn LK, 2005, OBES RES, V13, P574, DOI 10.1038/oby.2005.61; Heilbronn LK, 2005, AM J CLIN NUTR, V81, P69; HEYDARI AR, 1993, MOL CELL BIOL, V13, P2909, DOI 10.1128/MCB.13.5.2909; Higami Y, 2003, FASEB J, V17, P415, DOI 10.1096/fj.03-0678fje; Hisahara S, 2005, J PHARMACOL SCI, V98, P200, DOI 10.1254/jphs.FMJ05001X2; HOLLOSZY JO, 1988, J GERONTOL, V43, pB149, DOI 10.1093/geronj/43.6.B149; Ingram DK, 2006, BIOGERONTOLOGY, V7, P143, DOI 10.1007/s10522-006-9013-2; JAMES SJ, 1994, CANCER RES, V54, P5508; Kealy RD, 2002, J AM VET MED ASSOC, V220, P1315, DOI 10.2460/javma.2002.220.1315; Larson-Meyer DE, 2006, DIABETES CARE, V29, P1337, DOI 10.2337/dc05-2565; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Leibiger IB, 2006, NAT MED, V12, P34, DOI 10.1038/nm0106-34; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Ling C, 2004, J CLIN INVEST, V114, P1518, DOI 10.1172/JCI200421889; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Masoro EJ, 2001, AGING-CLIN EXP RES, V13, P261; Mattison JA, 2003, EXP GERONTOL, V38, P35, DOI 10.1016/S0531-5565(02)00146-8; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; Mulligan JD, 2008, EXP GERONTOL, V43, P146, DOI 10.1016/j.exger.2007.10.011; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Redman LM, 2007, J CLIN ENDOCR METAB, V92, P865, DOI 10.1210/jc.2006-2184; RETZLAFF E, 1966, GERIATRICS, V21, P171; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Selsby JT, 2005, EXP GERONTOL, V40, P37, DOI 10.1016/j.exger.2004.08.012; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Swindell WR, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-353; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Varady KA, 2007, AM J CLIN NUTR, V86, P7, DOI 10.1093/ajcn/86.1.7; Walford RL, 2002, J GERONTOL A-BIOL, V57, pB211, DOI 10.1093/gerona/57.6.B211; Willcox DC, 2006, BIOGERONTOLOGY, V7, P173, DOI 10.1007/s10522-006-9008-z; Wolkow CA, 2002, TRENDS NEUROSCI, V25, P212, DOI 10.1016/S0166-2236(02)02133-1; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	56	57	58	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2008	3	9							e3211	10.1371/journal.pone.0003211	http://dx.doi.org/10.1371/journal.pone.0003211			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	422KX	18791640	Green Submitted, gold, Green Published			2023-01-03	WOS:000264427700006
J	Wofford, B				Wofford, Ben			One hundred thousand cows - A fable	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												jbenwofford@charter.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 3	2008	300	9					1005	1005		10.1001/jama.300.9.1005	http://dx.doi.org/10.1001/jama.300.9.1005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342YN	18768405				2023-01-03	WOS:000258819600001
J	Yoshiike, Y; Kimura, T; Yamashita, S; Furudate, H; Mizoroki, T; Murayama, M; Takashima, A				Yoshiike, Yuji; Kimura, Tetsuya; Yamashita, Shunji; Furudate, Hiroyuki; Mizoroki, Tatsuya; Murayama, Miyuki; Takashima, Akihiko			GABA(A) Receptor-Mediated Acceleration of Aging-Associated Memory Decline in APP/PS1 Mice and Its Pharmacological Treatment by Picrotoxin	PLOS ONE			English	Article								Advanced age and mutations in the genes encoding amyloid precursor protein (APP) and presenilin (PS1) are two serious risk factors for Alzheimer's disease (AD). Finding common pathogenic changes originating from these risks may lead to a new therapeutic strategy. We observed a decline in memory performance and reduction in hippocampal long-term potentiation (LTP) in both mature adult (9-15 months) transgenic APP/PS1 mice and old (19-25 months) non-transgenic (nonTg) mice. By contrast, in the presence of bicuculline, a GABA(A) receptor antagonist, LTP in adult APP/PS1 mice and old nonTg mice was larger than that in adult nonTg mice. The increased LTP levels in bicuculline-treated slices suggested that GABA(A) receptor-mediated inhibition in adult APP/PS1 and old nonTg mice was upregulated. Assuming that enhanced inhibition of LTP mediates memory decline in APP/PS1 mice, we rescued memory deficits in adult APP/PS1 mice by treating them with another GABA(A) receptor antagonist, picrotoxin (PTX), at a non-epileptic dose for 10 days. Among the saline vehicle-treated groups, substantially higher levels of synaptic proteins such as GABA(A) receptor alpha 1 subunit, PSD95, and NR2B were observed in APP/PS1 mice than in nonTg control mice. This difference was insignificant among PTX-treated groups, suggesting that memory decline in APP/PS1 mice may result from changes in synaptic protein levels through homeostatic mechanisms. Several independent studies reported previously in aged rodents both an increased level of GABA(A) receptor alpha 1 subunit and improvement of cognitive functions by long term GABA(A) receptor antagonist treatment. Therefore, reduced LTP linked to enhanced GABA(A) receptor-mediated inhibition may be triggered by aging and may be accelerated by familial AD-linked gene products like A beta and mutant PS1, leading to cognitive decline that is pharmacologically treatable at least at this stage of disease progression in mice.	[Yoshiike, Yuji; Kimura, Tetsuya; Yamashita, Shunji; Mizoroki, Tatsuya; Murayama, Miyuki; Takashima, Akihiko] RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama, Japan; [Furudate, Hiroyuki] Saitama Univ, Fac Sci, Dept Regulat Biol, Lab Endocrinol & Neuroethol, Saitama, Japan	RIKEN; Saitama University	Yoshiike, Y (corresponding author), RIKEN, Brain Sci Inst, Lab Alzheimers Dis, Wako, Saitama, Japan.	kenneth@brain.riken.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [Grant-in-Aid]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We have no financial, personal, or professional conflicts of interests for the work presented in this manuscript. This work was partly supported by Grant-in-Aid for Scientific Research on Priority Areas (Research on Pathomechanisms on Brain Disorders) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARISPE N, 1994, ANN NY ACAD SCI, V747, P256; Barnes CA, 2003, PHILOS T R SOC B, V358, P765, DOI 10.1098/rstb.2002.1244; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bourtchouladze R, 2003, P NATL ACAD SCI USA, V100, P10518, DOI 10.1073/pnas.1834280100; Burrone J, 2003, CURR OPIN NEUROBIOL, V13, P560, DOI 10.1016/j.conb.2003.09.007; Chapouthier Georges, 2002, Current Topics in Medicinal Chemistry, V2, P841, DOI 10.2174/1568026023393552; Chen BS, 2007, NEUROPHARMACOLOGY, V53, P362, DOI 10.1016/j.neuropharm.2007.05.018; Cotman C.W, 2000, AGING MIND OPPORTUNI, P114; Fernandez F, 2007, NAT NEUROSCI, V10, P411, DOI 10.1038/nn1860; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; Guo Q, 1999, NAT MED, V5, P101, DOI 10.1038/4789; Gutierrez A, 1996, NEUROSCIENCE, V74, P341, DOI 10.1016/0306-4522(96)00137-6; Jankowsky JL, 2005, J NEUROSCI, V25, P5217, DOI 10.1523/JNEUROSCI.5080-04.2005; Jankowsky JL, 2003, J NEUROPATH EXP NEUR, V62, P1220, DOI 10.1093/jnen/62.12.1220; Jeong YH, 2006, FASEB J, V20, P729, DOI 10.1096/fj.05-4265fje; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; KHACHATURIAN ZS, 1994, ANN NY ACAD SCI, V747, P1; Kimura T, 2007, EMBO J, V26, P5143, DOI 10.1038/sj.emboj.7601917; Kleschevnikov AM, 2004, J NEUROSCI, V24, P8153, DOI 10.1523/JNEUROSCI.1766-04.2004; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; LaFerla FM, 2002, NAT REV NEUROSCI, V3, P862, DOI 10.1038/nrn960; Lalonde R, 2005, NEUROSCI LETT, V390, P87, DOI 10.1016/j.neulet.2005.08.028; LANDFIELD PW, 1981, SCIENCE, V214, P581, DOI 10.1126/science.6270791; Lee HK, 2005, NAT NEUROSCI, V8, P1657, DOI 10.1038/nn1586; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Nyffeler M, 2007, NEUROBIOL AGING, V28, P143, DOI 10.1016/j.neurobiolaging.2005.11.003; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Palop JJ, 2006, NATURE, V443, P768, DOI 10.1038/nature05289; Parent A, 1999, NEUROBIOL DIS, V6, P56, DOI 10.1006/nbdi.1998.0207; Parsons CG, 2007, NEUROPHARMACOLOGY, V53, P699, DOI 10.1016/j.neuropharm.2007.07.013; Pybus R, 2003, NEUROBIOL DIS, V12, P212, DOI 10.1016/S0969-9961(03)00016-0; Rissman RA, 2007, J NEUROCHEM, V103, P1285, DOI 10.1111/j.1471-4159.2007.04832.x; Roselli F, 2005, J NEUROSCI, V25, P11061, DOI 10.1523/JNEUROSCI.3034-05.2005; Ruano D, 2000, J BIOL CHEM, V275, P19585, DOI 10.1074/jbc.M000700200; Savonenko A, 2005, NEUROBIOL DIS, V18, P602, DOI 10.1016/j.nbd.2004.10.022; Schneider I, 2001, J BIOL CHEM, V276, P11539, DOI 10.1074/jbc.M010977200; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Smith-Swintosky V L, 1994, J Neural Transm Suppl, V44, P29; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Squire Larry R., 1994, P203; Stutzmann GE, 2006, J NEUROSCI, V26, P5180, DOI 10.1523/JNEUROSCI.0739-06.2006; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; van Gaalen MM, 2000, BEHAV BRAIN RES, V115, P95, DOI 10.1016/S0166-4328(00)00240-0; Vela J, 2003, J NEUROCHEM, V85, P368, DOI 10.1046/j.1471-4159.2003.01681.x; WISNIEWSKI KE, 1985, ANN NEUROL, V17, P278, DOI 10.1002/ana.410170310; Wolf SA, 2006, BIOL PSYCHIAT, V60, P1314, DOI 10.1016/j.biopsych.2006.04.004; Zaman SH, 2000, NEUROBIOL DIS, V7, P54, DOI 10.1006/nbdi.1999.0271	49	82	84	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2008	3	8							e3029	10.1371/journal.pone.0003029	http://dx.doi.org/10.1371/journal.pone.0003029			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	422KO	18716656	gold, Green Submitted, Green Published			2023-01-03	WOS:000264426800007
J	Cheson, BD; Leonard, JP				Cheson, Bruce D.; Leonard, John P.			Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PHASE-II TRIAL; CHRONIC LYMPHOCYTIC-LEUKEMIA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; HUMANIZED ANTI-CD22 ANTIBODY; REFRACTORY LOW-GRADE; ADVANCED FOLLICULAR LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; PROGRESSION-FREE SURVIVAL; IODINE I-131 TOSITUMOMAB		[Cheson, Bruce D.] Georgetown Univ Hosp, Div Hematol Oncol, Washington, DC 20007 USA; [Leonard, John P.] Weill Cornell Med Coll, Ctr Lymphoma & Myeloma, New York, NY USA	Georgetown University; Cornell University	Cheson, BD (corresponding author), Georgetown Univ Hosp, Div Hematol Oncol, 3800 Reservoir Rd NW, Washington, DC 20007 USA.	bdc4@georgetown.edu	Leonard, John/M-4379-2014	Leonard, John/0000-0002-5083-1115				Advani R, 2006, BLOOD, V108, p209A; Alas S, 2001, CANCER RES, V61, P5137; Ansell SM, 2002, J CLIN ONCOL, V20, P3885, DOI 10.1200/JCO.2002.10.143; Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Bennett JM, 2005, BLOOD, V105, P4576, DOI 10.1182/blood-2004-12-4690; Bohen SP, 2003, P NATL ACAD SCI USA, V100, P1926, DOI 10.1073/pnas.0437875100; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Byrd JC, 2006, BLOOD, V108, p14A, DOI 10.1182/blood.V108.11.32.32; Byrd JC, 2007, CLIN CANCER RES, V13, P4448, DOI 10.1158/1078-0432.CCR-06-1463; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Chaperot L, 1999, EXP HEMATOL, V27, P479, DOI 10.1016/S0301-472X(98)00059-9; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Coiffier B, 1998, BLOOD, V92, P1927; Coiffier B, 2008, BLOOD, V111, P1094, DOI 10.1182/blood-2007-09-111781; Coiffier B, 2006, BLOOD, V108, p804A, DOI 10.1182/blood.V108.11.2842.2842; Colombat P, 2006, BLOOD, V108, p147A; Croonian lecture, 1900, P R SOC LOND, V66, P424, DOI [DOI 10.1098/RSPL.1899.0121, 10.1098/rspl.1899.0121]; CZUCZMAN M, IN PRESS ANN ONCOL; Czuczman MS, 2005, J CLIN ONCOL, V23, P4390, DOI 10.1200/JCO.2005.09.018; Czuczman MS, 2004, J CLIN ONCOL, V22, P4711, DOI 10.1200/JCO.2004.04.020; Czuczman MS, 2005, J CLIN ONCOL, V23, P694, DOI 10.1200/JCO.2005.02.172; CZUCZMAN MS, 2005, J CLIN ONCOL, V23, P248, DOI DOI 10.1200/JCO.2004.04.020; Czuczman MS, 2007, J CLIN ONCOL, V25, P4285, DOI 10.1200/JCO.2006.09.2882; Davis TA, 1999, J CLIN ONCOL, V17, P1851, DOI 10.1200/JCO.1999.17.6.1851; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; DeNardo GL, 1998, J CLIN ONCOL, V16, P3246, DOI 10.1200/JCO.1998.16.10.3246; Farag SS, 2004, BLOOD, V103, P1472, DOI 10.1182/blood-2003-07-2548; Feugier P, 2005, J CLIN ONCOL, V23, P4117, DOI 10.1200/JCO.2005.09.131; Fisher RI, 2005, J CLIN ONCOL, V23, P8447, DOI 10.1200/JCO.2005.03.1674; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Foran JM, 2000, J CLIN ONCOL, V18, P317, DOI 10.1200/JCO.2000.18.2.317; Forstpointner R, 2004, BLOOD, V104, P3064, DOI 10.1182/blood-2004-04-1323; Forstpointner R, 2006, BLOOD, V108, P4003, DOI 10.1182/blood-2006-04-016725; Ghielmini M, 2004, BLOOD, V103, P4416, DOI 10.1182/blood-2003-10-3411; Gisselbrecht C, 2007, BLOOD, V110, p159A, DOI 10.1182/blood.V110.11.517.517; Golay J, 2000, BLOOD, V95, P3900; Gopal AK, 2003, BLOOD, V102, P2351, DOI 10.1182/blood-2003-02-0622; Gordan LN, 2005, J CLIN ONCOL, V23, P1096, DOI 10.1200/JCO.2005.12.171; Gordon LI, 2004, BLOOD, V103, P4429, DOI 10.1182/blood-2003-11-3883; Grillo-Lopez AJ, 2002, INT J HEMATOL, V76, P385, DOI 10.1007/BF02982803; Grillo-Lopez AJ, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.20444; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Hagenbeek A, 2005, BLOOD, V106, p270B; Hagenbeek A, 2007, BLOOD, V110, p198A, DOI 10.1182/blood.V110.11.643.643; Hainsworth JD, 2003, J CLIN ONCOL, V21, P1746, DOI 10.1200/JCO.2003.09.027; Hainsworth JD, 2005, J CLIN ONCOL, V23, P1088, DOI 10.1200/JCO.2005.12.191; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Herold M, 2007, J CLIN ONCOL, V25, P1986, DOI 10.1200/JCO.2006.06.4618; Hiddemann W, 2005, BLOOD, V106, P3725, DOI 10.1182/blood-2005-01-0016; Hillmen P, 2007, J CLIN ONCOL, V25, P5616, DOI 10.1200/JCO.2007.12.9098; Hochster HS, 2005, BLOOD, V106, p106A; Horning SJ, 2005, J CLIN ONCOL, V23, P712, DOI 10.1200/JCO.2005.07.040; Horwitz SM, 2004, BLOOD, V103, P777, DOI 10.1182/blood-2003-04-1257; Howard OM, 2002, J CLIN ONCOL, V20, P1288, DOI 10.1200/JCO.20.5.1288; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Igarashi T, 2002, ANN ONCOL, V13, P928, DOI 10.1093/annonc/mdf155; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kaminski MS, 2005, NEW ENGL J MED, V352, P441, DOI 10.1056/NEJMoa041511; Kaminski MS, 2000, BLOOD, V96, P1259, DOI 10.1182/blood.V96.4.1259.h8001259_1259_1266; Kaminski MS, 2001, J CLIN ONCOL, V19, P3918, DOI 10.1200/JCO.2001.19.19.3918; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Kim DH, 2006, BLOOD, V108, P2720, DOI 10.1182/blood-2006-01-009480; Kimby E, 1994, Ann Oncol, V5 Suppl 2, P67; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krishnan A, 2008, J CLIN ONCOL, V26, P90, DOI 10.1200/JCO.2007.11.9248; Lenz G, 2005, J CLIN ONCOL, V23, P1984, DOI 10.1200/JCO.2005.08.133; Leonard JP, 2007, ANN ONCOL, V18, P1216, DOI 10.1093/annonc/mdm114; Leonard JP, 2005, J CLIN ONCOL, V23, P5044, DOI 10.1200/JCO.2005.13.821; Leonard JP, 2003, J CLIN ONCOL, V21, P3051, DOI 10.1200/JCO.2003.01.082; Leonard JP, 2004, CLIN CANCER RES, V10, P5327, DOI 10.1158/1078-0432.CCR-04-0294; Link BK, 2001, BLOOD, V98, p606A; Liu YY, 2007, BLOOD, V110, P339, DOI 10.1182/blood-2006-09-049189; Lundin J, 2002, BLOOD, V100, P768, DOI 10.1182/blood-2002-01-0159; Maloney DG, 1997, J CLIN ONCOL, V15, P3266, DOI 10.1200/JCO.1997.15.10.3266; MALONEY DG, 1994, BLOOD, V84, P2457; Maloney DG, 1997, BLOOD, V90, P2188; MARCUS RE, IN PRESS J CLIN ONCO; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; Micallef INM, 2006, CANCER-AM CANCER SOC, V107, P2826, DOI 10.1002/cncr.22342; MILLER RA, 1982, NEW ENGL J MED, V306, P517, DOI 10.1056/NEJM198203043060906; MILLER RA, 1989, NEW ENGL J MED, V321, P851, DOI 10.1056/NEJM198909283211302; Morschhauser F, 2005, BLOOD, V106, p683A; Morschhauser F, 2007, BLOOD, V110, P54, DOI 10.1182/blood-2007-01-068056; Mounier N, 2003, BLOOD, V101, P4279, DOI 10.1182/blood-2002-11-3442; Nademanee A, 2005, BLOOD, V106, P2896, DOI 10.1182/blood-2005-03-1310; NADLER LM, 1981, J CLIN INVEST, V67, P134, DOI 10.1172/JCI110005; Nguyen DT, 1999, EUR J HAEMATOL, V62, P76, DOI 10.1111/j.1600-0609.1999.tb01725.x; Nyman H, 2007, BLOOD, V109, P4930, DOI 10.1182/blood-2006-09-047068; Pathan NI, 2008, BLOOD, V111, P1594, DOI 10.1182/blood-2007-03-082024; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; Piro LD, 1999, ANN ONCOL, V10, P655, DOI 10.1023/A:1008389119525; Press OW, 2006, J CLIN ONCOL, V24, P4143, DOI 10.1200/JCO.2006.05.8198; Press OW, 2005, BLOOD, V106, p107A; Rai KR, 2001, BLOOD, V98, p365A; RANKIN EM, 1985, BLOOD, V65, P1373, DOI 10.1182/blood.V65.6.1373.bloodjournal6561373; Romaguera, 2006, J CLIN ONCOL, V24, P724, DOI 10.1200/JCO.2006.12.002; Romaguera JE, 2005, J CLIN ONCOL, V23, P7013, DOI 10.1200/JCO.2005.01.1825; Ruf P, 2001, BLOOD, V98, P2526, DOI 10.1182/blood.V98.8.2526; Sehn LH, 2005, J CLIN ONCOL, V23, P5027, DOI 10.1200/JCO.2005.09.137; Stein R, 2004, CLIN CANCER RES, V10, P2868, DOI 10.1158/1078-0432.CCR-03-0493; Stein R, 2006, BLOOD, V108, P2736, DOI 10.1182/blood-2006-04-017921; Swenson WT, 2005, J CLIN ONCOL, V23, P5019, DOI 10.1200/JCO.2005.04.503; Treon SP, 2001, J IMMUNOTHER, V24, P272, DOI 10.1097/00002371-200105000-00012; van Oers MHJ, 2006, BLOOD, V108, P3295, DOI 10.1182/blood-2006-05-021113; Vose JM, 2001, J CLIN ONCOL, V19, P389, DOI 10.1200/JCO.2001.19.2.389; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Winter, 2007, BLOOD, V109, P2292; Winter JN, 2006, BLOOD, V107, P4207, DOI 10.1182/blood-2005-10-4222; Wiseman GA, 2002, BLOOD, V99, P4336, DOI 10.1182/blood.V99.12.4336; Witzig TE, 2005, J CLIN ONCOL, V23, P1103, DOI 10.1200/JCO.2005.12.052; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Zhao XB, 2007, BLOOD, V110, P2569, DOI 10.1182/blood-2006-12-062927	117	315	383	1	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 7	2008	359	6					613	626		10.1056/NEJMra0708875	http://dx.doi.org/10.1056/NEJMra0708875			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	334IY	18687642				2023-01-03	WOS:000258216700009
J	De Gennaro, L; Fratello, F; Marzano, C; Moroni, F; Curcio, G; Tempesta, D; Pellicciari, MC; Pirulli, C; Ferrara, M; Rossini, PM				De Gennaro, Luigi; Fratello, Fabiana; Marzano, Cristina; Moroni, Fabio; Curcio, Giuseppe; Tempesta, Daniela; Pellicciari, Maria Concetta; Pirulli, Cornelia; Ferrara, Michele; Rossini, Paolo Maria			Cortical Plasticity Induced by Transcranial Magnetic Stimulation during Wakefulness Affects Electroencephalogram Activity during Sleep	PLOS ONE			English	Article							PAIRED ASSOCIATIVE STIMULATION; LONG-TERM POTENTIATION; HUMAN MOTOR CORTEX; EVOKED-POTENTIALS; EXCITABILITY; DEPRESSION; LTP; DEPRIVATION; EEG; TOPOGRAPHY	Background: Sleep electroencephalogram (EEG) brain oscillations in the low-frequency range show local signs of homeostatic regulation after learning. Such increases and decreases of slow wave activity are limited to the cortical regions involved in specific task performance during wakefulness. Here, we test the hypothesis that reorganization of motor cortex produced by long-term potentiation (LTP) affects EEG activity of this brain area during subsequent sleep. Methodology/Principal Findings: By pairing median nerve stimulation with transcranial magnetic stimulation over the contralateral motor cortex, one can potentiate the motor output, which is presumed to reflect plasticity of the neural circuitry. This paired associative stimulation increases M1 cortical excitability at interstimulus intervals of 25 ms. We compared the scalp distribution of sleep EEG power following paired associative stimulation at 25 ms to that following a control paradigm with 50 ms intervals. It is shown that the experimental manipulation by paired associative stimulation at 25 ms induces a 48% increase in amplitude of motor evoked potentials. This LTP-like potentiation, induced during waking, affects delta and theta EEG power in both REM and non-REM sleep, measured during the following night. Slow-wave activity increases in some frontal and prefrontal derivations and decreases at sites neighboring and contralateral to the stimulated motor cortex. The magnitude of increased amplitudes of motor evoked potentials by the paired associative stimulation at 25 ms predicts enhancements of slow-wave activity in prefrontal regions. Conclusions/Significance: An LTP-like paradigm, presumably inducing increased synaptic strength, leads to changes in local sleep regulation, as indexed by EEG slow-wave activity. Enhancement and depression of slow-wave activity are interpreted in terms of a simultaneous activation of both excitatory and inhibitory circuits consequent to the paired associative stimulation at 25 ms.	[De Gennaro, Luigi; Fratello, Fabiana; Marzano, Cristina; Moroni, Fabio; Curcio, Giuseppe] Univ Roma La Sapienza, Dept Psychol, Rome, Italy; [De Gennaro, Luigi; Pellicciari, Maria Concetta; Pirulli, Cornelia] Hosp Fatebenefratelli, IRCCS Centro S Giovanni Dio, Brescia, Italy; [Curcio, Giuseppe; Rossini, Paolo Maria] IRCCS S Raffaele Pisana, Casa Cura S Raffaele Cassino, Rome, Italy; [Tempesta, Daniela] Univ Laquila, Fac Psychol, Lab Sleep Psychophysiol, Laquila, Italy; [Ferrara, Michele] Univ Laquila, Dept Internal Med & Publ Hlth, Laquila, Italy; [Rossini, Paolo Maria] Isola Tiberina, Hosp Fatebenefratelli, Dept Neurosci, AFaR, Rome, Italy; [Rossini, Paolo Maria] Univ Campus Biomed, Neurol Clin, Rome, Italy	Sapienza University Rome; IRCCS Fatebenefratelli; IRCCS San Raffaele Pisana; University of L'Aquila; University of L'Aquila; University Campus Bio-Medico - Rome Italy	De Gennaro, L (corresponding author), Univ Roma La Sapienza, Dept Psychol, Rome, Italy.	luigi.degennaro@uniroma1.it	Rossini, Paolo M./D-4994-2013; De Gennaro, Luigi/L-8711-2015; Curcio, Giuseppe/M-1635-2014; Tempesta, Daniela/AAB-7539-2022; Ferrara, Michele/AAB-7574-2022; Pirulli, Cornelia/K-1518-2016; Pellicciari, Maria Concetta/A-6815-2012	Rossini, Paolo M./0000-0003-2665-534X; De Gennaro, Luigi/0000-0003-3613-6631; Tempesta, Daniela/0000-0002-6942-5336; Ferrara, Michele/0000-0003-2304-7576; Pirulli, Cornelia/0000-0003-1865-5833; Pellicciari, Maria Concetta/0000-0003-2455-8220; Curcio, Giuseppe/0000-0003-2248-781X; Moroni, Fabio/0000-0003-0587-0614	MUR [PRIN 2006-2006062871]	MUR(Ministry of Education, Universities and Research (MIUR))	This work is supported by the M.U.R. grant "PRIN 2006-2006062871" (to LDG).	Andersen P, 1977, Ciba Found Symp, P87; Bergmann TO, 2008, EUR J NEUROSCI, V27, P2241, DOI 10.1111/j.1460-9568.2008.06178.x; Bonato C, 2006, CLIN NEUROPHYSIOL, V117, P1699, DOI 10.1016/j.clinph.2006.05.006; Borbely A A, 1982, Hum Neurobiol, V1, P195; BORBELY AA, 1992, J SLEEP RES, V1, P63, DOI 10.1111/j.1365-2869.1992.tb00013.x; BRUNNER DP, 1993, SLEEP, V16, P100, DOI 10.1093/sleep/16.2.100; Buonomano DV, 1998, J NEUROPHYSIOL, V80, P1765, DOI 10.1152/jn.1998.80.4.1765; Classen Joseph, 2004, Suppl Clin Neurophysiol, V57, P563; Crupi D, 2008, BRAIN RES BULL, V75, P107, DOI 10.1016/j.brainresbull.2007.07.029; Enomoto H, 2001, CLIN NEUROPHYSIOL, V112, P2154, DOI 10.1016/S1388-2457(01)00667-8; Esser SK, 2006, BRAIN RES BULL, V69, P86, DOI 10.1016/j.brainresbull.2005.11.003; Esser SK, 2005, J NEUROPHYSIOL, V94, P622, DOI 10.1152/jn.01230.2004; Ferrara M, 2002, CEREB CORTEX, V12, P737, DOI 10.1093/cercor/12.7.737; Fratello F, 2006, CLIN NEUROPHYSIOL, V117, P2667, DOI 10.1016/j.clinph.2006.07.315; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; Huber R, 2000, J NEUROPHYSIOL, V84, P1888, DOI 10.1152/jn.2000.84.4.1888; Huber R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000276; Huber R, 2006, NAT NEUROSCI, V9, P1169, DOI 10.1038/nn1758; Ilmoniemi RJ, 1997, NEUROREPORT, V8, P3537, DOI 10.1097/00001756-199711100-00024; Ishikawa S, 2007, CLIN NEUROPHYSIOL, V118, P1033, DOI 10.1016/j.clinph.2007.02.003; Litvak V, 2007, EUR J NEUROSCI, V25, P2862, DOI 10.1111/j.1460-9568.2007.05531.x; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MARIORENZI R, 1991, ELECTROEN CLIN NEURO, V81, P90, DOI 10.1016/0168-5597(91)90002-F; Mima T, 2000, CLIN NEUROPHYSIOL, V111, P326, DOI 10.1016/S1388-2457(99)00229-1; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P374, DOI 10.1152/jn.1957.20.4.374; Murakami T, 2008, EXP BRAIN RES, V184, P339, DOI 10.1007/s00221-007-1103-0; Nuwer MR, 1998, ELECTROEN CLIN NEURO, V106, P259, DOI 10.1016/S0013-4694(97)00106-5; Oleksenko A.I., 1992, Journal of Sleep Research, V1, P40; Rattenborg NC, 1999, NATURE, V397, P397, DOI 10.1038/17037; RECHTSHAFFEN A, 1968, MANUAL STANDARDIZED; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; ROSSINI PM, 1994, ELECTROEN CLIN NEURO, V91, P79, DOI 10.1016/0013-4694(94)90029-9; Rothwell J C, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P97; Royer S, 2003, NATURE, V422, P518, DOI 10.1038/nature01530; Stefan K, 2004, J NEUROPHYSIOL, V92, P66, DOI 10.1152/jn.00383.2003; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Stefan K, 2006, CEREB CORTEX, V16, P376, DOI 10.1093/cercorbhi116; Stefan K, 2000, BRAIN, V123, P572, DOI 10.1093/brain/123.3.572; TOBLER I, 1992, J SLEEP RES, V1, P125, DOI 10.1111/j.1365-2869.1992.tb00024.x; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Tsuji T, 2002, J PHYSIOL-LONDON, V540, P367, DOI 10.1113/jphysiol.2001.013504; Vyazovskiy VV, 2008, NAT NEUROSCI, V11, P200, DOI 10.1038/nn2035; Vyazovskiy VV, 2002, J NEUROPHYSIOL, V88, P2280, DOI 10.1152/jn.00304.2002; Wawryko P, 2004, BRAIN RES, V1029, P1, DOI 10.1016/j.brainres.2004.09.019; Weise D, 2006, BRAIN, V129, P2709, DOI 10.1093/brain/awl221; Wolters A, 2005, J PHYSIOL-LONDON, V565, P1039, DOI 10.1113/jphysiol.2005.084954; Wolters A, 2003, J NEUROPHYSIOL, V89, P2339, DOI 10.1152/jn.00900.2002; Ziemann U, 2004, J NEUROSCI, V24, P1666, DOI 10.1523/JNEUROSCI.5016-03.2004	50	40	40	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2008	3	6							e2483	10.1371/journal.pone.0002483	http://dx.doi.org/10.1371/journal.pone.0002483			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	406IK	18575583	Green Submitted, gold, Green Published			2023-01-03	WOS:000263288000013
J	Zimmermann, C; Riechelmann, R; Krzyzanowska, M; Rodin, G; Tannock, I				Zimmermann, Camilla; Riechelmann, Rachel; Krzyzanowska, Monika; Rodin, Gary; Tannock, Ian			Effectiveness of specialized palliative - Care a systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CANCER-PATIENTS; HOME-CARE; CLUSTER RANDOMIZATION; LUNG-CANCER; FAMILY SATISFACTION; COST-EFFECTIVENESS; CONSORT STATEMENT; COORDINATED CARE	Context Specialized palliative care teams are increasingly providing care for the terminally ill. However, the impact of such teams on quality of life, satisfaction with care, and economic cost has not been examined systematically using detailed criteria for study quality. Objective To systematically review the evidence for effectiveness of specialized palliative care. Data Sources We performed a keyword search of the following databases from their inception to January 2008: MEDLINE, Ovid Healthstar, CINAHL, EMBASE, and the Cochrane Central Register of Controlled Trials. Study Selection We included all randomized controlled trials in which specialized palliative care was the intervention and for which outcomes included quality of life, satisfaction with care, or economic cost. Data Extraction Data on population, intervention, outcome, methods, and methodological quality were extracted by 2 investigators using standardized criteria. Results Of 396 reports of randomized controlled trials, 22 met our inclusion criteria. There was most consistent evidence for effectiveness of specialized palliative care in improvement of family satisfaction with care ( 7 of 10 studies favored the intervention). Only 4 of 13 studies assessing quality of life and 1 of 14 assessing symptoms showed a significant benefit of the intervention; however, most studies lacked statistical power to report conclusive results, and quality- of- life measures were not specific for terminally ill patients. There was evidence of significant cost savings of specialized palliative care in only 1 of the 7 studies that assessed this outcome. Methodological limitations were identified in all trials, including contamination of the control group, failure to account for clustering in cluster randomization studies, and substantial problems with recruitment, attrition, and adherence. Conclusions The evidence for benefit from specialized palliative care is sparse and limited by methodological shortcomings. Carefully planned trials, using a standardized palliative care intervention and measures constructed specifically for this population, are needed.	[Zimmermann, Camilla; Rodin, Gary] Princess Margaret Hosp, Palliat Care Serv, Dept Psychosocial Oncol & Palliat Care, Univ Hlth Network, Toronto, ON M5G 2M9, Canada; [Krzyzanowska, Monika; Tannock, Ian] Princess Margaret Hosp, Dept Med Oncol, Univ Hlth Network, Toronto, ON M5G 2M9, Canada; [Riechelmann, Rachel] Albert Einstein Hosp, Dept Med Oncol, Sao Paulo, Brazil; [Zimmermann, Camilla; Krzyzanowska, Monika; Tannock, Ian] Univ Toronto, Div Med Oncol & Hematol, Dept Med, Toronto, ON, Canada; [Zimmermann, Camilla; Rodin, Gary] Univ Toronto, Dept Psychiat, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Hospital Israelita Albert Einstein; University of Toronto; University of Toronto	Zimmermann, C (corresponding author), Princess Margaret Hosp, Palliat Care Serv, Dept Psychosocial Oncol & Palliat Care, Univ Hlth Network, 610 Univ Ave,16-712, Toronto, ON M5G 2M9, Canada.	camilla.zimmermann@uhn.on.ca	Krzyzanowska, Monika K./ABG-3505-2020; Riechelmann, R/Q-6239-2017	Krzyzanowska, Monika K./0000-0001-5533-7418; Zimmermann, Camilla/0000-0003-4889-0244; Rodin, Gary/0000-0002-6626-6974				AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Ahronheim J C, 2000, J Palliat Med, V3, P265, DOI 10.1089/jpm.2000.3.265; Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; Aspinal F, 2003, J ADV NURS, V42, P324, DOI 10.1046/j.1365-2648.2003.02624.x; Baker R, 2000, J AM GERIATR SOC, V48, pS61, DOI 10.1111/j.1532-5415.2000.tb03143.x; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Boni-Saenz AA, 2005, CLIN GERIATR MED, V21, P147, DOI 10.1016/j.cger.2004.08.010; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Bryce CL, 2004, MED CARE, V42, P423, DOI 10.1097/01.mlr.000012425.62354.57; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Campbell MK, 2004, COMPUT BIOL MED, V34, P113, DOI 10.1016/S0010-4825(03)00039-8; Campbell MK, 2000, FAM PRACT, V17, P192, DOI 10.1093/fampra/17.2.192; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; Casarett D, 2005, JAMA-J AM MED ASSOC, V294, P211, DOI 10.1001/jama.294.2.211; CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Clark Matthew M, 2006, Am J Hosp Palliat Care, V23, P185, DOI 10.1177/1049909106289074; *COCHR EPOC, DAT ABSTR TEMPL; COHEN SR, 1995, PALLIATIVE MED, V9, P207, DOI 10.1177/026921639500900306; Costantini M, 1999, J PAIN SYMPTOM MANAG, V18, P243, DOI 10.1016/S0885-3924(99)00084-6; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; Desbiens NA, 1996, CRIT CARE MED, V24, P1953, DOI 10.1097/00003246-199612000-00005; Dibble S L, 1998, Oncol Nurs Forum, V25, P577; DONNER A, 1990, INT J EPIDEMIOL, V19, P795, DOI 10.1093/ije/19.4.795; Eldridge Sandra M, 2004, Clin Trials, V1, P80, DOI 10.1191/1740774504cn006rr; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Engelhardt JB, 2006, AM J MANAG CARE, V12, P93; FERRIS FD, 2002, MODEL GUIDE HOSP PAL; Grande GE, 2000, PALLIATIVE MED, V14, P375, DOI 10.1191/026921600701536200; Grande GE, 1999, BRIT MED J, V319, P1472, DOI 10.1136/bmj.319.7223.1472; Grimshaw J, 2003, QUAL SAF HEALTH CARE, V12, P298, DOI 10.1136/qhc.12.4.298; Groenvold M, 2006, EUR J CANCER, V42, P55, DOI 10.1016/j.ejca.2005.06.022; Hanks GW, 2002, BRIT J CANCER, V87, P733, DOI 10.1038/sj.bjc.6600522; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Heyland DK, 2006, CAN MED ASSOC J, V174, P627, DOI 10.1503/cmaj.050626; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Higginson IJ, 2002, J PAIN SYMPTOM MANAG, V23, P96, DOI 10.1016/S0885-3924(01)00406-7; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; Hughes SL, 2000, JAMA-J AM MED ASSOC, V284, P2877, DOI 10.1001/jama.284.22.2877; Huwiler-Muntener K, 2002, JAMA-J AM MED ASSOC, V287, P2801, DOI 10.1001/jama.287.21.2801; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JENICEK M, 1989, J CLIN EPIDEMIOL, V42, P35, DOI 10.1016/0895-4356(89)90023-1; Jordhoy MS, 1999, PALLIATIVE MED, V13, P299, DOI 10.1191/026921699668963873; Jordhoy MS, 2000, LANCET, V356, P888, DOI 10.1016/S0140-6736(00)02678-7; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Kaasa S, 2003, PALLIATIVE MED, V17, P11, DOI 10.1191/0269216303pm662ra; Kaasa S, 2002, LANCET ONCOL, V3, P175, DOI 10.1016/S1470-2045(02)00682-4; KANE RL, 1985, MED CARE, V23, P189, DOI 10.1097/00005650-198503000-00001; KANE RL, 1986, J CHRON DIS, V39, P735, DOI 10.1016/0021-9681(86)90156-6; KANE RL, 1985, JAMA-J AM MED ASSOC, V253, P2683, DOI 10.1001/jama.253.18.2683; KANE RL, 1984, LANCET, V1, P890; KIRKWOOD BR, 1989, J BIOSOC SCI, P79; Kirkwood BR, 1997, TROP MED INT HEALTH, V2, P1022, DOI 10.1046/j.1365-3156.1997.d01-188.x; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Li Yan-qun, 2006, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V31, P538; Lorenz KA, 2008, ANN INTERN MED, V148, P147, DOI 10.7326/0003-4819-148-2-200801150-00010; Lynn J, 1997, J AM GERIATR SOC, V45, P526; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; McMillan SC, 2006, CANCER, V106, P214, DOI 10.1002/cncr.21567; McMillan SC, 1998, CANCER PRACT, V6, P282, DOI 10.1046/j.1523-5394.1998.00023.x; McMillan SC, 2007, ONCOL NURS FORUM, V34, P313, DOI 10.1188/07.ONF.313-321; MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Miller Douglas K, 2005, J Palliat Med, V8, P333, DOI 10.1089/jpm.2005.8.333; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Moore S, 2002, BMJ-BRIT MED J, V325, P1145, DOI 10.1136/bmj.325.7373.1145; Morrison RS, 2000, ARCH INTERN MED, V160, P743, DOI 10.1001/archinte.160.6.743; Paes P, 2005, PALLIATIVE MED, V19, P505, DOI 10.1177/026921630501900614; Pearson, 1969, DEATH DYING, P49; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Rinck GC, 1997, J CLIN ONCOL, V15, P1697, DOI 10.1200/JCO.1997.15.4.1697; Ringdal GI, 2002, J PAIN SYMPTOM MANAG, V24, P53, DOI 10.1016/S0885-3924(02)00417-7; Rodin G, 2007, J PAIN SYMPTOM MANAG, V33, P661, DOI 10.1016/j.jpainsymman.2006.09.034; Rummans TA, 2006, J CLIN ONCOL, V24, P635, DOI 10.1200/JCO.2006.06.209; Salisbury C, 1999, PALLIATIVE MED, V13, P3, DOI 10.1191/026921699677461429; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Sepulveda C, 2002, J PAIN SYMPTOM MANAG, V24, P91, DOI 10.1016/S0885-3924(02)00440-2; SIMPSON JM, 1995, AM J PUBLIC HEALTH, V85, P1378, DOI 10.2105/AJPH.85.10.1378; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser Karen E, 2004, Palliat Support Care, V2, P3; Strasser S, 1995, J Health Care Mark, V15, P34; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Torgerson DJ, 2001, BMJ-BRIT MED J, V322, P355, DOI 10.1136/bmj.322.7282.355; TOSELAND RW, 1995, SOC SCI MED, V40, P517, DOI 10.1016/0277-9536(94)E0093-8; Ware J.E., 1993, SF 36 HLTH SURVEY MA; WARE JE, 1976, HEALTH SERV RES, V11, P396; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wilkinson EK, 1999, PALLIATIVE MED, V13, P197, DOI 10.1191/026921699673563105; World Health Organization, 2002, WHO DEF PALL CAR; ZIMMER JG, 1984, J AM GERIATR SOC, V32, P288, DOI 10.1111/j.1532-5415.1984.tb02023.x; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	102	320	327	2	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 9	2008	299	14					1698	1709		10.1001/jama.299.14.1698	http://dx.doi.org/10.1001/jama.299.14.1698			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285AL	18398082				2023-01-03	WOS:000254749600026
J	Milton, JC; Hill-Smith, I; Jackson, SHD				Milton, James C.; Hill-Smith, Ian; Jackson, Stephen H. D.			Prescribing for older people	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GROWING EVIDENCE BASE; ELDERLY-PATIENTS; DRUG-USE; COMMUNITY PHARMACISTS; HEART-FAILURE; POLYPHARMACY; INDICATORS; BLOCKERS; CRITERIA; QUALITY		[Milton, James C.; Jackson, Stephen H. D.] Kings Coll Hosp Fdn Trust, Clin Age Res Unit, Dept Clin Gerontol, London SE5 9PJ, England; [Hill-Smith, Ian] Churchfield Med Ctr, Stopsley Grp Practice, Luton LU2 9SB, Beds, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Milton, JC (corresponding author), Kings Coll Hosp Fdn Trust, Clin Age Res Unit, Dept Clin Gerontol, London SE5 9PJ, England.	jim_milton@hotmail.com						[Anonymous], 2007, PHARM J; [Anonymous], INT J PHARM PRACT, DOI DOI 10.1111/J.2042-7174.1998.TB00920.X; Batty G. M, 2001, BR J CLIN GOVERN, V6, P252, DOI DOI 10.1108/14664100110408608.BEERS; Batty GM, 2004, J EVAL CLIN PRACT, V10, P273, DOI 10.1111/j.1365-2753.2003.00454.x; Batty GM, 2003, AGE AGEING, V32, P292, DOI 10.1093/ageing/32.3.292; Bond C, 2000, BRIT J GEN PRACT, V50, P271; Campbell SE, 2004, AGE AGEING, V33, P110, DOI 10.1093/ageing/afh036; *DEP HLTH, 2004, PRESCR DISP COMM 199; Department of Health, 2001, MED OLD PEOPL IMPL M; Dhesi JK, 2006, BRIT J CLIN PHARMACO, V61, P521, DOI 10.1111/j.1365-2125.2006.02612.x; Edwards Rebecca F, 2003, Consult Pharm, V18, P37; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; FRANKLIN BD, 2007, INT J PHARM PRACT, V15, P133, DOI DOI 10.1211/ijpp.15.2.0009; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Frazier Susan C, 2005, J Gerontol Nurs, V31, P4; Freemantle N, 2002, BRIT J GEN PRACT, V52, P290; Green Jacqueline L, 2007, Am J Geriatr Pharmacother, V5, P31, DOI 10.1016/j.amjopharm.2007.03.004; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; *INF CTR HLTH CAR, 2007, PRESCR DISP COMM STA; Lapane KL, 2007, J AM GERIATR SOC, V55, P1254, DOI 10.1111/j.1532-5415.2007.01248.x; MA Thomson O'Brien, 2000, COCHRANE DB SYST REV; Mallet L, 2007, LANCET, V370, P185, DOI 10.1016/S0140-6736(07)61092-7; Mangoni AA, 2006, BRIT J CLIN PHARMACO, V61, P513, DOI 10.1111/j.1365-2125.2006.02611.x; Mangoni AA, 2006, BRIT J CLIN PHARMACO, V61, P494, DOI 10.1111/j.1365-2125.2006.02609.x; Mangoni AA, 2006, BRIT J CLIN PHARMACO, V61, P502, DOI 10.1111/j.1365-2125.2006.02610.x; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; *MIDDL PRIM CAR TR, GUID SUPP PROD REP P; *NAT HLTH SERV, 2008, EPRESCRIBING; National Collaborating Centre for Chronic Conditions, 2006, ATR FIBR NAT CLIN GU; Noyce PR, 2007, ANN PHARMACOTHER, V41, P861, DOI 10.1345/aph.1K015; Oborne CA, 1997, BRIT J CLIN PHARMACO, V43, P91, DOI 10.1111/j.1365-2125.1997.tb00038.x; Oborne CA, 2003, AGE AGEING, V32, P102; *OFF NAT STAT, 2005, KEY POP VIT STAT; Rollason V, 2003, DRUG AGING, V20, P817, DOI 10.2165/00002512-200320110-00003; SWIFT CG, 1988, BRIT MED J, V296, P913, DOI 10.1136/bmj.296.6626.913; Wu JYF, 2006, BMJ-BRIT MED J, V333, P522, DOI 10.1136/bmj.38905.447118.2F	37	152	164	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2008	336	7644					606	609		10.1136/bmj.39503.424653.80	http://dx.doi.org/10.1136/bmj.39503.424653.80			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279OM	18340075	Green Published			2023-01-03	WOS:000254364500035
J	Goodwin, SC; Spies, JB				Goodwin, Scott C.; Spies, James B.			Uterine Fibroid Embolization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTICENTER RETROSPECTIVE COHORT; RANDOMIZED CONTROLLED-TRIAL; ARTERY EMBOLIZATION; PATHOLOGICAL FEATURES; TERM OUTCOMES; EMMY TRIAL; LEIOMYOMATA; HYSTERECTOMY; REGISTRY; SYMPTOM	A 45-year-old, premenopausal black woman (gravida 3, para 2, with a history of one spontaneous abortion) presents with menorrhagia and dysmenorrhea that has worsened progressively over a period of 10 years. She does not wish to have any more children. On physical examination, she has a firm, nontender, enlarged uterus. The ovaries are not palpable. Laboratory tests in the past had revealed intermittent mild anemia that was correctable with iron supplementation, but more severe anemia has been noted recently, and she has had increasing difficulty managing her menstrual bleeding. In-office ultrasound examinations have shown several intramural uterine masses consistent with uterine fibroids that have been slowly increasing in size; the largest measures 6.5 cm at the point of its greatest dimension. The adnexa are normal. The patient's gynecologist has recommended a hysterectomy. However, the patient does not want to undergo a hysterectomy, and her gynecologist suggests uterine fibroid embolization as an alternative. She is referred to an interventional radiologist who orders a magnetic resonance imaging (MRI) scan. The results of the MRI confirm the ultrasound findings and rule out adenomyosis. The interventional radiologist discusses with the patient uterine fibroid embolization as an alternative to hysterectomy. What treatment should be recommended for this patient?	[Goodwin, Scott C.] Univ Calif Irvine, Dept Radiol Sci, Orange, CA 92868 USA; [Spies, James B.] Georgetown Univ, Med Ctr, Dept Radiol, Washington, DC 20007 USA	University of California System; University of California Irvine; Georgetown University	Goodwin, SC (corresponding author), Univ Calif Irvine, Dept Radiol Sci, 101 City Dr S,Rte 140, Orange, CA 92868 USA.	sgoodwin@uci.edu						*AM COLL OBST GYN, 2008, OBSTET GYNECOL, V112, P387, DOI DOI 10.1097/AOG.0B013E318183FBAB; Bruno J, 2004, J VASC INTERV RADIOL, V15, P801, DOI 10.1097/01.RVI.0000136983.45640.E4; Chen CR, 2001, AM J EPIDEMIOL, V153, P20, DOI 10.1093/aje/153.1.20; Colgan TJ, 2003, AM J SURG PATHOL, V27, P167, DOI 10.1097/00000478-200302000-00004; CRAMER SF, 1990, AM J CLIN PATHOL, V94, P435, DOI 10.1093/ajcp/94.4.435; Czeyda-Pommersheim F, 2006, CARDIOVASC INTER RAD, V29, P1136, DOI 10.1007/s00270-005-0245-3; DAYBAIRD D, 2003, AM J OBSTET GYNECOL, V188, P100; de Blok S, 2003, J VASC INTERV RADIOL, V14, P779, DOI 10.1097/01.RVI.0000079988.80153.61; Dembek CJ, 2007, J VASC INTERV RADIOL, V18, P1207, DOI 10.1016/j.jvir.2007.07.007; Dietz DM, 2004, OBSTET GYNECOL, V104, P1159, DOI 10.1097/01.AOG.0000141567.25541.26; Dutton S, 2007, BJOG-INT J OBSTET GY, V114, P1340, DOI 10.1111/j.1471-0528.2007.01526.x; Edwards RD, 2007, NEW ENGL J MED, V356, P360; El-Shalakany AH, 2003, BJOG-INT J OBSTET GY, V110, P215, DOI 10.1046/j.1471-0528.2003.01151.x; Flynn M, 2006, AM J OBSTET GYNECOL, V195, P955, DOI 10.1016/j.ajog.2006.02.020; Goodwin SC, 1997, J VASC INTERV RADIOL, V8, P517, DOI 10.1016/S1051-0443(97)70603-1; Goodwin SC, 1999, J VASC INTERV RADIOL, V10, P991, DOI 10.1016/S1051-0443(99)70177-6; Goodwin SC, 2008, OBSTET GYNECOL, V111, P22, DOI 10.1097/01.AOG.0000296526.71749.c9; Hehenkamp WJK, 2005, AM J OBSTET GYNECOL, V193, P1618, DOI 10.1016/j.ajog.2005.05.017; Hehenkamp WJK, 2008, RADIOLOGY, V246, P823, DOI 10.1148/radiol.2463070260; Hirst A, 2008, HEALTH TECHNOL ASSES, V12, P1; Hovsepian DM, 2004, CARDIOVASC INTER RAD, V27, P307, DOI 10.1007/s00270-004-0087-4; Khaund A, 2004, BJOG-INT J OBSTET GY, V111, P700, DOI 10.1111/j.1471-0528.2004.00158.x; Lanocita R, 1999, SMIT CIMIT 11 ANN SC; Lefebvre GG, 2004, J OBSTET GYNAECOL CA, V26, P913; Lefebvre Guylaine G, 2004, J Obstet Gynaecol Can, V26, P899; Mara M, 2008, CARDIOVASC INTER RAD, V31, P73, DOI 10.1007/s00270-007-9195-2; Marshall LM, 1997, OBSTET GYNECOL, V90, P967, DOI 10.1016/S0029-7844(97)00534-6; McCluggage WG, 2000, INT J GYNECOL PATHOL, V19, P342, DOI 10.1097/00004347-200010000-00008; Nikolic B, 2003, J VASC INTERV RADIOL, V14, P1147, DOI 10.1097/01.RVI.0000086540.44800.FE; Parker WH, 2007, FERTIL STERIL, V88, P255, DOI 10.1016/j.fertnstert.2007.06.044; Parker WH, 2007, FERTIL STERIL, V87, P725, DOI 10.1016/j.fertnstert.2007.01.093; Pelage JP, 2005, RADIOGRAPHICS, V25, pS99, DOI 10.1148/rg.25si055510; Pelage JP, 2005, RADIOLOGY, V234, P948, DOI 10.1148/radiol.2343031697; Pelage JP, 2004, RADIOLOGY, V230, P803, DOI 10.1148/radiol.2303030111; Pron G, 2005, OBSTET GYNECOL, V105, P67, DOI 10.1097/01.AOG.0000149156.07061.1f; Pron G, 2003, FERTIL STERIL, V79, P120, DOI 10.1016/S0015-0282(02)04538-7; Spies J, 2001, J VASC INTERV RADIOL, V12, P19, DOI 10.1016/S1051-0443(07)61396-7; Spies JB, 2005, OBSTET GYNECOL, V106, P1309, DOI 10.1097/01.AOG.0000188386.53878.49; Spies JB, 2005, OBSTET GYNECOL, V106, P933, DOI 10.1097/01.AOG.0000182582.64088.84; Spies JB, 2002, OBSTET GYNECOL, V100, P873, DOI 10.1016/S0029-7844(02)02341-4; Spies JB, 2002, RADIOLOGY, V222, P45, DOI 10.1148/radiol.2221010661; Spies JB, 2001, OBSTET GYNECOL, V98, P29, DOI 10.1016/S0029-7844(01)01382-5; Stewart EA, 2001, LANCET, V357, P293, DOI 10.1016/S0140-6736(00)03622-9; Sultana CJ, 2002, AM J OBSTET GYNECOL, V187, P1726, DOI 10.1067/mob.2002.128989; Vashisht A, 1999, LANCET, V354, P307, DOI 10.1016/S0140-6736(99)02987-6; Walker CL, 2005, SCIENCE, V308, P1589, DOI 10.1126/science.1112063; Walker WJ, 2006, AM J OBSTET GYNECOL, V195, P1266, DOI 10.1016/j.ajog.2006.04.011; Weichert W, 2005, AM J SURG PATHOL, V29, P955, DOI 10.1097/01.pas.0000159776.77912.ce; Wise LA, 2005, OBSTET GYNECOL, V105, P563, DOI 10.1097/01.AOG.0000154161.03418.e3; Wise LA, 2004, AM J EPIDEMIOL, V159, P113, DOI 10.1093/aje/kwh016; Worthington-Kirsch R, 2005, OBSTET GYNECOL, V106, P52, DOI 10.1097/01.AOG.0000165828.68787.a9; WORTHINGTONKIRS.R, 2005, OBSTET GYNECOL, V106, P869; Yousefi S, 2006, J VASC INTERV RADIOL, V17, P1923, DOI 10.1097/01.RVI.0000244851.04692.B5; 2009, J VASC INTERV RADIOL, V20, P419	54	48	52	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 13	2009	361	7					690	697		10.1056/NEJMct0806942	http://dx.doi.org/10.1056/NEJMct0806942			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	482JX	19675331				2023-01-03	WOS:000268884100009
J	Hulley, S; Grady, D				Hulley, Stephen; Grady, Deborah			Postmenopausal Hormone Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; ESTROGEN PLUS PROGESTIN; CONJUGATED EQUINE ESTROGENS; MILD COGNITIVE IMPAIRMENT; HEALTH INITIATIVE MEMORY; CARDIOVASCULAR-DISEASE; WOMEN; THERAPY; REPLACEMENT; DEMENTIA		[Hulley, Stephen] Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, San Francisco, CA 94107 USA; [Grady, Deborah] Univ Calif San Francisco, Dept Med, Sch Med, San Francisco, CA 94107 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Hulley, S (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Sch Med, 185 Berry St,Ste 5700, San Francisco, CA 94107 USA.	shulley@epi.ucsf.edu						Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Ettinger B, 2004, OBSTET GYNECOL, V104, P443, DOI 10.1097/01.AOG.0000137833.43248.79; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; GRADY D, 1992, ANN INTERN MED, V117, P1038; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hulley SB, 2004, JAMA-J AM MED ASSOC, V291, P1769, DOI 10.1001/jama.291.14.1769; JEMAL A, RECENT TRENDS BREAST; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Utian WH, 2001, FERTIL STERIL, V75, P1065, DOI 10.1016/S0015-0282(01)01791-5; Wilson RA, 1966, FEMININE FOREVER	15	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	2009	301	23					2493	2495		10.1001/jama.2009.847	http://dx.doi.org/10.1001/jama.2009.847			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	458MO	19531791				2023-01-03	WOS:000267028100029
J	Morrhaye, G; Kermani, H; Legros, JJ; Baron, F; Beguin, Y; Moutschen, M; Cheynier, R; Martens, HJ; Geenen, V				Morrhaye, Gabriel; Kermani, Hamid; Legros, Jean-Jacques; Baron, Frederic; Beguin, Yves; Moutschen, Michel; Cheynier, Remi; Martens, Henri J.; Geenen, Vincent			Impact of Growth Hormone (GH) Deficiency and GH Replacement upon Thymus Function in Adult Patients	PLOS ONE			English	Article								Background: Despite age-related adipose involution, T cell generation in the thymus (thymopoiesis) is maintained beyond puberty in adults. In rodents, growth hormone (GH), insulin-like growth factor-1 (IGF-1), and GH secretagogues reverse age-related changes in thymus cytoarchitecture and increase thymopoiesis. GH administration also enhances thymic mass and function in HIV-infected patients. Until now, thymic function has not been investigated in adult GH deficiency (AGHD). The objective of this clinical study was to evaluate thymic function in AGHD, as well as the repercussion upon thymopoiesis of GH treatment for restoration of GH/IGF-1 physiological levels. Methodology/Principal Findings: Twenty-two patients with documented AGHD were enrolled in this study. The following parameters were measured: plasma IGF-1 concentrations, signal-joint T-cell receptor excision circle (sjTREC) frequency, and sj/beta TREC ratio. Analyses were performed at three time points: firstly on GH treatment at maintenance dose, secondly one month after GH withdrawal, and thirdly one month after GH resumption. After 1-month interruption of GH treatment, both plasma IGF-1 concentrations and sjTREC frequency were decreased (p<0.001). Decreases in IGF-1 and sjTREC levels were correlated (r = 0.61, p<0.01). There was also a decrease in intrathymic T cell proliferation as indicated by the reduced sj/beta TREC ratio (p<0.01). One month after reintroduction of GH treatment, IGF-1 concentration and sjTREC frequency regained a level equivalent to the one before GH withdrawal. The sj/beta TREC ratio also increased with GH resumption, but did not return to the level measured before GH withdrawal. Conclusions: In patients with AGHD under GH treatment, GH withdrawal decreases thymic T cell output, as well as intrathymic T cell proliferation. These parameters of thymus function are completely or partially restored one month after GH resumption. These data indicate that the functional integrity of the somatotrope GH/IGF-1 axis is important for the maintenance of a normal thymus function in human adults. Trial Registration: ClinicalTrials.gov NTC00601419			Morrhaye, G (corresponding author), Univ Liege, Ctr Immunol, Lab Immunoendocrinol, Inst Pathol, CHU-B23, Liege, Belgium.	hmartens@ulg.ac.be	Cheynier, Remi/E-9921-2010	Cheynier, Remi/0000-0003-1146-660X; Geenen, Vincent/0000-0002-8733-7284; Moutschen, Michel/0000-0002-6405-1785; Martens, Henri/0000-0003-4713-8982				ARKINS S, 1993, ENDOCRINOLOGY, V133, P2334, DOI 10.1210/en.133.5.2334; BINZ K, 1990, P NATL ACAD SCI USA, V87, P3690, DOI 10.1073/pnas.87.10.3690; Castermans E, 2008, HAEMATOLOGICA, V93, P240, DOI 10.3324/haematol.11708; Chu YW, 2008, BLOOD, V112, P2836, DOI 10.1182/blood-2008-04-149435; Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157; Coelho VDM, 2002, NEUROENDOCRINOLOGY, V75, P139, DOI 10.1159/000048230; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Dixit VD, 2007, J CLIN INVEST, V117, P2778, DOI 10.1172/JCI30248; Dorshkind K, 2001, BIOESSAYS, V23, P288, DOI 10.1002/1521-1878(200103)23:3<288::AID-BIES1039>3.0.CO;2-P; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Dulude G, 2008, J IMMUNOL, V181, P7818, DOI 10.4049/jimmunol.181.11.7818; Foster MP, 2000, CLIN IMMUNOL, V96, P140, DOI 10.1006/clim.2000.4889; Geenen V, 2003, J ENDOCRINOL, V176, P305, DOI 10.1677/joe.0.1760305; GEENEN V, 1993, THYMUS, V21, P115; Geenen V, 2004, IMMUNOENDOCRINOLOGY, P337; Herrington J, 2000, ONCOGENE, V19, P2585, DOI 10.1038/sj.onc.1203526; Hinton PS, 1998, AM J PHYSIOL-REG I, V274, pR912, DOI 10.1152/ajpregu.1998.274.4.R912; Kecha O, 2000, ENDOCRINOLOGY, V141, P1209, DOI 10.1210/en.141.3.1209; Kecha O, 1999, J NEUROENDOCRINOL, V11, P435; KELLEY KW, 1986, P NATL ACAD SCI USA, V83, P5663, DOI 10.1073/pnas.83.15.5663; Kong FK, 2002, J IMMUNOL, V168, P6500, DOI 10.4049/jimmunol.168.12.6500; Kong FK, 1998, IMMUNITY, V8, P97, DOI 10.1016/S1074-7613(00)80462-8; KOOIJMAN R, 1995, J ENDOCRINOL, V147, P203, DOI 10.1677/joe.0.1470203; LEONARD WJ, 2003, FUNDAMENTAL IMMUNOLO, P701; Molitch ME, 2006, J CLIN ENDOCR METAB, V91, P1621, DOI 10.1210/jc.2005-2227; Montecino-Rodriguez E, 1998, ENDOCRINOLOGY, V139, P4120, DOI 10.1210/en.139.10.4120; MURPHY WJ, 1993, J EXP MED, V178, P231, DOI 10.1084/jem.178.1.231; Napolitano LA, 2002, AIDS, V16, P1103, DOI 10.1097/00002030-200205240-00003; Napolitano LA, 2008, J CLIN INVEST, V118, P1085, DOI 10.1172/JCI32830; PIERPAOLI W, 1968, J IMMUNOL, V101, P1036; Poulin JF, 1999, J EXP MED, V190, P479, DOI 10.1084/jem.190.4.479; Redelman D, 2008, CELL IMMUNOL, V252, P111, DOI 10.1016/j.cellimm.2007.12.003; Savino W, 2002, SCAND J IMMUNOL, V55, P442, DOI 10.1046/j.1365-3083.2002.01077.x; Savino W, 2000, ENDOCR REV, V21, P412, DOI 10.1210/er.21.4.412; Smith PE, 1930, ANAT REC, V47, P119, DOI 10.1002/ar.1090470110; Sneppen SB, 2002, CLIN ENDOCRINOL, V57, P787, DOI 10.1046/j.1365-2265.2002.01670.x; Sportes C, 2008, J EXP MED, V205, P1701, DOI 10.1084/jem.20071681; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; TAUB DD, 1994, J CLIN INVEST, V94, P293, DOI 10.1172/JCI117320; van den Dool C, 2006, J IMMUNOL, V177, P4391, DOI 10.4049/jimmunol.177.7.4391	41	39	41	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 22	2009	4	5							e5668	10.1371/journal.pone.0005668	http://dx.doi.org/10.1371/journal.pone.0005668			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	449LD	19479077	Green Published, gold			2023-01-03	WOS:000266331200006
J	Sokol, DK				Sokol, Daniel K.			Observations Ethics Man Rethinking ward rounds	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London, London WC1E 7HU, England	University of London	Sokol, DK (corresponding author), Univ London, London WC1E 7HU, England.	daniel.sokol@talk21.com						GODLEE F, 2009, BRIT MED J, V338, pB913; Soar J, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b220	2	7	7	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 4	2009	338								b879	10.1136/bmj.b879	http://dx.doi.org/10.1136/bmj.b879			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	417EC	19261674				2023-01-03	WOS:000264058300005
J	Pham, HH; O'Malley, AS; Bach, PB; Saiontz-Martinez, C; Schrag, D				Pham, Hoangmai H.; O'Malley, Ann S.; Bach, Peter B.; Saiontz-Martinez, Cynthia; Schrag, Deborah			Primary Care Physicians' Links to Other Physicians Through Medicare Patients: The Scope of Care Coordination	ANNALS OF INTERNAL MEDICINE			English	Article							PERFORMANCE	Background: Primary care physicians are expected to coordinate care for their patients. Objective: To assess the number of physician peers providing care to the Medicare patients of a primary care physician. Design: Cross-sectional analysis of claims data. Setting: Fee-for-service Medicare in 2005. Participants: 2284 primary care physicians who responded to the 2004 to 2005 Community Tracking Study Physician Survey. Measurements: Primary patients for each physician were defined as beneficiaries for whom the physician billed for more evaluation and management visits than any other physician in 2005. The number of physician peers for each physician was the sum of other unique physicians that the index physician's primary patients visited plus other unique physicians who served as the primary physician for each of the index physician's nonprimary patients during 2005. Results: The typical primary care physician has 229 (interquartile range, 125 to 340) other physicians working in 117 ( interquartile range, 66 to 175) practices with which care must be coordinated, equivalent to an additional 99 physicians and 53 practices for every 100 Medicare beneficiaries managed by the primary care physician. When only the 31% of a primary care physician's primary patients who had 4 or more chronic conditions was considered, the median number of peers involved was still substantial ( 86 physicians in 36 practices). The number of peers varied with geographic region, practice type, and reliance on Medicaid revenues. Limitations: Estimates are based only on fee-for-service Medicare patients and physician peers, and the number of peers is therefore probably an underestimate. The modest response rate of the Community Tracking Study Physician Survey may bias results in unpredictable directions. Conclusion: In caring for his or her own primary and nonprimary patients during a single year, each primary care physician potentially must coordinate with a large number of individual physician colleagues who also provide care to these patients.	[Pham, Hoangmai H.] Ctr Studying Hlth Syst Change, Washington, DC 20024 USA; Mem Sloan Kettering Canc Ctr, Hlth Outcomes Res Grp, New York, NY 10021 USA; Social & Sci Syst, Silver Spring, MD USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Memorial Sloan Kettering Cancer Center; Social & Scientific Systems; Harvard University; Dana-Farber Cancer Institute	Pham, HH (corresponding author), Ctr Studying Hlth Syst Change, 600 Maryland Ave SW,Suite 550, Washington, DC 20024 USA.	mpham@hschange.org			National Institute on Aging; American Medical Group Association; Robert Wood Johnson Foundation; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025687] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Medical Group Association; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institute on Aging, American Medical Group Association, and the Robert Wood Johnson Foundation.	*AG HEALTHC RES QU, PUBL AG HEALTHC RES; Agency for Healthcare Research and Quality, CAHPS CLIN GROUP SUR; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Barr M, 2008, ADV MED HOME PATIENT; Bartschat Wanda, 2006, J AHIMA, V77, p64A; BERENSON RA, 2003, HLTH AFF MILLWOOD S; Bynum JPW, 2007, HEALTH SERV RES, V42, P45, DOI 10.1111/j.1475-6773.2006.00633.x; *CTR STUD HLTH SYS, TECHN PUBL CTR STUD, V38; Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Hwang W, 2001, HEALTH AFFAIR, V20, P267, DOI 10.1377/hlthaff.20.6.267; Institute of Medicine, 1996, PRIM CAR AM HLTH NEW; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Kwait J, 2001, J URBAN HEALTH, V78, P468, DOI 10.1093/jurban/78.3.468; Pham HH, 2007, NEW ENGL J MED, V356, P1130, DOI 10.1056/NEJMsa063979; Schrag D, 2006, MED CARE, V44, P560, DOI 10.1097/01.mlr.0000215811.68308.ae; Starfield B, 1998, PRIMARY CARE BALANCI; US Census Bureau, CENS REG DIV US; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503	20	162	162	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 17	2009	150	4					236	U23		10.7326/0003-4819-150-4-200902170-00004	http://dx.doi.org/10.7326/0003-4819-150-4-200902170-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410FI	19221375	Green Accepted			2023-01-03	WOS:000263562500002
J	Lawton, BA; Rose, SB; Elley, CR; Dowell, AC; Fenton, A; Moyes, SA				Lawton, Beverley A.; Rose, Sally B.; Elley, C. Raina; Dowell, Anthony C.; Fenton, Anna; Moyes, Simon A.			Exercise on prescription for women aged 40-74 recruited through primary care: two year randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-HEALTH-CARE; PHYSICAL-ACTIVITY; LIFE-STYLE; GENERAL-PRACTICE; BLOOD-PRESSURE; INTERVENTION; PREVENTION; RISK	Objective To assess the effectiveness of a primary care based programme of exercise on prescription among relatively inactive women over a two year period. Design Randomised controlled trial. Setting 17 primary care practices in Wellington, New Zealand. Participants 1089 women aged 40- 74 not undertaking 30 minutes of moderate intensity physical activity on at least five days of the week. Intervention Brief physical activity intervention led by nurse with six month follow- up visit and monthly telephone support over nine months. Main outcome measure Physical activity assessed at baseline and 12 and 24 months. Secondary outcomes were quality of life ( SF- 36), weight, waist circumference, blood pressure, concentrations of fasting serum lipids, glycated haemoglobin ( HbA(1c)), glucose, insulin, and physical fitness. Results Mean age was 58.9 ( SD 7) years. Trial retention rates were 93% and 89% at 12 and 24 months, respectively. At baseline, 10% of intervention participants and 11% of control participants were achieving 150 minutes of at least moderate intensity physical activity a week. At 12 months rates increased to 43% and 30% and at 24 months to 39.3% and 32.8% ( P< 0.001), respectively. SF- 36 physical functioning ( P= 0.03) and mental health ( P< 0.05) scores improved more in intervention compared with control participants, but role physical scores were significantly lower ( P< 0.01). There were no significant differences in clinical outcomes. More falls ( P< 0.001) and injuries ( P= 0.03) were recorded in the intervention group. Conclusions This programme of exercise on prescription increased physical activity and quality of life over two years, although falls and injuries also increased. This finding supports the use of exercise on prescription programmes as part of population strategies to reduce physical inactivity. Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR) ANZCTRN012605000490673.	[Lawton, Beverley A.; Rose, Sally B.; Dowell, Anthony C.] Univ Otago, Womens Hlth Res Ctr, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand; [Elley, C. Raina; Moyes, Simon A.] Univ Auckland, Dept Gen Practice & Primary Hlth Care, Sch Populat Hlth, Auckland 1, New Zealand; [Fenton, Anna] Christchurch Womens Hosp, Christchurch, New Zealand	University of Otago; University of Auckland	Lawton, BA (corresponding author), Univ Otago, Womens Hlth Res Ctr, Dept Primary Hlth Care & Gen Practice, POB 7343, Wellington, New Zealand.	Bev.Lawton@otago.ac.nz	Moyes, Simon A/D-2574-2017	Moyes, Simon A/0000-0001-9580-1545	National Heart Foundation of New Zealand [1091, 1222]; Lottery Health Research Grants Board; Hutt Valley District Health Board; Sport and Recreation New Zealand; Maori Health Directorate (Ministry of Health)	National Heart Foundation of New Zealand; Lottery Health Research Grants Board; Hutt Valley District Health Board; Sport and Recreation New Zealand; Maori Health Directorate (Ministry of Health)	This work was supported by the National Heart Foundation of New Zealand (grant number 1091 and grant-in-aid numbers 1091 and 1222), the Lottery Health Research Grants Board, the Hutt Valley District Health Board, Sport and Recreation New Zealand, and the Maori Health Directorate ( Ministry of Health).	Canadian Society for Exercise Physiology, 2002, PHYS ACT READ QUEST; CHAUDHURY M, 2006, CARDIOVASCULAR DIS R, V1, P111; Chief Medical Officer, 2004, LEAST 5 WEEK EV IMP; Colditz GA, 2002, CANCER CAUSE CONTROL, V13, P199, DOI 10.1023/A:1015040702565; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Dalziel K, 2006, AUST NZ J PUBL HEAL, V30, P57, DOI 10.1111/j.1467-842X.2006.tb00087.x; Elley CR, 2003, BRIT MED J, V326, P793, DOI 10.1136/bmj.326.7393.793; Elley CR, 2003, PREV MED, V37, P342, DOI 10.1016/S0091-7435(03)00142-7; Elley Raina, 2004, N Z Med J, V117, pU1216; Fox KR, 1999, PUBLIC HEALTH NUTR, V2, P411, DOI 10.1017/S1368980099000567; Hillsdon M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003180.pub.2; Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961; Kinmonth AL, 2008, LANCET, V371, P41, DOI 10.1016/S0140-6736(08)60070-7; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Lee IM, 2001, MED SCI SPORT EXER, V33, pS459, DOI 10.1097/00005768-200106001-00016; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; McLean G, 2004, NZ PHYS ACTIVITY QUE; MOY K, 2003, VALIDATION MOH SHORT; NICE, 2006, RAP REV EFF EX REF S; *NZ SPORT RECR NZ, 2008, WHAT AR GREEN PRESCR; Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537; Rose Sally, 2004, N Z Med J, V117, pU1206; Rose SB, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-166; Rose Sally B, 2008, N Z Med J, V121, pU2897; Salmond C, 1998, AUST NZ J PUBL HEAL, V22, P835, DOI 10.1111/j.1467-842X.1998.tb01505.x; Schulze MB, 2005, ANNU REV PUBL HEALTH, V26, P445, DOI 10.1146/annurev.publhealth.26.021304.144532; Simons-Morton DG, 2001, JAMA-J AM MED ASSOC, V286, P677; Sorensen JB, 2006, SCAND J PRIM HEALTH, V24, P69, DOI 10.1080/02813430600700027; *SPORT RECR NZ, GREEN PRESCR; Stevens W, 1998, BRIT J SPORT MED, V32, P236, DOI 10.1136/bjsm.32.3.236; Tsai JC, 2004, CLIN EXP HYPERTENS, V26, P255, DOI 10.1081/CEH-120030234; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; VANAALST I, 2003, SPARC FACTS RESULTS; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351	36	126	126	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 11	2008	337								a2509	10.1136/bmj.a2509	http://dx.doi.org/10.1136/bmj.a2509			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399CB	19074218	hybrid, Green Published			2023-01-03	WOS:000262776900002
J	Sokol, DK				Sokol, Daniel K.			Paving the way for assisted suicide	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Sokol, Daniel K.] Univ London, Univ London St Georges Hosp, London WC1E 7HU, England	St Georges University London; University of London	Sokol, DK (corresponding author), Univ London, Univ London St Georges Hosp, London WC1E 7HU, England.	daniel.sokol@talk21.com							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 11	2008	337								a3010	10.1136/bmj.a3010	http://dx.doi.org/10.1136/bmj.a3010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	399CB	19074231				2023-01-03	WOS:000262776900018
J	Boukovinas, I; Papadaki, C; Mendez, P; Taron, M; Mavroudis, D; Koutsopoulos, A; Sanchez-Ronco, M; Sanchez, JJ; Trypaki, M; Staphopoulos, E; Georgoulias, V; Rosell, R; Souglakos, J				Boukovinas, Ioannis; Papadaki, Chara; Mendez, Pedro; Taron, Miquel; Mavroudis, Dimitris; Koutsopoulos, Anastasios; Sanchez-Ronco, Maria; Javier Sanchez, Jose; Trypaki, Maria; Staphopoulos, Eustathios; Georgoulias, Vassilis; Rosell, Rafael; Souglakos, John			Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients	PLOS ONE			English	Article							PLATINUM-BASED CHEMOTHERAPY; RIBONUCLEOTIDE REDUCTASE; PHASE-III; HUMAN BREAST; CISPLATIN; SURVIVAL; RESISTANCE; CHEMORESISTANCE; OVEREXPRESSION; REGIMENS	Background: Overexpression of RRM1 and RRM2 has been associated with gemcitabine resistance. BRCA1 overexpression increases sensitivity to paclitaxel and docetaxel. We have retrospectively examined the effect of RRM1, RRM2 and BRCA1 expression on outcome to gemcitabine plus docetaxel in advanced non-small-cell lung cancer (NSCLC) patients. Methodology and Principal Findings: Tumor samples were collected from 102 chemotherapy-naive advanced NSCLC patients treated with gemcitabine plus docetaxel as part of a randomized trial. RRM1, RRM2 and BRCA1 mRNA levels were assessed by quantitative PCR and correlated with response, time to progression and survival. As BRCA1 levels increased, the probability of response increased (Odds Ratio [OR], 1.09: p = 0.01) and the risk of progression decreased (hazard ratio [HR], 0.99; p = 0.36). As RRM1 and RRM2 levels increased, the probability of response decreased (RRM1: OR, 0.97; p = 0.82; RRM2: OR, 0.94; p<0.0001) and the risk of progression increased (RRM1: HR, 1.02; p = 0.001; RRM2: HR, 1.005; p = 0.01). An interaction observed between BRCA1 and RRM1 allowed patients to be classified in three risk groups according to combinations of gene expression levels, with times to progression of 10.13, 4.17 and 2.30 months (p = 0.001). Low BRCA1 expression was the only factor significantly associated with longer time to progression in 31 patients receiving cisplatin-based second-line therapy. Conclusions: The mRNA expression of BRCA1, RRM1 and RRM2 is potentially a useful tool for selecting NSCLC patients for individualized chemotherapy and warrants further investigation in prospective studies.	[Boukovinas, Ioannis] Theagenion Krankenhauses, Thessaloniki, Greece; [Papadaki, Chara; Mavroudis, Dimitris; Trypaki, Maria; Georgoulias, Vassilis; Souglakos, John] Univ Crete, Sch Med, Lab Tumor Cell Biol, Iraklion, Greece; [Mendez, Pedro; Taron, Miquel; Rosell, Rafael] Hosp Germans Trias Pujol, Catalan Inst Oncol, Barcelona, Spain; [Taron, Miquel; Rosell, Rafael] USP Dexeus Univ, C Sabino Arana 5, Barcelona, Spain; [Mavroudis, Dimitris; Georgoulias, Vassilis; Souglakos, John] Univ Gen Hosp Heraklion, Dept Med Oncol, Iraklion, Greece; [Koutsopoulos, Anastasios; Staphopoulos, Eustathios] Univ Gen Hosp Heraklion, Dept Pathol, Iraklion, Greece; [Sanchez-Ronco, Maria] Univ Alcala Henares, Alcala De Henares, Spain; [Javier Sanchez, Jose] Univ Autonoma Madrid, E-28049 Madrid, Spain	University of Crete; Catalan Institute of Oncology; Hospital Germans Trias i Pujol; University Hospital of Heraklion; University Hospital of Heraklion; Universidad de Alcala; Autonomous University of Madrid	Boukovinas, I (corresponding author), Theagenion Krankenhauses, Thessaloniki, Greece.	rrosell@ico.scs.es; georgsec@med.uoc.gr	Koutsopoulos, Anastasios/AAO-9498-2020	Koutsopoulos, Anastasios/0000-0002-8430-7565; PAPADAKI, CHARA/0000-0002-4591-3757	Cretan Association for Biomedical Research (CABR) [fellowship]	Cretan Association for Biomedical Research (CABR)	This work was partly supported by the Cretan Association for Biomedical Research (CABR). Dr. John Souglakos is the recipient of a CABR research fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bae I, 2005, CELL CYCLE, V4, P1641, DOI 10.4161/cc.4.11.2152; Booton R, 2007, J THORAC ONCOL, V2, P902, DOI 10.1097/JTO.0b013e318155a637; Burdett S, 2007, J THORAC ONCOL, V2, pS337, DOI 10.1097/01.JTO.0000283148.83670.80; Ceppi P, 2006, ANN ONCOL, V17, P1818, DOI 10.1093/annonc/mdl300; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chen XW, 2006, CANCER RES, V66, P5039, DOI 10.1158/0008-5472.CAN-05-4194; Cobo M, 2007, J CLIN ONCOL, V25, P2747, DOI 10.1200/JCO.2006.09.7915; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Deeb KK, 2007, CANCER RES, V67, P8065, DOI 10.1158/0008-5472.CAN-07-1515; Duxbury MS, 2004, SURGERY, V136, P261, DOI 10.1016/j.surg.2004.04.029; Eelen G, 2008, ONCOGENE, V27, P4233, DOI 10.1038/onc.2008.51; Fossella F, 2003, J CLIN ONCOL, V21, P3016, DOI 10.1200/JCO.2003.12.046; Georgoulias V, 2005, J CLIN ONCOL, V23, P2937, DOI 10.1200/JCO.2005.04.016; Georgoulias V, 2001, LANCET, V357, P1478, DOI 10.1016/S0140-6736(00)04644-4; Goan YG, 1999, CANCER RES, V59, P4204; Husain A, 1998, CANCER RES, V58, P1120; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Quinn JE, 2003, CANCER RES, V63, P6221; Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083; Rosell R, 2004, CLIN CANCER RES, V10, p4215S, DOI 10.1158/1078-0432.CCR-040006; Rosell R, 2004, CLIN CANCER RES, V10, P1318, DOI 10.1158/1078-0432.CCR-03-0156; Rosell R, 2003, ONCOGENE, V22, P3548, DOI 10.1038/sj.onc.1206419; Rosell R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001129; Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Simon G, 2007, J CLIN ONCOL, V25, P2741, DOI 10.1200/JCO.2006.08.2099; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Souglakos J, 2008, BRIT J CANCER, V98, P1710, DOI 10.1038/sj.bjc.6604344; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Xu X, 2008, CANCER RES, V68, P2652, DOI 10.1158/0008-5472.CAN-07-5873	37	106	115	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2008	3	11							e3695	10.1371/journal.pone.0003695	http://dx.doi.org/10.1371/journal.pone.0003695			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	432WS	19002265	Green Published, gold, Green Submitted			2023-01-03	WOS:000265165600002
J	Shipman, C; Gysels, M; White, P; Worth, A; Murray, SA; Barclay, S; Forrest, S; Shepherd, J; Dale, J; Dewar, S; Peters, M; White, S; Richardson, A; Lorenz, K; Koffman, J; Higginson, IJ				Shipman, Cathy; Gysels, Marjolein; White, Patrick; Worth, Allison; Murray, Scott A.; Barclay, Stephen; Forrest, Sarah; Shepherd, Jonathan; Dale, Jeremy; Dewar, Steve; Peters, Marilyn; White, Suzanne; Richardson, Alison; Lorenz, Karl; Koffman, Jonathan; Higginson, Irene J.			Improving generalist end of life care: national consultation with practitioners, commissioners, academics, and service user groups	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY PALLIATIVE CARE; GOLD-STANDARDS-FRAMEWORK; CANCER; DEATH; COMMUNICATION; COUNTRIES; TRENDS; FAMILY; PLACE; DIE	Objective To identify major concerns of national and local importance in the provision, commissioning, research, and use of generalist end of life care. Design A national consultation and prioritising exercise using a modified form of the nominal group technique. Participants Healthcare practitioners, commissioners, academics, and representatives of user and voluntary groups. Setting Primary and secondary care, specialist palliative care, and academic and voluntary sectors in England and Scotland. Results 74% of those invited ( 210/ 285) participated. The stage of life to which "end of life care" referred was not understood in a uniform way. Perceptions ranged from a period of more than a year to the last few days of life. Prominent concerns included difficulties in prognosis and the availability of adequate support for patients with advanced non- malignant disease. Generalists in both primary and secondary care were usually caring for only a few patients approaching the end of life at any one time at a point in time. It was therefore challenging to maintain skills and expertise particularly as educational opportunities were often limited. End of life care took place among many other competing and incentivised activities for general practitioners in the community. More needs to be known about models of end of life care and how these can be integrated in a generalist's workload. A greater evidence base is needed about the effectiveness and application of current tools such as the gold standards framework and Liverpool care pathway and about models of palliation in patients with diseases other than cancer. Conclusions Definitions of end of life care need clarification and standardisation. A greater evidence base is needed to define models of good practice together with a commitment to provide education and training and adequate resources for service provision. More needs to be known about the context of provision and the influence of competing priorities and incentives.	[Shipman, Cathy; Gysels, Marjolein; Koffman, Jonathan; Higginson, Irene J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Weston Educ Ctr, London SE5 9RJ, England; [Shipman, Cathy; White, Patrick; Peters, Marilyn; White, Suzanne] Kings Coll London, Dept Gen Practice & Primary Care, London SE11 6SP, England; [Worth, Allison; Murray, Scott A.] Univ Edinburgh, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland; [Barclay, Stephen; Forrest, Sarah] Univ Cambridge, Gen Practice & Primary Care Res Unit, Dept Publ Hlth & Primary Care, Cambridge CB2 2SR, England; [Shepherd, Jonathan; Dale, Jeremy] Univ Warwick, Ctr Primary Hlth Care Studies, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England; [Dewar, Steve] Kings Fund, London W1G 0AN, England; [Richardson, Alison] Kings Coll London, Florence Nightingale Sch Nursing & Midwifery, London SE1 8WA, England; [Lorenz, Karl] Univ Calif Los Angeles, Sch Med, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of London; King's College London; University of London; King's College London; University of Edinburgh; University of Cambridge; University of Warwick; University of London; King's College London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Shipman, C (corresponding author), Kings Coll London, Dept Palliat Care Policy & Rehabil, Weston Educ Ctr, London SE5 9RJ, England.	Catherine.shipman@kcl.ac.uk	green, sam/C-2608-2008; Higginson, Irene J/C-7309-2012; White, Patrick/AAN-7799-2020	Higginson, Irene J/0000-0002-3687-1313; Koffman, Jonathan/0000-0001-8513-5681; Barclay, Stephen/0000-0002-4505-7743; Gysels, Marjolein/0000-0002-2355-1732; White, Patrick/0000-0002-2047-8787; Dale, Jeremy/0000-0001-9256-3553	National Institute of Health Research Service Development and Organisation research and development programme	National Institute of Health Research Service Development and Organisation research and development programme(National Institute for Health Research (NIHR))	National Institute of Health Research Service Development and Organisation research and development programme.	ADDINGTONHALL J, 1995, PALLIATIVE MED, V9, P295, DOI 10.1177/026921639500900404; ADDINGTONHALL J, 1995, STROKE, V26, P2242, DOI 10.1161/01.STR.26.12.2242; Armitage M, 2007, CLIN MED, V7, P436, DOI 10.7861/clinmedicine.7-5-436; BARCLAY S, 2001, PALLIATIVE CARE NONC; Brazil K, 2007, J PALLIAT CARE, V23, P113, DOI 10.1177/082585970702300206; CARTWRIGHT A, 1991, J PUBLIC HEALTH MED, V13, P81; Clark D, 2000, PALLIATIVE MED, V14, P479, DOI 10.1191/026921600701536408; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; DAVIES E, 2004, PALLIATIVE CARE SOLI; *DEP HLTH, 2006, BETT END LIF CAR PAT; *DEP HLTH, 2007, CHOIC MATT 2007 8 PU; Department of Health, 2007, OP FRAM 2007 08 PCT; Department of Health, 2008, END LIF CAR STRAT PR; Espinosa-Roca AA, 2006, BRIT MED J, V332, P668, DOI 10.1136/bmj.332.7542.668; Flory J, 2004, HEALTH AFFAIR, V23, P194, DOI 10.1377/hlthaff.23.3.194; Forrest S, 2007, BRIT J GEN PRACT, V57, P503; Gomes B, 2006, BMJ-BRIT MED J, V332, P515, DOI 10.1136/bmj.38740.614954.55; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Hansford P, 2007, END LIFE CARE, V1, P1; HEAM J, 1998, PALLIATIVE MED, V12, P317; Higginson I J, 2000, J Palliat Med, V3, P287, DOI 10.1089/jpm.2000.3.287; HIGGINSON IJ, 2007, 1 NIHR SERV DEL ORG; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; Lorenz Karl A, 2005, J Palliat Med, V8 Suppl 1, pS4; Mahmood-Yousuf K, 2008, BRIT J GEN PRACT, V58, P256, DOI 10.3399/bjgp08X279760; Munday D, 2007, FAM PRACT, V24, P486, DOI 10.1093/fampra/cmm045; Murray SA, 2004, BMJ-BRIT MED J, V329, P1056, DOI 10.1136/bmj.329.7474.1056; Murray SA, 2003, BRIT MED J, V326, P368, DOI 10.1136/bmj.326.7385.368; *NHS CONF, 2005, LEAD EDG, P12; *OFF NAT STAT, 2007, MORT STAT REV REG GE; RICHARDS M, 2007, END LIFE CARE STRATE; *ROYAL COLL PHYS W, 2007, PALL CAR SERV M NEED; *SCOTT PARTN PALL, 2006, MAK GOOD CAR BETT NA; Scottish Government, 2007, BETT HLTH BETT CAR; Scottish Partnership for Palliative Care, 2006, JOIN THINK JOIN CAR; *SDO RES SUMM, 2007, CAR PROV GEN END LIF; SHIPMAN C, 2007, 3 NIHR SERV DEL ORG; Shugarman LR, 2005, CLIN GERIATR MED, V21, P255, DOI 10.1016/j.cger.2004.08.008; St John of God Health Care, 2019, OUR VIS; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Wang XS, 2004, J PAIN SYMPTOM MANAG, V27, P125, DOI 10.1016/j.jpainsymman.2003.06.002; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607	42	111	111	0	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 11	2008	337	7674							a1720	10.1136/bmj.a1720	http://dx.doi.org/10.1136/bmj.a1720			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	358FU	18829640	Green Submitted, hybrid, Green Published			2023-01-03	WOS:000259903300032
J	Watts, G				Watts, Geoff			What happened to the polypill?	BRITISH MEDICAL JOURNAL			English	Editorial Material							CARDIOVASCULAR-DISEASE					geoff@scileg.freeserve.co.uk						Rodgers A, 2003, BMJ-BRIT MED J, V326, P1407, DOI 10.1136/bmj.326.7404.1407; *U AUCKL CLIN TRIA, 2008, PILL PIL PROGR IMPR; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419	3	7	8	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 4	2008	337	7673							a1822	10.1136/bmj.a1822	http://dx.doi.org/10.1136/bmj.a1822			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	356SN	18819953				2023-01-03	WOS:000259798000030
J	Carbajal, R; Rousset, A; Danan, C; Coquery, S; Nolent, P; Ducrocq, S; Saizou, C; Lapillonne, A; Granier, M; Durand, P; Lenclen, R; Coursol, A; Hubert, P; de Saint Blanquat, L; Boelle, PY; Annequin, D; Cimerman, P; Anand, KJS; Breart, G				Carbajal, Ricardo; Rousset, Andre; Danan, Claude; Coquery, Sarah; Nolent, Paul; Ducrocq, Sarah; Saizou, Carole; Lapillonne, Alexandre; Granier, Michele; Durand, Philippe; Lenclen, Richard; Coursol, Anne; Hubert, Philippe; de Saint Blanquat, Laure; Boelle, Pierre-Yves; Annequin, Daniel; Cimerman, Patricia; Anand, K. J. S.; Breart, Gerard			Epidemiology and treatment of painful procedures in neonates in intensive care units	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRETERM INFANTS; NEWBORN-INFANTS; ANALGESIA; RESPONSES; MORPHINE; REACTIVITY; EXPOSURE; STRESS; BABIES	Context Effective strategies to improve pain management in neonates require a clear understanding of the epidemiology and management of procedural pain. Objective To report epidemiological data on neonatal pain collected from a geographically defined region, based on direct bedside observation of neonates. Design, Setting, and Patients Between September 2005 and January 2006, data on all painful and stressful procedures and corresponding analgesic therapy from the first 14 days of admission were prospectively collected within a 6- week period from 430 neonates admitted to tertiary care centers in the Paris region of France ( 11.3 millions inhabitants) for the Epidemiology of Procedural Pain in Neonates ( EPIPPAIN) study. Main Outcome Measure Number of procedures considered painful or stressful by health personnel and corresponding analgesic therapy. Results The mean ( SD) gestational age and intensive care unit stay were 33.0 ( 4.6) weeks and 8.4 ( 4.6) calendar days, respectively. Neonates experienced 60 969 first- attempt procedures, with 42 413 ( 69.6%) painful and 18 556 ( 30.4%) stressful procedures; 11 546 supplemental attempts were performed during procedures including 10 366 ( 89.8%) for painful and 1180 ( 10.2%) for stressful procedures. Each neonate experienced a median of 115 ( range, 4- 613) procedures during the study period and 16 ( range, 0- 62) procedures per day of hospitalization. Of these, each neonate experienced a median of 75( range, 3- 364) painful procedures during the study period and 10 ( range, 0- 51) painful procedures per day of hospitalization. Of the 42 413 painful procedures, 2.1% were performed with pharmacological- only therapy; 18.2% with nonpharmacological- only interventions, 20.8% with pharmacological, nonpharmacological, or both types of therapy; and 79.2% without specific analgesia, and 34.2% were performed while the neonate was receiving concurrent analgesic or anesthetic infusions for other reasons. Prematurity, category of procedure, parental presence, surgery, daytime, and day of procedure after the first day of admission were associated with greater use of specific preprocedural analgesia, whereas mechanical ventilation, noninvasive ventilation and administration of nonspecific concurrent analgesia were associated with lower use of specific preprocedural analgesia. Conclusion During neonatal intensive care in the Paris region, large numbers of painful and stressful procedures were performed, the majority of which were not accompanied by analgesia.	[Carbajal, Ricardo; Cimerman, Patricia] Hop Enfants Armand Trousseau, Assistance Publ Hop Paris, Ctr Natl Ressources Lutte Douleur, F-75012 Paris, France; [Nolent, Paul] Hop Enfants Armand Trousseau, Assistance Publ Hop Paris, Unite Reanimat Neonatale & Pediat, F-75012 Paris, France; [Annequin, Daniel] Hop Enfants Armand Trousseau, Assistance Publ Hop Paris, Unite Fonct Analgesie Pediat, F-75012 Paris, France; [Carbajal, Ricardo; Breart, Gerard] Hop Tenon, Assistance Publ Hop Paris, INSERM, UMR S149,Epidemiol Res Unit Perinatal & Womens Hl, F-75970 Paris, France; [Rousset, Andre] CHI Andre Gregoire, Unite Reanimat Neonatale, Montreuil, France; [Danan, Claude] Ctr Hosp Gen Intercommunal Creteil, Unite Reanimat Neonatale, Creteil, France; [Coquery, Sarah] Hop Antoine Beclere, Assistance Publ Hop Paris, Unite Reanimat Neonatale, Clamart, France; [Ducrocq, Sarah] Hop Cochin Port Royal, Assistance Publ Hop Paris, Unite Reanimat Neonatale, Paris, France; [Saizou, Carole] Hop Robert Debre, Assistance Publ Hop Paris, Unite Reanimat Neonatale & Pediat, F-75019 Paris, France; [Lapillonne, Alexandre] Hop St Vincent de Paul, Assistance Publ Hop Paris, Unite Reanimat Neonatale & Pediat, F-75674 Paris, France; [de Saint Blanquat, Laure] Hop St Vincent de Paul, Assistance Publ Hop Paris, Unite Reanimat Chirurg, F-75674 Paris, France; [Granier, Michele] Hop Louise Michel, Unite Reanimat Neonatale, Evry, France; [Durand, Philippe] Hop Bicetre, Assistance Publ Hop Paris, Unite Reanimat Neonatale & Pediat, Le Kremlin Bicetre, France; [Lenclen, Richard] CHI Poissy St Germain en Laye, Unite Reanimat Neonatale, St Germain En Laye, France; [Coursol, Anne] Ctr Hosp Rene Dubos, Unite Reanimat Neonatale, Pontoise, France; [Hubert, Philippe] Hop Necker Enfants Malad, Assistance Publ Hop Paris, Unite Reanimat Neonatale & Pediat, Paris, France; [Boelle, Pierre-Yves] Hop St Antoine, Assistance Publ Hop Paris, Dept Sante Publ, INSERM UMR S707, F-75571 Paris, France; [Boelle, Pierre-Yves] Hop St Antoine, Assistance Publ Hop Paris, Dept Sante Publ, UPMC,UMR S 707, F-75571 Paris, France; [Anand, K. J. S.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Saclay; Hospital Chi of Poissy Saint Germain; Centre Hospitalier Rene Dubos, Pontoise; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sorbonne Universite; University of Arkansas System; University of Arkansas Medical Sciences	Carbajal, R (corresponding author), Hop Enfants Armand Trousseau, Assistance Publ Hop Paris, Ctr Natl Ressources Lutte Douleur, 26 Av Dr Netter, F-75012 Paris, France.	ricardo.carbajal@trs.aphp.fr	Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483; Annequin, Daniel/0000-0001-6425-4016; breart, gerard/0000-0003-3142-9128; Boelle, Pierre-Yves/0000-0002-5367-8232				Allegaert K, 2007, EUR J PAIN, V11, P910, DOI 10.1016/j.ejpain.2007.01.007; Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; Anand KJS, 1998, BIOL NEONATE, V73, P1, DOI 10.1159/000013953; Anand KJS, 2004, ANESTHESIOLOGY, V101, P527, DOI 10.1097/00000542-200408000-00033; Anand KJS, 1996, PAIN, V67, P3, DOI 10.1016/0304-3959(96)03135-1; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; [Anonymous], 1979, Pain, V6, P249; Aranda JV, 2005, CLIN THER, V27, P877, DOI 10.1016/j.clinthera.2005.06.019; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; Bartocci M, 2006, PAIN, V122, P109, DOI 10.1016/j.pain.2006.01.015; Benis Marilyn M., 2001, Pediatric Research, V49, p392A; Carbajal R, 2005, PEDIATRICS, V115, P1494, DOI 10.1542/peds.2004-1425; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; De Lima J, 1999, BRIT J ANAESTH, V83, P662, DOI 10.1093/bja/83.4.662; FITZGERALD M, 1988, LANCET, V1, P292; FITZGERALD M, 1989, PAIN, V39, P31, DOI 10.1016/0304-3959(89)90172-3; Grunau R, 2002, CLIN PERINATOL, V29, P373; Grunau R., 2007, PAIN NEONATES INFANT, P45; Grunau RE, 2005, PAIN, V113, P293, DOI 10.1016/j.pain.2004.10.020; Grunau RE, 2000, CLIN J PAIN, V16, P37, DOI 10.1097/00002508-200003000-00007; Grunau RE, 2001, PEDIATRICS, V107, P105, DOI 10.1542/peds.107.1.105; Holsti L, 2005, EARLY HUM DEV, V81, P293, DOI 10.1016/j.earlhumdev.2004.08.002; Johnston CC, 1997, CLIN J PAIN, V13, P308, DOI 10.1097/00002508-199712000-00008; Johnston CC, 1996, PEDIATRICS, V98, P925; Lemons JA, 2000, PEDIATRICS, V105, P454; Moustogiannis AN, 1996, NEUROL RES, V18, P440; Porter F. L., 1998, RES CLIN FORUMS, V20, P9; Porter FL, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e13; Ruda MA, 2000, SCIENCE, V289, P628, DOI 10.1126/science.289.5479.628; Simons SHP, 2003, ARCH PEDIAT ADOL MED, V157, P1058, DOI 10.1001/archpedi.157.11.1058; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Slater R, 2006, J NEUROSCI, V26, P3662, DOI 10.1523/JNEUROSCI.0348-06.2006; Slater R, 2006, PAIN, V123, P332, DOI 10.1016/j.pain.2006.05.009; Whitfield MF, 2000, CLIN PERINATOL, V27, P363, DOI 10.1016/S0095-5108(05)70026-9; WILSON G, 1991, EARLY HUM DEV, V25, P87, DOI 10.1016/0378-3782(91)90187-8	36	579	609	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2008	300	1					60	70		10.1001/jama.300.1.60	http://dx.doi.org/10.1001/jama.300.1.60			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320NW	18594041	Bronze			2023-01-03	WOS:000257242800025
J	Toscano, F; El Fajoui, Z; Gay, F; Lalaoui, N; Parmentier, B; Chayvialle, JA; Scoazec, JY; Micheau, O; Abello, J; Saurin, JC				Toscano, F.; El Fajoui, Z.; Gay, F.; Lalaoui, N.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Micheau, O.; Abello, J.; Saurin, J-C			p53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells	ONCOGENE			English	Article						oxaliplatin; TRAIL; antagonism; p53; DcR1; colon cancer	TRAIL-INDUCED APOPTOSIS; DECOY RECEPTORS; CHEMOTHERAPEUTIC-AGENTS; COLORECTAL-CANCER; DEATH RECEPTORS; TARGETING DEATH; IN-VITRO; C-FLIP; LIGAND; P53	Oxaliplatin hasemerged as a major chemotherapeutic drug in the treatment of advanced colorectal cancer, yet like most conventional cancer therapeutics, its efficacy is often compromised due to p53 mutations. Unlike oxaliplatin, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in a p53-independent manner, and chemotherapy is known to overcome tumour resistance to TRAIL-induced cell death in most cancer cells. Using a panel of colon cancer cell lines, we assessed the ability of oxaliplatin to sensitize to TRAIL-induced apoptosis. We demonstrate that while both drugs additively or synergistically induced apoptosis in almost all cell lines tested, p53 wild-type colon cancer cells such as HCT116, LS513 or LS174T remained resistant. Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase. According to our finding, downregulation of DcR1 using siRNA, in p53 wild-type colon cancer cells, restored oxaliplatin/TRAIL synergistic apoptotic activity. On the contrary, exogenous DcR1 overexpression in SW480, a p53-mutated cell line, abolished the synergy between the two drugs. Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through DcR1 upregulation. Our findings could have important implications for future therapeutic strategies, and suggest that the association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.	[Toscano, F.; El Fajoui, Z.; Gay, F.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Abello, J.; Saurin, J-C] Fac Med Laennec, INSERM, Unite 865, Inst Fed Rech Lyon Est, F-69372 Lyon 08, France; [Toscano, F.; El Fajoui, Z.; Gay, F.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Abello, J.; Saurin, J-C] Univ Lyon 1, Fac Laennec, F-69008 Lyon, France; [Lalaoui, N.; Micheau, O.] Univ Bourgogne, INSERM, U866, F-21079 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Abello, J (corresponding author), Fac Med Laennec, INSERM, Unite 865, Inst Fed Rech Lyon Est, 7 Rue G Paradin, F-69372 Lyon 08, France.	abello@lyon.inserm.fr	saurin, jean christophe/AAB-4077-2020; micheau, olivier/C-3574-2011; Lalaoui, Najoua/C-1410-2014	micheau, olivier/0000-0001-8499-7984; Lalaoui, Najoua/0000-0002-0165-3324				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Davidovich IA, 2004, CANCER LETT, V211, P189, DOI 10.1016/j.canlet.2004.03.026; de Almodovar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Gramont Aimery de, 2005, Semin Oncol, V32, P11, DOI 10.1053/j.seminoncol.2005.06.004; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Jang SH, 2004, INT J MOL MED, V13, P181; Jin H, 2004, CANCER RES, V64, P4900, DOI 10.1158/0008-5472.CAN-04-0408; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Liu XG, 2005, CANCER RES, V65, P9169, DOI 10.1158/0008-5472.CAN-05-0939; Merino D, 2007, EXPERT OPIN THER TAR, V11, P1299, DOI 10.1517/14728222.11.10.1299; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Mita MM, 2006, ANN ONCOL, V17, P313, DOI 10.1093/annonc/mdj067; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Nagane M, 2000, CANCER RES, V60, P847; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Toscano F, 2007, BIOCHEM PHARMACOL, V74, P392, DOI 10.1016/j.bcp.2007.05.001; van Geelen CM, 2006, J CLIN ONCOL, V24, P4998, DOI 10.1200/JCO.2006.06.8809; Vignati S, 2002, EUR J CANCER, V38, P177, DOI 10.1016/S0959-8049(01)00345-8; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266	39	35	38	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4161	4171		10.1038/onc.2008.52	http://dx.doi.org/10.1038/onc.2008.52			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345033				2023-01-03	WOS:000257496800003
J	Eckel, RH				Eckel, Robert H.			Nonsurgical management of obesity in adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEIGHT-LOSS MAINTENANCE; LONG-TERM MANAGEMENT; LOW-FAT DIET; PHYSICAL-ACTIVITY; BODY-WEIGHT; BEHAVIORAL TREATMENT; BARIATRIC SURGERY; RANDOMIZED-TRIAL; LOW-CARBOHYDRATE; HEART-DISEASE		[Eckel, Robert H.] Univ Colorado Denver, Div Endocrinol Diabet & Metab, Aurora, CO 80045 USA; [Eckel, Robert H.] Univ Colorado Denver, Div Cardiol, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Eckel, RH (corresponding author), Univ Colorado Denver, Div Endocrinol Diabet & Metab, Anschutz Med Campus,MS 8106,RC1 South,Rm 7107,128, Aurora, CO 80045 USA.	robert.eckel@uchsc.edu						ADAMS SO, 1986, J AM DIET ASSOC, V86, P485; Grundy Scott M, 2005, Crit Pathw Cardiol, V4, P198; Anderson JW, 2001, AM J CLIN NUTR, V74, P579; Ashley JM, 2001, ARCH INTERN MED, V161, P1599, DOI 10.1001/archinte.161.13.1599; Boudreaux ED, 2003, AM J HEALTH PROMOT, V17, P329, DOI 10.4278/0890-1171-17.5.329; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Butryn ML, 2007, OBESITY, V15, P3091, DOI 10.1038/oby.2007.368; Christensen R, 2008, LANCET, V371, P558; Christensen R, 2007, LANCET, V370, P1706, DOI 10.1016/S0140-6736(07)61721-8; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; DeMaria EJ, 2007, NEW ENGL J MED, V356, P2176, DOI 10.1056/NEJMct067019; Due A, 2004, INT J OBESITY, V28, P1283, DOI 10.1038/sj.ijo.0802767; Ebbeling CB, 2007, JAMA-J AM MED ASSOC, V298, P627; Ebbeling CB, 2007, JAMA-J AM MED ASSOC, V297, P2092, DOI 10.1001/jama.297.19.2092; Flegal KM, 2007, JAMA-J AM MED ASSOC, V298, P2028, DOI 10.1001/jama.298.17.2028; Foster GD, 2005, AM J CLIN NUTR, V82, p230S, DOI 10.1093/ajcn/82.1.230S; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Frank A, 2004, OBES RES, V12, P1821, DOI 10.1038/oby.2004.226; GARDNER CD, 2007, JAMA-J AM MED ASSOC, V298, P178; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Grundy, 2004, CIRCULATION, V110, P763, DOI 10.1161/01.CIR.0000140446.06098.6B; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Halford JCG, 2006, CURR OPIN INVEST DR, V7, P312; Heymsfield SB, 2003, INT J OBESITY, V27, P537, DOI 10.1038/sj.ijo.0802258; Hill JO, 2005, J APPL PHYSIOL, V99, P765, DOI 10.1152/japplphysiol.00137.2005; Howarth NC, 2001, NUTR REV, V59, P129, DOI 10.1111/j.1753-4887.2001.tb07001.x; Hvizdos KM, 1999, DRUGS, V58, P743, DOI 10.2165/00003495-199958040-00015; Kaplan LM, 2005, GASTROENTEROL CLIN N, V34, P91, DOI 10.1016/j.gtc.2004.12.002; Klein S, 2001, OBES RES, V9, p354S, DOI 10.1038/oby.2001.142; Li ZP, 2005, ANN INTERN MED, V142, P532, DOI 10.7326/0003-4819-142-7-200504050-00012; Mancini MC, 2006, EXPERT OPIN INV DRUG, V15, P897, DOI 10.1517/13543784.15.8.897; Miller WC, 1997, INT J OBESITY, V21, P941, DOI 10.1038/sj.ijo.0800499; Noakes M, 2005, AM J CLIN NUTR, V81, P1298; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Pagotto U, 2006, ENDOCR REV, V27, P73, DOI 10.1210/er.2005-0009; Perri MG, 2001, J CONSULT CLIN PSYCH, V69, P722, DOI 10.1037/0022-006X.69.4.722; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/CIRCULATIONAHA.106.171016; Poston WSC, 2000, AM FAM PHYSICIAN, V61, P3615; Raatz SK, 2005, J NUTR, V135, P2387, DOI 10.1093/jn/135.10.2387; SCHLUNDT DG, 1992, AM J CLIN NUTR, V55, P645, DOI 10.1093/ajcn/55.3.645; Schoeller DA, 1997, AM J CLIN NUTR, V66, P551, DOI 10.1093/ajcn/66.3.551; Shick SM, 1998, J AM DIET ASSOC, V98, P408, DOI 10.1016/S0002-8223(98)00093-5; Sjostrom L, 2007, NEW ENGL J MED, V357, P741, DOI 10.1056/NEJMoa066254; Slentz CA, 2004, ARCH INTERN MED, V164, P31, DOI 10.1001/archinte.164.1.31; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Svetkey LP, 2008, JAMA-J AM MED ASSOC, V299, P1139, DOI 10.1001/jama.299.10.1139; Torgerson JS, 2004, DIABETES CARE, V27, P155, DOI 10.2337/diacare.27.1.155; Torgerson JS, 2004, DIABETES CARE, V27, P856; Truby H, 2006, BRIT MED J, V332, P1418; Truby H, 2006, BMJ-BRIT MED J, V332, P1309, DOI 10.1136/bmj.38833.411204.80; van Baak MA, 2003, AM J CLIN NUTR, V78, P209; Vogels N, 2005, AM J CLIN NUTR, V82, P740, DOI 10.1093/ajcn/82.4.740; Wadden TA, 2003, ENDOCRIN METAB CLIN, V32, P981, DOI 10.1016/S0889-8529(03)00072-0; Wadden TA, 2005, NEW ENGL J MED, V353, P2111, DOI 10.1056/NEJMoa050156; Wadden TA, 2000, OBES RES, V8, P431, DOI 10.1038/oby.2000.53; Westerterp-Plantenga MS, 2005, APPETITE, V45, P187, DOI 10.1016/j.appet.2005.02.005; Willett W C, 2002, Obes Rev, V3, P59, DOI 10.1046/j.1467-789X.2002.00060.x; Wilmore JH, 1999, AM J CLIN NUTR, V70, P346; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883; WOOD PD, 1994, MED SCI SPORT EXER, V26, P838; Zhu SK, 2002, AM J CLIN NUTR, V76, P743, DOI 10.1093/ajcn/76.4.743; 1998, OBES RES, V6, P464	64	106	110	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 1	2008	358	18					1941	1950		10.1056/NEJMcp0801652	http://dx.doi.org/10.1056/NEJMcp0801652			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294ER	18450605				2023-01-03	WOS:000255387900008
J	Moore, DR; Shannon, RV				Moore, David R.; Shannon, Robert V.			Beyond cochlear implants: awakening the deafened brain	NATURE NEUROSCIENCE			English	Article							PRIMARY AUDITORY-CORTEX; ELECTRICAL-STIMULATION; STEM IMPLANT; SPEECH RECOGNITION; DISTORTED SPEECH; CRITICAL PERIOD; CHILDREN; HEARING; PERFORMANCE; PERCEPTION	Cochlear implants have provided hearing to more than 120,000 deaf people. Recent surgical developments include direct electrical stimulation of the brain, bilateral implants and implantation in children less than 1 year old. However, research is beginning to refocus on the role of the brain in providing benefits to implant users. The auditory system is able to use the highly impoverished input provided by implants to interpret speech, but this only works well in those who have developed language before their deafness or in those who receive their implant at a very young age. We discuss recent evidence suggesting that developing the ability of the brain to learn how to use an implant may be as important as further improvements of the implant technology.	[Moore, David R.] MRC, Inst Hearing Res, Nottingham, England; [Moore, David R.] Natl Biomed Res Unit Hearing, Nottingham, England; [Shannon, Robert V.] House Ear Res Inst, Los Angeles, CA USA	University of Nottingham; House Research Institute	Moore, DR (corresponding author), MRC, Inst Hearing Res, Nottingham, England.	david.moore@ihr.mrc.ac.uk			MRC [MC_U135097130] Funding Source: UKRI; Medical Research Council [MC_U135097130] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Brown SDM, 2008, NAT REV GENET, V9, P277, DOI 10.1038/nrg2309; Colletti V, 2005, LARYNGOSCOPE, V115, P1974, DOI 10.1097/01.mlg.0000178327.42926.ec; Colletti V, 2007, OTOL NEUROTOL, V28, P39, DOI 10.1097/01.mao.0000247808.47712.02; Dahmen JC, 2007, CURR OPIN NEUROBIOL, V17, P456, DOI 10.1016/j.conb.2007.07.004; Davis MH, 2005, J EXP PSYCHOL GEN, V134, P222, DOI 10.1037/0096-3445.134.2.222; de Villers-Sidani E, 2007, J NEUROSCI, V27, P180, DOI 10.1523/JNEUROSCI.3227-06.2007; Eggermont JJ, 2008, AM J AUDIOL, V17, pS162, DOI 10.1044/1059-0889(2008/07-0025); Eisen MD, 2003, OTOL NEUROTOL, V24, P500, DOI 10.1097/00129492-200305000-00025; Eisenberg LS, 2000, J ACOUST SOC AM, V107, P2704, DOI 10.1121/1.428656; Fallon JB, 2009, J COMP NEUROL, V512, P101, DOI 10.1002/cne.21886; Faulkner A, 2006, EAR HEARING, V27, P139, DOI 10.1097/01.aud.0000202357.40662.85; Friesen LM, 2001, J ACOUST SOC AM, V110, P1150, DOI 10.1121/1.1381538; Fu QJ, 2008, HEARING RES, V242, P198, DOI 10.1016/j.heares.2007.11.010; GALVIN JJ, ANN N Y ACA IN PRESS; Harris JA, 2008, J NEUROSCI, V28, P10990, DOI 10.1523/JNEUROSCI.2697-08.2008; HYSON RL, 1989, J NEUROSCI, V9, P2835; Kamke MR, 2005, NEURON, V48, P675, DOI 10.1016/j.neuron.2005.09.014; Knudsen EI, 2004, J COGNITIVE NEUROSCI, V16, P1412, DOI 10.1162/0898929042304796; Kral A, 2006, PROG BRAIN RES, V157, P283, DOI 10.1016/S0079-6123(06)57018-9; Krueger B, 2008, OTOL NEUROTOL, V29, P509, DOI 10.1097/MAO.0b013e318171972f; Kuhl PK, 2004, NAT REV NEUROSCI, V5, P831, DOI 10.1038/nrn1533; Leake PA, 2008, HEARING RES, V242, P86, DOI 10.1016/j.heares.2008.06.002; Lenarz T, 2006, OTOL NEUROTOL, V27, P838, DOI 10.1097/01.mao.0000232010.01116.e9; Levi DM, 2009, PHILOS T R SOC B, V364, P399, DOI 10.1098/rstb.2008.0203; Loebach JL, 2008, J ACOUST SOC AM, V124, P552, DOI 10.1121/1.2931948; Maurer MH, 2008, PROTEOM CLIN APPL, V2, P437, DOI 10.1002/prca.200780044; Moore CM, 2002, HEARING RES, V164, P82, DOI 10.1016/S0378-5955(01)00415-4; Moore DR, 2008, HEARING RES, V238, P147, DOI 10.1016/j.heares.2007.11.013; Moore DR, 2009, PHILOS T R SOC B, V364, P409, DOI 10.1098/rstb.2008.0187; Moore DR, 2005, BRAIN LANG, V94, P72, DOI 10.1016/j.bandl.2004.11.009; MOORE DR, 1992, NEUROREPORT, V3, P269, DOI 10.1097/00001756-199203000-00014; Mossop JE, 2000, HEARING RES, V147, P183, DOI 10.1016/S0378-5955(00)00054-X; Norena AJ, 2006, NAT NEUROSCI, V9, P932, DOI 10.1038/nn1720; Otto SR, 2002, J NEUROSURG, V96, P1063, DOI 10.3171/jns.2002.96.6.1063; Otto SR, 2008, OTOL NEUROTOL, V29, P1147, DOI 10.1097/MAO.0b013e31818becb4; Parks T. N., 2004, PLASTICITY AUDITORY; Polley DB, 2006, J NEUROSCI, V26, P4970, DOI 10.1523/JNEUROSCI.3771-05.2006; Sabes JH, 2007, INT J AUDIOL, V46, P374, DOI 10.1080/14992020701297565; SHANNON RV, 1990, HEARING RES, V47, P159, DOI 10.1016/0378-5955(90)90173-M; SHANNON RV, 1995, SCIENCE, V270, P303, DOI 10.1126/science.270.5234.303; SHANNON RV, 1993, OTOLARYNG HEAD NECK, V108, P634, DOI 10.1177/019459989310800603; Sharma A, 2007, INT J AUDIOL, V46, P494, DOI 10.1080/14992020701524836; Spahr AJ, 2004, ARCH OTOLARYNGOL, V130, P624, DOI 10.1001/archotol.130.5.624; Stacey PC, 2008, J SPEECH LANG HEAR R, V51, P526, DOI 10.1044/1092-4388(2008/038); Svirsky MA, 2000, PSYCHOL SCI, V11, P153, DOI 10.1111/1467-9280.00231; Tallal P, 1996, SCIENCE, V271, P81, DOI 10.1126/science.271.5245.81; Tierney TS, 1997, J COMP NEUROL, V378, P295, DOI 10.1002/(SICI)1096-9861(19970210)378:2<295::AID-CNE11>3.0.CO;2-R; TUCCI DL, 1987, ANN OTO RHINOL LARYN, V96, P343, DOI 10.1177/000348948709600321; Vongpaisal T, 2006, J SPEECH LANG HEAR R, V49, P1091, DOI 10.1044/1092-4388(2006/078); Wright BA, 2009, PHILOS T R SOC B, V364, P301, DOI 10.1098/rstb.2008.0262	50	150	155	0	43	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256			NAT NEUROSCI	Nat. Neurosci.	JUN	2009	12	6					686	691		10.1038/nn.2326	http://dx.doi.org/10.1038/nn.2326			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	450DJ	19471266				2023-01-03	WOS:000266380900008
J	Hack, M; Stork, E				Hack, Maureen; Stork, Eileen			Resuscitation at birth and long-term follow-up	LANCET			English	Editorial Material							NEONATAL ENCEPHALOPATHY; ASPHYXIA; CHILDREN		[Hack, Maureen; Stork, Eileen] Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Hack, M (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA.	mxh7@po.cwru.edu						*AM HEART ASS, 2006, TXB NEON RES; Barnett A, 2002, NEUROPEDIATRICS, V33, P242, DOI 10.1055/s-2002-36737; BAX M, 1993, DEV MED CHILD NEUROL, V35, P1015; HandleyDerry M, 1997, DEV MED CHILD NEUROL, V39, P508; Odd DE, 2008, ARCH DIS CHILD-FETAL, V93, pF115, DOI 10.1136/adc.2007.123745; Odd DE, 2009, LANCET, V373, P1615, DOI 10.1016/S0140-6736(09)60244-0; ROBERTSON CMT, 1989, J PEDIATR-US, V114, P753, DOI 10.1016/S0022-3476(89)80132-5; Rutherford M, 1996, ARCH DIS CHILD-FETAL, V75, pF145, DOI 10.1136/fn.75.3.F145; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Volpe JJ., 2001, NEUROLOGY NEWBORN, V4	10	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 9	2009	373	9675					1581	1582		10.1016/S0140-6736(09)60228-2	http://dx.doi.org/10.1016/S0140-6736(09)60228-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	445QJ	19386356				2023-01-03	WOS:000266066300005
J	Goud, R; de Keizer, NF; ter Riet, G; Wyatt, JC; Hasman, A; Hellemans, IM; Peek, N				Goud, Rick; de Keizer, Nicolette F.; ter Riet, Gerben; Wyatt, Jeremy C.; Hasman, Arie; Hellemans, Irene M.; Peek, Niels			Effect of guideline based computerised decision support on decision making of multidisciplinary teams: cluster randomised trial in cardiac rehabilitation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; IMPLEMENTATION RESEARCH; SECONDARY PREVENTION; REMINDER SYSTEM; PRIMARY-CARE; MANAGEMENT; DESIGN; ERRORS; INTERVENTION; INFORMATICS	Objective To determine the extent to which computerised decision support can improve concordance of multidisciplinary teams with therapeutic decisions recommended by guidelines. Design Multicentre cluster randomised trial. Participants Multidisciplinary cardiac rehabilitation teams in Dutch centres and their cardiac rehabilitation patients. Interventions Teams received an electronic patient record system with or without additional guideline based decision support. Main outcome measures Concordance with guideline recommendations assessed for two standard rehabilitation treatments-exercise and education therapy-and for two new but evidence based rehabilitation treatments-relaxation and lifestyle change therapy; generalised estimating equations were used to account for intra-cluster correlation and were adjusted for patient's age, sex, and indication for cardiac rehabilitation and for type and volume of centre. Results Data from 21 centres, including 2787 patients, were analysed. Computerised decision support increased concordance with guideline recommended therapeutic decisions for exercise therapy by 7.9% (control 84.7%; adjusted difference 3.5%, 95% confidence 0.1% to 5.2%), for education therapy by 25.7% (control 63.9%; adjusted difference 23.7%, 15.5% to 29.4%), and for relaxation therapy by 25.5% (control 34.1%; adjusted difference 41.6%, 25.2% to 51.3%). The concordance for lifestyle change therapy increased by 3.2% ( control 54.1%; adjusted difference 7.1%, -2.9% to 18.3%). Computerised decision support reduced cases of both overtreatment and undertreatment. Conclusions In a multidisciplinary team motivated to adopt a computerised decision support aid that assists in formulating guideline based care plans, computerised decision support can be effective in improving the team's concordance with guidelines. Therefore, computerised decision support may also be considered to improve implementation of guidelines in such settings.	[de Keizer, Nicolette F.; ter Riet, Gerben; Hasman, Arie; Hellemans, Irene M.; Peek, Niels] Univ Amsterdam, Acad Med Ctr, Dept Med Informat, NL-1100 DD Amsterdam, Netherlands; [ter Riet, Gerben] Univ Zurich, Horten Ctr, Zurich, Switzerland; [Wyatt, Jeremy C.] Univ Dundee, Hlth Informat Ctr, Dundee DD2 4BF, Scotland	University of Amsterdam; Academic Medical Center Amsterdam; University of Zurich; University of Dundee	Peek, N (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Informat, Meibergdreef 15, NL-1100 DD Amsterdam, Netherlands.	n.b.peek@amc.uva.nl	Peek, Niels/AAD-9334-2019; Hasman, Arie/F-1816-2013; Wyatt, Jeremy/F-8160-2010; Riet, Gerben ter/A-6943-2011	Peek, Niels/0000-0002-6393-9969; Wyatt, Jeremy/0000-0001-7008-1473; Riet, Gerben ter/0000-0002-2231-7637	ZonMW; Netherlands Organisation for Health Research and Development; Health Care Efficiency Research Program 2004 [945-14-205]	ZonMW(Netherlands Organization for Health Research and Development); Netherlands Organisation for Health Research and Development(Netherlands Organization for Health Research and Development); Health Care Efficiency Research Program 2004	This project was funded by ZonMW, the Netherlands Organisation for Health Research and Development, Health Care Efficiency Research Program 2004, subprogram Implementation, under project no. 945-14-205. The researchers were independent from the funder. ZonMW had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.	ADAMS ID, 1986, BRIT MED J, V293, P800, DOI 10.1136/bmj.293.6550.800; Ades PA, 2001, NEW ENGL J MED, V345, P892, DOI 10.1056/NEJMra001529; Bates DW, 1999, AM J MED, V106, P144, DOI 10.1016/S0002-9343(98)00410-0; Bethell H, 2009, HEART, V95, P271, DOI 10.1136/hrt.2007.134338; Burack RC, 2003, PREV MED, V36, P547, DOI 10.1016/S0091-7435(02)00062-2; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell MK, 2005, CLIN TRIALS, V2, P99, DOI 10.1191/1740774505cn071oa; Campbell MK, 2001, STAT MED, V20, P391, DOI 10.1002/1097-0258(20010215)20:3<391::AID-SIM800>3.0.CO;2-Z; CARTER S, 2003, QUALITY SAFETY HL S1, V12, P25; Chuang JH, 2002, J AM MED INFORM ASSN, V9, P230, DOI 10.1197/jamia.M0997; Chuang JH, 2000, J AM MED INFORM ASSN, P146; Dexter PR, 2001, NEW ENGL J MED, V345, P965, DOI 10.1056/NEJMsa010181; Eccles M, 2003, QUAL SAF HEALTH CARE, V12, P47, DOI 10.1136/qhc.12.1.47; Eccles M, 2002, BMJ-BRIT MED J, V325, P941, DOI 10.1136/bmj.325.7370.941; Ellrodt G, 1997, JAMA-J AM MED ASSOC, V278, P1687, DOI 10.1001/jama.278.20.1687; Filippi A, 2003, DIABETES CARE, V26, P1497, DOI 10.2337/diacare.26.5.1497; Friedman C.F., 2006, EVALUATION METHODS M; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Goud R, 2005, COMPUT CARDIOL, V32, P323; Goud R, 2008, COMPUT METH PROG BIO, V91, P145, DOI 10.1016/j.cmpb.2008.03.006; Goud R, 2008, ST HEAL T, V136, P193; Grimshaw Jeremy, 2004, J Contin Educ Health Prof, V24 Suppl 1, pS31, DOI 10.1002/chp.1340240506; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Jones PE, 2000, ERGONOMICS, V43, P1129, DOI 10.1080/00140130050084914; Kaplan B, 2001, INT J MED INFORM, V64, P15, DOI 10.1016/S1386-5056(01)00183-6; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Lanceley A, 2008, INT J GYNECOL CANCER, V18, P215, DOI 10.1111/j.1525-1438.2007.00991.x; Lobach DF, 1997, AM J MED, V102, P89, DOI 10.1016/S0002-9343(96)00382-8; Long JS, 2000, AM STAT, V54, P217, DOI 10.2307/2685594; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Mazzini MJ, 2008, AM J CARDIOL, V101, P1084, DOI 10.1016/j.amjcard.2007.11.063; MCPHEE SJ, 1991, JAMA-J AM MED ASSOC, V266, P538, DOI 10.1001/jama.266.4.538; Murray DM, 2004, AM J PUBLIC HEALTH, V94, P423, DOI 10.2105/AJPH.94.3.423; *NETH HEART FDN RE, 2004, GUID CARD REH 2004; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Poller L, 1998, LANCET, V352, P1505, DOI 10.1016/S0140-6736(98)04147-6; Randolph AG, 1999, JAMA-J AM MED ASSOC, V282, P67, DOI 10.1001/jama.282.1.67; Samore MH, 2005, JAMA-J AM MED ASSOC, V294, P2305, DOI 10.1001/jama.294.18.2305; San Martin-Rodriguez Leticia, 2005, J Interprof Care, V19 Suppl 1, P132; Shiffman RN, 1999, J AM MED INFORM ASSN, V6, P99, DOI 10.1136/jamia.1999.0060099; Shiffman RN, 1999, J AM MED INFORM ASSN, V6, P104, DOI 10.1136/jamia.1999.0060104; Short Robert, 2008, BMJ, V336, P1095, DOI 10.1136/bmj.39580.625891.DB; Skinner JS, 2007, BRIT MED J, V334, P1112, DOI 10.1136/bmj.39204.531586.AD; Thomas RJ, 2007, J AM COLL CARDIOL, V50, P1400, DOI 10.1016/j.jacc.2007.04.033; Unsworth C, 1996, AM J PHYS MED REHAB, V75, P483, DOI 10.1097/00002060-199611000-00019; World Health Organization [WHO], 1993, NEEDS ACT PRIOR CARD; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; Wyatt JC, 2000, J ROY SOC MED, V93, P299, DOI 10.1177/014107680009300606; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 2008, JAMA, V299, P1534	54	56	56	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	2009	338								b1440	10.1136/bmj.b1440	http://dx.doi.org/10.1136/bmj.b1440			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	440JR	19398471	Green Submitted, hybrid, Green Published, Green Accepted			2023-01-03	WOS:000265697100005
J	Kloxin, AM; Kasko, AM; Salinas, CN; Anseth, KS				Kloxin, April M.; Kasko, Andrea M.; Salinas, Chelsea N.; Anseth, Kristi S.			Photodegradable Hydrogels for Dynamic Tuning of Physical and Chemical Properties	SCIENCE			English	Article							MESENCHYMAL STEM-CELLS; CHONDROGENIC DIFFERENTIATION; BEHAVIOR; TISSUE; DEGRADATION; MIGRATION; GROWTH; BIOMATERIALS; NETWORKS; POLYMERS	We report a strategy to create photodegradable poly(ethylene glycol)-based hydrogels through rapid polymerization of cytocompatible macromers for remote manipulation of gel properties in situ. Postgelation control of the gel properties was demonstrated to introduce temporal changes, creation of arbitrarily shaped features, and on-demand pendant functionality release. Channels photodegraded within a hydrogel containing encapsulated cells allow cell migration. Temporal variation of the biochemical gel composition was used to influence chondrogenic differentiation of encapsulated stem cells. Photodegradable gels that allow real-time manipulation of material properties or chemistry provide dynamic environments with the scope to answer fundamental questions about material regulation of live cell function and may affect an array of applications from design of drug delivery vehicles to tissue engineering systems.	[Kloxin, April M.; Kasko, Andrea M.; Salinas, Chelsea N.; Anseth, Kristi S.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80309 USA; [Kasko, Andrea M.; Anseth, Kristi S.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Anseth, KS (corresponding author), Univ Colorado, Dept Chem & Biol Engn, 424 UCB ECCH 111, Boulder, CO 80309 USA.	Kristi.Anseth@colorado.edu			Howard Hughes Medical Institute; NIH [DE12998, DE16523]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE016523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012998] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank C. Bowman, T. Scott, and C. Kloxin for comments on early versions of this manuscript and valuable discussions; A. Aimetti for peptide synthesis training; J. McCall and S. Anderson for cell culture assistance; M. Schwartz for cell migration discussions; C. Bowman and his laboratory for use of and assistance with the rheometer and profilometer; C. Kloxin for assistance with image analysis; C. DeForest, Carl Zeiss, Inc., and the Howard Hughes Medical Institute Janelia Farms campus for assistance with and use of the Zeiss 710 two-photon confocal LSM; and the Howard Hughes Medical Institute and the NIH (grants DE12998 and DE16523) for research support. A.K. thanks the NASA Graduate Student Researchers Program fellowship and the Department of Education Graduate Assistance in Areas of National Need fellowship for support. A patent related to this work has been submitted (U.S. Patent Application No. 11/374,471).	Alvarez M, 2008, ADV MATER, V20, P4563, DOI 10.1002/adma.200800746; [Anonymous], 1991, INTRO POLYM; Boontheekul T, 2003, CURR OPIN BIOTECH, V14, P559, DOI 10.1016/j.copbio.2003.08.004; Bryant SJ, 2000, J BIOMAT SCI-POLYM E, V11, P439, DOI 10.1163/156856200743805; BRYANT SJ, 2005, SCAFFOLDING TISSUE E, P69; Chan G, 2008, TRENDS BIOTECHNOL, V26, P382, DOI 10.1016/j.tibtech.2008.03.011; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Hahn MS, 2006, ADV MATER, V18, P2679, DOI 10.1002/adma.200600647; Hudalla GA, 2008, BIOMACROMOLECULES, V9, P842, DOI 10.1021/bm701179s; Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491; Khademhosseini A, 2007, BIOMATERIALS, V28, P5087, DOI 10.1016/j.biomaterials.2007.07.021; KHAN SA, 1992, RHEOL ACTA, V31, P151, DOI 10.1007/BF00373237; Langer R, 2003, AICHE J, V49, P2990, DOI 10.1002/aic.690491202; Luo Y, 2004, NAT MATER, V3, P249, DOI 10.1038/nmat1092; Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055; Mahoney MJ, 2006, BIOMATERIALS, V27, P2265, DOI 10.1016/j.biomaterials.2005.11.007; Metters A, 2005, BIOMACROMOLECULES, V6, P290, DOI 10.1021/bm049607o; Nuttelman CR, 2005, MATRIX BIOL, V24, P208, DOI 10.1016/j.matbio.2005.03.004; Raeber GP, 2005, BIOPHYS J, V89, P1374, DOI 10.1529/biophysj.104.050682; Rice MA, 2006, BIOMACROMOLECULES, V7, P1968, DOI 10.1021/bm060086+; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Salinas CN, 2008, BIOMATERIALS, V29, P2370, DOI 10.1016/j.biomaterials.2008.01.035; Salinas CN, 2007, TISSUE ENG, V13, P1025, DOI 10.1089/ten.2006.0126; Sands RW, 2007, CURR OPIN BIOTECH, V18, P448, DOI 10.1016/j.copbio.2007.10.004; Seliktar D, 2004, J BIOMED MATER RES A, V68A, P704, DOI 10.1002/jbm.a.20091; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587; Tavella S, 1997, J CELL SCI, V110, P2261; Tayalia P, 2008, ADV MATER, V20, P4494, DOI 10.1002/adma.200801319; Weibel DB, 2007, NAT REV MICROBIOL, V5, P209, DOI 10.1038/nrmicro1616; Wosnick JH, 2008, CHEM MATER, V20, P55, DOI 10.1021/cm071158m; Zhao YR, 2004, J AM CHEM SOC, V126, P4653, DOI 10.1021/ja036958m	34	1290	1341	31	1038	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	2009	324	5923					59	63		10.1126/science.1169494	http://dx.doi.org/10.1126/science.1169494			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	427TN	19342581	Green Accepted			2023-01-03	WOS:000264802100030
J	Grande, D; Asch, DA				Grande, David; Asch, David A.			Commercial versus Social Goals of Tracking What Doctors Do	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Grande, David] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Asch, David A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Asch, David A.] Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center	Grande, D (corresponding author), Univ Penn, Sch Med, Philadelphia, PA 19104 USA.		Grande, David/AAJ-8191-2021	Grande, David/0000-0002-6717-6735; Asch, David/0000-0002-7970-286X				*IMS HLTH, IMS CORP OV; POTTENGER B, FREECONOMICS HLTH CA	2	8	8	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2009	360	8					747	749		10.1056/NEJMp0810410	http://dx.doi.org/10.1056/NEJMp0810410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	408CN	19228616				2023-01-03	WOS:000263411300002
J	Kiboneka, A; Nyatia, RJ; Nabiryo, C; Anema, A; Cooper, CL; Fernandes, KA; Montaner, JSG; Mills, EJ				Kiboneka, Andrew; Nyatia, Ricky Jones; Nabiryo, Christine; Anema, Aranka; Cooper, Curtis L.; Fernandes, Kimberly Ann; Montaner, Julio S. G.; Mills, Edward J.			Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INDIVIDUALS; ADHERENCE; COUNTRIES; KAMPALA	Objective To measure the clinical and immunological outcomes of HIV positive adult patients receiving combination antiretroviral therapy in conflict affected northern Uganda. Design Prospective cohort study. Setting Gulu District, northern Uganda. Participants 1625 adults (aged over 14 years) receiving combination antiretroviral therapy. Main outcome measures Primary outcome: all cause mortality. Secondary outcomes: impact of covariates (sex, age, CD4 count at start, adherence, tuberculosis at start, duration of treatment, and internally displaced person status) on mortality. Results Sixty nine (4.2%) patients died during follow-up. The mortality incidence rate was 3.48 (95% confidence interval 2.66 to 4.31) per 100 person years. Patients started treatment with a median CD4 count of 157 (interquartile range 90-220) cells/mu l; most (1009; 63%) had World Health Organization stage 2 defined illness. Sixty two patients had pulmonary tuberculosis at the start of treatment. Of the 1521 patients with adherence data, 118 (7.8%) had adherence of less than 95% and 1403 (92.2%) had adherence of 95% or above. Conclusion Patients receiving combination antiretroviral therapy in conflict affected northern Uganda had a mortality comparable to that of patients in peaceful, low income settings and better adherence than patients in higher income settings. These favourable findings highlight the need to expand access to combination antiretroviral therapy in populations affected by armed conflict.	[Kiboneka, Andrew; Nabiryo, Christine; Mills, Edward J.] AIDS Support Org TASO, Kampala, Uganda; [Nyatia, Ricky Jones] TASO, Gulu, Uganda; [Anema, Aranka; Fernandes, Kimberly Ann; Montaner, Julio S. G.; Mills, Edward J.] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Cooper, Curtis L.] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada	B.C. Centre for Excellence in HIV/AIDS; University of Ottawa; Ottawa Hospital Research Institute	Mills, EJ (corresponding author), St Pauls Hosp, Room 627,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	emills@cfenet.ubc.ca	Kiboneka, Andrew/U-5381-2019; Montaner, Julio/K-7621-2012; Cooper, Curtis/M-9320-2019					Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Chamla Dick D, 2007, Confl Health, V1, P12, DOI 10.1186/1752-1505-1-12; Culbert H, 2007, PLOS MED, V4, P794, DOI 10.1371/journal.pmed.0040129; Fabiani Massimo, 2007, Confl Health, V1, P3, DOI 10.1186/1752-1505-1-3; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Inter-Agency Standing Committee (IASC), 2003, GUID HIV AIDS INT EM; *JOINT UN PROGR HI, 2007, UN ACC SCAL PRIOR HI; Lutalo T, 2007, AIDS, V21, pS15, DOI 10.1097/01.aids.0000299406.44775.de; Mills EJ, 2007, CLIN INFECT DIS, V45, P916, DOI 10.1086/521249; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; *OCHA, 2006, NO UG BRIEF PAP; Oyugi JH, 2007, AIDS, V21, P965, DOI 10.1097/QAD.0b013e32802e6bfa; Phillips AN, 2008, LANCET, V371, P1443, DOI 10.1016/S0140-6736(08)60624-8; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Singh Sonal, 2007, Confl Health, V1, P1, DOI 10.1186/1752-1505-1-1; Spacek LA, 2006, CLIN INFECT DIS, V42, P252, DOI 10.1086/499044; Spiegel PB, 2007, LANCET, V369, P2187, DOI 10.1016/S0140-6736(07)61015-0; Spiegel PB, 2004, DISASTERS, V28, P322, DOI 10.1111/j.0361-3666.2004.00261.x; Steering Committee for Humanitarian Response, 2004, SPHER PROJ HUM CHART; Tibaijuka, 2005, REPORT FACT FINDING; *UCDP, 2006, CUST REP ACT CONFL A; *UN HIGH COMM REF, STAT WORLDS REF 2006; *UN HIGH COMM REF, 2007, CLIN GUID ANT THER M; *UN HIGH COMM REF, 2007, ANT MED POL REF; *UN HIGH COMM REF, 2008, GLOB APP 2008 2009; *UN OCHA, 2007, CONS APP UG 2008; *WHO, 2006, ANT DRUGS EM ENGL FE; *WHO REP UG MIN HL, HLTH MORT SURV INT D; ZUCCA M, 2004, 15 INT AIDS C BANGK	29	25	26	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 17	2009	338								b201	10.1136/bmj.b201	http://dx.doi.org/10.1136/bmj.b201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	417CE	19223338	Green Published, hybrid			2023-01-03	WOS:000264051900005
J	Worth, A; Irshad, T; Bhopal, R; Brown, D; Lawton, J; Grant, E; Murray, S; Kendall, M; Adam, J; Gardee, R; Sheikh, A				Worth, Allison; Irshad, Tasneem; Bhopal, Raj; Brown, Duncan; Lawton, Julia; Grant, Elizabeth; Murray, Scott; Kendall, Marilyn; Adam, James; Gardee, Rafik; Sheikh, Aziz			Vulnerability and access to care for South Asian Sikh and Muslim patients with life limiting illness in Scotland: prospective longitudinal qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPECIALIST PALLIATIVE CARE; HEALTH-CARE; ETHNIC DIVERSITY; SERVICES; CANCER; COMMUNITY; VIEWS; END; UK; PROFESSIONALS	Objectives To examine the care experiences of South Asian Sikh and Muslim patients in Scotland with life limiting illness and their families and to understand the reasons for any difficulties with access to services and how these might be overcome. Design Prospective, longitudinal, qualitative design using in-depth interviews. Setting Central Scotland. Participants 25 purposively selected South Asian Sikh and Muslim patients, 18 family carers, and 20 key health professionals. Results 92 interviews took place. Most services struggled to deliver responsive, culturally appropriate care. Barriers to accessing effective end of life care included resource constrained services; institutional and, occasionally, personal racial and religious discrimination; limited awareness and understanding among South Asian people of the role of hospices; and difficulty discussing death. The most vulnerable patients, including recent migrants and those with poor English language skills, with no family advocate, and dying of non-malignant diseases were at particularly high risk of inadequate care. Conclusions Despite a robust Scottish diversity policy, services for South Asian Sikh and Muslim patients with life limiting illness were wanting in many key areas. Active case management of the most vulnerable patients and carers, and "real time" support, from where professionals can obtain advice specific to an individual patient and family, are the approaches most likely to instigate noticeable improvements in access to high quality end of life care. Improving access to palliative care for all, particularly those with non-malignant illnesses, as well as focusing on the specific needs of ethnic minority groups, is required.	[Bhopal, Raj; Murray, Scott; Sheikh, Aziz] Univ Edinburgh, Ctr Populat Hlth Sci, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland; [Brown, Duncan] St Columbas Hosp, Edinburgh, Midlothian, Scotland; [Adam, James] Marie Curie Hosp, Glasgow, Lanark, Scotland; [Gardee, Rafik] Natl Resource Ctr Ethn Minor Hlth, Glasgow, Lanark, Scotland	University of Edinburgh; University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Ctr Populat Hlth Sci, Primary Palliat Care Res Grp, Edinburgh EH8 9DX, Midlothian, Scotland.	Aziz.Sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056	Chief Scientist Office, Scottish Government Health Department	Chief Scientist Office, Scottish Government Health Department	Chief Scientist Office, Scottish Government Health Department. The research team is independent of the funders and the views expressed are those of the researchers, not the funding body.	Ahmed N, 2004, PALLIATIVE MED, V18, P525, DOI 10.1191/0269216304pm921oa; Bhopal R, 2007, ETHNICITY RACE HLTH; Boyd KJ, 2004, EUR J HEART FAIL, V6, P585, DOI 10.1016/j.ejheart.2003.11.018; Carstairs V., 1991, DEPRIVATION HLTH SCO; Clark J, 2003, BRIT MED J, V327, P174, DOI 10.1136/bmj.327.7408.174; CONILL C, 1990, CANCER, V65, P1864, DOI 10.1002/1097-0142(19900415)65:8<1864::AID-CNCR2820650832>3.0.CO;2-U; Darzi A, 2008, HIGH QUALITY CARE AL; DAVIES E, 2004, PALLIATIVE CARE SOLI; Davies E, 2004, BETTER PALLIATIVE CA; Elkan R, 2007, EUR J CANCER CARE, V16, P109, DOI 10.1111/j.1365-2354.2006.00726.x; Equalities Review, 2007, FAIRN FREED FIN REP; Exley C, 2005, PALLIATIVE MED, V19, P76, DOI 10.1191/0269216305pm973oa; Firth S, 2001, WIDER HORIZONS CARE; Gatrad AR, 2003, BRIT MED J, V327, P176, DOI 10.1136/bmj.327.7408.176; GATRAD R, 2007, PALLIATIVE CARE S AS; *GEN REG OFF SCOTL, 2008, SCOTL CENS 2001; Grande GE, 2006, AGE AGEING, V35, P267, DOI 10.1093/ageing/afj071; Gunaratnam Y., 2007, IMPROVING QUALITY PA; Higginson IJ, 1999, J PUBLIC HEALTH MED, V21, P22, DOI 10.1093/pubmed/21.1.22; HILL D, 1995, OPENING DOORS IMPROV; Jones K, 2005, J RES NURS, V10, P431, DOI 10.1177/174498710501000406; Kai J, 2001, MED EDUC, V35, P262, DOI 10.1046/j.1365-2923.2001.00880.x; Kai J, 2006, VALUING DIVERSITY RE; Kai J, 2007, PLOS MED, V4, P1766, DOI 10.1371/journal.pmed.0040323; Karim K, 2000, PALLIATIVE MED, V14, P471, DOI 10.1191/026921600701536390; Kendall M, 2007, BMJ-BRIT MED J, V334, P521, DOI 10.1136/bmj.39097.582639.55; Kessler D, 2005, PALLIATIVE MED, V19, P105, DOI 10.1191/0269216305pm980oa; Koffman J, 2007, PALLIATIVE MED, V21, P145, DOI 10.1177/0269216306074639; Krakauer EL, 2002, J AM GERIATR SOC, V50, P182, DOI 10.1046/j.1532-5415.2002.50027.x; Lingard L, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.39602.690162.47; Merrell J, 2006, HEALTH SOC CARE COMM, V14, P197, DOI 10.1111/j.1365-2524.2006.00610.x; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Murray SA, 2008, BRIT MED J, V336, P958, DOI 10.1136/bmj.39535.491238.94; Murray SA, 2006, LANCET, V368, P901, DOI 10.1016/S0140-6736(06)69350-1; Nazroo JY, 1998, SOCIOL HEALTH ILL, V20, P710, DOI 10.1111/1467-9566.00126; NBCWN, 2008, WE CAR TOO PUTT BLAC; Netuveli G, 2005, LANCET, V365, P312, DOI 10.1016/S0140-6736(05)17785-X; Owens A, 2004, HEALTH SOC CARE COMM, V12, P414, DOI 10.1111/j.1365-2524.2004.00511.x; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Richardson A, 2006, EUR J ONCOL NURS, V10, P93, DOI 10.1016/j.ejon.2005.05.002; ROBINSON LA, 1995, BRIT MED J, V311, P315, DOI 10.1136/bmj.311.7000.315; Sadiq A, 2008, CARING MUSLIM PATIEN, V2nd; Salway S., 2007, LONG TERM ILL HLTH P; *SCOTT EX, 2002, 200251 NHS HDL SCOTT; Seamark DA, 2007, J ROY SOC MED, V100, P225, DOI 10.1258/jrsm.100.5.225; Sheikh A, 2006, PLOS MED, V3, P166, DOI 10.1371/journal.pmed.0030049; Sheikh A, 2007, BRIT MED J, V334, P74, DOI 10.1136/bmj.39072.347720.68; Shi LY, 2005, J GEN INTERN MED, V20, P148, DOI 10.1111/j.1525-1497.2005.40136.x; Shipman C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1720; Sultana K, 2008, J ROY SOC MED, V101, P463, DOI 10.1258/jrsm.2008.080007; Szczepura A, 2005, POSTGRAD MED J, V81, P141, DOI 10.1136/pgmj.2004.026237; WEBB E, 2005, ARCH DIS CHILDHOOD-E, V90, P11; Wild SH, 2006, BRIT J CANCER, V94, P1079, DOI 10.1038/sj.bjc.6603031	53	76	76	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2009	338								b183	10.1136/bmj.b183	http://dx.doi.org/10.1136/bmj.b183			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	414OX	19190015	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000263876200003
J	Rodriguez-Gonzalez, A; Cyrus, K; Salcius, M; Kim, K; Crews, CM; Deshaies, RJ; Sakamoto, KM				Rodriguez-Gonzalez, A.; Cyrus, K.; Salcius, M.; Kim, K.; Crews, C. M.; Deshaies, R. J.; Sakamoto, K. M.			Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer	ONCOGENE			English	Article						steroid hormone receptors; ubiquitination; degradation; breast cancer; prostate cancer	HUMAN ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; COMBINATORIAL CHEMISTRY; RESPONSIVE ELEMENT; GROWTH-FACTOR; CELL-LINES; IN-VIVO; ALPHA; GENE; PROTEIN	Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the ubiquitin-dependent proteolytic system of eukaryotic cells. We designed two Protacs that contain the peptide 'degron' from hypoxia-inducible factor-1 alpha, which binds to the Von-Hippel-Lindau (VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-alpha (ER alpha; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ER alpha in a proteasome-dependent manner. Protac-B inhibited the proliferation of ER alpha-dependent breast cancer cells by inducing G(1) arrest, inhibition of retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer cells that lacked ERa expression. Similarly, Protac-A treatment of androgen-dependent prostate cancer cells induced G(1) arrest but did not affect cells that do not express AR. Our results suggest that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer cells through degradation of the ERa and AR, respectively.	[Rodriguez-Gonzalez, A.; Sakamoto, K. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, Los Angeles, CA 90095 USA; [Rodriguez-Gonzalez, A.; Sakamoto, K. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, Los Angeles, CA 90095 USA; [Rodriguez-Gonzalez, A.; Deshaies, R. J.; Sakamoto, K. M.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Cyrus, K.; Kim, K.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Pharmacol, New Haven, CT USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Chem, New Haven, CT USA; [Deshaies, R. J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Sakamoto, K. M.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; California Institute of Technology; University of Kentucky; Yale University; Yale University; Yale University; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Sakamoto, KM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, A2-412 MDCC CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kms@ucla.edu	Deshaies, Raymond/B-8354-2014; Crews, Craig M./ABH-9346-2020	Deshaies, Raymond/0000-0002-3671-9354; Crews, Craig M./0000-0002-8456-2005; Sakamoto, Kathleen/0000-0003-0494-8838	National Institutes of Health [CA-16042, AI-28697]; Jonsson Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA; Department of Defense (USA) Prostate Cancer Research [W81XWH-06-1-0192]; Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright [EX 2005-0517, NIH R21 R21 CA118631];  [NIH R21 CA108545]; NATIONAL CANCER INSTITUTE [P30CA016042, R21CA108545, R21CA118631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jonsson Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA(University of California System); Department of Defense (USA) Prostate Cancer Research(United States Department of Defense); Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright(Spanish Government); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Tammy Phung for her kind assistance in the flow cytometry performance in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research FlowCore Facility that is supported by the National Institutes of Health awards CA-16042 and AI-28697, by the Jonsson Cancer Center, the UCLA AIDS Institute and the David Geffen School of Medicine at UCLA. This work was supported by NIH R21 CA108545 (KMS), Department of Defense (USA) Prostate Cancer Research Program W81XWH-06-1-0192 (AR), Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright EX 2005-0517 (AR) and NIH R21 R21 CA118631 (CMC). RJD is an Investigator of the Howard Hughes Medical Institute.	Alarid ET, 2003, ENDOCRINOLOGY, V144, P3469, DOI 10.1210/en.2002-0092; Bakin RE, 2003, CANCER RES, V63, P1981; Bargagna-Mohan P, 2005, BIOORG MED CHEM LETT, V15, P2724, DOI 10.1016/j.bmcl.2005.04.008; Blundell TL, 1996, NATURE, V384, P23; Borras M, 1996, J STEROID BIOCHEM, V57, P203, DOI 10.1016/0960-0760(95)00272-3; Bubendorf L, 1999, CANCER RES, V59, P803; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Buzdar AU, 2003, ONCOLOGIST, V8, P335, DOI 10.1634/theoncologist.8-4-335; Clarke R, 1996, Cancer Treat Res, V87, P263; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CULIG Z, 1994, CANCER RES, V54, P5474; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Franco OE, 2003, PROSTATE, V56, P319, DOI 10.1002/pros.10258; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Godoy-Tundidor S, 2002, CLIN CANCER RES, V8, P2356; Hogan JC, 1996, NATURE, V384, P17; HUGGINS C, 1967, CANCER RES, V27, P1925; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kirschberg TA, 2003, ORG LETT, V5, P3459, DOI 10.1021/ol035234c; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Linja MJ, 2001, CANCER RES, V61, P3550; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Moul JW, 2000, J UROLOGY, V163, P1632, DOI 10.1016/S0022-5347(05)67511-8; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pink JJ, 1996, CANCER RES, V56, P2321; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Rau KM, 2005, ENDOCR-RELAT CANCER, V12, P511, DOI 10.1677/erc.1.01026; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; SANTEN RJ, 1992, J CLIN ENDOCR METAB, V75, P685, DOI 10.1210/jc.75.3.685; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Schneekloth JS, 2004, J AM CHEM SOC, V126, P3748, DOI 10.1021/ja039025z; Taplin ME, 1999, CANCER RES, V59, P2511; Thiele B, 1999, J CLIN ENDOCR METAB, V84, P1751, DOI 10.1210/jc.84.5.1751; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Verdine GL, 1996, NATURE, V384, P11; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	51	125	185	18	76	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7201	7211		10.1038/onc.2008.320	http://dx.doi.org/10.1038/onc.2008.320			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794799	Green Accepted			2023-01-03	WOS:000261384100007
J	Kaur, H; Goodman, C; Thompson, E; Thompson, KA; Masanja, I; Kachur, SP; Abdulla, S				Kaur, Harparkash; Goodman, Catherine; Thompson, Eloise; Thompson, Katy-Anne; Masanja, Irene; Kachur, S. Patrick; Abdulla, Salim			A Nationwide Survey of the Quality of Antimalarials in Retail Outlets in Tanzania	PLOS ONE			English	Article								Introduction: Retail pharmaceutical products are commonly used to treat fever and malaria in sub-Saharan African countries. Small scale studies have suggested that poor quality antimalarials are widespread throughout the region, but nationwide data are not available that could lead to generalizable conclusions about the extent to which poor quality drugs are available in African communities. This study aimed to assess the quality of antimalarials available from retail outlets across mainland Tanzania. Methods and Findings: We systematically purchased samples of oral antimalarial tablets from retail outlets across 21 districts in mainland Tanzania in 2005. A total of 1080 antimalarial formulations were collected including 679 antifol antimalarial samples (394 sulfadoxine/pyrimethamine and 285 sulfamethoxypyrazine/pyrimethamine), 260 amodiaquine samples, 63 quinine samples, and 51 artemisinin derivative samples. A systematic subsample of 304 products was assessed for quality by laboratory based analysis to determine the amount of the active ingredient and dissolution profile by following the published United States Pharmacopoeia (USP) monogram for the particular tablet being tested. Products for which a published analytical monogram did not exist were assessed on amount of active ingredient alone. Overall 38 or 12.2% of the samples were found to be of poor quality. Of the antifolate antimalarial drugs tested 13.4% were found to be of poor quality by dissolution and content analysis using high-performance liquid chromatography (HPLC). Nearly one quarter (23.8%) of quinine tablets did not comply within the tolerance limits of the dissolution and quantification analysis. Quality of amodiaquine drugs was relatively better but still unacceptable as 7.5% did not comply within the tolerance limits of the dissolution analysis. Formulations of the artemisinin derivatives all contained the stated amount of active ingredient when analysed using HPLC alone. Conclusions: Substandard antimalarial formulations were widely available in Tanzania at the time of this study. No products were detected that did not contain any amount of the stated active ingredient. Quinine and sulfadoxine/pyrimethamine products were the most widely available and also the most likely to be of poor quality. Substandard products were identified in all parts of the country and were labeled as made by both domestic and international manufacturers. With the expansion of the retail pharmaceutical sector as a delivery channel for antimalarial formulations the need for regular nationwide monitoring of their quality will become increasingly important.	[Kaur, Harparkash] London Sch Hyg & Trop Med, Clin Res Unit, London WC1, England; [Goodman, Catherine] London Sch Hyg & Trop Med, Hlth Policy Unit, London, England; [Thompson, Eloise] London Sch Hyg & Trop Med, Immunol Unit, London, England; [Thompson, Katy-Anne] London Sch Hyg & Trop Med, London, England; [Masanja, Irene; Abdulla, Salim] Ifakara Hlth Res & Dev Ctr, Dar Es Salaam, Tanzania; [Kachur, S. Patrick] US Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; Ifakara Health Institute; Centers for Disease Control & Prevention - USA	Kaur, H (corresponding author), London Sch Hyg & Trop Med, Clin Res Unit, London WC1, England.	Harparkash.Kaur@lshtm.ac.uk; cgoodman@nairobi.kemri-wellcome.org	Kachur, Patrick/ABE-7220-2021	Goodman, Catherine/0000-0002-2241-3485	US Centers for Disease Control and Prevention; US Agency for International Development; Wellcome Trust; UK Department for International Development; Bill and Melinda Gates Foundation	US Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); US Agency for International Development(United States Agency for International Development (USAID)); Wellcome Trust(Wellcome TrustEuropean Commission); UK Department for International Development; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation)	This study was completed as part of the Interdisciplinary Monitoring Project for Antimalarial Combination Therapy in Tanzania (IMPACT-Tz) with funding from the US Centers for Disease Control and Prevention, the US Agency for International Development and the Wellcome Trust. Catherine Goodman's participation was partially supported by the Consortium for Research in Equitable Health Systems which is funded by the UK Department for International Development. H. Kaur is grateful to the Gates Malaria Partnership for providing support for the analytical facility through an award from the Bill and Melinda Gates Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin AA, 2007, J CLIN PHARM THER, V32, P429, DOI 10.1111/j.1365-2710.2007.00847.x; [Anonymous], 11 NIH FOG INT CTR; Atemnkeng MA, 2007, TROP MED INT HEALTH, V12, P68, DOI 10.1111/j.1365-3156.2006.01769.x; Basco LK, 2004, AM J TROP MED HYG, V70, P245, DOI 10.4269/ajtmh.2004.70.245; Bate R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002132; BATTERBY A, 2003, IMPROVING SUPPLY DIS, P1; BRAUN M, 2005, QUALITY ASSESSMENT A; Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x; Goodman C., 2004, THESIS U LONDON; Goodman C, 2007, AM J TROP MED HYG, V77, P203, DOI 10.4269/ajtmh.2007.77.203; Goodman C, 2007, HEALTH POLICY PLANN, V22, P393, DOI 10.1093/heapol/czm033; *GOV TANZ CLINT FD, TANZ PIL ACT SUBS RE; HANSON K, 2008, BMC PUBLI H IN PRESS; HETZEL M, 2006, MAL J, V5; Kachur SP, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-25; Minzi OMS, 2003, J CLIN PHARM THER, V28, P117, DOI 10.1046/j.1365-2710.2003.00470.x; Newton PN, 2008, PLOS MED, V5, P209, DOI 10.1371/journal.pmed.0050032; Risha PG, 2002, TROP MED INT HEALTH, V7, P701, DOI 10.1046/j.1365-3156.2002.00937.x; *TANZ NAT COORD ME, 2007, GLOB FUND PROP ROUND; *US PHARM CONV INC, 2000, M WASH DC APR 12 16; White N, 1999, PHILOS T R SOC B, V354, P739, DOI 10.1098/rstb.1999.0426; World Health Organization, 1999, DEF DIAGN CLASS DI 1; [No title captured]	23	53	53	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2008	3	10							e3403	10.1371/journal.pone.0003403	http://dx.doi.org/10.1371/journal.pone.0003403			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	432GP	18923672	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000265121800004
J	Ludwig, DS; Kabat-Zinn, J				Ludwig, David S.; Kabat-Zinn, Jon			Mindfulness in medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							STRESS REDUCTION; MEDITATION; PROGRAM		[Ludwig, David S.] Childrens Hosp, Dept Med, Boston, MA 02115 USA; [Kabat-Zinn, Jon] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Harvard University; Boston Children's Hospital; University of Massachusetts System; University of Massachusetts Worcester	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu		Ludwig, David/0000-0003-3307-8544				Creswell JD, 2007, PSYCHOSOM MED, V69, P560, DOI 10.1097/PSY.0b013e3180f6171f; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Grepmair L, 2007, PSYCHOTHER PSYCHOSOM, V76, P332, DOI 10.1159/000107560; Groopman J, 2007, DOCTORS THINK; KABATZINN J, 1982, GEN HOSP PSYCHIAT, V4, P33, DOI 10.1016/0163-8343(82)90026-3; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Ospina Maria B, 2007, Evid Rep Technol Assess (Full Rep), P1; Proulx Kathryn, 2008, Eat Disord, V16, P52, DOI 10.1080/10640260701773496; Santorelli S, 1998, HEAL THY SELF; Shapiro SL, 1998, J BEHAV MED, V21, P581, DOI 10.1023/A:1018700829825; Speca M, 2000, PSYCHOSOM MED, V62, P613, DOI 10.1097/00006842-200009000-00004; Tang YY, 2007, P NATL ACAD SCI USA, V104, P17152, DOI 10.1073/pnas.0707678104; Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037//0022-006X.68.4.615; Wansink B, 2005, OBES RES, V13, P93, DOI 10.1038/oby.2005.12	15	471	478	7	189	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 17	2008	300	11					1350	1352		10.1001/jama.300.11.1350	http://dx.doi.org/10.1001/jama.300.11.1350			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	348ST	18799450				2023-01-03	WOS:000259231100033
J	Robertson, NJ; Nakakeeto, M; Hagmann, C; Cowan, FM; Acolet, D; Iwata, O; Allen, E; Elbourne, D; Costello, A; Jacobs, I				Robertson, Nicola J.; Nakakeeto, Margaret; Hagmann, Cornelia; Cowan, Frances M.; Acolet, Dominique; Iwata, Osuke; Allen, Elizabeth; Elbourne, Diana; Costello, Anthony; Jacobs, Ian			Therapeutic hypothermia for birth asphyxia in low-resource settings: a pilot randomised controlled trial	LANCET			English	Letter							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; NEONATAL ENCEPHALOPATHY; NEWBORN		[Robertson, Nicola J.; Nakakeeto, Margaret; Hagmann, Cornelia; Jacobs, Ian] Uganda Womens Hlth Initiat, Kampala, Uganda; [Robertson, Nicola J.; Hagmann, Cornelia; Iwata, Osuke; Jacobs, Ian] UCL, EGA UCL Inst Womens Hlth, London WC1E 7HX, England; [Nakakeeto, Margaret] Mulago Hosp, Neonatal Unit, Kampala, Uganda; [Cowan, Frances M.; Acolet, Dominique] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Paediat & Imaging Sci, London, England; [Allen, Elizabeth; Elbourne, Diana] London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England; [Costello, Anthony] Inst Child Hlth, Int Perinatal Care Unit, London, England	University of London; University College London; Mulago National Referral Hospital; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London	Robertson, NJ (corresponding author), Uganda Womens Hlth Initiat, Kampala, Uganda.	n.robertson@ucl.ac.uk	Robertson, Nicola/GWR-2021-2022	Jacobs, Ian/0000-0002-5005-2672				BURNARD ED, 1958, BRIT MED J, V2, P1197, DOI 10.1136/bmj.2.5106.1197; Dubowitz L, 1998, J PEDIATR-US, V133, P406, DOI 10.1016/S0022-3476(98)70279-3; Ellis M, 2000, BMJ-BRIT MED J, V320, P1229, DOI 10.1136/bmj.320.7244.1229; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Horn AR, 2006, SAMJ S AFR MED J, V96, P976; IWATA S, IN PRESS ARCH DIS CH; JACOBS S, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003311.PUB2; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; SCHULZKE S, 2007, BMC PEDIAT, V5, P30; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Thompson CM, 1997, ACTA PAEDIATR, V86, P757, DOI 10.1111/j.1651-2227.1997.tb08581.x	12	131	137	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 6	2008	372	9641					801	803		10.1016/S0140-6736(08)61329-X	http://dx.doi.org/10.1016/S0140-6736(08)61329-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	347FB	18774411				2023-01-03	WOS:000259124900015
J	Contopoulos-Ioannidis, DG; Alexiou, GA; Gouvias, TC; Ioannidis, JPA				Contopoulos-Ioannidis, Despina G.; Alexiou, George A.; Gouvias, Theodore C.; Ioannidis, John P. A.			Medicine - Life cycle of translational research for medical interventions	SCIENCE			English	Editorial Material									[Alexiou, George A.; Gouvias, Theodore C.; Ioannidis, John P. A.] Univ Ioannina, Clin Trials & Evidence Based Med Unit, Dept Hyg & Epidemiol, Sch Med, GR-45110 Ioannina, Greece; [Contopoulos-Ioannidis, Despina G.] Univ Ioannina, Sch Med, Dept Pediat, GR-45110 Ioannina, Greece; [Contopoulos-Ioannidis, Despina G.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20037 USA; [Ioannidis, John P. A.] Tufts Med Ctr, Dept Med, Boston, MA 02111 USA; [Ioannidis, John P. A.] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA; [Ioannidis, John P. A.] Fdn Res & Technol Hellas, Inst Biomed Res, Ioannina, Greece	University of Ioannina; University of Ioannina; George Washington University; Tufts Medical Center; Tufts University; Foundation for Research & Technology - Hellas (FORTH)	Ioannidis, JPA (corresponding author), Univ Ioannina, Clin Trials & Evidence Based Med Unit, Dept Hyg & Epidemiol, Sch Med, GR-45110 Ioannina, Greece.	jioannid@cc.uoi.gr	Ioannidis, John P. A./G-9836-2011; Alexiou, George A/B-3995-2012	Alexiou, George A/0000-0003-0257-4481				Booth B, 2004, NAT REV DRUG DISCOV, V3, P451, DOI 10.1038/nrd1384; Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a; Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5; Cuatrecasas P, 2006, J CLIN INVEST, V116, P2837, DOI 10.1172/JCI29999; Duyk G, 2003, SCIENCE, V302, P603, DOI 10.1126/science.1090521; Hackam DG, 2006, JAMA-J AM MED ASSOC, V296, P1731, DOI 10.1001/jama.296.14.1731; Ioannidis JP, 2004, J TRANSL MED, V2, P5, DOI DOI 10.1186/1479-5876-2-5; Ioannidis JPA, 2005, JAMA-J AM MED ASSOC, V294, P218, DOI 10.1001/jama.294.2.218; Marincola Francesco M, 2003, J Transl Med, V1, P1, DOI 10.1186/1479-5876-1-1; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Zerhouni EA, 2005, JAMA-J AM MED ASSOC, V294, P1352, DOI 10.1001/jama.294.11.1352; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	12	133	140	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 5	2008	321	5894					1298	1299		10.1126/science.1160622	http://dx.doi.org/10.1126/science.1160622			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	344GG	18772421				2023-01-03	WOS:000258914300031
J	Riemersma-van Der Lek, RF; Swaab, DF; Twisk, J; Hol, EM; Hoogendijk, WJG; Van Someren, EJW				Riemersma-van der Lek, Rixt F.; Swaab, Dick F.; Twisk, Jos; Hol, Elly M.; Hoogendijk, Witte J. G.; Van Someren, Eus J. W.			Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIAL; LONG-TERM-CARE; ALZHEIMERS-DISEASE; NURSING-HOME; SUPRACHIASMATIC NUCLEUS; STATISTICAL ISSUES; CORNELL SCALE; WORK GROUP; DEMENTIA; SLEEP	Context Cognitive decline, mood, behavioral and sleep disturbances, and limitations of activities of daily living commonly burden elderly patients with dementia and their caregivers. Circadian rhythm disturbances have been associated with these symptoms. Objective To determine whether the progression of cognitive and noncognitive symptoms may be ameliorated by individual or combined long- term application of the 2 major synchronizers of the circadian timing system: bright light and melatonin. Design, Setting, and Participants A long- term, double- blind, placebo-controlled, 2 x 2 factorial randomized trial performed from 1999 to 2004 with 189 residents of 12 group care facilities in the Netherlands; mean ( SD) age, 85.8 ( 5.5) years; 90% were female and 87% had dementia. Interventions Random assignment by facility to long- term daily treatment with whole-day bright ( +/- 1000 lux) or dim ( +/- 300 lux) light and by participant to evening melatonin ( 2.5 mg) or placebo for a mean ( SD) of 15 ( 12) months ( maximum period of 3.5 years). Main Outcome Measures Standardized scales for cognitive and noncognitive symptoms, limitations of activities of daily living, and adverse effects assessed every 6 months. Results Light attenuated cognitive deterioration by a mean of 0.9 points ( 95% confidence interval [ CI], 0.04- 1.71) on the Mini- Mental State Examination or a relative 5%. Light also ameliorated depressive symptoms by 1.5 points ( 95% CI, 0.24- 2.70) on the Cornell Scale for Depression in Dementia or a relative 19%, and attenuated the increase in functional limitations over time by 1.8 points per year( 95% CI, 0.61- 2.92) on the nurse-informant activities of daily living scale or a relative 53% difference. Melatonin shortened sleep onset latency by 8.2 minutes( 95% CI, 1.08- 15.38) or 19% and increased sleep duration by 27 minutes( 95% CI, 9- 46) or6%. However, melatonin adversely affected scores on the Philadelphia Geriatric Centre Affect Rating Scale, both for positive affect (- 0.5 points; 95% CI, - 0.10 to - 1.00) and negative affect ( 0.8 points; 95% CI, 0.20- 1.44). Melatonin also increased withdrawn behavior by 1.02 points ( 95% CI, 0.18- 1.86) on the Multi Observational Scale for Elderly Subjects scale, although this effect was not seen if given in combination with light. Combined treatment also attenuated aggressive behavior by 3.9 points ( 95% CI, 0.88- 6.92) on the Cohen- Mansfield Agitation Index or 9%, increased sleep efficiency by 3.5% ( 95% CI, 0.8%- 6.1%), and improved nocturnal restlessness by 1.00 minute per hour each year ( 95% CI, 0.26- 1.78) or 9% ( treatment x time effect). Conclusions Light has a modest benefit in improving some cognitive and noncognitive symptoms of dementia. To counteract the adverse effect of melatonin on mood, it is recommended only in combination with light. Trial Registration controlled- trials. com/isrctn Identifier: ISRCTN93133646.	[Riemersma-van der Lek, Rixt F.; Swaab, Dick F.; Hol, Elly M.; Van Someren, Eus J. W.] Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, NL-1105 BA Amsterdam, Netherlands; [Twisk, Jos] Vrije Univ Amsterdam Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands; [Hoogendijk, Witte J. G.] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Dept Clin Neurophysiol, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Dept Med Psychol, Amsterdam, Netherlands; [Hoogendijk, Witte J. G.] Vrije Univ Amsterdam Med Ctr, Res Inst Neurosci CNCR, Amsterdam, Netherlands; [Van Someren, Eus J. W.] Vrije Univ Amsterdam Med Ctr, Alzheimer Ctr, Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Van Someren, EJW (corresponding author), Royal Netherlands Acad Arts & Sci, Netherlands Inst Neurosci, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.	e.van.someren@nin.knaw.nl	Hol, Elly/J-2025-2019; Van Someren, Eus/AAA-6789-2020; Hol, Elly M/F-1891-2013	Hol, Elly/0000-0001-5604-2603; Hol, Elly M/0000-0001-5604-2603; Swaab, Dick/0000-0002-9665-7845				ALEXOPOULOS GS, 1988, BIOL PSYCHIAT, V23, P271, DOI 10.1016/0006-3223(88)90038-8; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; AncoliIsrael S, 1997, SLEEP, V20, P24, DOI 10.1093/sleep/20.1.24; Banerjee S, 2003, J NEUROL NEUROSUR PS, V74, P1315, DOI 10.1136/jnnp.74.9.1315; Bentham P, 2004, LANCET, V363, P2105; Burback D, 1999, DEMENT GERIATR COGN, V10, P534, DOI 10.1159/000017201; CARMAN JS, 1976, AM J PSYCHIAT, V133, P1181; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cho KW, 2001, NAT NEUROSCI, V4, P567, DOI 10.1038/88384; COHENMANSFIELD J, 1989, J GERONTOL, V44, pM77, DOI 10.1093/geronj/44.3.M77; de Jonghe J F M, 2003, Tijdschr Gerontol Geriatr, V34, P74; deJonghe JFM, 1996, J AM GERIATR SOC, V44, P888, DOI 10.1111/j.1532-5415.1996.tb03762.x; Devanand DP, 1997, ARCH GEN PSYCHIAT, V54, P257; Donaldson C, 1998, INT J GERIATR PSYCH, V13, P248; Dorenlot P, 2005, INT J GERIATR PSYCH, V20, P471, DOI 10.1002/gps.1238; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; FEKETE M, 1985, PHYSIOL BEHAV, V34, P883, DOI 10.1016/0031-9384(85)90008-3; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Gimeno V, 1998, NEUROPSYCHOBIOLOGY, V38, P108, DOI 10.1159/000026525; Gonzalez-Salvador T, 2000, INT J GERIATR PSYCH, V15, P181, DOI 10.1002/(SICI)1099-1166(200002)15:2<181::AID-GPS96>3.0.CO;2-I; Harwood DG, 1998, AM J GERIAT PSYCHIAT, V6, P212; HELMES E, 1987, J GERONTOL, V42, P395, DOI 10.1093/geronj/42.4.395; HOLMES D, 1990, GERONTOLOGIST, V30, P178, DOI 10.1093/geront/30.2.178; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/appi.neuropsych.12.2.233; Kavirajan H, 2007, LANCET NEUROL, V6, P782, DOI 10.1016/S1474-4422(07)70195-3; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; Lawton MP, 1996, J GERONTOL B-PSYCHOL, V51, pP3, DOI 10.1093/geronb/51B.1.P3; LAWTON MP, 1975, J GERONTOL, V30, P85, DOI 10.1093/geronj/30.1.85; Lee HCB, 2003, BIOL PSYCHIAT, V54, P353, DOI 10.1016/S0006-3223(03)00543-2; Liu RY, 2000, J NEUROPATH EXP NEUR, V59, P314, DOI 10.1093/jnen/59.4.314; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Middleton B, 2002, NEUROSCI LETT, V329, P41, DOI 10.1016/S0304-3940(02)00574-8; MISHIMA K, 1994, ACTA PSYCHIAT SCAND, V89, P1, DOI 10.1111/j.1600-0447.1994.tb01477.x; MOE KE, 1995, J SLEEP RES, V4, P15, DOI 10.1111/j.1365-2869.1995.tb00145.x; Moore RY, 1996, PROG BRAIN RES, V111, P103, DOI 10.1016/S0079-6123(08)60403-3; Petkova E, 2002, PSYCHOSOM MED, V64, P531, DOI 10.1097/00006842-200205000-00018; Purandare N, 2001, INT J GERIATR PSYCH, V16, P960, DOI 10.1002/gps.449; RIEMERSMA RF, 2004, NEUROENDOCRINE IMMUN, V4, P195; Ryden M B, 1989, J Gerontol Nurs, V15, P27; Salzman C, 2002, BIOL PSYCHIAT, V52, P265, DOI 10.1016/S0006-3223(02)01337-9; Serfaty M, 2002, INT J GERIATR PSYCH, V17, P1120, DOI 10.1002/gps.760; Siddiqui O, 1998, J Biopharm Stat, V8, P545; Singer C, 2003, SLEEP, V26, P893, DOI 10.1093/sleep/26.7.893; Sink KM, 2005, JAMA-J AM MED ASSOC, V293, P596, DOI 10.1001/jama.293.5.596; Slaughter S, 2006, J AM GERIATR SOC, V54, P1436, DOI 10.1111/j.1532-5415.2006.00851.x; Sloane P., 1990, AM J ALZHEIMER CARE, P22, DOI DOI 10.1177/153331759000500606; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; TOZAWA T, 1998, NEUROBIOL AGING, V19, pS182; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; TWISK JWR, 2003, APPL LONGITUDINAL DA, P280; Van Someren EJW, 2000, EXP GERONTOL, V35, P1229, DOI 10.1016/S0531-5565(00)00191-1; Van Someren EJW, 1999, CHRONOBIOL INT, V16, P505, DOI 10.3109/07420529908998724; Van Someren EJW, 2002, PROG BRAIN RES, V138, P205, DOI 10.1016/S0079-6123(02)38080-4; Van Someren EJW, 2007, SLEEP MED REV, V11, P465, DOI 10.1016/j.smrv.2007.07.003; Van Someren EJW, 2007, J SLEEP RES, V16, P269, DOI 10.1111/j.1365-2869.2007.00592.x; VanSomeren EJW, 1997, BIOL PSYCHIAT, V41, P955, DOI 10.1016/S0006-3223(97)89928-3; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Zhdanova IV, 2001, J CLIN ENDOCR METAB, V86, P4727, DOI 10.1210/jc.86.10.4727; Zhdanova IV, 1997, SLEEP, V20, P899; Zhou JN, 2001, ARCH GEN PSYCHIAT, V58, P655, DOI 10.1001/archpsyc.58.7.655	62	455	462	3	103	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 11	2008	299	22					2642	2655		10.1001/jama.299.22.2642	http://dx.doi.org/10.1001/jama.299.22.2642			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311FN	18544724	Bronze			2023-01-03	WOS:000256586200021
J	Thomas, SJ; Hughes, C; Atkinson, C; Ness, AR; Revington, P				Thomas, Steven J.; Hughes, Ceri; Atkinson, Charlotte; Ness, Andrew R.; Revington, Peter			Is there an epidemic of admissions for surgical treatment of dental abscesses in the UK?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							GREAT-BRITAIN; EXPERIENCE; CHILDREN		[Thomas, Steven J.; Hughes, Ceri] Univ Bristol, Div Oral & Maxillofacial Surg, Bristol BS1 2LY, Avon, England; [Atkinson, Charlotte; Ness, Andrew R.] Univ Bristol, Dept Oral & Dent Sci, Bristol BS1 2LY, Avon, England; [Revington, Peter] N Bristol NHS Trust, Bristol BS16 1LE, Avon, England	University of Bristol; University of Bristol; North Bristol NHS Trust	Thomas, SJ (corresponding author), Univ Bristol, Div Oral & Maxillofacial Surg, Bristol BS1 2LY, Avon, England.	Steve.Thomas@bristol.ac.uk	Berryman, Katie/J-4236-2014; Atkinson, Charlotte/AGA-4037-2022; Ness, Andy R/M-7612-2013	Ness, Andy R/0000-0003-3548-9523				Bulut M, 2004, EMERG MED J, V21, P122, DOI 10.1136/emj.2003.002865; Carter L, 2006, BRIT DENT J, V200, P243, DOI 10.1038/sj.bdj.4813368; Green AW, 2001, BRIT DENT J, V190, P529, DOI 10.1038/sj.bdj.4801024a; Morris G, 2006, BRIT DENT J, V200, P601, DOI 10.1038/sj.bdj.4813695; *NAT AUD OFF, 2004, REF NHS DENT ENS EFF; *NAT COMM PAT PUBL, 2007, DENT WATCH REP; *NAT I HLTH CLIN E, 2004, DENT REC REC INT ROU; *OFF NAT STAT, 2000, AD DENT HLTH SURV OR; Pitts NB, 2007, COMMUNITY DENT HLTH, V24, P59; Pitts NB, 2006, COMMUNITY DENT HLTH, V23, P44; Steele JG, 2000, BRIT DENT J, V189, P598, DOI 10.1038/sj.bdj.4800840a	11	40	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 31	2008	336	7655					1219	1220		10.1136/bmj.39549.605602.BE	http://dx.doi.org/10.1136/bmj.39549.605602.BE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	311PS	18511797	Green Published			2023-01-03	WOS:000256612700027
J	McGuigan, AP; Bruzewicz, DA; Glavan, A; Butte, M; Whitesides, GM				McGuigan, Alison P.; Bruzewicz, Derek A.; Glavan, Ana; Butte, Manish; Whitesides, George M.			Cell Encapsulation in Sub-mm Sized Gel Modules Using Replica Molding	PLOS ONE			English	Article							3-DIMENSIONAL CULTURES; COLLAGEN GEL; HEPATOCYTES; FIBROBLASTS; CONTRACTION; FABRICATION; MICROARRAY; SPHEROIDS; PHENOTYPE; HYDROGEL	For many types of cells, behavior in two-dimensional (2D) culture differs from that in three-dimensional (3D) culture. Among biologists, 2D culture on treated plastic surfaces is currently the most popular method for cell culture. In 3D, no analogous standard method-one that is similarly convenient, flexible, and reproducible-exists. This paper describes a soft-lithographic method to encapsulate cells in 3D gel objects (modules) in a variety of simple shapes (cylinders, crosses, rectangular prisms) with lateral dimensions between 40 and 1000 mu m, cell densities of 10(5) - 10(8) cells/cm(3), and total volumes between 1x10(-7) and 8x10(-4) cm(3). By varying (i) the initial density of cells at seeding, and (ii) the dimensions of the modules, the number of cells per module ranged from 1 to 2500 cells. Modules were formed from a range of standard biopolymers, including collagen, Matrigel (TM), and agarose, without the complex equipment often used in encapsulation. The small dimensions of the modules allowed rapid transport of nutrients by diffusion to cells at any location in the module, and therefore allowed generation of modules with cell densities near to those of dense tissues (10(8) - 10(9) cells/cm(3)). This modular method is based on soft lithography and requires little special equipment; the method is therefore accessible, flexible, and well suited to (i) understanding the behavior of cells in 3D environments at high densities of cells, as in dense tissues, and (ii) developing applications in tissue engineering.	[McGuigan, Alison P.; Bruzewicz, Derek A.; Glavan, Ana; Butte, Manish; Whitesides, George M.] Harvard Univ, Cambridge, MA 02138 USA	Harvard University	McGuigan, AP (corresponding author), Harvard Univ, Cambridge, MA 02138 USA.	gwhitesides@gmwgroup.harvard.edu	Butte, Manish/AAM-8604-2020; McGuigan, Alison/B-4744-2010; Butte, Manish/T-8860-2019	Butte, Manish/0000-0002-4490-5595; Butte, Manish/0000-0002-4490-5595; McGuigan, Alison/0000-0003-2803-0917	NIH EHS [GM 065364]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065364] Funding Source: NIH RePORTER	NIH EHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH EHS grant GM 065364	Abu-Absi SF, 2002, EXP CELL RES, V274, P56, DOI 10.1006/excr.2001.5467; AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; Albrecht DR, 2005, LAB CHIP, V5, P111, DOI 10.1039/b406953f; [Anonymous], PRINCIPLES TISSUE EN; Barralet JE, 2005, J MATER SCI-MATER M, V16, P515, DOI 10.1007/s10856-005-0526-z; BELL E, 1979, P NATL ACAD SCI USA, V76, P1274, DOI 10.1073/pnas.76.3.1274; Berthiaume F, 1996, FASEB J, V10, P1471, DOI 10.1096/fasebj.10.13.8940293; Bhatia SN, 1999, FASEB J, V13, P1883, DOI 10.1096/fasebj.13.14.1883; Choi NW, 2007, NAT MATER, V6, P908, DOI 10.1038/nmat2022; Cygan ZT, 2005, LANGMUIR, V21, P3629, DOI 10.1021/la0471137; Ehrlich HP, 2000, J CELL PHYSIOL, V185, P432, DOI 10.1002/1097-4652(200012)185:3<432::AID-JCP14>3.0.CO;2-R; Feinberg AW, 2007, SCIENCE, V317, P1366, DOI 10.1126/science.1146885; FINESMITH TH, 1990, J CELL PHYSIOL, V144, P99, DOI 10.1002/jcp.1041440113; Fukuda J, 2006, BIOMATERIALS, V27, P5259, DOI 10.1016/j.biomaterials.2006.05.044; Hui EE, 2007, P NATL ACAD SCI USA, V104, P5722, DOI 10.1073/pnas.0608660104; Humphreys P, 1996, J NEUROSCI METH, V66, P23, DOI 10.1016/0165-0270(95)00142-5; Kamamoto F, 2003, ARTIF ORGANS, V27, P701, DOI 10.1046/j.1525-1594.2003.07277.x; Karp JM, 2007, LAB CHIP, V7, P786, DOI 10.1039/b705085m; Kono Y, 1996, BIOCHEM BIOPH RES CO, V220, P628, DOI 10.1006/bbrc.1996.0454; LAZAR A, 1995, IN VITRO CELL DEV-AN, V31, P340, DOI 10.1007/BF02634282; LAZAR A, 1995, CELL TRANSPLANT, V4, P259, DOI 10.1016/0963-6897(94)00058-R; Li GN, 2007, TISSUE ENG, V13, P1035, DOI 10.1089/ten.2006.0251; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Liu H, 2005, TISSUE ENG, V11, P319, DOI 10.1089/ten.2005.11.319; McGuigan AP, 2006, NAT PROTOC, V1, P2963, DOI 10.1038/nprot.2006.443; Mcguigan AP, 2007, TISSUE ENG, V13, P1069, DOI 10.1089/ten.2006.0253; McGuigan AP, 2006, P NATL ACAD SCI USA, V103, P11461, DOI 10.1073/pnas.0602740103; MORRA M, 1990, Clinical Materials, V5, P147, DOI 10.1016/0267-6605(90)90014-M; Nomi M, 2002, MOL ASPECTS MED, V23, P463, DOI 10.1016/S0098-2997(02)00008-0; PHILLIPS HJ, 1957, EXP CELL RES, V13, P341, DOI 10.1016/0014-4827(57)90013-7; Powers MJ, 2002, TISSUE ENG, V8, P499, DOI 10.1089/107632702760184745; Puri S, 2007, DEV BIOL, V306, P82, DOI 10.1016/j.ydbio.2007.03.003; Radisic M, 2006, TISSUE ENG, V12, P2077, DOI 10.1089/ten.2006.12.2077; SORANZO C, 1986, TUMORI, V72, P459, DOI 10.1177/030089168607200502; Tan W, 2005, J BIOMED MATER RES A, V72A, P146, DOI 10.1002/jbm.a.30182; Tan W, 2004, BIOMATERIALS, V25, P1355, DOI 10.1016/j.biomaterials.2003.08.021; Tan W, 2003, BIOMED MICRODEVICES, V5, P235, DOI 10.1023/A:1025764310391; Tsang VL, 2007, FASEB J, V21, P790, DOI 10.1096/fj.06-7117com; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Yeh J, 2006, BIOMATERIALS, V27, P5391, DOI 10.1016/j.biomaterials.2006.06.005	41	75	76	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2008	3	5							e2258	10.1371/journal.pone.0002258	http://dx.doi.org/10.1371/journal.pone.0002258			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	391UK	18493609	Green Published, gold			2023-01-03	WOS:000262258700058
J	Applbaum, AI; Tilburt, JC; Collins, MT; Wendler, D				Applbaum, Arthur Isak; Tilburt, Jon C.; Collins, Michael T.; Wendler, David			A family's request for complementary medicine after patient brain death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; FUTILITY	A 19- year- old woman living with relatives in the United States who was admitted for elective cranial surgery for complications related to a congenital disorder developed an acute intracranial hemorrhage 10 days after surgery. The patient was declared dead following repeat negative apnea tests. The patient's father requested that the treating team administer an unverified traditional medicinal substance to the patient. Because of the unusual nature of this request, the treating team called an ethics consultation. The present article reviews this case and discusses other cases that share key features to determine whether and when it is appropriate to accommodate requests for interventions on patients who have been declared dead.	[Wendler, David] NIH, Dept Bioeth, Bethesda, MD 20892 USA; [Applbaum, Arthur Isak] Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; [Applbaum, Arthur Isak] Harvard Univ, Edmond J Safra Fdn Ctr Eth, Cambridge, MA 02138 USA; [Tilburt, Jon C.] Mayo Clin, Rochester, MN USA; [Collins, Michael T.] NIDR, Clin Studies Unit, Cranial Facial & Skeletal Dis Branch, Bethesda, MD 20892 USA; [Collins, Michael T.] Natl Inst Craniofacial Res, Clin Studies Unit, Cranial Facial & Skeletal Dis Branch, Bethesda, MD USA; [Wendler, David] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; Harvard University; Harvard University; Mayo Clinic; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC)	Wendler, D (corresponding author), NIH, Dept Bioeth, 1C-119 Bldg 10, Bethesda, MD 20892 USA.	dwendler@cc.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000649] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DE000649-13] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; *NEW YORK STAT DEP, GUID DET BRAIN DEATH; Rawls J., 1995, POLITICAL LIBERALISM; SCHAUER F, 1985, HARVARD LAW REV, V99, P361, DOI 10.2307/1341127; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Truog RD, 2007, J LAW MED ETHICS, V35, P273, DOI 10.1111/j.1748-720X.2007.00136.x; von Gunten CF, 2000, JAMA-J AM MED ASSOC, V284, P3051, DOI 10.1001/jama.284.23.3051	9	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 14	2008	299	18					2188	2193		10.1001/jama.299.18.2188	http://dx.doi.org/10.1001/jama.299.18.2188			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	299XX	18477786	Green Accepted			2023-01-03	WOS:000255790000026
J	Levine, S; Nguyen, T; Taylor, N; Friscia, ME; Budak, MT; Rothenberg, P; Zhu, JL; Sachdeva, R; Sonnad, S; Kaiser, LR; Rubinstein, NA; Powers, SK; Shrager, JB				Levine, Sanford; Nguyen, Taitan; Taylor, Nyali; Friscia, Michael E.; Budak, Murat T.; Rothenberg, Pamela; Zhu, Jianliang; Sachdeva, Rajeev; Sonnad, Seema; Kaiser, Larry R.; Rubinstein, Neal A.; Powers, Scott K.; Shrager, Joseph B.			Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; UBIQUITIN-PROTEASOME PATHWAY; SKELETAL-MUSCLE; OXIDATIVE STRESS; INJURY; MECHANISMS; EXPRESSION; CYTOKINES; FAILURE; MYOSIN	Background: The combination of complete diaphragm inactivity and mechanical ventilation (for more than 18 hours) elicits disuse atrophy of myofibers in animals. We hypothesized that the same may also occur in the human diaphragm. Methods: We obtained biopsy specimens from the costal diaphragms of 14 brain-dead organ donors before organ harvest (case subjects) and compared them with intraoperative biopsy specimens from the diaphragms of 8 patients who were undergoing surgery for either benign lesions or localized lung cancer (control subjects). Case subjects had diaphragmatic inactivity and underwent mechanical ventilation for 18 to 69 hours; among control subjects diaphragmatic inactivity and mechanical ventilation were limited to 2 to 3 hours. We carried out histologic, biochemical, and gene-expression studies on these specimens. Results: As compared with diaphragm-biopsy specimens from controls, specimens from case subjects showed decreased cross-sectional areas of slow-twitch and fast-twitch fibers of 57% (P=0.001) and 53% (P=0.01), respectively, decreased glutathione concentration of 23% (P=0.01), increased active caspase-3 expression of 100% (P=0.05), a 200% higher ratio of atrogin-1 messenger RNA (mRNA) transcripts to MBD4 (a housekeeping gene) (P=0.002), and a 590% higher ratio of MuRF-1 mRNA transcripts to MBD4 (P=0.001). Conclusions: The combination of 18 to 69 hours of complete diaphragmatic inactivity and mechanical ventilation results in marked atrophy of human diaphragm myofibers. These findings are consistent with increased diaphragmatic proteolysis during inactivity.	[Levine, Sanford; Nguyen, Taitan; Taylor, Nyali; Friscia, Michael E.; Budak, Murat T.; Rothenberg, Pamela; Zhu, Jianliang; Sonnad, Seema; Kaiser, Larry R.; Shrager, Joseph B.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Rubinstein, Neal A.] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA; [Levine, Sanford; Budak, Murat T.; Rubinstein, Neal A.; Shrager, Joseph B.] Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; [Levine, Sanford] Gift Life Donor Program, Philadelphia, PA USA; [Levine, Sanford; Nguyen, Taitan; Sachdeva, Rajeev; Shrager, Joseph B.] Dept Vet Affairs Med Ctr, Med Res Surg & Lab Med Serv, Philadelphia, PA 19104 USA; [Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Gainesville, FL 32611 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; State University System of Florida; University of Florida	Levine, S (corresponding author), 1495 Wesleys Run, Gladwyne, PA 19035 USA.	sdlevine@mail.med.upenn.edu	Budak, Murat/I-8358-2013; Kaiser, Larry/L-7940-2019	Budak, Murat/0000-0002-5059-9651; 	NHLBI NIH HHS [R01-HL-078834] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078834] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams GR, 2003, J APPL PHYSIOL, V95, P2185, DOI 10.1152/japplphysiol.00346.2003; AMADO JA, 1995, METABOLISM, V44, P812, DOI 10.1016/0026-0495(95)90198-1; Belperio JA, 2006, SEMIN RESP CRIT CARE, V27, P350, DOI 10.1055/s-2006-948289; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Castro MJ, 1999, J APPL PHYSIOL, V86, P350, DOI 10.1152/jappl.1999.86.1.350; Conover W.J., 1999, PRACTICAL NONPARAMET, V3rd; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Falk DJ, 2006, J APPL PHYSIOL, V101, P1017, DOI 10.1152/japplphysiol.00104.2006; Gayan-Ramirez G, 2005, CRIT CARE MED, V33, P2804, DOI 10.1097/01.CCM.0000191250.32988.A3; Hudson NJ, 2002, J EXP BIOL, V205, P2297; Laghi F, 2003, AM J RESP CRIT CARE, V167, P120, DOI 10.1164/rccm.200210-1246OC; Larionov A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-62; Lawler JM, 1998, CAN J APPL PHYSIOL, V23, P23, DOI 10.1139/h98-002; Levine S, 2003, AM J RESP CRIT CARE, V168, P706, DOI 10.1164/rccm.200209-1070OC; Levine S, 2006, J APPL PHYSIOL, V101, P1297, DOI 10.1152/japplphysiol.01607.2005; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Moore AJ, 2006, J APPL PHYSIOL, V101, P1400, DOI 10.1152/japplphysiol.01614.2005; NARUSAWA M, 1987, J CELL BIOL, V104, P447, DOI 10.1083/jcb.104.3.447; NAUMANN K, 1994, DIFFERENTIATION, V55, P203, DOI 10.1046/j.1432-0436.1994.5530203.x; Ohira Y, 2000, JPN J PHYSIOL, V50, P41, DOI 10.2170/jjphysiol.50.41; Powers SK, 2005, AM J PHYSIOL-REG I, V288, pR337, DOI 10.1152/ajpregu.00469.2004; Reid MB, 2005, AM J PHYSIOL-REG I, V288, pR1423, DOI 10.1152/ajpregu.00545.2004; Sacheck JM, 2007, FASEB J, V21, P140, DOI 10.1096/fj.06-6604com; Shanely RA, 2002, AM J RESP CRIT CARE, V166, P1369, DOI 10.1164/rccm.200202-088OC; Trapp R.G., 2004, BASIC CLIN BIOSTATIS, V4th; Vassilakopoulos T, 2004, AM J RESP CRIT CARE, V169, P336, DOI 10.1164/rccm.200304-489CP; VATER R, 1994, HISTOCHEM J, V26, P916	29	887	972	4	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 27	2008	358	13					1327	1335		10.1056/NEJMoa070447	http://dx.doi.org/10.1056/NEJMoa070447			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	278TE	18367735				2023-01-03	WOS:000254308400003
J	Svetkey, LP; Stevens, VJ; Brantley, PJ; Appel, LJ; Hollis, JF; Loria, CM; Vollmer, WM; Gullion, CM; Funk, K; Smith, P; Samuel-Hodge, C; Myers, V; Lien, LF; Laferriere, D; Kennedy, B; Jerome, GJ; Heinith, F; Harsha, DW; Evans, P; Erlinger, TP; Dalcin, AT; Coughlin, J; Charleston, J; Champagne, CM; Bauck, A; Ard, JD; Aicher, K				Svetkey, Laura P.; Stevens, Victor J.; Brantley, Phillip J.; Appel, Lawrence J.; Hollis, Jack F.; Loria, Catherine M.; Vollmer, William M.; Gullion, Christina M.; Funk, Kristine; Smith, Patti; Samuel-Hodge, Carmen; Myers, Valerie; Lien, Lillian F.; Laferriere, Daniel; Kennedy, Betty; Jerome, Gerald J.; Heinith, Fran; Harsha, David W.; Evans, Pamela; Erlinger, Thomas P.; Dalcin, Arline T.; Coughlin, Janelle; Charleston, Jeanne; Champagne, Catherine M.; Bauck, Alan; Ard, Jamy D.; Aicher, Kathleen		Weight Loss Maintenance Collaborat	Comparison of strategies for sustaining weight loss - The weight loss maintenance randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIFE-STYLE INTERVENTION; BLOOD-PRESSURE; DIETARY PATTERNS; CONTROL REGISTRY; MISSING DATA; HYPERTENSION; OVERWEIGHT; REDUCTION; METAANALYSIS; PREVENTION	Context Behavioral weight loss interventions achieve short- term success, but regain is common. Objective To compare 2 weight loss maintenance interventions with a self- directed control group. Design, Setting, and Participants Two- phase trial in which 1032 overweight or obese adults ( 38% African American, 63% women) with hypertension, dyslipidemia, or both who had lost at least 4 kg during a 6- month weight loss program ( phase 1) were randomized to a weight- loss maintenance intervention ( phase 2). Enrollment at 4 academic centers occurred August 2003- July 2004 and randomization, February-December 2004. Data collection was completed in June 2007. Interventions After the phase 1 weight- loss program, participants were randomized to one of the following groups for 30 months: monthly personal contact, unlimited access to an interactive technology - based intervention, or self- directed control. Main Outcome Changes in weight from randomization. Results Mean entry weight was 96.7 kg. During the initial 6- month program, mean weight loss was 8.5 kg. After randomization, weight regain occurred. Participants in the personal- contact group regained less weight ( 4.0 kg) than those in the self- directed group ( 5.5 kg; mean difference at 30 months, - 1.5 kg; 95% confidence interval [ CI], - 2.4 to - 0.6 kg; P=. 001). At 30 months, weight regain did not differ between the interactive technology - based ( 5.2 kg) and self- directed groups ( 5.5 kg; mean difference - 0.3 kg; 95% CI, - 1.2 to 0.6 kg; P=. 51); however, weight regain was lower in the interactive technology - based than in the self- directed group at 18 months ( mean difference, - 1.1 kg; 95% CI, - 1.9 to - 0.4 kg; P=. 003) and at 24 months ( mean difference, - 0.9 kg; 95% CI, - 1.7 to - 0.02 kg; P=. 04). At 30 months, the difference between the personal-contact and interactive technology - based group was - 1.2 kg ( 95% CI - 2.1 to - 0.3; P=. 008). Effects did not differ significantly by sex, race, age, and body mass index subgroups. Overall, 71% of study participants remained below entry weight. Conclusions The majority of individuals who successfully completed an initial behavioral weight loss program maintained a weight below their initial level. Monthly brief personal contact provided modest benefit in sustaining weight loss, whereas an interactive techonology - based intervention provided early but transient benefit. Trial Registration clinicaltrials. gov Identifier: NCT00054925.	[Svetkey, Laura P.; Aicher, Kathleen] Duke Univ, Med Ctr, Duke Hypertens Ctr, Div Nephrol,Dept Med, Durham, NC 27710 USA; [Lien, Lillian F.] Duke Univ, Med Ctr, Duke Hypertens Ctr, Div Endocrinol,Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Sarah W Stedman Nutr & Metab Ctr, Durham, NC 27710 USA; [Stevens, Victor J.; Hollis, Jack F.; Vollmer, William M.; Gullion, Christina M.; Funk, Kristine; Laferriere, Daniel; Heinith, Fran; Evans, Pamela; Bauck, Alan] Kaiser Permanente NW, Hlth Sci Programs, Ctr Hlth Res, Portland, OR USA; [Brantley, Phillip J.; Smith, Patti; Myers, Valerie] Louisiana State Univ, Pennington Biomed Res Ctr, Behav Med Lab, Baton Rouge, LA 70808 USA; [Appel, Lawrence J.; Jerome, Gerald J.; Dalcin, Arline T.; Coughlin, Janelle; Charleston, Jeanne] Johns Hopkins Univ, Prohlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA; [Loria, Catherine M.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA; [Samuel-Hodge, Carmen] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; [Samuel-Hodge, Carmen] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Erlinger, Thomas P.] Univ Texas Austin, Med Branch, Dept Med, Austin, TX 78712 USA; [Ard, Jamy D.] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA	Duke University; Duke University; Duke University; Kaiser Permanente; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Texas System; University of Texas Austin; University of Alabama System; University of Alabama Birmingham	Svetkey, LP (corresponding author), Duke Univ, Med Ctr, Duke Hypertens Ctr, Div Nephrol,Dept Med, Box 3075, Durham, NC 27710 USA.	Svetk001@mc.duke.edu	Appel, Larry/GLT-2608-2022; Jerome, Gerald/R-2979-2018; Champagne, Catherine/N-1956-2017; Brantley, Phillip/N-1952-2017	Jerome, Gerald/0000-0003-0612-2626; Champagne, Catherine/0000-0001-6127-1072; Brantley, Phillip/0000-0003-4721-7445; Ard, Jamy/0000-0002-1643-6795; Samuel-Hodge, Carmen D/0000-0002-3700-7578; Coughlin, Janelle/0000-0001-7924-5892	NHLBI NIH HHS [5-U01 HL68790, 5-U01 HL68734, 5-U01 HL68920, 5-U01 HL68676, -HL68955] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL068734, U01HL068676, U01HL068955, U01HL068790, U01HL068920] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aickin M, 1996, AM J PUBLIC HEALTH, V86, P726, DOI 10.2105/AJPH.86.5.726; Appel Lawrence J., 1995, Annals of Epidemiology, V5, P149, DOI 10.1016/1047-2797(94)00059-3; Appel LJ, 2003, JAMA-J AM MED ASSOC, V289, P2083, DOI 10.1001/jama.289.16.2083; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Appel LJ, 2000, CIRCULATION, V102, P852, DOI 10.1161/01.CIR.102.8.852; Ard JD, 2000, J NATL MED ASSOC, V92, P515; Bassett DR, 2000, MED SCI SPORT EXER, V32, pS471, DOI 10.1097/00005768-200009001-00006; BRANTLEY PJ, IN PRESS J SOC CLIN; Collins LM, 2001, PSYCHOL METHODS, V6, P330, DOI 10.1037//1082-989X.6.4.330; Dansinger ML, 2007, ANN INTERN MED, V147, P41, DOI 10.7326/0003-4819-147-1-200707030-00007; Eddy DM, 2005, ANN INTERN MED, V143, P251, DOI 10.7326/0003-4819-143-4-200508160-00006; ELMER PJ, 1995, PREV MED, V24, P378, DOI 10.1006/pmed.1995.1062; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Hamman RF, 2006, DIABETES CARE, V29, P2102, DOI 10.2337/dc06-0560; Harlan L C, 1990, Epidemiology, V1, P224, DOI 10.1097/00001648-199005000-00008; Hill JO, 2005, J NUTR EDUC BEHAV, V37, P206, DOI 10.1016/S1499-4046(06)60248-0; HOLM S, 1979, SCAND J STAT, V6, P65; Ikeda J, 2005, J NUTR EDUC BEHAV, V37, P203, DOI 10.1016/S1499-4046(06)60247-9; Jakicic JM, 2003, JAMA-J AM MED ASSOC, V290, P1323, DOI 10.1001/jama.290.10.1323; Jakicic JM, 1999, JAMA-J AM MED ASSOC, V282, P1554, DOI 10.1001/jama.282.16.1554; Jeffery RW, 2000, HEALTH PSYCHOL, V19, P5, DOI 10.1037/0278-6133.19.Suppl1.5; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; KUMANYAKA SK, 1991, AM J CLIN NUTR, V53, pS1631, DOI 10.1093/ajcn/53.6.1631S; Kumanyika S., 2007, HDB OBESITY PREVENTI; Kumanyika SK, 2003, AM J CLIN NUTR, V77, P1342; Miller ER, 1998, CIRCULATION, V98, P2390, DOI 10.1161/01.CIR.98.22.2390; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; National Heart Lung and Blood Institute., 2004, NIH PUBL, V04-5230; National Heart Lung and Blood Institute, 1998, NIH PUBL, V98-4083; Neter JE, 2003, HYPERTENSION, V42, P878, DOI 10.1161/01.HYP.0000094221.86888.AE; Obarzanek E, 2001, AM J CLIN NUTR, V74, P80; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Orleans CT, 2000, HEALTH PSYCHOL, V19, P76, DOI 10.1037/0278-6133.19.Suppl1.76; Phelan S, 2005, ARCH INTERN MED, V165, P2430, DOI 10.1001/archinte.165.20.2430-a; Proschan MA, 2000, CONTROL CLIN TRIALS, V21, P527, DOI 10.1016/S0197-2456(00)00106-9; Rubin D.B., 2004, MULTIPLE IMPUTATION, V81; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Stevens Victor J, 2008, J Med Internet Res, V10, pe1, DOI 10.2196/jmir.931; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; Subar AF, 2003, AM J EPIDEMIOL, V158, P1, DOI 10.1093/aje/kwg092; Svetkey LP, 1999, ARCH INTERN MED, V159, P285, DOI 10.1001/archinte.159.3.285; Svetkey LP, 2005, J HUM HYPERTENS, V19, P21, DOI 10.1038/sj.jhh.1001770; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Wadden TA, 2004, OBES RES, V12, p151S, DOI 10.1038/oby.2004.282; Wadden TA, 2000, MED CLIN N AM, V84, P441, DOI 10.1016/j.psc.2004.09.008; Wadden TA, 2007, GASTROENTEROLOGY, V132, P2226, DOI 10.1053/j.gastro.2007.03.051; Wagner E H, 2001, Jt Comm J Qual Improv, V27, P63; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Wing RR, 2007, J CONSULT CLIN PSYCH, V75, P652, DOI 10.1037/0022-006X.75.4.652; Wing RR, 2006, NEW ENGL J MED, V355, P1563, DOI 10.1056/NEJMoa061883; Wing RR, 2005, AM J CLIN NUTR, V82, p222S, DOI 10.1093/ajcn/82.1.222S; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801	53	522	533	0	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	2008	299	10					1139	1148		10.1001/jama.299.10.1139	http://dx.doi.org/10.1001/jama.299.10.1139			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272CE	18334689	Bronze			2023-01-03	WOS:000253835000017
J	Teng, ACT; Adamo, K; Tesson, F; Stewart, AFR				Teng, Allen C. T.; Adamo, Kristi; Tesson, Frederique; Stewart, Alexandre F. R.			Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss	FASEB JOURNAL			English	Article						fatty acid; genetics; MyoD; obesity	TRANSCRIPTION FACTORS; FTO GENE; OBESITY; MYOGENESIS; COFACTOR; MYOD	Diet-induced weight loss is affected by a wide range of factors, including genetic variation. Identifying functional polymorphisms will help to elucidate mechanisms that account for variation in dietary metabolism. Previously, we reported a strong association between a common single nucleotide polymorphism (SNP) rs2419621 (C>T) in the promoter of acyl-CoA synthetase long chain 5 (ACSL5), rapid weight loss in obese Caucasian females, and elevated ACSL5 mRNA levels in skeletal muscle biopsies. Here, we showed by electrophoretic mobility shift assay (EMSA) that the T allele creates a functional cis-regulatory E-box element (CANNTG) that is recognized by the myogenic regulatory factor MyoD. The T allele promoted MyoD-dependent activation of a 1089-base pair ACSL5 promoter fragment in nonmuscle CV1 cells. Differentiation of skeletal myoblasts significantly elevated expression of the ACSL5 promoter. The T allele sustained promoter activity 48 h after differentiation, whereas the C allele showed a significant decline. These results reveal a mechanism for elevated transcription of ACSL5 in skeletal muscle of carriers of the rs2419621(T) allele, associated with more rapid diet-induced weight loss. Natural selection favoring promoter polymorphisms that reduced expression of catabolic genes in skeletal muscle likely accounts for the resistance of obese individuals to dietary intervention.-Teng, A. C., Adamo, K., Tesson, F., Stewart, A. F. R. Functional characterization of a promoter polymorphism that drives ACSL5 gene expression in skeletal muscle and associates with diet-induced weight loss. FASEB J. 23, 1705-1709 (2009)	[Adamo, Kristi; Tesson, Frederique] Univ Ottawa, Inst Heart, Lab Genet Cardiac Dis, Ottawa, ON K1Y 4W7, Canada; [Teng, Allen C. T.; Tesson, Frederique; Stewart, Alexandre F. R.] Univ Ottawa, Fac Med, Program Human & Mol Genet, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4W7, Canada; [Teng, Allen C. T.; Adamo, Kristi; Tesson, Frederique; Stewart, Alexandre F. R.] John & Jennifer Ruddy Canadian Cardiovasc Genet C, Ottawa, ON, Canada; [Adamo, Kristi] Childrens Hosp Eastern Ontario, Res Inst, Healthy Act Living & Obes Res Grp, Chalmers Res Grp, Ottawa, ON K1H 8L1, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario	Tesson, F (corresponding author), Univ Ottawa, Inst Heart, Lab Genet Cardiac Dis, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.	ftesson@ottawaheart.ca; astewart@ottawaheart.ca	Stewart, Alexandre F.R./A-5677-2011; Tesson, Frederique/A-3218-2013	Stewart, Alexandre/0000-0003-2673-9164; Adamo, Kristi/0000-0001-7925-1889	Canadian Institutes of Health Research (CIHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank N. Mikhael and M. Belanger for plasmid construction. A.F.R.S. and F.T. are funded by the Canadian Institutes of Health Research (CIHR). We also thank Dr. S. Dandona for reviewing the manuscript.	Adamo KB, 2007, OBESITY, V15, P1068, DOI 10.1038/oby.2007.630; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Cecil JE, 2008, NEW ENGL J MED, V359, P2558, DOI 10.1056/NEJMoa0803839; Chen HH, 2004, GENESIS, V39, P273, DOI 10.1002/gene.20055; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Donoviel DB, 1996, MOL CELL BIOL, V16, P1649; Haupt A, 2008, OBESITY, V16, P1969, DOI 10.1038/oby.2008.283; Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Mashek DG, 2006, J BIOL CHEM, V281, P945, DOI 10.1074/jbc.M507646200; Mashek DG, 2006, J LIPID RES, V47, P2004, DOI 10.1194/jlr.M600150-JLR200; Muller TD, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-85; Poirier P, 2006, ARTERIOSCL THROM VAS, V26, P968, DOI 10.1161/01.ATV.0000216787.85457.f3; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SKERJANC IS, 1994, DEV BIOL, V163, P125, DOI 10.1006/dbio.1994.1128; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WILLIG TN, 1993, DEV MED CHILD NEUROL, V35, P1074, DOI 10.1111/j.1469-8749.1993.tb07925.x; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yamashita Y, 2000, ONCOGENE, V19, P5919, DOI 10.1038/sj.onc.1203981; Zhou Y, 2007, ARTERIOSCL THROM VAS, V27, P2198, DOI 10.1161/ATVBAHA.107.148429; ZHUANG Y, 1992, P NATL ACAD SCI USA, V89, P12132, DOI 10.1073/pnas.89.24.12132	22	19	21	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2009	23	6					1705	1709		10.1096/fj.08-120998	http://dx.doi.org/10.1096/fj.08-120998			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZW	19218499	Green Accepted			2023-01-03	WOS:000266652400010
J	Alipour, M; Suntres, ZE; Halwani, M; Azghani, AO; Omri, A				Alipour, Misagh; Suntres, Zacharias E.; Halwani, Majed; Azghani, Ali O.; Omri, Abdelwahab			Activity and Interactions of Liposomal Antibiotics in Presence of Polyanions and Sputum of Patients with Cystic Fibrosis	PLOS ONE			English	Article								Background: To compare the effectiveness of liposomal tobramycin or polymyxin B against Pseudomonas aeruginosa in the Cystic Fibrosis (CF) sputum and its inhibition by common polyanionic components such as DNA, F-actin, lipopolysaccharides (LPS), and lipoteichoic acid (LTA). Methodology: Liposomal formulations were prepared from a mixture of 1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC) or 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC) and Cholesterol (Chol), respectively. Stability of the formulations in different biological milieus and antibacterial activities compared to conventional forms in the presence of the aforementioned inhibitory factors or CF sputum were evaluated. Results: The formulations were stable in all conditions tested with no significant differences compared to the controls. Inhibition of antibiotic formulations by DNA/F-actin and LPS/LTA was concentration dependent. DNA/F-actin (125 to 1000 mg/L) and LPS/LTA (1 to 1000 mg/L) inhibited conventional tobramycin bioactivity, whereas, liposome-entrapped tobramycin was inhibited at higher concentrations - DNA/F-actin (500 to 1000 mg/L) and LPS/LTA (100 to 1000 mg/L). Neither polymyxin B formulation was inactivated by DNA/F-actin, but LPS/LTA (1 to 1000 mg/L) inhibited the drug in conventional form completely and higher concentrations of the inhibitors (100 to 1000 mg/L) was required to inhibit the liposome-entrapped polymyxin B. Co-incubation with inhibitory factors (1000 mg/L) increased conventional (16-fold) and liposomal (4-fold) tobramycin minimum bactericidal concentrations (MBCs), while both polymyxin B formulations were inhibited 64-fold. Conclusions: Liposome-entrapment reduced antibiotic inhibition up to 100-fold and the CFU of endogenous P. aeruginosa in sputum by 4-fold compared to the conventional antibiotic, suggesting their potential applications in CF lung infections.			Alipour, M (corresponding author), Laurentian Univ, Dept Chem & Biochem, Novel Drug & Vaccine Delivery Syst Facil, Sudbury, ON P3E 2C6, Canada.	aomri@laurentian.ca	Azghani, Ali/GNW-5689-2022; Omri, Abdelwahab/G-3172-2010	Azghani, Ali/0000-0002-7626-5967; Omri, Abdelwahab/0000-0002-4093-5762; Halwani, Majed/0000-0002-2192-3264				Alipour M, 2008, INT J PHARM, V355, P293, DOI 10.1016/j.ijpharm.2007.11.035; Allison SD, 2007, J INFUS MURS, V30, P89, DOI 10.1097/01.NAN.0000264712.26219.67; BATAILLON V, 1992, J ANTIMICROB CHEMOTH, V29, P499, DOI 10.1093/jac/29.5.499; Boyle MP, 2007, JAMA-J AM MED ASSOC, V298, P1787, DOI 10.1001/jama.298.15.1787; Broughton-Head VJ, 2007, PULM PHARMACOL THER, V20, P708, DOI 10.1016/j.pupt.2006.08.008; Bucki R, 2007, EUR RESPIR J, V29, P624, DOI 10.1183/09031936.00080806; Bucki R, 2007, J ANTIMICROB CHEMOTH, V60, P535, DOI 10.1093/jac/dkm218; Cannella CA, 2006, AM J HEALTH-SYST PH, V63, P1858, DOI 10.2146/ajhp060196; Ceri H, 1999, J CLIN MICROBIOL, V37, P1771, DOI 10.1128/JCM.37.6.1771-1776.1999; Chuchalin Alexander, 2007, Paediatr Drugs, V9 Suppl 1, P21, DOI 10.2165/00148581-200709001-00004; Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006; Davies JC, 2007, SEMIN RESP CRIT CARE, V28, P312, DOI 10.1055/s-2007-981652; DAVIES M, 1978, BIOCHIM BIOPHYS ACTA, V508, P260, DOI 10.1016/0005-2736(78)90329-2; DAVIS SD, 1978, AM REV RESPIR DIS, V117, P176; Driscoll JA, 2007, DRUGS, V67, P351, DOI 10.2165/00003495-200767030-00003; Eisenberg J, 1997, CHEST, V111, P955, DOI 10.1378/chest.111.4.955; Elizur A, 2008, CHEST, V133, P489, DOI 10.1378/chest.07-1631; Fabretti F, 2006, INFECT IMMUN, V74, P4164, DOI 10.1128/IAI.00111-06; Falagas ME, 2005, CLIN INFECT DIS, V40, P1333, DOI 10.1086/429323; Fernandes B, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006682.pub2; Geller DE, 2007, PEDIATR PULM, V42, P307, DOI 10.1002/ppul.20594; Govan J, 2002, HOSP MED, V63, P421, DOI 10.12968/hosp.2002.63.7.1987; Halwani M, 2007, J ANTIMICROB CHEMOTH, V60, P760, DOI 10.1093/jac/dkm289; Hancock R E, 2001, Lancet Infect Dis, V1, P156, DOI 10.1016/S1473-3099(01)00092-5; Hermann T, 2007, CELL MOL LIFE SCI, V64, P1841, DOI 10.1007/s00018-007-7034-x; Hodson ME, 2002, EUR RESPIR J, V20, P658, DOI 10.1183/09031936.02.00248102; Horianopoulou M, 2005, J CHEMOTHERAPY, V17, P536, DOI 10.1179/joc.2005.17.5.536; HUNT BE, 1995, ANTIMICROB AGENTS CH, V39, P34, DOI 10.1128/AAC.39.1.34; Iredell JR, 2007, SEMIN RESP CRIT CARE, V28, P656, DOI 10.1055/s-2007-996412; Kater A, 2007, ANN NY ACAD SCI, V1112, P140, DOI 10.1196/annals.1415.006; Kaye D, 2004, INFECT DIS CLIN N AM, V18, P669, DOI 10.1016/j.idc.2004.04.007; Kharitonov Sergei A., 2007, V14, P83, DOI 10.1159/000107056; Kirov SM, 2007, MICROBIOL-SGM, V153, P3264, DOI 10.1099/mic.0.2007/009092-0; Lahiri T, 2007, CLIN CHEST MED, V28, P307, DOI 10.1016/j.ccm.2007.02.003; Landry RM, 2006, MOL MICROBIOL, V59, P142, DOI 10.1111/j.1365-2958.2005.04941.x; Lenoir Gerard, 2007, Paediatr Drugs, V9 Suppl 1, P11, DOI 10.2165/00148581-200709001-00003; LETHEM MI, 1990, EUR RESPIR J, V3, P19; LEVY J, 1983, J INFECT DIS, V148, P1069, DOI 10.1093/infdis/148.6.1069; Macfarlane ELA, 1999, MOL MICROBIOL, V34, P305, DOI 10.1046/j.1365-2958.1999.01600.x; MARSHALL AJH, 1994, J ANTIMICROB CHEMOTH, V34, P465, DOI 10.1093/jac/34.4.465; Meers P, 2008, J ANTIMICROB CHEMOTH, V61, P859, DOI 10.1093/jac/dkn059; Merlo CA, 2007, CHEST, V132, P562, DOI 10.1378/chest.06-2888; Mozafari MR, 2006, J SCI FOOD AGR, V86, P2038, DOI 10.1002/jsfa.2576; Mozafari MR, 2008, J LIPOSOME RES, V18, P309, DOI [10.1080/08982100802465941 , 10.1080/08982100802465941]; Mugabe C, 2006, INT J PHARMACEUT, V307, P244, DOI 10.1016/j.ijpharm.2005.10.005; Mugabe C, 2006, ANTIMICROB AGENTS CH, V50, P2016, DOI 10.1128/AAC.01547-05; Murray TS, 2007, CURR OPIN PEDIATR, V19, P83, DOI 10.1097/MOP.0b013e3280123a5d; NICAS TI, 1980, J BACTERIOL, V143, P872, DOI 10.1128/JB.143.2.872-878.1980; Omri A, 2002, BIOCHEM PHARMACOL, V64, P1407, DOI 10.1016/S0006-2952(02)01346-1; POTTER JL, 1965, PEDIATRICS, V36, P714; RAMPHAL R, 1988, J ANTIMICROB CHEMOTH, V22, P483, DOI 10.1093/jac/22.4.483; Remmington T, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005405; Rogan MP, 2004, J INFECT DIS, V190, P1245, DOI 10.1086/423821; Sagel Scott D, 2007, Proc Am Thorac Soc, V4, P406, DOI 10.1513/pats.200703-044BR; Sanders NN, 2000, AM J RESP CRIT CARE, V162, P1905, DOI 10.1164/ajrccm.162.5.9909009; Sanders NN, 2002, PHARMACEUT RES, V19, P451, DOI 10.1023/A:1015139527747; Sanders NN, 2001, AM J RESP CRIT CARE, V164, P486, DOI 10.1164/ajrccm.164.3.2011041; Schiffelers R, 2001, J ANTIMICROB CHEMOTH, V48, P333, DOI 10.1093/jac/48.3.333; Sobieszczyk ME, 2004, J ANTIMICROB CHEMOTH, V54, P566, DOI 10.1093/jac/dkh369; SOMEYA A, 1979, J ANTIBIOT, V32, P156, DOI 10.7164/antibiotics.32.156; Son MS, 2007, INFECT IMMUN, V75, P5313, DOI 10.1128/IAI.01807-06; Stern M, 1998, GENE THER, V5, P91, DOI 10.1038/sj.gt.3300556; Swan SK, 1997, SEMIN NEPHROL, V17, P27; Tang JX, 2005, AM J PHYSIOL-LUNG C, V289, pL599, DOI 10.1152/ajplung.00061.2005; Touw DJ, 2007, J CYST FIBROS, V6, P327, DOI 10.1016/j.jcf.2006.12.007; VASCONCELLOS CA, 1994, SCIENCE, V263, P969, DOI 10.1126/science.8310295; Walker TS, 2005, INFECT IMMUN, V73, P3693, DOI 10.1128/IAI.73.6.3693-3701.2005; Weiner DJ, 2003, AM J RESP CELL MOL, V28, P738, DOI 10.1165/rcmb.2002-0191OC; Westerman EM, 2007, J CYST FIBROS, V6, P284, DOI 10.1016/j.jcf.2006.10.010; Zavascki AP, 2007, J ANTIMICROB CHEMOTH, V60, P1206, DOI 10.1093/jac/dkm357	70	52	54	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5724	10.1371/journal.pone.0005724	http://dx.doi.org/10.1371/journal.pone.0005724			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479000	gold, Green Published, Green Submitted			2023-01-03	WOS:000266415100015
J	Katz, PR; Karuza, J; Intrator, O; Mor, V				Katz, Paul R.; Karuza, Jurgis; Intrator, Orna; Mor, Vincent			Nursing Home Physician Specialists: A Response to the Workforce Crisis in Long-Term Care	ANNALS OF INTERNAL MEDICINE			English	Article							HOSPITAL MEDICINE; INTERNAL-MEDICINE; RESIDENTS; QUALITY; PATTERNS; STATE; STAFF	Marginalization of physicians in the nursing home threatens the overall care of increasingly frail nursing home residents who have medically complex illnesses. The authors propose that creating a nursing home medicine specialty, which recognizes the nursing home as a unique practice site, would go a long way toward remedying existing problems with care in skilled nursing facilities and would best serve the needs of the 1.6 million nursing home residents in the United States. Reviewing what is known about physician practice in nursing homes and hospitals, and taking a lead from the hospitalist movement, the specialty would be characterized in 3 dimensions: the degree of physicians' commitment, physicians' practice competencies, and the structure of the medical staff organization in which they practice. Challenges to the adoption of a nursing home specialist model include mainstream medicine's failure to recognize the nursing home as a legitimate medical practice, the need for the nursing home industry and policymakers to appreciate the links between physician practice and quality, and assurance of financial viability. Implications for quality of care, health policy, and research needs are discussed in this article.	[Katz, Paul R.] Univ Rochester, Sch Med & Dent, Rochester, NY 14620 USA; SUNY Buffalo, Buffalo, NY 14260 USA; Brown Univ, Providence, RI 02912 USA	University of Rochester; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Brown University	Katz, PR (corresponding author), Univ Rochester, Sch Med & Dent, 435 E Henrietta Rd, Rochester, NY 14620 USA.	Paul_Katz@urmc.rochester.edu			National Institute on Aging [R21 AG025246]; NATIONAL INSTITUTE ON AGING [R21AG025246] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant Support: Dr. Katz was supported by the National Institute on Aging (grant R21 AG025246).	*AM MED DIR ASS, CMS IMPL REV SURV GU; Baron RJ, 2008, JAMA-J AM MED ASSOC, V299, P1595, DOI 10.1001/jama.299.13.1595; Blumenthal D, 2001, JAMA-J AM MED ASSOC, V286, P1027, DOI 10.1001/jama.286.9.1027; Borger C, 2006, HEALTH AFFAIR, V25, pW61, DOI 10.1377/hlthaff.25.w61; Caprio T. V., 2006, ANNALS OF LONG TERM, V14, P17; Caprio TV, 2009, J AM MED DIR ASSOC, V10, P93, DOI 10.1016/j.jamda.2008.07.007; DeFrances C. J, 2007, 2005 NATL HOSP DISCH, V385; FLOOD AB, 1978, J HEALTH SOC BEHAV, V19, P240, DOI 10.2307/2136557; Glasheen JJ, 2008, J GEN INTERN MED, V23, P1110, DOI 10.1007/s11606-008-0646-5; Gruneir A, 2007, MED CARE RES REV, V64, P351, DOI 10.1177/1077558707301810; Iglehart JK, 2008, NEW ENGL J MED, V358, P1741, DOI 10.1056/NEJMhpr0800058; Institute of Medicine, 2008, RET AG AM BUILD HLTH; Intrator O, 1999, MED CARE, V37, P228, DOI 10.1097/00005650-199903000-00003; Jones Adrienne, 2002, Vital Health Stat 13, P1; KARUZA J, 1994, J AM GERIATR SOC, V42, P787, DOI 10.1111/j.1532-5415.1994.tb06543.x; Kasper J, 2007, CHANGES CHARACTERIST; Katz PR, 2006, J AM MED DIR ASSOC, V7, P394, DOI 10.1016/j.jamda.2006.05.003; Katz Paul R, 2003, J Am Med Dir Assoc, V4, P115, DOI 10.1016/S1525-8610(04)70288-1; Katz PR, 1997, J AM GERIATR SOC, V45, P911, DOI 10.1111/j.1532-5415.1997.tb02958.x; KATZ PR, 1993, J GEN INTERN MED, V8, P691, DOI 10.1007/BF02598291; Katz PR, 2005, J AM GERIATR SOC, V53, P1826, DOI 10.1111/j.1532-5415.2005.53509.x; Kirch DG, 2008, JAMA-J AM MED ASSOC, V299, P2680, DOI 10.1001/jama.299.22.2680; Landrigan CP, 2006, PEDIATRICS, V117, P1736, DOI 10.1542/peds.2005-0609; Leibovitz A, 2004, AGING CLIN EXP RES, V16, P314; *MED PAYM ADV COMM, 2008, DAT BOOK HLTH CAR SP; Medina-Walpole A, 2002, J AM GERIATR SOC, V50, P949, DOI 10.1046/j.1532-5415.2002.50225.x; Roemer M., 1971, DOCTORS HOSP MED STA; Schmidt IK, 2002, SOC SCI MED, V54, P1767, DOI 10.1016/S0277-9536(01)00146-0; Schols J M G A, 2004, J Am Med Dir Assoc, V5, P207, DOI 10.1097/01.JAM.0000123031.43619.60; SHORTELL S, 1976, ORG RES HOSP; SHORTELL SM, 1981, MED CARE, V19, P1041, DOI 10.1097/00005650-198110000-00006; Shortell SM, 2005, MED CARE RES REV, V62, P407, DOI 10.1177/1077558705277389; Sloane PD, 2003, J AM GERIATR SOC, V51, P1587, DOI 10.1046/j.1532-5415.2003.51511.x; Spillman BC, 2000, NEW ENGL J MED, V342, P1409, DOI 10.1056/NEJM200005113421906; Spillman BC, 2002, MED CARE, V40, P965, DOI 10.1097/00005650-200210000-00013; *US, 1987, ANN REV POPUL LAW, V14, P473; Wachter RM, 2008, MED CLIN N AM, V92, P265, DOI 10.1016/j.mcna.2007.10.008; Zimmerman S, 2002, J AM GERIATR SOC, V50, P1987, DOI 10.1046/j.1532-5415.2002.50610.x; CERTIFIED MED DIRECT	39	81	81	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 17	2009	150	6					411	W73		10.7326/0003-4819-150-6-200903170-00010	http://dx.doi.org/10.7326/0003-4819-150-6-200903170-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	423AJ	19293074	Green Accepted			2023-01-03	WOS:000264468500007
J	Singer, MS; Mace, KC; Bernays, EA				Singer, Michael S.; Mace, Kevi C.; Bernays, Elizabeth A.			Self-Medication as Adaptive Plasticity: Increased Ingestion of Plant Toxins by Parasitized Caterpillars	PLOS ONE			English	Article							PYRROLIZIDINE ALKALOIDS; PHENOTYPIC PLASTICITY; NEST MATERIAL; DIET CHOICE; GENERALIST; RESISTANCE; BEHAVIOR; CONSEQUENCES; PARASITOIDS; CHIMPANZEES	Self-medication is a specific therapeutic behavioral change in response to disease or parasitism. The empirical literature on self-medication has so far focused entirely on identifying cases of self-medication in which particular behaviors are linked to therapeutic outcomes. In this study, we frame self-medication in the broader realm of adaptive plasticity, which provides several testable predictions for verifying self-medication and advancing its conceptual significance. First, self-medication behavior should improve the fitness of animals infected by parasites or pathogens. Second, self-medication behavior in the absence of infection should decrease fitness. Third, infection should induce self-medication behavior. The few rigorous studies of self-medication in non-human animals have not used this theoretical framework and thus have not tested fitness costs of self-medication in the absence of disease or parasitism. Here we use manipulative experiments to test these predictions with the foraging behavior of woolly bear caterpillars (Grammia incorrupta; Lepidoptera: Arctiidae) in response to their lethal endoparasites (tachinid flies). Our experiments show that the ingestion of plant toxins called pyrrolizidine alkaloids improves the survival of parasitized caterpillars by conferring resistance against tachinid flies. Consistent with theoretical prediction, excessive ingestion of these toxins reduces the survival of unparasitized caterpillars. Parasitized caterpillars are more likely than unparasitized caterpillars to specifically ingest large amounts of pyrrolizidine alkaloids. This case challenges the conventional view that self-medication behavior is restricted to animals with advanced cognitive abilities, such as primates, and empowers the science of self-medication by placing it in the domain of adaptive plasticity theory.	[Singer, Michael S.; Mace, Kevi C.] Wesleyan Univ, Dept Biol, Middletown, CT 06459 USA; [Bernays, Elizabeth A.] Univ Arizona, Dept Entomol, Tucson, AZ 85721 USA	Wesleyan University; University of Arizona	Singer, MS (corresponding author), Wesleyan Univ, Dept Biol, Middletown, CT 06459 USA.	msinger@wesleyan.edu			NSF [IOS 0744676]; Wesleyan University; Division Of Integrative Organismal Systems [0744676] Funding Source: National Science Foundation	NSF(National Science Foundation (NSF)); Wesleyan University; Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO))	This work was supported by NSF grant IOS 0744676 and Wesleyan University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal AA, 2001, SCIENCE, V294, P321, DOI 10.1126/science.1060701; Agrawal AA, 2007, FRONT ECOL ENVIRON, V5, P145, DOI 10.1890/1540-9295(2007)5[145:FKGIPA]2.0.CO;2; Benard MF, 2004, ANNU REV ECOL EVOL S, V35, P651, DOI 10.1146/annurev.ecolsys.35.021004.112426; BERENBAUM MR, 1992, EVOLUTION, V46, P1373, DOI 10.1111/j.1558-5646.1992.tb01130.x; Bernays EA, 2005, NATURE, V436, P476, DOI 10.1038/436476a; Bernays EA, 2002, PHYSIOL ENTOMOL, V27, P312, DOI 10.1046/j.1365-3032.2002.00304.x; BOPPRE M, 1984, J CHEM ECOL, V10, P1151, DOI 10.1007/BF00987520; Chapman RF, 2003, ANNU REV ENTOMOL, V48, P455, DOI 10.1146/annurev.ento.48.091801.112629; Chapuisat M, 2007, P ROY SOC B-BIOL SCI, V274, P2013, DOI 10.1098/rspb.2007.0531; Christe P, 2003, ECOL LETT, V6, P19, DOI 10.1046/j.1461-0248.2003.00395.x; CLARK L, 1988, OECOLOGIA, V77, P174, DOI 10.1007/BF00379183; CLARK L, 1985, OECOLOGIA, V67, P169, DOI 10.1007/BF00384280; Dyer LA, 2003, J CHEM ECOL, V29, P2499, DOI 10.1023/A:1026310001958; EISNER T. E, 2003, LOVE INSECTS, V448; Engel C, 2002, WILD HLTH; Fordyce JA, 2006, J EXP BIOL, V209, P2377, DOI 10.1242/jeb.02271; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Godfray HCJ, 1994, PARASITOIDS BEHAV EV, P488; Gols R, 2008, J CHEM ECOL, V34, P132, DOI 10.1007/s10886-008-9429-z; Hartmann T, 2005, INSECT BIOCHEM MOLEC, V35, P1083, DOI 10.1016/j.ibmb.2005.05.011; Hartmann T, 2004, J CHEM ECOL, V30, P229, DOI 10.1023/B:JOEC.0000017975.16399.c3; HAWKINS BA, 1994, PATTERN PROCESS HOST, P200; Huffman MA, 2004, PRIMATES, V45, P113, DOI 10.1007/s10329-003-0065-5; Huffman MA, 2003, P NUTR SOC, V62, P371, DOI 10.1079/PNS2003257; Huffman MA, 2001, BIOSCIENCE, V51, P651, DOI 10.1641/0006-3568(2001)051[0651:SMBITA]2.0.CO;2; Huffman MA, 1997, YEARB PHYS ANTHROPOL, V40, P171; Huffman MA, 2001, INT J PRIMATOL, V22, P329, DOI 10.1023/A:1010734310002; Huffman MA, 1996, INT J PRIMATOL, V17, P475, DOI 10.1007/BF02735188; Hunter MD, 2003, AGR FOREST ENTOMOL, V5, P1, DOI 10.1046/j.1461-9563.2003.00168.x; Hutchings MR, 2006, MAMMAL REV, V36, P1, DOI 10.1111/j.1365-2907.2006.00080.x; Hutchings MR, 2003, P NUTR SOC, V62, P361, DOI 10.1079/PNS2003243; Janzen D.H., 1978, P73; Karban R, 1997, ECOLOGY, V78, P603, DOI 10.1890/0012-9658(1997)078[0603:TPAHPC]2.0.CO;2; Krishnamani R, 2000, ANIM BEHAV, V59, P899, DOI 10.1006/anbe.1999.1376; Lampert EC, 2008, J CHEM ECOL, V34, P783, DOI 10.1007/s10886-008-9481-8; Lee KP, 2006, P ROY SOC B-BIOL SCI, V273, P823, DOI 10.1098/rspb.2005.3385; Lozano GA, 1998, ADV STUD BEHAV, V27, P291; Miner BG, 2005, TRENDS ECOL EVOL, V20, P685, DOI 10.1016/j.tree.2005.08.002; Mooney KA, 2008, SPECIALIZATION, SPECIATION, AND RADIATION: THE EVOLUTIONARY BIOLOGY OF HERBIVOROUS INSECTS, P43; Ode PJ, 2006, ANNU REV ENTOMOL, V51, P163, DOI 10.1146/annurev.ento.51.110104.151110; RODRIGUEZ E, 1993, RECENT ADV PHYTOCHEM, V27, P89; SAS Institute, 2007, JMP VERS 7 0; Schmitz OJ, 2004, ECOL LETT, V7, P153, DOI 10.1111/j.1461-0248.2003.00560.x; Singer MS, 2003, OIKOS, V100, P554, DOI 10.1034/j.1600-0706.2003.11720.x; Singer MS, 2004, AM NAT, V164, P423, DOI 10.1086/423152; SMILANICH AM, 2008, THESIS TULANE U; Stireman JO, 2002, ECOL ENTOMOL, V27, P588, DOI 10.1046/j.1365-2311.2002.00450.x; Villalba JJ, 2006, ANIM BEHAV, V71, P1131, DOI 10.1016/j.anbehav.2005.09.012; WRANGHAM R W, 1983, Primates, V24, P276, DOI 10.1007/BF02381090; WRANGHAM RW, 1995, AM J PRIMATOL, V37, P297, DOI 10.1002/ajp.1350370404; YAMAMOTO RT, 1969, J ECON ENTOMOL, V62, P1427, DOI 10.1093/jee/62.6.1427	51	184	186	4	106	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2009	4	3							e4796	10.1371/journal.pone.0004796	http://dx.doi.org/10.1371/journal.pone.0004796			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437OE	19274098	Green Published, gold			2023-01-03	WOS:000265496000029
J	Damarla, M; Hasan, E; Boueiz, A; Le, A; Pae, HH; Montouchet, C; Kolb, T; Simms, T; Myers, A; Kayyali, US; Gaestel, M; Peng, XQ; Reddy, SP; Damico, R; Hassoun, PM				Damarla, Mahendra; Hasan, Emile; Boueiz, Adel; Le, Anne; Pae, Hyun Hae; Montouchet, Calypso; Kolb, Todd; Simms, Tiffany; Myers, Allen; Kayyali, Usamah S.; Gaestel, Matthias; Peng, Xinqi; Reddy, Sekhar P.; Damico, Rachel; Hassoun, Paul M.			Mitogen Activated Protein Kinase Activated Protein Kinase 2 Regulates Actin Polymerization and Vascular Leak in Ventilator Associated Lung Injury	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; SPHINGOSINE 1-PHOSPHATE; XANTHINE OXIDOREDUCTASE; MECHANICAL VENTILATION; DEPENDENT REGULATION; ENDOTHELIAL-CELLS; MAP-KINASES; STRESS; PHOSPHORYLATION; SUSCEPTIBILITY	Mechanical ventilation, a fundamental therapy for acute lung injury, worsens pulmonary vascular permeability by exacting mechanical stress on various components of the respiratory system causing ventilator associated lung injury. We postulated that MK2 activation via p38 MAP kinase induced HSP25 phosphorylation, in response to mechanical stress, leading to actin stress fiber formation and endothelial barrier dysfunction. We sought to determine the role of p38 MAP kinase and its downstream effector MK2 on HSP25 phosphorylation and actin stress fiber formation in ventilator associated lung injury. Wild type and MK2(-/-) mice received mechanical ventilation with high (20 ml/kg) or low (7 ml/kg) tidal volumes up to 4 hrs, after which lungs were harvested for immunohistochemistry, immunoblotting and lung permeability assays. High tidal volume mechanical ventilation resulted in significant phosphorylation of p38 MAP kinase, MK2, HSP25, actin polymerization, and an increase in pulmonary vascular permeability in wild type mice as compared to spontaneous breathing or low tidal volume mechanical ventilation. However, pretreatment of wild type mice with specific p38 MAP kinase or MK2 inhibitors abrogated HSP25 phosphorylation and actin polymerization, and protected against increased lung permeability. Finally, MK2(-/-) mice were unable to phosphorylate HSP25 or increase actin polymerization from baseline, and were resistant to increases in lung permeability in response to HV(T) MV. Our results suggest that p38 MAP kinase and its downstream effector MK2 mediate lung permeability in ventilator associated lung injury by regulating HSP25 phosphorylation and actin cytoskeletal remodeling.	[Damarla, Mahendra; Hasan, Emile; Boueiz, Adel; Le, Anne; Pae, Hyun Hae; Montouchet, Calypso; Kolb, Todd; Simms, Tiffany; Myers, Allen; Peng, Xinqi; Damico, Rachel; Hassoun, Paul M.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Kayyali, Usamah S.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Gaestel, Matthias] Hannover Med Sch, Dept Biochem, D-3000 Hannover, Germany; [Reddy, Sekhar P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Johns Hopkins University; Tufts University; Hannover Medical School; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Damarla, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.	phassoun@jhmi.edu	Boueiz, Adel El/AAV-5966-2021; Kolb, Todd/ABD-8204-2020; Gaestel, Matthias/A-6560-2013	Boueiz, Adel El/0000-0003-1638-8575; Gaestel, Matthias/0000-0002-4944-4652; Le, Anne/0000-0002-2958-8149	NIH [HL049441, HL090297, P50 HL073994]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL073994, R29HL049441, F32HL090297, R01HL049441] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the NIH (HL049441, HL090297, and P50 HL073994). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdulnour REE, 2006, AM J PHYSIOL-LUNG C, V291, pL345, DOI 10.1152/ajplung.00453.2005; Birukov KG, 2003, AM J PHYSIOL-LUNG C, V285, pL785, DOI 10.1152/ajplung.00336.2002; Birukova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL75, DOI 10.1152/ajplung.00447.2004; BOGATCHEVA NV, 2006, AM J PHYSIOL-LUNG C; BOGATCHEVA NV, 2009, MICROVASC RES; Borbiev T, 2004, AM J PHYSIOL-LUNG C, V287, pL911, DOI 10.1152/ajplung.00372.2003; BRYAN J, 2004, J CELL BIOCHEM, V92, P1075; CHAUDHURI S, 2008, AM J RESP CELL MOL B; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Dolinay T, 2004, AM J RESP CRIT CARE, V170, P613, DOI 10.1164/rccm.200401-023OC; Dolinay T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001601; Dudek SM, 2001, J APPL PHYSIOL, V91, P1487, DOI 10.1152/jappl.2001.91.4.1487; Fan E, 2005, JAMA-J AM MED ASSOC, V294, P2889, DOI 10.1001/jama.294.22.2889; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALEN B, 1998, J CELLULAR PHYSL, V177, P575; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Grishko V, 2001, AM J PHYSIOL-LUNG C, V280, pL1300, DOI 10.1152/ajplung.2001.280.6.L1300; Guay J, 1997, J CELL SCI, V110, P357; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Itoh T, 2007, AM J PHYSIOL-LUNG C, V293, pL446, DOI 10.1152/ajplung.00412.2005; Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LE A, 2008, J APPL PHYSIOL, P90689; Le A, 2008, J APPL PHYSIOL, V105, P1282, DOI 10.1152/japplphysiol.90689.2008; MacIntyre NR, 2005, CHEST, V128, p561S, DOI 10.1378/chest.128.5_suppl_2.561S; Moxley MA, 2000, AM J PHYSIOL-LUNG C, V279, pL985, DOI 10.1152/ajplung.2000.279.5.L985; Naumanen P, 2008, J MICROSC-OXFORD, V231, P446, DOI 10.1111/j.1365-2818.2008.02057.x; Parker JC, 2002, AM J PHYSIOL-LUNG C, V283, pL1203, DOI 10.1152/ajplung.00488.2001; PATTERSON CE, 1992, J APPL PHYSIOL, V72, P865, DOI 10.1152/jappl.1992.72.3.865; Peng XQ, 2004, AM J RESP CRIT CARE, V169, P1245, DOI 10.1164/rccm.200309-1258OC; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; SCHMIDT EP, 2008, AM J PHYSL LUNG CELL; Verin AD, 2001, AM J PHYSIOL-LUNG C, V281, pL565, DOI 10.1152/ajplung.2001.281.3.L565; Vertii A, 2006, J BIOL CHEM, V281, P26966, DOI 10.1074/jbc.M602134200; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; YAN J, 2008, J PHARMACOL EXP THER; 2000, N ENGL J MED, V342, P1301	40	47	51	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 25	2009	4	2							e4600	10.1371/journal.pone.0004600	http://dx.doi.org/10.1371/journal.pone.0004600			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	601TH	19240800	Green Published, gold, Green Submitted			2023-01-03	WOS:000278086700014
J	Eisenberg, MS; Psaty, BM				Eisenberg, Mickey S.; Psaty, Bruce M.			Defining and Improving Survival Rates From Cardiac Arrest in US Communities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICAN-HEART-ASSOCIATION; HEALTH-PROFESSIONALS; CARE COMMITTEE; RESUSCITATION; STATEMENT; CARDIOPULMONARY; OUTCOMES; COUNCIL		[Eisenberg, Mickey S.] Seattle King Cty Dept Publ Hlth, King Cty Emergency Med Serv Div, Seattle, WA USA; [Eisenberg, Mickey S.; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA USA; [Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; [Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Group Health Cooperative	Psaty, BM (corresponding author), Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.	psaty@u.washington.edu			NHLBI NIH HHS [HL085251, HL087652, HL74745, HL080295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080295, R01HL087652, U01HL080295, R01HL074745, R01HL085251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; Dunne RB, 2007, RESUSCITATION, V72, P59, DOI 10.1016/j.resuscitation.2006.04.017; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; Holzer M, 2002, NEW ENGL J MED, V346, P549; Institute of Medicine, EM MED SERV CROSSR; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Lombardi Gary, 1994, JAMA (Journal of the American Medical Association), V271, P678, DOI 10.1001/jama.271.9.678; National Cancer Institute, 1975, SEER CANC STAT REV; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nichol G, 2008, CIRCULATION, V117, P2299, DOI 10.1161/CIRCULATIONAHA.107.189472; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; Rea TD, 2006, CIRCULATION, V114, P2760, DOI 10.1161/CIRCULATIONAHA.106.654715; White RD, 2005, RESUSCITATION, V65, P279, DOI 10.1016/j.resuscitation.2004.10.018	15	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	2009	301	8					860	862		10.1001/jama.2009.193	http://dx.doi.org/10.1001/jama.2009.193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	410WV	19244194				2023-01-03	WOS:000263609900028
J	Falit, BP; Gross, CP				Falit, Benjamin P.; Gross, Cary P.			Access to Experimental Drugs for Terminally Ill Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Falit, Benjamin P.; Gross, Cary P.] Yale Univ, Sch Med, Primary Care Ctr, Gen Internal Med Sect, New Haven, CT 06520 USA; [Gross, Cary P.] Yale Univ, Sch Med, Robert Wood Johnson Clin Scholars Program, New Haven, CT USA	Yale University; Yale University	Gross, CP (corresponding author), Yale Univ, Sch Med, Primary Care Ctr, Gen Internal Med Sect, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	cary.gross@yale.edu						DiMasi JA, 2007, J CLIN ONCOL, V25, P209, DOI 10.1200/JCO.2006.09.0803; Jacobson PD, 2007, JAMA-J AM MED ASSOC, V297, P205, DOI 10.1001/jama.297.2.205; Krohmal BJ, 2007, ARCH INTERN MED, V167, P433, DOI 10.1001/archinte.167.5.433; STGEORGE D, 2004, WASH POST       0118, pW10; 2006, FED REG, V71, P75147	5	21	21	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2008	300	23					2793	2795		10.1001/jama.2008.828	http://dx.doi.org/10.1001/jama.2008.828			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384FJ	19088356				2023-01-03	WOS:000261730400025
J	Epstein, H				Epstein, Helen			AIDS and the irrational	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CONCURRENT SEXUAL PARTNERSHIPS; HIV-INFECTION; TRANSMITTED INFECTIONS; AFRICAN-AMERICANS; YOUNG MEN; BEHAVIOR; RISK; PREVENTION; SPREAD; COMMUNITIES					helenepstein@yahoo.com						Adimora AA, 2004, ANN EPIDEMIOL, V14, P155, DOI 10.1016/S1047-2797(03)00129-7; Adimora AA, 2003, JAIDS-J ACQ IMM DEF, V34, P423, DOI 10.1097/00126334-200312010-00010; ANKRAH M, 1993, AIDS UGANDA ANAL SOC; Baeten JM, 2005, J INFECT DIS, V191, P546, DOI 10.1086/427656; BARTON T, 1997, EPIDEMICS BEHA UNPUB; BECKER MH, 1988, AM J PUBLIC HEALTH, V78, P394, DOI 10.2105/AJPH.78.4.394; BOGART L, 2005, J ACQ IMMUN DEF SYND, V38, P2; CARAEL M, 2001, AFRICAN J REPROD HLT, V5, P83, DOI DOI 10.2307/3583201; Carael M., 1995, SEXUAL BEHAV AIDS DE; Carter MW, 2007, AIDS BEHAV, V11, P822, DOI 10.1007/s10461-006-9203-6; Christakis NA, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1675; Coffee MP, 2005, J INFECT DIS, V191, pS159, DOI 10.1086/425270; Colvin M, 1998, INT J STD AIDS, V9, P548, DOI 10.1258/0956462981922683; Drumright LN, 2004, SEX TRANSM DIS, V31, P437, DOI 10.1097/01.olq.0000129949.30114.37; England R, 2008, BRIT MED J, V336, P1072, DOI 10.1136/bmj.39569.497708.94; EPSTEIN H, 2004, DISCOVER         FEB; EPSTEIN H, 2005, AIDSLINK         SEP, P93; Epstein Helen, 2008, INVISIBLE CURE AFRIC; *FAM HLTH INT, 2002, SWAZ BEH SURV SURV; GARNETT GP, 1993, PHILOS T R SOC B, V342, P137, DOI 10.1098/rstb.1993.0143; GILGEN D, 2000, NATURAL HIST HIV AID; Gray RH, 2008, LANCET, V371, P2064, DOI 10.1016/S0140-6736(08)60896-X; Hallett T B, 2006, Sex Transm Infect, V82 Suppl 1, pi1; Halperin DT, 2007, S AFR J HIV MED, P19; Hearst N, 2004, STUD FAMILY PLANN, V35, P39, DOI 10.1111/j.1728-4465.2004.00004.x; HEATON L, 2006, 16 INT AIDS C 13 18; Helleringer S, 2007, AIDS, V21, P2323, DOI 10.1097/QAD.0b013e328285df98; HUDSON CP, 1993, INT J STD AIDS, V4, P249, DOI 10.1177/095646249300400501; HUDSON CP, 1994, AIDS, V8, P1739, DOI 10.1097/00002030-199412000-00021; Hudson CP, 1996, INT J STD AIDS, V7, P236, DOI 10.1258/0956462961917906; HUDSON CP, 1993, AIDS, V7, P286, DOI 10.1097/00002030-199302000-00024; Human Rights Watch, 2007, HIDD MEAL MEAL GEND; KALEEBA N, 2002, WE MISS YOU ALL AIDS; Lagarde E, 2001, AIDS, V15, P877, DOI 10.1097/00002030-200105040-00008; MAH T, 2008, 225 CTR SOC SCI RES; MAH T, 2008, AIDS BEHAV      0722; MAJIRIOGHENE B, 2008, NIGERIANS AM    1013; Matovu JKB, 2007, AIDS BEHAV, V11, P71, DOI 10.1007/s10461-006-9170-y; Mattson CL, 2007, SEX TRANSM DIS, V34, P731, DOI 10.1097/01.olq.0000261335.42480.89; MEYERSON B, TCM EXPOSURE HIV REL; Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012; Morris M, 2001, SEX TRANSM DIS, V28, P504, DOI 10.1097/00007435-200109000-00005; MORRIS M, 2007, SEXUALLY TRANSMITTED; Moszynski P, 2007, BRIT MED J, V334, P712, DOI 10.1136/bmj.39171.431736.DB; MUSINGUZI J, 1996, RESULTS POPULATION B; MUSSA A, 2001, THESIS U WASHINGTON; Nelson KE, 1996, NEW ENGL J MED, V335, P297, DOI 10.1056/NEJM199608013350501; OBBO C, 1993, SOC SCI MED, V36, P949, DOI 10.1016/0277-9536(93)90086-J; Parker W, 2007, CONCURRENT SEXUAL PA; PARKER W, 2007, NAMIBIA MIDTERM HOUS; Peltzer K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-255; PIOT P, 1994, HIV EPIDEMIOLOGY, P77; Piot P, 2008, LANCET, V372, P845, DOI 10.1016/S0140-6736(08)60888-0; *POP COUNC, 2006, AD GIRLS SOC SUPP LI; Potts M, 2008, SCIENCE, V320, P749, DOI 10.1126/science.1153843; Pronyk PM, 2006, LANCET, V368, P1973, DOI 10.1016/S0140-6736(06)69744-4; Roehr B, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2566; Shelton JD, 2004, BMJ-BRIT MED J, V328, P891, DOI 10.1136/bmj.328.7444.891; *SO AFR DEV COMM, 2006, REP EXP THINK TANK M; STANDING H, 1989, SEXUAL BEHAV AIDS SU; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; SULLIVAN J, 2006, AIDS; TALLE A, 1995, YOUNG PEOPLE RISK FI; Tuffs A, 2007, BRIT MED J, V334, P712, DOI 10.1136/bmj.39170.736412.DB; *UG MIN HLTH, 1995, UG DEM HLTH SURV 199; UNAIDS, 2001, HIV PREV NEEDS SUCC; *UNAIDS, 2006, REP GLOB AIDS EP 200, P127; *UNAIDS, 2008, REP GLOB AIDS EP 200, P36; Voeten HACM, 2004, SEX TRANSM DIS, V31, P481, DOI 10.1097/01.olq.0000135989.14131.9d; WATTS CH, 1992, MATH BIOSCI, V108, P89, DOI 10.1016/0025-5564(92)90006-I; Wellings K, 2006, LANCET, V368, P1706, DOI 10.1016/S0140-6736(06)69479-8; Wilson D, 2008, LANCET, V372, P423, DOI 10.1016/S0140-6736(08)60883-1; *WORLD BANK, 2003, ED HIV AIDS SOUR HIV	73	16	16	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 25	2008	337								a2638	10.1136/bmj.a2638	http://dx.doi.org/10.1136/bmj.a2638			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385QA	19033334				2023-01-03	WOS:000261827500017
J	Sturkenboom, MCJM; Verhamme, KMC; Nicolosi, A; Murray, ML; Neubert, A; Caudri, D; Picelli, G; Sen, EF; Giaquinto, C; Cantarutti, L; Baiardi, P; Felisi, MG; Ceci, A; Wong, ICK				Sturkenboom, Miriam C. J. M.; Verhamme, Katia M. C.; Nicolosi, Alfredo; Murray, Macey L.; Neubert, Antje; Caudri, Daan; Picelli, Gino; Sen, Elif Fatma; Giaquinto, Carlo; Cantarutti, Luigi; Baiardi, Paola; Felisi, Maria-Grazia; Ceci, Adriana; Wong, Ian C. K.		TEDDY European Network Excellence	Drug use in children: cohort study in three European countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ORAL-CONTRACEPTIVE USE; YOUNG SWEDISH WOMEN; INFECTIOUS CONJUNCTIVITIS; VENOUS THROMBOEMBOLISM; PATIENT RECORDS; STROKE; SUPPRESSION; IMPACT; GROWTH; ACID	Objective To provide an overview of drug use in children in three European countries. Design Retrospective cohort study, 2000-5. Setting Primary care research databases in the Netherlands (IPCI), United Kingdom (IMS-DA), and Italy (Pedianet). Participants 675 868 children aged up to 14 (Italy) or 18 (UK and Netherlands). Main outcome measure Prevalence of use per year calculated by drug class (anatomical and therapeutic). Prevalence of "recurrent/chronic" use (three or more prescriptions a year) and "non-recurrent" or "acute" use (less than three prescriptions a year) within each therapeutic class. Descriptions of the top five most commonly used drugs evaluated for off label status within each anatomical class. Results Three levels of drug use could be distinguished in the study population: high (> 10/100 children per year), moderate (1-10/100 children per year), and low (< 1/100 children per year). For all age categories, anti-infective, dermatological, and respiratory drugs were in the high use group, whereas cardiovascular and antineoplastic drugs were always in the low use group. Emollients, topical steroids, and asthma drugs had the highest prevalence of recurrent use, but relative use of low prevalence drugs was more often recurrent than acute. In the top five highest prevalence drugs topical inhaled and systemic steroids, oral contraceptives, and topical or systemic antifungal drugs were most commonly used off label. Conclusion This overview of outpatient paediatric prescription patterns in a large European population could provide information to prioritise paediatric therapeutic research needs.	[Sturkenboom, Miriam C. J. M.; Verhamme, Katia M. C.; Caudri, Daan; Sen, Elif Fatma] Erasmus Univ, Dept Med Informat, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Sturkenboom, Miriam C. J. M.] Erasmus Univ, Dept Epidemiol, Med Ctr, NL-3000 CA Rotterdam, Netherlands; [Nicolosi, Alfredo] CNR, Inst Biomed Technol, Dept Epidemiol & Med Informat, I-20090 Milan, Italy; [Nicolosi, Alfredo] Columbia Univ, Sch Publ Hlth, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Murray, Macey L.; Neubert, Antje; Wong, Ian C. K.] Univ London, Sch Pharm, Ctr Paediat Pharm Res, London WC1N 1AX, England; [Murray, Macey L.; Neubert, Antje; Wong, Ian C. K.] Univ London, Inst Child Hlth, London WC1N 1AX, England; [Picelli, Gino] Int Pharmacoecon Res Ctr, I-20033 Desio, Italy; [Giaquinto, Carlo] Univ Hosp, Dept Paediat, Padua, Italy; [Cantarutti, Luigi] Soc Servizi Telemat, I-35138 Padua, Italy; [Baiardi, Paola; Felisi, Maria-Grazia; Ceci, Adriana] Consorzio Valutazioni Biol & Farmacol, I-27100 Pavia, Italy	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Columbia University; University of London; University College London; University of London School of Pharmacy; University of London; University College London; University of Padua; Azienda Ospedaliera - Universita di Padova	Sturkenboom, MCJM (corresponding author), Erasmus Univ, Dept Med Informat, Med Ctr, NL-3000 CA Rotterdam, Netherlands.	m.sturkenboom@erasmusmc.nl	Giaquinto, Carlo/AAB-5016-2020; Ceci, Adriana/D-1328-2014; Neubert, Antje/A-7496-2010; Baiardi, Paola/AAB-9060-2020	Baiardi, Paola/0000-0002-1622-8400; Murray, Macey/0000-0001-6418-0854; GIAQUINTO, CARLO/0000-0001-9365-0413; Wong, Ian Chi Kei/0000-0001-8242-0014; Verhamme, Katia/0000-0001-8162-4904	European Community's 6th Framework Programme [LSHB-CT-2005-005216]; UK Department of Health Public Health Career Scientist Award	European Community's 6th Framework Programme; UK Department of Health Public Health Career Scientist Award	The study was funded by the European Community's 6th Framework Programme, project No LSHB-CT-2005-005216: TEDDY: Task force in Europe for Drug Development for the Young. The funding agency had no role in the collection of data, the analysis or interpretation of the data, or of the decision to submit. ICKW's post was funded by a UK Department of Health Public Health Career Scientist Award.	Allen David B, 2006, Adv Pediatr, V53, P101, DOI 10.1016/j.yapd.2006.04.006; Allen DB, 1996, ENDOCRIN METAB CLIN, V25, P699, DOI 10.1016/S0889-8529(05)70348-0; Choonara I, 2002, DRUG SAFETY, V25, P1, DOI 10.2165/00002018-200225010-00001; CLAVENNA A, 2008, EUR J PEDIAT    0430; Cromer BA, 2006, J ADOLESCENT HEALTH, V39, P296, DOI 10.1016/j.jadohealth.2006.03.011; David MA, 2005, J PERIPHER NERV SYST, V10, P18; EIGEN H, 1995, J PEDIATR-US, V126, P515, DOI 10.1016/S0022-3476(95)70343-8; *EUR MED AG, 2006, EMEA496772006; European Medicines Agency, 2004, EMEA1263272004; Gulliver T, 2005, IMMUNOL ALLERGY CLIN, V25, P541, DOI 10.1016/j.iac.2005.04.001; Hamerlynck J V T H, 2007, Ned Tijdschr Geneeskd, V151, P594; Hartard M, 2004, BONE, V35, P836, DOI 10.1016/j.bone.2004.05.017; Heinemann LAJ, 1998, CONTRACEPTION, V57, P29, DOI 10.1016/S0010-7824(97)00204-7; Heinemann LAJ, 1997, BRIT MED J, V315, P1502, DOI 10.1136/bmj.315.7121.1502; Horen B, 2002, BRIT J CLIN PHARMACO, V54, P665, DOI 10.1046/j.1365-2125.2002.t01-3-01689.x; Lewis MA, 1998, AM J OBSTET GYNECOL, V179, pS68, DOI 10.1053/ob.1998.v179.a93122; Lloyd T, 2002, OBSTET GYNECOL, V100, P235, DOI 10.1016/S0029-7844(02)02056-2; Madsen H, 2001, EUR J CLIN PHARMACOL, V57, P159, DOI 10.1007/s002280100279; Neubert A, 2004, DRUG SAFETY, V27, P1059, DOI 10.2165/00002018-200427130-00006; NEUBERT A, PHARM RES IN PRESS; Pandolfini C, 2005, EUR J PEDIATR, V164, P552, DOI 10.1007/s00431-005-1698-8; Rietveld RP, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-54; Rietveld RP, 2005, BRIT J GEN PRACT, V55, P924; Rose K., 2006, GUIDE PAEDIAT CLIN R, P33, DOI [10.1159/000097774, DOI 10.1159/000097774]; Rose P, 2007, EXPERT OPIN PHARMACO, V8, P1903, DOI 10.1517/14656566.8.12.1903; Samuelsson E, 2005, EUR J EPIDEMIOL, V20, P509, DOI 10.1007/s10654-005-4266-7; Samuelsson E, 2004, ACTA OBSTET GYN SCAN, V83, P674, DOI 10.1111/j.0001-6349.2004.00574.x; Schirm E, 2000, BRIT J CLIN PHARMACO, V50, P473, DOI 10.1046/j.1365-2125.2000.00275.x; Sharfstein JM, 2007, NEW ENGL J MED, V357, P2321, DOI 10.1056/NEJMp0707400; Silwer L, 2005, PHARMACOEPIDEM DR S, V14, P813, DOI 10.1002/pds.1124; Sturkenboom M, 2005, PEDIATRICS, V116, pE26, DOI 10.1542/peds.2004-0040; STURKENBOOM MCJ, 2007, PHARMACOVIGILANCE; Sutcliffe AG, 2003, BMJ-BRIT MED J, V326, P64, DOI 10.1136/bmj.326.7380.64; Thrane N, 1999, ACTA PAEDIATR, V88, P1131, DOI 10.1080/08035259950168216; TJONG G, 2002, BRIT MED J, V324, P1314; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; *US FDA, 2005, PED EXCL LAB CHANG J; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; Vlug AE, 1999, METHOD INFORM MED, V38, P339; Watson Rory, 2006, BMJ, V332, P1352, DOI 10.1136/bmj.332.7554.1352-c; WHO, 2007, MAK MED CHILD SIZ; Wong ICK, 2005, BRIT J CLIN PHARMACO, V59, P750, DOI 10.1111/j.1365-2125.2005.02450.x	42	133	135	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2008	337								a2245	10.1136/bmj.a2245	http://dx.doi.org/10.1136/bmj.a2245			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385PZ	19029175	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000261827400001
J	Prausnitz, MR; Langer, R				Prausnitz, Mark R.; Langer, Robert			Transdermal drug delivery	NATURE BIOTECHNOLOGY			English	Review							LOW-FREQUENCY SONOPHORESIS; PENETRATION ENHANCERS; TOPICAL DELIVERY; SKIN ELECTROPORATION; STRATUM-CORNEUM; MICRONEEDLES; IONTOPHORESIS; IMMUNIZATION; SYSTEM; PAIN	Transdermal drug delivery has made an important contribution to medical practice, but has yet to fully achieve its potential as an alternative to oral delivery and hypodermic injections. First-generation transdermal delivery systems have continued their steady increase in clinical use for delivery of small, lipophilic, low-dose drugs. Second-generation delivery systems using chemical enhancers, noncavitational ultrasound and iontophoresis have also resulted in clinical products; the ability of iontophoresis to control delivery rates in real time provides added functionality. Third-generation delivery systems target their effects to skin's barrier layer of stratum corneum using microneedles, thermal ablation, microdermabrasion, electroporation and cavitational ultrasound. Microneedles and thermal ablation are currently progressing through clinical trials for delivery of macromolecules and vaccines, such as insulin, parathyroid hormone and influenza vaccine. Using these novel second- and third-generation enhancement strategies, transdermal delivery is poised to significantly increase its impact on medicine.	[Prausnitz, Mark R.] Georgia Inst Technol, Sch Chem & Biomol Engn, Atlanta, GA 30332 USA; [Langer, Robert] MIT, Dept Chem Engn, Cambridge, MA 02139 USA	University System of Georgia; Georgia Institute of Technology; Massachusetts Institute of Technology (MIT)	Prausnitz, MR (corresponding author), Georgia Inst Technol, Sch Chem & Biomol Engn, 311 Ferst Dr, Atlanta, GA 30332 USA.	prausnitz@gatech.edu		Prausnitz, Mark/0000-0002-9076-8448	National Institutes of Health; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB006369] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Daniel Bucks, Gary Cleary, Robert Gale, Samir Mitragotri and Audra Stinchcomb for helpful discussions. M. R. P. is the Emerson-Lewis Faculty Fellow and works at the Center for Drug Design, Development and Delivery and the Institute for Bioengineering and Bioscience at Georgia Tech. This work was supported in part by the National Institutes of Health.	Arora A, 2008, INT J PHARMACEUT, V364, P227, DOI 10.1016/j.ijpharm.2008.08.032; Badkar AV, 2007, PHARM RES-DORDR, V24, P1389, DOI 10.1007/s11095-007-9308-2; Banga A.K., 1998, ELECT ASSISTED TRANS; Beauchamp M, 2005, PEDIATR PULM, V39, P507, DOI 10.1002/ppul.20226; Becker BM, 2005, ACAD EMERG MED, V12, P289, DOI 10.1197/j.aem.2004.11.019; Bouwstra JA, 2003, J INVEST DERMATOL, V120, P750, DOI 10.1046/j.1523-1747.2003.12128.x; Bramson J, 2003, GENE THER, V10, P251, DOI 10.1038/sj.gt.3301886; Bronaugh R.L., 2005, PERCUTANEOUS ABSORPT; Chaturvedula A, 2005, PHARM RES-DORDR, V22, P1313, DOI 10.1007/s11095-005-5335-z; Chen YP, 2006, NAT BIOTECHNOL, V24, P455, DOI 10.1038/nbt1193; Chuang Han, 2004, Diabetes Technol Ther, V6, P21, DOI 10.1089/152091504322783378; Denet AR, 2004, ADV DRUG DELIVER REV, V56, P659, DOI 10.1016/j.addr.2003.10.027; Doukas AG, 2004, ADV DRUG DELIVER REV, V56, P559, DOI 10.1016/j.addr.2003.10.031; *FDA, 2007, APPR DRUG PROD THER; Foldvari Marianna, 2006, Current Drug Delivery, V3, P17, DOI 10.2174/156720106775197493; Gill HS, 2007, J CONTROL RELEASE, V117, P227, DOI 10.1016/j.jconrel.2006.10.017; Glenn GM, 2006, CURR TOP MICROBIOL, V304, P247; Glenn GM, 2007, EXPERT REV VACCINES, V6, P809, DOI 10.1586/14760584.6.5.809; Guy R. H., 2003, TRANSDERMAL DRUG DEL; HEMDON TO, 2004, BMC MED, V2, P12; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Karande P, 2005, P NATL ACAD SCI USA, V102, P4688, DOI 10.1073/pnas.0501176102; Karande P, 2004, NAT BIOTECHNOL, V22, P192, DOI 10.1038/nbt928; Kim YC, 2007, J CONTROL RELEASE, V122, P375, DOI 10.1016/j.jconrel.2007.05.031; Kiptoo PK, 2006, J CONTROL RELEASE, V113, P137, DOI 10.1016/j.jconrel.2006.04.003; Kogan A, 2006, ADV COLLOID INTERFAC, V123, P369, DOI 10.1016/j.cis.2006.05.014; Kreyden Oliver P, 2004, J Cosmet Dermatol, V3, P211, DOI 10.1111/j.1473-2130.2004.00126.x; Laurent PE, 2007, VACCINE, V25, P8833, DOI 10.1016/j.vaccine.2007.10.020; Lee JW, 2008, BIOMATERIALS, V29, P2113, DOI 10.1016/j.biomaterials.2007.12.048; Levin G, 2005, PHARM RES-DORDR, V22, P550, DOI 10.1007/s11095-005-2498-6; Li S, 2008, ELECTROPORATION PROT; Machet L, 2002, INT J PHARMACEUT, V243, P1, DOI 10.1016/S0378-5173(02)00299-5; Mayes S, 2006, ANN PHARMACOTHER, V40, P2178, DOI 10.1345/aph.1H135; Miller MA, 1999, B WORLD HEALTH ORGAN, V77, P808; Mitragotri S, 2000, PHARMACEUT RES, V17, P1354, DOI 10.1023/A:1007522114438; Morgan TM, 1998, J PHARM SCI, V87, P1213, DOI 10.1021/js980025k; Morrel EM, 2006, CLIN INFECT DIS, V43, P460, DOI 10.1086/505872; Ogura M, 2008, ADV DRUG DELIVER REV, V60, P1218, DOI 10.1016/j.addr.2008.03.006; Paliwal S, 2006, J INVEST DERMATOL, V126, P1095, DOI 10.1038/sj.jid.5700248; Park EJ, 2007, PHARM RES-DORDR, V24, P1396, DOI 10.1007/s11095-007-9306-4; Park JH, 2008, INT J PHARMACEUT, V359, P94, DOI 10.1016/j.ijpharm.2008.03.032; Pikal MJ, 2001, ADV DRUG DELIVER REV, V46, P281, DOI 10.1016/S0169-409X(00)00138-1; Pliquett U, 2007, IEEE T BIO-MED ENG, V54, P536, DOI 10.1109/TBME.2006.886828; Prausnitz MR, 1996, ADV DRUG DELIVER REV, V18, P395, DOI 10.1016/0169-409X(95)00081-H; Prausnitz MR, 2004, NAT REV DRUG DISCOV, V3, P115, DOI 10.1038/nrd1304; PRAUSNITZ MR, CURR TOP MI IN PRESS; Prausnitz MR, 2008, MICRONEEDLES DRUG DE, V2, P1295; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Sieg Anke, 2005, Diabetes Technol Ther, V7, P174, DOI 10.1089/dia.2005.7.174; Sivamani RK, 2007, EXPERT OPIN DRUG DEL, V4, P19, DOI 10.1517/17425247.4.1.19; Sloan KB, 2006, PHARM RES-DORDR, V23, P2729, DOI 10.1007/s11095-006-9108-0; Smith E. W., 2006, PERCUTANEOUS PENETRA, V2; Subramony JA, 2006, INT J PHARMACEUT, V317, P1, DOI 10.1016/j.ijpharm.2006.03.053; Tamada JA, 1999, JAMA-J AM MED ASSOC, V282, P1839, DOI 10.1001/jama.282.19.1839; Touitou E, 2007, ENHANCEMENT DRUG DEL, P255; Venkatraman S, 1998, BIOMATERIALS, V19, P1119, DOI 10.1016/S0142-9612(98)00020-9; Weniger BG, 2008, VACCINES-BASEL, Vfifth, P1357, DOI [10.1016/B978-1-4160-3611-1.50065-9, DOI 10.1016/B978-1-4160-3611-1.50065-9, 10.1016/b978-1-4160-3611-1.50065-9]; Wermeling DP, 2008, P NATL ACAD SCI USA, V105, P2058, DOI 10.1073/pnas.0710355105; Williams AC, 2004, ADV DRUG DELIVER REV, V56, P603, DOI 10.1016/j.addr.2003.10.025; Williams AC, 2003, TRANSDERMAL TOPICAL, P27; Wu J, 2006, EMERGING THERAPEUTIC ULTRASOUND, P1, DOI 10.1142/9789812774125; Zempsky WT, 2004, CLIN THER, V26, P1110, DOI 10.1016/S0149-2918(04)90183-X; Zhao YL, 2006, VACCINE, V24, P1282, DOI 10.1016/j.vaccine.2005.09.035	63	1866	2008	53	1163	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2008	26	11					1261	1268		10.1038/nbt.1504	http://dx.doi.org/10.1038/nbt.1504			8	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371LG	18997767	Green Accepted			2023-01-03	WOS:000260832200021
J	Murphy, HR; Rayman, G; Lewis, K; Kelly, S; Johal, B; Duffield, K; Fowler, D; Campbell, PJ; Temple, RC				Murphy, Helen R.; Rayman, Gerry; Lewis, Karen; Kelly, Susan; Johal, Balroop; Duffield, Katherine; Fowler, Duncan; Campbell, Peter J.; Temple, Rosemary C.			Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GESTATIONAL-AGE INFANTS; BIRTH-WEIGHT; GLYCEMIC CONTROL; MATERNAL GLUCOSE; TYPE-1; MELLITUS; OUTCOMES; MACROSOMIA; INSULIN; NATIONWIDE	Objective To evaluate the effectiveness of continuous glucose monitoring during pregnancy on maternal glycaemic control, infant birth weight, and risk of macrosomia in women with type 1 and type 2 diabetes. Design Prospective, open label randomised controlled trial. Setting Two secondary care multidisciplinary obstetric clinics for diabetes in the United Kingdom. Participants 71 women with type 1 diabetes (n=46) or type 2 diabetes (n=25) allocated to antenatal care plus continuous glucose monitoring (n=38) or to standard antenatal care (n=33). Intervention Continuous glucose monitoring was used as an educational tool to inform shared decision making and future therapeutic changes at intervals of 4-6 weeks during pregnancy. All other aspects of antenatal care were equal between the groups. Main outcome measures The primary outcome was maternal glycaemic control during the second and third trimesters from measurements of HbA(1c) levels every four weeks. Secondary outcomes were birth weight and risk of macrosomia using birthweight standard deviation scores and customised birthweight centiles. Statistical analyses were done on an intention to treat basis. Results Women randomised to continuous glucose monitoring had lower mean HbA(1c) levels from 32 to 36 weeks' gestation compared with women randomised to standard antenatal care: 5.8% (SD 0.6) v 6.4% (SD 0.7). Compared with infants of mothers in the control arm those of mothers in the intervention arm had decreased mean birthweight standard deviation scores (0.9 v 1.6; effect size 0.7 SD, 95% confidence interval 0.0 to 1.3), decreased median customised birthweight centiles (69% v 93%), and a reduced risk of macrosomia (odds ratio 0.36, 95% confidence interval 0.13 to 0.98). Conclusion Continuous glucose monitoring during pregnancy is associated with improved glycaemic control in the third trimester, lower birth weight, and reduced risk of macrosomia. Trial registration Current Controlled Trials ISRCTN84461581.	[Murphy, Helen R.; Rayman, Gerry; Lewis, Karen; Fowler, Duncan] Ipswich Hosp NHS Trust, Dept Diabet & Endocrinol, Ipswich, Suffolk, England; [Kelly, Susan] Ipswich Hosp NHS Trust, Dept Diabet, Ipswich, Suffolk, England; [Kelly, Susan; Johal, Balroop] Ipswich Hosp NHS Trust, Dept Obstet, Ipswich, Suffolk, England; [Duffield, Katherine; Temple, Rosemary C.] Elsie Bertram Diabet Ctr, Norwich, Norfolk, England; [Duffield, Katherine; Temple, Rosemary C.] Norwich Univ Hosp NHS Trust, Norwich, Norfolk, England; [Campbell, Peter J.] Wellcome Trust Sanger Inst, Cambridge, England	Ipswich Hospital NHS Trust; Ipswich Hospital; Ipswich Hospital NHS Trust; Ipswich Hospital; Ipswich Hospital NHS Trust; Ipswich Hospital; Wellcome Trust Sanger Institute	Murphy, HR (corresponding author), Ipswich Hosp NHS Trust, Dept Diabet & Endocrinol, Ipswich, Suffolk, England.	Helen.Murphy@ipswichhospital.nhs.uk						Boulet SL, 2003, AM J OBSTET GYNECOL, V188, P1372, DOI 10.1067/mob.2003.302; BUCKLER JMH, 1994, ARCH DIS CHILD, V71, P516, DOI 10.1136/adc.71.6.516; CEMACH, 2005, CONF ENQ MAT CHILD H; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4&lt;407::AID-SIM742&gt;3.0.CO;2-L; COMBS CA, 1992, DIABETES CARE, V15, P1251, DOI 10.2337/diacare.15.10.1251; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; Diabetes Research in Children Network (DIRECNET) Study Group, 2003, Diabetes Technol Ther, V5, P781; Evers IM, 2002, DIABETOLOGIA, V45, P1484, DOI 10.1007/s00125-002-0958-7; Farrar D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005542; Herranz L, 2007, DIABETES RES CLIN PR, V75, P42, DOI 10.1016/j.diabres.2006.05.019; Hovorka R, 2006, DIABETIC MED, V23, P1, DOI 10.1111/j.1464-5491.2005.01672.x; Hovorka R, 2007, AM J PHYSIOL-ENDOC M, V293, pE610, DOI 10.1152/ajpendo.00546.2006; Howorka K, 2001, DIABETIC MED, V18, P965, DOI 10.1046/j.1464-5491.2001.00621.x; Jensen DM, 2004, DIABETES CARE, V27, P2819, DOI 10.2337/diacare.27.12.2819; Johnstone FD, 2006, OBSTET GYNECOL, V107, P1297, DOI 10.1097/01.AOG.0000218706.38886.10; Jolly MC, 2003, EUR J OBSTET GYN R B, V111, P9, DOI 10.1016/S0301-2115(03)00154-4; JOVANOVICPETERSON L, 1991, AM J OBSTET GYNECOL, V164, P103, DOI 10.1016/0002-9378(91)90637-7; *JUV DIAB RES FDN, 2008, N ENGL J MED    0908; Kerssen A, 2006, DIABETOLOGIA, V49, P25, DOI 10.1007/s00125-005-0057-7; Kerssen A, 2007, DIABETES CARE, V30, P1069, DOI 10.2337/dc05-1985; Klonoff DC, 2005, DIABETES CARE, V28, P1231, DOI 10.2337/diacare.28.5.1231; LANGER O, 1991, AM J OBSTET GYNECOL, V165, P831, DOI 10.1016/0002-9378(91)90424-P; Macintosh MCM, 2006, BRIT MED J, V333, P177, DOI 10.1136/bmj.38856.692986.AE; Manderson JG, 2003, AM J OBSTET GYNECOL, V189, P507, DOI 10.1067/S0002-9378(03)00497-6; Murphy HR, 2007, DIABETES CARE, V30, P2785, DOI 10.2337/dc07-0500; Murtaugh MA, 2003, DIABETES CARE, V26, P187, DOI 10.2337/diacare.26.1.187; Persson B, 1996, BRIT J OBSTET GYNAEC, V103, P427, DOI 10.1111/j.1471-0528.1996.tb09768.x; Roland JM, 2005, DIABETIC MED, V22, P1774, DOI 10.1111/j.1464-5491.2005.01784.x; Sachedina N, 2003, DIABETIC MED, V20, P1012, DOI 10.1046/j.1464-5491.2003.01037.x; Sacks DA, 2006, AM J OBSTET GYNECOL, V194, P501, DOI 10.1016/j.ajog.2005.07.042; Temple RC, 2006, DIABETES CARE, V29, P1744, DOI 10.2337/dc05-2265; Van Assche EA, 1998, J PERINAT MED, V26, P337; *W MIDL PER I NHS, 2007, GEST NETW; Yogev Y, 2003, DIABETIC MED, V20, P558, DOI 10.1046/j.1464-5491.2003.00959.x; Yogev Y, 2003, OBSTET GYNECOL, V101, P633, DOI 10.1016/S0029-7844(02)02714-X; 2008, NICE GUIDELINE 63 DI	36	206	210	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 18	2008	337	7675							a1680	10.1136/bmj.a1680	http://dx.doi.org/10.1136/bmj.a1680			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360YE	18818254	hybrid, Green Published			2023-01-03	WOS:000260093900033
J	Wright, AA; Zhang, BH; Ray, A; Mack, JW; Trice, E; Balboni, T; Mitchell, SL; Jackson, VA; Block, SD; Maciejewski, PK; Prigerson, HG				Wright, Alexi A.; Zhang, Baohui; Ray, Alaka; Mack, Jennifer W.; Trice, Elizabeth; Balboni, Tracy; Mitchell, Susan L.; Jackson, Vicki A.; Block, Susan D.; Maciejewski, Paul K.; Prigerson, Holly G.			Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVANCED CANCER-PATIENTS; TREATMENT PREFERENCES; FAMILY CAREGIVERS; IMMINENT DEATH; SERIOUSLY ILL; BAD-NEWS; COMMUNICATION; PROGNOSIS; PHYSICIANS; ILLNESS	Context Talking about death can be difficult. Without evidence that end- of- life discussions improve patient outcomes, physicians must balance their desire to honor patient autonomy against a concern of inflicting psychological harm. Objective To determine whether end- of- life discussions with physicians are associated with fewer aggressive interventions. Design, Setting, and Participants A US multisite, prospective, longitudinal cohort study of patients with advanced cancer and their informal caregivers ( n= 332 dy-ads), September 2002- February 2008. Patients were followed up from enrollment to death, a median of 4.4 months later. Bereaved caregivers' psychiatric illness and quality of life was assessed a median of 6.5 months later. Main Outcome Measures Aggressive medical care ( eg, ventilation, resuscitation) and hospice in the final week of life. Secondary outcomes included patients' mental health and caregivers' bereavement adjustment. Results One hundred twenty- three of 332 ( 37.0%) patients reported having end-of-life discussions before baseline. Such discussions were not associated with higher rates of major depressive disorder ( 8.3% vs 5.8%; adjusted odds ratio [ OR], 1.33; 95% confidence interval [ CI], 0.54- 3.32), or more worry ( mean McGill score, 6.5 vs 7.0; P=. 19). After propensity- score weighted adjustment, end- of- life discussions were associated with lower rates of ventilation ( 1.6% vs 11.0%; adjusted OR, 0.26; 95% CI, 0.08- 0.83), resuscitation ( 0.8% vs 6.7%; adjusted OR, 0.16; 95% CI, 0.03- 0.80), ICU admission ( 4.1% vs 12.4%; adjusted OR, 0.35; 95% CI, 0.14- 0.90), and earlier hospice enrollment ( 65.6% vs 44.5%; adjusted OR, 1.65; 95% CI, 1.04- 2.63). In adjusted analyses, more aggressive medical care was associated with worse patient quality of life ( 6.4 vs 4.6; F= 3.61, P=. 01) and higher risk of major depressive disorder in bereaved caregivers ( adjusted OR, 3.37; 95% CI, 1.12- 10.13), whereas longer hospice stays were associated with better patient quality of life ( mean score, 5.6 vs 6.9; F= 3.70, P=. 01). Better patient quality of life was associated with better caregiver quality of life at follow- up (beta=. 20; P=. 001). Conclusions End- of- life discussions are associated with less aggressive medical care near death and earlier hospice referrals. Aggressive care is associated with worse patient quality of life and worse bereavement adjustment.	[Wright, Alexi A.; Trice, Elizabeth] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wright, Alexi A.; Zhang, Baohui; Ray, Alaka; Trice, Elizabeth; Balboni, Tracy; Block, Susan D.; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA; [Mack, Jennifer W.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA; [Ray, Alaka; Jackson, Vicki A.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Balboni, Tracy] Harvard Univ, Harvard Radiat Oncol Program, Boston, MA USA; [Jackson, Vicki A.; Block, Susan D.; Prigerson, Holly G.] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA; [Mitchell, Susan L.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Block, Susan D.; Maciejewski, Paul K.; Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital	Wright, AA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 550 Shields Warren,44 Binney St, Boston, MA 02115 USA.	awright2@partners.org	Prigerson, Holly/L-3800-2019; Balboni, Tracy/AAH-4490-2020; Wright, Alexi/T-5793-2019; Prigerson, Holly/GWV-3283-2022	Prigerson, Holly/0000-0002-7075-4268; 	National Cancer Institute [CA 106370]; National Institute of Mental Health [MH63892]; National Cancer Institute's "Program in Cancer Outcomes Research Training" [CA 92044343]; Dana-Farber Cancer Institute's Friends Fellowship; NATIONAL CANCER INSTITUTE [R01CA106370, T32CA009172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG033640] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Cancer Institute's "Program in Cancer Outcomes Research Training"; Dana-Farber Cancer Institute's Friends Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was supported by grants CA 106370 from the National Cancer Institute and MH63892 from the National Institute of Mental Health. Dr Wright was supported, in part, by grant CA 92044343, which is part of the National Cancer Institute's "Program in Cancer Outcomes Research Training" and by the Dana-Farber Cancer Institute's Friends Fellowship.	Albano JD, 2007, JNCI-J NATL CANCER I, V99, P1384, DOI 10.1093/jnci/djm127; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Back Anthony L, 2003, Ann Intern Med, V138, P439; Baile WF, 2002, J CLIN ONCOL, V20, P2189, DOI 10.1200/JCO.2002.08.004; Balboni TA, 2007, J CLIN ONCOL, V25, P555, DOI 10.1200/JCO.2006.07.9046; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cherlin E, 2005, J PALLIAT MED, V8, P1176, DOI 10.1089/jpm.2005.8.1176; Christakis NA, 1999, DEATH FORETOLD PROPH; Chu KC, 2007, J NATL MED ASSOC, V99, P1092; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; ENDICOTT J, 1984, CANCER, V53, P2243; First M, 2016, STRUCTURED CLIN INTE; Fried TR, 2003, J AM GERIATR SOC, V51, P1398, DOI 10.1046/j.1532-5415.2003.51457.x; Gessert Charles E., 2001, Ethnicity and Disease, V11, P97; Gordon EJ, 2003, BIOETHICS, V17, P142, DOI 10.1111/1467-8519.00330; Hagerty RG, 2004, J CLIN ONCOL, V22, P1721, DOI 10.1200/JCO.2004.04.095; Hagerty RG, 2005, J CLIN ONCOL, V23, P1278, DOI 10.1200/JCO.2005.11.138; Hancock K, 2007, PALLIATIVE MED, V21, P507, DOI 10.1177/0269216307080823; Harrington SE, 2008, JAMA-J AM MED ASSOC, V299, P2667, DOI 10.1001/jama.299.22.2667; Helft PR, 2005, J CLIN ONCOL, V23, P3146, DOI 10.1200/JCO.2005.07.003; Hofmann JC, 1997, ANN INTERN MED, V127, P1, DOI 10.7326/0003-4819-127-1-199707010-00001; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Kris AE, 2006, AM J GERIAT PSYCHIAT, V14, P264, DOI 10.1097/01.JGP.0000194642.86116.ce; Lamont E B, 2000, J Palliat Med, V3, P27, DOI 10.1089/jpm.2000.3.27; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lehmann L, 2007, J CLIN ONCOL, V25; Leydon GM, 2000, BMJ-BRIT MED J, V320, P909, DOI 10.1136/bmj.320.7239.909; Maciejewski PK, 2007, JAMA-J AM MED ASSOC, V297, P716, DOI 10.1001/jama.297.7.716; Mack JW, 2008, CANCER-AM CANCER SOC, V112, P2509, DOI 10.1002/cncr.23476; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; PRIGERSON HG, 1992, J HEALTH SOC BEHAV, V33, P378, DOI 10.2307/2137315; Ptacek JT, 2001, J BEHAV MED, V24, P205, DOI 10.1023/A:1010766732373; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Ray A, 2006, J PALLIAT MED, V9, P1359, DOI 10.1089/jpm.2006.9.1359; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Selman L, 2007, HEART, V93, P963, DOI 10.1136/hrt.2006.106518; Siegel MD, 2008, CRIT CARE MED, V36, P1722, DOI 10.1097/CCM.0b013e318174da72; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Sullivan AM, 2007, J PALLIAT MED, V10, P882, DOI 10.1089/jpm.2007.0189; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; The AM, 2001, WESTERN J MED, V174, P247, DOI 10.1136/ewjm.174.4.247; Trice ED, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.6506; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630	49	1791	1799	7	156	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2008	300	14					1665	1673		10.1001/jama.300.14.1665	http://dx.doi.org/10.1001/jama.300.14.1665			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	356YF	18840840	Green Accepted, Bronze			2023-01-03	WOS:000259812800028
J	Vermorken, JB; Mesia, R; Rivera, F; Remenar, E; Kawecki, A; Rottey, S; Erfan, J; Zabolotnyy, D; Kienzer, HR; Cupissol, D; Peyrade, F; Benasso, M; Vynnychenko, I; De Raucourt, D; Bokemeyer, C; Schueler, A; Amellal, N; Hitt, R				Vermorken, Jan B.; Mesia, Ricard; Rivera, Fernando; Remenar, Eva; Kawecki, Andrzej; Rottey, Sylvie; Erfan, Jozsef; Zabolotnyy, Dmytro; Kienzer, Heinz-Roland; Cupissol, Didier; Peyrade, Frederic; Benasso, Marco; Vynnychenko, Ihor; De Raucourt, Dominique; Bokemeyer, Carsten; Schueler, Armin; Amellal, Nadia; Hitt, Ricardo			Platinum-based chemotherapy plus cetuximab in head and neck cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; PHASE-II MULTICENTER; ANTIBODY CETUXIMAB; ONCOLOGY-GROUP; SINGLE-AGENT; COPY NUMBER; CISPLATIN; RECURRENT; FLUOROURACIL	Background: Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus platinum-based chemotherapy as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. Methods: We randomly assigned 220 of 442 eligible patients with untreated recurrent or metastatic squamous-cell carcinoma of the head and neck to receive cisplatin (at a dose of 100 mg per square meter of body-surface area on day 1) or carboplatin (at an area under the curve of 5 mg per milliliter per minute, as a 1-hour intravenous infusion on day 1) plus fluorouracil (at a dose of 1000 mg per square meter per day for 4 days) every 3 weeks for a maximum of 6 cycles and 222 patients to receive the same chemotherapy plus cetuximab (at a dose of 400 mg per square meter initially, as a 2-hour intravenous infusion, then 250 mg per square meter, as a 1-hour intravenous infusion per week) for a maximum of 6 cycles. Patients with stable disease who received chemotherapy plus cetuximab continued to receive cetuximab until disease progression or unacceptable toxic effects, whichever occurred first. Results: Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracil) significantly prolonged the median overall survival from 7.4 months in the chemotherapy-alone group to 10.1 months in the group that received chemotherapy plus cetuximab (hazard ratio for death, 0.80; 95% confidence interval, 0.64 to 0.99; P=0.04). The addition of cetuximab prolonged the median progression-free survival time from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P<0.001) and increased the response rate from 20% to 36% (P<0.001). The most common grade 3 or 4 adverse events in the chemotherapy-alone and cetuximab groups were anemia (19% and 13%, respectively), neutropenia (23% and 22%), and thrombocytopenia (11% in both groups). Sepsis occurred in 9 patients in the cetuximab group and in 1 patient in the chemotherapy-alone group (P=0.02). Of 219 patients receiving cetuximab, 9% had grade 3 skin reactions and 3% had grade 3 or 4 infusion-related reactions. There were no cetuximab-related deaths. Conclusions: As compared with platinum-based chemotherapy plus fluorouracil alone, cetuximab plus platinum-fluorouracil chemotherapy improved overall survival when given as first-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. (ClinicalTrials.gov number, NCT00122460.).	[Vermorken, Jan B.] Univ Antwerp Hosp, Dept Med Oncol, B-2650 Edegem, Belgium; [Rottey, Sylvie] Ghent Univ Hosp, B-9000 Ghent, Belgium; [Mesia, Ricard] Hosp Llobregat, Inst Catala Oncol, Barcelona, Spain; [Rivera, Fernando] Hosp Univ Marques de Valdecilla, Santander, Spain; [Hitt, Ricardo] Hosp 12 Octubre, E-28041 Madrid, Spain; [Remenar, Eva] Orszagos Onkol Intezet, Budapest, Hungary; [Erfan, Jozsef] Szabolcs Szatmar Bereg Megyei Josa Andras Korh, Nyiregyhaza, Hungary; [Kawecki, Andrzej] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland; [Zabolotnyy, Dmytro] Ukraine Acad Med Sci, Inst Otolaryngol, Kiev, Ukraine; [Vynnychenko, Ihor] Sumy Reg Oncol Ctr, Sumy, Ukraine; [Kienzer, Heinz-Roland] Kaiser Franz Josef Spital, Ludwig Boltzmann Inst Appl Canc Res, Vienna, Austria; [Cupissol, Didier] Ctr Val Aurelle, Paul Lamarque Serv Oncol, Montpellier, France; [Peyrade, Frederic] Ctr Antoine Lacassagne, F-06054 Nice, France; [De Raucourt, Dominique] Ctr Francois Baclesse, F-14021 Caen, France; [Benasso, Marco] Ist Nazl Ric Canc, I-16132 Genoa, Italy; [Bokemeyer, Carsten] Universitaetskrankenhaus Hamburg Eppendorf, Hamburg, Germany; [Schueler, Armin; Amellal, Nadia] Merck, Darmstadt, Germany	University of Antwerp; Ghent University; Ghent University Hospital; Catalan Institute of Oncology; University of Barcelona; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario 12 de Octubre; Maria Sklodowska-Curie National Research Institute of Oncology; National Academy of Medical Sciences of Ukraine; Kolomiychenko Institute of Otolaryngology of the National Academy of Medical Sciences of Ukraine; Ministry of Education & Science of Ukraine; Sumy State University; Kaiser-Franz-Josef Hospital; Ludwig Boltzmann Institute; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); UNICANCER; Centre Antoine Lacassagne; UNICANCER; Centre Francois Baclesse; University of Genoa; IRCCS AOU San Martino IST; University of Hamburg; University Medical Center Hamburg-Eppendorf; Merck & Company; Merck & Company Germany	Vermorken, JB (corresponding author), Univ Antwerp Hosp, Dept Med Oncol, Wilrijkstr 10, B-2650 Edegem, Belgium.	jan.b.vermorken@uza.be	Vynnychenko, Ihor O/E-1684-2012	Vynnychenko, Ihor O/0000-0002-2339-6509; Schueler, Armin/0000-0003-3833-5757	Merck (Darmstadt)	Merck (Darmstadt)(Merck & Company)	Supported by Merck (Darmstadt).	Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Bourhis J, 2006, J CLIN ONCOL, V24, P2866, DOI 10.1200/JCO.2005.04.3547; Burtness B, 2005, J CLIN ONCOL, V23, P8646, DOI 10.1200/JCO.2005.02.4646; Burtness B, 2006, J CLIN ONCOL, V24, P724; Chung CH, 2006, J CLIN ONCOL, V24, P4170, DOI 10.1200/JCO.2006.07.2587; COLLETT D, 2003, MODELLING SURVIVAL D, P49; FAN Z, 1993, CANCER RES, V53, P4637; FORASTIERE AA, 1992, J CLIN ONCOL, V10, P1245, DOI 10.1200/JCO.1992.10.8.1245; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Herbst RS, 2005, J CLIN ONCOL, V23, P5578, DOI 10.1200/JCO.2005.07.120; JACOBS C, 1992, J CLIN ONCOL, V10, P257, DOI 10.1200/JCO.1992.10.2.257; Kang X, 2007, J CLIN ONCOL S, V25, p128s; Kimura H, 2007, CANCER SCI, V98, P1275, DOI 10.1111/j.1349-7006.2007.00510.x; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Lokich J, 1998, ANN ONCOL, V9, P13, DOI 10.1023/A:1008215213739; Lokich J, 1998, ANN ONCOL, V9, P341, DOI 10.1023/A:1017142015279; Sato J D, 1983, Mol Biol Med, V1, P511; Schantz SPHL, 2001, CANC PRINCIPLES PRAC, P797; Temam S, 2007, J CLIN ONCOL, V25, P2164, DOI 10.1200/JCO.2006.06.6605; Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; WITTES RE, 1977, CANCER TREAT REP, V61, P359; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021	24	2317	2387	1	101	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 11	2008	359	11					1116	1127		10.1056/NEJMoa0802656	http://dx.doi.org/10.1056/NEJMoa0802656			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	346ON	18784101	Bronze			2023-01-03	WOS:000259078200007
J	Watts, G				Watts, Geoff			How clean is your water?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												geoff@scileg.freeserve.co.uk						*ASS PRESS, 2008, SEN BLAST EPA NEWS D; Collier AC, 2007, ECOHEALTH, V4, P164, DOI 10.1007/s10393-007-0105-5; DONN J, 2008, PHARM LURKING US DRI; *DRINK WAT INSP, 2001, PHARM RES DRINK WAT; *EUR MED AG, HUM MED EMEA PRES PR; Heberer T, 2002, J HYDROL, V266, P175, DOI 10.1016/S0022-1694(02)00165-8; Johnson AC, 2008, J HYDROL, V348, P167, DOI 10.1016/j.jhydrol.2007.09.054; Loos R, 2007, ANAL BIOANAL CHEM, V387, P1469, DOI 10.1007/s00216-006-1036-7; Pomati F, 2006, ENVIRON SCI TECHNOL, V40, P2442, DOI 10.1021/es051715a	9	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 12	2008	337	7661							a237	10.1136/bmj.a237	http://dx.doi.org/10.1136/bmj.a237			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330SA	18595920	Green Published			2023-01-03	WOS:000257961900029
J	Stillman, MD				Stillman, Michael D.			Physicians behaving badly	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												michael.stillman@bmc.org						Moore C, 2007, ARCH INTERN MED, V167, P1305, DOI 10.1001/archinte.167.12.1305; Sijstermans R, 2007, INT J MED INFORM, V76, P336, DOI 10.1016/j.ijmedinf.2007.01.007	2	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 2	2008	300	1					21	22		10.1001/jama.300.1.21	http://dx.doi.org/10.1001/jama.300.1.21			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	320NW	18594028				2023-01-03	WOS:000257242800001
J	Martinez-Gonzalez, MA; de la Fuente-Arrillaga, C; Nunez-Cordoba, JM; Basterra-Gortari, FJ; Beunza, JJ; Vazquez, Z; Benito, S; Tortosa, A; Bes-Rastrollo, M				Martinez-Gonzalez, M. A.; de la Fuente-Arrillaga, C.; Nunez-Cordoba, J. M.; Basterra-Gortari, F. J.; Beunza, J. J.; Vazquez, Z.; Benito, S.; Tortosa, A.; Bes-Rastrollo, M.			Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; VIRGIN OLIVE OIL; LIFE-STYLE; MYOCARDIAL-INFARCTION; ENDOTHELIAL DYSFUNCTION; PLASMA-CONCENTRATIONS; MONOUNSATURATED-FAT; METABOLIC SYNDROME; SURVIVAL; INFLAMMATION	Objective To assess the relation between adherence to a Mediterranean diet and the incidence of diabetes among initially healthy participants. Design Prospective cohort study with estimates of relative risk adjusted for sex, age, years of university education, total energy intake, body mass index, physical activity, sedentary habits, smoking, family history of diabetes, and personal history of hypertension. Setting Spanish university department. Participants 13 380 Spanish university graduates without diabetes at baseline followed up fora median of 4.4 years. Main outcome measures Dietary habits assessed at baseline with a validated 136 item food frequency questionnaire and scored on a nine point index. New cases of diabetes confirmed through medical reports and an additional detailed questionnaire posted to those who self reported a new diagnosis of diabetes by a doctor during follow-up. Confirmed cases of type 2 diabetes. Results Participants who adhered closely to a Mediterranean diet had a lower risk of diabetes. The incidence rate ratios adjusted for sex and age were 0.41 (95% confidence interval 0.19 to 0.87) for those with moderate adherence (score 3-6) and 0.17 (0.04 to 0.75) for those with the highest adherence (score 7-9) compared with those with low adherence (score <3). In the fully adjusted analyses the results were similar. A two point increase in the score was associated with a 35% relative reduction in the risk of diabetes (incidence rate ratio 0.65, 0.44 to 0.95), with a significant inverse linear trend (P=0.04) in the multivariate analysis. Conclusion Adherence to a Mediterranean diet is associated with a reduced risk of diabetes.	[Martinez-Gonzalez, M. A.; de la Fuente-Arrillaga, C.; Nunez-Cordoba, J. M.; Basterra-Gortari, F. J.; Beunza, J. J.; Vazquez, Z.; Benito, S.; Tortosa, A.; Bes-Rastrollo, M.] Univ Navarra, Sch Med, Clin Univ, Dept Prevent Med & Publ Hlth, E-31080 Pamplona, Spain; [Nunez-Cordoba, J. M.] Hosp Virgen Camino, Dept Prevent Med & Qual Management, Pamplona, Spain; [Basterra-Gortari, F. J.] Hosp Navarra, Dept Endocrinol, Pamplona, Spain	University of Navarra; Hospital Virgen del Camino; Servicio Navarro de Salud - Osasunbidea; Servicio Navarro de Salud - Osasunbidea	Martinez-Gonzalez, MA (corresponding author), Univ Navarra, Sch Med, Clin Univ, Dept Prevent Med & Publ Hlth, E-31080 Pamplona, Spain.	mamartinez@unav.es	Vázquez-Ruiz, Zenaida/AAB-7202-2020; Martinez-Gonzalez, Miguel A./AAE-7669-2019; Beunza, Juan-Jose/ABF-4650-2020; Bes-Rastrollo, Maira/A-1329-2009	Vázquez-Ruiz, Zenaida/0000-0002-6828-9627; Bes-Rastrollo, Maira/0000-0002-9139-4206; Martinez-Gonzalez, Miguel A./0000-0002-3917-9808; Beunza, Juan-Jose/0000-0001-8192-2952				Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Alberti KGMM, 2007, DIABETIC MED, V24, P451, DOI 10.1111/j.1464-5491.2007.02157.x; Bach A, 2006, PUBLIC HEALTH NUTR, V9, P132, DOI 10.1079/PHN2005936; Bes-Rastrollo M., 2005, REV ESP OBES, V3, P352; Biesalski H. K., 2004, European Journal of Nutrition, V43, DOI 10.1007/s00394-004-0493-z; Biesalski HK, 2004, EUR J NUTR, V43, P26, DOI 10.1007/s00394-004-1106-6; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Fito M, 2008, EUR J CLIN NUTR, V62, P570, DOI 10.1038/sj.ejcn.1602724; Fung TT, 2005, AM J CLIN NUTR, V82, P163; Garg A, 1998, AM J CLIN NUTR, V67, p577S, DOI 10.1093/ajcn/67.3.577S; Gonzalez-Clemente JM, 2007, REV ESP CARDIOL, V60, P1167, DOI 10.1157/13111789; Hossain P, 2007, NEW ENGL J MED, V356, P213, DOI 10.1056/NEJMp068177; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; Iestra J, 2006, EUR J CARDIOV PREV R, V13, P894, DOI 10.1097/01.hjr.0000201517.36214.ba; *INT DIAB FED, 2006, DIAB ATL; Knoops KTB, 2004, JAMA-J AM MED ASSOC, V292, P1433, DOI 10.1001/jama.292.12.1433; Lopez-Garcia E, 2004, AM J CLIN NUTR, V80, P1029, DOI 10.1093/ajcn/80.4.1029; Mantzoros CS, 2006, AM J CLIN NUTR, V84, P328; Martinez-Gonzalez MA, 2005, PUBLIC HEALTH NUTR, V8, P920, DOI 10.1079/PHN2005745; Martinez-Gonzalez MA, 2004, EUR J EPIDEMIOL, V19, P9, DOI 10.1023/B:EJEP.0000013351.60227.7b; Martinez-Gonzalez MA, 2002, EUR J NUTR, V41, P153, DOI 10.1007/s00394-002-0370-6; Martinez-Gonzalez MA, 2002, NUTR NEUROSCI, V5, P65, DOI 10.1080/10284150290007047; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Meigs JB, 2004, JAMA-J AM MED ASSOC, V291, P1978, DOI 10.1001/jama.291.16.1978; Mitrou PN, 2007, ARCH INTERN MED, V167, P2461, DOI 10.1001/archinte.167.22.2461; Mozaffarian D, 2007, LANCET, V370, P667, DOI 10.1016/S0140-6736(07)61343-9; Paniagua JA, 2007, J AM COLL NUTR, V26, P434, DOI 10.1080/07315724.2007.10719633; Perez-Jimenez F, 2005, EUR J CLIN INVEST, V35, P421, DOI 10.1111/j.1365-2362.2005.01516.x; Perez-Jimenez F, 2002, ATHEROSCLEROSIS, V163, P385, DOI 10.1016/S0021-9150(02)00033-3; Perez-Martinez P, 2007, ATHEROSCLEROSIS, V194, pE141, DOI 10.1016/j.atherosclerosis.2006.11.033; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Ramachandran A, 2006, DIABETOLOGIA, V49, P289, DOI 10.1007/s00125-005-0097-z; Rocca AS, 2001, ENDOCRINOLOGY, V142, P1148, DOI 10.1210/en.142.3.1148; Ros E, 2003, AM J CLIN NUTR, V78, p617S, DOI 10.1093/ajcn/78.3.617S; SALASSALVADO J, 2007, EUR J CLIN NUTR 0418; Salmeron J, 2001, AM J CLIN NUTR, V73, P1019; Schroder H, 2007, J NUTR BIOCHEM, V18, P149, DOI 10.1016/j.jnutbio.2006.05.006; Schulze MB, 2007, ARCH INTERN MED, V167, P956, DOI 10.1001/archinte.167.9.956; Segui-Gomez M, 2006, INT J EPIDEMIOL, V35, P1417, DOI 10.1093/ije/dyl223; Tortosa A, 2007, DIABETES CARE, V30, P2957, DOI 10.2337/dc07-1231; Trichopoulou A, 2007, EUR J EPIDEMIOL, V22, P871, DOI 10.1007/s10654-007-9190-6; Trichopoulou A, 2005, ARCH INTERN MED, V165, P929, DOI 10.1001/archinte.165.8.929; TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457; Trichopoulou A, 2005, BMJ-BRIT MED J, V330, P991, DOI 10.1136/bmj.38415.644155.8F; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Willett WC, 2006, PUBLIC HEALTH NUTR, V9, P105, DOI 10.1079/PHN2005931	48	343	346	0	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 14	2008	336	7657					1348	1351		10.1136/bmj.39561.501007.BE	http://dx.doi.org/10.1136/bmj.39561.501007.BE			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18511765	Green Submitted, Green Published, Bronze			2023-01-03	WOS:000256984700039
J	Godlee, F				Godlee, Fiona			Running the gauntlet to improve patient care	BRITISH MEDICAL JOURNAL			English	Editorial Material												fgodlee@bmj.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 26	2008	336	7650					947	947		10.1136/bmj.39541.660289.94	http://dx.doi.org/10.1136/bmj.39541.660289.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	296KC	18397949	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000255540900034
J	Bernheim, JL; Deschepper, R; Distelmans, W; Mullie, A; Bilsen, J; Deliens, L				Bernheim, Jan L.; Deschepper, Reginald; Distelmans, Wim; Mullie, Arsene; Bilsen, Johan; Deliens, Luc			Development of palliative care and legalisation of euthanasia: antagonism or synergy?	BRITISH MEDICAL JOURNAL			English	Editorial Material							EUROPEAN COUNTRIES; TASK-FORCE; BELGIUM; NETHERLANDS; ETHICS		[Bernheim, Jan L.; Deschepper, Reginald; Distelmans, Wim; Mullie, Arsene; Bilsen, Johan; Deliens, Luc] Vrije Univ Brussels, Dept Med Sociol & Hlth Sci, End Life Care Res Grp, B-1090 Brussels, Belgium	Vrije Universiteit Brussel	Bernheim, JL (corresponding author), Vrije Univ Brussels, Dept Med Sociol & Hlth Sci, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	jan.bernheim@vub.ac.be	Deschepper, Reginald/B-8103-2013	Deschepper, Reginald/0000-0002-4222-3945; Bernheim, Jan/0000-0003-1610-5790; Deliens, Luc/0000-0002-8158-2422				*BELG MED DISC BOA, 2003, REC REG PALL CAR EUT; Bernheim J. L., 1996, WAARDIG STERVEN, P67; Bernheim JL, 1990, BIOETHIEK, P103; BILSEN J, 2007, SOC SCI MED     0507; Broeckaert B, 2001, EUR J HEALTH LAW, V8, P95; Broeckaert Bert, 2002, Ethical Perspect, V9, P156, DOI 10.2143/EP.9.2.503854; Broekaert B., 2005, EUTHANASIA PALLIATIV, P35; *CATH U LEUV AC CT, 2003, POS MED END OF LIF D; Centeno C, 2007, PALLIATIVE MED, V21, P463, DOI 10.1177/0269216307081942; CHILDRESS JF, 1998, REGULATING WE DIE ET, P120; Clark D, 2000, PALLIATIVE MED, V14, P479, DOI 10.1191/026921600701536408; DEKEYSER E, 2003, NIEUW JURIDISCH WEEK, V2, P1067; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DESCHEPPER R, 2003, CAREFULLY DYING HOME; DISTELMANS W, 2008, BELG J MED ONCOL, V2, P16; DISTELMANS W, 2004, TIJDSCHR VR GK, V60, P232; DISTELMANS W, 2005, EUR J PALLIAT CARE, V12, P170; *EUR ASS PALL CAR, EAPC TASKF PALL CAR; *FLEM PALL CAR FED, 2003, DEAL EUTH OTH KINDS; Gastmans C, 2004, J MED ETHICS, V30, P212, DOI 10.1136/jme.2003.005082; Gastmans Chris, 2002, Ethical Perspect, V9, P134, DOI 10.2143/EP.9.2.503852; Hamel R, 1998, Health Prog, V79, P54; HOTTOIS G, 1988, BIOETHIQUE LIBRE EXA; Hurst SA, 2006, PALLIATIVE MED, V20, P107, DOI 10.1191/0269216306pm1109oa; LEONTINE S, 1996, WHY EUTHANASIA YET; Loop J, 2003, PALLIATIVE MED, V17, P174, DOI 10.1191/0269216303pm727op; Materstvedt LJ, 2003, PALLIATIVE MED, V17, P97, DOI 10.1191/0269216303pm673oa; Schotsmans P, 2005, EUTHANASIA PALLIATIV; SUZANNE C, 1990, EUTHANASIE; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143	32	68	70	5	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR 19	2008	336	7649					864	867		10.1136/bmj.39497.397257.AD	http://dx.doi.org/10.1136/bmj.39497.397257.AD			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	290QH	18420693	Green Published			2023-01-03	WOS:000255136800031
J	Paul, F; Waiczies, S; Wuerfel, J; Bellmann-Strobl, J; Dorr, J; Waiczies, H; Haertle, M; Wernecke, KD; Volk, HD; Aktas, O; Zipp, F				Paul, Friedemann; Waiczies, Sonia; Wuerfel, Jens; Bellmann-Strobl, Judith; Doerr, Jan; Waiczies, Helmar; Haertle, Mareile; Wernecke, Klaus D.; Volk, Hans-Dieter; Aktas, Orhan; Zipp, Frauke			Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis	PLOS ONE			English	Article							DOUBLE-BLIND; CELLS; COMBINATION; PARALYSIS; STATINS; LESIONS; TRIAL	Background: Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS. Methodology/Principal Findings: Safety, tolerability and effects on disease activity of atorvastatin given alone or in combination with interferon-beta (IFN-beta) were assessed in a phase II open-label baseline-to-treatment trial in relapsing-remitting MS (RRMS). Patients with at least one gadolinium-enhancing lesion (CEL) at screening by magnetic resonance imaging (MRI) were eligible for the study. After a baseline period of 3 monthly MRI scans (months 22 to 0), patients followed a 9-month treatment period on 80 mg atorvastatin daily. The number of CEL in treatment months 6 to 9 compared to baseline served as the primary endpoint. Other MRI-based parameters as well as changes in clinical scores and immune responses served as secondary endpoints. Of 80 RRMS patients screened, 41 were included, among them 16 with IFN-beta comedication. The high dose of 80 mg atorvastatin was well tolerated in the majority of patients, regardless of IFN-beta comedication. Atorvastatin treatment led to a substantial reduction in the number and volume of CEL in two-sided multivariate analysis (p = 0.003 and p = 0.008). A trend towards a significant decrease in number and volume of CEL was also detected in patients with IFN-beta comedication (p = 0.060 and p = 0.062), in contrast to patients without IFN-beta comedication (p = 0.170 and p = 0.140). Immunological investigations showed no suppression in T cell response but a significant increase in IL-10 production. Conclusions/Significance: Our data suggest that high-dose atorvastatin treatment in RRMS is safe and well tolerated. Moreover, MRI analysis indicates a possible beneficial effect of atorvastatin, alone or in combination with IFN-beta, on the development of new CEL. Thus, our findings provide a rationale for phase II/III trials, including combination of atorvastatin with already approved immunomodulatory therapy regimens. Trial Registration: ClinicalTrials.gov NCT00616187	[Paul, Friedemann; Waiczies, Sonia; Wuerfel, Jens; Bellmann-Strobl, Judith; Doerr, Jan; Waiczies, Helmar; Haertle, Mareile; Aktas, Orhan; Zipp, Frauke] Charite, Cecilie Vogt Clin Neurol, HELIOS Clin Berlin Buch, D-13353 Berlin, Germany; [Doerr, Jan] HELIOS Clin Berlin Buch, Dept Neurol, Berlin, Germany; [Wernecke, Klaus D.] Dept Med Stat, Berlin, Germany; [Volk, Hans-Dieter] Univ Med Berlin Charite, Inst Immunol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Paul, F (corresponding author), Charite, Cecilie Vogt Clin Neurol, HELIOS Clin Berlin Buch, D-13353 Berlin, Germany.	frauke.zipp@charite.de	volk, hans-dieter/AAV-8053-2021; Aktas, Orhan/B-7623-2009; Waiczies, Sonia/H-4181-2012; Zipp, Frauke/C-9968-2015; Paul, Friedemann/ABF-9415-2020	volk, hans-dieter/0000-0002-7743-6668; Aktas, Orhan/0000-0002-2020-9210; Waiczies, Sonia/0000-0002-9916-9572; Zipp, Frauke/0000-0002-1231-1928; Waiczies, Helmar/0000-0001-6651-4790; Wuerfel, Jens/0000-0002-0034-8053; Bellmann-Strobl, Judith/0000-0003-2615-1643; paul, friedemann/0000-0002-6378-0070	German Research Council (DFG) [SFB 650]; Federal Ministry of Education and Research (BMBF); Pfizer GmbH Germany	German Research Council (DFG)(German Research Foundation (DFG)); Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); Pfizer GmbH Germany	This work was supported by a grant from the German Research Council (DFG) to FZ (SFB 650), the Federal Ministry of Education and Research (BMBF), and by a limited grant from Pfizer GmbH Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The corresponding author had full access to all the data in the study and was responsible for the decision to submit for publication.	Aktas O, 2003, J EXP MED, V197, P725, DOI 10.1084/jem.20021425; Bergh FT, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-19; Bielekova B, 2004, P NATL ACAD SCI USA, V101, P8705, DOI 10.1073/pnas.0402653101; Birnbaum G, 2007, NEUROLOGY, V68, pA206; Brunner E., 2002, NONPARAMETRIC ANAL L; Dunn SE, 2006, J EXP MED, V203, P401, DOI 10.1084/jem.20051129; KANO Y, 1988, CANCER RES, V48, P351; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Maron DJ, 2000, CIRCULATION, V101, P207, DOI 10.1161/01.CIR.101.2.207; Massacesi L, 2005, ARCH NEUROL-CHICAGO, V62, P1843, DOI 10.1001/archneur.62.12.1843; McCarey DW, 2004, LANCET, V363, P2015, DOI 10.1016/S0140-6736(04)16449-0; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Neuhaus O, 2002, NEUROLOGY, V59, P990, DOI 10.1212/WNL.59.7.990; Richert ND, 1998, AM J NEURORADIOL, V19, P1705; Stanislaus R, 2001, J NEUROSCI RES, V66, P155, DOI 10.1002/jnr.1207; TROIANO R, 1984, ANN NEUROL, V15, P257, DOI 10.1002/ana.410150309; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Waiczies S, 2005, J IMMUNOL, V174, P5630, DOI 10.4049/jimmunol.174.9.5630; Wandinger KP, 2003, LANCET, V361, P2036, DOI 10.1016/S0140-6736(03)13641-0; Wuerfel J, 2004, BRAIN, V127, P111, DOI 10.1093/brain/awh007; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zipp F, 2007, TRENDS PHARMACOL SCI, V28, P342, DOI 10.1016/j.tips.2007.05.001	22	93	96	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1928	10.1371/journal.pone.0001928	http://dx.doi.org/10.1371/journal.pone.0001928			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398457	Green Published, gold, Green Accepted			2023-01-03	WOS:000260795500008
J	Rietjens, J; van Delden, J; Onwuteaka-Philipsen, B; Buiting, H; van der Maas, P; van der Heide, A				Rietjens, Judith; van Delden, Johannes; Onwuteaka-Philipsen, Bregje; Buiting, Hilde; van der Maas, Paul; van der Heide, Agnes			Continuous deep sedation for patients nearing death in the Netherlands: descriptive study	BRITISH MEDICAL JOURNAL			English	Article							PALLIATIVE SEDATION; TERMINAL SEDATION; EUTHANASIA; LIFE; SYMPTOMS	Objectives To study the practice of continuous deep sedation in 2005 in the Netherlands and compare it with findings from 2001. Design Questionnaire study about random samples of deaths reported to a central death registry in 2005 and 2001. Setting Nationwide physician study in the Netherlands. Participants Reporting physicians received a questionnaire about the medical decisions that preceded the patient's death; 78% (n=6860) responded in 2005 and 74% (n=5617) in 2001. Main outcome measures Characteristics of continuous deep sedation (attending physician, types of patients, drugs used, duration, estimated effect on shortening life, palliative consultation). Requests for euthanasia. Results The use of continuous deep sedation increased from 5.6% (95% confidence interval 5.0% to 6.2%) of deaths in 2001 to 7.1% (6.5% to 7.6%) in 2005, mostly in patients treated by general practitioners and in those with cancer (in 2005, 47% of sedated patients had cancer v 33% in 2001). In 83% of cases sedation was induced by benzodiazepines, and in 94% patients were sedated for periods of less than one week until death. Nine per cent of those who received continuous deep sedation had previously requested euthanasia but their requests were not granted. Nine percent of the physicians had consulted a palliative expert. Conclusions The increased use of continuous deep sedation for patients nearing death in the Netherlands and the limited use of palliative consultation suggests that this practice is increasingly considered as part of regular medical practice.	[Rietjens, Judith; Buiting, Hilde; van der Maas, Paul; van der Heide, Agnes] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [van Delden, Johannes] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; [Onwuteaka-Philipsen, Bregje] Vrije Univ Amsterdam Med Ctr, Dept Publ & Occupat Hlth, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Rietjens, J (corresponding author), Erasmus MC, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	j.rietjens@erasmusmc.nl						Chiu TY, 2001, J PAIN SYMPTOM MANAG, V21, P467, DOI 10.1016/S0885-3924(01)00286-X; De Graeff A, 2007, J PALLIAT MED, V10, P67, DOI 10.1089/jpm.2006.0139; Fainsinger RL, 2000, PALLIATIVE MED, V14, P257, DOI 10.1191/026921600666097479; Hasselaar JGJ, 2007, ARCH INTERN MED, V167, P1166, DOI 10.1001/archinte.167.11.1166; Miccinesi G, 2006, J PAIN SYMPTOM MANAG, V31, P122, DOI 10.1016/j.jpainsymman.2005.07.004; Muller-Busch H Christof, 2003, BMC Palliat Care, V2, P2, DOI 10.1186/1472-684X-2-2; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Rietjens JAC, 2006, ARCH INTERN MED, V166, P749, DOI 10.1001/archinte.166.7.749; Rietjens JAC, 2004, ANN INTERN MED, V141, P178, DOI 10.7326/0003-4819-141-3-200408030-00006; *STICHT FARM KENG, 2006, PHARM WEEKBLAD, V141, P81; Stone P, 1997, PALLIATIVE MED, V11, P140, DOI 10.1177/026921639701100208; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; Verkerk M, 2007, J PAIN SYMPTOM MANAG, V34, P666, DOI 10.1016/j.jpainsymman.2007.01.005	13	104	105	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	APR	2008	336	7648					810	813		10.1136/bmj.39504.531505.25	http://dx.doi.org/10.1136/bmj.39504.531505.25			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	292ER	18344245	Green Published, Bronze, Green Submitted			2023-01-03	WOS:000255249800043
J	Takeshita, M; Ishida, Y; Akamatsu, E; Ohmori, Y; Sudoh, M; Uto, H; Tsubouchi, H; Kataoka, H				Takeshita, Masahiko; Ishida, Yo-ichi; Akamatsu, Ena; Ohmori, Yusuke; Sudoh, Masayuki; Uto, Hirofumi; Tsubouchi, Hirohito; Kataoka, Hiroaki			Proanthocyanidin from Blueberry Leaves Suppresses Expression of Subgenomic Hepatitis C Virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-ENTRY SITE; TRANSLATION FACTOR EIF3; MASS-SPECTROMETRY; VIRAL-HEPATITIS; PROTEASE INHIBITOR; BINDING PROTEIN; SYNCYTIAL VIRUS; PLUS RIBAVIRIN; SP-303; PROCYANIDINS	Hepatitis C virus (HCV) infection is a major cause of chronic liver disease such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma. While searching for new natural anti-HCV agents in agricultural products, we found a potent inhibitor of HCV RNA expression in extracts of blueberry leaves when examined in an HCV subgenomic replicon cell culture system. This activity was observed in a methanol extract fraction of blueberry leaves and was purified by repeated fractionations in reversed-phase high-performance liquid chromatography. The final purified fraction showed a 63-fold increase in specific activity compared with the initial methanol extracts and was composed only of carbon, hydrogen, and oxygen. Liquid chromatography/mass- ion trap-time of flight analysis and butanol-HCl hydrolysis analysis of the purified fraction revealed that the blueberry leaf-derived inhibitor was proanthocyanidin. Furthermore, structural analysis using acid thiolysis indicated that the mean degree of polymerization of the purified proanthocyanidin was 7.7, consisting predominantly of epicatechin. Proanthocyanidin with a polymerization degree of 8 to 9 showed the greatest potency at inhibiting the expression of subgenomic HCV RNA. Purified proanthocyanidin showed dose-dependent inhibition of expression of the neomycin-resistant gene and the NS-3 protein gene in the HCV subgenome in replicon cells. While characterizing the mechanism by which proanthocyanidin inhibited HCV subgenome expression, we found that heterogeneous nuclear ribonucleoprotein A2/B1 showed affinity to blueberry leaf-derived proanthocyanidin and was indispensable for HCV subgenome expression in replicon cells. These data suggest that proanthocyanidin isolated from blueberry leaves may have potential usefulness as an anti-HCV compound by inhibiting viral replication.	[Kataoka, Hiroaki] Miyazaki Univ, Fac Med, Dept Pathol, Sect Oncopathol & Regenerat Biol, Miyazaki 8891692, Japan; [Ishida, Yo-ichi; Akamatsu, Ena] Miyazaki Prefectural Ind Support Fdn, Miyazaki 8800303, Japan; Minami Nippon Dairy Coop Co Ltd, Div Res, Miyazaki 8850073, Japan; [Ohmori, Yusuke; Sudoh, Masayuki] Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Kanagawa 2478530, Japan; [Uto, Hirofumi; Tsubouchi, Hirohito] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Digest Dis & Life Style Related Dis, Kagoshima 8908520, Japan	University of Miyazaki; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Kagoshima University	Kataoka, H (corresponding author), Miyazaki Univ, Fac Med, Dept Pathol, Sect Oncopathol & Regenerat Biol, 5200 Kihara, Miyazaki 8891692, Japan.	mejina@fc.miyazaki-u.ac.jp			Collaboration of Regional virgatum Aiton); Japan Science and Technology Agency	Collaboration of Regional virgatum Aiton); Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	This study was supported by a grant from the Collaboration of Regional virgatum Aiton), which is cultivated in southern areas of Japan. Entities for the Advancement of Technological Excellence (CREATE) from Japan Science and Technology Agency.	ARNOLD RA, 1978, AM J ENOL VITICULT, V29, P150; BARNARD DL, 1993, CHEMOTHERAPY, V39, P203, DOI 10.1159/000239127; BARNARD DL, 1993, CHEMOTHERAPY, V39, P212, DOI 10.1159/000239128; Brossaud F, 2001, AUST J GRAPE WINE R, V7, P33, DOI 10.1111/j.1755-0238.2001.tb00191.x; CHEN ZP, 1994, PLANTA MED, V60, P541, DOI 10.1055/s-2006-959567; Cheng Hua-Yew, 2002, Antivir Chem Chemother, V13, P223; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; De Franceschi L, 2000, HEPATOLOGY, V31, P997, DOI 10.1053/he.2000.5789; DIBISCEGLIE AM, 1991, AM J GASTROENTEROL, V86, P335; Dillon JF, 2004, J VIRAL HEPATITIS, V11, P23, DOI 10.1111/j.1365-2893.2004.00573.x; Fried MW, 2002, NEW ENGL J MED, V347, P975, DOI 10.1056/NEJMoa020047; GILBERT BE, 1993, ANTIVIR RES, V21, P37, DOI 10.1016/0166-3542(93)90065-Q; Gu LW, 2002, J AGR FOOD CHEM, V50, P4852, DOI 10.1021/jf020214v; Guyot S, 2001, J AGR FOOD CHEM, V49, P14, DOI 10.1021/jf000814z; Hahn B, 1998, J VIROL, V72, P8782, DOI 10.1128/JVI.72.11.8782-8788.1998; Harris D, 2006, MOL CELL PROTEOMICS, V5, P1006, DOI 10.1074/mcp.M500429-MCP200; Hwang B, 2009, BIOCHEM BIOPH RES CO, V378, P584, DOI 10.1016/j.bbrc.2008.11.091; Kim CS, 2007, J VIROL, V81, P3852, DOI 10.1128/JVI.01311-06; Kim JH, 2004, MOL CELL BIOL, V24, P7878, DOI 10.1128/MCB.24.18.7878-7890.2004; Kovtun YV, 2007, CANCER LETT, V255, P232, DOI 10.1016/j.canlet.2007.04.010; Lamarre D, 2003, NATURE, V426, P186, DOI 10.1038/nature02099; Li DS, 2004, J VIROL, V78, P12075, DOI 10.1128/JVI.78.21.12075-12081.2004; Lu H, 2004, J PROTEOME RES, V3, P949, DOI 10.1021/pr0499592; Manns MP, 2006, GUT, V55, P1350, DOI 10.1136/gut.2005.076646; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Marouga R, 2005, ANAL BIOANAL CHEM, V382, P669, DOI 10.1007/s00216-005-3126-3; McCown MF, 2008, ANTIMICROB AGENTS CH, V52, P1604, DOI 10.1128/AAC.01317-07; Myles D C, 2001, Curr Opin Drug Discov Devel, V4, P411; Nahmias Y, 2008, HEPATOLOGY, V47, P1437, DOI 10.1002/hep.22197; Ni ZJ, 2004, CURR OPIN DRUG DISC, V7, P446; OrozcoTopete R, 1997, ANTIVIR RES, V35, P91, DOI 10.1016/S0166-3542(97)00015-6; Pacheco A, 2008, PROTEOMICS, V8, P4782, DOI 10.1002/pmic.200800338; Pawlotsky JM, 2006, ANTIVIR THER, V11, P397; Porter L.J., 1988, FLAVONOIDS, P21, DOI DOI 10.1007/978-1-4899-2913-6_2; PORTER LJ, 1985, PHYTOCHEMISTRY, V25, P223, DOI 10.1016/S0031-9422(00)94533-3; Pudi R, 2005, J VIROL, V79, P9842, DOI 10.1128/JVI.79.15.9842-9853.2005; Reesink HW, 2006, GASTROENTEROLOGY, V131, P997, DOI 10.1053/j.gastro.2006.07.013; Romero-Lopez C, 2007, CELL MOL LIFE SCI, V64, P2994, DOI 10.1007/s00018-007-7345-y; SAFRIN S, 1994, ANTIVIR RES, V25, P185, DOI 10.1016/0166-3542(94)90002-7; Sakamoto H, 2005, NAT CHEM BIOL, V1, P333, DOI 10.1038/nchembio742; Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1767, DOI 10.1053/j.gastro.2007.02.037; Sarrazin C, 2007, GASTROENTEROLOGY, V132, P1270, DOI 10.1053/j.gastro.2007.01.041; Seeff L.B., 1999, AM J MED, V107, P10, DOI [10.1016/S0002-9343(99)00374-5, DOI 10.1016/S0002-9343(99)00374-5]; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shoji T, 2006, J AGR FOOD CHEM, V54, P884, DOI 10.1021/jf052260b; SIDWELL RW, 1994, CHEMOTHERAPY, V40, P42, DOI 10.1159/000239169; Siridechadilok B, 2005, SCIENCE, V310, P1513, DOI 10.1126/science.1118977; Stauber RE, 2006, J CLIN VIROL, V36, P87, DOI 10.1016/j.jcv.2006.02.003; Tonge R, 2001, PROTEOMICS, V1, P377; Williams J E, 2001, Altern Med Rev, V6, P567; Wilson MA, 2006, AGING CELL, V5, P59, DOI 10.1111/j.1474-9726.2006.00192.x; Xu L, 2008, EXP CLIN ENDOCR DIAB, V116, P215, DOI 10.1055/s-2007-993188; Zhou M, 2008, P NATL ACAD SCI USA, V105, P18139, DOI 10.1073/pnas.0801313105	53	89	106	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 7	2009	284	32					21165	21176		10.1074/jbc.M109.004945	http://dx.doi.org/10.1074/jbc.M109.004945			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	478CC	19531480	Green Published, hybrid			2023-01-03	WOS:000268564400009
J	Hupperets, MDW; Verhagen, EALM; van Mechelen, W				Hupperets, Maarten D. W.; Verhagen, Evert A. L. M.; van Mechelen, Willem			Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROSPECTIVE COHORT; PROGRAM; STRENGTH; INJURIES; PREVENTION; RISK; EVERSION; PLAYERS	Objective To evaluate the effectiveness of an unsupervised proprioceptive training programme on recurrences of ankle sprain after usual care in athletes who had sustained an acute sports related injury to the lateral ankle ligament. Design Randomised controlled trial, with one year follow-up. Setting Primary care. Participants 522 athletes, aged 12-70, who had sustained a lateral ankle sprain up to two months before inclusion; 256 (120 female and 136 male) in the intervention group; 266 (128 female and 138 male) in the control group. Intervention Both groups received treatment according to usual care. Athletes allocated to the intervention group additionally received an eight week home based proprioceptive training programme. Main outcome measure Self reported recurrence of ankle sprain. Results During the one year follow-up, 145 athletes reported a recurrent ankle sprain: 56 (22%) in the intervention group and 89 (33%) in the control group. Nine athletes needed to be treated to prevent one recurrence (number needed to treat). The intervention programme was associated with a 35% reduction in risk of recurrence. Cox regression analysis showed significantly fewer recurrent ankle sprains in the intervention than in the control group. This effect was found for self reported recurrent ankle sprains (relative risk 0.63, 95% confidence interval 0.45 to 0.88), recurrent ankle sprains leading to loss of sports time (0.53, 0.32 to 0.88), and recurrent ankle sprains resulting in healthcare costs or lost productivity costs (0.25, 0.12 to 0.50). No significant differences were found between medically treated athletes in the intervention group and medically treated controls. Athletes in the intervention group who were not medically treated had a significantly lower risk of recurrence than controls who were not medically treated. Conclusions The use of a proprioceptive training programme after usual care of an ankle sprain is effective for the prevention of self reported recurrences. This proprioceptive training was specifically beneficial in athletes whose original sprain was not medically treated.	[Hupperets, Maarten D. W.; Verhagen, Evert A. L. M.; van Mechelen, Willem] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, NL-1081 BT Amsterdam, Netherlands; [Verhagen, Evert A. L. M.; van Mechelen, Willem] TNO VUmc, Body Work Res Ctr Phys Act Work & Hlth, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; Netherlands Organization Applied Science Research	van Mechelen, W (corresponding author), Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	w.vanmechelen@vumc.nl	van Mechelen, Willem/C-8463-2013; Verhagen, Evert/A-1502-2013	Verhagen, Evert/0000-0001-9227-8234; van Mechelen, Willem/0000-0001-7136-6382	Netherlands Organization for Health Research and Development (ZonMw) [750-20-002]	Netherlands Organization for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development)	This study was supported by a grant from the Netherlands Organization for Health Research and Development (ZonMw), grant number 750-20-002. No author or related institution has received any financial benefit from research in this study.	Bahr R, 1997, SCAND J MED SCI SPOR, V7, P166, DOI 10.1111/j.1600-0838.1997.tb00134.x; Bernier JN, 1998, J ORTHOP SPORT PHYS, V27, P264, DOI 10.2519/jospt.1998.27.4.264; Eils E, 2001, MED SCI SPORT EXER, V33, P1991, DOI 10.1097/00005768-200112000-00003; EKSTRAND J, 1990, FOOT ANKLE, V11, P41, DOI 10.1177/107110079001100108; Emery CA, 2005, CAN MED ASSOC J, V172, P749, DOI 10.1503/cmaj.1040805; Fong DTP, 2007, SPORTS MED, V37, P73, DOI 10.2165/00007256-200737010-00006; Freeman M A, 1965, J Bone Joint Surg Br, V47, P669; HANDOLL HH, 2001, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000018; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hoiness P, 2003, SCAND J MED SCI SPOR, V13, P266, DOI 10.1034/j.1600-0838.2003.10140.x; Holme E, 1999, SCAND J MED SCI SPOR, V9, P104; Hupperets MDW, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-71; Kaminski TW, 1999, J ATHL TRAINING, V34, P239; Kaminski TW, 2003, BRIT J SPORT MED, V37, P410, DOI 10.1136/bjsm.37.5.410; KANNUS P, 1991, J BONE JOINT SURG AM, V73A, P305, DOI 10.2106/00004623-199173020-00021; Meeuwisse WH, 2007, CLIN J SPORT MED, V17, P205, DOI 10.1097/JSM.0b013e318057518f; MILGROM C, 1991, FOOT ANKLE, V12, P26, DOI 10.1177/107110079101200105; Parkkari J, 2001, SPORTS MED, V31, P985, DOI 10.2165/00007256-200131140-00003; SAUNDERS EA, 1980, AM FAM PHYSICIAN, V22, P132; Sekir U, 2007, KNEE SURG SPORT TR A, V15, P654, DOI 10.1007/s00167-006-0108-8; Soligard T, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2469; SURVE I, 1994, AM J SPORT MED, V22, P601, DOI 10.1177/036354659402200506; TROPP H, 1985, AM J SPORT MED, V13, P259, DOI 10.1177/036354658501300408; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; Verhagen E, 2004, AM J SPORT MED, V32, P1385, DOI 10.1177/0363546503262177; VERHAGEN EAL, 2004, ANKLE SPRAINS VOLLEY; Verhagen EALM, 2005, BRIT J SPORT MED, V39, P111, DOI 10.1136/bjsm.2003.011031; Verhagen EALM, 2004, BRIT J SPORT MED, V38, P477, DOI 10.1136/bjsm.2003.005785; Vriend I, 2005, ONGEVALSLETSELS SPOR; Wedderkopp N, 2003, SCAND J MED SCI SPOR, V13, P371, DOI 10.1046/j.1600-0838.2003.00336.x; Willems T, 2002, J ATHL TRAINING, V37, P487	31	127	133	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 9	2009	339								b2684	10.1136/bmj.b2684	http://dx.doi.org/10.1136/bmj.b2684			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	469LA	19589822	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000267898500006
J	Jansen, JO; Thomas, R; Loudon, MA; Brooks, A				Jansen, Jan O.; Thomas, Rhys; Loudon, Malcolm A.; Brooks, Adam			Damage control resuscitation for patients with major trauma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RED-BLOOD-CELL; EARLY COAGULOPATHY; MORTALITY; INJURY; HYPOPERFUSION; TRANSFUSIONS; REGISTRY; PLASMA; RATIO				Jansen, JO (corresponding author), Aberdeen Royal Infirm, Aberdeen AB25 2ZN, Scotland.	jan.jansen@nhs.net						BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Boyd JH, 2008, CURR OPIN CRIT CARE, V14, P379, DOI 10.1097/MCC.0b013e3283069d5c; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Dutton RP, 2002, J TRAUMA, V52, P1141, DOI 10.1097/00005373-200206000-00020; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Hodgetts T J, 2007, J R Army Med Corps, V153, P299; Holcomb JB, 2005, J TRAUMA, V59, P990, DOI 10.1097/01.ta.0000188010.65920.26; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Kirkman E, 2008, J ROY ARMY MED CORPS, V153, P302; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maegele M, 2008, VOX SANG, V95, P112, DOI 10.1111/j.1423-0410.2008.01074.x; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Martin RS, 2005, SHOCK, V24, P114, DOI 10.1097/01.shk.0000169726.25189.b1; Nahas GG, 1998, DRUGS, V55, P191, DOI 10.2165/00003495-199855020-00003; Rotondo MF, 1997, SURG CLIN N AM, V77, P761, DOI 10.1016/S0039-6109(05)70582-X; Shapiro MB, 2000, J TRAUMA, V49, P969, DOI 10.1097/00005373-200011000-00033; Sperry JL, 2008, J TRAUMA, V65, P986, DOI 10.1097/TA.0b013e3181878028; Turner J., 2000, HEALTH TECHNOL ASSES, V4, P1, DOI [10.3310/hta4310, DOI 10.3310/hta4310]	25	87	96	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 5	2009	338								b1778	10.1136/bmj.b1778	http://dx.doi.org/10.1136/bmj.b1778			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	455AJ	19502278				2023-01-03	WOS:000266726600002
J	Liu, JF; Gu, X; Robbins, D; Li, G; Shi, RH; McCord, JM; Zhao, YF				Liu, Jianfeng; Gu, Xin; Robbins, Delira; Li, Guohong; Shi, Runhua; McCord, Joe M.; Zhao, Yunfeng			Protandim, a Fundamentally New Antioxidant Approach in Chemoprevention Using Mouse Two-Stage Skin Carcinogenesis as a Model	PLOS ONE			English	Article							NF-KAPPA-B; SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; GENE-EXPRESSION; PROTEIN-KINASE; CANCER; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; INFLAMMATION; APOPTOSIS; CYTOKINES	Oxidative stress is an important contributor to cancer development. Consistent with that, antioxidant enzymes have been demonstrated to suppress tumorigenesis when being elevated both in vitro and in vivo, making induction of these enzymes a more potent approach for cancer prevention. Protandim, a well-defined combination of widely studied medicinal plants, has been shown to induce superoxide dismutase (SOD) and catalase activities and reduce superoxide generation and lipid peroxidation in healthy human subjects. To investigate whether Protandim can suppress tumor formation by a dietary approach, a two-stage mouse skin carcinogenesis study was performed. At the end of the study, the mice on a Protandim-containing basal diet had similar body weight compared with those on the basal diet, which indicated no overt toxicity by Protandim. After three weeks on the diets, there was a significant increase in the expression levels of SOD and catalase, in addition to the increases in SOD activities. Importantly, at the end of the carcinogenesis study, both skin tumor incidence and multiplicity were reduced in the mice on the Protandim diet by 33% and 57% respectively, compared with those on basal diet. Biochemical and histological studies revealed that the Protandim diet suppressed tumor promoter-induced oxidative stress (evidenced by reduction of protein carbonyl levels), cell proliferation (evidenced by reduction of skin hyperplasia and suppression of PKC/JNK/Jun pathway), and inflammation (evidenced by reduction of ICAM-1/VCAM-1 expression, NF-kappa B binding activity, and nuclear p65/p50 levels). Overall, induction of antioxidant enzymes by Protandim may serve as a practical and potent approach for cancer prevention.			Liu, JF (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71105 USA.	yzhao1@lsuhsc.edu	McCord, Joe/GWU-8607-2022		NHLBI NIH HHS [R01 HL087990] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087990] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Avila GE, 2005, J PHARMACOL EXP THER, V315, P170, DOI 10.1124/jpet.105.087585; Ballaz Santiago, 2003, Clin Lung Cancer, V5, P46, DOI 10.3816/CLC.2003.n.021; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Bauer JA, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001313; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Cataisson C, 2005, J IMMUNOL, V174, P1686, DOI 10.4049/jimmunol.174.3.1686; Chaurasia SS, 2000, PHARMACOL RES, V41, P663, DOI 10.1006/phrs.1999.0634; Chowdhuri DK, 2002, PHYTOTHER RES, V16, P639, DOI 10.1002/ptr.1023; Clark J, 2006, MOL NUTR FOOD RES, V50, P144, DOI 10.1002/mnfr.200500135; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Das M, 2002, PHYTOTHER RES, V16, pS40, DOI 10.1002/ptr.797; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; DIKSHIT M, 1995, INDIAN J MED RES, V101, P31; Dressler J, 2000, FORENSIC SCI INT, V113, P173, DOI 10.1016/S0379-0738(00)00258-9; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Fox JG, 2007, J CLIN INVEST, V117, P60, DOI 10.1172/JCI30111; Fujiki H, 2005, CHEM REC, V5, P119, DOI 10.1002/tcr.20039; FUJISAWA H, 1992, Journal of Dermatology (Tokyo), V19, P78; Gazak R, 2007, CURR MED CHEM, V14, P315, DOI 10.2174/092986707779941159; Halliwell B, 2007, BIOCHEM J, V401, P1, DOI 10.1042/BJ20061131; Hoshiyama Y, 2005, J EPIDEMIOL, V15, pS109, DOI 10.2188/jea.15.S109; Israel A, 2003, NATURE, V423, P596, DOI 10.1038/423596a; Jakubikova J, 2006, J AGR FOOD CHEM, V54, P1656, DOI 10.1021/jf052717h; Jayaprakasam B, 2003, LIFE SCI, V74, P125, DOI 10.1016/j.lfs.2003.07.007; Lu YP, 1997, CANCER RES, V57, P1468; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marks Friedrich, 2007, V174, P37; Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3; Na HK, 2008, ARCH BIOCHEM BIOPHYS, V476, P171, DOI 10.1016/j.abb.2008.04.003; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Narayanan BA, 2006, CURR CANCER DRUG TAR, V6, P711, DOI 10.2174/156800906779010218; Nelson SK, 2006, FREE RADICAL BIO MED, V40, P341, DOI 10.1016/j.freeradbiomed.2005.08.043; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1984, METHOD ENZYMOL, V105, P457; OBERLEY LW, 1979, CANCER RES, V39, P1141; Pries R, 2006, EXPERT REV ANTICANC, V6, P1195, DOI 10.1586/14737140.6.9.1195; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rose-John Stefan, 2007, V174, P57; Ruckert R, 2000, BRIT J DERMATOL, V143, P1036, DOI 10.1046/j.1365-2133.2000.03784.x; Russo A, 2005, PHYTOMEDICINE, V12, P305, DOI 10.1016/j.phymed.2003.12.008; Schaar D, 2006, CANCER CHEMOTH PHARM, V57, P789, DOI 10.1007/s00280-005-0125-1; Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353; Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009; Singh RP, 2006, ENDOCR-RELAT CANCER, V13, P751, DOI 10.1677/erc.1.01126; Singh Sarvjeet, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P259, DOI 10.2174/187152006776930918; Soto C, 2003, COMP BIOCHEM PHYS C, V136, P205, DOI 10.1016/S1532-0456(03)00214-X; Stuart EC, 2006, LIFE SCI, V79, P2329, DOI 10.1016/j.lfs.2006.07.036; Velmurugan K, 2009, FREE RADICAL BIO MED, V46, P430, DOI 10.1016/j.freeradbiomed.2008.10.050; Wright TI, 2006, J AM ACAD DERMATOL, V54, P933, DOI 10.1016/j.jaad.2005.08.062; Zhang XP, 2007, CLIN CANCER RES, V13, P7181, DOI 10.1158/1078-0432.CCR-07-1133; Zhao YF, 2001, CANCER RES, V61, P6082; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zhao YF, 2001, ANTIOXID REDOX SIGN, V3, P375, DOI 10.1089/15230860152409022; Zhao Yunfeng, 2003, Methods Mol Biol, V218, P177; Zheng X, 2006, CLIN CANCER RES, V12, P3444, DOI 10.1158/1078-0432.CCR-05-2823	56	37	39	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2009	4	4							e5284	10.1371/journal.pone.0005284	http://dx.doi.org/10.1371/journal.pone.0005284			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437VB	19384424	Green Published, gold, Green Submitted			2023-01-03	WOS:000265513900017
J	Sharma, G; Fletcher, KE; Zhang, D; Kuo, YF; Freeman, JL; Goodwin, JS				Sharma, Gulshan; Fletcher, Kathlyn E.; Zhang, Dong; Kuo, Yong-Fang; Freeman, Jean L.; Goodwin, James S.			Continuity of Outpatient and Inpatient Care by Primary Care Physicians for Hospitalized Older Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROVIDER CONTINUITY; UNITED-STATES; INFORMATION-TECHNOLOGY; PATIENT RELATIONSHIP; PREVENTIVE SERVICES; FAMILY PHYSICIANS; HEALTH-CARE; CLAIMS DATA; QUALITY; CANCER	Context Little is known about the extent of continuity of care across the transition from outpatient care to hospitalization. Objectives To describe continuity of care in older hospitalized patients, change in continuity over time, and factors associated with discontinuity. Design, Setting, and Participants A retrospective cohort study of 3 020 770 hospital admissions between 1996 and 2006 using enrollment and claims data for a 5% national sample of Medicare beneficiaries older than 66 years. Data files were constructed to include the patients' demographic and enrollment information (denominator file) and claims for hospital stays (MEDPAR file) and physician services (carrier claims file). Characteristics of the hospitals were included in annual provider of services files. Being seen by a physician was defined as when a physician had submitted a bill for evaluation and management services for that patient. Main Outcome Measures Percentage of patients who during hospitalization were seen by any outpatient physician they had visited in the year before hospitalization ( continuity with any outpatient physician) or by their primary care physician (PCP) (continuity with a PCP). Results In 1996, 50.5% (95% confidence interval [CI], 50.3%-50.7%) of hospitalized patients were seen by at least 1 physician that they had visited in an outpatient setting in the prior year, and 44.3% (95% CI, 44.1%-44.6%) of patients with an identifiable PCP were seen by that physician while hospitalized. These percentages decreased to 39.8% ( 95% CI, 39.6%-40.0%) and 31.9% (95% CI, 31.6%-32.1%), respectively, in 2006. Greater absolute decreases in continuity with any outpatient physician between 1996 and 2006 occurred in patients admitted on weekends (13.9%; 95% CI, 12.9%-14.7%) and those living in large metropolitan areas (11.7%; 95% CI, 11.1%12.3%) and in New England (16.2%; 95% CI, 14.4%-18.0%). In multivariable multilevel models, increasing involvement of hospitalists was associated with approximately one-third of the decrease in continuity of care between 1996 and 2006. Conclusion Between 1996 and 2006, physician continuity from outpatient to inpatient settings decreased in the Medicare population.	[Sharma, Gulshan; Kuo, Yong-Fang; Freeman, Jean L.; Goodwin, James S.] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Sharma, Gulshan; Zhang, Dong; Kuo, Yong-Fang; Freeman, Jean L.; Goodwin, James S.] Univ Texas Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA; [Fletcher, Kathlyn E.] Med Coll Wisconsin, Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI 53226 USA; [Fletcher, Kathlyn E.] Med Coll Wisconsin, Dept Gen Internal Med, Milwaukee, WI 53226 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Medical College of Wisconsin; Medical College of Wisconsin	Sharma, G (corresponding author), Univ Texas Med Branch, Dept Internal Med, 301 Univ Blvd,JSA 5-112, Galveston, TX 77555 USA.	gulshan.sharma@utmb.edu			National Cancer Institute [P50 CA 105631]; National Institute on Aging [K-08 AG 031583, P60 AG 17231]; NATIONAL CANCER INSTITUTE [P50CA105631, K05CA134923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG031583, P60AG017231, P30AG024832] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by grant P50 CA 105631 from the National Cancer Institute and grants K-08 AG 031583 and P60 AG 17231 from the National Institute on Aging.	Arday SL, 2000, HEALTH CARE FINANC R, V21, P107; Arora V, 2009, ARCH INTERN MED, V169, P199, DOI 10.1001/archinternmed.2008.565; Atlas SJ, 2006, J GEN INTERN MED, V21, P973, DOI 10.1007/BF02743147; Atlas SJ, 2009, ANN INTERN MED, V150, P325, DOI 10.7326/0003-4819-150-5-200903030-00008; Bach PB, 2002, MED CARE, V40, P19; Baldwin LM, 2002, MED CARE, V40, P82; Bates DW, 2005, HEALTH AFFAIR, V24, P1180, DOI 10.1377/hlthaff.24.5.1180; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; BRESLAU N, 1976, J HEALTH SOC BEHAV, V17, P339, DOI 10.2307/2136712; Burge F, 2003, MED CARE, V41, P992, DOI 10.1097/00005650-200308000-00012; Burge Frederick, 2003, J Palliat Med, V6, P911, DOI 10.1089/109662103322654794; Christakis DA, 2001, PEDIATRICS, V107, P524, DOI 10.1542/peds.107.3.524; Citro R, 1997, IEEE Trans Inf Technol Biomed, V1, P189, DOI 10.1109/4233.654862; Coleman EA, 2004, HEALTH SERV RES, V39, P1449, DOI 10.1111/j.1475-6773.2004.00298.x; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; *COMM FUT PRIM CAR, 1996, PRIM CAR AM HLTH NEW; *CTR MED MED SERV, NON DAT FIL PROV SER; *CTR MED MED SERV, STAND AN FIL; EJLERTSSON G, 1984, MED CARE, V22, P231, DOI 10.1097/00005650-198403000-00006; Ettner SL, 1999, MED CARE, V37, P547, DOI 10.1097/00005650-199906000-00004; Ettner SL, 1996, AM J PUBLIC HEALTH, V86, P1748, DOI 10.2105/AJPH.86.12.1748; Finison K S, 1999, Eff Clin Pract, V2, P120; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; Gallagher TC, 2001, MED CARE, V39, P1086, DOI 10.1097/00005650-200110000-00006; Gill JM, 1998, ARCH FAM MED, V7, P352, DOI 10.1001/archfami.7.4.352; Guthrie B, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a867; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Kerse N, 2004, ANN FAM MED, V2, P455, DOI 10.1370/afm.139; Klabunde CN, 2000, J CLIN EPIDEMIOL, V53, P1258, DOI 10.1016/S0895-4356(00)00256-0; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Lambrew JM, 1996, MED CARE, V34, P138, DOI 10.1097/00005650-199602000-00006; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Lindenauer PK, 2007, NEW ENGL J MED, V357, P2589, DOI 10.1056/NEJMsa067735; Love MM, 2000, J FAM PRACTICE, V49, P998; Mainous AG, 2001, FAM MED, V33, P22; Mainous AG, 2004, ANN FAM MED, V2, P452, DOI 10.1370/afm.84; Mainous AG, 2004, FAM MED, V36, P35; Mainous AG, 1998, AM J PUBLIC HEALTH, V88, P1539, DOI 10.2105/AJPH.88.10.1539; Moore Kent J, 2005, Fam Pract Manag, V12, P29; OMalley AS, 1997, ARCH INTERN MED, V157, P1462, DOI 10.1001/archinte.157.13.1462; Pantilat SZ, 2001, AM J MED, V111, P15, DOI 10.1016/S0002-9343(01)00964-0; Parchman ML, 2004, FAM MED, V36, P22; Pham HH, 2008, HEALTH AFFAIR, V27, P1315, DOI 10.1377/hlthaff.27.5.1315; Pham HH, 2007, NEW ENGL J MED, V356, P1130, DOI 10.1056/NEJMsa063979; Research Data Assistance Center, MED DAT FIL DESCR; Riall TS, 2007, J GASTROINTEST SURG, V11, P1242, DOI 10.1007/s11605-007-0245-5; Rodriguez HP, 2008, J GEN INTERN MED, V23, P1499, DOI 10.1007/s11606-008-0692-z; Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; Scholle SH, 2009, AM J MANAG CARE, V15, P67; Shah BR, 2007, HEALTH SERV RES, V42, P1783, DOI 10.1111/j.1475-6773.2006.00681.x; Shahinian VB, 2007, J CLIN ONCOL, V25, P5359, DOI 10.1200/JCO.2006.09.9580; Sharma G, 2009, ARCH INTERN MED, V169, P81, DOI 10.1001/archinternmed.2008.514; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; Slater B, 1996, Int J Health Care Qual Assur, V9, P34, DOI 10.1108/09526869610109143; SMEDBY O, 1986, MED CARE, V24, P511; Sobel ME., 1982, SOCIOL METHODOL, P290, DOI [10.2307/270723, DOI 10.2307/270723]; STEINWACHS DM, 1979, MED CARE, V17, P551, DOI 10.1097/00005650-197906000-00001; Stokes T, 2005, ANN FAM MED, V3, P353, DOI 10.1370/afm.351; US Census Bureau, CENS REG DIV US; Weiner M, 2006, J GEN INTERN MED, V21, pS35, DOI 10.1111/j.1525-1497.2006.00307.x; Weiner M, 2003, ANN INTERN MED, V139, P430, DOI 10.7326/0003-4819-139-5_Part_2-200309021-00010; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742	64	85	85	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	2009	301	16					1671	1680		10.1001/jama.2009.517	http://dx.doi.org/10.1001/jama.2009.517			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	435NN	19383958	Bronze, Green Accepted			2023-01-03	WOS:000265350700023
J	Lopez, MV; Viale, DL; Cafferata, EGA; Bravo, AI; Carbone, C; Gould, D; Chernajovsky, Y; Podhajcer, OL				Lopez, M. Veronica; Viale, Diego L.; Cafferata, Eduardo G. A.; Bravo, Alicia I.; Carbone, Cecilia; Gould, David; Chernajovsky, Yuti; Podhajcer, Osvaldo L.			Tumor Associated Stromal Cells Play a Critical Role on the Outcome of the Oncolytic Efficacy of Conditionally Replicative Adenoviruses	PLOS ONE			English	Article							SPARC EXPRESSION; GENE-EXPRESSION; CYSTEINE SPARC; NEOPLASTIC PROGRESSION; COLORECTAL-CANCER; VIRAL REPLICATION; UP-REGULATION; PROTEIN; PROMOTER; MELANOMA	The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-associated stromal cells, targeting both cell compartments may profoundly influence viral efficacy. Therefore, we developed SPARC promoter-based CRAds since the SPARC gene is expressed both in malignant cells and in tumor-associated stromal cells. These CRAds, expressing or not the Herpes Simplex thymidine kinase gene (Ad-F512 and Ad(I)-F512-TK, respectively) exerted a lytic effect on a panel of human melanoma cells expressing SPARC; but they were completely attenuated in normal cells of different origins, including fresh melanocytes, regardless of whether cells expressed or not SPARC. Interestingly, both CRAds displayed cytotoxic activity on SPARC positive-transformed human microendothelial HMEC-1 cells and WI-38 fetal fibroblasts. Both CRAds were therapeutically effective on SPARC positive-human melanoma tumors growing in nude mice but exhibited restricted efficacy in the presence of co-administered HMEC-1 or WI-38 cells. Conversely, co-administration of HMEC-1 cells enhanced the oncolytic efficacy of Ad(I)-F512-TK on SPARC-negative MIA PaCa-2 pancreatic cancer cells in vivo. Moreover, conditioned media produced by stromal cells pre-infected with the CRAds enhanced the in vitro viral oncolytic activity on pancreatic cancer cells, but not on melanoma cells. The whole data indicate that stromal cells might play an important role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses.			Lopez, MV (corresponding author), IIBBA CONICET, Inst Leloir, Lab Mol & Cellular Therapy, Buenos Aires, DF, Argentina.	opodhajcer@leloir.org.ar	Cafferata, Eduardo/AAY-1076-2021	podhajcer, osvaldo/0000-0002-6512-8553; Cafferata, Eduardo G/0000-0001-5089-3757	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Alemany R, 2007, MOL ASPECTS MED, V28, P42, DOI 10.1016/j.mam.2006.12.002; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Bilbao R, 2000, GENE THER, V7, P1824, DOI 10.1038/sj.gt.3301312; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Chlenski A, 2007, ONCOGENE, V26, P4513, DOI 10.1038/sj.onc.1210247; CLARK CJ, 2008, J CELL BIOCH; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DOMINGUEZ P, 1991, J BONE MINER RES, V6, P1127; Fisher K, 2006, CURR OPIN MOL THER, V8, P301; Gonzalez R, 2006, J VIROL, V80, P964, DOI 10.1128/JVI.80.2.964-974.2006; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Gros A, 2008, CANCER RES, V68, P8928, DOI 10.1158/0008-5472.CAN-08-1145; Hafner M, 1995, MATRIX BIOL, V14, P733, DOI 10.1016/S0945-053X(05)80016-2; HEDLEY SJ, 2006, CANC IMMUNOL IMMUNOT; HODGE LD, 1969, VIROLOGY, V37, P554, DOI 10.1016/0042-6822(69)90273-6; Infante JR, 2007, J CLIN ONCOL, V25, P319, DOI 10.1200/JCO.2006.07.8824; Jakubczak JL, 2003, CANCER RES, V63, P1490; Kadonaga JT, 2002, EXP MOL MED, V34, P259, DOI 10.1038/emm.2002.36; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kato Y, 2001, BIOCHEM BIOPH RES CO, V287, P422, DOI 10.1006/bbrc.2001.5622; Kim JH, 2006, JNCI-J NATL CANCER I, V98, P1482, DOI 10.1093/jnci/djj397; Koukourakis MI, 2003, CANCER RES, V63, P5376; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Lieber A, 1996, J VIROL, V70, P8944, DOI 10.1128/JVI.70.12.8944-8960.1996; Lopez MV, 2006, MOL CANCER THER, V5, P2503, DOI 10.1158/1535-7163.MCT-06-0286; Martin-Duque P, 2004, HUM GENE THER, V15, P995, DOI 10.1089/hum.2004.15.995; Marx J, 2008, SCIENCE, V320, P38, DOI 10.1126/science.320.5872.38; Mathis JM, 2005, ONCOGENE, V24, P7775, DOI 10.1038/sj.onc.1209044; Mok W, 2007, CANCER RES, V67, P10664, DOI 10.1158/0008-5472.CAN-07-3107; Nettelbeck DM, 2004, INT J CANCER, V108, P136, DOI 10.1002/ijc.11563; Petersen S, 2001, DIS COLON RECTUM, V44, P322, DOI 10.1007/BF02234727; PODHAJCER OL, 2008, CANC METASTASIS REV; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Rempel SA, 2001, J NEURO-ONCOL, V53, P149, DOI 10.1023/A:1012201300188; Rempel SA, 1999, CLIN CANCER RES, V5, P237; Rivera AA, 2004, GENE THER, V11, P1694, DOI 10.1038/sj.gt.3302346; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; Sakai N, 2001, HUM PATHOL, V32, P1064, DOI 10.1053/hupa.2001.28244; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Savontaus MJ, 2002, GENE THER, V9, P972, DOI 10.1038/sj.gt.3301747; Selden C, 2007, J GENE MED, V9, P67, DOI 10.1002/jgm.1000; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; Sova P, 2004, MOL THER, V9, P496, DOI 10.1016/j.ymthe.2003.12.008; Sugimoto H, 2006, CANCER BIOL THER, V5, P1640, DOI 10.4161/cbt.5.12.3354; Thomas R, 2000, CLIN CANCER RES, V6, P1140; Vaha-Koskela MJV, 2007, CANCER LETT, V254, P178, DOI 10.1016/j.canlet.2007.02.002; VERNON RB, 1991, BIOL REPROD, V44, P157, DOI 10.1095/biolreprod44.1.157; Volk AL, 2003, CANCER BIOL THER, V2, P511, DOI 10.4161/cbt.2.5.440; Waehler R, 2007, NAT REV GENET, V8, P573, DOI 10.1038/nrg2141; Yamamoto M, 2003, GASTROENTEROLOGY, V125, P1203, DOI 10.1016/S0016-5085(03)01196-X; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201	59	30	30	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 8	2009	4	4							e5119	10.1371/journal.pone.0005119	http://dx.doi.org/10.1371/journal.pone.0005119			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437RX	19337591	Green Published, Green Submitted, gold			2023-01-03	WOS:000265505700018
J	Phelps, AC; Maciejewski, PK; Nilsson, M; Balboni, TA; Wright, AA; Paulk, ME; Trice, E; Schrag, D; Peteet, JR; Block, SD; Prigerson, HG				Phelps, Andrea C.; Maciejewski, Paul K.; Nilsson, Matthew; Balboni, Tracy A.; Wright, Alexi A.; Paulk, M. Elizabeth; Trice, Elizabeth; Schrag, Deborah; Peteet, John R.; Block, Susan D.; Prigerson, Holly G.			Religious Coping and Use of Intensive Life-Prolonging Care Near Death in Patients With Advanced Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; ILL ELDERLY-PATIENTS; TREATMENT PREFERENCES; DECISION-MAKING; AFRICAN-AMERICANS; MENTAL-HEALTH; END; QUESTIONNAIRE; ACKNOWLEDGMENT; RESUSCITATION	Context Patients frequently rely on religious faith to cope with cancer, but little is known about the associations between religious coping and the use of intensive life-prolonging care at the end of life. Objective To determine the way religious coping relates to the use of intensive life-prolonging end-of-life care among patients with advanced cancer. Design, Setting, and Participants A US multisite, prospective, longitudinal cohort of 345 patients with advanced cancer, who were enrolled between January 1, 2003, and August 31, 2007. The Brief RCOPE assessed positive religious coping. Baseline interviews assessed psychosocial and religious/spiritual measures, advance care planning, and end-of-life treatment preferences. Patients were followed up until death, a median of 122 days after baseline assessment. Main Outcome Measures Intensive life-prolonging care, defined as receipt of mechanical ventilation or resuscitation in the last week of life. Analyses were adjusted for demographic factors significantly associated with positive religious coping and any end-of-life outcome at P < .05 (ie, age and race/ethnicity). The main outcome was further adjusted for potential psychosocial confounders (eg, other coping styles, terminal illness acknowledgment, spiritual support, preference for heroics, and advance care planning). Results A high level of positive religious coping at baseline was significantly associated with receipt of mechanical ventilation compared with patients with a low level (11.3% vs 3.6%; adjusted odds ratio [AOR], 2.81 [95% confidence interval {CI}, 1.03-7.69]; P = .04) and intensive life-prolonging care during the last week of life (13.6% vs 4.2%; AOR, 2.90 [ 95% CI, 1.14-7.35]; P = .03) after adjusting for age and race. In the model that further adjusted for other coping styles, terminal illness acknowledgment, support of spiritual needs, preference for heroics, and advance care planning (do-not-resuscitate order, living will, and health care proxy/durable power of attorney), positive religious coping remained a significant predictor of receiving intensive life-prolonging care near death (AOR, 2.90 [95% CI, 1.07-7.89]; P = .04). Conclusions Positive religious coping in patients with advanced cancer is associated with receipt of intensive life-prolonging medical care near death. Further research is needed to determine the mechanisms for this association.	[Phelps, Andrea C.] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA; [Phelps, Andrea C.; Maciejewski, Paul K.; Nilsson, Matthew; Balboni, Tracy A.; Wright, Alexi A.; Trice, Elizabeth; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, Boston, MA 02115 USA; [Balboni, Tracy A.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; [Wright, Alexi A.; Trice, Elizabeth; Schrag, Deborah] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Peteet, John R.; Block, Susan D.; Prigerson, Holly G.] Dana Farber Canc Inst, Dept Psychooncol & Palliat Care, Boston, MA 02115 USA; [Paulk, M. Elizabeth] Univ Texas SW Med Ctr Dallas, Parkland Hosp, Dallas, TX 75390 USA; [Paulk, M. Elizabeth] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Maciejewski, Paul K.; Peteet, John R.; Block, Susan D.; Prigerson, Holly G.] Brigham & Womens Hosp, Dept Psychiat, Boston, MA 02115 USA; [Block, Susan D.; Prigerson, Holly G.] Harvard Univ, Sch Med, Ctr Palliat Care, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Prigerson, HG (corresponding author), Dana Farber Canc Inst, Ctr Psychooncol & Palliat Care Res, 44 Binney St,Room 268, Boston, MA 02115 USA.	Holly_Prigerson@dfci.harvard.edu	Wright, Alexi/T-5793-2019; Prigerson, Holly/L-3800-2019; Balboni, Tracy/AAH-4490-2020; Prigerson, Holly/GWV-3283-2022	Prigerson, Holly/0000-0002-7075-4268; 	National Cancer Institute [CA 106370]; National Institute of Mental Health [MH63892]; Fetzer Institute; NATIONAL CANCER INSTITUTE [T32CA009172, R01CA106370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063892] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Fetzer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by grant CA 106370 from the National Cancer Institute, grant MH63892 from the National Institute of Mental Health, and a Fetzer Institute grant on spirituality at the end of life.	Ano GG, 2005, J CLIN PSYCHOL, V61, P461, DOI 10.1002/jclp.20049; Balboni TA, 2007, J CLIN ONCOL, V25, P555, DOI 10.1200/JCO.2006.07.9046; Braun UK, 2008, J GEN INTERN MED, V23, P267, DOI 10.1007/s11606-007-0487-7; Bullock K, 2006, J PALLIAT MED, V9, P183, DOI 10.1089/jpm.2006.9.183; Canada AL, 2006, GYNECOL ONCOL, V101, P102, DOI 10.1016/j.ygyno.2005.09.045; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Chatters LM, 2000, ANNU REV PUBL HEALTH, V21, P335, DOI 10.1146/annurev.publhealth.21.1.335; Cohen SR, 1996, CANCER-AM CANCER SOC, V77, P576, DOI 10.1002/(SICI)1097-0142(19960201)77:3<576::AID-CNCR22>3.0.CO;2-0; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; Curlin FA, 2007, AM J PSYCHIAT, V164, P1825, DOI 10.1176/appi.ajp.2007.06122088; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Fitchett G, 2004, INT J PSYCHIAT MED, V34, P179, DOI 10.2190/UCJ9-DP4M-9C0X-835M; Goodlin SJ, 1999, JAMA-J AM MED ASSOC, V282, P2333, DOI 10.1001/jama.282.24.2333; Jacobs LM, 2008, ARCH SURG-CHICAGO, V143, P730, DOI 10.1001/archsurg.143.8.730; Johnson KS, 2005, J AM GERIATR SOC, V53, P711, DOI 10.1111/j.1532-5415.2005.53224.x; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; Kershaw TS, 2008, ANN BEHAV MED, V36, P117, DOI 10.1007/s12160-008-9058-3; Larson D.B., 2001, HDB RELIG HLTH; Lutgendorf SK, 2002, CANCER, V94, P131, DOI 10.1002/cncr.10155; McKinley ED, 1996, J GEN INTERN MED, V11, P651, DOI 10.1007/BF02600155; Pargament KI, 2000, J CLIN PSYCHOL, V56, P519, DOI 10.1002/(SICI)1097-4679(200004)56:4<519::AID-JCLP6>3.3.CO;2-T; Pargament KI, 1998, J CLIN PSYCHOL, V54, P77; Pargament KI, 2004, J HEALTH PSYCHOL, V9, P713, DOI 10.1177/1359105304045366; Pargament KI, 2001, ARCH INTERN MED, V161, P1881, DOI 10.1001/archinte.161.15.1881; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; PRIGERSON HG, 1992, J HEALTH SOC BEHAV, V33, P378, DOI 10.2307/2137315; Ray A, 2006, J PALLIAT MED, V9, P1359, DOI 10.1089/jpm.2006.9.1359; Sears SR, 2007, J BEHAV MED, V30, P533, DOI 10.1007/s10865-007-9128-1; Silvestri GA, 2003, J CLIN ONCOL, V21, P1379, DOI 10.1200/JCO.2003.08.036; Smith AK, 2008, J CLIN ONCOL, V26, P4131, DOI 10.1200/JCO.2007.14.8452; Sullivan MA, 2004, PSYCHOSOMATICS, V45, P119, DOI 10.1176/appi.psy.45.2.119; Sulmasy DP, 2006, JAMA-J AM MED ASSOC, V296, P1385, DOI 10.1001/jama.296.11.1385; Tarakeshwar N, 2006, J PALLIAT MED, V9, P646, DOI 10.1089/jpm.2006.9.646; True G, 2005, ANN BEHAV MED, V30, P174, DOI 10.1207/s15324796abm3002_10; Van Ness PH, 2008, J AGING HEALTH, V20, P545, DOI 10.1177/0898264308317538; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	39	286	289	1	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	2009	301	11					1140	1147		10.1001/jama.2009.341	http://dx.doi.org/10.1001/jama.2009.341			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	419UC	19293414	Green Accepted, Bronze			2023-01-03	WOS:000264244200019
J	Mair, W; Panowski, SH; Shaw, RJ; Dillin, A				Mair, William; Panowski, Siler H.; Shaw, Reuben J.; Dillin, Andrew			Optimizing Dietary Restriction for Genetic Epistasis Analysis and Gene Discovery in C. elegans	PLOS ONE			English	Article							LIFE-SPAN EXTENSION; ACTIVATED PROTEIN-KINASE; NEMATODE CAENORHABDITIS-ELEGANS; CALORIE RESTRICTION; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; MEDIATES LONGEVITY; REPRODUCTION; PATHWAY; GROWTH	Dietary restriction (DR) increases mammalian lifespan and decreases susceptibility to many age-related diseases. Lifespan extension due to DR is conserved across a wide range of species. Recent research has focused upon genetically tractable model organisms such as C. elegans to uncover the genetic mechanisms that regulate the response to DR, in the hope that this information will provide insight into the mammalian response and yield potential therapeutic targets. However, no consensus exists as to the best protocol to apply DR to C. elegans and potential key regulators of DR are protocol-specific. Here we define a DR method that better fulfills criteria required for an invertebrate DR protocol to mirror mammalian studies. The food intake that maximizes longevity varies for different genotypes and informative epistasis analysis with another intervention is only achievable at this 'optimal DR' level. Importantly therefore, the degree of restriction imposed using our method can easily be adjusted to determine the genotype-specific optimum DR level. We used this protocol to test two previously identified master regulators of DR in the worm. In contrast to previous reports, we find that DR can robustly extend the lifespan of worms lacking the AMP-activated protein kinase catalytic subunit AAK2 or the histone deacetylase SIR-2.1, highlighting the importance of first optimizing DR to identify universal regulators of DR mediated longevity.	[Mair, William; Panowski, Siler H.; Shaw, Reuben J.; Dillin, Andrew] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA; [Mair, William; Panowski, Siler H.; Dillin, Andrew] Howard Hughes Med Inst, La Jolla, CA USA	Salk Institute; Howard Hughes Medical Institute	Mair, W (corresponding author), Salk Inst Biol Studies, Mol & Cell Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	mair@salk.edu; dillin@salk.edu		Mair, William/0000-0002-0661-1342	George E. Hewitt Foundation for Medical Research; National Institutes of Health (NIH) [UCSD CMG Training Grant, R01 DK080425, P01 CA120964]; NIH/NIA; The Ellison Medical Foundation; American Diabetes Association; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [P01CA120964] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080425] Funding Source: NIH RePORTER	George E. Hewitt Foundation for Medical Research; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); The Ellison Medical Foundation(Lawrence Ellison Foundation); American Diabetes Association(American Diabetes Association); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	WM is funding by the George E. Hewitt Foundation for Medical Research, SP is funded by the National Institutes of Health (NIH) UCSD CMG Training Grant, RS is funded by the NIH R01 DK080425 and P01 CA120964 and AD is supported by grants from the NIH/NIA, The Ellison Medical Foundation, the American Diabetes Association and the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Arantes-Oliveira N, 2003, SCIENCE, V302, P611, DOI 10.1126/science.1089169; AVERY L, 1993, GENETICS, V133, P897; Bishop NA, 2007, NAT REV GENET, V8, P835, DOI 10.1038/nrg2188; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Boivin A, 2008, MECH AGEING DEV, V129, P714, DOI 10.1016/j.mad.2008.09.011; BRENNER S, 1974, GENETICS, V77, P71; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Dirkswager E., 2002, TEACHERS OWNERS KEY; Easlon E, 2007, J BIOL CHEM, V282, P6161, DOI 10.1074/jbc.M607661200; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Garigan D, 2002, GENETICS, V161, P1101; Gems D, 1998, GENETICS, V150, P129; Gems D, 2000, GENETICS, V154, P1597; Giannakou ME, 2008, AGING CELL, V7, P187, DOI 10.1111/j.1474-9726.2007.00362.x; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Hansen M, 2005, PLOS GENET, V1, P119, DOI 10.1371/journal.pgen.0010017; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Henderson ST, 2006, J GERONTOL A-BIOL, V61, P444, DOI 10.1093/gerona/61.5.444; HOLEHAN AM, 1985, MECH AGEING DEV, V33, P19, DOI 10.1016/0047-6374(85)90106-X; HOLLIDAY R, 1989, BIOESSAYS, V10, P125, DOI 10.1002/bies.950100408; HOPE IA, 1999, C ELEGANS; HOSONO R, 1989, EXP GERONTOL, V24, P251, DOI 10.1016/0531-5565(89)90016-8; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Houthoofd K, 2002, EXP GERONTOL, V37, P1371, DOI 10.1016/S0531-5565(02)00173-0; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jolly CA, 2007, CURR OPIN LIPIDOL, V18, P53, DOI 10.1097/MOL.0b013e3280115416; Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2002, MOL CELL BIOL, V22, P8056, DOI 10.1128/MCB.22.22.8056-8066.2002; KAEBERLEIN TL, 2006, AGING CELL; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lamming DW, 2005, SCIENCE, V309, P1861, DOI 10.1126/science.1113611; LEE GD, 2006, AGING CELL; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Magwere T, 2004, J GERONTOL A-BIOL, V59, P3; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440; Narbonne P, 2009, NATURE, V457, P210, DOI 10.1038/nature07536; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Piper MDW, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030057; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; Shanley DP, 2000, EVOLUTION, V54, P740, DOI 10.1111/j.0014-3820.2000.tb00076.x; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Walker G, 2005, MECH AGEING DEV, V126, P929, DOI 10.1016/j.mad.2005.03.014; Wang XM, 2006, GLOBAL ENVIRON CHANG, V16, P48, DOI 10.1016/j.gloenvcha.2005.06.006; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Weindruch R., 1988, RETARDATION AGING DI; Yamawaki TM, 2008, GENETICS, V178, P513, DOI 10.1534/genetics.107.083253	61	60	60	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 20	2009	4	2							e4535	10.1371/journal.pone.0004535	http://dx.doi.org/10.1371/journal.pone.0004535			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437KK	19229346	Green Submitted, gold, Green Published			2023-01-03	WOS:000265486200012
J	Grandison, RC; Wong, R; Bass, TM; Partridge, L; Piper, MDW				Grandison, Richard C.; Wong, Richard; Bass, Timothy M.; Partridge, Linda; Piper, Matthew D. W.			Effect of a Standardised Dietary Restriction Protocol on Multiple Laboratory Strains of Drosophila melanogaster	PLOS ONE			English	Article							LIFE-SPAN; CALORIC RESTRICTION; HISTORY; SENESCENCE; LONGEVITY; SELECTION; REPRODUCTION; WOLBACHIA; EVOLUTION; GENOTYPE	Background: Outcomes of lifespan studies in model organisms are particularly susceptible to variations in technical procedures. This is especially true of dietary restriction, which is implemented in many different ways among laboratories. Principal Findings: In this study, we have examined the effect of laboratory stock maintenance, genotype differences and microbial infection on the ability of dietary restriction (DR) to extend life in the fruit fly Drosophila melanogaster. None of these factors block the DR effect. Conclusions: These data lend support to the idea that nutrient restriction genuinely extends lifespan in flies, and that any mechanistic discoveries made with this model are of potential relevance to the determinants of lifespan in other organisms.	[Grandison, Richard C.; Wong, Richard; Bass, Timothy M.; Partridge, Linda; Piper, Matthew D. W.] UCL, UCL Inst Hlth Ageing, Dept Genet Evolut & Environm, London, England	University of London; University College London	Grandison, RC (corresponding author), UCL, UCL Inst Hlth Ageing, Dept Genet Evolut & Environm, London, England.	l.partridge@ucl.ac.uk	Wong, Richard/H-5189-2015; Partridge, Linda/E-7342-2015; Partridge, Linda/A-5501-2010; Piper, Matthew/C-1714-2008	Wong, Richard/0000-0002-4382-1568; Piper, Matthew/0000-0003-3245-7219; Partridge, Linda/0000-0001-9615-0094; Grandison, Richard/0000-0002-4552-0494	Wellcome Trust Strategic Award; Medical Research Council; Research into Ageing; Biotechnology and Biological Science Research Council	Wellcome Trust Strategic Award(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Research into Ageing; Biotechnology and Biological Science Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This work was supported by Wellcome Trust Strategic Award (MP and LP); Medical Research Council (RW); Research into Ageing (RG); and the Biotechnology and Biological Science Research Council (TB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anson RM, 2005, AGE, V27, P17, DOI 10.1007/s11357-005-3286-2; Bass TM, 2007, J GERONTOL A-BIOL, V62, P1071, DOI 10.1093/gerona/62.10.1071; Carey JR, 2002, AGING CELL, V1, P140, DOI 10.1046/j.1474-9728.2002.00019.x; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy David J., 2001, Drosophila Information Service, V84, P168; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Cooper TM, 2004, FASEB J, V18, P1591, DOI 10.1096/fj.03-1464fje; Forster MJ, 2003, FASEB J, V17, P690, DOI 10.1096/fj.02-0533fje; Garsin DA, 2001, P NATL ACAD SCI USA, V98, P10892, DOI 10.1073/pnas.191378698; Giannakou ME, 2008, AGING CELL, V7, P187, DOI 10.1111/j.1474-9726.2007.00362.x; GOODRICK CL, 1990, MECH AGEING DEV, V55, P69, DOI 10.1016/0047-6374(90)90107-Q; HAMILTON WD, 1966, J THEOR BIOL, V12, P12, DOI 10.1016/0022-5193(66)90184-6; Harper JM, 2006, AGING CELL, V5, P441, DOI 10.1111/j.1474-9726.2006.00236.x; HARRISON DE, 1987, J NUTR, V117, P376, DOI 10.1093/jn/117.2.376; IWASAKI K, 1988, J GERONTOL, V43, pB5, DOI 10.1093/geronj/43.1.B5; Jiang JC, 2000, FASEB J, V14, P2135; Kirk KL, 2001, J GERONTOL A-BIOL, V56, pB123, DOI 10.1093/gerona/56.3.B123; KIRKWOOD TBL, 1979, PROC R SOC SER B-BIO, V205, P531, DOI 10.1098/rspb.1979.0083; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Kopec S, 1928, BR J EXP BIOL, V5, P204; Le Bourg E, 2005, AGEING RES REV, V4, P409, DOI 10.1016/j.arr.2004.12.001; Le Bourg E., 1991, AGE NUTR, V2, P90; Linnen C, 2001, EVOL ECOL RES, V3, P877; LUCKINBILL LS, 1984, EVOLUTION, V38, P996, DOI 10.1111/j.1558-5646.1984.tb00369.x; MAEDA H, 1985, J GERONTOL, V40, P671, DOI 10.1093/geronj/40.6.671; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; MIN KJ, 2008, AGING CELL IN PRESS; Min KT, 1997, P NATL ACAD SCI USA, V94, P10792, DOI 10.1073/pnas.94.20.10792; Oishi K, 2004, NEUROREPORT, V15, P739, DOI 10.1097/00001756-200403220-00034; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Partridge L, 2002, NAT REV GENET, V3, P165, DOI 10.1038/nrg753; PARTRIDGE L, 1992, EVOLUTION, V46, P76, DOI [10.2307/2409806, 10.1111/j.1558-5646.1992.tb01986.x]; Piper MDW, 2008, CELL METAB, V8, P99, DOI 10.1016/j.cmet.2008.06.012; Piper MDW, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030057; R Development Core Team, 2005, R LANG ENV STAT COMP; ROSE MR, 1984, EVOLUTION, V38, P1004, DOI 10.1111/j.1558-5646.1984.tb00370.x; Sgro CM, 2000, AM NAT, V156, P341, DOI 10.1086/303394; Sgro CM, 1999, SCIENCE, V286, P2521, DOI 10.1126/science.286.5449.2521; Sutphin GL, 2008, EXP GERONTOL, V43, P130, DOI 10.1016/j.exger.2007.10.019; Toivonen JM, 2007, PLOS GENET, V3, P973, DOI 10.1371/journal.pgen.0030095; VAN NOORDWIJK AJ, 1986, AM NAT, V128, P137, DOI 10.1086/284547; Weindruch R., 1988, RETARDATION AGING DI; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587; WILLIAMS GC, 1966, AM NAT, V100, P687, DOI 10.1086/282461; Zhou WG, 1998, P ROY SOC B-BIOL SCI, V265, P509, DOI 10.1098/rspb.1998.0324	46	73	75	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 1	2009	4	1							e4067	10.1371/journal.pone.0004067	http://dx.doi.org/10.1371/journal.pone.0004067			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437FR	19119322	gold, Green Published, Green Submitted			2023-01-03	WOS:000265472600001
J	Zhang, YP; Deng, MM				Zhang, Y. Philip; Deng, Michelle M.			Enforcing pharmaceutical and biotech patent rights in China	NATURE BIOTECHNOLOGY			English	Editorial Material								Companies with a significant intellectual property stake in China should put in place an effective protection and enforcement strategy against local and overseas competitors.	[Zhang, Y. Philip] Cooley Godward Kronish LLP, Boston, MA 02199 USA; [Deng, Michelle M.] Genzyme Corp, Cambridge, MA 02142 USA	Sanofi-Aventis; Genzyme Corporation	Zhang, YP (corresponding author), Cooley Godward Kronish LLP, 800 Boylston St,46th Floor, Boston, MA 02199 USA.	pzhang@cooley.com; michelle.deng@genzyme.com						Gong YD, 2005, SCIENCE, V309, P735, DOI 10.1126/science.309.5735.735; Guo J, 2006, SCIENCE, V314, P1232, DOI 10.1126/science.314.5803.1232; Hu Y., 2007, J MED MARKETING DEVI, V7, P295; Jia H, 2007, NAT BIOTECHNOL, V25, P1337, DOI 10.1038/nbt1207-1337; *WIPO, PAR CONV MADR AGR IN; 2008, CHEM ENG NEWS   0519	6	8	8	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2008	26	11					1235	1241		10.1038/nbt1108-1235	http://dx.doi.org/10.1038/nbt1108-1235			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371LG	18997760				2023-01-03	WOS:000260832200015
J	Guthrie, B; Saultz, JW; Freeman, GK; Haggerty, JL				Guthrie, Bruce; Saultz, John W.; Freeman, George K.; Haggerty, Jeannie L.			Continuity of care matters	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							MEDICAL-CARE		[Guthrie, Bruce] Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4BF, Scotland; [Saultz, John W.] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA; [Freeman, George K.] Univ London St Georges Hosp, Community Hlth Sci Div, London, England; [Haggerty, Jeannie L.] Univ Sherbrooke, Dept Sci Sante Communautaire, Quebec City, PQ, Canada; [Haggerty, Jeannie L.] Univ Sherbrooke, Dept Family Med, Quebec City, PQ, Canada	University of Dundee; Oregon Health & Science University; St Georges University London; University of Sherbrooke; University of Sherbrooke	Guthrie, B (corresponding author), Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4BF, Scotland.	b.guthrie@dundee.ac.uk	Haggerty, Jeannie/GSD-7271-2022; Guthrie, Bruce/HHM-9696-2022	Guthrie, Bruce/0000-0003-4191-4880	Harkness fellowship from the Commonwealth Fund	Harkness fellowship from the Commonwealth Fund	All four authors have researched continuity in primary and secondary care. BG, JWS, and GKF are practising family physicians. The paper draws on their knowledge of the research literature, including systematic and narrative reviews conducted by them (JWS, JLH, GKF), policy and research scoping work (JLH, GKF), and review and summary of multiproject research programmes in the UK and Canada (BG, JLH, GKF). BG wrote the first draft, which was separately revised by JWS, JLH, and GKF, with BG coordinating rewriting and agreement of the final article. BG is the guarantor During the initial writing, BG was supported by a Harkness fellowship from the Commonwealth Fund, The views presented here are those of the authors.	Adair CE, 2005, PSYCHIAT SERV, V56, P1061, DOI 10.1176/appi.ps.56.9.1061; Balint M., 1957, DOCTOR; BARR M, 2006, ADV MED HOME PATIENT; Boulton M, 2006, BRIT J GEN PRACT, V56, P749; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Guthrie Bruce, 2006, BMC Fam Pract, V7, P11, DOI 10.1186/1471-2296-7-11; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; Kearley KE, 2001, BRIT J GEN PRACT, V51, P712; Lester H, 2007, BRIT MED J, V335, P1130, DOI 10.1136/bmj.39385.406192.AD; Nutting Paul A, 2003, Ann Fam Med, V1, P149, DOI 10.1370/afm.63; *ROYAL COLL GEN PR, 2004, FUT ACC GEN PRACT BA; Royal College of General Practitioners, 2004, FUT GEN PRACT; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; Schers H, 2002, BRIT J GEN PRACT, V52, P459; Solberg LI, 2006, ANN FAM MED, V4, P109, DOI 10.1370/afm.424; Starfield B, 2004, PEDIATRICS, V113, P1493; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Windridge K, 2004, BRIT J GEN PRACT, V54, P364	19	107	109	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 6	2008	337	7669							a867	10.1136/bmj.a867	http://dx.doi.org/10.1136/bmj.a867			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18687724				2023-01-03	WOS:000259420900031
J	Osipo, C; Patel, P; Rizzo, P; Clementz, AG; Hao, L; Golde, TE; Miele, L				Osipo, C.; Patel, P.; Rizzo, P.; Clementz, A. G.; Hao, L.; Golde, T. E.; Miele, L.			ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor	ONCOGENE			English	Article						ErbB-2; trastuzumab; Notch-1; GSI; breast cancer	PHASE-II TRIAL; TRASTUZUMAB RESISTANCE; TAMOXIFEN RESISTANCE; MONOCLONAL-ANTIBODY; WEEKLY VINORELBINE; 1ST-LINE THERAPY; RECEPTOR; GROWTH; HER2; CHEMOTHERAPY	ErbB-2 overexpression in breast tumors is associated with poor survival. Expression of Notch-1 and its ligand, Jagged-1, is associated with the poorest survival, including ErbB-2-positive tumors. Trastuzumab plus chemotherapy is the standard of care for ErbB-2-positive breast cancer. A proportion of tumors are initially resistant to trastuzumab and acquired resistance to trastuzumab occurs in metastatic breast cancer and is associated with poor prognosis. Thus, we investigated whether Notch-1 contributes to trastuzumab resistance. ErbB-2-positive cells have low Notch transcriptional activity compared to non-overexpressing cells. Trastuzumab or a dual epidermal growth factor receptor (EGFR)/ErbB-2 tyrosine kinase inhibitor (TKI) increased Notch activity by 2- to 6-fold in SKBr3, BT474 and MCF-7/HER2-18 cells. The increase in activity was abrogated by a Notch inhibitor, gamma-secretase inhibitor (GSI) or Notch-1 small-interfering RNA ( siRNA). Trastuzumab decreased Notch-1 (TM) precursor, increased amount and nuclear accumulation of active Notch-1(IC) and increased expression of targets, Hey1 and Deltex1 mRNAs, and Hes5, Hey1, Hes1 proteins. Importantly, trastuzumab-resistant BT474 cells treated with trastuzumab for 6 months expressed twofold higher Notch-1, twofold higher Hey1, ninefold higher Deltex1 mRNAs and threefold higher Notch-1 and Hes5 proteins, compared to trastuzumab-sensitive BT474 cells. The increase in Hey1 and Deltex1 mRNAs in resistant cells was abrogated by a Notch-1 siRNA. Cell proliferation was inhibited more effectively by trastuzumab or TKI plus a GSI than either agent alone. Decreased Notch-1 by siRNA increased efficacy of trastuzumab in BT474 sensitive cells and restored sensitivity in resistant cells. Trastuzumab plus a GSI increased apoptosis in sensitive cells by 20-30%. A GSI alone was sufficient to increase apoptosis in trastuzumab-resistant BT474 cells by 20%, which increased to 30% with trastuzumab. Notch-1 siRNA alone decreased cell growth by 30% in sensitive and more than 50% in resistant BT474 cells. Furthermore, growth of both trastuzumab sensitive and resistant cells was completely inhibited by combining trastuzumab plus Notch-1 siRNA. More importantly, Notch-1 siRNA or a GSI resensitized trastuzumab-resistant BT474 cells to trastuzumab. These results demonstrate that ErbB-2 overexpression suppresses Notch-1 activity, which can be reversed by trastuzumab or TKI. These results suggest that Notch-1 might play a novel role in resistance to trastuzumab, which could be prevented or reversed by inhibiting Notch-1.	[Osipo, C.; Rizzo, P.; Hao, L.; Miele, L.] Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, Maywood, IL 60153 USA; [Osipo, C.; Patel, P.; Clementz, A. G.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Mol & Cellular Biochem Program, Maywood, IL 60153 USA; [Hao, L.; Miele, L.] Loyola Univ, Cardinal Bernardin Canc Ctr, Med Ctr, Program Mol Biol, Maywood, IL 60153 USA; [Golde, T. E.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA; [Miele, L.] Loyola Univ, Dept Pharmacol & Mol Therapeut, Cardinal Bernardin Canc Ctr, Med Ctr, Maywood, IL 60153 USA	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Mayo Clinic; Loyola University Chicago	Osipo, C (corresponding author), Loyola Univ, Inst Oncol, Med Ctr, Cardinal Bernardin Canc Ctr,Dept Pathol, 2160 S 1st Ave, Maywood, IL 60153 USA.	cosipo@lumc.edu		Miele, Lucio/0000-0002-5853-7287; rizzo, paola/0000-0001-7174-9674				Amar S, 2008, BREAST CANCER RES TR, V109, P1, DOI 10.1007/s10549-007-9636-2; Arpino G, 2005, JNCI-J NATL CANCER I, V97, P1254, DOI 10.1093/jnci/dji249; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baonza A, 2005, DEV CELL, V8, P529, DOI 10.1016/j.devcel.2005.01.019; Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1016/S0093-7754(01)90276-3; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Calzavara E, 2008, J CELL BIOCHEM, V103, P1405, DOI 10.1002/jcb.21527; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Efstratiadis A, 2007, CELL CYCLE, V6, P418, DOI 10.4161/cc.6.4.3838; Farnie G, 2007, JNCI-J NATL CANCER I, V99, P616, DOI 10.1093/jnci/djk133; Florena AM, 2007, PATHOBIOLOGY, V74, P317, DOI 10.1159/000110024; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jahanzeb M, 2002, ONCOLOGIST, V7, P410, DOI 10.1634/theoncologist.7-5-410; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Lu YH, 2004, INT J CANCER, V108, P334, DOI 10.1002/ijc.11445; Menendez JA, 2006, J CLIN ONCOL, V24, P3735, DOI 10.1200/JCO.2005.04.3489; Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570; Miele L, 1999, J CELL PHYSIOL, V181, P393, DOI 10.1002/(SICI)1097-4652(199912)181:3<393::AID-JCP3>3.0.CO;2-6; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nabholtz JM, 2001, SEMIN ONCOL, V28, P1; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2006, CANCER LETT, V232, P123, DOI 10.1016/j.canlet.2005.01.041; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; O'Neill CF, 2007, AM J PATHOL, V171, P1023, DOI 10.2353/ajpath.2007.061029; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Osipo C, 2003, J NATL CANCER I, V95, P1597, DOI 10.1093/jnci/djg079; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Papaldo P, 2006, ANN ONCOL, V17, P630, DOI 10.1093/annonc/mdj110; Parks AL, 2000, DEVELOPMENT, V127, P1373; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; REEDIJK M, 2007, BREAST CANC RES TREA; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Vooijs M, 2004, J BIOL CHEM, V279, P50864, DOI 10.1074/jbc.M409430200; Weber U, 2003, DEV CELL, V5, P559, DOI 10.1016/S1534-5807(03)00273-9; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; Weng AP, 2006, GENE DEV, V20, P2096, DOI 10.1101/gad.1450406; Xia W, 2006, P NATL ACAD SCI USA, V103, P7795, DOI 10.1073/pnas.0602468103; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yokoyama Goro, 2005, Int J Clin Oncol, V10, P139	67	170	182	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					5019	5032		10.1038/onc.2008.149	http://dx.doi.org/10.1038/onc.2008.149			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18469855				2023-01-03	WOS:000258914800005
J	Karagiannis, ED; Anderson, DG				Karagiannis, Emmanouil D.; Anderson, Daniel G.			Minicells overcome tumor drug-resistance	NATURE BIOTECHNOLOGY			English	Editorial Material							SOLID TUMORS; DELIVERY; CANCER; CHEMOTHERAPEUTICS		[Karagiannis, Emmanouil D.; Anderson, Daniel G.] MIT, David H Koch Inst Integrated Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Karagiannis, ED (corresponding author), MIT, David H Koch Inst Integrated Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	dgander@mit.edu	Karagiannis, Emmanouil D./CAA-0759-2022	Karagiannis, Emmanouil/0000-0003-0131-6552				Aouadi M, 2009, NATURE, V458, P1180, DOI 10.1038/nature07774; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Jain RK, 2001, ADV DRUG DELIVER REV, V46, P149, DOI 10.1016/S0169-409X(00)00131-9; Langer R, 1998, NATURE, V392, P5; MacDiarmid JA, 2007, CELL CYCLE, V6, P2099, DOI 10.4161/cc.6.17.4648; MacDiarmid JA, 2007, CANCER CELL, V11, P431, DOI 10.1016/j.ccr.2007.03.012; MacDiarmid JA, 2009, NAT BIOTECHNOL, V27, P643, DOI 10.1038/nbt.1547; Peer D, 2007, NAT NANOTECHNOL, V2, P751, DOI 10.1038/nnano.2007.387; Rubin BP, 2006, LAB INVEST, V86, P981, DOI 10.1038/labinvest.3700466; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742	11	11	19	0	17	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2009	27	7					620	621		10.1038/nbt0709-620	http://dx.doi.org/10.1038/nbt0709-620			2	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	469OF	19587665				2023-01-03	WOS:000267908500016
J	Campbell, MS; Gottlieb, GS; Hawes, SE; Nickle, DC; Wong, KG; Deng, WJ; Lampinen, TM; Kiviat, NB; Mullins, JI				Campbell, Mary S.; Gottlieb, Geoffrey S.; Hawes, Stephen E.; Nickle, David C.; Wong, Kim G.; Deng, Wenjie; Lampinen, Thomas M.; Kiviat, Nancy B.; Mullins, James I.			HIV-1 Superinfection in the Antiretroviral Therapy Era: Are Seroconcordant Sexual Partners at Risk?	PLOS ONE			English	Article								Background: Acquisition of more than one strain of human immunodeficiency virus type 1 (HIV-1) has been reported to occur both during and after primary infection, but the risks and repercussions of dual and superinfection are incompletely understood. In this study, we evaluated a longitudinal cohort of chronically HIV-infected men who were sexual partners to determine if individuals acquired their partners' viral strains. Methodology: Our cohort of HIV-positive men consisted of 8 couples that identified themselves as long-term sexual partners. Viral sequences were isolated from each subject and analyzed using phylogenetic methods. In addition, strain-specific PCR allowed us to search for partners' viruses present at low levels. Finally, we used computational algorithms to evaluate for recombination between partners' viral strains. Principal Findings/Conclusions: All couples had at least one factor associated with increased risk for acquisition of new HIV strains during the study, including detectable plasma viral load, sexually transmitted infections, and unprotected sex. One subject was dually HIV-1 infected, but neither strain corresponded to that of his partner. Three couples' sequences formed monophyletic clusters at the entry visit, with phylogenetic analysis suggesting that one member of the couple had acquired an HIV strain from his identified partner or that both had acquired it from the same source outside their partnership. The 5 remaining couples initially displayed no evidence of dual infection, using phylogenetic analysis and strain-specific PCR. However, in 1 of these couples, further analysis revealed recombinant viral strains with segments of viral genomes in one subject that may have derived from the enrolled partner. Thus, chronically HIV-1 infected individuals may become superinfected with additional HIV strains from their seroconcordant sexual partners. In some cases, HIV-1 superinfection may become apparent when recombinant viral strains are detected.			Campbell, MS (corresponding author), Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.	msc6@u.washington.edu	Nickle, David/ABF-2727-2020	Gottlieb, Geoffrey/0000-0002-5749-481X	NCI NIH HHS [R01 CA055488, R01CA055488] Funding Source: Medline; NIAID NIH HHS [P01AI57005, T32 AI007044, K08 AI074424, R37AI047734, P30AI27757, T32AI007044, K08AI074424, R37 AI047734, P30 AI027757, P01 AI057005] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055488] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757, K08AI074424, R37AI047734, P01AI057005, T32AI007044] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altfeld M, 2002, NATURE, V420, P434, DOI 10.1038/nature01200; Anderson JP, 2003, MOL BIOL EVOL, V20, P1168, DOI 10.1093/molbev/msg128; ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; Battegay M, 2006, LANCET INFECT DIS, V6, P280, DOI 10.1016/S1473-3099(06)70463-7; Becker-Pergola G, 2000, AIDS RES HUM RETROV, V16, P1099, DOI 10.1089/088922200414938; Brenner B, 2004, AIDS, V18, P1653, DOI 10.1097/01.aids.0000131377.28694.04; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Chakraborty B, 2004, AIDS, V18, P132, DOI 10.1097/01.aids.0000096893.73209.0e; Chohan B, 2005, J VIROL, V79, P10701, DOI 10.1128/JVI.79.16.10701-10708.2005; DIAZ RS, 1995, J VIROL, V69, P3272; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Fang WB, 2004, J GEOPHYS ENG, V1, P153, DOI 10.1088/1742-2132/1/2/008; Gerhardt M, 2005, J VIROL, V79, P8249, DOI 10.1128/JVI.79.13.8249-8261.2005; Golden MR, 2008, JAIDS-J ACQ IMM DEF, V49, P212, DOI 10.1097/QAI.0b013e31818455e8; Gonzales MJ, 2003, J INFECT DIS, V188, P397, DOI 10.1086/376534; Gottlieb GS, 2008, J INFECT DIS, V197, P1011, DOI 10.1086/529206; Gottlieb GS, 2007, CLIN INFECT DIS, V45, P501, DOI 10.1086/520024; Gottlieb GS, 2004, LANCET, V363, P619, DOI 10.1016/S0140-6736(04)15596-7; Grobler J, 2004, J INFECT DIS, V190, P1355, DOI 10.1086/423940; Herbinger KH, 2006, AIDS RES HUM RETROV, V22, P599, DOI 10.1089/aid.2006.22.599; Janini LM, 1998, J INFECT DIS, V177, P227, DOI 10.1086/517360; Jost S, 2002, NEW ENGL J MED, V347, P731, DOI 10.1056/NEJMoa020263; Koelsch KK, 2003, AIDS, V17, pF11, DOI 10.1097/00002030-200305020-00001; Kozaczynska K, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-59; Lampinen TM, 2000, AIDS, V14, pF69, DOI 10.1097/00002030-200003310-00001; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Liu SL, 1997, J VIROL, V71, P4284, DOI 10.1128/JVI.71.6.4284-4295.1997; Liu SL, 1996, SCIENCE, V273, P415, DOI 10.1126/science.273.5274.415; MADDISON WP, 2001, MACCLADE ANAL PHYLOG, P503; Manigart O, 2004, AIDS, V18, P1645, DOI 10.1097/01.aids.0000131333.30548.db; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Pernas M, 2006, JAIDS-J ACQ IMM DEF, V42, P12, DOI 10.1097/01.qai.0000214810.65292.73; PIANTADOSI A, 2008, AIDS RES HUM RETROVI; Piantadosi A, 2007, PLOS PATHOG, V3, P1745, DOI 10.1371/journal.ppat.0030177; Plantier JC, 2004, AIDS, V18, P2444; Ramos A, 2002, J VIROL, V76, P7444, DOI 10.1128/JVI.76.15.7444-7452.2002; Rodrigo AG, 1997, AIDS RES HUM RETROV, V13, P737, DOI 10.1089/aid.1997.13.737; Rousseau CM, 2007, J VIROL, V81, P4492, DOI 10.1128/JVI.02050-06; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; Smith DM, 2006, VIROLOGY, V355, P1, DOI 10.1016/j.virol.2006.08.009; Smith DM, 2005, AIDS, V19, P1251, DOI 10.1097/01.aids.0000180095.12276.ac; Smith DM, 2004, JAMA-J AM MED ASSOC, V292, P1177, DOI 10.1001/jama.292.10.1177; Streeck H, 2008, J EXP MED, V205, P1789, DOI 10.1084/jem.20080281; Swofford D. L., 1999, PAUP 4 0 PHYLOGENETI; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsui R, 2004, J VIROL, V78, P94, DOI 10.1128/JVI.78.1.94-103.2004; van der Kuyl AC, 2005, NEW ENGL J MED, V352, P2557, DOI 10.1056/NEJM200506163522420; Vernazza P, 2008, B MED SUISSES, V89, P165, DOI DOI 10.4414/BMS.2008.13252; Willberg CB, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000185; Yerly S, 2004, AIDS, V18, P1413, DOI 10.1097/01.aids.0000131330.28762.0c	50	35	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 28	2009	4	5							e5690	10.1371/journal.pone.0005690	http://dx.doi.org/10.1371/journal.pone.0005690			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QE	19479055	gold, Green Published, Green Submitted			2023-01-03	WOS:000266415100004
J	Benito, N; Miro, JM; de Lazzari, E; Cabell, CH; del Rio, A; Altclas, J; Commerford, P; Delahaye, F; Dragulescu, S; Giamarellou, H; Habib, G; Kamarulzaman, A; Kumar, AS; Nacinovich, FM; Suter, F; Tribouilloy, C; Venugopal, K; Moreno, A; Fowler, VG				Benito, Natividad; Miro, Jose M.; de Lazzari, Elisa; Cabell, Christopher H.; del Rio, Ana; Altclas, Javier; Commerford, Patrick; Delahaye, Francois; Dragulescu, Stefan; Giamarellou, Helen; Habib, Gilbert; Kamarulzaman, Adeeba; Kumar, A. Sampath; Nacinovich, Francisco M.; Suter, Fredy; Tribouilloy, Christophe; Venugopal, Krishnan; Moreno, Asuncion; Fowler, Vance G., Jr.		ICE-PCS Investigators	Health Care-Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition	ANNALS OF INTERNAL MEDICINE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; BLOOD-STREAM INFECTIONS; COMMUNITY-ACQUIRED BACTEREMIA; 6-MONTH MORTALITY; INTERNATIONAL COLLABORATION; PROSPECTIVE COHORT; PROGNOSTIC-FACTORS; MEDICAL PROGRESS; SURGERY; IMPACT	Background: The clinical profile and outcome of nosocomial and non-nosocomial health care-associated native valve endocarditis are not well defined. Objective: To compare the characteristics and outcomes of community-associated and nosocomial and non-nosocomial health care-associated native valve endocarditis. Design: Prospective cohort study. Setting: 61 hospitals in 28 countries. Patients: Patients with definite native valve endocarditis and no history of injection drug use who were enrolled in the ICE-PCS (International Collaboration on Endocarditis Prospective Cohort Study) from June 2000 to August 2005. Measurements: Clinical and echocardiographic findings, microbiology, complications, and mortality. Results: Health care-associated native valve endocarditis was present in 557 (34%) of 1622 patients (303 with nosocomial infection [54%] and 254 with non-nosocomial infection [46%]). Staphylococcus aureus was the most common cause of health care-associated infection (nosocomial, 47%; non-nosocomial, 42%; P = 0.30); a high proportion of patients had methicillin-resistant S. aureus (nosocomial, 57%; non-nosocomial, 41%; P = 0.014). Fewer patients with health care-associated native valve endocarditis had cardiac surgery (41% vs. 51% of community-associated cases; P < 0.001), but more of the former patients died (25% vs. 13%; P < 0.001). Multivariable analysis confirmed greater mortality associated with health care-associated native valve endocarditis (incidence risk ratio, 1.28 [95% CI, 1.02 to 1.59]). Limitations: Patients were treated at hospitals with cardiac surgery programs. The results may not be generalizable to patients receiving care in other types of facilities or to those with prosthetic valves or past injection drug use. Conclusion: More than one third of cases of native valve endocarditis in non-injection drug users involve contact with health care, and non-nosocomial infection is common, especially in the United States. Clinicians should recognize that outpatients with extensive out-of-hospital health care contacts who develop endocarditis have clinical characteristics and outcomes similar to those of patients with nosocomial infection. Primary Funding Source: None.	Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, E-08193 Barcelona, Spain; Univ Barcelona, Hosp Clin IDIBAPS, Barcelona, Spain; Duke Univ, Med Ctr, Durham, NC USA; Sanat Mitre & Inst Cardiovasc, Buenos Aires, DF, Argentina; Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; Hop Louis Pradel, Lyon, France; Fac Med Marseille, F-13385 Marseille, France; S Hosp Amiens, Amiens, France; Victor Babes Univ Med & Pharm, Timisoara, Romania; Attikon Univ, Gen Hosp, Athens, Greece; Univ Malaya, Med Ctr, Kuala Lumpur, Malaysia; All India Inst Med Sci, New Delhi, India; Med Coll Calicut, Calicut, Kerala, India; Osped Riuniti Bergamo, I-24100 Bergamo, Italy	Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Duke University; University of Cape Town; CHU Lyon; UDICE-French Research Universities; Aix-Marseille Universite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens; Victor Babes University of Medicine & Pharmacy, Timisoara; University Hospital Attikon; Universiti Malaya; All India Institute of Medical Sciences (AIIMS) New Delhi; Ospedali Riuniti di Bergamo	Miro, JM (corresponding author), Hosp Clin Univ, Helios Villarroel Bldg,Desk 26,Villarroel 170, Barcelona 08036, Spain.	jmmiro@ub.edu	Fournier, Pierre-Edouard/AAC-6155-2021; De Rosa, Francesco Giuseppe/J-3049-2013; Bouza, Emilio/D-8661-2014; RAOULT, Didier/A-8434-2008; KAMARULZAMAN, ADEEBA/B-5216-2010; Fowler, Vance/AAW-2017-2021; Giannitsioti, Efthymia/AAQ-5897-2020; Benito, Natividad/D-1855-2010; Muñoz, Patricia/E-9431-2017; Marco, Francesc D/K-2900-2017; Altclas, Javier/AFN-4965-2022; Gonzalez Ramallo, Victor José/Y-6248-2018; Cervera, Carlos/U-4538-2018; McBryde, Emma/D-2220-2018	Fournier, Pierre-Edouard/0000-0001-8463-8885; Bouza, Emilio/0000-0001-6967-9267; RAOULT, Didier/0000-0002-0633-5974; Benito, Natividad/0000-0001-6410-013X; Muñoz, Patricia/0000-0001-5706-5583; Marco, Francesc D/0000-0002-1863-6379; Gonzalez Ramallo, Victor José/0000-0002-9867-1472; Cervera, Carlos/0000-0002-0161-1749; McBryde, Emma/0000-0002-9570-9172; Athan, Eugene/0000-0001-9838-6471; Moreno Camacho, Asuncion/0000-0002-5850-5007; De Lazzari, Elisa/0000-0003-2614-6545; Selton-Suty, Christine/0000-0003-4129-5784; Gordon, David/0000-0003-3276-9685; Giamarellou, Helen/0000-0002-7387-5065; Fernandez-Hidalgo, Nuria/0000-0002-2115-344X; Falces, Carlos/0000-0002-3483-3786; Ionac, Adina/0000-0003-0635-8663; Falco, Vicenc/0000-0001-9626-0023; alla, francois/0000-0002-5793-7190	National Institutes of Health [R01-AI068804]; American Heart Association [0455802U]; Ministerio de Sanidad y Consumo; Instituto de Salud Carlos III; Spanish Network for the Research in Infectious Diseases [REIPI RD06/0008]; Fundacion Privada Maximo Soriano Jimenez, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer; Conselleria de Salut de la Generalitat de Catalunya, Barcelona, Spain; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068804] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); Ministerio de Sanidad y Consumo(Instituto de Salud Carlos III); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Network for the Research in Infectious Diseases; Fundacion Privada Maximo Soriano Jimenez, Barcelona, Spain; Institut d'Investigacions Biomediques August Pi i Sunyer; Conselleria de Salut de la Generalitat de Catalunya, Barcelona, Spain(Generalitat de Catalunya); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	By the National Institutes of Health (grant R01-AI068804); the American Heart Association (grant 0455802U); the Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III, Spanish Network for the Research in Infectious Diseases (grant REIPI RD06/0008); and the Fundacion Privada Maximo Soriano Jimenez, Barcelona, Spain (grant supporting the Hospital Clinic Endocarditis database). Dr. Miro received a Research Grant from the Institut d'Investigacions Biomediques August Pi i Sunyer and the Conselleria de Salut de la Generalitat de Catalunya, Barcelona, Spain.	Aksoy O, 2007, CLIN INFECT DIS, V44, P364, DOI 10.1086/510583; Ben-Ami R, 2004, CLIN INFECT DIS, V38, P843, DOI 10.1086/381971; Bishara J, 2001, CLIN INFECT DIS, V33, P1636, DOI 10.1086/323785; Bouza E, 2001, MEDICINE, V80, P298, DOI 10.1097/00005792-200109000-00003; Cabell CH, 2002, ARCH INTERN MED, V162, P90, DOI 10.1001/archinte.162.1.90; Cabell CH, 2002, INFECT DIS CLIN N AM, V16, P255, DOI 10.1016/S0891-5520(01)00007-1; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P322; Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025; CHEN SCA, 1992, AM J CARDIOL, V70, P1449, DOI 10.1016/0002-9149(92)90298-D; Chu VH, 2008, CLIN INFECT DIS, V46, P232, DOI 10.1086/524666; Dickerman SA, 2007, AM HEART J, V154, P1086, DOI 10.1016/j.ahj.2007.07.023; DURACK DT, 1994, AM J MED, V96, P200, DOI 10.1016/0002-9343(94)90143-0; Edmond MB, 1999, CLIN INFECT DIS, V29, P239, DOI 10.1086/520192; Fernandez-Hidalgo N, 2008, CLIN INFECT DIS, V47, P1287, DOI 10.1086/592576; FERNANDEZGUERRERO ML, 1995, CLIN INFECT DIS, V20, P16, DOI 10.1093/clinids/20.1.16; Ferreiros E, 2006, AM HEART J, V151, P545, DOI 10.1016/j.ahj.2005.04.008; Fowler VG, 2005, JAMA-J AM MED ASSOC, V293, P3012, DOI 10.1001/jama.293.24.3012; FRIEDLAND G, 1984, INFECT CONT HOSP EP, V5, P284, DOI 10.1017/S0195941700060343; Friedman ND, 2002, ANN INTERN MED, V137, P791, DOI 10.7326/0003-4819-137-10-200211190-00007; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Gasink LB, 2008, MED CLIN N AM, V92, P295, DOI 10.1016/j.mcna.2007.10.002; Giamarellou H, 2002, J HOSP INFECT, V50, P91, DOI 10.1053/jhin.2001.1144; Gilleece A, 2000, J HOSP INFECT, V46, P83, DOI 10.1053/jhin.2000.0802; GILLEECE A, 1998, J INFECTION, V36, pA22; GILLEECE A, 1998, J INFECTION, V36, pA10; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; Guerrero MLF, 2007, MEDICINE, V86, P363, DOI 10.1097/MD.0b013e31815d5386; GUZE LB, 1963, ARCH INTERN MED, V112, P56, DOI 10.1001/archinte.1963.03860010102011; Hill EE, 2007, EUR HEART J, V28, P196, DOI 10.1093/eurheartj/ehl427; Hoen B, 2002, JAMA-J AM MED ASSOC, V288, P75, DOI 10.1001/jama.288.1.75; Kourany WM, 2006, SCAND J INFECT DIS, V38, P613, DOI 10.1080/00365540600617017; Lamas CC, 1998, HEART, V79, P442, DOI 10.1136/hrt.79.5.442; Lesens O, 2005, INFECT CONT HOSP EP, V26, P204, DOI 10.1086/502527; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Martin-Davila P, 2005, CHEST, V128, P772, DOI 10.1378/chest.128.2.772; Miro JM, 2002, INFECT DIS CLIN N AM, V16, P273, DOI 10.1016/S0891-5520(01)00008-3; Moreillon P, 2004, LANCET, V363, P139, DOI 10.1016/S0140-6736(03)15266-X; Morin CA, 2001, J INFECT DIS, V184, P1029, DOI 10.1086/323459; Morpeth S, 2007, ANN INTERN MED, V147, P829, DOI 10.7326/0003-4819-147-12-200712180-00002; Mourvillier B, 2004, INTENS CARE MED, V30, P2046, DOI 10.1007/s00134-004-2436-9; Mylonakis E, 2001, NEW ENGL J MED, V345, P1318, DOI 10.1056/NEJMra010082; Naimi TS, 2003, JAMA-J AM MED ASSOC, V290, P2976, DOI 10.1001/jama.290.22.2976; SANABRIA TJ, 1990, ARCH INTERN MED, V150, P1305, DOI 10.1001/archinte.150.6.1305; Shorr AF, 2006, CRIT CARE MED, V34, P2588, DOI 10.1097/01.CCM.0000239121.09533.09; Siegman-Igra Y, 2002, CLIN INFECT DIS, V34, P1431, DOI 10.1086/339809; Tacconelli E, 2004, J ANTIMICROB CHEMOTH, V53, P474, DOI 10.1093/jac/dkh107; Tenover FC, 2004, ANTIMICROB AGENTS CH, V48, P275, DOI 10.1128/AAC.48.1.275-280.2004; TERPENNING MS, 1988, ARCH INTERN MED, V148, P1601, DOI 10.1001/archinte.148.7.1601; Tleyjeh IM, 2005, JAMA-J AM MED ASSOC, V293, P3022, DOI 10.1001/jama.293.24.3022; Tleyjeh IM, 2007, CIRCULATION, V115, P1721, DOI 10.1161/CIRCULATIONAHA.106.658831; *US REN DAT SYST, 2008 ANN DAT REP ATL; Valles J, 2008, J INFECTION, V56, P27, DOI 10.1016/j.jinf.2007.10.001; Vikram HR, 2003, JAMA-J AM MED ASSOC, V290, P3207, DOI 10.1001/jama.290.24.3207; Wang A, 2007, JAMA-J AM MED ASSOC, V297, P1354, DOI 10.1001/jama.297.12.1354; Wenzel RP, 2001, EMERG INFECT DIS, V7, P174, DOI 10.3201/eid0702.010203; Whitener CJ, 2004, CLIN INFECT DIS, V38, P1049, DOI 10.1086/382357	57	172	177	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 5	2009	150	9					586	U5		10.7326/0003-4819-150-9-200905050-00004	http://dx.doi.org/10.7326/0003-4819-150-9-200905050-00004			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443IQ	19414837	Green Accepted			2023-01-03	WOS:000265903800002
J	Collins, R; Peto, R; Hennekens, C; Doll, R; Bubes, V; Buring, J; Dushkesas, R; Gaziano, M; Brennam, P; Meade, T; Rudnicka, A; Hansson, L; Warnold, I; Zanchetti, A; Avanzini, F; Roncaglioni, MC; Tognoni, G; Chown, M; Gaziano, M; Hennekens, C; Baigent, C; Barton, I; Baxter, A; Bhala, N; Blackwell, L; Boreham, J; Bowman, L; Buck, G; Collins, R; Emberson, J; Godwin, J; Halls, H; Holland, L; Kearney, P; Peto, R; Reith, C; Wilson, K; Baigent, C; Blackwell, L; Patrono, C				Collins, Rory; Peto, Richard; Hennekens, Charles; Doll, Richard; Bubes, Vadim; Buring, Julie; Dushkesas, Rimma; Gaziano, Michael; Brennam, Patrick; Meade, Tom; Rudnicka, Alicja; Hansson, Lennart; Warnold, Ingrid; Zanchetti, Alberto; Avanzini, Fausto; Roncaglioni, Maria Carla; Tognoni, Gianni; Chown, Marilyn; Gaziano, Michael; Hennekens, Charles; Baigent, Colin; Barton, Ian; Baxter, Alex; Bhala, Neeraj; Blackwell, Lisa; Boreham, Jill; Bowman, Louise; Buck, Georgina; Collins, Rory; Emberson, Jonathan; Godwin, Jon; Halls, Heather; Holland, Lisa; Kearney, Patricia; Peto, Richard; Reith, Christina; Wilson, Kate; Baigent, Colin; Blackwell, Lisa; Patrono, Carlo		Antithrombotic Trialists Collabora	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials	LANCET			English	Article							LOW-DOSE ASPIRIN; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; EVENTS; CANCER; WOMEN; RISK; MEN; AGE	Background Low-dose aspirin is of definite and substantial net benefit for many people who already have occlusive vascular disease. We have assessed the benefits and risks in primary prevention. Methods We undertook meta-analyses of serious vascular events (myocardial infarction, stroke, or vascular death) and major bleeds in six primary prevention trials (95000 individuals at low average risk, 660000 person-years, 3554 serious vascular events) and 16 secondary prevention trials (17000 individuals at high average risk, 43 000 person-years, 3306 serious vascular events) that compared long-term aspirin versus control. We report intention-to-treat analyses of first events during the scheduled treatment period. Findings in the primary prevention trials, aspirin allocation yielded a 12% proportional reduction in serious vascular events (0.51% aspirin vs 0.57% control per year, p=0.0001), due mainly to a reduction of about a fifth in non-fatal myocardial infarction (0.18% vs 0.23% per year, p<0.0001). The net effect on stroke was not significant (0.20% vs 0.21% per year, p=0.4: haernorrhagic stroke 0.04% vs 0.03%, p=0.05; other stroke 0.16% vs 0.18% per year, p=0.08). Vascular mortality did not differ significantly (0.19% vs 0.19% per year, p=0.7). Aspirin allocation increased major gastrointestinal and extracranial bleeds (0.10% vs 0.07% per year, p<0.0001), and the main risk factors for coronary disease were also risk factors for bleeding. In the secondary prevention trials, aspirin allocation yielded a greater absolute reduction in serious vascular events (6.7% vs 8.2% per year, p<0.0001), with a non-significant increase in haernorrhagic stroke but reductions of about a fifth in total stroke (2.08% vs 2.54% per year, p=0.002) and in coronary events (4.3% vs 5.3% per year, p<0.0001). In both primary and secondary prevention trials, the proportional reductions in the aggregate of all serious vascular events seemed similar for men and women. Interpretation In primary prevention without previous disease, aspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds. Further trials are in progress. Funding UK Medical Research Council, British Heart Foundation, Cancer Research UK, and the European Community Biomed Programme.	[Buring, Julie] Harvard Univ, Brigham & Womens Hosp, Boston, MA 02115 USA; [Peto, Richard; Godwin, Jon] Univ Oxford, CTSU, Oxford, England; [Hennekens, Charles] Florida Atlantic Univ, Charles Schmidt Coll Biomed Sci, Boca Raton, FL 33431 USA; [Hennekens, Charles] Florida Atlantic Univ, Ctr Excellence, Boca Raton, FL 33431 USA; [Kearney, Patricia] Univ Dublin Trinity Coll, Dept Med Gerontol, Dublin 2, Ireland; [Meade, Tom] Univ London, London Sch Hyg & Trop Med, London, England; [Patrono, Carlo] Catholic Univ, Sch Med, Rome, Italy; [Roncaglioni, Maria Carla] Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; [Zanchetti, Alberto] Univ Milan, Ist Auxol Italiano, Milan, Italy	Harvard University; Brigham & Women's Hospital; University of Oxford; State University System of Florida; Florida Atlantic University; State University System of Florida; Florida Atlantic University; Trinity College Dublin; University of London; London School of Hygiene & Tropical Medicine; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Auxologico Italiano; University of Milan	Collins, R (corresponding author), Univ Oxford, Clin Trial Serv Unit, ATT Collaborat, Richard Doll Bldg, Oxford OX3 7LF, England.	colin.baigent@ctsu.ox.ac.uk	roncaglioni, maria carla/AAB-1875-2020; Collins, Rory/ABA-8487-2020; Kearney, Patricia M/AAE-8501-2020	roncaglioni, maria carla/0000-0002-2029-7847; Buck, Georgina/0000-0001-5909-4265; Avanzini, Fausto/0000-0002-4029-2891; Bhala, Neeraj/0000-0003-2502-1177; Kearney, Patricia/0000-0001-9599-3540; Emberson, Jonathan/0000-0001-7792-9422; Patrono, Carlo/0000-0002-6447-2424	UK MRC; BHF; Cancer Research UK; European Community Biomed Programme; B H F Intermediate Research Fellowship; Medical Research Council [G9534799, MC_U137686849, G0701113, MC_U137686861] Funding Source: researchfish; MRC [G0701113, MC_U137686861, MC_U137686849, G9534799] Funding Source: UKRI	UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BHF(British Heart Foundation); Cancer Research UK(Cancer Research UK); European Community Biomed Programme; B H F Intermediate Research Fellowship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank the trial participants and investigators. Sources of funding of each individual trial are described in its publications. The CTSU is supported by a core grant from the UK MRC, the BHF, and Cancer Research UK, and has previously received funding from the European Community Biomed Programme. C Baigent is supported by the MRC, R Collins by a B H F Personal Chair, and J Emberson by a B H F Intermediate Research Fellowship. This paper is dedicated to the memory of Richard Doll (1912-2005), in collaboration with whom the first primary prevention trial<SUP>10</SUP> was undertaken.	ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Belch J, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1840; Berger JS, 2006, JAMA-J AM MED ASSOC, V295, P306, DOI 10.1001/jama.295.3.306; Bulugahapitiya U, 2008, HEART, V94, P1429, DOI 10.1136/hrt.2008.150698; Buse JB, 2007, DIABETES CARE, V30, P162, DOI 10.2337/dc07-9917; Calonge N, 2009, ANN INTERN MED, V150, P396; Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X; De Berardis G, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-21; Elwood P, 2005, BMJ-BRIT MED J, V330, P1440, DOI 10.1136/bmj.330.7505.1440; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Greving JP, 2008, CIRCULATION, V117, P2875, DOI 10.1161/CIRCULATIONAHA.107.735340; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Meade TW, 1998, LANCET, V351, P233; Nelson MR, 2003, DRUG AGING, V20, P897, DOI 10.2165/00002512-200320120-00004; Ogawa H, 2008, JAMA-J AM MED ASSOC, V300, P2134, DOI 10.1001/jama.2008.623; Pearson TA, 2002, CIRCULATION, V106, P388, DOI 10.1161/01.CIR.0000020190.45892.75; PETO R, 1988, BRIT MED J, V296, P313, DOI 10.1136/bmj.296.6618.313; Ridker PM, 2008, NEW ENGL J MED, V359, P2195, DOI 10.1056/NEJMoa0807646; Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613; Tognoni G, 2001, LANCET, V357, P89, DOI 10.1016/S0140-6736(00)03539-X; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Whitlock G, 2009, LANCET, V373, P1083, DOI 10.1016/S0140-6736(09)60318-4; Wood D, 2005, HEART, V91, P1, DOI 10.1136/hrt.2005.079988	27	2460	2580	7	179	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2009	373	9678					1849	1860						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	453ND	19482214	Green Published, Bronze, Green Accepted			2023-01-03	WOS:000266616400028
J	Aouadi, M; Tesz, GJ; Nicoloro, SM; Wang, MX; Chouinard, M; Soto, E; Ostroff, GR; Czech, MP				Aouadi, Myriam; Tesz, Gregory J.; Nicoloro, Sarah M.; Wang, Mengxi; Chouinard, My; Soto, Ernesto; Ostroff, Gary R.; Czech, Michael P.			Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; IN-VIVO DELIVERY; NONHUMAN-PRIMATES; RNA INTERFERENCE; GENE-EXPRESSION; ADULT MICE; GALACTOSAMINE; INHIBITION; RESISTANCE; LETHALITY	Gene silencing by double-stranded RNA, denoted RNA interference, represents a new paradigm for rational drug design(1). However, the transformative therapeutic potential of short interfering RNA ( siRNA) has been stymied by a key obstacle-safe delivery to specified target cells in vivo(2). Macrophages are particularly attractive targets for RNA interference therapy because they promote pathogenic inflammatory responses in diseases such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and diabetes(3). Here we report the engineering of beta 1,3-D-glucan-encapsulated siRNA particles (GeRPs) as efficient oral delivery vehicles that potently silence genes in mouse macrophages in vitro and in vivo. Oral gavage of mice with GeRPs containing as little as 20 mu g kg(-1) siRNA directed against tumour necrosis factor alpha (Tnf-alpha) depleted its messenger RNA in macrophages recovered from the peritoneum, spleen, liver and lung, and lowered serum Tnf-a levels. Screening with GeRPs for inflammation genes revealed that the mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) is a previously unknown mediator of cytokine expression. Importantly, silencing Map4k4 in macrophages in vivo protected mice from lipopolysaccharide-induced lethality by inhibiting Tnf-alpha and interleukin-1 beta production. This technology defines a new strategy for oral delivery of siRNA to attenuate inflammatory responses in human disease.	[Aouadi, Myriam; Tesz, Gregory J.; Nicoloro, Sarah M.; Wang, Mengxi; Chouinard, My; Soto, Ernesto; Ostroff, Gary R.; Czech, Michael P.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Czech, MP (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	gary.ostroff@umassmed.edu; michael.czech@umassmed.edu		Nicoloro, Sarah/0000-0002-8638-4556	The University of Massachusetts Diabetes and Endocrinology Center [DK 32520]; Diabetes Genome Anatomy Project [DK 60837]; Commonwealth Medicine; NIH [DK 30898]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060837, R37DK030898, R01DK030898, P30DK032520] Funding Source: NIH RePORTER	The University of Massachusetts Diabetes and Endocrinology Center; Diabetes Genome Anatomy Project; Commonwealth Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We appreciate critical reading of the manuscript and suggestions by C. Mello, V. Ambros, G. Hannon, S. Corvera and J. Sullivan. We thank P. Zamore for advice on methods. We also appreciate the technical help of P. Furcinitti, A. Burkhart and A. Goller. This work was supported by The University of Massachusetts Diabetes and Endocrinology Center (DK 32520), including its Genomics, Bioinformatics and Imaging Cores, the Diabetes Genome Anatomy Project ( DK 60837), Commonwealth Medicine and NIH grant DK 30898.	Barthel R, 2003, MOL CELL BIOL, V23, P526, DOI 10.1128/MCB.23.2.526-533.2003; Beier R, 1998, AM J PHYSIOL-GASTR L, V275, pG130, DOI 10.1152/ajpgi.1998.275.1.G130; Bouzakri K, 2007, J BIOL CHEM, V282, P7783, DOI 10.1074/jbc.M608602200; Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240; Endo Y, 1999, BRIT J PHARMACOL, V128, P5, DOI 10.1038/sj.bjp.0702747; Ferrante AW, 2007, J INTERN MED, V262, P408, DOI 10.1111/j.1365-2796.2007.01852.x; Filleur S, 2003, CANCER RES, V63, P3919; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Frank-Kamenetsky M, 2008, P NATL ACAD SCI USA, V105, P11915, DOI 10.1073/pnas.0805434105; Grimm D, 2007, J CLIN INVEST, V117, P3633, DOI 10.1172/JCI34129; Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882; Herre J, 2004, MOL IMMUNOL, V40, P869, DOI 10.1016/j.molimm.2003.10.007; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; Peer D, 2007, P NATL ACAD SCI USA, V104, P4095, DOI 10.1073/pnas.0608491104; Shealy D. J., 2008, V181, P101; Shoda LKM, 2005, IMMUNITY, V23, P115, DOI 10.1016/j.immuni.2005.08.002; Silverstein R, 2004, J ENDOTOXIN RES, V10, P147, DOI 10.1179/096805104225004879; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5; Soto ER, 2008, BIOCONJUGATE CHEM, V19, P840, DOI 10.1021/bc700329p; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Tang XQ, 2006, P NATL ACAD SCI USA, V103, P2087, DOI 10.1073/pnas.0507660103; Tesz GJ, 2007, J BIOL CHEM, V282, P19302, DOI 10.1074/jbc.M700665200; Tsytsykova AV, 2007, J BIOL CHEM, V282, P11629, DOI 10.1074/jbc.M611418200; Vazquez-Torres A, 1999, NATURE, V401, P804, DOI 10.1038/44593; Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086; Zhou YH, 1999, J LEUKOCYTE BIOL, V65, P265, DOI 10.1002/jlb.65.2.265; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	30	416	451	6	171	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 30	2009	458	7242					1180	U116		10.1038/nature07774	http://dx.doi.org/10.1038/nature07774			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	441FL	19407801	Green Accepted			2023-01-03	WOS:000265754600049
J	Regnard, C; Randall, F				Regnard, Claud; Randall, Fiona			Should hospices be exempt from following national cardiopulmonary resuscitation guidelines? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Regnard, Claud] St Oswalds Hosp, Newcastle Hosp NHS Trust, Newcastle Upon Tyne NE3 1EE, Tyne & Wear, England; [Regnard, Claud] Northumberland Tyne & Wear NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England; [Randall, Fiona] Royal Bournemouth & Christchurch NHS Fdn Trust, Christchurch, Dorset, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Regnard, C (corresponding author), St Oswalds Hosp, Newcastle Hosp NHS Trust, Newcastle Upon Tyne NE3 1EE, Tyne & Wear, England.	claudregnard@stoswaldsuk.org						Adults with Incapacity (Scotland) Act 2000, 2000, ADULTS INCAPACITY SC; *PUBL GUARD OFF, 2007, MENT CAP ACT 2005 CO; *ROYAL COLL NURS B, 2007, DEC REL CARD RES JOI; UK Government, 2005, MENT CAP ACT 2005	4	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 26	2009	338								b986	10.1136/bmj.b986	http://dx.doi.org/10.1136/bmj.b986			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425LR	19325182				2023-01-03	WOS:000264639700007
J	Hasadsri, L; Kreuter, J; Hattori, H; Iwasaki, T; George, JM				Hasadsri, Linda; Kreuter, Joerg; Hattori, Hiroaki; Iwasaki, Tadao; George, Julia M.			Functional Protein Delivery into Neurons Using Polymeric Nanoparticles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; BLOOD-BRAIN-BARRIER; CHAPERONE-MEDIATED AUTOPHAGY; SOLID LIPID NANOPARTICLES; RESONANCE ENERGY-TRANSFER; ALPHA-SYNUCLEIN; GENE DELIVERY; HIGH-EFFICIENCY; NEURODEGENERATIVE DISEASES; PARKINSONS-DISEASE	An efficient route for delivering specific proteins and peptides into neurons could greatly accelerate the development of therapies for various diseases, especially those involving intracellular defects such as Parkinson disease. Here we report the novel use of polybutylcyanoacrylate nanoparticles for delivery of intact, functional proteins into neurons and neuronal cell lines. Uptake of these particles is primarily dependent on endocytosis via the low density lipoprotein receptor. The nanoparticles are rapidly turned over and display minimal toxicity to cultured neurons. Delivery of three different functional cargo proteins is demonstrated. When primary neuronal cultures are treated with recombinant Escherichia coli beta-galactosidase as nanoparticle cargo, persistent enzyme activity is measured beyond the period of nanoparticle degradation. Delivery of the small GTPase rhoG induces neurite outgrowth and differentiation in PC12 cells. Finally, a monoclonal antibody directed against synuclein is capable of interacting with endogenous alpha-synuclein in cultured neurons following delivery via nanoparticles. Polybutylcyanoacrylate nanoparticles are thus useful for intracellular protein delivery in vitro and have potential as carriers of therapeutic proteins for treatment of neuronal disorders in vivo.	[George, Julia M.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; [Hasadsri, Linda] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA; [Hasadsri, Linda] Univ Illinois, Coll Med, Med Scholars Program, Urbana, IL 61801 USA; [Kreuter, Joerg] Univ Frankfurt, Biozentrum, Inst Pharmazeut Technol, D-60439 Frankfurt, Germany; [Hattori, Hiroaki; Iwasaki, Tadao] BML Inc, Dept Adv Med Technol & Dev, Kawagoe, Saitama 3501101, Japan	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Goethe University Frankfurt; BML, Inc.	George, JM (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.	j-george@illinois.edu	George, Julia M/B-2169-2008	George, Julia M/0000-0001-6194-6914	NIA NIH HHS [R01 AG13762] Funding Source: Medline; NIGMS NIH HHS [5T32 GM07283] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007283] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013762] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Almeida CG, 2006, J NEUROSCI, V26, P4277, DOI 10.1523/JNEUROSCI.5078-05.2006; AltmanHamamdzic S, 1997, GENE THER, V4, P815, DOI 10.1038/sj.gt.3300458; ALYAUTDIN R, 1995, EUR J PHARM BIOPHARM, V41, P44; Amalfitano Andrea, 2002, Current Gene Therapy, V2, P111, DOI 10.2174/1566523024605618; Barka T, 2000, J HISTOCHEM CYTOCHEM, V48, P1453, DOI 10.1177/002215540004801102; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Bender FLP, 2007, HISTOCHEM CELL BIOL, V127, P439, DOI 10.1007/s00418-006-0247-5; Bergen JM, 2008, PHARM RES-DORDR, V25, P983, DOI 10.1007/s11095-007-9439-5; Berges BK, 2007, MOL THER, V15, P20, DOI 10.1038/sj.mt.6300018; Blasi P, 2007, ADV DRUG DELIVER REV, V59, P454, DOI 10.1016/j.addr.2007.04.011; Buchser WJ, 2006, BIOTECHNIQUES, V41, P619, DOI 10.2144/000112279; Cai D, 2005, NAT METHODS, V2, P449, DOI 10.1038/NMETH761; Cesnulevicius K, 2006, STEM CELLS, V24, P2776, DOI 10.1634/stemcells.2006-0176; CHANDLER LP, 1985, J BIOL CHEM, V260, P3360; Chauvierre C, 2007, INT J PHARM, V338, P327, DOI 10.1016/j.ijpharm.2007.01.034; Day RN, 2003, MOL ENDOCRINOL, V17, P333, DOI 10.1210/me.2002-0136; Dehouck B, 1997, J CELL BIOL, V138, P877, DOI 10.1083/jcb.138.4.877; DOUGLAS SJ, 1987, CRIT REV THER DRUG, V3, P233; Ehrengruber MU, 2001, MOL CELL NEUROSCI, V17, P855, DOI 10.1006/mcne.2001.0982; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; Elkabetz Y, 2003, J BIOL CHEM, V278, P18922, DOI 10.1074/jbc.M208730200; Emadi S, 2004, BIOCHEMISTRY-US, V43, P2871, DOI 10.1021/bi036281f; Fallon L, 2006, NAT CELL BIOL, V8, P834, DOI 10.1038/ncb1441; Gartner A, 2006, METHOD ENZYMOL, V406, P374, DOI 10.1016/S0076-6879(06)06027-7; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Goppert TM, 2005, J DRUG TARGET, V13, P179, DOI 10.1080/10611860500071292; Gresch O, 2004, METHODS, V33, P151, DOI 10.1016/j.ymeth.2003.11.009; Gulyaev AE, 1999, PHARM RES-DORDR, V16, P1564, DOI 10.1023/A:1018983904537; HAYLETT T, 1991, J BIOL CHEM, V266, P8322; Huang CJ, 2006, J MOL BIOL, V364, P323, DOI 10.1016/j.jmb.2006.08.062; Janson CG, 2001, TRENDS NEUROSCI, V24, P706, DOI 10.1016/S0166-2236(00)01954-8; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kaushik S., 2008, V445, P227, DOI 10.1007/978-1-59745-157-4_15; Kenworthy AK, 2001, METHODS, V24, P289, DOI 10.1006/meth.2001.1189; KINGSLEY DM, 1984, P NATL ACAD SCI-BIOL, V81, P5454, DOI 10.1073/pnas.81.17.5454; Kosaka S, 2001, CIRCULATION, V103, P1142, DOI 10.1161/01.CIR.103.8.1142; Kreuter J, 2003, PHARM RES-DORDR, V20, P409, DOI 10.1023/A:1022604120952; Kreuter J, 2002, J DRUG TARGET, V10, P317, DOI 10.1080/10611860290031877; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; KREUTER J, 1995, BRAIN RES, V674, P171, DOI 10.1016/0006-8993(95)00023-J; KUBIAK C, 1989, BIOMATERIALS, V10, P553, DOI 10.1016/0142-9612(89)90062-8; Leclere PG, 2005, J NEUROSCI METH, V142, P137, DOI 10.1016/j.jneumeth.2004.08.012; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; McLean PJ, 2002, J NEUROCHEM, V83, P846, DOI 10.1046/j.1471-4159.2002.01190.x; MERESSE S, 1989, J NEUROCHEM, V53, P340, DOI 10.1111/j.1471-4159.1989.tb07340.x; Messer A, 2006, BIODRUGS, V20, P327, DOI 10.2165/00063030-200620060-00002; Mills JC, 1997, EXP CELL RES, V231, P337, DOI 10.1006/excr.1997.3474; Mochizuki H, 1998, J VIROL, V72, P8873, DOI 10.1128/JVI.72.11.8873-8883.1998; MOGHIMI SM, 1993, BIOCHIM BIOPHYS ACTA, V1179, P157, DOI 10.1016/0167-4889(93)90137-E; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MULLER RH, 1992, INT J PHARM, V84, P1, DOI 10.1016/0378-5173(92)90209-K; Nagel F, 2008, J NEUROCHEM, V105, P853, DOI 10.1111/j.1471-4159.2007.05204.x; Ohki EC, 2001, J NEUROSCI METH, V112, P95, DOI 10.1016/S0165-0270(01)00441-1; Olivier JC, 1999, PHARMACEUT RES, V16, P1836, DOI 10.1023/A:1018947208597; Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775; Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02-0088com; Reis SA, 2004, J MOL HISTOL, V35, P389; Royo NC, 2008, BRAIN RES, V1190, P15, DOI 10.1016/j.brainres.2007.11.015; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; Slack RS, 1996, CURR OPIN NEUROBIOL, V6, P576, DOI 10.1016/S0959-4388(96)80088-2; SMITH RL, 1995, J VIROL, V69, P4593, DOI 10.1128/JVI.69.8.4593-4599.1995; Soto C, 2008, ARCH NEUROL-CHICAGO, V65, P184, DOI 10.1001/archneurol.2007.56; Takahashi M, 2001, CLIN GENET, V59, P290, DOI 10.1034/j.1399-0004.2001.590414.x; Teruel MN, 1999, J NEUROSCI METH, V93, P37, DOI 10.1016/S0165-0270(99)00112-0; VASILE E, 1983, J CELL BIOL, V96, P1677, DOI 10.1083/jcb.96.6.1677; Vauthier C, 2003, ADV DRUG DELIVER REV, V55, P519, DOI 10.1016/S0169-409X(03)00041-3; Vogiatzi T, 2008, J BIOL CHEM, V283, P23542, DOI 10.1074/jbc.M801992200; Washbourne P, 2002, CURR OPIN NEUROBIOL, V12, P566, DOI 10.1016/S0959-4388(02)00365-3; Whittlesey KJ, 2006, BIOMATERIALS, V27, P2477, DOI 10.1016/j.biomaterials.2005.11.016; Windisch M, 2008, NEURODEGENER DIS, V5, P218, DOI 10.1159/000113707; Windisch M, 2004, J MOL NEUROSCI, V24, P155, DOI 10.1385/JMN:24:1:155; Winklhofer KF, 2008, EMBO J, V27, P336, DOI 10.1038/sj.emboj.7601930; Yu L, 2001, J CONTROL RELEASE, V72, P179, DOI 10.1016/S0168-3659(01)00274-7; Zeitelhofer M, 2007, NAT PROTOC, V2, P1692, DOI 10.1038/nprot.2007.226; Zhou C, 2004, MOL THER, V10, P1023, DOI 10.1016/j.ymthe.2004.08.019	75	102	127	0	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 13	2009	284	11					6972	6981		10.1074/jbc.M805956200	http://dx.doi.org/10.1074/jbc.M805956200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	415FF	19129199	Green Published, hybrid			2023-01-03	WOS:000263919000045
J	Thompson, ND; Perz, JF; Moorman, AC; Holmberg, SD				Thompson, Nicola D.; Perz, Joseph F.; Moorman, Anne C.; Holmberg, Scott D.			Nonhospital Health Care-Associated Hepatitis B and C Virus Transmission: United States, 1998-2008	ANNALS OF INTERNAL MEDICINE			English	Review							NOSOCOMIAL TRANSMISSION; INFECTION-CONTROL; OUTBREAK; PREVALENCE	In the United States, transmission of hepatitis B virus (HBV) and hepatitis C virus (HCV) from health care exposures has been considered uncommon. However, a review of outbreak information revealed 33 outbreaks in nonhospital health care settings in the past decade: 12 in outpatient clinics, 6 in hemodialysis centers, and 15 in long-term care facilities, resulting in 448 persons acquiring HBV or HCV infection. In each setting, the putative mechanism of infection was patient-to-patient transmission through failure of health care personnel to adhere to fundamental principles of infection control and aseptic technique (for example, reuse of syringes or lancing devices). Difficult to detect and investigate, these recognized outbreaks indicate a wider and growing problem as health care is increasingly provided in outpatient settings in which infection control training and oversight may be inadequate. A comprehensive approach involving better viral hepatitis surveillance and case investigation, health care provider education and training, professional oversight, licensing, and public awareness is needed to ensure that patients are always afforded basic levels of protection against viral hepatitis transmission.	[Thompson, Nicola D.; Moorman, Anne C.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA; [Perz, Joseph F.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Thompson, ND (corresponding author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,MS G-37, Atlanta, GA 30333 USA.	ndthompson@cdc.gov		Moorman, Anne/0000-0003-2411-2798				Abramson JS, 2000, PEDIATRICS, V105, P1361; Allos BM, 2007, J INFECT DIS, V195, P1245, DOI 10.1086/513436; Alter MJ, 1999, J HEPATOL, V31, P88, DOI 10.1016/S0168-8278(99)80381-X; Anonymous, 2008, Morbidity and Mortality Weekly Report, V57, P875; Bernstein AB, 2003, DHHS PUBLICATION, V2004-1031; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P901; Centers for Disease Control and Prevention (CDC), 1977, 41 US DEP HHS PHS CD, P12, DOI DOI 10.1111/J.1478-3231.2008.01699.X; Murillo-Zumbado Gustavo, 2021, Tecnología en Marcha, V34, P130, DOI [10.18845/tm.v34i4.5274, 10.1103/PhysRevE.106.055304]; Comstock RD, 2004, INFECT CONT HOSP EP, V25, P576, DOI 10.1086/502442; de Oliveira AM, 2005, ANN INTERN MED, V142, P898, DOI 10.7326/0003-4819-142-11-200506070-00007; Garner JS, 1996, INFECT CONT HOSP EP, V17, P54, DOI 10.1017/S0195941700006123; GOODMAN RA, 1991, JAMA-J AM MED ASSOC, V265, P2377, DOI 10.1001/jama.265.18.2377; GUTELIUS BJ, 2008, 57 ANN EP INT SERV C; Henderson DK, 2008, INFECT CONT HOSP EP, V29, P294, DOI 10.1086/587440; Janowski MC, 2005, INF DIS SOC AM 43 AN; Jarvis WR, 2001, EMERG INFECT DIS, V7, P170, DOI 10.3201/eid0702.010202; *JOINT COMM, 2008, NEW YORK STAT DEP HL; Khan AJ, 2002, INFECT CONT HOSP EP, V23, P313, DOI 10.1086/502057; Krause G, 2003, INFECT CONT HOSP EP, V24, P122, DOI 10.1086/502176; Labus B., 2008, Morbidity and Mortality Weekly Report, V57, P513; Lee KC, 2005, INF DIS SOC AM 43 AN; Louie RF, 2005, POINT CARE, V4, P158, DOI 10.1097/01.poc.0000189933.35225.77; Maki DG, 2005, ARCH INTERN MED, V165, P2565, DOI 10.1001/archinte.165.22.2565; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Marx M, 2004, 53 ANN EP INT SERV C; Nainan OV, 2006, GASTROENTEROLOGY, V131, P478, DOI 10.1053/j.gastro.2006.06.007; National Center for Health Statistics, 2007, HLTH US 2007 CHARTB; PATEL AS, CONTROL HOS IN PRESS; Patel PR, 2006, JAMA-J AM MED ASSOC, V296, P2005, DOI 10.1001/jama.296.16.2005; Perz JF, 2006, J AM MED DIR ASSOC, V7, P65, DOI 10.1016/j.jamda.2005.09.008; Petrosillo N, 2001, AM J KIDNEY DIS, V37, P1004, DOI 10.1016/S0272-6386(05)80017-4; Rynn L., 2008, Morbidity and Mortality Weekly Report, V57, P1; Samandari T, 2005, INFECT CONT HOSP EP, V26, P745, DOI 10.1086/502612; Sanderson RA, 2006, AM J INFECT CONTROL, V34, pE90; Siegel J, 2007, GUIDELINES ISOLATION; SOUTHWICK KL, 2007, CLUSTER HEPATITIS B; Thompson N, 2008, NAT KIDN FDN SPRING; Tugwell BD, 2005, ANN INTERN MED, V143, P648, DOI 10.7326/0003-4819-143-9-200511010-00008; Webb R., 2005, Morbidity and Mortality Weekly Report, V54, P220; Williams IT, 2004, CLIN INFECT DIS, V38, P1592, DOI 10.1086/420935; WILLIAMS IT, 2006, INF DIS SOC AM 44 AN	41	177	185	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 6	2009	150	1					33	W7		10.7326/0003-4819-150-1-200901060-00007	http://dx.doi.org/10.7326/0003-4819-150-1-200901060-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	397IC	19124818				2023-01-03	WOS:000262655100005
J	Nichol, G; Thomas, E; Callaway, CW; Hedges, J; Powell, JL; Aufderheide, TP; Rea, T; Lowe, R; Brown, T; Dreyer, J; Davis, D; Idris, A; Stiell, I				Nichol, Graham; Thomas, Elizabeth; Callaway, Clifton W.; Hedges, Jerris; Powell, Judy L.; Aufderheide, Tom P.; Rea, Tom; Lowe, Robert; Brown, Todd; Dreyer, John; Davis, Dan; Idris, Ahamed; Stiell, Ian			Regional variation in out-of-hospital cardiac arrest incidence and outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY MEDICAL-SERVICES; AMERICAN-HEART-ASSOCIATION; MYOCARDIAL-INFARCTION; SOCIOECONOMIC-STATUS; COMATOSE SURVIVORS; DISEASE; CARE; RESUSCITATION; MORTALITY; COMMITTEE	Context The health and policy implications of regional variation in incidence and outcome of out-of-hospital cardiac arrest remain to be determined. Objective To evaluate whether cardiac arrest incidence and outcome differ across geographic regions. Design, Setting, and Patients Prospective observational study ( the Resuscitation Outcomes Consortium) of all out- of- hospital cardiac arrests in 10 North American sites ( 8 US and 2 Canadian) from May 1, 2006, to April 30, 2007, followed up to hospital discharge, and including data available as of June 28, 2008. Cases ( aged 0- 108 years) were assessed by organized emergency medical services ( EMS) personnel, did not have traumatic injury, and received attempts at external defibrillation or chest compressions or resuscitation was not attempted. Census data were used to determine rates adjusted for age and sex. Main Outcome Measures Incidence rate, mortality rate, case- fatality rate, and survival to discharge for patients assessed or treated by EMS personnel or with an initial rhythm of ventricular fibrillation. Results Among the 10 sites, the total catchment population was 21.4 million, and there were 20 520 cardiac arrests. A total of 11 898 ( 58.0%) had resuscitation attempted; 2729 ( 22.9% of treated) had initial rhythm of ventricular fibrillation or ventricular tachycardia or rhythms that were shockable by an automated external defibrillator; and 954 ( 4.6% of total) were discharged alive. The median incidence of EMS- treated cardiac arrest across sites was 52.1 ( interquartile range [ IQR], 48.0- 70.1) per 100 000 population; survival ranged from 3.0% to 16.3%, with a median of 8.4% ( IQR, 5.4%- 10.4%). Median ventricular fibrillation incidence was 12.6 ( IQR, 10.6- 5.2) per 100 000 population; survival ranged from 7.7% to 39.9%, with a median of 22.0% ( IQR, 15.0%- 24.4%), with significant differences across sites for incidence and survival ( P <. 001). Conclusion In this study involving 10 geographic regions in North America, there were significant and important regional differences in out- of- hospital cardiac arrest incidence and outcome.	[Nichol, Graham] Univ Washington, Harborview Ctr Prehosp Emergency Care, Dept Med, Seattle, WA 98104 USA; [Nichol, Graham; Thomas, Elizabeth; Powell, Judy L.] Univ Washington, Clin Trial Ctr, Dept Biostat, Seattle, WA 98195 USA; [Rea, Tom] Seattle King Cty Dept Publ Hlth, Seattle, WA USA; [Callaway, Clifton W.] Univ Pittsburgh, Pittsburgh, PA USA; [Hedges, Jerris; Lowe, Robert] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Aufderheide, Tom P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Brown, Todd] Univ Alabama Birmingham, Birmingham, AL USA; [Dreyer, John] Univ Western Ontario, London, ON, Canada; [Davis, Dan] Univ Calif San Diego, San Diego, CA 92103 USA; [Idris, Ahamed] SW Texas State Univ, Dallas, TX USA; [Stiell, Ian] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Oregon Health & Science University; Medical College of Wisconsin; University of Alabama System; University of Alabama Birmingham; Western University (University of Western Ontario); University of California System; University of California San Diego; Texas State University System; Texas State University San Marcos; University of Ottawa	Nichol, G (corresponding author), Univ Washington, Harborview Ctr Prehosp Emergency Care, Dept Med, Box 359727,325 9th Ave, Seattle, WA 98104 USA.	nichol@u.washington.edu	Nichol, Graham/Z-4996-2019; Lowe, Robert A/A-4926-2008; Hedges, Jerris/AAC-1847-2021	Lowe, Robert A/0000-0002-4732-9634; Idris, Ahamed/0000-0001-7113-6499; Stiell, Ian/0000-0002-2583-6408; Callaway, Clifton/0000-0002-3309-1573	National Heart, Lung, and Blood Institute [5U01 HL077863, 5U01 HL077881, 5U01 HL077871, 5U01 HL077873, 5U01 HL077872, 5U01 HL077866, 5U01 HL077908, 5U01 HL077867, 5U01 HL077885]; National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research Institute of Circulatory and Respiratory Health; Defence Research and Development Canada; American Heart Association; Heart and Stroke Foundation of Canada; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077908, U01HL077872, U01HL077885, U01HL077863, U01HL077881, U01HL077871, U01HL077873, U01HL077866, U01HL077867] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Canadian Institutes of Health Research Institute of Circulatory and Respiratory Health(Canadian Institutes of Health Research (CIHR)); Defence Research and Development Canada; American Heart Association(American Heart Association); Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by a cooperative agreement (grants 5U01 HL077863, HL077881, HL077871, HL077873, HL077872, HL077866, HL077908, HL077867, HL077885, and HL077885) with the National Heart, Lung, and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, the Canadian Institutes of Health Research Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the American Heart Association, and the Heart and Stroke Foundation of Canada. Medtronic Physio-Control Inc loaned equipment to several EMS agencies participating in the Alabama ROC site. These devices were used routinely in the course of the EMS duties and were not exclusively for ROC, but they were also used with ROC patients.	BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; Bergner L, 1983, Am J Emerg Med, V1, P259, DOI 10.1016/0735-6757(83)90101-8; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brooks SC, 2007, CIRCULATION, V116, P934; Domanski MJ, 2003, J CARD FAIL, V9, P354, DOI 10.1054/S1071-9164(03)00133-7; Dorian P, 2002, NEW ENGL J MED, V346, P884, DOI 10.1056/NEJMoa013029; Dunne RB, 2007, RESUSCITATION, V72, P59, DOI 10.1016/j.resuscitation.2006.04.017; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EKSTROM L, 1994, RESUSCITATION, V27, P181, DOI 10.1016/0300-9572(94)90031-0; FRANDSEN F, 1991, CARDIOLOGY, V79, P256, DOI 10.1159/000174888; Galea S, 2007, AM J EPIDEMIOL, V166, P534, DOI 10.1093/aje/kwm102; Govindarajan A, 2003, ANN EMERG MED, V41, P481, DOI 10.1067/mem.2003.108; Graham J. W., 1999, STAT STRATEGIES SMAL, V50, P1, DOI DOI 10.1177/0013164496056006006; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; Grmec S, 2007, RESUSCITATION, V72, P404, DOI 10.1016/j.resuscitation.2006.07.012; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Herlitz J, 2003, HEART, V89, P25, DOI 10.1136/heart.89.1.25; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hsu JWY, 1996, ANN EMERG MED, V28, P597, DOI 10.1016/S0196-0644(96)70080-X; Institute of Medicine, 2006, EM MED SERV CROSSR; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Knafelj R, 2007, RESUSCITATION, V74, P227, DOI 10.1016/j.resuscitation.2007.01.016; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; Laurent I, 2005, J AM COLL CARDIOL, V46, P432, DOI 10.1016/j.jacc.2005.04.039; Little R. J. A., 1987, STAT ANAL MISSING DA; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; Luepker RV, 2000, JAMA-J AM MED ASSOC, V284, P60, DOI 10.1001/jama.284.1.60; Menon V, 2006, AM J MED, V119, P584, DOI 10.1016/j.amjmed.2006.01.018; Mitchell LB, 2003, J AM COLL CARDIOL, V42, P81, DOI 10.1016/S0735-1097(03)00498-4; Morrison LJ, 2008, RESUSCITATION, V78, P161, DOI 10.1016/j.resuscitation.2008.02.020; Nichol G, 1999, ANN EMERG MED, V34, P517, DOI 10.1016/S0196-0644(99)80054-7; Nichol G, 2008, CIRCULATION, V117, P2299, DOI 10.1161/CIRCULATIONAHA.107.189472; O'Connor GT, 1999, JAMA-J AM MED ASSOC, V281, P627, DOI 10.1001/jama.281.7.627; PEDERSEN TR, 1994, LANCET, V344, P1383; Rea TD, 2004, AM J CARDIOL, V93, P1455, DOI 10.1016/j.amjcard.2004.03.002; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Singh GK, 2002, INT J EPIDEMIOL, V31, P600, DOI 10.1093/ije/31.3.600; Soo LH, 1999, EUR HEART J, V20, P535, DOI 10.1053/euhj.1998.1334; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Stiell IG, 2009, ANN EMERG MED, V53, P241, DOI 10.1016/j.annemergmed.2008.03.018; Stiell IG, 1998, ANN EMERG MED, V32, P180, DOI 10.1016/S0196-0644(98)70135-0; TILLINGHAST SJ, 1991, AM J EPIDEMIOL, V134, P851, DOI 10.1093/oxfordjournals.aje.a116160; Ting HH, 2007, CIRCULATION, V116, P729, DOI 10.1161/CIRCULATIONAHA.107.699934; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; VANDERHOEVEN JG, 1995, NETH J MED, V46, P123, DOI 10.1016/0300-2977(94)00106-J; Wilkins R., 2002, HLTH REP S, V13, P45	50	1448	1513	1	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 24	2008	300	12					1423	1431		10.1001/jama.300.12.1423	http://dx.doi.org/10.1001/jama.300.12.1423			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351FR	18812533	Green Accepted, Bronze			2023-01-03	WOS:000259410400020
J	Li, JX; Wu, HB; Hong, J; Xu, XQ; Yang, HL; Wu, BX; Wang, YP; Zhu, JH; Lai, R; Jiang, XG; Lin, DH; Prescott, MC; Rees, HH				Li, Jianxu; Wu, Hongbing; Hong, Jing; Xu, Xueqing; Yang, Hailong; Wu, Bingxian; Wang, Yipeng; Zhu, Jianhua; Lai, Ren; Jiang, Xinguo; Lin, Donghai; Prescott, Mark C.; Rees, Huw H.			Odorranalectin Is a Small Peptide Lectin with Potential for Drug Delivery and Targeting	PLOS ONE			English	Article								Background: Lectins are sugar-binding proteins that specifically recognize sugar complexes. Based on the specificity of protein-sugar interactions, different lectins could be used as carrier molecules to target drugs specifically to different cells which express different glycan arrays. In spite of lectin's interesting biological potential for drug targeting and delivery, a potential disadvantage of natural lectins may be large size molecules that results in immunogenicity and toxicity. Smaller peptides which can mimic the function of lectins are promising candidates for drug targeting. Principal Findings: Small peptide with lectin-like behavior was screened from amphibian skin secretions and its structure and function were studied by NMR, NMR-titration, SPR and mutant analysis. A lectin-like peptide named odorranalectin was identified from skin secretions of Odorrana grahami. It was composed of 17 aa with a sequence of YASPKCFRYPNGVLACT. L-fucose could specifically inhibit the haemagglutination induced by odorranalectin. (125)I-odorranalectin was stable in mice plasma. In experimental mouse models, odorranalectin was proved to mainly conjugate to liver, spleen and lung after i.v. administration. Odorranalectin showed extremely low toxicity and immunogenicity in mice. The small size and single disulfide bridge of odorranalectin make it easy to manipulate for developing as a drug targeting system. The cyclic peptide of odorranalectin disclosed by solution NMR study adopts a beta-turn conformation stabilized by one intramolecular disulfide bond between Cys6-Cys16 and three hydrogen bonds between Phe7-Ala15, Tyr9-Val13, Tyr9-Gly12. Residues K5, C6, F7, C16 and T17 consist of the binding site of L-fucose on odorranalectin determined by NMR titration and mutant analysis. The structure of odorranalectin in bound form is more stable than in free form. Conclusion: These findings identify the smallest lectin so far, and show the application potential of odorranalectin for drug delivery and targeting. It also disclosed a new strategy of amphibian anti-infection.	[Li, Jianxu; Xu, Xueqing; Yang, Hailong; Wang, Yipeng; Lai, Ren] Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Biotoxin Units, Kunming, Yunnan, Peoples R China; [Wu, Hongbing; Wu, Bingxian; Zhu, Jianhua; Jiang, Xinguo] Fudan Univ, Sch Pharm, Shanghai, Peoples R China; [Hong, Jing; Lin, Donghai] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai, Peoples R China; [Prescott, Mark C.; Rees, Huw H.] Univ Liverpool, Sch Biol Sci, Liverpool, Merseyside, England; [Li, Jianxu; Hong, Jing; Xu, Xueqing; Wang, Yipeng] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China	Chinese Academy of Sciences; Kunming Institute of Zoology; Fudan University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; University of Liverpool; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Li, JX (corresponding author), Chinese Acad Sci, Kunming Inst Zool, Key Lab Anim Models & Human Dis Mech, Biotoxin Units, Kunming, Yunnan, Peoples R China.	rlai@mail.kiz.ac.cn; xgjiang@shmu.edu.cn; dhlin@mail.shcnc.ac.cn	yang, hailong/GXH-9625-2022; Wang, Yipeng/AAA-1499-2020; Li, Jianxu/I-5723-2013	Wang, Yipeng/0000-0003-1385-4470; 	Ministry of Science and Technology of the People's Republic of China [2007AA02Z192]; Chinese Academy of Sciences [KSCX2-YW-G-024, KSCX2-YW-R-20]	Ministry of Science and Technology of the People's Republic of China(Ministry of Science and Technology, China); Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by 2007AA02Z192 from the Ministry of Science and Technology of the People's Republic of China, and KSCX2-YW-G-024, KSCX2-YW-R-20 from the Chinese Academy of Sciences.	BEVINS CL, 1990, ANNU REV BIOCHEM, V59, P395, DOI 10.1146/annurev.biochem.59.1.395; Bies C, 2004, ADV DRUG DELIVER REV, V56, P425, DOI 10.1016/j.addr.2003.10.030; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cash HL, 2006, SCIENCE, V313, P1126, DOI 10.1126/science.1127119; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ezekowitz RA, 2003, J INFECT DIS, V187, pS335, DOI 10.1086/374746; KAWAGISHI H, 1990, BIOCHIM BIOPHYS ACTA, V1034, P247, DOI 10.1016/0304-4165(90)90045-X; KAWAGISHI H, 1994, FEBS LETT, V340, P56, DOI 10.1016/0014-5793(94)80172-X; Kobayashi Y, 2004, J BIOL CHEM, V279, P53048, DOI 10.1074/jbc.M407997200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lehr CM, 2004, ADV DRUG DELIVER REV, V56, P419, DOI 10.1016/j.addr.2003.10.013; Li JX, 2007, MOL CELL PROTEOMICS, V6, P882, DOI 10.1074/mcp.M600334-MCP200; Lu SY, 1999, J PROTEIN CHEM, V18, P609, DOI 10.1023/A:1020663619657; Nadesalingam J, 2005, J IMMUNOL, V175, P1785, DOI 10.4049/jimmunol.175.3.1785; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Rieping W, 2007, BIOINFORMATICS, V23, P381, DOI 10.1093/bioinformatics/btl589; Robinson MA, 2004, P NATL ACAD SCI USA, V101, P14527, DOI 10.1073/pnas.0303574101; Scott MG, 2007, NAT BIOTECHNOL, V25, P465, DOI 10.1038/nbt1288; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; SHORE A, 1959, J PHARMACOL EXP THER, V127, P182; Sobal G, 2004, NUCL MED BIOL, V31, P381, DOI 10.1016/j.nucmedbio.2003.10.010; Tchernychev B, 1996, FEBS LETT, V397, P139, DOI 10.1016/S0014-5793(96)01154-4; Wang W, 2003, J IMMUNOL, V170, P4708, DOI 10.4049/jimmunol.170.9.4708; WESTERHOFF HV, 1995, EUR J BIOCHEM, V228, P257; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Xu XQ, 2006, TOXICON, V47, P459, DOI 10.1016/j.toxicon.2006.01.002; Yan H, 2001, ANTIMICROB AGENTS CH, V45, P1558, DOI 10.1128/AAC.45.5.1558-1560.2001; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	32	60	66	1	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2008	3	6							e2381	10.1371/journal.pone.0002381	http://dx.doi.org/10.1371/journal.pone.0002381			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	405UD	18584053	Green Published, gold, Green Submitted			2023-01-03	WOS:000263248800021
J	Vogelzang, NJ				Vogelzang, Nicholas J.			Chemotherapy for malignant pleural mesothelioma	LANCET			English	Editorial Material							LUNG-CANCER; PHASE-III; CISPLATIN		Nevada Canc Inst, Las Vegas, NV 89135 USA	University of California System; University of California San Diego	Vogelzang, NJ (corresponding author), Nevada Canc Inst, Las Vegas, NV 89135 USA.	nvogelzang@nvcancer.org						Fennell DA, 2008, NAT CLIN PRACT ONCOL, V5, P136, DOI 10.1038/ncponc1039; Karrison T, 2007, J CLIN ONCOL, V25; Muers MF, 2008, LANCET, V371, P1685, DOI 10.1016/S0140-6736(08)60727-8; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Steele JPC, 2000, J CLIN ONCOL, V18, P3912, DOI 10.1200/JCO.2000.18.23.3912; van Meerbeeck JP, 2005, J CLIN ONCOL, V23, P6881, DOI 10.1200/JCO.20005.14.589; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136	7	20	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 17	2008	371	9625					1640	1642		10.1016/S0140-6736(08)60703-5	http://dx.doi.org/10.1016/S0140-6736(08)60703-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	302XB	18486725				2023-01-03	WOS:000256002200005
J	Fung, SY; Yang, H; Chen, P				Fung, Shan Yu; Yang, Hong; Chen, P.			Sequence Effect of Self-Assembling Peptides on the Complexation and In Vitro Delivery of the Hydrophobic Anticancer Drug Ellipticine	PLOS ONE			English	Article								A special class of self-assembling peptides has been found to be capable of stabilizing the hydrophobic anticancer agent ellipticine in aqueous solution. Here we study the effect of peptide sequence on the complex formation and its anticancer activity in vitro. Three peptides, EAK16-II, EAK16-IV and EFK16-II, were selected to have either a different charge distribution (EAK16-II vs. EAK16-IV) or a varying hydrophobicity (EAK16-II vs. EFK16-II). Results on their complexation with ellipticine revealed that EAK16-II and EAK16-IV were able to stabilize protonated ellipticine or ellipticine microcrystals depending on the peptide concentration; EFK16-II could stabilize neutral ellipticine molecules and ellipticine microcrystals. These different molecular states of ellipticine were expected to affect ellipticine delivery. The anticancer activity of these complexes was tested against two cancer cell lines: A549 and MCF-7, and related to the cell viability. The viability results showed that the complexes with protonated ellipticine were effective in eradicating both cancer cells (viability<0.05), but their dilutions in water were not stable, leading to a fast decrease in their toxicity. In contrast, the complexes formulated with EFK16-II were relatively stable upon dilution, but their original toxicity was relatively low compared to that with protonated ellipticine. Overall, the charge distribution of the peptides seemed not to affect the complex formation and its therapeutic efficacy in vitro; however, the increase in hydrophobicity of the peptides significantly altered the state of stabilized ellipticine and increased the stability of the complexes. This work provides essential information for peptide sequence design in the development of self-assembling peptide-based delivery of hydrophobic anticancer drugs.	[Fung, Shan Yu; Yang, Hong; Chen, P.] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada	University of Waterloo	Chen, P (corresponding author), Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.	p4chen@cape.uwaterloo.ca	Fung, Shan-Yu/E-3477-2014; Yang, Hong/AAZ-1061-2020; Yang, Hong/E-3478-2014	Fung, Shan-Yu/0000-0002-4547-8740; Yang, Hong/0000-0002-6707-8481	Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI); Canada Research Chairs (CRC)	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Foundation for Innovation (CFI)(Canada Foundation for Innovation); Canada Research Chairs (CRC)(Canada Research Chairs)	Support for this research has been provided by the Natural Sciences and Engineering Research Council of Canada (NSERC), Canada Foundation for Innovation (CFI) and the Canada Research Chairs (CRC) Program for one of the coauthors (PC).	Aggeli Amalia, 1999, Molecular Medicine Today, V5, P512, DOI 10.1016/S1357-4310(99)01610-X; Biswas ME, 2005, J COLLOID INTERF SCI, V286, P14, DOI 10.1016/j.jcis.2005.01.011; Bokhari MA, 2005, BIOMATERIALS, V26, P5198, DOI 10.1016/j.biomaterials.2005.01.040; Caplan MR, 2002, BIOMATERIALS, V23, P219, DOI 10.1016/S0142-9612(01)00099-0; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80; Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103; Eastoe J, 2000, ADV COLLOID INTERFAC, V85, P103, DOI 10.1016/S0001-8686(99)00017-2; Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103; Ellis-Behnke RG, 2006, NANOMED-NANOTECHNOL, V2, P207, DOI 10.1016/j.nano.2006.08.001; Fung SY, 2007, COLLOID SURFACE B, V55, P200, DOI 10.1016/j.colsurfb.2006.12.002; Fung SY, 2006, J PHYS CHEM A, V110, P11446, DOI 10.1021/jp062778y; FUNG SY, 2005, HDB NANOSTRUCTURED B, P1; FUNG SY, 2008, ACS NANO UNPUB; Garbett Nichola C., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P149, DOI 10.2174/1568011043482070; Gu FX, 2007, NANO TODAY, V2, P14, DOI 10.1016/S1748-0132(07)70083-X; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Hong YS, 2003, BIOMACROMOLECULES, V4, P1433, DOI 10.1021/bm0341374; Hsieh PCH, 2006, CIRCULATION, V114, P637, DOI 10.1161/CIRCULATIONAHA.106.639831; Hsieh PCH, 2006, J CLIN INVEST, V116, P237, DOI 10.1172/JCI25878; Jun S, 2004, BIOPHYS J, V87, P1249, DOI 10.1529/biophysj.103.038166; Keyes-Baig C, 2004, J AM CHEM SOC, V126, P7522, DOI 10.1021/ja0381297; Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lindgren M, 2005, BIOPHYS J, V88, P4200, DOI 10.1529/biophysj.104.049700; Liu JB, 2004, J PHARM SCI-US, V93, P132, DOI 10.1002/jps.10533; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Nagai Y, 2006, J CONTROL RELEASE, V115, P18, DOI 10.1016/j.jconrel.2006.06.031; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162; Segers VF, 2007, CIRCULATION, V116, P69; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Temsamani J, 2004, DRUG DISCOV TODAY, V9, P1012, DOI 10.1016/S1359-6446(04)03279-9; Torrent J, 2004, BIOCHEMISTRY-US, V43, P7162, DOI 10.1021/bi049939d; Yang H, 2006, LANGMUIR, V22, P8553, DOI 10.1021/la061238p; Yang H, 2007, J AM CHEM SOC, V129, P12200, DOI 10.1021/ja073168u; ZHANG SG, 1994, BIOPOLYMERS, V34, P663, DOI 10.1002/bip.360340508; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874	40	44	47	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1956	10.1371/journal.pone.0001956	http://dx.doi.org/10.1371/journal.pone.0001956			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398476	gold, Green Submitted, Green Published			2023-01-03	WOS:000260795500027
J	Carlile, A				Carlile, Alex			Assisted Suicide The law as it stands on assisted suicide could not be clearer	BRITISH MEDICAL JOURNAL			English	Editorial Material												carlileqc@aol.com							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	AUG 5	2009	339								b3169	10.1136/bmj.b3169	http://dx.doi.org/10.1136/bmj.b3169			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	481KD	19656830				2023-01-03	WOS:000268808000009
J	Albain, KS; Swann, RS; Rusch, VW; Turrisi, AT; Shepherd, FA; Smith, C; Chen, Y; Livingston, RB; Feins, RH; Gandara, DR; Fry, WA; Darling, G; Johnson, DH; Green, MR; Miller, RC; Ley, J; Sause, WT; Cox, JD				Albain, Kathy S.; Swann, R. Suzanne; Rusch, Valerie W.; Turrisi, Andrew T., III; Shepherd, Frances A.; Smith, Colum; Chen, Yuhchyau; Livingston, Robert B.; Feins, Richard H.; Gandara, David R.; Fry, Willard A.; Darling, Gail; Johnson, David H.; Green, Mark R.; Miller, Robert C.; Ley, Joanne; Sause, Willliam T.; Cox, James D.			Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial	LANCET			English	Article							THERAPY-ONCOLOGY-GROUP; INDUCTION CHEMOTHERAPY; THORACIC RADIOTHERAPY; CHEST RADIOTHERAPY; CLINICAL-TRIALS; SURGERY; CONCURRENT; RADIATION; CISPLATIN	Background Results from phase 11 studies in patients with stage IIIA non-small-cell lung cancer with ipsilateral mediastinal nodal metastases (N2) have shown the feasibility of resection after concurrent chemotherapy and radiotherapy with promising rates of survival. We therefore did this phase III trial to compare concurrent chemotherapy and radiotherapy followed by resection with standard concurrent chemotherapy and definitive radiotherapy without resection. Methods Patients with stage T1-3pN2M0 non-small-cell lung cancer were randomly assigned in a 1:1 ratio to concurrent induction chemotherapy (two cycles of cisplatin [50 mg/m(2) on days 1, 8, 29, and 361 and etoposide [50 mg/m(2) on days 1-5 and 29-33]) plus radiotherapy (45 Gy) in multiple academic and community hospitals. if no progression, patients in group 1 underwent resection and those in group 2 continued radiotherapy uninterrupted up to 61 Gy. Two additional cycles of cisplatin and etoposide were given in both groups. The primary endpoint was overall survival (OS). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00002550. Findings 202 patients (median age 59 years, range 31-77) were assigned to group 1 and 194 (61 years, 32-78) to group 2. Median OS was 23.6 months (IQR 9.0-not reached) in group 1 versus 22.2 months (9.4-52.7) in group 2 (hazard ratio [HR] 0.87 [0.70-1.10]; p=0.24). Number of patients alive at 5 years was 37 (point estimate 27%) in group 1 and 24 (point estimate 20%) in group 2 (odds ratio 0.63 [0.36-1.10]; p=0.10). With NO status at thoracotomy, the median OS was 34.4 months (IQR 15.7-not reached; 19 [point estimate 41%] patients alive at 5 years). Progression-free survival (PFS) was better in group 1 than in group 2, median 12.8 months (5.3-42.2) vs 10.5 months (4.8-20.6), HR 0.77 [0.62-0.96]; p=0.017); the number of patients without disease progression at 5 years was 32 (point estimate 22%) versus 13 (point estimate 11%), respectively. Neutropenia and oesophagitis were the main grade 3 or 4 toxicities associated with chemotherapy plus radiotherapy in group 1 (77 [38%] and 20 [10%], respectively) and group 2 (80 [41%] and 44 [23%], respectively). In group 1, 16 (8%) deaths were treatment related versus four (2%) in group 2. in an exploratory analysis, OS was improved for patients who underwent lobectomy, but not pneumonectomy, versus chemotherapy plus radiotherapy. Interpretation Chemotherapy plus radiotherapy with or without resection (preferably lobectomy) are options for patients with stage IIIA(N2) non-small-cell lung cancer.	[Albain, Kathy S.] Loyola Univ Chicago, Stritch Sch Med, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA; [Swann, R. Suzanne; Ley, Joanne] Radiat Therapy Oncol Grp, Philadelphia, PA USA; [Rusch, Valerie W.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Turrisi, Andrew T., III] Wayne State Univ, Detroit, MI USA; [Shepherd, Frances A.] Univ Hlth Network, Princess Margaret Hosp Site, Toronto, ON, Canada; [Smith, Colum] Tom Baker Canc Clin, Calgary, AB, Canada; [Chen, Yuhchyau] Univ Rochester, Med Ctr, Rochester, NY 14642 USA; [Livingston, Robert B.] Univ Arizona, Ctr Canc, Tucson, AZ USA; [Feins, Richard H.] Univ N Carolina, Chapel Hill, NC USA; [Gandara, David R.] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; [Fry, Willard A.] NorthShore Univ Hlth Syst, Evanston Hosp, Evanston, IL USA; [Darling, Gail] Univ Hlth Network, Toronto Gen Hosp Site, Toronto, ON, Canada; [Johnson, David H.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Green, Mark R.] Med Univ S Carolina, Charleston, SC 29425 USA; [Miller, Robert C.] Mayo Clin, Rochester, MN USA; [Sause, Willliam T.] Intermt Med Ctr, Salt Lake City, UT USA; [Cox, James D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	Loyola University Chicago; Radiation Therapy Oncology Group (RTOG); Memorial Sloan Kettering Cancer Center; Wayne State University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Tom Baker Cancer Clinic; University of Calgary; University of Rochester; University of Arizona; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Davis; NorthShore University Health System; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Vanderbilt University; Medical University of South Carolina; Mayo Clinic; Intermountain Healthcare; Intermountain Medical Center; University of Texas System; UTMD Anderson Cancer Center	Albain, KS (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Cardinal Bernardin Canc Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA.	kalbain@lumc.edu	Johnson, David/AHI-8369-2022	Miller, Robert/0000-0001-8932-2732; Rusch, Valerie/0000-0003-2345-6900	National Cancer Institute [CA21661, CA37422, CA32115, CA46441, CA77202, CA49957, CA03927, CA25224]; Canadian Cancer Society [NCIC10362]; NATIONAL CANCER INSTITUTE [U10CA021661, U10CA077202, U10CA037422, U10CA180846, U10CA049957, R44CA121661, U10CA032115, U10CA003927, U10CA025224, U10CA046441] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Canadian Cancer Society(Canadian Cancer Society (CCS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This trial was funded by the National Cancer Institute (pHs Cooperative Agreement grant numbers CA21661, CA37422, CA32115, CA46441, CA77202, CA49957, CA03927, CA25224) with high priority designation, and Canadian Cancer Society (NCIC10362), and administered by the Radiation Therapy Oncology Group (RTOG, R9309), with participation by Southwest Oncology Group, National Cancer Institute of Canada Clinical Trials Group, Eastern Cooperative Oncology Group, Cancer and Leukemia Group B, and North Central Cancer Treatment Group. We thank the many North American Intergroup discipline chairs and others who provided advice or assistance during the design of this study or while the study was in progress; the members of the Lung Cancer Committees of the Southwest Oncology Group, National Cancer Institute of Canada Clinical Trials Group, Eastern Cooperative Oncology Group, Cancer and Leukemia Group B, and the North Central Cancer Treatment Group for their support of this study over the long accrual period; and especially the lung cancer survivors who were treated and followed up on this protocol, and the lay advocates who supported this trial design.	ALBAIN KS, 1995, J CLIN ONCOL, V13, P1880, DOI 10.1200/JCO.1995.13.8.1880; Albain KS, 2005, J CLIN ONCOL, V23, p624S; Albain KS, 2002, J CLIN ONCOL, V20, P3454, DOI 10.1200/JCO.2002.03.055; ALBAIN KS, 2003, P AN M AM SOC CLIN, V22, P621; COX DR, 1972, J R STAT SOC B, V187, P220; Curran WJ, 2003, P AN M AM SOC CLIN, V22, P621; Depierre A, 2002, J CLIN ONCOL, V20, P247, DOI 10.1200/JCO.20.1.247; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; Eberhardt WE, 2003, LUNG CANCER-J IASLC, V42, pS9, DOI 10.1016/S0169-5002(03)00300-3; Farray D, 2005, J CLIN ONCOL, V23, P3257, DOI 10.1200/JCO.2005.03.008; Furuse K, 1999, J CLIN ONCOL, V17, P2692, DOI 10.1200/JCO.1999.17.9.2692; JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAKATOS E, 1988, BIOMETRICS, V44, P229, DOI 10.2307/2531910; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; MARTINI N, 1987, SURG CLIN N AM, V67, P1037; MOUNTAIN CF, 1988, SEMIN ONCOL, V15, P236; PEREZ CA, 1987, CANCER, V59, P1874, DOI 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z; PISTERS K, 2005, LUNG CANC PRINCIPLES, P626; Pritchard RS, 1996, ANN INTERN MED, V125, P723, DOI 10.7326/0003-4819-125-9-199611010-00003; ROSELL R, 1994, NEW ENGL J MED, V330, P153, DOI 10.1056/NEJM199401203300301; ROTH JA, 1994, J NATL CANCER I, V86, P673, DOI 10.1093/jnci/86.9.673; SAUSE WT, 1995, J NATL CANCER I, V87, P198, DOI 10.1093/jnci/87.3.198; van Meerbeeck JP, 2007, JNCI-J NATL CANCER I, V99, P442, DOI 10.1093/jnci/djk093; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	25	1012	1039	0	69	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 1	2009	374	9687					379	386		10.1016/S0140-6736(09)60737-6	http://dx.doi.org/10.1016/S0140-6736(09)60737-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481MJ	19632716	Green Accepted, Green Published			2023-01-03	WOS:000268815200021
J	Neuman, P; Cubanski, J				Neuman, Patricia; Cubanski, Juliette			Medicare Part D Update - Lessons Learned and Unfinished Business	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRESCRIPTION-DRUG BENEFIT; NATIONAL-SURVEY; COVERAGE; BENEFICIARIES; NONADHERENCE; SENIORS		[Neuman, Patricia; Cubanski, Juliette] Henry J Kaiser Family Fdn, Medicare Policy Project, Washington, DC USA		Neuman, P (corresponding author), Henry J Kaiser Family Fdn, Medicare Policy Project, Washington, DC USA.							Aitken M, 2009, HEALTH AFFAIR, V28, pW151, DOI 10.1377/hlthaff.28.1.w151; Altman DE, 2004, NEW ENGL J MED, V350, P9, DOI 10.1056/NEJMp038224; [Anonymous], 2007, 2007 ANN REP BOARDS; *AV HLTH, 2008, AV BEN TOP 10 PDPS F; BERNDT ER, 2007, SURV CURR BUS, V87, P59; *CTR MED MED SERV, 2009, 2009 ENR INF; *CTR MED MED SERV, 2008, THINGS THINK YOU COM; Cubanski J, 2007, HEALTH AFFAIR, V26, pW1, DOI 10.1377/hlthaff.26.1.w1; DANZON P, 2004, HLTH AFF MILLWOOD S; *DAT CTR MED MED S, 2004, PRESCR MED MOD MED D; DUGGAN M, 2008, 13917 NBER; Dulio A., 2007, VOICES BENEFICIARIES; *FAM US, 2007, NO BARG MED DRUG PLA; Frank RG, 2008, HEALTH AFFAIR, V27, P33, DOI 10.1377/hlthaff.27.1.33; GRUBER J, 2009, MEDICARE BENEFICIARI; HARGRAVE E, 2009, 091 MED PAYM ADV COM; HARGRAVE E, 2009, MEDICARE PRESCRIPTIO; HEATON E, 2006, ASSESSING MEDICARE P; Heiss F, 2006, HEALTH AFFAIR, V25, pW344, DOI 10.1377/hlthaff.25.w344; HOADLEY J, 2008, MED PAY ADV COMM DEC; Hoadley J, 2008, MEDICARE D; Iglehart JK, 2004, NEW ENGL J MED, V350, P826, DOI 10.1056/NEJMhpr045002; Ketcham J. D., 2008, 14326 NBER; LEVY H, 2009, 14692 NBER; Lichtenberg FR, 2007, HEALTH AFFAIR, V26, P1735, DOI 10.1377/hlthaff.26.6.1735; Madden JM, 2008, JAMA-J AM MED ASSOC, V299, P1922, DOI 10.1001/jama.299.16.1922; Neuman P, 2007, HEALTH AFFAIR, V26, pW630, DOI 10.1377/hlthaff.26.5.w630; *OFF INSP GEN, 2009, PUBL OFF INSP GEN; PEAR R, 2003, NY TIMES        0607; Raebel MA, 2008, MED CARE, V46, P1116, DOI 10.1097/MLR.0b013e318185cddd; Regan JF, 2007, HEALTH CARE FINANC R, V29, P119; RICE T, 2008, ACADEMYHEALTH ANN RE; SAFRAN DG, 2005, HLTH AFF MILLWOOD S; Schneeweiss S, 2009, HEALTH AFFAIR, V28, pW305, DOI 10.1377/hlthaff.28.2.w305; Sisko A, 2009, HEALTH AFFAIR, V28, pW346, DOI 10.1377/hlthaff.28.2.w346; Soumerai SB, 2006, ARCH INTERN MED, V166, P1829, DOI 10.1001/archinte.166.17.1829; Summer L, 2008, MEDICARE D; The Boards of Trustees Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, 2004, 2004 ANN REP BOARDS; The Boards of Trustees Federal Hospital Insurance and Federal Supplemetary Medical Insurance Trust Funds, 2008, 2008 ANN REP BOARDS; US House of Representatives. Committee on Oversight and Government Reform, 2008, MED D; WILL GF, 2008, WASHINGTON POST 0921, pB7; Yin W, 2008, ANN INTERN MED, V148, P169, DOI 10.7326/0003-4819-148-3-200802050-00200; Zhang Y, 2009, HEALTH AFFAIR, V28, pW317, DOI 10.1377/hlthaff.28.2.w317; 2008, NY TIMES        0902	44	37	37	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 23	2009	361	4					406	414		10.1056/NEJMhpr0809949	http://dx.doi.org/10.1056/NEJMhpr0809949			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	473DC	19625722				2023-01-03	WOS:000268184500014
J	Murat, A; Migliavacca, E; Hussain, SF; Heimberger, AB; Desbaillets, I; Hamou, MF; Ruegg, C; Stupp, R; Delorenzi, M; Hegi, ME				Murat, Anastasia; Migliavacca, Eugenia; Hussain, S. Farzana; Heimberger, Amy B.; Desbaillets, Isabelle; Hamou, Marie-France; Rueegg, Curzio; Stupp, Roger; Delorenzi, Mauro; Hegi, Monika E.			Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia	PLOS ONE			English	Article								Glioblastoma are rapidly proliferating brain tumors in which hypoxia is readily recognizable, as indicated by focal or extensive necrosis and vascular proliferation, two independent diagnostic criteria for glioblastoma. Gene expression profiling of glioblastoma revealed a gene expression signature associated with hypoxia-regulated genes. The correlated gene set emerging from unsupervised analysis comprised known hypoxia-inducible genes involved in angiogenesis and inflammation such as VEGF and BIRC3, respectively. The relationship between hypoxia-modulated angiogenic genes and inflammatory genes was associated with outcome in our cohort of glioblastoma patients treated within prospective clinical trials of combined chemoradiotherapy. The hypoxia regulation of several new genes comprised in this cluster including ZNF395, TNFAIP3, and TREM1 was experimentally confirmed in glioma cell lines and primary monocytes exposed to hypoxia in vitro. Interestingly, the cluster seems to characterize differential response of tumor cells, stromal cells and the macrophage/microglia compartment to hypoxic conditions. Most genes classically associated with the inflammatory compartment are part of the NF-kappaB signaling pathway including TNFAIP3 and BIRC3 that have been shown to be involved in resistance to chemotherapy. Our results associate hypoxia-driven tumor response with inflammation in glioblastoma, hence underlining the importance of tumor-host interaction involving the inflammatory compartment.			Murat, A (corresponding author), CHUV, Univ Lausanne Hosp, Lab Brain Tumor Biol & Genet, Lausanne, Switzerland.	Monika.Hegi@chuv.ch	Stupp, Roger/L-3303-2019; Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495	NCI NIH HHS [R01 CA120813] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA120813] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bostrom P, 2006, ARTERIOSCL THROM VAS, V26, P1871, DOI 10.1161/01.ATV.0000229665.78997.0b; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Bredel M, 2006, J CLIN ONCOL, V24, P274, DOI 10.1200/JCO.2005.02.9405; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Colli S, 1999, THROMB HAEMOSTASIS, V81, P576; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Fu YC, 2004, BLOOD CELL MOL DIS, V32, P182, DOI 10.1016/j.bcmd.2003.09.002; Fujino T, 2008, J COMP NEUROL, V507, P1831, DOI 10.1002/cne.21649; Getz G, 2000, P NATL ACAD SCI USA, V97, P12079, DOI 10.1073/pnas.210134797; Godard S, 2003, CANCER RES, V63, P6613; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hiden U, 2007, REV ENDOCR METAB DIS, V8, P31, DOI 10.1007/s11154-007-9030-8; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Ho CC, 2008, AM J RESP CRIT CARE, V177, P763, DOI 10.1164/rccm.200704-641OC; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373; Le Jan S, 2006, FEBS LETT, V580, P3395, DOI 10.1016/j.febslet.2006.05.011; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li HL, 2006, J CELL PHYSIOL, V208, P307, DOI 10.1002/jcp.20665; Manderscheid M, 2001, J AM SOC NEPHROL, V12, P1151, DOI 10.1681/ASN.V1261151; Mead EJ, 2007, BRIT J PHARMACOL, V151, P1143, DOI 10.1038/sj.bjp.0707295; Mead EJ, 2007, ENDOCRINOLOGY, V148, P140, DOI 10.1210/en.2006-0818; Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164; Murphy KG, 2005, J NEUROENDOCRINOL, V17, P519, DOI 10.1111/j.1365-2826.2005.01328.x; Nabors LLB, 2003, CANCER RES, V63, P4181; Nomura T, 2005, ONCOL REP, V14, P993; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Tanaka K, 2004, J BIOL CHEM, V279, P7275, DOI 10.1074/jbc.M310726200; Valdez BC, 2008, LEUKEMIA RES, V32, P1684, DOI 10.1016/j.leukres.2008.01.016; Vaziri SAJ, 2003, ANTICANCER RES, V23, P3657; Vendrell JA, 2007, ONCOGENE, V26, P4656, DOI 10.1038/sj.onc.1210269; Wang N, 1996, J BIOL CHEM, V271, P8837, DOI 10.1074/jbc.271.15.8837; Yabe H, 2008, ONCOL REP, V19, P129; Zeng H, 2007, EUR J IMMUNOL, V37, P2300, DOI 10.1002/eji.200737270	48	84	85	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2009	4	6							e5947	10.1371/journal.pone.0005947	http://dx.doi.org/10.1371/journal.pone.0005947			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	458NC	19536297	Green Published, gold, Green Submitted			2023-01-03	WOS:000267029700017
J	Desai, M; Nolte, E; Mays, N; Nikolentzos, A				Desai, Monica; Nolte, Ellen; Mays, Nicholas; Nikolentzos, Athanasios			International experience of paying for expensive medicines	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CELL LUNG-CANCER; CHEMOTHERAPY		[Nolte, Ellen; Mays, Nicholas] Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Nolte, E (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.	enolte@rand.org		Nolte, Ellen/0000-0002-2289-117X	National Institute for Health Research [ACF-2008-20-002] Funding Source: researchfish; Department of Health [0510002] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		APPLEBY J, 2008, BMJ-BRIT MED J, V337, P1122; Chu DT, 2007, LUNG CANCER, V56, P433, DOI 10.1016/j.lungcan.2007.01.028; Clarke R, 2008, CLIN ONCOL-UK, V20, P771, DOI 10.1016/j.clon.2008.09.005; Department of Health, 2009, GUID NHS PAT WHO WIS; Department of Health, 2004, COD COND PRIV PRACT; DoHSC (Department of Health & Social Care), 2021, NHS CONST ENGL; FLOOD C, 2007, MCGILL HLTH LAW PUBL, V1, P7; Gubb J, 2008, BMJ-BRIT MED J, V336, P1104, DOI [10.1136/bmj.39563.453183.AD, 10.1136/bmj.39563.493218.AD]; KHOO K, 2007, REPORT CARD CANC CAN, V10, P40; *NAT I HLTH CLIN E, APPR LIF EXT END LIF; NIKOLENTZOS A, PAYING EXPENSIVE DRU; *PROV WORK GROUP, 2006, REP PROV WORK GROUP; *RAR CANC FOR, 2008, TAK EXC AUD POL PROC; Richards M, 2008, IMPROVING ACCESS MED; SATCHELL G, 2008, BBC NEWS        1223; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; TEMPLETON S, 2008, SUNDAY TIMES    0601; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	18	3	3	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2009	338								b1993	10.1136/bmj.b1993	http://dx.doi.org/10.1136/bmj.b1993			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WV	19482871	Green Accepted			2023-01-03	WOS:000266502500003
J	Al-Ejeh, F; Darby, JM; Brown, MP				Al-Ejeh, Fares; Darby, Jocelyn M.; Brown, Michael P.			Chemotherapy Synergizes with Radioimmunotherapy Targeting La Autoantigen in Tumors	PLOS ONE			English	Article								Background: To date, inefficient delivery of therapeutic doses of radionuclides to solid tumors limits the clinical utility of radioimmunotherapy. We aim to test the therapeutic utility of Yttrium-90 (Y-90)-radio-conjugates of a monoclonal antibody, which we showed previously to bind specifically to the abundant intracellular La ribonucleoprotein revealed in dead tumor cells after DNA-damaging treatment. Methodology/Principal Findings: Immunoconjugates of the DAB4 clone of the La-specific monoclonal antibody, APOMAB (R), were prepared using the metal chelator, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and then radiolabeled with Y-90. Mice bearing established subcutaneous tumors were treated with Y-90-DOTA-DAB4 alone or after chemotherapy. Non-radiosensitizing cyclophosphamide/etoposide chemotherapy was used for the syngeneic EL4 lymphoma model. Radiosensitizing cisplatin/gemcitabine chemotherapy was used for the syngeneic Lewis Lung carcinoma (LL2) model, and for the xenograft models of LNCaP prostatic carcinoma and Panc-1 pancreatic carcinoma. We demonstrate the safety, specificity, and efficacy of Y-90-DOTA-DAB4-radioimmunotherapy alone or combined with chemotherapy. EL4 lymphoma-bearing mice either were cured at higher doses of radioimmunotherapy alone or lower doses of radioimmunotherapy in synergy with chemotherapy. Radioimmunotherapy alone was less effective in chemo-and radio-resistant carcinoma models. However, radioimmunotherapy synergized with radiosensitizing chemotherapy to retard significantly tumor regrowth and so prolong the survival of mice bearing LL2, LNCaP, or Panc-1 subcutaneous tumor implants. Conclusions/Significance: We report proof-of-concept data supporting a unique form of radioimmunotherapy, which delivers bystander killing to viable cancer cells after targeting the universal cancer antigen, La, created by DNA-damaging treatment in neighboring dead cancer cells. Subsequently we propose that DAB4-targeted ionizing radiation induces additional cycles of tumor cell death, which further augments DAB4 binding to produce a tumor-lethal 'genotoxic chain reaction'. Clinically, this approach may be useful as consolidation treatment after a drug-induced cell death among (small-volume) metastatic deposits, the commonest cause of cancer death. This article is part II of a two-part series providing proof-of-concept for the diagnostic and therapeutic use of the DAB4 clone of the La-specific monoclonal antibody, APOMAB (R).	[Al-Ejeh, Fares; Darby, Jocelyn M.; Brown, Michael P.] Hanson Inst, Expt Therapeut Lab, Adelaide, SA, Australia; [Brown, Michael P.] Univ Adelaide, Royal Adelaide Hosp, Dept Med Oncol, Adelaide, SA 5005, Australia; [Brown, Michael P.] Univ Adelaide, Sch Med, Adelaide, SA 5005, Australia	Hanson Institute; Royal Adelaide Hospital; University of Adelaide; University of Adelaide	Al-Ejeh, F (corresponding author), Hanson Inst, Expt Therapeut Lab, Adelaide, SA, Australia.	michael.brown@health.sa.gov.au	Al-Ejeh, Fares/M-7032-2016; Brown, Michael/C-2081-2014	Al-Ejeh, Fares/0000-0002-1553-0077; Darby, Jocelyn/0000-0002-1819-6000; Brown, Michael/0000-0002-5796-1932	Oncaidia Ltd; National Health and Medical Research Council Research [ID511303]	Oncaidia Ltd; National Health and Medical Research Council Research	Oncaidia Ltd funded the salary of FA for 2007, the salary of JMD as well as equipment and research. National Health and Medical Research Council Research also supplied funding through Project Grant ID511303. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Ejeh F, 2007, CLIN CANCER RES, V13, p5519S, DOI 10.1158/1078-0432.CCR-07-0964; Al-Ejeh F, 2007, CLIN CANCER RES, V13, p5509S, DOI 10.1158/1078-0432.CCR-07-0922; ALEJEH F, NUCL MED BI IN PRESS; Ayukawa K, 2000, J BIOL CHEM, V275, P34465, DOI 10.1074/jbc.M003673200; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Buchholz TA, 2003, CANCER J, V9, P33, DOI 10.1097/00130404-200301000-00007; Chang J, 2000, CANCER-AM CANCER SOC, V89, P2145, DOI 10.1002/1097-0142(20001201)89:11<2145::AID-CNCR1>3.0.CO;2-S; Chen SL, 2005, J CLIN ONCOL, V23, P1538, DOI 10.1200/JCO.2005.06.108; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Clancy RM, 2006, J CLIN INVEST, V116, P2413, DOI 10.1172/JCI27803; Davis DW, 2003, CLIN CANCER RES, V9, P955; Deb N, 1996, CLIN CANCER RES, V2, P1289; EPSTEIN AL, 1988, CANCER RES, V48, P5842; Erickson HK, 2006, CANCER RES, V66, P4426, DOI 10.1158/0008-5472.CAN-05-4489; Goldenberg DM, 2006, Q J NUCL MED MOL IM, V50, P248; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoeppner Luke H, 2006, Cancer Immun, V6, P1; Koppe MJ, 2004, J NUCL MED, V45, P1224; Kovtun YV, 2006, CANCER RES, V66, P3214, DOI 10.1158/0008-5472.CAN-05-3973; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Lang D, 1998, ONCOGENE, V16, P1593, DOI 10.1038/sj.onc.1201665; Lawrence TS, 2003, SEMIN RADIAT ONCOL, V13, P13, DOI 10.1053/srao.2003.50002; Lee CH, 2007, HUM GENE THER, V18, P27, DOI 10.1089/hum.2005.239; Leers MPG, 2002, CELL MOL LIFE SCI, V59, P1358, DOI 10.1007/s00018-002-8513-8; Liu S, 2001, BIOCONJUGATE CHEM, V12, P7, DOI 10.1021/bc000070v; Mayer A, 2006, CLIN CANCER RES, V12, P6509, DOI 10.1158/1078-0432.CCR-06-0769; McArthur C, 2002, ARCH ORAL BIOL, V47, P443, DOI 10.1016/S0003-9969(02)00025-0; Milas L, 1999, CANCER RES, V59, P107; MILLER BK, 1993, HOOSIER FARMLAND WIL, V1, P2; Milowsky MI, 2004, J CLIN ONCOL, V22, P2522, DOI 10.1200/JCO.2004.09.154; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Rokhlin OW, 2000, ONCOGENE, V19, P1959, DOI 10.1038/sj.onc.1203453; SCHMIDBERGER H, 1991, CANCER RES, V51, P1883; Sgouros G, 2008, CANCER BIOTHER RADIO, V23, P74, DOI 10.1089/cbr.2007.0408; Shewach DS, 2007, J CLIN ONCOL, V25, P4043, DOI 10.1200/JCO.2007.11.5287; Smith-Jones PM, 2003, J NUCL MED, V44, P610; Soini Y, 1998, AM J PATHOL, V153, P1041, DOI 10.1016/S0002-9440(10)65649-0; Tan EM, 2008, IMMUNOL REV, V222, P328, DOI 10.1111/j.1600-065X.2008.00611.x; THIERRY B, ADV MAT IN PRESS; Tran HB, 2002, ARTHRITIS RHEUM, V46, P202, DOI 10.1002/1529-0131(200201)46:1<202::AID-ART10062>3.0.CO;2-Y; Truksa J, 2003, CELL PROLIFERAT, V36, P199, DOI 10.1046/j.1365-2184.2003.00280.x; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Wang XJ, 2005, NEW ENGL J MED, V353, P1224, DOI 10.1056/NEJMoa051931; Wood W, 2000, DEVELOPMENT, V127, P5245; Wu AM, 2005, NAT BIOTECHNOL, V23, P1137, DOI 10.1038/nbt1141; Zhao M, 2001, NAT MED, V7, P1241, DOI 10.1038/nm1101-1241	49	25	27	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2009	4	2							e4630	10.1371/journal.pone.0004630	http://dx.doi.org/10.1371/journal.pone.0004630			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437LA	19247485	Green Published, gold			2023-01-03	WOS:000265487800012
J	Vlasselaers, D; Milants, I; Desmet, L; Wouters, PJ; Vanhorebeek, I; van den Heuvel, I; Mesotten, D; Casaer, MP; Meyfroidt, G; Ingels, C; Muller, J; Van Cromphaut, S; Schetz, M; Van den Berghe, G				Vlasselaers, Dirk; Milants, Ilse; Desmet, Lars; Wouters, Pieter J.; Vanhorebeek, Ilse; van den Heuvel, Ingeborg; Mesotten, Dieter; Casaer, Michael P.; Meyfroidt, Geert; Ingels, Catherine; Muller, Jan; Van Cromphaut, Sophie; Schetz, Miet; Van den Berghe, Greet			Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study	LANCET			English	Article							CRITICALLY-ILL PATIENTS; BLOOD-GLUCOSE CONTROL; CRITICAL ILLNESS; STRESS HYPERGLYCEMIA; HYPOGLYCEMIA; CHILDREN; DEATH; CONSEQUENCES; SURGERY; IMPACT	Background Critically ill infants and children often develop hyperglycaemia, which is associated with adverse outcome; however, whether lowering blood glucose concentrations to age-adjusted normal fasting values improves outcome is unknown. We investigated the effect of targeting age-adjusted normoglycaemia with insulin infusion in critically ill infants and children on outcome. Methods In a prospective, randomised controlled study, we enrolled 700 critically ill patients, 317 infants (aged <1 year) and 383 children (aged >= 1 year), who were admitted to the paediatric intensive care unit (PICU) of the University Hospital of Leuven, Belgium. Patients were randomly assigned by blinded envelopes to target blood glucose concentrations of 2.8-4.4 mmol/L in infants and 3.9-5.6 mmol/L in children with insulin infusion throughout PICU stay (intensive group [n=349]), or to insulin infusion only to prevent blood glucose from exceeding 11 . 9 mmol/L (conventional group [n=351]). Patients and laboratory staff were blinded to treatment allocation. Primary endpoints were duration of PICU stay and inflammation. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00214916. Findings Mean blood glucose concentrations were lower in the intensive group than in the conventional group (infants: 4.8 [SD 1. 2] mmol/L vs 6.4 [1.2] mmol/L, p<0.0001; children: 5.3 [1 . 1] mmol/L vs 8.2 [3.3] mmol/L, p<0.0001). Hypoglycaemia (defined as blood glucose <= 2.2 mmol/L) occurred in 87 (25%) patients in the intensive group (p<0 . 0001) versus five (1%) patients in the conventional group; hypoglycaemia defined as blood glucose less than 1. 7 mmol/L arose in 17 (5%) patients versus three (1%) (p=0 . 001). Duration of PICU stay was shortest in the intensively treated group (5.51 days [95% Cl 4.65-6.37] vs 6.15 days [5.25-7.05], p=0.017). The inflammatory response was attenuated at day 5, as indicated by lower C-reactive protein in the intensive group compared with baseline (-9 . 75 mg/L [95% Cl -19 . 93 to 0 . 43] vs 8 . 97 mg/L [-0 . 9 to 18.84], p=0. 007). The number of patients with extended (>rnedian) stay in PICU was 132 (38%) in the intensive group versus 165 (47%) in the conventional group (p=0.013). Nine (3%) patients died in the intensively treated group versus 20 (6%) in the conventional group (p=0 . 038). Interpretation Targeting of blood glucose concentrations to age-adjusted normal fasting concentrations improved short-term outcome of patients in PICU. The effect on long-term survival, morbidity, and neurocognitive development needs to be investigated. Funding Research Foundation (Belgium); Research Fund of the University of Leuven (Belgium) and the EU Information Society Technologies Integrated project "CLINICIP"; and Institute for Science and Technology (Belgium).	[Vlasselaers, Dirk; Milants, Ilse; Desmet, Lars; Wouters, Pieter J.; Vanhorebeek, Ilse; van den Heuvel, Ingeborg; Mesotten, Dieter; Casaer, Michael P.; Meyfroidt, Geert; Ingels, Catherine; Muller, Jan; Van Cromphaut, Sophie; Schetz, Miet; Van den Berghe, Greet] Catholic Univ Louvain, Dept Intens Care Med, Paediat Intens Care Unit, B-3000 Louvain, Belgium	Universite Catholique Louvain	Van den Berghe, G (corresponding author), Catholic Univ Louvain, Dept Intens Care Med, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.	greet.vandenberghe@med.kuleuven.be	Mesotten, Dieter/ABE-4176-2020; Casaer, Michael/Y-7131-2019; Van den Berghe, Greet/J-6788-2018	Mesotten, Dieter/0000-0002-3258-4720; Casaer, Michael/0000-0002-7087-0795; Van den Berghe, Greet/0000-0002-5320-1362; Meyfroidt, Geert/0000-0003-4259-3935; Vanhorebeek, Ilse/0000-0002-5261-5192	Research Foundation-Flanders, Belgium (FWO) [G.0533.06]; Research Fund of the University of Leuven [OT/03/56, GOA/2007/14]; EU Information Society Technologies Integrated project "CLINICIP" [506965]; Institute for Science and Technology-Flanders, Belgium [IWT 070695]; Clinical Research Fund of the University Hospital Gasthuisberg; University of Leuven; Methusalern programme; Flemish Government	Research Foundation-Flanders, Belgium (FWO)(FWO); Research Fund of the University of Leuven; EU Information Society Technologies Integrated project "CLINICIP"(European Commission); Institute for Science and Technology-Flanders, Belgium; Clinical Research Fund of the University Hospital Gasthuisberg; University of Leuven(KU Leuven); Methusalern programme; Flemish Government(European Commission)	We thank the clinical fellows and the PICU nursing staff for excellent patient care and protocol compliance; Magaly Boussemaere, Nathalie Rubbens, Nele Nijs, and Mona Eerdekens for technical support; An Andries, Jenny Gielens, and Myriam Vandenbergh for secretarial help: and Peter Lauwers, Roger Bouillon, and Marc Van den Berghe for critical manuscript review. This research was fully supported by official research grants from the Research Foundation-Flanders, Belgium (FWO) (G.0533.06); the Research Fund of the University of Leuven (OT/03/56 and GOA/2007/14) and the EU Information Society Technologies Integrated project "CLINICIP" contract number 506965; and Institute for Science and Technology-Flanders, Belgium (IWT 070695). DV and GM are clinical PhD fellows and IV and SVC are post-doctoral fellows of the Research Foundation, Flanders, Belgium (FWO). DM is a post-doctoral fellow supported by the Clinical Research Fund of the University Hospital Gasthuisberg. GVdB, via the University of Leuven, receives structural research financing via the Methusalern programme, funded by the Flemish Government.	Branco Ricardo G, 2005, Pediatr Crit Care Med, V6, P470, DOI 10.1097/01.PCC.0000161284.96739.3A; BROWN TCK, 1980, AUST PAEDIATR J, V16, P28; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Cornblath M, 2000, PEDIATRICS, V105, P1141, DOI 10.1542/peds.105.5.1141; Ellger B, 2006, DIABETES, V55, P1096, DOI 10.2337/diabetes.55.04.06.db05-1434; Ellger B, 2008, ENDOCRINOLOGY, V149, P3148, DOI 10.1210/en.2007-1558; Falcao G, 2008, PEDIATR CARDIOL, V29, P628, DOI 10.1007/s00246-007-9178-8; Falciglia M, 2007, CURR OPIN CLIN NUTR, V10, P498, DOI 10.1097/MCO.0b013e3281a3bf0a; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Genuth S, 2007, NEW ENGL J MED, V356, P1842; Hansen TK, 2003, J CLIN ENDOCR METAB, V88, P1082, DOI 10.1210/jc.2002-021478; Jenkins KJ, 2002, J THORAC CARDIOV SUR, V123, P110, DOI 10.1067/mtc.2002.119064; Langouche L, 2005, J CLIN INVEST, V115, P2277, DOI 10.1172/JCI25385; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; MEHTA N, 2006, PEDIAT CRITICAL CARE, P1069; PAGANA KD, 2003, MOSBYS DIAGNOSTIC LA, P457; Piper HG, 2006, PEDIATRICS, V118, P1176, DOI 10.1542/peds.2006-0347; Skillman HE, 2008, JPEN-PARENTER ENTER, V32, P520, DOI 10.1177/0148607108322398; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Su H, 2007, AM J PHYSIOL-ENDOC M, V293, pE629, DOI 10.1152/ajpendo.00221.2007; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Van den Berghe G, 2004, J CLIN INVEST, V114, P1187, DOI 10.1172/JCI200423506; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; Vanhorebeek I, 2005, LANCET, V365, P53, DOI 10.1016/S0140-6736(04)17665-4; Vriesendorp TM, 2006, CRIT CARE MED, V34, P2714, DOI 10.1097/01.CCM.0000241155.36689.91; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22	33	391	402	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	2009	373	9663					547	556		10.1016/S0140-6736(09)60044-1	http://dx.doi.org/10.1016/S0140-6736(09)60044-1			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	406ZO	19176240				2023-01-03	WOS:000263333600033
J	Komarova, NL; Katouli, AA; Wodarz, D				Komarova, Natalia L.; Katouli, Allen A.; Wodarz, Dominik			Combination of Two but Not Three Current Targeted Drugs Can Improve Therapy of Chronic Myeloid Leukemia	PLOS ONE			English	Article								Chronic myeloid leukemia (CML) is a cancer of the hematopoietic system and has been treated with the drug Imatinib relatively successfully. Drug resistance, acquired by mutations, is an obstacle to success. Two additional drugs are now considered and could be combined with Imatinib to prevent resistance, Dasatinib and Nilotinib. While most mutations conferring resistance to one drug do not confer resistance to the other drugs, there is one mutation (T315I) that induces resistance against all three drugs. Using computational methods, the combination of two drugs is found to increase the probability of treatment success despite this cross-resistance. Combining more than two drugs, however, does not provide further advantages. We also explore possible combination therapies using drugs currently under development. We conclude that among the targeted drugs currently available for the treamtent of CML, only the two most effective ones should be used in combination for the prevention of drug resistance.	[Komarova, Natalia L.; Katouli, Allen A.; Wodarz, Dominik] Univ Calif Irvine, Dept Math, Irvine, CA 92717 USA; [Komarova, Natalia L.; Wodarz, Dominik] Univ Calif Irvine, Dept Ecol & Evolut Biol, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Komarova, NL (corresponding author), Univ Calif Irvine, Dept Math, Irvine, CA 92717 USA.	dwodarz@uci.edu			NIH [R01 CA129286]; NATIONAL CANCER INSTITUTE [R01CA129286] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work has been funded in part by NIH grant R01 CA129286. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bradeen HA, 2006, BLOOD, V108, P2332, DOI 10.1182/blood-2006-02-004580; Burley SK, 2005, BLOOD, V106, p206A, DOI 10.1182/blood.V106.11.698.698; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Carter TA, 2005, P NATL ACAD SCI USA, V102, P11011, DOI 10.1073/pnas.0504952102; COLDMAN AJ, 1983, MATH BIOSCI, V65, P291, DOI 10.1016/0025-5564(83)90066-4; COLDMAN AJ, 1986, B MATH BIOL, V48, P279, DOI 10.1016/S0092-8240(86)90028-5; Daley GQ, 2003, SEMIN HEMATOL, V40, P11, DOI 10.1053/shem.2003.50035; Daub H, 2004, NAT REV DRUG DISCOV, V3, P1001, DOI 10.1038/nrd1579; Deininger MWN, 2007, EXP HEMATOL, V35, P144, DOI 10.1016/j.exphem.2007.01.023; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Druker BJ, 2004, ADV CANCER RES, V91, P1, DOI 10.1016/S0065-230X(04)91001-9; Druker BJ, 2003, MOL CANCER THER, V2, P225; Duncan EA, 2008, MOL CANCER THER, V7, P391, DOI 10.1158/1535-7163.MCT-07-0305; Gambacorti-Passerini CB, 2003, LANCET ONCOL, V4, P75, DOI 10.1016/S1470-2045(03)00979-3; GOLDIE JH, 1998, DRUG RESISTANCE CANC; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102; Melo JV, 2007, CANCER LETT, V249, P121, DOI 10.1016/j.canlet.2006.07.010; Melo Junia V, 2003, Hematology Am Soc Hematol Educ Program, P132; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; O'Hare T, 2008, P NATL ACAD SCI USA, V105, P5507, DOI 10.1073/pnas.0800587105; Quintas-Cardama A, 2007, NAT REV DRUG DISCOV, V6, P834, DOI 10.1038/nrd2324; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ribeiro RM, 2000, P NATL ACAD SCI USA, V97, P7681, DOI 10.1073/pnas.97.14.7681; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shannon KM, 2002, CANCER CELL, V2, P99, DOI 10.1016/S1535-6108(02)00101-0; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Weisberg E, 2007, NAT REV CANCER, V7, P345, DOI 10.1038/nrc2126; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yoshida C, 2004, INT J HEMATOL, V79, P420, DOI 10.1532/IJH97.04032; Young MA, 2006, CANCER RES, V66, P1007, DOI 10.1158/0008-5472.CAN-05-2788	34	43	45	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2009	4	2							e4423	10.1371/journal.pone.0004423	http://dx.doi.org/10.1371/journal.pone.0004423			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437JO	19204794	Green Submitted, Green Published, gold			2023-01-03	WOS:000265484000012
J	Jack, BW; Chetty, VK; Anthony, D; Greenwald, JL; Sanchez, GM; Johnson, AE; Forsythe, SR; O'Donnell, JK; Paasche-Orlow, MK; Manasseh, C; Martin, S; Culpepper, L				Jack, Brian W.; Chetty, Veerappa K.; Anthony, David; Greenwald, Jeffrey L.; Sanchez, Gail M.; Johnson, Anna E.; Forsythe, Shaula R.; O'Donnell, Julie K.; Paasche-Orlow, Michael K.; Manasseh, Christopher; Martin, Stephen; Culpepper, Larry			A Reengineered Hospital Discharge Program to Decrease Rehospitalization A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENTS AFTER-DISCHARGE; ADVERSE EVENTS; HEALTH LITERACY; PATIENT SAFETY; FOLLOW-UP; CARE; INTERVENTION; CONTINUITY; INPATIENT; SEVERITY	Background: Emergency department visits and rehospitalization are common after hospital discharge. Objective: To test the effects of an intervention designed to minimize hospital utilization after discharge. Design: Randomized trial using block randomization of 6 and 8. Randomly arranged index cards were placed in opaque envelopes labeled consecutively with study numbers, and participants were assigned a study group by revealing the index card. Setting: General medical service at an urban, academic, safety-net hospital. Patients: 749 English-speaking hospitalized adults (mean age, 49.9 years). Intervention: A nurse discharge advocate worked with patients during their hospital stay to arrange follow-up appointments, confirm medication reconciliation, and conduct patient education with an individualized instruction booklet that was sent to their primary care provider. A clinical pharmacist called patients 2 to 4 days after discharge to reinforce the discharge plan and review medications. Participants and providers were not blinded to treatment assignment. Measurements: Primary outcomes were emergency department visits and hospitalizations within 30 days of discharge. Secondary outcomes were self-reported preparedness for discharge and frequency of primary care providers' follow-up within 30 days of discharge. Research staff doing follow-up were blinded to study group assignment. Results: Participants in the intervention group (n = 370) had a lower rate of hospital utilization than those receiving usual care (n = 368) (0.314 vs. 0.451 visit per person per month; incidence rate ratio, 0.695 [95% CI, 0.515 to 0.937]; P = 0.009). The intervention was most effective among participants with hospital utilization in the 6 months before index admission (P = 0.014). Adverse events were not assessed; these data were collected but are still being analyzed. Limitation: This was a single-center study in which not all potentially eligible patients could be enrolled, and outcome assessment sometimes relied on participant report. Conclusion: A package of discharge services reduced hospital utilization within 30 days of discharge.	[Jack, Brian W.] Boston Univ, Sch Med, Dept Family Med, Boston Med Ctr, Boston, MA 02118 USA; Brown Univ, Alpert Med Sch, Pawtucket, RI USA	Boston Medical Center; Boston University; Brown University	Jack, BW (corresponding author), Boston Univ, Sch Med, Dept Family Med, Boston Med Ctr, 1 BMC Pl,Dowling 5 S, Boston, MA 02118 USA.	brian.jack@bmc.org	Paasche-Orlow, Michael/ABF-7919-2020; Martin, Stephen A/L-9381-2013	Paasche-Orlow, Michael/0000-0002-9276-7190; Martin, Stephen A/0000-0002-0356-5440; Culpepper, Larry/0000-0002-7655-0477; Jack, Brian/0000-0002-6497-2437; Manasseh, Christopher/0000-0001-5736-6589; Chetty, Veerappa/0000-0002-2640-3874	Agency for Healthcare Research and Quality; National Heart, Lung, and Blood Institute; National Institutes of Health; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [UC1HS014289, U18HS015905] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081307] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Agency for Healthcare Research and Quality and National Heart, Lung, and Blood Institute, National Institutes of Health.	Al-Rashed SA, 2002, BRIT J CLIN PHARMACO, V54, P657, DOI 10.1046/j.1365-2125.2002.01707.x; Andersen HE, 2000, STROKE, V31, P1038, DOI 10.1161/01.STR.31.5.1038; Anderson Cheryl, 2005, Congest Heart Fail, V11, P315, DOI 10.1111/j.1527-5299.2005.04458.x; Anthony D., 2005, ADV PATIENT SAFETY R; Baker DW, 2002, AM J PUBLIC HEALTH, V92, P1278, DOI 10.2105/AJPH.92.8.1278; Balaban RB, 2008, J GEN INTERN MED, V23, P1228, DOI 10.1007/s11606-008-0618-9; Blue L, 2001, BRIT MED J, V323, P715, DOI 10.1136/bmj.323.7315.715; Bula CJ, 2001, ARCH INTERN MED, V161, P2609, DOI 10.1001/archinte.161.21.2609; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Davis T C, 1993, Fam Med, V25, P391; Dudas V, 2001, AM J MED, V111, P26, DOI 10.1016/S0002-9343(01)00966-4; EVANS RL, 1993, MED CARE, V31, P358, DOI 10.1097/00005650-199304000-00007; Forster AJ, 2004, CAN MED ASSOC J, V170, P345; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; Greenwald JL., 2007, J PATIENT SAF, V3, P97, DOI 10.1097/01.jps.0000236916.94696.12; Holland R, 2005, BMJ-BRIT MED J, V330, P293, DOI 10.1136/bmj.38338.674583.AE; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LACHIN JM, 1988, CONTROL CLIN TRIALS, V9, P365, DOI 10.1016/0197-2456(88)90049-9; LEVIT K, 2005, HCUP FACTS FIGURES S; Makaryus AN, 2005, MAYO CLIN PROC, V80, P991, DOI 10.4065/80.8.991; MARQUIS KH, 1976, MED CARE, V14, P913, DOI 10.1097/00005650-197611000-00002; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Moore C, 2007, ARCH INTERN MED, V167, P1305, DOI 10.1001/archinte.167.12.1305; *NAT QUAL FOR, NAT QUAL FOR END CON; National Quality Forum (NQF), 2007, SAF PRACT BETT HEALT; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor M D, 1993, Image J Nurs Sch, V25, P73; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; PAASCHE O, 2007, MED MANAGEMENT VULNE, P101; Paasche-Orlow MK, 2006, J GEN INTERN MED, V21, P884, DOI 10.1111/j.1525-1497.2006.00544.x; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Ritter PL, 2001, J CLIN EPIDEMIOL, V54, P136, DOI 10.1016/S0895-4356(00)00261-4; Roberts RO, 1996, J CLIN EPIDEMIOL, V49, P989, DOI 10.1016/0895-4356(96)00143-6; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; Schnipper JL, 2006, ARCH INTERN MED, V166, P565, DOI 10.1001/archinte.166.5.565; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; Siu AL, 1996, ARCH INTERN MED, V156, P76, DOI 10.1001/archinte.156.1.76; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; Tsilimingras D, 2008, JT COMM J QUAL PATIE, V34, P85, DOI 10.1016/S1553-7250(08)34011-2; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x; van Walraven C, 2002, J GEN INTERN MED, V17, P186, DOI 10.1046/j.1525-1497.2002.10741.x; Wachter RM, 2004, NEW ENGL J MED, V350, P1935, DOI 10.1056/NEJMp038201; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; Weinberger M, 1996, NEW ENGL J MED, V334, P1441, DOI 10.1056/NEJM199605303342206	49	1070	1087	1	129	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 3	2009	150	3					178	+		10.7326/0003-4819-150-3-200902030-00007	http://dx.doi.org/10.7326/0003-4819-150-3-200902030-00007			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402RA	19189907	Green Accepted			2023-01-03	WOS:000263029600004
J	Cheyne, H; Hundley, V; Dowding, D; Bland, JM; McNamee, P; Greer, I; Styles, M; Barnett, CA; Scotland, G; Niven, C				Cheyne, Helen; Hundley, Vanora; Dowding, Dawn; Bland, J. Martin; McNamee, Paul; Greer, Ian; Styles, Maggie; Barnett, Carol A.; Scotland, Graham; Niven, Catherine			Effects of algorithm for diagnosis of active labour: cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL DECISION-MAKING; CESAREAN-SECTION; COMPLEX INTERVENTIONS; RESEARCH INFORMATION; SUPPORT-SYSTEMS; NHS DIRECT; MANAGEMENT; NURSES; WOMEN; CARE	Objective To compare the effectiveness of an algorithm for diagnosis of active labour in primiparous women with standard care in terms of maternal and neonatal outcomes. Design Cluster randomised trial. Setting Maternity units in Scotland with at least 800 annual births. Participants 4503 women giving birth for the first time, in 14 maternity units. Seven experimental clusters collected data from a baseline sample of 1029 women and a post-implementation sample of 896 women. The seven control clusters had a baseline sample of 1291 women and a post- implementation sample of 1287 women. Intervention Use of an algorithm by midwives to assist their diagnosis of active labour, compared with standard care. Main outcomes Primary outcome: use of oxytocin for augmentation of labour. Secondary outcomes: medical interventions in labour, admission management, and birth outcome. Results No significant difference was found between groups in percentage use of oxytocin for augmentation of labour ( experimental minus control, difference= 0.3, 95% confidence interval - 9.2 to 9.8; P= 0.9) or in the use of medical interventions in labour. Women in the algorithm group were more likely to be discharged from the labour suite after their first labour assessment ( difference= - 19.2, - 29.9 to - 8.6; P= 0.002) and to have more pre-labour admissions ( 0.29, 0.04 to 0.55; P= 0.03). Conclusions Use of an algorithm to assist midwives with the diagnosis of active labour in primiparous women did not result in a reduction in oxytocin use or in medical intervention in spontaneous labour. Significantly more women in the experimental group were discharged home after their first labour ward assessment. Trial registration Current Controlled Trials ISRCTN00522952.	[Cheyne, Helen; Hundley, Vanora; Niven, Catherine] Univ Stirling, Nursing Midwifery & Allied Hlth Profess Res Unit, Stirling FK9 4LA, Scotland; [Dowding, Dawn; Bland, J. Martin] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Dowding, Dawn; Greer, Ian] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England; [McNamee, Paul; Scotland, Graham] Univ Aberdeen, Hlth Econ Res Unit, Inst Appl Hlth Sci, Aberdeen AB25 2ZD, Scotland; [Styles, Maggie] Univ Stirling, Dept Nursing & Midwifery, Stirling FK9 4LA, Scotland; [Barnett, Carol A.] Kings Cross Hosp, NHS Tayside, Dundee DD3 8EA, Scotland	University of Stirling; University of York - UK; University of Hull; University of York - UK; University of Aberdeen; University of Stirling	Cheyne, H (corresponding author), Univ Stirling, Nursing Midwifery & Allied Hlth Profess Res Unit, Stirling FK9 4LA, Scotland.	h.l.cheyne@stir.ac.uk	Dowding, Dawn/J-9945-2019	Dowding, Dawn/0000-0001-5672-8605; Cheyne, Helen/0000-0001-5738-8390	Scottish Executive Chief Scientist Office Health Service Research Committee [CZH/4/245]; Chief Scientist Office [HERU1, HERU2] Funding Source: researchfish	Scottish Executive Chief Scientist Office Health Service Research Committee; Chief Scientist Office	This work was supported by the Scottish Executive Chief Scientist Office Health Service Research Committee (CZH/4/245). The research was independent of the funders.	Alfirevic Z, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006066; Anim-Somuah M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub2; Arkes HR, 2007, MED DECIS MAKING, V27, P189, DOI 10.1177/0272989X06297391; Ball JA., 1996, BIRTHRATE PLUS FRAME; BOYLAN P, 1991, AM J PERINAT, V8, P373, DOI 10.1055/s-2007-999419; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Carlton T, 2005, J PERINAT NEONAT NUR, V19, P145, DOI 10.1097/00005237-200504000-00011; CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; Cheyne H, 2006, J ADV NURS, V53, P625, DOI 10.1111/j.1365-2648.2006.03769.x; Cheyne H, 2003, MIDWIFERY, V19, P221, DOI 10.1016/S0266-6138(03)00020-2; Cheyne H, 2007, BR J MIDWIFERY, V15, P604, DOI DOI 10.12968/BJ0M.2007.15.10.27341; CHEYNE H, 2004, FEASIBILITY STUDY CL; Cheyne H, 2008, MIDWIFERY, V24, P199, DOI 10.1016/j.midw.2006.12.005; COREY GA, 1987, J FAM PRACTICE, V25, P127; Creedy DK, 2000, BIRTH-ISS PERINAT C, V27, P104, DOI 10.1046/j.1523-536x.2000.00104.x; Dawes R., 2002, HEURISTICS BIASES PS, P716, DOI DOI 10.1017/CBO9780511808098.042; *DEP HLTH GOV STAT, 2005, NHS MAT STAT ENGL 20; DOWING D, 2007, DO NURSES USE NEW TE; Downe S, 2001, Pract Midwife, V4, P10; Freeman JM, 2007, NEUROTHERAPEUTICS, V4, P549, DOI 10.1016/j.nurt.2007.04.003; FRIGOLETTO FD, 1995, NEW ENGL J MED, V333, P745, DOI 10.1056/NEJM199509213331201; Garg AX, 2005, JAMA-J AM MED ASSOC, V293, P1223, DOI 10.1001/jama.293.10.1223; Green J, 2003, GREATER EXPECTATIONS; Gross MM, 2006, BJOG-INT J OBSTET GY, V113, P289, DOI 10.1111/j.1471-0528.2006.00817.x; HEMMINKI E, 1986, EUR J OBSTET GYN R B, V22, P85, DOI 10.1016/0028-2243(86)90093-6; Holmes P, 2001, BRIT J OBSTET GYNAEC, V108, P1120, DOI 10.1016/S0306-5456(01)00265-0; Hundley V, 2004, MIDWIFERY, V20, P27, DOI 10.1016/S0266-6138(03)00050-0; HUNDLEY VA, 1994, BRIT MED J, V309, P1400, DOI 10.1136/bmj.309.6966.1400; *ISD SCOTL, BIRTHS BAB; Jackson DJ, 2003, JOGNN, V32, P147, DOI 10.1177/0884217503252045; Janssen Patricia A, 2003, J Obstet Gynaecol Can, V25, P734; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Klein MC, 2006, BIRTH-ISS PERINAT C, V33, P74, DOI 10.1111/j.0730-7659.2006.00076.x; Klein Michael C, 2004, J Obstet Gynaecol Can, V26, P641; Lauzon L, 2001, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000936, DOI 10.1002/14651858.CD000936]; LOPEZZENO JA, 1992, NEW ENGL J MED, V326, P450, DOI 10.1056/NEJM199202133260705; McCaughan D, 2005, FAM PRACT, V22, P490, DOI 10.1093/fampra/cmi042; McCaughan D, 2002, J ADV NURS, V39, P46, DOI 10.1046/j.1365-2648.2002.02241.x; McNiven PS, 1998, BIRTH-ISS PERINAT C, V25, P5, DOI 10.1046/j.1523-536x.1998.00005.x; Medical Research Council (MRC), 2000, FRAM DEV EV RCTS COM; Murray SF, 2000, BRIT MED J, V321, P1501, DOI 10.1136/bmj.321.7275.1501; National Collaborating Centre for Women's and Children's Health, 2007, INTR CAR CAR HLTH WO; O'Cathain A, 2004, J ADV NURS, V45, P280, DOI 10.1046/j.1365-2648.2003.02894.x; O'cathain Alicia, 2004, J Health Serv Res Policy, V9, P226, DOI 10.1258/1355819042250221; Oakley A, 2006, BRIT MED J, V332, P413, DOI 10.1136/bmj.332.7538.413; ODRISCOLL K, 1984, OBSTET GYNECOL, V63, P485; ROSENTHAL GE, 1992, J GEN INTERN MED, V7, P304, DOI 10.1007/BF02598089; Ruston A, 2006, HEALTH RISK SOC, V8, P257, DOI 10.1080/13698570600871729; Sadler LC, 2000, BRIT J OBSTET GYNAEC, V107, P909, DOI 10.1111/j.1471-0528.2000.tb11091.x; *SAF MOTH, 1996, CAR NORM BIRTH PRACT; *SCOTT EX, 2002, REP EXP GROUP AC MAT; *SCOTT PROGR CLIN, 2003, OP VAG DEL SCOTL 20; SCRIMSHAW SCM, 1982, SOC SCI MED, V16, P1473, DOI 10.1016/0277-9536(82)90062-4; Shiell A, 2008, BMJ-BRIT MED J, V336, P1281, DOI 10.1136/bmj.39569.510521.AD; SPILBY H, 2006, LABOURING BETTER EFF; Tavakoli M, 2000, J EVAL CLIN PRACT, V6, P111, DOI 10.1046/j.1365-2753.2000.00233.x; Thompson Carl, 2004, Evid Based Nurs, V7, P68; Torgerson DJ, 2001, BMJ-BRIT MED J, V322, P355, DOI 10.1136/bmj.322.7282.355; Treasure T, 1998, BRIT MED J, V317, P362; Trinder L, 2000, EVIDENCE BASED PRACT, P212, DOI DOI 10.1002/9780470699003.CH10; Turnbull D, 1996, LANCET, V348, P213; TURNER MJ, 1986, J OBSTET GYNAECOL, V7, P79, DOI 10.3109/01443618609112275; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; Villar J, 2007, BRIT MED J, V335, P1025, DOI 10.1136/bmj.39363.706956.55	64	37	37	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 8	2008	337								a2396	10.1136/bmj.a2396	http://dx.doi.org/10.1136/bmj.a2396			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	399BY	19064606	Green Submitted, hybrid, Green Published			2023-01-03	WOS:000262776600002
J	Lawrence, S				Lawrence, Stacy			Biotech patents-business as usual?	NATURE BIOTECHNOLOGY			English	News Item																			0	4	4	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2008	26	12					1326	1326		10.1038/nbt1208-1326	http://dx.doi.org/10.1038/nbt1208-1326			1	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	382FR	19060861				2023-01-03	WOS:000261591300007
J	Ceesay, SJ; Casals-Pascual, C; Erskine, J; Anya, SE; Duah, NO; Fulford, AJC; Sesay, SSS; Abubakar, I; Dunyo, S; Sey, O; Palmer, A; Fofana, M; Corrah, T; Bojang, KA; Whittle, HC; Greenwood, BM; Conway, DJ				Ceesay, Serign J.; Casals-Pascual, Climent; Erskine, Jamie; Anya, Samuel E.; Duah, Nancy O.; Fulford, Anthony J. C.; Sesay, Sanie S. S.; Abubakar, Ismaela; Dunyo, Samuel; Sey, Omar; Palmer, Ayo; Fofana, Malang; Corrah, Tumani; Bojang, Kalifa A.; Whittle, Hilton C.; Greenwood, Brian M.; Conway, David J.			Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis	LANCET			English	Article							TREATED BED NETS; MOSQUITO NETS; RURAL AREA; FOLLOW-UP; MORTALITY; CHILDREN; MORBIDITY; AFRICA; TRIAL; RISK	Background Malaria is a major cause of morbidity and mortality in Africa. International effort and funding for control has been stepped up, with substantial increases from 2003 in the delivery of malaria interventions to pregnant women and children younger than 5 years in The Gambia. We investigated the changes in malaria indices in this country, and the causes and public-health significance of these changes. Methods We undertook a retrospective analysis of original records to establish numbers and proportions of malaria inpatients, deaths, and blood-slide examinations at one hospital over 9 years (January, 1999-December, 2007), and at four health facilities in three different administrative regions over 7 years (January, 2001-December, 2007). We obtained additional data from single sites for haernoglobin concentrations in paediatric admissions and for age distribution of malaria admissions. Findings From 2003 to 2007, at four sites with complete slide examination records, the proportions of malaria-positive slides decreased by 82% (3397/10861 in 2003 to 337/6142 in 2007), 85% (137/1259 to 6/368), 73% (3664/16932 to 666/11333), and 50% (1206/3304 to 336/1853). At three sites with complete admission records, the proportions of malaria admissions fell by 74% (435/2530 to 69/1531), 69% (797/2824 to 89/1032), and 27% (2204/4056 to 496/1251.). Proportions of deaths attributed to malaria in two hospitals decreased by 100% (seven of 115 in 2003 to none of 117 in 2007) and 90% (22/122 in 2003 to one of 58 in 2007). Since 2004, mean haemoglobin concentrations for all-cause admissions increased by 12 g/L (85 g/L in 2000-04 to 97 g/L in 2005-07), and mean age of paediatric malaria admissions increased from 3.9 years (95% CI 3.7-4 . 0) to 5.6 years (5.0-6.2). Interpretation A large proportion of the malaria burden has been alleviated in The Gambia. Our results encourage consideration of a policy to eliminate malaria as a public-health problem, while emphasising the importance of accurate and continuous surveillance. Funding UK Medical Research Council,	[Ceesay, Serign J.; Casals-Pascual, Climent; Duah, Nancy O.; Fulford, Anthony J. C.; Sesay, Sanie S. S.; Abubakar, Ismaela; Dunyo, Samuel; Corrah, Tumani; Bojang, Kalifa A.; Whittle, Hilton C.; Conway, David J.] MRC Labs, Banjul, Gambia; [Erskine, Jamie] WEC Mission Hosp, Sibanor, Western Region, Gambia; [Anya, Samuel E.] Univ Gambia, Sch Med & Allied Hlth Sci, Kanifing, Gambia; [Anya, Samuel E.; Palmer, Ayo] CIAM Publ Hlth Res & Dev Ctr, Kanifing, Gambia; [Fulford, Anthony J. C.; Greenwood, Brian M.; Conway, David J.] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; [Sey, Omar] AFPRC Farafenni Hosp, N Bank Region, Gambia; [Fofana, Malang] NMCP, Banjul, Gambia	MRC Laboratory Molecular Biology; University of the Gambia; University of London; London School of Hygiene & Tropical Medicine	Conway, DJ (corresponding author), MRC Labs, POB 273, Banjul, Gambia.	dconway@mrc.gm	Sesay, Sanie Samuel Sogoyan/M-2982-2014; Casals-Pascual, Climent/N-7692-2018	Sesay, Sanie Samuel Sogoyan/0000-0001-6233-7854; Casals-Pascual, Climent/0000-0002-0867-8954; Conway, David/0000-0002-8711-3037; Duah-Quashie, Nancy/0000-0001-8819-1793; Bojang, Kalifa/0000-0001-7506-0938	UK Medical Research Council; MRC [MC_U190074193] Funding Source: UKRI; Medical Research Council [MC_U190074193] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Financial support for the research was provided by the UK Medical Research Council (MRC). We thank Jula Jaiteh. and Lamin Sanyang (Senior Nursing Officers at Government health facilities) for providing hospital records and helping to extract data; Gibril Bah, Lamin Manneh, Bernard Ndaye, Lamin Gibba. Fabakary Sanyang, Hawa Manneh. Demba B T Sainbou, and Yorro Bah (MRC staff) for data extraction of the haematology laboratory) and ward records: Aja Abbie Khan (Head of Regional Health Team for Western Division) for support in implementing the project at the Government health facilities: Andrew Prentice (Head of MRC Nutrition Research Programme) for supporting the Keneba laboratory record database management: Pamela Collier Njie and Muminatou Jallow for help with the provision of clinical data front the MRC ward in Fajara; and many other colleagues and partner organisations who have encouraged this work.	ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; [Anonymous], 2007, LANCET, V370, P1459; Anya SE, 2004, AM J TROP MED HYG, V70, P510, DOI 10.4269/ajtmh.2004.70.510; Bhattarai A, 2007, PLOS MED, V4, P1784, DOI 10.1371/journal.pmed.0040309; Binka FN, 2002, T ROY SOC TROP MED H, V96, P597, DOI 10.1016/S0035-9203(02)90321-4; BRUCECHWATT LJ, 1973, LANCET, V2, P547; Butler D, 2007, NATURE, V450, P144, DOI 10.1038/450144b; Caputo B, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-182; Cavanagh DR, 1998, J IMMUNOL, V161, P347; Chambers RG, 2008, LANCET, V371, P1399, DOI 10.1016/S0140-6736(08)60609-1; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Diallo DA, 2004, B WORLD HEALTH ORGAN, V82, P85; Drakeley CJ, 2005, P NATL ACAD SCI USA, V102, P5108, DOI 10.1073/pnas.0408725102; Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014; Fegan GW, 2007, LANCET, V370, P1035, DOI 10.1016/S0140-6736(07)61477-9; GREENWOOD BM, 1993, T ROY SOC TROP MED H, V87, P3, DOI 10.1016/0035-9203(93)90169-Q; GREENWOOD BM, 1988, LANCET, V1, P1121; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3; Jaffar S, 1997, TROP MED INT HEALTH, V2, P28, DOI 10.1046/j.1365-3156.1997.d01-131.x; Kouyate B, 2007, PLOS MED, V4, P997, DOI 10.1371/journal.pmed.0040127; MARSDEN P. D., 1964, TRANS ROY SOC TROP MED HYG, V58, P455, DOI 10.1016/0035-9203(64)90101-4; MCGREGOR IA, 1956, BRIT MED J, V2, P686, DOI 10.1136/bmj.2.4994.686; Meerman L, 2005, J INFECT DIS, V192, P1651, DOI 10.1086/496887; MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L; MENON A, 1990, T ROY SOC TROP MED H, V84, P638, DOI 10.1016/0035-9203(90)90130-7; *MICS, 2002, GAMB MULT IND CLUST, P1; *MICS, 2007, GAMB MULT IND CLUST, P1; Nyarango PM, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-33; Okiro EA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-151; Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031; Shanks GD, 2008, LANCET INFECT DIS, V8, P564, DOI 10.1016/S1473-3099(08)70130-0; Sharp BL, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-52; Sharp BL, 2007, AM J TROP MED HYG, V76, P42, DOI 10.4269/ajtmh.2007.76.42; Snow RW, 2008, PLOS MED, V5, P1068, DOI 10.1371/journal.pmed.0050142; SNOW RW, 1988, T ROY SOC TROP MED H, V82, P838, DOI 10.1016/0035-9203(88)90011-9; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; *UNICEF, 2007, MAL CHILDR PROGR INT, P1; *WHO, 2008, IMP LONG LAST INS NE; Williams Christopher J, 2007, Travel Med Infect Dis, V5, P295, DOI 10.1016/j.tmaid.2007.05.001	41	307	311	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 1	2008	372	9649					1545	1554		10.1016/S0140-6736(08)61654-2	http://dx.doi.org/10.1016/S0140-6736(08)61654-2			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	367ZG	18984187	Green Published, Green Accepted			2023-01-03	WOS:000260590500026
J	Kritchevsky, SB; Braun, BI; Bush, AJ; Bozikis, MR; Kusek, L; Burke, JP; Wong, ES; Jernigan, J; Davis, CC; Simmons, B				Kritchevsky, Stephen B.; Braun, Barbara I.; Bush, Andrew J.; Bozikis, Michele R.; Kusek, Linda; Burke, John P.; Wong, Edward S.; Jernigan, John; Davis, Cralen C.; Simmons, Bryan		TRAPE Study Grp	The effect of a quality improvement collaborative to improve antimicrobial prophylaxis in surgical patients - A randomized trial	ANNALS OF INTERNAL MEDICINE			English	Article							INFECTION PREVENTION PROJECT; OF-CARE; US HOSPITALS; SURGERY; FEEDBACK; OUTCOMES; LESSONS; BASE	Background: Quality improvement collaboratives are used to improve health care quality, but their efficacy remains controversial. Objective: To assess the effects of a quality improvement collaborative on preoperative antimicrobial prophylaxis. Design: Longitudinal cluster randomized trial, with the quality improvement collaborative as the intervention. Setting: United States. Participants: 44 acute care hospitals, each of which randomly sampled approximately 100 selected surgical cases (cardiac, hip or knee replacement, and hysterectomy) at both the baseline and remeasurement phases. Intervention: All hospitals received a comparative feedback report. Hospitals randomly assigned to the intervention group (n = 22) participated in a quality improvement collaborative comprising 2 in-person meetings led by experts, monthly teleconferences, and receipt of supplemental materials over 9 months. Measurements: Change in the proportion of patients receiving at least 1 antibiotic dose within 60 minutes of surgery (primary outcome) and change in the proportions of patients given any antibiotics, given antibiotics for 24 hours or less, given an appropriate drug, and given a single preoperative dose and receipt of any of the 5 measures (secondary outcome). Results: The groups did not differ in the change in proportion of patients who received a properly timed antimicrobial prophylaxis dose (-3.8 percentage points [95% CI, -13.9 to 6.2 percentage points]) after adjustment for region, hospital size, and surgery type. Similarly, the groups did not differ in individual measures of antibiotic duration; use of appropriate drug; receipt of a single preoperative dose; or an all-or-none measure combining timing, duration, and selection. Limitations: Hospitals volunteered for the effort, thereby resulting in selection for participants who were motivated to change. Implementation of the surgical infection prevention measure reporting requirements by the Centers for Medicare & Medicaid Services and The Joint Commission may have motivated improvement in prophylaxis performance. Conclusion: At a time of heightened national attention toward measures of antimicrobial prophylaxis performance, the trial did not demonstrate a benefit of participation in a quality improvement collaborative over performance feedback for improvement of these measures.	[Braun, Barbara I.] Int Joint Commiss, Div Qual Measurement & Res, Oak Brook Terrace, IL 60181 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; J Paul Sticht Ctr Aging, Winston Salem, NC USA; Univ Tennessee, Memphis, TN USA; LDS Hosp, Salt Lake City, UT USA; McGuire Vet Affairs Med Ctr, Richmond, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Methodist Hlth Syst, Memphis, TN USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Tennessee System; University of Tennessee Health Science Center; Hunter Holmes McGuire Veterinary Affairs Medical Center; Virginia Commonwealth University; Centers for Disease Control & Prevention - USA	Braun, BI (corresponding author), Int Joint Commiss, Div Qual Measurement & Res, 1 Renaissance Blvd, Oak Brook Terrace, IL 60181 USA.	bbraun@jointcommission.org		Kritchevsky, Stephen/0000-0003-3336-6781; Jernigan, John/0000-0001-8163-925X; Woeltje, Keith/0000-0002-6385-3970	Agency for Healthcare Research and Quality [R01 HS11331-01A1]; Centers for Disease Control and Prevention; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS011331] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	By grant R01 HS11331-01A1 from the Agency for Healthcare Research and Quality and initial support from the Centers for Disease Control and Prevention.	[Anonymous], 2005, MMWR MORB MORTAL WKL; Beek CA, 2005, JAMA-J AM MED ASSOC, V294, P309, DOI 10.1001/jama.294.3.309; Bradley EH, 2004, QUAL SAF HEALTH CARE, V13, P26, DOI 10.1136/qhc.13.1.26; Bratzler DW, 2006, CLIN INFECT DIS, V43, P322, DOI 10.1086/505220; Bratzler DW, 2004, CLIN INFECT DIS, V38, P1706, DOI 10.1086/421095; Bratzler DW, 2005, ARCH SURG-CHICAGO, V140, P174, DOI 10.1001/archsurg.140.2.174; Burke JP, 2003, NEW ENGL J MED, V348, P651, DOI 10.1056/NEJMhpr020557; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; *CTR MED MED SERV, REP HOSP QUAL DAT AN; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Dellinger EP, 2005, AM J SURG, V190, P9, DOI 10.1016/j.amjsurg.2004.12.001; Ferguson TB, 2003, JAMA-J AM MED ASSOC, V290, P49, DOI 10.1001/jama.290.1.49; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Goldberg H I, 1998, Jt Comm J Qual Improv, V24, P130; Grol R, 1999, Jt Comm J Qual Improv, V25, P503; *HOSP QUAL ALL, QUAL MEAS; Jamtvedt G, 2006, QUAL SAF HEALTH CARE, V15, P433, DOI 10.1136/qshc.2006.018549; Kilo C M, 1998, Qual Manag Health Care, V6, P1; KRITCHEVSKY SB, 1995, INFECT CONT HOSP EP, V16, P33; Landon BE, 2004, ANN INTERN MED, V140, P887, DOI 10.7326/0003-4819-140-11-200406010-00010; Landon BE, 2007, NEW ENGL J MED, V356, P921, DOI 10.1056/NEJMsa062860; Mittman BS, 2004, ANN INTERN MED, V140, P897, DOI 10.7326/0003-4819-140-11-200406010-00011; Murray D.M., 1998, DESIGN ANAL GROUP RA; Nelson Eugene C, 2002, Jt Comm J Qual Improv, V28, P472; Ornstein S, 2004, ANN INTERN MED, V141, P523, DOI 10.7326/0003-4819-141-7-200410050-00008; Ovretveit J, 2002, QUAL SAF HEALTH CARE, V11, P345, DOI 10.1136/qhc.11.4.345; Render ML, 2006, JT COMM J QUAL PATIE, V32, P253, DOI 10.1016/S1553-7250(06)32033-8; Shojania KG, 2005, HEALTH AFFAIR, V24, P138, DOI 10.1377/hlthaff.24.1.138; Solberg LI, 2005, ANN FAM MED, V3, P198, DOI 10.1370/afm.304; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; Strom K L, 2001, J Healthc Qual, V23, P4; Williams SC, 2005, NEW ENGL J MED, V353, P255, DOI 10.1056/NEJMsa043778; Wilson Tim, 2003, Jt Comm J Qual Saf, V29, P85	33	40	40	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 7	2008	149	7					472	W93		10.7326/0003-4819-149-7-200810070-00007	http://dx.doi.org/10.7326/0003-4819-149-7-200810070-00007			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	359QY	18838727				2023-01-03	WOS:000260004400004
J	Milloy, MJS; Kerr, T; Tyndall, M; Montaner, J; Wood, E				Milloy, M-J. S.; Kerr, Thomas; Tyndall, Mark; Montaner, Julio; Wood, Evan			Estimated Drug Overdose Deaths Averted by North America's First Medically-Supervised Safer Injection Facility	PLOS ONE			English	Article							NONFATAL HEROIN OVERDOSE; USERS; COHORT; RISK; INTERVENTION; AUSTRALIA; MORTALITY	Background: Illicit drug overdose remains a leading cause of premature mortality in urban settings worldwide. We sought to estimate the number of deaths potentially averted by the implementation of a medically supervised safer injection facility (SIF) in Vancouver, Canada. Methodology/Principal Findings: The number of potentially averted deaths was calculated using an estimate of the local ratio of non-fatal to fatal overdoses. Inputs were derived from counts of overdose deaths by the British Columbia Vital Statistics Agency and non-fatal overdose rates from published estimates. Potentially-fatal overdoses were defined as events within the SIF that required the provision of naloxone, a 911 call or an ambulance. Point estimates and 95% Confidence Intervals (95% CI) were calculated using a Monte Carlo simulation. Between March 1, 2004 and July 1, 2008 there were 1004 overdose events in the SIF of which 453 events matched our definition of potentially fatal. In 2004, 2005 and 2006 there were 32, 37 and 38 drug-induced deaths in the SIF's neighbourhood. Owing to the wide range of non-fatal overdose rates reported in the literature (between 5% and 30% per year) we performed sensitivity analyses using non-fatal overdose rates of 50, 200 and 300 per 1,000 person years. Using these model inputs, the number of averted deaths were, respectively: 50.9 (95% CI: 23.6-78.1); 12.6 (95% CI: 9.6-15.7); 8.4 (95% CI: 6.5-10.4) during the study period, equal to 1.9 to 11.7 averted deaths per annum. Conclusions/Significance: Based on a conservative estimate of the local ratio of non-fatal to fatal overdoses, the potentially fatal overdoses in the SIF during the study period could have resulted in between 8 and 51 deaths had they occurred outside the facility, or from 6% to 37% of the total overdose mortality burden in the neighborhood during the study period. These data should inform the ongoing debates over the future of the pilot project.	[Milloy, M-J. S.; Kerr, Thomas; Tyndall, Mark; Montaner, Julio; Wood, Evan] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Milloy, M-J. S.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Kerr, Thomas; Tyndall, Mark; Montaner, Julio; Wood, Evan] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of British Columbia	Milloy, MJS (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	uhri-ew@cfenet.ubc.ca	Montaner, Julio/K-7621-2012; Milloy, M-J/AAY-3618-2020	Tyndall, Mark/0000-0003-4450-5679	Health Canada; Canadian Institutes of Health Research; Vancouver Coastal Health	Health Canada; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Vancouver Coastal Health	The SIF evaluation was originally funded by a contribution from Health Canada, although the views expressed in this analysis do not represent the official policies of Health Canada. The evaluation is now supported by the Canadian Institutes of Health Research and Vancouver Coastal Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANDRESEN M, 2008, COST BENEFIT COST EF; Bargagli AM, 2006, EUR J PUBLIC HEALTH, V16, P198, DOI 10.1093/eurpub/cki168; BENNETT GA, 1999, ACCIDENTAL OVERDOSE; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; *BRIT COL VIT STAT, 2002, ANN REP 2001 BRIT CO; *BRIT COL VIT STAT, 2005, ANN REP 2004 BRIT CO; *BRIT COL VIT STAT, 1999, ANN REP 1998 BRIT CO; *BRIT COL VIT STAT, 2006, ANN REP 2005 BRIT CO; *BRIT COL VIT STAT, 2001, ANN REP 2000 BRIT CO; *BRIT COL VIT STAT, 2007, ANN REP 2006 BRIT CO; *BRIT COL VIT STAT, 2000, ANN REP 1999 BRIT CO; *BRIT COL VIT STAT, 2003, ANN REP 2002 BRIT CO; *BRIT COL VIT STAT, 2004, ANN REP 2003 BRIT CO; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI [10.1197/j.aem.2007.04.005, 10.1111/j.1553-2712.2007.tb01846.x]; Darke S, 2005, DRUG ALCOHOL REV, V24, P425, DOI 10.1080/09595230500286005; Darke S, 2003, ADDICTION, V98, P1169, DOI 10.1046/j.1360-0443.2003.00474.x; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; Darke S, 1996, ADDICTION, V91, P405, DOI 10.1111/j.1360-0443.1996.tb02289.x; Darke S, 2007, J URBAN HEALTH, V84, P283, DOI 10.1007/s11524-006-9156-0; Degenhardt Louisa, 2005, J Clin Forensic Med, V12, P187, DOI 10.1016/j.jcfm.2004.11.003; Fischer B, 2004, CAN MED ASSOC J, V171, P235, DOI 10.1503/cmaj.1031416; Fischer B, 2006, CAN J PUBLIC HEALTH, V97, P384, DOI 10.1007/BF03405347; Gossop M, 1996, BRIT MED J, V313, P402; Hulse GK, 1999, ADDICTION, V94, P221, DOI 10.1046/j.1360-0443.1999.9422216.x; Kerr T, 2005, LANCET, V366, P316, DOI 10.1016/S0140-6736(05)66475-6; Kerr T, 2007, INT J DRUG POLICY, V18, P37, DOI 10.1016/j.drugpo.2006.12.008; Kerr T, 2007, DRUG ALCOHOL DEPEN, V87, P39, DOI 10.1016/j.drugalcdep.2006.07.009; Kerr T, 2006, INT J DRUG POLICY, V17, P436, DOI 10.1016/j.drugpo.2006.05.008; McGregor C, 1998, ADDICTION, V93, P701, DOI 10.1046/j.1360-0443.1998.9357016.x; Milloy MJS, 2008, AM J DRUG ALCOHOL AB, V34, P499, DOI 10.1080/00952990802122457; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P1263, DOI 10.1001/jama.279.16.1263-a; Ochoa KC, 2005, DRUG ALCOHOL DEPEN, V80, P297, DOI 10.1016/j.drugalcdep.2005.04.012; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x; POSCHADE S, 2003, EVALUATION ARBEIT DR; Remis R.S, 1998, CONSORTIUM CHARACTER; SCHECHTER MT, 1999, GUESSTIMATING NUMBER; SELBY P, 2007, CANADIAN MED ASS J E; *STAND COMM HLTH P, 2008, EV THURSD MAY 29 200; Uniting, 2021, UN MED SUP INJ CTR; Van Beek I., 2004, CRIT PUBLIC HEALTH, V14, P391, DOI DOI 10.1080/09581590400027528; Vingoe L., 1999, J SUBSTANCE USE, V4, P88; Warner-Smith M, 2002, ADDICTION, V97, P963, DOI 10.1046/j.1360-0443.2002.00132.x; Wood E, 2006, NEW ENGL J MED, V354, P2512, DOI 10.1056/NEJMc052939; Wood E, 2000, AIDS, V14, P1229, DOI 10.1097/00002030-200006160-00021; Wood E, 2006, AM J PUBLIC HEALTH, V96, P770, DOI 10.2105/AJPH.2004.057828; Wood E, 2006, ADDICTION, V101, P689, DOI 10.1111/j.1360-0443.2006.01385.x; Wood E, 2004, CAN MED ASSOC J, V171, P731, DOI 10.1503/cmaj.1040774; Wood E, 2006, CAN MED ASSOC J, V175, P1399, DOI 10.1503/cmaj.060863; Wood Evan, 2004, Harm Reduct J, V1, P9, DOI 10.1186/1477-7517-1-9; WOOD RA, 2008, INT J DRUG POLICY; 2007, MMWR MORBIDITY MORTA, V56, P93	51	80	80	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 7	2008	3	10							e3351	10.1371/journal.pone.0003351	http://dx.doi.org/10.1371/journal.pone.0003351			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	432DM	18839040	Green Published, gold, Green Submitted			2023-01-03	WOS:000265113700001
J	Welton, AJ; Vickers, MR; Kim, J; Ford, D; Lawton, BA; MacLennan, AH; Meredith, SK; Martin, J; Meade, TW				Welton, Amanda J.; Vickers, Madge R.; Kim, Joseph; Ford, Deborah; Lawton, Beverley A.; MacLennan, Alastair H.; Meredith, Sarah K.; Martin, Jeannett; Meade, Tom W.		WISDOM Team	Health related quality of life after combined hormone replacement therapy: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ESTROGEN PLUS PROGESTIN; CORONARY-HEART-DISEASE; POSTMENOPAUSAL WOMEN; OVARIECTOMIZED RATS; PHYSICAL HEALTH; SLEEP DURATION; DOUBLE-BLIND; OLDER WOMEN; ESTRADIOL; MENOPAUSE	Objective To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life. Design Randomised placebo controlled double blind trial. Setting General practices in United Kingdom (384), Australia (94), and New Zealand (24). Participants Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively. Interventions Conjugated equine ciestrogen 0.625 mg plus mechroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year. Main outcome measures Health related quality of life and psychological wellbeing as measured by the women's health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiologic Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively. Results After one year small but significant improvements were observed in three of nine components of the women's health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P<0.001), sexual functioning (P<0.001), and steep problems (P<0.001). Significantly fewer women in the combined HRT group reported hot flushes (P<0.001), night sweats (P<0.001), aching joints and muscles (P=0.001), insomnia (P<0.001), and vaginal dryness (P<0.0ol) than in the placebo group, but greater proportions reported breast tenderness (P<0.001) or vaginal discharge (P<0.001). Hot flushes were experienced in the combined HRT and placebo groups by. 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year. Conclusions Combined HRT started many years after the menopause can improve health related quality of life. Trial registration ISRCTN 63718836.	[MacLennan, Alastair H.] Univ Adelaide, Womens & Childrens Hosp, Discipline Obstet & Gynaecol, Sch Paediat & Reprod Med, Adelaide, SA 5005, Australia; [Welton, Amanda J.; Vickers, Madge R.; Martin, Jeannett] MRC Gen Practice Res Framework, London NW1 2ND, England; [Kim, Joseph; Meade, Tom W.] London Sch Hyg & Trop Med, London WC1, England; [Ford, Deborah; Meredith, Sarah K.] MRC, Clin Trials Unit, London, England; [Lawton, Beverley A.] Wellington Sch Med & Hlth Sci, Womens Hlth Res Ctr, Dept Primary Hlth Care & Gen Practice, Wellington, New Zealand	University of Adelaide; Womens & Childrens Hospital Australia; University of London; London School of Hygiene & Tropical Medicine; Medical Research Council Clinical Trials Unit; University of Otago	MacLennan, AH (corresponding author), Univ Adelaide, Womens & Childrens Hosp, Discipline Obstet & Gynaecol, Sch Paediat & Reprod Med, Adelaide, SA 5005, Australia.	alastair.maclennan@adelaide.edu.au	Marley, John/F-1239-2010; Stocks, Nigel P/I-1083-2012	Stocks, Nigel/0000-0002-9018-0361; Lawton, Beverley/0000-0003-2447-8386	MRC [G0701113] Funding Source: UKRI; British Heart Foundation Funding Source: Medline; Medical Research Council [G0701113, MC_U122797165] Funding Source: Medline; Department of Health Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		Almeida OP, 2006, NEUROBIOL AGING, V27, P141, DOI 10.1016/j.neurobiolaging.2004.12.012; Archer DF, 2001, FERTIL STERIL, V75, P1080, DOI 10.1016/S0015-0282(01)01792-7; Ayas NT, 2003, ARCH INTERN MED, V163, P205, DOI 10.1001/archinte.163.2.205; Basson R, 2006, NEW ENGL J MED, V354, P1497, DOI 10.1056/NEJMcp050154; Brunner RL, 2005, ARCH INTERN MED, V165, P1976, DOI 10.1001/archinte.165.17.1976; CELLA DF, 1995, SUPPORT CARE CANCER, V3, P11, DOI 10.1007/BF00343916; Christgau S, 2004, MENOPAUSE, V11, P508, DOI 10.1097/01.WCB.0000121484.18437.98; DALY E, 1993, BRIT MED J, V307, P836, DOI 10.1136/bmj.307.6908.836; de Boer AGEM, 2004, QUAL LIFE RES, V13, P311, DOI 10.1023/B:QURE.0000018499.64574.1f; Dolan P, 1995, SOCIAL TARIFF EUROQO; Dorman P, 1998, STROKE, V29, P63, DOI 10.1161/01.STR.29.1.63; Dorman PJ, 1997, STROKE, V28, P1876, DOI 10.1161/01.STR.28.10.1876; Gangwisch JE, 2006, HYPERTENSION, V47, P833, DOI 10.1161/01.HYP.0000217362.34748.e0; Gordon FT, 1996, HORM BEHAV, V30, P244, DOI 10.1006/hbeh.1996.0029; Gottlieb DJ, 2005, ARCH INTERN MED, V165, P863, DOI 10.1001/archinte.165.8.863; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; HUNTER M, 1992, PSYCHOL HEALTH, V7, P45, DOI 10.1080/08870449208404294; Hunter M, 2000, QUAL LIFE RES, V9, P733, DOI 10.1023/A:1008973822876; Hyland ME, 1996, QUAL LIFE RES, V5, P469, DOI 10.1007/BF00540019; Hyland Michael E, 2003, Health Qual Life Outcomes, V1, P24, DOI 10.1186/1477-7525-1-24; Jenkinson C, 1997, MED CARE, V35, P1109, DOI 10.1097/00005650-199711000-00003; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V102, P16, DOI 10.1016/S0091-6749(98)70048-X; Kind P., 1996, QUALITY LIFE PHARMAC, V2nd; Kuba T, 2006, HORM BEHAV, V49, P441, DOI 10.1016/j.yhbeh.2005.09.007; LIAO KLM, 1995, PSYCHOL HEALTH, V10, P171, DOI 10.1080/08870449508401947; LIMOUZINLAMOTHE MA, 1994, AM J OBSTET GYNECOL, V170, P618, DOI 10.1016/S0002-9378(94)70239-X; Lopes AA, 2004, NEW ENGL J MED, V350, P622; Maki PM, 2007, NEUROLOGY, V69, P1322, DOI 10.1212/01.wnl.0000277275.42504.93; Minelli C, 2004, BMJ-BRIT MED J, V328, P371, DOI 10.1136/bmj.328.7436.371; Morrison MF, 2004, BIOL PSYCHIAT, V55, P406, DOI 10.1016/j.biopsych.2003.08.011; Mottola C A, 1993, Decubitus, V6, P56; Ockene JK, 2005, JAMA-J AM MED ASSOC, V294, P183, DOI 10.1001/jama.294.2.183; Phillips LS, 2005, FERTIL STERIL, V83, P558, DOI 10.1016/j.fertnstert.2004.11.012; Pines A, 2007, CLIMACTERIC, V10, P181, DOI 10.1080/13697130701361657; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROBERTS RE, 1983, AM J PSYCHIAT, V140, P41; Rosenthal MB, 2003, MENOPAUSE, V10, P4, DOI 10.1097/01.GME.0000043670.63447.A3; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Salpeter SR, 2006, J GEN INTERN MED, V21, P363, DOI 10.1111/j.1525-1497.2006.00389.x; Salpeter SR, 2004, J GEN INTERN MED, V19, P791, DOI 10.1111/j.1525-1497.2004.30281.x; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Soares CD, 2001, ARCH GEN PSYCHIAT, V58, P529; Szoeke CEI, 2005, CLIMACTERIC, V8, P49, DOI 10.1080/13697130400012296; TESTA MA, 1994, ANNU REV PUBL HEALTH, V15, P535; VANAGT HME, 1994, SOC SCI MED, V39, P1537, DOI 10.1016/0277-9536(94)90005-1; Vickers M, 2002, CLIMACTERIC, V5, P317, DOI 10.1080/713605309; Vickers Madge R, 2007, BMC Womens Health, V7, P2, DOI 10.1186/1472-6874-7-2; Vickers MR, 2007, BMJ-BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD; Zethraeus N, 1997, BRIT J OBSTET GYNAEC, V104, P1191, DOI 10.1111/j.1471-0528.1997.tb10945.x	50	110	114	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 6	2008	337	7669							a1190	10.1136/bmj.a1190	http://dx.doi.org/10.1136/bmj.a1190			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	351JP	18719013	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000259420900032
J	Shai, I; Schwarzfuchs, D; Henkin, Y; Shahar, DR; Witkow, S; Greenberg, I; Golan, R; Fraser, D; Bolotin, A; Vardi, H; Tangi-Rozental, O; Zuk-Ramot, R; Sarusi, B; Brickner, D; Schwartz, Z; Sheiner, E; Marko, R; Katorza, E; Thiery, J; Fiedler, GM; Bluher, M; Stumvoll, M; Stampfer, MJ				Shai, Iris; Schwarzfuchs, Dan; Henkin, Yaakov; Shahar, Danit R.; Witkow, Shula; Greenberg, Ilana; Golan, Rachel; Fraser, Drora; Bolotin, Arkady; Vardi, Hilel; Tangi-Rozental, Osnat; Zuk-Ramot, Rachel; Sarusi, Benjamin; Brickner, Dov; Schwartz, Ziva; Sheiner, Einat; Marko, Rachel; Katorza, Esther; Thiery, Joachim; Fiedler, Georg Martin; Blueher, Matthias; Stumvoll, Michael; Stampfer, Meir J.		DIRECT Grp	Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIOVASCULAR RISK-FACTORS; HEART-DISEASE; INSULIN-RESISTANCE; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; FOOD-FREQUENCY; OBESITY; OVERWEIGHT; NUTRITION; HEALTH	Background: Trials comparing the effectiveness and safety of weight-loss diets are frequently limited by short follow-up times and high dropout rates. Methods: In this 2-year trial, we randomly assigned 322 moderately obese subjects (mean age, 52 years; mean body-mass index [the weight in kilograms divided by the square of the height in meters], 31; male sex, 86%) to one of three diets: low-fat, restricted-calorie; Mediterranean, restricted-calorie; or low-carbohydrate, non-restricted-calorie. Results: The rate of adherence to a study diet was 95.4% at 1 year and 84.6% at 2 years. The Mediterranean-diet group consumed the largest amounts of dietary fiber and had the highest ratio of monounsaturated to saturated fat (P<0.05 for all comparisons among treatment groups). The low-carbohydrate group consumed the smallest amount of carbohydrates and the largest amounts of fat, protein, and cholesterol and had the highest percentage of participants with detectable urinary ketones (P<0.05 for all comparisons among treatment groups). The mean weight loss was 2.9 kg for the low-fat group, 4.4 kg for the Mediterranean-diet group, and 4.7 kg for the low-carbohydrate group (P<0.001 for the interaction between diet group and time); among the 272 participants who completed the intervention, the mean weight losses were 3.3 kg, 4.6 kg, and 5.5 kg, respectively. The relative reduction in the ratio of total cholesterol to high-density lipoprotein cholesterol was 20% in the low-carbohydrate group and 12% in the low-fat group (P=0.01). Among the 36 subjects with diabetes, changes in fasting plasma glucose and insulin levels were more favorable among those assigned to the Mediterranean diet than among those assigned to the low-fat diet (P<0.001 for the interaction among diabetes and Mediterranean diet and time with respect to fasting glucose levels). Conclusions: Mediterranean and low-carbohydrate diets may be effective alternatives to low-fat diets. The more favorable effects on lipids (with the low-carbohydrate diet) and on glycemic control (with the Mediterranean diet) suggest that personal preferences and metabolic considerations might inform individualized tailoring of dietary interventions. (ClinicalTrials.gov number, NCT00160108.).	[Shai, Iris; Shahar, Danit R.; Witkow, Shula; Greenberg, Ilana; Golan, Rachel; Fraser, Drora; Bolotin, Arkady; Vardi, Hilel; Tangi-Rozental, Osnat] Ben Gurion Univ Negev, S Daniel Abraham Int Ctr Hlth & Nutr, Dept Epidemiol & Hlth Syst Evaluat, IL-84105 Beer Sheva, Israel; [Schwarzfuchs, Dan; Zuk-Ramot, Rachel; Sarusi, Benjamin; Brickner, Dov; Schwartz, Ziva; Sheiner, Einat; Marko, Rachel; Katorza, Esther] Nucl Res Ctr Negev, Dimona, Israel; [Henkin, Yaakov] Soroka Univ, Med Ctr, Dept Cardiol, Beer Sheva, Israel; [Thiery, Joachim; Fiedler, Georg Martin] Univ Hosp Leipzig, Inst Lab Med, Leipzig, Germany; [Blueher, Matthias; Stumvoll, Michael] Univ Leipzig, Dept Med, Leipzig, Germany; [Stampfer, Meir J.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; [Stampfer, Meir J.] Harvard Univ, Sch Med, Boston, MA USA; [Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Stampfer, Meir J.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Ben Gurion University; Ben Gurion University; Soroka Medical Center; Leipzig University; Leipzig University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Shai, I (corresponding author), Ben Gurion Univ Negev, S Daniel Abraham Int Ctr Hlth & Nutr, Dept Epidemiol & Hlth Syst Evaluat, POB 653, IL-84105 Beer Sheva, Israel.	irish@bgu.ac.il	Moller, Kirsten/A-4751-2009; Fiedler, Georg Martin/C-8341-2011; Stumvoll, Michael/ABE-1121-2021; Manzoni, Gian Mauro/L-3891-2019; Castelnuovo, Gianluca/AAC-1780-2019; Golan, Rachel/AAA-5961-2021; Shahar, Danit R/B-4280-2012; SHEINER, EYAL/F-1488-2012	Moller, Kirsten/0000-0003-3058-1072; Fiedler, Georg Martin/0000-0001-5689-4574; Stumvoll, Michael/0000-0001-6225-8240; Manzoni, Gian Mauro/0000-0003-3384-0359; Castelnuovo, Gianluca/0000-0003-2633-9822; Shai, Iris/0000-0001-9050-4605; Shahar, Danit/0000-0003-1000-1819				Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Atkins RC, 2002, DR ATKINS NEW DIET R; Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4; Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; Covas MI, 2006, ANN INTERN MED, V145, P333, DOI 10.7326/0003-4819-145-5-200609050-00006; Dansinger ML, 2007, ANN INTERN MED, V147, P41, DOI 10.7326/0003-4819-147-1-200707030-00007; Dansinger ML, 2005, JAMA-J AM MED ASSOC, V293, P43, DOI 10.1001/jama.293.1.43; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; GARDNER CD, 2007, JAMA-J AM MED ASSOC, V298, P178; Gardner CD, 2007, JAMA-J AM MED ASSOC, V297, P969, DOI 10.1001/jama.297.9.969; Gavin JR, 1997, DIABETES CARE, V20, P1183; Haffner SM, 1997, DIABETES CARE, V20, P1087, DOI 10.2337/diacare.20.7.1087; Krauss RM, 2000, CIRCULATION, V102, P2284; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Lara-Castro C, 2004, J CLIN ENDOCR METAB, V89, P4197, DOI 10.1210/jc.2004-0683; Malik VS, 2007, NAT CLIN PRACT CARD, V4, P34, DOI 10.1038/ncpcardio0726; Mayer-Davis EJ, 2004, ANN EPIDEMIOL, V14, P763, DOI 10.1016/j.annepidem.2004.02.004; McManus K, 2001, INT J OBESITY, V25, P1503, DOI 10.1038/sj.ijo.0801796; Nordmann, 2006, ARCH INTERN MED, V166, P932; Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285; Okie S, 2007, NEW ENGL J MED, V357, P1465, DOI 10.1056/NEJMp078152; Poirier P, 2006, CIRCULATION, V113, P898, DOI 10.1161/CIRCULATIONAHA.106.171016; Rucker D, 2007, BMJ-BRIT MED J, V335, P1194, DOI 10.1136/bmj.39385.413113.25; Schwenke DC, 2005, CURR OPIN LIPIDOL, V16, P55, DOI 10.1097/00041433-200502000-00010; Serra-Majem L, 2006, NUTR REV, V64, pS27, DOI 10.1301/nr.2006.feb.S27-S47; Shai I, 2005, J NUTR, V135, P573, DOI 10.1093/jn/135.3.573; Shai I, 2004, PUBLIC HEALTH NUTR, V7, P745, DOI 10.1079/PHN2004599; Shai I, 2003, PUBLIC HEALTH NUTR, V6, P401, DOI 10.1079/PHN2002445; Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007; Thomas H, 2006, HEALTH EDUC RES, V21, P783, DOI 10.1093/her/cyl143; WHO Consultation, 2000, WHO TECH REP SER, V894, P1; WILLETT WC, 2001, HARVARD MED SCH GUID; Yancy WS, 2004, ANN INTERN MED, V140, P769, DOI 10.7326/0003-4819-140-10-200405180-00006	35	1255	1283	5	309	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2008	359	3					229	241		10.1056/NEJMoa0708681	http://dx.doi.org/10.1056/NEJMoa0708681			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326KD	18635428	Bronze			2023-01-03	WOS:000257656600003
J	Schwab, U; Seppanen-Laakso, T; Yetukuri, L; Agren, J; Kolehmainen, M; Laaksonen, DE; Ruskeepaa, AL; Gylling, H; Uusitupa, M; Oresic, M				Schwab, Ursula; Seppanen-Laakso, Tuulikki; Yetukuri, Laxman; Agren, Jyrki; Kolehmainen, Marjukka; Laaksonen, David E.; Ruskeepaa, Anna-Liisa; Gylling, Helena; Uusitupa, Matti; Oresic, Matej		GENOBIN Study Grp	Triacylglycerol Fatty Acid Composition in Diet-Induced Weight Loss in Subjects with Abnormal Glucose Metabolism - the GENOBIN Study	PLOS ONE			English	Article							LOW-DENSITY-LIPOPROTEIN; INSULIN SENSITIVITY; MASS-SPECTROMETRY; SERUM-LIPIDS; MULTIPLE PRECURSOR; PLASMA; LYSOPHOSPHATIDYLCHOLINE; PHOSPHOLIPIDS; CHOLESTEROL; ADIPOSE	Background: The effect of weight loss on different plasma lipid subclasses at the molecular level is unknown. The aim of this study was to examine whether a diet-induced weight reduction result in changes in the extended plasma lipid profiles (lipidome) in subjects with features of metabolic syndrome in a 33-week intervention. Methodology/Principal Findings: Plasma samples of 9 subjects in the weight reduction group and 10 subjects in the control group were analyzed using mass spectrometry based lipidomic and fatty acid analyses. Body weight decreased in the weight reduction group by 7.8 +/- 2.9% (p<0.01). Most of the serum triacylglycerols and phosphatidylcholines were reduced. The decrease in triacylglycerols affected predominantly the saturated short chain fatty acids. This decrease of saturated short chain fatty acid containing triacylglycerols correlated with the increase of insulin sensitivity. However, levels of several longer chain fatty acids, including arachidonic and docosahexanoic acid, were not affected by weight loss. Levels of other lipids known to be associated with obesity such as sphingolipids and lysophosphatidylcholines were not altered by weight reduction. Conclusions/Significance: Diet-induced weight loss caused significant changes in global lipid profiles in subjects with abnormal glucose metabolism. The observed changes may affect insulin sensitivity and glucose metabolism in these subjects.	[Schwab, Ursula; Kolehmainen, Marjukka; Gylling, Helena; Uusitupa, Matti] Univ Kuopio, Dept Clin Nutr & Food, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland; [Schwab, Ursula; Gylling, Helena] Kuopio Univ Hosp, Kuopio, Finland; [Seppanen-Laakso, Tuulikki; Yetukuri, Laxman; Ruskeepaa, Anna-Liisa; Oresic, Matej] VTT Tech Res Ctr Finland, Espoo, Finland; [Agren, Jyrki; Laaksonen, David E.] Univ Kuopio, Dept Physiol, Kuopio, Finland; [Laaksonen, David E.] Kuopio Univ Hosp, Dept Med, Kuopio, Finland	University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; VTT Technical Research Center Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland	Schwab, U (corresponding author), Univ Kuopio, Dept Clin Nutr & Food, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland.	ursula.schwab@uku.fi; matej.oresic@vtt.fi	Oresic, Matej/K-7673-2016; Oresic, Matej/AAV-3978-2020; Uusitupa, Matti Ilmari Julius/AAX-4929-2020	Oresic, Matej/0000-0002-2856-9165; 	Sigrid Juselius foundation, the Academy of Finland [209445, 211497]; EVO [5179, 5198]	Sigrid Juselius foundation, the Academy of Finland(Academy of FinlandSigrid Juselius Foundation); EVO	The study was financially supported by grants from Sigrid Juselius foundation, the Academy of Finland (no. 209445, no. 211497), and EVO funding (no. 5179, no. 5198). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agren JJ, 2006, CLIN CHIM ACTA, V366, P309, DOI 10.1016/j.cca.2005.11.006; Boston Ray C, 2003, Diabetes Technol Ther, V5, P1003, DOI 10.1089/152091503322641060; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Ekroos K, 2002, ANAL CHEM, V74, P941, DOI 10.1021/ac015655c; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Han XL, 2003, J LIPID RES, V44, P1071, DOI 10.1194/jlr.R300004-JLR200; Hermansson M, 2005, ANAL CHEM, V77, P2166, DOI 10.1021/ac048489s; Houjou T, 2005, RAPID COMMUN MASS SP, V19, P654, DOI 10.1002/rcm.1836; Katajamaa M, 2006, BIOINFORMATICS, V22, P634, DOI 10.1093/bioinformatics/btk039; KOLEHMAINEN M, 2007, INT J OBESITY, DOI DOI 10.1038/SJ.IJ0.0803718; Krauss RM, 2000, CIRCULATION, V102, P2284; Laaksonen DE, 2002, DIABETIC MED, V19, P456, DOI 10.1046/j.1464-5491.2002.00707.x; Laaksonen R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000097; LAITINEN JH, 1993, J AM DIET ASSOC, V93, P276, DOI 10.1016/0002-8223(93)91552-2; Lelliott C, 2004, INT J OBESITY, V28, pS22, DOI 10.1038/sj.ijo.0802854; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MATSUDA Y, 1993, CIRC RES, V72, P1103, DOI 10.1161/01.RES.72.5.1103; McAnoy AM, 2005, J AM SOC MASS SPECTR, V16, P1498, DOI 10.1016/j.jasms.2005.04.017; Medina-Gomez G, 2005, DIABETES, V54, P1706, DOI 10.2337/diabetes.54.6.1706; Medina-Gomez G, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030064; Mehta D, 2005, AM J PHYSIOL-LUNG C, V289, pL174, DOI 10.1152/ajplung.00165.2005; Metz JA, 2000, ARCH INTERN MED, V160, P2150, DOI 10.1001/archinte.160.14.2150; Moller DE, 2005, ANNU REV MED, V56, P45, DOI 10.1146/annurev.med.56.082103.104751; Murugesan G, 1996, J CLIN INVEST, V97, P2736, DOI 10.1172/JCI118728; Nelson J, 2006, AM J EPIDEMIOL, V163, P903, DOI 10.1093/aje/kwj140; Pietilainen KH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000218; RABINI RA, 1994, DIABETES, V43, P915, DOI 10.2337/diabetes.43.7.915; Samad F, 2006, DIABETES, V55, P2579, DOI 10.2337/db06-0330; Sarkkinen E, 1996, EUR J CLIN NUTR, V50, P592; SCHMIDT K, 1992, BIOCHEM BIOPH RES CO, V182, P302, DOI 10.1016/S0006-291X(05)80145-7; Schwudke D, 2006, ANAL CHEM, V78, P585, DOI 10.1021/ac051605m; Seppanen-Laakso T, 2002, ANAL CHIM ACTA, V465, P39, DOI 10.1016/S0003-2670(02)00397-5; SHALINA S, 2000, GLIA, V30, P92; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Stefanick ML, 1998, NEW ENGL J MED, V339, P12, DOI 10.1056/NEJM199807023390103; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Storlien LH, 1996, DIABETOLOGIA, V39, P621, DOI 10.1007/BF00418533; Summers LKM, 2002, DIABETOLOGIA, V45, P369, DOI 10.1007/s00125-001-0768-3; Sweeney G, 1996, CLIN INVEST MED, V19, P243; Tremblay AJ, 2004, METABOLISM, V53, P310, DOI 10.1016/j.metabol.2003.10.011; Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057; Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620; VESSBY B, 1994, DIABETOLOGIA, V37, P1044, DOI 10.1007/s001250050215; VESSBY B, 1994, DIABETES, V43, P1353, DOI 10.2337/diabetes.43.11.1353; Vessby B, 2003, CURR OPIN LIPIDOL, V14, P15, DOI 10.1097/00041433-200302000-00004; Warensjo E, 2005, DIABETOLOGIA, V48, P1999, DOI 10.1007/s00125-005-1897-x; Watson AD, 2006, J LIPID RES, V47, P2101, DOI 10.1194/jlr.R600022-JLR200; Wei YR, 2006, AM J PHYSIOL-ENDOC M, V291, pE275, DOI 10.1152/ajpendo.00644.2005; Willett W., 1998, NUTR EPIDEMIOLOGY; Yang LV, 2005, BLOOD, V105, P1127, DOI 10.1182/blood-2004-05-1916; Yetukuri L, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-12; Yu-Poth S, 1999, AM J CLIN NUTR, V69, P632	52	71	71	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2008	3	7							e2630	10.1371/journal.pone.0002630	http://dx.doi.org/10.1371/journal.pone.0002630			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	417GZ	18612464	Green Submitted, Green Published, gold			2023-01-03	WOS:000264065800032
J	Souza, GR; Yonel-Gumruk, E; Fan, D; Easley, J; Rangel, R; Guzman-Rojas, L; Miller, JH; Arap, W; Pasqualini, R				Souza, Glauco R.; Yonel-Gumruk, Esra; Fan, Davin; Easley, Jeffrey; Rangel, Roberto; Guzman-Rojas, Liliana; Miller, J. Houston; Arap, Wadih; Pasqualini, Renata			Bottom-Up Assembly of Hydrogels from Bacteriophage and Au Nanoparticles: The Effect of Cis- and Trans-Acting Factors	PLOS ONE			English	Article								Hydrogels have become a promising research focus because of their potential for biomedical application. Here we explore the long-range, electrostatic interactions by following the effect of trans-acting (pH) and cis-acting factors (peptide mutation) on the formation of Au-phage hydrogels. These bioinorganic hydrogels can be generated from the bottom-up assembly of Au nanoparticles (Au NP) with either native or mutant bacteriophage (phage) through electrostatic interaction of the phage pVIII major capsid proteins (pVIII). The cis-acting factor consists of a peptide extension displayed on the pVIII that mutates the phage. Our results show that pH can dictate the direct-assembly and stability of Au-phage hydrogels in spite of the differences between the native and the mutant pVIII. The first step in characterizing the interactions of Au NP with phage was to generate a molecular model that identified the charge distribution and structure of the native and mutant pVIII. This model indicated that the mutant peptide extension carried a higher positive charge relative to the native pVIII at all pHs. Next, by monitoring the Au-phage interaction by means of optical microscopy, elastic light scattering, fractal dimension analysis as well as Uv-vis and surface plasmon resonance spectroscopy, we show that the positive charge of the mutant peptide extension favors the opposite charge affinity between the phage and Au NP as the pH is decreased. These results show the versatility of this assembly method, where the stability of these hydrogels can be achieved by either adjusting the pH or by changing the composition of the phage pVIII without the need of phage display libraries.	[Souza, Glauco R.; Rangel, Roberto; Guzman-Rojas, Liliana; Arap, Wadih; Pasqualini, Renata] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; [Souza, Glauco R.; Rangel, Roberto; Guzman-Rojas, Liliana; Arap, Wadih; Pasqualini, Renata] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX USA; [Fan, Davin; Easley, Jeffrey; Miller, J. Houston] Massachusetts Inst Technol, Dept Chem Engn, Boston, MA USA; [Yonel-Gumruk, Esra] George Washington Univ, Dept Chem, Washington, DC USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Massachusetts Institute of Technology (MIT); George Washington University	Souza, GR (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.	rpasqual@mdanderson.org	Rangel, Roberto/AHE-6583-2022; Miller, John Houston/B-7324-2009	Rangel, Roberto/0000-0002-9088-7957; Miller, John Houston/0000-0002-6686-1976	Odyssey Program at The University of Texas M.D. Anderson Cancer Center; Department of Defense [Breast Cancer Concept Award]; Gillson-Longenbaugh Foundation	Odyssey Program at The University of Texas M.D. Anderson Cancer Center; Department of Defense(United States Department of Defense); Gillson-Longenbaugh Foundation	G.S. is a Scholar from the Odyssey Program at The University of Texas M.D. Anderson Cancer Center and a recipient of the Breast Cancer Concept Award from DOD. R.R. is also a Scholar from the Odyssey Program at The University of Texas M.D. Anderson Cancer Center. This work was supported by a grant from the Department of Defense and by an award from the Gillson-Longenbaugh Foundation (to W.A. and R.P.). Besides funding the work, the sponsors did not have any role in designing or conducting these studies.	Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Chen C, 2006, NANO LETT, V6, P611, DOI 10.1021/nl0600878; Chen LM, 2004, CHEM BIOL, V11, P1081, DOI 10.1016/j.chembiol.2004.05.019; Hajitou A, 2006, CELL, V125, P385, DOI 10.1016/j.cell.2006.02.042; HANDLEY D A, 1989, P23; Huang Y, 2005, NANO LETT, V5, P1429, DOI 10.1021/nl050795d; LEITE ER, 2004, ENCY NANOSCIENCE NAN, P537; Lin Y, 2003, LANGMUIR, V19, P10000, DOI 10.1021/la0350251; Peterson AW, 2002, J AM CHEM SOC, V124, P14601, DOI 10.1021/ja0279996; Sarikaya M, 2003, NAT MATER, V2, P577, DOI 10.1038/nmat964; Shipway AN, 2000, LANGMUIR, V16, P8789, DOI [10.1021/la000316k, 10.1021/1a000316k]; Sigal GB, 1996, ANAL CHEM, V68, P490, DOI 10.1021/ac9504023; Souza GR, 2006, ANAL CHEM, V78, P6232, DOI 10.1021/ac060483a; Souza GR, 2006, P NATL ACAD SCI USA, V103, P1215, DOI 10.1073/pnas.0509739103; Souza GR, 2001, J AM CHEM SOC, V123, P6734, DOI 10.1021/ja005919x; SOUZA GR, 2006, ANN REV PLASMONICS; Weisbecker CS, 1996, LANGMUIR, V12, P3763, DOI 10.1021/la950776r; ZACHER AN, 1980, GENE, V9, P127, DOI 10.1016/0378-1119(80)90171-7; Zhong ZY, 2004, J PHYS CHEM B, V108, P4046, DOI 10.1021/jp037056a	20	39	40	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 21	2008	3	5							e2242	10.1371/journal.pone.0002242	http://dx.doi.org/10.1371/journal.pone.0002242			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	391UK	18493583	Green Published, Green Submitted, gold			2023-01-03	WOS:000262258700050
J	Hammell, CL; Henning, JD				Hammell, Clare L.; Henning, J. D.			Prehospital management of severe traumatic brain injury	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ENDOTRACHEAL INTUBATION; VENTILATION; IMPACT		[Hammell, Clare L.] Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England; [Henning, J. D.] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Hammell, Clare L.; Henning, J. D.] Great N Air Ambulance Serv, Darlington DL1 5NQ, Durham, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; James Cook University Hospital	Hammell, CL (corresponding author), Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England.	cham37uk@yahoo.com						Alderson P, 2004, COCHRANE DB SYST REV, V18, P1048; *ASS AN GREAT BRIT, 2006, TRANSF PAT BRAIN INJ; *BRAIN TRAUM FDN, GUID PREH MAN TRAUM; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Deitch Sean, 2003, Prehosp Emerg Care, V7, P380, DOI 10.1080/10903120390936617; FINDLAY G, 2007, TRAUMA WHO CARES NAT; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Himmelseher S, 2005, ANESTH ANALG, V101, P524, DOI 10.1213/01.ANE.0000160585.43587.5B; Hoyle JD, 2007, PREHOSP EMERG CARE, V11, P330, DOI 10.1080/10903120701205083; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476; *NIH CLIN EXC, 2004, CLIN COST EFF PREH I; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; POON WS, 1991, INJURY, V22, P323, DOI 10.1016/0020-1383(91)90016-8; *ROY COLL SURG ENG, 1999, REP WORK PART MAN PA; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	25	12	12	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 19	2009	338								b1683	10.1136/bmj.b1683	http://dx.doi.org/10.1136/bmj.b1683			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	448NR	19454738				2023-01-03	WOS:000266269800002
J	Song, SX; Liu, D; Peng, JL; Deng, HW; Guo, Y; Xu, LX; Miller, AD; Xu, YH				Song, Shuxian; Liu, Dan; Peng, Jinliang; Deng, Hongwei; Guo, Yan; Xu, Lisa X.; Miller, Andrew D.; Xu, Yuhong			Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo	FASEB JOURNAL			English	Article						AutoDock; epidermal growth factor; computer aided design; proteomic code; PEG; lipid	EPIDERMAL-GROWTH-FACTOR; PROLONGED CIRCULATION TIME; EFFICIENT DRUG-DELIVERY; FACTOR RECEPTOR; AUTOMATED DOCKING; TARGETED DELIVERY; COATED LIPOSOMES; TUMOR-CELLS; IMMUNOLIPOSOMES; DOXORUBICIN	Epidermal growth factor receptor (EGF-R) is an important target in anticancer therapy. Here we report how a novel EGF-R peptide ligand (D4: Leu-Ala-Arg-Leu-Leu-Thr) is identified using a computer-aided design approach from a virtual peptide library of putative EGF-R binding peptides by screening against the EGF-R X-ray crystal structure in silico and in vitro. The selected peptide is conjugated with a polyethylene glycol (PEG) lipid, and the lipid moiety of the peptide-PEG-lipid conjugate is inserted into liposome membranes by a postmodification process. D4 peptide-conjugated liposomes are found to bind to and enter cells by endocytosis specifically and efficiently in vitro in a process apparently mediated by EGF-R high-expressing cancer cells (H1299). In vivo, the D4 peptide-conjugated liposomes are found to accumulate in EGF-R-expressing xenograft tumor tissues up to 80 h after intravenous delivery, in marked contrast to controls. These results demonstrate how structure-based peptide design can be an efficient approach to identify highly novel binding ligands against important receptors. These data could have important consequences for the development of peptide-directed drug delivery systems with engineered specificities and prolonged times of action.-Song, S., Liu, D., Peng, J., Deng, H., Guo, Y., Xu, L. X., Miller, A. D., Xu, Y. Novel peptide ligand directs liposomes toward EGF-R high-expressing cancer cells in vitro and in vivo. FASEB J. 23, 1396-1404 (2009)	[Miller, Andrew D.] Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England; [Song, Shuxian; Liu, Dan; Guo, Yan; Xu, Lisa X.] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China; [Peng, Jinliang] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Shanghai 200240, Peoples R China; [Deng, Hongwei; Xu, Yuhong] Shanghai Jiao Tong Univ, Sch Pharm, Shanghai 200240, Peoples R China; [Miller, Andrew D.] ImuThes Ltd, London, England	Imperial College London; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Miller, AD (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Chem, Genet Therapies Ctr, London SW7 2AZ, England.	a.miller@imperial.ac.uk; yhxu@sjtu.edu.cn	Xu, Yuhong/E-4247-2012; Miller, Andrew/G-8291-2019	Miller, Andrew/0000-0003-0661-249X	National Science Foundation of China [30472097]; Fok Ying Tong Education Foundation [91035]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fok Ying Tong Education Foundation(Fok Ying Tung Education Foundation)	Funding was provided by National Science Foundation of China grant 30472097 and Fok Ying Tong Education Foundation grant 91035.	Bhakoo A, 2004, MOL IMMUNOL, V41, P1217, DOI 10.1016/j.molimm.2004.05.011; Blessing T, 2001, BIOCONJUGATE CHEM, V12, P529, DOI 10.1021/bc0001488; Chen P, 2002, NUCL MED BIOL, V29, P693, DOI 10.1016/S0969-8051(02)00325-6; de Graaf C, 2005, J MED CHEM, V48, P2308, DOI 10.1021/jm049650u; de Menezes DEL, 1998, CANCER RES, V58, P3320; DERKSEN JTP, 1988, BIOCHIM BIOPHYS ACTA, V971, P127, DOI 10.1016/S0005-2728(88)80099-9; GABIZON A, 1994, CANCER RES, V54, P987; Gabizon A, 2003, CLIN CANCER RES, V9, P6551; Gabizon AA, 2006, J LIPOSOME RES, V16, P175, DOI 10.1080/08982100600848769; Goren D, 1996, BRIT J CANCER, V74, P1749, DOI 10.1038/bjc.1996.625; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; HARAN G, 1994, BBA-BIOMEMBRANES, V1190, P197; Heal JR, 2002, CHEMBIOCHEM, V3, P137, DOI 10.1002/1439-7633(20020301)3:2/3<136::AID-CBIC136>3.0.CO;2-7; Hetenyi C, 2002, PROTEIN SCI, V11, P1729, DOI 10.1110/ps.0202302; Hsu AR, 2006, MOL IMAGING BIOL, V8, P315, DOI 10.1007/s11307-006-0059-y; Huwyler J, 1997, J PHARMACOL EXP THER, V282, P1541; Ishida T, 1999, FEBS LETT, V460, P129, DOI 10.1016/S0014-5793(99)01320-4; Jinno H, 1996, CANCER CHEMOTH PHARM, V38, P303, DOI 10.1007/s002800050487; Kamaly N, 2008, BIOCONJUGATE CHEM, V19, P118, DOI 10.1021/bc7001715; Ke S, 2003, CANCER RES, V63, P7870; Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199; Koning GA, 2003, PHARMACEUT RES, V20, P1249, DOI 10.1023/A:1025009300562; Koning GA, 2001, PHARMACEUT RES, V18, P1291, DOI 10.1023/A:1013085811044; Kullberg EB, 2003, PHARMACEUT RES, V20, P229, DOI 10.1023/A:1022223204460; LEE RJ, 1995, BBA-BIOMEMBRANES, V1233, P134, DOI 10.1016/0005-2736(94)00235-H; Li ZH, 2005, FASEB J, V19, P1978, DOI 10.1096/fj.05-4058com; Liu X, 2002, CANCER GENE THER, V9, P100, DOI 10.1038/sj/cgt/7700400; Lutsenko SV, 2002, J DRUG TARGET, V10, P567, DOI 10.1080/1061186021000038058; Ma GB, 2007, APPL OPTICS, V46, P1650, DOI 10.1364/AO.46.001650; Mamot C, 2005, CANCER RES, V65, P11631, DOI 10.1158/0008-5472.CAN-05-1093; Mamot C, 2003, CANCER RES, V63, P3154; Mamot C, 2006, J DRUG TARGET, V14, P215, DOI 10.1080/10611860600691049; Maruyama K, 1997, FEBS LETT, V413, P177, DOI 10.1016/S0014-5793(97)00905-8; MARUYAMA K, 1995, BBA-BIOMEMBRANES, V1234, P74, DOI 10.1016/0005-2736(94)00263-O; Mastrobattista E, 1999, ADV DRUG DELIVER REV, V40, P103, DOI 10.1016/S0169-409X(99)00043-5; Matsumura Y, 2004, ANN ONCOL, V15, P517, DOI 10.1093/annonc/mdh092; MAYER LD, 1990, BIOCHIM BIOPHYS ACTA, V1025, P143, DOI 10.1016/0005-2736(90)90091-2; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; PARK JW, 1995, P NATL ACAD SCI USA, V92, P1327, DOI 10.1073/pnas.92.5.1327; Perez-Soler R, 2004, ONCOLOGIST, V9, P58, DOI 10.1634/theoncologist.9-1-58; Rogers JP, 2006, J MED CHEM, V49, P1658, DOI 10.1021/jm051033y; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sapra P, 2004, CLIN CANCER RES, V10, P1100, DOI 10.1158/1078-0432.CCR-03-0041; Schiffelers RM, 2003, J CONTROL RELEASE, V91, P115, DOI 10.1016/S0168-3659(03)00240-2; Schmidt M, 1997, BRIT J CANCER, V75, P1575, DOI 10.1038/bjc.1997.270; Song SX, 2008, INT J PHARMACEUT, V363, P155, DOI 10.1016/j.ijpharm.2008.07.012; Terada T, 2006, J DRUG TARGET, V14, P536, DOI 10.1080/10611860600849498	47	108	115	2	42	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2009	23	5					1396	1404		10.1096/fj.08-117002	http://dx.doi.org/10.1096/fj.08-117002			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	453ZP	19124558				2023-01-03	WOS:000266651700016
J	Machado, ES; Afonso, AO; Nissley, DV; Lemey, P; Cunha, SM; Oliveira, RH; Soares, MA				Machado, Elizabeth S.; Afonso, Adriana O.; Nissley, Dwight V.; Lemey, Philippe; Cunha, Silvia M.; Oliveira, Ricardo H.; Soares, Marcelo A.			Emergency of Primary NNRTI Resistance Mutations without Antiretroviral Selective Pressure in a HAART-Treated Child	PLOS ONE			English	Article								Objective: The use of antiretrovirals (ARV) during pregnancy has drastically reduced the rate of the human immunodeficiency virus perinatal transmission (MTCT). As a consequence of widespread ARV use, transmission of drug resistant strains from mothers to their babies is increasing. Ultra-sensitive PCR techniques have permitted the quantification of minority viral populations, but little is known about the transmission of drug-resistant HIV-1 minority population in the setting of MTCT. Methodology/Principal Findings: We describe the case of a female child born to an HIV-infected mother, which had not taken any ARV during the pregnancy. The child's first genotype demonstrated a minor non-nucleoside reverse transcriptase inhibitor (K101E), and during her treatment with reverse transcriptase and protease inhibitors full resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) emerged (G190A). Phenotypic/genotypic analysis of variant quasispecies through yeast TyHRT assay was conducted to characterize minority resistant viral strains circulating in both mother and child. Maximum likelihood and Bayesian MCMC phylogenetic analyses were performed with samples from the pair to assess genetic relatedness among minor viral strains. The analysis showed that the child received a minor NNRTI resistant variant, containing the mutation K101E that was present in less than 1% of the mother's quasispecies. Phylogenetic analyses have suggested common ancestry between the mother's virus strain carrying K101E with the viral sequences from the child. Conclusion: This is the first documentation of MTCT of a minority resistant strain of HIV-1. The transmission of minor resistant variants carries the threat of emergence of multi-drug primary mutations without identified specific selective pressures.	[Machado, Elizabeth S.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil; [Machado, Elizabeth S.; Afonso, Adriana O.; Soares, Marcelo A.] Univ Fed Rio de Janeiro, Dept Genet, Rio De Janeiro, Brazil; [Nissley, Dwight V.] NCI, NIH, Gene Regulat & Chromosome Biol Lab, Frederick, MD USA; [Nissley, Dwight V.] NCI, SAIC Frederick Inc, NIH, Basic Sci Program, Frederick, MD USA; [Lemey, Philippe] Univ Oxford, Dept Zool, Oxford OX1 2JD, England; [Cunha, Silvia M.; Oliveira, Ricardo H.] Univ Fed Rio de Janeiro, Inst Puericult Pediat Martagao Gesteira, Rio De Janeiro, Brazil; [Soares, Marcelo A.] Inst Nacl Canc, Div Genet, Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Oxford; Universidade Federal do Rio de Janeiro; National Cancer Institute (Inca)	Machado, ES (corresponding author), Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Rio De Janeiro, Brazil.	masoares@biologia.ufrj.br	Soares, Marcelo A/G-5662-2010; Lemey, Philippe/C-3755-2018	Lemey, Philippe/0000-0003-2826-5353	National Institutes of Health [R01 HD37780-01]; Brazilian Ministry of Health; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); National Cancer Institute, National Institutes of Health [N01-CO-12400]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Brazilian Ministry of Health; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study has been funded by grants of the National Institutes of Health R01 HD37780-01 (U.S.A.), by the Brazilian Ministry of Health and by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) - Research Grant to ESM. This project has been also partly funded with federal funds from the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bacheler L, 2001, J VIROL, V75, P4999, DOI 10.1128/JVI.75.11.4999-5008.2001; Bauer GR, 2006, AIDS, V20, P1707, DOI 10.1097/01.aids.0000242816.80462.81; Colgrove RC, 1998, AIDS, V12, P2281, DOI 10.1097/00002030-199817000-00009; Dorenbaum A, 2002, JAMA-J AM MED ASSOC, V288, P189, DOI 10.1001/jama.288.2.189; Eshleman SH, 2005, AIDS, V19, P2167, DOI 10.1097/01.aids.0000194800.43799.94; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Guindon S, 2003, SYST BIOL, V52, P696, DOI 10.1080/10635150390235520; Halvas EK, 2006, J CLIN MICROBIOL, V44, P2612, DOI 10.1128/JCM.00449-06; Iglesias-Ussel MD, 2002, J GEN VIROL, V83, P93, DOI 10.1099/0022-1317-83-1-93; Johnson VA, 2001, J INFECT DIS, V183, P1688, DOI 10.1086/320697; Kamkamidze G, 2001, J CLIN VIROL, V22, P143, DOI 10.1016/S1386-6532(01)00178-0; Karchava M, 2006, JAIDS-J ACQ IMM DEF, V42, P614, DOI 10.1097/01.qai.0000225871.87456.e7; Little SJ, 2008, J VIROL, V82, P5510, DOI 10.1128/JVI.02579-07; Llibre JM, 2008, J ANTIMICROB CHEMOTH, V62, P909, DOI 10.1093/jac/dkn297; Martinson NA, 2007, JAIDS-J ACQ IMM DEF, V44, P148, DOI 10.1097/QAI.0b013e31802b920e; Metzner KJ, 2005, AIDS, V19, P1819, DOI 10.1097/01.aids.0000189878.97480.ed; Nissley DV, 1998, P NATL ACAD SCI USA, V95, P13905, DOI 10.1073/pnas.95.23.13905; NISSLEY DV, 1996, NATURE, V380, P330; Schmitz T, 2006, PEDIATR INFECT DIS J, V25, P275, DOI 10.1097/01.inf.0000202142.34502.5e; WANG J, 2007, 14 C RETR OPP INF LO	20	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 11	2009	4	3							e4806	10.1371/journal.pone.0004806	http://dx.doi.org/10.1371/journal.pone.0004806			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437OF	19277127	Green Published, gold, Green Submitted			2023-01-03	WOS:000265496100023
J	Hall, CB; Weinberg, GA; Iwane, MK; Blumkin, AK; Edwards, KM; Staat, MA; Auinger, P; Griffin, MR; Poehling, KA; Erdman, D; Grijalva, CG; Zhu, YW; Szilagyi, P				Hall, Caroline Breese; Weinberg, Geoffrey A.; Iwane, Marika K.; Blumkin, Aaron K.; Edwards, Kathryn M.; Staat, Mary A.; Auinger, Peggy; Griffin, Marie R.; Poehling, Katherine A.; Erdman, Dean; Grijalva, Carlos G.; Zhu, Yuwei; Szilagyi, Peter			The Burden of Respiratory Syncytial Virus Infection in Young Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; HUMAN METAPNEUMOVIRUS; TRACT INFECTIONS; 1ST YEAR; INFLUENZA; HOSPITALIZATION; INFANTS; DISEASE; RATES; RSV	Background The primary role of respiratory syncytial virus ( RSV) in causing infant hospitalizations is well recognized, but the total burden of RSV infection among young children remains poorly defined. Methods We conducted prospective, population- based surveillance of acute respiratory infections among children under 5 years of age in three U. S. counties. We enrolled hospitalized children from 2000 through 2004 and children presenting as outpatients in emergency departments and pediatric offices from 2002 through 2004. RSV was detected by culture and reverse- transcriptase polymerase chain reaction. Clinical information was obtained from parents and medical records. We calculated population- based rates of hospitalization associated with RSV infection and estimated the rates of RSV- associated outpatient visits. Results Among 5067 children enrolled in the study, 919 ( 18%) had RSV infections. Overall, RSV was associated with 20% of hospitalizations, 18% of emergency department visits, and 15% of office visits for acute respiratory infections from November through April. Average annual hospitalization rates were 17 per 1000 children under 6 months of age and 3 per 1000 children under 5 years of age. Most of the children had no coexisting illnesses. Only prematurity and a young age were independent risk factors for hospitalization. Estimated rates of RSV- associated office visits among children under 5 years of age were three times those in emergency departments. Outpatients had moderately severe RSV- associated illness, but few of the illnesses ( 3%) were diagnosed as being caused by RSV. Conclusions RSV infection is associated with substantial morbidity in U. S. children in both inpatient and outpatient settings. Most children with RSV infection were previously healthy, suggesting that control strategies targeting only high- risk children will have a limited effect on the total disease burden of RSV infection.	[Hall, Caroline Breese; Weinberg, Geoffrey A.; Blumkin, Aaron K.; Auinger, Peggy; Szilagyi, Peter] Univ Rochester, Sch Med & Dent, Div Infect Dis, Dept Pediat, Rochester, NY 14642 USA; [Hall, Caroline Breese] Univ Rochester, Sch Med & Dent, Div Infect Dis, Dept Med, Rochester, NY 14642 USA; [Iwane, Marika K.; Erdman, Dean] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA; [Edwards, Kathryn M.; Poehling, Katherine A.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA; [Griffin, Marie R.; Grijalva, Carlos G.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN 37232 USA; [Zhu, Yuwei] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Staat, Mary A.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA	University of Rochester; University of Rochester; Centers for Disease Control & Prevention - USA; Vanderbilt University; Vanderbilt University; Vanderbilt University; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Hall, CB (corresponding author), Univ Rochester, Sch Med & Dent, Div Infect Dis, Dept Pediat, 601 Elmwood Ave,Box 689, Rochester, NY 14642 USA.	caroline_hall@urmc.rochester.edu	Weinberg, Geoffrey A./W-7510-2019	Weinberg, Geoffrey A./0000-0002-3900-379X; Grijalva, Carlos/0000-0002-2329-7797	MedImmune; Astellas; GlaxoSmithKline; Merck; Pfizer; Wyeth; NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES [K01IP000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI065805] Funding Source: NIH RePORTER	MedImmune(AstraZenecaMedimmune); Astellas(Astellas Pharmaceuticals); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Pfizer(Pfizer); Wyeth(Wyeth); NATIONAL CENTER FOR IMMUNICATION AND RESPIRATORY DISEASES(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported through cooperative agreements with the CDC.; Dr. Hall reports receiving grant support and consulting fees from MedImmune; Dr. Weinberg, research support from Astellas and MedImmune and consulting fees from MedImmune; Dr. Staat, consulting fees or fees for serving on paid advisory boards from GlaxoSmithKline, Merck, and MedImmune, lecture fees from Merck, and research support from MedImmune; Dr. Griffin, grant support from MedImmune and Pfizer; and Dr. Grijalva, lecture fees from Wyeth. No other potential conflict of interest relevant to this article was reported.; The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the CDC.; We thank the children and their parents who participated in this study; all the members of the New Vaccine Surveillance Network, including Geraldine Lofthus, Kenneth Schnabel, Andrea Marino, Lynne Shelley, Jennifer Carnahan, Linda Anderson, Gladys Lathan, Charlene Freundlich, Christina Albertin, and Rebecca Martinez at the University of Rochester; John Williams, Diane Kent, Ann Clay, Ayesha Khan, Yi Wei Tang, Haijing Li, Jennifer Doersam, Amondrea Blackman, Nayleen Whitehead, Erin Keckley, and Jody Peters at Vanderbilt University; Linda Jamison, David Witte, David Bernstein, Emilie Grube, Vanessa Florian, Pamela Groen, and Joel Mortensen at the Cincinnati Children's Medical Center; and Ranee Seither, Aaron Curns, Larry Anderson, Carolyn B. Bridges, Benjamin Schwartz, Frances Walker, John Copeland, Alicia Fry, Jennifer Reuer, and John Zhang at the CDC.	Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Carbonell-Estrany Xavier, 2004, Pediatr Infect Dis J, V23, pS193, DOI 10.1097/01.inf.0000144664.31888.53; Casella G, 2002, STAT INFERENCE, P240; Collins Peter L, 2005, Proc Am Thorac Soc, V2, P166, DOI 10.1513/pats.200501-011AW; Comperat E, 2007, PROG UROL, V17, P5, DOI 10.1016/S1166-7087(07)92218-6; Englund J, 2005, J INFECT DIS, V191, P1036, DOI 10.1086/427998; Erdman DD, 2003, J CLIN MICROBIOL, V41, P4298, DOI 10.1128/JCM.41.9.4298-4303.2003; Griffin Marie R, 2004, Pediatr Infect Dis J, V23, pS188, DOI 10.1097/01.inf.0000144660.53024.64; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135, DOI 10.1093/oxfordjournals.aje.a115826; Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Law BJ, 2004, PEDIATR INFECT DIS J, V23, P806, DOI 10.1097/01.inf.0000137568.71589.bd; Leader S, 2003, J PEDIATR-US, V143, pS127, DOI 10.1067/S0022-3476(03)00510-9; Littel-van den Hurk SV, 2007, REV MED VIROL, V17, P5, DOI 10.1002/rmv.518; Meissner HC, 2004, PEDIATR INFECT DIS J, V23, P284, DOI 10.1097/01.inf.0000121203.33560.f9; Miller EK, 2008, PEDIATRICS, V121, P1, DOI 10.1542/peds.2007-1053; Miller EK, 2007, J INFECT DIS, V195, P773, DOI 10.1086/511821; Mullins JA, 2004, EMERG INFECT DIS, V10, P700, DOI 10.3201/eid1004.030555; *NAT I ALL INF DIS, 2002, JORD REP ACC DEV VAC; Nicholson KG, 2006, VACCINE, V24, P102, DOI 10.1016/j.vaccine.2005.02.004; Nielsen HE, 2003, ACTA PAEDIATR, V92, P1314, DOI 10.1080/08035250310006304; Nokes DJ, 2008, CLIN INFECT DIS, V46, P50, DOI 10.1086/524019; Peck AJ, 2005, PEDIATR INFECT DIS J, V24, P342, DOI 10.1097/01.inf.0000157250.95880.91; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Reeve CA, 2006, J PAEDIATR CHILD H, V42, P248, DOI 10.1111/j.1440-1754.2006.00849.x; Romero JR, 2003, PEDIATR INFECT DIS J, V22, pS46, DOI 10.1097/00006454-200302001-00007; Rossi GA, 2007, EUR J PEDIATR, V166, P1267, DOI 10.1007/s00431-007-0418-y; Schanzer DL, 2006, PEDIATR INFECT DIS J, V25, P795, DOI 10.1097/01.inf.0000232632.86800.8c; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Simoes EAF, 2003, J PEDIATR-US, V143, pS118, DOI 10.1067/S0022-3476(03)00511-0; StataCorp L, 2007, STAT DAT AN STAT SOF; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; von Linstow ML, 2008, EUR J PEDIATR, V167, P1125, DOI 10.1007/s00431-007-0643-4; Weinberg GA, 2004, J INFECT DIS, V189, P706, DOI 10.1086/381456; WEINBERG GA, J PEDIAT IN PRESS; WELLIVER RC, 2004, PAEDIATR RESPIR REV, pS127	38	1359	1414	1	79	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2009	360	6					588	598		10.1056/NEJMoa0804877	http://dx.doi.org/10.1056/NEJMoa0804877			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402QS	19196675	Green Accepted, Bronze			2023-01-03	WOS:000263028800005
J	Lewis, SC; Warlow, CP; Bodenham, AR; Colam, B; Rothwell, PM; Torgerson, D; Dellagrammaticas, D; Horrocks, M; Liapis, C; Banning, AP; Gough, M; Gough, MJ				Lewis, S. C.; Warlow, C. P.; Bodenham, A. R.; Colam, B.; Rothwell, P. M.; Torgerson, D.; Dellagrammaticas, D.; Horrocks, M.; Liapis, C.; Banning, A. P.; Gough, M.; Gough, M. J.		GALA Trial Collaborative Grp	General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial	LANCET			English	Article							ENDARTERECTOMY; STENOSIS	Background The effect of carotid endarterectomy in lowering the risk of stroke ipsilateral to severe atherosclerotic carotid-artery stenosis is offset by complications during or soon after surgery. We compared surgery under general anaesthesia with that under local anaesthesia because prediction and avoidance of perioperative strokes might be easier under local anaesthesia than under general anaesthesia. Methods We undertook a parallel group, multicentre, randomised controlled trial of 3526 patients with symptomatic or asymptomatic carotid stenosis from 95 centres in 24 countries. Participants were randomly assigned to surgery under general (n=1753) or local (n=1773) anaesthesia between June, 1999 and October, 2007. The primary outcome was the proportion of patients with stroke (including retinal infarction), myocardial infarction, or death between randomisation and 30 days after surgery. Analysis was by intention to treat. The trial is registered with Current Control Trials number ISRCTNO0525237. Findings A primary outcome occurred in 84 (4.8%) patients assigned to surgery under general anaesthesia and 80 (4 . 5%) of those assigned to surgery under local anaesthesia; three events per 1000 treated were prevented with local anaesthesia (95% CI -11 to 17; risk ratio [RR] 0 . 94 [95% CI 0 . 70 to 1. 27]). The two groups did not significantly differ for quality of life, length of hospital stay, or the primary outcome in the prespecified subgroups of age, contralateral carotid occlusion, and baseline surgical risk. Interpretation We have not shown a definite difference in outcomes between general and local anaesthesia for carotid surgery. The anaesthetist and surgeon, in consultation with the patient, should decide which anaesthetic technique to use on an individual basis. Funding The Health Foundation (UK) and European Society of Vascular Surgery.	[Lewis, S. C.] Western Gen Hosp, Neurosci Trials Unit, Div Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Lewis, SC (corresponding author), Western Gen Hosp, Neurosci Trials Unit, Div Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	steff.lewis@ed.ac.uk	Taba, Pille/B-1014-2019; Finocchi, Cinzia/AAA-7409-2020; Ferrante, Angela Maria Rosaria/AIC-4170-2022; Hrbac, Tomas/M-9596-2017; banning, adrian p/AAF-7229-2021; Modugno, Pietro/U-2975-2019; Sunar, Hasan/A-8685-2018; Gillgren, Peter/AAB-4724-2020; Sieunarine, Kishore/AAI-5548-2020; Mansilha, Armando/ABF-1229-2020; Rothwell, Peter/ABE-5913-2020; Sudlow, Cathie LM/F-3420-2010; Hankey, Graeme J/H-4968-2014; Karpenko, Andrei/AAH-1725-2020; DE TROIA, ALESSANDRO/V-1292-2018; MWIPATAYI, Bibombe Patrice/AAE-3000-2019; Macleod, Malcolm Robert/B-2052-2010; Torgerson, David/L-4566-2019; Azevedo, Elsa I/C-1060-2014; Dellagrammaticas, Demosthenes/J-7158-2018; Tutkavul, Kemal/AAE-2126-2019; Di Lazzaro, Vincenzo/L-3731-2018; Smrcka, Martin/AAM-8872-2021; GABRIELLI, ROBERTO/M-9253-2016; Michalek, Pavel/N-9123-2017; Cinelli, Giuseppe/F-5155-2011	Finocchi, Cinzia/0000-0003-4385-1203; Ferrante, Angela Maria Rosaria/0000-0002-5653-6934; Hrbac, Tomas/0000-0002-6401-9849; Gillgren, Peter/0000-0003-0538-3496; Sieunarine, Kishore/0000-0003-4151-5505; Mansilha, Armando/0000-0002-6722-0476; Rothwell, Peter/0000-0001-9739-9211; Hankey, Graeme J/0000-0002-6044-7328; DE TROIA, ALESSANDRO/0000-0002-7392-9764; MWIPATAYI, Bibombe Patrice/0000-0003-1977-0382; Macleod, Malcolm Robert/0000-0001-9187-9839; Torgerson, David/0000-0002-1667-4275; Azevedo, Elsa I/0000-0003-3731-4508; Dellagrammaticas, Demosthenes/0000-0002-4429-7147; Tutkavul, Kemal/0000-0002-0986-3924; chetter, ian/0000-0002-2566-6859; Tommasino, Concezione/0000-0001-8856-6866; Di Lazzaro, Vincenzo/0000-0002-9113-5925; Pinotic, Kresimir/0000-0003-4559-5485; Iborra, Elena/0000-0003-0668-5285; Rutherford, John/0000-0002-0873-977X; Priban, Vladimir/0000-0001-6051-9910; Przywara, Stanislaw/0000-0002-8855-3974; Ferrero, Emanuele/0000-0002-6242-6192; Bukhari, Marwan/0000-0003-4311-5222; Myslinski, Wojciech/0000-0003-1134-5920; Smrcka, Martin/0000-0002-9191-8700; Murray, Gordon/0000-0001-9866-4734; GABRIELLI, ROBERTO/0000-0001-7192-5076; Michalek, Pavel/0000-0001-8119-5927; Verzar, Zsofia/0000-0001-5323-0748; Schneider, Gerhard/0000-0002-4903-0118; LIAPIS, CHRISTOS/0000-0002-1195-9108; gossetti, bruno/0000-0001-6805-1785; Kvolik, Slavica/0000-0002-5244-9585; Vlachovsky, Robert/0000-0002-2899-3580; fiedler, jiri/0000-0001-7886-6021; Karpenko, Andrey/0000-0002-8064-1857; Poppert, Holger/0000-0003-2189-7681; Setacci, Francesco/0000-0002-8007-9462; SUNAR, HASAN/0000-0002-1276-8549; VENTURA, Marco/0000-0003-2573-8573; PIROLI, Alba/0000-0002-1722-6490; Sudlow, Cathie/0000-0002-7725-7520; GHILARDI, GIORGIO/0000-0002-0269-5761; Lumb, Andrew/0000-0002-6684-9205; Taba, Pille/0000-0002-1315-1065; Ciccozzi, Alessandra/0000-0003-0250-7991; Lewis, Steff/0000-0003-1210-2314; PETRASSI, Carla/0000-0002-5933-2507; Pal, Endre/0000-0001-6525-0754; Eckstein, Hans-Henning/0000-0002-0743-1642; White, Nicholas/0000-0002-1897-1978; SIRIGNANO, Pasqualino/0000-0002-1312-1915; corsi, fabio massimo/0000-0002-4219-4283; CREA, Maria Antonietta/0000-0003-3142-4175; SPARTERA, Carlo/0000-0003-0401-7937; Banning, Adrian/0000-0002-2842-7861; Howell, Simon/0000-0001-8467-1466; GIMENEZ-GAIBAR, ANTONIO/0000-0002-1837-4989; Lioupis, Christos/0000-0001-6197-3218; Cinelli, Giuseppe/0000-0002-5319-537X; Aksoy, Murat/0000-0002-9116-3985; Milo, Ron/0000-0001-8556-2579; Rosengren, Lars/0000-0003-0505-8896; Modugno, Pietro/0000-0002-8194-7567				Altman D.G., 2000, STAT CONFIDENCE, Vsecond; [Anonymous], 2001, BANDOLIER; Bond R, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD000160.PUB2; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Gough MJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-28; Hakl M, 2007, BRIT J ANAESTH, V99, P415, DOI 10.1093/bja/aem171; Halliday A, 2004, LANCET, V363, P1491; McCleary AJ, 1996, EUR J VASC ENDOVASC, V12, P173, DOI 10.1016/S1078-5884(96)80103-1; Pandit JJ, 2007, BRIT J ANAESTH, V99, P159, DOI 10.1093/bja/aem160; RERKASEM K, 1996, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000126, DOI 10.1002/14651858.CD000126]; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Rothwell PM, 2004, LANCET, V363, P915, DOI 10.1016/S0140-6736(04)15785-1; Rothwell PM, 2003, LANCET, V361, P107, DOI 10.1016/S0140-6736(03)12228-3; Rothwell PM, 1999, LANCET, V353, P2105, DOI 10.1016/S0140-6736(98)11415-0; Warlow C, 2003, LANCET, V362, P1211, DOI 10.1016/S0140-6736(03)14544-8	16	367	381	2	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC-JAN	2008	372	9656					2132	2142		10.1016/S0140-6736(08)61699-2	http://dx.doi.org/10.1016/S0140-6736(08)61699-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	386PB	19041130	Green Submitted			2023-01-03	WOS:000261894000036
J	Russell, ARB; Steer, PJ				Russell, A. R. Bedford; Steer, P. J.			Antibiotics in preterm labour - the ORACLE speaks	LANCET			English	Editorial Material							BROAD-SPECTRUM ANTIBIOTICS; PRELABOR RUPTURE; RANDOMIZED TRIAL; CESAREAN-SECTION; MEMBRANES; TERM		[Steer, P. J.] Univ London Imperial Coll Sci Technol & Med, Div Surg Anaesthet Oncol & Reprod Med, Fac Med, London SW10 9NH, England; [Steer, P. J.] Chelsea & Westminster NHS Fdn Trust, London SW10 9NH, England; [Russell, A. R. Bedford] Warwick Med Sch, Warwick, England; [Russell, A. R. Bedford] Heart England NHS Trust, Neonatol Unit, Birmingham, W Midlands, England	Imperial College London; Imperial College London; University of Warwick; Heart of England NHS Foundation Trust	Steer, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Surg Anaesthet Oncol & Reprod Med, Fac Med, London SW10 9NH, England.	p.steer@imperial.ac.uk						Agnew G, 2006, OBSTET GYNECOL, V108, P452, DOI 10.1097/01.AOG.0000232163.87409.27; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; Hannah M, 2001, LANCET, V357, P973, DOI 10.1016/S0140-6736(00)04253-7; Hannah ME, 2000, LANCET, V356, P1375, DOI 10.1016/S0140-6736(00)02840-3; *HLTH PROT AG, 2007, HLTH PROT REP, V1, P9; Inder T E, 2000, Semin Neonatol, V5, P3, DOI 10.1053/siny.1999.0112; Jacobsson B, 2004, BEST PRACT RES CL OB, V18, P425, DOI 10.1016/j.bpobgyn.2004.02.011; KENYON S, 2008, LANCET          0918; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; LIGGINS GC, 1972, PEDIATRICS, V50, P515; PEARSON A, 2004, CDR WEEKLY, V15, P4; Russell ARB, 2006, BJOG-INT J OBSTET GY, V113, P758, DOI 10.1111/j.1471-0528.2006.00952.x; Steer PJ, 2005, BMJ-BRIT MED J, V331, P645, DOI 10.1136/bmj.331.7518.645; Tan S, 2003, LANCET, V361, P437, DOI 10.1016/S0140-6736(03)12420-8	15	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 11	2008	372	9646					1276	1278		10.1016/S0140-6736(08)61248-9	http://dx.doi.org/10.1016/S0140-6736(08)61248-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	360MB	18804275				2023-01-03	WOS:000260060500005
J	Greenhalgh, T				Greenhalgh, Trisha			Anyone for Club Med?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									UCL, London, England	University of London; University College London	Greenhalgh, T (corresponding author), UCL, London, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Martinez-Gonzalez MA, 2008, BMJ-BRIT MED J, V336, P1348, DOI 10.1136/bmj.39561.501007.BE	1	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 19	2008	337	7662							a677	10.1136/bmj.a677	http://dx.doi.org/10.1136/bmj.a677			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	330SB	18614468	Green Published			2023-01-03	WOS:000257962000048
J	Kamerow, D				Kamerow, Douglas			Placebo pills for children	BRITISH MEDICAL JOURNAL			English	Editorial Material									RTI Int, Res Triangle Pk, NC 27709 USA	Research Triangle Institute	Kamerow, D (corresponding author), RTI Int, Res Triangle Pk, NC 27709 USA.	dkamerow@rti.org		Kamerow, Douglas/0000-0001-7000-9957					0	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JUN 14	2008	336	7657					1339	1339		10.1136/bmj.39603.698889.59	http://dx.doi.org/10.1136/bmj.39603.698889.59			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	316YB	18556311	Green Published			2023-01-03	WOS:000256984700034
J	Tonks, A				Tonks, Alison			Cabin fever	BRITISH MEDICAL JOURNAL			English	Editorial Material							FLIGHT MEDICAL EMERGENCIES; AIRCRAFT; AIRLINES; EVENTS; AIR					atonks@bmj.com						BRAY A, 2008, INDEPENDENT IE  0129; Cocks R, 2007, EMERG MED AUSTRALAS, V19, P1, DOI 10.1111/j.1742-6723.2006.00928.x; Delaune EF, 2003, AVIAT SPACE ENVIR MD, V74, P62; Dowdall N, 2000, BRIT MED J, V321, P1336, DOI 10.1136/bmj.321.7272.1336; Gendreau MA, 2002, NEW ENGL J MED, V346, P1067, DOI 10.1056/NEJMra012774; General Medical Council, 2006, GOOD MED PRACT; Goodwin T, 2000, BRIT MED J, V321, P1338, DOI 10.1136/bmj.321.7272.1338; HAMER M, 2005, NEW SCI         0520, P8; KIRBY D, 2008, MANCHESTER EVEN 0225; Kuczkowski KM, 2007, CAN J ANAESTH, V54, P401, DOI 10.1007/BF03022669; Qureshi A, 2005, EMERG MED J, V22, P658, DOI 10.1136/emj.2005.024505; Shepherd B, 2006, J ROY SOC MED, V99, P628, DOI 10.1258/jrsm.99.12.628; Sirven JI, 2002, NEUROLOGY, V58, P1739, DOI 10.1212/WNL.58.12.1739; Thibeault C, 2007, AVIAT SPACE ENVIR MD, V78, P1170, DOI 10.3357/ASEM.2188.2007; WALLACE WA, 1995, BRIT MED J, V311, P374, DOI 10.1136/bmj.311.7001.374; *WORLD MED ASS, 2006, INT COD ETH	16	13	13	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	MAR 15	2008	336	7644					584	586		10.1136/bmj.39511.444618.AD	http://dx.doi.org/10.1136/bmj.39511.444618.AD			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	279OM	18340070	Green Published			2023-01-03	WOS:000254364500027
J	Van den Block, L; Deschepper, R; Bilsen, J; Bossuyt, N; Van Casteren, V; Deliens, L				Van den Block, Lieve; Deschepper, Reginald; Bilsen, Johan; Bossuyt, Nathalie; Van Casteren, Viviane; Deliens, Luc			Euthanasia and other end of life decisions and care provided in final three months of life: nationwide retrospective study in Belgium	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; 6 EUROPEAN COUNTRIES; PALLIATIVE CARE; MEDICAL-PRACTICE; NETWORK; PRACTITIONERS; FLANDERS; DEATH	Objective To explore the relation between the care provided in the final three months of life and the prevalence and types of end of life decisions in Belgium. Design Two year nationwide retrospective study, 2005-6 (SENTI-MELC study). Setting Data collection via the sentinel network of general practitioners, an epidemiological surveillance system representative of all general practitioners in Belgium. Subjects 1690 non-sudden deaths in practices of the sentinel general practitioners. Main outcome measures Non-sudden deaths of patients (aged >1 year) reported each week. Reported care provided in the final three months of life and the end of life decisions made. Multivariable regression analysis controlled for age, sex, cause, and place of death. Results Use of specialist multidisciplinary palliative care services was associated with intensified alleviation of symptoms (odds ratio 2.1, 95% confidence interval 1.6 to 2.6), continuous deep sedation forgoing food/fluid (2.9, 1.7 to 4.9), and the total of decisions explicitly intended to shorten life (1.5, 1.1 to 2.1) but not with euthanasia or physician assisted suicide in particular. To a large extent receiving spiritual care was associated with higher frequencies of euthanasia or physician assisted suicide than receiving little spiritual care (18.5, 2.0 to 172.7). Conclusions End of life decisions that shorten life, including euthanasia or physician assisted suicide, are not related to a lower use of palliative care in Belgium and often occur within the context of multidisciplinary care.	[Van den Block, Lieve; Deschepper, Reginald; Bilsen, Johan; Deliens, Luc] Vrije Univ Brussel, End Life Care Res Grp, B-1090 Brussels, Belgium; [Van den Block, Lieve] Vrije Univ Brussel, Dept Gen Practice, B-1090 Brussels, Belgium; [Bossuyt, Nathalie; Van Casteren, Viviane] Sci Inst Publ Hlth, Dept Epidemiol, B-1040 Brussels, Belgium; [Bilsen, Johan] Vrije Univ Brussel, Dept Publ Hlth, B-1090 Brussels, Belgium; [Deliens, Luc] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, NL-1007 MB Amsterdam, Netherlands; [Deschepper, Reginald] Vrije Univ Brussel, Dept Crit Care, B-1090 Brussels, Belgium	Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vrije Universiteit Amsterdam; Vrije Universiteit Brussel	Van den Block, L (corresponding author), Vrije Univ Brussel, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	lvdblock@vub.ac.be	Van den Block, Lieve/D-1247-2011; Deschepper, Reginald/B-8103-2013	Van den Block, Lieve/0000-0002-7770-348X; Deschepper, Reginald/0000-0002-4222-3945; Deliens, Luc/0000-0002-8158-2422; Bossuyt, Nathalie/0000-0002-4213-9209	Fund for Scientific Research in Flanders, Belgium; Research Council of the Vrije Universiteit Brussel in Belgium [GOA27 20032007]; Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO) [050158]; Flemish and Walloon Ministry of Welfare, Public Health and Family	Fund for Scientific Research in Flanders, Belgium; Research Council of the Vrije Universiteit Brussel in Belgium; Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO); Flemish and Walloon Ministry of Welfare, Public Health and Family	LVdB is a postdoctoral researcher of the Fund for Scientific Research in Flanders, Belgium. This study was funded by the Research Council of the Vrije Universiteit Brussel in Belgium ( project GOA27 20032007) and the Institute for the Promotion of Innovation by Science and Technology in Flanders as a Strategic Basic Research project (SBO) ( contract SBO IWT 050158) (2006- 2010), as part of the Monitoring Quality of End-of-Life Care ( MELC) Study. The Belgian Sentinel Network of GPs is supported by the Flemish and Walloon Ministry of Welfare, Public Health and Family. The sponsors had no role in design and conduct of the study, in the collection, analysis, and interpretation of the data, in the writing of the report or in the decision to submit the article for publication. The researchers are independent from the funders. Competing interest: None declared.	BAYINGANA K, 2006, D200625054 SCI I PUB; Bernheim JL, 2008, BRIT MED J, V336, P864, DOI 10.1136/bmj.39497.397257.AD; BOFFIN N, 2007, 2007013 IPHEPI SCI I; Clark D, 2000, PALLIATIVE MED, V14, P479, DOI 10.1191/026921600701536408; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; Emanuel EJ, 2000, ANN INTERN MED, V133, P527, DOI 10.7326/0003-4819-133-7-200010030-00011; *FED EV PALL ZORG, 2005, EV PALL ZORG OV UITB; Hermsen MA, 2002, J PAIN SYMPTOM MANAG, V23, P517, DOI 10.1016/S0885-3924(02)00401-3; Hinkka H, 2002, J MED ETHICS, V28, P109, DOI 10.1136/jme.28.2.109; Kuhse H, 1997, MED J AUSTRALIA, V166, P191, DOI 10.5694/j.1326-5377.1997.tb140074.x; LOBET MP, 1987, INT J EPIDEMIOL, V16, P612, DOI 10.1093/ije/16.4.612; Materstvedt LJ, 2003, PALLIATIVE MED, V17, P97, DOI 10.1191/0269216303pm673oa; Meier DE, 2003, ARCH INTERN MED, V163, P1537, DOI 10.1001/archinte.163.13.1537; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Miccinesi G, 2006, J PAIN SYMPTOM MANAG, V31, P122, DOI 10.1016/j.jpainsymman.2005.07.004; Onwuteaka-Philipsen BD, 2006, ARCH INTERN MED, V166, P921, DOI 10.1001/archinte.166.8.921; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2007, NEW ENGL J MED, V356, P1911, DOI 10.1056/NEJMp078061; SEALE C, 1995, SOC SCI MED, V40, P581, DOI 10.1016/0277-9536(94)00171-O; Seale C, 2006, PALLIATIVE MED, V20, P3, DOI 10.1191/0269216306pm1094oa; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Van den Block L, 2008, ARCH INTERN MED, V168, P1747, DOI 10.1001/archinte.168.16.1747; Van den Block L, 2007, JAMA-J AM MED ASSOC, V298, P1638, DOI 10.1001/jama.298.14.1638; Van den Block L, 2006, J CLIN ONCOL, V24, P2842, DOI 10.1200/JCO.2005.03.7531; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; VANDENBLOCK L, 2007, BMC PALLIAT CARE, V8, P6; Weide MCJV, 2005, ARCH INTERN MED, V165, P1698, DOI 10.1001/archinte.165.15.1698; World Health Organization, 2002, NAT CANC CONTR PROGR	29	42	42	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 30	2009	339								b2772	10.1136/bmj.b2772	http://dx.doi.org/10.1136/bmj.b2772			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	479PI	19643825	hybrid, Green Published			2023-01-03	WOS:000268673000002
J	Van Cutsem, E; Kohne, CH; Hitre, E; Zaluski, J; Chien, CRC; Makhson, A; D'Haens, G; Pinter, T; Lim, R; Bodoky, G; Roh, JK; Folprecht, G; Ruff, P; Stroh, C; Tejpar, S; Schlichting, M; Nippgen, J; Rougier, P				Van Cutsem, Eric; Koehne, Claus-Henning; Hitre, Erika; Zaluski, Jerzy; Chien, Chung-Rong Chang; Makhson, Anatoly; D'Haens, Geert; Pinter, Tamas; Lim, Robert; Bodoky, Gyoergy; Roh, Jae Kyung; Folprecht, Gunnar; Ruff, Paul; Stroh, Christopher; Tejpar, Sabine; Schlichting, Michael; Nippgen, Johannes; Rougier, Philippe			Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							K-RAS MUTATIONS; 1ST-LINE TREATMENT; PLUS IRINOTECAN; PHASE-III; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; KRAS; COMBINATION; TRIAL	Background We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. Results A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P = 0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P = 0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P = 0.03) but not for progression-free survival (P = 0.07) or overall survival (P = 0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P = 0.008). Conclusions First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)	[Van Cutsem, Eric] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Louvain, Belgium; [D'Haens, Geert] Imelda Ziekenhuis, Bonheiden, Belgium; [Koehne, Claus-Henning] Klinikum Oldenburg, Oldenburg, Germany; [Folprecht, Gunnar] Univ Klinikum Carl Gustav Carus, Dresden, Germany; [Stroh, Christopher; Schlichting, Michael; Nippgen, Johannes] E Merck AG, D-6100 Darmstadt, Germany; [Hitre, Erika] Orszagos Onkol Intezet, Budapest, Hungary; [Pinter, Tamas] Petz Aladar Cty Teaching Hosp, Gyor, Hungary; [Bodoky, Gyoergy] St Laszlo Hosp, Budapest, Hungary; [Zaluski, Jerzy] Wielkopolskie Ctr Onkol, Poznan, Poland; [Chien, Chung-Rong Chang] Chang Gung Mem Hosp, Tao Yuan, Taiwan; [Makhson, Anatoly] Moscow City Oncol Clin Hosp 62, Moscow, Russia; [Lim, Robert] Natl Univ Singapore Hosp, Singapore 119074, Singapore; [Roh, Jae Kyung] Yonsei Univ, Coll Med, Seoul, South Korea; [Ruff, Paul] Univ Witwatersrand, Johannesburg, South Africa; [Rougier, Philippe] Hop Ambroise Pare, Boulogne, France	KU Leuven; University Hospital Leuven; Imeldaziekenhuis; Klinikum Oldenburg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Merck KGaA; Szent Laszlo Hospital; Wielkopolskie Centrum Onkologii; Chang Gung Memorial Hospital; National University of Singapore; Yonsei University; Yonsei University Health System; University of Witwatersrand; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Van Cutsem, E (corresponding author), Univ Hosp Gasthuisberg, Digest Oncol Unit, Herestr 49, B-3000 Louvain, Belgium.	eric.vancutsem@uz.kuleuven.ac.be	Van+Cutsem, Eric/ABE-1762-2021; Folprecht, Gunnar/F-8638-2011	Folprecht, Gunnar/0000-0002-9321-9911; Bodoky, Gyorgy/0000-0002-5659-2020	Merck (Darmstadt); Roche; Sanofi- Aventis	Merck (Darmstadt)(Merck & Company); Roche(Roche Holding); Sanofi- Aventis(Sanofi-Aventis)	Supported by Merck (Darmstadt).; Dr. Van Cutsem reports receiving consulting or advisory fees from Amgen, Merck (Darmstadt), Pfizer, Roche, and Sanofi-Aventis; lecture fees from Amgen, Merck (Darmstadt), Roche, and Sanofi- Aventis; and grant support from Merck (Darmstadt) and Roche; Dr. Kohne, consulting or advisory fees and lecture fees from Amgen, Merck (Darmstadt), Pfizer, Roche, and Sanofi- Aventis; Dr. Lim, lecture fees from Roche; Dr. Folprecht, advisory fees from Roche, lecture fees from Merck (Darmstadt), Pfizer, and Sanofi- Aventis, and grant support from Merck (Darmstadt) and Sanofi- Aventis; Dr. Tejpar, grant support from Merck (Darmstadt); and Dr. Rougier, consulting or advisory fees from Merck (Darmstadt), Pfizer, Roche, and Sanofi- Aventis and lecture fees from Merck (Darmstadt), Pfizer, and Sanofi- Aventis. Drs. Stroh, Schlichting, and Nippgen report being employees of Merck (Darmstadt). No other potential conflict of interest relevant to this article was reported.; We thank our patients and nursing staff, contributors from other centers, and Merck (Darmstadt) personnel.	Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Arnold D, 2008, ANN ONCOL, V19, P1442, DOI 10.1093/annonc/mdn150; Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397; Bokernever C, 2007, EJC SUPPL, V5, P236, DOI 10.1016/S1359-6349(07)70932-1; CERVANTEE A, 2008, J CLIN ONCOL S, V26, pS210; Chen CY, 2004, CLIN CHEM, V50, P481, DOI 10.1373/clinchem.2003.024505; Collett D, 2015, MODELLING SURVIVAL D; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Douillard JY, 2000, LANCET, V355, P1372; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Folprecht G, 2006, ANN ONCOL, V17, P450, DOI 10.1093/annonc/mdj084; Food and Drug Administration, CLIN TRIAL ENDP APPR; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Lenz HJ, 2006, J CLIN ONCOL, V24, P4914, DOI 10.1200/JCO.2006.06.7595; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; MCLELLAN EA, 1993, GUT, V34, P392, DOI 10.1136/gut.34.3.392; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Rougier P, 2004, J CLIN ONCOL, V22, p248S; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Schilsky RL, 2002, CLIN CANCER RES, V8, P935; Simeonov A, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf090; Tabernero J, 2007, J CLIN ONCOL, V25, P5225, DOI 10.1200/JCO.2007.13.2183; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Van Cutsem E, 2007, BEST PRACT RES CL GA, V21, P1089, DOI 10.1016/j.bpg.2007.10.020; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620	35	2954	3013	2	215	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	2009	360	14					1408	1417		10.1056/NEJMoa0805019	http://dx.doi.org/10.1056/NEJMoa0805019			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	427AL	19339720				2023-01-03	WOS:000264751800006
J	Casaburi, R; ZuWallack, R				Casaburi, Richard; ZuWallack, Richard			Pulmonary Rehabilitation for Management of Chronic Obstructive Pulmonary Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIRWAY-OBSTRUCTION; EXERCISE; PREDICTORS; BENEFITS; VENTILATION; MORTALITY; ADHERENCE; SURVIVAL; MUSCLE; COPD	A 61-year-old woman is referred for pulmonary consultation. She smoked one pack of cigarettes a day for 45 years but quit a year ago. For 2 years she has noted progressive exertional dyspnea, with breathlessness occurring when she is walking up one flight of stairs or hurrying on level ground. A diagnosis of chronic obstructive pulmonary disease (COPD) was made a year ago, and she was treated with inhaled medications. She is sedentary and recently gained 15 lb (6.8 kg); her only frequent social activity is playing cards. Her physical examination is normal except for a weight of 195 lb (88.5 kg) (body-mass index [the weight in kilograms divided by the square of the height in meters], 32) and for decreased breath sounds and prolonged expiration on chest auscultation. Spirometry reveals moderate airway obstruction; an echocardiogram is normal. The pulmonary consultant recommends enrollment in a pulmonary rehabilitation program.	[Casaburi, Richard] Harbor UCLA Med Ctr, Lo Angeles Biomed Res Inst, Rehabil Clin Trials Ctr, Torrance, CA 90502 USA; [ZuWallack, Richard] St Francis Hosp & Med Ctr, Hartford, CT USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Saint Francis Hospital & Medical Center	Casaburi, R (corresponding author), Harbor UCLA Med Ctr, Lo Angeles Biomed Res Inst, Rehabil Clin Trials Ctr, 1124 W Carson St,Bldg J4, Torrance, CA 90502 USA.	casaburi@ucla.edu						Agusti AGN, 2002, AM J RESP CRIT CARE, V166, P485, DOI 10.1164/rccm.2108013; [Anonymous], 1999, AM J RESP CRIT CARE, V159, pS1; BABB TG, 1991, J APPL PHYSIOL, V70, P223, DOI 10.1152/jappl.1991.70.1.223; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Bourbeau J, 2006, CHEST, V130, P1704, DOI 10.1378/chest.130.6.1704; *CAL PULM REH COLL, 2004, CARDIOPULM REHABIL, V24, P52; Casaburi R, 2005, CHEST, V127, P809, DOI 10.1378/chest.127.3.809; Casaburi R, 1997, AM J RESP CRIT CARE, V155, P1541, DOI 10.1164/ajrccm.155.5.9154855; Casaburi R, 2004, AM J RESP CRIT CARE, V170, P870, DOI 10.1164/rccm.200305-617OC; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9, DOI 10.1164/ajrccm/143.1.9; Casaburi R, 1993, PRINCIPLES PRACTICE, P204; Casaburi R, 2008, AM J RESP CRIT CARE, V177, P805, DOI 10.1164/rccm.200801-181ED; Celli BR, 2006, EUR RESPIR J, V27, P242, DOI 10.1183/09031936.06.00129305; CELLI BR, 1986, NEW ENGL J MED, V314, P1485, DOI 10.1056/NEJM198606053142305; Decramer M, 2005, RESP MED, V99, pS3, DOI 10.1016/j.rmed.2005.09.010; Emtner M, 2003, AM J RESP CRIT CARE, V168, P1034, DOI 10.1164/rccm.200212-1525OC; Fan VS, 2008, COPD, V5, P105, DOI 10.1080/15412550801941190; FERREIRA IM, 2008, COCHRANE DB SYST REV, V2; Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145; Garrod R, 2006, EUR RESPIR J, V27, P788, DOI 10.1183/09031936.06.00130605; Griffiths TL, 2001, THORAX, V56, P779, DOI 10.1136/thorax.56.10.779; Griffiths TL, 2000, LANCET, V355, P1280; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; Haas F, 1993, PRINCIPLES PRACTICE, P241; Huiart L, 2005, CHEST, V128, P2640, DOI 10.1378/chest.128.4.2640; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; Lacasse Yves, 2002, J Cardiopulm Rehabil, V22, P148, DOI 10.1097/00008483-200205000-00004; Maltais F, 2000, THORAX, V55, P848, DOI 10.1136/thorax.55.10.848; McGhan R, 2007, CHEST, V132, P1748, DOI 10.1378/chest.06-3018; Morgan MDL, 2001, THORAX, V56, P827; Nici L, 2006, AM J RESP CRIT CARE, V173, P1390, DOI 10.1164/rccm.200508-1211ST; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pepin Veronique, 2007, COPD, V4, P195, DOI 10.1080/15412550701480489; PETTY TL, 1969, ANN INTERN MED, V70, P1109, DOI 10.7326/0003-4819-70-6-1109; Pinto-Plata VM, 2004, EUR RESPIR J, V23, P28, DOI 10.1183/09031936.03.00034603; Pitta F, 2008, CHEST, V134, P273, DOI 10.1378/chest.07-2655; Porszasz J, 2005, CHEST, V128, P2025, DOI 10.1378/chest.128.4.2025; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003; Ries AL, 2003, AM J RESP CRIT CARE, V167, P880, DOI 10.1164/rccm.200204-318OC; Ries AL, 2007, CHEST, V131, p4S, DOI 10.1378/chest.06-2418; Saey D, 2003, AM J RESP CRIT CARE, V168, P425, DOI 10.1164/rccm.200208-856OC; Sewell L, 2005, CHEST, V128, P1194, DOI 10.1378/chest.128.3.1194; Steele BG, 2008, ARCH PHYS MED REHAB, V89, P404, DOI 10.1016/j.apmr.2007.11.003; Troosters T, 2005, AM J RESP CRIT CARE, V172, P19, DOI 10.1164/rccm.200408-1109SO; Troosters T, 2001, J Cardiopulm Rehabil, V21, P10, DOI 10.1097/00008483-200101000-00004; van Eeden SF, 2008, RESPIRATION, V75, P224, DOI 10.1159/000111820; Wagner PD, 2006, RESPIROLOGY, V11, P681, DOI 10.1111/j.1440-1843.2006.00939.x; Wasserman K, 2004, PRINCIPLES EXERCISE, V4th; Weisberg J, 2002, CHEST, V121, P1070, DOI 10.1378/chest.121.4.1070	53	170	181	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	2009	360	13					1329	1335		10.1056/NEJMct0804632	http://dx.doi.org/10.1056/NEJMct0804632			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	423VP	19321869				2023-01-03	WOS:000264524100008
J	Pantilat, SZ				Pantilat, Steven Z.			Communicating With Seriously Ill Patients Better Words to Say	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE; END; SKILLS		Univ Calif San Francisco, Dept Med, Div Hosp Med, Palliat Care Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Pantilat, SZ (corresponding author), Univ Calif San Francisco, Dept Med, Div Hosp Med, Palliat Care Program, Box 0903,521 Parnassus Ave,Ste C-126, San Francisco, CA 94143 USA.	stevep@medicine.ucsf.edu						Apa Pesidential Task Force, 2006, AM PSYCHOL, V61, P271, DOI 10.1037/0003-066X.61.4.271; Block S D, 1998, J Palliat Med, V1, P347, DOI 10.1089/jpm.1998.1.347; Jackson VA, 2008, J PALLIAT MED, V11, P893, DOI 10.1089/jpm.2007.2480; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Lienard A, 2006, ANN ONCOL, V17, P1450, DOI 10.1093/annonc/mdl142; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Meisel A, 2000, JAMA-J AM MED ASSOC, V284, P2495, DOI 10.1001/jama.284.19.2495; QUILL TE, 1995, ANN INTERN MED, V122, P368, DOI 10.7326/0003-4819-122-5-199503010-00008; Quill TE, 2001, ANN INTERN MED, V135, P551, DOI 10.7326/0003-4819-135-7-200110020-00022; Saba GW, 2006, ANN FAM MED, V4, P54, DOI 10.1370/afm.393; Schofield PE, 2003, ANN ONCOL, V14, P48, DOI 10.1093/annonc/mdg010; Selph RB, 2008, J GEN INTERN MED, V23, P1311, DOI 10.1007/s11606-008-0643-8; Stapleton RD, 2006, CRIT CARE MED, V34, P1679, DOI 10.1097/01.CCM.0000218409.58256.AA; Tulsky JA, 2005, JAMA-J AM MED ASSOC, V294, P359, DOI 10.1001/jama.294.3.359	14	33	33	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	2009	301	12					1279	1281		10.1001/jama.2009.396	http://dx.doi.org/10.1001/jama.2009.396			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	423JO	19318656				2023-01-03	WOS:000264492800029
J	Kondo, M; Shibata, R; Miura, R; Shimano, M; Kondo, K; Li, P; Ohashi, T; Kihara, S; Maeda, N; Walsh, K; Ouchi, N; Murohara, T				Kondo, Megumi; Shibata, Rei; Miura, Rie; Shimano, Masayuki; Kondo, Kazuhisa; Li, Ping; Ohashi, Taiki; Kihara, Shinji; Maeda, Norikazu; Walsh, Kenneth; Ouchi, Noriyuki; Murohara, Toyoaki			Caloric Restriction Stimulates Revascularization in Response to Ischemia via Adiponectin-mediated Activation of Endothelial Nitric-oxide Synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONKEYS MACACA-MULATTA; PROTEIN-KINASE; DIETARY RESTRICTION; TISSUE ISCHEMIA; NO SYNTHASE; ANGIOGENESIS; OBESITY; MICE; EXPRESSION; DISEASE	Caloric restriction (CR) can extend longevity and modulate the features of obesity-related metabolic and vascular diseases. However, the functional roles of CR in regulation of revascularization in response to ischemia have not been examined. Here we investigated whether CR modulates vascular response by employing a murine hindlimb ischemia model. Wild-type (WT) mice were randomly divided into two groups that were fed either ad libitum (AL) or CR (65% of the diet consumption of AL). Four weeks later, mice were subjected to unilateral hindlimb ischemic surgery. Body weight of WT mice fed CR (CR-WT) was decreased by 26% compared with WT mice fed AL (AL-WT). Revascularization of ischemic hindlimb relative to the contralateral limb was accelerated in CR-WT compared with AL-WT as evaluated by laser Doppler blood flow and capillary density analyses. CR-WT mice had significantly higher plasma levels of the fat-derived hormone adiponectin compared with AL-WT mice. In contrast to WT mice, CR did not affect the revascularization of ischemic limbs of adiponectindeficient (APN-KO) mice. CR stimulated the phosphorylation of endothelial nitric-oxide synthase (eNOS) in the ischemic limbs of WT mice. CR increased plasma adiponectin levels in eNOS-KO mice but did not stimulate limb perfusion in this strain. CR-WT mice showed enhanced phosphorylation of AMP-activated protein kinase (AMPK) in ischemic muscle, and administration of AMPK inhibitor compound C abolished CR-induced increase in limb perfusion and eNOS phosphorylation in WT mice. Our observations indicate that CR can promote revascularization in response to tissue ischemia via an AMPK-eNOS-dependent mechanism that is mediated by adiponectin.	[Kondo, Megumi; Shibata, Rei; Miura, Rie; Shimano, Masayuki; Kondo, Kazuhisa; Li, Ping; Ohashi, Taiki; Murohara, Toyoaki] Nagoya Univ, Grad Sch Med, Dept Cardiol, Nagoya, Aichi 4668550, Japan; [Walsh, Kenneth; Ouchi, Noriyuki] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kihara, Shinji; Maeda, Norikazu] Osaka Univ, Dept Metab Med, Suita, Osaka 5650871, Japan	Nagoya University; Boston University; Osaka University	Shibata, R (corresponding author), Nagoya Univ, Grad Sch Med, Dept Cardiol, 65 Tsurumai, Nagoya, Aichi 4668550, Japan.	rshibata@med.nagoya-u.ac.jp	Li, Ping/GYV-4914-2022; Murohara, Toyoaki/M-4958-2014; OUCHI, Noriyuki/I-7306-2014		National Institutes of Health [HL86785, HL91949, HL81587]; The Nakashima Foundation; The Aichi D. R. G. Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081587, R01HL086785, R01HL091949] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Nakashima Foundation; The Aichi D. R. G. Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL86785, HL91949, and HL81587 (to K. W.). This work was also supported by a grant-in-aid for young scientists A, The Nakashima Foundation, and The Aichi D. R. G. Foundation (to R. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" U. S. C. Section 1734 solely to indicate this fact.	Abaci A, 1999, CIRCULATION, V99, P2239, DOI 10.1161/01.CIR.99.17.2239; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Cheng KKY, 2007, DIABETES, V56, P1387, DOI 10.2337/db06-1580; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Iwashima Y, 2006, ATHEROSCLEROSIS, V188, P384, DOI 10.1016/j.atherosclerosis.2005.10.039; Kanda T, 2007, INT J CARDIOL, V119, P310, DOI 10.1016/j.ijcard.2006.07.181; Kobayashi H, 2004, CIRC RES, V94, pE27, DOI 10.1161/01.RES.0000119921.86460.37; Lago F, 2007, NAT CLIN PRACT RHEUM, V3, P716, DOI 10.1038/ncprheum0674; Lane MA, 2000, MECH AGEING DEV, V112, P185, DOI 10.1016/S0047-6374(99)00087-1; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P149, DOI 10.1016/S1089-8603(02)00111-8; Li P, 2008, HYPERTENSION, V51, P252, DOI 10.1161/HYPERTENSIONAHA.107.097394; Mahoney LB, 2006, LIPIDS HEALTH DIS, V5, DOI 10.1186/1476-511X-5-13; Matsuda M, 2002, J BIOL CHEM, V277, P37487, DOI 10.1074/jbc.M206083200; McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Nishimura M, 2008, CIRCULATION, V117, P216, DOI 10.1161/CIRCULATIONAHA.107.725044; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Ouchi N, 2005, CIRC RES, V96, P838, DOI 10.1161/01.RES.0000163633.10240.3b; Ouchi N, 2004, J BIOL CHEM, V279, P1304, DOI 10.1074/jbc.M310389200; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/00041433-200312000-00003; Ouchi N, 2007, CLIN CHIM ACTA, V380, P24, DOI 10.1016/j.cca.2007.01.026; Reilly MP, 2003, CIRCULATION, V108, P1546, DOI 10.1161/01.CIR.0000088846.10655.E0; Schiekofer S, 2005, ARTERIOSCL THROM VAS, V25, P1603, DOI 10.1161/01.ATV.0000171994.89106.ca; Seymour EM, 2006, J MOL CELL CARDIOL, V41, P661, DOI 10.1016/j.yjmcc.2006.07.012; Shibata R, 2004, J BIOL CHEM, V279, P28670, DOI 10.1074/jbc.M402558200; Shibata R, 2008, FEBS LETT, V582, P1607, DOI 10.1016/j.febslet.2008.04.006; Shibata R, 2007, CARDIOVASC RES, V74, P471, DOI 10.1016/j.cardiores.2007.02.010; Shinmura K, 2007, CIRCULATION, V116, P2809, DOI 10.1161/CIRCULATIONAHA.107.725697; Stein O, 2003, BIOCHEM BIOPH RES CO, V308, P29, DOI 10.1016/S0006-291X(03)01313-5; Tirziu D, 2005, CIRCULATION, V112, P2501, DOI 10.1161/CIRCULATIONAHA.105.542829; Verdery RB, 1998, ARCH INTERN MED, V158, P900, DOI 10.1001/archinte.158.8.900; Verdery RB, 1997, AM J PHYSIOL-ENDOC M, V273, pE714, DOI 10.1152/ajpendo.1997.273.4.E714; Williams IL, 2002, INT J OBESITY, V26, P754, DOI 10.1038/sj.ijo.0801995; YAROM R, 1992, J PATHOL, V166, P265, DOI 10.1002/path.1711660308; Yilmaz MB, 2003, INT J OBESITY, V27, P1541, DOI 10.1038/sj.ijo.0802474; Yu J, 2005, P NATL ACAD SCI USA, V102, P10999, DOI 10.1073/pnas.0501444102; Zhu M, 2004, EXP GERONTOL, V39, P1049, DOI 10.1016/j.exger.2004.03.024; ZIMMERMAN J, 1984, ARTERIOSCLEROSIS, V4, P115, DOI 10.1161/01.ATV.4.2.115	41	98	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	2009	284	3					1718	1724		10.1074/jbc.M805301200	http://dx.doi.org/10.1074/jbc.M805301200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392VK	18990685	Green Published, hybrid			2023-01-03	WOS:000262330100041
J	Trivedi, AN; Swaminathan, S; Mor, V				Trivedi, Amal N.; Swaminathan, Shailender; Mor, Vincent			Insurance Parity and the Use of Outpatient Mental Health Care Following a Psychiatric Hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGED CARE; FEDERAL-EMPLOYEES; SUBSTANCE-ABUSE; SERVICES; QUALITY; LEGISLATION; COVERAGE; BENEFITS; TRENDS; READMISSION	Context Mental health services are typically subject to higher cost sharing than other health services. In 2008, the US Congress enacted legislation requiring parity in insurance coverage for mental health services in group health plans and Medicare Part B. Objective To determine the relationship between mental health insurance parity and the use of timely follow- up care after a psychiatric hospitalization. Design, Setting, and Population We reviewed cost- sharing requirements for outpatient mental health and general medical services for 302 Medicare health plans from 2001 to 2006. Among 43 892 enrollees in 173 health plans who were hospitalized for a mental illness, we determined the relation between parity in cost sharing and receipt of timely outpatient mental health care after discharge using cross- sectional analyses of all Medicare plans and longitudinal analyses of 10 plans that discontinued parity compared with 10 matched control plans that maintained parity. Main Outcome Measures Outpatient mental health visits within 7 and 30 days following a discharge for a psychiatric hospitalization. Results More than three- quarters of Medicare plans, representing 79% of Medicare enrollees, required greater cost sharing for mental health care compared with primary or specialty care. The adjusted rate of follow- up within 30 days after a psychiatric hospitalization was 10.9 percentage points greater ( 95% confidence interval [CI], 4.6- 17.3; P <. 001) in plans with equivalent cost sharing for mental health and primary care compared with plans with mental health cost sharing greater than primary and specialty care cost sharing. The association of parity with follow- up care was increased for enrollees from areas of low income and less education. Rates of follow- up visits within 30 days decreased by 7.7 percentage points ( 95% CI, - 12.9 to - 2.4; P=. 004) in plans that discontinued parity and increased by 7.5 percentage points ( 95% CI, 2.012.9; P=. 008) among control plans that maintained parity ( adjusted difference in difference, 14.2 percentage points; 95% CI, 4.5- 23.9; P=. 007). Conclusion Medicare enrollees in health plans with insurance parity for mental health and primary care have markedly higher use of clinically appropriate mental health services following a psychiatric hospitalization.	[Trivedi, Amal N.; Swaminathan, Shailender; Mor, Vincent] Brown Univ, Dept Community Hlth, Warren Alpert Med Sch, Providence, RI 02912 USA; [Trivedi, Amal N.] Providence VA Med Ctr, Res Enhancement Award Program, Providence, RI USA	Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Trivedi, AN (corresponding author), Brown Univ, Dept Community Hlth, Warren Alpert Med Sch, Box G-S121, Providence, RI 02912 USA.	amal_trivedi@brown.edu			Health Policy Scholars Award; Agency for Healthcare Research and Quality [T32 HS000011]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000011] Funding Source: NIH RePORTER	Health Policy Scholars Award; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	This study was supported by a Health Policy Scholars Award to Dr Trivedi from the Pfizer Foundation. Dr Swaminathan was supported by a postdoctoral training grant (T32 HS000011) from the Agency for Healthcare Research and Quality, of which Dr Mor is principal investigator.	*AG HEALTHC RES QU, 2004, 2004 NAT HEALTHC QUA; [Anonymous], 2001, INTERSTUDY COMPETITI; Bao YH, 2004, HEALTH SERV RES, V39, P1361, DOI 10.1111/j.1475-6773.2004.00294.x; Barry CL, 2003, HEALTH AFFAIR, V22, P127, DOI 10.1377/hlthaff.22.5.127; Buchmueller TC, 2007, HEALTH AFFAIR, V26, pW483, DOI 10.1377/hlthaff.26.4.w483; Busch AB, 2006, MED CARE, V44, P506, DOI 10.1097/01.mlr.0000215890.30756.b2; DORWART RA, 1994, AM J PUBLIC HEALTH, V84, P1229, DOI 10.2105/AJPH.84.8.1229; Druss BG, 2002, AM J PSYCHIAT, V159, P860, DOI 10.1176/appi.ajp.159.5.860; FRANK R, 1999, 7052 NAT BUR EC RES; Frank RG, 2001, NEW ENGL J MED, V345, P1701, DOI 10.1056/NEJM200112063452311; Glied SA, 2006, BETTER BUT NOT WELL; Glied SA, 2008, NEW ENGL J MED, V359, P113, DOI 10.1056/NEJMp0804447; Goldman HH, 2006, NEW ENGL J MED, V354, P1378, DOI 10.1056/NEJMsa053737; Harman JS, 2003, J BEHAV HEALTH SER R, V30, P332, DOI 10.1007/BF02287321; Harris KM, 2006, MED CARE, V44, P499, DOI 10.1097/01.mlr.0000215813.16211.00; *HLTH CAR FIN ADM, 301998 HEDIS HLTH CA; Hodgkin D, 2003, MED CARE RES REV, V60, P101, DOI 10.1177/1077558702250248; KEELER E B, 1985, Journal of the American Medical Association, V254, P1926, DOI 10.1001/jama.254.14.1926; KEELER EB, 1988, J HEALTH ECON, V7, P369, DOI 10.1016/0167-6296(88)90021-5; Kerry SM, 1998, BRIT MED J, V316, P549, DOI 10.1136/bmj.316.7130.549; Kessler RC, 2005, NEW ENGL J MED, V352, P2515, DOI 10.1056/NEJMsa043266; Klinkenberg WD, 1996, PSYCHIATR SERV, V47, P487; LURIE N, 1989, AM J PUBLIC HEALTH, V79, P640, DOI 10.2105/AJPH.79.5.640; MANNING WG, 1986, J HUM RESOUR, V21, P293, DOI 10.2307/145965; MECHANIC D, 1993, MILBANK Q, V71, P349, DOI 10.2307/3350406; Mechanic D, 2003, PSYCHIAT SERV, V54, P1227, DOI 10.1176/appi.ps.54.9.1227; MECHANIC D, 1995, MILBANK Q, V73, P19, DOI 10.2307/3350312; Nelson EA, 2000, PSYCHIAT SERV, V51, P885, DOI 10.1176/appi.ps.51.7.885; Pacula RL, 2000, HEALTH SERV RES, V35, P263; Patel KK, 2006, HEALTH AFFAIR, V25, P681, DOI 10.1377/hlthaff.25.3.681; Pincus HA, 1998, JAMA-J AM MED ASSOC, V279, P526, DOI 10.1001/jama.279.7.526; Regier DA, 2008, HEALTH AFFAIR, V27, pW70, DOI 10.1377/hlthaff.27.1.w70; ROSENFIELD S, 1986, J APPL BEHAV SCI, V22, P411, DOI 10.1177/002188638602200405; Sakauye K, 2005, PSYCHIAT SERV, V56, P795; SCHOENBAUM SC, 1995, PSYCHIATR SERV, V46, P943; SOLOMON P, 1986, HOSP COMMUNITY PSYCH, V37, P708; Sturm R, 1997, JAMA-J AM MED ASSOC, V278, P1533, DOI 10.1001/jama.278.18.1533; Sturm R, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.5.182; Sturm Roland, 2000, J Ment Health Policy Econ, V3, P209; Trivedi AN, 2008, NEW ENGL J MED, V358, P375, DOI 10.1056/NEJMsa070929; Trivedi AN, 2005, NEW ENGL J MED, V353, P692, DOI 10.1056/NEJMsa051207; WINSTON A, 1977, HOSP COMMUNITY PSYCH, V28, P118; Zuvekas Samuel H., 1998, J Ment Health Policy Econ, V1, P135, DOI 10.1002/(SICI)1099-176X(1998100)1:3<135::AID-MHP17>3.0.CO;2-S	43	31	31	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	2008	300	24					2879	2885						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	386ZG	19109116	Green Accepted, Bronze			2023-01-03	WOS:000261920900021
J	Ernst, E				Ernst, E.			Frankincense: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BOSWELLIA-SERRATA EXTRACT; DOUBLE-BLIND; OSTEOARTHRITIS; TRIAL; THERAPY; KNEE; EFFICACY; COLITIS; ACIDS; RESIN	Objective To assess evidence from randomised clinical trials about the effectiveness of extracts of Boswellia serrata ( frankincense). Design Systematic review. Data sources Electronic searches on Medline, Embase, Cinahl, Amed, and Cochrane Library. Hand searches of conference proceedings, bibliographies, and departmental files. Review methods All randomised clinical trials of B serrata extract as a treatment for any human medical condition were included and studies of B serrata preparations combined with other ingredients were excluded. Titles and abstracts of all retrieved articles were read and hard copies of all relevant articles were obtained. Selection of studies, data extraction and validation were done by the author. The Jadad score was used to evaluate the methodological quality of all included trials. Results Of 47 potentially relevant studies, seven met all inclusion criteria ( five placebo controlled, two with active controls). The included trials related to asthma, rheumatoid arthritis, Crohn's disease, osteoarthritis, and collagenous colitis. Results of all trials indicated that B serrata extracts were clinically effective. Three studies were of good methodological quality. No serious safety issues were noted. Conclusions The evidence for the effectiveness of B serrata extracts is encouraging but not compelling.	[Ernst, E.] Univ Exeter, Peninsula Med Sch, Exeter EX2 4NT, Devon, England; [Ernst, E.] Univ Plymouth, Exeter EX2 4NT, Devon, England	University of Exeter; University of Plymouth	Ernst, E (corresponding author), Univ Exeter, Peninsula Med Sch, Exeter EX2 4NT, Devon, England.	edzard.ernst@pms.ac.uk						AMMON HP, 2008, PLANTA MED, V72, P1100; BADRIA FA, 2002, ALT COMPL THER   DEC, P341; Chopra A, 2004, JCR-J CLIN RHEUMATOL, V10, P236, DOI 10.1097/01.rhu.0000138087.47382.6d; EMST E, 2007, COMPLEMENTARY THERAP; Ernst E, 2004, POSTGRAD MED J, V80, P249, DOI 10.1136/pgmj.2004.021527; Ernst E, 1997, NATURE, V385, P480, DOI 10.1038/385480c0; Gerhardt H, 2001, Z GASTROENTEROL, V39, P11, DOI 10.1055/s-2001-10708; Gupta I, 1998, Eur J Med Res, V3, P511; Gupta I, 2001, PLANTA MED, V67, P391, DOI 10.1055/s-2001-15802; Gupta I, 1997, Eur J Med Res, V2, P37; HUGHES K, 2007, INCENSE BIBLE; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kimmatkar N, 2003, PHYTOMEDICINE, V10, P3, DOI 10.1078/094471103321648593; Knaus U, 1996, PHYTOMEDICINE, V3, P77, DOI 10.1016/S0944-7113(96)80016-X; KULKARNI RR, 1991, J ETHNOPHARMACOL, V33, P91, DOI 10.1016/0378-8741(91)90167-C; Madisch A, 2007, INT J COLORECTAL DIS, V22, P1445, DOI 10.1007/s00384-007-0364-1; PARDHY RS, 1978, INDIAN J CHEM B, V16, P176; Sander O, 1998, Z RHEUMATOL, V57, P11, DOI 10.1007/s003930050051; Sengupta K, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2461; Sontakke S, 2007, INDIAN J PHARMACOL, V39, P27	20	45	51	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2008	337								a2813	10.1136/bmj.a2813	http://dx.doi.org/10.1136/bmj.a2813			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	390SW	19091760	Green Published, hybrid			2023-01-03	WOS:000262185000006
J	Steinbrook, R				Steinbrook, Robert			Physician-Assisted Death - From Oregon to Washington State.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						GANZINI L, 2008, BMJ-BRIT MED J, V337, P973; Ganzini L, 2008, J GEN INTERN MED, V23, P154, DOI 10.1007/s11606-007-0476-x; Quill TE, 2007, NEW ENGL J MED, V356, P1911, DOI 10.1056/NEJMp078061; *TASK FORC IMPR CA, OR DEATH DIGN ACT GU	4	21	23	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 11	2008	359	24					2513	2515		10.1056/NEJMp0809394	http://dx.doi.org/10.1056/NEJMp0809394			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	381KG	19073972				2023-01-03	WOS:000261534200001
J	Vincent, C; Aylin, P; Franklin, BD; Holmes, A; Iskander, S; Jacklin, A; Moorthy, K				Vincent, Charles; Aylin, Paul; Franklin, Bryony Dean; Holmes, Alison; Iskander, Sandra; Jacklin, Ann; Moorthy, Krishna			Is health care getting safer?	BRITISH MEDICAL JOURNAL			English	Editorial Material							ADVERSE EVENTS; PATIENT SAFETY; ERRORS		[Vincent, Charles; Iskander, Sandra] St Marys Hosp, Imperial Ctr Patient Safety & Serv Qual, Dept Biosurg & Technol, London W2 1NY, England; [Aylin, Paul] Univ London Imperial Coll Sci Technol & Med, Div Epidemiol & Publ Hlth, London, England; [Aylin, Paul] Univ London Imperial Coll Sci Technol & Med, Dr Foster Unit, London, England; [Franklin, Bryony Dean; Holmes, Alison; Jacklin, Ann; Moorthy, Krishna] Imperial Coll Healthcare NHS Trust, Ctr Med Safety & Serv Qual, London, England; [Franklin, Bryony Dean; Jacklin, Ann] Univ London, Sch Pharm, London WC1N 1AX, England; [Moorthy, Krishna] Univ London Imperial Coll Sci Technol & Med, Clin Safety Res Unit, London, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of London; University College London; University of London School of Pharmacy; Imperial College London	Vincent, C (corresponding author), St Marys Hosp, Imperial Ctr Patient Safety & Serv Qual, Dept Biosurg & Technol, Praed St, London W2 1NY, England.	c.vincent@imperial.ac.uk	Aylin, Paul/A-1073-2014; Vincent, Charles A/D-1134-2010	Vincent, Charles A/0000-0003-0270-0222; Aylin, Paul/0000-0003-4589-1743; Moorthy, Krishna/0000-0001-8960-465X; Franklin, Bryony/0000-0002-2892-1245				Agency for Healthcare Research and Quality, 2008, QUAL IND; [Anonymous], 2003, 2003 REP NAT CONF EN; Audit Commission, 2004, INF DAT QUAL NHS KEY; Barber N, 2006, SAFER FASTER BETTER; Blendon RJ, 2002, NEW ENGL J MED, V347, P1933, DOI 10.1056/NEJMsa022151; Bottle A., 2008, HLTH CARE RISK R MAY, P12; BOTTLE A, QUAL SAFETY IN PRESS; Bridgewater B, 2007, HEART, V93, P744, DOI 10.1136/hrt.2006.106393; Department of Health National Audit Office, 2005, SAF PLAC PAT LEARN I; Franklin BD, 2005, DRUG SAFETY, V28, P891, DOI 10.2165/00002018-200528100-00005; Hansell A, 2001, J PUBLIC HEALTH MED, V23, P51, DOI 10.1093/pubmed/23.1.51; Health Protection Agency, 2006, MAND SURV HEALTHC AS; Healthcare Commission, 2007, HEALTHC ASS INF WHAT; *HLTH PROT AG, 2008, Q REP RES CLOS DIFF; Holmes AH, 2007, J HOSP INFECT, V65, P191, DOI 10.1016/S0195-6701(07)60042-5; Jarman B, 1999, BMJ-BRIT MED J, V318, P1515, DOI 10.1136/bmj.318.7197.1515; Neale G, 2001, J ROY SOC MED, V94, P322, DOI 10.1177/014107680109400702; O'Neill, 2008, SAFE BIRTHS EVERYBOD; *OFF NAT STAT, 2008, HLTH STAT Q, V37, P7; Sari ABA, 2007, BMJ-BRIT MED J, V334, P79, DOI 10.1136/bmj.39031.507153.AE; *SCOTT AUD SURG MO, 2008, PERC CAS ADV EV MAN; Vincent C, 2001, BRIT MED J, V322, P517, DOI 10.1136/bmj.322.7285.517; Vincent C., 2006, PATIENT SAFETY	23	116	116	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 13	2008	337								a2426	10.1136/bmj.a2426	http://dx.doi.org/10.1136/bmj.a2426			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	385AE	19008272	Green Submitted			2023-01-03	WOS:000261784500010
J	Bobrow, BJ; Clark, LL; Ewy, GA; Chikani, V; Sanders, AB; Berg, RA; Richman, PB; Kern, KB				Bobrow, Bentley J.; Clark, Lani L.; Ewy, Gordon A.; Chikani, Vatsal; Sanders, Arthur B.; Berg, Robert A.; Richman, Peter B.; Kern, Karl B.			Minimally interrupted cardiac resuscitation by emergency medical services for out-of-hospital cardiac arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE PROFESSIONALS; CARDIOPULMONARY-RESUSCITATION; CARDIOCEREBRAL RESUSCITATION; VENTRICULAR-FIBRILLATION; CHEST COMPRESSIONS; VENTILATION; DEFIBRILLATION; STATEMENT; SURVIVAL; HEART	Context Out- of- hospital cardiac arrest is a major public health problem. Objective To investigate whether the survival of patients with out- of- hospital cardiac arrest would improve with minimally interrupted cardiac resuscitation ( MICR), an alternate emergency medical services ( EMS) protocol. Design, Setting, and Patients A prospective study of survival- to- hospital discharge between January 1, 2005, and November 22, 2007. Patients with out- ofhospital cardiac arrests in 2 metropolitan cities in Arizona before and after MICR training of fire department emergency medical personnel were assessed. In a second analysis of protocol compliance, patients from the 2 metropolitan cities and 60 additional fire departments in Arizona who actually received MICR were compared with patients who did not receive MICR but received standard advanced life support. Intervention Instruction for EMS personnel in MICR, an approach that includes an initial series of 200 uninterrupted chest compressions, rhythm analysis with a single shock, 200 immediate postshock chest compressions before pulse check or rhythm reanalysis, early administration of epinephrine, and delayed endotracheal intubation. Main Outcome Measure Survival- to- hospital discharge. Results Among the 886 patients in the 2 metropolitan cities, survival- to- hospital discharge increased from 1.8% ( 4/ 218) before MICR training to 5.4% ( 36/ 668) after MICR training ( odds ratio [ OR], 3.0; 95% confidence interval [ CI], 1.1- 8.9). In the subgroup of 174 patients with witnessed cardiac arrest and ventricular fibrillation, survival increased from 4.7% ( 2/ 43) before MICR training to 17.6% ( 23/ 131) after MICR training ( OR, 8.6; 95% CI, 1.8- 42.0). In the analysis of MICR protocol compliance involving 2460 patients with cardiac arrest, survival was significantly better among patients who received MICR than those who did not ( 9.1% [ 60/ 661] vs 3.8% [ 69/ 1799]; OR, 2.7; 95% CI, 1.9- 4.1), as well as patients with witnessed ventricular fibrillation ( 28.4% [ 40/ 141] vs 11.9% [ 46/ 387]; OR, 3.4; 95% CI, 2.0- 5.8). Conclusions Survival- to- hospital discharge of patients with out- of- hospital cardiac arrest increased after implementation of MICR as an alternate EMS protocol. These results need to be confirmed in a randomized trial.	[Bobrow, Bentley J.; Richman, Peter B.] Mayo Clin, Dept Emergency Med, Scottsdale, AZ 85259 USA; [Bobrow, Bentley J.; Clark, Lani L.; Chikani, Vatsal] Arizona Dept Hlth Serv, Bur Emergency Med Serv & Trauma Syst, Phoenix, AZ 85007 USA; [Bobrow, Bentley J.; Clark, Lani L.; Ewy, Gordon A.; Sanders, Arthur B.; Berg, Robert A.; Kern, Karl B.] Univ Arizona, Coll Med, Sarver Heart Ctr, Tucson, AZ USA; [Ewy, Gordon A.; Kern, Karl B.] Univ Arizona, Coll Med, Dept Med, Tucson, AZ USA; [Sanders, Arthur B.] Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ USA; [Berg, Robert A.] Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ USA	Mayo Clinic; Mayo Clinic Phoenix; Arizona Department of Health Services; University of Arizona; University of Arizona; University of Arizona; University of Arizona	Bobrow, BJ (corresponding author), Mayo Clin, Dept Emergency Med, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	bobrow.bentley@mayo.edu		Chikani, Vatsal/0000-0003-0904-7887				American Heart Association, 2000, CIRCULATION, V102, P122; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Becker LB, 1997, CIRCULATION, V96, P2102, DOI 10.1161/01.CIR.96.6.2102; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; Berg RA, 1997, CIRCULATION, V95, P1635; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Bobrow B, 2006, CIRCULATION, V114, P354; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; Eckstein M, 2005, ANN EMERG MED, V45, P504, DOI 10.1016/j.annemergmed.2004.11.024; Ewy GA, 2006, AM J MED, V119, P6, DOI 10.1016/j.amjmed.2005.06.067; Ewy GA, 2005, CIRCULATION, V111, P2134, DOI 10.1161/01.CIR.0000162503.57657.FA; Ewy GA, 2003, RESUSCITATION, V58, P271, DOI 10.1016/S0300-9572(03)00268-5; Ewy Gordon A, 2007, Cleve Clin J Med, V74 Suppl 1, pS105; Ewy GA, 2007, LANCET, V369, P882, DOI 10.1016/S0140-6736(07)60422-X; Ewy GA, 2006, CURR OPIN CRIT CARE, V12, P189, DOI 10.1097/01.ccx.0000224859.25217.5b; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kellum MJ, 2006, AM J MED, V119, P335, DOI 10.1016/j.amjmed.2005.11.014; Kern KB, 2005, RESUSCITATION, V64, P261, DOI 10.1016/j.resuscitation.2004.08.009; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V27, P678; MILANDER MM, 1995, ACAD EMERG MED, V2, P708, DOI 10.1111/j.1553-2712.1995.tb03622.x; Nichol G, 1996, ANN EMERG MED, V27, P700, DOI 10.1016/S0196-0644(96)70187-7; Ornato JP, 2006, CIRCULATION, V114, P2754, DOI 10.1161/CIRCULATIONAHA.106.668095; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; Rea TD, 2006, CIRCULATION, V114, P2760, DOI 10.1161/CIRCULATIONAHA.106.654715; *SAS KANTO STUD GR, 2007, LANCET, V369, P920; *US BUR CENS, AM FACT FIND POP FAC; Vaillancourt C, 2004, CAN J CARDIOL, V20, P1081; Valenzuela TD, 2005, CIRCULATION, V112, P1259, DOI 10.1161/CIRCULATIONAHA.105.537282; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Zheng ZJ, 2001, CIRCULATION, V104, P2158, DOI 10.1161/hc4301.098254	35	383	402	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 12	2008	299	10					1158	1165		10.1001/jama.299.10.1158	http://dx.doi.org/10.1001/jama.299.10.1158			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272CE	18334691	Bronze			2023-01-03	WOS:000253835000019
J	Bartelink, H; Arriagada, R				Bartelink, Harry; Arriagada, Rodrigo			Hypofractionation in radiotherapy for breast cancer	LANCET			English	Editorial Material							RECURRENCE; MASTECTOMY; SURVIVAL; FRACTION; TRIAL; BOOST		[Bartelink, Harry] Netherlands Canc Inst, NL-1066 CX Amsterdam, Netherlands; [Arriagada, Rodrigo] Inst Gustave Roussy, Villejuif, France; [Arriagada, Rodrigo] Karolinska Inst, Stockholm, Sweden	Netherlands Cancer Institute; UNICANCER; Gustave Roussy; Karolinska Institutet	Bartelink, H (corresponding author), Netherlands Canc Inst, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.bartelink@nki.nl		Arriagada, Rodrigo/0000-0002-3134-1735				Abe O, 2005, LANCET, V366, P2087; ARRIAGADA R, 1995, J CLIN ONCOL, V13, P2869, DOI 10.1200/JCO.1995.13.12.2869; AUQUIER A, 1992, EUR J CANCER, V28A, P433, DOI 10.1016/S0959-8049(05)80070-X; Bartelink H, 2001, NEW ENGL J MED, V345, P1378, DOI 10.1056/NEJMoa010874; Bartelink H, 2007, J CLIN ONCOL, V25, P3259, DOI 10.1200/JCO.2007.11.4991; Bentzen SM, 2008, LANCET, V371, P1098, DOI 10.1016/S0140-6736(08)60348-7; Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]; Bourhis J, 2006, LANCET, V368, P843, DOI 10.1016/S0140-6736(06)69121-6; Curran D, 1998, EUR J CANCER, V34, P307, DOI 10.1016/S0959-8049(97)00312-2; Hooning MJ, 2007, JNCI-J NATL CANCER I, V99, P365, DOI 10.1093/jnci/djk064; Jung H, 2001, RADIOTHER ONCOL, V61, P233, DOI 10.1016/S0167-8140(01)00457-1; Owen JR, 2006, LANCET ONCOL, V7, P467, DOI 10.1016/S1470-2045(06)70699-4; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Regaud C, 1927, CR SOC BIOL, V97, P431; Romestaing P, 1997, J CLIN ONCOL, V15, P963, DOI 10.1200/JCO.1997.15.3.963; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Yarnold J, 2005, RADIOTHER ONCOL, V75, P9, DOI 10.1016/j.radonc.2005.01.005	17	17	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1050	1052		10.1016/S0140-6736(08)60349-9	http://dx.doi.org/10.1016/S0140-6736(08)60349-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18355914				2023-01-03	WOS:000254442700006
J	Stebe, KJ; Lewandowski, E; Ghosh, M				Stebe, Kathleen J.; Lewandowski, Eric; Ghosh, Moniraj			Oriented Assembly of Metamaterials	SCIENCE			English	Editorial Material							INDEX		[Stebe, Kathleen J.; Lewandowski, Eric] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Ghosh, Moniraj] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA	University of Pennsylvania; Johns Hopkins University	Stebe, KJ (corresponding author), Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.	kstebe@seas.upenn.edu						Aizenberg J, 2000, PHYS REV LETT, V84, P2997, DOI 10.1103/PhysRevLett.84.2997; DENKOV ND, 1992, LANGMUIR, V8, P3183, DOI 10.1021/la00048a054; Engheta N., 2006, METAMATERIALS PHYS E, DOI 10.1002/0471784192.; Engheta N, 2007, SCIENCE, V317, P1698, DOI 10.1126/science.1133268; Glotzer SC, 2007, NAT MATER, V6, P557, DOI 10.1038/nmat1949; Harris DJ, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.148301; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; John BS, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2819091; Lee JH, 2009, OPT LETT, V34, P443, DOI 10.1364/OL.34.000443; Loudet JC, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.018301; Ming T, 2008, ANGEW CHEM INT EDIT, V47, P9685, DOI 10.1002/anie.200803642; Rycenga M, 2008, ADV MATER, V20, P2416, DOI 10.1002/adma.200800360; Shalaev VM, 2005, OPT LETT, V30, P3356, DOI 10.1364/OL.30.003356; Valentine J, 2008, NATURE, V455, P376, DOI 10.1038/nature07247; Yin YD, 2001, J AM CHEM SOC, V123, P8718, DOI 10.1021/ja011048v; Zhao K, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.268301	16	161	162	3	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 10	2009	325	5937					159	160		10.1126/science.1174401	http://dx.doi.org/10.1126/science.1174401			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	468FK	19589992				2023-01-03	WOS:000267802000034
J	Zhang, Y; Donohue, JM; Lave, JR; O'Donnell, G; Newhouse, JP				Zhang, Yuting; Donohue, Julie M.; Lave, Judith R.; O'Donnell, Gerald; Newhouse, Joseph P.			The Effect of Medicare Part D on Drug and Medical Spending.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BENEFICIARIES; ADJUSTMENT; COVERAGE; EVENTS; COSTS	Background: It is not known what effect the increased use of prescription drugs by enrollees in Medicare Part D has had on spending for other medical care. Methods: We compared spending for prescription drugs and other medical care 2 years before the implementation of Part D in January 2006 with such expenditures 2 years after the program's implementation in four groups of elderly beneficiaries: Medicare Advantage enrollees with stable, uncapped, employer-based drug coverage throughout the study period (no-cap group), those who had no previous drug coverage, and those who had previous limited benefits (with either a $150 or a $350 quarterly cap) before they were covered by Part D in 2006. Results: Between December 2005 and December 2007, as compared with the increase in the no-cap group, the increase in total monthly drug spending was $41 higher (95% confidence interval [CI], $33 to $50) (74%) among enrollees with no previous drug coverage, $27 higher (95% CI, $20 to $34) (27%) among those with a previous $150 quarterly cap, and $13 higher (95% CI, $8 to $18) (11%) among those with a previous $350 cap. The use of both lipid-lowering and antidiabetic medications rose in the groups with no or minimal previous drug coverage. As compared with expenditures in the no-cap group, monthly medical expenditures (excluding drugs) were $33 lower (95% CI, $29 to $37) in the group with no previous coverage and $46 lower (95% CI, $29 to $63) in the group with a previous $150 quarterly cap, whereas medical spending was $30 higher (95% CI, $25 to $36) in the group with a previous $350 cap. Conclusions: Enrollment in Medicare Part D was associated with increased spending on prescription drugs. Groups that had no or minimal drug coverage before the implementation of Part D had reductions in other medical spending that approximately offset the increased spending on drugs, but medical spending increased in the group that had more generous previous coverage. N Engl J Med 2009;361:52-61.	[Zhang, Yuting; Donohue, Julie M.; Lave, Judith R.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA; [O'Donnell, Gerald] Highmark, Pittsburgh, PA USA; [Newhouse, Joseph P.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Newhouse, Joseph P.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Newhouse, Joseph P.] Harvard Univ, Harvard Kennedy Sch, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Donohue, JM (corresponding author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 De Soto St,Crabtree Hall 613, Pittsburgh, PA 15261 USA.	jdonohue@pitt.edu	Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022	Zhang, Yuting/0000-0002-6460-6779; Donohue, Julie/0000-0003-2418-6017	National Center for Research Resources; NIH [KL2-RR024154-03]; Alfred P. Sloan Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024154] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by grants from the National Center for Research Resources, a component of the National Institutes of Health (NIH); the NIH Roadmap for Medical Research (KL2-RR024154-03, to Dr. Donohue); and the Alfred P. Sloan Foundation (to Dr. Newhouse).	*BUR LAB STAT, 2008, PROD PRIC IND IND DA; *C BUDG OFF, 2002, ISS DES PRESCR DRUG; *C BUDG OFF, 2008, MARCH 2008 BAS MED; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; Cook T.D., 1979, QUASIEXPERIMENTATION; Curtis LH, 2004, ARCH INTERN MED, V164, P1621, DOI 10.1001/archinte.164.15.1621; Field TS, 2005, MED CARE, V43, P1171, DOI 10.1097/01.mlr.0000185690.10336.70; Fortess EE, 2001, J AM GERIATR SOC, V49, P793, DOI 10.1046/j.1532-5415.2001.49158.x; Gaynor M, 2007, FORUM HLTH EC POLICY, V10, P1; Gold M, 2001, HEALTH AFFAIR, V20, P120, DOI 10.1377/hlthaff.20.4.120; Heisler M, 2004, MED CARE, V42, P626, DOI 10.1097/01.mlr.0000129352.36733.cc; *HJ KAIS FAM FDN, 2005, MED CHARTB; *HJ KAIS FAM FDN, 2007, FACT SHEET MED PRESC; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; LI F, 2007, P AM STAT ASS JOINT; Madden JM, 2008, JAMA-J AM MED ASSOC, V299, P1922, DOI 10.1001/jama.299.16.1922; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Rosen AB, 2005, ANN INTERN MED, V143, P89, DOI 10.7326/0003-4819-143-2-200507190-00007; Sato T, 2003, EPIDEMIOLOGY, V14, P680, DOI 10.1097/01.EDE.0000081989.82616.7d; Shetty Sharashchandra, 2005, J Manag Care Pharm, V11, P559; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Stuart B, 2004, CLIN THER, V26, P1688, DOI 10.1016/j.clinthera.2004.10.012; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	27	109	109	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 2	2009	361	1					52	61		10.1056/NEJMsa0807998	http://dx.doi.org/10.1056/NEJMsa0807998			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	464UK	19571283	Bronze, Green Accepted			2023-01-03	WOS:000267533100009
J	Degos, L; Amalberti, R; Bacou, J; Carlet, J; Bruneau, C				Degos, Laurent; Amalberti, Rene; Bacou, Jean; Carlet, Jean; Bruneau, Charles			Breaking the mould in patient safety	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							ADVERSE EVENTS; PRIMARY-CARE; HEALTH; PROPHYLAXIS; ANESTHESIA; MORTALITY; SYSTEMS		[Degos, Laurent; Amalberti, Rene; Bacou, Jean; Carlet, Jean; Bruneau, Charles] HAS, F-93218 La Plaine St Denis, France		Amalberti, R (corresponding author), HAS, 2 Ave Stade France, F-93218 La Plaine St Denis, France.	r.amalberti@has-sante.fr						Auroy Y, 2009, ANESTHESIOLOGY, V110, P209, DOI 10.1097/ALN.0b013e318194caea; Baker GR, 2004, CAN MED ASSOC J, V170, P1678, DOI 10.1503/cmaj.1040498; Bellam S, 2008, ARCH INTERN MED, V168, P2404, DOI 10.1001/archinte.168.22.2404; Berry LL, 2003, ANN INTERN MED, V139, P568, DOI 10.7326/0003-4819-139-7-200310070-00009; Botney R, 2008, INT J RADIAT ONCOL, V71, pS182, DOI 10.1016/j.ijrobp.2007.05.095; Bramhall SR, 2001, WORLD J GASTROENTERO, V7, P602; Bratzler DW, 2005, ARCH SURG-CHICAGO, V140, P174, DOI 10.1001/archsurg.140.2.174; Cameron JI, 2008, STROKE, V39, P2637, DOI 10.1161/STROKEAHA.107.501064; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7; Donnan Geoffrey A, 2003, Adv Neurol, V92, P347; Dorner D., 1996, LOGIC FAILURE WHY TH; FABRY J, 2002, HELICS FINAL REPORT; Forster AJ, 2003, ANN INTERN MED, V138, P161, DOI 10.7326/0003-4819-138-3-200302040-00007; Gandhi TK, 2006, ANN INTERN MED, V145, P488, DOI 10.7326/0003-4819-145-7-200610030-00006; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gusmano MK, 2006, HEALTH AFFAIR, V25, P510, DOI 10.1377/hlthaff.25.2.510; Leape LL, 2005, JAMA-J AM MED ASSOC, V293, P2384, DOI 10.1001/jama.293.19.2384; Lester H, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2095; Lienhart A, 2006, ANESTHESIOLOGY, V105, P1087, DOI 10.1097/00000542-200612000-00008; Longo DR, 2005, JAMA-J AM MED ASSOC, V294, P2858, DOI 10.1001/jama.294.22.2858; Michel P, 2007, QUAL SAF HEALTH CARE, V16, P369, DOI 10.1136/qshc.2005.016964; Nolte E, 2008, HEALTH AFFAIR, V27, P58, DOI 10.1377/hlthaff.27.1.58; Olsson Lars-Eric, 2006, J Orthop Surg Res, V1, P3, DOI 10.1186/1749-799X-1-3; *ORG EC COOP DEV, 2006, HLTH CAR QUAL IND PR; OVRETVEIT J, 2005, WHICH INTERVENTIONS; Royal S, 2006, QUAL SAF HEALTH CARE, V15, P23, DOI 10.1136/qshc.2004.012153; Schiele F, 2005, EUR HEART J, V26, P873, DOI 10.1093/eurheartj/ehi107; Seiden SC, 2006, ARCH SURG-CHICAGO, V141, P931, DOI 10.1001/archsurg.141.9.931; Seliger SL, 2008, J AM SOC NEPHROL, V19, P2414, DOI 10.1681/ASN.2008010022; Smith PC, 2005, JAMA-J AM MED ASSOC, V293, P565, DOI 10.1001/jama.293.5.565; STUART B, 2008, DIS BURDEN INFLUENCE; VINCENT C, 2001, CLIN RISK MANAGEMENT; Vincent C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2426; Winterstein AG, 2002, ANN PHARMACOTHER, V36, P1238, DOI 10.1345/aph.1A225	35	6	6	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2009	339								b2585	10.1136/bmj.b2585	http://dx.doi.org/10.1136/bmj.b2585			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	466QV	19564180				2023-01-03	WOS:000267678300005
J	Mintzes, B; Morgan, S; Wright, JM				Mintzes, Barbara; Morgan, Steve; Wright, James M.			Twelve Years' Experience with Direct-to-Consumer Advertising of Prescription Drugs in Canada: A Cautionary Tale	PLOS ONE			English	Article							ADVERTISEMENTS; TELEVISION	Background: Direct-to-consumer advertising (DTCA) of prescription drugs is illegal in Canada as a health protection measure, but is permitted in the United States. However, in 2000, Canadian policy was changed to allow 'reminder' advertising of prescription drugs. This is a form of advertising that states the brand name without health claims. 'Reminder' advertising is prohibited in the US for drugs that have 'black box' warnings of serious risks. This study examines spending on DTCA in Canada from 1995 to 2006, 12 years spanning this policy shift. We ask how annual per capita spending compares to that in the US, and whether drugs with Canadian or US regulatory safety warnings are advertised to the Canadian public in reminder advertising. Methodology/Principal Findings: Prescription drug advertising spending data were extracted from a data set on health sector spending in Canada obtained from a market research company, TNS Media Inc. Spending was adjusted for inflation and compared with US spending. Inflation-adjusted spending on branded DTCA in Canada grew from under CAD$2 million per year before 1999 to over $22 million in 2006. The major growth was in broadcast advertising, accounting for 83% of spending in 2006. US annual per capita spending was on average 24 times Canadian levels. Celebrex (celecoxib), which has a US black box and was subject to three safety advisories in Canada, was the most heavily advertised drug on Canadian television in 2005 and 2006. Of 8 brands with >$500,000 spending, which together accounted for 59% of branded DTCA in all media, 6 were subject to Canadian safety advisories, and 4 had US black box warnings. Conclusions/Significance: Branded 'reminder' advertising has grown rapidly in Canada since 2000, mainly due to a growth in television advertising. Although DTCA spending per capita is much lower in Canada than in the US, there is no evidence of safer content or product choice; many heavily-advertised drugs in Canada have been subject to safety advisories. For governments searching for compromise solutions to industry pressure for expanded advertising, Canada's experience stands as a stark warning.			Mintzes, B (corresponding author), Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada.		Morgan, Steven/J-8814-2015; Mintzes, Barbara/AFK-6613-2022	Mintzes, Barbara/0000-0002-8671-915X; Morgan, Steven/0000-0002-7529-0028				Bell RA, 2000, J FAM PRACTICE, V49, P1092; Brownfield ED, 2004, J HEALTH COMMUN, V9, P491, DOI 10.1080/10810730490523115; Cotter J, 2005, CAN MED ASSOC J, V172, P1299, DOI 10.1503/cmaj.050456; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; FDA Alert, 2007, INF HEALTHC PROF ER; Frosch DL, 2007, ANN FAM MED, V5, P6, DOI 10.1370/afm.611; Frosst Merck, 1996, DIRECT TO CONSUMER A; Gardner DM, 2003, CAN MED ASSOC J, V169, P425; Graham DJ, 2005, LANCET, V365, P475, DOI 10.1016/S0140-6736(05)17864-7; Health Canada, 2005, HLTH CAN HAS ASK PFI; *HLTH CAN, 2004, UPD SAF INF INCR CAR; *HLTH CAN, 2003, PUBL ADV DIAN 35 RIS; IMS Health, 2008, TOT US PROM SPEND TY; Institute of Medicine of the National Academies, 2006, FUT DRUG SAF PROM PR; Kallen A, 2007, HEALTH AFFAIR, V26, P1392, DOI 10.1377/hlthaff.26.5.1392; Kaphingst KA, 2005, J HEALTH COMMUN, V10, P609, DOI 10.1080/10810730500267647; Law MR, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1055; *MARK HLTH PROD DI, 2002, IMP SAF CONC US DIAN; Mintzes B, 2005, CAN MED ASSOC J, V173, P1313, DOI 10.1503/cmaj.050567; Mintzes B, 2003, CAN MED ASSOC J, V169, P405; NICHOLS DM, 2005, DISTINCTION ADVERTIS; PhRMA, 2005, GUID PRINC DIR TO CO; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; ROWSELL LB, 2000, ADVERTISING CAMPAIGN; Standing Committee on Health, 2004, OP MED CAB 1 REP HLT; STUPAK B, 2008, DIRECT TO CONSUMER A; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; U. S. Food and Drug Administration, 2005, FDA UPD LAB ORTH EVR; *US GOV ACC OFF, 2006, PRESCR DRUGS IMPR NE; Woloshin S, 2001, LANCET, V358, P1141, DOI 10.1016/S0140-6736(01)06254-7; 2002, ADVISORY        0523; 2005, ADVISORY        0726; 2005, MED MARKETING M 0802	33	23	24	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5699	10.1371/journal.pone.0005699	http://dx.doi.org/10.1371/journal.pone.0005699			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	450QD	19479084	Green Submitted, Green Published, gold			2023-01-03	WOS:000266415000011
J	Muss, HB; Berry, DA; Cirrincione, CT; Theodoulou, M; Mauer, AM; Kornblith, AB; Partridge, AH; Dressler, LG; Cohen, HJ; Becker, HP; Kartcheske, PA; Wheeler, JD; Perez, EA; Wolff, AC; Gralow, JR; Burstein, HJ; Mahmood, AA; Magrinat, G; Parker, BA; Hart, RD; Grenier, D; Norton, L; Hudis, CA; Winer, EP				Muss, Hyman B.; Berry, Donald A.; Cirrincione, Constance T.; Theodoulou, Maria; Mauer, Ann M.; Kornblith, Alice B.; Partridge, Ann H.; Dressler, Lynn G.; Cohen, Harvey J.; Becker, Heather P.; Kartcheske, Patricia A.; Wheeler, Judith D.; Perez, Edith A.; Wolff, Antonio C.; Gralow, Julie R.; Burstein, Harold J.; Mahmood, Ahmad A.; Magrinat, Gutav; Parker, Barbara A.; Hart, Ronald D.; Grenier, Debjani; Norton, Larry; Hudis, Clifford A.; Winer, Eric P.		CALGB Investigators	Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSENSUS RECOMMENDATIONS; DOSE-INTENSITY; FOLLOW-UP; PHASE-II; THERAPY; SURVIVAL; CYCLOPHOSPHAMIDE; DOXORUBICIN; TRIAL; AGE	BACKGROUND Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who were 65 years of age or older. METHODS We randomly assigned patients with stage I, II, IIIA, or IIIB breast cancer to standard chemotherapy (either cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide plus doxorubicin) or capecitabine. Endocrine therapy was recommended after chemotherapy in patients with hormone-receptor-positive tumors. A Bayesian statistical design was used with a range in sample size from 600 to 1800 patients. The primary end point was relapse-free survival. RESULTS When the 600th patient was enrolled, the probability that, with longer follow-up, capecitabine therapy was highly likely to be inferior to standard chemotherapy met a prescribed level, and enrollment was discontinued. After an additional year of follow-up, the hazard ratio for disease recurrence or death in the capecitabine group was 2.09 (95% confidence interval, 1.38 to 3.17; P<0.001). Patients who were randomly assigned to capecitabine were twice as likely to have a relapse and almost twice as likely to die as patients who were randomly assigned to standard chemotherapy (P = 0.02). At 3 years, the rate of relapse-free survival was 68% in the capecitabine group versus 85% in the standard-chemotherapy group, and the overall survival rate was 86% versus 91%. Two patients in the capecitabine group died of treatment-related complications; as compared with patients receiving capecitabine, twice as many patients receiving standard chemotherapy had moderate-to-severe toxic effects (64% vs. 33%). CONCLUSIONS Standard adjuvant chemotherapy is superior to capecitabine in patients with early-stage breast cancer who are 65 years of age or older. (ClinicalTrials.gov number, NCT00024102.)	[Muss, Hyman B.] Univ Vermont, Burlington, VT 05405 USA; [Berry, Donald A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Cirrincione, Constance T.; Kartcheske, Patricia A.] Duke Univ, Med Ctr, Ctr Stat, CALGB, Durham, NC USA; [Theodoulou, Maria; Norton, Larry; Hudis, Clifford A.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Mauer, Ann M.; Becker, Heather P.] CALGB, Chicago, IL USA; [Kornblith, Alice B.; Partridge, Ann H.; Cohen, Harvey J.; Winer, Eric P.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Muss, Hyman B.] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27599 USA; [Perez, Edith A.] N Cent Canc Treatment Grp, Rochester, MN USA; [Wolff, Antonio C.] Eastern Cooperat Oncol Grp, Philadelphia, PA USA; [Gralow, Julie R.] SW Oncol Grp, Ann Arbor, MI USA; [Magrinat, Gutav] SE Canc Control Consortium, Community Clin Oncol Program, Goldsboro, NC USA; [Parker, Barbara A.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Hart, Ronald D.] Mt Sinai Sch Med, New York, NY USA; [Grenier, Debjani] Canadian Canc Soc Res Inst, Toronto, ON, Canada	University of Vermont; University of Texas System; UTMD Anderson Cancer Center; Duke University; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; University of North Carolina; University of North Carolina Chapel Hill; Southwest Oncology Group; University of California System; University of California San Diego; Icahn School of Medicine at Mount Sinai	Muss, HB (corresponding author), Univ N Carolina, Div Hematol Oncol, 170 Manning Dr,Campus Box 7305,3rd Fl, Chapel Hill, NC 27599 USA.	hyman.muss@gmail.com	Hudis, Clifford/AAW-9482-2021; Wolff, Antonio C./T-8796-2019	Hudis, Clifford/0000-0001-7144-8791; Wolff, Antonio C./0000-0003-3734-1063; Norton, Larry/0000-0003-3701-9250	NATIONAL CANCER INSTITUTE [U10CA085850, U10CA031946, U10CA033601] Funding Source: NIH RePORTER; NCI NIH HHS [U10 CA033601, U10 CA031946, CA33601, U10 CA031946-21, U10 CA085850, CA31946, U10CA85850, U10 CA085850-02, U10 CA033601-24] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658; Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P2356; Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927; Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518; Blum JL, 1999, J CLIN ONCOL, V17, P485, DOI 10.1200/JCO.1999.17.2.485; Bonneterre J, 2005, J CLIN ONCOL, V23, P2686, DOI 10.1200/JCO.2005.05.059; Budman DR, 1998, J NATL CANCER I, V90, P1205, DOI 10.1093/jnci/90.16.1205; CHRISTMAN K, 1992, JAMA-J AM MED ASSOC, V268, P57, DOI 10.1001/jama.268.1.57; Clarke M, 2008, LANCET, V371, P29, DOI 10.1016/S0140-6736(08)60069-0; Eaker S, 2006, PLOS MED, V3, P321, DOI 10.1371/journal.pmed.0030025; Fargeot P, 2004, J CLIN ONCOL, V22, P4674, DOI 10.1200/JCO.2004.02.145; Fargeot P, 2005, J CLIN ONCOL, V23, P4238, DOI 10.1200/JCO.2005.01.2286; Fisher B, 2001, J CLIN ONCOL, V19, P931, DOI 10.1200/JCO.2001.19.4.931; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; Gradishar W J, 2001, Oncology (Williston Park), V15, P69; Hebert-Croteau N, 1999, CANCER-AM CANCER SOC, V85, P1104, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1104::AID-CNCR14>3.0.CO;2-1; Hebert-Croteau N, 2004, J CLIN ONCOL, V22, P3685, DOI 10.1200/JCO.2004.07.018; Hudis CA, 2007, J CLIN ONCOL, V25, P2127, DOI 10.1200/JCO.2006.10.3523; Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706; Ibrahim NK, 1996, ARCH INTERN MED, V156, P882, DOI 10.1001/archinte.156.8.882; Jones S, 2009, J CLIN ONCOL, V27, P1177, DOI 10.1200/JCO.2008.18.4028; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kemeny MM, 2003, J CLIN ONCOL, V21, P2268, DOI 10.1200/JCO.2003.09.124; KEMENY MM, 2004, J CLIN ONCOL, V22, P4811; Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010; Liu G, 1997, J CLIN ONCOL, V15, P110, DOI 10.1200/JCO.1997.15.1.110; Lyman GH, 2003, J CLIN ONCOL, V21, P4524, DOI 10.1200/JCO.2003.05.002; Muss HB, 2005, JAMA-J AM MED ASSOC, V293, P1073, DOI 10.1001/jama.293.9.1073; Muss HB, 2007, J CLIN ONCOL, V25, P3699, DOI 10.1200/JCO.2007.10.9710; *NAT CANC I, 2008, COMM TOX CRIT; O'Shaughnessy JA, 2001, ANN ONCOL, V12, P1247, DOI 10.1023/A:1012281104865; OReilly SM, 1998, P AM SOC CLIN ONCOLO, V17, p163A; PARTRIDGE AH, 2008, J CLIN ONCOL S, V26, pS347; Patt DA, 2007, J CLIN ONCOL, V25, P3871, DOI 10.1200/JCO.2007.12.0832; Pinder MC, 2007, J CLIN ONCOL, V25, P3808, DOI 10.1200/JCO.2006.10.4976; Sateren WB, 2002, J CLIN ONCOL, V20, P2109, DOI 10.1200/JCO.2002.08.056; *SURV EP END RES, SURV EP END RES CANC; Wildiers H, 2007, LANCET ONCOL, V8, P1101, DOI 10.1016/S1470-2045(07)70378-9; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885	40	388	402	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2009	360	20					2055	2065		10.1056/NEJMoa0810266	http://dx.doi.org/10.1056/NEJMoa0810266			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444WN	19439741	Green Accepted, Green Published, Bronze			2023-01-03	WOS:000266011200004
J	Schwartz, LM; Woloshin, S; Welch, HG				Schwartz, Lisa M.; Woloshin, Steven; Welch, H. Gilbert			Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials	ANNALS OF INTERNAL MEDICINE			English	Article							TO-CONSUMER ADVERTISEMENTS; PRESCRIPTION DRUGS; TELEPHONE SURVEY; NONRESPONSE; EXPERIENCE; RISK	Background: Direct-to-consumer prescription drug ads typically fail to provide fundamental information that consumers need to make informed decisions: data on how well the drug works. Objective: To see whether providing consumers with a drug facts box-a table quantifying outcomes with and without the drug improves knowledge and affects judgments about prescription medications. Design: Two randomized, controlled trials conducted between October 2006 and April 2007: a symptom drug box trial using direct-to-consumer ads for a histamine-2 blocker and a proton-pump inhibitor to treat heartburn, and a prevention drug box trial using direct-to-consumer ads for a statin and clopidogrel to prevent cardiovascular events. Setting: National sample of U. S. adults identified by random-digit dialing. Participants: Adults age 35 to 70 years who completed a mailed survey; the final samples comprised 231 participants with completed surveys in the symptom drug box trial (49% response rate) and 219 in the prevention drug box trial (46% response rate). Intervention: In both trials, the control group received 2 actual drug ads (including both the front page and brief summary). The drug box group received the same ads, except that the brief summary was replaced by a drug facts box. Measurements: Choice between drugs (primary outcome of the symptom drug box trial) and accurate perceptions of drug benefits and side effects (primary outcome of the prevention drug box trial). Results: In the symptom drug box trial, 70% of the drug box group and 8% of the control group correctly identified the PPI as being "a lot more effective" than the histamine-2 blocker (P < 0.001), and 80% and 38% correctly recognized that the side effects of the 2 drugs were similar (P < 0.001). When asked what they would do if they had bothersome heartburn and could have either drug for free, 68% of the drug box group and 31% of the control group chose the proton-pump inhibitor, the superior drug (P < 0.001). In the prevention drug box trial, the drug box improved consumers' knowledge of the benefits and side effects of a statin and clopidogrel. For example, 72% of the drug box group and 9% of the control group correctly quantified the benefit (absolute risk reduction) of the statin (P < 0.001). Most of the control participants overestimated this benefit, and 65% did so by a factor of 10 or more. Limitations: The trials tested drug boxes in only 4 direct-to-consumer ads. If other direct-to-consumer ads were to communicate outcome data better, the effect of the drug box would be reduced. Conclusion: A drug facts box improved U. S. consumers' knowledge of prescription drug benefits and side effects. It resulted in better choices between drugs for current symptoms and corrected the overestimation of benefit in the setting of prevention.	Dartmouth Inst Hlth Policy & Clin Practice, Ctr Med Media, Hanover, NH USA; Vet Affairs Outcomes Grp, White River Jct, VT USA	Dartmouth College	Woloshin, S (corresponding author), Vet Affairs Outcomes Grp 111B, Dept Vet Affairs Med Ctr, White River Jct, VT 05009 USA.	steven.woloshin@dartmouth.edu			Robert Wood Johnson; National Cancer Institute [R01CA104721]; Attorney General Consumer and Prescriber Education; NATIONAL CANCER INSTITUTE [R01CA104721] Funding Source: NIH RePORTER	Robert Wood Johnson(Robert Wood Johnson Foundation (RWJF)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Attorney General Consumer and Prescriber Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Drs. Schwartz and Woloshin were supported by Robert Wood Johnson Generalist Faculty Scholars Awards. The study was supported by the National Cancer Institute (grant R01CA104721) and the Attorney General Consumer and Prescriber Education grant program.	Avorn J, 2008, NEW ENGL J MED, V359, P991, DOI 10.1056/NEJMp0805922; Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Bell RA, 2000, J FAM PRACTICE, V49, P1092; Biener L, 2004, AM J PREV MED, V27, P254, DOI 10.1016/j.amepre.2004.05.006; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; *COMM ASS US DRUG, 2006, FUT DRUG SAF PROM PR; Curtin R, 2005, PUBLIC OPIN QUART, V69, P87, DOI 10.1093/poq/nfi002; Davis J, 2007, J HEALTH COMMUN, V12, P607, DOI 10.1080/10810730701615164; Davis JJ, 2007, HEALTH AFFAIR, V26, P863, DOI 10.1377/hlthaff.26.3.863; Frosch DL, 2007, ANN FAM MED, V5, P6, DOI 10.1370/afm.611; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; *I MED, 2007, UND BEN RISKS PHARM; Johnsson F, 2003, SCAND J GASTROENTERO, V38, P347, DOI 10.1080/00365520310002157; Kallen A, 2007, HEALTH AFFAIR, V26, P1392, DOI 10.1377/hlthaff.26.5.1392; Keeter S, 2006, PUBLIC OPIN QUART, V70, P759, DOI 10.1093/poq/nfl035; Kravitz RL, 2005, JAMA-J AM MED ASSOC, V293, P1995, DOI 10.1001/jama.293.16.1995; National Center for Health Statistics, NAT HLTH NUTR EX SUR; *OR HLTH SCI U, DRUG EFF REV PROJ DE; RUSH DR, 1995, J FAM PRACTICE, V41, P126; Schwartz LM, 2007, MED DECIS MAKING, V27, P655, DOI 10.1177/0272989x07306786; Schwartz LM, 1997, ANN INTERN MED, V127, P966, DOI 10.7326/0003-4819-127-11-199712010-00003; The American Association for Public Opinion Research, 2008, STAND DEF FIN DISP C; *US FDA, 2004, GUID IND BRIEF SUMM; *US FDA, 2007, 020839 NDA US FDA; *US FDA, OFF MAN BUDG FORM PR; VANPINXTEREN B, 2001, COCHRANE DB SYST REV, P2095; Woloshin S, 2001, LANCET, V358, P1141, DOI 10.1016/S0140-6736(01)06254-7; WOLOSHIN S, 2004, HLTH AFFAIRS S   JAN; Woloshin S, 2008, KNOW YOUR CHANCES UN; Woloshin S, 2007, ANN INTERN MED, V146, P256, DOI 10.7326/0003-4819-146-4-200702200-00004; 2008, DTC PERSPECTIVES, V7, P10	31	186	186	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 21	2009	150	8					516	W93		10.7326/0003-4819-150-8-200904210-00106	http://dx.doi.org/10.7326/0003-4819-150-8-200904210-00106			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	437AD	19221371				2023-01-03	WOS:000265457000002
J	Sung, JJY; Barkun, A; Kuipers, EJ; Mossner, J; Jensen, DM; Stuart, R; Lau, JY; Ahlbom, H; Kilhamn, J; Lind, T				Sung, Joseph J. Y.; Barkun, Alan; Kuipers, Ernst J.; Mossner, Joachim; Jensen, Dennis M.; Stuart, Robert; Lau, James Y.; Ahlbom, Henrik; Kilhamn, Jan; Lind, Tore		Peptic Ulcer Bleed Study Grp	Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							PUMP INHIBITOR THERAPY; PLACEBO-CONTROLLED MULTICENTER; ENDOSCOPIC TREATMENT; COCHRANE-COLLABORATION; CONTINUOUS-INFUSION; ACID SUPPRESSION; INTRAGASTRIC PH; METAANALYSIS; OMEPRAZOLE; COAGULATION	Background: Use of proton-pump inhibitors in the management of peptic ulcer bleeding is controversial because discrepant results have been reported in different ethnic groups. Objective: To determine whether intravenous esomeprazole prevents recurrent peptic ulcer bleeding better than placebo in a multi-ethnic patient sample. Design: Randomized trial conducted between October 2005 and December 2007; patients, providers, and researchers were blinded to group assignment. Setting: 91 hospital emergency departments in 16 countries. Patients: Patients 18 years or older with peptic ulcer bleeding from a single gastric or duodenal ulcer showing high-risk stigmata. Intervention: Intravenous esomeprazole bolus, 80 mg, followed by 8-mg/h infusion, over 72 hours or matching placebo, each given after successful endoscopic hemostasis. Intervention was allocated by computer-generated randomization. After infusion, both groups received oral esomeprazole, 40 mg/d, for 27 days. Measurements: The primary end point was rate of clinically significant recurrent bleeding within 72 hours. Recurrent bleeding within 7 and 30 days, death, surgery, endoscopic re-treatment, blood transfusions, hospitalization, and safety were also assessed. Results: Of 767 patients randomly assigned, 764 provided data for an intention-to-treat analysis (375 esomeprazole recipients and 389 placebo recipients). Fewer patients receiving intravenous esomeprazole (22 of 375) had recurrent bleeding within 72 hours than those receiving placebo (40 of 389) (5.9% vs. 10.3%; difference, 4.4 percentage points [95% Cl, 0.6% to 8.3%]; P = 0.026). The difference in bleeding recurrence remained significant at 7 days and 30 days (P = 0.010). Esomeprazole also reduced endoscopic retreatment (6.4% vs. 11.6%; difference, 5.2 percentage points [95% Cl of difference, 1.1 percentage points to 9.2 percentage points]; P = 0.012), surgery (2.7% vs. 5.4%), and all-cause mortality rates (0.8% vs. 2.1%) more than placebo, although differences for the latter 2 comparisons were not significant. About 10% and 40% of patients in both groups reported serious and nonserious adverse events, respectively. Limitation: Endoscopic therapy was not completely standardized; some patients received epinephrine injection, thermal coagulation, or hemoclips alone, whereas others received combination therapy, but there were similar proportions with single therapy in each group. Conclusion: High-dose intravenous esomeprazole given after successful endoscopic therapy to patients with high-risk peptic ulcer bleeding reduced recurrent bleeding at 72 hours and had sustained clinical benefits for up to 30 days.	Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; McGill Univ, Ctr Hlth, Montreal, PQ, Canada; Erasmus MC Univ, Med Ctr, Rotterdam, Netherlands; Univ Leipzig, Med Klin & Poliklin 2, Leipzig, Germany; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; Digest Dis Res Ctr, Ctr Ulcer Res & Educ, Los Angeles, CA USA; Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland; AstraZeneca Res & Dev, Molndal, Sweden	Chinese University of Hong Kong; McGill University; Erasmus University Rotterdam; Erasmus MC; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Glasgow; AstraZeneca	Sung, JJY (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.	joesung@cuhk.edu.hk	Kuipers, Ernst J/H-3293-2019; Lau, James Y. W./O-2612-2016; Sung, Joseph J. Y./R-3203-2018	Kuipers, Ernst J/0000-0002-0633-3098; Lau, James Y. W./0000-0003-0122-4068; Sung, Joseph J. Y./0000-0003-3125-5199	AstraZeneca Research and Development	AstraZeneca Research and Development(AstraZeneca)	Primary Funding Source: AstraZeneca Research and Development.	Andriulli A, 2005, AM J GASTROENTEROL, V100, P207, DOI 10.1111/j.1572-0241.2005.40636.x; Barkun A, 2004, AM J GASTROENTEROL, V99, P1238, DOI 10.1111/j.1572-0241.2004.30272.x; Barkun AN, 1999, ALIMENT PHARM THER, V13, P1565; Berstad A, 1997, SCAND J GASTROENTERO, V32, P396, DOI 10.3109/00365529709007691; British Society of Gastroenterology, 2007, UK COMP AUD UPP GAST; CHAIMOFF C, 1978, AM J SURG, V136, P257, DOI 10.1016/0002-9610(78)90241-6; COLLINS R, 1985, NEW ENGL J MED, V313, P660, DOI 10.1056/NEJM198509123131104; DeMuckadell OBS, 1997, SCAND J GASTROENTERO, V32, P320, DOI 10.3109/00365529709007679; FORREST JAH, 1974, LANCET, V2, P394; Goldstein JA, 2001, BRIT J CLIN PHARMACO, V52, P349, DOI 10.1046/j.0306-5251.2001.01499.x; GREEN FW, 1978, GASTROENTEROLOGY, V74, P38; Hasselgren G, 1997, SCAND J GASTROENTERO, V32, P328, DOI 10.3109/00365529709007680; Jensen DM, 2006, AM J GASTROENTEROL, V101, P1991, DOI 10.1111/j.1572-0241.2006.00773.x; JENSEN DM, 2006, AM J GASTROENTEROL, V101, P2170; Khuroo MS, 2005, J GASTROEN HEPATOL, V20, P11, DOI 10.1111/j.1440-1746.2004.03441.x; Khuroo MS, 1997, NEW ENGL J MED, V336, P1054, DOI 10.1056/NEJM199704103361503; Lau JY, 2007, NEW ENGL J MED, V356, P1631, DOI 10.1056/NEJMoa065703; Lau JYW, 2000, NEW ENGL J MED, V343, P310, DOI 10.1056/NEJM200008033430501; Leontiadis GI, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002094.pub3; Leontiadis GI, 2005, ALIMENT PHARM THER, V21, P1055, DOI 10.1111/j.1365-2036.2005.02441.x; Leontiadis GI, 2005, BMJ-BRIT MED J, V330, P568, DOI 10.1136/bmj.38356.641134.8F; Leontiadis GI, 2007, MAYO CLIN PROC, V82, P286; Levine JE, 2002, ALIMENT PHARM THERAP, V16, P1137, DOI 10.1046/j.1365-2036.2002.01274.x; Li YY, 2000, J GASTROEN HEPATOL, V15, P148, DOI 10.1046/j.1440-1746.2000.02055.x; Lin HJ, 1998, ARCH INTERN MED, V158, P54, DOI 10.1001/archinte.158.1.54; Marmo R, 2007, AM J GASTROENTEROL, V102, P469; Marmo R, 2007, AM J GASTROENTEROL, V102, P279, DOI 10.1111/j.1572-0241.2006.01023.x; Netzer P, 1999, AM J GASTROENTEROL, V94, P351; PATCHETT SE, 1989, GUT, V30, P1704, DOI 10.1136/gut.30.12.1704; Sung JJY, 2008, ALIMENT PHARM THER, V27, P666, DOI 10.1111/j.1365-2036.2008.03631.x; Sung JJY, 2007, GUT, V56, P1364, DOI 10.1136/gut.2007.123976; VANRENSBURG CJ, 2004, CAN J GASTROENTE SSA, V18; Vreeburg EM, 2001, ALIMENT PHARM THER, V15, P639, DOI 10.1046/j.1365-2036.2001.00978.x; YAVORSKI RT, 1995, AM J GASTROENTEROL, V90, P568; Zargar SA, 2006, J GASTROEN HEPATOL, V21, P716, DOI 10.1111/j.1440-1746.2006.04292.x	35	131	152	1	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 7	2009	150	7					455	+		10.7326/0003-4819-150-7-200904070-00105	http://dx.doi.org/10.7326/0003-4819-150-7-200904070-00105			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	432EZ	19221370				2023-01-03	WOS:000265117600003
J	Kiatpongsan, S; Sipp, D				Kiatpongsan, Sorapop; Sipp, Douglas			Monitoring and Regulating Offshore Stem Cell Clinics	SCIENCE			English	Editorial Material									[Sipp, Douglas] RIKEN, Ctr Dev Biol, Kobe, Hyogo 6500047, Japan; [Kiatpongsan, Sorapop] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynecol, Bangkok 10330, Thailand; [Kiatpongsan, Sorapop] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Vincent Obstet & Gynecol Serv,Vincent Ctr Reprod, Boston, MA 02114 USA; [Kiatpongsan, Sorapop] Harvard Univ, John F Kennedy Sch Govt, Sci Technol & Publ Policy Program, Sci Technol & Globalizat Project,Belfer Ctr Sci &, Cambridge, MA 02138 USA; [Sipp, Douglas] Kyoto Univ, Ctr iPS Res & Applicat, Inst Integrated Cell Mat Sci, Kyoto 6068501, Japan	RIKEN; Chulalongkorn University; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Kyoto University	Sipp, D (corresponding author), RIKEN, Ctr Dev Biol, Kobe, Hyogo 6500047, Japan.	sipp@cdb.riken.jp	Sipp, Doug/C-9218-2017; Kiatpongsan, Sorapop/ABG-7845-2021	Sipp, Doug/0000-0002-5979-0938; 				Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Arom Kitipan V, 2008, Asian Cardiovasc Thorac Ann, V16, P143; BOSELEY S, 2006, GUARDIAN        0501; DU J, 2005, STEM CELL MISSION CH; EBBIN M, 2007, BERMUDA SUN     0914; EINHORN B, 2005, BUSINESS WEEK   0110, P34; Enserink M, 2006, SCIENCE, V313, P160, DOI 10.1126/science.313.5784.160; Halme DG, 2006, NEW ENGL J MED, V355, P1730, DOI 10.1056/NEJMhpr063086; *INT SOC STEM CELL, 2008, GUID CLIN TRANSL STE; *JUV DIAB RES FDN, PART CLIN TRIAL; Lau D, 2008, CELL STEM CELL, V3, P591, DOI 10.1016/j.stem.2008.11.001; ONO D, 2007, KABC TV NEWS; Porat Y, 2006, BRIT J HAEMATOL, V135, P703, DOI 10.1111/j.1365-2141.2006.06344.x; PRENTICE D, 2004, MONITORING STEM CELL; PRICE S, 2007, NATION NEWS BAR 1126; SIPP D, 2007, STEM CELL REPORT, V2, P62; STEELE J, 2007, VESCELL ADULT S 1219; *US FTC, FREQ ASK ADV QUEST G; Zarembo A., 2005, LOS ANGELES TIM 0220; 2008, ROYAL GAZETTE   0818; 2008, BANGKOK POST    0622	21	76	77	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	2009	323	5921					1564	1565		10.1126/science.1168451	http://dx.doi.org/10.1126/science.1168451			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	421EN	19299604				2023-01-03	WOS:000264342300022
J	Brekke, M; Gjelsvik, B				Brekke, Mette; Gjelsvik, Bjorn			Secondary cardiovascular risk prevention-we can do better	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; EUROPEAN GUIDELINES; CLINICAL-PRACTICE; REHABILITATION		[Brekke, Mette; Gjelsvik, Bjorn] Univ Oslo, Inst Gen Practice & Community Med, NO-0318 Oslo, Norway	University of Oslo	Brekke, M (corresponding author), Univ Oslo, Inst Gen Practice & Community Med, NO-0318 Oslo, Norway.	mette.brekke@medisin.uio.no						Avendano M, 2006, HEART, V92, P461, DOI 10.1136/hrt.2005.065532; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; Getz L, 2004, SCAND J PRIM HEALTH, V22, P202, DOI 10.1080/02813430410006693; Graham I, 2007, EUR HEART J, V28, P2375, DOI 10.1093/eurheartj/ehm316; Kotseva K, 2009, LANCET, V373, P929, DOI 10.1016/S0140-6736(09)60330-5; Mildestvedt T, 2007, SCAND J PUBLIC HEALT, V35, P591, DOI 10.1080/14034940701349241; *STAT NORW, STEAD DECL NUMB DAIL; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Wood DA, 2008, LANCET, V371, P1999, DOI 10.1016/S0140-6736(08)60868-5	9	5	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 14	2009	373	9667					873	875		10.1016/S0140-6736(09)60524-9	http://dx.doi.org/10.1016/S0140-6736(09)60524-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	418OU	19286069				2023-01-03	WOS:000264158700007
J	Smith, AK; Sudore, RL; Perez-Stable, EJ				Smith, Alexander K.; Sudore, Rebecca L.; Perez-Stable, Eliseo J.			Palliative Care for Latino Patients and Their Families Whenever We Prayed, She Wept	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-LIFE CARE; LIMITED ENGLISH PROFICIENCY; FUNCTIONAL HEALTH LITERACY; AFRICAN-AMERICAN; MEDICAL INTERPRETATION; TREATMENT PREFERENCES; ETHNIC-DIFFERENCES; DECISION-MAKING; SELF-MANAGEMENT; ADVANCED CANCER	Latinos account for 15% of the US population, a proportion projected to grow to 30% by the year 2050. Although there is tremendous diversity within this community, commonalities of language, beliefs, attitudes, and behaviors unite Latinos, making them more similar than different. Differences by national origin, although important, are attenuated when immigrants come to the United States, dominated by an English-language, Anglo-centric culture. Fornon-Latino and non-Spanish-speaking clinicians, communication barriers and cultural misunderstandings can impede the care of dying Latino patients and their families. We present the case of a young, pregnant, Spanish-speaking woman from Central America diagnosed with a fatal leukemia. As illustrated by this case, Latino immigrants face a number of external challenges to optimal end-of-life care: (1) geographic distance as well as political and economic realities of ten separate patients from their valued families; ( 2) undocumented immigrants are frequently uninsured and fear of deportation may create a barrier to accessing health services; (3) language and literacy barriers; and (4) concerns about discrimination. Other Latino issues that may be more pronounced in end-of-life settings include cultural themes and religious and spiritual influences. We recommend that professional interpreters must be used for discussions about goals of care with Spanish-speaking patients and families or when negotiating conflict between the patient, family, and the health care team. Concrete suggestions are provided for clinicians in working with interpreters, eliciting culturally based attitudes and beliefs, and implementing universal strategies for clear health communication.	[Smith, Alexander K.; Sudore, Rebecca L.] Univ Calif San Francisco, Div Geriatr, Dept Med, San Francisco, CA 94121 USA; [Perez-Stable, Eliseo J.] Univ Calif San Francisco, Div Gen Internal Med, Dept Med, Med Effectiveness Res Ctr Diverse Populat, San Francisco, CA 94121 USA; [Smith, Alexander K.; Sudore, Rebecca L.] Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Smith, AK (corresponding author), Univ Calif San Francisco, Div Geriatr, Dept Med, 4150 Clement St,181G, San Francisco, CA 94121 USA.	aksmith@ucsf.edu	Sudore, Rebecca/AAF-1635-2021		NATIONAL INSTITUTE ON AGING [R01AG028481, P30AG015272] Funding Source: NIH RePORTER; NIA NIH HHS [R01AG028481, R01 AG028481, P30-AG15272, R01 AG028481-02S1, P30 AG015272-13, P30 AG015272] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abraido-Lanza AF, 2007, ETHNIC DIS, V17, P153; Back AL, 2005, CA-CANCER J CLIN, V55, P164, DOI 10.3322/canjclin.55.3.164; Baker DW, 2006, J GEN INTERN MED, V21, P878, DOI 10.1111/j.1525-1497.2006.00540.x; Baker DW, 1996, ARCH FAM MED, V5, P329, DOI 10.1001/archfami.5.6.329; Balboni TA, 2007, J CLIN ONCOL, V25, P555, DOI 10.1200/JCO.2006.07.9046; Blackhall LJ, 1999, SOC SCI MED, V48, P1779, DOI 10.1016/S0277-9536(99)00077-5; BLACKHALL LJ, 1995, JAMA-J AM MED ASSOC, V274, P820, DOI 10.1001/jama.274.10.820; Braun UK, 2008, J GEN INTERN MED, V23, P267, DOI 10.1007/s11606-007-0487-7; BRUERA E, 1993, J PAIN SYMPTOM MANAG, V8, P365, DOI 10.1016/0885-3924(93)90054-Y; Burchard EG, 2005, AM J PUBLIC HEALTH, V95, P2161, DOI 10.2105/AJPH.2005.068668; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; Carrillo JE, 1999, ANN INTERN MED, V130, P829, DOI 10.7326/0003-4819-130-10-199905180-00017; Castro CM, 2007, AM J HEALTH BEHAV, V31, pS85; Cianelli R, 2008, CULT HEALTH SEX, V10, P297, DOI 10.1080/13691050701861439; Cohen LL, 2008, J PALLIAT MED, V11, P763, DOI 10.1089/jpm.2007.0216; Crawley L, 2000, JAMA-J AM MED ASSOC, V284, P2518, DOI 10.1001/jama.284.19.2518; Crawley LM, 2008, CANCER EPIDEM BIOMAR, V17, P1937, DOI 10.1158/1055-9965.EPI-08-0005; Crawley Lavera M, 2002, J Palliat Med, V5, P775, DOI 10.1089/109662102320880697; Crawley LM, 2001, J NATL MED ASSOC, V93, p14S; Crawley LM, 2002, ANN INTERN MED, V136, P673, DOI 10.7326/0003-4819-136-9-200205070-00010; Cristancho S, 2008, QUAL HEALTH RES, V18, P633, DOI 10.1177/1049732308316669; DAIMOND LC, 2009, JAMA-J AM MED ASSOC, V301, P426; DeLima L, 1997, J PAIN SYMPTOM MANAG, V13, P213, DOI 10.1016/S0885-3924(96)00325-9; DeWalt DA, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-30; Doak C.C., 1996, TEACHING PATIENTS LO, DOI DOI 10.1097/00000446-199612000-00022; Fernandez A, 2004, J GEN INTERN MED, V19, P167, DOI 10.1111/j.1525-1497.2004.30266.x; Fischer SM, 2007, J PALLIAT MED, V10, P1023, DOI 10.1089/jpm.2007.0070; Flores G, 2003, PEDIATRICS, V111, P6, DOI 10.1542/peds.111.1.6; Florez KR, 2009, J IMMIGR MINOR HEALT, V11, P291, DOI 10.1007/s10903-008-9118-6; Fortuny K., 2007, CHARACTERISTICS UNAU; Gelfand D E, 2001, Am J Hosp Palliat Care, V18, P391, DOI 10.1177/104990910101800608; Greiner KA, 2003, J AM GERIATR SOC, V51, P970, DOI 10.1046/j.1365-2389.2003.51310.x; Grubbs V, 2006, J GEN INTERN MED, V21, P683, DOI 10.1111/j.1525-1497.2006.00492.x; Hakimzadeh S., 2007, ENGLISH USAGE HISPAN; HASNIANWYNIA R, HOSP LANGUAGE SERVIC; *HISP HER MONTH 20, 2007, FACTS FEAT; HOLLAND JC, 1987, CANCER INVEST, V5, P151, DOI 10.3109/07357908709018468; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Karliner LS, 2007, HEALTH SERV RES, V42, P727, DOI 10.1111/j.1475-6773.2006.00629.x; Karliner LS, 2004, J GEN INTERN MED, V19, P175, DOI 10.1111/j.1525-1497.2004.30268.x; Kindig DA, 2004, HLTH LITERACY PRESCR; KIRSCH IS, 1993, ADULT LIT AM 1 LOOK; Kleinman A., 1988, ILLNESS NARRATIVES; Krakauer EL, 2002, J AM GERIATR SOC, V50, P182, DOI 10.1046/j.1532-5415.2002.50027.x; Kripalani S, 2006, J GEN INTERN MED, V21, P888, DOI 10.1111/j.1525-1497.2006.00543.x; Kutner M, 2005, 1 LOOK LIT AM ADULTS; Lauderdale DS, 2006, MED CARE, V44, P914, DOI 10.1097/01.mlr.0000220829.87073.f7; Lee KC, 2006, JAMA-J AM MED ASSOC, V296, P1050, DOI 10.1001/jama.296.9.1050; MALONE N, 2000, FOREIGN BORN POPULAT; Mancuso CA, 2006, J ASTHMA, V43, P41, DOI 10.1080/02770900500447052; MARIN G, 1990, HISPANIC J BEHAV SCI, V12, P422, DOI 10.1177/07399863900124006; Morrison RS, 2004, ARCH INTERN MED, V164, P2421, DOI 10.1001/archinte.164.22.2421; Napoles-Springer AM, 2005, HEALTH EXPECT, V8, P4, DOI 10.1111/j.1369-7625.2004.00298.x; Norris Wendi M, 2005, J Palliat Med, V8, P1016, DOI 10.1089/jpm.2005.8.1016; Ortega AN, 2007, ARCH INTERN MED, V167, P2354, DOI 10.1001/archinte.167.21.2354; OTEROSABOGAL R, 2003, HEALTH EDUC BEHAV, P337; Paasche-Orlow MK, 2007, AM J HEALTH BEHAV, V31, pS19; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-1291OC; Paasche-Orlow MK, 2005, J GEN INTERN MED, V20, P175, DOI 10.1111/j.1525-1497.2005.40245.x; Paosche-Orlow MK, 2008, J GEN INTERN MED, V23, P100, DOI 10.1007/s11606-007-0447-2; Passell J. S., 2005, ESTIMATES SIZE CHARA; Perez-Stable E. J., 2004, CLIN CORNERSTONE, V6, P62; Perez-Stable Eliseo J, 2004, Clin Cornerstone, V6, P49, DOI 10.1016/S1098-3597(04)80064-4; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; Pham K, 2008, CHEST, V134, P109, DOI 10.1378/chest.07-2852; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Potocky-Tripodi M., 2002, BEST PRACTICES SOCIA; Raffaelli M, 2004, SEX ROLES, V50, P287, DOI 10.1023/B:SERS.0000018886.58945.06; Roll IJ, 2009, J PAIN SYMPTOM MANAG, V37, P325, DOI 10.1016/j.jpainsymman.2008.02.015; SABOGAL F, 1995, HISPANIC J BEHAV SCI, V17, P139, DOI 10.1177/07399863950172001; SABOGAL F, 1987, HISPANIC J BEHAV SCI, V9, P397, DOI 10.1177/07399863870094003; Schenker Y, 2008, ANN INTERN MED, V149, P264, DOI 10.7326/0003-4819-149-4-200808190-00008; Schillinger D, 2003, ARCH INTERN MED, V163, P83, DOI 10.1001/archinte.163.1.83; Schillinger D, 2004, PATIENT EDUC COUNS, V52, P315, DOI 10.1016/S0738-3991(03)00107-1; SCHLOSBERG C, 1998, IMPACT INS PUBLIC CH; Smedley BD, 2003, UNEQUAL TREATMENT CO, DOI [10.17226/12875, DOI 10.17226/12875]; Smith AK, 2008, J CLIN ONCOL, V26, P4131, DOI 10.1200/JCO.2007.14.8452; Smith AK, 2007, J PALLIAT MED, V10, P938, DOI 10.1089/jpm.2006.0244; Smith AK, 2009, J AM GERIATR SOC, V57, P153, DOI 10.1111/j.1532-5415.2008.02081.x; SONTAG D, 2008, NY TIMES        0803, pA1; Sudore RL, 2006, J AM GERIATR SOC, V54, P770, DOI 10.1111/j.1532-5415.2006.00691.x; Sudore RL, 2006, J GEN INTERN MED, V21, P867, DOI 10.1111/j.1525-1497.2006.00535.x; Sudore Rebecca L, 2009, J Clin Outcomes Manag, V16, P20; Sulmasy DP, 2006, JAMA-J AM MED ASSOC, V296, P1385, DOI 10.1001/jama.296.11.1385; Talamantes M A, 1995, Hosp J, V10, P35; Talamantes MA, 2000, CULTURAL ISSUES END, P83, DOI [10.4135/9781452204819.n7, DOI 10.4135/9781452204819.N7]; Thornton JD, 2009, CRIT CARE MED, V37, P89, DOI 10.1097/CCM.0b013e3181926430; TRIANDIS HC, 1984, J PERS SOC PSYCHOL, V47, P1363, DOI 10.1037/0022-3514.47.6.1363; Walter N, 2002, J GEN INTERN MED, V17, P221, DOI 10.1046/j.1525-1497.2002.10501.x; Weinick RM, 2004, MED CARE, V42, P313, DOI 10.1097/01.mlr.0000118705.27241.7c; Wenk R, 2008, J PALLIAT MED, V11, P717, DOI 10.1089/jpm.2007.0212; WILLIAMS MV, 1995, JAMA-J AM MED ASSOC, V274, P1677; Yoon J, 2004, J AM BOARD FAM PRACT, V17, P165, DOI 10.3122/jabfm.17.3.165; ZIV TA, 1995, NEW ENGL J MED, V332, P1095, DOI 10.1056/NEJM199504203321612; PERCENT PROJECTED PO; CHANGING FAITHS LATI; 1998, FED REG, V63, P41658; GUIDELINES USE MED I	98	96	96	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	2009	301	10					1047	1057		10.1001/jama.2009.308	http://dx.doi.org/10.1001/jama.2009.308			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	416OQ	19278947	Green Accepted			2023-01-03	WOS:000264015800029
J	Inskip, HM; Crozier, SR; Godfrey, KM; Borland, SE; Cooper, C; Robinson, SM				Inskip, Hazel M.; Crozier, Sarah R.; Godfrey, Keith M.; Borland, Sharon E.; Cooper, Cyrus; Robinson, Sian M.		Southampton Womens Survey Study Gr	Women's compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MODERATE ALCOHOL-CONSUMPTION; PRECONCEPTIONAL FOLIC-ACID; NEURAL-TUBE DEFECTS; UNINTENDED PREGNANCY; FERTILITY; TIME; HEALTH; BRITAIN	Objective To examine the extent to which women planning a pregnancy comply with recommendations for nutrition and lifestyle. Design Prospective cohort study. Setting Southampton, United Kingdom. Participants 12 445 non-pregnant women aged 20-34 recruited to the Southampton Women's Survey through general practices, 238 of whom became pregnant within three months of being interviewed. Main outcome measures Folic acid supplement intake, alcohol consumption, smoking, diet, and physical activity before pregnancy. Results The 238 women who became pregnant within three months of the interview were only marginally more likely to comply with recommendations for those planning a pregnancy than those who did not become pregnant in this period. Among those who became pregnant, 2.9% (95% confidence interval 1.2% to 6.0%) were taking 400 mu g or more of folic acid supplements a day and drinking four or fewer units of alcohol a week, compared with 0.66% (0.52% to 0.82%) of those who did not become pregnant. 74% of those who became pregnant were nonsmokers compared with 69% of those who did not become pregnant (P=0.08). Women in both groups were equally likely to consume five or more portions of fruit and vegetables a day (53% in each group, P=1.0), but only 57% of those who became pregnant had taken any strenuous exercise in the past three months compared with 64% in those who did not become pregnant (P=0.03). Conclusion Only a small proportion of women planning a pregnancy follow the recommendations for nutrition and lifestyle. Greater publicity for the recommendations is needed, but as many pregnancies are unplanned, improved nutrition and lifestyles of women of childbearing age is also required.	[Inskip, Hazel M.; Crozier, Sarah R.; Godfrey, Keith M.; Borland, Sharon E.; Cooper, Cyrus; Southampton Womens Survey Study Gr] Univ Southampton, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England	University of Southampton	Inskip, HM (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England.	hmi@mrc.soton.ac.uk	; Inskip, Hazel/L-5467-2018	Cooper, Cyrus/0000-0003-3510-0709; Inskip, Hazel/0000-0001-8897-1749; Godfrey, Keith/0000-0002-4643-0618; Crozier, Sarah/0000-0002-9524-1127; Robinson, Sian/0000-0003-1766-7269	UK Medical Research Council; University of Southampton; Dunhill Medical Trust; Medical Research Council [U1475000001, U1475000004] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10082] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Southampton; Dunhill Medical Trust(Dunhill Medical Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This component of the Southampton Women's Survey was funded by the UK Medical Research Council, the University of Southampton, and the Dunhill Medical Trust. None of the funders had any role in the design of this study; collection, analysis, and interpretation of the data; writing the report; or the decision to submit the article for publication.	Amitai Y, 2008, PREV MED, V46, P166, DOI 10.1016/j.ypmed.2007.09.005; Axmon A, 2005, FERTIL STERIL, V84, P966, DOI 10.1016/j.fertnstert.2005.04.030; Chapin RE, 2004, ENVIRON HEALTH PERSP, V112, P69, DOI 10.1289/ehp.6261; Coll O, 2004, EUR J OBSTET GYN R B, V115, P173, DOI 10.1016/j.ejogrb.2003.12.009; CROZIER SR, 2009, PAED PERINA IN PRESS; Custer M, 2008, PAEDIATR PERINAT EP, V22, P195, DOI 10.1111/j.1365-3016.2007.00896.x; D'Angelo Denise, 2007, Morbidity and Mortality Weekly Report, V56, P1; *FAM PLANN ASS, 2008, PREGN TRY GET PREGN; Floyd RL, 1999, AM J PREV MED, V17, P101, DOI 10.1016/S0749-3797(99)00059-8; *FOOD STAND AG, 2008, EAT WELL BE WELL; FORSTER DA, 2007, MIDWIFERY, DOI DOI 10.1016/J.MIDW.2007.01.01; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Goddard E, 2008, GEN HOUSEHOLD SURVEY; Goldberg BB, 2006, BIRTH DEFECTS RES A, V76, P193, DOI 10.1002/bdra.20239; Hellerstedt WL, 1998, AM J PUBLIC HEALTH, V88, P663, DOI 10.2105/AJPH.88.4.663; HERRICK K, 2003, MATERNAL INFANT HLTH; Howell F, 1997, LANCET, V350, P664, DOI 10.1016/S0140-6736(05)63357-0; Inskip HM, 2006, INT J EPIDEMIOL, V35, P42, DOI 10.1093/ije/dyi202; Jensen TK, 1998, BRIT MED J, V317, P505, DOI 10.1136/bmj.317.7157.505; Joffe M, 2000, LANCET, V355, P1961, DOI 10.1016/S0140-6736(00)02328-X; Joffe M, 1996, LANCET, V347, P1519, DOI 10.1016/S0140-6736(96)90673-X; Juhl M, 2001, HUM REPROD, V16, P2705, DOI 10.1093/humrep/16.12.2705; Lakha F, 2006, LANCET, V368, P1782, DOI 10.1016/S0140-6736(06)69737-7; Li ZW, 2007, PUBLIC HEALTH NUTR, V10, P471, DOI 10.1017/S1368980007223869; MCFADEN A, 2008, NICE MAT CHILD NUTR; McGovern E, 1997, BRIT J GEN PRACT, V47, P635; Morin P, 2002, PREV MED, V35, P143, DOI 10.1006/pmed.2002.1041; *NIH CLIN EXC PUBL, 2008, NIH CLIN EXC PUBL HL; *PAT UK, 2008, PLANN BEC PREGN; Perlow JH, 2001, AM J OBSTET GYNECOL, V184, P1263, DOI 10.1067/mob.2001.112974; Robinson S, 1996, EUR J CLIN NUTR, V50, P302; Robinson SM, 2004, EUR J CLIN NUTR, V58, P1174, DOI 10.1038/sj.ejcn.1601946; *SCI ADV COMM NUTR, 2006, FOL DIS PREV; Sillender M, 2000, J Obstet Gynaecol, V20, P271; Slama R, 2004, EPIDEMIOLOGY, V15, P458, DOI 10.1097/01.ede.0000129520.84568.87; Tam LE, 2005, J OBSTET GYNAECOL CA, V27, P232, DOI 10.1016/S1701-2163(16)30515-1; *US DHHS, 2008, HLTH PREGN; WALD N, 1993, ANN NY ACAD SCI, V678, P112; Wild J, 1997, LANCET, V350, P30, DOI 10.1016/S0140-6736(05)66239-3	39	130	133	1	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 12	2009	338								b481	10.1136/bmj.b481	http://dx.doi.org/10.1136/bmj.b481			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	415ZY	19213768	Green Published, hybrid			2023-01-03	WOS:000263976200007
J	Doig, GS; Simpson, F; Finfer, S; Delaney, A; Davies, AR; Mitchell, I; Dobb, G				Doig, Gordon S.; Simpson, Fiona; Finfer, Simon; Delaney, Anthony; Davies, Andrew R.; Mitchell, Imogen; Dobb, Geoff		ANZICS Clin Trials Grp	Effect of Evidence-Based Feeding Guidelines on Mortality of Critically Ill Adults A Cluster Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-PRACTICE GUIDELINES; ACUTE-RENAL-FAILURE; NUTRITION SUPPORT; ENTERAL NUTRITION; MULTICENTER; QUALITY; IMPLEMENTATION; DISSEMINATION; INTERVENTION; LIMITATIONS	Context Evidence demonstrates that providing nutritional support to intensive care unit ( ICU) patients within 24 hours of ICU admission reduces mortality. However, early feeding is not universally practiced. Changing practice in complex multidisciplinary environments is difficult. Evidence supporting whether guidelines can improve ICU feeding practices and patient outcomes is contradictory. Objective To determine whether evidence- based feeding guidelines, implemented using a multifaceted practice change strategy, improve feeding practices and reduce mortality in ICU patients. Design, Setting, and Patients Cluster randomized trial in ICUs of 27 community and tertiary hospitals in Australia and New Zealand. Between November 2003 and May 2004, 1118 critically ill adult patients expected to remain in the ICU longer than 2 days were enrolled. All participants completed the study. Interventions Intensive care unitswererandomlyassigned to guideline or control groups. Guideline ICUs developed an evidence- based guideline using Browman's Clinical Practice Guideline Development Cycle. A practice- change strategy composed of 18 specific interventions, leveraged by educational outreach visits, was implemented in guideline ICUs. Main Outcome Measures Hospital discharge mortality. Secondary outcomes included ICU and hospital length of stay, organ dysfunction, and feeding process measures. Results Guideline and control ICUs enrolled 561 and 557 patients, respectively. Guideline ICUs fed patients earlier ( 0.75 vs 1.37 mean days to enteral nutrition start; difference, - 0.62 [ 95% confidence interval {CI}, - 0.82 to - 0.36]; P <. 001 and 1.04 vs 1.40 mean days to parenteral nutrition start; difference, - 0.35 [ 95% CI, - 0.61 to - 0.01]; P=. 04) and achieved caloric goals more often ( 6.10 vs 5.02 mean days per 10 fed patient- days; difference, 1.07 [ 95% CI, 0.12 to 2.22]; P=. 03). Guideline and control ICUs did not differ with regard to hospital discharge mortality ( 28.9% vs 27.4%; difference, 1.4% [ 95% CI, - 6.3% to 12.0%]; P=. 75) or to hospital length of stay ( 24.2 vs 24.3 days; difference, - 0.08 [ 95% CI, - 3.8 to 4.4]; P=. 97) or ICU length of stay ( 9.1 vs 9.9 days; difference, - 0.86 [ 95% CI, - 2.6 to 1.3]; P=. 42). Conclusions Using a multifaceted practice change strategy, ICUs successfully developed and introduced an evidence- based nutritional support guideline that promoted earlier feeding and greater nutritional adequacy. However, use of the guideline did not improve clinical outcomes. Trial Registration anzctr. org. au Identifier: ACTRN12608000407392.	[Doig, Gordon S.; Simpson, Fiona; Finfer, Simon; Delaney, Anthony] Univ Sydney, Royal N Shore Hosp, No Clin Sch, Sydney, NSW 2006, Australia; [Finfer, Simon] Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; [Davies, Andrew R.] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia; [Mitchell, Imogen] Canberra Hosp, Canberra, ACT, Australia; [Dobb, Geoff] Royal Perth Hosp, Perth, WA, Australia	Royal North Shore Hospital; University of Sydney; University of Sydney; Florey Institute of Neuroscience & Mental Health; Monash University; Australian National University; Canberra Hospital; Royal Perth Hospital; University of Western Australia	Doig, GS (corresponding author), Univ Sydney, Royal N Shore Hosp, No Clin Sch, Sydney, NSW 2006, Australia.	gdoig@med.usyd.edu.au	Joyce, Christopher/B-7437-2013; Delaney, Anthony/AAE-3365-2019	Finfer, Simon/0000-0002-2785-5864; Simpson, Fiona/0000-0002-4598-2488; Delaney, Anthony/0000-0002-1015-7146; Doig, Gordon/0000-0003-2141-7000; Mitchell, Imogen/0000-0001-6013-4922; Ferrie, Suzie/0000-0001-6100-0117	Australian and New Zealand Intensive Care (ANZIC) Foundation (http: //www.intensivecareappeal.com/); Novartis; Abbott Laboratories; Nutricia; Fresenius-Kabi; Baxter	Australian and New Zealand Intensive Care (ANZIC) Foundation (http: //www.intensivecareappeal.com/); Novartis(Novartis); Abbott Laboratories(Abbott Laboratories); Nutricia(Danone Nutricia); Fresenius-Kabi; Baxter	This work was supported in full by a peer-reviewed grant from the Australian and New Zealand Intensive Care (ANZIC) Foundation (http: //www.intensivecareappeal.com/). The ANZIC foundation received major support from Novartis and Abbott Laboratories and significant support from Nutricia, Fresenius-Kabi, and Baxter.	ABEL RM, 1973, NEW ENGL J MED, V288, P695, DOI 10.1056/NEJM197304052881401; Bernard GR, 1995, AM J RESP CRIT CARE, V151, pA323; Borbas C, 2000, CHEST, V118, p24S, DOI 10.1378/chest.118.2_suppl.24S; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; Buchan H, 2004, MED J AUSTRALIA, V180, pS48; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; COOK DJ, 1995, UPD INT CAR, V19, pR19; Doig GS, 2006, CURR OPIN CRIT CARE, V12, P126, DOI 10.1097/01.ccx.0000216579.34310.84; Doig GS, 2005, ANESTH ANALG, V100, P527, DOI 10.1213/01.ANE.0000141676.12552.D0; DOIG GS, 2005, EVIDENCE BASED GUIDE; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; Donner A, 1996, J CLIN EPIDEMIOL, V49, P435, DOI 10.1016/0895-4356(95)00511-0; Greenhalgh T, 2004, MILBANK Q, V82, P581, DOI 10.1111/j.0887-378X.2004.00325.x; GRILLI R, 1994, MED CARE, V32, P202, DOI 10.1097/00005650-199403000-00002; Grimshaw J, 2006, J GEN INTERN MED, V21, pS14, DOI 10.1111/j.1525-1497.2006.00357.x; Gross PA, 2001, MED CARE, V39, pII55; Halpern SD, 2002, JAMA-J AM MED ASSOC, V288, P358, DOI 10.1001/jama.288.3.358; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P74, DOI 10.1177/014860710302700174; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; HISS RG, 1978, P 17 ANN C RES MED E, P283; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Jain MK, 2006, CRIT CARE MED, V34, P2362, DOI 10.1097/01.CCM.0000234044.91893.9C; *JOINT FAC INT CAR, MIN STAND INT CAR UN; Kerry SM, 1998, BRIT MED J, V316, P1455, DOI 10.1136/bmj.316.7142.1455; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Landsberger HA, 1958, HAWTHORNE REVISITED; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Localio AR, 2001, ANN INTERN MED, V135, P112, DOI 10.7326/0003-4819-135-2-200107170-00012; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; PRENTICE RL, 1989, STAT MED, V8, P431, DOI 10.1002/sim.4780080407; Roberts PR, 1997, AM J RESP CRIT CARE, V156, P1265, DOI 10.1164/ajrccm.156.4.9607003; Rogers E.M, 1995, DIFFUSION INNOVATION; ROGERS EM, 1995, JOINT COMM J QUAL IM, V21, P324, DOI 10.1016/S1070-3241(16)30155-9; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Simpson F, 2007, J EVAL CLIN PRACT, V13, P709, DOI 10.1111/j.1365-2753.2006.00717.x; Sinuff T, 2007, CRIT CARE MED, V35, P2083, DOI 10.1097/01.ccm.0000281446.15342.74; *STAT CORP, 2001, STAT COMP PROGR REL; TOBACK FG, 1977, KIDNEY INT, V12, P193, DOI 10.1038/ki.1977.100; Walters SJ, 2009, PHARM STAT, V8, P163, DOI 10.1002/pst.334; *WHO, 2000, ACLUSTER COMP PROGR; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; ENTERAL NUTR EN FEED; 2001, STATA 7 USERS GUIDE	44	282	301	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	2008	300	23					2731	2741		10.1001/jama.2008.826	http://dx.doi.org/10.1001/jama.2008.826			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	384FJ	19088351	Bronze			2023-01-03	WOS:000261730400020
J	Hall, AJ; Logan, JE; Toblin, RL; Kaplan, JA; Kraner, JC; Bixler, D; Crosby, AE; Paulozzi, LJ				Hall, Aron J.; Logan, Joseph E.; Toblin, Robin L.; Kaplan, James A.; Kraner, James C.; Bixler, Danae; Crosby, Alex E.; Paulozzi, Leonard J.			Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; OPIOID ANALGESICS; CHRONIC PAIN; DEATHS	Context Use and abuse of prescription narcotic analgesics have increased dramatically in the United States since 1990. The effect of this pharmacoepidemic has been most pronounced in rural states, including West Virginia, which experienced the nation's largest increase in drug overdose mortality rates during 1999- 2004. Objective To evaluate the risk characteristics of persons dying of unintentional pharmaceutical overdose in West Virginia, the types of drugs involved, and the role of drug abuse in the deaths. Design, Setting, and Participants Population- based, observational study using data from medical examiner, prescription drug monitoring program, and opiate treatment program records. The study population was all state residents who died of unintentional pharmaceutical overdoses in West Virginia in 2006. Main Outcome Measures Rates and rate ratios for selected demographic variables. Prevalence of specific drugs among decedents and proportion that had been prescribed to decedents. Associations between demographics and substance abuse indicators and evidence of pharmaceutical diversion, defined as a death involving a prescription drug without a documented prescription and having received prescriptions for controlled substances from 5 or more clinicians during the year prior to death ( ie, doctor shopping). Results Of 295 decedents, 198 ( 67.1%) were men and 271 ( 91.9%) were aged 18 through 54 years. Pharmaceutical diversion was associated with 186 ( 63.1%) deaths, while 63 ( 21.4%) were accompanied by evidence of doctor shopping. Prevalence of diversion was greatest among decedents aged 18 through 24 years and decreased across each successive age group. Having prescriptions for a controlled substance from 5 or more clinicians in the year prior to death was more common among women (30 [ 30.9%]) and decedents aged 35 through 44 years ( 23 [ 30.7%]) compared with men ( 33 [ 16.7%]) and other age groups ( 40 [ 18.2%]). Substance abuse indicators were identified in 279 decedents ( 94.6%), with nonmedical routes of exposure and illicit contributory drugs particularly prevalent among drug diverters. Multiple contributory substances were implicated in 234 deaths ( 79.3%). Opioid analgesics were taken by 275 decedents (93.2%), of whom only 122 ( 44.4%) had ever been prescribed these drugs. Conclusion The majority of overdose deaths in West Virginia in 2006 were associated with nonmedical use and diversion of pharmaceuticals, primarily opioid analgesics.	[Hall, Aron J.; Logan, Joseph E.; Toblin, Robin L.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30333 USA; [Logan, Joseph E.; Toblin, Robin L.; Crosby, Alex E.; Paulozzi, Leonard J.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA; [Hall, Aron J.; Bixler, Danae] W Virginia Dept Hlth & Human Resources, Div Surveillance & Dis Control, Charleston, WV USA; [Kaplan, James A.; Kraner, James C.] W Virginia Dept Hlth & Human Resources, Off Chief Med Examiner, Charleston, WV USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Hall, AJ (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,Mailstop A-47, Atlanta, GA 30333 USA.	ajhall@cdc.gov						[Anonymous], MOD POL US CONTR SUB; BISHAW A, EVALUATION POVERTY E; *CDCP, 2007, CDC WONDER; *CDCP, HLTH US 2006 CHARTB; Drug Abuse Warning Network, 2005, NAT EST DRUG REL EM; *DRUG ENF ADM, 2007, DEA APP REP W VIRG 2; Drug Enforcement Administration Diversion Control Division, STAT PRESCR DRUG MON; Foley K, 2000, JAMA-J AM MED ASSOC, V283, P115, DOI 10.1001/jama.283.1.115; Gilson AM, 2007, CA-CANCER J CLIN, V57, P341, DOI 10.3322/CA.57.6.341; Haddox JD, 1997, CLIN J PAIN, V13, P6; Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x; *NAT DRUG INT CTR, 2008, 2008R0813001 US DEP; Paulozzi L., 2007, Morbidity and Mortality Weekly Report, V56, P93; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; Substance Abuse and Mental Health Services Administration, DRUG AB WARN NETW DA; Substance Abuse and Mental Health Services Administration, RES 2005 NAT SURV DR; Substance Abuse and Mental Health Services Administration Office of Applied Studies, NSDUH REP PATT TREND; Sullivan MD, 2006, ARCH INTERN MED, V166, P2087, DOI 10.1001/archinte.166.19.2087; Toombs JD, 2005, AM FAM PHYSICIAN, V71, P1353; Trescot Andrea M, 2006, Pain Physician, V9, P1; TURLEY E, DRUG VIOLENT CRIME C; *US BUR CENS, POP AR HOUS UN DENS; *US BUR CENS, 2006 AM COMM SURV; *US BUR CENS, SMALL AR INC POV EST; *US BUR CENS, 2006 ANN STAT POP ES; *US DEP JUST DRUG, ARCOS AUT REP CONS O; Washington State Agency Medical Directors' Group, 2010, INT GUID OP DOS CHRO; Wilson PR, 1997, ANESTHESIOLOGY, V86, P995	29	615	621	1	44	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 10	2008	300	22					2613	2620		10.1001/jama.2008.802	http://dx.doi.org/10.1001/jama.2008.802			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380YW	19066381	Bronze			2023-01-03	WOS:000261503000020
J	Alkire, MT; Hudetz, AG; Tononi, G				Alkire, Michael T.; Hudetz, Anthony G.; Tononi, Giulio			Consciousness and Anesthesia	SCIENCE			English	Review							CEREBRAL-BLOOD-FLOW; COGNITIVE NEUROSCIENCE; GENERAL-ANESTHESIA; NEURONAL PATHWAYS; BISPECTRAL INDEX; NITROUS-OXIDE; SLEEP; BRAIN; ISOFLURANE; AWARENESS	When we are anesthetized, we expect consciousness to vanish. But does it always? Although anesthesia undoubtedly induces unresponsiveness and amnesia, the extent to which it causes unconsciousness is harder to establish. For instance, certain anesthetics act on areas of the brain's cortex near the midline and abolish behavioral responsiveness, but not necessarily consciousness. Unconsciousness is likely to ensue when a complex of brain regions in the posterior parietal area is inactivated. Consciousness vanishes when anesthetics produce functional disconnection in this posterior complex, interrupting cortical communication and causing a loss of integration; or when they lead to bistable, stereotypic responses, causing a loss of information capacity. Thus, anesthetics seem to cause unconsciousness when they block the brain's ability to integrate information.	[Tononi, Giulio] Univ Wisconsin, Dept Psychiat, Madison, WI 53719 USA; [Alkire, Michael T.] Univ Calif Irvine, Dept Anesthesiol, Irvine, CA 92868 USA; [Alkire, Michael T.] Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92868 USA; [Hudetz, Anthony G.] Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Irvine; University of California System; University of California Irvine; Medical College of Wisconsin	Tononi, G (corresponding author), Univ Wisconsin, Dept Psychiat, Madison, WI 53719 USA.	gtononi@wisc.edu	Tononi, Giulio/B-8387-2009		NIH Director's Pioneer Award; James S. McDonnell Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056398] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD000579] Funding Source: NIH RePORTER	NIH Director's Pioneer Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James S. McDonnell Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the NIH Director's Pioneer Award and the James S. McDonnell Foundation (G.T.). G.T. has a patent pending on the use of TMS-EEG in anesthesia.	Alkire MT, 2008, P NATL ACAD SCI USA, V105, P1722, DOI 10.1073/pnas.0711651105; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Alkire MT, 2005, PROG BRAIN RES, V150, P229, DOI 10.1016/S0079-6123(05)50017-7; Alkire MT, 2000, CONSCIOUS COGN, V9, P370, DOI 10.1006/ccog.1999.0423; ALKIRE MT, 2007, ANESTHESIOLOGY, V104, pA1219; ANGEL A, 1993, BRIT J ANAESTH, V71, P148, DOI 10.1093/bja/71.1.148; [Anonymous], 2006, ANESTHESIOLOGY, V104, P847; Baars BJ, 2005, PROG BRAIN RES, V150, P45, DOI 10.1016/S0079-6123(05)50004-9; Balduzzi D, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000091; Blumenfeld H, 2005, PROG BRAIN RES, V150, P271, DOI 10.1016/S0079-6123(05)50020-7; Campagna JA, 2003, NEW ENGL J MED, V348, P2110, DOI 10.1056/NEJMra021261; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Crick FC, 2005, PHILOS T R SOC B, V360, P1271, DOI 10.1098/rstb.2005.1661; Dehaene S, 2003, P NATL ACAD SCI USA, V100, P8520, DOI 10.1073/pnas.1332574100; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; FRENCH JD, 1955, J NEUROPHYSIOL, V18, P74, DOI 10.1152/jn.1955.18.1.74; Guillery RW, 2002, NEURON, V33, P163, DOI 10.1016/S0896-6273(01)00582-7; Gyulai FE, 1996, ANESTH ANALG, V83, P291, DOI 10.1097/00000539-199608000-00016; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hobson JA, 2000, BEHAV BRAIN SCI, V23, P793, DOI 10.1017/S0140525X00003976; Hudetz A., 2006, SEMIN ANESTH PERIO M, V25, P196, DOI [DOI 10.1053/j.sane.2006.09.003, 10.1053/j.sane.2006.09.003]; Hudetz AG, 2008, INT ANESTHESIOL CLIN, V46, P25, DOI 10.1097/AIA.0b013e3181755db5; Hudetz AG, 2007, ANESTHESIOLOGY, V107, P983, DOI 10.1097/01.anes.0000291471.80659.55; Imas OA, 2005, NEUROSCI LETT, V387, P145, DOI 10.1016/j.neulet.2005.06.018; Imas OA, 2006, NEUROSCI LETT, V402, P216, DOI 10.1016/j.neulet.2006.04.003; John ER, 2005, ANESTHESIOLOGY, V102, P447, DOI 10.1097/00000542-200502000-00030; Jones EG, 2002, PHILOS T R SOC B, V357, P1659, DOI 10.1098/rstb.2002.1168; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Langsjo JW, 2005, ANESTHESIOLOGY, V103, P258; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Lydic R, 2005, ANESTHESIOLOGY, V103, P1268; Magnin M, 2004, CEREB CORTEX, V14, P858, DOI 10.1093/cercor/bhh044; Maquet P, 2000, J SLEEP RES, V9, P207; Markowitsch HJ, 2000, EXP BRAIN RES, V133, P94, DOI 10.1007/s002210000404; Mashour GA, 2004, ANESTHESIOLOGY, V100, P428, DOI 10.1097/00000542-200402000-00035; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Massimini M, 2007, P NATL ACAD SCI USA, V104, P8496, DOI 10.1073/pnas.0702495104; MILLER JW, 1990, NEUROPHARMACOLOGY, V29, P649, DOI 10.1016/0028-3908(90)90026-N; MUNGLANI R, 1993, BRIT J ANAESTH, V71, P633, DOI 10.1093/bja/71.5.633; Myles PS, 2004, LANCET, V363, P1757, DOI 10.1016/S0140-6736(04)16300-9; NAKAKIMURA K, 1988, ANESTHESIOLOGY, V68, P777, DOI 10.1097/00000542-198805000-00017; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; POSNER JB, 2007, CONT NEUROLOGY SER, V71; Ries CR, 1999, J NEUROPHYSIOL, V81, P1795, DOI 10.1152/jn.1999.81.4.1795; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schneider G, 2003, BRIT J ANAESTH, V91, P329, DOI 10.1093/bja/aeg188; Sebel PS, 2004, ANESTH ANALG, V99, P833, DOI 10.1213/01.ANE.0000130261.90896.6C; Steriade M, 2001, J NEUROPHYSIOL, V85, P1969, DOI 10.1152/jn.2001.85.5.1969; Steyn-Ross ML, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011917; Super H, 2001, NAT NEUROSCI, V4, P304, DOI 10.1038/85170; Tononi Giulio, 2004, BMC Neurosci, V5, P42, DOI 10.1186/1471-2202-5-42; TOPULOS GP, 1993, J CLIN ANESTH, V5, P369, DOI 10.1016/0952-8180(93)90099-Z; TUCKER MR, 1984, J ORAL MAXIL SURG, V42, P668, DOI 10.1016/0278-2391(84)90210-6; Vahle-Hinz C, 2007, EXP BRAIN RES, V176, P159, DOI 10.1007/s00221-006-0604-6; Velly LJ, 2007, ANESTHESIOLOGY, V107, P202, DOI 10.1097/01.anes.0000270734.99298.b4; Veselis RA, 2004, ANESTH ANALG, V99, P399, DOI 10.1213/01.ANE.0000131971.92180.DF; Veselis RA, 2002, ANESTHESIOLOGY, V97, P329, DOI 10.1097/00000542-200208000-00008; VILLABLANCA J, 1972, ARCH ITAL BIOL, V110, P383; Vogeley K, 2004, J COGNITIVE NEUROSCI, V16, P817, DOI 10.1162/089892904970799; Voss L, 2007, BEST PRACT RES-CLIN, V21, P313, DOI 10.1016/j.bpa.2007.04.003; White NS, 2003, NEUROIMAGE, V19, P402, DOI 10.1016/S1053-8119(03)00103-4; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606	66	764	781	5	175	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 7	2008	322	5903					876	880		10.1126/science.1149213	http://dx.doi.org/10.1126/science.1149213			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369DI	18988836	Green Accepted			2023-01-03	WOS:000260674100030
J	Tran, TA; de Herve, MGD; Hendel-Chavez, H; Dembele, B; Le Nevot, E; Abbed, K; Pallier, C; Goujard, C; Gasnault, J; Delfraissy, JF; Balazuc, AM; Taoufik, Y				Tran, Tu-Anh; de Herve, Marie-Ghislaine de Goer; Hendel-Chavez, Houria; Dembele, Bamory; Le Nevot, Emilie; Abbed, Karim; Pallier, Coralie; Goujard, Cecile; Gasnault, Jacques; Delfraissy, Jean-Francois; Balazuc, Anne-Marie; Taoufik, Yassine			Resting Regulatory CD4 T Cells: A Site of HIV Persistence in Patients on Long-Term Effective Antiretroviral Therapy	PLOS ONE			English	Article								Background: In HIV-infected patients on long-term HAART, virus persistence in resting long-lived CD4 T cells is a major barrier to curing the infection. Cell quiescence, by favouring HIV latency, reduces the risk of recognition and cell destruction by cytotoxic lymphocytes. Several cell-activation-based approaches have been proposed to disrupt cell quiescence and then virus latency, but these approaches have not eradicated the virus. CD4(+)CD25(+) regulatory T cells (Tregs) are a CD4(+) T-cell subset with particular activation properties. We investigated the role of these cells in virus persistence in patients on long-term HAART. Methodology/Principal Findings: We found evidence of infection of resting Tregs (HLADR(-)CD69(-)CD25(hi)FoxP3(+)CD4(+) T cells) purified from patients on prolonged HAART. HIV DNA harbouring cells appear more abundant in the Treg subset than in non-Tregs. The half-life of the Treg reservoir was estimated at 20 months. Since Tregs from patients on prolonged HAART showed hyporesponsiveness to cell activation and inhibition of HIV-specific cytotoxic T lymphocyte-related functions upon activation, therapeutics targeting cell quiescence to induce virus expression may not be appropriate for purging the Treg reservoir. Conclusions: Our results identify Tregs as a particular compartment within the latent reservoir that may require a specific approach for its purging.	[Tran, Tu-Anh; de Herve, Marie-Ghislaine de Goer; Dembele, Bamory; Goujard, Cecile; Gasnault, Jacques; Delfraissy, Jean-Francois; Taoufik, Yassine] Univ Paris 11, INSERM, U802, Le Kremlin Bicetre, France; [Hendel-Chavez, Houria; Le Nevot, Emilie; Abbed, Karim; Taoufik, Yassine] AP HP, Hop Bicetre, Unite Immunol Biol, Le Kremlin Bicetre, France; [Goujard, Cecile; Gasnault, Jacques; Delfraissy, Jean-Francois] AP HP, Hop Bicetre, Serv Med Interne, Le Kremlin Bicetre, France; [Pallier, Coralie] AP HP, Hop Bicetre, Lab Virol, Le Kremlin Bicetre, France; [Balazuc, Anne-Marie] Inst Pasteur, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Tran, TA (corresponding author), Univ Paris 11, INSERM, U802, Le Kremlin Bicetre, France.	yacine.taoufik@bct.aphp.fr		TRAN, Tu-Anh/0000-0001-6587-1876; DEMBELE, Bamory/0000-0002-6165-9090	INSERM; ANRS; SIDACTION; Universite Paris 11	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANRS(ANRSFrench National Research Agency (ANR)); SIDACTION; Universite Paris 11	The work was supported by grants from INSERM, ANRS, SIDACTION and Universite Paris 11.	Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454-2459.2004; Ahmadzadeh M, 2006, BLOOD, V107, P2409, DOI 10.1182/blood-2005-06-2399; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245, DOI 10.4049/jimmunol.167.3.1245; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454; Camara NOS, 2003, EUR J IMMUNOL, V33, P3473, DOI 10.1002/eji.200323966; Chase AJ, 2007, J VIROL, V81, P12748, DOI 10.1128/JVI.00841-07; Chun TW, 2007, J INFECT DIS, V195, P1762, DOI 10.1086/518250; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Demoustier A, 2002, AIDS, V16, P1749, DOI 10.1097/00002030-200209060-00006; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; GEERAERT L, 2007, ANN REV MED; Grant C, 2006, PLOS PATHOG, V2, P303, DOI 10.1371/journal.ppat.0020033; Harnaha J, 2006, DIABETES, V55, P158, DOI 10.2337/diabetes.55.01.06.db05-0340; Hermankova M, 2003, J VIROL, V77, P7383, DOI 10.1128/JVI.77.13.7383-7392.2003; Iyasere C, 2003, J VIROL, V77, P10900, DOI 10.1128/JVI.77.20.10900-10909.2003; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Kinter A, 2007, P NATL ACAD SCI USA, V104, P3390, DOI 10.1073/pnas.0611423104; Kinter AL, 2007, AIDS RES HUM RETROV, V23, P438, DOI 10.1089/aid.2006.0162; Lambotte O, 2002, AIDS, V16, P2151, DOI 10.1097/00002030-200211080-00007; Lambotte O, 2000, J ACQ IMMUN DEF SYND, V23, P114; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Li LQ, 2005, BLOOD, V106, P3068, DOI 10.1182/blood-2005-04-1531; Lim HW, 2005, J IMMUNOL, V175, P4180, DOI 10.4049/jimmunol.175.7.4180; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Malek TR, 2004, NAT REV IMMUNOL, V4, P665, DOI 10.1038/nri1435; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Piccirillo CA, 2001, J IMMUNOL, V167, P1137, DOI 10.4049/jimmunol.167.3.1137; Pierson T, 2000, ANNU REV IMMUNOL, V18, P665, DOI 10.1146/annurev.immunol.18.1.665; Ramratnam B, 2004, JAIDS-J ACQ IMM DEF, V35, P33, DOI 10.1097/00126334-200401010-00004; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Rouse BT, 2006, IMMUNOL REV, V212, P272, DOI 10.1111/j.0105-2896.2006.00412.x; Sagot-Lerolle N, 2008, AIDS, V22, P1125, DOI 10.1097/QAD.0b013e3282fd6ddc; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Siliciano JD, 2007, J INFECT DIS, V195, P833, DOI 10.1086/511823; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Takahashi T, 1998, INT IMMUNOL, V10, P1969, DOI 10.1093/intimm/10.12.1969; von Boehmer H, 2003, J EXP MED, V198, P845, DOI 10.1084/jem.20031358; Wang FX, 2005, J CLIN INVEST, V115, P128, DOI 10.1172/JCI200522574; Weiss L, 2004, BLOOD, V104, P3249, DOI 10.1182/blood-2004-01-0365; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yang QE, 2004, MED SCI MONITOR, V10, pRA155; Ylisastigui L, 2004, AIDS, V18, P1101, DOI 10.1097/00002030-200405210-00003; Younes SA, 2003, J EXP MED, V198, P1909, DOI 10.1084/jem.20031598; Ziegler SF, 2006, ANNU REV IMMUNOL, V24, P209, DOI 10.1146/annurev.immunol.24.021605.090547	51	67	67	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 1	2008	3	10							e3305	10.1371/journal.pone.0003305	http://dx.doi.org/10.1371/journal.pone.0003305			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	427RU	18827929	Green Published, Green Submitted, gold			2023-01-03	WOS:000264797200010
J	Shen, L; Peterson, S; Sedaghat, AR; McMahon, MA; Callender, M; Zhang, HL; Zhou, Y; Pitt, E; Anderson, KS; Acosta, EP; Siliciano, RF				Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.; McMahon, Moira A.; Callender, Marc; Zhang, Haili; Zhou, Yan; Pitt, Eleanor; Anderson, Karen S.; Acosta, Edward P.; Siliciano, Robert F.			Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs	NATURE MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; DARUNAVIR-RITONAVIR; VIRAL DYNAMICS; INFECTION; THERAPY; PHARMACODYNAMICS; SUSCEPTIBILITY; REPLICATION; ZIDOVUDINE	Highly active antiretroviral therapy (HAART) can control HIV-1 replication(1,2), but suboptimal treatment allows for the evolution of resistance and rebound viremia(3-8). A comparative measure of antiviral activity under clinically relevant conditions would guide drug development and the selection of regimens that maximally suppress replication. Here we show that current measures of antiviral activity, including IC(50) and inhibitory quotient, neglect a key dimension, the dose-response curve slope. Using infectivity assays with wide dynamic range, we show that this slope has noteworthy effects on antiviral activity. Slope values are class specific for antiviral drugs and define intrinsic limitations on antiviral activity for some classes. Nucleoside reverse transcriptase inhibitors and integrase inhibitors have slopes of similar to 1, characteristic of noncooperative reactions, whereas non-nucleoside reverse transcriptase inhibitors, protease inhibitors and fusion inhibitors unexpectedly show slopes >1. Instantaneous inhibitory potential (IIP), the log reduction in single-round infectivity at clinical drug concentrations, is strongly influenced by slope and varies by >8 logs for anti-HIV drugs. IIP provides a more accurate measure of antiviral activity and in general correlates with clinical outcomes. Only agents with slopes >1 achieve high-level inhibition of single-round infectivity, a finding with profound implications for drug and vaccine development.	[Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.; McMahon, Moira A.; Callender, Marc; Zhang, Haili; Zhou, Yan; Pitt, Eleanor; Siliciano, Robert F.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Shen, Lin; McMahon, Moira A.] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; [Anderson, Karen S.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Acosta, Edward P.] Univ Alabama, Med Sch Birmingham, Div Clin Pharmacol, Birmingham, AL 35294 USA; [Siliciano, Robert F.] Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Yale University; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute	Siliciano, RF (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, 733 N Broadway, Baltimore, MD 21205 USA.	rsiliciano@jhmi.edu		Wilson, Eleanor/0000-0002-4855-514X; McMahon, Moira/0000-0001-9810-8623; Shen, Lin/0000-0003-2392-3353	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043222, R37AI051178, R01AI051178] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R37 AI051178-06A1, AI51178, R01 AI051178, R37 AI051178, R37 AI051178-07, R01 AI043222-10, R01 AI051178-05, R01 AI043222-08, R01 AI043222, AI43222, R01 AI043222-09] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACOSTA EP, 2007, ANTIRETROVIRAL PHARM, P115; Ambrose Z, 2006, J VIROL, V80, P2578, DOI 10.1128/JVI.80.5.2578-2581.2006; BARTLETT JG, 2007, 2007 MED MANAGEMENT, V510; CHOU TC, 1976, J THEOR BIOL, V59, P253, DOI 10.1016/0022-5193(76)90169-7; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clotet B, 2007, LANCET, V369, P1169, DOI 10.1016/S0140-6736(07)60497-8; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Ferguson NM, 2001, TRENDS PHARMACOL SCI, V22, P97, DOI 10.1016/S0165-6147(00)01615-1; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hoefnagel JGM, 2005, ANTIVIR THER, V10, P879; HOFFMAN A, 1994, J PHARMACOKINET BIOP, V2, P449; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; Madruga JV, 2007, LANCET, V370, P49, DOI 10.1016/S0140-6736(07)61049-6; McMahon MA, 2007, NEW ENGL J MED, V356, P2614, DOI 10.1056/NEJMoa067710; Morse GD, 2006, LANCET INFECT DIS, V6, P215, DOI 10.1016/S1473-3099(06)70436-4; ORTIZ R, 1948, AIDS IN PRESS; Pandey KK, 2007, J VIROL, V81, P12189, DOI 10.1128/JVI.02863-06; Pommier Y, 2005, NAT REV DRUG DISCOV, V4, P236, DOI 10.1038/nrd1660; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sedaghat AR, 2008, P NATL ACAD SCI USA, V105, P4832, DOI 10.1073/pnas.0711372105; Talal AH, 2006, HEPATOLOGY, V43, P943, DOI 10.1002/hep.21136; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481; Zhang HL, 2004, J VIROL, V78, P1718, DOI 10.1128/JVI.78.4.1718-1729.2004; 2008, PANEL ANTIRETROVIRAL	29	237	241	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	JUL	2008	14	7					762	766		10.1038/nm1777	http://dx.doi.org/10.1038/nm1777			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	323NL	18552857	Bronze, Green Accepted			2023-01-03	WOS:000257452700024
J	Goldstein, NE; Genden, E; Morrison, RS				Goldstein, Nathan E.; Genden, Eric; Morrison, R. Sean			Palliative care for patients with head and neck cancer - "I would like a quick return to a normal lifestyle"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; RADIATION-INDUCED XEROSTOMIA; SQUAMOUS-CELL CARCINOMA; INDUCED ORAL MUCOSITIS; HUMAN-PAPILLOMAVIRUS; PROGNOSTIC-FACTORS; LARYNGEAL-CANCER; PHASE-III; MANAGEMENT	Head and neck cancers constitute a diverse group of diseases including malignancies of the oral cavity, oropharynx, larynx, sinuses, and skull base. Treatment of these cancers includes a combination of surgical resection, chemotherapy, and radiation. Due to both the patterns of disease recurrence and the adverse effects of treatments, patients with head and neck cancer often have a complex and prolonged course of illness that is marked by periods of freedom from disease and symptoms interspersed with bouts of serious illness, debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia. Thus, management of this disease is best provided by an interdisciplinary team that includes individuals from the disciplines of otolaryngology, palliative care, radiation oncology, oncology, nutrition, speech, and physical and occupational therapy. Using the case of Mr K, we describe the symptoms encountered by patients with head and neck cancer and suggest options for management. We discuss the psychological aspects that affect these patients, including issues such as changes in body image, quality of life, anxiety, and guilt. Finally, we discuss the importance of the interdisciplinary team in the care of these patients and outline the roles of each team member. By providing comprehensive care to patients with malignancies of the head and neck, clinicians can increase the likelihood that patients and their families will be able to obtain the best possible outcomes and quality of life.	[Goldstein, Nathan E.; Morrison, R. Sean] Mt Sinai Sch Med, Hertzberg Palliat Care Inst, Brookdale Dept Geriatr & Adult Dev, New York, NY 10029 USA; [Genden, Eric] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; [Goldstein, Nathan E.; Morrison, R. Sean] James J Peters VA Med Ctr, Bronx, NY USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center	Goldstein, NE (corresponding author), Mt Sinai Sch Med, Dept Geriatr, Box 1070,1 Gustave Levy Pl, New York, NY 10029 USA.	nathan.goldstein@mssm.edu			NIA NIH HHS [K23AG025933, K24AG22345] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K24AG022345, K23AG025933] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abuksis G, 2000, AM J GASTROENTEROL, V95, P128; Agar MH., 2004, CLIN PRACT GUID QUAL, DOI 10.4135/9781848608191; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Babin E, 2008, EUR ARCH OTO-RHINO-L, V265, P265, DOI 10.1007/s00405-007-0561-0; Baghi M, 2007, LARYNGOSCOPE, V117, P712, DOI 10.1097/mlg.0b013e318031d0b4; Ballonoff A, 2006, OTOLARYNG CLIN N AM, V39, P365, DOI 10.1016/j.otc.2005.11.004; Birkhaug EJ, 2002, EUR ARCH OTO-RHINO-L, V259, P197, DOI 10.1107/s00405-001-0444-8; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; Boffetta P, 1997, AM J EPIDEMIOL, V145, P1100; Bolderston A, 2006, SUPPORT CARE CANCER, V14, P802, DOI 10.1007/s00520-006-0063-4; Boldt AM, 2006, J PALLIAT MED, V9, P1128, DOI 10.1089/jpm.2006.9.1128; Bourhis J, 2002, SEMIN ONCOL, V29, P61, DOI 10.1053/sonc.2002.37349; Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339; Brosky Mary Elizabeth, 2007, J Support Oncol, V5, P215; Buentzel J, 2006, INT J RADIAT ONCOL, V64, P684, DOI 10.1016/j.ijrobp.2005.08.005; Callahan C, 2004, SOC WORK HEALTH CARE, V40, P73, DOI 10.1300/J010v40n02_05; Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740; Chambers MS, 2007, HEAD NECK-J SCI SPEC, V29, P58, DOI 10.1002/hed.20456; Chan Alexandre, 2005, J Oncol Pharm Pract, V11, P139, DOI 10.1191/1078155205jp166oa; Clarkson JE, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001973.pub3; Cohen James, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P110, DOI 10.1097/00020840-200404000-00010; Cooper JS, 2004, NEW ENGL J MED, V350, P1937, DOI 10.1056/NEJMoa032646; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056/NEJMoa065497; DAHLIN C, 2001, TXB PALLIATIVE NURSI, P122; de Bree R, 2008, EUR ARCH OTO-RHINO-L, V265, P1, DOI 10.1007/s00405-007-0413-y; Dikshit RP, 2005, INT J CANCER, V117, P992, DOI 10.1002/ijc.21244; Dirix P, 2006, CANCER-AM CANCER SOC, V107, P2525, DOI 10.1002/cncr.22302; Dropkin M J, 1989, Semin Oncol Nurs, V5, P213, DOI 10.1016/0749-2081(89)90095-8; Duffy SA, 2007, PSYCHOSOMATICS, V48, P142, DOI 10.1176/appi.psy.48.2.142; Ellershaw J, 2003, BRIT MED J, V326, P30, DOI 10.1136/bmj.326.7379.30; EMANUEL LL, 1999, EPEC PARTICIPANTS HD; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Foley KM, 2001, IMPROVING PALLIATIVE; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Forastiere AA, 2000, ONCOLOGY-NY, V14, P163; Frampton M, 2001, BRIT J ORAL MAX SURG, V39, P67, DOI 10.1054/bjom.2000.0547; Ganzini L, 2003, NEW ENGL J MED, V349, P359, DOI 10.1056/NEJMsa035086; Genden EM, 2006, AURIS NASUS LARYNX, V33, P1, DOI 10.1016/j.anl.2005.09.008; Genden EM, 2007, ORAL ONCOL, V43, P431, DOI 10.1016/j.oraloncology.2006.08.007; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Goldstein NE, 2005, CRIT REV ONCOL HEMAT, V54, P157, DOI 10.1016/j.critrevonc.2005.01.001; Gould Lisa, 2006, Br J Nurs, V15, P1091; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Hammerlid E, 2001, BRIT J CANCER, V84, P149, DOI 10.1054/bjoc.2000.1576; HANKS G, 2005, OXFORD TXB PALLIATIV, P316; Hearn J, 1998, PALLIATIVE MED, V12, P317, DOI 10.1191/026921698676226729; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Himmerich H, 2006, DIABETES CARE, V29, P170, DOI 10.2337/diacare.29.1.170; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Laimer M, 2006, J CLIN PSYCHIAT, V67, P421, DOI 10.4088/JCP.v67n0313; Lazarus C L, 2000, Semin Speech Lang, V21, P293, DOI 10.1055/s-2000-8383; Ledeboer QCP, 2005, CLIN OTOLARYNGOL, V30, P303, DOI 10.1111/j.1365-2273.2005.01035.x; Lussier D, 2004, ONCOLOGIST, V9, P571, DOI 10.1634/theoncologist.9-5-571; MEIER D, 2005, OXFORD TXB PALLIATIV, P935; Meier DE, 2001, JAMA-J AM MED ASSOC, V286, P3007, DOI 10.1001/jama.286.23.3007; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; MURPHY BA, 2005, OXFORD TXB PALLIATIV, P658; Murphy BA, 2007, CRIT REV ONCOL HEMAT, V62, P251, DOI 10.1016/j.critrevonc.2006.07.005; Ouwens MMMTJ, 2007, HEAD NECK-J SCI SPEC, V29, P378, DOI 10.1002/hed.20532; Pandey M, 2007, PSYCHO-ONCOL, V16, P582, DOI 10.1002/pon.1123; PAYNE R, 2005, OXFORD TXB PALLIATIV, P288; Posner M, 2007, ONCOLOGIST, V12, P967, DOI 10.1634/theoncologist.12-8-967; Rodriguez KL, 2007, J PALLIAT MED, V10, P99, DOI 10.1089/jpm.2006.0155; Rosenquist Kerstin, 2005, Swed Dent J Suppl, P1; Sanders DS, 2000, AM J GASTROENTEROL, V95, P1472, DOI 10.1111/j.1572-0241.2000.02079.x; Scharloo M, 2005, HEAD NECK-J SCI SPEC, V27, P857, DOI 10.1002/hed.20251; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; Scully C, 2004, HEAD NECK-J SCI SPEC, V26, P77, DOI 10.1002/hed.10326; Shiboski CH, 2007, ORAL SURG ORAL MED O, V103, pS66, DOI 10.1016/j.tripleo.2006.11.013; Stalfors J, 2007, ACTA OTO-LARYNGOL, V127, P82, DOI 10.1080/00016480600740589; Stokman MA, 2006, J DENT RES, V85, P690, DOI 10.1177/154405910608500802; Tagay S, 2006, QUAL LIFE RES, V15, P695, DOI 10.1007/s11136-005-3689-7; Treister Nathaniel, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P123, DOI 10.1097/MOO.0b013e3280523ad6; Twaddle ML, 2007, J PALLIAT MED, V10, P86, DOI 10.1089/jpm.2006.0048; Vakharia KT, 2007, OTOLARYNG HEAD NECK, V136, P405, DOI 10.1016/j.otohns.2006.10.018; Verdonck-de Leeuw IM, 2007, LARYNGOSCOPE, V117, P238, DOI 10.1097/01.mlg.0000250169.10241.58; Worthington HV, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub3	81	32	34	1	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 16	2008	299	15					1818	1825		10.1001/jama.299.15.1818	http://dx.doi.org/10.1001/jama.299.15.1818			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	287ZA	18413876				2023-01-03	WOS:000254954800026
J	Clatworthy, MR; Williams, P; Watson, CJ; Jamieson, NV				Clatworthy, Menna R.; Williams, Paul; Watson, Christopher J.; Jamieson, Neville V.			The calcified abdominal cocoon	LANCET			English	Editorial Material									[Clatworthy, Menna R.; Williams, Paul] Addenbrookes Hosp, Dept Renal Med, Cambridge CB2 0QQ, England; [Watson, Christopher J.; Jamieson, Neville V.] Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 0QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Clatworthy, MR (corresponding author), Addenbrookes Hosp, Dept Renal Med, Cambridge CB2 0QQ, England.	mrc38@cam.ac.uk						GHANDI VC, 1980, ARCH INTERN MED, V140, P1201	1	9	10	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR-MAY	2008	371	9622					1452	1452		10.1016/S0140-6736(08)60625-X	http://dx.doi.org/10.1016/S0140-6736(08)60625-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	294XW	18440427	Bronze			2023-01-03	WOS:000255440600026
J	Garcia-Alias, G; Barkhuysen, S; Buckle, M; Fawcett, JW				Garcia-Alias, Guillermo; Barkhuysen, Stanley; Buckle, Miranda; Fawcett, James W.			Chondroitinase ABC treatment opens a window of opportunity for task-specific rehabilitation	NATURE NEUROSCIENCE			English	Article							SPINAL-CORD-INJURY; CENTRAL-NERVOUS-SYSTEM; IMPROVES FUNCTIONAL RECOVERY; SENSORIMOTOR CORTEX LESIONS; FORELIMB MOTOR FUNCTION; CORTICOSPINAL TRACT; SYNAPTIC PLASTICITY; PYRAMIDAL TRACT; BRAIN-INJURY; ADULT RATS	Chondroitinase ABC treatment promotes spinal cord plasticity. We investigated whether chondroitinase-induced plasticity combined with physical rehabilitation promotes recovery of manual dexterity in rats with cervical spinal cord injuries. Rats received a C4 dorsal funiculus cut followed by chondroitinase ABC or penicillinase as a control. They were assigned to two alternative rehabilitation procedures, the first reinforcing skilled reaching and the second reinforcing general locomotion. Chondroitinase treatment enhanced sprouting of corticospinal axons independently of the rehabilitation regime. Only the rats receiving the combination of chondroitinase and specific rehabilitation showed improved manual dexterity. Rats that received general locomotor rehabilitation were better at ladder walking, but had worse skilled-reaching abilities than rats that received no treatment. Our results indicate that chondroitinase treatment opens a window during which rehabilitation can promote recovery. However, only the trained skills are improved and other functions may be negatively affected.	[Garcia-Alias, Guillermo; Barkhuysen, Stanley; Buckle, Miranda; Fawcett, James W.] Univ Cambridge, Dept Clin Neurosci, Ctr Brain Repair, Cambridge, England	University of Cambridge	Fawcett, JW (corresponding author), Univ Cambridge, Dept Clin Neurosci, Ctr Brain Repair, Cambridge, England.	jf108@cam.ac.uk	Garcia-Alias, Guillermo/AAB-8595-2021	Fawcett, James/0000-0002-7990-4568; Buckle, Miranda/0000-0002-6722-7125	Medical Research Council; Wellcome Trust; Christopher and Dana Reeve Foundation Consortium; EU Framework 6 Network of Excellence NeuroNE; Henry Smith Charity and Action Medical Research; MRC [G9828345, G0701518] Funding Source: UKRI; Medical Research Council [G9828345, G0701518] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Christopher and Dana Reeve Foundation Consortium; EU Framework 6 Network of Excellence NeuroNE; Henry Smith Charity and Action Medical Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The authors acknowledge key advice and assistance from H. Steenson in animal care and testing. This work was funded by grants from the Medical Research Council, The Wellcome Trust, The Christopher and Dana Reeve Foundation Consortium, The EU Framework 6 Network of Excellence NeuroNE, the Henry Smith Charity and Action Medical Research.	Adkins DL, 2008, EXP NEUROL, V212, P14, DOI 10.1016/j.expneurol.2008.01.031; Allred RP, 2008, EXP NEUROL, V210, P172, DOI 10.1016/j.expneurol.2007.10.010; Anderson KD, 2005, EXP NEUROL, V194, P161, DOI 10.1016/j.expneurol.2005.02.006; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; Anderson KD, 2007, EXP NEUROL, V206, P318, DOI 10.1016/j.expneurol.2007.05.024; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Beazley LD, 2003, J NEUROTRAUM, V20, P1263, DOI 10.1089/089771503770802925; Benowitz LI, 1999, P NATL ACAD SCI USA, V96, P13486, DOI 10.1073/pnas.96.23.13486; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Blochlinger S, 2001, J COMP NEUROL, V433, P426, DOI 10.1002/cne.1150; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; Cho SH, 2007, NEUROSCI LETT, V426, P123, DOI 10.1016/j.neulet.2007.08.049; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dunlop SA, 2008, TRENDS NEUROSCI, V31, P410, DOI 10.1016/j.tins.2008.05.004; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Freund P, 2007, J COMP NEUROL, V502, P644, DOI 10.1002/cne.21321; Galtrey CM, 2008, EUR J NEUROSCI, V27, P1373, DOI 10.1111/j.1460-9568.2008.06108.x; Galtrey CM, 2007, BRAIN, V130, P926, DOI 10.1093/brain/awl372; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Garcia-Alias G., 2006, SOC NEUR ABSTR; Garcia-Alias G, 2008, EXP NEUROL, V210, P331, DOI 10.1016/j.expneurol.2007.11.002; Girgis J, 2007, BRAIN, V130, P2993, DOI 10.1093/brain/awm245; Grill R, 1997, J NEUROSCI, V17, P5560; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; Kozlowski DA, 1996, J NEUROSCI, V16, P4776; Kwok JCF, 2008, RESTOR NEUROL NEUROS, V26, P131; Lemon RN, 2005, MUSCLE NERVE, V32, P261, DOI 10.1002/mus.20333; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; McKenna JE, 1999, J NEUROSCI, V19, P1885; Petruska JC, 2007, J NEUROSCI, V27, P4460, DOI 10.1523/JNEUROSCI.2302-06.2007; Pettersson LG, 2007, ACTA PHYSIOL, V189, P141, DOI 10.1111/j.1748-1716.2006.01650.x; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Plunet WT, 2008, EXP NEUROL, V213, P28, DOI 10.1016/j.expneurol.2008.04.011; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Ribotta MGY, 2000, J NEUROSCI, V20, P5144; Starkey ML, 2005, EXP NEUROL, V195, P524, DOI 10.1016/j.expneurol.2005.06.017; Steward O, 2004, J COMP NEUROL, V472, P463, DOI 10.1002/cne.20090; WHISHAW IQ, 1993, BEHAV BRAIN RES, V56, P59, DOI 10.1016/0166-4328(93)90022-I; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Yamamoto M, 2009, BRAIN RES, V1265, P47, DOI 10.1016/j.brainres.2009.02.019; Ying Z, 2005, EXP NEUROL, V193, P411, DOI 10.1016/j.expneurol.2005.01.015	49	348	353	1	22	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2009	12	9					1145	U16		10.1038/nn.2377	http://dx.doi.org/10.1038/nn.2377			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	487ZD	19668200				2023-01-03	WOS:000269317300016
J	Lanaspa, MA; Andres-Hernando, A; Rivard, CJ; Dai, Y; Li, NX; Berl, T				Lanaspa, Miguel A.; Andres-Hernando, Ana; Rivard, Christopher J.; Dai, Yue; Li, Nanxing; Berl, Tomas			ZAC1 Is Up-regulated by Hypertonicity and Decreases Sorbitol Dehydrogenase Expression, Allowing Accumulation of Sorbitol in Kidney Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING PROTEIN; ALDOSE REDUCTASE; OSMOTIC-STRESS; CELLULAR-RESPONSE; DIABETIC-RATS; RENAL-CELLS; GENE; TONICITY; ADAPTATION; MEDULLA	Affymetrix GeneChip technology was employed to detect differentially expressed genes in inner medullary collecting duct (IMCD3) cells grown under isotonic and hypertonic conditions. A marked up-regulation was found for the zinc-finger protein ZAC1 under hypertonic stress (219-fold, p < 0.001). Changes in expression for ZAC1 were verified by quantitative PCR for message and Western blotting for protein. In mouse and human kidney tissues, ZAC1 expression was substantial in the papilla and was absent in the cortex. Furthermore, ZAC1 expression significantly increased in the papilla of mice following 36 h of fluid restriction and decreased in polyuric mice consuming sucrose in water. Because ZAC1 has been described to be a potential negative regulator of sorbitol dehydrogenase (SDH) in hippocampal cells, we examined whether this relationship also occurs in kidney cells under hypertonic stress. We found that stable IMCD3 clones silenced for ZAC1 to varying levels demonstrated an inverse effect on SDH expression. ZAC1 binds to a consensus repression site within the promoter of SDH, pointing to a mechanism whereby ZAC1 acts by repressing SDH transcriptional activity during hypertonic conditions. Taken together, these data strongly suggest that ZAC1 is up-regulated under hypertonic stress and negatively regulates expression of SDH, allowing for accumulation of sorbitol as a compatible organic osmolyte.	[Lanaspa, Miguel A.; Andres-Hernando, Ana; Rivard, Christopher J.; Dai, Yue; Li, Nanxing; Berl, Tomas] Univ Colorado, Dept Renal Dis & Hypertens, Hlth Sci Ctr, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Berl, T (corresponding author), Univ Colorado, Dept Renal Dis & Hypertens, Hlth Sci Ctr, 12700 E 19th Ave,C281, Aurora, CO 80045 USA.	tomas.berl@ucdenver.edu	Lanaspa, Miguel/AAO-4971-2020	Andres-Hernando, Ana/0000-0002-0676-0188	National Institutes of Health [DK-19928, DK-66544]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066544, P01DK019928] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK-19928 and DK-66544 (to T.B.).	Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 2007, J CELL PHYSIOL, V210, P16, DOI 10.1002/jcp.20835; Andres-Hernando A, 2008, J BIOL CHEM, V283, P25082, DOI 10.1074/jbc.M802381200; Barz T, 2006, CANCER RES, V66, P11975, DOI 10.1158/0008-5472.CAN-06-1529; Beck FX, 1998, PFLUG ARCH EUR J PHY, V436, P814, DOI 10.1007/s004240050710; Berl T, 2000, AM J KIDNEY DIS, V35, pXLVII, DOI 10.1016/S0272-6386(00)70035-7; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Burger-Kentischer A, 1999, KIDNEY INT, V55, P1417, DOI 10.1046/j.1523-1755.1999.00382.x; Capasso JM, 2003, ANN NY ACAD SCI, V986, P410, DOI 10.1111/j.1749-6632.2003.tb07222.x; Capasso JM, 2001, AM J PHYSIOL-RENAL, V280, pF768, DOI 10.1152/ajprenal.2001.280.5.F768; Dmitrieva NI, 2005, MUTAT RES-FUND MOL M, V569, P65, DOI 10.1016/j.mrfmmm.2004.06.053; Flogel U, 1996, DEV NEUROSCI-BASEL, V18, P449, DOI 10.1159/000111440; Grunewald RW, 1998, CELL PHYSIOL BIOCHEM, V8, P293, DOI 10.1159/000016291; Handler JS, 2001, KIDNEY INT, V60, P408, DOI 10.1046/j.1523-1755.2001.060002408.x; Handler JS, 2001, NEPHRON, V87, P106, DOI 10.1159/000045897; Handler JS, 1996, KIDNEY INT, V49, P1682, DOI 10.1038/ki.1996.246; Hoffmann A, 2003, MOL CELL BIOL, V23, P988, DOI 10.1128/MCB.23.3.988-1003.2003; Hoffmann A, 1998, ANN NY ACAD SCI, V865, P49, DOI 10.1111/j.1749-6632.1998.tb11162.x; Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298; Jeon US, 2006, ACTA PHYSIOL, V187, P241, DOI 10.1111/j.1748-1716.2006.01551.x; Kador PF, 1998, EXP EYE RES, V67, P203, DOI 10.1006/exer.1998.0502; Klawitter J, 2008, NEPHRON PHYSIOL, V109, pP1, DOI 10.1159/000129074; Lanaspa MA, 2007, P NATL ACAD SCI USA, V104, P13672, DOI 10.1073/pnas.0702752104; LEE AYW, 1995, P NATL ACAD SCI USA, V92, P2780, DOI 10.1073/pnas.92.7.2780; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; Pagotto U, 1999, ENDOCRINOLOGY, V140, P987, DOI 10.1210/en.140.2.987; Petrash JM, 2004, CELL MOL LIFE SCI, V61, P737, DOI 10.1007/s00018-003-3402-3; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Raccah D, 1998, J DIABETES COMPLICAT, V12, P154, DOI 10.1016/S1056-8727(97)00093-7; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Rivard CJ, 2007, J BIOL CHEM, V282, P6644, DOI 10.1074/jbc.M609432200; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Woo SK, 2002, INT REV CYTOL, V215, P189	36	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 24	2009	284	30					19974	19981		10.1074/jbc.M109.001792	http://dx.doi.org/10.1074/jbc.M109.001792			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	471ZO	19423711	Green Published, hybrid			2023-01-03	WOS:000268097400024
J	Hyder, AA; Merritt, MW				Hyder, Adnan A.; Merritt, Maria W.			Ancillary Care for Public Health Research in Developing Countries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MEDICAL RESEARCHERS; CLINICAL CARE; RESPONSIBILITIES		[Hyder, Adnan A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA; Johns Hopkins Berman Inst Bioeth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Hyder, AA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St,Ste E-8132, Baltimore, MD 21205 USA.	ahyder@jhsph.edu	Hyder, Adnan/AAT-9503-2021	Hyder, Adnan/0000-0002-7292-577X	FOGARTY INTERNATIONAL CENTER [D43TW007292, R25TW001604] Funding Source: NIH RePORTER; FIC NIH HHS [R25-TW01604, D43 TW007292, R25 TW001604] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		[Anonymous], 2008, PLOS MED, V5, pe90; Belsky L, 2004, BRIT MED J, V328, P1494, DOI 10.1136/bmj.328.7454.1494; Dickert N, 2007, LANCET, V369, P874, DOI 10.1016/S0140-6736(07)60416-4; Richardson HS, 2007, AM J PUBLIC HEALTH, V97, P1956, DOI 10.2105/AJPH.2006.093658; Richardson HS, 2004, HASTINGS CENT REP, V34, P25, DOI 10.2307/3528248; Watkins Kevin., 2007, HUMAN DEV REPORT 200	6	28	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 22	2009	302	4					429	431		10.1001/jama.2009.1072	http://dx.doi.org/10.1001/jama.2009.1072			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	472NQ	19622822	Green Accepted			2023-01-03	WOS:000268139200026
J	Hefele, B; Naumann, N; Trollmann, R; Dittrich, K; Rascher, W				Hefele, Barbara; Naumann, Nora; Trollmann, Regina; Dittrich, Katalin; Rascher, Wolgang			Fast-in, fast-out	LANCET			English	Editorial Material							GAMMA-HYDROXYBUTYRATE		[Hefele, Barbara; Naumann, Nora; Trollmann, Regina; Dittrich, Katalin; Rascher, Wolgang] Univ Erlangen Nurnberg, Hosp Children & Adolescents, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Hefele, B (corresponding author), Univ Erlangen Nurnberg, Hosp Children & Adolescents, Loschgestr 15, D-91054 Erlangen, Germany.	Barbara.Hefele@uk-erlange.de						Brenneisen R, 2004, J ANAL TOXICOL, V28, P625, DOI 10.1093/jat/28.8.625; European Monitoring Centre for Drugs and Drug Addiction, 2008, EMCDDA THEM PAP GHB; Miro O, 2002, J TOXICOL-CLIN TOXIC, V40, P129, DOI 10.1081/CLT-120004400; Ricaurte GA, 2005, LANCET, V365, P2137, DOI 10.1016/S0140-6736(05)66737-2; Snead OC, 2005, NEW ENGL J MED, V352, P2721, DOI 10.1056/NEJMra044047	5	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 18	2009	373	9672					1398	1398		10.1016/S0140-6736(09)60570-5	http://dx.doi.org/10.1016/S0140-6736(09)60570-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	434UR	19376455				2023-01-03	WOS:000265300100038
J	Tomson, CRV				Tomson, Charles R. V.			Blood pressure and outcome in patients on dialysis	LANCET			English	Editorial Material							REVERSE EPIDEMIOLOGY; ESRD PATIENTS; HEMODIALYSIS; HYPERTENSION; MORTALITY; SURVIVAL; FALL		Southmead Hosp, Dept Renal Med, Bristol BS10 5NB, Avon, England	Southmead Hospital	Tomson, CRV (corresponding author), Southmead Hosp, Dept Renal Med, Bristol BS10 5NB, Avon, England.	charlie.tomson@nbt.nhs.uk		Tomson, Charles/0000-0002-0224-8726				Dasselaar JJ, 2009, NEPHROL DIAL TRANSPL, V24, P604, DOI 10.1093/ndt/gfn501; Fishbane S, 1996, AM J KIDNEY DIS, V28, P257, DOI 10.1016/S0272-6386(96)90309-1; Inrig JK, 2007, KIDNEY INT, V71, P454, DOI 10.1038/sj.ki.5002077; Kalantar-Zadeh K, 2003, KIDNEY INT, V63, P793, DOI 10.1046/j.1523-1755.2003.00803.x; Kalantar-Zadeh K, 2005, HYPERTENSION, V45, P811, DOI 10.1161/01.HYP.0000154895.18269.67; LAMBERSHEERSPIN.HJ, 2009, LANCET, V373, P1009, DOI DOI 10.1016/S0140-6736(09)60212-9; Leypoldt JK, 2002, KIDNEY INT, V61, P266, DOI 10.1046/j.1523-1755.2002.00099.x; Luik AJ, 1998, BLOOD PURIFICAT, V16, P197, DOI 10.1159/000014335; Lynn KL, 2002, KIDNEY INT, V62, P2281, DOI 10.1046/j.1523-1755.2002.00685.x; Mazzuchi N, 2000, KIDNEY INT, V58, P2147; Shaldon S, 2008, NEPHROL DIAL TRANSPL, V23, P2118, DOI 10.1093/ndt/gfn175; Shoji T, 2004, KIDNEY INT, V66, P1212, DOI 10.1111/j.1523-1755.2004.00812.x; Strippoli GFM, 2004, J AM SOC NEPHROL, V15, P411, DOI 10.1097/01.ASN.0000100125.21491.46	13	5	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 21	2009	373	9668					981	982		10.1016/S0140-6736(09)60213-0	http://dx.doi.org/10.1016/S0140-6736(09)60213-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	422AA	19249093				2023-01-03	WOS:000264398200004
J	Hacini-Rachinel, F; Gheit, H; Le Luduec, JB; Dif, F; Nancey, S; Kaiserlian, D				Hacini-Rachinel, Feriel; Gheit, Hanane; Le Luduec, Jean-Benoit; Dif, Fariel; Nancey, Stephane; Kaiserlian, Dominique			Oral Probiotic Control Skin Inflammation by Acting on Both Effector and Regulatory T Cells	PLOS ONE			English	Article								Probiotics are believed to alleviate allergic and inflammatory skin disorders, but their impact on pathogenic effector T cells remains poorly documented. Here we show that oral treatment with the probiotic bacteria L. casei (DN-114 001) alone alleviates antigen-specific skin inflammation mediated by either protein-specific CD4(+) T cells or hapten-specific CD8(+) T cells. In the model of CD8(+) T cell-mediated skin inflammation, which reproduces allergic contact dermatitis in human, inhibition of skin inflammation by L. casei is not due to impaired priming of hapten-specific IFN gamma-producing cytolytic CD8(+) effector T cells. Alternatively, L. casei treatment reduces the recruitment of CD8(+) effector T cells into the skin during the elicitation (i.e. symptomatic) phase of CHS. Inhibition of skin inflammation by L. casei requires MHC class II-restricted CD4(+) T cells but not CD1d-restricted NK-T cells. L casei treatment enhanced the frequency of FoxP3(+) Treg in the skin and increased the production of IL-10 by CD4(+)CD25(+) regulatory T cells in skin draining lymph nodes of hapten-sensitized mice. These data demonstrate that orally administered L. casei (DN-114 001) efficiently alleviate T cell-mediated skin inflammation without causing immune suppression, via mechanisms that include control of CD8(+) effector T cells and involve regulatory CD4(+) T cells. L. casei (DN-114 001) may thus represent a probiotic of potential interest for immunomodulation of T cell-mediated allergic skin diseases in human.	[Hacini-Rachinel, Feriel; Gheit, Hanane; Le Luduec, Jean-Benoit; Nancey, Stephane; Kaiserlian, Dominique] Univ Lyon, Lyon, France; [Hacini-Rachinel, Feriel; Gheit, Hanane; Le Luduec, Jean-Benoit; Nancey, Stephane; Kaiserlian, Dominique] INSERM, U851, Lyon, France; [Hacini-Rachinel, Feriel; Gheit, Hanane; Le Luduec, Jean-Benoit; Nancey, Stephane; Kaiserlian, Dominique] Univ Lyon 1, IFR128, Lyon, France; [Dif, Fariel] Danone Res, Palaiseau, France; [Nancey, Stephane] Ctr Hosp Lyon Sud, Serv Gastroenterol, Hospices Civils Lyon, Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Danone Nutricia; CHU Lyon	Hacini-Rachinel, F (corresponding author), Univ Lyon, Lyon, France.	dominique.kaiserlian@inserm.fr	KAISERLIAN, Dominique/G-3325-2013; NANCEY, STEPHANE/Y-5093-2019	KAISERLIAN, Dominique/0000-0001-6252-4916; NANCEY, STEPHANE/0000-0003-2088-1442; LE LUDUEC, Jean-Benoit/0000-0002-1046-2941	INSERM; Danone Research Center Palaiseau, France; DANONE	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Danone Research Center Palaiseau, France(Danone Nutricia); DANONE(Danone Nutricia)	This work was supported by institutional grant from INSERM (infrastructure charges), and from grant from Danone Research Center (Palaiseau, France). F. Hacini-Rachinel is the recipient of a CIFRE this grant from DANONE. Danone as a private company has no role in study design, data collection or interpretation. The authors have no financial conflict of interest.	Akiba H, 2002, J IMMUNOL, V168, P3079, DOI 10.4049/jimmunol.168.6.3079; Baba N, 2008, J LEUKOCYTE BIOL, V84, P468, DOI 10.1189/jlb.0108017; Boirivant M, 2007, CURR OPIN GASTROEN, V23, P679, DOI 10.1097/MOG.0b013e3282f0cffc; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; Chapat L, 2004, EUR J IMMUNOL, V34, P2520, DOI 10.1002/eji.200425139; Chen JP, 2005, EUR J IMMUNOL, V35, P690, DOI 10.1002/eji.200425577; Desvignes C, 2000, J IMMUNOL, V164, P2515, DOI 10.4049/jimmunol.164.5.2515; Di Giacinto C, 2005, J IMMUNOL, V174, P3237, DOI 10.4049/jimmunol.174.6.3237; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; ENK AH, 1995, J INVEST DERMATOL, V105, P80; Foligne B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000313; Gionchetti P, 2000, GASTROENTEROLOGY, V119, P305, DOI 10.1053/gast.2000.9370; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Krasteva M, 1998, J IMMUNOL, V160, P1181; Le Borgne M, 2006, IMMUNITY, V24, P191, DOI 10.1016/j.immuni.2006.01.005; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Mahnke K, 2007, EUR J IMMUNOL, V37, P2117, DOI 10.1002/eji.200636841; Menard S, 2004, GUT, V53, P821, DOI 10.1136/gut.2003.026252; Nancey S, 2006, GASTROENTEROLOGY, V131, P485, DOI 10.1053/j.gastro.2006.05.018; Okazaki F, 2002, J DERMATOL, V29, P699, DOI 10.1111/j.1346-8138.2002.tb00206.x; Reid G, 2003, J CLIN GASTROENTEROL, V37, P105, DOI 10.1097/00004836-200308000-00004; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Roelofs-Haarhuis K, 2004, J IMMUNOL, V173, P1043, DOI 10.4049/jimmunol.173.2.1043; Sartor RB, 2004, GASTROENTEROLOGY, V126, P1620, DOI 10.1053/j.gastro.2004.03.024; Schultz M, 2005, J MICROBIOL METH, V61, P389, DOI 10.1016/j.mimet.2005.01.007; Sheil B, 2004, GUT, V53, P694, DOI 10.1136/gut.2003.027789; So JS, 2008, MOL IMMUNOL, V45, P2690, DOI 10.1016/j.molimm.2007.12.010; Vocanson M, 2006, J INVEST DERMATOL, V126, P815, DOI 10.1038/sj.jid.5700174; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001	35	78	80	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 20	2009	4	3							e4903	10.1371/journal.pone.0004903	http://dx.doi.org/10.1371/journal.pone.0004903			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437OM	19300508	Green Published, Green Submitted, gold			2023-01-03	WOS:000265496800005
J	Weaver, LK				Weaver, Lindell K.			Carbon Monoxide Poisoning	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WHITE-MATTER HYPERINTENSITIES; HYPERBARIC-OXYGEN; CARBOXYHEMOGLOBIN LEVELS; RAT-BRAIN; INTOXICATION; SEQUELAE; PHOSPHORYLATION; SPECTROSCOPY; IMPAIRMENT; PREDICTION	A 39-year-old female executive has a several-month history of fatigue, headache, and memory lapse. Multiple specialists have performed evaluations, but no diagnosis has been established. During a period of feeling worse than usual, she called a friend, who arrived at the residence to find the woman semicomatose and called 911. The patient was given supplemental oxygen and transported to the emergency department, where she is alert and has nonfocal findings on examination. Her carboxyhemoglobin level is 18%. How should she be treated? What is the expected outcome?	[Weaver, Lindell K.] Latter Day St Hosp, Dept Hyperbar Med, Salt Lake City, UT 84143 USA; [Weaver, Lindell K.] Intermt Med Ctr, Dept Hyperbar Med, Murray, UT USA	Intermountain Healthcare; Intermountain Medical Center	Weaver, LK (corresponding author), Latter Day St Hosp, Dept Hyperbar Med, 8th Ave & C St, Salt Lake City, UT 84143 USA.	lindell.weaver@imail.org						Alonso JR, 2003, PHARMACOL TOXICOL, V93, P142, DOI 10.1034/j.1600-0773.2003.930306.x; Amitai Y, 1998, ARCH NEUROL-CHICAGO, V55, P845, DOI 10.1001/archneur.55.6.845; Annane D, 2001, INTENS CARE MED, V27, P1776, DOI 10.1007/s00134-001-1127-z; BALZAN MV, 1994, POSTGRAD MED J, V70, P699, DOI 10.1136/pgmj.70.828.699; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; BROWN SD, 1992, J CLIN INVEST, V89, P666, DOI 10.1172/JCI115633; Chin BY, 2007, P NATL ACAD SCI USA, V104, P5109, DOI 10.1073/pnas.0609611104; CHOI IS, 1983, ARCH NEUROL-CHICAGO, V40, P433, DOI 10.1001/archneur.1983.04050070063016; Cronje FJ, 2004, FREE RADICAL BIO MED, V37, P1802, DOI 10.1016/j.freeradbiomed.2004.08.022; den Heijer T, 2006, NEUROLOGY, V66, P540, DOI 10.1212/01.wnl.0000198256.54809.0e; DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9; Durak AC, 2005, ACTA RADIOL, V46, P322, DOI 10.1080/02841850510021085; Ernst A, 1998, NEW ENGL J MED, V339, P1603, DOI 10.1056/NEJM199811263392206; Gale SD, 1999, BRAIN INJURY, V13, P229, DOI 10.1080/026990599121601; Gesell L, 2008, HYPERBARIC OXYGEN TH; Hampson NB, 2007, UNDERSEA HYPERBAR M, V34, P163; Hampson NB, 2008, AM J EMERG MED, V26, P665, DOI 10.1016/j.ajem.2007.10.005; Hampson Neil B., 1995, Journal of Emergency Medicine, V13, P227, DOI 10.1016/0736-4679(94)00144-8; Hopkins RO, 2007, AM J RESP CRIT CARE, V176, P1001, DOI 10.1164/rccm.200702-290OC; Hopkins RO, 2008, UNDERSEA HYPERBAR M, V35, P258; Jasper BW, 2005, COGN BEHAV NEUROL, V18, P127, DOI 10.1097/01.wnn.0000160820.07836.cf; JUURLINK DN, 2005, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.PUB2; Kalay N, 2007, AM J CARDIOL, V99, P322, DOI 10.1016/j.amjcard.2006.08.030; KIM J K, 1987, Yonsei Medical Journal, V28, P266; KLEES M, 1985, SCI TOTAL ENVIRON, V44, P165, DOI 10.1016/0048-9697(85)90120-2; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; Mannaioni PF, 2006, INFLAMM RES, V55, P261, DOI 10.1007/s00011-006-0084-y; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; MYERS RAM, 1985, ANN EMERG MED, V14, P1163, DOI 10.1016/S0196-0644(85)81022-2; *NAT CTR ENV ASS O, 2000, EPA PUBL; Parkinson RB, 2002, NEUROLOGY, V58, P1525, DOI 10.1212/WNL.58.10.1525; Penney D, 2008, CARBON MONOXIDE POIS, P551; PETERSON JE, 1970, ARCH ENVIRON HEALTH, V21, P165, DOI 10.1080/00039896.1970.10667215; Piantadosi C.A., 1996, CARBON MONOXIDE, P163; Piantadosi CA, 1997, EXP NEUROL, V147, P103, DOI 10.1006/exnr.1997.6584; Pulsipher DT, 2006, UNDERSEA HYPERBAR M, V33, P245; RAPHAEL JC, 1989, LANCET, V2, P414; Satran D, 2005, J AM COLL CARDIOL, V45, P1513, DOI 10.1016/j.jacc.2005.01.044; Scheinkestel CD, 1999, MED J AUSTRALIA, V170, P203, DOI 10.5694/j.1326-5377.1999.tb140318.x; Smith EE, 2008, ARCH NEUROL-CHICAGO, V65, P94, DOI 10.1001/archneurol.2007.23; Suliman HB, 2007, J CELL SCI, V120, P299, DOI 10.1242/jcs.03318; Taille C, 2003, J BIOL CHEM, V278, P27160, DOI 10.1074/jbc.M300364200; Terajima K, 2008, EUR NEUROL, V59, P55, DOI 10.1159/000109262; Thom SR, 2008, PHYSL MED HYPERBARIC, V321, P347; Thom SR, 2006, AM J RESP CRIT CARE, V174, P1239, DOI 10.1164/rccm.200604-557OC; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; TOUGER M, 1995, ANN EMERG MED, V25, P481, DOI 10.1016/S0196-0644(95)70262-8; *UL, 1996, 2034 UL; VANHOESEN KB, 1989, JAMA-J AM MED ASSOC, V261, P1039, DOI 10.1001/jama.261.7.1039; VANHOESEN KB, 1990, JAMA-J AM MED ASSOC, V273, P2750; Weaver LK, 2007, AM J RESP CRIT CARE, V176, P491, DOI 10.1164/rccm.200701-026OC; Weaver LK, 2000, CHEST, V117, P801, DOI 10.1378/chest.117.3.801; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Weaver LK, 2008, UNDERSEA HYPERBAR M, P258; Wolf SJ, 2008, ANN EMERG MED, V51, P138, DOI 10.1016/j.annemergmed.2007.10.012; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	56	464	493	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 19	2009	360	12					1217	1225		10.1056/NEJMcp0808891	http://dx.doi.org/10.1056/NEJMcp0808891			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	420IU	19297574				2023-01-03	WOS:000264283400008
J	Roehr, B				Roehr, Bob			Should men who have ever had sex with men be allowed to give blood? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							TRANSFUSION					bobroehr@aol.com						Brooks JP, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b318; Germain M, 2003, TRANSFUSION, V43, P25, DOI 10.1046/j.1537-2995.2003.00281.x; Hladik W, 2006, NEW ENGL J MED, V355, P1331, DOI 10.1056/NEJMoa055009; Hurley R, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b779; Lebbe Celeste, 2008, Transplant Rev (Orlando), V22, P252, DOI 10.1016/j.trre.2008.05.004; Moore R J, 1991, Transfus Med, V1, P201, DOI 10.1111/j.1365-3148.1991.tb00034.x; O'Brien SF, 2007, TRANSFUSION, V47, P316, DOI 10.1111/j.1537-2995.2007.01108.x; Schrimshaw EW, 2006, ARCH SEX BEHAV, V35, P225, DOI 10.1007/s10508-005-9006-2; VAMVAKAS EC, 2009, BLOOD           0202; Weber B, 2006, EXPERT REV MOL DIAGN, V6, P399, DOI 10.1586/14737159.6.3.399	10	12	12	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	FEB 26	2009	338								b311	10.1136/bmj.b311	http://dx.doi.org/10.1136/bmj.b311			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	417DS	19246548				2023-01-03	WOS:000264056300006
J	Slutsky, AS; Hudson, LD; Dubler, NN; Weijer, C; Tonelli, MR				Slutsky, Arthur S.; Hudson, Leonard D.; Dubler, Nancy N.; Weijer, Charles; Tonelli, Mark R.			Care of an Unresponsive Patient with a Poor Prognosis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SURVIVAL		[Slutsky, Arthur S.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Slutsky, Arthur S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Hudson, Leonard D.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA; [Hudson, Leonard D.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Dubler, Nancy N.] Montefiore Med Ctr, Montefiore Einstein Ctr Bioeth, Bronx, NY 10467 USA; [Weijer, Charles] Univ Western Ontario, Dept Philosophy, London, ON, Canada; [Weijer, Charles] Univ Western Ontario, Dept Med, London, ON, Canada; [Tonelli, Mark R.] Univ Washington, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA; [Tonelli, Mark R.] Univ Washington, Med Ctr, Dept Bioeth & Humanities, Seattle, WA 98195 USA	University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Slutsky, AS (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.		Slutsky, Arthur/M-3325-2019					Annas GJ, 2005, NEW ENGL J MED, V352, P1710, DOI 10.1056/NEJMlim050643; Berger JT, 2008, ANN INTERN MED, V149, P48, DOI 10.7326/0003-4819-149-1-200807010-00010; Buchanan AE., 1990, DECIDING OTHERS ETHI; Dubler N. N., 2004, BIOETHICS MEDIATION; DUBLER NN, 1995, KENNEDY INST ETHIC J, V5, P289; Helft PR, 2000, NEW ENGL J MED, V343, P293, DOI 10.1056/NEJM200007273430411; Kapp M B, 1997, Univ Toledo Law Rev, V28, P521; LUCE JM, 1995, CRIT CARE MED, V23, P760, DOI 10.1097/00003246-199504000-00027; *PC, 1983, DEC FOR LIF SUST TRE; Reisfield GM, 2006, RESUSCITATION, V71, P152, DOI 10.1016/j.resuscitation.2006.02.022; Tonelli MR, 1997, J LAW MED ETHICS, V25, P22, DOI 10.1111/j.1748-720X.1997.tb01392.x; Toussaint LG, 2005, NEUROSURGERY, V57, P25, DOI 10.1227/01.NEU.0000163086.23124.70; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Weijer C, 1998, CAN MED ASSOC J, V159, P817	14	13	13	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	2009	360	5					527	531		10.1056/NEJMclde0808330	http://dx.doi.org/10.1056/NEJMclde0808330			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	399PS	19179322				2023-01-03	WOS:000262812400017
J	Beaver, K; Tysver-Robinson, D; Campbell, M; Twomey, M; Williamson, S; Hindley, A; Susnerwala, S; Dunn, G; Luker, K				Beaver, Kinta; Tysver-Robinson, Debbie; Campbell, Malcolm; Twomey, Mary; Williamson, Susan; Hindley, Andrew; Susnerwala, Shabbir; Dunn, Graham; Luker, Karen			Comparing hospital and telephone follow-up after treatment for breast cancer: randomised equivalence trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFORMATION NEEDS; ROUTINE FOLLOW; WOMEN	Objective To compare traditional hospital follow- up with telephone follow- up by specialist nurses after treatment for breast cancer. Design A two centre randomised equivalence trial in which women remained in the study for a mean of 24 months. Setting Outpatient clinics in two NHS hospital trusts in the north west of England. Participants 374 women treated for breast cancer who were at low to moderate risk of recurrence. Interventions Participants were randomised to traditional hospital follow- up ( consultation, clinical examination, and mammography as per hospital policy) or telephone follow- up by specialist nurses ( consultation with structured intervention and mammography according to hospital policy). Main outcome measures Psychological morbidity ( state-trait anxiety inventory, general health questionnaire ( GHQ- 12)), participants' needs for information, participants' satisfaction, clinical investigations ordered, and time to detection of recurrent disease. Results The 95% confidence interval for difference in mean state- trait scores adjusted for treatment received (- 3.33 to 2.07) was within the predefined equivalence region (- 3.5 to 3.5). The women in the telephone group were no more anxious as a result of foregoing clinic examinations and face- to- face consultations and reported higher levels of satisfaction than those attending hospital clinics ( intention to treat P< 0.001). The numbers of clinical investigations ordered did not differ between groups. Recurrences were few ( 4.5%), with no differences between groups for time to detection ( median 60.5 ( range 37- 131) days in hospital group v 39.0 ( 10- 152) days in telephone group; P= 0.228). Conclusions Telephone follow- up was well received by participants, with no physical or psychological disadvantage. It is suitable for women at low to moderate risk of recurrence and those with long travelling distances or mobility problems and decreases the burden on busy hospital clinics. Trial registration National Cancer Research Institute 1477.	[Beaver, Kinta; Campbell, Malcolm; Twomey, Mary; Williamson, Susan; Luker, Karen] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England; [Tysver-Robinson, Debbie] Blackpool Fylde & Wyre Hosp NHS Fdn Trust, Blackpool, Lancs, England; [Hindley, Andrew; Susnerwala, Shabbir] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England; [Dunn, Graham] Univ Manchester, Hlth Methodol Res Grp, Manchester M13 9PL, Lancs, England	University of Manchester; Royal Preston Hospital; University of Manchester	Beaver, K (corresponding author), Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England.	kinta.beaver@manchester.ac.uk	Campbell, Malcolm/D-3925-2011; Luker, Karen A/E-8735-2010	Campbell, Malcolm/0000-0002-6125-5731; Luker, Karen A/0000-0002-2437-2904; Beaver, Kinta/0000-0002-6552-2323	Medical Research Council (UK); Rosemere Cancer Foundation (UK)	Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Rosemere Cancer Foundation (UK)	The trial was funded by the Medical Research Council (UK) and a project grant from Rosemere Cancer Foundation (UK). The funding agencies had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, or in the preparation, review or approval of the manuscript	Armitage P, 2001, STAT METHODS MED RES, V4th; Ashkanani F, 2001, AM J SURG, V182, P207, DOI 10.1016/S0002-9610(01)00704-8; Baildam A, 2002, EUR J CANCER, V38, pS136, DOI 10.1016/S0959-8049(02)80448-8; Beaver K, 2005, PSYCHO-ONCOLOGY, V14, P94, DOI 10.1002/pon.824; Beaver K, 2006, EUR J ONCOL NURS, V10, P378, DOI 10.1016/j.ejon.2006.02.004; Boekhorst DST, 2001, EUR J SURG, V167, P490; Churn M, 2001, CLIN ONCOL-UK, V13, P187, DOI 10.1007/s001740170073; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; DEWAR JA, 1985, BRIT MED J, V291, P1464, DOI 10.1136/bmj.291.6507.1464; Donnelly J, 2001, INT J CLIN PRACT, V55, P431; Dunn G, 2007, STAT MED, V26, P4719, DOI 10.1002/sim.2891; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Goldberg D, 1978, MANUAL GEN HLTH QUES; Gotay C C, 1998, Eur J Cancer Care (Engl), V7, P225; GRUNFELD E, 1995, FAM PRACT, V12, P60, DOI 10.1093/fampra/12.1.60; Grunfeld E, 1996, BMJ-BRIT MED J, V313, P665; HAUSMAN JA, 1978, ECONOMETRICA, V46, P1251, DOI 10.2307/1913827; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Kitchener HC, 2006, BJOG-INT J OBSTET GY, V113, P1007, DOI 10.1111/j.1471-0528.2006.01035.x; Luker KA, 1996, J ADV NURS, V23, P487, DOI 10.1111/j.1365-2648.1996.tb00010.x; McArdle JMC, 1996, BMJ-BRIT MED J, V312, P813; Nagelkerke N, 2000, STAT MED, V19, P1849, DOI 10.1002/1097-0258(20000730)19:14<1849::AID-SIM506>3.0.CO;2-1; *NAT I HLTH CLIN E, 2002, IMPR OUTC BREAST CAN; NORUSIS MJ, 2007, SPSS 15 ADV STAT PRO; *OFF NAT STAT, HLTH BREAST CANC; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Rojas MP, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001768.pub2; Snee M, 1994, Clin Oncol (R Coll Radiol), V6, P154, DOI 10.1016/S0936-6555(94)80053-7; Spielberger C.D, 1983, PSYCTESTS DATASET, DOI DOI 10.1037/T06496; White IR, 2005, STAT METHODS MED RES, V14, P327, DOI 10.1191/0962280205sm406oa	30	111	112	1	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	2009	338								a3147	10.1136/bmj.a3147	http://dx.doi.org/10.1136/bmj.a3147			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405AA	19147478	hybrid, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000263193100003
J	Tang, JL; Liu, BY; Ma, KW				Tang, Jin-Ling; Liu, Bao-Yan; Ma, Kan-Wen			Traditional Chinese medicine	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS		[Tang, Jin-Ling] Chinese Univ Hong Kong, Hong Kong Cochrane Ctr, Sch Publ Hlth, Fac Med, Hong Kong, Peoples R China; [Liu, Bao-Yan] Chinese Acad Med Sci, Beijing 100037, Peoples R China; [Ma, Kan-Wen] UCL, Wellcome Trust Ctr Hist Med, London, England	Chinese University of Hong Kong; Chinese Academy of Medical Sciences - Peking Union Medical College; University of London; University College London	Tang, JL (corresponding author), Chinese Univ Hong Kong, Hong Kong Cochrane Ctr, Sch Publ Hlth, Fac Med, Hong Kong, Peoples R China.	jltang@cuhk.edu.hk	Al-Bayati, Lubna Lubna al Bayati/E-5100-2019; Tang, JL/G-1759-2013; Tang, Jin-Ling/AAJ-4090-2021; Ran, Mao-Sheng/I-7957-2013					*BEIJ U CHIN MED, 2006, CHIN STAT YB CHIN ME; BROWN AC, 2002, POTENTIALLY LIFE THR; European Medicines Agency, 2005, PUBL STAT RISK ASS U; Ezzo JM, 2006, COCHRANE DB SYST REV, V19, P2285, DOI DOI 10.1002/14651858.CD002285.PUB2; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; KAPTCHUK TJ, 2000, WEB THAT HAS NO WEAV; Keji C., 2003, EUR REV, V11, P225, DOI [10.1017/S106279870300022X, DOI 10.1017/S106279870300022X]; Liang MX, 1998, PREDICAMENTS FUTURE, P1; MA KW, 1993, EW MED EXCHANGES THE, P154; *MED HEALTHC PROD, 2006, TOUGH ACT UK MED REG; Pittler MH, 1999, CLIN INFECT DIS, V28, P597, DOI 10.1086/515148; STRATHERN P, 2005, BRIEF HIST MED, P179; Tang JL, 2006, BMJ-BRIT MED J, V333, P391, DOI 10.1136/bmj.333.7564.391; Tang JL, 1999, BMJ-BRIT MED J, V319, P160, DOI 10.1136/bmj.319.7203.160; Tomlinson B, 2000, J CLIN PHARMACOL, V40, P451, DOI 10.1177/00912700022009206; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Vines G, 2004, HERBAL HARVESTS FUTU; Wang G, 2007, CLIN THER, V29, P1456, DOI 10.1016/j.clinthera.2007.07.023; Zhang W, 2005, COCHRANE DB SYST REV, V2	19	305	314	8	91	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 6	2008	372	9654					1938	1940		10.1016/S0140-6736(08)61354-9	http://dx.doi.org/10.1016/S0140-6736(08)61354-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	380NE	18930523				2023-01-03	WOS:000261471600010
J	Arnon, TI; Markel, G; Bar-Ilan, A; Hanna, J; Fima, E; Benchetrit, F; Galili, R; Cerwenka, A; Benharroch, D; Sion-Vardy, N; Porgador, A; Mandelboim, O				Arnon, Tal I.; Markel, Gal; Bar-Ilan, Ahuva; Hanna, Jacob; Fima, Eyal; Benchetrit, Fabrice; Galili, Ruth; Cerwenka, Adelheid; Benharroch, Daniel; Sion-Vardy, Netta; Porgador, Angel; Mandelboim, Ofer			Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy	PLOS ONE			English	Article								The natural cytotoxic receptors (NCRs) are a unique set of activating proteins expressed mainly on the surface of natural killer (NK) cells. The NCRs, which include three members; NKp46, NKp44 and NKp30, are critically involved in NK cytotoxicity against different targets, including a wide range of tumor cells derived from various origins. Even though the tumor ligands of the NCRs have not been identified yet, the selective manner by which these receptors target tumor cells may provide an excellent basis for the development of novel anti-tumor therapies. To test the potential use of the NCRs as anti-tumor agents, we generated soluble NCR-Ig fusion proteins in which the constant region of human IgG1 was fused to the extracellular portion of the receptor. We demonstrate, using two different human prostate cancer cell lines, that treatment with NKp30-Ig, dramatically inhibits tumor growth in vivo. Activated macrophages were shown to mediate an ADCC response against the NKp30-Ig coated prostate cell lines. Finally, the Ig fusion proteins were also demonstrated to discriminate between benign prostate hyperplasia and prostate cancer. This may provide a novel diagnostic modality in the difficult task of differentiating between these highly common pathological conditions.	[Arnon, Tal I.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Markel, Gal] Sheba Med Ctr, Sheba Canc Res Ctr, Tel Hashomer, Israel; [Bar-Ilan, Ahuva; Fima, Eyal; Benchetrit, Fabrice; Porgador, Angel] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, Shraga Segal Dept Microbiol & Immunol, Beer Sheva, Israel; [Hanna, Jacob] Whitehead Inst Biomed Res, Cambridge, MA USA; [Galili, Ruth; Mandelboim, Ofer] Hebrew Univ Hadassah Med Sch, Lautenberg Ctr General & Tumor Immunol, Jerusalem, Israel; [Cerwenka, Adelheid] German Canc Res Ctr, Div Innate Immun, Heidelberg, Germany; [Benharroch, Daniel; Sion-Vardy, Netta] Soroka Hosp, Pathol Dept, Beer Sheva, Israel	California Institute of Technology; Chaim Sheba Medical Center; Ben Gurion University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Hebrew University of Jerusalem; Helmholtz Association; German Cancer Research Center (DKFZ); Ben Gurion University; Soroka Medical Center	Arnon, TI (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	angel@bgu.ac.il; oferman@md2.huji.ac.il	Hanna, Jacob/K-1339-2012	Hanna, Jacob/0000-0003-2042-9974; Cerwenka, Adelheid/0000-0001-6977-3536; Porgador, Angel/0000-0003-1540-4449; Mandelboim, Ofer/0000-0002-9354-1855				Adams JY, 2002, NAT MED, V8, P891, DOI 10.1038/nm743; Arnon TI, 2005, NAT IMMUNOL, V6, P515, DOI 10.1038/ni1190; Arnon TI, 2004, BLOOD, V103, P664, DOI 10.1182/blood-2003-05-1716; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Blattman JN, 2004, SCIENCE, V305, P200, DOI 10.1126/science.1100369; Bloushtain N, 2004, J IMMUNOL, V173, P2392, DOI 10.4049/jimmunol.173.4.2392; Caplan Aaron, 2002, Am J Clin Pathol, V117 Suppl, pS104; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Coiffier B, 2003, BLOOD REV, V17, P25, DOI 10.1016/S0268-960X(02)00059-0; Costello RT, 2004, TRENDS IMMUNOL, V25, P328, DOI 10.1016/j.it.2004.04.005; Costello RT, 2002, BLOOD, V99, P3661, DOI 10.1182/blood.V99.10.3661; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Glennie MJ, 2003, DRUG DISCOV TODAY, V8, P503, DOI 10.1016/S1359-6446(03)02714-4; HERSHKOVITZ O, 2007, GLYCOBIOLOGY    1115; Hershkovitz O, 2007, BIOCHEMISTRY-US, V46, P7426, DOI 10.1021/bi7000455; Iannello A, 2005, CANCER METAST REV, V24, P487, DOI 10.1007/s10555-005-6192-2; Liossis SNC, 2005, J ALLERGY CLIN IMMUN, V116, P721, DOI 10.1016/j.jaci.2005.06.035; Lodoen MB, 2005, NAT REV MICROBIOL, V3, P59, DOI 10.1038/nrmicro1066; Lowe FC, 2005, DRUG TODAY, V41, P179, DOI 10.1358/dot.2005.41.3.892523; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Milas L, 2000, CLIN CANCER RES, V6, P701; Moretta L, 2002, SCAND J IMMUNOL, V55, P229, DOI 10.1046/j.1365-3083.2002.01055.x; Moretta L, 2002, EUR J IMMUNOL, V32, P1205, DOI 10.1002/1521-4141(200205)32:5<1205::AID-IMMU1205>3.0.CO;2-Y; Moretta Lorenzo, 2001, Current Opinion in Pharmacology, V1, P387, DOI 10.1016/S1471-4892(01)00067-4; Pende D, 1999, J EXP MED, V190, P1505, DOI 10.1084/jem.190.10.1505; Pessino A, 1998, J EXP MED, V188, P953, DOI 10.1084/jem.188.5.953; Porgador A, 2005, THESCIENTIFICWORLDJO, V5, P151, DOI 10.1100/tsw.2005.22; PRESS OW, 2001, IMMUNOTHERAPY NONHOD, P221; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Shaffer DR, 2003, LANCET ONCOL, V4, P407, DOI 10.1016/S1470-2045(03)01138-0; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sivori S, 1997, J EXP MED, V186, P1129, DOI 10.1084/jem.186.7.1129; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; Swindle P, 2003, RADIOLOGY, V228, P144, DOI 10.1148/radiol.2281011808; Vitale M, 1998, J EXP MED, V187, P2065, DOI 10.1084/jem.187.12.2065; Yokoyama WM, 2005, ADV EXP MED BIOL, V560, P57; Zilka A, 2005, BIOCHEMISTRY-US, V44, P14477, DOI 10.1021/bi051241s	42	27	28	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2008	3	5							e2150	10.1371/journal.pone.0002150	http://dx.doi.org/10.1371/journal.pone.0002150			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	390OE	18478075	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000262172800015
J	Movsesyan, N; Ghochikyan, A; Mkrtichyan, M; Petrushina, I; Davtyan, H; Olkhanud, PB; Head, E; Biragyn, A; Cribbs, DH; Agadjanyan, MG				Movsesyan, Nina; Ghochikyan, Anahit; Mkrtichyan, Mikayel; Petrushina, Irina; Davtyan, Hayk; Olkhanud, Purevdorj B.; Head, Elizabeth; Biragyn, Arya; Cribbs, David H.; Agadjanyan, Michael G.			Reducing AD-Like Pathology in 3xTg-AD Mouse Model by DNA Epitope Vaccine - A Novel Immunotherapeutic Strategy	PLOS ONE			English	Article								Background: The development of a safe and effective AD vaccine requires a delicate balance between providing an adequate anti-A beta antibody response sufficient to provide therapeutic benefit, while eliminating an adverse T cell-mediated proinflammatory autoimmune response. To achieve this goal we have designed a prototype chemokine-based DNA epitope vaccine expressing a fusion protein that consists of 3 copies of the self-B cell epitope of A beta(42) (A beta(1-11)), a non-self T helper cell epitope (PADRE), and macrophage-derived chemokine (MDC/CCL22) as a molecular adjuvant to promote a strong anti-inflammatory Th2 phenotype. Methods and Findings: We generated pMDC-3A beta(1-11)-PADRE construct and immunized 3xTg-AD mouse model starting at age of 3-4 months old. We demonstrated that prophylactic immunizations with the DNA epitope vaccine generated a robust Th2 immune response that induced high titers of anti-A beta antibody, which in turn inhibited accumulation of A beta pathology in the brains of older mice. Importantly, vaccination reduced glial activation and prevented the development of behavioral deficits in aged animals without increasing the incidence of microhemorrhages. Conclusions: Data from this transitional pre-clinical study suggest that our DNA epitope vaccine could be used as a safe and effective strategy for AD therapy. Future safety and immunology studies in large animals with the goal to achieve effective humoral immunity without adverse effects should help to translate this study to human clinical trials.	[Movsesyan, Nina; Ghochikyan, Anahit; Mkrtichyan, Mikayel; Davtyan, Hayk; Agadjanyan, Michael G.] Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA USA; [Movsesyan, Nina; Petrushina, Irina; Head, Elizabeth; Cribbs, David H.; Agadjanyan, Michael G.] Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA USA; [Olkhanud, Purevdorj B.; Biragyn, Arya] NIA, Lab Immunol, Immunotherapeut Unit, Baltimore, MD USA; [Head, Elizabeth; Cribbs, David H.] Univ Calif Irvine, Dept Neurol, Irvine, CA USA	University of California System; University of California Irvine; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of California System; University of California Irvine	Movsesyan, N (corresponding author), Inst Mol Med, Dept Mol Immunol, Huntington Beach, CA USA.	magadjanyan@immed.org		Ghochikyan, Anahit/0000-0001-5436-0616	NIH [AG20241, NS50895, NS057395, AG00538, AG00096, P50 AG16573]; Alzheimers Association [IIRG036279, IIRG0728314]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS057395, R01NS050895] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG016573, R01AG020241, ZIAAG000770, P01AG000538] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alzheimers Association(Alzheimer's Association); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by funding from the NIH: AG20241 (DHC & MGA), NS50895 (DHC & MGA), NS057395 (MGA), AG00538(DHC) and from the Alzheimers Association IIRG036279 (MGA & DHC), IIRG0728314 (AG). NM was supported by NIA training grant AG00096. The 3xTg-AD homozygous mice and amyloid peptides were provided by UCI-Alzheimers Disease Research Center (ADRC) under the NIH/NIA P50 AG16573 grant.	Agadjanyan MG, 2005, J IMMUNOL, V174, P1580, DOI 10.4049/jimmunol.174.3.1580; ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bayer AJ, 2005, NEUROLOGY, V64, P94, DOI 10.1212/01.WNL.0000148604.77591.67; Berzofsky JA, 2001, NAT REV IMMUNOL, V1, P209, DOI 10.1038/35105075; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Biragyn A, 2004, BLOOD, V104, P1961, DOI 10.1182/blood-2004-02-0637; Biragyn A, 2002, BLOOD, V100, P1153, DOI 10.1182/blood-2002-01-0086; Biragyn A, 2001, J IMMUNOL, V167, P6644, DOI 10.4049/jimmunol.167.11.6644; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chen GQ, 2007, J NEUROSCI, V27, P2654, DOI 10.1523/JNEUROSCI.3710-06.2007; Cribbs DH, 2003, INT IMMUNOL, V15, P505, DOI 10.1093/intimm/dxg049; CRIBBS DH, 2005, CURR IMMUNOL REV, V1, P139; Dodart JC, 2002, NAT NEUROSCI, V5, P452, DOI 10.1038/nn842; Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x; Ghochikyan A, 2006, VACCINE, V24, P2275, DOI 10.1016/j.vaccine.2005.11.039; Ghochikyan A, 2003, EUR J IMMUNOL, V33, P3232, DOI 10.1002/eji.200324000; Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kim HD, 2007, IMMUNOL LETT, V112, P30, DOI 10.1016/j.imlet.2007.06.006; Kutzler MA, 2006, VACCINE, V24, P4630, DOI 10.1016/j.vaccine.2005.08.036; Lemere CA, 2006, REJUV RES, V9, P77, DOI 10.1089/rej.2006.9.77; Lewis J, 2001, SCIENCE, V293, P1487, DOI 10.1126/science.1058189; Li QY, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-22; Mamikonyan G, 2007, J BIOL CHEM, V282, P22376, DOI 10.1074/jbc.M700088200; Masliah E, 2005, NEUROLOGY, V64, P129, DOI 10.1212/01.WNL.0000148590.39911.DF; Monsonego A, 2003, J CLIN INVEST, V112, P415, DOI 10.1172/JCI200318104; Monsonego A, 2001, P NATL ACAD SCI USA, V98, P10273, DOI 10.1073/pnas.191118298; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Nicoll JAR, 2006, J NEUROPATH EXP NEUR, V65, P1040, DOI 10.1097/01.jnen.0000240466.10758.ce; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Oddo S, 2003, NEUROBIOL AGING, V24, P1063, DOI 10.1016/j.neurobiolaging.2003.08.012; Oddo S., 2006, J BIOL CHEM; Okura Y, 2006, P NATL ACAD SCI USA, V103, P9619, DOI 10.1073/pnas.0600966103; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Pasquali JL, 2007, J AUTOIMMUN, V29, P250, DOI 10.1016/j.jaut.2007.07.006; Patton RL, 2006, AM J PATHOL, V169, P1048, DOI 10.2353/ajpath.2006.060269; Petrushina I, 2003, NEUROSCI LETT, V338, P5, DOI 10.1016/S0304-3940(02)01357-5; Petrushina I, 2007, J NEUROSCI, V27, P12721, DOI 10.1523/JNEUROSCI.3201-07.2007; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; Qu BX, 2004, ARCH NEUROL-CHICAGO, V61, P1859, DOI 10.1001/archneur.61.12.1859; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Schiavo R, 2006, BLOOD, V107, P4597, DOI 10.1182/blood-2005-08-3207; Schultz JG, 2004, J MOL MED, V82, P706, DOI 10.1007/s00109-004-0570-z; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; WILCOCK DM, 2007, NEUROSCIENC IN PRESS; Zaliauskiene L, 2002, J IMMUNOL, V169, P2337, DOI 10.4049/jimmunol.169.5.2337	53	97	111	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2008	3	5							e2124	10.1371/journal.pone.0002124	http://dx.doi.org/10.1371/journal.pone.0002124			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	382YX	18461171	Green Published, gold			2023-01-03	WOS:000261642400045
J	Larroque, B; Ancel, PY; Marret, S; Marchand, L; Andre, M; Arnaud, C; Pierrat, V; Roze, JC; Messer, J; Thiriez, G; Burguet, A; Picaud, JC; Breart, G; Kaminski, M				Larroque, Beatrice; Ancel, Pierre-Yves; Marret, Stephane; Marchand, Laetitia; Andre, Monique; Arnaud, Catherine; Pierrat, Veronique; Roze, Jean-Christophe; Messer, Jean; Thiriez, Gerard; Burguet, Antoine; Picaud, Jean-Charles; Breart, Gerard; Kaminski, Monique		EPIPAGE Study Grp	Neurodevelopmental disabilities and special care of 5-year-old children born before 33 weeks of gestation (the EPIPAGE study): a longitudinal cohort study	LANCET			English	Article							LOW-BIRTH-WEIGHT; SCHOOL-AGED CHILDREN; CEREBRAL-PALSY; PRETERM INFANTS; EARLY INTERVENTION; LESS-THAN-32 WEEKS; OUTCOMES; 1990S; PERFORMANCE; POPULATION	Background The increasing survival rates of children who are born very preterm raise issues about the risks of neurological disabilities and cognitive dysfunction. We aimed to investigate neurodevelopmental outcome and use of special health care at 5 years of age in a population-based cohort of very preterm children. Methods We included all 2901 livebirths between 22 and 32 completed weeks of gestation from nine regions in France in Jan 1-Dec 31, 1997, and a reference group of 667 children from the same regions born at 39-40 weeks of gestation. At 5 years of age, children had a medical examination and a cognitive assessment with the Kaufman assessment battery for children (K-ABC), with scores on the mental processing composite (MPC) scale recorded. Data for health-care use were collected from parents. Severe disability was defined as non-ambulatory cerebral palsy, MPC score less than 55, or severe visual or hearing deficiency; moderate deficiency as cerebral palsy walking with aid or MPC score of 55-69; and minor disability as cerebral palsy walking without aid, MPC score of 70-84, or visual deficit (<3/10 for one eye). Findings In total, 1817 (77%) of the 2357 surviving children born very preterm had a medical assessment at 5 years and 396 (60%) of 664 in the reference group. Cerebral palsy was diagnosed in 159 (9%) of children born very preterm. Scores for MPC were available for 1534 children born very preterm: 503 (32%) had an MPC score less than 85 and 182 (12%) had an MPC score less than 70. Of the 320 children in the reference group, the corresponding values were 37 (12%) and 11 (3%), respectively. In the very preterm group, 83 (5%) had severe disability, 155 (9%) moderate disability, and 398 (25%) minor disability. Disability was highest in children born at 24-28 completed weeks of gestation (195 children [49%]), but the absolute number of children with disabilities was higher for children born at 29-32 weeks (441 children [36%]). Special health-care resources were used by 188 (42%) of children born at 24-28 weeks and 424 (31%) born at 29-32 weeks, compared with only 63 (16%) of those born at 39-40 weeks. Interpretation In children who are born very preterm, cognitive and neuromotor impairments at 5 years of age increase with decreasing gestational age. Many of these children need a high level of specialised care. Prevention of the learning disabilities associated with cognitive deficiencies in this group is an important goal for modern perinatal care for children who are born very preterm and for their families.	[Larroque, Beatrice; Ancel, Pierre-Yves; Marchand, Laetitia; Burguet, Antoine; Breart, Gerard; Kaminski, Monique] INSERM, Res Unit Perinatal Hlth & Womens Hlth, UMR S149, IFR69, Villejuif, France; [Larroque, Beatrice; Ancel, Pierre-Yves; Marchand, Laetitia; Burguet, Antoine; Breart, Gerard; Kaminski, Monique] Univ Paris 06, Paris, France; [Marret, Stephane] Rouen Univ Hosp, Dept Neonatol Med, Rouen, France; [Marret, Stephane] Univ Rouen, Inserm Avenir Res Grp, Inst Biomed Res, Rouen, France; [Andre, Monique] Reg Matern Univ Hosp, Nancy, France; [Arnaud, Catherine] Fac Med Toulouse, INSERM, Res Unit Epidemiol & Publ Hlth, U558, F-31073 Toulouse, France; [Pierrat, Veronique] Jeanne de Flandres Hosp, Dept Neonatol, Lille, France; [Roze, Jean-Christophe] Childrens Hosp, Dept Neonatol, Nantes, France; [Messer, Jean] Hautepierre Hosp, Dept Neonatol, Strasbourg, France; [Thiriez, Gerard] Hop St Jacques, Paediat Intens Care Unit, F-25030 Besancon, France; [Burguet, Antoine] Dept Neonatol, Poitiers, France; [Picaud, Jean-Charles] Hop Arnaud Villeneuve, CHU Montpellier, Dept Neonatol, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Nantes Universite; CHU de Nantes; CHU Strasbourg; Universite de Franche-Comte; CHU Besancon; Universite de Montpellier; CHU de Montpellier	Larroque, B (corresponding author), INSERM, U149, 16 Ave Paul Vaillant, F-94807 Villejuif, France.	Larroque@vjf.inserm.fr	roze, jean christophe/B-5433-2012; ARNAUD, Catherine/AAC-5646-2019; Rozé, Jean-Christophe/AAS-1314-2021	ARNAUD, Catherine/0000-0002-4002-802X; breart, gerard/0000-0003-3142-9128; Marchand-Martin, Laetitia/0000-0002-8036-8387; Marret, Stephane/0000-0002-2858-148X; Roze, Jean-Christophe/0000-0003-3367-512X; ANCEL, pierre-yves/0000-0001-9632-7494				Anderson P, 2003, JAMA-J AM MED ASSOC, V289, P3264, DOI 10.1001/jama.289.24.3264; Aylward GP, 2002, MENT RETARD DEV D R, V8, P234, DOI 10.1002/mrdd.10043; Bhutta AT, 2002, JAMA-J AM MED ASSOC, V288, P728, DOI 10.1001/jama.288.6.728; Blauw-Hospers CH, 2005, DEV MED CHILD NEUROL, V47, P421, DOI 10.1017/S0012162205000824; Blondel B, 2001, J Gynecol Obstet Biol Reprod (Paris), V30, P552; Bodeau-Livinec F, 2007, ARCH DIS CHILD, V92, P1099, DOI 10.1136/adc.2007.117416; Bowen JR, 2002, J PAEDIATR CHILD H, V38, P438, DOI 10.1046/j.1440-1754.2002.00039.x; Buitendijk S, 2003, EUR J OBSTET GYN R B, V111, pS66, DOI 10.1016/j.ejogrb.2003.09.007; Callanan C, 2001, J PAEDIATR CHILD H, V37, P152, DOI 10.1046/j.1440-1754.2001.00621.x; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; Clements KM, 2007, PEDIATRICS, V119, pE866, DOI 10.1542/peds.2006-1729; Cooke RWI, 2003, ARCH DIS CHILD, V88, P482, DOI 10.1136/adc.88.6.482; Grunau RE, 2002, ARCH PEDIAT ADOL MED, V156, P615, DOI 10.1001/archpedi.156.6.615; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; Hack M, 2000, Semin Neonatol, V5, P89, DOI 10.1053/siny.1999.0001; Hille ETM, 2005, PEDIATRICS, V116, pE662, DOI 10.1542/peds.2005-0682; HILLE ETM, 1994, J PEDIATR-US, V125, P426, DOI 10.1016/S0022-3476(05)83290-1; Himmelmann K, 2005, ACTA PAEDIATR, V94, P287, DOI 10.1111/j.1651-2227.2005.tb03071.x; Hintz SR, 2006, ACTA PAEDIATR, V95, P1239, DOI 10.1080/08035250600599727; Johnson S, 2005, ARCH DIS CHILD, V90, P909, DOI 10.1136/adc.2004.057620; Kaufman A, 1983, KAUFMANN ASSESSMENT; KLEBANOV PK, 1994, J DEV BEHAV PEDIATR, V15, P248, DOI 10.1097/00004703-199408000-00005; Larroque B, 2003, J PEDIATR-US, V143, P477, DOI 10.1067/S0022-3476(03)00417-7; Marlow N, 2005, NEW ENGL J MED, V352, P9, DOI 10.1056/NEJMoa041367; Petrou S, 2006, EARLY HUM DEV, V82, P77, DOI 10.1016/j.earlhumdev.2006.01.002; Platt MJ, 2007, LANCET, V369, P43, DOI 10.1016/S0140-6736(07)60030-0; ROSSANO R, 1970, Bulletin des Societes d'Ophtalmologie de France, V70, P648; Saigal S, 2000, PEDIATRICS, V105, P325, DOI 10.1542/peds.105.2.325; Tin W, 1997, BMJ-BRIT MED J, V314, P107, DOI 10.1136/bmj.314.7074.107; VANZEBENVANDERAA TM, 1989, LANCET, V1, P253; VEEN S, 1991, LANCET, V338, P33, DOI 10.1016/0140-6736(91)90015-H; Vincer MJ, 2006, PEDIATRICS, V118, pE1621, DOI 10.1542/peds.2006-1522; Vohr BR, 2005, PEDIATRICS, V116, P635, DOI 10.1542/peds.2004-2247; Whitfield MF, 1997, ARCH DIS CHILD-FETAL, V77, pF85, DOI 10.1136/fn.77.2.F85; Wocadlo C, 2006, EARLY HUM DEV, V82, P29, DOI 10.1016/j.earlhumdev.2005.06.005; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201	37	546	571	0	57	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 8	2008	371	9615					813	820		10.1016/S0140-6736(08)60380-3	http://dx.doi.org/10.1016/S0140-6736(08)60380-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	272NQ	18328928				2023-01-03	WOS:000253866500028
J	de Boer, M; van Deurzen, CHM; van Dijck, JAAM; Borm, GF; van Diest, PJ; Adang, EMM; Nortier, JWR; Rutgers, EJT; Seynaeve, C; Menke-Pluymers, MBE; Bult, P; Tjan-Heijnen, VCG				de Boer, Maaike; van Deurzen, Carolien H. M.; van Dijck, Jos A. A. M.; Borm, George F.; van Diest, Paul J.; Adang, Eddy M. M.; Nortier, Johan W. R.; Rutgers, Emiel J. T.; Seynaeve, Caroline; Menke-Pluymers, Marian B. E.; Bult, Peter; Tjan-Heijnen, Vivianne C. G.			Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	31st San Antonio Breast Cancer Symposium	DEC 10-14, 2008	San Antonio, TX				LYMPH-NODE MICROMETASTASES; PROGNOSTIC-SIGNIFICANCE; GUIDELINE TREATMENT; METASTASES; SURVIVAL; BIOPSY; NUMBER; WOMEN	Background The association of isolated tumor cells and micrometastases in regional lymph nodes with the clinical outcome of breast cancer is unclear. Methods We identified all patients in the Netherlands who underwent a sentinel-node biopsy for breast cancer before 2006 and had breast cancer with favorable primary-tumor characteristics and isolated tumor cells or micrometastases in the regional lymph nodes. Patients with node-negative disease were randomly selected from the years 2000 and 2001. The primary end point was disease-free survival. Results We identified 856 patients with node-negative disease who had not received systemic adjuvant therapy ( the node-negative, no-adjuvant-therapy cohort), 856 patients with isolated tumor cells or micrometastases who had not received systemic adjuvant therapy ( the node-positive, no-adjuvant-therapy cohort), and 995 patients with isolated tumor cells or micrometastases who had received such treatment ( the node-positive, adjuvant-therapy cohort). The median follow-up was 5.1 years. The adjusted hazard ratio for disease events among patients with isolated tumor cells who did not receive systemic therapy, as compared with women with node-negative disease, was 1.50 (95% confidence interval [CI], 1.15 to 1.94); among patients with micrometastases, the adjusted hazard ratio was 1.56 ( 95% CI, 1.15 to 2.13). Among patients with isolated tumor cells or micrometastases, the adjusted hazard ratio was 0.57 ( 95% CI, 0.45 to 0.73) in the node-positive, adjuvant-therapy cohort, as compared with the node-positive, no-adjuvant-therapy cohort. Conclusions Isolated tumor cells or micrometastases in regional lymph nodes were associated with a reduced 5-year rate of disease-free survival among women with favorable early-stage breast cancer who did not receive adjuvant therapy. In patients with isolated tumor cells or micrometastases who received adjuvant therapy, disease-free survival was improved.	[Tjan-Heijnen, Vivianne C. G.] Maastricht Univ, Med Ctr, Dept Internal Med, Div Med Oncol, NL-6202 AZ Maastricht, Netherlands; [de Boer, Maaike; van Dijck, Jos A. A. M.] Radboud Univ Nijmegen, Med Ctr, Comprehens Canc Ctr E, NL-6525 ED Nijmegen, Netherlands; [van Dijck, Jos A. A. M.; Borm, George F.; Adang, Eddy M. M.] Radboud Univ Nijmegen, Med Ctr, Div Epidemiol Biostat & HTA, NL-6525 ED Nijmegen, Netherlands; [Bult, Peter] Radboud Univ Nijmegen, Med Ctr, Div Pathol, NL-6525 ED Nijmegen, Netherlands; [van Deurzen, Carolien H. M.; van Diest, Paul J.] Univ Med Ctr Utrecht, Div Pathol, Utrecht, Netherlands; [Nortier, Johan W. R.] Leiden Univ, Med Ctr, Div Med Oncol, Leiden, Netherlands; [Rutgers, Emiel J. T.] Netherlands Canc Inst, Div Surg, Amsterdam, Netherlands; [Seynaeve, Caroline] Dr Daniel Den Hoed Canc Ctr, Erasmus Med Ctr, Div Med Oncol, NL-3008 AE Rotterdam, Netherlands; [Menke-Pluymers, Marian B. E.] Dr Daniel Den Hoed Canc Ctr, Erasmus Med Ctr, Div Surg, NL-3008 AE Rotterdam, Netherlands	Maastricht University; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Netherlands Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Tjan-Heijnen, VCG (corresponding author), Maastricht Univ, Med Ctr, Dept Internal Med, Div Med Oncol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	vcg.tjan.heijnen@mumc.nl	Rutgers, Emiel J T/C-5934-2015; Adang, E.M.M./L-4169-2015; van Dijck, Jos/A-1676-2016; Bult, Peter/L-4236-2015	Bult, Peter/0000-0001-6427-9889				Bleiweiss IJ, 2006, J CLIN ONCOL, V24, P2013, DOI 10.1200/JCO.2005.04.7076; Bolster MJ, 2006, ANN SURG ONCOL, V13, P1466, DOI 10.1245/s10434-006-9084-y; Chen SL, 2007, ANN SURG ONCOL, V14, P3378, DOI 10.1245/s10434-007-9513-6; Colleoni M, 2005, J CLIN ONCOL, V23, P1379, DOI 10.1200/JCO.2005.07.094; Cote RJ, 1999, LANCET, V354, P896, DOI 10.1016/S0140-6736(98)11104-2; Cox CE, 2008, J AM COLL SURGEONS, V206, P261, DOI 10.1016/j.jamcollsurg.2007.08.024; Cserni G, 2003, EUR J CANCER, V39, P1654, DOI 10.1016/S0959-8049(03)00203-X; Cummings MC, 2002, AM J SURG PATHOL, V26, P1286, DOI 10.1097/00000478-200210000-00005; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; *DUTCH I HEALTHC I, 2002, TREATM BREAST CANC G; Ernst-Kruis M R, 2003, Ned Tijdschr Geneeskd, V147, P1126; Fan YG, 2005, ANN SURG ONCOL, V12, P705, DOI 10.1245/ASO.2005.08.020; FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3; Gobardhan PD, 2009, ANN ONCOL, V20, P41, DOI 10.1093/annonc/mdn535; Grabau D, 2007, APMIS, V115, P828, DOI 10.1111/j.1600-0463.2007.apm_442.x; GREEN EL, 2002, AJCC CANC STAGING MA; Kuijt GP, 2005, EJSO, V31, P500, DOI 10.1016/j.ejso.2005.01.001; Lyman GH, 2005, J CLIN ONCOL, V23, P7703, DOI 10.1200/JCO.2005.08.001; Maibenco DC, 2006, CANCER, V107, P1234, DOI 10.1002/cncr.22112; Millis RR, 2002, BRIT J CANCER, V86, P396, DOI 10.1038/sj.bjc.6600070; Rutgers E J Th, 2002, Ned Tijdschr Geneeskd, V146, P2144; SAS Institute, 1999, SAS STAT US GUID VER; Sobin LH., 2002, CANCER, V6th; Struikmans H, 2008, Ned Tijdschr Geneeskd, V152, P2507; Tan LK, 2008, J CLIN ONCOL, V26, P1803, DOI 10.1200/JCO.2007.12.6425; Truong PT, 2008, EUR J CANCER, V44, P1670, DOI 10.1016/j.ejca.2008.05.011; van der Heiden-vander Loo M, 2006, EJSO-EUR J SURG ONC, V32, P710, DOI 10.1016/j.ejso.2006.04.001; van Deurzen CHM, 2009, AM J SURG PATHOL, V33, P106, DOI 10.1097/PAS.0b013e31817eec40	28	372	375	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	2009	361	7					653	663		10.1056/NEJMoa0904832	http://dx.doi.org/10.1056/NEJMoa0904832			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	482JX	19675329	Green Published			2023-01-03	WOS:000268884100005
J	Feart, C; Samieri, C; Rondeau, V; Amieva, H; Portet, F; Dartigues, JF; Scarmeas, N; Barberger-Gateau, P				Feart, Catherine; Samieri, Cecilia; Rondeau, Virginie; Amieva, Helene; Portet, Florence; Dartigues, Jean-Francois; Scarmeas, Nikolaos; Barberger-Gateau, Pascale			Adherence to a Mediterranean Diet, Cognitive Decline, and Risk of Dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; ALZHEIMERS-DISEASE; PATTERNS; HEALTH; ASSOCIATION; POPULATION; 3-CITY; CONSUMPTION; IMPAIRMENT; SYMPTOMS	Context Higher adherence to a Mediterranean-type diet is linked to lower risk for mortality and chronic diseases, but its association with cognitive decline is unclear. Objective To investigate the association of a Mediterranean diet with change in cognitive performance and risk for dementia in elderly French persons. Design, Setting, and Participants Prospective cohort study of 1410 adults (>= 65 years) from Bordeaux, France, included in the Three-City cohort in 20012002 and reexamined at least once over 5 years. Adherence to a Mediterranean diet ( scored as 0 to 9) was computed from a food frequency questionnaire and 24-hour recall. Main Outcome Measures Cognitive performance was assessed on 4 neuropsychological tests: the Mini-Mental State Examination (MMSE), Isaacs Set Test (IST), Benton Visual Retention Test (BVRT), and Free and Cued Selective Reminding Test (FCSRT). Incident cases of dementia (n=99) were validated by an independent expert committee of neurologists. Results Adjusting for age, sex, education, marital status, energy intake, physical activity, depressive symptomatology, taking 5 medications/d or more, apolipoprotein E genotype, cardiovascular risk factors, and stroke, higher Mediterranean diet score was associated with fewer MMSE errors (beta=-0.006; 95% confidence interval [CI], -0.01 to -0.0003; P=.04 for 1 point of the Mediterranean diet score). Performance on the IST, BVRT, or FCSRT over time was not significantly associated with Mediterranean diet adherence. Greater adherence as a categorical variable (score 6-9) was not significantly associated with fewer MMSE errors and better FCSRT scores in the entire cohort, but among individuals who remained free from dementia over 5 years, the association for the highest compared with the lowest group was significant (adjusted for all factors, for MMSE: beta=-0.03; 95% CI, -0.05 to -0.001; P=.04; for FCSRT: beta=0.21; 95% CI, 0.008 to 0.41; P=. 04). Mediterranean diet adherence was not associated with the risk for incident dementia (fully adjusted model: hazard ratio, 1.12; 95% CI, 0.60 to 2.10; P=.72), although power to detect a difference was limited. Conclusions Higher adherence to a Mediterranean diet was associated with slower MMSE cognitive decline but not consistently with other cognitive tests. Higher adherence was not associated with risk for incident dementia. JAMA. 2009; 302(6):638-648 www.jama.com	[Feart, Catherine] Univ Bordeaux 2, INSERM, Equipe Epidemiol Nutr & Comportements Alimentaire, Res Ctr,ISPED Case 11,U897, F-33076 Bordeaux, France; [Portet, Florence] Univ Montpellier I, INSERM, U888, Montpellier, France; [Scarmeas, Nikolaos] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Columbia University	Feart, C (corresponding author), Univ Bordeaux 2, INSERM, Equipe Epidemiol Nutr & Comportements Alimentaire, Res Ctr,ISPED Case 11,U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	catherine.feart@isped.u-bordeaux2.fr	Amieva, Helene/T-4170-2019; Scarmeas, Nikolaos/AAD-2517-2020; Samieri, Cécilia/E-3334-2014; rondeau, virginie/E-4192-2014; Samieri, Cecilia/T-3267-2019; Scarmeas, Nikolaos/AAD-2512-2020; rondeau, virginie/T-9763-2019; Amieva, Helene/E-4850-2014; DARTIGUES, Jean François/T-4513-2019; FEART, Catherine/A-3339-2016	Amieva, Helene/0000-0002-0119-7242; Scarmeas, Nikolaos/0000-0001-6453-8908; Samieri, Cécilia/0000-0001-9809-7506; rondeau, virginie/0000-0001-7109-4831; Samieri, Cecilia/0000-0001-9809-7506; Scarmeas, Nikolaos/0000-0001-6453-8908; rondeau, virginie/0000-0001-7109-4831; FEART, Catherine/0000-0002-7959-1610	Institut National de la Sante et de la Recherche Medicale (INSERM); Institut de Sante Publique et Developpement of the Victor Segalen Bordeaux 2 University; Sanofi-Aventis; The Fondation pour la Recherche Medicale; Caisse Nationale Maladie des Travailleurs Salaries; Direction Generale de la Sante, Mutuelle Generale de l'Education Nationale; Institut de la Longevite; Regional Governments of Aquitaine and Bourgogne; Fondation de France; Ministry of Research-INSERM Programme; French National Research Agency [ANR-06PNRA-005]; Association France Alzheimer; Aquitaine Regional Government	Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut de Sante Publique et Developpement of the Victor Segalen Bordeaux 2 University; Sanofi-Aventis(Sanofi-Aventis); The Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Caisse Nationale Maladie des Travailleurs Salaries; Direction Generale de la Sante, Mutuelle Generale de l'Education Nationale; Institut de la Longevite; Regional Governments of Aquitaine and Bourgogne(Region Nouvelle-Aquitaine); Fondation de France(Fondation de France); Ministry of Research-INSERM Programme(Institut National de la Sante et de la Recherche Medicale (Inserm)); French National Research Agency(French National Research Agency (ANR)); Association France Alzheimer; Aquitaine Regional Government(Region Nouvelle-Aquitaine)	The Three-City (3C) Study is conducted under a partnership agreement between the Institut National de la Sante et de la Recherche Medicale (INSERM), the Institut de Sante Publique et Developpement of the Victor Segalen Bordeaux 2 University, and Sanofi-Aventis. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, Mutuelle Generale de l'Education Nationale, Institut de la Longevite, Regional Governments of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research-INSERM Programme "Cohortes et collections de donnees biologiques." Financial support for the 3C-COGINUT project was provided by the French National Research Agency (ANR-06PNRA-005). Dr Feart was funded by Association France Alzheimer; Dr Samieri was funded by Aquitaine Regional Government.	Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920; Amieva H, 2008, ANN NEUROL, V64, P492, DOI 10.1002/ana.21509; Bach A, 2006, PUBLIC HEALTH NUTR, V9, P132, DOI 10.1079/PHN2005936; Bach-Faig A, 2006, PUBLIC HEALTH NUTR, V9, P1110, DOI 10.1017/S1368980007668499; Barberger-Gateau P, 2007, NEUROLOGY, V69, P1921, DOI 10.1212/01.wnl.0000278116.37320.52; Benton A, 1965, MANUEL APPL TEST RET; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; Cummings JL, 2004, NEW ENGL J MED, V351, P56, DOI 10.1056/NEJMra040223; Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Giugliano D, 2008, CURR OPIN LIPIDOL, V19, P63, DOI 10.1097/MOL.0b013e3282f2fa4d; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; ISAACS B, 1973, BRIT J PSYCHIAT, V123, P467, DOI 10.1192/bjp.123.4.467; JacqminGadda H, 1997, AM J EPIDEMIOL, V145, P498; Jacques PF, 2001, AM J CLIN NUTR, V73, P1, DOI 10.1093/ajcn/73.1.1; Kant AK, 2004, J AM DIET ASSOC, V104, P615, DOI 10.1016/j.jada.2004.01.010; Lamarca R, 1998, J GERONTOL A-BIOL, V53, pM337, DOI 10.1093/gerona/53A.5.M337; Letenneur L, 2007, AM J EPIDEMIOL, V165, P1364, DOI 10.1093/aje/kwm036; Luchsinger JA, 2004, LANCET NEUROL, V3, P579, DOI 10.1016/S1474-4422(04)00878-6; Panza F, 2007, EXP GERONTOL, V42, P6, DOI 10.1016/j.exger.2006.09.011; Reynolds E, 2006, LANCET NEUROL, V5, P949, DOI 10.1016/S1474-4422(06)70598-1; Rock CL, 2007, AM J CLIN NUTR, V85, p277S, DOI 10.1093/ajcn/85.1.277S; Samieri C, 2008, J AM DIET ASSOC, V108, P1461, DOI 10.1016/j.jada.2008.06.437; Sanchez-Villegas A, 2006, PUBLIC HEALTH NUTR, V9, P1104, DOI 10.1017/S1368980007668578; Scarmeas N, 2009, ARCH NEUROL-CHICAGO, V66, P216, DOI 10.1001/archneurol.2008.536; Scarmeas N, 2006, ANN NEUROL, V59, P912, DOI 10.1002/ana.20854; SIMERMANN J, 2007, 25 ANN C SOC FRANC N; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Solfrizzi V, 2006, NEUROBIOL AGING, V27, P1694, DOI 10.1016/j.neurobiolaging.2005.09.026; Stampfer MJ, 2005, NEW ENGL J MED, V352, P245, DOI 10.1056/NEJMoa041152; Steele M, 2007, EXP GERONTOL, V42, P28, DOI 10.1016/j.exger.2006.06.002; Tamers SL, 2009, EUR J CLIN NUTR, V63, P11, DOI 10.1038/ejcn.2008.2; Touvier M, 2009, EUR J CLIN NUTR, V63, P39, DOI 10.1038/sj.ejcn.1602907; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S	39	465	473	1	98	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	2009	302	6					638	648		10.1001/jama.2009.1146	http://dx.doi.org/10.1001/jama.2009.1146			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	481ZI	19671905	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000268852300022
J	Thangaraj, H; van Dolleweerd, CJ; McGowan, EG; Ma, JKC				Thangaraj, Harry; van Dolleweerd, Craig J.; McGowan, Edward G.; Ma, Julian K-C			Dynamics of global disclosure through patent and journal publications for biopharmaceutical products	NATURE BIOTECHNOLOGY			English	Editorial Material								Examining the relationships between invention disclosure type in industry and academia and geographical disclosure trends, using plant-made pharmaceuticals as a single-sector model for the biopharmaceutical industry.	[Thangaraj, Harry; van Dolleweerd, Craig J.; McGowan, Edward G.; Ma, Julian K-C] Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Med, Mol Immunol Unit, London SW17 0RE, England	St Georges University London; University of London; University College London; UCL Medical School	Thangaraj, H (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Med, Mol Immunol Unit, Cranmer Terrace, London SW17 0RE, England.	hthangar@sgul.ac.uk		van Dolleweerd, Craig/0000-0002-1380-6930; Ma, Julian/0000-0003-0767-0042				Crespi RS, 1998, TRENDS BIOTECHNOL, V16, P450, DOI 10.1016/S0167-7799(98)01228-1; *EPO, 2004, R BERG MARK RES EUR; Geuna A, 2006, RES POLICY, V35, P790, DOI 10.1016/j.respol.2006.04.005; HALL S, 2008, SCIENTIST        AUG, P30; JENSEN PH, 2008, 0108 IPRIA; Ma JKC, 2005, EMBO REP, V6, P593, DOI 10.1038/sj.embor.7400470; *MARKS CLERK, 2007, AC OUTP CORP BIOT EU; Parida DK, 2008, NAT BIOTECHNOL, V26, P763, DOI 10.1038/nbt0708-763; ROYLE M, 2008, GEN ENG NEWS    SEP; *THOMS TEUT, 2008, AN GLOB PAT ACT US S; Thursby JG, 2003, SCIENCE, V301, P1052, DOI 10.1126/science.1087473; von Gabain A, 2003, EMBO REP, V4, P642, DOI 10.1038/sj.embor.embor891; WEBSTER P, 2005, INNOVATIONS PHARM TE; World Intellectual Property Organization, 2008, WORLD PAT REP STAT R; Yiannaka A, 2006, INT J IND ORGAN, V24, P177, DOI 10.1016/j.ijindorg.2005.06.001; 2008, INVESTORS CHRON 0711, P16	16	10	10	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2009	27	7					614	619		10.1038/nbt0709-614	http://dx.doi.org/10.1038/nbt0709-614			6	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	469OF	19587663				2023-01-03	WOS:000267908500015
J	Nakamuta, JS; Danoviz, ME; Marques, FLN; dos Santos, L; Becker, C; Goncalves, GA; Vassallo, PF; Schettert, IT; Tucci, PJF; Krieger, JE				Nakamuta, Juliana S.; Danoviz, Maria E.; Marques, Fabio L. N.; dos Santos, Leonardo; Becker, Claudia; Goncalves, Giovana A.; Vassallo, Paula F.; Schettert, Isolmar T.; Tucci, Paulo J. F.; Krieger, Jose E.			Cell Therapy Attenuates Cardiac Dysfunction Post Myocardial Infarction: Effect of Timing, Routes of Injection and a Fibrin Scaffold	PLOS ONE			English	Article							MESENCHYMAL STEM-CELLS; PROGENITOR CELLS; ISCHEMIC-MYOCARDIUM; MUSCLE-CELLS; OPTIMAL TIME; TRANSPLANTATION; HEART; SURVIVAL; REPAIR; INTRACORONARY	Background: Cell therapy approaches for biologic cardiac repair hold great promises, although basic fundamental issues remain poorly understood. In the present study we examined the effects of timing and routes of administration of bone marrow cells (BMC) post-myocardial infarction (MI) and the efficacy of an injectable biopolymer scaffold to improve cardiac cell retention and function. Methodology/Principal Findings: Tc-99m-labeled BMC (6x10(6) cells) were injected by 4 different routes in adult rats: intravenous (IV), left ventricular cavity (LV), left ventricular cavity with temporal aorta occlusion (LV+) to mimic coronary injection, and intramyocardial (IM). The injections were performed 1, 2, 3, or 7 days post-MI and cell retention was estimated by gamma-emission counting of the organs excised 24 hs after cell injection. IM injection improved cell retention and attenuated cardiac dysfunction, whereas IV, LV or LV* routes were somewhat inefficient (< 1%). Cardiac BMC retention was not influenced by timing except for the IM injection that showed greater cell retention at 7 (16%) vs. 1, 2 or 3 (average of 7%) days post-MI. Cardiac cell retention was further improved by an injectable fibrin scaffold at day 3 post-MI (17 vs. 7%), even though morphometric and function parameters evaluated 4 weeks later displayed similar improvements. Conclusions/Significance: These results show that cells injected post-MI display comparable tissue distribution profile regardless of the route of injection and that there is no time effect for cardiac cell accumulation for injections performed 1 to 3 days post-MI. As expected the IM injection is the most efficient for cardiac cell retention, it can be further improved by co-injection with a fibrin scaffold and it significantly attenuates cardiac dysfunction evaluated 4 weeks post myocardial infarction. These pharmacokinetic data obtained under similar experimental conditions are essential for further development of these novel approaches.			Nakamuta, JS (corresponding author), Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.	krieger@incor.usp.br	Schettert, Isolmar/D-1355-2012; Navarro Marques, Fabio Luiz/ABI-7774-2020; Pereira, Alexandre/HHN-1038-2022; dos Santos, Leonardo/B-6509-2013; Krieger, Jose E/C-3117-2011; Marques, Fabio LN/C-4153-2012; Tucci, Paulo/D-1441-2015	Navarro Marques, Fabio Luiz/0000-0001-7383-926X; dos Santos, Leonardo/0000-0002-4340-6364; Krieger, Jose E/0000-0001-5464-1792; Marques, Fabio LN/0000-0001-7383-926X; Tucci, Paulo/0000-0001-9793-670X				Abbott JD, 2004, CIRCULATION, V110, P3300, DOI 10.1161/01.CIR.0000147780.30124.CF; Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; de Oliveira SA, 2006, EUR J CARDIO-THORAC, V29, pS259, DOI 10.1016/j.ejcts.2006.02.005; *AM PLC, INS PACKDG CER PROD; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Becker C, 2006, INT J CARDIOL, V113, P348, DOI 10.1016/j.ijcard.2005.11.060; Brown RP, 1997, TOXICOL IND HEALTH, V13, P407, DOI 10.1177/074823379701300401; Chin BB, 2003, NUCL MED COMMUN, V24, P1149, DOI 10.1097/00006231-200311000-00005; Christman KL, 2004, J AM COLL CARDIOL, V44, P654, DOI 10.1016/j.jacc.2004.04.040; Christman KL, 2004, TISSUE ENG, V10, P403, DOI 10.1089/107632704323061762; Collins SD, 2007, CARDIOVASC REVASCULA, V8, P43, DOI 10.1016/j.carrev.2006.11.005; Dow J, 2005, CARDIOVASC RES, V67, P301, DOI 10.1016/j.cardiores.2005.04.011; Fernandez P, 1999, J NUCL MED, V40, P1756; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Gowdak LHW, 2008, INT J CARDIOL, V127, P295, DOI 10.1016/j.ijcard.2007.05.048; Halkos ME, 2008, BASIC RES CARDIOL, V103, P525, DOI 10.1007/s00395-008-0741-0; Hodgson DM, 2004, AM J PHYSIOL-HEART C, V287, pH471, DOI 10.1152/ajpheart.01247.2003; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; HOU D, 2005, CIRCULATION S, V1, P156; Hou DM, 2005, CIRCULATION, V112, pI150, DOI 10.1161/CIRCULATIONAHA.104.526749; Hu XY, 2007, EUR J CARDIO-THORAC, V31, P438, DOI 10.1016/j.ejcts.2006.11.057; Huang NF, 2005, TISSUE ENG, V11, P1860, DOI 10.1089/ten.2005.11.1860; Iso Y, 2007, BIOCHEM BIOPH RES CO, V354, P700, DOI 10.1016/j.bbrc.2007.01.045; Jiang CY, 2008, J ZHEJIANG UNIV-SC B, V9, P630, DOI 10.1631/jzus.B0820004; Li RK, 2001, ANN THORAC SURG, V72, P1957, DOI 10.1016/S0003-4975(01)03216-7; Liu YG, 2004, MICROVASC RES, V68, P156, DOI 10.1016/j.mvr.2004.06.008; Lu L, 2004, BIOCHEM BIOPH RES CO, V320, P907, DOI 10.1016/j.bbrc.2004.06.034; Melo LG, 2004, CIRCULATION, V109, P2386, DOI 10.1161/01.CIR.0000128597.37025.00; Muller-Ehmsen J, 2002, J MOL CELL CARDIOL, V34, P107, DOI 10.1006/jmcc.2001.1491; NEIRINCKX RD, 1987, J NUCL MED, V28, P191; Olivares EL, 2004, AM J PHYSIOL-HEART C, V287, pH464, DOI 10.1152/ajpheart.01141.2003; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Radosevich M, 1997, VOX SANG, V72, P133, DOI 10.1046/j.1423-0410.1997.7230133.x; Reinlib L, 2000, CIRCULATION, V101, pE182; Roy S, 2006, PHYSIOL GENOMICS, V25, P364, DOI 10.1152/physiolgenomics.00013.2006; Schachinger V, 2006, NEW ENGL J MED, V355, P1210, DOI 10.1056/NEJMoa060186; Schuster MD, 2004, AM J PHYSIOL-HEART C, V287, pH525, DOI 10.1152/ajpheart.00058.2004; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suzuki K, 2004, FASEB J, V18, P1153, DOI 10.1096/fj.03-1308fje; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Vandervelde S, 2005, J MOL CELL CARDIOL, V39, P363, DOI 10.1016/j.yjmcc.2005.05.012; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; Wolf K, 2009, SEMIN CELL DEV BIOL, V20, P931, DOI 10.1016/j.semcdb.2009.08.005; Yasuda T, 2005, J THORAC CARDIOV SUR, V129, P904, DOI 10.1016/j.jtcvs.2004.06.027; Zhang M, 2001, J MOL CELL CARDIOL, V33, P907, DOI 10.1006/jmcc.2001.1367; Zhang SH, 2004, LIFE SCI, V74, P2853, DOI 10.1016/j.lfs.2003.10.035	49	66	71	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2009	4	6							e6005	10.1371/journal.pone.0006005	http://dx.doi.org/10.1371/journal.pone.0006005			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	462JI	19547700	Green Submitted, gold, Green Published			2023-01-03	WOS:000267347900004
J	Beckstead, WA; Ebbert, MTW; Rowe, MJ; McClellan, DA				Beckstead, Wesley A.; Ebbert, Mark T. W.; Rowe, Mark J.; McClellan, David A.			Evolutionary Pressure on Mitochondrial Cytochrome b Is Consistent with a Role of CytbI7T Affecting Longevity during Caloric Restriction	PLOS ONE			English	Article							AMINO-ACID PROPERTIES; BC(1) COMPLEX; LIFE-SPAN; ADAPTATION; MECHANISMS; RESOLUTION; STABILITY; SUBSTRATE; OXIDATION; SELECTION	Background: Metabolism of energy nutrients by the mitochondrial electron transport chain (ETC) is implicated in the aging process. Polymorphisms in core ETC proteins may have an effect on longevity. Here we investigate the cytochrome b (cytb) polymorphism at amino acid 7 (cytbI7T) that distinguishes human mitochondrial haplogroup H from haplogroup U. Principal Findings: We compared longevity of individuals in these two haplogroups during historical extremes of caloric intake. Haplogroup H exhibits significantly increased longevity during historical caloric restriction compared to haplogroup U (p = 0.02) while during caloric abundance they are not different. The historical effects of natural selection on the cytb protein were estimated with the software TreeSAAP using a phylogenetic reconstruction for 107 mammal taxa from all major mammalian lineages using 13 complete protein-coding mitochondrial gene sequences. With this framework, we compared the biochemical shifts produced by cytbI7T with historical evolutionary pressure on and near this polymorphic site throughout mammalian evolution to characterize the role cytbI7T had on the ETC during times of restricted caloric intake. Significance: Our results suggest the relationship between caloric restriction and increased longevity in human mitochondrial haplogroup H is determined by cytbI7T which likely enhances the ability of water to replenish the Q(i) binding site and decreases the time ubisemiquinone is at the Q(o) site, resulting in a decrease in the average production rate of radical oxygen species (ROS).			Beckstead, WA (corresponding author), Natl Canc Inst, Oncogenom Sect, Pediat Oncol Branch, Adv Technol Ctr, Gaithersburg, MD USA.	dmcclellan@bigelow.org		Ebbert, Mark/0000-0001-9158-4440; McClellan, David/0000-0002-2595-3620				Aguilaniu H, 2005, GENE DEV, V19, P2399, DOI 10.1101/gad.1366505; Aguilaniu H, 2001, J BIOL CHEM, V276, P35396, DOI 10.1074/jbc.M101796200; Allen JF, 2003, PHILOS T R SOC B, V358, P19, DOI 10.1098/rstb.2002.1191; Barja G, 2004, TRENDS NEUROSCI, V27, P595, DOI 10.1016/j.tins.2004.07.005; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611; Chamala Srikar, 2007, Int J Bioinform Res Appl, V3, P504, DOI 10.1504/IJBRA.2007.015418; Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100; Crofts AR, 2004, ANNU REV PHYSIOL, V66, P689, DOI 10.1146/annurev.physiol.66.032102.150251; Cutler R G, 1985, Basic Life Sci, V35, P15; Dato S, 2004, EUR J HUM GENET, V12, P1080, DOI 10.1038/sj.ejhg.5201278; De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532; DeLano W., 2002, PYMOL OPEN SOURCE MO, P700; Ebbert Mark T W, 2007, Int J Bioinform Res Appl, V3, P471, DOI 10.1504/IJBRA.2007.015415; Gao XG, 2003, BIOCHEMISTRY-US, V42, P9067, DOI 10.1021/bi0341814; Gromiha MM, 1999, J PROTEIN CHEM, V18, P565, DOI 10.1023/A:1020603401001; Gromiha MM, 1997, J BIOL PHYS, V23, P151, DOI 10.1023/A:1004981409616; GROMIHA MM, 1993, J THEOR BIOL, V165, P97; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Horner DS, 2003, PHILOS T ROY SOC B, V358, P37; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Hunte C, 2003, FEBS LETT, V545, P39, DOI 10.1016/S0014-5793(03)00391-0; Kolling DRJ, 2003, J BIOL CHEM, V278, P39747, DOI 10.1074/jbc.M305913200; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Lane N., 2005, POWER SEX SUICIDE MI; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; Liu XX, 2005, GENE DEV, V19, P2424, DOI 10.1101/gad.1352905; McClellan DA, 2005, MOL BIOL EVOL, V22, P437, DOI 10.1093/molbev/msi028; McClellan DA, 2001, MOL BIOL EVOL, V18, P917, DOI 10.1093/oxfordjournals.molbev.a003892; MIQUEL J, 1980, EXP GERONTOL, V15, P575, DOI 10.1016/0531-5565(80)90010-8; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Novotny M, 2007, ACTA CRYSTALLOGR D, V63, P270, DOI [10.1107/S0907444906044118, 10.1101/S0907444906044118]; OOBATAKE M, 1993, PROG BIOPHYS MOL BIO, V59, P237, DOI 10.1016/0079-6107(93)90002-2; Pearl R., 1928, RATE LIVING; Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wenz T, 2007, J BIOL CHEM, V282, P3977, DOI 10.1074/jbc.M606482200; Woolley S, 2003, BIOINFORMATICS, V19, P671, DOI 10.1093/bioinformatics/btg043; Wright AF, 2004, NAT GENET, V36, P1153, DOI 10.1038/ng1448	45	29	29	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2009	4	6							e5836	10.1371/journal.pone.0005836	http://dx.doi.org/10.1371/journal.pone.0005836			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	454XN	19503808	Green Published, Green Submitted, gold			2023-01-03	WOS:000266717400015
J	Drecoll, E; Gaertner, FC; Miederer, M; Blechert, B; Vallon, M; Muller, JM; Alke, A; Seidl, C; Bruchertseifer, F; Morgenstern, A; Senekowitsch-Schmidtke, R; Essler, M				Drecoll, Enken; Gaertner, Florian C.; Miederer, Matthias; Blechert, Birgit; Vallon, Mario; Mueller, Jan M.; Alke, Andrea; Seidl, Christof; Bruchertseifer, Frank; Morgenstern, Alfred; Senekowitsch-Schmidtke, Reingard; Essler, Markus			Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide Bi-213-DTPA-[F3](2) into the Nucleus of Tumor Cells	PLOS ONE			English	Article							IN-VIVO; ENDOTHELIAL-CELLS; ALPHA-THERAPY; CANCER; RADIOIMMUNOTHERAPY; VASCULATURE; GENERATOR; AC-225; TH-229	Background: alpha-particle emitting isotopes are effective novel tools in cancer therapy, but targeted delivery into tumors is a prerequisite of their application to avoid toxic side effects. Peritoneal carcinomatosis is a widespread dissemination of tumors throughout the peritoneal cavity. As peritoneal carcinomatosis is fatal in most cases, novel therapies are needed. F3 is a tumor homing peptide which is internalized into the nucleus of tumor cells upon binding to nucleolin on the cell surface. Therefore, F3 may be an appropriate carrier for alpha-particle emitting isotopes facilitating selective tumor therapies. Principal Findings: A dimer of the vascular tumor homing peptide F3 was chemically coupled to the alpha-emitter Bi-213(Bi-213-DTPA-[F3](2)). We found Bi-213-DTPA-[F3](2) to accumulate in the nucleus of tumor cells in vitro and in intraperitoneally growing tumors in vivo. To study the anti-tumor activity of Bi-213-DTPA-[F3](2) we treated mice bearing intraperitoneally growing xenograft tumors with Bi-213-DTPA-[F3](2). In a tumor prevention study between the days 4-14 after inoculation of tumor cells 6x1.85 MBq (50 mu Ci) of Bi-213-DTPA-[F3](2) were injected. In a tumor reduction study between the days 16-26 after inoculation of tumor cells 6x1.85 MBq of Bi-213-DTPA-[F3](2) were injected. The survival time of the animals was increased from 51 to 93.5 days in the prevention study and from 57 days to 78 days in the tumor reduction study. No toxicity of the treatment was observed. In bio-distribution studies we found Bi-213-DTPA-[F3](2) to accumulate in tumors but only low activities were found in control organs except for the kidneys, where Bi-213-DTPA-[F3](2) is found due to renal excretion. Conclusions/Significance: In conclusion we report that Bi-213-DTPA-[F3](2) is a novel tool for the targeted delivery of alpha-emitters into the nucleus of tumor cells that effectively controls peritoneal carcinomatosis in preclinical models and may also be useful in oncology.			Drecoll, E (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Nucl Med, D-8000 Munich, Germany.	Markus.Essler@gmx.de	Miederer, Matthias/ABA-5988-2020; Miederer, Matthias/C-4405-2014	Miederer, Matthias/0000-0001-5075-5995; 				Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399; Apostolidis C, 2005, ANAL CHEM, V77, P6288, DOI 10.1021/ac0580114; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Beck R, 2007, CANCER SCI, V98, P1215, DOI 10.1111/j.1349-7006.2007.00525.x; Beyer GJ, 2004, EUR J NUCL MED MOL I, V31, P547, DOI 10.1007/s00259-003-1413-9; Bloechl S, 2005, CLIN CANCER RES, V11, p7070S, DOI 10.1158/1078-0432.CCR-1004-0017; Borchardt PE, 2003, CANCER RES, V63, P5084; Buchhorn HM, 2007, EUR J NUCL MED MOL I, V34, P841, DOI 10.1007/s00259-006-0311-3; Cherukuri S, 2008, MOL BIOL CELL, V19, P1816, DOI 10.1091/mbc.E07-10-1018; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Glehen O, 2004, LANCET ONCOL, V5, P219, DOI 10.1016/S1470-2045(04)01425-1; Gunn AJ, 2007, EXPERT OPIN DRUG DEL, V4, P389, DOI 10.1517/17425247.4.4.389; Kinuya S, 2007, NUCL MED COMMUN, V28, P129, DOI 10.1097/MNM.0b013e328013e5a8; Koppe MJ, 2006, J NUCL MED, V47, P1867; McDevitt MR, 2001, SCIENCE, V294, P1537, DOI 10.1126/science.1064126; Miederer M, 2008, ADV DRUG DELIVER REV, V60, P1371, DOI 10.1016/j.addr.2008.04.009; Miederer M, 2008, CLIN CANCER RES, V14, P3555, DOI 10.1158/1078-0432.CCR-07-4647; Milenic D, 2004, CANCER BIOTHER RADIO, V19, P135, DOI 10.1089/108497804323071904; Nayak TK, 2007, NUCL MED BIOL, V34, P185, DOI 10.1016/j.nucmedbio.2006.11.006; Palm S, 2007, INT J RADIAT ONCOL, V69, P572, DOI 10.1016/j.ijrobp.2007.06.023; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Porkka K, 2002, P NATL ACAD SCI USA, V99, P7444, DOI 10.1073/pnas.062189599; Raja C, 2007, CANCER BIOL THER, V6, P846, DOI 10.4161/cbt.6.6.4089; Reubi JC, 2005, J NUCL MED, V46, p67S; Ruoslahti E, 2000, SEMIN CANCER BIOL, V10, P435, DOI 10.1006/scbi.2000.0334; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stavila V, 2006, COORDIN CHEM REV, V250, P2782, DOI 10.1016/j.ccr.2006.02.032; Zielinska B, 2007, SOLVENT EXTR ION EXC, V25, P339, DOI 10.1080/07366290701285108	28	46	48	3	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 27	2009	4	5							e5715	10.1371/journal.pone.0005715	http://dx.doi.org/10.1371/journal.pone.0005715			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	450QD	19479088	Green Submitted, Green Published, gold			2023-01-03	WOS:000266415000022
J	Kroenke, K; Bair, MJ; Damush, TM; Wu, JW; Hoke, S; Sutherland, J; Tu, WZ				Kroenke, Kurt; Bair, Matthew J.; Damush, Teresa M.; Wu, Jingwei; Hoke, Shawn; Sutherland, Jason; Tu, Wanzhu			Optimized Antidepressant Therapy and Pain Self-management in Primary Care Patients With Depression and Musculoskeletal Pain A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-BACK-PAIN; LATE-LIFE DEPRESSION; COGNITIVE-BEHAVIORAL THERAPY; LONGER-TERM OUTCOMES; COLLABORATIVE CARE; CLINICAL-TRIALS; OLDER-ADULTS; IMMPACT RECOMMENDATIONS; SYMPTOM SYNDROMES; MENTAL-DISORDERS	Context Pain and depression are the most common physical and psychological symptoms in primary care, respectively. Moreover, they co-occur 30% to 50% of the time and have adverse effects on quality of life, disability, and health care costs. Objective To determine if a combined pharmacological and behavioral intervention improves both depression and pain in primary care patients with musculoskeletal pain and comorbid depression. Design, Setting, and Patients Randomized controlled trial (Stepped Care for Affective Disorders and Musculoskeletal Pain [SCAMP]) conducted at 6 community-based clinics and 5 Veterans Affairs general medicine clinics in Indianapolis, Indiana. Recruitment occurred from January 2005 to June 2007 and follow-up concluded in June 2008. The 250 patients had low back, hip, or knee pain for 3 months or longer and at least moderate depression severity (Patient Health Questionnaire 9 score >= 10). Intervention Patients were randomly assigned to the intervention (n=123) or to usual care (n=127). The intervention consisted of 12 weeks of optimized antidepressant therapy (step 1) followed by 6 sessions of a pain self-management program over 12 weeks (step 2), and a continuation phase of therapy for 6 months (step 3). Main Outcome Measures Depression (20-item Hopkins Symptom Checklist), pain severity and interference (Brief Pain Inventory), and global improvement in pain at 12 months. Results At 12 months, 46 of the 123 intervention patients (37.4%) had a 50% or greater reduction in depression severity from baseline compared with 21 of 127 usual care patients (16.5%) (relative risk [RR], 2.3; 95% confidence interval [CI], 1.5-3.2), corresponding to a much lower number of patients with major depression (50[40.7%] vs 87 [68.5%], respectively; RR, 0.6 [95% CI, 0.4-0.8]). Also, a clinically significant (>= 30%) reduction in pain was much more likely in intervention patients ( 51 intervention patients [41.5%] vs 22 usual care patients [ 17.3%]; RR, 2.4 [95% CI, 1.6-3.2]), as was global improvement in pain (58[47.2%] vs 16 [12.6%], respectively; RR, 3.7 [95% CI, 2.3-6.1]). More intervention patients also experienced benefits in terms of the primary outcome, which was a combined improvement in both depression and pain (32 intervention patients [26.0%] vs 10 usual care patients [7.9%]; RR, 3.3 [95% CI, 1.8-5.4]). Conclusion Optimized antidepressant therapy followed by a pain self-management program resulted in substantial improvement in depression as well as moderate reductions in pain severity and disability. Trial Registration clinicaltrials.gov Identifier: NCT00118430 JAMA. 2009; 301(20):2099-2110 www.jama.com	[Kroenke, Kurt; Bair, Matthew J.; Damush, Teresa M.; Hoke, Shawn; Tu, Wanzhu] Regenstrief Inst Inc, Indianapolis, IN 46202 USA; [Kroenke, Kurt; Bair, Matthew J.; Damush, Teresa M.] Indiana Univ, Sch Med, Div Gen Internal Med, Indianapolis, IN USA; [Kroenke, Kurt; Bair, Matthew J.; Damush, Teresa M.] Indiana Univ, Sch Med, Div Geriatr, Indianapolis, IN USA; [Wu, Jingwei; Tu, Wanzhu] Indiana Univ, Sch Med, Div Biostat, Indianapolis, IN USA; [Kroenke, Kurt; Damush, Teresa M.; Hoke, Shawn] Roudebush VAMC, VA HSR&D Ctr Excellence Implementat Evidence Base, Indianapolis, IN USA; [Sutherland, Jason] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Dartmouth College	Kroenke, K (corresponding author), Regenstrief Inst Inc, 6th Floor,1050 Wishard Blvd, Indianapolis, IN 46202 USA.	kkroenke@regenstrief.org	Wu, Jing/GZK-5063-2022	Kroenke, Kurt/0000-0002-0114-4669	National Institute of Mental Health [R01 MH-071268]; Eli Lilly; Pfizer; Wyeth; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH071268] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Eli Lilly(Eli Lilly); Pfizer(Pfizer); Wyeth(Wyeth); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This study was supported by grant R01 MH-071268 ( awarded to Dr Kroenke) from the National Institute of Mental Health.	Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; BANDURA A, 1986, SOCIAL FDN THOUGHT A; Callahan CM, 2006, J GEN INTERN MED, V21, P1125, DOI 10.1111/j.1525-1497.2006.00603.x; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Cintron A, 2006, J PALLIAT MED, V9, P1454, DOI 10.1089/jpm.2006.9.1454; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; Damush TM, 2003, ARTHRIT RHEUM-ARTHR, V49, P179, DOI 10.1002/art.10995; Damush TM, 2003, ARCH INTERN MED, V163, P2632, DOI 10.1001/archinte.163.21.2632; Damush TM, 2002, ARTHRIT RHEUM-ARTHR, V47, P372, DOI 10.1002/art.10382; Dietrich AJ, 2004, BMJ-BRIT MED J, V329, P602, DOI 10.1136/bmj.38219.481250.55; Dobscha SK, 2009, JAMA-J AM MED ASSOC, V301, P1242, DOI 10.1001/jama.2009.377; Dworkin RH, 2005, PAIN, V113, P9, DOI 10.1016/j.pain.2004.09.012; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Gilbody S, 2006, ARCH INTERN MED, V166, P2314, DOI 10.1001/archinte.166.21.2314; Gill D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001312.pub2; Herbert RD, 2000, AUST J PHYSIOTHER, V46, P309, DOI 10.1016/S0004-9514(14)60292-0; Holman HR, 2006, ANN INTERN MED, V144, P617, DOI 10.7326/0003-4819-144-8-200604180-00014; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Jackson JL, 2006, CNS SPECTRUMS, V11, P212, DOI 10.1017/S1092852900014383; JENSEN MP, 1992, PAIN, V50, P157, DOI 10.1016/0304-3959(92)90156-6; Jung AC, 1997, J GEN INTERN MED, V12, P384, DOI 10.1007/s11606-006-5088-3; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; Katon WJ, 2005, ARCH GEN PSYCHIAT, V62, P1313, DOI 10.1001/archpsyc.62.12.1313; Keller MB, 2003, JAMA-J AM MED ASSOC, V289, P3152, DOI 10.1001/jama.289.23.3152; Krebs EE, 2008, PSYCHOSOMATICS, V49, P191, DOI 10.1176/appi.psy.49.3.191; Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947; Kroenke K, 2003, INT J METH PSYCH RES, V12, P34, DOI 10.1002/mpr.140; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2000, PSYCHOTHER PSYCHOSOM, V69, P205, DOI 10.1159/000012395; KROENKE K, GEN HOSP PS IN PRESS; Kroenke K, 2008, PAIN, V134, P209, DOI 10.1016/j.pain.2007.09.021; Kroenke K, 2007, GEN HOSP PSYCHIAT, V29, P506, DOI 10.1016/j.genhosppsych.2007.08.005; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Lin EHB, 2003, JAMA-J AM MED ASSOC, V290, P2428, DOI 10.1001/jama.290.18.2428; Lorig K, 2003, MED CARE, V41, P699, DOI 10.1097/00005650-200306000-00001; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Lynch ME, 2001, J PSYCHIATR NEUROSCI, V26, P30; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Newman S, 2004, LANCET, V364, P1523, DOI 10.1016/S0140-6736(04)17277-2; Pariser Dave, 2005, J Geriatr Phys Ther, V28, P67; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Rubenstein LV, 2006, ANN INTERN MED, V145, P544, DOI 10.7326/0003-4819-145-7-200610030-00013; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; Rush AJ, 2006, NEW ENGL J MED, V354, P1231, DOI 10.1056/NEJMoa052963; SCHADT M, 1992, DISPLAYS, V13, P11, DOI 10.1016/0141-9382(92)90004-B; SPITZER RL, 1995, JAMA-J AM MED ASSOC, V274, P1511, DOI 10.1001/jama.274.19.1511; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Sternbach RA, 1986, CLIN J PAIN, V2, P49, DOI DOI 10.1097/00002508-198602010-00008; Stewart WF, 2003, JAMA-J AM MED ASSOC, V290, P2443, DOI 10.1001/jama.290.18.2443; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Thielke SM, 2007, AM J GERIAT PSYCHIAT, V15, P699, DOI 10.1097/JGP.0b013e3180325a2d; Trivedi MH, 2006, NEW ENGL J MED, V354, P1243, DOI 10.1056/NEJMoa052964; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Unutzer J, 2008, AM J MANAG CARE, V14, P95; Von Korff M, 2001, ANN INTERN MED, V134, P911, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00016; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Wang PS, 2007, JAMA-J AM MED ASSOC, V298, P1401, DOI 10.1001/jama.298.12.1401; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283; Warsi A, 2003, ARTHRITIS RHEUM-US, V48, P2207, DOI 10.1002/art.11210; Williams JW, 2007, GEN HOSP PSYCHIAT, V29, P91, DOI 10.1016/j.genhosppsych.2006.12.003; Williams JW, 2000, JAMA-J AM MED ASSOC, V284, P1519, DOI 10.1001/jama.284.12.1519; Williams LS, 2003, J NEUROL NEUROSUR PS, V74, P1587, DOI 10.1136/jnnp.74.11.1587; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	69	298	299	0	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	2009	301	20					2099	2110		10.1001/jama.2009.723	http://dx.doi.org/10.1001/jama.2009.723			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	449KF	19470987	Bronze, Green Accepted			2023-01-03	WOS:000266328800022
J	Plint, AC; Johnson, DW; Patel, H; Wiebe, N; Math, M; Correll, R; Brant, R; Mitton, C; Gouin, S; Bhatt, M; Joubert, G; Black, KJL; Turner, T; Whitehouse, S; Klassen, TP				Plint, Amy C.; Johnson, David W.; Patel, Hema; Wiebe, Natasha; Math, M.; Correll, Rhonda; Brant, Rollin; Mitton, Craig; Gouin, Serge; Bhatt, Maala; Joubert, Gary; Black, Karen J. L.; Turner, Troy; Whitehouse, Sandra; Klassen, Terry P.		Pediat Emergency Res Canada	Epinephrine and Dexamethasone in Children with Bronchiolitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEBULIZED RACEMIC ADRENALINE; ACUTE VIRAL BRONCHIOLITIS; SHORT-TERM; CLINICAL-EFFICACY; RANDOMIZED TRIAL; DOUBLE-BLIND; INFANTS; SALBUTAMOL; CORTICOSTEROIDS; SUPPRESSION	BACKGROUND Although numerous studies have explored the benefit of using nebulized epinephrine or corticosteroids alone to treat infants with bronchiolitis, the effectiveness of combining these medications is not well established. METHODS We conducted a multicenter, double-blind, placebo-controlled trial in which 800 infants (6 weeks to 12 months of age) with bronchiolitis who were seen in the pediatric emergency department were randomly assigned to one of four study groups. One group received two treatments of nebulized epinephrine (3 ml of epinephrine in a 1: 1000 solution per treatment) and a total of six oral doses of dexamethasone (1.0 mg per kilogram of body weight in the emergency department and 0.6 mg per kilogram for an additional 5 days) (the epinephrine-dexamethasone group), the second group received nebulized epinephrine and oral placebo (the epinephrine group), the third received nebulized placebo and oral dexamethasone (the dexamethasone group), and the fourth received nebulized placebo and oral placebo (the placebo group). The primary outcome was hospital admission within 7 days after the day of enrollment (the initial visit to the emergency department). RESULTS Baseline clinical characteristics were similar among the four groups. By the seventh day, 34 infants (17.1%) in the epinephrine-dexamethasone group, 47 (23.7%) in the epinephrine group, 51 (25.6%) in the dexamethasone group, and 53 (26.4%) in the placebo group had been admitted to the hospital. In the unadjusted analysis, only the infants in the epinephrine-dexamethasone group were significantly less likely than those in the placebo group to be admitted by day 7 (relative risk, 0.65; 95% confidence interval, 0.45 to 0.95, P = 0.02). However, with adjustment for multiple comparisons, this result was rendered insignificant (P = 0.07). There were no serious adverse events. CONCLUSIONS Among infants with bronchiolitis treated in the emergency department, combined therapy with dexamethasone and epinephrine may significantly reduce hospital admissions. (Current Controlled Trials number, ISRCTN56745572.)	[Plint, Amy C.] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Plint, Amy C.] Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; [Plint, Amy C.] Univ Ottawa, Dept Emergency Med, Ottawa, ON K1N 6N5, Canada; [Johnson, David W.] Univ Calgary, Dept Pediat, Calgary, AB T2N 1N4, Canada; [Johnson, David W.] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB T2N 1N4, Canada; [Johnson, David W.] Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; [Patel, Hema; Bhatt, Maala] McGill Univ, Dept Pediat, Montreal, PQ H3A 2T5, Canada; [Patel, Hema; Bhatt, Maala] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada; [Wiebe, Natasha] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Turner, Troy; Klassen, Terry P.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Correll, Rhonda] Childrens Hosp Eastern Ontario, Res Inst, Clin Res Unit, Ottawa, ON K1H 8L1, Canada; [Brant, Rollin] Univ British Columbia, Dept Stat, Vancouver, BC V5Z 1M9, Canada; [Whitehouse, Sandra] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Brant, Rollin] British Columbia Childrens Hosp, Child & Family Res Inst, Vancouver, BC V6H 3V4, Canada; [Mitton, Craig] Univ British Columbia Okanagan, Dept Hlth Studies, Kelowna, BC, Canada; [Gouin, Serge] Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada; [Gouin, Serge] Ctr Hosp Univ St Justing, Montreal, PQ, Canada; [Joubert, Gary] Univ Western Ontario, Dept Pediat, London, ON N6A 3K7, Canada; [Joubert, Gary] Univ Western Ontario, Dept Med, London, ON N6A 3K7, Canada; [Joubert, Gary] London Hlth Sci Ctr, London, ON, Canada; [Joubert, Gary] Childrens Hosp, London, ON, Canada; [Black, Karen J. L.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; [Black, Karen J. L.] Dalhousie Univ, Dept Emergency Med, Halifax, NS, Canada; [Black, Karen J. L.] IWK Hlth Ctr, Halifax, NS, Canada; [Turner, Troy; Klassen, Terry P.] Stollery Childrens Hosp, Edmonton, AB, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; University of Calgary; University of Calgary; Alberta Childrens Hospital; University of Calgary; McGill University; McGill University; University of Alberta; University of Alberta; University of Ottawa; Children's Hospital of Eastern Ontario; University of British Columbia; University of British Columbia; BC Childrens Hospital; Child & Family Research Institute; University of British Columbia; University of British Columbia; University of British Columbia Okanagan; Universite de Montreal; Western University (University of Western Ontario); Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Dalhousie University; Dalhousie University; Dalhousie University; Stollery Children's Hospital	Plint, AC (corresponding author), Childrens Hosp Eastern Ontario, 401 Smyth Ave, Ottawa, ON K1H 8L1, Canada.	plint@cheo.on.ca	Wiebe, Natasha/V-7803-2019; Plint, Amy/AAE-2250-2020; Bhatt, Maala/AGF-6509-2022	Wiebe, Natasha/0000-0002-5613-1582; Brant, Rollin/0000-0002-8026-2451; Klassen, Terry/0000-0002-5309-7091; Bhatt, Maala/0000-0003-1265-3482	Canadian Institutes of Health Research; Alberta Children's Hospital Foundation	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Children's Hospital Foundation	Supported by grants from the Canadian Institutes of Health Research and Alberta Children's Hospital Foundation. Dr. Plint was supported in part by a salary award from the Canadian Institutes of Health Research.	Barnes PJ, 2007, EUR RESPIR J, V29, P587, DOI 10.1183/09031936.00080306; Bentur L, 2005, ACTA PAEDIATR, V94, P866, DOI 10.1080/08035250510028407; Blackmon LR, 2002, PEDIATRICS, V109, P330; CORNELI HM, 2008, NEW ENGL J MED, V359, P1972; Corneli HM, 2007, NEW ENGL J MED, V357, P331, DOI 10.1056/NEJMoa071255; Fisher L.D., 1990, STAT ISSUES DRUG RES, P331, DOI DOI 10.1201/9780203738610; Flores G, 1997, PEDIATRICS, V100, P233, DOI 10.1542/peds.100.2.233; Giembycz MA, 2008, BRIT J PHARMACOL, V153, P1090, DOI 10.1038/sj.bjp.0707627; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Halliday HL, 2003, COCHRANE DB SYST REV, V1; Hartling L, 2003, ARCH PEDIAT ADOL MED, V157, P957, DOI 10.1001/archpedi.157.10.957; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hothorn T, 2008, BIOMETRICAL J, V50, P346, DOI 10.1002/bimj.200810425; KLASSEN TP, 1991, J PEDIATR-US, V118, P807, DOI 10.1016/S0022-3476(05)80051-4; KLASSEN TP, 1991, J PEDIATR, V119, P1010; KRISTJANSSON S, 1993, ARCH DIS CHILD, V69, P650, DOI 10.1136/adc.69.6.650; Kuyucu S, 2004, PEDIATR INT, V46, P539, DOI 10.1111/j.1442-200x.2004.01944.x; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; LOWELL DI, 1987, PEDIATRICS, V79, P939; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; MENON K, 1995, J PEDIATR-US, V126, P1004, DOI 10.1016/S0022-3476(95)70234-2; MILNER AD, 1989, THORAX, V44, P1, DOI 10.1136/thx.44.1.1; NJOO H, 2001, RESP DIS CANADA, P65; Patel H, 2003, J PEDIATR-US, V142, P509, DOI 10.1067/mpd.2003.196; Pauwels RA, 1998, NEW ENGL J MED, V338, P139; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; REIJONEN T, 1995, ARCH PEDIAT ADOL MED, V149, P686, DOI 10.1001/archpedi.1995.02170190096017; SANCHEZ I, 1993, J PEDIATR-US, V122, P145, DOI 10.1016/S0022-3476(05)83508-5; Schuh S, 2002, J PEDIATR-US, V140, P27, DOI 10.1067/mpd.2002.120271; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Stang P, 2001, ARCH PEDIAT ADOL MED, V155, P95, DOI 10.1001/archpedi.155.1.95; STRECK WF, 1979, AM J MED, V66, P910, DOI 10.1016/0002-9343(79)90444-3; TAL A, 1983, PEDIATRICS, V71, P13; Welliver J R, 1993, Pediatr Rev, V14, P134, DOI 10.1542/pir.14-4-134; WENNERGREN G, 1991, ACTA PAEDIATR SCAND, V80, P375, DOI 10.1111/j.1651-2227.1991.tb11865.x; WENNING GK, 1994, ACTA NEUROL SCAND, V89, P270; Westfall PH, 1997, J AM STAT ASSOC, V92, P299, DOI 10.2307/2291474; ZORA JA, 1986, J ALLERGY CLIN IMMUN, V77, P9, DOI 10.1016/0091-6749(86)90315-5	39	162	167	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2009	360	20					2079	2089		10.1056/NEJMoa0900544	http://dx.doi.org/10.1056/NEJMoa0900544			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444WN	19439742				2023-01-03	WOS:000266011200006
J	Harris, JC				Harris, James C.			Toward a Restorative Medicine-The Science of Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PATIENT; MATTER; MIND		Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA	Johns Hopkins University	Harris, JC (corresponding author), Johns Hopkins Univ, Sch Med, CMSC 341,600 N Wolfe St, Baltimore, MD 21287 USA.	jamesharris@erols.com						Beauregard M, 2007, PROG NEUROBIOL, V81, P218, DOI 10.1016/j.pneurobio.2007.01.005; Carter CS, 2008, PROG BRAIN RES, V170, P331, DOI 10.1016/S0079-6123(08)00427-5; Colloca L, 2005, NAT REV NEUROSCI, V6, P545, DOI 10.1038/nrn1705; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; ENGEL GL, 1977, JOHNS HOPKINS MED J, V140, P222; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; MEYER A, 1915, JAMA-J AM MED ASSOC, V65, P861; Mookadam F, 2004, ARCH INTERN MED, V164, P1514, DOI 10.1001/archinte.164.14.1514; Oglesby P, 1991, CARING PHYS LIFE FW; Patel VL, 2002, J BIOMED INFORM, V35, P8, DOI 10.1016/S1532-0464(02)00002-3; Patel VL, 2000, J AM MED INFORM ASSN, V7, P569, DOI 10.1136/jamia.2000.0070569; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; Peabody FW, 1928, J AMER MED ASSOC, V90, P1193, DOI 10.1001/jama.1928.92690420002009; Porges SW, 2003, ANN NY ACAD SCI, V1008, P31, DOI 10.1196/annals.1301.004; Winston JS, 2002, NAT NEUROSCI, V5, P277, DOI 10.1038/nn816	15	10	10	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	2009	301	16					1710	1712		10.1001/jama.2009.465	http://dx.doi.org/10.1001/jama.2009.465			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435NN	19383963				2023-01-03	WOS:000265350700028
J	Tanaka, MM; Kendal, JR; Laland, KN				Tanaka, Mark M.; Kendal, Jeremy R.; Laland, Kevin N.			From Traditional Medicine to Witchcraft: Why Medical Treatments Are Not Always Efficacious	PLOS ONE			English	Article							CHINESE MEDICINE; SEXUAL SELECTION; TRANSMISSION; EVOLUTION; HOMEOPATHY; BEHAVIOR; SAFETY; FADS	Complementary medicines, traditional remedies and home cures for medical ailments are used extensively world-wide, representing more than US$60 billion sales in the global market. With serious doubts about the efficacy and safety of many treatments, the industry remains steeped in controversy. Little is known about factors affecting the prevalence of efficacious and non-efficacious self-medicative treatments. Here we develop mathematical models which reveal that the most efficacious treatments are not necessarily those most likely to spread. Indeed, purely superstitious remedies, or even maladaptive practices, spread more readily than efficacious treatments under specified circumstances. Low-efficacy practices sometimes spread because their very ineffectiveness results in longer, more salient demonstration and a larger number of converts, which more than compensates for greater rates of abandonment. These models also illuminate a broader range of phenomena, including the spread of innovations, medical treatment of animals, foraging behaviour, and self-medication in non-human primates.			Tanaka, MM (corresponding author), Univ New S Wales, Sch Biotechnol & Biomol Sci, Evolut & Ecol Res Ctr, Sydney, NSW, Australia.	m.tanaka@unsw.edu.au	Laland, Kevin N/C-9482-2011	Laland, Kevin/0000-0002-2457-0900; Kendal, Jeremy/0000-0001-8644-3117	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Abbot NC, 1996, NATURE, V381, P361, DOI 10.1038/381361a0; Abbott A, 2005, NATURE, V436, P898, DOI 10.1038/436898b; Ang HH, 2006, FOOD CHEM TOXICOL, V44, P1245, DOI 10.1016/j.fct.2006.01.014; BECK M, 1989, J COMP PSYCHOL, V103, P132, DOI 10.1037/0735-7036.103.2.132; Bentley RA, 2007, EVOL HUM BEHAV, V28, P151, DOI 10.1016/j.evolhumbehav.2006.10.002; Bentley RA, 2004, P ROY SOC B-BIOL SCI, V271, P1443, DOI 10.1098/rspb.2004.2746; BIKHCHANDANI S, 1992, J POLIT ECON, V100, P992, DOI 10.1086/261849; Bikhchandani S, 1998, J ECON PERSPECT, V12, P151, DOI 10.1257/jep.12.3.151; Boyd R., 1985, CULTURE EVOLUTIONARY; Cavalli-Sforza L.L., 1981, CULTURAL TRANSMISSIO; Coultas JC, 2004, GROUP PROCESS INTERG, V7, P317, DOI 10.1177/1368430204046141; Dawkins R., 1976, SELFISH GENE; De Allegri M, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-22; Ewens W.J., 1979, MATH POPULATION GENE, V9; Fiot J, 2006, J ETHNOPHARMACOL, V106, P173, DOI 10.1016/j.jep.2005.12.030; Garnier R, 2006, PRESSE MED, V35, P1177, DOI 10.1016/S0755-4982(06)74776-5; Giles J, 2007, NATURE, V446, P352, DOI 10.1038/446352a; Giraldeau LA, 2002, PHILOS T R SOC B, V357, P1559, DOI 10.1098/rstb.2002.1065; Hahn MW, 2003, P ROY SOC B-BIOL SCI, V270, pS120, DOI 10.1098/rsbl.2003.0045; Henrich J, 1998, EVOL HUM BEHAV, V19, P215, DOI 10.1016/S1090-5138(98)00018-X; Henrich J, 2001, EVOL HUM BEHAV, V22, P165, DOI 10.1016/S1090-5138(00)00071-4; HEYES CM, 1994, BIOL REV, V69, P207, DOI 10.1111/j.1469-185X.1994.tb01506.x; Hsieh SC, 2006, PHARMACOEPIDEM DR S, V15, P889, DOI 10.1002/pds.1340; Huffman MA, 2004, PRIMATES, V45, P113, DOI 10.1007/s10329-003-0065-5; HUFFMAN MA, 2003, P NUT SOC, V62, P113; Karlin S., 1975, 1 COURSE STOCHASTIC; KIRKPATRICK M, 1982, EVOLUTION, V36, P1, DOI 10.1111/j.1558-5646.1982.tb05003.x; Laland KN, 1997, ANIM BEHAV, V53, P1161, DOI 10.1006/anbe.1996.0318; LALAND KN, 1994, THEOR POPUL BIOL, V45, P1, DOI 10.1006/tpbi.1994.1001; LEFEBVRE L, 1994, ANIM BEHAV, V47, P331, DOI 10.1006/anbe.1994.1046; LOSADA M, 2006, ECON BOT, V60, P374; Mace R, 2000, ANIM BEHAV, V59, P1, DOI 10.1006/anbe.1999.1287; Nesse R.M., 1994, WHY WE GET SICK NEW; Normile D, 2003, SCIENCE, V299, P188, DOI 10.1126/science.299.5604.188; Okeke TA, 2006, J BIOSOC SCI, V38, P491, DOI 10.1017/S002193200502660X; Pagel M, 2004, NATURE, V428, P275, DOI 10.1038/428275a; Palombo EA, 2006, PHYTOTHER RES, V20, P717, DOI 10.1002/ptr.1907; Patwardhan B, 2005, EVID-BASED COMPL ALT, V2, P465, DOI 10.1093/ecam/neh140; Reader S.M., 2003, ANIMAL INNOVATION; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; SILVER IA, 1983, EQUINE VET J S, V1, P1; Tanaka MM, 2002, THEOR POPUL BIOL, V62, P111, DOI 10.1006/tpbi.2002.1585; WERNER D, 1983, WHERE THERE IS DOCTO; WHITEN A, 1992, ADV STUD BEHAV, V21, P239, DOI 10.1016/S0065-3454(08)60146-1; Whiten A, 1999, NATURE, V399, P682, DOI 10.1038/21415; *WHO, 2002, WHO TRAD MED SURG 20	46	58	61	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2009	4	4							e5192	10.1371/journal.pone.0005192	http://dx.doi.org/10.1371/journal.pone.0005192			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	437TS	19367333	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000265510400005
J	Flynn, KE; Pina, IL; Whellan, DJ; Lin, L; Blumenthal, JA; Ellis, SJ; Fine, LJ; Howlett, JG; Keteyian, SJ; Kitzman, DW; Kraus, WE; Miller, NH; Schulman, KA; Spertus, JA; O'Connor, CM; Weinfurt, KP				Flynn, Kathryn E.; Pina, Ileana L.; Whellan, David J.; Lin, Li; Blumenthal, James A.; Ellis, Stephen J.; Fine, Lawrence J.; Howlett, Jonathan G.; Keteyian, Steven J.; Kitzman, Dalane W.; Kraus, William E.; Miller, Nancy Houston; Schulman, Kevin A.; Spertus, John A.; O'Connor, Christopher M.; Weinfurt, Kevin P.			Effects of Exercise Training on Health Status in Patients With Chronic Heart Failure HF-ACTION Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	81st Annual Scientific Session of the American-Heart-Association	NOV 08-12, 2008	New Orleans, LA	Amer Heart Assoc			QUALITY-OF-LIFE; CARDIAC RESYNCHRONIZATION; ELDERLY-PATIENTS; PREDICTORS; CAPACITY; OUTCOMES; MIRACLE; SAFETY	Context Findings from previous studies of the effects of exercise training on patient-reported health status have been inconsistent. Objective To test the effects of exercise training on health status among patients with heart failure. Design, Setting, and Patients Multicenter, randomized controlled trial among 2331 medically stable outpatients with heart failure with left ventricular ejection fraction of 35% or less. Patients were randomized from April 2003 through February 2007. Interventions Usual care plus aerobic exercise training (n = 1172), consisting of 36 supervised sessions followed by home-based training, vs usual care alone (n = 1159). Randomization was stratified by heart failure etiology, which was a covariate in all models. Main Outcome Measures Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary scale and key subscales at baseline, every 3 months for 12 months, and annually thereafter for up to 4 years. The KCCQ is scored from 0 to 100 with higher scores corresponding to better health status. Treatment group effects were estimated using linear mixed models according to the intention-to-treat principle. Results Median follow-up was 2.5 years. At 3 months, usual care plus exercise training led to greater improvement in the KCCQ overall summary score (mean, 5.21; 95% confidence interval, 4.42 to 6.00) compared with usual care alone (3.28; 95% confidence interval, 2.48 to 4.09). The additional 1.93-point increase (95% confidence interval, 0.84 to 3.01) in the exercise training group was statistically significant (P < .001). After 3 months, there were no further significant changes in KCCQ score for either group (P = .85 for the difference between slopes), resulting in a sustained, greater improvement overall for the exercise group (P < .001). Results were similar on the KCCQ subscales, and no subgroup interactions were detected. Conclusions Exercise training conferred modest but statistically significant improvements in self-reported health status compared with usual care without training. Improvements occurred early and persisted over time. Trial Registration clinicaltrials.gov Identifier: NCT00047437.	[Flynn, Kathryn E.] Duke Univ, Sch Med, Duke Clin Res Inst, Ctr Clin & Genet Econ, Durham, NC 27715 USA; [Flynn, Kathryn E.; Blumenthal, James A.; Weinfurt, Kevin P.] Duke Univ, Sch Med, Dept Psychiat & Behav Sci, Durham, NC 27715 USA; [Kraus, William E.; Schulman, Kevin A.; O'Connor, Christopher M.] Duke Univ, Sch Med, Dept Med, Durham, NC 27715 USA; [Pina, Ileana L.] Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; [Whellan, David J.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA; [Fine, Lawrence J.] NHLBI, Div Prevent & Populat Sci, Bethesda, MD 20892 USA; [Miller, Nancy Houston] Stanford Univ, Dept Med, Stanford, CA 94305 USA; [Howlett, Jonathan G.] Dalhousie Univ, Queen Elizabeth Hlth Sci Ctr 2, Halifax, NS, Canada; [Keteyian, Steven J.] Henry Ford Hosp, Div Cardiovasc Med, Detroit, MI 48202 USA; [Kitzman, Dalane W.] Wake Forest Univ, Sch Med, Dept Internal Med, Winston Salem, NC 27109 USA; [Spertus, John A.] St Lukes Hlth Syst, Mid Amer Heart Inst, Kansas City, MO USA; [Spertus, John A.] Univ Missouri Kansas City, Kansas City, MO USA	Duke University; Duke University; Duke University; Case Western Reserve University; Jefferson University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Stanford University; Dalhousie University; Queen Elizabeth II Health Sciences Centre; Henry Ford Health System; Henry Ford Hospital; Wake Forest University; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City	Flynn, KE (corresponding author), Duke Univ, Sch Med, Duke Clin Res Inst, Ctr Clin & Genet Econ, POB 17969, Durham, NC 27715 USA.	kathryn.flynn@duke.edu	Spertus, John/ABD-3075-2021; Howlett, Jonathan/T-2589-2019; Flynn, Kathryn E/M-5346-2013	Flynn, Kathryn E/0000-0002-4427-3583; Hittinger, Luc/0000-0003-1933-5815; Howlett, Jonathan/0000-0002-0535-9771; Handberg, Eileen/0000-0002-7805-9577; Hershberger, Ray/0000-0001-5683-6526; Zile, Michael/0000-0001-7076-221X; Kraus, William E/0000-0003-1930-9684	NHLBI NIH HHS [U01 HL066461, U01 HL068973, 5U01HL068980, U01 HL064264, U01 HL066491-06, U01 HL063747, U01 HL064265, U01 HL066461-06S1, U01 HL064250, 5U01HL066494, U01 HL064264-05, U01 HL066501, 5U01HL066482, 5U01HL064264, 5U01HL066461, U01 HL064257, U01 HL068980-05, U01 HL066497-04, U01 HL068980, U01 HL068973-06, 5U01HL068973, U01 HL066494-04, U01 HL066491, 5U01HL064265, 5U01HL064250, 5U01HL066497, U01 HL066482-04, U01 HL066497, 5U01HL064257, U01 HL066482, 5U01HL063747, 5U01HL066491, U01 HL064250-06, U01 HL063747-06S1, U01 HL066501-06, U01 HL064265-04, U01 HL066494, U01 HL064257-01A2, 5U01HL066501] Funding Source: Medline; NIA NIH HHS [R37 AG018915] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173; Brunner EJ, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002128.pub2; Chien CL, 2008, AUST J PHYSIOTHER, V54, P87, DOI 10.1016/S0004-9514(08)70041-2; COATS AJS, 1990, LANCET, V335, P63, DOI 10.1016/0140-6736(90)90536-E; DRACUP K, 1992, J HEART LUNG TRANSPL, V11, P273; Gary RA, 2004, HEART LUNG, V33, P210, DOI 10.1016/j.hrtlng.2004.01.004; GIBBONS RD, 1993, ARCH GEN PSYCHIAT, V50, P739; Green CP, 2000, J AM COLL CARDIOL, V35, P1245, DOI 10.1016/S0735-1097(00)00531-3; Havranek EP, 2004, J AM COLL CARDIOL, V44, P2333, DOI 10.1016/j.jacc.2004.09.034; Keteyian SJ, 1996, ANN INTERN MED, V124, P1051, DOI 10.7326/0003-4819-124-12-199606150-00004; Keteyian SJ, 1999, AM HEART J, V138, P233, DOI 10.1016/S0002-8703(99)70106-7; KRAEMER HC, 1989, J CONSULT CLIN PSYCH, V57, P148, DOI 10.1037/0022-006X.57.1.148; Krumholz HM, 1998, CIRCULATION, V97, P958; McKelvie RS, 2008, HEART FAIL REV, V13, P3, DOI 10.1007/s10741-007-9052-z; McKelvie RS, 2002, AM HEART J, V144, P23, DOI 10.1067/mhj.2002.123310; Metra M, 2000, CIRCULATION, V102, P546; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Pires LA, 2006, AM HEART J, V151, P837, DOI 10.1016/j.ahj.2005.06.024; Raudenbush, 1992, HIERARCHICAL LINEAR; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Shah MR, 2001, AM J CARDIOL, V88, P987, DOI 10.1016/S0002-9149(01)01975-0; Spertus J, 2005, AM HEART J, V150, P707, DOI 10.1016/j.ahj.2004.12.010; Whellan DJ, 2007, AM HEART J, V153, P201, DOI 10.1016/j.ahj.2006.11.007; Wielenga RP, 1998, CORONARY ARTERY DIS, V9, P765, DOI 10.1097/00019501-199809110-00010; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685	25	496	517	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	2009	301	14					1451	1459		10.1001/jama.2009.457	http://dx.doi.org/10.1001/jama.2009.457			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	429MN	19351942	Bronze, Green Accepted			2023-01-03	WOS:000264924900025
J	Dobscha, SK; Corson, K; Perrin, NA; Hanson, GC; Leibowitz, RQ; Doak, MN; Dickinson, KC; Sullivan, MD; Gerrity, MS				Dobscha, Steven K.; Corson, Kathryn; Perrin, Nancy A.; Hanson, Ginger C.; Leibowitz, Ruth Q.; Doak, Melanie N.; Dickinson, Kathryn C.; Sullivan, Mark D.; Gerrity, Martha S.			Collaborative Care for Chronic Pain in Primary Care A Cluster Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC NONCANCER PAIN; CLINICALLY IMPORTANT DIFFERENCE; IMPROVING PRIMARY-CARE; BACK-PAIN; DEPRESSION CARE; CHRONIC ILLNESS; SCREENING-TEST; HEALTH-STATUS; DISABILITY; MANAGEMENT	Context Chronic pain is common in primary care patients and is associated with distress, disability, and increased health care use. Objective To assess whether a collaborative intervention can improve chronic pain related outcomes, including comorbid depression severity, in a Department of Veterans Affairs primary care setting. Design, Setting, and Participants Cluster randomized controlled trial of a collaborative care assistance with pain treatment intervention vs treatment as usual at 5 primary care clinics of 1 Department of Veterans Affairs Medical Center. Forty-two primary care clinicians were randomized to the assistance with pain treatment intervention group or the treatment as usual group. The 401 patients had musculoskeletal pain diagnoses, moderate or greater pain intensity, and disability lasting 12 weeks or longer and were assigned to the same treatment groups as their clinicians. Recruitment occurred from January 2006 to January 2007 and follow-up concluded in January 2008. Intervention Assistance with pain treatment included a 2-session clinician education program, patient assessment, education and activation, symptom monitoring, feedback and recommendations to clinicians, and facilitation of specialty care. Main Outcome Measures Changes over 12 months in pain-related disability (Roland-Morris Disability Questionnaire, range of 0-24), pain intensity (Chronic Pain Grade [CPG] Pain Intensity subscale, range of 0-100), and depression (Patient Health Questionnaire 9 [PHQ-9], range of 0-27), measured as beta coefficients (difference in slopes in points per month). Results Intervention patients had a mean (SD) of 10.6 (4.5) contacts with the assistance with pain treatment team. Compared with the patients receiving treatment as usual, intervention patients showed greater improvements in pain-related disability (Roland-Morris Disability Questionnaire beta, -0.101 [95% confidence interval {CI}, -0.163 to -0.040]; P=.004 and CPG Pain Intensity subscale beta, -0.270 [95% CI, -0.480 to -0.061]; P=.01). Among patients with baseline depression (PHQ-9 score >= 10), there was greater improvement in depression severity in patients receiving the intervention compared with patients receiving treatment as usual (PHQ-9 beta, -0.177 [95% CI, -0.295 to -0.060]; P=.003). The differences in scores between baseline and 12 months for the assistance with pain treatment intervention group and the treatment as usual group, respectively, were -1.4 vs -0.2 for the Roland-Morris Disability Questionnaire, -4.7 vs -0.6 for the CPG Pain Intensity subscale, and -3.7 vs -1.2 for PHQ-9. Conclusion The assistance with pain treatment collaborative intervention resulted in modest but statistically significant improvement in a variety of outcome measures. Trial Registration clinicaltrials.gov Identifier: NCT00129480	[Dobscha, Steven K.; Corson, Kathryn; Leibowitz, Ruth Q.; Dickinson, Kathryn C.; Gerrity, Martha S.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR 97239 USA; [Doak, Melanie N.] Portland VA Med Ctr, Div Primary Care, Portland, OR 97239 USA; [Gerrity, Martha S.] Portland VA Med Ctr, Div Hosp & Specialty Med, Portland, OR 97239 USA; [Dobscha, Steven K.; Corson, Kathryn] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA; [Doak, Melanie N.; Gerrity, Martha S.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; [Perrin, Nancy A.; Hanson, Ginger C.] Oregon Hlth & Sci Univ, Sch Nursing, Portland, OR 97201 USA; [Sullivan, Mark D.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle	Dobscha, SK (corresponding author), Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, 3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.	steven.dobscha@va.gov		Gerrity, Martha/0000-0002-8772-4591; Hanson, Ginger/0000-0003-3306-752X	Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service [PMI 03-195, REA 06-174]; Greenwall Foundation	Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service(US Department of Veterans Affairs); Greenwall Foundation	Funding/Support: This research was supported by the Department of Veterans Affairs, Veterans Health Administration, and Health Services Research and Development Service Projects PMI 03-195 and REA 06-174. Some research team members received training on chronic pain communication skills developed with a grant from the Greenwall Foundation.	Ahles TA, 2006, ANN FAM MED, V4, P341, DOI 10.1370/afm.527; *AM CHRON PAIN ASS, 2005, PATHW PAIN; [Anonymous], 1998, J Am Geriatr Soc, V46, P635; Bair MJ, 2005, J GEN INTERN MED, V20, P62; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; BALDERSON B, 2004, UNDERSTANDING TREATI; Becker N, 2000, PAIN, V84, P203, DOI 10.1016/S0304-3959(99)00209-2; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Chelminski PR, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-3; Cherkin DC, 1996, SPINE, V21, P345, DOI 10.1097/00007632-199602010-00019; Clark JD, 2002, J PAIN SYMPTOM MANAG, V23, P131, DOI 10.1016/S0885-3924(01)00396-7; Cocco KM, 1998, PSYCHOL ASSESSMENT, V10, P408, DOI 10.1037/1040-3590.10.4.408; Crosby FE, 2006, PAIN MANAG NURS, V7, P12, DOI 10.1016/j.pmn.2005.12.001; Dobscha SK, 2008, PAIN MED, V9, P1050, DOI 10.1111/j.1526-4637.2008.00457.x; Dobscha SK, 2007, IMPLEMENT SCI, V2, DOI 10.1186/1748-5908-2-16; Elliott AM, 2000, PAIN, V88, P303, DOI 10.1016/S0304-3959(00)00337-7; Eriksen J, 2006, PAIN, V125, P172, DOI 10.1016/j.pain.2006.06.009; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Ferrell B, 2002, J AM GERIATR SOC, V50, pS205, DOI 10.1046/j.1532-5415.50.6s.1.x; Grotle M, 2005, SPINE, V30, P130, DOI 10.1097/01.brs.0000149184.16509.73; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Harper R, 1997, THORAX, V52, P879, DOI 10.1136/thx.52.10.879; Jenkinson C, 1997, MED CARE, V35, P1109, DOI 10.1097/00005650-199711000-00003; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; KERNS RD, 1988, J CONSULT CLIN PSYCH, V56, P870, DOI 10.1037/0022-006X.56.6.870; Kirsch B, 2000, VHSJ, P49; KIRSCH B, 2000, VET HLTH SYSTEM J, V5, P53; KIRSCH B, 2000, VHSJ, V5, P47; KIRSCH B, 2000, VET HLTH SYSTEM J, V5, P59; Koike AK, 2002, AM J PSYCHIAT, V159, P1738, DOI 10.1176/appi.ajp.159.10.1738; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lauridsen HH, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-82; Lin EHB, 1997, MED CARE, V35, P831, DOI 10.1097/00005650-199708000-00008; Lin EHB, 2003, JAMA-J AM MED ASSOC, V290, P2428, DOI 10.1001/jama.290.18.2428; Liu CF, 2007, AM J MANAG CARE, V13, P652; Luo N, 2005, MED CARE, V43, P1078, DOI 10.1097/01.mlr.0000182493.57090.c1; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Raudenbush S. W., 2002, HIERARCHICAL LINEAR; Raudenbush Stephen, 2004, HLM 6; Reid MC, 2002, J GEN INTERN MED, V17, P173, DOI 10.1046/j.1525-1497.2002.10435.x; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; Saha S, 2008, J GEN INTERN MED, V23, P654, DOI 10.1007/s11606-008-0521-4; Sloan KL, 2003, MED CARE, V41, P761, DOI 10.1097/00005650-200306000-00009; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stratford PW, 1998, PHYS THER, V78, P1186, DOI 10.1093/ptj/78.11.1186; Sullivan MD, 2006, J GEN INTERN MED, V21, P360, DOI 10.1111/j.1525-1497.2006.00352.x; Turk DC, 2002, CLIN J PAIN, V18, P355, DOI 10.1097/00002508-200211000-00003; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; *US BUR CENS, VET 2000 CENS 2000; *US DEP VET AFF, VETOPO2007 VERS 1 0; *VA DEP DEF, MAN OP THER CHRON PA; *VA OFF QUAL PERF, VET SAT PERC PAT REP; Verhaak PFM, 1998, PAIN, V77, P231, DOI 10.1016/S0304-3959(98)00117-1; Von Korff M, 2005, PAIN, V113, P323, DOI 10.1016/j.pain.2004.11.007; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; Weathers F.W., 1993, ANN CONVENTION INT S; Weathers FW, 1996, MEASUREMENT STRESS T; Weingarten SR, 2002, BRIT MED J, V325, P925, DOI 10.1136/bmj.325.7370.925; Weinger K, 2003, DIABETES SPECTRUM, V16, P104, DOI DOI 10.2337/; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Williams JW, 2007, GEN HOSP PSYCHIAT, V29, P91, DOI 10.1016/j.genhosppsych.2006.12.003	67	226	226	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	2009	301	12					1242	1252		10.1001/jama.2009.377	http://dx.doi.org/10.1001/jama.2009.377			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	423JO	19318652				2023-01-03	WOS:000264492800024
J	Hurley, R				Hurley, Richard			Public Health Bad blood: gay men and blood donation	BRITISH MEDICAL JOURNAL			English	Editorial Material							EVER HAD SEX		BMJ, London WC1H 9JR, England		Hurley, R (corresponding author), BMJ, London WC1H 9JR, England.	rhurley@bmj.com						[Anonymous], 2008, BBC NEWS        1104; Brooks JP, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b318; *CAN BLOOD SERV, IND DEF; *CARE2PETITIONSITE, ALL GAY PEOPL BLOOD; *DEP HLTH HUM SERV, 2006, BLOOD SAF AV ADV COM; *FOOD DRUG ADM, FDA POL BLOOD DON ME; *HLTH PROT AG, 2007, TEST TIM HIV OTH SEX; IRVINE C, 2008, DAILY TELEGRAPH 1112; *NAT BLOOD SERV EN, WHO CAN GIV BLOOD; *NHS BLOOD TRANSP, 2008, EXCL MEN WHO HAV SEX; *PRIM MIN OFF, 2007, BLOODB EP RESP; Roehr B, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b311; *SCOTT PARL INF CT, 2008, BRIEF PUBL PET COMM; Soldan K, 2003, VOX SANG, V84, P265, DOI 10.1046/j.1423-0410.2003.00295.x; *STON, STON CALLS END BLOOD; *TERR HIGG TRUST, BLOOD DON PEOPL HIGH; *UK BLOOD TRANSF S, 2007, BLOOD DON SEL MIN RI; 2008, BEHAV DONOR DEFERRAL; 2007, MCGILL TRIBUNE  0306; 2008, US NEWS         0204	20	12	12	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 26	2009	338								b779	10.1136/bmj.b779	http://dx.doi.org/10.1136/bmj.b779			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	417DS	19246551				2023-01-03	WOS:000264056300003
J	Teno, JM; Connor, SR				Teno, Joan M.; Connor, Stephen R.			Referring a Patient and Family to High-Quality Palliative Care at the Close of Life "We Met a New Personality ... With This Level of Compassion and Empathy"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPICE CARE; MEMBERS PERCEPTIONS; ILL PATIENTS	Palliative care services are increasingly available to primary care physicians for both expert consultations and services to seriously ill patients. The United States now has more than 1400 hospital- based palliative care teams and more than 4700 hospice programs. We use an illustrative case of a palliative care hospitalization and intervention for a middle- aged man with severe pain from spinal metastases to discuss 4 key questions that a primary care physician faces in caring for the seriously ill patient with difficult symptom management: ( 1) Should I refer a patient to a hospital- based palliative care team or to hospice services for difficult symptom management? ( 2) If the patient is referred to a hospital- based palliative care team, what should I, as the primary care physician, expect? ( 3) When should I refer to hospice services a patient initially referred to a hospital- based palliative care team? and ( 4) How can I choose a hospice program that will provide competent, coordinated, and compassionate patient- and family-centered care? Primary care physicians now may choose among hospice programs, and the programs may vary in their quality of care. Validated tools to measure patient and family perceptions of the quality of hospice care are now available but progress in defining and measuring the quality of hospice care is still needed before actionable information will be available to guide the choice of hospice programs for physicians and consumers.	[Teno, Joan M.] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA; [Connor, Stephen R.] Natl Hospice & Palliat Care Org, Washington, DC USA	Brown University	Teno, JM (corresponding author), Brown Univ, Warren Alpert Sch Med, 2 Stimson Ave, Providence, RI 02912 USA.	Joan_Teno@brown.edu	Connor, Stephen R/B-3353-2009	Connor, Stephen R/0000-0003-0332-2067	Archstone Foundation	Archstone Foundation	The Perspectives on Care at the Close of Life section is made possible by a grant from the Archstone Foundation.	[Anonymous], NAT FRAM PREF PRACT; Carlson MDA, 2008, J PAIN SYMPTOM MANAG, V36, P107, DOI 10.1016/j.jpainsymman.2007.09.014; Casarett D, 2005, J AM GERIATR SOC, V53, P249, DOI 10.1111/j.1532-5415.2005.53110.x; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Connor SR, 2005, J PAIN SYMPTOM MANAG, V30, P9, DOI 10.1016/j.jpainsymman.2005.04.001; Connor SR, 2004, J PAIN SYMPTOM MANAG, V28, P316, DOI 10.1016/j.jpainsymman.2004.07.003; DY S, 2008, QUALITY MEASURES HOS; HANSON L, 2008, MEASURING QUALITY CA; Larson DG, 2000, JAMA-J AM MED ASSOC, V284, P1573, DOI 10.1001/jama.284.12.1573; Lorenz Karl A, 2002, J Palliat Med, V5, P507, DOI 10.1089/109662102760269742; Mitchell SL, 2007, J PAIN SYMPTOM MANAG, V34, P7, DOI 10.1016/j.jpainsymman.2007.01.003; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; *NAT CONS PROJ QUA, 2004, PRACT GUID QUAL PALL; *NAT HOSP FDN, SEL HOSP PROGR; *NAT QUAL FOR, 2006, PREV REV NAT QUAL FO; *ORG NHPCO, NHPCO FACTS FIG HOSP; Pan C X, 2001, J Palliat Med, V4, P315, DOI 10.1089/109662101753123922; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rhodes RL, 2007, J PAIN SYMPTOM MANAG, V34, P472, DOI 10.1016/j.jpainsymman.2007.06.004; Rickerson E, 2005, J AM GERIATR SOC, V53, P819, DOI 10.1111/j.1532-5415.2005.53259.x; SAUNDERS C, 2001, MONOGRAPH COMMEMORAT; Schoen C, 2008, HLTH AFFAIRS MILLWOO, V28, pw1, DOI DOI 10.1377/HLTHAFF.28.1.W1; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Smith Thomas J, 2005, J Palliat Med, V8, P736, DOI 10.1089/jpm.2005.8.736; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Teno JM, 2001, J PAIN SYMPTOM MANAG, V22, P738, DOI 10.1016/S0885-3924(01)00335-9; Teno JM, 2007, J PAIN SYMPTOM MANAG, V34, P120, DOI 10.1016/j.jpainsymman.2007.04.014; Teno Joan M, 2005, J Palliat Med, V8 Suppl 1, pS42; Virnig BA, 2000, J AM GERIATR SOC, V48, P1117, DOI 10.1111/j.1532-5415.2000.tb04789.x; VONGUNTEN CF, 2001, CTR ADV PALLIATIVE C; who, WHO DEF PALL CAR; 2008, FED REG, V73, P32089	32	34	34	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	2009	301	6					651	659		10.1001/jama.2009.109	http://dx.doi.org/10.1001/jama.2009.109			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	405MN	19211472				2023-01-03	WOS:000263229000029
J	Bottiger, BW; Arntz, H; Chamberlain, DA; Bluhmki, E; Belmans, A; Danays, T; Carli, PA; Adgey, JA; Bode, C; Wenzel, V				Bottiger, Bernd W.; Arntz, Hans-Richard; Chamberlain, Douglas A.; Bluhmki, Erich; Belmans, Ann; Danays, Thierry; Carli, Pierre A.; Adgey, Jennifer A.; Bode, Christoph; Wenzel, Volker		TROICA Trial Investigators; European Resuscitation Council Stu	Thrombolysis during Resuscitation for Out-of-Hospital Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	28th Congress of the European-Society-of-Cardiology/World Congress of Cardiology	SEP 02-06, 2006	Barcelona, SPAIN	European Soc Cardiol, World Heart Federat			TISSUE-PLASMINOGEN ACTIVATOR; CHEST COMPRESSION DEVICE; CARDIOPULMONARY-RESUSCITATION; TERM SURVIVAL; TENECTEPLASE; EPINEPHRINE; THERAPY; SAFETY; REPERFUSION; ADHESION	Background: Approximately 70% of persons who have an out-of-hospital cardiac arrest have underlying acute myocardial infarction or pulmonary embolism. Therefore, thrombolysis during cardiopulmonary resuscitation may improve survival. Methods: In a double-blind, multicenter trial, we randomly assigned adult patients with witnessed out-of-hospital cardiac arrest to receive tenecteplase or placebo during cardiopulmonary resuscitation. Adjunctive heparin or aspirin was not used. The primary end point was 30-day survival; the secondary end points were hospital admission, return of spontaneous circulation, 24-hour survival, survival to hospital discharge, and neurologic outcome. Results: After blinded review of data from the first 443 patients, the data and safety monitoring board recommended discontinuation of enrollment of asystolic patients because of low survival, and the protocol was amended. Subsequently, the trial was terminated prematurely for futility after enrolling a total of 1050 patients. Tenecteplase was administered to 525 patients and placebo to 525 patients; the two treatment groups had similar clinical profiles. We did not detect any significant differences between tenecteplase and placebo in the primary end point of 30-day survival (14.7% vs. 17.0%; P=0.36; relative risk, 0.87; 95% confidence interval, 0.65 to 1.15) or in the secondary end points of hospital admission (53.5% vs. 55.0%, P=0.67), return of spontaneous circulation (55.0% vs. 54.6%, P=0.96), 24-hour survival (30.6% vs. 33.3%, P=0.39), survival to hospital discharge (15.1% vs. 17.5%, P=0.33), or neurologic outcome (P=0.69). There were more intracranial hemorrhages in the tenecteplase group. Conclusions: When tenecteplase was used without adjunctive antithrombotic therapy during advanced life support for out-of-hospital cardiac arrest, we did not detect an improvement in outcome, in comparison with placebo. (ClinicalTrials.gov number, NCT00157261.).	[Bottiger, Bernd W.] Univ Cologne, Dept Anesthesiol & Postoperat Intens Care Med, D-50937 Cologne, Germany; [Bottiger, Bernd W.] Heidelberg Univ, Heidelberg, Germany; [Arntz, Hans-Richard] Benjamin Franklin Med Ctr, Charite, Berlin, Germany; [Chamberlain, Douglas A.] Cardiff Univ, Prehosp Emergency Res Unit, Sch Med, Cardiff, Wales; [Bluhmki, Erich] Boehringer Ingelheim KG, Biberach, Germany; [Belmans, Ann] Katholieke Univ Leuven, Ctr Biostat, Louvain, Belgium; [Danays, Thierry] Boehringer Ingelheim KG, Reims, France; [Carli, Pierre A.] Hop Necker Enfants Malad, Serv Aide Med Urgence Paris, Paris, France; [Adgey, Jennifer A.] Royal Victoria Hosp, Reg Med Cardiol Ctr, Belfast BT12 6BA, Antrim, North Ireland; [Bode, Christoph] Univ Freiburg, Freiburg, Germany; [Wenzel, Volker] Innsbruck Med Univ, Innsbruck, Austria	University of Cologne; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Cardiff University; Boehringer Ingelheim; KU Leuven; Boehringer Ingelheim; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Freiburg; Medical University of Innsbruck	Bottiger, BW (corresponding author), Univ Cologne, Dept Anesthesiol & Postoperat Intens Care Med, Kerpener Str 62, D-50937 Cologne, Germany.	bernd.boettiger@uk-koeln.de	Hachimi Idrissi, Said/I-6422-2018; Blobner, Manfred/R-4411-2017; Roessler, Markus Soeren/I-7834-2013; Pesenti, Antonio/H-7483-2012	Hachimi Idrissi, Said/0000-0002-8455-1410; Blobner, Manfred/0000-0002-0370-5247; Pesenti, Antonio/0000-0003-2593-729X; Breckwoldt, Jan/0000-0003-1716-1970; Valentin, Andreas/0000-0001-7443-3595; tazarourte, karim/0000-0002-3376-1258; Rosell-Ortiz, Fernando/0000-0003-0260-9955; Genzwuerker, Harald/0000-0002-5495-629X				AbuLaban RB, 2003, NEW ENGL J MED, V349, P1487; Afshar-Kharghan V, 2006, CURR OPIN HEMATOL, V13, P34, DOI 10.1097/01.moh.0000190107.54790.de; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Arntz HR, 2008, RESUSCITATION, V76, P180, DOI 10.1016/j.resuscitation.2007.07.012; BOTTIGER BW, 1995, CIRCULATION, V92, P2572, DOI 10.1161/01.CIR.92.9.2572; Bottiger BW, 2002, CRIT CARE MED, V30, P2473, DOI 10.1097/01.CCM.0000034689.78033.E2; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Bottiger BW, 1996, ACTA ANAESTH SCAND, V40, P631; Bozeman WP, 2006, RESUSCITATION, V69, P399, DOI 10.1016/j.resuscitation.2005.09.027; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Fatovich DM, 2004, RESUSCITATION, V61, P309, DOI 10.1016/j.resuscitation.2004.01.016; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; Fischer M, 1996, INTENS CARE MED, V22, P1214; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; Gurbel PA, 2005, BLOOD COAGUL FIBRIN, V16, P1, DOI 10.1097/00001721-200501000-00001; Hallstrom A, 2006, JAMA-J AM MED ASSOC, V295, P2620, DOI 10.1001/jama.295.22.2620; Hoke RS, 2004, RESUSCITATION, V63, P327, DOI 10.1016/j.resuscitation.2004.05.019; Human Milk Banking Association of North America, 1995, GUID GOOD CLIN PRACT, P1; *INT CONS SCI, 2000, CIRCULATION S1, V102, P1; Janata K, 2003, RESUSCITATION, V57, P49, DOI 10.1016/S0300-9572(02)00430-6; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4; Lederer W, 2004, RESUSCITATION, V61, P123, DOI 10.1016/j.resuscitation.2003.12.016; Lederer W, 2001, RESUSCITATION, V50, P71, DOI 10.1016/S0300-9572(01)00317-3; Li X, 2006, RESUSCITATION, V70, P31, DOI 10.1016/j.resuscitation.2005.11.016; Nolan J, 2005, RESUSCITATION, V64, P5, DOI 10.1016/S0300-9572(04)00468-X; Ong MEH, 2006, JAMA-J AM MED ASSOC, V295, P2629, DOI 10.1001/jama.295.22.2629; Rea TD, 2004, RESUSCITATION, V63, P17, DOI 10.1016/j.resuscitation.2004.03.025; SILFVAST T, 1991, J INTERN MED, V229, P331, DOI 10.1111/j.1365-2796.1991.tb00355.x; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Spohr F, 2005, EUR J CLIN INVEST, V35, P315, DOI 10.1111/j.1365-2362.2005.01491.x; Spohr F, 2003, DRUG SAFETY, V26, P367; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; Van de Werf F, 2001, EUR HEART J, V22, P2253, DOI 10.1053/euhj.2001.2686; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; 2005, CIRCULATION S4, V112, P1	37	242	265	1	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 18	2008	359	25					2651	2662		10.1056/NEJMoa070570	http://dx.doi.org/10.1056/NEJMoa070570			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	384PS	19092151	Bronze			2023-01-03	WOS:000261757300005
J	Gunnell, D; Hawton, K; Ho, D; Evans, J; O'Connor, S; Potokar, J; Donovan, J; Kapur, N				Gunnell, David; Hawton, Keith; Ho, Davidson; Evans, Jonathan; O'Connor, Susan; Potokar, John; Donovan, Jenny; Kapur, Nav			Hospital admissions for self harm after discharge from psychiatric inpatient care: cohort study	BRITISH MEDICAL JOURNAL			English	Article							SUICIDE-PREVENTION; RISK; ADOLESCENTS; MANAGEMENT	Objective To determine the risk of non- fatal self harm in the 12 months after discharge from psychiatric inpatient care. Design Cohort study based on national hospital episode statistics. Setting England. Population Patients aged 16- 64 years discharged from psychiatric inpatient care between 1 April 2004 and 31 March 2005 and followed up for one year. Results 75 401 people were discharged from psychiatric inpatient care over the study period, 4935 ( 6.5%) of whom were admitted at least once for self harm in the following 12 months. Risk of self harm was greatest in the four weeks after discharge; one third ( 32%, n= 1578) of admissions for self harm occurred in this period. The strongest risk factor for self harm after discharge was admission for self harm in the previous 12 months ( hazard ratio 4.9, 95% confidence interval 4.6 to 5.2). The risk of self harm was also higher in females, younger people, those with diagnoses of depression, personality disorders, and substance misuse, and those with short lengths of stay. Conclusion More than 6% of patients discharged from psychiatric inpatient care are readmitted for an episode of self harm within 12 months, with one third of these episodes occurring in the month after discharge. Self harm after discharge from hospital shares many of the features of suicide after discharge. Interventions should be developed to reduce risk in this period.	[Gunnell, David; Ho, Davidson; Donovan, Jenny] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; [Hawton, Keith] Univ Oxford, Warneford Hosp, Dept Psychiat, Ctr Suicide Res, Oxford, England; [Ho, Davidson] SW Publ Hlth Observ, Bristol, Avon, England; [Evans, Jonathan; Potokar, John] Univ Bristol, Acad Unit Psychiat, Bristol, Avon, England; [O'Connor, Susan] Avon & Wiltshire Partnership NHS Trust, Chippenham, Wilts, England; [Kapur, Nav] Univ Manchester, Ctr Suicide Prevent, Manchester M13 9PL, Lancs, England	University of Bristol; University of Oxford; University of Bristol; University of Manchester	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	d.j.gunnell@bristol.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470; Kapur, Nav/0000-0002-3100-3234; Evans, Jonathan/0000-0003-3171-640X	National Institute of Health Research	National Institute of Health Research(National Institute for Health Research (NIHR))	This work was funded by a National Institute of Health Research programme grant for applied research.	Department of Health, 2002, NAT SUIC PREV STRAT; GEDDES JR, 1995, BRIT MED J, V311, P357, DOI 10.1136/bmj.311.7001.357; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldston DB, 1999, J AM ACAD CHILD PSY, V38, P660, DOI 10.1097/00004583-199906000-00012; Gunnell D, 2005, J PUBLIC HEALTH-UK, V27, P67, DOI 10.1093/pubmed/fdh192; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; King EA, 2001, BRIT J PSYCHIAT, V178, P531, DOI 10.1192/bjp.178.6.531; Meehan J, 2006, BRIT J PSYCHIAT, V188, P129, DOI 10.1192/bjp.188.2.129; Motto JA, 2001, PSYCHIATR SERV, V52, P828, DOI 10.1176/appi.ps.52.6.828; MOTTO JA, 1976, SUICIDE LIFE-THREAT, V6, P223; National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (NCISH). Manchester: University of Manchester, 2006, MAKING MENTAL HLTH C; Prinstein MJ, 2008, J CONSULT CLIN PSYCH, V76, P92, DOI 10.1037/0022-006X.76.1.92; Qin P, 2005, ARCH GEN PSYCHIAT, V62, P427, DOI 10.1001/archpsyc.62.4.427; SELLAR C, 1990, J EPIDEMIOL COMMUN H, V44, P313, DOI 10.1136/jech.44.4.313; Skeem JL, 2006, BEHAV SCI LAW, V24, P731, DOI 10.1002/bsl.726; Taylor SJ, 1997, ACTA PSYCHIAT SCAND, V95, P457, DOI 10.1111/j.1600-0447.1997.tb10132.x	16	62	62	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 18	2008	337								a2278	10.1136/bmj.a2278	http://dx.doi.org/10.1136/bmj.a2278			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	397HQ	19018041	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000262653900003
J	Schenck, S				Schenck, Sarah			A Lesson Learned by Accident	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												sschenck@christianacare.org							0	0	0	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 12	2008	300	18					2101	2101		10.1001/jama.2008.630	http://dx.doi.org/10.1001/jama.2008.630			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	370WM	19001611				2023-01-03	WOS:000260793800001
J	Ram, N; Weiss, N; Texier-Nogues, I; Aroui, S; Andreotti, N; Pirollet, F; Ronjat, M; Sabatier, JM; Darbon, H; Jacquemond, V; De Waard, M				Ram, Narendra; Weiss, Norbert; Texier-Nogues, Isabelle; Aroui, Sonia; Andreotti, Nicolas; Pirollet, Fabienne; Ronjat, Michel; Sabatier, Jean-Marc; Darbon, Herve; Jacquemond, Vincent; De Waard, Michel			Design of a disulfide-less, pharmacologically inert, and chemically competent analog of maurocalcine for the efficient transport of impermeant compounds into cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE FIBERS; AMINO-ACID-RESIDUES; RYANODINE RECEPTOR; SCORPION TOXINS; CA2+ RELEASE; PEPTIDE; PENETRATION; MAUROTOXIN; BINDING; DEPOLARIZATION	Maurocalcine is a 33-mer peptide initially isolated from the venom of a Tunisian scorpion. It has proved itself valuable as a pharmacological activator of the ryanodine receptor and has helped the understanding of the molecular basis underlying excitation-contraction coupling in skeletal muscles. Because of its positively charged nature, it is also an innovative vector for the cell penetration of various compounds. We report a novel maurocalcine analog with improved properties: (i) the complete loss of pharmacological activity, (ii) preservation of the potent ability to carry cargo molecules into cells, and (iii) coupling chemistries not affected by the presence of internal cysteine residues of maurocalcine. We did this by replacing the six internal cysteine residues of maurocalcine by isosteric 2-aminobutyric acid residues and by adding an additional N-terminal biotinylated lysine (for a proof of concept analog) or an N-terminal cysteine residue (for a chemically competent coupling analogue). Additional replacement of a glutamate residue by alanyl at position 12 further improves the potency of these analogues. Coupling to several cargo molecules or nanoparticles are presented to illustrate the cell penetration potency and usefulness of these pharmacologically inactive analogs.	[Ram, Narendra; Aroui, Sonia; Pirollet, Fabienne; Ronjat, Michel; De Waard, Michel] Univ Grenoble 1, Grenoble Inst Neurosci, U836, Res Grp Calcium Channels Funct & Pathol 3, F-38042 Grenoble 09, France; [Weiss, Norbert; Jacquemond, Vincent] Univ Lyon 1, CNRS, UMR Physiol Integrat Cellulaire & Mol 5123, F-69622 Villeurbanne, France; [Texier-Nogues, Isabelle] CEA Grenoble LETI DTBS, F-38054 Grenoble, France; [Andreotti, Nicolas; Sabatier, Jean-Marc] Univ Mediterannee Ambrillia Biopharm, Fac Med Nord ERT62, Marseille 20, France; [Darbon, Herve] Univ Aix Marseille, CNRS, AFMB, UMR 6098, F-13288 Marseille 09, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA; UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	De Waard, M (corresponding author), Univ Grenoble 1, Grenoble Inst Neurosci, U836, Res Grp Calcium Channels Funct & Pathol 3, BP 170, F-38042 Grenoble 09, France.	michel.dewaard@ujf-grenoble.fr	De Waard, Michel/G-7406-2014; Weiss, Norbert/G-5330-2014; Pirollet, Fabienne/L-3088-2013	De Waard, Michel/0000-0002-2782-9615; Weiss, Norbert/0000-0002-0040-1109; SABATIER, Jean-Marc/0000-0002-9040-5647; Ronjat, Michel/0000-0002-9728-6425; Jacquemond, Vincent/0000-0003-4944-270X; Texier, Isabelle/0000-0002-8859-8283	INSERM; CEA	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); CEA(French Atomic Energy Commission)	This work was supported in part by INSERM and the Fonds de Valorisation of the CEA. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. Section 1734 solely to indicate this fact.	Altafaj X, 2005, J BIOL CHEM, V280, P4013, DOI 10.1074/jbc.C400433200; Boisseau S, 2006, BBA-BIOMEMBRANES, V1758, P308, DOI 10.1016/j.bbamem.2006.02.007; Cai WB, 2006, NANO LETT, V6, P669, DOI 10.1021/nl052405t; Collet C, 1999, J PHYSIOL-LONDON, V520, P417, DOI 10.1111/j.1469-7793.1999.00417.x; Csernoch L, 1998, BIOPHYS J, V75, P957, DOI 10.1016/S0006-3495(98)77584-8; Davidson TJ, 2004, J NEUROSCI, V24, P10040, DOI 10.1523/JNEUROSCI.3643-04.2004; di Luccio E, 2002, BIOCHEM J, V361, P409, DOI 10.1042/0264-6021:3610409; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; Esteve E, 2005, J BIOL CHEM, V280, P12833, DOI 10.1074/jbc.M412521200; Esteve E, 2003, J BIOL CHEM, V278, P37822, DOI 10.1074/jbc.M305798200; Fajloun Z, 2000, J BIOL CHEM, V275, P39394, DOI 10.1074/jbc.M006810200; Fajloun Z, 2000, J BIOL CHEM, V275, P13605, DOI 10.1074/jbc.275.18.13605; GALLO V, 1987, J NEUROSCI, V7, P2203; Jacquemond V, 1997, BIOPHYS J, V73, P920, DOI 10.1016/S0006-3495(97)78124-4; KIM DH, 1983, J BIOL CHEM, V258, P9662; Liang JF, 2005, BIOORG MED CHEM LETT, V15, P5071, DOI 10.1016/j.bmcl.2005.07.087; Mabrouk K, 2007, BBA-BIOMEMBRANES, V1768, P2528, DOI 10.1016/j.bbamem.2007.06.030; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; Nascimento FD, 2007, J BIOL CHEM, V282, P21349, DOI 10.1074/jbc.M604876200; Pouvreau S, 2006, BIOPHYS J, V91, P2206, DOI 10.1529/biophysj.105.078089; Ram N, 2008, J BIOL CHEM, V283, P24274, DOI 10.1074/jbc.M709971200; Shahbazzadeh D, 2007, BIOCHEM J, V404, P89, DOI 10.1042/BJ20061404; Zhu SY, 2003, FASEB J, V17, P1765, DOI 10.1096/fj.02-1044fje	23	27	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2008	283	40					27048	27056		10.1074/jbc.M804727200	http://dx.doi.org/10.1074/jbc.M804727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	353RT	18621738	Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000259586600025
J	Bentzen, SM; Agrawal, RK; Aird, EGA; Barrett, JM; Barrett-Lee, PJ; Bliss, JM; Brown, J; Dewar, JA; Dobbs, HJ; Haviland, JS; Hoskin, PJ; Hopwood, P; Lawton, PA; Magee, BJ; Mills, J; Morgan, DAL; Owen, JR; Simmons, S; Sumo, G; Sydenham, MA; Venables, K; Yarnold, JR				Bentzen, S. M.; Agrawal, R. K.; Aird, E. G. A.; Barrett, J. M.; Barrett-Lee, P. J.; Bliss, J. M.; Brown, J.; Dewar, J. A.; Dobbs, H. J.; Haviland, J. S.; Hoskin, P. J.; Hopwood, P.; Lawton, P. A.; Magee, B. J.; Mills, J.; Morgan, D. A. L.; Owen, J. R.; Simmons, S.; Sumo, G.; Sydenham, M. A.; Venables, K.; Yarnold, J. R.		START Trialists Grp	The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial	LANCET			English	Article							QUALITY-OF-LIFE; FRACTIONATION SCHEDULE; EUROPEAN-ORGANIZATION; LOCAL RECURRENCE; CLINICAL-TRIAL; SURGERY; WOMEN; IRRADIATION; LUMPECTOMY; RADIATION	Background The international standard radiotherapy schedule for early breast cancer delivers 50 Gy in 25 fractions of 2. 0 Gy over 5 weeks, but there is a long history of non-standard regimens delivering a lower total dose using fewer, larger fractions (hypofractionation). We aimed to test the benefits of radiotherapy schedules using fraction sizes larger than 2 - 0 Gy in terms of local-regional tumour control, normal tissue responses, quality of life, and economic consequences in women prescribed post-operative radiotherapy. Methods Between 1999 and 2001, 2215 women with early breast cancer (pT1-3a pN0-1 M0) at 23 centres in the UK were randomly assigned after primary surgery to receive 50 Gy in 25 fractions of 2 - 0 Gy over 5 weeks or 40 Gy in 15 fractions of 2.67 Gy over 3 weeks. Women were eligible for the trial if they were aged over 18 years, did not have an immediate reconstruction, and were available for follow-up. Randomisation method was computer generated and was not blinded. The protocol-specified principal endpoints were local-regional tumour relapse, defined as reappearance of cancer at irradiated sites, late normal tissue effects, and quality of life. Analysis was by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN59368779. Findings 1105 women were assigned to the 50 Gy group and 1110 to the 40 Gy group. After a median follow up of 6.0 years (IQR 5.0-6.2) the rate of local-regional tumour relapse at 5 years was 2.2% (95% Cl 1.3-3.1) in the 40 Gy group and 3.3% (95% Cl 2.2 to 4. 5) in the 50 Gy group, representing an absolute difference of -0 . 7% (95% Cl -1 . 7% to 0.9%)-ie, the absolute difference in local-regional relapse could be up to 1 . 7% better and at most 1% worse after 40 Gy than after 50 Gy. Photographic and patient self-assessments indicated lower rates of late adverse effects after 40 Gy than after 50 Gy. Interpretation A radiation schedule delivering 40 Gy in 15 fractions seems to offer rates of local-regional tumour relapse and late adverse effects at least as favourable as the standard schedule of 50 Gy in 25 fractions.	[Agrawal, R. K.] Shrewsbury & Telford Hosp NHS Trust, Shrewsbury, Salop, England; [Aird, E. G. A.; Hoskin, P. J.; Venables, K.] Mt Vernon Hosp, Northwood HA6 2RN, Middx, England; [Barrett, J. M.] Royal Berkshire NHS Fdn Trust, Reading, Berks, England; [Barrett-Lee, P. J.] Velindre Hosp NHS Trust, Cardiff, Wales; [Bentzen, S. M.] Univ Wisconsin, Sch Med, Madison, WI USA; [Bliss, J. M.; Haviland, J. S.; Mills, J.; Simmons, S.; Sumo, G.; Sydenham, M. A.] ICR CTSU, Sutton, Surrey, England; [Brown, J.] Univ Bristol, MRC Hlth Serv Res Collaborat, Bristol BS8 1TH, Avon, England; [Dewar, J. A.] Ninewells Hosp, Dundee DD1 9SY, Scotland; [Dobbs, H. J.] Guys & St Thomas NHS Trust, London, England; [Hopwood, P.; Magee, B. J.] Christie Hosp, Manchester, Lancs, England; [Lawton, P. A.] City Hosp Nottingham, Nottingham, England; [Morgan, D. A. L.] Univ Nottingham Hosp NHS Trust, Nottingham, England; [Owen, J. R.] Cheltenham Gen Hosp, Cheltenham, Glos, England; [Yarnold, J. R.] Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England	Royal Berkshire Hospital; Velindre Hospital; University of Wisconsin System; University of Wisconsin Madison; University of London; Institute of Cancer Research - UK; University of Bristol; University of Dundee; Guy's & St Thomas' NHS Foundation Trust; Christie NHS Foundation Trust; Christie Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Yarnold, JR (corresponding author), Royal Marsden Hosp, Dept Clin Radiotherapy, Downs Rd, Sutton SM2 5PT, Surrey, England.		Bentzen, Soren M/O-7787-2019; Bentzen, Søren M/E-3997-2012	Bentzen, Soren M/0000-0002-7444-7564; Bentzen, Søren M/0000-0002-7444-7564; Haviland, Joanne/0000-0001-5728-3636; Bliss, Judith/0000-0001-7957-7424; Barrett-Lee, peter/0000-0002-6246-7357; Hoskin, Peter/0000-0001-8323-9567; Morgan, David/0000-0002-2291-1740	MRC [G9600656] Funding Source: UKRI; Cancer Research UK [CRUK/96/001] Funding Source: Medline; Medical Research Council [G9600656] Funding Source: Medline; Department of Health [G9600656] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health		AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Abe O, 2005, LANCET, V366, P2087; Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; [Anonymous], 1993, 62 ICRU, P357; Ash D V, 1995, Clin Oncol (R Coll Radiol), V7, P93, DOI 10.1016/S0936-6555(05)80808-8; Bentzen SM, 2008, LANCET ONCOL, V9, P331, DOI [10.1016/S1470-2045(08)60348-7, 10.1016/S1470-2045(08)70077-9]; Clark RM, 1996, J NATL CANCER I, V88, P1659, DOI 10.1093/jnci/88.22.1659; Dische S, 1998, LANCET, V351, P1967, DOI 10.1016/S0140-6736(05)78663-3; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; Fyles AW, 2004, NEW ENGL J MED, V351, P963, DOI 10.1056/NEJMoa040595; Hopwood P, 2001, EUR J CANCER, V37, P189, DOI 10.1016/S0959-8049(00)00353-1; Hopwood P, 2007, BREAST, V16, P241, DOI 10.1016/j.breast.2006.11.003; Magee B, 1999, CLIN ONCOL-UK, V11, P40, DOI 10.1053/clon.1999.9007; McBain CA, 2003, CLIN ONCOL-UK, V15, P25, DOI 10.1053/clon.2002.0165; Olivotto IA, 1996, RADIOTHER ONCOL, V41, P7, DOI 10.1016/S0167-8140(96)01824-5; OVERGAARD M, 1987, RADIOTHER ONCOL, V9, P1, DOI 10.1016/S0167-8140(87)80213-X; Owen JR, 2006, LANCET ONCOL, V7, P467, DOI 10.1016/S1470-2045(06)70699-4; PATERSON R, 1948, TREATMENT MALIGNANT; Rodger A, 1998, BMJ-BRIT MED J, V317, P155, DOI 10.1136/bmj.317.7152.155; RUBIN P, 1967, J AMER MED ASSOC, V200, P132; Shelley W, 2000, INT J RADIAT ONCOL, V47, P1219, DOI 10.1016/S0360-3016(00)00567-8; Sprangers MAG, 1996, J CLIN ONCOL, V14, P2756, DOI 10.1200/JCO.1996.14.10.2756; van Dongen J A, 1992, J Natl Cancer Inst Monogr, P15; Venables K, 2006, BRIT J RADIOL, V79, P734, DOI 10.1259/bjr/80814021; Venables K, 2005, CLIN ONCOL-UK, V17, P337, DOI 10.1016/j.clon.2005.03.006; Venables K, 2004, RADIOTHER ONCOL, V71, P303, DOI 10.1016/j.radonc.2004.02.008; Venables K, 2003, INT J RADIAT ONCOL, V55, P271, DOI 10.1016/S0360-3016(02)03808-7; Venables K, 2001, PHYS MED BIOL, V46, P1937, DOI 10.1088/0031-9155/46/7/314; Venables K, 2001, RADIOTHER ONCOL, V60, P311, DOI 10.1016/S0167-8140(01)00376-0; Venables K, 2000, BRIT J RADIOL, V73, P1313, DOI 10.1259/bjr.73.876.11205676; VERONESI U, 1993, NEW ENGL J MED, V328, P1587, DOI 10.1056/NEJM199306033282202; Whelan T, 2002, J NATL CANCER I, V94, P1143; WILLIAMS M, 1985, INT J RADIAT ONCOL, V11, P1570, DOI 10.1016/0360-3016(85)90349-9; Williams SR, 2003, AATCC REV, V3, P14; Yamada Y, 1999, INT J RADIAT ONCOL, V44, P99, DOI 10.1016/S0360-3016(98)00507-0; Yarnold J, 2005, RADIOTHER ONCOL, V75, P9, DOI 10.1016/j.radonc.2005.01.005; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	795	808	0	38	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2008	371	9618					1098	1107						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	280RA	18355913	Bronze, Green Published			2023-01-03	WOS:000254442700028
J	MacDiarmid, JA; Amaro-Mugridge, NB; Madrid-Weiss, J; Sedliarou, I; Wetzel, S; Kochar, K; Brahmbhatt, VN; Phillips, L; Pattison, ST; Petti, C; Stillman, B; Graham, RM; Brahmbhatt, H				MacDiarmid, Jennifer A.; Amaro-Mugridge, Nancy B.; Madrid-Weiss, Jocelyn; Sedliarou, Ilya; Wetzel, Stefanie; Kochar, Kartini; Brahmbhatt, Vatsala N.; Phillips, Leo; Pattison, Scott T.; Petti, Carlotta; Stillman, Bruce; Graham, Robert M.; Brahmbhatt, Himanshu			Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug	NATURE BIOTECHNOLOGY			English	Article							SMALL INTERFERING RNA; EPIDERMAL-GROWTH-FACTOR; MULTIDRUG-RESISTANCE; CONTAINING NANOPARTICLES; SYSTEMIC DELIVERY; ESCHERICHIA-COLI; FACTOR RECEPTOR; IN-VIVO; CANCER; INHIBITORS	The dose-limiting toxicity of chemotherapeutics, heterogeneity and drug resistance of cancer cells, and difficulties of targeted delivery to tumors all pose daunting challenges to effective cancer therapy. We report that small interfering RNA ( siRNA) duplexes readily penetrate intact bacterially derived minicells previously shown to cause tumor stabilization and regression when packaged with chemotherapeutics. When targeted via antibodies to tumor-cell-surface receptors, minicells can specifically and sequentially deliver to tumor xenografts first siRNAs or short hairpin RNA (shRNA)-encoding plasmids to compromise drug resistance by knocking down a multidrug resistance protein. Subsequent administration of targeted minicells containing cytotoxic drugs eliminate formerly drug-resistant tumors. The two waves of treatment, involving minicells loaded with both types of payload, enable complete survival without toxicity in mice with tumor xenografts, while involving several thousandfold less drug, siRNA and antibody than needed for conventional systemic administration of cancer therapies.	[MacDiarmid, Jennifer A.; Amaro-Mugridge, Nancy B.; Madrid-Weiss, Jocelyn; Sedliarou, Ilya; Wetzel, Stefanie; Kochar, Kartini; Brahmbhatt, Vatsala N.; Phillips, Leo; Pattison, Scott T.; Petti, Carlotta; Brahmbhatt, Himanshu] EnGeneIC Pty Ltd, Sydney, NSW, Australia; [Stillman, Bruce] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Graham, Robert M.] Victor Chang Cardiac Res Inst, Darlinghurst, NSW, Australia; [Graham, Robert M.] Univ New S Wales, Kensington, NSW 2033, Australia	Cold Spring Harbor Laboratory; Victor Chang Cardiac Research Institute; University of New South Wales Sydney	Brahmbhatt, H (corresponding author), EnGeneIC Pty Ltd, Sydney, NSW, Australia.	hbrahmbhatt@engeneic.com	Brahmbhatt, Himanshu/AAY-9997-2020	Sedliarou, Ilya/0000-0002-0001-2568; Stillman, Bruce/0000-0002-9453-4091				Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Ausubel F.M., 2003, CURRENT PROTOCOLS MO; Bartlett DW, 2008, BIOTECHNOL BIOENG, V99, P975, DOI 10.1002/bit.21668; Bartlett DW, 2007, BIOCONJUGATE CHEM, V18, P456, DOI 10.1021/bc0603539; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; CUMMINGS J, 1985, J CHROMATOGR, V341, P401, DOI 10.1016/S0378-4347(00)84053-0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; El-Rayes BF, 2004, BRIT J CANCER, V91, P418, DOI 10.1038/sj.bjc.6601921; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Heidel JD, 2007, CLIN CANCER RES, V13, P2207, DOI 10.1158/1078-0432.CCR-06-2218; Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607; Itoh T, 2004, J PHARM PHARM SCI, V7, P13; Kaszubiak A, 2007, INT J ONCOL, V31, P419; Kawakami S, 2007, DRUG METAB PHARMACOK, V22, P142, DOI 10.2133/dmpk.22.142; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Larson Rodney R, 2003, Appl Occup Environ Hyg, V18, P109; MacDiarmid JA, 2007, CELL CYCLE, V6, P2099, DOI 10.4161/cc.6.17.4648; MacDiarmid JA, 2007, CANCER CELL, V11, P431, DOI 10.1016/j.ccr.2007.03.012; Mamot C, 2003, CANCER RES, V63, P3154; Mayer LD, 2001, CANCER METAST REV, V20, P87, DOI 10.1023/A:1013108524062; McNamara JO, 2006, NAT BIOTECHNOL, V24, P1005, DOI 10.1038/nbt1223; Meade BR, 2008, ADV DRUG DELIVER REV, V60, P530, DOI 10.1016/j.addr.2007.10.004; MEAGHER RB, 1977, CELL, V10, P521, DOI 10.1016/0092-8674(77)90039-3; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Pirollo KF, 2008, CANCER RES, V68, P1247, DOI 10.1158/0008-5472.CAN-07-5810; Poeck H, 2008, NAT MED, V14, P1256, DOI 10.1038/nm.1887; Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705; Reilly RM, 2000, J NUCL MED, V41, P903; Robbins M, 2008, HUM GENE THER, V19, P991, DOI 10.1089/hum.2008.131; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Sato J D, 1983, Mol Biol Med, V1, P511; Sharma A, 1997, INT J CANCER, V71, P103, DOI 10.1002/(SICI)1097-0215(19970328)71:1<103::AID-IJC17>3.0.CO;2-J; Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101; Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5; Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841; Sun JZ, 1999, CANCER RES, V59, P4919; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Villares GJ, 2008, CANCER RES, V68, P9078, DOI 10.1158/0008-5472.CAN-08-2397; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; Wilson M, 1998, INFECT IMMUN, V66, P2401, DOI 10.1128/IAI.66.6.2401-2409.1998; Wu H, 2003, CANCER RES, V63, P1515; YUAN F, 1994, CANCER RES, V54, P3352; Zheng JH, 2001, AAPS PHARMSCI, V3	45	197	241	3	64	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2009	27	7					643	U97		10.1038/nbt.1547	http://dx.doi.org/10.1038/nbt.1547			12	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	469OF	19561595				2023-01-03	WOS:000267908500021
J	Pui, CH; Campana, D; Pei, DQ; Bowman, WP; Sandlund, JT; Kaste, SC; Ribeiro, RC; Rubnitz, JE; Raimondi, SC; Onciu, M; Coustan-Smith, E; Kun, LE; Jeha, S; Cheng, C; Howard, SC; Simmons, V; Bayles, A; Metzger, ML; Boyett, JM; Leung, W; Handgretinger, R; Downing, JR; Evans, WE; Relling, MV				Pui, Ching-Hon; Campana, Dario; Pei, Deqing; Bowman, W. Paul; Sandlund, John T.; Kaste, Sue C.; Ribeiro, Raul C.; Rubnitz, Jeffrey E.; Raimondi, Susana C.; Onciu, Mihaela; Coustan-Smith, Elaine; Kun, Larry E.; Jeha, Sima; Cheng, Cheng; Howard, Scott C.; Simmons, Vickey; Bayles, Amy; Metzger, Monika L.; Boyett, James M.; Leung, Wing; Handgretinger, Rupert; Downing, James R.; Evans, William E.; Relling, Mary V.			Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINIMAL RESIDUAL DISEASE; NERVOUS-SYSTEM RELAPSE; CHILDRENS CANCER GROUP; LOW LEUKOCYTE COUNTS; EVENT-FREE SURVIVAL; CEREBROSPINAL-FLUID; RANDOMIZED-TRIAL; LUMBAR PUNCTURE; TOTAL THERAPY; CHEMOTHERAPY	Background Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse. Methods We conducted a clinical trial to test whether prophylactic cranial irradiation could be omitted from treatment in all children with newly diagnosed ALL. A total of 498 patients who could be evaluated were enrolled. Treatment intensity was based on presenting features and the level of minimal residual disease after remission-induction treatment. The duration of continuous complete remission in the 71 patients who previously would have received prophylactic cranial irradiation was compared with that of 56 historical controls who received it. Results The 5-year event-free and overall survival probabilities for all 498 patients were 85.6% (95% confidence interval [CI], 79.9 to 91.3) and 93.5% (95% CI, 89.8 to 97.2), respectively. The 5-year cumulative risk of isolated CNS relapse was 2.7% (95% CI, 1.1 to 4.3), and that of any CNS relapse (including isolated relapse and combined relapse) was 3.9% (95% CI, 1.9 to 5.9). The 71 patients had significantly longer continuous complete remission than the 56 historical controls (P = 0.04). All 11 patients with isolated CNS relapse remained in second remission for 0.4 to 5.5 years. CNS leukemia (CNS-3 status) or a traumatic lumbar puncture with blast cells at diagnosis and a high level of minimal residual disease (>= 1%) after 6 weeks of remission induction were significantly associated with poorer event-free survival. Risk factors for CNS relapse included the genetic abnormality t(1; 19)(TCF3-PBX1), any CNS involvement at diagnosis, and T-cell immunophenotype. Common adverse effects included allergic reactions to asparaginase, osteonecrosis, thrombosis, and disseminated fungal infection. Conclusions With effective risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL. (ClinicalTrials.gov number, NCT00137111.)	[Pui, Ching-Hon; Campana, Dario; Sandlund, John T.; Kaste, Sue C.; Ribeiro, Raul C.; Rubnitz, Jeffrey E.; Coustan-Smith, Elaine; Jeha, Sima; Howard, Scott C.; Simmons, Vickey; Metzger, Monika L.; Leung, Wing; Handgretinger, Rupert] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA; [Pui, Ching-Hon; Campana, Dario; Raimondi, Susana C.; Onciu, Mihaela; Downing, James R.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; [Pei, Deqing; Cheng, Cheng; Boyett, James M.] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Kaste, Sue C.; Kun, Larry E.] St Jude Childrens Res Hosp, Dept Radiol Sci, Memphis, TN 38105 USA; [Evans, William E.; Relling, Mary V.] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; [Pui, Ching-Hon; Campana, Dario; Sandlund, John T.; Kaste, Sue C.; Ribeiro, Raul C.; Rubnitz, Jeffrey E.; Raimondi, Susana C.; Onciu, Mihaela; Kun, Larry E.; Jeha, Sima; Howard, Scott C.; Metzger, Monika L.; Leung, Wing; Downing, James R.; Evans, William E.; Relling, Mary V.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Memphis, TN USA; [Evans, William E.; Relling, Mary V.] Univ Tennessee, Hlth Sci Ctr, Coll Pharm, Memphis, TN USA; [Bowman, W. Paul; Bayles, Amy] Cook Childrens Med Ctr, Ft Worth, TX USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Cook Children's Medical Center	Pui, CH (corresponding author), St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.	ching-hon.pui@stjude.org	Evans, William E./C-2069-2012; Downing, James R./N-8102-2018; Rubnitz, Jeffrey E/N-2619-2018; Cheng, Cheng/N-8075-2018; Relling, Mary/N-5032-2018; Kaste, Sue C/N-8165-2018; Raimondi, Susana C/N-8166-2018; Jeha, Sima C/N-8163-2018; Howard, Scott C/K-3401-2013; Pui, Ching-Hon/N-8076-2018	Evans, William E./0000-0002-9333-5322; Rubnitz, Jeffrey E/0000-0001-9885-3527; Howard, Scott C/0000-0003-2244-1686; Pui, Ching-Hon/0000-0003-0303-5658; Leung, Wing Hang/0000-0002-2996-7229	National Institutes of Health [CA21765, CA60419, CA51001, CA78224, CA36401, GM61393]; American Cancer Society F. M. Kirby Clinical Research Professorship; American Lebanese Syrian Associated Charities; Enzon Pharmaceuticals; Genzyme; Sanofi-Aventis; EUSA Pharma; Enzon Pharmaceutical; NATIONAL CANCER INSTITUTE [R01CA060419, R01CA051001, U01CA060419, R01CA078224, R37CA036401, P30CA021765, R01CA036401, R29CA051001] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society F. M. Kirby Clinical Research Professorship(American Cancer Society); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); Enzon Pharmaceuticals; Genzyme(Sanofi-AventisGenzyme Corporation); Sanofi-Aventis(Sanofi-Aventis); EUSA Pharma; Enzon Pharmaceutical; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Supported by grants from the National Institutes of Health CA21765; CA60419, to Drs. Campana and Pui; and CA51001, CA78224, CA36401, and GM61393 to Drs. Relling, Pui, and Evans) and an American Cancer Society F. M. Kirby Clinical Research Professorship (to Dr. Pui); and by the American Lebanese Syrian Associated Charities. Dr. Pui reports receiving lecture fees from Enzon Pharmaceuticals; Dr. Cheng, receiving grant support from Enzon Pharmaceuticals; Dr. Jeha, receiving grant support from Genzyme, Sanofi-Aventis, and EUSA Pharma; Dr. Downing, serving as a council member with the American Society for Investigative Pathology; Dr. Relling, receiving grant support from Enzon Pharmaceutical and consulting fees from Genome Explorations; Dr. Evans, being an inventor on a patent concerning molecular diagnosis of thiopurine-S-methyltransferase deficiency (Drs. Evans and Relling and St. Jude Children's Research Hospital, receiving royalties from licensing of this patent). No other potential conflict of interest relevant to this article was reported.; We thank Julie Groff for assistance with an earlier draft of the figure; Jeana Cromer, Emily Baum, and Linda Holloway for data management; Dr. Sheila Shurtleff for molecular analysis; and our clinical and laboratory colleagues and the many patients and parents who participated in the research program.	Barredo JC, 2006, J CLIN ONCOL, V24, P3142, DOI 10.1200/JCO.2005.03.3373; BLANEY SM, 1995, J CLIN ONCOL, V13, P177, DOI 10.1200/JCO.1995.13.1.177; Bostrom BC, 2003, BLOOD, V101, P3809, DOI 10.1182/blood-2002-08-2454; Burger B, 2003, J CLIN ONCOL, V21, P184, DOI 10.1200/JCO.2003.04.096; Conter V, 1997, J CLIN ONCOL, V15, P2786, DOI 10.1200/JCO.1997.15.8.2786; Conter V, 2000, LEUKEMIA, V14, P2196, DOI 10.1038/sj.leu.2401963; Coustan-Smith E, 2000, BLOOD, V96, P2691, DOI 10.1182/blood.V96.8.2691; Duval M, 2002, BLOOD, V99, P2734, DOI 10.1182/blood.V99.8.2734; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; Evans WE, 1998, NEW ENGL J MED, V338, P499, DOI 10.1056/NEJM199802193380803; Gajjar A, 2000, BLOOD, V96, P3381; Gaynon PS, 2000, LEUKEMIA, V14, P2223, DOI 10.1038/sj.leu.2401939; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; Gustafsson G, 2000, LEUKEMIA, V14, P2267, DOI 10.1038/sj.leu.2401961; Hagedorn N, 2007, BLOOD, V110, P4022, DOI 10.1182/blood-2007-04-082040; Harms DO, 2003, BLOOD, V102, P2736, DOI 10.1182/blood-2002-08-2372; Hijiya N, 2007, JAMA-J AM MED ASSOC, V297, P1207, DOI 10.1001/jama.297.11.1207; Hill FGH, 2004, BRIT J HAEMATOL, V124, P33, DOI 10.1046/j.1365-2141.2003.04738.x; Howard SC, 2002, JAMA-J AM MED ASSOC, V288, P2001, DOI 10.1001/jama.288.16.2001; Kager L, 2005, J CLIN INVEST, V115, P110, DOI 10.1172/JCI200522477; Kamps WA, 2002, LEUKEMIA, V16, P1099, DOI 10.1038/sj.leu.2402489; Kishi S, 2007, BLOOD, V109, P4151, DOI 10.1182/blood-2006-10-054528; Lange BJ, 2002, BLOOD, V99, P825, DOI 10.1182/blood.V99.3.825; MAHMOUD HH, 1993, NEW ENGL J MED, V329, P314, DOI 10.1056/NEJM199307293290504; Manera R, 2000, LEUKEMIA, V14, P1354, DOI 10.1038/sj.leu.2401835; Matloub Y, 2006, BLOOD, V108, P1165, DOI 10.1182/blood-2005-12-011809; Mitchell CD, 2005, BRIT J HAEMATOL, V129, P734, DOI 10.1111/j.1365-2141.2005.05509.x; Moricke A, 2008, BLOOD, V111, P4477, DOI 10.1182/blood-2007-09-112920; Moghrabi A, 2007, BLOOD, V109, P896, DOI 10.1182/blood-2006-06-027714; Neale GAM, 2004, LEUKEMIA, V18, P934, DOI 10.1038/sj.leu.2403348; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Pession A, 2005, J CLIN ONCOL, V23, P7161, DOI 10.1200/JCO.2005.11.411; Pui CH, 2000, LEUKEMIA, V14, P2286, DOI 10.1038/sj.leu.2401938; Pui CH, 2003, NEW ENGL J MED, V349, P1299; Pui CH, 2004, BLOOD, V104, P2690, DOI 10.1182/blood-2004-04-1616; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Pui CH, 1998, NEW ENGL J MED, V339, P605, DOI 10.1056/NEJM199808273390907; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; Pui CH, 2003, JAMA-J AM MED ASSOC, V290, P2001, DOI 10.1001/jama.290.15.2001; Pui CH, 2008, LANCET ONCOL, V9, P257, DOI 10.1016/S1470-2045(08)70070-6; Pulte D, 2008, JNCI-J NATL CANCER I, V100, P1301, DOI 10.1093/jnci/djn276; Relling MV, 1999, BLOOD, V93, P2817; Salzer W, 2001, CANCER CHEMOTH PHARM, V48, P235, DOI 10.1007/s002800100328; Schrappe M, 2000, BLOOD, V95, P3310; te Loo DMWM, 2006, J CLIN ONCOL, V24, P2332, DOI 10.1200/JCO.2005.03.9727; Vilmer E, 2000, LEUKEMIA, V14, P2257, DOI 10.1038/sj.leu.2401960; Waber DP, 2007, J CLIN ONCOL, V25, P4914, DOI 10.1200/JCO.2007.10.8464; Yang L, 2008, J CLIN ONCOL, V26, P1932, DOI 10.1200/JCO.2007.13.8404	48	839	887	2	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 25	2009	360	26					2730	2741		10.1056/NEJMoa0900386	http://dx.doi.org/10.1056/NEJMoa0900386			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	461RC	19553647	Green Accepted			2023-01-03	WOS:000267286600007
J	Pormann, PE				Pormann, Peter E.			The art of medicine Female patients and practitioners in medieval Islam	LANCET			English	Editorial Material									Univ Warwick, Dept Class & Ancient Hist, Coventry CV4 7AL, W Midlands, England	University of Warwick	Pormann, PE (corresponding author), Univ Warwick, Dept Class & Ancient Hist, Coventry CV4 7AL, W Midlands, England.	p.e.pormann@warwick.ac.uk						Brockopp Jonathan E., 2008, MUSLIM MED ETHICS TH; El Fadl K. A., 2001, SPEAKING GODS NAME I; Giladi A., 1999, INFANTS PARENTS WET, V34; Musallam B., 1983, SEX SOC ISLAM BIRTH; Nutton V., 2008, RUFUS EPHESUS MELANC, P139; Pormann P.E., 2007, MEDIEVAL ISLAMIC MED	6	14	14	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 9	2009	373	9675					1598	1599		10.1016/S0140-6736(09)60895-3	http://dx.doi.org/10.1016/S0140-6736(09)60895-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	445QJ	19437603				2023-01-03	WOS:000266066300016
J	Sadowski, LS; Kee, RA; VanderWeele, TJ; Buchanan, D				Sadowski, Laura S.; Kee, Romina A.; VanderWeele, Tyler J.; Buchanan, David			Effect of a Housing and Case Management Program on Emergency Department Visits and Hospitalizations Among Chronically Ill Homeless Adults A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-STATUS; RISK-FACTORS; CARE; HIV	Context Homeless adults, especially those with chronic medical illnesses, are frequent users of costly medical services, especially emergency department and hospital services. Objective To assess the effectiveness of a case management and housing program in reducing use of urgent medical services among homeless adults with chronic medical illnesses. Design, Setting, and Participants Randomized controlled trial conducted at a public teaching hospital and a private, nonprofit hospital in Chicago, Illinois. Participants were 407 social worker-referred homeless adults with chronic medical illnesses (89% of referrals) from September 2003 until May 2006, with follow-up through December 2007. Analysis was by intention-to-treat. Intervention Housing offered as transitional housing after hospitalization discharge, followed by placement in long-term housing; case management offered on-site at primary study sites, transitional housing, and stable housing sites. Usual care participants received standard discharge planning from hospital social workers. Main Outcome Measures Hospitalizations, hospital days, and emergency department visits measured using electronic surveillance, medical records, and interviews. Models were adjusted for baseline differences in demographics, insurance status, prior hospitalization or emergency department visit, human immunodeficiency virus infection, current use of alcohol or other drugs, mental health symptoms, and other factors. Results The analytic sample (n=405 [n=201 for the intervention group, n=204 for the usual care group]) was 78% men and 78% African American, with a median duration of homelessness of 30 months. After 18 months, 73% of participants had at least 1 hospitalization or emergency department visit. Compared with the usual care group, the intervention group had unadjusted annualized mean reductions of 0.5 hospitalizations (95% confidence interval [CI], -1.2 to 0.2), 2.7 fewer hospital days (95% CI, -5.6 to 0.2), and 1.2 fewer emergency department visits (95% CI, -2.4 to 0.03). Adjusting for baseline covariates, compared with the usual care group, the intervention group had a relative reduction of 29% in hospitalizations (95% CI, 10% to 44%), 29% in hospital days (95% CI, 8% to 45%), and 24% in emergency department visits (95% CI, 3% to 40%). Conclusion After adjustment, offering housing and case management to a population of homeless adults with chronic medical illnesses resulted in fewer hospital days and emergency department visits, compared with usual care. Trial Registration clinicaltrials.gov Identifier: NCT00490581	[Sadowski, Laura S.; Kee, Romina A.] John H Stroger Jr Hosp Cook Cty, Dept Med, Collaborat Res Unit, Chicago, IL 60612 USA; [Kee, Romina A.] Rush Univ, Med Ctr, Chicago, IL 60612 USA; [VanderWeele, Tyler J.] Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; [Buchanan, David] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Buchanan, David] Erie Family Hlth Ctr, Chicago, IL USA	John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rush University; University of Chicago; Northwestern University; Feinberg School of Medicine	Sadowski, LS (corresponding author), John H Stroger Jr Hosp Cook Cty, Dept Med, Collaborat Res Unit, 1900 W Polk St,Room 1606, Chicago, IL 60612 USA.	sadowski@cchil.org			Department of Housing [IL01B210064-IL18096]; Urban Development Supportive Housing [IL01B20031-IL18064]; AIDS Special Projects of National Significance [IL-H02-0015]; Michael Reese Health Trust; AIDS foundation of Chicago; Polk Bros Foundation; Chicago Community Trust	Department of Housing; Urban Development Supportive Housing; AIDS Special Projects of National Significance; Michael Reese Health Trust; AIDS foundation of Chicago; Polk Bros Foundation; Chicago Community Trust	The intervention housing rental subsidies and case management were funded by Department of Housing and Urban Development Supportive Housing Program grants IL01B210064-IL18096 and IL01B20031-IL18064, Housing Opportunities for People with AIDS Special Projects of National Significance grant IL-H02-0015, the Michael Reese Health Trust, the AIDS foundation of Chicago, and the Polk Bros Foundation. The trial was funded by the Michael Reese Health Trust, the Chicago Community Trust, and the AIDS Foundation of Chicago.	ACTG Outcomes Committee, ACTG QOL 601 602 QOL; Buchanan D, 2006, AM J PUBLIC HEALTH, V96, P1278, DOI 10.2105/AJPH.2005.067850; Culhane DP, 2002, HOUS POLICY DEBATE, V13, P107, DOI 10.1080/10511482.2002.9521437; Fleischman S, 1992, DELIVERING HLTH CARE, P79; Hwang SW, 2005, AM J PREV MED, V29, P311, DOI 10.1016/j.amepre.2005.06.017; Hwang SW, 1998, ARCH INTERN MED, V158, P1454, DOI 10.1001/archinte.158.13.1454; Kalichman S, 2004, AIDS CARE, V16, pS6, DOI 10.1080/09540120412331315312; Kidder DP, 2007, AM J PUBLIC HEALTH, V97, P2238, DOI 10.2105/AJPH.2006.090209; Kushel MB, 2001, JAMA-J AM MED ASSOC, V285, P200, DOI 10.1001/jama.285.2.200; Kushel MB, 2002, AM J PUBLIC HEALTH, V92, P778, DOI 10.2105/AJPH.92.5.778; Leaver CA, 2007, AIDS BEHAV, V11, pS85, DOI 10.1007/s10461-007-9246-3; MARTELL JV, 1992, ANN INTERN MED, V116, P299, DOI 10.7326/0003-4819-116-4-299; *NAT COAL HOM, 2 NAT COAL HOM; O'Connell J., 1999, UTILIZATION COSTS ME; ROBERTSON MJ, 1986, AM J PUBLIC HEALTH, V76, P561, DOI 10.2105/AJPH.76.5.561; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tsemberis S, 2004, AM J PUBLIC HEALTH, V94, P651, DOI 10.2105/AJPH.94.4.651; VUONG QH, 1989, ECONOMETRICA, V57, P307, DOI 10.2307/1912557; Wu AW, 2005, HIV CLIN TRIALS, V6, P147, DOI 10.1310/BPNB-XELF-AXFQ-QQTL; ZANIS DA, 1994, J SUBST ABUSE TREAT, V11, P541, DOI 10.1016/0740-5472(94)90005-1; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455	23	326	327	0	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	2009	301	17					1771	1778		10.1001/jama.2009.561	http://dx.doi.org/10.1001/jama.2009.561			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	441AU	19417194				2023-01-03	WOS:000265742500026
J	Pasley, BN; Allen, EA; Freeman, RD				Pasley, Brian N.; Allen, Elena A.; Freeman, Ralph D.			State-Dependent Variability of Neuronal Responses to Transcranial Magnetic Stimulation of the Visual Cortex	NEURON			English	Article							HUMAN MOTOR CORTEX; LOCAL-FIELD POTENTIALS; SINGLE-UNIT ACTIVITY; CAT CEREBRAL-CORTEX; CORTICAL EXCITABILITY; BRAIN-STIMULATION; TOP-DOWN; VIRTUAL LESION; REPETITIVE TMS; IN-VIVO	Electrical brain stimulation is a promising tool for both experimental and clinical applications. However, the effects of stimulation on neuronal activity are highly variable and poorly understood. To investigate the basis of this variability, we performed extracellular recordings in the visual cortex following application of transcranial magnetic stimulation (TMS). Our measurements of spiking and local field potential activity exhibit two types of response patterns which are characterized by the presence or absence of spontaneous discharge following stimulation. This variability can be partially explained by state-dependent effects, in which higher pre-TMS activity predicts larger post-TMS responses. These results reveal the possibility that variability in the neural response to TMS can be exploited to optimize the effects of stimulation. It is conceivable that this feature could be utilized in real time during the treatment of clinical disorders.	[Pasley, Brian N.; Allen, Elena A.; Freeman, Ralph D.] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Pasley, Brian N.; Allen, Elena A.; Freeman, Ralph D.] Univ Calif Berkeley, Sch Optometry, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Freeman, RD (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.	freeman@neurovision.berkeley.edu			National Eye Institute [EY01175, EY03176]; NSF [2003014861]; NATIONAL EYE INSTITUTE [R01EY001175, P30EY003176] Funding Source: NIH RePORTER	National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NSF(National Science Foundation (NSF)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We thank R. Bartholomew, N. Lines, A. Koukarine, and L. Gibson for assistance in developing the electrophysiological apparatus and data acquisition software. This work was supported by research and CORE grants from the National Eye Institute (EY01175 and EY03176, respectively) and by NSF graduate research fellowship 2003014861.	Allen EA, 2007, SCIENCE, V317, P1918, DOI 10.1126/science.1146426; Ambraseys NN, 2003, SOIL DYN EARTHQ ENG, V23, P1, DOI 10.1016/S0267-7261(02)00153-7; BARKER AT, 1985, LANCET, V1, P1106; Belitski A, 2008, J NEUROSCI, V28, P5696, DOI 10.1523/JNEUROSCI.0009-08.2008; Berardelli A, 1998, EXP BRAIN RES, V122, P79, DOI 10.1007/s002210050493; Bestmann S, 2008, CEREB CORTEX, V18, P1281, DOI 10.1093/cercor/bhm159; Bestmann S, 2007, CURR BIOL, V17, P134, DOI 10.1016/j.cub.2006.11.063; Bohning DE, 1999, BIOL PSYCHIAT, V45, P385, DOI 10.1016/S0006-3223(98)00368-0; Brighina F, 2004, J NEUROL SCI, V227, P67, DOI 10.1016/j.jns.2004.08.008; Brighina F, 2002, EXP BRAIN RES, V145, P177, DOI 10.1007/s00221-002-1096-7; Bruns A, 2004, J NEUROSCI METH, V137, P321, DOI 10.1016/j.jneumeth.2004.03.002; Burt T, 2002, INT J NEUROPSYCHOPH, V5, P73, DOI 10.1017/S1461145702002791; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Butefisch CM, 2000, P NATL ACAD SCI USA, V97, P3661, DOI 10.1073/pnas.050350297; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Cahn SD, 2003, J CLIN NEUROPHYSIOL, V20, P371, DOI 10.1097/00004691-200309000-00009; Canolty RT, 2006, SCIENCE, V313, P1626, DOI 10.1126/science.1128115; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cohen J., 2002, APPL MULTIPLE REGRES, V3rd, DOI 10.4324/9780203774441; Couturier JL, 2005, J PSYCHIATR NEUROSCI, V30, P83; de Labra C, 2007, CEREB CORTEX, V17, P1376, DOI 10.1093/cercor/bhl048; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Efron B., 1994, INTRO BOOTSTRAP, DOI DOI 10.1201/9780429246593; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Fregni F, 2005, J NEUROL NEUROSUR PS, V76, P1614, DOI 10.1136/jnnp.2005.069849; Fries P, 2001, SCIENCE, V291, P1560, DOI 10.1126/science.1055465; FRITSCH G, 1870, UEBER ELEKT ERREGARK; George MS, 1996, J NEUROPSYCH CLIN N, V8, P373; Gross M, 2007, ACTA PSYCHIAT SCAND, V116, P165, DOI 10.1111/j.1600-0447.2007.01049.x; Gur M, 2006, CEREB CORTEX, V16, P888, DOI 10.1093/cercor/bhj032; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Henrie JA, 2005, J NEUROPHYSIOL, V94, P479, DOI 10.1152/jn.00919.2004; Holscher C, 1997, J NEUROSCI, V17, P6470; Horsley V, 1908, BRAIN, V31, P45, DOI 10.1093/brain/31.1.45; Houweling AR, 2008, NATURE, V451, P65, DOI 10.1038/nature06447; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Huber D, 2008, NATURE, V451, P61, DOI 10.1038/nature06445; IZHIKEVICH EM, 2006, BURSTING SCHOLARPEDI, V1, P1300; Jarvis MR, 2001, NEURAL COMPUT, V13, P717, DOI 10.1162/089976601300014312; Jing HK, 2000, CLIN NEUROPHYSIOL, V111, P1620, DOI 10.1016/S1388-2457(00)00357-6; Kringelbach ML, 2007, NAT REV NEUROSCI, V8, P623, DOI 10.1038/nrn2196; Lachaux JP, 1999, HUM BRAIN MAPP, V8, P194, DOI 10.1002/(SICI)1097-0193(1999)8:4<194::AID-HBM4>3.0.CO;2-C; Lisanby SH, 2000, DEPRESS ANXIETY, V12, P178, DOI 10.1002/1520-6394(2000)12:3<178::AID-DA10>3.0.CO;2-N; Liu J, 2006, J NEUROSCI, V26, P7779, DOI 10.1523/JNEUROSCI.5052-05.2006; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Logothetis NK, 2007, NEURON, V55, P809, DOI 10.1016/j.neuron.2007.07.027; MANLY CFJ, 1991, RANDOMIZATION MONTE; Mantovani M, 2006, NEUROCHEM INT, V49, P347, DOI 10.1016/j.neuint.2006.02.008; Martin JLR, 2003, BRIT J PSYCHIAT, V182, P480, DOI 10.1192/bjp.182.6.480; Massimini M, 2005, SCIENCE, V309, P2228, DOI 10.1126/science.1117256; Miller G, 2007, SCIENCE, V317, P1846; Mitra PP, 1999, BIOPHYS J, V76, P691, DOI 10.1016/S0006-3495(99)77236-X; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; Moliadze V, 2003, J PHYSIOL-LONDON, V553, P665, DOI 10.1113/jphysiol.2003.050153; Moliadze V, 2005, J PHYSIOL-LONDON, V566, P955, DOI 10.1113/jphysiol.2005.086090; Niessing J, 2005, SCIENCE, V309, P948, DOI 10.1126/science.1110948; Oliveri M, 2003, J NEUROL NEUROSUR PS, V74, P1136, DOI 10.1136/jnnp.74.8.1136; Oliviero A, 2003, EXP BRAIN RES, V149, P107, DOI 10.1007/s00221-002-1344-x; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; PATTON HD, 1954, J NEUROPHYSIOL, V17, P345, DOI 10.1152/jn.1954.17.4.345; Paus T, 2005, PHILOS T R SOC B, V360, P1109, DOI 10.1098/rstb.2005.1652; Pereda E, 2005, PROG NEUROBIOL, V77, P1, DOI 10.1016/j.pneurobio.2005.10.003; Pesaran B, 2002, NAT NEUROSCI, V5, P805, DOI 10.1038/nn890; Reich DS, 2000, J NEUROSCI, V20, P1964; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Romei V, 2008, CEREB CORTEX, V18, P2010, DOI 10.1093/cercor/bhm229; Ruff CC, 2006, CURR BIOL, V16, P1479, DOI 10.1016/j.cub.2006.06.057; Saalmann YB, 2007, SCIENCE, V316, P1612, DOI 10.1126/science.1139140; Sack AT, 2007, CEREB CORTEX, V17, P2841, DOI 10.1093/cercor/bhm013; Salinas FS, 2007, PHYS MED BIOL, V52, P2879, DOI 10.1088/0031-9155/52/10/016; Sauseng P, 2009, NEUROPSYCHOLOGIA, V47, P284, DOI 10.1016/j.neuropsychologia.2008.07.021; Siegel M, 2003, J NEUROSCI, V23, P4251; Silvanto J, 2008, NEUROIMAGE, V39, P549, DOI 10.1016/j.neuroimage.2007.09.008; Silvanto J, 2007, EUR J NEUROSCI, V25, P1874, DOI 10.1111/j.1460-9568.2007.05440.x; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2; Stevens CF, 1998, NAT NEUROSCI, V1, P210, DOI 10.1038/659; Stewart LM, 2001, NEUROPSYCHOLOGIA, V39, P415, DOI 10.1016/S0028-3932(00)00130-5; Strens LHA, 2002, CLIN NEUROPHYSIOL, V113, P1279, DOI 10.1016/S1388-2457(02)00151-7; Tehovnik EJ, 2006, J NEUROPHYSIOL, V96, P512, DOI 10.1152/jn.00126.2006; Terao Y, 2002, J CLIN NEUROPHYSIOL, V19, P322, DOI 10.1097/00004691-200208000-00006; Theodore William H., 2003, Epilepsy Curr, V3, P191, DOI 10.1046/j.1535-7597.2003.03607.x; THOMSON DJ, 1982, P IEEE, V70, P1055, DOI 10.1109/PROC.1982.12433; Van Der Werf YD, 2006, EXP BRAIN RES, V175, P246, DOI 10.1007/s00221-006-0548-x; Wespatat V, 2004, J NEUROSCI, V24, P9067, DOI 10.1523/JNEUROSCI.2221-04.2004; Ziemann U, 2002, CLIN NEUROPHYSIOL, V113, P1308, DOI 10.1016/S1388-2457(02)00171-2	87	97	98	3	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	APR 30	2009	62	2					291	303		10.1016/j.neuron.2009.03.012	http://dx.doi.org/10.1016/j.neuron.2009.03.012			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	441MU	19409273	Green Accepted, Bronze			2023-01-03	WOS:000265774100016
J	Post, R				Post, Robert			Prescribing Records and the First Amendment-New Hampshire's Data-Mining Statute	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Post, Robert] Yale Univ, Sch Law, New Haven, CT 06520 USA	Yale University	Post, R (corresponding author), Yale Univ, Sch Law, New Haven, CT 06520 USA.							Post R, 2000, UCLA LAW REV, V48, P1; Post R, 2007, U ILLINOIS LAW REV, P939	2	5	5	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 19	2009	360	8					745	747		10.1056/NEJMp0810339	http://dx.doi.org/10.1056/NEJMp0810339			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	408CN	19228615				2023-01-03	WOS:000263411300001
J	Rousseau, P				Rousseau, Paul			Southern Comfort	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												palliativedoctor@aol.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	2009	301	7					704	704		10.1001/jama.2009.142	http://dx.doi.org/10.1001/jama.2009.142			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	407MX	19224740				2023-01-03	WOS:000263370100001
J	Tol, J; Koopman, M; Cats, A; Rodenburg, CJ; Creemers, GJM; Schrama, JG; Erdkamp, FLG; Vos, AH; van Groeningen, CJ; Sinnige, HAM; Richel, DJ; Voest, EE; Dijkstra, JR; Vink-Borger, ME; Antonini, NF; Mol, L; van Krieken, JHJM; Dalesio, O; Punt, CJA				Tol, Jolien; Koopman, Miriam; Cats, Annemieke; Rodenburg, Cees J.; Creemers, Geert J. M.; Schrama, Jolanda G.; Erdkamp, Frans L. G.; Vos, Allert H.; van Groeningen, Cees J.; Sinnige, Harm A. M.; Richel, Dirk J.; Voest, Emile E.; Dijkstra, Jeroen R.; Vink-Borger, Marianne E.; Antonini, Ninja F.; Mol, Linda; van Krieken, Johan H. J. M.; Dalesio, Otilia; Punt, Cornelis J. A.			Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; PHASE-III; COMBINATION CHEMOTHERAPY; PLUS OXALIPLATIN; 1ST-LINE THERAPY; FINAL REPORT; CAPECITABINE; IRINOTECAN; FLUOROURACIL; LEUCOVORIN	Background Fluoropyrimidine- based chemotherapy plus the anti - vascular endothelial growth factor ( VEGF) antibody bevacizumab is standard first- line treatment for metastatic colorectal cancer. We studied the effect of adding the anti - epidermal growth factor receptor ( EGFR) antibody cetuximab to a combination of capecitabine, oxaliplatin, and bevacizumab for metastatic colorectal cancer. Methods We randomly assigned 755 patients with previously untreated metastatic colorectal cancer to capecitabine, oxaliplatin, and bevacizumab ( CB regimen, 378 patients) or the same regimen plus weekly cetuximab ( CBC regimen, 377 patients). The primary end point was progression- free survival. The mutation status of the KRAS gene was evaluated as a predictor of outcome. Results The median progression- free survival was 10.7 months in the CB group and 9.4 in the CBC group ( P = 0.01). Quality- of- life scores were lower in the CBC group. The overall survival and response rates did not differ significantly in the two groups. Treated patients in the CBC group had more grade 3 or 4 adverse events, which were attributed to cetuximab- related adverse cutaneous effects. Patients treated with cetuximab who had tumors bearing a mutated KRAS gene had significantly decreased progression- free survival as compared with cetuximab- treated patients with wildtype - KRAS tumors or patients with mutated- KRAS tumors in the CB group. Conclusions The addition of cetuximab to capecitabine, oxaliplatin, and bevacizumab resulted in significantly shorter progression- free survival and inferior quality of life. Mutation status of the KRAS gene was a predictor of outcome in the cetuximab group. (ClinicalTrials. gov number, NCT00208546.).	[Tol, Jolien; Koopman, Miriam; Dijkstra, Jeroen R.; Vink-Borger, Marianne E.; van Krieken, Johan H. J. M.; Punt, Cornelis J. A.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands; [Cats, Annemieke; Antonini, Ninja F.; Dalesio, Otilia] Netherlands Canc Inst, Amsterdam, Netherlands; [Rodenburg, Cees J.] Meander Med Ctr, Amersfoort, Netherlands; [Creemers, Geert J. M.] Catharina Hosp, Eindhoven, Netherlands; [Schrama, Jolanda G.] Spaarne Hosp, Hoofddorp, Netherlands; [Erdkamp, Frans L. G.] Maasland Hosp, Sittard, Netherlands; [Vos, Allert H.] Bernhoven Hosp, Oss, Netherlands; [van Groeningen, Cees J.] Free Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Sinnige, Harm A. M.] Jeroen Bosch Hosp, Shertogenbosch, Netherlands; [Richel, Dirk J.] Amsterdam Med Ctr, Amsterdam, Netherlands; [Voest, Emile E.] Univ Utrecht, Med Ctr, Utrecht, Netherlands; [Mol, Linda] Ctr Comprehens Canc E, Nijmegen, Netherlands	Radboud University Nijmegen; Netherlands Cancer Institute; Meander Medisch Centrum; Catharina Hospital; Spaarne Hospital; Maasland Hospital; Vrije Universiteit Amsterdam; Jeroen Bosch Ziekenhuis; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University	Punt, CJA (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	c.punt@onco.umcn.nl	van Krieken, Joannes H J M/D-4138-2009; Dijkstra, Jeroen R/N-4383-2015; Tol, J./L-4695-2015	van Krieken, Joannes H J M/0000-0001-6544-1040; Mol, Linda/0000-0002-4155-1605				BOKEMEYER C, 2007, EUR CANC C 2007 BARC; Bokemeyer C, 2008, J CLIN ONCOL, V26, P1783, DOI 10.1200/JCO.2007.15.2991; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; Diaz-Rubio E, 2007, J CLIN ONCOL, V25, P4224, DOI 10.1200/JCO.2006.09.8467; HECHT JR, 2008, 2008 GASTR CANC S; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834; Jung YD, 2002, EUR J CANCER, V38, P1133, DOI 10.1016/S0959-8049(02)00013-8; Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Nowacki M, 2007, P AN M AM SOC CLIN, V25, p164s; Porschen R, 2007, J CLIN ONCOL, V25, P4217, DOI 10.1200/JCO.2006.09.2684; Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930; Saltz LB, 2008, J CLIN ONCOL, V26, P511, DOI 10.1200/JCO.2007.15.0383; Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949; SCARTOZZI M, 2008, ANN ONCOL       1007; Seymour MT, 2007, LANCET, V370, P566; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tol J, 2008, ANN ONCOL, V19, P734, DOI 10.1093/annonc/mdm607; Tonra JR, 2006, CLIN CANCER RES, V12, P2197, DOI 10.1158/1078-0432.CCR-05-1682; Van Cutsem E, 2008, J CLIN ONCOL S, V26, p5s	27	1062	1165	1	46	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 5	2009	360	6					563	572		10.1056/NEJMoa0808268	http://dx.doi.org/10.1056/NEJMoa0808268			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	402QS	19196673	Green Published			2023-01-03	WOS:000263028800003
J	Wodarz, D; Komarova, N				Wodarz, Dominik; Komarova, Natalia			Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection	PLOS ONE			English	Article							VIRAL REPLICATION; TRANSMISSION; VIROTHERAPY; PATHOGEN; GROWTH	Oncolytic viruses are viruses that specifically infect cancer cells and kill them, while leaving healthy cells largely intact. Their ability to spread through the tumor makes them an attractive therapy approach. While promising results have been observed in clinical trials, solid success remains elusive since we lack understanding of the basic principles that govern the dynamical interactions between the virus and the cancer. In this respect, computational models can help experimental research at optimizing treatment regimes. Although preliminary mathematical work has been performed, this suffers from the fact that individual models are largely arbitrary and based on biologically uncertain assumptions. Here, we present a general framework to study the dynamics of oncolytic viruses that is independent of uncertain and arbitrary mathematical formulations. We find two categories of dynamics, depending on the assumptions about spatial constraints that govern that spread of the virus from cell to cell. If infected cells are mixed among uninfected cells, there exists a viral replication rate threshold beyond which tumor control is the only outcome. On the other hand, if infected cells are clustered together ( e. g. in a solid tumor), then we observe more complicated dynamics in which the outcome of therapy might go either way, depending on the initial number of cells and viruses. We fit our models to previously published experimental data and discuss aspects of model validation, selection, and experimental design. This framework can be used as a basis for model selection and validation in the context of future, more detailed experimental studies. It can further serve as the basis for future, more complex models that take into account other clinically relevant factors such as immune responses.	[Wodarz, Dominik] Univ Calif Irvine, Dept Ecol & Evolut, Irvine, CA 92717 USA; [Komarova, Natalia] Univ Calif Irvine, Dept Math, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Wodarz, D (corresponding author), Univ Calif Irvine, Dept Ecol & Evolut, Irvine, CA 92717 USA.	dwodarz@uci.edu			NIH [1R01AI058153-04]; Dr. Wodarz's university; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058153] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr. Wodarz's university; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	NIH Grant: 1R01AI058153-04 and Institutional funding from Dr. Wodarz's university. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam J, 1997, MODELING SIMULATION; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; ANDERSON R M, 1991; Bansal S, 2007, J R SOC INTERFACE, V4, P879, DOI 10.1098/rsif.2007.1100; BARBOUR A, 1990, STOCHASTIC PROCESSES; Begon M, 1999, P ROY SOC B-BIOL SCI, V266, P1939, DOI 10.1098/rspb.1999.0870; Bell JC, 2007, CURR CANCER DRUG TAR, V7, P127, DOI 10.2174/156800907780058844; Bell John C., 2003, Cancer Cell, V4, P7, DOI 10.1016/S1535-6108(03)00170-3; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; Crompton AM, 2007, CURR CANCER DRUG TAR, V7, P133; Davis JJ, 2005, J GENE MED, V7, P1380, DOI 10.1002/jgm.800; Dezso Z, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.055103; Friedman A, 2006, CANCER RES, V66, P2314, DOI 10.1158/0008-5472.CAN-05-2661; Goodrum FD, 1997, J VIROL, V71, P548, DOI 10.1128/JVI.71.1.548-561.1997; Harrison D, 2001, HUM GENE THER, V12, P1323, DOI 10.1089/104303401750270977; Kaplan JM, 2005, CURR GENE THER, V5, P595, DOI 10.2174/156652305774964677; Kelly E, 2007, MOL THER, V15, P651, DOI 10.1038/sj.mt.6300108; Kirn DH, 1996, MOL MED TODAY, V2, P519, DOI 10.1016/S1357-4310(97)81456-6; Korn WM, 2006, CANCER GENE THER, V13, P792, DOI 10.1038/sj.cgt.7700947; Lorence RM, 2003, CURR OPIN MOL THER, V5, P618; May RM, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.066112; McCallum H, 2001, TRENDS ECOL EVOL, V16, P295, DOI 10.1016/S0169-5347(01)02144-9; McCormick F, 2005, ONCOGENE, V24, P7817, DOI 10.1038/sj.onc.1209064; McCormick F, 2003, CANCER BIOL THER, V2, pS157; Newman MEJ, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.016128; Novozhilov AS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-6; Nowak MA., 2000, VIRUS DYNAMICS MATH; O'Shea CC, 2005, ONCOGENE, V24, P7640, DOI 10.1038/sj.onc.1209047; Parato KA, 2005, NAT REV CANCER, V5, P965, DOI 10.1038/nrc1750; Pastor-Satorras R, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.066117; Post Dawn E, 2005, Future Oncol, V1, P247, DOI 10.1517/14796694.1.2.247; Roberts MS, 2006, CURR OPIN MOL THER, V8, P314; SHIRLEY MD, 2005, ECOL COMPLEX, V2; Vaha-Koskela M. J., 2007, CANC LETT; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Wodarz D, 2003, HUM GENE THER, V14, P153, DOI 10.1089/104303403321070847; Wodarz D, 2001, CANCER RES, V61, P3501; Wodarz D., 2004, GENES THER MOL BIOL, V8, P137	38	55	56	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 30	2009	4	1							e4271	10.1371/journal.pone.0004271	http://dx.doi.org/10.1371/journal.pone.0004271			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549YF	19180240	Green Submitted, Green Published, gold			2023-01-03	WOS:000274089700004
J	Yu, DH; Macdonald, J; Liu, GH; Lee, AS; Ly, MM; Davis, T; Ke, N; Zhou, D; Wong-Staal, F; Li, QX				Yu, De-Hua; Macdonald, James; Liu, Guohong; Lee, Amy S.; Ly, Mimi; Davis, Timothy; Ke, Ning; Zhou, Demin; Wong-Staal, Flossie; Li, Qi-Xiang			Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination Therapy	PLOS ONE			English	Article							DRUG-RESISTANCE; GRP78 PROMOTER; TUMOR-CELLS; CANCER; STRESS; INDUCTION; KINASE; ACTIVATION; IDENTIFICATION; EXPRESSION	We identified pyrvinium pamoate, an old anthelminthic medicine, which preferentially inhibits anchorage-independent growth of cancer cells over anchorage-dependent growth (, 10 fold). It was also reported by others to have anti-tumor activity in vivo and selective toxicity against cancer cells under glucose starvation in vitro, but with unknown mechanism. Here, we provide evidence that pyrvinium suppresses the transcriptional activation of GRP78 and GRP94 induced by glucose deprivation or 2-deoxyglucose (2DG, a glycolysis inhibitor), but not by tunicamycin or A23187. Other UPR pathways induced by glucose starvation, e. g. XBP-1, ATF4, were also found suppressed by pyrvinium. Constitutive expression of GRP78 via transgene partially protected cells from pyrvinium induced cell death under glucose starvation, suggesting that suppression of the UPR is involved in pyrvinium mediated cytotoxicity under glucose starvation. Xenograft experiments showed rather marginal overall anti-tumor activity for pyrvinium as a monotherapy. However, the combination of pyrvinium and Doxorubicin demonstrated significantly enhanced efficacy in vivo, supporting a mechanistic treatment concept based on tumor hypoglycemia and UPR.	[Yu, De-Hua; Macdonald, James; Liu, Guohong; Lee, Amy S.; Ly, Mimi; Davis, Timothy; Ke, Ning; Zhou, Demin; Wong-Staal, Flossie; Li, Qi-Xiang] iTherX Pharmaceut Inc, San Diego, CA USA; [Lee, Amy S.] Univ So Calif, Keck Sch Med, Norris Comprehensive Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA USA	University of Southern California	Yu, DH (corresponding author), iTherX Pharmaceut Inc, San Diego, CA USA.	yu@itherx.com; hqxl@yahoo.com		Lee, Amy/0000-0002-0378-5443	NIH [1R43CA130386-01A1, CA27607]; NATIONAL CANCER INSTITUTE [R01CA027607, R37CA027607, R43CA130386] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	iTherX Pharmaceuticals, Inc. was the major study sponsor and responsible for decision for publication. Yu DH was partially supported by NIH grant 1R43CA130386-01A1. ASL was supported by NIH grant CA27607. NIH had no role in study design, data collection and analysis, desicion to publish, or preparation of the manuscript.	Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018; Bernales S, 2006, ANNU REV CELL DEV BI, V22, P487, DOI 10.1146/annurev.cellbio.21.122303.120200; Brown JM, 1998, CANCER RES, V58, P1408; CLAASSEN G, 2004, PRECLINICA, V2, P435; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Esumi H, 2004, CANCER SCI, V95, P685, DOI 10.1111/j.1349-7006.2004.tb03330.x; Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hensley ML, 1999, J CLIN ONCOL, V17, P3333, DOI 10.1200/JCO.1999.17.10.3333; Izuishi K, 2000, CANCER RES, V60, P6201; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Ke N, 2006, EXP CELL RES, V312, P2726, DOI 10.1016/j.yexcr.2006.05.001; Koomagi R, 1999, ANTICANCER RES, V19, P4333; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Luo SZ, 2003, J BIOL CHEM, V278, P37375, DOI 10.1074/jbc.M303619200; Park HR, 2004, JNCI-J NATL CANCER I, V96, P1300, DOI 10.1093/jnci/djh243; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Shuda M, 2003, J HEPATOL, V38, P605, DOI 10.1016/S0168-8278(03)00029-1; Song MS, 2001, CANCER RES, V61, P8322; Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Yu DH, 2006, EXP CELL RES, V312, P865, DOI 10.1016/j.yexcr.2005.12.006; Yu DH, 2005, ASSAY DRUG DEV TECHN, V3, P401, DOI 10.1089/adt.2005.3.401	35	54	56	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 16	2008	3	12							e3951	10.1371/journal.pone.0003951	http://dx.doi.org/10.1371/journal.pone.0003951			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	437AR	19079611	Green Published, Green Submitted, gold			2023-01-03	WOS:000265458400010
J	Aggarwal, S				Aggarwal, Saurabh			What's fueling the biotech engine-2007	NATURE BIOTECHNOLOGY			English	Editorial Material								Despite losses in revenue from erythropoietins, historically the highest earner of all biologics, more than 100 biotech drugs continued their upward trend in sales begun in 2006, with antibodies and insulin analogs fueling growth at double-digit rates.				saurabhaggarwal@gmail.com						Aggarwal S, 2007, NAT BIOTECHNOL, V25, P1097, DOI 10.1038/nbt1007-1097; Johnston MI, 2008, NEW ENGL J MED, V359, P888, DOI 10.1056/NEJMp0806162; Kim JJ, 2008, NEW ENGL J MED, V359, P821, DOI 10.1056/NEJMsa0707052; Kuter DJ, 2008, EUR J HAEMATOL, V80, P9, DOI 10.1111/j.1600-0609.2007.00999.x; Lanthier M, 2008, NAT REV DRUG DISCOV, V7, P733, DOI 10.1038/nrd2636; LONG D, 2008, US PHARM MARKET TREN; Mack GS, 2007, NAT BIOTECHNOL, V25, P1331, DOI 10.1038/nbt1207-1331; Ratner Mark, 2008, Nat Biotechnol, V26, P485, DOI 10.1038/nbt0508-485b; Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342; Schneider CK, 2008, NAT BIOTECHNOL, V26, P985, DOI 10.1038/nbt0908-985; Steinbrook R, 2007, NEW ENGL J MED, V356, P2448, DOI 10.1056/NEJMp078100	11	39	41	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	NOV	2008	26	11					1227	1233		10.1038/nbt1108-1227	http://dx.doi.org/10.1038/nbt1108-1227			7	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	371LG	18997759				2023-01-03	WOS:000260832200014
J	Needham, DM				Needham, Dale M.			Mobilizing patients in the intensive care unit - Improving neuromuscular weakness and physical function	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	1st International Meeting of Physical Rehabilitation in the Critically Ill	MAY 17, 2008	Toronto, CANADA				QUALITY-OF-LIFE; RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL PATIENTS; ACUTE LUNG INJURY; MECHANICALLY VENTILATED PATIENTS; BED REST; CRITICAL ILLNESS; SKELETAL-MUSCLE; PULMONARY-FUNCTION; SURVIVORS	Early mobilization of patients in the hospital and the intensive care unit has a strong historical precedent. However, in more recent times, deep sedation and bed rest have been part of routine medical care for many mechanically ventilated patients. A growing body of literature demonstrates that survivors of severe critical illness commonly have significant and prolonged neuromuscular complications that impair their physical function and quality of life after hospital discharge. Bed rest, and its associated mechanisms, may play an important role in the pathogenesis of neuromuscular weakness in critically ill patients. A new approach for managing mechanically ventilated patients includes reducing deep sedation and increasing rehabilitation therapy and mobilization soon after admission to the intensive care unit. Emerging research in this field provides preliminary evidence supporting the safety, feasibility, and potential benefits of early mobilization in critical care medicine.	[Needham, Dale M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; [Needham, Dale M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Needham, DM (corresponding author), Johns Hopkins Univ, Div Pulm & Crit Care Med, 1830 E Monument St,5th Floor, Baltimore, MD 21205 USA.	dale.needham@jhmi.edu						[Anonymous], 1948, BRIT MED J, V2, P1026; Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87; Berg HE, 1997, J APPL PHYSIOL, V82, P182, DOI 10.1152/jappl.1997.82.1.182; BERGEL RR, 1990, RHEUM DIS CLIN N AM, V16, P791; Bolton CF, 2007, CHEST, V131, P1273, DOI 10.1378/chest.07-0367; BURNS JR, 1975, CHEST, V68, P608; Chiang LL, 2006, PHYS THER, V86, P1271, DOI 10.2522/ptj.20050036; Convertino VA, 1997, MED SCI SPORT EXER, V29, P187, DOI 10.1097/00005768-199702000-00004; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; De Jonghe B, 2005, CRIT CARE MED, V33, P120, DOI 10.1097/01.CCM.0000150268.04228.68; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; de Letter MACJ, 2001, CRIT CARE MED, V29, P2281, DOI 10.1097/00003246-200112000-00008; Dock W., 1944, JAMA-J AM MED ASSOC, V125, P1085; Dowdy DW, 2006, INTENS CARE MED, V32, P1115, DOI 10.1007/s00134-006-0217-3; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Ferrando AA, 1996, AM J PHYSIOL-ENDOC M, V270, pE627, DOI 10.1152/ajpendo.1996.270.4.E627; Fink H, 2008, CRIT CARE MED, V36, P910, DOI 10.1097/CCM.0B013E3181659669; Fortney S.M., 1996, HDB PHYSL, P889, DOI DOI 10.1002/CPHY.CP040239; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Hamburg NM, 2007, ARTERIOSCL THROM VAS, V27, P2650, DOI 10.1161/ATVBAHA.107.153288; Hermans G, 2007, AM J RESP CRIT CARE, V175, P480, DOI 10.1164/rccm.200605-665OC; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hopkins RO, 2007, CRIT CARE CLIN, V23, P81, DOI 10.1016/j.ccc.2006.11.004; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hough CL, 2007, CURR OPIN CRIT CARE, V13, P489, DOI 10.1097/MCC.0b013e3282efea3a; Hough CL, 2006, CLIN CHEST MED, V27, P691, DOI 10.1016/j.ccm.2006.07.002; HUNG J, 1983, AM J CARDIOL, V51, P344, DOI 10.1016/S0002-9149(83)80063-0; Keys A., 1944, FED PROC, V3, P189; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Leijten FSS, 1997, EUR J NEUROL, V4, P124, DOI 10.1111/j.1468-1331.1997.tb00317.x; Maramattom BV, 2006, CRIT CARE MED, V34, P2835, DOI 10.1097/01.CCM.0000239436.63452.81; Martin UJ, 2005, CRIT CARE MED, V33, P2259, DOI 10.1097/01.CCM.0000181730.02238.9B; Morris PE, 2008, CRIT CARE MED, V36, P2238, DOI 10.1097/CCM.0b013e318180b90e; Nava S, 1998, ARCH PHYS MED REHAB, V79, P849, DOI 10.1016/S0003-9993(98)90369-0; Needham DM, 2007, J CRIT CARE, V22, P275, DOI 10.1016/j.jcrc.2007.02.001; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; Petty TL, 1998, CHEST, V114, P360, DOI 10.1378/chest.114.2.360; Ross G, 1972, Phys Ther, V52, P519; Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103; Schelling G, 2000, INTENS CARE MED, V26, P1304, DOI 10.1007/s001340051342; SCIAKY AJ, 1994, PHYS THER PRACT, V3, P69; Stein TP, 2005, J NUTR, V135, p1824S, DOI 10.1093/jn/135.7.1824S; Stevens RD, 2007, INTENS CARE MED, V33, P1876, DOI 10.1007/s00134-007-0772-2; Stiller Kathy, 2004, Physiotherapy Theory and Practice, V20, P175, DOI 10.1080/09593980490487474; Thomsen GE, 2008, CRIT CARE MED, V36, P1119, DOI 10.1097/CCM.0b013e318168f986; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D; Winkelman C, 2007, CRIT CARE CLIN, V23, P21, DOI 10.1016/j.ccc.2006.11.002; Winkelman C, 2005, DIMENS CRIT CARE NUR, V24, P281, DOI 10.1097/00003465-200511000-00011	50	309	338	1	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2008	300	14					1685	1690		10.1001/jama.300.14.1685	http://dx.doi.org/10.1001/jama.300.14.1685			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	356YF	18840842				2023-01-03	WOS:000259812800030
J	Chen, YS; Lin, JW; Yu, HY; Ko, WJ; Jerng, JS; Chang, WT; Chen, WJ; Huang, SC; Chi, NH; Wang, CH; Chen, LC; Tsai, PR; Wang, SS; Hwang, JJ; Lin, FY				Chen, Yih-Sharng; Lin, Jou-Wei; Yu, Hsi-Yu; Ko, Wen-Je; Jerng, Jih-Shuin; Chang, Wei-Tien; Chen, Wen-Jone; Huang, Shu-Chien; Chi, Nai-Hsin; Wang, Chih-Hsien; Chen, Li-Chin; Tsai, Pi-Ru; Wang, Sheoi-Shen; Hwang, Juey-Jen; Lin, Fang-Yue			Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis	LANCET			English	Article							MEMBRANE-OXYGENATION; MYOCARDIAL-INFARCTION; CIRCULATORY SUPPORT; CARDIOGENIC-SHOCK; IMPROVED SURVIVAL; EXPERIENCE; OUTCOMES; CPR; PREDICTION; REGISTRY	Background Extracorporeal life-support as an adjunct to cardiac resuscitation has shown encouraging outcomes in patients with cardiac arrest. However, there is little evidence about the benefit of the procedure compared with conventional cardiopulmonary resuscitation (CPR), especially when continued for more than 10 min. We aimed to assess whether extracorporeal CPR was better than conventional CPR for patients with in-hospital cardiac arrest of cardiac origin. Methods We did a 3-year prospective observational study on the use of extracorporeal life-support for patients aged 18-75 years with witnessed in-hospital cardiac arrest of cardiac origin undergoing CPR of more than 10 min compared with patients receiving conventional CPR. A matching process based on propensity-score was done to equalise potential prognostic factors in both groups, and to formulate a balanced 1:1 matched cohort study. The primary endpoint was survival to hospital discharge, and analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00173615. Findings Of the 975 patients with in-hospital cardiac arrest events who underwent CPR for longer than 10 min, 113 were enrolled in the conventional CPR group and 59 were ertrolled in the extracorporeal CPR group. Unmatched patients who underwent extracorporeal CPR had a higher survival rate to discharge (log-rank p<0 . 0001) and a better 1-year survival than those who received conventional CPR (log rank p=0.007). Between the propensity-score matched groups, there was still a significant difference in survival to discharge (hazard ratio [HR] 0. 51, 95% CI 0.35-0.74, p<0.0001), 30-day survival (HR 0 .47, 95% CI 0 . 28-0.77, p=0.003), and 1-year survival (HR 0.53, 95% Cl 0.33-0.83, p=0.006) favouring extracorporeal CPR over conventional CPR. Interpretation Extracorporeal CPR had a short-term and long-term survival benefit over conventional CPR in patients with in-hospital cardiac arrest of cardiac origin. Funding National Science Council, Taiwan.	[Chen, Yih-Sharng; Yu, Hsi-Yu; Ko, Wen-Je; Huang, Shu-Chien; Chi, Nai-Hsin; Wang, Chih-Hsien; Tsai, Pi-Ru; Wang, Sheoi-Shen; Lin, Fang-Yue] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Jerng, Jih-Shuin; Chen, Wen-Jone; Chen, Li-Chin; Hwang, Juey-Jen] Natl Taiwan Univ Hosp, Dept Med, Taipei 100, Taiwan; [Chang, Wei-Tien] Natl Taiwan Univ Hosp, Dept Emergency, Taipei 100, Taiwan; [Lin, Jou-Wei; Hwang, Juey-Jen] Natl Taiwan Univ Hosp, Ctr Cardiovasc, Yun Lin Branch, Dou Liou City, Yun Lin, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Lin, FY (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan.	yschen1234@gmail.com	Huang, Shu-chien/F-7885-2010	Huang, Shu-chien/0000-0002-0590-3474; Chi, Nai-Hsin/0000-0002-4731-1653; Chen, Yih-Sharng/0000-0003-3846-8162; WANG, CHIH-HSIEN/0000-0003-3214-6867; CHANG, WEI-TIEN/0000-0002-1880-7932; JERNG, JIH-SHUIN/0000-0002-5324-8523; Yu, Hsi-Yu/0000-0001-6669-4699; Hwang, Juey-Jen/0000-0001-6437-0455; Wang, Shoei-Shen/0000-0003-3201-4143; CHI, NAI-HSIN/0000-0003-1829-6084; CHEN, WEN-JONE/0000-0002-2098-5922	National Science Council, Taiwan [NSC 93-2314-B-002-235, NSC 94-2314-B-002-121, NSC 95-2745-B-002-232, NSC 96-2314-B-002-166]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	The study was supported by grants from the National Science Council, Taiwan: NSC 93-2314-B-002-235, 94-2314-B-002-121, 95-2745-B-002-232, and 96-2314-B-002-166.	*2005 AM HEART ASS, 2005, CIRCULATION S, V112, P203; Abella BS, 2007, RESUSCITATION, V73, P54, DOI 10.1016/j.resuscitation.2006.10.027; Ahmed A, 2007, EUR HEART J, V28, P1334, DOI 10.1093/eurheartj/ehm091; Alsoufi B, 2007, J THORAC CARDIOV SUR, V134, P952, DOI 10.1016/j.jtcvs.2007.05.054; Chen JS, 2006, CRIT CARE MED, V34, P950, DOI 10.1097/01.CCM.0000206103.35460.1F; Chen YS, 2005, J HEART LUNG TRANSPL, V24, P81, DOI 10.1016/j.healun.2003.09.038; Chen YS, 2004, AM J TRANSPLANT, V4, P1818, DOI 10.1111/j.1600-6143.2004.00578.x; Chen YS, 2003, J AM COLL CARDIOL, V41, P197, DOI 10.1016/S0735-1097(02)02716-X; Chen YS, 2001, J HEART LUNG TRANSPL, V20, P850, DOI 10.1016/S1053-2498(01)00267-4; Cooper S, 2006, RESUSCITATION, V68, P231, DOI 10.1016/j.resuscitation.2005.06.012; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; FEINSTEIN A, 1984, STAT MED, V3, P341, DOI 10.1002/sim.4780030409; Hajbaghery MA, 2005, RESUSCITATION, V66, P317, DOI 10.1016/j.resuscitation.2005.04.004; Haviland A, 2007, PSYCHOL METHODS, V12, P247, DOI 10.1037/1082-989X.12.3.247; Huang SC, 2004, J THORAC CARDIOV SUR, V128, P776, DOI 10.1016/j.jtcvs.2004.03.042; KENNEDY JH, 1966, J AMER MED ASSOC, V197, P615, DOI 10.1001/jama.197.8.615; Ko WJ, 2002, ANN THORAC SURG, V73, P538, DOI 10.1016/S0003-4975(01)03330-6; Kramer-Johansen J, 2007, RESUSCITATION, V74, P406, DOI 10.1016/j.resuscitation.2007.01.024; Massetti M, 2005, ANN THORAC SURG, V79, P178, DOI 10.1016/j.athoracsur.2004.06.095; Morris Marilyn C, 2004, Pediatr Crit Care Med, V5, P440, DOI 10.1097/01.PCC.0000137356.58150.2E; Nagao K, 2000, J AM COLL CARDIOL, V36, P776, DOI 10.1016/S0735-1097(00)00779-8; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Prohl J, 2007, CRIT CARE MED, V35, P1230, DOI 10.1097/01.CCM.0000261892.10559.85; Schwarz B, 2003, CRIT CARE MED, V31, P758, DOI 10.1097/01.CCM.0000053522.55711.E3; Shih CL, 2007, RESUSCITATION, V72, P394, DOI 10.1016/j.resuscitation.2006.07.020; Smedira NG, 2001, J THORAC CARDIOV SUR, V122, P92, DOI 10.1067/mtc.2001.114351; Sung K, 2006, ANN THORAC SURG, V82, P651, DOI 10.1016/j.athoracsur.2006.03.017; Takasu A, 2007, RESUSCITATION, V73, P394, DOI 10.1016/j.resuscitation.2006.10.014; Tayara W, 2006, J HEART LUNG TRANSPL, V25, P504, DOI 10.1016/j.healun.2005.10.011; Thiagarajan RR, 2007, CIRCULATION, V116, P1693, DOI 10.1161/CIRCULATIONAHA.106.680678	30	752	787	3	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 16	2008	372	9638					554	561		10.1016/S0140-6736(08)60958-7	http://dx.doi.org/10.1016/S0140-6736(08)60958-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339MS	18603291	Green Submitted			2023-01-03	WOS:000258582300029
J	Kanerva, A; Lavilla-Alonso, S; Raki, M; Kangasniemi, L; Bauerschmitz, GJ; Takayama, K; Ristimaki, A; Desmond, RA; Hemminki, A				Kanerva, Anna; Lavilla-Alonso, Sergio; Raki, Mari; Kangasniemi, Lotta; Bauerschmitz, Gerd J.; Takayama, Koichi; Ristimaki, Ari; Desmond, Renee A.; Hemminki, Akseli			Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; CONDITIONALLY REPLICATIVE ADENOVIRUS; OVARIAN-CANCER; CYCLOOXYGENASE-2 PROMOTER; ENHANCED INFECTIVITY; GENE-TRANSCRIPTION; FACTOR VEGF; EXPRESSION; VECTOR; CARCINOMA	Clinical trials have confirmed the safety of selectively oncolytic adenoviruses for treatment of advanced cancers. However, increasingly effective viruses could result in more toxicity and therefore it would be useful if replication could be abrogated if necessary. We analyzed viruses containing the cyclooxygenase-2 (Cox-2) or vascular endothelial growth factor (VEGF) promoter for controlling replication. Anti-inflammatory agents can lower Cox-2 protein levels and therefore we hypothesized that also the promoter might be affected. As Cox-2 modulates expression of VEGF, also the VEGF promoter might be controllable. First, we evaluated the effect of anti-inflammatory agents on promoter activity or adenovirus infectivity in vitro. Further, we analyzed the oncolytic potency of the viruses in vitro and in vivo with and without the reagents. Moreover, the effect of on virus replication was analyzed. We found that RGD-4C or Ad5/3 modified fibers improved the oncolytic potency of the viruses in vitro and in vivo. We found that both promoters could be downregulated with dexamethasone, sodium salicylate, or salicylic acid. Oncolytic efficacy correlated with the promoter activity and in vitro virus production could be abrogated with the substances. In vivo, we saw good therapeutic efficacy of the viruses in a model of intravenous therapy of metastatic cervical cancer, but the inhibitory effect of dexamethasone was not strong enough to provide significant differences in a complex in vivo environment. Our results suggest that anti-inflammatory drugs may affect the replication of adenovirus, which might be relevant in case of replication associated side effects.	[Kanerva, Anna; Lavilla-Alonso, Sergio; Raki, Mari; Kangasniemi, Lotta; Bauerschmitz, Gerd J.; Hemminki, Akseli] Univ Helsinki, Canc Gene Therapy Grp, Mol Canc Biol Program, Helsinki, Finland; [Kanerva, Anna] Helsinki Univ Cent Hosp HUCH, Dept Obstet & Gynecol, Helsinki, Finland; [Lavilla-Alonso, Sergio; Raki, Mari; Kangasniemi, Lotta; Bauerschmitz, Gerd J.; Hemminki, Akseli] Helsinki Univ Cent Hosp HUCH, HUSLAB, Transplantation Lab, Helsinki, Finland; [Bauerschmitz, Gerd J.] Univ Dusseldorf, Dept Obstet & Gynecol, Dusseldorf, Germany; [Takayama, Koichi] Kyushu Univ, Res Inst Dis Chest, Fukuoka, Japan; [Ristimaki, Ari] Univ Helsinki, Genome Scale Biol Program, Helsinki Univ Cent Hosp, HUSLAB, Helsinki, Finland; [Desmond, Renee A.] Univ Alabama Birmingham, Biostat & Bioinformat Unit, Comprehensive Canc Ctr, Birmingham, AL USA	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Heinrich Heine University Dusseldorf; Kyushu University; University of Helsinki; Helsinki University Central Hospital; University of Alabama System; University of Alabama Birmingham	Kanerva, A (corresponding author), Univ Helsinki, Canc Gene Therapy Grp, Mol Canc Biol Program, Helsinki, Finland.	akseli.hemminki@helsinki.fi		Takayama, Koichi/0000-0002-7723-8960	EU FP6 THERADPOX; APOTHERAPY; HUCH Research Funds (EVO); Sigrid Juselius Foundation; Academy of Finland; Emil Aaltonen Foundation; Finnish Cancer Society; University of Helsinki; Sohlberg Foundation; Instrumentarium Research Fund; Finnish Oncology Association; Helsinki Biomedical Graduate School; Helsinki Graduate School in Biotechnology and Molecular Biology; Finnish Cultural Foundation; Research Foundation of Bayer Schering Pharma; Deutsche Forschungsgemeinschaft/DFG; Biocentrum Helsinki; Finnish Cancer Institute	EU FP6 THERADPOX(European Commission); APOTHERAPY; HUCH Research Funds (EVO); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Emil Aaltonen Foundation; Finnish Cancer Society; University of Helsinki; Sohlberg Foundation; Instrumentarium Research Fund; Finnish Oncology Association; Helsinki Biomedical Graduate School; Helsinki Graduate School in Biotechnology and Molecular Biology; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Research Foundation of Bayer Schering Pharma; Deutsche Forschungsgemeinschaft/DFG(German Research Foundation (DFG)); Biocentrum Helsinki; Finnish Cancer Institute	This work was supported by EU FP6 THERADPOX and APOTHERAPY, HUCH Research Funds (EVO), Sigrid Juselius Foundation, Academy of Finland, Emil Aaltonen Foundation, Finnish Cancer Society, University of Helsinki, Sohlberg Foundation, Instrumentarium Research Fund, Finnish Oncology Association, Helsinki Biomedical Graduate School, Helsinki Graduate School in Biotechnology and Molecular Biology, Finnish Cultural Foundation, Research Foundation of Bayer Schering Pharma, Deutsche Forschungsgemeinschaft/DFG and Biocentrum Helsinki. A.H. is K. Albin Johansson Research Professor of the Finnish Cancer Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker AH, 2007, MOL THER, V15, P1410, DOI 10.1038/sj.mt.6300206; Barker SD, 2003, J GENE MED, V5, P300, DOI 10.1002/jgm.341; Bauerschmitz GJ, 2002, CANCER RES, V62, P1266; Bauerschmitz GJ, 2004, INT J CANCER, V111, P303, DOI 10.1002/ijc.20217; Benckert C, 2003, CANCER RES, V63, P1083; Binley K, 2003, GENE THER, V10, P540, DOI 10.1038/sj.gt.3301944; BLAIR GE, 1989, VIRUS RES, V14, P339, DOI 10.1016/0168-1702(89)90026-9; Bruning A, 2001, HUM GENE THER, V12, P391, DOI 10.1089/10430340150504019; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Casado E, 2001, CLIN CANCER RES, V7, P2496; Cheng WF, 1999, OBSTET GYNECOL, V93, P761, DOI 10.1016/S0029-7844(98)00505-5; Chow NH, 1997, HUM PATHOL, V28, P698, DOI 10.1016/S0046-8177(97)90179-9; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Eibl G, 2005, CANCER RES, V65, P982; Fechner H, 2003, GENE THER, V10, P1680, DOI 10.1038/sj.gt.3302051; Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973; Fujimoto J, 1999, BRIT J CANCER, V80, P827, DOI 10.1038/sj.bjc.6690428; Gralla RJ, 1999, J CLIN ONCOL, V17, P2971, DOI 10.1200/JCO.1999.17.9.2971; Hemminki A, 2003, CANCER RES, V63, P847; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; Insel PA, 1996, PHARMACOL BASIS THER, P617; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kanerva A, 2002, CLIN CANCER RES, V8, P275; Kanerva A, 2004, INT J CANCER, V110, P475, DOI 10.1002/ijc.20129; Kanerva A, 2004, GENE THER, V11, P552, DOI 10.1038/sj.gt.3302181; Kanerva A, 2007, EXPERT OPIN BIOL TH, V7, P1347, DOI 10.1517/14712598.7.9.1347; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Krasnykh V, 2001, J VIROL, V75, P4176, DOI 10.1128/JVI.75.9.4176-4183.2001; Kulkarni S, 2001, CLIN CANCER RES, V7, P429; Lam JT, 2004, J GENE MED, V6, P1333, DOI 10.1002/jgm.635; Loncaster JA, 2000, BRIT J CANCER, V83, P620, DOI 10.1054/bjoc.2000.1319; Manome Y, 1998, HUM GENE THER, V9, P1409, DOI 10.1089/hum.1998.9.10-1409; Moriuchi M, 2001, J VIROL, V75, P192, DOI 10.1128/JVI.75.1.192-198.2001; Nagi P, 2003, J GASTROINTEST SURG, V7, P364, DOI 10.1016/S1091-255X(02)00437-7; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pruzanski W, 1998, BBA-MOL CELL RES, V1403, P47, DOI 10.1016/S0167-4889(98)00029-9; Rajecki M, 2007, MOL CANCER THER, V6, P742, DOI 10.1158/1535-7163.MCT-06-0403; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Rein DT, 2004, J GENE MED, V6, P1281, DOI 10.1002/jgm.606; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Russell WC, 2000, J GEN VIROL, V81, P2573, DOI 10.1099/0022-1317-81-11-2573; Sarkioja M, 2008, J GENE MED, V10, P744, DOI 10.1002/jgm.1193; Small EJ, 2006, MOL THER, V14, P107, DOI 10.1016/j.ymthe.2006.02.011; Suzuki K, 2001, CLIN CANCER RES, V7, P120; Symensma TL, 2003, J VIROL, V77, P12753, DOI 10.1128/JVI.77.23.12753-12763.2003; TORDJMAN C, 1995, BBA-LIPID LIPID MET, V1256, P249, DOI 10.1016/0005-2760(95)00026-9; WALSH D, 1992, CLEV CLIN J MED, V59, P505, DOI 10.3949/ccjm.59.5.505; Wesseling JG, 2001, CANCER GENE THER, V8, P990, DOI 10.1038/sj.cgt.7700403; Xu XM, 1999, P NATL ACAD SCI USA, V96, P5292, DOI 10.1073/pnas.96.9.5292; Yamamoto M, 2003, GASTROENTEROLOGY, V125, P1203, DOI 10.1016/S0016-5085(03)01196-X; Yamamoto M, 2001, MOL THER, V3, P385, DOI 10.1006/mthe.2001.0275; Yu W, 2007, CURR CANCER DRUG TAR, V7, P141, DOI 10.2174/156800907780058817; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	56	10	10	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2008	3	8							e2917	10.1371/journal.pone.0002917	http://dx.doi.org/10.1371/journal.pone.0002917			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	422FK	18698374	Green Published, gold, Green Submitted			2023-01-03	WOS:000264412600005
J	Ugolev, Y; Berdichevsky, Y; Weinbaum, C; Pick, E				Ugolev, Yelena; Berdichevsky, Yevgeny; Weinbaum, Carolyn; Pick, Edgar			Dissociation of Rac1(GDP)center dot RhoGDI complexes by the cooperative action of anionic liposomes containing phosphatidylinositol 3,4,5-trisphosphate, rac guanine nucleotide exchange factor, and GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-OXIDASE ACTIVATION; CELL-FREE SYSTEM; DEPENDENT SUPEROXIDE PRODUCTION; PLECKSTRIN HOMOLOGY DOMAINS; RESPIRATORY BURST OXIDASE; SODIUM DODECYL-SULFATE; BETA-GAMMA-SUBUNITS; MEMBRANE TRANSLOCATION; RHO-GTPASES; PHOSPHOINOSITIDE 3-KINASE	Rac plays a pivotal role in the assembly of the superoxide-generating NADPH oxidase of phagocytes. In resting cells, Rac is found in the cytosol in complex with Rho GDP dissociation inhibitor (RhoGDI). NADPH oxidase assembly involves dissociation of the Rac center dot RhoGDI complex and translocation of Rac to the membrane. We reported that liposomes containing high concentrations of monovalent anionic phospholipids cause Rac center dot RhoGDI complex dissociation (Ugolev, Y., MolshanskiMor, S., Weinbaum, C., and Pick, E. (2006) J. Biol. Chem. 281, 19204 - 19219). We now designed an in vitro model mimicking membrane phospholipid remodeling during phagocyte stimulation in vivo. We showed that liposomes of "resting cell membrane" composition (less than 20 mol % monovalent anionic phospholipids), supplemented with 1 mol % of polyvalent anionic phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) in conjunction with constitutively active forms of the guanine nucleotide exchange factors (GEFs) for Rac, Trio, or Tiam1 and a non-hydrolyzable GTP analogue, cause dissociation of Rac1(GDP)center dot RhoGDI complexes, GDP to GTP exchange on Rac1, and binding of Rac1(GTP) to the liposomes. Complexes were not dissociated in the absence of GEF and GTP, and optimal dissociation required the presence of PtdIns(3,4,5) P-3 in the liposomes. Dissociation of Rac1(GDP)center dot RhoGDI complexes was correlated with the affinity of particular GEF constructs, via the N-terminal pleckstrin homology domain, for PtdIns(3,4,5) P-3 and involved GEF-mediated GDP to GTP exchange on Rac1. Phagocyte membranes enriched in PtdIns(3,4,5) P-3 responded by NADPH oxidase activation upon exposure in vitro to Rac1(GDP)center dot RhoGDI complexes, p67(phox), GTP, and Rac GEF constructs with affinity for PtdIns( 3,4,5) P3 at a level superior to that of native membranes.	[Pick, Edgar] Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; [Ugolev, Yelena; Berdichevsky, Yevgeny; Pick, Edgar] Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Infect Dis, IL-69978 Tel Aviv, Israel; [Weinbaum, Carolyn] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Duke University	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel.	epick@post.tau.ac.il	Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233; Berdichevsky, Yevgeny/0000-0002-5038-6816	NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABO A, 1991, J BIOL CHEM, V266, P23577; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Barber MA, 2007, J BIOL CHEM, V282, P29967, DOI 10.1074/jbc.M701877200; Baumeister MA, 2006, BIOCHEM J, V400, P563, DOI 10.1042/BJ20061020; Bellanger JM, 2003, BIOL CELL, V95, P625, DOI 10.1016/j.biolcel.2003.10.002; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bokoch GM, 2006, ANTIOXID REDOX SIGN, V8, P1533, DOI 10.1089/ars.2006.8.1533; Bokoch GM, 2005, TRENDS CELL BIOL, V15, P163, DOI 10.1016/j.tcb.2005.01.002; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; Ceccarelli DFJ, 2007, J BIOL CHEM, V282, P13864, DOI 10.1074/jbc.M700505200; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; DerMardirossian C, 2005, TRENDS CELL BIOL, V15, P356, DOI 10.1016/j.tcb.2005.05.001; Dovas A, 2005, BIOCHEM J, V390, P1, DOI 10.1042/BJ20050104; Estrach S, 2002, CURR BIOL, V12, P307, DOI 10.1016/S0960-9822(02)00658-9; Faure J, 1999, EUR J BIOCHEM, V262, P879, DOI 10.1046/j.1432-1327.1999.00458.x; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Gao Y, 2001, J BIOL CHEM, V276, P47530, DOI 10.1074/jbc.M108865200; Gorzalczany Y, 2002, J BIOL CHEM, V277, P18605, DOI 10.1074/jbc.M202114200; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Groemping Y, 2005, BIOCHEM J, V386, P401, DOI 10.1042/BJ20041835; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Heo WD, 2006, SCIENCE, V314, P1458, DOI 10.1126/science.1134389; Hill K, 2005, J BIOL CHEM, V280, P4166, DOI 10.1074/jbc.M411262200; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; JOSEPH G, 1994, J BIOL CHEM, V269, P29024; JOUAN A, 1993, ANAL BIOCHEM, V214, P252, DOI 10.1006/abio.1993.1485; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; MASON RJ, 1972, J CLIN INVEST, V51, P2399, DOI 10.1172/JCI107052; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Mizrahi A, 2005, J BIOL CHEM, V280, P3802, DOI 10.1074/jbc.M410257200; Moissoglu K, 2006, MOL BIOL CELL, V17, P2770, DOI 10.1091/mbc.E06-01-0005; Molshanski-Mor Shahar, 2007, V412, P385, DOI 10.1007/978-1-59745-467-4_25; Muroya K, 2007, BIOCHEM BIOPH RES CO, V355, P85, DOI 10.1016/j.bbrc.2007.01.131; Nauseef WM, 2004, HISTOCHEM CELL BIOL, V122, P277, DOI 10.1007/s00418-004-0679-8; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Pechlivanis M, 2007, BIOCHEMISTRY-US, V46, P5341, DOI 10.1021/bi602353k; Perisic O, 2004, ADV ENZYME REGUL, V44, P279, DOI 10.1016/j.advenzreg.2003.11.003; PICK E, 1993, EUR J BIOCHEM, V217, P441, DOI 10.1111/j.1432-1033.1993.tb18264.x; PICK E, 1987, J BIOL CHEM, V262, P16476; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Quinn Peter J, 2002, Subcell Biochem, V36, P39; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sarfstein R, 2004, J BIOL CHEM, V279, P16007, DOI 10.1074/jbc.M312394200; SASAKI T, 1993, J BIOL CHEM, V268, P23959; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; Sigal N, 2003, INFLAMMATION, V27, P147, DOI 10.1023/A:1023869828688; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Ueyama T, 2005, J IMMUNOL, V175, P2381, DOI 10.4049/jimmunol.175.4.2381; Ugolev Y, 2006, J BIOL CHEM, V281, P19204, DOI 10.1074/jbc.M600042200; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yeung T, 2007, IMMUNOL REV, V219, P17, DOI 10.1111/j.1600-065X.2007.00546.x; Yeung T, 2006, SCIENCE, V313, P347, DOI 10.1126/science.1129551	67	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 8	2008	283	32					22257	22271		10.1074/jbc.M800734200	http://dx.doi.org/10.1074/jbc.M800734200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	332WV	18505730	hybrid, Green Published			2023-01-03	WOS:000258114700045
J	Sokol, DK				Sokol, Daniel K.			Clarifying best interests - What should doctors consider when determining what's best for their patients?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London, St Georges, London WC1E 7HU, England	University of London	Sokol, DK (corresponding author), Univ London, St Georges, London WC1E 7HU, England.	daniel.sokol@talk21.com							0	2	2	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 2	2008	337	7664							a994	10.1136/bmj.a994	http://dx.doi.org/10.1136/bmj.a994			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	339EN	18667474				2023-01-03	WOS:000258561000025
J	Lutz, A; Brefczynski-Lewis, J; Johnstone, T; Davidson, RJ				Lutz, Antoine; Brefczynski-Lewis, Julie; Johnstone, Tom; Davidson, Richard J.			Regulation of the Neural Circuitry of Emotion by Compassion Meditation: Effects of Meditative Expertise	PLOS ONE			English	Article							BRAIN; COGNITION; EMPATHY	Recent brain imaging studies using functional magnetic resonance imaging (fMRI) have implicated insula and anterior cingulate cortices in the empathic response to another's pain. However, virtually nothing is known about the impact of the voluntary generation of compassion on this network. To investigate these questions we assessed brain activity using fMRI while novice and expert meditation practitioners generated a loving-kindness-compassion meditation state. To probe affective reactivity, we presented emotional and neutral sounds during the meditation and comparison periods. Our main hypothesis was that the concern for others cultivated during this form of meditation enhances affective processing, in particular in response to sounds of distress, and that this response to emotional sounds is modulated by the degree of meditation training. The presentation of the emotional sounds was associated with increased pupil diameter and activation of limbic regions (insula and cingulate cortices) during meditation (versus rest). During meditation, activation in insula was greater during presentation of negative sounds than positive or neutral sounds in expert than it was in novice meditators. The strength of activation in insula was also associated with self-reported intensity of the meditation for both groups. These results support the role of the limbic circuitry in emotion sharing. The comparison between meditation vs. rest states between experts and novices also showed increased activation in amygdala, right temporo-parietal junction (TPJ), and right posterior superior temporal sulcus (pSTS) in response to all sounds, suggesting, greater detection of the emotional sounds, and enhanced mentation in response to emotional human vocalizations for experts than novices during meditation. Together these data indicate that the mental expertise to cultivate positive emotion alters the activation of circuitries previously linked to empathy and theory of mind in response to emotional stimuli.	[Lutz, Antoine; Davidson, Richard J.] Univ Wisconsin, Madison, WI 53706 USA; [Brefczynski-Lewis, Julie] West Virginia Univ, Morgantown, WV USA; [Johnstone, Tom] Univ Reading, Reading, England	University of Wisconsin System; University of Wisconsin Madison; West Virginia University; University of Reading	Lutz, A (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	alutz@wisc.edu; rjdavids@wisc.edu	LUTZ, Antoine/AAE-5114-2020; Johnstone, Tom/C-5909-2011	LUTZ, Antoine/0000-0002-0258-3233; Johnstone, Tom/0000-0001-8635-8158; Davidson, Richard/0000-0002-8506-4964	NCCAM [U01AT002114-01A1]; Fyssen foundation; NIMH [P50-MH069315]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT002114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH069315] Funding Source: NIH RePORTER	NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Fyssen foundation; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Support was provided by NCCAM U01AT002114-01A1, Fyssen foundation to AL and NIMH P50-MH069315 to RJD, and by gifts from Adrianne and Edwin Cook-Ryder, Bryant Wangard and Ralph Robinson, Keith and Arlene Bronstein and the John W. Kluge Foundation. No funders or sponsors participated in the design or conduct of the study, or in the analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Beatty J., 2000, HDB PSYCHOPHYSIOLOGY, P142; Bradley MM, 2000, PSYCHOPHYSIOLOGY, V37, P204, DOI 10.1111/1469-8986.3720204; Brefczynski-Lewis JA, 2007, P NATL ACAD SCI USA, V104, P11483, DOI 10.1073/pnas.0606552104; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; COXRW, 1996, COMPUT BIOMED RES, V29, P162; Dalai Lama, 1995, WORLD TIBETAN BUDDHI; Dalgleish T, 2004, NAT REV NEUROSCI, V5, P583, DOI 10.1038/nrn1432; Damasio A, 2001, NATURE, V413, P781, DOI 10.1038/35101669; Damasio A., 1999, FEELING WHAT HAPPENS; Davidson RJ, 2004, PHILOS T R SOC B, V359, P1395, DOI 10.1098/rstb.2004.1510; de Vignemont F, 2006, TRENDS COGN SCI, V10, P435, DOI 10.1016/j.tics.2006.08.008; Gethin R., 1998, FDN BUDDHISM; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Jaffer FA, 1997, JMRI-J MAGN RESON IM, V7, P1122, DOI 10.1002/jmri.1880070627; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Preston S. D., 2002, BEHAV BRAIN SCI, V25, P20, DOI [10.1017/S0140525X02380014, DOI 10.1017/S0140525X023]; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; RUBY P, 2007, SENSORIMOTOR FDN HIG; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Sommerville JA, 2006, PSYCHON B REV, V13, P179, DOI 10.3758/BF03193831; Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833; Urry HL, 2006, J NEUROSCI, V26, P4415, DOI 10.1523/JNEUROSCI.3215-05.2006	29	479	491	3	150	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1897	10.1371/journal.pone.0001897	http://dx.doi.org/10.1371/journal.pone.0001897			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370KZ	18365029	Green Submitted, Green Published, gold			2023-01-03	WOS:000260762400035
